<SEC-DOCUMENT>0001193125-22-194928.txt : 20220715
<SEC-HEADER>0001193125-22-194928.hdr.sgml : 20220715
<ACCEPTANCE-DATETIME>20220715160443
ACCESSION NUMBER:		0001193125-22-194928
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		33
FILED AS OF DATE:		20220715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Delaware Inc.
		CENTRAL INDEX KEY:			0001937653
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266160
		FILM NUMBER:		221086335

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		206-337-1030

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>d722206ds4.htm
<DESCRIPTION>S-4
<TEXT>
<HTML><HEAD>
<TITLE>S-4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on July 15, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-4</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks Delaware Inc.* </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">88-3099146</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>108 Patriot Drive, Suite A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Middletown, Delaware 19709 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(302) <FONT STYLE="white-space:nowrap">274-8744</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including Zip Code, and Telephone Number, Including Area Code, of the Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kenneth Galbraith </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chair,
President and Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>108 Patriot Drive, Suite A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Middletown, Delaware 19709 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(302) <FONT STYLE="white-space:nowrap">274-8744</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>With a copy to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tony Jeffries</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bryan D. King</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilson
Sonsini Goodrich&nbsp;&amp; Rosati, P.C.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>650 Page Mill Road</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, California 94304</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">493-9300</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Joseph A. Garcia, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jamie Kariya, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Blake,
Cassels&nbsp;&amp; Graydon LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>595 Burrard Street, Suite 2600</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vancouver, British Columbia, Canada V7X 1L3</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(604)&nbsp;631-3300</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale of the securities to the public: </B>As soon as practicable after the effectiveness of this registration
statement and the satisfaction or waiver of all other conditions to the transactions described herein. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If the securities being registered on this form are
being offered in connection with the formation of a holding company and there is compliance with General Instruction G, please check the following box.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or emerging growth company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. (Check one): </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">13e-4(i)</FONT> (Cross-Border Issuer Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">14d-1(d)</FONT> (Cross-Border Third-Party Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">* Zymeworks Delaware Inc. (the &#147;Registrant&#148;) is a Delaware corporation and a wholly-owned subsidiary of Zymeworks Inc. In connection with the
Redomicile Transactions, and subject to the satisfaction or waiver of the conditions to the Redomicile Transactions, the Registrant will change its corporate name to Zymeworks Inc. </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>Information contained herein is subject to completion or amendment. A registration
statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This proxy
statement/prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>PRELIMINARY &#151; SUBJECT TO COMPLETION &#151;
DATED JULY 15, 2022 </B></FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR SPECIAL MEETING OF ZYMEWORKS INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS FOR SHARES OF COMMON STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>OF ZYMEWORKS DELAWARE INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSED REDOMICILE TRANSACTION &#151; YOUR VOTE IS IMPORTANT </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced on July 15,<B> </B>2022, Zymeworks Inc. (&#147;<B>Zymeworks</B>&#148;), a company continued under the Business Corporations Act
(British Columbia) (the &#147;<B>BCBCA</B>&#148;), is proposing and submitting to the holders of common shares of Zymeworks (the &#147;<B>Zymeworks Common Shares</B>&#148; and the holders thereof, the &#147;<B>Zymeworks Shareholders</B>&#148;), the
holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Zymeworks Common Shares (the &#147;<B>Zymeworks Warrants</B>&#148; and the holders thereof, the &#147;<B>Zymeworks Warrantholders</B>&#148;) and the holders of equity
incentive awards of Zymeworks (&#147;<B>Zymeworks Incentive Awards</B>&#148; and the holders thereof, the &#147;<B>Zymeworks Incentive Awardholders</B>&#148;, and together with the Zymeworks Shareholders and the Zymeworks Warrantholders, the
&#147;<B>Zymeworks Securityholders</B>&#148;) for approval, a corporate redomicile transaction of Zymeworks that is described in detail below. In order to implement the corporate redomicile transaction, a special meeting of Zymeworks Securityholders
(the &#147;<B>Special Meeting</B>&#148;) will be held on [&#9679;], 2022, at the [&#9679;], at [&#9679;],&nbsp;Pacific time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Special Meeting,
Zymeworks Securityholders will be asked to consider a resolution (the &#147;<B>Redomicile Resolution</B>&#148;) to approve a series of transactions, including the corporate redomicile (collectively, the &#147;<B>Redomicile Transactions</B>&#148;),
which will include a proposed plan of arrangement under the BCBCA that provides for, among other things, (i)&nbsp;the issuance to Zymeworks Shareholders, at their election and subject to applicable eligibility criteria, for their Zymeworks Common
Shares, either (a)&nbsp;shares of Zymeworks Delaware Inc., a Delaware corporation, (&#147;<B>Parent</B>&#148;) common stock, par value $0.00001 per share (the &#147;<B>Delaware Common Stock</B>&#148;) on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or (b)&nbsp;exchangeable shares (the &#147;<B>Exchangeable Shares</B>&#148; and recipients thereof, the &#147;<B>Exchangeable Shareholders</B>&#148;) in the capital of Zymeworks ExchangeCo
Ltd., a company existing under the laws of the Province of British Columbia and a direct wholly-owned subsidiary of Callco (&#147;<B>ExchangeCo</B>&#148;), on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or a mix of Exchangeable Shares and Delaware Common Stock (in such aggregate number that is equal to the number of Zymeworks Common Shares exchanged
for them) (the &#147;<B>Mixed Election</B>&#148;), but subject to a cap on the aggregate number of Exchangeable Shares that is equal to 18% of (1)&nbsp;the number of Zymeworks Common Shares issued and outstanding, less (2)&nbsp;the number of
Zymeworks Common Shares held by any Zymeworks Shareholders who exercise their Dissent Rights, (the &#147;<B>Exchangeable Share Cap</B>&#148;); (ii) the entry by Parent, Zymeworks CallCo ULC, an unlimited liability company existing under the laws of
the Province of British Columbia and a direct, wholly-owned subsidiary of Parent (&#147;<B>Callco</B>&#148;) and ExchangeCo into the Exchangeable Share Support Agreement (the &#147;<B>Support Agreement</B>&#148;); and (iii)&nbsp;the entry by Parent,
ExchangeCo, Callco and Computershare Trust Company of Canada, a trust company existing under the laws of Canada (the &#147;<B>Share Trustee</B>&#148;) into the Voting and Exchange Trust Agreement (the &#147;<B>Trust Agreement</B>&#148;) for the
benefit of the Exchangeable Shareholders. After the Redomicile Transactions are complete, Zymeworks Shareholders will hold one share of Delaware Common Stock or one Exchangeable Share, as applicable, for each Zymeworks Common Share owned immediately
prior to the Redomicile Transactions (with the aggregate number of Exchangeable Shares being equal to or less than the Exchangeable Share Cap). If the Exchangeable Share Cap is reached, then the Exchangeable Shares shall be allocated proportionally
among the applicable Exchangeable Shareholders based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder, in which case, the Eligible Holder will also be issued Delaware
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock under a Mixed Election. The Share Trustee will hold one share of Parent preferred stock, par value $0.00001 per share (the &#147;<B>Special Voting Stock</B>&#148;), which will be
held by the Share Trustee under the terms of the Trust Agreement, and which shall have certain variable voting rights as further described in this Proxy Statement/Prospectus. Zymeworks Incentive Awardholders will hold Parent Incentive Awards
identical to the Zymeworks Incentive Awards in all material respects but in respect of Delaware Common Stock in the place and stead of Zymeworks Common Shares, and Zymeworks Warrantholders will be entitled to receive Delaware Common Stock instead of
Zymeworks Common Shares under their Zymeworks Warrants. The directors and officers of Parent will continue to be the same as the directors and officers of Zymeworks immediately prior to the Redomicile Transactions. Parent will indirectly hold
through subsidiaries the business, assets and liabilities of Zymeworks immediately prior to the Redomicile Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
Redomicile Transactions, Parent will assume the Zymeworks Incentive Plans (as defined in this Proxy Statement/Prospectus) and each outstanding Zymeworks Incentive Award. The assumed Zymeworks Incentive Awards will remain subject to the terms and
conditions of the existing Zymeworks Incentive Plans, except that the security issuable upon exercise or settlement of the Zymeworks Incentive Award, as applicable, will be shares of Delaware Common Stock rather than Zymeworks Common Shares. Parent
will also assume the outstanding Zymeworks Warrants, except that the security issuable upon exercise will be shares of Delaware Common Stock rather than Zymeworks Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The board of directors of Zymeworks (the &#147;Zymeworks Board&#148;) recommends that Zymeworks Securityholders vote <U>FOR</U> the Redomicile Resolution.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board believes that the opportunity to enhance long-term value for shareholders will be greater as a Delaware corporation than as a
British Columbia corporation. The Zymeworks Board believes that the U.S. investor base, in addition to representing a majority of current Zymeworks Shareholders, represents the greatest source of potential additional investment. Due to the fact that
Zymeworks is a British Columbia corporation, certain U.S. institutional investors and state-level investment vehicles are prohibited from investing in Zymeworks Common Shares or are limited in the size of such investment. Although the converse can
also apply with respect to certain Canadian institutional investors (i.e., Canadian institutional investors may face prohibitions or limitations on investing in U.S. corporations or may have adopted internal policies limiting such holdings), the
Zymeworks Board believes that becoming a Delaware corporation would provide greater opportunities to expand the institutional investor base, which would provide opportunities for increased value of Zymeworks Common Shares. In addition, as a Delaware
corporation, Parent may be eligible for inclusion in certain leading indices, such as the Russell and S&amp;P indices, which could also increase demand for Parent shares through passive investment by certain index funds. Moreover, the Zymeworks
Board believes that, if zanidatamab is approved, the United States will be a key geography for the commercialization of zanidatamab, and that a significant portion of counterparties in potential monetization opportunities for the Company&#146;s
early-stage product candidates are located in the United States. Being a Delaware corporation could simplify commercialization efforts by reducing some of the cross-border legal, regulatory and tax complexities related to such efforts. Lastly, the
Zymeworks Board believes being incorporated in Delaware may provide greater comparability to other U.S. public companies, many of which are incorporated in Delaware, including many of Zymeworks&#146; peer group companies. For additional information
on these and the other factors considered by the Zymeworks Board, see section titled &#147;<I>The Redomicile Transactions &#151; Reasons for the Redomicile Transactions</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Delaware Common Stock are anticipated to be listed for trading on the NYSE immediately prior to when the Redomicile Transactions become effective
under the Plan of Arrangement and the Transaction Agreement (the &#147;<B>Effective Date</B>&#148;). See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Stock
Exchange Listings</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Zymeworks Shareholders, much will remain unchanged following the Redomicile Transactions. The stockholders of Parent
will be the same persons and entities who were Zymeworks Shareholders immediately prior to the Redomicile Transactions, other than Dissenting Shareholders (as defined herein) and holders of Exchangeable Shares prior to exchanging them for Delaware
Common Stock. However, given the differences between the laws of British Columbia and Delaware law, your rights as a shareholder of Zymeworks and a </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder of Parent will be different. In addition, there are differences between Zymeworks&#146; existing articles and the amended and restated certificate of incorporation that Parent expects
to adopt at or prior to the time of the Redomicile Transactions (the &#147;<B>Parent Certificate of Incorporation</B>&#148;) and the amended and restated bylaws that Parent intends to adopt at or prior to the time of the Redomicile Transactions (the
&#147;<B>Parent Bylaws</B>&#148;) as they will be in effect upon the completion of the Redomicile Transactions. See section titled &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent Stockholders</I>&#148; and &#147;<I>Description of
Parent Capital Stock</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board weighed the estimated corporate tax liability arising from the Redomicile Transactions and, with the
assistance of professional advisors and based on and subject to current assumptions, does not anticipate it will incur material corporate-level Canadian or United States federal income tax resulting from the Redomicile Transactions. Parent&#146;s
effective tax rate may be affected by the Redomicile Transactions or by changes in tax laws. See section titled &#147;<I>Risk Factors</I> &#151; <I>Parent&#146;s effective tax rate may change in the future, including as a result of the Redomicile
Transactions</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions may have different tax consequences for Zymeworks Shareholders resident in Canada and elsewhere,
including the United States. In addition, there may be different income tax treatment that applies to Canadian Holders (and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders) and U.S. holders of shares of Delaware Common Stock or
Exchangeable Shares in respect of dividend and withholding taxes, as compared to the tax consequences that apply in respect of holding Zymeworks Common Shares. The Canadian federal income tax consequences of the Redomicile Transactions for Zymeworks
Shareholders will depend on a number of factors. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Particulars of the Redomicile Transactions</I>&#148; and &#147;<I>Material Canadian Federal Income Tax
Considerations</I>&#148;. As described in more detail in the section of the Proxy Statement/Prospectus entitled &#147;<I>Material Canadian Federal Income Tax Considerations</I>&#148;, there are circumstances where the disposition of Zymeworks Common
Shares pursuant to the Redomicile Transactions may be a taxable transaction to a Zymeworks Shareholder for Canadian federal income tax purposes. The U.S. federal income tax consequences of the Redomicile Transactions to U.S. holders will also depend
on a number of factors. See section titled &#147;<I>Material U.S. Federal Income Tax Considerations</I>&#148;.<B> </B>Zymeworks Shareholders are urged to carefully read the sections of the Proxy Statement/Prospectus entitled &#147;<I>Material
Canadian Federal Income Tax Considerations</I>&#148; and &#147;<I>Material U.S. Federal Income Tax Considerations</I>&#148;, as applicable, and to consult with their own tax and other advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of all other conditions precedent, if both (i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks
Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately, approve the Redomicile Resolution, it is anticipated that the Redomicile Transactions will be completed as soon as practicable
following the approval of the Supreme Court of British Columbia (the &#147;<B>Court</B>&#148;) in respect of the Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy
Statement/Prospectus is dated [&#9679;], 2022 and is first being mailed on or about [&#9679;], 2022 to Zymeworks Securityholders of record as of [&#9679;], 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>We urge you to read this Proxy Statement/Prospectus and the documents incorporated by reference herein carefully and in their entirety. In particular, you
should consider the matters discussed in the section entitled &#147;</B><B><I><A HREF="#rom722206_6">Risk Factors</A></I></B><B>&#148;, beginning on page&nbsp;29 of this Proxy Statement/Prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the U.S. Securities and Exchange Commission nor any state securities commission or Canadian securities regulatory authority has approved or
disapproved of the securities to be issued in connection with the Redomicile Transactions described in this Proxy Statement/Prospectus or determined if this Proxy Statement/Prospectus is accurate or complete. Any representation to the contrary is a
criminal offense. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;], 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
Zymeworks Securityholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are invited to attend a special meeting (the &#147;<B>Special Meeting</B>&#148;) of the holders of common shares (the
&#147;<B>Zymeworks Common Shares</B>&#148; and the holders thereof, the &#147;<B>Zymeworks Shareholders</B>&#148;), the holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Zymeworks Common Shares (the
&#147;<B>Zymeworks Warrants</B>&#148; and the holders thereof, the &#147;<B>Zymeworks Warrantholders</B>&#148;) and the holders of equity incentive awards (&#147;<B>Zymeworks Incentive Awards</B>&#148; and the holders thereof, the &#147;<B>Zymeworks
Incentive Awardholders</B>&#148;, and together with the Zymeworks Shareholders and the Zymeworks Warrantholders, the &#147;<B>Zymeworks Securityholders</B>&#148;) of Zymeworks Inc. (&#147;<B>Zymeworks</B>&#148;) to be held on [&#9679;], 2022, at the
[&#9679;], at [&#9679;]&nbsp;Pacific time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>The Redomicile Transactions </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Special Meeting, Zymeworks Securityholders will be asked to consider a resolution (the &#147;<B>Redomicile Resolution</B>&#148;) to approve a series of
transactions, including the corporate redomicile (collectively, the &#147;<B>Redomicile Transactions</B>&#148;), which will include a proposed plan of arrangement under the BCBCA that provides for, among other things, (i)&nbsp;the issuance to
Zymeworks Shareholders, at their election and subject to applicable eligibility criteria, for their Zymeworks Common Shares, either (a)&nbsp;shares of Zymeworks Delaware Inc., a Delaware corporation, (&#147;<B>Parent</B>&#148;) common stock, par
value $0.00001 per share (the &#147;<B>Delaware Common Stock</B>&#148;) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or (b)&nbsp;exchangeable shares (the &#147;<B>Exchangeable
Shares</B>&#148; and recipients thereof, the &#147;<B>Exchangeable Shareholders</B>&#148;) in the capital of Zymeworks ExchangeCo Ltd., a company existing under the laws of the Province of British Columbia and a direct wholly-owned subsidiary of
Callco (&#147;<B>ExchangeCo</B>&#148;), on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or a mix of Exchangeable Shares and Delaware Common Stock (in such aggregate number that is equal to the
number of Zymeworks Common Shares exchanged for them) (the &#147;<B>Mixed Election</B>&#148;), subject to a cap on the aggregate number of Exchangeable Shares that is equal to 18% of (1)&nbsp;the number of Zymeworks Common Shares issued and
outstanding, less (2)&nbsp;the number of Zymeworks Common Shares held by any Zymeworks Shareholders who exercise their Dissent Rights, (the &#147;<B>Exchangeable Share Cap</B>&#148;); (ii) the entry by Parent, Zymeworks CallCo ULC, an unlimited
liability company existing under the laws of the Province of British Columbia and a direct, wholly-owned subsidiary of Parent (&#147;<B>Callco</B>&#148;) and ExchangeCo into the Exchangeable Share Support Agreement (the &#147;<B>Support
Agreement</B>&#148;); and (iii)&nbsp;the entry by Parent, ExchangeCo, Callco and Computershare Trust Company of Canada, a trust company existing under the laws of Canada (the &#147;<B>Share Trustee</B>&#148;) into the Voting and Exchange Trust
Agreement (the &#147;<B>Trust Agreement</B>&#148;) for the benefit of the Exchangeable Shareholders. After the Redomicile Transactions are complete, Zymeworks Shareholders will hold one share of Delaware Common Stock or one Exchangeable Share, as
applicable, for each Zymeworks Common Share owned immediately prior to the Redomicile Transactions (with the aggregate number of Exchangeable Shares that is equal to or less than the Exchangeable Share Cap). If the Exchangeable Share Cap is reached,
then the Exchangeable Shares shall be allocated proportionally among the applicable Exchangeable Shareholders based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder,
in which case, the Eligible Holder will also be issued Delaware Common Stock under a Mixed Election. The Share Trustee will hold one share of Parent preferred stock, par value $0.00001 per share (the &#147;<B>Special Voting Stock</B>&#148;), which
will be held by the Share Trustee under the terms of the Trust Agreement, and which shall have certain variable voting rights as further described in this Proxy Statement/Prospectus. Zymeworks Incentive Awardholders will hold Parent Incentive Awards
identical to the Zymeworks Incentive Awards in all material respects but in respect of Delaware Common Stock in the place and stead of Zymeworks Common Shares, and Zymeworks Warrantholders will be entitled to receive Delaware Common Stock instead of
Zymeworks Common Shares under their Zymeworks Warrants. The directors and officers of Parent will continue to be the same as the directors and officers of Zymeworks immediately prior to the Redomicile Transactions. Parent will indirectly hold
through subsidiaries the business, assets and liabilities of Zymeworks immediately prior to the Redomicile Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
Redomicile Transactions, Parent will assume the Zymeworks Incentive Plans (as defined in this Proxy Statement/Prospectus) and each outstanding Zymeworks Incentive Award. The assumed Zymeworks Incentive Awards will remain subject to the terms and
conditions of the existing Zymeworks Incentive Plans, except that the security issuable upon exercise or settlement of the Zymeworks Incentive Award, as applicable, will be shares of Delaware Common Stock rather than Zymeworks Common Shares. Parent
will also assume the outstanding Zymeworks Warrants, except that the security issuable upon exercise will be shares of Delaware Common Stock rather than Zymeworks Common Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Board of Directors Recommendation </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors of Zymeworks (the &#147;<B>Zymeworks Board</B>&#148;) recommends that Zymeworks Securityholders vote <B><U>FOR</U></B> the Redomicile
Resolution. In making its determination, the Zymeworks Board considered a number of factors as described in the Proxy Statement/Prospectus under &#147;<I>The Redomicile Transactions &#151; Reasons for the Redomicile Transactions</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Tax Treatment for Zymeworks Shareholders </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Redomicile Transactions may have different tax consequences for Zymeworks Shareholders resident in Canada and elsewhere, including the United States. In addition, there may be different income tax treatment that applies to Canadian (and other <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders) and U.S. resident holders of shares of Delaware Common Stock or Exchangeable Shares in respect of dividend and withholding taxes, as compared to the tax consequences that apply in respect of
holding Zymeworks Common Shares. Zymeworks Shareholders are urged to carefully read the sections of the Proxy Statement/Prospectus entitled &#147;<I>Material Canadian Federal Income Tax Considerations</I>&#148; and &#147;<I>Material U.S. Federal
Income Tax Considerations</I>&#148; and to consult with their own tax and other advisors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Redomicile Transactions Completion Date </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of all other conditions precedent, if both (i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks
Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately, approve the Redomicile Resolution, it is anticipated that the Redomicile Transactions will be completed as soon as practicable
following the approval of the Supreme Court of British Columbia in respect of the Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please refer to the Proxy Statement/Prospectus for a more
detailed description of the Redomicile Transactions and a more detailed description of Zymeworks&#146; reasons for the Redomicile Transactions and the risk factors relating to the Redomicile Transactions. Please give the Proxy Statement/Prospectus
your careful consideration and consult your financial, tax or other professional advisors regarding the consequences of the Redomicile Transactions to you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Zymeworks Board recommends that Zymeworks Securityholders vote <U>FOR</U> the Redomicile Resolution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Voting Your Zymeworks Common Shares, Zymeworks Warrants and/or Zymeworks Incentive Awards </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is very important regardless of the number of Zymeworks Common Shares, Zymeworks Warrants and/or Zymeworks Incentive Awards that you own.</B>
Enclosed with this letter is the Notice of Special Meeting and Proxy Statement/Prospectus and a form of proxy or voting instruction form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are
unable to attend the Special Meeting in person please complete and deliver either the enclosed form of proxy or voting instruction form, as applicable, on the Internet, or by telephone, mail or fax, so that it is received prior to
[&#9679;]&nbsp;Pacific time on [&#9679;], 2022, to ensure your representation at the Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you require assistance with voting your
Zymeworks Common Shares, Zymeworks Warrants and/or Zymeworks Incentive Awards, please contact Zymeworks&#146; strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kingsdale Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 King Street West, Suite 2950 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toronto, Ontario M5X 1E2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call
Toll-Free (within North America): <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-476-7981</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call Collect (outside North America):
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-416-867-2272</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email at contactus@kingsdaleadvisors.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
behalf of Zymeworks, I would like to thank you for your continuing support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chair, President&nbsp;&amp; CEO </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF SPECIAL MEETING OF SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN that, pursuant to an interim order of the Supreme Court of British Columbia (the &#147;<B>Court</B>&#148;) dated [&#9679;], 2022, made
pursuant to Section&nbsp;291 of the Business Corporations Act (British Columbia) (the &#147;<B>BCBCA</B>&#148;), as the same may be amended, modified, supplemented or varied by the Court (the &#147;<B>Interim Order</B>&#148;), a special meeting
(such meeting and any adjournments and postponements thereof referred to as the &#147;<B>Special Meeting</B>&#148;) of holders of common shares (&#147;<B>Zymeworks Common Shares</B>&#148; and the holders thereof, the &#147;<B>Zymeworks
Shareholders</B>&#148;), the holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Zymeworks Common Shares (the &#147;<B>Zymeworks Warrants</B>&#148; and the holders thereof, the &#147;<B>Zymeworks
Warrantholders</B>&#148;) and holders of equity incentive awards (&#147;<B>Zymeworks Incentive Awards</B>&#148; and the holders thereof, the &#147;<B>Zymeworks Incentive Awardholders</B>&#148;, and together with the Zymeworks Shareholders and the
Zymeworks Warrantholders, the &#147;<B>Zymeworks Securityholders</B>&#148;)<B> </B>of Zymeworks Inc. (&#147;<B>Zymeworks</B>&#148;) will be held on [&#9679;], 2022, at the [&#9679;], at [&#9679;],&nbsp;Pacific time, for the following purposes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. to consider and, if deemed advisable, to approve, with or without variation, a special resolution of the Zymeworks Securityholders (the
&#147;<B>Redomicile Resolution</B>&#148;) to approve a series of transactions, including the corporate redomicile (collectively, the &#147;<B>Redomicile Transactions</B>&#148;), which will include a proposed plan of arrangement under the BCBCA that
provides for, among other things, (i)&nbsp;the issuance to Zymeworks Shareholders, at their election and subject to applicable eligibility criteria, for their Zymeworks Common Shares, either (a)&nbsp;shares of Zymeworks Delaware Inc., a Delaware
corporation, (&#147;<B>Parent</B>&#148;) common stock, par value $0.00001 per share (the &#147;<B>Delaware Common Stock</B>&#148;) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or
(b)&nbsp;exchangeable shares (the &#147;<B>Exchangeable Shares</B>&#148; and recipients thereof, the &#147;<B>Exchangeable Shareholders</B>&#148;) in the capital of Zymeworks ExchangeCo Ltd., a company existing under the laws of the Province of
British Columbia and a direct wholly-owned subsidiary of Callco (&#147;<B>ExchangeCo</B>&#148;), on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or a mix of Exchangeable Shares and Delaware
Common Stock (in such aggregate number that is equal to the number of Zymeworks Common Shares exchanged for them) (the &#147;<B>Mixed Election</B>&#148;), subject to a cap on the aggregate number of Exchangeable Shares that is equal to 18% of
(1)&nbsp;the number of Zymeworks Common Shares issued and outstanding, less (2)&nbsp;the number of Zymeworks Common Shares held by any Zymeworks Shareholders who exercise their Dissent Rights, (the &#147;<B>Exchangeable Share Cap</B>&#148;); (ii)
the entry by Parent, Zymeworks CallCo ULC, an unlimited liability company existing under the laws of the Province of British Columbia and a direct, wholly-owned subsidiary of Parent (&#147;<B>Callco</B>&#148;) and ExchangeCo into the Exchangeable
Share Support Agreement (the &#147;<B>Support Agreement</B>&#148;); and (iii)&nbsp;the entry by Parent, ExchangeCo, Callco and Computershare Trust Company of Canada, a trust company existing under the laws of Canada (the &#147;<B>Share
Trustee</B>&#148;) into the Voting and Exchange Trust Agreement (the &#147;<B>Trust Agreement</B>&#148;) for the benefit of the Exchangeable Shareholders, as more particularly described in the accompanying proxy statement/prospectus of Zymeworks
dated [&#9679;], 2022 (as may be amended, supplemented or otherwise modified from time to time) (the &#147;<B>Proxy Statement/Prospectus</B>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. to transact such other business as may properly come before the Special Meeting or any adjournment thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This notice of special meeting of Zymeworks Securityholders (the &#147;<B>Notice of Special Meeting</B>&#148;) and the accompanying Proxy Statement/Prospectus
are available on Zymeworks&#146; website at www.zymeworks.com, on SEDAR at www.sedar.com and on the SEC&#146;s website at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
Interim Order, the close of business on [&#9679;], 2022 is the record date for determining Zymeworks Securityholders who are entitled to attend and vote at the Special Meeting (the &#147;<B>Record Date</B>&#148;). Only Zymeworks Shareholders,
Zymeworks Warrantholders and Zymeworks Incentive Awardholders whose names have been entered in the registers of Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, respectively, as of the Record Date are entitled
to receive notice of and vote at the Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Securityholders who are unable to attend the Special Meeting are encouraged to complete,
sign and return the enclosed form of proxy. To be valid, proxies must be deposited with Computershare Investor Services Inc., Proxy Department, 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1, before [&#9679;] p.m. (Pacific
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time) on [&#9679;], or if the Special Meeting is adjourned or postponed, no later than [&#9679;] p.m. (Pacific time) on the second business day preceding the day to which the Special Meeting is
adjourned or postponed. Notwithstanding the foregoing, the Chair of the Special Meeting has the discretion to accept proxies received after such deadline and the time limit for deposit of proxies may be waived or extended by the Chair of the Special
Meeting at his or her discretion, without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial <FONT STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks Shareholder,
the intermediary (usually a bank, trust company, broker, securities dealer or other financial institution) through which you hold your Zymeworks Common Shares will send you instructions on how to vote your Zymeworks Common Shares. Please follow the
instructions on your voting instruction form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Securityholders who are planning to return the form of proxy or voting instruction form are
encouraged to review the Proxy Statement/Prospectus carefully before submitting such form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Interim Order, registered Zymeworks
Shareholders as of the Record Date have been granted the right to dissent with respect to the Redomicile Resolution and, if the Redomicile Transactions become effective, to be paid the fair value of their Zymeworks Common Shares in accordance with
the provisions of Division 2 of Part 8 of the BCBCA, as may be modified by the Interim Order, the plan of arrangement, which will effect the Arrangement under the BCBCA (the &#147;<B>Plan of Arrangement</B>&#148;) and any other order of the Court.
Registered Zymeworks Shareholders who wish to dissent must provide a written objection to the Redomicile Resolution (a &#147;<B>Dissent Notice</B>&#148;) to Zymeworks, c/o Blake, Cassels&nbsp;&amp; Graydon LLP, 595 Burrard Street, Suite 2600,
Vancouver BC V7X 1L3, Attention: Sean Boyle and Alexandra Luchenko, which Dissent Notice must be received by [&#9679;], 2022, or such day that is two Business Days immediately preceding the date that any adjournment or postponement of the Special
Meeting is reconvened, and must otherwise strictly comply with the dissent procedures prescribed by the BCBCA, as may be modified and supplemented by the Interim Order, the Plan of Arrangement and any other order of the Court. A Zymeworks
Shareholder&#146;s right to dissent is more particularly described in the Proxy Statement/Prospectus under the heading &#147;<I>The Redomicile Transactions &#151; Dissent Rights</I>&#148;. A copy of the Plan of Arrangement is attached as Exhibit A
to the Transaction Agreement, which is set forth in Appendix B to the Proxy Statement/Prospectus. Copies of the text of Division 2 of Part 8 of the BCBCA and the Interim Order are set forth in Appendices C and D,<B> </B>respectively, to the Proxy
Statement/Prospectus.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Persons who are beneficial owners of Zymeworks Common Shares registered in the name of a broker, bank, trust company or
other intermediary or nominee who wish to dissent should be aware that only registered Zymeworks Shareholders are entitled to dissent. Accordingly, a beneficial owner of Zymeworks Common Shares desiring to exercise this right must make arrangements
for the Zymeworks Common Shares beneficially owned by such Zymeworks Shareholder to be registered in the Zymeworks Shareholder&#146;s name prior to the time the Dissent Notice is required to be received by Zymeworks, or, alternatively, make
arrangements for the registered holder of such Zymeworks Common Shares to dissent on the Zymeworks Shareholder&#146;s behalf. A Zymeworks Shareholder that votes in favor of the Redomicile Resolution will not be entitled to dissent rights but a
Zymeworks Shareholder&#146;s failure to vote against the Redomicile Resolution will not constitute a waiver of such shareholder&#146;s dissent rights and a vote against the Redomicile Resolution will not be deemed to satisfy notice requirements
under the BCBCA with respect to dissent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>It is strongly suggested that any Zymeworks Shareholder wishing to dissent seek independent legal
advice, as the failure to strictly comply with the requirements set forth in Division 2 of Part 8 of the BCBCA, as may be modified by the Interim Order, the Plan of Arrangement and any other order of the Court, may result in the loss of any right of
dissent. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Proxy Statement/Prospectus provides additional information relating to the matters to be dealt with at the Special Meeting and is
deemed to form part of this Notice of Special Meeting. Any adjourned or postponed meeting resulting from an adjournment or postponement of the Special Meeting will be held at a time and place to be specified either by the Zymeworks before the
Special Meeting or by the Chair at the Special Meeting. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions about the information contained in this Notice of Special Meeting and the
accompanying Proxy Statement/Prospectus or require assistance in voting your Zymeworks Common Shares, please contact Zymeworks&#146; strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kingsdale Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 King Street West, Suite 2950 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toronto, Ontario M5X 1E2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call
Toll-Free (within North America): <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-476-7981</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call Collect (outside North America):
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-416-867-2272</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email at contactus@kingsdaleadvisors.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DATED</B> at Vancouver, British Columbia, this [&#9679;] day of [&#9679;], 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BY ORDER OF THE BOARD OF DIRECTORS </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chair, President&nbsp;&amp; CEO </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks files annual, quarterly and current reports, proxy statements and other business and financial information with the U.S. Securities and Exchange
Commission (the &#147;<B>SEC</B>&#148;). Financial information about Zymeworks is provided in its consolidated financial statements as at December&nbsp;31, 2021 and 2020 and for the years ended December&nbsp;31, 2021, 2020 and 2019 and accompanying
management&#146;s discussion and analysis (&#147;<B>MD&amp;A</B>&#148;) for the year ended December&nbsp;31, 2021 and in Zymeworks&#146; unaudited consolidated financial statements for the three months ended March&nbsp;31, 2022 and accompanying
MD&amp;A for the three months ended March&nbsp;31, 2022. Zymeworks files reports and other business and financial information with the SEC electronically, and the SEC maintains a website located at www.sec.gov containing this information. Such
information is also available under Zymeworks&#146; profile on the System for Electronic Document Analysis and Retrieval (&#147;<B>SEDAR</B>&#148;) at www.sedar.com. You can also obtain these documents, free of charge, from Zymeworks at
www.zymeworks.com, under the heading &#147;Investors&nbsp;&amp; Media&#148;. The information contained on, or that may be accessed through, Zymeworks&#146; website is not incorporated by reference into, and is not a part of, this Proxy
Statement/Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent, which is currently a wholly-owned subsidiary of Zymeworks, has filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with respect to an aggregate of up to [&#9679;] shares of Delaware Common Stock to be issued in connection with the Redomicile Transactions, which includes up to [&#9679;] shares to be issued at closing, up to
[&#9679;] shares issuable upon the exercise of outstanding options to be assumed at closing, up to [&#9679;] shares issuable upon the settlement of restricted stock units to be assumed at closing, up to [&#9679;] shares issuable upon the exercise of
Zymeworks Warrants to be assumed at closing, up to [&#9679;] shares issuable upon the grant and subsequent exercise or settlement of equity incentive awards granted pursuant to the Zymeworks Incentive Plans, and up to [&#9679;] shares issuable upon
the exchange of Exchangeable Shares. This Proxy Statement/Prospectus forms a part of the registration statement. As permitted by SEC rules, this Proxy Statement/Prospectus does not contain all of the information included in the registration
statement or in the exhibits or schedules to the registration statement. You may read a copy of the registration statement, including any amendments, schedules and exhibits at the SEC&#146;s website mentioned above. Statements contained in this
Proxy Statement/Prospectus as to the contents of any contract or other documents referred to in this Proxy Statement/Prospectus are not necessarily complete. In each case, you should refer to the copy of the applicable agreement or other document
filed as an exhibit to the registration statement. <B>This Proxy Statement/Prospectus incorporates important business and financial information about Zymeworks from documents that are not attached to this Proxy Statement/Prospectus</B>. <B>This
information is available to you without charge upon your request</B>. <B>You can obtain the documents incorporated by reference into this Proxy Statement/Prospectus, including copies of financial statements and MD&amp;A, free of charge by requesting
them in writing or by telephone from Zymeworks or from its strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors:</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kingsdale Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 King Street West, Suite 2950 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toronto, Ontario M5X 1E2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call
Toll-Free (within North America): <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-476-7981</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call Collect (outside North America):
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-416-867-2272</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email at contactus@kingsdaleadvisors.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you
would like to request any documents, please do so by [&#9679;], 2022 in order to receive them before the Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more detailed description
of the information incorporated by reference into this Proxy Statement/Prospectus and how you may obtain it, see section titled &#147;<I>Where You Can Find More Information</I>&#148;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_1">ABOUT THIS PROXY STATEMENT/PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_3">INFORMATION CONTAINED IN PROXY STATEMENT/PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">viii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_4">QUESTIONS AND ANSWERS ABOUT THE REDOMICILE TRANSACTIONS AND THE
MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_5">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_7">VOTING INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_8">THE REDOMICILE TRANSACTIONS AND THE PLAN OF ARRANGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_9">SUMMARY OF THE TRANSACTION AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_10">DESCRIPTION OF EXCHANGEABLE SHARES AND RELATED AGREEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_11">INFORMATION CONCERNING PARENT, EXCHANGECO AND CALLCO</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_12">INFORMATION CONCERNING ZYMEWORKS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_15">MATERIAL CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_16">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_17">DESCRIPTION OF PARENT CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_18">COMPARISON OF RIGHTS OF ZYMEWORKS SHAREHOLDERS AND PARENT
STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_19">SHARE OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND DIRECTORS
 OF ZYMEWORKS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_20">STOCKHOLDER PROPOSALS AND NOMINATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_21">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_22">APPROVAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_23">GLOSSARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_24">APPENDIX A &#151; REDOMICILE RESOLUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_25">APPENDIX B &#151; TRANSACTION AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_26">APPENDIX C &#151; DIVISION 2 OF PART 8 OF THE BCBCA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_27">APPENDIX D &#151; INTERIM ORDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_28">APPENDIX E &#151; NOTICE OF HEARING OF PETITION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">E-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_29">APPENDIX F &#151; FORM OF ZYMEWORKS DELAWARE AMENDED AND RESTATED CERTIFICATE
 OF INCORPORATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom722206_30">APPENDIX G &#151; FORM OF ZYMEWORKS DELAWARE AMENDED AND RESTATED BYLAWS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc722206_31">APPENDIX H &#151; PRELIMINARY PROXY CARD </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">H-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_1"></A>ABOUT THIS PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement/Prospectus, which forms part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed with the SEC,
constitutes a prospectus under the U.S. Securities Act with respect to an aggregate of up to [&#9679;] shares of Delaware Common Stock of Parent to be issued to Zymeworks Shareholders in connection with the Redomicile Transactions, which includes up
to [&#9679;] shares to be issued at closing, up to [&#9679;] shares issuable upon the exercise of outstanding options to be assumed at closing, up to [&#9679;] shares issuable upon the settlement of restricted stock units to be assumed at closing,
up to [&#9679;] shares issuable upon the exercise of Zymeworks Warrants to be assumed at closing, up to [&#9679;] shares issuable upon the grant and subsequent exercise or settlement of equity incentive awards granted pursuant to the Zymeworks
Incentive Plans, and up to [&#9679;] shares issuable upon the exchange of Exchangeable Shares. This Proxy Statement/Prospectus also constitutes a notice of meeting with respect to the Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference into this Proxy Statement/Prospectus. No one has been authorized to provide
you with information that is different from that contained in, or incorporated by reference into, this Proxy Statement/Prospectus. This Proxy Statement/Prospectus is dated [&#9679;], 2022, and you should assume that the information contained in this
Proxy Statement/Prospectus is accurate only as of such date. You should also assume that the information incorporated by reference into this Proxy Statement/Prospectus is only accurate as of the date of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Proxy Statement/Prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy
in any jurisdiction to or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_2"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement/Prospectus includes &#147;forward-looking statements&#148; within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and &#147;forward-looking information&#148; within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to Zymeworks&#146; plans, objectives,
goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings &#147;<I>Information
Concerning Zymeworks</I>&#148;, &#147;<I>Information Concerning Parent</I>&#148;, &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent Stockholders</I>&#148;, &#147;<I>Business</I>&#148;, &#147;<I>Risk Factors</I>&#148; and
&#147;<I>Management</I><I>&#146;</I><I>s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; in this Proxy Statement/Prospectus, including the documents incorporated by reference herein. Forward-looking statements can
often be identified by the use of terminology such as &#147;subject to,&#148; &#147;believe,&#148; &#147;anticipate,&#148; &#147;plan,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;may,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;would,&#148; &#147;could,&#148; &#147;can,&#148; the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to
expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. In particular, these forward-looking statements include, but
are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anticipated benefits of the Redomicile Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of the Redomicile Transactions being completed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated outcomes of the Redomicile Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal steps of the Redomicile Transactions (including the Arrangement); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated tax impact of the Redomicile Transactions on Zymeworks, Parent and Zymeworks Shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the Special Meeting and Final Order; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Required Securityholder Approvals and regulatory and stock exchange approval of the Redomicile Transactions and
Court approval in respect of the Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated last day of trading Zymeworks Common Shares on the NYSE and the anticipated trading of the shares
of Delaware Common Stock on the NYSE; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated Effective Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the implementation of the Redomicile Transactions and its potential benefits, risks and costs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the opportunity to enhance long-term value for stockholders as a U.S. company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to attract passive investment capital in the U.S. and size of such increased investment;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits of Delaware law in connection with negotiations with potential acquirors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits of being a U.S. corporation on efforts to commercialize zanidatamab and the potential monetization
of early-stage product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operations in Canada and the United States following the Redomicile Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perception of Zymeworks by investors, analysts, customers, lenders or potential strategic partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the planned corporate, capital, governance and oversight structures of Parent and Zymeworks before and following
the Redomicile Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of Zymeworks&#146; addressable markets and its ability to commercialize product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of advances in and expansion of Zymeworks&#146; therapeutic platforms and antibody engineering
expertise; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of product candidate development and clinical trial progression, initiation or success;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to predict and manage government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to negotiate any required amendments to its contractual relationships to reflect the
Redomicile Transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Zymeworks&#146; business and
operations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All forward-looking statements, including, without limitation, those related to Zymeworks&#146; examination of historical
operating trends, are based upon Zymeworks&#146; current expectations and various assumptions. Certain assumptions made in preparing the forward-looking statements include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parent&#146;s eligibility for inclusion in certain indices following the Redomicile Transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to commercialize zanidatamab in the United States and potentially monetize early-stage product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the familiarity of potential future counterparties with Delaware law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to achieve the benefits of the restructuring announced in January 2022 and to manage the
size of its organization effectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of material adverse changes in Zymeworks&#146; industry or the global economy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to understand and predict trends in its industry and markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to maintain good business relationships with its strategic partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to comply with current and future regulatory standards; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to protect its intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; continued compliance with third-party license terms and the
<FONT STYLE="white-space:nowrap">non-infringement</FONT> of third-party intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to manage and integrate acquisitions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to retain key personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to raise sufficient debt or equity financing to support its continued growth.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks and
Parent may not realize Zymeworks&#146; expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among
others (including those set forth under &#147;<I>Risk Factors</I>&#148;), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the rights of Zymeworks Shareholders as a result of the Redomicile Transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions that could discourage a takeover of Parent in Parent&#146;s organizational documents and under the
General Corporation Law of the State of Delaware (&#147;<B>DGCL</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential limitations to stockholders&#146; ability to obtain a favorable judicial forum for disputes with Parent
or its directors or officers or other matters pertaining to Parent&#146;s internal affairs due to Parent&#146;s organizational documents designating the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of
actions and proceedings that may be initiated by stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">volatility in the market price for the shares of Delaware Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">zanidatamab may not be approved for commercialization in the United States or any other jurisdictions;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">counterparties for potential monetization transactions may not exist or may not be interested in Zymeworks&#146;
early-stage product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parent&#146;s ability to enter into new arrangements on favorable terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of additional shares of Delaware Common Stock may cause dilution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain the Required Securityholder Approvals, Court, regulatory, stock exchange and other third-party
approvals in a timely manner or on conditions acceptable to Zymeworks or the failure of the Redomicile Transactions to be completed for any other reason (or to be completed in a timely manner); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to achieve the perceived benefits of the Redomicile Transactions and the Redomicile Transactions causing
disruption to Zymeworks&#146; business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to have shares of Delaware Common Stock included in U.S. stock market indices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to attract the expected level of increased U.S. institutional investor interest following the
Redomicile Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated adverse tax consequences to Zymeworks, Parent and the Zymeworks Shareholders in connection with the
Redomicile Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the incurrence of material Canadian federal income tax and/or material U.S. federal income tax as a result of the
Redomicile Transactions of certain of its assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that incremental U.S. or Canadian tax will be imposed on Zymeworks or Parent following the
Redomicile Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in tax laws, regulations or future assessments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocation of time and incurrence of costs (including <FONT STYLE="white-space:nowrap">non-recurring</FONT>
costs) associated with the Redomicile Transactions beyond those estimated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks may choose to defer or abandon the Redomicile Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative publicity resulting from the Redomicile Transactions and its potential effect on Zymeworks&#146;
business and the market price of Zymeworks Common Shares and the shares of Delaware Common Stock of Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk of triggering certain provisions in agreements to which Zymeworks is a party as a result of the Redomicile
Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments in connection with the exercise of Dissent Rights may impact Parent&#146;s financial resources;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations of enforcement of rights against Parent in Canada; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the announcement and pendency of the Redomicile Transactions on Zymeworks&#146; business, results
of operations, and financial conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to obtain regulatory approval for its product candidates without significant delays;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the predictive value of Zymeworks&#146; current or planned clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays with respect to the development and commercialization of Zymeworks&#146; product candidates, which may
cause increased costs or delay receipt of product revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; or any of its partners&#146; ability to enroll subjects in clinical trials and thereby complete
trials on a timely basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design or Zymeworks&#146; execution of clinical trials may not support regulatory approval, including where
clinical trials are conducted outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which Zymeworks&#146; business may be adversely affected by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">global economic and political conditions, including as a result of the Russian invasion of Ukraine, and the
related impact on our business and the markets generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Fast Track and Breakthrough Therapy designations for any of Zymeworks&#146; product candidates may not
expedite regulatory review or approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;) may not accept data from trials Zymeworks
conducts outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions at the FDA and other government agencies caused by funding shortages or global health concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; discretion to discontinue or reprioritize the development of any of Zymeworks&#146; product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for Zymeworks&#146; product candidates to have undesirable side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no regulatory agency has made a determination that any of Zymeworks&#146; product candidates are safe or
effective for use by the general public or for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to face significant competition, including biosimilar products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of broad market acceptance of Zymeworks&#146; product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to obtain Orphan Drug Designation or exclusivity for some or all of its product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to commercialize products outside of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of reimbursement decisions by third-party payors relating to Zymeworks&#146; products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; expectations with respect to the market opportunities for any product that it or its strategic
partners develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to pursue product candidates that may be profitable or have a high likelihood of success;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to use its therapeutic platforms to build a pipeline of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to meet the requirements of ongoing regulatory review; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the threat of product liability lawsuits against Zymeworks or any of its strategic partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in product candidate manufacturing or formulation that may result in additional costs or delay;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential disruption of Zymeworks&#146; business and dilution of its shareholdings associated with
acquisitions and joint ventures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for governments to impose strict price controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk of security breaches and incidents or data loss, which could compromise sensitive business or health
information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">current and future legislation that may increase the difficulty and cost of commercializing Zymeworks&#146;
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic, political, regulatory and other risks associated with international operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; exposure to legal and reputational penalties as a result of any of its current and future
relationships with various third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to comply with export control and import laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; history of significant losses since inception; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to generate revenue from product sales and achieve profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; requirement for substantial additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential dilution to Zymeworks Shareholders associated with future financings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on Zymeworks&#146; ability to seek financing, which may be imposed by future debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to maintain existing and future strategic partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to realize the anticipated benefits of its strategic partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to secure future strategic partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; reliance on third-party manufacturers to produce its product candidate supplies and on other
third parties to provide supplies and store, monitor and transport bulk drug substance and drug product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; reliance on third parties to oversee clinical trials of its product candidates and, in some
cases, maintain regulatory files for those product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; reliance on third parties for various operational and administrative aspects of its business
including its reliance on third parties&#146; cloud-based software platforms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to operate without infringing the patents and other proprietary rights of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to obtain and enforce patent protection for its product candidates and related
technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; patents could be found invalid or unenforceable if challenged; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; intellectual property rights may not necessarily provide it with competitive advantages;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks may become involved in expensive and time-consuming patent lawsuits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the duration of Zymeworks&#146; patents will not adequately protect its competitive position;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to obtain protection under the Drug Price Competition and Patent Term Restoration Act of
1984 and similar legislation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks may be unable to protect the confidentiality of its proprietary information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to comply with procedural and administrative requirements relating to its patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk of claims challenging the inventorship of Zymeworks&#146; patents and other intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; intellectual property rights for some of its product candidates are dependent on the abilities of
third parties to assert and defend such rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent reform legislation and court decisions can diminish the value of patents in general, thereby impairing
Zymeworks&#146; ability to protect its products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks may not be able to protect its intellectual property rights throughout the world;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks will require FDA approval for any proposed product candidate names and any failure or delay associated
with such approval may adversely affect its business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk of employee misconduct including noncompliance with regulatory standards and insider trading;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to market its products in a manner that does not violate the law and subject it to civil
or criminal penalties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Zymeworks does not comply with laws regulating the protection of the environment and health and human safety,
its business could be adversely affected; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; ability to retain key executives and attract and retain qualified personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; exposure to potential securities class action litigation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if securities or industry analysts do not publish research or publish inaccurate or unfavorable research about
Zymeworks&#146; business, its share price and trading volume could decline. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consequently, forward-looking statements should be regarded
solely as Zymeworks&#146; and Parent&#146;s current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. Neither Zymeworks nor Parent can guarantee future results, events, levels of activity, performance
or achievements. Neither Zymeworks nor Parent undertake and each specifically declines any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated
events, except as required by law. The Risk Factors contained or incorporated by reference in this Proxy Statement/Prospectus are not guarantees that no such conditions exist as of the date of this Proxy Statement/Prospectus and should not be
interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we
believe&#148; and similar statements reflect Zymeworks&#146; and Parent&#146;s beliefs and opinions on the relevant subject. These statements are based upon information available to them as of the date of this Proxy Statement/Prospectus, and
although Zymeworks and Parent believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and the statements should not be read to indicate that either Zymeworks or Parent has conducted a
thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks owns or has rights to trademarks, service marks or trade names that it uses in connection with the operation of its business. In addition,
Zymeworks&#146; names, logos and website names and addresses are Zymeworks&#146; service marks or trademarks. Azymetric, Zymeworks, ZymeCAD, EFECT, ZymeLink and the phrase &#147;Building Better Biologics&#148; are Zymeworks&#146; registered
trademarks. The other trademarks, trade names and service marks appearing in this Proxy Statement/Prospectus are the property of its respective owners. Solely for convenience, the trademarks, service marks, tradenames and copyrights referred to in
this Proxy Statement/Prospectus are listed without the <SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP>, <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and TM symbols, but Zymeworks will assert, to the fullest extent under
applicable law, its rights or the rights of the applicable licensors to these trademarks, service marks and tradenames. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All amounts in this Proxy
Statement/Prospectus are expressed in U.S. dollars, except where otherwise indicated. References to &#147;$&#148; and &#147;US$&#148; are to U.S. dollars and references to &#147;C$&#148; are to Canadian dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, references in this Proxy Statement/Prospectus to &#147;Zymeworks,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148;
and &#147;our&#148; refer to the business and operations of Zymeworks Inc. and its subsidiaries, which will be the business of Parent and its subsidiaries after the Redomicile Transactions, if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_3"></A>INFORMATION CONTAINED IN PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is soliciting proxies of all Zymeworks Securityholders primarily by mail and electronic means, supplemented by telephone or other contact by
employees of Zymeworks (who will receive no additional compensation) and all such costs will be borne by Zymeworks. Zymeworks has also retained Kingsdale Advisors as its strategic shareholder advisor and proxy solicitation agent (the &#147;<B>Proxy
Solicitor</B>&#148;) to assist in the solicitation of proxies. For these proxy solicitation services, Kingsdale Advisors will receive an estimated fee of approximately CDN$60,000, plus reimbursement of reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and fees for any additional services. Zymeworks will also reimburse brokers, banks and other nominees for their expenses in sending proxy solicitation materials to the beneficial owners
of Zymeworks Common Shares and obtaining their proxies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement/Prospectus and proxy-related materials are being sent to all Zymeworks
Securityholders. Zymeworks does not send proxy-related materials directly to beneficial <FONT STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks Shareholders and is not relying on the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">notice-and-access</FONT></FONT> provisions of applicable securities laws for delivery of proxy-related materials to Zymeworks Shareholders. Zymeworks will deliver proxy-related materials to nominees, custodians and
fiduciaries, and they will be asked to promptly forward them to the beneficial <FONT STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks Shareholders. Zymeworks will reimburse such nominees, custodians and fiduciaries for their expenses in
sending proxy-related materials to the beneficial <FONT STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks Shareholders and obtaining their proxies. If you are a beneficial <FONT STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks
Shareholder, your nominee should send you a voting instruction form or form of proxy with this Proxy Statement/Prospectus. Zymeworks has also elected to pay for the delivery of its proxy-related materials to objecting beneficial <FONT
STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks has not authorized any person to give any information or to make any
representation in connection with the Redomicile Transactions or any other matters to be considered at the Special Meeting other than those contained in this Proxy Statement/Prospectus. If any such information or representation is given or made,
such information or representation should not be relied upon as having been authorized or as being accurate. For greater certainty, the information contained in, or that can be accessed through, Zymeworks&#146; website is not incorporated into this
Proxy Statement/Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement/Prospectus does not constitute an offer to sell, buy or exchange or a solicitation of an offer to sell,
buy or exchange any securities, or the solicitation of any vote, proxy or approval, by any person in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such an offer or solicitation is not
qualified to do so or to any person to whom it is unlawful to make such an offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Securityholders should not construe the
contents of this Proxy Statement/Prospectus as legal, tax or financial advice and should consult with their own legal, tax, financial and other professional advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>All summaries of, and references to, the Transaction Agreement and the Plan of Arrangement in this Proxy Statement/Prospectus are qualified in their
entirety by the complete text thereof, which is set forth in Appendix B to the Proxy Statement/Prospectus. Zymeworks Securityholders are urged to read carefully the full text of the Transaction Agreement and the Plan of Arrangement. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions about the information contained in this Proxy Statement/Prospectus or require
assistance in voting your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards, please contact Zymeworks&#146; strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kingsdale Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 King Street West, Suite 2950 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toronto, Ontario M5X 1E2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call
Toll-Free (within North America): <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-476-7981</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call Collect (outside North America):
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-416-867-2272</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email at contactus@kingsdaleadvisors.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except
as otherwise indicated, references in this Proxy Statement/Prospectus to &#147;Zymeworks,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to the business and operations of Zymeworks Inc. and its subsidiaries,
which will be the business of Parent and its subsidiaries after the Redomicile Transactions, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise stated, the information
contained in this Proxy Statement/Prospectus is given as of [&#9679;], 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice Regarding Tax Consequences of Redomicile Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Shareholders should be aware that the disposition of Zymeworks Common Shares pursuant to the Redomicile Transactions, and the acquisition, holding
and disposition of shares of Delaware Common Stock or Exchangeable Shares may have tax consequences in Canada, the United States and/or in the jurisdictions in which the Zymeworks Shareholders are resident which may not be described fully herein.
The tax consequences to such Zymeworks Shareholders of the Redomicile Transactions and of holding Delaware Common Stock or Exchangeable Shares is dependent on their individual circumstances, including (but not limited to) their jurisdiction of
residence. It is recommended that Zymeworks Shareholders consult their own tax advisors in this regard. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Currency and Exchange Rates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows, for the periods and dates indicated, certain information regarding the Canadian <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">dollar-to-U.S.</FONT></FONT> dollar exchange rate. The information is based on the Bank of Canada&#146;s closing Canadian <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-to-U.S.</FONT></FONT>
dollar exchange rate. Such exchange rate on July&nbsp;8, 2022 was C$1.00 = US$0.7711. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Three months ended March&nbsp;31, 2022 (C$ per US$)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, (C$ per US$)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note: </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The average of the daily exchange rates during the relevant period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise stated, in this Proxy Statement/Prospectus, all dollar amounts are expressed in United States dollars. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defined Terms </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement/Prospectus contains
defined terms. For a glossary of defined terms used herein, see section titled &#147;<I>Glossary</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_4"></A>QUESTIONS AND ANSWERS ABOUT THE REDOMICILE TRANSACTIONS AND THE
MEETING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following questions and answers are intended to briefly address some commonly asked questions regarding the Redomicile Transactions
and the Special Meeting. These questions and answers may not address all questions that may be important to you. To better understand these matters, and for a description of the legal terms governing the Redomicile Transactions, you should carefully
read this entire Proxy Statement/Prospectus, including the attached appendices, as well as the documents that have been incorporated by reference into this Proxy Statement/Prospectus. For more information, see section titled &#147;Information
Contained in Proxy Statement/Prospectus&#148;. Capitalized terms used but not otherwise defined in the questions and answers set forth below have the meanings set forth under the heading &#147;Glossary&#148;. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Why am I receiving this Notice of Special Meeting and Proxy Statement/Prospectus? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are receiving this Notice of Special Meeting and Proxy Statement/Prospectus because you are a Zymeworks Shareholder, Zymeworks Warrantholder or a Zymeworks
Incentive Awardholder as of the Record Date. You are entitled to vote for the Redomicile Resolution at the Special Meeting to be held on [&#9679;], 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement/Prospectus, which you should read carefully, contains important information about the proposed Redomicile Transactions and how to vote at
the Special Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: When and where will the Special Meeting be held? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Special Meeting will be held on [&#9679;], 2022, at the [&#9679;], at [&#9679;],&nbsp;Pacific time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are the Redomicile Transactions? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 15,
2022, Zymeworks announced the proposed Redomicile Transactions, pursuant to which, among other things, (i)&nbsp;Zymeworks Shareholders will receive, at their election and subject to applicable eligibility criteria, either (a)&nbsp;shares of Delaware
Common Stock, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis for their Zymeworks Common Shares, or (b)&nbsp;Exchangeable Shares on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis for their Zymeworks Common Shares, or a mix of Exchangeable Shares and Delaware Common Stock in such aggregate number that is equal to the number of Zymeworks Common Shares exchanged for
them (the &#147;<B>Mixed Election</B>&#148;), subject to the Exchangeable Share Cap; (ii)&nbsp;Parent, Callco and ExchangeCo will enter into the Support Agreement; and (iii)&nbsp;Parent, Callco, ExchangeCo and Share Trustee will enter into the Trust
Agreement for the benefit of the Exchangeable Shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Does the Zymeworks Board recommend that I vote <U>FOR</U> the Redomicile Resolution?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. The Zymeworks Board recommends that Zymeworks Securityholders vote <B><U>FOR</U></B> the Redomicile Resolution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are Zymeworks&#146; reasons for the Redomicile Transactions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board, in determining that the Redomicile Transactions are in the best interests of Zymeworks, considered a number of factors as described under
&#147;<I>The Redomicile Transactions &#151; Reasons for the Redomicile Transactions</I>&#148;, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand U.S. Institutional Investor Base</B> &#151; Due to the fact that Zymeworks is a British Columbia
corporation, certain U.S. institutional investors and state-level investment vehicles are prohibited from investing in Zymeworks Common Shares or are limited in the size of such investment. Although the converse can also apply with respect to
certain Canadian institutional investors (i.e., Canadian institutional investors may face prohibitions or limitations on investing in U.S. corporations or may have adopted internal policies limiting such holdings), the Zymeworks Board believes that
becoming a Delaware corporation would provide greater opportunities to expand the institutional investor base, which would provide opportunities for increased value of Zymeworks Common Shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Index Listing</B> &#151; As a Delaware corporation, Parent may be eligible for inclusion in certain leading
indices, such as the Russell and S&amp;P indices, which could also increase demand for Parent shares through passive investment by certain index funds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acquisition Proposals </B>&#151; Delaware law provides boards of directors with additional tools for
negotiating with potential acquirors, which may assist the board in increasing the value to stockholders in any proposed strategic transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>U.S.</B> <B>Stockholder Base </B>&#151; U.S. investors have greater familiarity with Delaware corporate law
and the Zymeworks Board believes this familiarity would make Zymeworks Common Shares a more attractive investment for such investors, which could provide opportunities for increased value to current shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Comparability to U.S. Public Companies</B> &#151; Parent is a Delaware corporation. While there are
differences between the BCBCA and the DGCL and shareholders&#146; rights may be different under the DGCL than the BCBCA depending on the specific set of circumstances, the Zymeworks Board believes being incorporated in Delaware may provide greater
comparability to other U.S. public companies, many of which are incorporated in Delaware, including many of Zymeworks&#146; peer group companies. See section titled &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent
Stockholders</I>&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commercialization of Zanidatamab </B>&#151; The Zymeworks Board believes that, if zanidatamab is approved, the
United States will be a key geography for the commercialization of zanidatamab. Commercialization in the United States may require, among other things, hiring additional U.S. employees and entering into additional agreements with U.S.
counterparties. The Zymeworks Board believes that being a Delaware corporation would simplify such efforts by reducing some of the cross-border legal, regulatory and tax complexities related to these efforts. Beyond these anticipated benefits
relating to commercialization, the Zymeworks Board expects to be able to reduce certain administrative costs and complexities as a Delaware corporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand Opportunities for Future Monetization of Early-Stage Product Candidates </B>&#151; The Zymeworks Board
may in the future consider monetization opportunities for the Company&#146;s early-stage product candidates. A significant portion of potential counterparties for such transactions are located in the United States. The Zymeworks Board believes that
being a Delaware corporation would make Zymeworks more attractive to potential counterparties because it may reduce the tax, legal and regulatory complexity inherent to cross-border transactions and the potential counterparties are familiar with
Delaware corporate law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continuing Operations in Canada </B>&#151; The Redomicile Transactions would not prevent Parent from
indirectly continuing a portion of its operations in Canada through its Canadian subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board considered a number
of other factors pertaining to the Redomicile Transactions as generally supporting its decision to recommend the Redomicile Transactions, including, but not limited to, the following material factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Required Securityholder Approvals and Court Approval </B>&#151; The Redomicile Transactions will be submitted
to a vote at the Special Meeting and must be approved by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast at the Special Meeting on the Redomicile Resolution, in person or by proxy, by both
(i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately. In addition, the Redomicile Transactions are subject to
review by the Court, which will consider, among other things, the fairness and reasonableness of the Redomicile Transactions, both from a substantive and a procedural point of view. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tax Deferred Rollover</B> &#151; Zymeworks Shareholders who are Eligible Holders will have the opportunity to
elect to receive consideration that includes Exchangeable Shares instead of shares of Delaware Common Stock (subject to the Exchangeable Share Cap) with respect to all or a portion of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
their Zymeworks Common Shares and may generally make a valid tax election with ExchangeCo to defer all or part of the Canadian income tax on any capital gain that would otherwise arise on the
disposition of their Zymeworks Common Shares under the Plan of Arrangement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Market Familiarity with Redomicile Transactions </B>&#151; The Zymeworks Board believes the proposed structure
of the Redomicile Transactions is similar to that adopted by other former Canadian companies and is familiar to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>U.S. GAAP Reporting</B> &#151; Immediately prior to the Redomicile Transactions, shares of Delaware Common
Stock of Parent will be listed for trading on the NYSE. Parent will also continue to report consolidated financial results in U.S. dollars and in accordance with U.S. GAAP and will file reports with the SEC and relevant Canadian securities
regulatory authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Dissent Rights </B>- Registered Shareholders will have the ability to exercise Dissent Rights in respect of
the Redomicile Transactions and to be paid the fair value of their Zymeworks Common Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Estimated Corporate Tax Liability </B>&#151; The Zymeworks Board weighed the estimated corporate tax liability
arising from the Redomicile Transactions and, with the assistance of professional advisors and based on and subject to current assumptions, does not anticipate Zymeworks will incur material corporate-level Canadian or U.S. federal income tax
resulting from the Redomicile Transactions. Parent&#146;s effective tax rate may be affected by the Redomicile Transactions or by changes in tax laws. See section titled &#147;<I>Risk Factors</I> &#151; <I>Parent&#146;s effective tax rate may change
in the future, including as a result of the Redomicile Transactions.&#148;</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course of their deliberations, the Zymeworks
Board, in consultation with management and after considering information provided to management by Zymeworks&#146; legal, accounting and tax advisors, also considered a variety of risks (as described in greater detail under the heading &#147;<I>Risk
Factors</I>&#148;) and other potentially negative factors relating to the Redomicile Transactions, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Conditions to the Redomicile Transactions </B>&#151; The Redomicile Transactions are conditional. The
Redomicile Transactions are subject to, among other things, receipt of the Required Securityholder Approval and approval by the Court. Such conditions may not be satisfied. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Failure to Realize Benefits to the Redomicile Transactions </B>&#151; Zymeworks may fail to realize the
perceived benefits of the Redomicile Transactions. For additional discussion of this risk, see the discussion under &#147;<I>Risk Factors</I>&#148;, including &#147;&#151;<I> Zymeworks may fail to realize certain benefits of the Redomicile
Transactions, including as a result of the shares of Delaware Common Stock not being included in a U.S. stock market index</I>&#148; and &#147;<I>The Redomicile Transactions may result in sales of shares of Delaware Common Stock by certain retail
and institutional shareholders or investment funds that are not permitted to hold shares of Delaware Common Stock under their internal guidelines</I>&#148;<I>.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Uncertainty </B>&#151; Zymeworks&#146; business may be impacted by the uncertainty associated with the
Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Costs </B>&#151; Zymeworks will allocate time and resources to effecting the Redomicile Transactions and incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> costs related to the Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Redomicile Transactions May Be Deferred or Abandoned </B>&#151; Zymeworks may choose to defer or abandon the
Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Negative Publicity </B>&#151; Negative publicity resulting from the Redomicile Transactions could adversely
affect Zymeworks&#146; business and the market price of the Zymeworks Common Shares and the shares of Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Impact on Agreements </B>&#151; Completion of the Redomicile Transactions may trigger certain provisions in
agreements to which Zymeworks is a party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exercise of Dissent Rights </B>&#151; Payments in connection with the exercise of Dissent Rights by Zymeworks
Shareholders may impact Parent&#146;s financial resources. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Limitation on Enforcement Against Parent in Canada </B>&#151; Enforcement of rights against Parent in Canada
may be limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tax Impact on <FONT STYLE="white-space:nowrap">Non-Eligible</FONT> Shareholders and Eligible Holders if the
Exchangeable Share Cap is Reached </B>&#151; The disposition of Zymeworks Common Shares in exchange for shares of Delaware Common Stock in connection with the Redomicile Transactions would be taxable to Zymeworks Shareholders who are residents of
Canada other than Eligible Holders that elect to receive Exchangeable Shares (subject to the Exchangeable Share Cap) and make a valid tax election with ExchangeCo to defer all or part of the Canadian income tax on any capital gain that would
otherwise arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. If the Exchangeable Share Cap is reached, then the Exchangeable Shares will be allocated proportionally among the Eligible Holders that elect to
receive Exchangeable Shares based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder. Any remaining Zymeworks Common Shares held by those Eligible Holders will be
exchanged for Delaware Common Stock and would be taxable to the Eligible Holders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Will the business of Zymeworks change following
the Redomicile Transactions? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No. Parent will continue to pursue through its subsidiaries Zymeworks&#146; business of the development of
next-generation multifunctional biotherapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Who will be the directors and executive officers of Parent following the Redomicile Transactions?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There will be no changes to the directors or executive officers as a result of the Redomicile Transactions. Once the Redomicile Transactions are
complete, the same individuals at Zymeworks will serve in the same capacities at Parent. See section titled &#147;<I>Information Concerning Parent, ExchangeCo and Callco &#151; Directors and Officers</I><B><I> </I></B><I>of Parent</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How will the directors and executive officers of Zymeworks vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors and executive officers of Zymeworks are in favor of the Redomicile Transactions and are expected to vote <B><U>FOR</U></B> the Redomicile
Resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record Date for the Special Meeting, the directors and executive officers of Zymeworks had the right to vote approximately
[&#9679;]<B> </B>Zymeworks Common Shares, representing approximately [&#9679;]% of the Zymeworks Common Shares then issued and outstanding and entitled to vote at the Special Meeting,<B></B>&nbsp;no<B> </B>Zymeworks Warrants then issued and
outstanding and entitled to vote at the Special Meeting and<B> </B>[&#9679;]<B> </B>Zymeworks Incentive Awards, representing approximately [&#9679;]% of the Zymeworks Incentive Awards then issued and outstanding and entitled to vote at the Special
Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What will I receive for my Zymeworks Common Shares under the Redomicile Transactions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Transaction Agreement (including, in particular, the Plan of Arrangement), following completion of the Redomicile Transactions, Zymeworks
Shareholders will receive either (i)&nbsp;the same number of shares of Delaware Common Stock that they previously held in Zymeworks Common Shares immediately prior to the Redomicile Transactions, or (ii)&nbsp;in the case of Eligible Holders who have
made a valid election with respect to all or a portion of their Zymeworks Common Shares, the same number of Exchangeable Shares, or the same number of a combination of Exchangeable Shares and Delaware Common Stock, subject to the Exchangeable Share
Cap, that they previously held in Zymeworks Common Shares immediately prior to the Redomicile Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Exchangeable Share Cap is reached,
then the Exchangeable Shares shall be allocated proportionally among the applicable Eligible Holders based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder, and any
other Zymeworks Common Shares held by them will be exchanged for Delaware Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How does the Support Agreement affect the Exchangeable Shares? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Plan of Arrangement, Parent, ExchangeCo and Callco will enter into a Support Agreement that requires, among other things, that Parent issue
shares of Delaware Common Stock as consideration when the holder calls for Exchangeable Shares to be retracted by ExchangeCo, when ExchangeCo redeems Exchangeable Shares from the holder, when Callco purchases Exchangeable Shares from the
Exchangeable Shareholder under Callco&#146;s overriding call rights, or when Parent purchases Exchangeable Shares from the Exchangeable Shareholder under the automatic exchange right upon a liquidation of Parent (which may be delegated by Parent to
Callco). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Support Agreement, Parent will reserve sufficient shares of Delaware Common Stock for this purpose and will agree to certain covenants
to maintain an economic equivalence between the holders of Exchangeable Shares and holders of shares of Delaware Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Why are certain
holders eligible to receive Exchangeable Shares in lieu of shares of Delaware Common Stock? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the following paragraph, Zymeworks Shareholders
who are residents of Canada for purposes of the Tax Act (including Eligible Holders that do not make a valid tax election as discussed below) will generally realize a taxable disposition of their Zymeworks Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders who are Eligible Holders may elect to receive consideration that includes Exchangeable Shares (subject to the Exchangeable Share Cap)
with respect to all or a portion of such Zymeworks Shareholders&#146; Zymeworks Common Shares. An Eligible Holder who elects to receive Exchangeable Shares and makes a valid tax election with ExchangeCo may generally defer all or a part of the
Canadian income tax on any capital gain that would otherwise arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What happens if the Exchangeable Share Cap is reached? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the number of Exchangeable Shares to be issued to Eligible Holders exceeds the Exchangeable Share Cap, then the maximum number of Exchangeable Shares will
be allocated among the Eligible Holders on a proportional basis based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any remaining Zymeworks Common Shares held by those Eligible Holders will be exchanged for Delaware Common Stock and will be a taxable disposition of their
Zymeworks Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are the requirements to qualify as an Eligible Holder? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Eligible Holder is a Zymeworks Shareholder that is (a)&nbsp;a resident of Canada for purposes of the Tax Act and not exempt from tax under Part I of the Tax
Act, or (b)&nbsp;a partnership, each member of which is a resident of Canada for purposes of the Tax Act and not exempt from tax under Part I of the Tax Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Will the Redomicile Transactions dilute my economic interest? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No, your fully diluted relative economic ownership will not change as a result of the Redomicile Transactions. The issuance of Delaware Common Stock and
Exchangeable Shares (which are exchangeable for Delaware Common Stock) to Zymeworks Shareholders is intended to maintain the same ownership of Parent following the Redomicile Transactions (other than those who validly exercise Dissent Rights and
holders of Exchangeable Shares prior to exchanging them for Delaware Common Stock), and Parent will become the direct or indirect owner of all of the assets and liabilities of Zymeworks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Will the shares of Delaware Common Stock issued under the Redomicile Transactions be listed on an
exchange? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Shares of Delaware Common Stock will be listed on the NYSE under the symbol ZYME. See section titled &#147;<I>The Redomicile
Transactions and the Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Stock Exchange Listings</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How do I receive
shares of Delaware Common Stock or Exchangeable Shares in exchange for my Zymeworks Common Shares? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosed with this Proxy Statement/Prospectus is a
Letter of Transmittal and Election Form which is being delivered to all Registered Shareholders as of the Record Date. The Letter of Transmittal and Election Form, when duly completed, executed and returned, together with the certificate or
certificates representing the holder&#146;s Zymeworks Common Shares or surrender of book-entry Zymeworks Common Shares and any other required documents, will enable the holder to ultimately receive shares of Delaware Common Stock or Exchangeable
Shares (subject to the Exchangeable Share Cap), as applicable, for their Zymeworks Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Shareholders will receive their shares of
Delaware Common Stock and Exchangeable Shares, as applicable, through the Intermediary through which their Zymeworks Common Shares are held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
Registered Shareholder who is an Eligible Holder will have the right to elect to receive Exchangeable Shares or a mix of Exchangeable Shares and Delaware Common Stock (subject to the Exchangeable Share Cap), by delivering a duly completed Letter of
Transmittal and Election Form to the Depository prior to the Election Deadline, being 5:00 p.m. (Vancouver time) on the date before the Special Meeting. Eligible Holders who do not make an election before the Election Deadline, or for whom their
election is not properly made with respect to their Zymeworks Common Shares, will receive Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Shareholders whose Zymeworks
Common Shares are registered in the name of an Intermediary should contact that Intermediary for instructions on making an election with respect to the Consideration that they wish to receive. See &#147;Procedure for the Exchange of Shares&#148;.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders who are not Eligible Holders will not have the right to make an election and will receive Delaware Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IF YOU ARE A REGISTERED ZYMEWORKS SHAREHOLDER, YOU MUST SURRENDER YOUR ZYMEWORKS COMMON SHARES THROUGH A LETTER OF TRANSMITTAL AND ELECTION FORM BY THE DAY
THAT IS THREE YEARS LESS ONE DAY FROM THE EFFECTIVE DATE IN ORDER TO RECEIVE THE SHARES OF DELAWARE COMMON STOCK OR EXCHANGEABLE SHARES TO WHICH YOU ARE ENTITLED UNDER THE PLAN OF ARRANGEMENT. <B>ON SUCH DATE, ANY AND ALL CONSIDERATION TO WHICH SUCH
FORMER HOLDER WAS ENTITLED WILL BE DEEMED TO HAVE BEEN </B><B><U>CANCELLED</U></B><B> AND NONE OF ZYMEWORKS, PARENT, EXCHANGECO OR ANY OTHER PERSON WILL HAVE ANY OBLIGATION TO ISSUE SUCH SHARES OF DELAWARE COMMON STOCK OR EXCHANGEABLE SHARES.</B>
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Can I sell my Zymeworks Common Shares on the NYSE for cash? Is there any restriction on selling Zymeworks Common Shares prior to completion of the
Redomicile Transactions? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Common Shares will continue to trade on the NYSE up to and including the Effective Date. Immediately prior to the
Effective Time, shares of Delaware Common Stock will be listed for trading on the NYSE. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Stock Exchange
Listings</I>&#148;. Generally speaking, Registered Shareholders who have not delivered their Zymeworks Common Shares to the Depositary and beneficial owners of Zymeworks Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares whose shares are held through an Intermediary may sell their Zymeworks Common Shares through the facilities of the NYSE for cash at any time up to and including the Effective Date.
Registered Shareholders will not be able to sell their Zymeworks Common Shares once they have delivered their Zymeworks Common Shares to the Depositary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Why am I being asked to approve the Redomicile Resolution, and what vote is required to approve the Redomicile Resolution? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be effective, the Redomicile Resolution must be approved, with or without variation, by the affirmative vote of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on the Redomicile Resolution, in person or by proxy, by both (i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a
single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Required Securityholder Approvals</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Is the ability of Zymeworks to complete the Redomicile Transactions (including the Arrangement) subject to any approvals other than the Required
Securityholder Approvals? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. The Redomicile Transactions must also be approved by the Court and the Redomicile Transactions cannot proceed without
such approval. The Court will be asked to make an order approving the Redomicile Transactions and to determine that the Redomicile Transactions are fair to Zymeworks Securityholders. Zymeworks will apply to the Court for this order if the Required
Securityholder Approvals are obtained at the Special Meeting. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Certain Legal and Regulatory Matters</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What happens if the Redomicile Transactions are not completed? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Redomicile Transactions are not completed for any reason, Zymeworks Shareholders will not receive shares of Delaware Common Stock or Exchangeable Shares
and Zymeworks will continue as a public company incorporated under the laws of British Columbia, with the Zymeworks Common Shares continuing to be listed for trading on the NYSE. The Depositary will return any shares previously delivered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How will the Redomicile Transactions affect the public disclosure Zymeworks provides to its shareholders? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Redomicile Transactions, Parent will be subject to the same reporting requirements of the SEC, the mandates of the Sarbanes-Oxley Act
and the applicable corporate governance rules of the NYSE as Zymeworks was before the Redomicile Transactions. Parent will be required to file periodic reports with the SEC on Forms <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT
STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> and comply with the proxy rules applicable to domestic issuers, as currently required of Zymeworks. Parent will also generally file with the relevant Canadian
securities regulatory authorities copies of its documents filed with the SEC under the U.S. Exchange Act in order to meet its Canadian continuous disclosure obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are the Original Rights? What happens to outstanding Original Rights in connection with the Redomicile Transactions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;9, 2022, the Zymeworks Board authorized and declared a dividend distribution of one right (each, an &#147;<B>Original Right</B>&#148;) for each
outstanding Zymeworks Common Share to Zymeworks Shareholders of record as of the close of business on June&nbsp;21, 2022. Each Original Right entitles the registered holder to purchase from Zymeworks one
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Series A Participating Preferred Share, no par value (the &#147;<B>Series A Preferred Shares</B>&#148;), of Zymeworks at an exercise price of $74.00, subject to adjustment. The complete
terms of the Original Rights are set forth in a Preferred Shares Rights Agreement (the &#147;<B>Zymeworks Rights Agreement</B>&#148;), dated as of June&nbsp;9, 2022, between the Company and Computershare Trust Company, N.A., as rights agent. For
more information with respect to the Zymeworks Rights Agreement, including a summary of its terms, please refer to Zymeworks&#146; Current Report on Form 8-K filed with the SEC on June 10, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board adopted the Zymeworks Rights Agreement to protect shareholders from coercive or
otherwise unfair takeover tactics. In general terms, it works by imposing a significant penalty upon any person or group that acquires 10&nbsp;percent or more (or 20&nbsp;percent or more in the case of certain institutional investors who report
their holdings on Schedule 13G) of the Zymeworks Common Shares without the approval of the Zymeworks Board. As a result, the overall effect of the Zymeworks Rights Agreement and the issuance of the Original Rights may be to render more difficult or
discourage a merger, amalgamation, arrangement, take-over bid, tender or exchange offer or other business combination involving the Company that is not approved by the Zymeworks Board. However, neither the Zymeworks Rights Agreement nor the Original
Rights should interfere with any merger, amalgamation, arrangement, take-over bid, tender or exchange offer or other business combination approved by the Zymeworks Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, the Original Rights will be terminated and Parent expects to adopt a stockholder rights plan with respect to
the Delaware Common Stock substantively similar in all material respects to the Zymeworks Rights Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What happens to outstanding Zymeworks
Incentive Awards in connection with the Redomicile Transactions? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, Parent will assume the Zymeworks
Incentive Plans, which will become Parent Incentive Plans, and each outstanding Zymeworks Incentive Award will be assumed and be deemed to be exchanged for a Parent Incentive Award. The assumed and exchanged Zymeworks Incentive Awards will remain
subject to the terms and conditions of the Zymeworks Incentive Plans, except that the security issuable upon exercise or settlement of the Zymeworks Incentive Award, as applicable, will be shares of Delaware Common Stock rather than Zymeworks Common
Shares. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Effect of the Redomicile Transactions on the Zymeworks Incentive Awards</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What happens to outstanding Zymeworks Warrants in connection with the Redomicile Transactions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent will assume the Zymeworks Warrants in accordance with their terms, and the security issuable upon exercise will be shares of Delaware Common Stock
rather than Zymeworks Common Shares. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Effect of the Redomicile Transactions on the Zymeworks Warrants</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Are there risks associated with the Redomicile Transactions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Before making a decision on whether and how to vote, you are urged to carefully read the section entitled &#147;<I>Risk Factors</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Are the Redomicile Transactions taxable transactions to Zymeworks Shareholders? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canadian Federal Income Tax Considerations for Zymeworks Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders should carefully read the information in this Proxy Statement/Prospectus under &#147;<I>Material Canadian Federal Income Tax
Considerations</I>&#148;, which qualifies the information set out below, and should consult their own tax advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the following paragraph,
Zymeworks Shareholders who are residents of Canada for purposes of the Tax Act (including Eligible Holders that do not make a valid tax election as discussed below or that are issued Delaware Common Stock) will generally realize a taxable
disposition of their Zymeworks Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the Exchangeable Share Cap, Zymeworks Shareholders who are Eligible Holders may elect to receive
consideration that includes Exchangeable Shares with respect to all or a portion of their Zymeworks Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares. An Eligible Holder who elects to receive Exchangeable Shares and makes a valid tax election with ExchangeCo may generally defer all or a part of the Canadian income tax on any capital
gain that would otherwise arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement, subject to the limitations in the Tax Act. See section titled &#147;<I>Material Canadian Federal Income Tax Considerations &#151;
Holders Resident in Canada &#151; Exchange of Zymeworks Common Shares for Exchangeable Shares &#151; Section</I><I></I><I>&nbsp;85 Election</I>&#148; or the section titled &#147;<I>Material Canadian Federal Income Tax Considerations &#151; Holders
Resident in Canada &#151; Exchange of Zymeworks Common Shares for Exchangeable Shares and Delaware Common Stock &#151; Section</I><I></I><I>&nbsp;85 Election</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders who are not residents of Canada for purposes of the Tax Act and that do not hold their Zymeworks Common Shares as &#147;taxable
Canadian property&#148; will generally not be subject to tax under the Tax Act on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Shareholders should consult with and rely on their own tax advisors for advice with respect to the Redomicile Transactions, including:
(i)&nbsp;the income tax consequences to them of disposing of their Zymeworks Common Shares pursuant to the Redomicile Transactions and (ii)&nbsp;holding and disposing of shares of Delaware Common Stock or Exchangeable Shares, all having regard to
their own particular circumstances. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Incentive Award holders and Zymeworks Warrant holders should consult their own tax advisors for
advice with respect to the Redomicile Transactions. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The brief summary provided above is qualified in its entirety by the section
&#147;</B><B><I>Material Canadian Federal Income Tax Considerations</I></B><B>&#148; below, which provides a summary of the principal Canadian federal income tax considerations generally applicable to certain Zymeworks Shareholders as a result of
the Redomicile Transactions and of the ownership and disposition of shares of Delaware Common Stock or Exchangeable Shares received pursuant to the Redomicile Transactions, including in respect of potential dividend and withholding taxes which may
be different as compared to the tax consequences of holding Zymeworks Common Shares. Zymeworks Shareholders are urged to consult with and rely on their own tax advisors to determine the particular tax consequences to them of the Redomicile
Transactions. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Considerations for Zymeworks Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions are intended to qualify as an exchange described in Section&nbsp;351 of the Code, and subject to the discussion under the caption
heading &#147;<I>Material U.S. Federal Income Tax Considerations</I> <I>&#151; PFIC Considerations</I>&#148; below, (i)&nbsp;no gain or loss will be recognized by a U.S. holder of Zymeworks Common Shares for U.S. federal income tax purposes on the
exchange of its Zymeworks Common Shares for Delaware Common Stock in the Redomicile Transactions; (ii)&nbsp;the aggregate tax basis of the Delaware Common Stock received in the Redomicile Transactions by a U.S. holder of Zymeworks Common Shares will
be equal to the aggregate tax basis of the Zymeworks Common Shares it exchanged in the Redomicile Transactions; and (iii)&nbsp;the tax holding period of the Delaware Common Stock received in the Redomicile Transactions by a U.S. holder of Zymeworks
Common Shares will include the holding period of the Zymeworks Common Shares that it surrendered in exchange therefor in the Redomicile Transactions. The Redomicile Transactions may also qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT>
reorganization under Section&nbsp;368(a) of the Code, in which case the tax consequences to U.S. holders will generally be similar to the tax treatment of the Redomicile Transactions under Section&nbsp;351 of the Code. If the Redomicile Transactions
fail to qualify as an exchange described in Section&nbsp;351 of the Code or a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization under Section&nbsp;368(a) of the Code, U.S. holders of Zymeworks Common Shares would be treated as if they
sold their Zymeworks Common Shares in a fully taxable transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The brief U.S. tax summary provided above is qualified in its entirety by the
section &#147;</B><B><I>Material U.S. Federal Income Tax Considerations</I></B><B>&#148; below, which provides a summary of the material U.S. federal income tax </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
considerations generally applicable to (i)&nbsp;U.S. holders participating in the Redomicile Transactions, and (ii)&nbsp;to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders regarding the
ownership and disposition of shares of Delaware Common Stock received by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders pursuant to the Redomicile Transactions. Zymeworks Shareholders are urged to consult with and rely on their own tax
advisors to determine the particular tax consequences to them of the Redomicile Transactions as well as the tax consequences of the ownership and disposition of shares of Delaware Common Stock or Exchangeable Shares received pursuant to the
Redomicile Transactions. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What are the corporate tax consequences of the Redomicile Transactions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canadian Federal Income Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Canadian
federal income tax purposes, Zymeworks does not expect the Redomicile Transactions to give rise to corporate-level Canadian federal income tax for Zymeworks or Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. federal
income tax purposes, Zymeworks does not expect the Redomicile Transactions to give rise to corporate-level U.S. federal income tax for Zymeworks or Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: When will the Redomicile Transactions become effective? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the satisfaction or waiver of all other conditions precedent, if the Required Securityholder Approvals are obtained as described above, it is
anticipated that the Redomicile Transactions will be completed as soon as practicable following the final approval of the Court of the Redomicile Transactions under the Final Order. It is also anticipated that the shares of Delaware Common Stock
will be listed for trading on the NYSE immediately prior to the Effective Date. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Stock Exchange Listings</I>&#148;.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Who is entitled to vote at the Special Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only Zymeworks Securityholders of record at the close of business on [&#9679;], 2022 (the &#147;<B>Record Date</B>&#148;), are entitled to notice of the
Special Meeting and to vote thereat or at any adjournment or postponement thereof. As of the close of business on the Record Date, [&#9679;] Zymeworks Common Shares, [&#9679;] Zymeworks Warrants and [&#9679;]&nbsp;Zymeworks<B> </B>Incentive
Awards<B> </B>were issued and outstanding. Each issued and outstanding Zymeworks Common Share, Zymeworks Warrant and Zymeworks Incentive Award on the Record Date is entitled to one vote on each of the resolutions to be considered and voted on at the
Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote is very important, regardless of the number of Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards that
you own. Whether or not you expect to attend, you should authorize a proxyholder to vote your Zymeworks Common Shares, Zymeworks Warrants and Zymeworks Incentive Awards<B> </B>as promptly as possible so that your Zymeworks Common Shares, Zymeworks
Warrants and Zymeworks Incentive Awards may be represented and voted at the Special Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What is the quorum for the Special Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order for business to be conducted at the Special Meeting, a quorum must be present. A quorum for the Special Meeting requires at least 30% of the Zymeworks
Common Shares entitled to vote be present or represented by proxy and at least two persons entitled to vote at the Special Meeting be present or represented by proxy. While Zymeworks Warrantholders and Zymeworks Incentive Awardholders will be
entitled to vote at the Special Meeting as described elsewhere in this Proxy Statement/Prospectus, there is no separate quorum requirement for them under the BCBCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders who submit a properly executed form of proxy or vote by telephone or the Internet
will be considered part of the quorum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How do I vote my Zymeworks Common Shares, Zymeworks Warrants and Zymeworks Incentive Awards? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a registered Zymeworks Shareholder or a Zymeworks Warrantholder or a Zymeworks Incentive Awardholder, there are a number of ways you can vote your
Common Shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In Person: You may vote in person at the Special Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Mail: You may sign the enclosed form of proxy appointing the named persons or some other person you choose,
who need not be a shareholder, to represent you as proxyholder and vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards at the Special Meeting. Return the form of proxy by mail to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Computershare Investor Services </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">100 University Avenue, 8th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Toronto, Ontario </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">M5J 2Y1 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Telephone: Zymeworks Securityholders located in Canada or in the United States may vote by telephone by
calling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-732-8683.</FONT></FONT></FONT> You will need to enter the <FONT STYLE="white-space:nowrap">15-digit</FONT> control number provided on
the form of proxy to vote your Common Shares over the phone. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Internet: You may vote over the Internet by going to www.investorvote.com. You will need to enter the <FONT
STYLE="white-space:nowrap">15-digit</FONT> control number provided on the form of proxy to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards over the internet. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Voting by telephone or on the Internet is fast, convenient and your vote is immediately confirmed and tabulated.
If you choose to vote by telephone or on the Internet, instructions to do so are set forth on the form of proxy. The telephone and Internet voting procedures are designed to authenticate votes cast by use of a control number, which appears on the
form of proxy. These procedures allow Zymeworks Securityholders to appoint a proxy to vote their Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards and to confirm that their instructions have been properly recorded. If you
vote by telephone, you will not be able to appoint a proxyholder. If you vote by telephone or on the Internet, your vote must be received by 1:00&nbsp;pm (Toronto time), on [&#9679;], 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Zymeworks or its strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors, may utilize the Broadridge QuickVote<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> service to assist <FONT STYLE="white-space:nowrap">non-registered</FONT> Shareholders with voting their Common Shares over the telephone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial Zymeworks Shareholder, the Intermediary (usually a bank, trust company, broker, securities dealer or other financial institution)
through which you hold your Zymeworks Common Shares will send you instructions on how to vote your Zymeworks Common Shares. Please follow the instructions on your voting instruction form. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What will happen if I abstain from voting or fail to vote at the Special Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards that you own as the holder of record will be voted as you instruct on your proxy
card. If you return your proxy with instructions to abstain from voting, such abstention has the legal effect of a vote &#147;AGAINST&#148; the Redomicile Resolution. For Zymeworks Shareholders, proxies with instructions to abstain from voting will
be counted for purposes of determining whether a quorum is present at the Special Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you do not timely return your proxy card, your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks
Incentive Awards will not be voted unless you or your proxyholder attends the Special Meeting and votes in person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What is a proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proxy is your legal designation of another person, referred to as a &#147;proxyholder&#148;, to vote your Zymeworks Common Shares, Zymeworks Warrants or
Zymeworks Incentive Awards. The document used to designate a proxyholder to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards is called a &#147;form of proxy.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Can I appoint someone other than the person(s) designated by management of Zymeworks to vote my Zymeworks Common Shares, Zymeworks Warrants or Zymeworks
Incentive Awards? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following applies to Zymeworks Shareholders, Zymeworks Warrantholders or Zymeworks Incentive Awardholders who wish to appoint
someone as their proxyholder other than the persons designated in the enclosed form of proxy or voting instruction form. This includes <FONT STYLE="white-space:nowrap">non-registered</FONT> Zymeworks Shareholders who wish to appoint themselves as
proxyholder to attend, participate or vote at the Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may appoint a person or company to represent you at the Special Meeting other than
the persons assigned in the form of proxy. Write the name of this person, who need not be a shareholder, in the blank space provided in the form of proxy. It is important to ensure that any other person you appoint is attending the Special Meeting
and is aware that he or she has been appointed to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards. Proxyholders should, upon arrival at the Special Meeting, register with Computershare. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: If I am not going to attend the Special Meeting, should I return my form of proxy or otherwise vote my Zymeworks Common Shares, Zymeworks Warrants or
Zymeworks Incentive Awards? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Completing, signing, dating and returning the form of proxy by mail, submitting a proxy by calling the number shown
on the form of proxy or submitting a proxy by visiting the website shown on the form of proxy ensures that your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards will be represented and voted at the Special Meeting, even if
you otherwise do not attend. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: What is the deadline to provide my proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be valid, proxies must be deposited with Computershare Investor Services Inc., Proxy Department, 100 University Avenue, 8th Floor, Toronto, Ontario, M5J
2Y1, before [&#9679;] p.m. (Pacific time) on [&#9679;], or if the Special Meeting is adjourned or postponed, no later than [&#9679;] p.m. (Pacific time) on the second business day preceding the day to which the Special Meeting is adjourned or
postponed. Notwithstanding the foregoing, the Chair of the Special Meeting has the discretion to accept proxies received after such deadline and the time limit for deposit of proxies may be waived or extended by the Chair of the Special Meeting at
his or her discretion, without notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Can I change or revoke my vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. If your Zymeworks Common Shares are registered in your name or you are a Zymeworks Incentive Awardholder or a Zymeworks Warrantholder, you can change or
revoke a previously delivered proxy in the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Send a written notice that is received by the deadline specified below stating that you revoke your proxy to the
Corporation&#146;s Corporate Secretary at the following address: 114 East 4th Avenue, Suite 800, Vancouver BC, Canada V5T 1G4. The statement must be signed by you or your attorney as authorized in writing or, if the shareholder is a corporation,
signed under its corporate seal or by a duly authorized officer or attorney of the corporation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you sent a form of proxy by mail, complete a new form of proxy bearing a later date and properly submit it so
that it is received before the deadline set forth below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Log onto the Internet website specified on the form of proxy in the same manner you would to submit your proxy
electronically or call the toll-free number specified on the form of proxy prior to the Special Meeting, in each case if you are eligible to do so, and follow the instructions on the form of proxy; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Appear in person at the Special Meeting, declare your prior proxy to be revoked and then vote in person at the
Special Meeting (although merely attending the Special Meeting will not revoke your proxy). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any revocation of a proxy must be delivered
either to the registered office of Zymeworks at any time up to and including the last business day preceding the day of the Special Meeting or any adjournment or postponement of the Special Meeting, or to the Chair of the Zymeworks Board on the day
of the Special Meeting, [&#9679;], 2022, or any adjournment or postponement of the Special Meeting, prior to the time of the Special Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: If my
Zymeworks Common Shares are held in &#147;street name&#148; by my broker, bank or other nominee, will my broker, bank or other nominee automatically vote my shares for me? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No. If your Zymeworks Common Shares are held in the name of a broker, bank or other nominee, you will receive separate instructions from your broker, bank or
other nominee describing how to vote your shares. Please check with your broker, bank or other nominee and follow the voting procedures provided by your broker, bank or other nominee on your voting instruction form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should instruct your broker, bank or other nominee how to vote your Zymeworks Common Shares. Under the rules applicable to broker-dealers, your broker,
bank or other nominee does not have discretionary authority to vote your shares in respect of the Redomicile Resolution. A <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;broker <FONT STYLE="white-space:nowrap">non-vote&#148;</FONT> results
when banks, brokers and other nominees return a valid proxy voting upon a matter or matters for which the applicable rules provide discretionary authority but do not vote on a particular proposal because they do not have discretionary authority to
vote on the matter and have not received specific voting instructions from the beneficial owner of such shares. Zymeworks does not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> at the Special Meeting because the rules
applicable to banks, brokers and other nominees only provide brokers with discretionary authority to vote on proposals that are considered routine, whereas the Redomicile Resolution to be presented at the Special Meeting is considered <FONT
STYLE="white-space:nowrap">non-routine.</FONT> As a result, no broker will be permitted to vote your Zymeworks Common Shares at the Special Meeting without receiving instructions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Who is making and paying for this proxy solicitation? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is making this proxy solicitation and will pay for all of the costs of soliciting these proxies. Its directors and certain of its employees may
solicit proxies in person or by telephone, fax or email. Zymeworks will pay these employees and directors no additional compensation for these services. Zymeworks has retained the services of the Proxy Solicitor to solicit proxies. Zymeworks will
deliver proxy-related materials to nominees, custodians and fiduciaries, and they will be asked to promptly forward them to the beneficial <FONT STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks Shareholders. Zymeworks will also reimburse
such nominees, custodians and fiduciaries for their expenses in sending proxy-related materials to the beneficial <FONT STYLE="white-space:nowrap">(non-registered)</FONT> Zymeworks Shareholders and obtaining their proxies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: How will shares of Delaware Common Stock of Parent differ from Zymeworks Common Shares? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of differences between Delaware law and the BCBCA, there will be differences between your rights as a stockholder of Parent under Delaware law and
your current rights as a shareholder of Zymeworks under the BCBCA. In addition, there are differences between the organizational documents of Zymeworks and Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These differences are discussed in detail under &#147;<I>Comparison of Rights of Zymeworks Shareholders and
Parent Stockholders</I>&#148;. Also refer to &#147;<I>Description of Parent Capital Stock</I>&#148; for a description of the shares of Delaware Common Stock. The Parent Certificate of Incorporation and Parent Bylaws, in the form substantially as
they will be in effect upon completion of the Redomicile Transactions, are attached as Appendices F and G, respectively, of this Proxy Statement/Prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Are Zymeworks Shareholders entitled to Dissent Rights? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. Under the Interim Order, Registered Shareholders are entitled to Dissent Rights if they strictly follow the procedures set out in Division 2 of Part 8 of
the BCBCA, as may be modified by the Interim Order, the Plan of Arrangement and any further order of the Court. Persons who are beneficial owners of Zymeworks Common Shares registered in the name of an Intermediary who wish to dissent should be
aware that only Registered Shareholders are entitled to Dissent Rights. Accordingly, a beneficial owner of Zymeworks Common Shares desiring to exercise Dissent Rights must make arrangements for the Zymeworks Common Shares beneficially owned by such
Zymeworks Shareholder to be registered in the Zymeworks Shareholder&#146;s name prior to the time the Dissent Notice is required to be received by Zymeworks, or, alternatively, make arrangements for the registered holder of such Zymeworks Common
Shares to dissent on the Zymeworks Shareholder&#146;s behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply strictly with the requirements set forth in Division 2 of Part 8 of the
BCBCA as may be modified by the Interim Order, the Plan of Arrangement, and any other order of the Court may result in the loss of any right to dissent. It is strongly suggested that any Zymeworks Shareholder wishing to dissent seek independent
legal advice. Be sure to read the section entitled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Dissent Rights</I>&#148; and consult your own legal advisor if you wish to exercise Dissent Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q: Who can answer my questions? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any
questions about the information contained in this Proxy Statement/Prospectus or require assistance in completing your form of proxy or voting instruction form, please contact Zymeworks&#146; strategic shareholder advisor and proxy solicitation
agent, Kingsdale Advisors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kingsdale Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 King Street West, Suite 2950 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toronto, Ontario M5X 1E2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call
Toll-Free (within North America): <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-476-7981</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call Collect (outside North America):
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-416-867-2272</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email at contactus@kingsdaleadvisors.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Q:
Where can I find more information about Zymeworks and the transactions contemplated by the Plan of Arrangement? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can find out more information
about Zymeworks and the transactions contemplated by the Plan of Arrangement by reading this Proxy Statement/Prospectus and from various sources described in the section entitled <I>&#147;Where You Can Find More Information</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_5"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of certain information contained elsewhere in this Proxy Statement/Prospectus. This summary is qualified in its entirety by the
more detailed information appearing elsewhere in this Proxy Statement/Prospectus, including the appendices hereto and the documents incorporated by reference herein. It is recommended that Zymeworks Securityholders carefully read this Proxy
Statement/Prospectus and consult with their own legal, tax, financial and other professional advisors with respect to the matters to be acted on at the Special Meeting. Capitalized terms used but not otherwise defined in this summary have the
meanings set forth under the heading &#147;<I>Glossary</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Date, Time and Place </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Special Meeting will be
held on [&#9679;], 2022, at the [&#9679;], at [&#9679;],&nbsp;Pacific time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Meeting Record Date and Zymeworks Securityholders Entitled to
Vote </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Zymeworks Securityholders of record at the close of business on [&#9679;], 2022, which is the Record Date for the Special Meeting, are
entitled to notice of the Special Meeting and to vote thereat or at any adjournment or postponement thereof. As of the close of business on the Record Date, [&#9679;] Zymeworks Common Shares, [&#9679;] Zymeworks Warrants and [&#9679;] Zymeworks
Incentive Awards were issued and outstanding. Each issued and outstanding Zymeworks Common Share is entitled to one vote on each of the resolutions to be considered and voted on at the Special Meeting. Each Zymeworks Warrant and Zymeworks Incentive
Award is entitled to one vote on the resolutions to be considered and voted on at the Special Meeting for each Zymeworks Common Share underlying the respective Zymeworks Warrant and Zymeworks Incentive Award, respectively, which will be voted
together with the holders of the Zymeworks Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote of Directors, Executive Officers and Affiliates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions must be approved by an affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes
cast at the Special Meeting on the Redomicile Resolution, in person or by proxy, by both (i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks
Shareholders, voting separately. As of the Record Date, directors, executive officers and their affiliates own [&#9679;]% of Zymeworks Common Shares, [&#9679;]% Zymeworks Incentive Awards and no warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To conduct business at the Special
Meeting, a quorum consisting of at least 30% of the Zymeworks Common Shares entitled to vote must be present or represented by proxy and at least two persons entitled to vote at the Special Meeting must be present or represented by proxy. If you
submit a properly executed form of proxy or vote by telephone or the Internet, you will be considered part of the quorum. While Zymeworks Warrantholders and Zymeworks Incentive Awardholders will be entitled to vote at the Special Meeting as
described elsewhere in this Proxy Statement/Prospectus, there is no separate quorum requirement for them under the BCBCA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purpose of the Special
Meeting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Special Meeting is for Zymeworks Securityholders to consider and, if thought advisable, to approve, with or without
variation, the Redomicile Resolution with respect to the Redomicile Transactions </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to which, among other things, (i)&nbsp;Zymeworks Shareholders will receive, at their election and subject to applicable eligibility criteria, for their Zymeworks Common Shares, either
(a)&nbsp;shares of Delaware Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or (b)&nbsp;Exchangeable Shares on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or a mix of Exchangeable Shares and Delaware Common Stock (in such aggregate number that is equal to the number of Zymeworks Common Shares exchanged
for them), subject to the Exchangeable Share Cap; (ii)&nbsp;Parent, Callco and ExchangeCo will enter into the Support Agreement; and (iii)&nbsp;Parent, ExchangeCo, Callco and Share Trustee will enter into the Trust Agreement for the benefit of the
Exchangeable Shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Redomicile Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions are being implemented in accordance with the terms of and subject to the conditions contained in the Transaction Agreement
(including, with respect to the Arrangement, the Plan of Arrangement). If approved by the Zymeworks Securityholders in the manner described herein, Zymeworks expects that the Redomicile Transactions will be completed as soon as practicable following
the approval of the Court in respect of the Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The result of the Redomicile Transactions will be that, among other things (i)&nbsp;Parent will
become the direct or indirect owner of all of the assets and liabilities of Zymeworks, (ii)&nbsp;Zymeworks Incentive Awardholders will hold Parent Incentive Awards identical to the Zymeworks Incentive Awards in all material respects but in respect
of Delaware Common Stock in the place and stead of Zymeworks Common Shares, (iii)&nbsp;Zymeworks Warrantholders will be entitled to receive Delaware Common Stock instead of Zymeworks Common Shares under their Zymeworks Warrants, and
(iv)&nbsp;Zymeworks Shareholders (other than Dissenting Shareholders) will hold one share of Delaware Common Stock or one Exchangeable Share, as applicable, for each Zymeworks Common Share owned immediately prior to the Redomicile Transactions (with
the aggregate number of Exchangeable Shares being equal to or less than the Exchangeable Share Cap). If the Exchangeable Share Cap is reached, then the Exchangeable Shares shall be allocated proportionally among the applicable Exchangeable
Shareholders based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder, in which case, the Eligible Holder will also be issued Delaware Common Stock under a Mixed
Election. All Exchangeable Shares issued under the Arrangement will be issued by ExchangeCo in reliance on the exemption from the registration requirements of the Securities Act provided by Section&nbsp;3(a)(10) thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning Parent, ExchangeCo and Callco </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent was incorporated on June&nbsp;30, 2022 as a Delaware corporation. Parent does not currently conduct any business. Following completion of the Redomicile
Transactions, Parent and its subsidiaries (including Zymeworks) will carry on the business currently conducted by Zymeworks and its subsidiaries. In connection with the Redomicile Transactions, Parent will rename itself as Zymeworks Inc. and
Zymeworks will rename itself Zymeworks BC Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent&#146;s principal executive offices are located at 108 Patriot Drive, Suite A, Middletown, Delaware
19709, and its telephone number is (302) <FONT STYLE="white-space:nowrap">274-8744.</FONT> Following the Redomicile Transactions, Parent will continue to consider this address and telephone number as its principal executive offices. Parent will have
physical operations and personnel in Canada and the United States, and will maintain offices in both countries. In addition, as a result of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic Zymeworks has implemented and expects
to continue implementing hybrid and virtual-only working arrangements. Its executive officers and directors will be located in several jurisdictions, including the United States, Canada and the United Kingdom. Accordingly Parent does not believe
that designating either its Vancouver or Seattle offices as the principal executive offices is appropriate. Parent intends to hold an annual meeting of stockholders, including for the election of directors, following completion of the Redomicile
Transactions. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ExchangeCo is a corporation incorporated under the <I>Business Corporations Act</I> (British Columbia) on
July 13, 2022 for the purpose of implementing the Arrangement. To date, ExchangeCo has not carried on any business except in connection with its role as a party to the Transaction Agreement. ExchangeCo is a direct wholly-owned subsidiary of Callco.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Callco is an unlimited liability company incorporated under the <I>Business Corporations Act</I> (British Columbia) on July 13, 2022. To date, Callco has
not carried on any business except in connection with its role as a party to the Transaction Agreement. Callco is a wholly-owned subsidiary of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See section titled &#147;<I>Information Concerning Parent, ExchangeCo and Callco</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning Zymeworks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is a
clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks&#146; suite of complementary therapeutic platforms and its fully integrated drug development engine provide the
flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. These capabilities have resulted in multiple product candidates with the potential to drive positive outcomes in large underserved and
unaddressed patient populations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is a public company trading on the NYSE under the symbol &#147;ZYME&#148;. Zymeworks was incorporated on
September&nbsp;8, 2003 under the Canada Business Corporations Act under the name &#147;Zymeworks Inc.&#148; On October&nbsp;22, 2003, Zymeworks was registered as an extra-provincial company under the Company Act (British Columbia), the predecessor
to the BCBCA. On May&nbsp;2, 2017, Zymeworks continued the Company to British Columbia under the BCBCA. Zymeworks&#146; principal office is located at 114 East 4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Avenue, Suite 800, Vancouver,
British Columbia, Canada, V5T 1G4, and its telephone number is (604) <FONT STYLE="white-space:nowrap">678-1388.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Parent, Zymeworks
has five wholly owned subsidiaries: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks Biopharmaceuticals Inc., located in Seattle, Washington; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks Management Inc., located in Vancouver, British Columbia; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Callco, located in Vancouver, British Columbia; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ExchangeCo, located in Vancouver, British Columbia; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks Biopharmaceuticals Limited, located in Dublin, Ireland. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information about Zymeworks can be found under its profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its
website at www.zymeworks.com. The information contained in, or that can be accessed through, Zymeworks&#146; website is not incorporated into this Proxy Statement/Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See section titled &#147;<I>Information Concerning Zymeworks</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Zymeworks Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At its meeting
held on July 14, 2022, after careful consideration of, among other things, the advice of management and after considering information provided to management by its tax, accounting and legal advisors, and such other matters as it considered relevant,
the Zymeworks Board determined that the Redomicile Transactions are in the best interests of Zymeworks. Accordingly, the Zymeworks Board recommends that Zymeworks Securityholders vote <B><U>FOR</U></B> the Redomicile Resolution. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Recommendation of
the Zymeworks Board</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the Redomicile Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board determined that the Redomicile Transactions (including the Plan of Arrangement and the transactions to be completed as soon as practicable
following the Arrangement as set forth in the Transaction Agreement) are in the best interests of Zymeworks and believes that the opportunity to enhance long-term value for shareholders will be greater as a Delaware corporation than as a British
Columbia corporation. In recommending that Zymeworks Securityholders vote in favor of the Redomicile Resolution, the Zymeworks Board considered and relied upon a number of factors, including, among other things, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand U.S. Institutional Investor Base</B> &#151; Due to the fact that Zymeworks is a British Columbia
corporation, certain U.S. institutional investors and state-level investment vehicles are prohibited from investing in Zymeworks Common Shares or are limited in the size of such investment. Although the converse can also apply with respect to
certain Canadian institutional investors (i.e., Canadian institutional investors may face prohibitions or limitations on investing in U.S. corporations or may have adopted internal policies limiting such holdings), the Zymeworks Board believes that
becoming a Delaware corporation would provide greater opportunities to expand the institutional investor base, which would provide opportunities for increased value of Zymeworks Common Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Index Listing</B> &#151; As a Delaware corporation, Parent may be eligible for inclusion in certain leading
indices, such as the Russell and S&amp;P indices, which could also increase demand for Parent shares through passive investment by certain index funds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acquisition Proposals </B>&#151; Delaware law provides boards of directors with additional tools for
negotiating with potential acquirors, which may assist the board in increasing the value to stockholders in any proposed strategic transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>U.S.</B> <B>Stockholder Base </B>&#151; U.S. investors have greater familiarity with Delaware corporate law
and the Zymeworks Board believes this familiarity would make Zymeworks Common Shares a more attractive investment for such investors, which could provide opportunities for increased value to current shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Comparability to U.S. Public Companies</B> &#151; Parent is a Delaware corporation. While there are
differences between the BCBCA and the DGCL and shareholders&#146; rights may be different under the DGCL than the BCBCA depending on the specific set of circumstances, the Zymeworks Board believes being incorporated in Delaware may provide greater
comparability to other U.S. public companies, many of which are incorporated in Delaware, including many of Zymeworks&#146; peer group companies. See section titled &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent
Stockholders</I>&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commercialization of Zanidatamab </B>&#151; The Zymeworks Board believes that, if zanidatamab is approved, the
United States will be a key geography for the commercialization of zanidatamab. Commercialization in the United States may require, among other things, hiring additional U.S. employees and entering into additional agreements with U.S.
counterparties. The Zymeworks Board believes that being a Delaware corporation would simplify such efforts by reducing some of the cross-border legal, regulatory and tax complexities related to these efforts. Beyond these anticipated benefits
relating to commercialization, the Zymeworks Board expects to be able to reduce certain administrative costs and complexities as a Delaware corporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand Opportunities for Future Monetization of Early-Stage Product Candidates </B>&#151; The Zymeworks Board
may in the future consider monetization opportunities for the Company&#146;s early-stage product candidates. A significant portion of potential counterparties for such transactions are located in the United States. The Zymeworks Board believes that
being a Delaware corporation would </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
make Zymeworks more attractive to potential counterparties because it may reduce the tax, legal and regulatory complexity inherent to cross-border transactions and the potential counterparties
are familiar with Delaware corporate law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continuing Operations in Canada </B>&#151; The Redomicile Transactions would not prevent Parent from
indirectly continuing a portion of its operations in Canada through its Canadian subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board considered a number
of other factors pertaining to the Redomicile Transactions as generally supporting its decision to recommend the Redomicile Transactions, including, but not limited to, the following material factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Required Securityholder Approvals and Court Approval </B>&#151; The Redomicile Transactions will be submitted
to a vote at the Special Meeting and must be approved by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast at the Special Meeting on the Redomicile Resolution, in person or by proxy, by both
(i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately. In addition, the Redomicile Transactions are subject to
review by the Court, which will consider, among other things, the fairness of the Redomicile Transactions, both from a substantive and a procedural point of view. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tax Deferred Rollover</B> &#151; Zymeworks Shareholders who are Eligible Holders will have the opportunity to
elect to receive consideration that includes Exchangeable Shares instead of shares of Delaware Common Stock (subject to the Exchangeable Share Cap) with respect to all or a portion of their Zymeworks Common Shares and may generally make a valid tax
election with ExchangeCo to defer all or part of the Canadian income tax on any capital gain that would otherwise arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Market Familiarity with Redomicile Transactionss </B>&#151; The Zymeworks Board believes the proposed
structure of the Redomicile Transactions is similar to that adopted by other former Canadian companies and is familiar to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>U.S. GAAP Reporting</B> &#151; Immediately prior to the Redomicile Transactions, shares of Delaware Common
Stock of Parent will be listed for trading on the NYSE. Parent will also continue to report consolidated financial results in U.S. dollars and in accordance with U.S. GAAP and will file reports with the SEC and relevant Canadian securities
regulatory authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Dissent Rights </B>&#151; Registered Shareholders will have the ability to exercise Dissent Rights in respect
of the Redomicile Transactions and to be paid the fair value of their Zymeworks Common Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Estimated Corporate Tax Liability </B>&#151; The Zymeworks Board weighed the estimated corporate tax liability
arising from the Redomicile Transactions and, with the assistance of professional advisors and based on and subject to current assumptions, does not anticipate Zymeworks will incur material corporate-level Canadian or U.S. federal income tax
resulting from the Redomicile Transactions. Parent&#146;s effective tax rate may be affected by the Redomicile Transactions or by changes in tax laws. See section titled &#147;<I>Risk Factors</I> &#151; <I>Parent&#146;s effective tax rate may change
in the future, including as a result of the Redomicile Transactions.&#148;</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course of their deliberations, the Zymeworks
Board, in consultation with management and after considering information provided to management by Zymeworks&#146; legal, accounting and tax advisors, also considered a variety of risks (as described in greater detail under the heading &#147;<I>Risk
Factors</I>&#148;) and other potentially negative factors relating to the Redomicile Transactions, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Conditions to the Redomicile Transactions </B>&#151; The Redomicile Transactions are conditional. The
Redomicile Transactions are subject to, among other things, receipt of the Required Securityholder Approval and approval by the Court. Such conditions may not be satisfied. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Failure to Realize Benefits to the Redomicile Transactions </B>&#151; Zymeworks may fail to realize the
perceived benefits of the Redomicile Transactions. For additional discussion of this risk, see the discussion under &#147;Risk Factors&#148;, including &#147;&#151;<I> Zymeworks may fail to realize certain benefits of the Redomicile Transactions,
including as a result of the shares of Delaware Common Stock not being included in a U.S. stock market index</I>&#148; and &#147;<I>The Redomicile Transactions may result in sales of shares</I> <I>of Delaware Common Stock by certain retail and
institutional shareholders or investment funds that are not permitted to hold shares of Delaware Common Stock under their internal guidelines.</I>&#148;<I>.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Uncertainty </B>&#151; Zymeworks&#146; business may be impacted by the uncertainty associated with the
Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Costs </B>&#151; Zymeworks will allocate time and resources to effecting the Redomicile Transactions and incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> costs related to the Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Redomicile Transactions May Be Deferred or Abandoned </B>&#151; Zymeworks may choose to defer or abandon the
Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Negative Publicity </B>&#151; Negative publicity resulting from the Redomicile Transactions could adversely
affect Zymeworks&#146; business and the market price of the Zymeworks Common Shares and the shares of Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Impact on Agreements </B>&#151; Completion of the Redomicile Transactions may trigger certain provisions in
agreements to which Zymeworks is a party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exercise of Dissent Rights </B>&#151; Payments in connection with the exercise of Dissent Rights by Zymeworks
Shareholders may impact Parent&#146;s financial resources. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Limitation on Enforcement Against Parent in Canada </B>&#151; Enforcement of rights against Parent in Canada
may be limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tax Impact on <FONT STYLE="white-space:nowrap">Non-Eligible</FONT> Shareholders and Eligible Holders if the
Exchangeable Share Cap is Reached </B>&#151; The disposition of Zymeworks Common Shares in exchange for shares of Delaware Common Stock in connection with the Redomicile Transactions would be taxable to Zymeworks Shareholders who are residents of
Canada other than Eligible Holders that elect to receive Exchangeable Shares (subject to the Exchangeable Share Cap) and make a valid tax election with ExchangeCo to defer all or part of the Canadian income tax on any capital gain that would
otherwise arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. If the Exchangeable Share Cap is reached, then the Exchangeable Shares will be allocated proportionally among the Eligible Holders that elect to
receive Exchangeable Shares based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder. Any remaining Zymeworks Common Shares held by those Eligible Holders will be
exchanged for Delaware Common Stock in a transaction generally treated as a taxable disposition of their Zymeworks Common Shares and would be taxable to the Eligible Holders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Reasons for the Redomicile Transactions</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions and the
transactions contemplated by the Transaction Agreement involve risks, some of which are related to the Redomicile Transactions and others of which are related to Zymeworks&#146; business and Parent&#146;s business. In considering the Redomicile
Transactions and the transactions contemplated by the Transaction Agreement, including whether to vote for the Redomicile Resolution, Zymeworks Securityholders should carefully consider the information about these risks set forth under the section
entitled </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<I>Risk Factors</I>&#148;, as well as the other information contained in and incorporated by reference into this Proxy Statement/Prospectus, and specifically, the factors described in the
section entitled &#147;Item 1A. Risk Factors&#148; in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Zymeworks for the year ended December&nbsp;31, 2021 and the Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rights of stockholders under Delaware law may differ from the rights of shareholders under the BCBCA.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delaware law and provisions in the Parent Certificate of Incorporation and Parent Bylaws might delay, discourage
or prevent a change in control of Parent or changes in its management, thereby depressing the market price of the Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Parent Bylaws will designate a state or federal court located within the State of Delaware as the exclusive
forum for substantially all disputes between Parent and its stockholders, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, each of
which could limit Parent&#146;s stockholders&#146; ability to choose the judicial forum for disputes with Parent or its directors, officers, stockholders or employees. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There has been no prior public trading for the shares of Delaware Common Stock on a national securities exchange
and the market price of the shares of Delaware Common Stock may be subject to volatility. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parent may need to enter into certain new arrangements which may not be on terms as favorable as arrangements
entered into by Zymeworks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parent&#146;s ability to pay dividends in the future is not guaranteed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The issuance of additional shares of Delaware Common Stock in connection with future equity financings,
acquisitions or growth opportunities, any Parent Incentive Plan or otherwise may dilute all other shareholdings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks may fail to realize certain benefits of the Redomicile Transactions, including as a result of the
shares of Delaware Common Stock not being included in a U.S. stock market index. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Redomicile Transactions may result in sales of shares of Delaware Common Stock by certain retail and
institutional shareholders or investment funds that are not permitted to hold shares of Delaware Common Stock under their internal guidelines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; business may be impacted by the uncertainty associated with the Redomicile Transactions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Redomicile Transactions are conditional, and the conditions may not be satisfied. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Distributions to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders of Delaware Common Stock may be subject
to U.S. withholding. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parent&#146;s effective tax rate may change in the future, including as a result of the Redomicile Transactions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks will allocate time and resources to effecting the Redomicile Transactions and incur <FONT
STYLE="white-space:nowrap">non-recurring</FONT> costs related to the Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks may choose to defer or abandon the Redomicile Transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Negative publicity resulting from the Redomicile Transactions could adversely affect Zymeworks&#146; business and
the market price of the Zymeworks Common Shares and the shares of Delaware Common Stock. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of the Redomicile Transactions may trigger certain provisions in agreements to which Zymeworks is a
party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Payments in connection with the exercise of Dissent Rights by Zymeworks Shareholders may impact Parent&#146;s
financial resources. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enforcement of rights against Parent in Canada may be limited. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Exchangeable Shares will not be listed on any stock exchange. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks Shareholders who elect to receive Exchangeable Shares will experience a delay in receiving Delaware
Common Stock from the date they request an exchange, which may affect the value of the shares the holder receives in such exchange. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There may be a taxable event for an Eligible Holder as a result of a transaction beyond such Eligible
Holder&#146;s control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Receipt of Delaware Common Stock by Eligible Holders who do not elect to receive all Exchangeable Shares will be
a taxable event for Canadian income tax purposes, and could also be a taxable event for Zymeworks Shareholders who are not U.S. holders (as defined below) in their home jurisdiction. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Comparative Per Share Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparative Per Share Data of Zymeworks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the closing market price per Zymeworks Common Share as reported by the NYSE on July 14, 2022, the last trading
day before the Redomicile Transactions were publicly announced, and on the last practicable trading day before the date of this Proxy Statement/Prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Trading Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Shares<BR>(ZYME)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 14, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparative Per Share Data of Parent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historical market price information regarding Parent is not provided because there is no public market for Parent capital stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Particulars of the Redomicile Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Redomicile Transactions are being implemented in accordance with the terms of and subject to the conditions contained in the Transaction Agreement (including, with respect to the Arrangement, the Plan of Arrangement). Subject to the satisfaction or
waiver of the conditions to the Transaction Agreement, Zymeworks expects the Redomicile Transactions to be completed as soon as practicable following obtaining approval of the Court in respect of the Arrangement. See section titled &#147;<I>Summary
of the Transaction Agreement</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Redomicile Transactions is to facilitate a series of transactions which will occur in a
specific sequence and as a consequence of which, among other things (i)&nbsp;Zymeworks Shareholders will receive, at their election and subject to applicable eligibility criteria, for their Zymeworks Common Shares, either (a)&nbsp;shares of Delaware
Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or (b)&nbsp;Exchangeable Shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT>
basis, or a mix of Exchangeable Shares and Delaware Common Stock (in such aggregate number that is equal to the number of Zymeworks Common Shares exchanged for them), subject to the Exchangeable Share Cap; (ii)&nbsp;Parent, Callco and ExchangeCo
will enter into the Support Agreement; and (iii)&nbsp;Parent, ExchangeCo, Callco and Share Trustee will enter into the Trust Agreement for the benefit of the Exchangeable Shareholders. Immediately prior to the
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Redomicile Transactions, shares of Parent Common Stock will be listed for trading on the NYSE under the symbol &#147;ZYME&#148;. See section titled &#147;<I>The Redomicile Transactions and the
Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Stock Exchange Listings</I>&#148; and &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Particulars of the Redomicile Transactions</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming the Redomicile Resolution is approved at the Special Meeting, following the Effective Time and completion of the Redomicile Transactions, the
stockholders of Parent will be the same persons who were Zymeworks Shareholders immediately prior to the Redomicile Transactions (other than those who have validly exercised Dissent Rights and holders of Exchangeable Shares prior to exchanging them
for Delaware Common Stock) and Parent will become the direct or indirect owner of all of the assets and liabilities of Zymeworks. As a result, there will be no effective change of control of Zymeworks as a result of the Redomicile Transactions, as
ultimate control will remain with the public stockholders. Upon completion of the Redomicile Transactions, Parent will have the general structure shown below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Structure Prior to the Redomicile Transactions </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n44.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Structure Following the Redomicile Transactions </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of the Redomicile Transactions on the Zymeworks Incentive Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, Parent will assume the Zymeworks Incentive Plans, which will become Parent Incentive Plans, and each
outstanding Zymeworks Incentive Award will be assumed and be deemed to be exchanged for a Parent Incentive Award. The assumed and exchanged Zymeworks Incentive Awards will remain subject to the terms and conditions of the Zymeworks Incentive Plans,
except that the security issuable upon exercise or settlement of the Zymeworks Incentive Award, as applicable, will be shares of Delaware Common Stock rather than Zymeworks Common Shares. See section titled &#147;<I>The Redomicile</I>
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Transactions and the Plan of Arrangement &#151; Effect of the Redomicile Transactions on the Zymeworks Incentive Awards</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of the Redomicile Transactions on the Zymeworks Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent will assume the Zymeworks Warrants, except that the security issuable upon exercise will be shares of Delaware Common Stock rather than Zymeworks Common
Shares. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Effect of the Redomicile Transactions on the Zymeworks Warrants</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Securityholder Approvals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be effective, the
Redomicile Resolution must be approved, with or without variation, by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on the Redomicile Resolution, in person or by proxy, by both
(i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board recommends that Zymeworks Securityholders vote <B><U>FOR</U></B> the Redomicile Resolution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Legal and Regulatory Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Court
Approval </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Arrangement under the BCBCA requires Court approval. Prior to the mailing of this Proxy Statement/Prospectus, Zymeworks obtained the
Interim Order providing for the calling and holding of the Special Meeting, the Dissent Rights and other procedural matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the
Plan of Arrangement and the Interim Order, including obtaining the Required Securityholder Approval as described above, the Company intends to make an application to the Court for a final order (the &#147;<B>Final Order</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Final Order is expected to take place via Microsoft Teams at the courthouse at 800 Smithe Street, Vancouver, British Columbia on [&#9679;]&nbsp;at
[&#9679;], Pacific Time, or as soon thereafter as counsel may be heard. Please see section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Court Approval</I>&#148; as well as
the Notice of Hearing of Petition, attached as Appendix E to this Proxy Statement/Prospectus, and the Interim Order, attached as Appendix D to this Proxy Statement/Prospectus, for further information on participating or presenting evidence at the
hearing for the Final Order. At the hearing, the Court will consider, among other things, the fairness of the Redomicile Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See section titled
&#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Court Approval</I>&#148; in this Proxy Statement/Prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Exchange Listings and Securities Law Filings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Delaware Common Stock will be listed on the NYSE under the symbol &#147;ZYME.&#148; When the Redomicile Transactions are completed, the Zymeworks
Common Shares currently listed on the NYSE will cease to be traded on the NYSE and will be deregistered under the U.S. Exchange Act. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Certain Legal and
Regulatory Matters &#151; Stock Exchange Listings</I>&#148;. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a result of the Redomicile Transactions, Parent will become a reporting issuer in all
jurisdictions in Canada, and Zymeworks will apply to cease to be a reporting issuer in all jurisdictions in Canada in which it is currently a reporting issuer. Parent will be subject to, and Zymeworks will terminate its, reporting obligations in
Canada following completion of the Redomicile Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dissent Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Interim Order, Registered Shareholders are entitled to Dissent Rights if they strictly follow the procedures set out in Division 2 of Part 8 of the
BCBCA as may be modified by the Interim Order, the Plan of Arrangement, and any further order of the Court. Persons who are beneficial owners of Zymeworks Common Shares registered in the name of an Intermediary who wish to dissent should be aware
that only Registered Shareholders are entitled to Dissent Rights. Accordingly, a beneficial owner of Zymeworks Common Shares desiring to exercise Dissent Rights must make arrangements for the Zymeworks Common Shares beneficially owned by such
Zymeworks Shareholder to be registered in the Zymeworks Shareholder&#146;s name prior to the time the Dissent Notice is required to be received by Zymeworks, or, alternatively, make arrangements for the registered holder of such Zymeworks Common
Shares to dissent on the Zymeworks Shareholder&#146;s behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply strictly with the requirements set forth in Division 2 of Part 8 of the
BCBCA as may be modified by the Interim Order, the Plan of Arrangement, and any other order of the Court may result in the loss of any right to dissent. It is strongly suggested that any Zymeworks Shareholder wishing to dissent seek independent
legal advice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#151; Dissent Rights</I>&#148; and Appendix C of this
Proxy Statement/Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment of the Redomicile Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions will be accounted for consistent with a reorganization of entities under common control. Accordingly, the transfer of certain
assets and liabilities and the exchange of shares will be recorded in the new entity (Parent) at their carrying amounts from the transferring entity (Zymeworks) at the date of transfer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Canadian Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders should carefully read the information in this Proxy Statement/Prospectus under &#147;<I>Material Canadian Federal Income Tax
Considerations</I>&#148; which qualifies the information set out below and should consult their own tax advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the following paragraph,
Zymeworks Shareholders who are residents of Canada for purposes of the Tax Act (including Eligible Holders that do not make a valid tax election as discussed below or that are issued Delaware Common Stock) will generally realize a taxable
disposition of their Zymeworks Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the Exchangeable Share Cap, Zymeworks Shareholders who are Eligible Holders may elect to receive
consideration that includes Exchangeable Shares. Such an Eligible Holder who elects to receive consideration that includes Exchangeable Shares with respect to all or a portion of their Zymeworks Common Shares and makes a valid tax election with
ExchangeCo may generally defer all or a part of the Canadian income tax on any capital gain that would otherwise arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement, subject to the limitations in the Tax Act. See
section titled &#147;<I>Material Canadian Federal Income Tax Considerations &#151; Holders Resident in Canada &#151; Exchange of Zymeworks Common Shares for Exchangeable Shares &#151; Section</I><I></I><I>&nbsp;85 Election</I>&#148; or the section
titled &#147;<I>Material Canadian Federal Income Tax</I> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Considerations &#151; Holders Resident in Canada &#151; Exchange of Zymeworks Common Shares for Exchangeable Shares and Delaware Common Stock &#151; Section</I><I></I><I>&nbsp;85
Election</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders who are not residents of Canada for purposes of the Tax Act and who do not hold their Zymeworks Common Shares
as &#147;taxable Canadian property&#148; will generally not be subject to tax under the Tax Act on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Shareholders should consult with and rely on their own tax advisors for advice with respect to the Redomicile Transactions, including:
(i)&nbsp;the income tax consequences to them of disposing of their Zymeworks Common Shares pursuant to the Redomicile Transactions and (ii)&nbsp;holding and disposing of shares of Delaware Common Stock or Exchangeable Shares, all having regard to
their own particular circumstances. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Incentive Award holders and Zymeworks Warrant holders should consult their own tax advisors for
advice with respect to the Redomicile Transactions. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions are intended to qualify as an exchange described in Section&nbsp;351 of the Code, and subject to the discussion under the caption
heading &#147;<I>Material U.S. Federal Income Tax Considerations</I> <I>&#151; PFIC Considerations</I>&#148; below, (i)&nbsp;no gain or loss will be recognized by a U.S. holder of Zymeworks Common Shares for U.S. federal income tax purposes on the
exchange of its Zymeworks Common Shares for Delaware Common Stock in the Redomicile Transactions; (ii)&nbsp;the aggregate tax basis of the Delaware Common Stock received in the Redomicile Transactions by a U.S. holder of Zymeworks Common Shares will
be equal to the aggregate tax basis of the Zymeworks Common Shares it exchanged in the Redomicile Transactions; and (iii)&nbsp;the tax holding period of the Delaware Common Stock received in the Redomicile Transactions by a U.S. holder of Zymeworks
Common Shares will include the holding period of the Zymeworks Common Shares that it surrendered in exchange therefor in the Redomicile Transactions. The Redomicile Transactions may also qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT>
reorganization under Section&nbsp;368(a) of the Code, in which case the tax consequences to U.S. holders will generally be similar to the tax treatment of the Redomicile Transactions under Section&nbsp;351 of the Code. If the Redomicile Transactions
fail to qualify as an exchange described in Section&nbsp;351 of the Code or a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization under Section&nbsp;368(a) of the Code, U.S. holders of Zymeworks Common Shares would be treated as if they
sold their Zymeworks Common Shares in a fully taxable transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. holders are strongly urged to consult their own tax advisors regarding the
U.S. federal income tax consequences of the Redomicile Transactions to them in their particular circumstances. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The brief U.S. tax summary provided
above is qualified in its entirety by the section &#147;</B><B><I>Material U.S. Federal Income Tax Considerations</I></B><B>&#148; below, which provides a summary of the material U.S. federal income tax considerations generally applicable to U.S.
holders of participating in the Redomicile Transactions, and to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders of the ownership and disposition of shares of Delaware Common Stock received by
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders pursuant to the Redomicile Transactions. Zymeworks Shareholders are urged to consult with and rely on their own tax advisors to determine the particular tax consequences to them of the
Redomicile Transactions as well as the tax consequences of the ownership and disposition of shares of Delaware Common Stock received pursuant to the Redomicile Transactions. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>There may be different income tax treatment that applies to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (including Canadian Holders) and U.S.
holders of shares of Delaware Common Stock in respect of dividend and withholding taxes, as compared to the tax consequences that apply in respect of holding Zymeworks Common Shares. See sections titled &#147;</B><B><I>Material Canadian Federal
Income Tax Considerations</I></B><B>&#148; and &#147;</B><B><I>Material U.S. Federal Income Tax Considerations</I></B><B>&#148;. </B></P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Shareholder Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the principal attributes of Zymeworks Common Shares and shares of Delaware Common Stock, will be similar. In addition, holders who receive Exchangeable
Shares in connection with the Redomicile Transactions are expected to have voting rights as beneficiaries under the Voting Trust Agreement equivalent to a holder of Delaware Common Stock. However, there are differences between what a
stockholder&#146;s rights will be under Delaware law and what they currently are under the BCBCA. In addition, there are differences between Zymeworks&#146; existing articles of incorporation and the Parent Certificate of Incorporation and Parent
Bylaws as they will be in effect upon the completion of the Redomicile Transactions. These differences are discussed under &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent Stockholders</I>&#148;. In addition, see section titled
&#147;<I>Description of Parent Capital Stock</I>&#148; for a summary of Parent&#146;s authorized capital stock and the rights and preferences thereof. Zymeworks Securityholders should also review the forms of the Parent Certificate of Incorporation
and Parent Bylaws, as they will be in effect upon completion of the Redomicile Transactions, which are attached as Appendices F and G, respectively, of this Proxy Statement/Prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in shares of Delaware Common Stock is subject to a number of risks. Prior to making any decision as to whether or not to vote in favor of the
Redomicile Resolution, Zymeworks Securityholders should carefully consider risk factors associated with holding shares of Delaware Common Stock, Parent Warrants and/or Parent Incentive Awards, Zymeworks&#146; business and the industry in which it
operates, together with all other information contained in this Proxy Statement/Prospectus, including, in particular the risk factors described below. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the following factors as well as the other information contained in and incorporated by reference into this Proxy
Statement/Prospectus, and specifically, the factors described in the section entitled &#147;Item 1A. Risk Factors&#148; in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Zymeworks for the year ended December&nbsp;31, 2021
and the Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022. For information about Zymeworks&#146; filings incorporated by reference in this Proxy Statement/Prospectus, see section titled
&#147;Where You Can Find More Information&#148;. The Risk Factors contained or incorporated by reference in this Proxy Statement/Prospectus are not guarantees that no such conditions exist as of the date of this Proxy Statement/Prospectus and should
not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to
Zymeworks&#146; Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read and consider the risk factors specific to Zymeworks&#146; business that will continue to affect Parent after
completion of the Redomicile Transactions. These risks are described in the section entitled &#147;Item 1A. Risk Factors&#148; in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Zymeworks for the year ended
December&nbsp;31, 2021, and the section entitled &#147;Item 1A. Risk Factors&#148; in the Quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Zymeworks for the quarter ended March&nbsp;31, 2022, each of which is incorporated by
reference into this Proxy Statement/Prospectus, and in other documents that are incorporated by reference into this Proxy Statement/Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Relating to Parent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The rights of stockholders under Delaware law may differ from the rights of shareholders under the BCBCA. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Redomicile Transactions are completed, Zymeworks Shareholders (other than Dissenting Shareholders (as defined herein) and holders of Exchangeable Shares
prior to exchanging them for Delaware Common Stock) will become stockholders of a Delaware corporation. There are differences between the BCBCA and the DGCL. For example, under the BCBCA, many significant corporate actions such as certain amendments
to a corporation&#146;s notice of articles and articles or consummating an amalgamation (other than a vertical short form or horizontal short form amalgamation among affiliated entities) require the approval of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by shareholders, whereas under the DGCL, in most cases, such actions require the approval of a majority of the voting power of outstanding stock entitled to vote on the matter.
Furthermore, shareholders under the BCBCA are entitled to appraisal rights under a number of extraordinary corporate actions, including an amalgamation with another unrelated corporation, certain amendments to a corporation&#146;s articles of
incorporation or the sale of all or substantially all of a corporation&#146;s assets, whereas under the DGCL, stockholders are only entitled to appraisal rights in connection with certain mergers, consolidations and similar transactions. As shown by
the examples above, if the Redomicile Transactions are completed, in certain circumstances, holders of shares of Delaware Common Stock will be afforded different protections under the DGCL than Zymeworks Shareholders had under the BCBCA. See section
titled &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent Stockholders</I>&#148; for further details. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware law and provisions in the Parent Certificate of Incorporation and Parent Bylaws might delay,
discourage or prevent a change in control of Parent or changes in its management, thereby depressing the market price of the Delaware Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent Certificate of Incorporation and Parent Bylaws will contain provisions that may make the acquisition of Parent more difficult or delay or prevent
changes in control of its management. Among other things, these provisions will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize Parent&#146;s board of directors to issue shares of preferred stock and determine the price and other
terms of those shares, including preferences and voting rights, without stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit only the board of directors to establish the number of directors and fill vacancies and newly created
directorships on the board, provided that the board of directors&#146; ability to increase the size of the board and fill vacancies and newly created directorships will be subject to the restrictions in the Parent Certificate of Incorporation and
Parent Bylaws and further discussed under the section titled &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent Stockholders</I>&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish that members of Parent&#146;s board of directors serve in one of three staggered terms of three years
each; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that Parent&#146;s directors may only be removed by the affirmative vote of at least 66 2/3% of the
voting power of the shares cast on such proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at
stockholder meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not provide for cumulative voting rights in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of Parent&#146;s stockholders may be called only by the board of directors, the
chairperson of the board of directors, Parent&#146;s chief executive officer or president or the secretary of Parent upon request from holders of no less than 20% of Parent&#146;s outstanding voting stock, subject to the limitations and requirements
set forth in the Parent Bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require a super-majority vote of stockholders to amend some of the provisions described above.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because Parent will be incorporated in Delaware, Parent will be governed by the provisions of Section&nbsp;203 of the
DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#147;interested stockholder&#148; for a period of three years following the date on which the stockholder became an
&#147;interested stockholder&#148; unless certain conditions are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, alone or together, could delay, discourage or prevent a
transaction involving a change in control of Parent. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and to cause Parent to take other corporate actions they
desire, any of which, under certain circumstances, could limit the opportunity for Parent&#146;s stockholders to receive a premium for their shares of Delaware Common Stock, and could also affect the price that some investors are willing to pay for
Delaware Common Stock. For more information, see section titled &#147;<I>Description of Parent Capital Stock &#150; Parent Certificate of Incorporation and Parent Bylaws Provisions</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Parent Bylaws will designate a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes
between Parent and its stockholders, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, each of which could limit Parent&#146;s
stockholders&#146; ability to choose the judicial forum for disputes with Parent or its directors, officers, stockholders or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent
Bylaws will provide that, unless Parent consents in writing to the selection of an alternative forum, the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on Parent&#146;s behalf, (2)&nbsp;any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action asserting a claim of breach of a fiduciary duty owed by any of Parent&#146;s directors, stockholders, officers or other employees to Parent or its stockholders, (3)&nbsp;any action arising
pursuant to any provision of the DGCL, the Parent Certificate of Incorporation or Parent Bylaws or (4)&nbsp;any other action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware
(or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware), except for any claim as to which such court determines that there is an indispensable party not
subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other
than such court or for which such court does not have subject matter jurisdiction. This provision would not apply to any action brought to enforce a duty or liability created by the Exchange Act and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;22 of the Securities Act establishes concurrent jurisdiction for federal and state courts over Securities Act claims. Accordingly, both state and
federal courts have jurisdiction to hear such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, the Parent Bylaws will also
provide that, unless Parent consents in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person or entity purchasing or otherwise acquiring or holding or owning (or continuing to hold or own) any interest in any of
Parent&#146;s securities shall be deemed to have notice of and consented to the foregoing bylaw provisions. Although Parent believes these exclusive forum provisions benefit Parent by providing increased consistency in the application of Delaware
law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum of its choosing for disputes with Parent or its current or
former directors, officers, stockholders or other employees, which may discourage such lawsuits against Parent and its current and former directors, officers, stockholders and other employees. Parent&#146;s stockholders will not be deemed to have
waived its compliance with the federal securities laws and the rules and regulations thereunder as a result of Parent&#146;s exclusive forum provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The enforceability of similar exclusive forum provisions in other companies&#146; organizational documents have been challenged in legal proceedings, and,
while certain courts have determined these provisions are enforceable, it is possible that a court of law could rule that these types of provisions are inapplicable or unenforceable if they are challenged in a proceeding or otherwise. If a court
were to find either exclusive forum provision contained in the Parent Bylaws to be inapplicable or unenforceable in an action, Parent may incur significant additional costs associated with resolving such action in other jurisdictions, all of which
could harm its results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior public trading for the shares of Delaware Common Stock on a national securities
exchange and the market price of the shares of Delaware Common Stock may be subject to volatility. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Zymeworks Common Shares have
historically been listed on the NYSE, there has been no public trading market for the shares of Delaware Common Stock. Following the listing of the shares of Delaware Common Stock on the NYSE, there can be no assurance that the trading market for
such shares will continue to be as active or liquid as was the trading market for the Zymeworks Common Shares prior to the Redomicile Transactions or that the trading price of the shares of Delaware Common Stock following the Redomicile Transactions
may not be effectively lower than the trading price of the Zymeworks Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with the Zymeworks Common Shares, the market price of
the shares of Delaware Common Stock may be volatile. The value of an investment in the shares of Delaware Common Stock may decrease or increase abruptly, and such volatility may bear little or no relation to Zymeworks&#146; performance. The price of
the shares of Delaware Common Stock may fall in response to market appraisal of Zymeworks&#146; strategy or if Zymeworks&#146; results of operations, clinical progress and/or prospects are below the expectations of market analysts or shareholders.
In addition, stock markets have, from time to time, experienced significant price and volume </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fluctuations that have affected the market price of securities, and may, in the future, experience similar fluctuations which may be unrelated to Parent&#146;s operating performance and prospects
but nevertheless affect the price of the shares of Delaware Common Stock. This volatility may affect the ability of holders of shares of Delaware Common Stock to sell these at an advantageous price. Broad market fluctuations, as well as economic
conditions generally, may adversely affect the market price of the shares of Delaware Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Parent may need to enter into certain new
arrangements which may not be on terms as favorable as arrangements entered into by Zymeworks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with or immediately following
completion of the Redomicile Transactions, Parent may need to enter into new arrangements as the ultimate parent company to Zymeworks and its subsidiaries. While Parent anticipates such terms will be materially consistent with the arrangements
currently in place for Zymeworks, there is no assurance that such arrangement will not impose additional operating or financial restrictions on Parent, or that such arrangements will be on commercially reasonable terms or terms that are acceptable
to Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Parent&#146;s ability to pay dividends in the future is not guaranteed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any future determination to pay dividends will be at the discretion of the Parent board of directors and will depend upon many factors, including Parent&#146;s
results of operations, financial position, capital requirements, distributable reserves, credit terms, general economic conditions and other factors as the Parent board of directors may deem relevant from time to time. Consequently, future dividends
payable to investors are not guaranteed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The issuance of additional shares of Delaware Common Stock in connection with future equity financings,
acquisitions or growth opportunities, any Parent Incentive Plan or otherwise may dilute all other shareholdings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent may seek to raise
financing for acquisitions or to fund future growth opportunities. In certain circumstances, Parent may, for these and other purposes, including pursuant to any Parent Incentive Plan, issue additional equity or convertible equity securities. As a
result, existing holders of shares of Delaware Common Stock may suffer dilution in their percentage ownership or the market price of such shares may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Redomicile Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zymeworks may fail to realize certain benefits of the Redomicile Transactions, including as a result of the shares of Delaware Common Stock not being
included in a U.S. stock market index. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks has pursued the Redomicile Transactions because it believes that the Redomicile Transactions will
enhance shareholder value over the long-term. Zymeworks believes that the Redomicile Transactions will raise the profile and marketability of Zymeworks&#146; capital stock in the United States through, among other things, the ability to attract
deeper and growing pools of passive investment capital in the United States, particularly if shares of Delaware Common Stock are included in certain U.S. stock market indices and other investment vehicles that only include securities of
U.S.-incorporated companies. However, following the Redomicile Transactions, if shares of Delaware Common Stock are not included in such U.S. stock market indices, this could result in increased selling pressure and/or decreased demand for
Parent&#146;s shares that would increase stock price volatility or cause the market price of the shares of Delaware Common Stock to fall. Initial inclusion and continued inclusion in a stock market index or fund is not guaranteed and is subject to
numerous factors which can be applied subjectively by the entity managing the index or fund. There are no assurances that Parent will be included in any U.S. stock market indices or funds in a timely manner, or at all. Even if Parent is included in
a U.S. stock market index or fund, the entities managing such indices or funds may change their inclusion criteria, resulting in the future exclusion from such index or fund. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of the Redomicile Transactions will depend, in part, on the ability of Zymeworks to realize the
anticipated benefits associated with the Redomicile Transactions and associated reorganization of Zymeworks&#146; corporate structure, and Zymeworks may not be able to realize such benefits on a timely basis or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Redomicile Transactions may result in sales of shares of Delaware Common Stock by certain retail and institutional shareholders or investment funds
that are not permitted to hold shares of Delaware Common Stock under their internal guidelines. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions may result in sales of
shares of Delaware Common Stock by certain retail and institutional shareholders or investment funds (including Canadian-focused funds) that are not permitted to hold shares of Delaware Common Stock under their internal guidelines, or are limited in
the size of any such investments. Such sales could result in increased selling pressure and/or decreased demand for Parent&#146;s shares of Delaware Common Stock, which could increase stock price volatility or cause the market price of the shares of
Delaware Common Stock to fall. As a result of the foregoing, certain of these investors may be required under their internal guidelines to sell their shares at times when, or at prices for which, they would otherwise not have sold. If an investor
sells its shares at a time when the market price is lower than their cost basis in the shares, the investor will suffer a loss that could be significant to such investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of the Redomicile Transactions will depend, in part, on the ability of Zymeworks to realize the anticipated benefits associated with the
Redomicile Transactions and associated reorganization of Zymeworks&#146; corporate structure, and Zymeworks may not be able to realize such benefits on a timely basis or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zymeworks&#146; business may be impacted by the uncertainty associated with the Redomicile Transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Parent expects to maintain Zymeworks&#146; existing physical operations in Canada and Washington state, the Company&#146;s principal executive offices
will be located in Middletown, Delaware, which reflects the ongoing evolution of our workforce toward hybrid and remote, with maintenance of our historical physical operations. As a result of this shift, certain relationships, including with
employees, suppliers, contract research organizations, partners, collaborators, governments and other stakeholders, may be subject to disruption due to uncertainty associated with the Redomicile Transactions. Specifically, certain stakeholders may
be reluctant to engage in business with Zymeworks prior to, or with Parent following completion of, the Redomicile Transactions, or may impose additional conditions on or apply less favorable terms to transactions involving Zymeworks and/or Parent.
This could have an adverse effect on the business and operations of Zymeworks prior to, or Parent following, completion of the Redomicile Transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Redomicile Transactions are conditional, and the conditions may not be satisfied. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Completion of the Redomicile Transactions is conditional, among other things, upon the receipt of approvals and the satisfaction of other conditions, including
(i)&nbsp;the authorization, upon official notice of issuance, of the listing of the shares of Delaware Common Stock on the NYSE, (ii)&nbsp;the approval of the Court in respect of the Arrangement, and (iii)&nbsp;the receipt of the Required
Securityholder Approvals. Although Zymeworks is diligently applying its efforts to take, or cause to be taken, all actions to do, or cause to be done, all things necessary, proper or advisable to obtain the requisite approvals, there can be no
assurance that these conditions will be fulfilled or that the Redomicile Transactions will be completed. Further, even if the Required Securityholder Approvals have been obtained, the Zymeworks Board may decide to delay or not proceed with the
Redomicile Transactions if it determines that the Redomicile Transactions are no longer advisable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions to
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders of Delaware Common Stock may be subject to U.S. withholding </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions by Parent on
Delaware Common Stock held by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders (as defined below) (including constructive distributions) may be subject to a U.S. federal withholding tax (generally, at a rate of 30% of the gross amount of the
dividend or such lower rate as may be specified by an applicable income tax treaty between </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the United States and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s country of residence). For more information, see section titled &#147;<I>Material U.S. Federal Income Tax
Considerations &#150; Material U.S. Federal Income Tax Considerations to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Ownership and Disposition of Delaware Common Stock &#150; Distributions</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Parent&#146;s effective tax rate may change in the future, including as a result of the Redomicile Transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Redomicile Transactions, Parent will be subject to U.S. federal income taxes on its earnings and the earnings of its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries in a manner that may adversely impact the company&#146;s effective tax rate. For example, Parent may have to include additional amounts in income under the
<FONT STYLE="white-space:nowrap">so-called</FONT> &#147;global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income&#148; regime or as a result of the application of &#147;controlled foreign corporation&#148; rules. In addition,
Parent may have to comply with U.S. withholding tax requirements on U.S. federal distributions paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders. Currently, the U.S. federal corporate income tax rate is 21%, and the Canadian corporate
income tax rate (federal and provincial) is 27%. However, the Biden Administration has proposed several changes to the U.S. corporate tax regime, which, if adopted, could result in increased taxation of Parent&#146;s U.S. and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> operations. In addition, Zymeworks&#146;s tax attributes (including net operating loss and tax credit carryforwards and deductible Scientific Research and Experimental Development Expenditure carryforwards)
will generally not be available to offset U.S. income and may be subject to limitation following the Redomicile Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Parent&#146;s
future operations and business structure may result in increased tax burden. For example, changes in Parent&#146;s clinical development plans and business or commercialization strategies may result in an increased effective tax rate. Taxation of
international business operations and intercompany transactions, including transactions between Parent and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries, is complicated. Any changes in the U.S. or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxation of such activities may increase Parent&#146;s worldwide effective tax rate and harm Parent&#146;s business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zymeworks will allocate time and resources to effecting the Redomicile Transactions and incur <FONT STYLE="white-space:nowrap">non-recurring</FONT>
costs related to the Redomicile Transactions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks and its management have allocated and will continue to be required to allocate time and
resources to effecting the completion of the Redomicile Transactions and related and incidental activities. There is a risk that the challenges associated with managing these various initiatives as described in this Proxy Statement/Prospectus may
have a business impact and that consequently the underlying businesses will not perform in line with expectations. This could have an adverse effect on the business, financial condition and reputation of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Zymeworks expects to incur a number of <FONT STYLE="white-space:nowrap">non-recurring</FONT> costs associated with the Redomicile Transactions,
including legal fees, accountants&#146; fees, proxy solicitor fees, filing fees, mailing expenses and financial printing expenses. There can be no assurance that the actual costs will not exceed those estimated and the actual completion of the
Redomicile Transactions may result in additional and unforeseen expenses. Most of these costs will be payable whether or not the Redomicile Transactions are completed. While it is expected that benefits of the Redomicile Transactions achieved by
Parent will offset these transaction costs over time, this net benefit may not be achieved in the short-term or at all, particularly if the Redomicile Transactions are delayed or does not happen at all. These combined factors could adversely affect
the business and overall financial condition of Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zymeworks may choose to defer or abandon the Redomicile Transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if the Required Securityholder Approvals have been obtained and other conditions required to complete the Redomicile Transactions have been satisfied,
Zymeworks may decide to defer or abandon the Redomicile Transactions at any time prior to the Effective Time of the Redomicile Transactions and in such case Zymeworks will have incurred costs and will have directed attention and resources relating
to the Redomicile Transactions, but will not realize any of the anticipated benefits of the Redomicile Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative publicity resulting from the Redomicile Transactions could adversely affect Zymeworks&#146;
business and the market price of the Zymeworks Common Shares and the shares of Delaware Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions similar to the Redomicile
Transactions that have been undertaken by other companies have in some cases generated significant news coverage, some of which has been negative. Negative publicity generated by the Redomicile Transactions could cause certain persons with whom
Zymeworks has a business relationship to be more reluctant to do business with Zymeworks prior to the Redomicile Transactions, or Parent following the Redomicile Transactions. In addition, negative publicity could cause certain of Zymeworks&#146;
employees, particularly those in Canada, to perceive uncertainty regarding future opportunities available to them. Either of these events could have a significant adverse impact on Zymeworks&#146; business. Negative publicity could also cause some
Zymeworks Shareholders to sell Zymeworks Common Shares or decrease the demand for new investors to purchase such shares, which could have an adverse impact on the price of the Zymeworks Common Shares and the shares of Delaware Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Completion of the Redomicile Transactions may trigger certain provisions in agreements to which Zymeworks is a party. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Redomicile Transactions will not result in an effective change of control of Zymeworks, the completion of the Redomicile Transactions may trigger
certain technical change in control, right of first offer, notice, consent, assignment or other provisions in agreements to which Zymeworks or its subsidiaries are a party. If Zymeworks and/or Parent are unable to assert that such provisions should
not apply, or is unable to comply with or negotiate waivers of those provisions, the counterparties may exercise their rights and remedies under the agreements, including potentially terminating such agreements or seeking monetary damages. Even if
Zymeworks is able to negotiate waivers, the counterparties may require a fee for such waivers or seek to renegotiate the agreements on terms less favorable to Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments in connection with the exercise of Dissent Rights by Zymeworks Shareholders may impact Parent&#146;s financial resources. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, Registered Shareholders who (i)&nbsp;do not vote in favor of the Redomicile Resolution, (ii)&nbsp;deliver to Zymeworks a Dissent Notice,
(iii)&nbsp;continuously hold their Zymeworks Common Shares through the Effective Time, and (iv)&nbsp;otherwise comply with the requirements and procedures of Division 2 of Part 8 of the BCBCA (as may be modified by the Interim Order, the Plan of
Arrangement, and any further order of the Court), are entitled to receive payment in cash of the &#147;fair value&#148; of their Zymeworks Common Shares. Should a material number of Zymeworks Shareholders exercise Dissent Rights, a substantial cash
payment may be required to be made to such Dissenting Shareholders that could have an adverse effect on Parent&#146;s financial condition and cash resources if the Redomicile Transactions are completed. It is a condition precedent to completion of
the Redomicile Transactions that the time period for the exercise of any Dissent Rights conferred upon Zymeworks Shareholders in respect of the Redomicile Transactions shall have expired and Zymeworks Shareholders shall not have exercised (or
otherwise be deemed to have exercised) Dissent Rights for greater than 10% of the outstanding Zymeworks Common Shares, or such other amount that would make it inadvisable to proceed with the implementation of the Redomicile Transactions, as
determined by Zymeworks in its sole discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enforcement of rights against Parent in Canada may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent&#146;s principal executive offices will be located in Middletown, Delaware and the majority of its directors, officers and experts are likely to reside
outside of Canada. Accordingly, it may not be possible for Parent stockholders to effect service of process within Canada upon Parent or the majority of its directors, officers or experts, or to enforce judgments obtained in Canadian courts against
Parent or the majority of its directors, officers or experts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Exchangeable Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Exchangeable Shares will not be listed on any stock exchange. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchangeable Shares are not expected to be listed on any stock exchange. Although each Exchangeable Share will be exchangeable at the option of the holder
for shares of Delaware Common Stock, there is no market through which the Exchangeable Shares may be sold, and holders may not be able to sell their Exchangeable Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zymeworks Shareholders who elect to receive Exchangeable Shares will experience a delay in receiving Delaware Common Stock from the date they request an
exchange, which may affect the value of the shares the holder receives in such exchange. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Shareholders who elect to receive Exchangeable
Shares as part of the Consideration with respect to all or a portion of their Zymeworks Common Shares and later request to receive shares of Delaware Common Stock in exchange for their Exchangeable Shares may not receive shares of Delaware Common
Stock until a period of time after the applicable request is received. During this period, the market price of the shares of Delaware Common Stock may increase or decrease. Any such increase or decrease would affect the value of the Consideration to
be received by such a holder of Exchangeable Shares upon a subsequent sale of shares of Delaware Common Stock received in the exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
pursuant to the terms of the Support Agreement and following completion of the Redomicile Transactions, Parent will file a registration statement or a prospectus supplement to an existing registration statement to register the issuance of Delaware
Common Stock issued upon exchange of the Exchangeable Shares. If Parent is delayed in filing such registration statement or prospectus supplement to an existing registration statement, or if the effectiveness of such registration statement or
prospectus supplement to an existing registration statement is delayed or suspended, shares of Delaware Common Stock issued upon exchange of the Exchangeable Shares would not be registered, which could impact a holder&#146;s ability to sell such
shares in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There may be a taxable event for an Eligible Holder as a result of a transaction beyond such Eligible Holder&#146;s
control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Eligible Holder who (a)&nbsp;disposes of Zymeworks Common Shares pursuant to the Plan of Arrangement and who receives consideration
that includes Exchangeable Shares, and (b)&nbsp;validly makes a joint election under subsection 85(1) or subsection 85(2) of the Tax Act (as applicable and as described in the sections titled &#147;<I>Material Canadian Federal Income Tax
Considerations &#151; Exchange of Zymeworks Common Shares for Exchangeable Shares &#151; Section</I><I></I><I>&nbsp;85 Election</I>&#148; and &#147;<I>Material Canadian Federal Income Tax Considerations &#151; Exchange of Zymeworks Common Shares for
Exchangeable Shares and Delaware Common Stock &#151; Section</I><I></I><I>&nbsp;85 Election</I>&#148;) in respect of such shares, may obtain a full or partial tax deferral of any capital gain that may otherwise arise on the exchange of such
Zymeworks Common Shares. However, a holder of Exchangeable Shares will be considered to have disposed of Exchangeable Shares (i)&nbsp;on a redemption (including pursuant to a retraction request) of such Exchangeable Shares by ExchangeCo, and
(ii)&nbsp;on an acquisition of such Exchangeable Shares by Callco or Parent. Although each is a taxable event, the Canadian federal income tax consequences of the disposition will be different depending on whether the event giving rise to the
disposition is a redemption or an acquisition. Further, if the Exchangeable Share Cap is reached, then the Exchangeable Shares will be allocated proportionally among the Eligible Holders that elect to receive Exchangeable Shares based on the number
of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder. Any remaining Zymeworks Common Shares held by those Eligible Holders will be exchanged for Delaware Common Stock and would be
taxable to the Eligible Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Sunset Date, ExchangeCo may redeem Exchangeable Shares in limited circumstances, and ExchangeCo shall
redeem the Exchangeable Shares on the Sunset Date. Accordingly, an Eligible Holder may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have a taxable event in a transaction beyond their control. See section titled &#147;<I>Material Canadian Federal Income Tax Considerations</I>&#148; for further information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Receipt of Delaware Common Stock by Eligible Holders who do not elect to receive Exchangeable Shares with respect to any portion of their Zymeworks
Common Shares will be a taxable event for Canadian income tax purposes, and could also be taxable to Zymeworks Shareholders who are not U.S. holders (as defined below). </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Eligible Holder who does not elect to receive Exchangeable Shares with respect to any portion of their Zymeworks Common Shares and instead disposes of
Zymeworks Common Shares for Delaware Common Stock will realize proceeds of disposition equal to the aggregate fair market value, at the time of the disposition, of the Delaware Common Stock acquired on the exchange. Such Eligible Holder will realize
a capital gain (or capital loss) equal to the amount by which the proceeds of disposition, net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base to such Eligible Holder of the Zymeworks Common Shares. See
section titled &#147;<I>Material Canadian Federal Income Tax Considerations</I>&#148; for further information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, receipt of Delaware Common Stock
by Zymeworks Shareholders who are not U.S. holders (as defined below) could be taxable to such Zymeworks Shareholders under the laws of their respective jurisdictions. Such Zymeworks Shareholders should consult with their own tax advisors regarding
the tax consequences of the Redomicile Transactions in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The tax treatment of Exchangeable Shares for <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> tax purposes is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax treatment of Exchangeable Shares for <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> tax purposes, including U.S. federal income tax purposes, is uncertain and may differ from the general tax consequences described in section titled &#147;<I>Material Canadian Federal Income Tax
Considerations</I>&#148;. Exchangeable Shareholders who are subject to taxation in jurisdictions other than Canada should consult with their tax advisors regarding the tax treatment of Exchangeable Shares under
<FONT STYLE="white-space:nowrap">non-Canadian</FONT> tax laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_7"></A>VOTING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Shares and Principal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record
Date for the Special Meeting, [&#9679;] Zymeworks Common Shares, [&#9679;] Zymeworks Warrants and [&#9679;] Zymeworks Incentive Awards were outstanding. The Zymeworks Common Shares trade under the stock symbol &#147;ZYME&#148; on the NYSE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record Date for the Special Meeting, the directors and executive officers of Zymeworks had the right to vote approximately [&#9679;] Zymeworks
Common Shares, representing approximately [&#9679;]% of the Zymeworks Common Shares then outstanding and entitled to vote at the Special Meeting, no Zymeworks Warrants and [&#9679;] Zymeworks<B> </B>Incentive Awards, representing approximately
[&#9679;]% of the Zymeworks Incentive Awards then outstanding and entitled to vote at the Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information regarding each person known by
Zymeworks to beneficially own 5% or more of the outstanding Zymeworks Common Shares and information regarding beneficial ownership of Zymeworks Common Shares by directors and executive officers of Zymeworks, see section titled &#147;<I>Share
Ownership of Certain Beneficial Owners and Management and Directors of Zymeworks</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is expected that each of the directors and executive
officers of Zymeworks will vote <B><U>FOR</U></B> the Redomicile Resolution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date and Entitlement to Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Zymeworks Securityholder of record at the close of business on [&#9679;], 2022, which is the Record Date of the Special Meeting, will be entitled to vote
at the Special Meeting the Zymeworks Common Shares, Zymeworks Warrants and Zymeworks Incentive Awards registered in his, her or its name on that date. Each Zymeworks Common Share, Zymeworks Warrant and Zymeworks Incentive Award<B> </B>carries the
right to one vote for the Redomicile Resolution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order for business to be conducted at the Special Meeting, a quorum must be present. A quorum for the Special Meeting requires at least 30% of the Zymeworks
Common Shares entitled to vote be present or represented by proxy and at least two persons entitled to vote at the Special Meeting be present or represented by proxy. While Zymeworks Warrantholders and Zymeworks Incentive Awardholders will be
entitled to vote at the Special Meeting as described elsewhere in this Proxy Statement/Prospectus, there is no separate quorum requirement under the BCBCA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The persons named in the form of proxy must
vote or withhold from voting your Zymeworks Common Shares, Zymeworks Warrant or Zymeworks Incentive Awards in accordance with your instructions on the form of proxy. Signing the form of proxy gives authority to the persons named therein, each of
whom is either a director or officer of Zymeworks, to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards at the Special Meeting in accordance with your voting instructions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In the absence of such instructions, however, your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards will be voted <U>FOR</U> the
Redomicile Resolution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a registered Zymeworks Shareholder, Zymeworks Warrantholder or Zymeworks Incentive Awardholder, you may vote by
completing and returning a proxy according to the instructions below, or by attending the Special Meeting in person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proxy must be in writing and must be executed by you or by an attorney duly authorized in writing or, if
the shareholder is a corporation or other legal entity, by a duly authorized officer or attorney. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The persons named in the form of proxy will have
discretionary authority with respect to amendments or variations to matters identified in the Notice of Special Meeting and with respect to other matters that properly come before the Special Meeting. As of the date of this Proxy
Statement/Prospectus, Zymeworks&#146; management knows of no such amendment, variation or other matter expected to come before the Special Meeting. If any other matters properly come before the Special Meeting, the persons named in the form of proxy
will vote on them in accordance with their best judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial Zymeworks Shareholder, the Intermediary (usually a bank, trust company,
broker, securities dealer or other financial institution) through which you hold your Zymeworks Common Shares will send you instructions on how to vote your Zymeworks Common Shares. Please follow the instructions on your voting instruction form.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can contact Computershare,
Zymeworks&#146; transfer agent as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By mail:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Computershare Investor Services Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxy Department</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 University Avenue, 8th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Toronto, Ontario, M5J
2Y1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By telephone:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">within North America
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at&nbsp;1-800-564-6253</FONT></FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">all other
countries at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-514-982-7555</FONT></FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">for
broker inquiries at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-838-1405</FONT></FONT></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registered Shareholder, Zymeworks Warrantholder and Zymeworks Incentive Awardholder Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are a Registered Shareholder if your name appears on your share certificate or your Direct Registration (DRS) confirmation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How to Vote </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are eligible to vote and you
are a Registered Shareholder, Zymeworks Warrantholder or Zymeworks Incentive Awardholder, you can vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards<B> </B>in person at the Special Meeting or by proxy, as explained
below. Voting by proxy is the easiest way to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting by Proxy
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below are the different ways in which you can give your instructions, details of which are found in the proxy form accompanying this Proxy
Statement/Prospectus. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Mail: You may sign the enclosed form of proxy appointing the named persons or some other person you choose,
who need not be a shareholder, to represent you as proxyholder and vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards at the Special Meeting. Return the form of proxy by mail to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Computershare Investor Services </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">100 University Avenue, 8th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Toronto, Ontario </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">M5J 2Y1 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Telephone: Zymeworks Securityholders located in Canada or in the United States may vote by telephone by
calling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-732-8683.</FONT></FONT></FONT> You will need to enter the <FONT STYLE="white-space:nowrap">15-digit</FONT> control number provided on
the form of proxy to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards over the phone. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Internet: You may vote over the Internet by going to www.investorvote.com. You will need to enter the <FONT
STYLE="white-space:nowrap">15-digit</FONT> control number provided on the form of proxy to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards over the internet. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Voting by telephone or on the Internet is fast, convenient and your vote is immediately confirmed and tabulated.
If you choose to vote by telephone or on the Internet, instructions to do so are set forth on the form of proxy. The telephone and Internet voting procedures are designed to authenticate votes cast by use of a control number, which appears on the
form of proxy. These procedures allow Zymeworks Securityholders to appoint a proxy to vote their Zymeworks Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards and to confirm that their instructions have been properly recorded. If you
vote by telephone, you will not be able to appoint a proxyholder. If you vote by telephone or on the Internet, your vote must be received by 1:00&nbsp;pm (Toronto time), on [&#9679;], 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Zymeworks or its strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors, may utilize the Broadridge QuickVote<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> service to assist <FONT STYLE="white-space:nowrap">non-registered</FONT> Shareholders with voting their Common Shares over the telephone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The persons named in the enclosed form of proxy are either directors or officers of Zymeworks. Please see section titled &#147;<I>Voting Information &#151;
Proxy Voting</I>&#148; above. <B>You have the right to appoint some other person of your choice, who need not be a Zymeworks Shareholder, director or officer, to attend and act on your behalf at the Special Meeting</B>. If you wish to do so, please
write the name of this person or entity, who need not be a shareholder, in the blank space provided in the form of proxy. <I>If you decide to vote by telephone or by the Internet, you cannot appoint a person to vote your Zymeworks Common Shares,
Zymeworks Warrants or Zymeworks Incentive Awards other than Zymeworks&#146; directors or officers whose printed names appear on the form of proxy. It is important to ensure that any other person you appoint as proxy is attending the Special Meeting
and is aware that his or her appointment has been made to vote your Zymeworks Common Shares, Zymeworks Warrants or Zymeworks</I> <I>Incentive Awards</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting in Person </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you wish to vote in person,
you do not need to complete or return your form of proxy. On the day of Special Meeting you will have to present yourself to a representative of Computershare at the registration table. Your vote will be taken and counted at the Special Meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any COVID protocols mandated by applicable local authorities that are in effect on the date of the Special Meeting will apply, to the extent applicable
to the Special Meeting. All attendees will be asked to present a valid government-issued photo identification, such as a driver&#146;s license or passport. The name on your photo identification will be verified against the list of Zymeworks
Securityholders of record as of the Record Date prior to your being admitted to the Special Meeting. If you do not have valid photo identification and we are unable to verify your ownership of Zymeworks Common Shares, Zymeworks Warrants or Zymeworks
Incentive Awards as of the Record Date, you will not be admitted into the Special Meeting. In order to expedite admission to the Special Meeting, you are encouraged to register in advance, by contacting Computershare at 1-800-564-6253 (from within
North America) or 1-514-982-7555 (from all other countries). Please include the following in your request: your name and complete mailing address; the name(s) of any immediate family member(s) who will accompany you; and proof that you own Zymeworks
Common Shares, Zymeworks Warrants or Zymeworks Incentive Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deadline for Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your duly completed form of proxy must be deposited with Computershare Investor Services Inc., Proxy Department, 100 University Avenue, 8th Floor, Toronto,
Ontario, M5J 2Y1, before [&#9679;] p.m. (Pacific time) on [&#9679;], or if the Special Meeting is adjourned or postponed, no later than [&#9679;] p.m. (Pacific time) on the second business day preceding the day to which the Special Meeting is
adjourned or postponed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revoking your Proxy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a Registered Shareholder, Zymeworks Warrantholder or Zymeworks Incentive Awardholder, you can change or revoke a previously delivered proxy in the following
ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Send a written notice that is received by the deadline specified below stating that you revoke your proxy to the
Corporation&#146;s Corporate Secretary at the following address: 114 East 4th Avenue, Suite 800, Vancouver BC, Canada V5T 1G4. The statement must be signed by you or your attorney as authorized in writing or, if the shareholder is a corporation,
signed under its corporate seal or by a duly authorized officer or attorney of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you sent a form of proxy by mail, complete a new form of proxy bearing a later date and properly submit it so
that it is received before the deadline set forth below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Log onto the Internet website specified on the form of proxy in the same manner you would to submit your proxy
electronically or call the toll-free number specified on the form of proxy prior to the Special Meeting, in each case if you are eligible to do so, and follow the instructions on the form of proxy; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Appear in person at the Special Meeting, declare your prior proxy to be revoked and then vote in person at the
Special Meeting (although merely attending the Special Meeting will not revoke your proxy). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any revocation of a proxy must be delivered
either to the registered office of Zymeworks at any time up to and including the last business day preceding the day of the Special Meeting or any adjournment or postponement of the Special Meeting, or to the Chair of the Zymeworks Board on the day
of the Special Meeting, [&#9679;], 2022, or any adjournment or postponement of the Special Meeting, prior to the time of the Special Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Beneficial Shareholder Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are a beneficial
Zymeworks Shareholder if your Zymeworks Common Shares are held in a nominee&#146;s name such as a bank, trust company, securities broker or other nominee. Typically, the form of proxy or voting instruction form sent or to be sent by your nominee
indicates whether you are a beneficial Zymeworks Shareholder. Generally, without specific instructions, brokers and their agents or nominees are prohibited from voting shares for their client. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How to Vote </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are eligible to vote and you
are a beneficial Zymeworks Shareholder, you can vote your Zymeworks Common Shares in person at the Special Meeting or by voting instructions, as explained below. Voting by providing voting instructions is the easiest way to vote your Zymeworks
Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Instructions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless
you have previously informed your nominee that you do not wish to receive material relating to the Special Meeting, you will have received this Proxy Statement/Prospectus from your nominee, together with a request for voting instructions for the
number of Zymeworks Common Shares you hold. If you do not plan on attending the Special Meeting, or do not otherwise wish to vote in person at the Special Meeting, please follow the voting instructions provided by your nominee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each nominee has its own procedures, which you should carefully follow to ensure that your Zymeworks Common
Shares are voted at the Special Meeting. These procedures generally allow voting in person or by proxy (telephone, fax, mail or Internet). Beneficial Shareholders should contact their nominee for instructions in this regard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Whether or not you attend the Special Meeting, you can appoint someone else to attend and vote as your proxyholder</B>. To do this, please follow the
procedures of your nominee carefully. The persons already named in the form of proxy are either directors or officers of Zymeworks. Please see section titled &#147;<I>Voting Information</I> &#151; <I>Proxy Voting</I>&#148; above. <I>It is important
to ensure that any other person you appoint as proxy is either attending the Special Meeting in person or returning a proxy reflecting your instructions and is aware that his or her appointment has been made to vote your Zymeworks Common Shares</I>.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting in Person </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you wish to vote in
person at the Special Meeting, insert your own name in the space provided on the request for voting instructions or form of proxy to appoint yourself as proxyholder and follow the instructions of your nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you wish to attend and vote your Zymeworks Common Shares at the Special Meeting, Zymeworks will have no record of your shareholdings or of your entitlement
to vote unless your nominee has appointed you as proxyholder. Therefore, if you wish to vote in person at the Special Meeting, insert your own name in the space provided on the voting instruction form sent to you by your nominee. Then sign and
return the voting instruction form by following the signing and returning instructions provided by your nominee. By doing so, you are instructing your nominee to appoint you as proxyholder. Do not otherwise complete the voting instruction form as
your vote will be taken at the Special Meeting. Please register with the transfer agent, Computershare, upon arrival at the Special Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deadline for Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If voting by voting
instructions, your nominee must receive your voting instructions in sufficient time for your nominee to act on them. Every nominee has its own procedures which you should carefully follow to ensure that your Zymeworks Common Shares are voted at the
Special Meeting. For your vote to count it must be deposited with our Transfer Agent before [&#9679;] p.m. (Pacific time) on [&#9679;], or if the Special Meeting is adjourned or postponed, no later than [&#9679;] p.m. (Pacific time) on the second
business day preceding the day to which the Special Meeting is adjourned or postponed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revoking Voting Instructions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To revoke your voting instructions, follow the procedures provided by your nominee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_8"></A>THE REDOMICILE TRANSACTIONS AND THE PLAN OF ARRANGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background to the Redomicile Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our
continuous evaluation of our business, the Zymeworks Board, along with management, monitors investor sentiment and capital market trends for opportunities to enhance shareholder value. From time to time, over the past several years, we have analyzed
a potential redomiciling of our business to the state of Delaware as a way to help build shareholder value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with executive management and
other organizational changes in January 2022, management began revisiting the potential of redomiciling to the state of Delaware, and in February 2022 management commenced a detailed review of the proposed Redomicile Transactions, with the
assistance of financial, legal, accounting and tax advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2022, management presented to the Zymeworks Board its initial analysis
regarding a potential redomiciling transaction, including available transaction structures, tax implications, anticipated benefits and potential risks. As part of its review, the Zymeworks Board discussed with management and its advisors the
potential Redomicile Transactions and how the proposed transaction could enhance shareholder value. Among other reasons, management discussed with the Zymeworks Board that the Redomicile Transactions (i)&nbsp;would eliminate restrictions on
investments imposed on certain U.S. institutional shareholders by virtue of Zymeworks being incorporated outside of the United States, (ii)&nbsp;may make Zymeworks eligible for inclusion in certain leading stock indices, such as the Russell and
S&amp;P indices, which are not available to foreign corporations and which, if included in such indices, could potentially increase passive investment interest and provide opportunities for increased value for our shareholders, (iii)&nbsp;could
provide enhanced flexibility for the monetization of <FONT STYLE="white-space:nowrap">non-core</FONT> assets, (iv)&nbsp;could simplify future transactions with potential U.S. counterparties by eliminating or reducing the complexities inherent in
cross-border transactions, and (v)&nbsp;would provide Zymeworks with the benefits of Delaware corporate law, which is widely recognized as the preeminent jurisdiction for incorporation in the United States and is better understood by U.S. investors
due to the significant number of U.S.-listed companies that are incorporated by Delaware, including the vast majority of Zymeworks&#146; peer companies. As part of the presentation, management also discussed with the Zymeworks Board other
opportunities that could benefit shareholders if Zymeworks were to have a Delaware-incorporated company as the public company. Among other reasons, the Redomicile Transactions could help streamline U.S. commercialization of our lead product
candidate, zanidatamab, by reducing or eliminating cross-border legal, regulatory and tax complexities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the potential benefits of the
Redomicile Transactions, management discussed with the Zymeworks Board potential risks associated with the Redomicile Transactions, including tax considerations and complexities related to available transaction structures. In light of the potential
benefits and with due consideration given to the potential risks, the Zymeworks Board directed management to review the costs of the potential Redomicile Transactions and to continue additional work to analyze the merits and risks of having a
Delaware incorporated company as the public company, as well as associated corporate governance and capital structure changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;23, 2022,
management presented to the Zymeworks Board an updated analysis regarding the potential Redomicile Transactions, including key transaction steps, estimated timeline to complete the Redomicile Transactions, and factors that could impact that
timeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 14, 2022, management and management&#146;s advisors presented to the Zymeworks Board their final analysis and recommendations regarding
the potential reincorporation, including updated key transaction steps, estimated timelines to complete the potential reincorporation and related considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to a review of management&#146;s recommendations, the Zymeworks Board discussed with management and management&#146;s advisors the potential
benefits and risks of the redomicile to Delaware, including those set </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forth in the section of this proxy statement/prospectus titled &#147;<I>Risk Factors &#151; Risks Relating to the Redomicile Transactions</I>&#148;. The Zymeworks Board also received advice
regarding the anticipated tax treatment applicable to Canadian and U.S. shareholders, as discussed in the section of this proxy statement/prospectus titled &#147;<I>Risk Factors &#151; Risks Relating to the Exchangeable Shares</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board reviewed the plan for the Redomicile Transactions and the Transaction Agreement and associated Plan of Arrangement. Following extensive
discussion of the key considerations of the Redomicile Transactions, including those noted under &#147;<I>The Redomicile Transactions &#151; Reasons for the Redomicile Transactions</I>&#148;, and after consulting with management and receiving
information provided to management by its advisors, the Zymeworks Board determined that the Redomicile Transactions are in the best interests of Zymeworks. Then, the Zymeworks Board approved proceeding with the Redomicile Transactions and
recommended that Zymeworks Securityholders vote in favor of the Redomicile Resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 15, 2022, prior to the opening of trading on the NYSE,
Zymeworks issued a news release announcing the Redomicile Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Zymeworks Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At its meeting held on July 14, 2022, after careful consideration of, among other things, the advice of management and after considering information provided
to management by Zymeworks&#146; tax, accounting and legal advisors and such other matters considered relevant, the Zymeworks Board determined that the Redomicile Transactions (including the Plan of Arrangement and the transactions to be completed
as soon as practicable following the Arrangement as set forth in the Transaction Agreement) are in the best interests of Zymeworks. Accordingly, the Zymeworks Board recommends that Zymeworks Securityholders vote <B><U>FOR</U></B> the Redomicile
Resolution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the Redomicile Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board determined that the Redomicile Transactions (including the Plan of Arrangement and the transactions to be completed as soon as practicable
following the Arrangement as set forth in the Transaction Agreement) are in the best interests of Zymeworks and believes that the opportunity to enhance long-term value for shareholders will be greater as a Delaware corporation than as a British
Columbia corporation. In recommending that Zymeworks Securityholders vote in favor of the Redomicile Resolution, the Zymeworks Board considered and relied upon a number of factors, including, among other things, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand U.S. Institutional Investor Base</B> &#151; Due to the fact that Zymeworks is a British Columbia
corporation, certain U.S. institutional investors and state-level investment vehicles are prohibited from investing in Zymeworks Common Shares or are limited in the size of such investment. Although the converse can also apply with respect to
certain Canadian institutional investors (i.e., Canadian institutional investors may face prohibitions or limitations on investing in U.S. corporations or may have adopted internal policies limiting such holdings), the Zymeworks Board believes that
becoming a Delaware corporation would provide greater opportunities to expand the institutional investor base, which would provide opportunities for increased value of Zymeworks Common Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Index Listing</B> &#151; As a Delaware corporation, Parent may be eligible for inclusion in certain leading
indices, such as the Russell and S&amp;P indices, which could also increase demand for Parent shares through passive investment by certain index funds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acquisition Proposals </B>&#151; Delaware law provides boards of directors with additional tools for
negotiating with potential acquirors, which may assist the board in increasing the value to stockholders in any proposed strategic transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>U.S.</B> <B>Stockholder Base </B>&#151; U.S. investors have greater familiarity with Delaware corporate law
and the Zymeworks Board believes this familiarity would make Zymeworks Common Shares a more attractive </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
investment for such investors, which could provide opportunities for increased value to current shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Comparability to U.S. Public Companies</B> &#151; Parent is a Delaware corporation. While there are
differences between the BCBCA and the DGCL and shareholders&#146; rights may be different under the DGCL than the BCBCA depending on the specific set of circumstances, the Zymeworks Board believes being incorporated in Delaware may provide greater
comparability to other U.S. public companies, many of which are incorporated in Delaware, including many of Zymeworks&#146; peer group companies. See section titled &#147;<I>Comparison of Rights of Zymeworks Shareholders and Parent
Stockholders</I>&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commercialization of Zanidatamab </B>&#151; The Zymeworks Board believes that, if zanidatamab is approved, the
United States will be a key geography for the commercialization of zanidatamab. Commercialization in the United States may require, among other things, hiring additional U.S. employees and entering into additional agreements with U.S.
counterparties. The Zymeworks Board believes that being a Delaware corporation would simplify such efforts by reducing some of the cross-border legal, regulatory and tax complexities related to these efforts. Beyond these anticipated benefits
relating to commercialization, the Zymeworks Board expects to be able to reduce certain administrative costs and complexities as a Delaware corporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand Opportunities for Future Monetization of Early-Stage Product Candidates </B>&#151; The Zymeworks Board
may in the future consider monetization opportunities for the Company&#146;s early-stage product candidates. A significant portion of potential counterparties for such transactions are located in the United States. The Zymeworks Board believes that
being a Delaware corporation would make Zymeworks more attractive to potential counterparties because it may reduce the tax, legal and regulatory complexity inherent to cross-border transactions and the potential counterparties are familiar with
Delaware corporate law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continuing Operations in Canada </B>&#151; The Redomicile Transactions would not prevent Parent from
indirectly continuing a portion of its operations in Canada through its Canadian subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board considered a number
of other factors pertaining to the Redomicile Transactions as generally supporting its decision to recommend the Redomicile Transactions, including, but not limited to, the following material factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Required Securityholder Approvals and Court Approval </B>&#151; The Redomicile Transactions will be submitted
to a vote at the Special Meeting and must be approved by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast at the Special Meeting on the Redomicile Resolution, in person or by proxy, by both
(i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately. In addition, the Redomicile Transactions are subject to
review by the Court, which will consider, among other things, the fairness of the Redomicile Transactions, both from a substantive and a procedural point of view. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tax Deferred Rollover</B> &#151; Zymeworks Shareholders who are Eligible Holders will have the opportunity to
elect to receive consideration that includes Exchangeable Shares instead of shares of Delaware Common Stock (subject to the Exchangeable Share Cap) with respect to all or a portion of their Zymeworks Common Shares and may generally make a valid tax
election with ExchangeCo to defer all or part of the Canadian income tax on any capital gain that would otherwise arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Market Familiarity with Redomicile Transactions </B>&#151; The Zymeworks Board believes the proposed structure
of the Redomicile Transactions is similar to that adopted by other former Canadian companies and is familiar to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>U.S. GAAP Reporting</B> &#151; Immediately prior to the Redomicile Transactions, shares of Delaware Common
Stock of Parent will be listed for trading on the NYSE. Parent will also continue to report </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
consolidated financial results in U.S. dollars and in accordance with U.S. GAAP and will file reports with the SEC and relevant Canadian securities regulatory authorities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Dissent Rights </B>- Registered Shareholders will have the ability to exercise Dissent Rights in respect of
the Redomicile Transactions and to be paid the fair value of their Zymeworks Common Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Estimated Corporate Tax Liability </B>&#151; The Zymeworks Board weighed the estimated corporate tax liability
arising from the Redomicile Transactions and, with the assistance of professional advisors and based on and subject to current assumptions, does not anticipate Zymeworks will incur material corporate-level Canadian or U.S. federal income tax
resulting from the Redomicile Transactions. Parent&#146;s effective tax rate may be affected by the Redomicile Transactions or by changes in tax laws. See section titled &#147;<I>Risk Factors</I> &#151; <I>Parent&#146;s effective tax rate may change
in the future, including as a result of the Redomicile Transactions.&#148;</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the course of their deliberations, the Zymeworks
Board, in consultation with management and after considering information provided to management by Zymeworks&#146; legal, accounting and tax advisors, also considered a variety of risks (as described in greater detail under the heading &#147;<I>Risk
Factors</I>&#148;) and other potentially negative factors relating to the Redomicile Transactions, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Conditions to the Redomicile Transactions </B>&#151; The Redomicile Transactions are conditional. The
Redomicile Transactions are subject to, among other things, receipt of the Required Securityholder Approval and approval by the Court. Such conditions may not be satisfied. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Failure to Realize Benefits to the Redomicile Transactions </B>&#151; Zymeworks may fail to realize the
perceived benefits of the Redomicile Transactions. For additional discussion of this risk, see the discussion under &#147;Risk Factors&#148;, including &#147;&#151;<I> Zymeworks may fail to realize certain benefits of the Redomicile Transactions,
including as a result of the shares of Delaware Common Stock not being included in a U.S. stock market index</I>&#148; and &#147;<I>The Redomicile Transactions may result in sales of shares of Delaware Common Stock by certain retail and
institutional shareholders or investment funds that are not permitted to hold shares of Delaware Common Stock under their internal guidelines.</I>&#148;<I>.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Uncertainty </B>&#151; Zymeworks&#146; business may be impacted by the uncertainty associated with the
Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Costs </B>&#151; Zymeworks will allocate time and resources to effecting the Redomicile Transactions and incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> costs related to the Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Redomicile Transactions May Be Deferred or Abandoned </B>&#151; Zymeworks may choose to defer or abandon the
Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Negative Publicity </B>&#151; Negative publicity resulting from the Redomicile Transactions could adversely
affect Zymeworks&#146; business and the market price of the Zymeworks Common Shares and the shares of Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Impact on Agreements </B>&#151; Completion of the Redomicile Transactions may trigger certain provisions in
agreements to which Zymeworks is a party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exercise of Dissent Rights </B>&#151; Payments in connection with the exercise of Dissent Rights by Zymeworks
Shareholders may impact Parent&#146;s financial resources. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Limitation on Enforcement Against Parent in Canada </B>&#151; Enforcement of rights against Parent in Canada
may be limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tax Impact on <FONT STYLE="white-space:nowrap">Non-Eligible</FONT> Shareholders and Eligible Holders if the
Exchangeable Share Cap is Reached</B> &#151; The disposition of Zymeworks Common Shares in exchange for shares of Delaware Common Stock in connection with the Redomicile Transactions would be taxable to Zymeworks Shareholders who are residents of
Canada other than Eligible Holders that elect to receive Exchangeable Shares (subject to the Exchangeable Share Cap) and make a valid tax election with ExchangeCo to defer all or part of the Canadian income tax on any capital gain that would
otherwise </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
arise on the disposition of their Zymeworks Common Shares under the Plan of Arrangement. If the Exchangeable Share Cap is reached, then the Exchangeable Shares will be allocated proportionally
among the Eligible Holders that elect to receive Exchangeable Shares based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder. Any remaining Zymeworks Common Shares held
by those Eligible Holders will be exchanged for Delaware Common Stock and will be a taxable disposition of their Zymeworks Common Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the information and factors considered by the Zymeworks Board includes the principal positive and negative factors considered by
them, but is not intended to be exhaustive and may not include all of the factors considered, and, in view of the number and complexity of factors considered by the Zymeworks Board, the Zymeworks Board did not find it practicable to, nor did it
attempt to, quantify, rank or otherwise assign relative weights to the specific factors considered by them in making their recommendations (and individual members of the Zymeworks Board may have given different weights to different factors). The
Zymeworks Board reached their recommendation based on the totality of the information presented to, and considered by, them through their deliberations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion of the information and factors considered by the Zymeworks Board is forward-looking in nature. This information should be read in
light of the factors set forth in the sections entitled &#147;<I>Information Contained in Proxy Statement/Prospectus</I>&#148;, &#147;<I>Cautionary Statement Regarding Forward-Looking Statements</I>&#148;, &#147;<I>The Redomicile Transactions and
the Plan of Arrangement &#151; Background to the Redomicile Transactions</I>&#148; and &#147;<I>Risk Factors</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Particulars of the Redomicile
Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The following summary of certain transaction steps of the Redomicile Transactions is qualified in its entirety by reference to the
full text of Transaction Agreement, which is set forth in Appendix B to this Proxy Statement/Prospectus, and the Plan of Arrangement, a copy of which is attached as Exhibit A to the Transaction Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions are being implemented in accordance with the terms of and subject to the conditions contained in the Transaction Agreement
(including, with respect to the Arrangement and the Plan of Arrangement). Pursuant to the terms of the Plan of Arrangement, the Arrangement will be completed at the Effective Time. The Redomicile Transactions are subject to the satisfaction or
waiver of the conditions thereto as set out in the Transaction Agreement. See section titled &#147;<I>Summary of the Transaction Agreement</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
purpose of the Redomicile Transactions is to facilitate a series of transactions which will occur in a specific sequence and as a consequence of which, among other things: (i)&nbsp;Zymeworks Shareholders will receive, at their election and subject
to applicable eligibility criteria, for their Zymeworks Common Shares, either (a)&nbsp;shares of Delaware Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or (b)&nbsp;Exchangeable
Shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or a mix of Exchangeable Shares and Delaware Common Stock (in such aggregate number that is equal to the number of Zymeworks Common Shares
exchanged for them), subject to the Exchangeable Share Cap; (ii)&nbsp;Parent, Callco and ExchangeCo will enter into the Support Agreement; and (iii)&nbsp;Parent, ExchangeCo, Callco and Share Trustee will enter into the Trust Agreement for the
benefit of the Exchangeable Shareholders. If the Exchangeable Share Cap is reached, then the Exchangeable Shares shall be allocated proportionally among the applicable Zymeworks Shareholders based on the number of Designated Zymeworks Common Shares
and rounded down to the nearest whole share in respect of each Eligible Holder, and any other Zymeworks Common Shares held by them will be exchanged for Delaware Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Delaware Common Stock will be listed on the NYSE under the symbol &#147;ZYME&#148;. See section titled &#147;<I>The Redomicile Transactions and the
Plan of Arrangement &#151; Certain Legal and Regulatory Matters &#151; Stock Exchange Listings</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Plan of Arrangement Steps </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Plan of Arrangement, commencing at [&#9679;] Pacific time on the Effective Date, each of the following events or transactions shall occur and
be deemed to occur in the following sequence and five minutes<B> </B>following the event(s) in the immediately preceding section, without any further act or formality, unless specifically noted: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to Section&nbsp;5.1 of the Plan of Arrangement, each of the Zymeworks Common Shares held by Dissenting
Shareholders shall be, and shall be deemed to be, transferred to Zymeworks (free and clear of any Liens) and cancelled in consideration for a debt claim against Zymeworks for the amount determined in accordance with Section&nbsp;3.1(a) of the Plan
of Arrangement, and: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such Dissenting Shareholders shall cease to be the holders of such Zymeworks Common Shares and to have any
rights as holders of such Zymeworks Common Shares (including for the purposes of any matter concerning the Zymeworks Common Shares or the Zymeworks Shareholders in the remainder of Section&nbsp;3.1 of the Plan of Arrangement), other than the right
to be paid fair value for such Zymeworks Common Shares as set out in Section&nbsp;3.1(a) of the Plan of Arrangement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such Dissenting Shareholders&#146; names shall be removed as the holders of such Zymeworks Common Shares from
the registers of Zymeworks Common Shares maintained by or on behalf of Zymeworks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Eligible</FONT> Holders and Eligible Holders who have not made an election
for the purposes of (c)&nbsp;below (and in each case excluding Dissenting Shareholders) will receive shares of Delaware Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Eligible Holders will receive, at their election, Exchangeable Shares on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or a mix of Exchangeable Shares and Delaware Common Stock (in such aggregate number that is equal to the number of Zymeworks Common Shares exchanged for them), subject to the Exchangeable
Share Cap. If the Exchangeable Share Cap is reached, then the Exchangeable Shares shall be allocated proportionally among the applicable Eligible Holders based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole
share in respect of each Eligible Holder, and any other Zymeworks Common Shares held by them will be exchanged for Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Zymeworks Shareholders who have surrendered their Zymeworks Common Shares in the exchange described in
(b)&nbsp;and (c) shall cease to be, and shall be deemed to cease to be, holders of such Zymeworks Common Shares and to have any rights as holders of such Zymeworks Common Shares other than the right to receive the consideration to which they are
entitled pursuant to the Plan of Arrangement, and such Zymeworks Shareholders&#146; names shall be removed as the holders from the register of Zymeworks Common Shares maintained by or on behalf of Zymeworks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent, Callco and ExchangeCo will enter into the Support Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent, ExchangeCo, Callco and Share Trustee will enter into the Trust Agreement for the benefit of the
Exchangeable Shareholders, and one share of Special Voting Stock will be issued to the Share Trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the term &#147;Change of Control&#148; as defined in the &#147;Inducement Stock Option and Equity Compensation
Plan&#148; and the &#147;Amended and Restated Stock Option and Equity Compensation Plan&#148; forming part of the Zymeworks Incentive Plans will be deemed to be amended to include any transaction, plan, scheme, reorganization or arrangement whereby
Parent acquires, directly or indirectly, greater than 50% of the Zymeworks Common Shares, such that Parent will be a successor to Zymeworks under such plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks will assign to Parent, and Parent will assume, all of Zymeworks&#146; rights and obligations under
the Zymeworks Incentive Plans, and such plans will become Parent Incentive Plans, and each Zymeworks Incentive Award outstanding immediately prior to the Effective Time will be assumed by
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Parent and be exchanged for a Parent Incentive Award identical to such Zymeworks Incentive Award in all material respects (except such award will cover shares of Delaware Common Stock instead of
Zymeworks Common Shares); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks will assign to Parent, and Parent shall assume, all of Zymeworks&#146; rights and obligations under
the Zymeworks Warrants, and in accordance with the provisions regarding &#147;Fundamental Transactions&#148; (as that term is defined in the Zymeworks Warrants), and the Zymeworks Warrantholders will be entitled to receive Delaware Common Stock
(instead of Zymeworks Common Shares) upon exercise of the Zymeworks Warrants in accordance with the terms of the Zymeworks Warrants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks and Parent may amend, modify and/or supplement the Plan of Arrangement at any time and from time to time prior to the Effective Date, provided that
any such amendment, modification or supplement must be contained in a written document which is: (i)&nbsp;filed with the Court and, if made following the Special Meeting and adversely affecting the economic interest of any Zymeworks Securityholder,
approved by the Court; and (ii)&nbsp;if required by the Court, communicated to the Zymeworks Securityholders in the manner required by the Court. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Arrangement Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the Effective
Time, and as part of the Redomicile Transactions, the following additional steps will take place: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the share capital of Zymeworks will be reorganized to create a second class of common shares having
substantially similar rights and restrictions as the existing common shares (the &#147;<B>New Common Shares</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ExchangeCo will exchange all of its existing Zymeworks Common Shares for an equal number of New Common Shares
of Zymeworks; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks will effect a distribution of all of the shares of Zymeworks Biopharmaceuticals Inc.
(&#147;<B>ZBI</B>&#148;) and Zymeworks Pharmaceuticals Limited (the &#147;<B>Irish Sub</B>&#148;) to Parent, in kind, as a reduction of capital on the Zymeworks Common Shares held by Parent, and ZBI and the Irish Sub will each become a wholly-owned
subsidiary of Parent. The shares of the Irish Sub are expected to have nominal value. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of the Redomicile Transactions on the
Original Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;9, 2022, the Zymeworks Board authorized and declared a dividend distribution of one Original Right for each outstanding
Zymeworks Common Share to Zymeworks Shareholders of record as of the close of business on June&nbsp;21, 2022. Each Original Right entitles the registered holder to purchase from Zymeworks one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of
a Series A Preferred Share of Zymeworks at an exercise price of $74.00, subject to adjustment. The complete terms of the Original Rights are set forth in the Zymeworks Rights Agreement. The complete terms of the Original Rights are set forth in the
Zymeworks Rights Agreement, dated as of June 9, 2022, between the Company and Computershare Trust Company, N.A., as rights agent. For more information with respect to the Zymeworks Rights Agreement, including a summary of its terms, please refer to
Zymeworks&#146; Current Report on Form&nbsp;8-K filed with the SEC on June 10, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board adopted the Zymeworks Rights Agreement to
protect shareholders from coercive or otherwise unfair takeover tactics. In general terms, it works by imposing a significant penalty upon any person or group that acquires 10&nbsp;percent or more (or 20&nbsp;percent or more in the case of certain
institutional investors who report their holdings on Schedule 13G) of the Zymeworks Common Shares without the approval of the Zymeworks Board. As a result, the overall effect of the Zymeworks Rights Agreement and the issuance of the Original Rights
may be to render more difficult or discourage a merger, amalgamation, arrangement, take-over bid, tender or exchange offer or other business combination involving the Company that is not approved by the Zymeworks Board. However, neither the
Zymeworks Rights Agreement nor the Original Rights should interfere with any merger, amalgamation, arrangement, take-over bid, tender or exchange offer or other business combination approved by the Zymeworks Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, the Original Rights will be terminated and Parent expects to
adopt a stockholder rights plan with respect to the Delaware Common Stock substantively similar in all material respects to the Zymeworks Rights Agreement. Parent expects that the new rights will accompany, and be evidenced by and trade with, the
Delaware Common Stock upon issuance pursuant to the Redomicile Transactions, and that holders of Exchangeable Shares will receive their new rights upon the exchange of their Exchangeable Shares for Delaware Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of the Redomicile Transactions on the Zymeworks Incentive Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, Parent will assume the Zymeworks Incentive Plans, which will become Parent Incentive Plans, and each
outstanding Zymeworks Incentive Award will be assumed and be deemed to be exchanged for a Parent Incentive Award. The assumed and exchanged Zymeworks Incentive Awards will remain subject to the terms and conditions of the Zymeworks Incentive Plans,
except that the security issuable upon exercise or settlement of the Zymeworks Incentive Award, as applicable, will be shares of Delaware Common Stock rather than Zymeworks Common Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of the Redomicile Transactions on the Zymeworks Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent will assume the Zymeworks Warrants in accordance with their terms, except that the security issuable upon exercise will be shares of Delaware Common
Stock rather than Zymeworks Common Shares.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Effect of the Redomicile Transactions on Parent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canadian Federal Income Tax Considerations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
Canadian federal income tax purposes, Zymeworks does not expect the Redomicile Transactions to give rise to corporate-level Canadian federal income tax for Zymeworks or Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Federal Income Tax Considerations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S.
federal income tax purposes, Zymeworks does not expect the Redomicile Transactions to give rise to corporate-level U.S. federal income tax for Zymeworks or Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Officers of Parent following the Redomicile Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The same persons currently serving as directors and officers of Zymeworks will serve as directors and officers of Parent following the Redomicile
Transactions.<B> </B>See section titled &#147;<I>Information Concerning Parent, ExchangeCo and Callco &#150; Directors and Officers</I><B><I> </I></B><I>of Parent</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Letter of Transmittal and Election Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Letter of
Transmittal and Election Form will be mailed, together with this Proxy Statement/Prospectus, to each person who was a registered holder of Zymeworks Common Shares on the Record Date. Each Registered Shareholder must forward a duly completed and
executed Letter of Transmittal and Election Form, with accompanying Zymeworks Common Share certificate(s) and/or such other documents and instruments as the Depositary may reasonably require, in order to receive the shares of Delaware Common Stock
or Exchangeable Shares, as applicable, to which such Zymeworks Shareholder is entitled under the Redomicile Transactions. It is recommended that Zymeworks Shareholders complete, sign and return the Letter of Transmittal and Election Form and
accompanying documents to the Depositary as soon as possible. All deposits of Zymeworks Common Shares made under a Letter of Transmittal and Election Form are irrevocable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Registered Shareholder who is an Eligible Holder will have the right to elect to receive Exchangeable Shares or a mix of Exchangeable Shares and Delaware
Common Stock (subject to the Exchangeable Share Cap), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by delivering a duly completed Letter of Transmittal and Election Form to the Depository prior to the Election Deadline, being 5:00 p.m. (Vancouver time) on the date before the Special Meeting.
Eligible Holders who do not make an election before the Election Deadline, or for whom their election is not properly made with respect to their Zymeworks Common Shares, will receive Delaware Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial Shareholders whose Zymeworks Common Shares are registered in the name of an Intermediary should contact that Intermediary for instructions on
making an election with respect to the Consideration that they wish to receive. See &#147;<I>Procedure for the Exchange of Shares</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks
Shareholders who are not Eligible Holders will not have the right to make an election and will receive Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Letter of Transmittal
and Election Form is available as an exhibit to the registration statement of which this Proxy Statement/Prospectus forms a part, and on Zymeworks&#146; website at www.zymeworks.com, on SEDAR at www.sedar.com and on the SEC&#146;s website at
www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any use of the mail to transmit a certificate for Zymeworks Common Shares or surrender book-entry Zymeworks Common Shares and a related
Letter of Transmittal and Election Form is at the risk of the Zymeworks Shareholder. If these documents are mailed, it is recommended that registered mail, properly insured, be used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not Zymeworks Shareholders forward the certificate(s) representing their Zymeworks Common Shares or surrender their book-entry Zymeworks Common
Shares, from and after completion of the Redomicile Transactions, and at the times contemplated in the Plan of Arrangement and the Transaction Agreement, each certificate, agreement, note, document, electronic record, book entry or other instrument
(as applicable) that immediately prior to the completion of the Redomicile Transactions represented Zymeworks Securities shall be deemed to represent only the right to receive the consideration in respect of such Zymeworks Securities required under
the Plan of Arrangement and the Transaction Agreement, as applicable, less any withholding amounts pursuant to the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The instructions
for exchanging certificates representing Zymeworks Common Shares and depositing such share certificates with the Depositary and surrendering book-entry Zymeworks Common Shares are set out in the Letter of Transmittal and Election Form. The Letter of
Transmittal and Election Form provides instructions with regard to lost certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IF YOU ARE A REGISTERED ZYMEWORKS SHAREHOLDER, YOU MUST SURRENDER
YOUR ZYMEWORKS COMMON SHARES THROUGH A LETTER OF TRANSMITTAL AND ELECTION FORM BY THE DAY THAT IS THREE YEARS LESS ONE DAY FROM THE EFFECTIVE DATE IN ORDER TO RECEIVE THE SHARES OF DELAWARE COMMON STOCK OR EXCHANGEABLE SHARES TO WHICH YOU ARE
ENTITLED UNDER THE PLAN OF ARRANGEMENT. <B>ON SUCH DATE, ANY AND ALL CONSIDERATION TO WHICH SUCH FORMER HOLDER WAS ENTITLED WILL BE DEEMED TO HAVE BEEN </B><B><U>CANCELLED</U></B><B> AND NONE OF ZYMEWORKS, PARENT, EXCHANGECO OR ANY OTHER PERSON WILL
HAVE ANY OBLIGATION TO ISSUE SUCH SHARES OF DELAWARE COMMON STOCK OR EXCHANGEABLE SHARES.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedure for the Exchange of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, such number of shares of Delaware Common Stock and Exchangeable Shares as is required pursuant to the
Redomicile Transactions will be deposited with the Depositary for the benefit of the Zymeworks Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon surrender to the Depositary for
cancellation of a certificate which immediately prior to the Effective Time represented outstanding Zymeworks Common Shares or book-entry Zymeworks Common Shares that were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchanged and transferred pursuant to the Plan of Arrangement and otherwise affected after giving effect to the Redomicile Transactions, together with the duly completed and executed Letter of
Transmittal and Election Form and such additional documents and instruments as the Depositary may reasonably require, the Zymeworks Shareholder surrendering such certificate or book-entry Zymeworks Common Shares will be entitled to receive in
exchange therefor, and the Depositary will deliver to such Zymeworks Shareholder, the consideration which such Zymeworks Shareholder has the right to receive under the Redomicile Transactions for such Zymeworks Common Shares (including certificates
representing the number of shares of Delaware Common Stock or Exchangeable Shares issued to such holder in accordance with the Redomicile Transactions), less any amounts withheld pursuant to the Plan of Arrangement, and any Zymeworks Common Share
certificate or book-entry Zymeworks Common Shares so surrendered will forthwith be cancelled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any exchange or transfer of Zymeworks Common Shares
pursuant to the Redomicile Transactions will be free and clear of any Liens. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Return of Zymeworks Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Redomicile Transactions are not completed, any deposited Zymeworks Common Shares will be returned to the depositing Zymeworks Shareholder at
Zymeworks&#146; expense upon written notice to the Depositary from Zymeworks, by returning the deposited Zymeworks Common Shares (and any other relevant documents) by first class insured mail in the name of and to the address specified by the
Zymeworks Shareholder in the Letter of Transmittal and Election Form or, if such name and address is not so specified, in such name and to such address as shown on the register maintained by Zymeworks&#146; transfer agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lost Certificates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any certificate which immediately
prior to the Effective Time represented one or more outstanding Zymeworks Common Shares that were transferred pursuant to the Plan of Arrangement has been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming
such certificate to be lost, stolen or destroyed, the Depositary will deliver in exchange for such lost, stolen or destroyed certificate, the consideration to which the holder is entitled pursuant to the Redomicile Transactions. When authorizing
such delivery in exchange for any lost, stolen or destroyed certificate, the Person to whom such consideration is to be delivered, will as a condition precedent to the delivery of such consideration, give a bond satisfactory to Parent and the
Depositary (each acting reasonably) in such sum as Parent may direct, or otherwise indemnify Parent and the Depositary in a manner satisfactory to Parent and the Depositary (each acting reasonably) against any claim that may be made against Parent
and the Depositary with respect to the certificate alleged to have been lost, stolen or destroyed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cancellation of Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until surrendered, each certificate that immediately prior to the Effective Time represented Zymeworks Common Shares or book-entry Zymeworks Common Shares will
be deemed after the Effective Time to represent only the right to receive upon such surrender the consideration to which the holder is entitled to receive. Any such certificate, agreement, note, document, electronic record, book entry or other
instrument (as applicable) formerly representing Zymeworks Common Shares not duly surrendered on or before the day that is three years less one day from the Effective Date will cease to represent a claim by or interest of any kind or nature against
Zymeworks, ExchangeCo or Parent, including without limitation shares of Delaware Common Stock or Exchangeable Shares. On such date, any and all consideration to which such former holder was entitled will be deemed to have been cancelled and none of
Zymeworks, Parent, ExchangeCo or any other Person will have any obligation to issue such shares of Delaware Common Stock or Exchangeable Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks, Parent, Callco, ExchangeCo
and the Depositary shall be entitled to deduct and withhold from any consideration payable to any Zymeworks Securityholder under the Redomicile Transactions, such amounts as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Zymeworks, Parent, Callco, ExchangeCo or the Depositary determines, acting reasonably, are required or reasonably believed to be required to be deducted and withheld from such consideration under
any provision of any Laws in respect of taxes. Any such amounts shall be treated for all purposes as having been paid to the Person in respect of which such deduction and withholding was made and such deducted and withheld amounts shall be remitted
to the appropriate Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks does not expect any withholding to be required for Canadian federal income tax purposes or U.S. federal
income tax purposes as a result of the Redomicile Transactions. Refer to &#147;<I>Material Canadian Federal Income Tax Considerations</I>&#148;<I> </I>and &#147;<I>Material U.S. Federal Income Tax Considerations</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fractional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No certificates representing
fractional Zymeworks Common Shares, shares of Delaware Common Stock or Exchangeable Shares shall be issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks has retained the services of the Depositary for the receipt of the Letter of Transmittal and Election Form and the certificates representing
Zymeworks Common Shares, the surrender of book-entry Zymeworks Common Shares and for the delivery of the shares of Delaware Common Stock and Exchangeable Shares in exchange for the Zymeworks Common Shares under the Redomicile Transactions. The
Depositary will receive reasonable and customary compensation for its services in connection with the Redomicile Transactions, will be reimbursed for certain reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and will be indemnified against certain liabilities, including liabilities under securities laws and expenses in connection therewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expenses of the Redomicile Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks
estimates that expenses in the aggregate amount of approximately $[&#9679;] will be incurred by Zymeworks in connection with the Redomicile Transactions, including legal, tax and accounting advisors, Depositary, transfer agents, proxy solicitor,
filing and printing costs and the cost of preparing and mailing this Proxy Statement/Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Securityholder Approvals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be effective, the Redomicile Resolution must be approved, with or without variation, by the affirmative vote of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on the Redomicile Resolution, in person or by proxy, by both (i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a
single class, and (ii)&nbsp;Zymeworks Shareholders, voting separately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Zymeworks Board recommends that Zymeworks Securityholders vote <U>FOR</U>
the Redomicile Resolution. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Legal and Regulatory Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Court Approval </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Arrangement under the BCBCA
requires Court approval. Prior to the mailing of this Proxy Statement/Prospectus, Zymeworks obtained the Interim Order providing for the calling and holding of the Special Meeting, the Dissent Rights and other procedural matters, including, but not
limited to: (a)&nbsp;the Required Securityholder Approval; (b)&nbsp;the Dissent Rights for Registered Shareholders; (c)&nbsp;the notice requirements with respect to the Court hearing of the application for the Final Order; (d)&nbsp;the ability of
Zymeworks to adjourn or postpone the Special Meeting from time to time in accordance with the terms of the Transaction Agreement without the need for additional approval of the Court; and (e)&nbsp;the Record Date for the Zymeworks Securityholders
entitled to notice of and to vote at the Special Meeting. A copy of the Interim Order is attached hereto as Appendix D. A copy of Zymeworks&#146; Notice of Hearing of Petition is attached hereto as Appendix E. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Transaction Agreement, and if the Redomicile Resolution is approved by the
Zymeworks Securityholders at the Special Meeting in the manner required by the Interim Order, Zymeworks intends to make an application to the Court for the Final Order. The Interim Order provides for a Final Order approving the Redomicile
Transactions to be heard via Microsoft Teams at the courthouse at 800 Smithe Street, Vancouver, British Columbia at [&#9679;] a.m. on [&#9679;], or as soon thereafter as counsel may be heard, or at any other date and time and by any other method as
the Court may direct. Any Zymeworks Securityholder or other interested party who wishes to participate, appear, or to be represented, and to present evidence or arguments at the hearing must file and serve a Response to Petition in the form
prescribed by the <I>Supreme Court Civil Rules (British Columbia)</I> together with any evidence or materials that such party intends to present to the Court, on or before [&#9679;] (Vancouver time) on [&#9679;], all as set out in the Interim Order
and Notice of Hearing of Petition. Service of such notice shall be effected by service upon the solicitors of Zymeworks: Blake, Cassels&nbsp;&amp; Graydon LLP, Suite 2600 &#150; 595 Burrard Street, Vancouver, British Columbia, V7X 1L3, Attention:
Sean Boyle and Alexandra Luchenko. In the event that the hearing is postponed, adjourned or rescheduled then, subject to further direction of the Court, only those persons having previously served a Response to Petition in compliance with the
Interim Order will be given notice of the adjournment or postponement, or the new date. Participation in the Court hearing of the application for the Final Order, including who may participate and present evidence or argument and the procedure for
doing so, is subject to the terms of the Interim Order and any subsequent direction of the Court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Court has broad discretion under the BCBCA when
making orders with respect to plans of arrangement and that the Court will consider at the hearing to obtain the Final Order, among other things, the fairness of the Redomicile Transactions, both from a substantive and a procedural point of view.
The Court may approve the Redomicile Transactions either as proposed or as amended in any manner the Court may direct, subject to compliance with such terms and conditions, if any, as the Court thinks fit. Depending upon the nature of any amendments
to the plan of arrangement required by the Court, Zymeworks may determine not to proceed with the Redomicile Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further information
regarding the Court hearing and your rights in connection with the Court hearing, see the form of the Notice of Hearing of Petition attached as Appendix E to this Proxy Statement/Prospectus. The Notice of Hearing of Petition constitutes notice of
the Court hearing of the application for the Final Order and is your only notice of the Court hearing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Exchange Listings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, the Zymeworks Common Shares trade on the NYSE under the symbol &#147;ZYME&#148;. Immediately prior to the Redomicile Transactions, the shares of
Delaware Common Stock will be listed for trading on the NYSE under the symbol &#147;ZYME&#148;. When the Redomicile Transactions are completed, the Zymeworks Common Shares currently listed on the NYSE will cease to be traded on the NYSE and will be
deregistered under the U.S. Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material Canadian Securities Law Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Delaware Common Stock and Exchangeable Shares to be issued pursuant to the Redomicile Transactions will be issued pursuant to an exemption from
the prospectus and registration requirements of applicable Canadian Securities Laws under Section&nbsp;2.11 of NI <FONT STYLE="white-space:nowrap">45-106</FONT> and will generally not be subject to any resale restrictions under applicable Canadian
Securities Laws, provided that the following conditions are satisfied: (a)&nbsp;the issuer of such shares, pursuant to Section&nbsp;2.9 of NI <FONT STYLE="white-space:nowrap">45-102,</FONT> is and has been a reporting issuer in a jurisdiction of
Canada for the four months immediately preceding the trade (upon completion of the Redomicile Transactions, Parent will be deemed to have been a reporting issuer from the time that Zymeworks became a reporting issuer, satisfying this requirement);
(b) the trade is not a control distribution; (c)&nbsp;no unusual effort is made to prepare the market or to create a demand for the security that is the subject of the trade; (d) no extraordinary commission or consideration is paid to a person or
company in respect of the trade; (e)&nbsp;if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
selling securityholder is an insider or officer of the issuer, the selling securityholder has no reasonable grounds to believe that the issuer is in default of securities legislation (each as set
out in Section&nbsp;2.6(3) of NI <FONT STYLE="white-space:nowrap">45-102);</FONT> and (f)&nbsp;such holder is not a person or company engaged in or holding itself out as engaging in the business of trading securities or such trade is made in
accordance with applicable dealer registration requirements or in reliance upon an exemption from such requirements. Zymeworks Shareholders should consult with their own financial and legal advisors with respect to any restrictions on the resale of
shares of Delaware Common Stock and Exchangeable Shares received on completion of the Redomicile Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Reporting Obligations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following completion of the Redomicile Transactions, Parent will be subject to the reporting requirements of the SEC as the successor issuer to
Zymeworks. Parent will also become a reporting issuer in each of the provinces and territories of Canada where Zymeworks is currently a reporting issuer and will become subject to the applicable Canadian continuous disclosure requirements in the
same manner as Zymeworks is currently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with how Zymeworks currently reports, Parent will report consolidated financial results in U.S. dollars
and in accordance with U.S. GAAP and will file reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> with the SEC and comply with the proxy rules
under the U.S. Exchange Act. In accordance with applicable Canadian securities laws, and consistent with Zymeworks&#146; current practice, Parent will generally file with the relevant Canadian securities regulatory authorities copies of its
documents filed with the SEC under the U.S. Exchange Act in order to meet its Canadian continuous disclosure obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dissent Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the provisions of Division 2 of Part 8 of the BCBCA, as modified by the Plan of Arrangement and the Interim Order, relating to a
Registered Shareholder&#146;s Dissent Rights in respect of the Redomicile Resolution. It is not a comprehensive statement of such rights and procedures and is qualified in its entirety by the reference to the full text of Division 2 of Part 8 of the
BCBCA (which is attached as Appendix C to this Proxy Statement/Prospectus), as may be modified by the Transaction Agreement and the Interim Order (which are attached as Appendix B and Appendix D<B> </B>to this Proxy Statement/Prospectus,
respectively) and any further order of the Court. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The statutory provisions dealing with the right of dissent are technical and complex. Any Zymeworks
Shareholder who intends to exercise Dissent Rights should carefully consider and comply with the provisions of Division 2 of Part 8 of the BCBCA, as modified by the Interim Order, the Plan of Arrangement, and any other order of the Court, and seek
legal advice. Failure to comply strictly with the provisions of Division 2 of Part 8 of the BCBCA, as may be modified by the Interim Order, the Plan of Arrangement, and any other order of the Court, and to adhere to the procedures established
therein, may result in the loss of all rights thereunder. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Interim Order, Registered Shareholders as of the Record Date have been
granted Dissent Rights with respect to the Redomicile Resolution. Each Dissenting Shareholder is entitled to be paid the fair value (determined as of the close of business on the last Business Day before the Redomicile Resolution was adopted at the
Special Meeting) of all, but not less than all, of the holder&#146;s Zymeworks Common Shares in accordance with the provisions of Division 2 of Part 8 of the BCBCA, as may be modified by the Interim Order, the Plan of Arrangement, and any other
order of the Court, provided that the holder duly dissents with respect to the Redomicile Resolution and the Redomicile Transactions become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;238 of the BCBCA, every Registered Shareholder who duly and validly dissents from the Redomicile Resolution in strict compliance with
Division 2 of Part 8 of the BCBCA, as may be modified by the Interim Order, the Plan of Arrangement, and any further order of the Court will be entitled to be paid the fair value of the Zymeworks Common Shares held by such Dissenting Shareholder
determined as at the point in time immediately before the passing of the Redomicile Resolution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Persons who are beneficial owners of Zymeworks Common Shares registered in the name of a broker, bank, trust
company or other intermediary or nominee who wish to dissent should be aware that only Registered Shareholders are entitled to exercise Dissent Rights. Accordingly, a Beneficial Shareholder desiring to exercise this right must make arrangements for
the Zymeworks Common Shares beneficially owned by such Zymeworks Shareholder to be registered in the Zymeworks Shareholder&#146;s name prior to the time the Dissent Notice is required to be received by Zymeworks, or, alternatively, make arrangements
for the registered holder of such Zymeworks Common Shares to dissent on the Zymeworks Shareholder&#146;s behalf. A Zymeworks Shareholder that votes in favor of the Redomicile Resolution will not be entitled to Dissent Rights but a Zymeworks
Shareholder&#146;s failure to vote against the Redomicile Resolution will not constitute a waiver of such shareholder&#146;s dissent rights and a vote against the Redomicile Resolution will not be deemed to satisfy notice requirements under the
BCBCA with respect to Dissent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered Zymeworks Shareholders who wish to dissent must provide a written objection to the Redomicile Resolution
(a &#147;<B>Dissent Notice</B>&#148;) to Zymeworks, c/o Blake, Cassels&nbsp;&amp; Graydon LLP, 595 Burrard Street, Suite 2600, Vancouver BC V7X 1L3, Attention: Sean Boyle and Alexandra Luchenko, which Dissent Notice must be received by [&#9679;],
2022, or such day that is two Business Days immediately preceding the date that any adjournment or postponement of the Special Meeting is reconvened, and must otherwise strictly comply with the dissent procedures prescribed by the BCBCA, as may be
modified and supplemented by the Interim Order, the Plan of Arrangement, and any other order of the Court. A copy of the Plan of Arrangement is attached as Exhibit A to the Transaction Agreement, which is set forth in Appendix B to the Proxy
Statement/Prospectus. Copies of the text of Division 2 of Part 8 of the BCBCA and the Interim Order are set forth in Appendices C and D,<B> </B>respectively, to the Proxy Statement/Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exercise Dissent Rights, a Registered Shareholder must dissent with respect to all Zymeworks Common Shares of which it is the registered and beneficial
owner, except as expressly set forth below. Beneficial Shareholders who wish to exercise Dissent Rights must cause the registered Zymeworks Shareholder holding their Zymeworks Common Shares to deliver the Dissent Notice. A Registered Shareholder
that votes in favour of the Redomicile Resolution will not be entitled to Dissent Rights but a Zymeworks Shareholder&#146;s failure to vote against the Redomicile Resolution will not constitute a waiver of such shareholder&#146;s Dissent Rights and
a vote against the Redomicile Resolution will not be deemed to satisfy notice requirements under the BCBCA with respect to Dissent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Registered
Shareholder must prepare a separate Dissent Notice for him, her or itself, if dissenting on his, her or its own behalf, and for each other Beneficial Shareholder who beneficially owns Zymeworks Common Shares registered in the Zymeworks
Shareholder&#146;s name and on whose behalf the Registered Shareholder is dissenting; and, if dissenting on its own behalf, must dissent with respect to all of the Zymeworks Common Shares registered in his, her or its name or if dissenting on behalf
of a beneficial Zymeworks Shareholder, with respect to all of the Zymeworks Common Shares registered in his, her or its name and beneficially owned by the beneficial Zymeworks Shareholder on whose behalf the Zymeworks Shareholder is dissenting. The
Dissent Notice must set out the number of Zymeworks Common Shares in respect of which the Dissent Rights are being exercised (the &#147;<B>Notice Shares</B>&#148;) and: (a)&nbsp;if such Zymeworks Common Shares constitute all of the Zymeworks Common
Shares of which the Zymeworks Shareholder is the registered and beneficial owner and the Zymeworks Shareholder owns no other Zymeworks Common Shares beneficially, a statement to that effect; (b)&nbsp;if such Zymeworks Common Shares constitute all of
the Zymeworks Common Shares of which the Registered Shareholder is both the registered and beneficial owner, but the Registered Shareholder beneficially owns additional Zymeworks Common Shares, a statement to that effect and the names of the
Registered Shareholders of those other Zymeworks Common Shares, the number of Zymeworks Common Shares held by each such Registered Shareholder and a statement that written notices of dissent are being or have been sent with respect to such other
Zymeworks Common Shares; or (c)&nbsp;if the Dissent Rights are being exercised by a Registered Shareholder who is not the Beneficial Shareholder, a statement to that effect and the name and address of the Beneficial Shareholder and a statement that
the Registered Shareholder is dissenting with respect to all Zymeworks Common Shares of the Beneficial Shareholder registered in such registered holder&#146;s name. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The delivery of a Dissent Notice does not deprive a Dissenting Shareholder of the right to vote at the
Special Meeting on the Redomicile Resolution; however, a Dissenting Shareholder is not entitled to exercise the Dissent Rights with respect to any of his or her Zymeworks Common Shares if the Dissenting Shareholder votes in favour of the Redomicile
Resolution. A vote against the Redomicile Resolution, whether in person or by proxy, does not constitute a Dissent Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Redomicile Resolution
is approved by the Zymeworks Securityholders and if Zymeworks notifies the Dissenting Shareholder of the Company&#146;s intention to act upon the Redomicile Resolution, the Dissenting Shareholder is then required, within one month after Zymeworks
gives such notice, to send to Zymeworks the certificates (if any) representing the Notice Shares and a written statement that requires Zymeworks to purchase all of the Notice Shares (including a written statement prepared in accordance with
Section&nbsp;244(1)(c) of the BCBCA if the dissent is being exercised by a Registered Shareholder on behalf of a Beneficial Shareholder), whereupon, subject to the provisions of the BCBCA relating to the termination of Dissent Rights, the Zymeworks
Shareholder becomes a Dissenting Shareholder, and is bound to sell, and Zymeworks is bound to purchase, those Zymeworks Common Shares. Such Dissenting Shareholder may not vote or exercise or assert any rights of a Zymeworks Shareholder in respect of
such Notice Shares, other than the rights set forth in Division 2 of Part 8 of the BCBCA, as modified by the Interim Order, the Plan of Arrangement, and any other order of the Court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dissenting Shareholder and Zymeworks may agree on the payout value of the Notice Shares; otherwise, either party may apply to the Court to determine the
fair value of the Notice Shares. There is no obligation on Zymeworks to make an application to the Court. If such Dissenting Shareholder does not reach an agreement with Zymeworks, such Dissenting Shareholder, or Zymeworks, may apply to the Court,
and the Court may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine the fair value of the Notice Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">join in the application of each Dissenting Shareholder who has not agreed with Zymeworks on the amount of the
fair value of the Notice Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make consequential orders and give directions as the Court considers appropriate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a determination of the payout value of the Notice Shares, the Dissenting Shareholder must then promptly be paid that amount. There can be no assurance
that the amount a Dissenting Shareholder may receive as fair value for its Zymeworks Common Shares will be more than or equal to the consideration under the Redomicile Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dissenting Shareholders who: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are ultimately entitled to be paid fair value for their Zymeworks Common Shares shall be deemed not to have
participated in the transactions in Article 3 of the Plan of Arrangement (other than Section&nbsp;3.1(a) of the Plan of Arrangement) or otherwise in the Redomicile Transactions and shall be paid an amount equal to such fair value by Zymeworks (less
any amounts withheld pursuant to the Plan of Arrangement) and will not be entitled to any other payment or consideration, including any payment that would be payable under the Arrangement or otherwise in the Redomicile Transactions had such
Zymeworks Shareholders not exercised their Dissent Rights in respect of such Zymeworks Common Shares, and they shall be deemed to have transferred their Zymeworks Common Shares for which Dissent Rights have been exercised to Zymeworks for
cancellation at the Effective Time; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are ultimately not entitled, for any reason, to be paid fair value for their Zymeworks Common Shares, shall be
deemed to have participated in the Arrangement, as of the Effective Time, and the remainder of the Redomicile Transactions on the same basis as a <FONT STYLE="white-space:nowrap">non-dissenting</FONT> holder of Zymeworks Common Shares and shall be
entitled to receive only the consideration contemplated in Section&nbsp;3.1(b) of the Plan of Arrangement (less any amounts withheld pursuant to the Plan of Arrangement) or otherwise in the Redomicile Transactions that such Zymeworks Shareholder
would have received pursuant to the Redomicile Transactions if such Zymeworks Shareholder had not exercised Dissent Rights, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that in no case shall Zymeworks, Parent or the Depositary or any other Person be required
to recognize Zymeworks Shareholders who exercise Dissent Rights as Zymeworks Shareholders after the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Dissenting Shareholder loses his or
her Dissent Right if, before full payment is made for the Notice Shares, Zymeworks abandons the corporate action that has given rise to the Dissent Right (namely, the Redomicile Transactions), a court permanently enjoins the action, or the
Dissenting Shareholder withdraws the Dissent Notice with Zymeworks&#146; written consent. When these events occur, Zymeworks must return the share certificates (if any) to the Dissenting Shareholder and the Dissenting Shareholder regains the ability
to vote and exercise shareholder rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no circumstances will Zymeworks, the Depositary or any other person be required to recognize a person as a
Dissenting Shareholder unless such person is the holder of the Zymeworks Common Shares in respect of which Dissent Rights are purported to be exercised immediately prior to the Effective Time of the Redomicile Transactions; (i)&nbsp;if such person
has voted or instructed a proxyholder to vote the Notice Shares in favour of the Redomicile Resolution; and (ii)&nbsp;unless such person has strictly complied with the procedures for exercising Dissent Rights set out in Division 2 of Part 8 of the
BCBCA, as modified by the Interim Order, the Plan of Arrangement, and any other order of the Court, and does not withdraw such person&#146;s Dissent Notice prior to the effective time of the Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event will Zymeworks, Parent or any other Person be required to recognize a Dissenting Shareholder as the holder of any Zymeworks Common Shares in
respect of which Dissent Rights have been validly exercised and not withdrawn at and after the Effective Time, and at the Effective Time the names of such Dissenting Shareholders will be deleted from the central securities register of Zymeworks as
at the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dissent Rights with respect to Notice Shares will terminate and cease to apply to the Dissenting Shareholder if, before full
payment is made for the Notice Shares, the Arrangement in respect of which the Dissent Notice was sent is abandoned or by its terms will not proceed, a court permanently enjoins or sets aside the corporate action approved by the Redomicile
Resolution, the Dissenting Shareholder votes in favour of the Redomicile Resolution, or the Dissenting Shareholder withdraws the Dissent Notice with Zymeworks&#146; written consent. If any of these events occur, Zymeworks must return the share
certificates representing the Zymeworks Common Shares to the Dissenting Shareholder and the Dissenting Shareholder regains the ability to vote and exercise its rights as a Shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Dissenting Shareholder fails to strictly comply with the requirements of the Dissent Rights set out in the Interim Order, it will lose its Dissent
Rights, Zymeworks will return to the Dissenting Shareholder the certificates representing the Notice Shares that were delivered to Zymeworks, if any, and if the Arrangement is completed, that Dissenting Shareholder will be deemed to have
participated in the Arrangement on the same terms as a Zymeworks Shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The discussion above is only a summary of the Dissent Rights, which are
technical and complex. A Zymeworks Shareholder who intends to exercise Dissent Rights should carefully consider and comply with the provisions of Division 2 of Part 8 of the BCBCA, as may be modified by the Interim Order, the Plan of Arrangement,
and any other order of the Court. Zymeworks suggests that any Zymeworks Shareholder wishing to avail themselves of the Dissent Rights seek their own legal advice as failure to comply strictly with the applicable provisions of the BCBCA, as may be
modified by the Plan of Arrangement, Interim Order and the Final Order may result in the loss of all Dissent Rights. Dissenting Shareholders should note that the exercise of Dissent Rights can be a complex, time-consuming and expensive process.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a general summary of certain income tax implications to a Dissenting Shareholder, see section titled &#147;<I>Material Canadian Federal Income
Tax Considerations</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_9"></A>SUMMARY OF THE TRANSACTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary description of certain material provisions of the Transaction Agreement, is not comprehensive and is qualified in its entirety by
reference to the complete text of the Transaction Agreement, copies of which are available under Zymeworks&#146; profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its website at www.zymeworks.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 14, 2022, Zymeworks, Parent, ExchangeCo and Callco entered into the Transaction Agreement, pursuant to which they agreed that, subject to the terms
and conditions set forth in the Transaction Agreement, Parent will acquire, directly or indirectly through ExchangeCo (a direct wholly-owned subsidiary of Callco), all outstanding Zymeworks Common Shares pursuant to the Arrangement. Upon completion
of the Arrangement, Zymeworks Shareholders will hold one share of Delaware Common Stock for each Zymeworks Common Share owned immediately prior to the Arrangement, or, in the case of the Exchangeable Shareholders to the extent of their election, one
Exchangeable Share for each Zymeworks Common Share owned immediately prior to the Arrangement, up to an aggregate number of Exchangeable Shares that is equal to or less than the Exchangeable Share Cap. If the Exchangeable Share Cap is reached, then
the Exchangeable Shares shall be allocated proportionally among the applicable Zymeworks Shareholders based on the number of Designated Zymeworks Common Shares and rounded down to the nearest whole share in respect of each Eligible Holder, and any
other Zymeworks Common Shares held by them will be exchanged for Delaware Common Stock. The Share Trustee will hold one share of the Special Voting Stock, which will be held by the Share Trustee under the terms of the Trust Agreement. The
Exchangeable Shares will be exchangeable for Delaware Common Stock in accordance with the Exchangeable Share Provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Representations and
Warranties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for its status as the contractual document that establishes and governs the legal relations among Zymeworks, Parent, ExchangeCo and
Callco with respect to the Arrangement, the Transaction Agreement is not a source of factual, business or operational information about Zymeworks, Parent, ExchangeCo or Callco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transaction Agreement contains representations and warranties made by each of Zymeworks, Parent, ExchangeCo and Callco to each other. The representations
and warranties relate to, among other things: (a)&nbsp;the due organization, existence and power and authority of each of Zymeworks, Parent, ExchangeCo and Callco to own, lease and operate their respective properties and to carry on their respective
business; (b)&nbsp;the corporate power and authority of each of Zymeworks, Parent, ExchangeCo and Callco to enter into the Transaction Agreement and perform their respective obligations thereunder; and (c)&nbsp;the execution and delivery of the
Transaction Agreement by each of Zymeworks, Parent, ExchangeCo and Callco, and the performance by each of them of their respective obligations thereunder and the completion of the Arrangement not resulting in a violation, conflict or default under
their respective constating documents or any applicable Law, or resulting in the creation of a lien against their respective properties and assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions Precedent to the Arrangement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations
of Zymeworks, Parent, ExchangeCo and Callco to consummate the Arrangement and the other transactions contemplated under the Transaction Agreement are subject to the satisfaction of the following conditions (which may be waived, to the extent
permitted by Law, by Zymeworks): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Redomicile Resolution having been approved and adopted by Zymeworks Securityholders at the Special Meeting
in accordance with the Interim Order; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Interim Order and the Final Order each having been obtained in form and on terms satisfactory to Zymeworks,
and not having been set aside or modified in a manner unacceptable to Zymeworks, on appeal or otherwise; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no writ, order, judgment, injunction, decision, determination, award, ruling, subpoena, verdict or decree
entered, issued or rendered by any Governmental Entity, or Law issued by any court of competent jurisdiction or other Governmental Entity, or other legal restraint or prohibition preventing the consummation of the transactions contemplated by the
Plan of Arrangement, the Support Agreement, the Trust Agreement, and each other agreement, document, instrument or certificate that is necessary, desirable or useful (as determined by Zymeworks or Parent) to give effect to the Arrangement
(collectively, the &#147;<B>Transactions</B>&#148;) shall be in effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all other material consents as may be desirable or useful in connection with the consummation of the Redomicile
Transactions, as determined by Zymeworks, will have been obtained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the registration statement of Parent on Form <FONT STYLE="white-space:nowrap">S-4</FONT> relating to the
Transactions and containing a prospectus for the Delaware Common Stock, among other things (the &#147;<B>Registration Statement</B>&#148;), shall have become effective in accordance with the provisions of the U.S. Securities Act, no stop order shall
have been issued by the SEC and shall remain in effect with respect to the Registration Statement, and no proceeding seeking such a stop order shall have been threatened or initiated by the SEC and remain pending; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dissent Rights having not been exercised in respect of more than 10% of the Zymeworks Common Shares, or such
other amount of Zymeworks Common Shares that, as determined by Zymeworks in its sole and unfettered discretion, it is no longer in the best interests of Zymeworks to proceed with the Transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transaction Agreement provides that:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent and Zymeworks shall prepare and mutually agree upon, and Parent shall file with the SEC the Registration
Statement, and use commercially reasonable efforts to (i)&nbsp;cause the Registration Statement to comply in all material respects with the applicable rules and regulations promulgated by the SEC; (ii)&nbsp;have the Registration Statement declared
effective under the U.S. Securities Act as soon as reasonably practicable after it is filed with the SEC; and (iii)&nbsp;keep the Registration Statement effective through the Effective Time in order to permit the consummation of the Transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as soon as reasonably practicable after the Registration Statement is declared effective by the SEC, Zymeworks
shall apply under Part 9, Division 5 of the BCBCA and shall prepare, file and pursue an application to the Court for the Interim Order in respect of the Arrangement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Parties will use reasonable commercial efforts to ensure that all Exchangeable Shares issued under the
Arrangement will be issued in reliance on the exemption from the registration requirements of the U.S. Securities Act provided by Section&nbsp;3(a)(10) thereunder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks shall take all steps necessary or desirable to submit the Arrangement to the Court and diligently
pursue an application for the Final Order pursuant to Part 9, Division 5 of the BCBCA, as soon as reasonably practicable after the required approval is obtained for the Redomicile Resolution as provided for in the Interim Order;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prior to or concurrently with the Effective Time, Parent and ExchangeCo, as applicable, shall deposit with the
Depositary sufficient Delaware Common Stock and Exchangeable Shares to satisfy the aggregate Consideration payable to the Zymeworks Shareholders pursuant to the terms of the Plan of Arrangement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent shall cause the shares of Delaware Common Stock issuable under the Arrangement to be listed for trading
on the NYSE under the symbol &#147;ZYME&#148; prior to the Effective Time, and shall use commercially reasonable efforts as soon as reasonably practicable following the Effective Time to cause the Delaware Common Stock issuable pursuant to the
exchange or exercise of the Exchangeable Shares to be listed for trading on the NYSE under the symbol &#147;ZYME&#148;, and in connection therewith, to satisfy any applicable initial and continuing listing requirements of NYSE in respect of the
Delaware Common Stock. Zymeworks </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
will cause the Zymeworks Common Shares currently listed on the NYSE to cease to be traded on the NYSE and to be deregistered under the U.S. Exchange Act, and for Canadian tax purposes will elect
to be treated as a private corporation immediately following the completion of the Arrangement. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Arrangement Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As soon as practicable following the Effective Time, Zymeworks, Parent, ExchangeCo and Callco shall use reasonable commercial efforts, and shall take such
corporate steps and actions, as may be necessary or desirable to effect and implement the following transactions in the order set forth below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the authorized share structure of Zymeworks shall be reorganized to create an unlimited number of New Common
Shares without par value, having special rights and restrictions that are substantially similar to the Zymeworks Common Shares, and in such form and substance as may be as determined by Zymeworks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ExchangeCo shall exchange all of the Zymeworks Common Shares then held by ExchangeCo for New Common Shares of
Zymeworks, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, pursuant to Section&nbsp;86 of the Tax Act, and in such form and substance as may be as determined by Zymeworks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks shall reduce the stated capital on the Zymeworks Common Shares (which will then be held solely by
Parent), by an amount equal to the fair market value of the issued and outstanding shares of ZBI (the &#147;<B>ZBI Stock</B>&#148;) and Irish Sub (the &#147;<B>Irish Sub Stock</B>&#148;), and in such manner and substance as Zymeworks may determine,
and shall effect the same by way of a transfer of the ZBI Stock and the Irish Sub Stock from Zymeworks to Parent free and clear of all Liens, in such form and substance as Zymeworks may determine; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks shall surrender to Parent, free and clear of all Liens and for cancellation by Parent without a
return of capital, the Delaware Common Stock issued by Parent to Zymeworks on the incorporation of Parent. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination of the
Transaction Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transaction Agreement may be terminated prior to the Effective Time upon written notice by Zymeworks to Parent, ExchangeCo
and Callco. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transaction Agreement
is governed by and construed in accordance with the Laws of the Province of British Columbia and other federal Laws of Canada applicable in British Columbia without giving effect to any choice of law or conflict of law provision or rule (whether of
the Province of British Columbia or any other jurisdiction) that would cause the application of the law of any jurisdiction other than the Province of British Columbia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transaction Agreement may only be amended
upon the written agreement of Zymeworks, Parent, ExchangeCo and Callco. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_10"></A>DESCRIPTION OF EXCHANGEABLE SHARES AND RELATED AGREEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Exchangeable Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Exchangeable Shares will be issued by ExchangeCo and will carry, as nearly as reasonably practicable, equivalent economic entitlements to those of the Delaware Common Stock, for which they are exchangeable. There are possible disadvantages or risks
of holding Exchangeable Shares. See section titled &#147;<I>Risks Factors &#151; Risks Relating to the Exchangeable Shares</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks
Shareholders who are Eligible Holders may wish to elect to receive Exchangeable Shares rather than Delaware Common Stock with respect to all or a portion of their Zymeworks Common Shares in order to take advantage of a full or partial tax deferral
available under the Tax Act. The Canadian tax consequences of receiving or holding Exchangeable Shares may differ significantly from the Canadian tax consequences of receiving or holding Delaware Common Stock depending upon the particular
circumstances of an Eligible Holder. Careful consideration should be given by Eligible Holders to the tax consequences in determining whether or not an election should be made to receive any Exchangeable Shares. See section titled &#147;<I>Material
Canadian Federal Income Tax Considerations</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary description of certain material provisions of the Exchangeable Share
Provisions is not comprehensive and is qualified in its entirety by reference to the complete text thereof, as set forth in the Articles of ExchangeCo, and in the form attached as Exhibit E to the Transaction Agreement, which is set forth in
Appendix B to the Proxy Statement/Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ranking </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchangeable Shares will be entitled to a preference over the common shares of ExchangeCo and any other shares ranking junior to the Exchangeable Shares
with respect to (i)&nbsp;the payment of dividends or other distributions to the extent provided in the Exchangeable Share Provisions, and (ii)&nbsp;the distribution of assets in the event of the liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo, whether voluntary or involuntary, or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs to the extent provided in the
Exchangeable Share Provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Other Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable Law (in this section, as defined in the Exchangeable Share Provisions) and except as otherwise set forth in the Exchangeable Share
Provisions, on each date (a <B>&#147;Parent Dividend Declaration Date</B>&#148;) on which the Parent board of directors declares any dividend or other distribution on the Delaware Common Stock (but excluding any distributions pursuant to a Preferred
Stock Rights Agreement)&nbsp;(i) a holder of an Exchangeable Share will be entitled to receive, and (ii)&nbsp;the ExchangeCo board of directors will declare a dividend or other distribution on each Exchangeable Share: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in case of a cash dividend or other distribution (but excluding any distributions pursuant to a Preferred Stock
Rights Agreement) declared on the Delaware Common Stock, in an amount in cash, payable in United States dollars, for each Exchangeable Share equal to the cash dividend or other distribution multiplied by the relevant Exchangeable Share Exchange
Ratio declared on each share of Delaware Common Stock on the Parent Dividend Declaration Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a stock or share dividend or other distribution declared on the Delaware Common Stock to be paid
in Delaware Common Stock (but excluding any distributions pursuant to a Preferred Stock Rights Agreement), by the issue or transfer by ExchangeCo of such number of Exchangeable Shares for each Exchangeable Share as is equal to the number of shares
of Delaware Common Stock to be paid on each share of Delaware Common Stock; provided, however, that ExchangeCo may, in lieu of such stock or share dividend or other distribution, elect to effect a corresponding, contemporaneous and economically
equivalent (as determined by the ExchangeCo board of directors) subdivision of the outstanding Exchangeable Shares; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a dividend or other distribution declared on the Delaware Common Stock in property other than
cash or Delaware Common Stock (but excluding any distributions pursuant to a Preferred Stock Rights Agreement), in such type and amount of property for each Exchangeable Share as is the same as or economically equivalent (as determined by the
ExchangeCo board of directors in accordance with the Exchangeable Share Provisions) and adjusted for the relevant Exchangeable Share Exchange Ratio to the type and amount of property declared as a dividend or other distribution on each share of
Delaware Common Stock, and </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such dividends or other distributions will be paid out of money, assets or property of ExchangeCo properly
applicable to the payment of dividends or other distributions, or out of authorized but unissued shares of ExchangeCo, as applicable; provided that the ExchangeCo board of directors may determine to adjust the Exchangeable Share Exchange Ratio as
provided in the Exchangeable Share Provisions in lieu of paying any such dividend or other distribution on the Exchangeable Shares; and provided further that the Exchangeable Share Exchange Ratio will be so adjusted only to the extent the ExchangeCo
board of directors determines in good faith and in its sole discretion that ExchangeCo would be liable for any unrecoverable tax as a result of paying any such dividend or distribution in cash. The holders of Exchangeable Shares will not be entitled
to any dividends or other distributions other than or in excess of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date for the determination of the holders of Exchangeable
Shares entitled to receive payment of, and the payment date for, any dividend or other distribution declared on the Exchangeable Shares will be the same dates as the record date and payment date, respectively, for the corresponding dividend or other
distribution declared on the Delaware Common Stock (but excluding any distributions pursuant to a Preferred Stock Rights Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If on any payment
date for any dividends or other distributions declared on the Exchangeable Shares, the dividends or other distributions are not paid in full on all of the Exchangeable Shares then outstanding, any such dividends or other distributions that remain
unpaid will be paid on a subsequent date or dates determined by the ExchangeCo board of directors on which ExchangeCo has sufficient monies, assets or property properly applicable to the payment of such dividends or other distributions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ExchangeCo board of directors is required to determine, in good faith and in its sole discretion (with the assistance of such financial or other advisors
as the ExchangeCo board of directors may determine), &#147;economic equivalence&#148; for the purposes of the Exchangeable Share Provisions and each such determination will be conclusive and binding on ExchangeCo and its shareholders. In making each
such determination, a number of factors set out in the Exchangeable Share Provisions will, without excluding other factors determined by the ExchangeCo board of directors to be relevant, be considered by the ExchangeCo board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Restrictions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as any of the
Exchangeable Shares are outstanding, ExchangeCo will not at any time without, but may at any time with, the approval of the holders of the Exchangeable Shares given as specified in the Exchangeable Share Provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pay any dividends or other distributions on the common shares of ExchangeCo or any other shares ranking junior
to the Exchangeable Shares with respect to the payment of dividends or other distributions, other than stock or share dividends payable in common shares of ExchangeCo or any such other shares ranking junior to the Exchangeable Shares, as the case
may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">redeem or purchase or make any capital distribution in respect of common shares of ExchangeCo or any other
shares ranking equally with or junior to the Exchangeable Shares with respect to the payment of dividends or the distribution of assets in the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo,
whether voluntary or involuntary, or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue any Exchangeable Shares or any other shares of ExchangeCo ranking equally with, or superior to, the
Exchangeable Shares, other than, in each case, by way of stock or share dividend to the holders of such Exchangeable Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
restrictions listed in paragraphs (a), (b) and (c)&nbsp;above will not apply if, in connection with all dividends or other distributions declared and paid on the Delaware Common Stock (but excluding any distributions pursuant to a Preferred Stock
Rights Agreement): (i) all dividends or other distributions on the outstanding Exchangeable Shares have been declared and paid in full on the Exchangeable Shares, or (ii)&nbsp;the Exchangeable Share Exchange Ratio has been adjusted in accordance
with the Exchangeable Share Provisions, in each case, prior to or as at the date of any such event referred to in paragraphs (a), (b) or (c)&nbsp;above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchangeable Share Exchange Ratio Adjustments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Exchangeable Share Exchange Ratio may be cumulatively adjusted from time to time after the Effective Date by increasing the Exchangeable Share Exchange Ratio on each date after the Effective Date on which the Parent board of directors pays any
dividend or other distribution on the Delaware Common Stock by an amount, rounded to the nearest five decimal places, equal to (a)(i) the amount of such dividend or other distribution (which, in the case of a
<FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, shall equal the fair value as determined by the ExchangeCo board of directors in good faith and in its sole discretion), expressed on a per Delaware Common Stock basis, multiplied
(ii)&nbsp;by the Exchangeable Share Exchange Ratio in effect on the Business Day (for purposes of this section, as defined in the Exchangeable Share Provisions) immediately preceding the record date set for such dividend or other distribution,
divided by (b)&nbsp;the Current Market Price on the record date set for such dividend or other distribution, and any such adjustment shall be determined by the ExchangeCo board of directors in good faith and in its sole discretion and any such
determination by the ExchangeCo board of directors shall be conclusive and binding; provided, however, that the Exchangeable Share Exchange Ratio will be so adjusted only to the extent that the ExchangeCo board of directors determines in good faith
and in its sole discretion that ExchangeCo would be liable for any unrecoverable tax as a result of paying any such dividend or distribution in cash and determines to adjust the Exchangeable Share Exchange Ratio in lieu of paying an Equivalent
Dividend on the Exchangeable Shares as contemplated by the Exchangeable Share Provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distribution on Liquidation and Associated Call Right
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable Laws and the due exercise by Callco of the Liquidation Call Right, in the event of the liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo, whether voluntary or involuntary, or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, a holder of Exchangeable Shares
will be entitled to receive from the assets of ExchangeCo in respect of each Exchangeable Share held by such holder on the effective date of such liquidation, dissolution, <FONT STYLE="white-space:nowrap">winding-up</FONT> or other distribution (the
&#147;<B>Liquidation Date</B>&#148;), before any distribution of any part of the assets of ExchangeCo among the holders of the common shares of ExchangeCo or any other shares ranking junior to the Exchangeable Shares, an amount per share (the
&#147;<B>Liquidation Amount</B>&#148;) equal to the Exchangeable Share Price on the last Business Day prior to the Liquidation Date, which will be satisfied in full by ExchangeCo delivering or causing to be delivered to such holder of Exchangeable
Shares the Exchangeable Share Consideration representing the Liquidation Amount for each Exchangeable Share held by such holder; provided that, for the avoidance of doubt, upon such a liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo, a holder of Exchangeable Shares will still have the rights set forth under &#147;<I>Retraction of Exchangeable Shares and Associated Call Right</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Support Agreement, Callco has the overriding right (the &#147;<B>Liquidation Call Right</B>&#148;), in the event of and notwithstanding the
proposed liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, to purchase from all but
not less than all of the holders of Exchangeable Shares (other than Parent or its subsidiaries (in this section, as defined in the Exchangeable Share Provisions)) on the Liquidation Date, all but not less than all of the Exchangeable Shares held by
each such holder on payment by Callco to each such holder of an amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
per share equal to the Exchangeable Share Price (payable in the form of the Exchangeable Share Consideration) on the last Business Day prior to the Liquidation Date (the &#147;<B>Liquidation Call
Purchase Price</B>&#148;). In the event of the exercise of the Liquidation Call Right by Callco, each holder of Exchangeable Shares (other than Parent and its subsidiaries) will be obligated to sell all of the Exchangeable Shares held by the holder
to Callco on the Liquidation Date upon payment by Callco to such holder of the Liquidation Call Purchase Price for each such share, and ExchangeCo will have no obligation to pay any Liquidation Amount to the holders of such shares so purchased. The
Liquidation Call Purchase Price will be satisfied in full by Callco depositing or causing to be deposited with the ExchangeCo Transfer Agent, on or before the Liquidation Date, the Exchangeable Share Consideration representing the aggregate
Liquidation Call Purchase Price less any amounts withheld on account of taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exercise the Liquidation Call Right, Callco must notify the ExchangeCo
Transfer Agent, as agent for the holders of Exchangeable Shares, and ExchangeCo of its intention to exercise such right (i)&nbsp;in the case of a voluntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo
or any other voluntary distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, at least fifteen (15)&nbsp;Business Days before the Liquidation Date, or (ii)&nbsp;in the case of an involuntary
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo or any other involuntary distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, at least five
(5)&nbsp;Business Days before the Liquidation Date. The ExchangeCo Transfer Agent will notify the holders of Exchangeable Shares as to whether or not Callco has exercised the Liquidation Call Right forthwith after the expiry of the period during
which the same may be exercised by Callco. If Callco exercises the Liquidation Call Right, then on the Liquidation Date, Callco will purchase and the holders of the Exchangeable Shares (other than Parent or its subsidiaries) will sell, all of the
Exchangeable Shares held by such holders on such date for a price per share equal to the Liquidation Call Purchase Price (payable in the form of the Exchangeable Share Consideration). If Callco does not notify the Exchange Transfer Agent and
ExchangeCo of its intention to exercise the Liquidation Call Right in the manner and timing described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that
Callco exercise the Liquidation Call Right in respect of the shares covered by the notice, in which case, Callco shall be deemed of have exercised the Liquidation Call Right and will be bound thereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retraction of Exchangeable Shares and Associated Call Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable Laws and the due exercise by Callco of the Retraction Call Right, a holder of Exchangeable Shares will be entitled at any time to require
ExchangeCo to redeem any or all Exchangeable Shares registered in the name of such holder and for an amount per share equal to the Exchangeable Share Price on the last Business Day prior to the Retraction Date (the &#147;<B>Retraction
Price</B>&#148;), which price will be satisfied in full by ExchangeCo delivering or causing to be delivered to such holder the Exchangeable Share Consideration representing the Retraction Price. A holder of Exchangeable Shares must give notice of a
request to redeem or purchase, as applicable, by presenting and surrendering to ExchangeCo (or to the ExchangeCo Transfer Agent) the certificate(s) representing the Exchangeable Shares that the holder desires to have ExchangeCo redeem, together with
(i)&nbsp;such documents, instruments and payments as the ExchangeCo Transfer Agent and ExchangeCo may reasonably require and (ii)&nbsp;a duly executed request (the &#147;<B>Retraction Request</B>&#148;) in accordance with the Exchangeable Share
Provisions: (A)&nbsp;specifying that the holder desires to have all or any number specified therein of the Exchangeable Shares represented by such certificate(s) (the &#147;<B>Retracted Shares</B>&#148;) redeemed by ExchangeCo; (B)&nbsp;stating the
Business Day on which the holder desires to have ExchangeCo redeem the Retracted Shares (the &#147;<B>Retraction Date</B>&#148;), provided that the Retraction Date will not be less than ten (10)&nbsp;Business Days nor more than fifteen
(15)&nbsp;Business Days after the date on which the Retraction Request is received by ExchangeCo, and further provided that, in the event that no such Business Day is specified by the holder in the Retraction Request, the Retraction Date will be
deemed to be the fifteenth (15th) Business Day after the date on which the Retraction Request is received by ExchangeCo, subject to the Exchangeable Share Provisions; and (C)&nbsp;acknowledging the overriding Retraction Call Right of Callco to
purchase all but not less than all the Retracted Shares directly from the holder and that the Retraction Request will be deemed to be a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revocable offer by the holder to sell the Retracted Shares to Callco in accordance with the Retraction Call Right on the Retraction Date for the Retraction Call Right Purchase Price and on the
other terms and conditions set out in the Exchangeable Share Provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Exchangeable Share Provisions, in the event that a holder
of Exchangeable Shares delivers a Retraction Request, Callco will have the overriding right (the &#147;<B>Retraction Call Right</B>&#148;), notwithstanding the proposed redemption of the Exchangeable Shares, to purchase from such holder on the
Retraction Date all but not less than all of the Retracted Shares held by such holder on payment by Callco of an amount per share equal to the Exchangeable Share Price applicable on the last Business Day prior to the Retraction Date (the
&#147;<B>Retraction Call Right Purchase Price</B>&#148;), which price will be satisfied in full by Callco delivering or causing to be delivered to such holder the Exchangeable Share Consideration representing the Retraction Call Right Purchase Price
less any amounts withheld on account of taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt by ExchangeCo of a Retraction Request, ExchangeCo will immediately notify Callco and will
provide Callco with a copy of the Retraction Request. To exercise its Retraction Call Right, Callco must notify ExchangeCo in writing of its determination to do so within five (5)&nbsp;Business Days after ExchangeCo notifies Callco. If Callco does
not so notify ExchangeCo within such five (5)&nbsp;Business Day period, ExchangeCo will notify the holder as soon as possible thereafter that Callco did not exercise the Retraction Call Right. If Callco delivers a Retraction Call Notice within such
five (5)&nbsp;Business Day period and duly exercises its Retraction Call Right, the obligation of ExchangeCo to redeem the Retracted Shares will terminate and, provided that the Retraction Request is not revoked by the holder of such Retracted
Shares in the manner described below), Callco will purchase from such holder and such holder will sell to Callco on the Retraction Date the Retracted Shares for an amount per share equal to the Retraction Call Right Purchase Price less any amounts
withheld on account of taxes. Provided that the aggregate Retraction Call Right Purchase Price has been deposited with the ExchangeCo Transfer Agent, the closing of the purchase and sale of the Retracted Shares pursuant to the Retraction Call Right
will be deemed to have occurred as at the close of business on the Retraction Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of Exchangeable Shares who has made a Retraction Request
may, by notice in writing given by the holder to ExchangeCo before the close of business on the Business Day immediately preceding the Retraction Date, withdraw such Retraction Request, in which event such Retraction Request will be null and void
and the revocable offer constituted by the Retraction Request to sell such Exchangeable Shares to Callco pursuant to the exercise of the Retraction Call Right will be deemed to have been revoked. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Callco does not notify the ExchangeCo Transfer Agent and ExchangeCo of its intention to exercise the Retraction Call Right in the manner and timing
described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that Callco exercise the Retraction Call Right in respect of the shares covered by the notice,
in which case, Callco shall be deemed of have exercised the Retraction Call Right and will be bound thereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of Exchangeable Shares and
Associated Call Right </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable Laws and the due exercise by Callco of the Redemption Call Right, ExchangeCo will on the Redemption
Date redeem all but not less than all of the then outstanding Exchangeable Shares (other than Exchangeable Shares held by Parent and its subsidiaries) for an amount per share (the &#147;<B>Redemption Price</B>&#148;) equal to the Exchangeable Share
Price on the last Business Day prior to the Redemption Date, which price will be satisfied in full by ExchangeCo delivering or causing to be delivered to each holder of Exchangeable Shares the Exchangeable Share Consideration for each Exchangeable
Share held by such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<B>Redemption Date</B>&#148; is the date, if any, established by the ExchangeCo board of directors for the
redemption by ExchangeCo of all but not less than all of the outstanding Exchangeable Shares, which date will be on the Sunset Date unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the aggregate number of Exchangeable Shares issued and outstanding (other than Exchangeable Shares held by
Parent and its subsidiaries) is less than 5% of the number of Exchangeable Shares issued and outstanding </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
on the Effective Date (as such number of shares may be adjusted as deemed appropriate by the ExchangeCo board of directors in certain circumstances set forth in the Exchangeable Share
Provisions), in which case the ExchangeCo board of directors may accelerate such Redemption Date to such date as it may determine, upon at least thirty (30)&nbsp;days&#146; prior written notice to the holders of the Exchangeable Shares; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Parent Control Transaction is proposed, in which case, provided that the ExchangeCo board of directors
determines in good faith that it is not practicable to substantially replicate the terms and conditions of the Exchangeable Shares in connection with such Parent Control Transaction or that the redemption of all but not less than all of the
outstanding Exchangeable Shares (other than Exchangeable Shares held by Parent and its subsidiaries) is necessary to enable the completion of such Parent Control Transaction in accordance with its terms, the ExchangeCo board of directors may
accelerate such Redemption Date to such date as it may determine, upon such number of days&#146; prior written notice to the holders of the Exchangeable Shares as the ExchangeCo board of directors may determine to be reasonably practicable in such
circumstances. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Support Agreement, Callco has the overriding right (the &#147;<B>Redemption Call Right</B>&#148;),
notwithstanding the proposed redemption of the Exchangeable Shares by ExchangeCo, to purchase from all but not less than all of the holders of Exchangeable Shares (other than Parent or any of its subsidiaries) on the Redemption Date all but not less
than all of the Exchangeable Shares held by each such holder on payment by Callco of an amount per share equal to the Exchangeable Share Price on the last Business Day prior to the Redemption Date (the &#147;<B>Redemption Call Purchase
Price</B>&#148;). In the event of the exercise of the Redemption Call Right by Callco, each holder of Exchangeable Shares will be obligated to sell all of the Exchangeable Shares held by the holder to Callco on the Redemption Date on payment by
Callco to the holder of the Redemption Call Purchase Price for each such share, and ExchangeCo will have no obligation to redeem, or pay the Redemption Price otherwise payable by ExchangeCo, in respect of the shares so purchased. The Redemption Call
Purchase Price will be satisfied in full by Callco depositing or causing to be deposited with the ExchangeCo Transfer Agent, on or before the Redemption Date, the Exchangeable Share Consideration representing the aggregate Redemption Call Purchase
Price less any amounts withheld on account of taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exercise the Redemption Call Right, Callco must notify the ExchangeCo Transfer Agent, as agent
for the holders of Exchangeable Shares, and ExchangeCo of its intention to exercise such right (i)&nbsp;in the case of a redemption occurring in connection with a Parent Control Transaction, on or before the Redemption Date, and (ii)&nbsp;in any
other case, at least fifteen (15)&nbsp;Business Days before the Redemption Date. The ExchangeCo Transfer Agent will notify the holders of Exchangeable Shares as to whether or not Callco has exercised the Redemption Call Right forthwith after the
expiry of the period during which the same may be exercised by Callco. If Callco exercises the Redemption Call Right, Callco will purchase and the holders of the Exchangeable Shares (other than Parent or its subsidiaries) will sell, on the
Redemption Date, all of the Exchangeable Shares held by such holders on such date for a price per share equal to the Redemption Call Purchase Price (payable in the form of the Exchangeable Share Consideration). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Callco does not notify the Transfer Agent and ExchangeCo of its intention to exercise the Redemption Call Right in the manner and timing described above,
each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that Callco exercise the Redemption Call Right in respect of the shares covered by the notice, in which case
Callco shall be deemed of have exercised the Redemption Call Right and will be bound thereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change of Law Call Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Support Agreement, Callco has the overriding right (the &#147;<B>Change of Law Call Right</B>&#148;), in the event of a Change of Law, to
purchase from all but not less than all of the holders of Exchangeable Shares (other than Parent or its subsidiaries) on the Change of Law Call Date all but not less than all of the Exchangeable Shares held by each such holder on payment by Callco
of an amount per share (the &#147;<B>Change of Law Call</B> <B>Purchase Price</B>&#148;) equal to the Exchangeable Share Price applicable on the last Business Day prior to the date on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which ExchangeCo acquires the Exchangeable Shares pursuant to the exercise of the Change of Law Call Right (the &#147;<B>Change of Law Call Date</B>&#148;). In the event of the exercise of the
Change of Law Call Right by Callco, each such holder of Exchangeable Shares will be obligated to sell all of the Exchangeable Shares held by the holder to Callco on the Change of Law Call Date upon payment by Callco to such holder of the Change of
Law Call Purchase Price (payable in the form of Exchangeable Share Consideration). The Change of Law Call Purchase Price will be satisfied in full by Callco depositing or causing to be deposited with the ExchangeCo Transfer Agent, on or before the
Change of Law Call Date, the Exchangeable Share Consideration representing the total Change of Law Call Purchase Price less any amounts withheld on account of taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exercise the Change of Law Call Right, Callco must notify the ExchangeCo Transfer Agent, as agent for the holders of Exchangeable Shares, and ExchangeCo of
its intention to exercise such right at least fifteen (15)&nbsp;days before the Change of Law Call Date. The ExchangeCo Transfer Agent will notify the holders of Exchangeable Shares that Callco has exercised the Change of Law Call Right forthwith
after receiving notice of such exercise. If Callco exercises the Change of Law Call Right, Callco will purchase, and the holders of the Exchangeable Shares will sell, on the Change of Law Call Date, all of the Exchangeable Shares then outstanding
for a price per share equal to the Change of Law Call Purchase Price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as required by applicable Laws and in respect of certain matters as further described in the Exchangeable Share Provisions, the holders of the
Exchangeable Shares will not be entitled as such to receive notice of or to attend any meeting of the shareholders of ExchangeCo or to vote at any such meeting. Without limiting the generality of the foregoing, the holders of the Exchangeable Shares
will not be entitled to class votes except as required by applicable Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment and Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any approval required to be given by the holders of the Exchangeable Shares to add to, change or remove any right, privilege, restriction or condition
attaching to the Exchangeable Shares or any other matter requiring the approval or consent of the holders of the Exchangeable Shares in accordance with applicable Laws will be deemed to have been sufficiently given if it has been given in accordance
with applicable Laws, subject to, in certain circumstances as provided for in the Exchangeable Share Provisions, a minimum requirement that such approval be evidenced by a resolution passed by not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on such resolution at a meeting of holders of Exchangeable Shares duly called and held at which the holders of at least 10% of the outstanding Exchangeable Shares at that time are
present in person or represented by proxy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Treatment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The treatment of Exchangeable Shares for U.S. federal income tax purposes is uncertain. Holders of Exchangeable Shares should consult their own advisors
regarding the tax consequences of owning and disposition of Exchangeable Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Support Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary description of certain material provisions that will be contained in the Support Agreement, is not comprehensive and is qualified in
its entirety by reference to the complete text of the Support Agreement the form of which is attached as Exhibit C to the Transaction Agreement, which is set forth in Appendix B to the Proxy Statement/Prospectus. The Support Agreement will be filed
on SEDAR and EDGAR following closing of the Arrangement, available under Zymeworks&#146; profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its website at www.zymeworks.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Covenants regarding Exchangeable Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Support Agreement, Parent will agree that, so long as any Exchangeable Shares not owned by Parent or its subsidiaries (as defined in such
agreement) are outstanding, Parent will, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not take any action that will result in the declaration or payment of any dividend or make any other
distribution on the Delaware Common Stock (but excluding any distributions pursuant to a Preferred Stock Rights Agreement) unless (i)&nbsp;ExchangeCo will (A)&nbsp;simultaneously, declare or pay, as the case may be, an equivalent dividend or other
distribution economically equivalent thereto (as determined in accordance with the Exchangeable Share Provisions) on the Exchangeable Shares (an &#147;<B>Equivalent Dividend</B>&#148;); (B) in the case of a cash dividend or other distribution,
receive sufficient money or other assets from Parent (through any intermediary entities) to enable the due declaration and the due and punctual payment, in accordance with applicable Law and the Exchangeable Share Provisions, of any such Equivalent
Dividend and (C)&nbsp;in the case of a dividend or other distribution that is a stock or share dividend or a distribution of stock or shares, have sufficient authorized but unissued securities available to enable the due declaration and the due and
punctual payment, in accordance with applicable Law and the Exchangeable Share Provisions, of any such Equivalent Dividend; provided, however, for the avoidance of doubt, that in no event may ExchangeCo elect to effect a dividend or other
distribution that is a stock or share dividend or a distribution of stock or shares in the form of cash or property other than stock or shares; or (ii)&nbsp;if the ExchangeCo board of directors so chooses, in its sole discretion, as an alternative
to taking the actions described in clause (i)&nbsp;above, ExchangeCo adjusts the Exchangeable Share Exchange Ratio in accordance with the Exchangeable Share Provisions (but excluding any distributions pursuant to a Preferred Stock Rights Agreement);
provided, however, that the Exchangeable Share Exchange Ratio will only be so adjusted to the extent that the ExchangeCo board of directors determines in good faith and in its sole discretion that ExchangeCo would be liable for any unrecoverable tax
as a result of taking any of the actions described in clause (i)&nbsp;above and determines to adjust the Exchangeable Share Exchange Ratio in lieu of taking any such action; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">advise ExchangeCo sufficiently in advance of the declaration by Parent of any dividend or other distribution on
the Delaware Common Stock (but excluding any distributions pursuant to a Preferred Stock Rights Agreement) and take all such other actions as are reasonably necessary or desirable, in <FONT STYLE="white-space:nowrap">co-operation</FONT> with
ExchangeCo, to ensure that the respective declaration date, record date and payment date for an Equivalent Dividend will be the same as those for any corresponding dividends or other distributions on the Delaware Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all actions and do all things as are reasonably necessary or desirable to enable and permit ExchangeCo, in
accordance with applicable Law, to pay and otherwise perform its obligations with respect to the satisfaction of the Liquidation Amount, the Retraction Price or the Redemption Price to the holders of the Exchangeable Shares in the event of a
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo, whether voluntary or involuntary, the delivery of a Retraction Request by a holder of Exchangeable Shares or a redemption of Exchangeable Shares by
ExchangeCo, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all actions and do all things as are reasonably necessary or desirable to enable and permit the Share
Trustee in accordance with applicable Law to perform its obligations under the Trust Agreement, including, without limitation, all such actions and all such things as are reasonably necessary or desirable to enable and permit the Share Trustee in
its capacity as trustee under the Trust Agreement to exercise such number of votes in respect of a Parent Meeting or a Parent Consent (as such terms are defined in the Trust Agreement) as is equal to the aggregate number of Exchangeable Shares
outstanding at the relevant time (other than those held by Parent and its affiliates), multiplied by the Exchangeable Share Exchange Ratio, and rounded down to the nearest whole vote in respect of any one Beneficiary (as that term is defined in the
Trust Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all actions and do all things as are reasonably necessary or desirable to enable and permit Callco, in
accordance with applicable Law, to perform its obligations arising upon the exercise by it of the Liquidation Call Right, the Retraction Call Right, the Change of Law Call Right or the Redemption Call Right; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all such actions and do all such things as are reasonably necessary or desirable to enable and permit
ExchangeCo, in accordance with applicable Law, to perform its obligations in connection with a Retraction Request pursuant to the Exchangeable Share Provisions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not, except as otherwise contemplated in the Exchangeable Share Provisions, (i)&nbsp;exercise its vote as a
shareholder of ExchangeCo to initiate the voluntary liquidation, dissolution or winding up of ExchangeCo or any other distribution of the assets of ExchangeCo for the purpose of winding up its affairs, or (ii)&nbsp;take any action or omit to take
any action that is designed to result in the liquidation, dissolution or winding up of ExchangeCo or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, without the prior written
consent of the holders of the Exchangeable Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Economic Equivalence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to protect the economic equivalence of the Exchangeable Shares, the Support Agreement will provide that, so long as any Exchangeable Shares not owned
by Parent or its subsidiaries are outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent will not without the prior approval of ExchangeCo and the prior approval of the holders of the
Exchangeable Shares given in accordance with the Exchangeable Share Provisions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute Delaware Common Stock (or securities exchangeable for or convertible into or carrying
rights to acquire Delaware Common Stock) to the holders of all or substantially all of the then outstanding Delaware Common Stock by way of stock or share dividend or other distribution, other than an issue of Delaware Common Stock (or securities
exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) to holders of Delaware Common Stock (A)&nbsp;who exercise an option to receive dividends in Delaware Common Stock (or securities exchangeable for or
convertible into or carrying rights to acquire Delaware Common Stock) in lieu of receiving cash dividends, (B)&nbsp;pursuant to any dividend reinvestment plan or scrip dividend or similar arrangement, or (C)&nbsp;pursuant to a Preferred Stock Rights
Agreement, as that term is defined in the Exchangeable Share Provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute rights, options or warrants to the holders of all or substantially all of the then
outstanding Delaware Common Stock entitling them to subscribe for or to purchase Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) (other than pursuant to a Preferred Stock
Rights Agreement, as that term is defined in the Exchangeable Share Provisions); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute to the holders of all or substantially all of the then outstanding Delaware Common Stock
(A)&nbsp;shares or securities of Parent of any class other than Delaware Common Stock (or securities convertible into or exchangeable for or carrying rights to acquire Delaware Common Stock), (B) rights, options, warrants or other assets other than
those referred to in paragraph (a)(ii) above, (C)&nbsp;evidence of indebtedness of Parent or (D)&nbsp;assets of Parent, except pursuant to a Preferred Stock Rights Agreement, as that term is defined in the Exchangeable Share Provisions,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, ExchangeCo issues or distributes the economic equivalent on a per share basis of such rights,
options, warrants, securities, shares, evidences of indebtedness or other assets simultaneously to holders of the Exchangeable Shares, including, without limitation, an adjustment to the Exchangeable Share Exchange Ratio in accordance with the terms
of the Exchangeable Share Provisions; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent will not, without the prior approval of ExchangeCo and the prior approval of the holders of the
Exchangeable Shares given in accordance with the Exchangeable Share Provisions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide, redivide or change the then outstanding Delaware Common Stock into a greater number of Delaware
Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce, combine, consolidate or change the then outstanding Delaware Common Stock into a lesser number of
Delaware Common Stock; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reclassify or otherwise change the Delaware Common Stock or effect an amalgamation, merger, combination,
reorganization or other transaction affecting the Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, the same or an
economically equivalent change is made simultaneously to, or in the rights of the holders of, the Exchangeable Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ExchangeCo board of directors
will determine, in good faith and in its sole discretion (with the assistance of such financial or other advisors as the ExchangeCo board of directors may determine), &#147;economic equivalence&#148; for the purposes of any event referred to in
paragraphs (a)&nbsp;or (b) above and each such determination will be conclusive and binding on Parent. Pursuant to the Support Agreement, ExchangeCo will agree that, to the extent required, upon due notice from Parent, ExchangeCo will use
commercially reasonable efforts to take or cause to be taken such steps as may be necessary for the purposes of ensuring that appropriate dividends are paid or other distributions are made by ExchangeCo, or the Exchangeable Share Exchange Ratio is
adjusted, in order to implement the required economic equivalence with respect to the Delaware Common Stock and Exchangeable Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tender Offers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Support Agreement will provide that, in the event that a tender offer, share exchange offer, issuer bid, takeover bid or similar transaction
with respect to Delaware Common Stock (an &#147;<B>Offer</B>&#148;) is proposed by Parent or is proposed to Parent or its stockholders and is recommended by the Parent board of directors, or is otherwise effected or to be effected with the consent
or approval of the Parent board of directors, and the Exchangeable Shares are not redeemed by ExchangeCo or purchased by Callco pursuant to the Redemption Call Right, Parent and ExchangeCo will use commercially reasonable efforts to take all such
actions and do all such things as are necessary or desirable to enable and permit holders of Exchangeable Shares (other than Parent and its affiliates) to participate in such Offer to the same extent and on an economically equivalent basis as the
holders of Delaware Common Stock, without discrimination. Without limiting the generality of the foregoing, Parent and ExchangeCo will use commercially reasonable efforts in good faith to ensure that all holders of Exchangeable Shares may
participate in such Offer without being required to retract Exchangeable Shares as against ExchangeCo (or, if so required, to ensure that any such retraction is effective only upon, and is conditional upon, the closing of such Offer and only to the
extent necessary to tender or deposit to the Offer). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership of ExchangeCo Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Support Agreement will also provide that, without the prior approval of ExchangeCo and the prior approval of the holders of the Exchangeable Shares given
in accordance with the Exchangeable Share Provisions, as long as any outstanding Exchangeable Shares not owned by Parent or any of its affiliates are outstanding, Parent will be and remain the direct or indirect beneficial owner of all issued and
outstanding common shares of ExchangeCo and Callco. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendments to the Support Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Support Agreement will provide that, with the exception of changes for the purpose of (i)&nbsp;adding to the covenants of any or all of the parties
thereto; (ii)&nbsp;evidencing the succession of successors to Parent and the covenants and obligations assumed by such successors; (iii)&nbsp;making such amendments or modifications not inconsistent with the Support Agreement as may be necessary or
desirable with respect to matters or questions arising thereunder or (iv)&nbsp;curing or correcting any ambiguities or defect or inconsistent provision or clerical omission or mistake or manifest errors (provided, in the case of clauses (i), (iii)
and (iv), that the board of directors of each of Parent, ExchangeCo and Callco are of the good faith opinion that such amendments are not prejudicial to the rights or interests of the holders of the Exchangeable Shares), the Support Agreement may
not be amended except by agreement in writing executed by Parent, Callco and ExchangeCo and approved by the holders of the Exchangeable Shares given in accordance with the Exchangeable Share Provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting of Exchangeable Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Support Agreement, each of Parent and Callco will agree not to, and to cause its affiliates not to, exercise any voting rights which may be
exercisable by holders of Exchangeable Shares from time to time with respect to any Exchangeable Shares owned by it or its affiliates in respect of any matter considered at meetings of holders of Exchangeable Shares (including any approval sought
from such holders in respect of matters arising under the Support Agreement). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement by Parent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent shall reimburse ExchangeCo for, and indemnify and hold ExchangeCo harmless against, any expense or liability incurred by ExchangeCo with respect to the
Exchangeable Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trust Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
is a summary description of certain material provisions that will be contained in the Trust Agreement, and is not comprehensive and is qualified in its entirety by reference to the complete text of the Trust Agreement, the form of which is attached
as Exhibit D to the Transaction Agreement, which is set forth in Appendix B to the Proxy Statement/Prospectus. The Trust Agreement will be filed on SEDAR and EDGAR following closing of the Arrangement, available under its profile on SEDAR at
www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its website at www.zymeworks.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Trust Agreement is to create
a trust for the benefit of the registered holders from time to time of Exchangeable Shares (other than Parent or affiliates of Parent) (the &#147;<B>Beneficiaries</B>&#148;). The Share Trustee will hold the Special Voting Stock in order to enable
the Share Trustee to exercise the voting rights attached thereto and will hold the Exchange Right and the Automatic Exchange Right (as such terms are defined in the Trust Agreement) in order to enable the Share Trustee to exercise or enforce such
rights, in each case as trustee for and on behalf of the Beneficiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Trust Agreement, Parent will issue to and deposit with the Share Trustee the Special Voting Stock to be held of record by the Share Trustee as
trustee for and on behalf of, and for the use and benefit of, the Beneficiaries and in accordance with the provisions of the Trust Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
Trust Agreement, the Share Trustee shall be entitled to exercise all of the voting rights, including the right to consent to or vote in person or by proxy, attaching to the Special Voting Stock on any matters, question, proposal or proposition that
may properly come before all meetings of stockholders of Parent or in connection with a Parent Consent (as such term is defined in the Trust Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to all meetings of stockholders of Parent at which stockholders of Parent are entitled to vote and with respect to all Parent Consents, each
Beneficiary shall be entitled to instruct the Share Trustee to cast and exercise, in the manner instructed, the number of votes to which a holder of one share of Delaware Common Stock is entitled with respect to such matter, proposition or question
for each Exchangeable Share owned of record by such Beneficiary at the close of business on the record date established by Parent or by applicable law, multiplied by the Exchangeable Share Exchange Ratio, and in respect of each Beneficiary, rounded
down to the nearest whole vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate voting rights attached to the Special Voting Stock at a meeting of stockholders of Parent at which
stockholders of Parent are entitled to vote shall consist of a number of votes equal to one vote per outstanding Exchangeable Share from time to time not owned by Parent and its affiliates on the record date established by Parent, multiplied by the
Exchangeable Share Exchange Ratio, and in respect of each Beneficiary, rounded down to the nearest whole vote, and for which the Share Trustee shall have received voting instructions from the holder of the Exchangeable Share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee will exercise each vote attached to the Special Voting Stock only as directed by the
relevant holder and, in the absence of instructions from a holder as to voting, the Share Trustee will not exercise voting rights with respect to such Exchangeable Share. A holder may, upon instructing the Share Trustee, obtain a proxy from the
Share Trustee entitling the holder to vote directly at the relevant meeting the votes attached to the Special Voting Stock to which the holder is entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee will send to the Beneficiaries by mail or electronic transmission the notice of each meeting or Parent Consent at which the stockholders of
Parent are entitled to vote, together with the related meeting materials and a statement as to the manner in which the holder may instruct the Share Trustee to exercise the votes attaching to the Special Voting Stock, at the same time as Parent
sends such notice and materials to the stockholders of Parent. The Share Trustee will also send to the holders of Exchangeable Shares copies of all information statements, interim and annual financial statements, reports and other materials sent by
Parent to the stockholders of Parent at the same time as such materials are sent to the stockholders of Parent. To the extent such materials are provided to the Share Trustee by Parent, the Share Trustee will also send to the holders all materials
sent by third parties to stockholders of Parent generally, including dissident proxy circulars and tender and exchange offer circulars, as soon as possible after such materials are first sent to the stockholders of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All rights of a holder of Exchangeable Shares to exercise votes attached to the Special Voting Stock will cease upon the exchange of such holder&#146;s
Exchangeable Shares for Delaware Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ExchangeCo Insolvency Event &#151; Exchange Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the occurrence and during the continuance of an Insolvency Event (as such term is defined in the Trust Agreement), the Share Trustee shall have the right
(the &#147;<B>Exchange Right</B>&#148;) to require Parent or Callco to purchase from each Beneficiary all or any part of the Exchangeable Shares from each or any Beneficiary, provided that the Share Trustee may exercise such right only on the basis
of instructions received from each such holder, and provided further that Parent may delegate its obligations thereunder to Callco. The purchase price payable by Parent or Callco, as the case may be, for each Exchangeable Share purchased pursuant to
the exercise of the Exchange Right will be the Exchangeable Share Price on the last Business Day prior to the closing of the purchase and sale of such Exchangeable Share, which price will be satisfied in full by Parent or Callco delivering the
Exchangeable Share Consideration representing such Exchangeable Share Price to the Share Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As soon as practicable following the occurrence of an
Insolvency Event or any event that with the passage of time or the giving of notice or both would be an Insolvency Event, Parent and Holdco will give written notice thereof to the Share Trustee. As soon as practicable after receiving such notice, or
upon the Share Trustee otherwise becoming aware of an Insolvency Event, the Share Trustee will give notice to each holder of Exchangeable Shares of such event and will advise the holder of its rights with respect to the Exchange Right. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Event &#151; Automatic Exchange Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective date of a Liquidation Event (as such term is defined in the Trust Agreement), each of the then outstanding Exchangeable
Shares (other than Exchangeable Shares held by Parent and its affiliates) shall be automatically exchanged for one share of Delaware Common Stock, multiplied by the Exchangeable Share Exchange Ratio, rounded down to the nearest whole share in
respect of each holder of Exchangeable Shares, together with a cash payment for any fractional interest equal to the fractional interest multiplied by the Current Market Price. Such automatic exchange shall be deemed to occur immediately prior to
the Liquidation Event Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELECTED COMPARATIVE PER SHARE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparative Per Share Data of Zymeworks </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table sets forth the closing market price per Zymeworks Common Share as reported by the NYSE on July 14, 2022, the last trading day before the Redomicile Transactions were publicly announced, and on the last practicable trading day before
the date of this Proxy Statement/Prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Shares<BR>(ZYME)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;14, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparative Per Share Data of Parent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historical market price information regarding Parent is not provided because there is no public market for Parent capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_11"></A>INFORMATION CONCERNING PARENT, EXCHANGECO AND CALLCO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Corporate Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent was formed on
June 30, 2022 as a Delaware corporation. The principal office of Parent is located at 108 Patriot Drive, Suite A, Middletown, Delaware 19709. Parent intends to hold an annual meeting of stockholders following completion of the Redomicile
Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intercorporate Relationships </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming the Redomicile Resolution is approved at the Special Meeting, following the Effective Time and completion of the Redomicile Transactions, the
stockholders of Parent will be the same persons who were Zymeworks Shareholders immediately prior to the Redomicile Transactions (other than those who have validly exercised Dissent Rights and holders of Exchangeable Shares prior to exchanging them
for Delaware Common Stock) and Parent will become the direct or indirect owner of all of the assets and liabilities of Zymeworks. As a result, there will be no effective change of control of Zymeworks as a result of the Redomicile Transactions, as
ultimate control will remain with the public stockholders. Upon completion of the Redomicile Transactions, Parent will have the general structure shown below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Structure Prior to the Redomicile Transactions </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n44.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Structure Following the Redomicile Transactions </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to
completion of the Redomicile Transactions, Parent will not have carried on any active business since its incorporation. Following completion of the Redomicile Transactions, Parent and its subsidiaries will carry on the business currently carried on
by Zymeworks and its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a description of the shares of Delaware Common Stock see section titled &#147;<I>Description of Parent Capital Stock</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Unaudited Pro Forma Condensed Consolidated Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Redomicile Transactions had occurred on January&nbsp;1, 2021, the pro forma balance sheet would have reflected a pro forma adjustment to reduce deferred
income tax liability by $1.2&nbsp;million with a corresponding increase in retained earnings by $1.2&nbsp;million. The pro forma income statement for the period ended March&nbsp;31, 2022 would increase tax expense by $0.1&nbsp;million. The pro forma
income statement for the year ended December&nbsp;31, 2021 would decrease tax expense by $0.4&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Officers of Parent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The persons who will serve as directors and officers of Parent after giving effect to the Redomicile Transactions are the same persons currently serving as
directors and officers of Zymeworks. For information regarding the persons who will become the directors of Parent after giving effect to the Redomicile Transactions, please refer to the information contained in Zymeworks&#146; Amendment No.&nbsp;1
to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, filed on SEDAR and EDGAR on May&nbsp;2, 2022, available under its profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s
website at www.sec.gov or its website at www.zymeworks.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent intends to adopt an amended and restated certificate of incorporation (the
&#147;<B>Parent Certificate of Incorporation</B>&#148;) that will become effective prior to completion of the Redomicile Transactions. The Parent Certificate of Incorporation will provide that each member of Parent&#146;s board of directors will be
elected to one of three staggered three-year terms. Only one such term expires at each annual meeting of stockholders, with directors serving under the other terms continuing for the remainder of their respective three-year terms. Zymeworks&#146;
current directors will be up for <FONT STYLE="white-space:nowrap">re-election</FONT> as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The terms of Troy M. Cox, Kenneth Hillan and Natalie Sacks will expire at the annual meeting of stockholders to
be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The terms of Hollings C. Renton and Lota Zoth will expire at the annual meeting of stockholders to be held in
2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The terms of Kenneth Galbraith, Susan Mahony and Kelvin Neu will expire at the annual meeting of stockholders to
be held in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information regarding the persons who will become the officers of Parent after giving effect to the Redomicile
Transactions, please refer to the information contained in Zymeworks&#146; Amendment No.&nbsp;1 to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, filed on SEDAR and EDGAR on May&nbsp;2,
2022, available under its profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its website at www.zymeworks.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Executive Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The director and
executive compensation programs currently offered by Zymeworks are described in Zymeworks&#146; Amendment No.&nbsp;1 to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, filed on SEDAR and
EDGAR on May&nbsp;2, 2022, available under its profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its website at www.zymeworks.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Beneficial Ownership of Securities of Parent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the Effective Time, Parent will be a wholly-owned subsidiary of Zymeworks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Auditor, Registrar and Transfer Agent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The auditor of
Parent following completion of the Redomicile Transactions will be KPMG LLP. The transfer agent and registrar for shares of Delaware Common Stock and Exchangeable Shares following completion of the Redomicile Transactions will be Computershare. The
transfer agent and registrar&#146;s address is 510 Burrard Street, 3rd Floor, Vancouver, B.C. V6C 3B9. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Contracts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described in this Proxy Statement/Prospectus, Parent and its predecessors do not expect to enter into any material contracts prior to the Effective
Time. Since Zymeworks&#146; last periodic filing, the only agreements entered into by Zymeworks or Parent that could reasonably be regarded as material to a proposed investor, other than contracts entered into in the ordinary course of business, are
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Preferred Shares Rights Agreement (the &#147;<B>Zymeworks Rights Agreement</B>&#148;), dated as of
June&nbsp;9, 2022, between Zymeworks and Computershare Trust Company, N.A., as rights agent, described in Zymeworks&#146; Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on June&nbsp;10, 2022; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Transaction Agreement entered into by Zymeworks and Parent. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance of Parent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate governance
practices of Parent, after giving effect to the Redomicile Transactions, will generally be the same as the corporate governance practices of Zymeworks. For information regarding the corporate governance practices of Zymeworks, please refer to the
information regarding the corporate governance practices of Zymeworks contained in Zymeworks&#146; Amendment No.&nbsp;1 to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, filed on SEDAR
and EDGAR on May&nbsp;2, 2022, available under its profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its website at www.zymeworks.com. There are differences between Zymeworks&#146; existing articles of
incorporation and the Parent Certificate of Incorporation and Parent Bylaws as they will be in effect upon the completion of the Redomicile Transactions. These differences are discussed under &#147;<I>Comparison of Rights of Zymeworks Shareholders
and Parent Stockholders</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee of Parent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately after giving effect to the Redomicile Transactions, the Audit Committee of Parent will be comprised of the same persons currently serving on the
Audit Committee of Zymeworks. For information regarding the Audit Committee of Parent after giving effect to the Redomicile Transactions, please refer to the information regarding the Audit Committee of Zymeworks contained in Zymeworks&#146;
Amendment No.&nbsp;1 to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 filed on SEDAR and EDGAR on May&nbsp;2, 2022, available under its profile on SEDAR at www.sedar.com, its profile on
the SEC&#146;s website at www.sec.gov or its website at www.zymeworks.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ExchangeCo Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ExchangeCo is a corporation incorporated under the <I>Business Corporations Act</I> (British Columbia) on July 13, 2022 for the purpose of implementing the
Arrangement. To date, ExchangeCo has not carried on any business except in connection with its role as a party to the Transaction Agreement. ExchangeCo is a direct wholly-owned subsidiary of Callco. ExchangeCo&#146;s registered and principal office
is located at Suite 2600, Three Bentall Centre, 595 Burrard Street, P.O. Box 49314, Vancouver, BC V7X 1L3. The sole director of ExchangeCo is Kenneth Galbraith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ExchangeCo Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The authorized capital of ExchangeCo consists of an unlimited number of common<B> </B>shares and an unlimited number of Exchangeable Shares. See section titled
&#147;<I>Description of Exchangeable Shares and Related Agreements &#151; Description of Exchangeable Shares</I>&#148; for a summary of certain provisions of the Exchangeable Shares which will be created prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date hereof, there are 10 common shares of ExchangeCo issued and outstanding, which are held by Callco. The sole holder of ExchangeCo&#146;s common
shares is expected to be Callco. The holders of ExchangeCo&#146;s common shares are entitled to receive notice of and to attend all meetings of ExchangeCo&#146;s shareholders and to one vote in respect of each Common share held at all such meetings.
The holders of ExchangeCo&#146;s common shares will, subject to the rights of the holders of Exchangeable Shares, be entitled to receive dividends if, as and when declared by the board of directors of ExchangeCo out of the assets of ExchangeCo
properly applicable to the payment of dividends in such amounts and payable in such manner as the board of directors of ExchangeCo may from time to time determine. In the event of the liquidation, dissolution or winding up of ExchangeCo or other
distribution of assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, the holders of ExchangeCo&#146;s common shares will, subject to the rights of the holders of Exchangeable Shares and any other class of shares of
ExchangeCo, be entitled to receive the assets of ExchangeCo. Such distribution will be made in equal amounts per share on all the common shares at the time outstanding without preference or distinction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Callco Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Callco is an unlimited liability company
incorporated under the <I>Business Corporations Act</I> (British Columbia) on July 13, 2022 for the purpose of implementing the Arrangement. To date, Callco has not carried on any business except in connection with its role as a party to the
Transaction Agreement. Callco is a wholly-owned subsidiary of Parent. Callco&#146;s registered and principal office is located at Suite 2600, Three Bentall Centre, 595 Burrard Street, P.O. Box 49314, Vancouver, BC V7X 1L3. The sole director of
Callco is Kenneth Galbraith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_12"></A>INFORMATION CONCERNING ZYMEWORKS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks&#146; suite
of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. These capabilities have resulted in
multiple product candidates with the potential to drive positive outcomes in large underserved and unaddressed patient populations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; lead
product candidate, zanidatamab, is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (&#147;<B>HER2</B>&#148;). Zanidatamab&#146;s unique binding properties result in multiple mechanisms of
action that may enable it to address unmet need in patient populations with HER2-expressing cancers. In clinical trials, zanidatamab monotherapy and zanidatamab in combination with chemotherapy have been well tolerated with promising antitumor
activity in patients with treatment-naive and heavily pretreated HER2-expressing cancers, including individuals whose disease had progressed on multiple prior treatment regimens that
<FONT STYLE="white-space:nowrap">included&nbsp;HER-targeted&nbsp;agents.</FONT> Based on these data, a number of global multicenter clinical trials have been initiated to evaluate zanidatamab in specific indications and lines of therapy. These
include pivotal clinical trials in (i)&nbsp;previously-treated HER2 gene amplified biliary tract cancer (&#147;<B>BTC</B>&#148;) and (ii)&nbsp;first-line locally advanced or metastatic HER2-positive gastroesophageal adenocarcinomas
(&#147;<B>GEA</B>&#148;) in combination with chemotherapy with or without BeiGene, Ltd.&#146;s tislelizumab, as well as proof of concept trials in (iii)&nbsp;first-line locally advanced or metastatic HER2-positive colorectal cancer, GEA, or BTC in
combination with standard of care chemotherapy, (iv)&nbsp;first-line locally advanced or metastatic HER2-positive GEA in combination with tislelizumab and chemotherapy, (v)&nbsp;first-line locally advanced or metastatic HER2-positive breast cancer
in combination with docetaxel, (vi)&nbsp;previously-treated locally advanced or metastatic HER2-positive, hormone receptor-positive breast cancer in combination with Pfizer&#146;s Ibrance (palbociclib) and fulvestrant, and
(vii)&nbsp;previously-treated locally advanced or metastatic HER2-expressing cancers (including HER2-positive <FONT STYLE="white-space:nowrap">and&nbsp;HER2-low&nbsp;breast</FONT> cancer) in combination with ALX Oncology Inc.&#146;s evorpacept
(ALX148). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; second product candidate, ZW49, combines the unique design of zanidatamab with Zymeworks&#146; ZymeLink antibody-drug conjugate
(&#147;<B>ADC</B>&#148;) platform, comprised of proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Zymeworks designed ZW49 to be
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;best-in-class&nbsp;HER2-targeting</FONT></FONT> ADC to further address unmet need across a range of HER2-expressing cancers. A Phase 1 clinical trial to establish safety and
antitumor activity of ZW49 is currently ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage
programs in oncology (including immuno-oncology agents) and other therapeutic areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; proprietary capabilities and technologies include
several modular, complementary therapeutic platforms that can be used in combination with each other and with existing approaches. This ability to layer technologies without compromising manufacturability enables Zymeworks to engineer
next-generation biotherapeutics with synergistic activity, which it believes will result in improved patient outcomes. Zymeworks&#146; platforms include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Azymetric, Zymeworks&#146; bispecific platform, which enables therapeutic antibodies to simultaneously bind
multiple distinct locations on a target (known as an epitope) or to multiple targets. This is achieved by tailoring multiple configurations of the antibody&#146;s Fab regions (locations on the antibody to which epitopes bind); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ZymeLink, Zymeworks&#146; ADC platform, comprised of cytotoxins and the linker technology used to couple these
cytotoxins to tumor-targeting antibodies or proteins. This platform can be used in conjunction with Zymeworks&#146; other therapeutic platforms to increase safety and efficacy as compared to existing ADC technologies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ProTECT, which enables tumor-specific activity that may reduce systemic toxicity, and simultaneously enhances
localized immune <FONT STYLE="white-space:nowrap">co-stimulation</FONT> or checkpoint modulation that may increase efficacy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; goal is to leverage its next-generation therapeutic platforms and proprietary protein engineering capabilities to become a leader in the
discovery, development and commercialization of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> multifunctional biotherapeutics for the treatment of cancer and other diseases with high unmet medical
need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks commenced operations in 2003 and has since devoted substantially all of its resources to research and development activities including
developing its therapeutic platforms, identifying and developing potential product candidates and undertaking preclinical studies and clinical trials. Additionally, Zymeworks has supported its research and development activities with general and
administrative support, as well as by raising capital, conducting business planning and protecting its intellectual property. Zymeworks has not generated any revenue from the sale of approved products to date and does not expect to do so until such
time as Zymeworks obtains regulatory approval and commercialize one or more of its product candidates. Zymeworks cannot be certain of the timing or success of approval of its product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information about Zymeworks can be found under its profile on SEDAR at www.sedar.com, its profile on the SEC&#146;s website at www.sec.gov or its
website at www.zymeworks.com. The information contained in, or that can be accessed through, Zymeworks&#146; website is not intended to be incorporated into this Proxy Statement/Prospectus. For information about Zymeworks&#146; filings incorporated
by reference in this Proxy Statement/Prospectus, see section titled &#147;<I>Where You Can Find More Information</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Auditor, Registrar and
Transfer Agent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP (&#147;<B>KPMG</B>&#148;) is the auditor of Zymeworks. Computershare is the registrar and transfer agent for the Zymeworks
Common Shares. Transfer of the Zymeworks Common Shares can be effected at Computershare&#146;s principal offices in Vancouver, British Columbia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of [&#9679;], 2022, Zymeworks had [&#9679;]
shareholders of record holding its common shares, of which [&#9679;] were U.S. shareholders. A substantially greater number of holders of Zymeworks&#146; common stock are &#147;street name&#148; or beneficial holders whose shares of record are held
by banks, brokers, and other financial institutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks has neither declared nor paid dividends on the Zymeworks Common Shares. Zymeworks has no present intention of paying dividends on its Zymeworks
Common Shares as it anticipates that all available funds will be invested to finance the growth of its business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prior Sales </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed below, within the last 12 months from the date of this Proxy Statement/Prospectus, no Zymeworks Common Shares have been issued, excluding
Zymeworks Common Shares purchased or sold pursuant to the exercise of options or the settlement of RSUs and Zymeworks Common Shares purchased pursuant to Zymeworks&#146; Amended and Restated Employee Stock Purchase Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2022, Zymeworks completed an underwritten public offering of 11,035,000 Zymeworks Common Shares at a price of $8.00 per Common Share,
including the exercise in full of the underwriters&#146; option </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to purchase 1,875,000 additional Zymeworks Common Shares, and, in lieu of Zymeworks Common Shares to certain <FONT STYLE="white-space:nowrap">investors,&nbsp;pre-funded&nbsp;warrants</FONT> to
purchase up to 3,340,000 Zymeworks Common Shares at a price of $7.9999 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Price
and Trading Volume of Zymeworks Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Common Shares are listed on the NYSE under the stock symbol &#147;ZYME&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets out the market price ranges and trading volumes on the NYSE on a monthly basis for a period from July 2021 to June 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Month</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High&nbsp;Price</B><br><B>(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low&nbsp;Price</B><br><B>(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Closing&nbsp;Price</B><br><B>(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Volume*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,908,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,990,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,479,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,484,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,474,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,848,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,529,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,257,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,923,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,622,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,319,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,989,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2022 (through July&nbsp;8, 2022)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,110,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the total number of Zymeworks Common Shares traded over the calendar month. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest of Informed Persons in Material Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as set forth in this Proxy Statement/Prospectus, Zymeworks is not aware of any material interests, direct or indirect, by way of beneficial
ownership of securities or otherwise, of any director or executive officer, nominee for election as a director or any Zymeworks Shareholder holding more than 10% of the voting rights attached to the Zymeworks Common Shares or an associate or
affiliate of any of the foregoing in any transaction since January&nbsp;1, 2021, or in any proposed or ongoing transaction of Zymeworks which has or would materially affect Zymeworks or any of its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, Zymeworks may
become involved in legal proceedings or be subject to claims arising in the ordinary course of its business. As of the date hereof, Zymeworks was not a party to any legal proceedings that, in the opinion of management, would reasonably be expected
to have a material adverse effect on Zymeworks&#146; business, financial condition, operating results or cash flows if determined adversely to it. Regardless of the outcome, litigation can have an adverse impact on Zymeworks because of defense and
settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legality of the shares of Delaware Common Stock issuable in the Arrangement will be passed upon by Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional
Corporation. Certain other legal matters in connection with the Redomicile Transactions will be passed upon by Blake, Cassels&nbsp;&amp; Graydon LLP, Canadian corporate and tax counsel to Zymeworks, and Wilson Sonsini Goodrich&nbsp;&amp; Rosati,
Professional Corporation, U.S. corporate and tax counsel to Zymeworks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Zymeworks as of December&nbsp;31, 2021 and 2020, and for each of the years in the three-year period ended
December&nbsp;31, 2021, and management&#146;s assessment of the effectiveness of internal control over financial reporting as of December&nbsp;31, 2021 have been incorporated by reference herein in reliance upon the reports of KPMG LLP, independent
registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representatives of KPMG LLP are not expected to be present at the Special Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_15"></A>MATERIAL CANADIAN FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is, as of the date hereof, a summary of the principal Canadian federal income tax considerations under the Tax Act generally applicable to a
beneficial owner of Zymeworks Common Shares who, for the purposes of the Tax Act and at all relevant times, (1)&nbsp;holds Zymeworks Common Shares, and will hold Exchangeable Shares and/or Delaware Common Stock, as applicable, as capital property;
and (2)&nbsp;deals at arm&#146;s length with, and is not affiliated with, Zymeworks, Parent, Callco or ExchangeCo (a &#147;<B>Holder</B>&#148;). Generally, Zymeworks Common Shares, Exchangeable Shares and/or Delaware Common Stock (collectively, the
&#147;<B>Shares</B>&#148;), as applicable, will be capital property to a Holder, provided that the Holder does not acquire or hold the Shares in the course of carrying on a business or as part of an adventure or concern in the nature of trade. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary does not apply to a Holder who acquired Zymeworks Common Shares under a Zymeworks Warrant or Zymeworks Incentive Award. Those Holders should
consult their own tax advisors. This summary also does not apply to Zymeworks Incentive Award holders or Zymeworks Warrant holders. Those holders should consult their own tax advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary is based on the current provisions of the Tax Act in force as of the date hereof and an understanding of the current administrative policies and
assessing practices of the Canada Revenue Agency (the &#147;<B>CRA</B>&#148;) published in writing by it prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act publicly announced by or on behalf of the
Minister of Finance (Canada) prior to the date hereof (the &#147;<B>Proposed Amendments</B>&#148;) and assumes that all Proposed Amendments will be enacted in the form proposed. However, no assurances can be given that the Proposed Amendments will
be enacted as proposed, or at all. This summary does not otherwise take into account or anticipate any changes in Law or administrative policy or assessing practice whether by legislative, administrative or judicial action nor does it take into
account tax legislation or considerations of any province, territory or foreign jurisdiction, which may differ from those discussed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This
summary is of a general nature only and is not, and is not intended to be, legal or tax advice to any particular Holder. This summary is not exhaustive of all Canadian federal income tax considerations applicable to the purchasing, holding and
disposing of the Zymeworks Common Shares, Exchangeable Shares or Delaware Common Stock. Accordingly, Holders should consult their own tax advisors having regard to their own particular circumstances. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, for purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of securities (including dividends, adjusted cost base
and proceeds of disposition) must be converted into Canadian dollars based on exchange rates as determined in accordance with the Tax Act. In particular, the amount of dividends to be included in the income of, and the amount of capital gains or
capital losses realized by, a Holder of Delaware Common Stock, and the amount of any capital gain realized on the disposition of Zymeworks Common Shares pursuant to the Plan of Arrangement, may be affected by fluctuation in the Canadian/U.S. dollar
exchange rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders Resident in Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
portion of the summary is generally applicable to a Holder who for the purposes of the Tax Act and any applicable tax treaty, is resident or is deemed to be resident in Canada at all times while they hold Zymeworks Common Shares, Exchangeable Shares
or Delaware Common Stock (a &#147;<B>Resident Holder</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain Resident Holders whose Zymeworks Common Shares or Exchangeable Shares might not
otherwise qualify as capital property may be entitled to make, or may have already made, an irrevocable election under subsection 39(4) of the Tax Act. This election may deem any Zymeworks Common Shares or Exchangeable Shares (and any other
&#147;Canadian security&#148;, as defined in the Tax Act) owned by such Resident Holder to be capital property in the taxation year in which the election is made and in all subsequent taxation years. Resident Holders whose Zymeworks Common Shares or
Exchangeable Shares might not otherwise be considered to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital property should consult their own tax advisors concerning this election. Exchangeable Shares received by an Eligible Holder under a section 85 election in respect of Zymeworks Common
Shares, as described below, will not be a &#147;Canadian security&#148; to such Resident Holder for this purpose. Resident Holders should consult with their own tax advisors for advice with respect to whether an election under subsection 39(4) is
available in their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This portion of the summary does not apply to a Zymeworks Shareholder (i)&nbsp;an interest in which is a
&#147;tax shelter investment&#148; as defined in the Tax Act; (ii)&nbsp;that is a &#147;financial institution&#148; for the purposes of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> rules
contained in the Tax Act; (iii)&nbsp;that is a &#147;specified financial institution&#148; as defined in the Tax Act; (iv)&nbsp;that has made a functional currency reporting election under the Tax Act; (v)&nbsp;that is a corporation resident in
Canada, and is, or becomes, or does not deal at arm&#146;s length with a corporation resident in Canada that is or becomes, as part of a transaction or event or series of transactions or events that includes the Plan of Arrangement, controlled by a <FONT
STYLE="white-space:nowrap">non-resident</FONT> person (or a group of persons that do not deal at arm&#146;s length) for purposes of the &#147;foreign affiliate dumping&#148; rules in section 212.3 of the Tax Act; (vi)&nbsp;that has, or will, enter
into, with respect to any Shares, a &#147;derivative forward agreement&#148; or a &#147;synthetic disposition agreement&#148;, as those terms are defined in the Tax Act; or (vii)&nbsp;in respect of whom Parent is or will be a &#147;foreign
affiliate&#148; as defined in the Tax Act. Those Zymeworks Shareholders should consult their own tax advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is assumed, for the purposes of this
portion of the summary, that ExchangeCo will be a &#147;taxable Canadian corporation&#148; within the meaning of the Tax Act at all relevant times. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Receipt of Ancillary Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who
receives Exchangeable Shares as part of the Consideration for Zymeworks Common Shares will also receive ancillary rights in respect of the Exchangeable Shares, described under &#147;<I>Description of Exchangeable Shares and Related Agreements &#151;
Description of Exchangeable Shares</I>&#148;. A Resident Holder will be required to account for the ancillary rights in determining the proceeds of disposition of such Resident Holder&#146;s Zymeworks Common Shares and the cost to the Resident
Holder of the Exchangeable Shares received in consideration therefor. Zymeworks considers that the ancillary rights have a nominal fair market value. This determination of value is not binding on the CRA and it is possible that the CRA could take a
contrary view. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Call Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder
who receives Exchangeable Shares as part of the Consideration for Zymeworks Common Shares will grant to Callco certain call rights, described under &#147;<I>Description of Exchangeable Shares and Related Agreements &#151; Description of Exchangeable
Shares</I>&#148; (the &#147;<B>Call Rights</B>&#148;). Zymeworks considers that the Call Rights have a nominal fair market value. This determination of value is not binding on the CRA and it is possible that the CRA could take a contrary view. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the view of Zymeworks, the granting of the Call Rights will not result in any material adverse income tax consequences to a Resident Holder. If the
Call Rights have a fair market value in excess of a nominal amount, however, Resident Holders who acquire Exchangeable Shares will realize a capital gain in an amount equal to the fair market value of the Call Rights. The general tax treatment of
capital gains and capital losses is discussed below under the section titled &#147;<I>&#151; Taxation of Capital Gain or Capital Loss</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange of Zymeworks Common Shares for Delaware Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who disposes of Zymeworks Common Shares for Delaware Common Stock will realize proceeds of disposition equal to the aggregate fair market
value, at the time of the disposition, of the Delaware Common Stock acquired on the exchange. The Resident Holder will realize a capital gain (or capital loss) equal to the amount by which the proceeds of disposition, net of any reasonable costs of
disposition, exceed (or are less than) the adjusted cost base to such Resident Holder of the Zymeworks Common Shares immediately before the disposition. The general tax treatment of capital gains and capital losses is discussed below under the
section titled &#147;<I>Taxation of Capital Gain or Capital Loss</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost to a Resident Holder of Delaware Common Stock acquired on the exchange will be equal to the fair
market value of the Delaware Common Stock at that time. The cost of Delaware Common Stock so acquired will be averaged with the adjusted cost base of any other Delaware Common Stock held by such Resident Holder as capital property for purposes of
determining such Resident Holder&#146;s adjusted cost base of all Delaware Common Stock held by such Resident Holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange of Zymeworks Common
Shares for Exchangeable Shares &#151; No Section&nbsp;85 Election </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who (a)&nbsp;disposes of Zymeworks Common Shares pursuant to
the Plan of Arrangement and who receives Exchangeable Shares including any ancillary rights, and (b)&nbsp;does not make a joint election under subsection 85(1) or subsection 85(2) of the Tax Act in respect of the disposition, will be considered to
have disposed of the Zymeworks Common Shares for proceeds of disposition equal to the sum of (i)&nbsp;the aggregate fair market value, at the time of the disposition, of the Exchangeable Shares acquired on the exchange, and (ii)&nbsp;the fair market
value of any ancillary rights acquired on the exchange. The Resident Holder will realize a capital gain (or capital loss) equal to the amount by which the proceeds of disposition of such Zymeworks Common Shares, net of any reasonable costs of
disposition, exceed (or are less than) the adjusted cost base to such Resident Holder of such Zymeworks Common Shares immediately before the disposition. The general tax treatment of capital gains and capital losses is discussed below under the
section titled &#147;<I>&#151; Taxation of Capital Gain or Capital Loss</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost to a Resident Holder of Exchangeable Shares acquired on the
exchange will be equal to the fair market value of the Exchangeable Shares at that time. The cost to the Resident Holder of ancillary rights acquired on the exchange will be equal to the fair market value, at the time of acquisition, of the
ancillary rights. As described above, Zymeworks is of the view that such rights have only nominal value (see the section titled &#147;<I>Receipt of Ancillary Rights</I>&#148; above). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange of Zymeworks Common Shares for Exchangeable Shares &#151; Section&nbsp;85 Election </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who (a)&nbsp;disposes of Zymeworks Common Shares pursuant to the Plan of Arrangement and who receives Exchangeable Shares including any
ancillary rights, and (b)&nbsp;validly makes a joint election under subsection 85(1) or subsection 85(2) of the Tax Act in respect of the disposition, may defer all or a portion of any capital gain otherwise arising on the exchange, depending on the
Elected Amount (as defined below) and the adjusted cost base to the Resident Holder of the Zymeworks Common Shares at the time of the exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;85 Election </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the limitations and
conditions described below, ExchangeCo will make a joint election under subsection 85(1) or subsection 85(2), as applicable, of the Tax Act (and the corresponding provisions of any applicable provincial tax legislation) with an Eligible Holder who
validly receives Exchangeable Shares (including any ancillary rights) as part of the Consideration, at the agreed amount selected by such Eligible Holder subject to the limitations under the Tax Act (the &#147;<B>Elected Amount</B>&#148;). Subject
to the limitations under the Tax Act described generally below, the Elected Amount will be treated for the purposes of the Tax Act as the Eligible Holder&#146;s proceeds of disposition of its Zymeworks Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to make an election under subsection 85(1) or subsection 85(2), as applicable, of the Tax Act (and the corresponding provisions of any applicable
provincial tax legislation), an Eligible Holder must provide two signed copies of the necessary prescribed election form(s) to the Depositary within sixty (60)&nbsp;days following the Effective Date, duly completed with the details of the number of
Zymeworks Common Shares transferred and the Elected Amount for the purposes of such election. It is the responsibility of each Eligible Holder who wishes to make such an election to obtain and complete the necessary forms as required by the Tax Act
(and applicable provincial income tax laws), including any necessary provincial election forms, and submit the forms for execution by ExchangeCo. Thereafter, subject to the election forms being correct and complete and complying
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the provisions of the Tax Act (and applicable provincial income tax law), the forms will be signed by ExchangeCo and returned to such former beneficial owner of Zymeworks Common Shares
within sixty (60)&nbsp;days after the receipt thereof by the Depositary for filing with the CRA (or the applicable provincial taxing authority) by such former Eligible Holder. ExchangeCo will not be responsible for the proper completion of any
election form and, except for ExchangeCo&#146;s obligation to sign and return (within sixty (60)&nbsp;days after the receipt thereof by the Depositary) duly completed election forms which are received by the Depositary within sixty (60)&nbsp;days of
the Effective Date, ExchangeCo will not be responsible for any taxes, interest or penalties resulting from the failure by a former beneficial owner of Zymeworks Common Shares to properly complete or file the election forms in the form and manner and
within the time prescribed by the Tax Act (or any applicable provincial legislation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The relevant tax election form is CRA Form T2057 (or, in the event
that the Zymeworks Common Shares are held as partnership property, CRA Form T2058). An Eligible Holder interested in making an election should so indicate in the Letter of Transmittal and Election Form in the space provided therein. Eligible Holders
should consult their own tax advisors to determine whether separate election forms must be filed with any other provincial taxing authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where
Zymeworks Common Shares are held in <FONT STYLE="white-space:nowrap">co-ownership</FONT> and two or more of the <FONT STYLE="white-space:nowrap">co-owners</FONT> wish to elect, one of the <FONT STYLE="white-space:nowrap">co-owners</FONT> designated
for such purpose by the <FONT STYLE="white-space:nowrap">co-owners</FONT> must file one copy of the CRA Form T2057 on behalf of all of the <FONT STYLE="white-space:nowrap">co-owners</FONT> (and where applicable, the corresponding form in duplicate
with the relevant provincial authorities). The CRA Form T2057 must be accompanied by a list containing the name, address, social insurance number or business number of all <FONT STYLE="white-space:nowrap">co-owners</FONT> electing as well as the
document signed by all <FONT STYLE="white-space:nowrap">co-owners</FONT> electing authorizing the designated <FONT STYLE="white-space:nowrap">co-owner</FONT> to complete and file the form. Where the Zymeworks Common Shares are held as partnership
property, a partner designated by the partnership must file one copy of the CRA Form T2058 on behalf of all members of the partnership (and where applicable, the corresponding form in duplicate with the relevant provincial authorities). The CRA Form
T2058 must be accompanied by a list containing the name, address, social insurance number or business number of each partner as well as the document signed by each partner authorizing the designated partner to complete and file the form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, the Elected Amount is subject to the following limitations in respect of the Zymeworks Common Shares that are the subject of the election: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Elected Amount may not be less than the aggregate fair market value at the Effective Time of any ancillary
rights received on the exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Elected Amount may not be less than the lesser of the adjusted cost base to the Eligible Holder of its
Zymeworks Common Shares disposed of, determined immediately before the time of the disposition, and the fair market value at the Effective Time of the Zymeworks Common Shares disposed of at that time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Elected Amount may not be greater than the fair market value at the Effective Time of the disposition of the
Zymeworks Common Shares so disposed of. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elected Amounts which do not comply with these limitations will be automatically adjusted
pursuant to the provisions of the Tax Act so that they comply. Any reference to an Elected Amount herein refers to the Elected Amount that complies (or is adjusted to comply) with these limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a Resident Holder who is an Eligible Holder and ExchangeCo make a joint election under subsection 85(1) or subsection 85(2) of the Tax Act, as
applicable, the tax treatment to such Eligible Holder generally will be as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Eligible Holder will be deemed to have disposed of the Zymeworks Common Shares for proceeds of disposition
equal to the Elected Amount; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the proceeds of disposition are equal to the aggregate of the adjusted cost base to the Eligible Holder of the
Zymeworks Common Shares, determined immediately before the disposition, and any reasonable costs of disposition, no capital gain or capital loss will be realized by the Eligible Holder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that the proceeds of disposition of the Zymeworks Common Shares exceed (or are less than) the
aggregate of the adjusted cost base to the Eligible Holder of the Zymeworks Common Shares, determined immediately before the exchange, and any reasonable costs of disposition, the Eligible Holder will, in general, realize a capital gain (or capital
loss); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to the Eligible Holder of any ancillary rights received on the exchange will be equal to the fair market
value thereof at the Effective Time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to the Eligible Holder of Exchangeable Shares received on the exchange will be equal to the amount by
which the proceeds of disposition exceed the fair market value at the Effective Time of the ancillary rights received on the exchange. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where an Eligible Holder and ExchangeCo make a joint election under subsection 85(1) or subsection 85(2) of the Tax Act, as applicable, the Eligible Holder
may realize a capital gain on the disposition of the Zymeworks Common Shares to the extent that the value of ancillary rights, net of any reasonable costs of disposition, exceeds the adjusted cost base to the Eligible Holder of the Zymeworks Common
Shares immediately before the disposition. As described above, Zymeworks is of the view that such rights have only nominal value (see the section titled &#147;<I>Receipt of Ancillary Rights</I>&#148; above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To avoid a late-filing penalty, the required election forms must be received by the appropriate tax authorities on or before the day that is the earliest of
the days on or before which either ExchangeCo or the electing Eligible Holder is required to file a Canadian tax return for the taxation year in which the disposition of the Zymeworks Common Shares occurs. The current taxation year of ExchangeCo is
scheduled to end on December&nbsp;31, 2022. Thus, if the exchange occurs prior to January&nbsp;1, 2023, the tax election forms will, in the case of an electing Eligible Holder who is an individual (other than a trust), generally be due by
April&nbsp;30, 2023. Electing Eligible Holders should consult their own advisors forthwith respecting the deadlines applicable to their own particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any Eligible Holder who does not ensure that ExchangeCo has received two duly completed copies of the necessary election forms on or before the 60th day
after the Effective Date may not be able to benefit from the rollover provisions of the Tax Act. Accordingly, all Eligible Holders who wish to enter into a tax election with ExchangeCo should give their immediate attention to this matter. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The comments herein with respect to such elections are provided for general assistance only. The Law in this area is complex and contains numerous technical
requirements. Eligible Holders should consult Information Circular <FONT STYLE="white-space:nowrap">76-19R3</FONT> and Interpretation Bulletin <FONT STYLE="white-space:nowrap">IT-291R3</FONT> (Archived), issued by the CRA, for further information
respecting the subsections 85(1) and (2)&nbsp;elections under the Tax Act. Eligible Holders wishing to make the election should consult their own tax advisors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange of Zymeworks Common Shares for Exchangeable Shares and Delaware Common Stock &#151; No Section&nbsp;85 Election </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who (a)&nbsp;disposes of Zymeworks Common Shares pursuant to the Plan of Arrangement and who receives Exchangeable Shares including any
ancillary rights and Delaware Common Stock, and (b)&nbsp;does not make a joint election under subsection 85(1) or subsection 85(2) of the Tax Act in respect of the disposition, will be considered to have disposed of the Zymeworks Common Shares for
proceeds of disposition equal to the sum of (i)&nbsp;the aggregate fair market value, at the time of the disposition, of the Exchangeable Shares and Delaware Common Stock acquired on the exchange, and (ii)&nbsp;the fair market value of any ancillary
rights acquired on the exchange. The Resident Holder will realize a capital gain (or capital loss) equal to the amount by which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeds of disposition of such Zymeworks Common Shares, net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base to such Resident Holder of such Zymeworks
Common Shares. The general tax treatment of capital gains and capital losses is discussed below under the section titled &#147;<I>Taxation of Capital Gain or Capital Loss</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost to a Resident Holder of Exchangeable Shares and Delaware Common Stock acquired on the exchange will be equal to the respective fair market value of
the Exchangeable Shares and Delaware Common Stock at that time. The cost to the Resident Holder of ancillary rights acquired on the exchange will be equal to the fair market value, at the time of acquisition, of the ancillary rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange of Zymeworks Common Shares for Exchangeable Shares and Delaware Common Stock &#151; Section&nbsp;85 Election </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who (a)&nbsp;disposes of Zymeworks Common Shares pursuant to the Plan of Arrangement and who receives Exchangeable Shares including any
ancillary rights and Delaware Common Stock, and (b)&nbsp;validly makes a joint election under subsection 85(1) or subsection 85(2) of the Tax Act in respect of the disposition, may defer all or a portion of any capital gain otherwise arising on the
exchange, depending on the Elected Amount and the adjusted cost base to the Resident Holder of the Zymeworks Common Shares at the time of the exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;85 Election </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the limitations and
conditions described below, ExchangeCo will make a joint election under subsection 85(1) or subsection 85(2), as applicable, of the Tax Act (and the corresponding provisions of any applicable provincial tax legislation) with an Eligible Holder who
validly receives Exchangeable Shares (including any ancillary rights) and Delaware Common Stock as part of the Consideration, at the Elected Amount. Subject to the limitations under the Tax Act described generally below, the Elected Amount will be
treated for the purposes of the Tax Act as the Eligible Holder&#146;s proceeds of disposition of its Zymeworks Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Section&nbsp;85
election forms and procedures, see section titled &#147;<I>Exchange of Zymeworks Common Shares for Exchangeable Shares &#151; Section</I><I></I><I>&nbsp;85 Election</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, the Elected Amount is subject to the following limitations in respect of the Zymeworks Common Shares that are the subject of the election: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Elected Amount may not be less than the aggregate fair market value of the Delaware Common Stock and any
ancillary rights received on the exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Elected Amount may not be less than the lesser of the adjusted cost base to the Eligible Holder of its
Zymeworks Common Shares disposed of, determined immediately before the time of the disposition, and the fair market value of the Zymeworks Common Shares disposed of at that time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Elected Amount may not be greater than the fair market value at the time of the disposition of the Zymeworks
Common Shares so disposed of. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elected Amounts which do not comply with these limitations will be automatically adjusted pursuant to the
provisions of the Tax Act so that they comply. Any reference to an Elected Amount herein refers to the Elected Amount that complies (or is adjusted to comply) with these limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a Resident Holder who is an Eligible Holder and ExchangeCo make a joint election under subsection 85(1) or subsection 85(2) of the Tax Act, as
applicable, the tax treatment to such Eligible Holder generally will be as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Eligible Holder will be deemed to realize proceeds of disposition equal to the Elected Amount;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the proceeds of disposition are equal to the aggregate of the adjusted cost base to the Eligible Holder of the
Zymeworks Common Shares, determined immediately before the disposition, and any reasonable costs of disposition, no capital gain or capital loss will be realized by the Eligible Holder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that the proceeds of disposition of the Zymeworks Common Shares exceed (or are less than) the
aggregate of the adjusted cost base to the Eligible Holder of the Zymeworks Common Shares, determined immediately before the exchange, and any reasonable costs of disposition, the Eligible Holder will, in general, realize a capital gain (or capital
loss); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to the Eligible Holder of any Delaware Common Stock and ancillary rights received on the exchange will
be equal to their respective fair market values at that time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to the Eligible Holder of Exchangeable Shares received on the exchange will be equal to the amount by
which the proceeds of disposition exceed the fair market value of the Delaware Common Stock and the ancillary rights received on the exchange. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where an Eligible Holder and ExchangeCo make a joint election under subsection 85(1) or subsection 85(2) of the Tax Act, as applicable, the Eligible Holder
may realize a capital gain on the disposition of the Zymeworks Common Shares to the extent that the value of the Delaware Common Stock and the ancillary rights, net of any reasonable costs of disposition, exceeds the adjusted cost base to the
Eligible Holder of the Zymeworks Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For applicable section 85 election deadlines, see section titled &#147;<I>Exchange of Zymeworks Common
Shares for Exchangeable Shares &#151; Section</I><I></I><I>&nbsp;85 Election</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The comments herein with respect to such elections are provided
for general assistance only. The Law in this area is complex and contains numerous technical requirements. Eligible Holders should consult Information Circular <FONT STYLE="white-space:nowrap">76-19R3</FONT> and Interpretation Bulletin <FONT
STYLE="white-space:nowrap">IT-291R3</FONT> (Archived), issued by the CRA, for further information respecting the subsections 85(1) and (2)&nbsp;elections under the Tax Act. Eligible Holders wishing to make the election should consult their own tax
advisors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends on Exchangeable Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
dividend received or deemed to be received on the Exchangeable Shares by a Resident Holder who is an individual (other than certain trusts) will be included in computing such Resident Holder&#146;s income for the taxation year in which such
dividends are received or deemed to be received, subject to the <FONT STYLE="white-space:nowrap">gross-up</FONT> and dividend tax credit rules normally applicable under the Tax Act to taxable dividends received from taxable Canadian corporations.
Certain dividends may be eligible for the enhanced <FONT STYLE="white-space:nowrap">gross-up</FONT> and dividend tax credit, to the extent designated as an &#147;eligible dividend&#148; by ExchangeCo. There are limitations on the ability of a
corporation to designate dividends and deemed dividends as eligible dividends. A dividend received by an individual, or certain trusts, may also give rise to alternative minimum tax under the Tax Act, depending on the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A dividend received or deemed to be received on Exchangeable Shares by a Resident Holder that is a corporation will be included in the corporation&#146;s
income for the taxation year in which such dividends are received or deemed to be received and will generally be deductible in computing its taxable income, subject to the restrictions and limitations under the Tax Act. Where a Resident Holder that
is a corporation receives or is deemed to receive a dividend on Exchangeable Shares and such dividend is deductible in computing such Resident Holder&#146;s income, all or part of the dividend may in certain circumstances be treated under the Tax
Act as a capital gain from the disposition of a capital property (or as proceeds of disposition of Exchangeable Shares potentially giving rise to a capital gain) the taxable portion of which must be included in computing the Resident Holder&#146;s
income for the year in which the dividend was received. Resident Holders that are corporations should consult their own tax advisors in this regard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain corporations, including &#147;private corporations&#148; and &#147;subject corporations&#148; (as such terms are defined in the Tax Act) may be liable
to pay a refundable tax under Part IV of the Tax Act to the extent that the dividends </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received or deemed to be received on Exchangeable Shares are deductible in computing taxable income. The Exchangeable Shares will be &#147;taxable preferred shares&#148; for purposes of the Tax
Act and therefore, Part IV.1 of the Tax Act will apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Parent or Callco, or any other person with whom Parent does not deal at arm&#146;s length (or
any trust or partnership of which such person is a beneficiary or member), is a &#147;specified financial institution&#148; for purposes of the Tax Act at the time that dividends are paid on the Exchangeable Shares, dividends received or deemed to
be received by a Resident Holder that is a corporation will not be deductible in computing such holder&#146;s taxable income. Zymeworks is of the view that, immediately after the Effective Time, neither Parent nor Callco will be a &#147;specified
financial institution&#148; for purposes of the Tax Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resident Holders should consult their own tax advisors in relation to any foreign tax credit or
deduction which may be available in respect of U.S. withholding tax, and the limitations under the Tax Act in that regard. Generally, a foreign tax credit or deduction in respect of a tax paid to a particular foreign country is limited to the
Canadian tax otherwise payable in respect of income sourced in that country. Dividends received or deemed to be received on Exchangeable Shares by a Resident Holder may not be treated as U.S. source income for these purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends on Delaware Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A dividend
received or deemed to be received on Delaware Common Stock by a Resident Holder who is an individual will be included in computing such Resident Holder&#146;s income for the taxation year in which such dividends are received and will not be subject
to the <FONT STYLE="white-space:nowrap">gross-up</FONT> and dividend tax credit rules in the Tax Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A dividend received or deemed to be received on
Delaware Common Stock by a Resident Holder that is a corporation will be included in the corporation&#146;s income and will generally not be deductible in computing its taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any U.S. <FONT STYLE="white-space:nowrap">non-resident</FONT> withholding tax paid by or on behalf of a Resident Holder on such dividends generally should be
eligible, subject to the specific rules and limitations under the Tax Act, to be credited against the Resident Holder&#146;s income tax or deducted from income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption, Retraction, Exchange and Disposition of Exchangeable Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder will be considered to have disposed of Exchangeable Shares (i)&nbsp;on a redemption (including pursuant to a Retraction Request) of such
Exchangeable Shares by ExchangeCo, and (ii)&nbsp;on an acquisition of such Exchangeable Shares by Callco. However, as described below, the Canadian federal income tax consequences of the disposition will be different depending on whether the event
giving rise to the disposition is a redemption or an acquisition. Resident Holders have certain rights under the Exchangeable Share Provisions that may affect whether the relevant disposition occurs by way of a redemption or an acquisition and such
Resident Holders should consult their own tax advisors in relation to the potential exercise of any such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the redemption (including pursuant to
a Retraction Request) of an Exchangeable Share by ExchangeCo, a Resident Holder will generally be deemed to receive a dividend equal to the amount, if any, by which the aggregate redemption proceeds exceed the
<FONT STYLE="white-space:nowrap">paid-up</FONT> capital (for purposes of the Tax Act) of the Exchangeable Share at the time the Exchangeable Share is so redeemed. On the redemption, the Resident Holder will be considered to have disposed of the
Exchangeable Share for proceeds of disposition equal to the redemption proceeds less the amount of the foregoing deemed dividend. The Resident Holder will realize a capital loss (or capital gain) equal to the amount by which the sum of (i)&nbsp;the
adjusted cost base to such Resident Holder of the Exchangeable Share immediately before the disposition, and (ii)&nbsp;any reasonable costs of disposition, exceeds (or is less than) the proceeds of disposition. For this purpose, the &#147;redemption
proceeds&#148; of such Exchangeable Share will be equal to the Exchangeable Share Price. The amount of any such deemed dividend will be generally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the tax treatment described in the section titled &#147;<I>&#151; Dividends on Exchangeable Shares</I>&#148; above. The general tax treatment of capital gains and capital losses is
discussed below under the section titled &#147;<I>Taxation of Capital Gain or Capital Loss</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of a Resident Holder of Exchangeable
Shares that is a corporation, in some circumstances, the amount of any such deemed dividend may be treated as proceeds of disposition and not as a dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the acquisition of an Exchangeable Share by Callco or Parent, a Resident Holder will generally be considered to realize a capital gain (or a capital loss)
equal to the amount by which the proceeds of disposition exceed (or are less than) the total of (i)&nbsp;the adjusted cost base of the Exchangeable Share to such Resident Holder, and (ii)&nbsp;any reasonable costs of disposition. For this purpose,
the proceeds of disposition in respect of an acquisition of an Exchangeable Share by Callco or Parent will be equal to the Exchangeable Share Price. The acquisition of an Exchangeable Share by Callco or Parent will not result in a deemed dividend.
The general tax treatment of capital gains and capital losses is discussed below under the section titled &#147;<I>&#151; Taxation of Capital Gain or Capital Loss</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A disposition or deemed disposition of Exchangeable Shares by a Resident Holder, other than on the redemption, retraction or other disposition of such shares
to ExchangeCo, will generally result in a capital gain (or capital loss) equal to the amount by which the proceeds of disposition exceed (or are less than) the total of (i)&nbsp;the adjusted cost base of the Exchangeable Share to such Resident
Holder, and (ii)&nbsp;any reasonable costs of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition and Disposition of Delaware Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost of Delaware Common Stock received by a Resident Holder on the redemption or retraction of an Exchangeable Share by ExchangeCo or on the acquisition of
an Exchangeable Share by Callco or Parent will be equal to the fair market value of such a Delaware Common Stock at the time of such event, and will be averaged with the adjusted cost base of any other Delaware Common Stock held at that time by such
Resident Holder as capital property for the purpose of determining the adjusted cost base of all Delaware Common Stock held by such Resident Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
disposition or deemed disposition of a Delaware Common Stock by a Resident Holder will generally result in a capital gain (or capital loss) equal to the amount by which the proceeds of disposition exceed (or are less than) the total of (i)&nbsp;the
adjusted cost base of the Delaware Common Stock to such Resident Holder immediately before the disposition, and (ii)&nbsp;any reasonable costs of disposition. The general tax treatment of capital gains and capital losses is discussed below under the
section titled &#147;<I>&#151; Taxation of Capital Gain or Capital Loss</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dissenting Resident Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who exercises Dissent Rights and receives from Zymeworks the fair value of such Resident Holder&#146;s Zymeworks Common Shares will be
considered to have disposed of the Zymeworks Common Shares and will generally be deemed to receive a dividend equal to the amount, if any, by which the aggregate proceeds (less the amount of any interest awarded by the Court) exceed the <FONT
STYLE="white-space:nowrap">paid-up</FONT> capital (for purposes of the Tax Act) of such Resident Holder&#146;s Zymeworks Common Shares. In certain circumstances, the dividend deemed to have been received by such Resident Holder that is a corporation
may be treated as proceeds of disposition. In addition, the Resident Holder will be considered to have disposed of such Zymeworks Common Shares for proceeds of disposition equal to the aggregate proceeds (less the amount of any interest awarded by
the Court) less the amount of any deemed dividend, as noted above. The Resident Holder will realize a capital loss (or capital gain) equal to the amount by which the sum of (i)&nbsp;the adjusted cost base to such Resident Holder of the Zymeworks
Common Shares immediately before the disposition, and (ii)&nbsp;any reasonable costs of disposition, exceeds (or is less than) the proceeds of disposition. The general tax treatment of capital gains and capital losses is discussed below under the
section titled &#147;<I>Taxation of Capital Gain or Capital Loss</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any interest awarded by the Court to a dissenting Resident Holder will be included in computing such
dissenting Resident Holder&#146;s income for purposes of the Tax Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Capital Gain or Capital Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, <FONT STYLE="white-space:nowrap">one-half</FONT> of a capital gain realized by a Resident Holder must be included in computing such Resident
Holder&#146;s income as a taxable capital gain. <FONT STYLE="white-space:nowrap">One-half</FONT> of a capital loss must be deducted as an allowable capital loss against taxable capital gains realized by the Resident Holder in the year and any excess
may be deducted against net taxable capital gains in any of the three preceding years or in any subsequent year, to the extent and under the circumstances set out in the Tax Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of any capital loss realized on the disposition or deemed disposition of Exchangeable Shares and Delaware Common Stock by a Resident Holder that is
a corporation may be reduced by the amount of dividends received or deemed to have been received by it on such Exchangeable Shares and Delaware Common Stock (as applicable) or shares substituted for such Exchangeable Shares and Delaware Common Stock
to the extent and in the circumstances specified by the Tax Act. Similar rules may apply where an Exchangeable Share or Delaware Common Stock is owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary.
Resident Holders to whom these rules may be relevant should consult their own tax advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder that is throughout the relevant taxation
year a &#147;Canadian-controlled private corporation&#148; as defined in the Tax Act may be liable to pay an additional refundable tax on its &#147;aggregate investment income&#148;, which is defined in the Tax Act to include taxable capital gains
and interest income. Proposed Amendments announced by the Minister of Finance on April&nbsp;7, 2022 are intended to extend this additional tax and refund mechanism to &#147;substantive Canadian-controlled private corporations&#148;, as defined in
the Proposed Amendments. The complete legislation for such Proposed Amendments has yet to be released. Resident Holders should consult their own tax advisors with respect to the application of these Proposed Amendments to their circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A taxable capital gain realized by an individual, or certain trusts, may give rise to a liability for alternative minimum tax under the Tax Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Property Information Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident
Holder who is a &#147;specified Canadian entity&#148; as defined in the Tax Act for a taxation year or fiscal period whose total cost amount of &#147;specified foreign property&#148; as defined in the Tax Act, which includes the Delaware Common
Stock and the Exchangeable Shares (including any ancillary rights), at any time in the year or fiscal period exceeds $100,000, is required to file an information return for the year or period disclosing prescribed information in respect of such
property. Resident Holders to whom these rules may be relevant should consult their own tax advisors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility for Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the provisions of the Tax Act and the regulations thereunder as of the date hereof, the Delaware Common Stock will be &#147;qualified
investments&#148; under the Tax Act for trusts governed by registered retirement savings plans (&#147;<B>RRSPs</B>&#148;), registered retirement income funds (&#147;<B>RRIFs</B>&#148;), deferred profit sharing plans (&#147;<B>DPSPs</B>&#148;),
registered education savings plans (&#147;<B>RESPs</B>&#148;), registered disability savings plans (&#147;<B>RDSPs</B>&#148;) and <FONT STYLE="white-space:nowrap">tax-free</FONT> savings accounts (&#147;<B>TFSAs</B>&#148;) (collectively, RRSPs,
RRIFs, RESPs, RDSPs and TFSAs are referred to as &#147;<B>Registered Plans</B>&#148;), provided that the Delaware Common Stock are listed on a &#147;designated stock exchange&#148; for the purposes of the Tax Act (which currently includes the NYSE).
Neither DPSPs nor Registered Plans are eligible to acquire Exchangeable Shares pursuant to the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annuitant, holder or subscriber,
as applicable of a Registered Plan will be subject to a penalty tax in respect of the Delaware Common Stock held by a trust governed by such Registered Plan, as the case may be, if such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Delaware Common Stock are a &#147;prohibited investment&#148; for such Registered Plan for the purposes of the Tax Act. The Delaware Common Stock will not be a prohibited investment for a
Registered Plan, provided that the annuitant, holder or subscriber of such a Registered Plan, as the case may be: (1)&nbsp;deals at arm&#146;s length with Parent for purposes of the Tax Act and (ii)&nbsp;does not have a &#147;significant
interest&#148; within the meaning of the Tax Act in Parent. In addition, the Delaware Common Stock will not be a prohibited investment if the Delaware Common Stock are &#147;excluded property&#148; as defined in the Tax Act for trusts governed by a
Registered Plan. Resident Holders who intend to hold Delaware Common Stock in a Registered Plan should consult their own tax advisors with respect to the application of the prohibited investment rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders Not Resident in Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This portion of the
summary is generally applicable to a Holder (a &#147;<B><FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder</B>&#148;) who (i)&nbsp;for the purposes of the Tax Act and any applicable tax treaty, is neither resident nor deemed to be resident
in Canada at any time while they hold Zymeworks Common Shares, Exchangeable Shares or Delaware Common Stock; and (ii)&nbsp;does not and will not use or hold and is not and will not be deemed to use or hold the Zymeworks Common Shares, Exchangeable
Shares or Delaware Common Stock in carrying on a business in Canada. Special rules, which are not discussed in this summary, may apply to a <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder that is an insurer carrying on business in Canada
and elsewhere or an authorized foreign bank. Such Holders should consult their own tax advisors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disposition of Zymeworks Common Shares Under the
Plan of Arrangement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder generally will not be subject to tax under the Tax Act in
respect of a capital gain realized on the disposition of a Zymeworks Common Share under the Plan of Arrangement unless the Zymeworks Common Share constitutes &#147;taxable Canadian property&#148; to the
<FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder thereof for purposes of the Tax Act, and the gain is not exempt from tax pursuant to the terms of an applicable tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, a Zymeworks Common Share will not constitute &#147;taxable Canadian property&#148; of a <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder
at a particular time provided that such share is listed on a designated stock exchange as defined in the Tax Act (which includes the NYSE) at that time, unless at any time during the <FONT STYLE="white-space:nowrap">60-month</FONT> period
immediately preceding the particular time (a)&nbsp;the <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder, persons with whom the <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder did not deal at arm&#146;s length, partnerships in
which the <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder or a <FONT STYLE="white-space:nowrap">non-arm&#146;s</FONT> length person holds a membership interest directly or indirectly through one or more partnerships, or the <FONT
STYLE="white-space:nowrap">Non-Resident</FONT> Holder together with such persons or partnerships, owned 25% or more of the issued shares of any class or series of shares of Zymeworks, and (b)&nbsp;more than 50% of the fair market value of the
Zymeworks Common Share was derived directly or indirectly from one or any combination of real or immovable property situated in Canada, &#147;Canadian resource properties&#148; (as defined in the Tax Act), &#147;timber resource properties&#148; (as
defined in the Tax Act), and options in respect of, or interests in, or for civil law rights in, any such properties (whether or not such property exists). If the Zymeworks Common Shares are not listed on a designated stock exchange as defined in
the Tax Act at the particular time, such shares will be considered &#147;taxable Canadian property&#148; of a <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder at the particular time if, at any time during the <FONT
STYLE="white-space:nowrap">60-month</FONT> period immediately preceding the particular time, the Zymeworks Common Shares derived (directly or indirectly) more than 50% of their fair market value from one or any combination of real or immovable
property situated in Canada, &#147;Canadian resource properties&#148; (as defined in the Tax Act), &#147;timber resource properties&#148; (as defined in the Tax Act) or options in respect of, or interests in or rights in respect of, any such
property (whether or not such property exists). Notwithstanding the foregoing, a Zymeworks Common Share may otherwise in certain circumstances be deemed to be taxable Canadian property to the <FONT STYLE="white-space:nowrap">Non-Resident</FONT>
Holder for the purposes of the Tax Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Zymeworks Common Shares constitute or are deemed to constitute taxable Canadian property to any <FONT
STYLE="white-space:nowrap">Non-Resident</FONT> Holder, such <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder may be entitled to relief under the provisions of an applicable income tax treaty or convention.
<FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holders whose Zymeworks Common Shares may be taxable Canadian property should consult their own tax advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dissenting <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder who exercises Dissent Rights and received from Zymeworks the fair value of such <FONT
STYLE="white-space:nowrap">Non-Resident</FONT> Holder&#146;s Zymeworks Common Shares will be deemed to receive a dividend and to realize a capital loss (or capital gain) as described under the heading &#147;<I>Holders Resident in Canada &#151;
Dissenting Resident Holders</I>&#148; above. Any deemed dividends paid to such <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holders will be subject to Canadian <FONT STYLE="white-space:nowrap">non-resident</FONT> withholding tax at a rate of
25%, unless the rate is reduced under the provisions of an applicable income tax treaty. A dissenting <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder for whom Zymeworks Common Shares are not taxable Canadian property (as described above
under the section titled &#147;<I>Holders Not Resident in Canada &#151; Disposition of Zymeworks Common Shares Under the Plan of Arrangement</I>&#148;) will not be subject to capital gains tax under the Tax Act on the disposition of such Zymeworks
Common Shares. Any interest paid to a dissenting <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder will not be subject to Canadian withholding tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any interest awarded by the Court to a dissenting <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder will not be subject to Canadian <FONT
STYLE="white-space:nowrap">non-resident</FONT> withholding tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends on Delaware Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A dividend received or deemed to be received on Delaware Common Stock by a <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder will not be subject to
Canadian withholding tax or other income tax under the Tax Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_16"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion sets forth the material U.S. federal income tax consequences of the Redomicile Transactions to U.S. holders (as defined below) of
Zymeworks Common Shares and of the ownership and disposition of shares of Delaware Common Stock received by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders (as defined below) pursuant to the Redomicile Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The summary is based on current provisions of the Code, applicable Treasury regulations issued thereunder, judicial authority and IRS administrative rulings
and pronouncements, all of which are subject to change, possibly with retroactive effect, or a different interpretation. Any such change or different interpretation could alter the tax consequences to the holders of Zymeworks Common Shares, as
described herein. This summary does not purport to address all U.S. federal income tax matters that may be relevant to a particular holder of Zymeworks Common Shares or Delaware Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion applies only to holders of Zymeworks Common Shares or Delaware Common Stock that hold Zymeworks Common Shares or Delaware Common Stock as
capital assets within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment), and does not address the tax consequences that may be relevant to holders of Zymeworks Common Shares or Delaware Common Stock who are
subject to special tax rules that apply to certain types of investors, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities or organizations (including an &#147;individual
retirement account&#148; or &#147;Roth IRA&#148; as defined in Sections 408 or 408A of the Code), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, broker-dealers, other financial institutions, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to mark to market, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other pass-through entities for U.S. federal income tax purposes, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders who hold the Zymeworks Common Shares or Delaware Common Stock as part of a hedge, straddle, constructive
sale or conversion transaction (or who may have acquired the Zymeworks Common Shares or Delaware Common Stock in a transaction subject to the gain rollover provisions of Section&nbsp;1045 of the Code) or as &#147;qualified small business
stock&#148;, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders who are subject to the alternative minimum tax or the Medicare tax on net investment income provisions of
the Code, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders whose functional currency is not the U.S. dollar, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders who acquired the Zymeworks Common Shares or Delaware Common Stock pursuant to the exercise of employee
incentive stock options or otherwise as compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the following discussion assumes that Delaware Common Stock received in
the Redomicile Transactions represents consideration for the Zymeworks Common Shares and not compensation. Finally, the following discussion does not address (i)&nbsp;the tax consequences under U.S. federal estate and gift tax laws, or state, local
or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws, (ii)&nbsp;the tax consequences of transactions occurring prior to, concurrently with or after the Redomicile Transactions (whether or not such transactions are in connection with the
Redomicile Transactions) including, without limitation, the conversion or exercise of warrants, options or rights to purchase Zymeworks Common Shares in anticipation of or in connection with the Redomicile Transactions, (iii)&nbsp;the tax
consequences to holders of notes, convertible notes, options or warrants, convertible equity securities, or other rights to acquire an equity interest in Zymeworks, (iv)&nbsp;the tax consequences regarding any compensatory payments made to the
holders of Zymeworks Common Shares in connection with the Redomicile Transactions, (v)&nbsp;the tax consequences that may be relevant to the holders of Zymeworks Common Shares that receive Exchangeable Shares in the Redomicile Transactions, or
(vi)&nbsp;the tax consequences with respect to holders of Zymeworks Common Shares who exercise appraisal or dissenter rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. holder&#148; is a beneficial owner of Zymeworks Common Shares
or Delaware Common Stock who is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States, as determined for U.S. federal income tax
purposes: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or
organized under the laws of the United States or any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, (i)&nbsp;the substantial decisions of which are controlled by one or more United States Persons (within
the meaning of the Code) and which is subject to the primary supervision of a United States court, or (ii)&nbsp;that has validly elected under applicable Treasury regulations to be treated as a United States person for U.S. federal income tax
purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate that is subject to U.S. federal income tax on its income regardless of source. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> holder&#148; is a beneficial owner of Zymeworks Common Shares or Delaware Common Stock who is not a
partnership (including any entity or arrangement treated as a partnership or other flow-through entity and the equity holders therein) and is not a U.S. holder for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity or an arrangement treated as a partnership or other flow-through entity for U.S. federal income tax purposes holds Zymeworks Common Shares or
Delaware Common Stock, the U.S. federal income tax consequences of the Redomicile Transactions or owning or disposing of Delaware Common Stock to a partner in such partnership (or owner of such entity) generally will depend on the status of the
partner (or owner of such entity) and the activities of the partnership (or entity). Any entity treated as a partnership or other flow-through entity for U.S. federal income tax purposes that holds Zymeworks Common Shares or Delaware Common Stock,
and any partners in such partnership, are urged to consult their tax advisors with respect to the tax consequences of the Redomicile Transactions or owning or disposing of Delaware Common Stock in their specific circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Warrants may be eligible to be treated as Zymeworks Common Shares for U.S. federal income tax purposes; however, the tax treatment of Zymeworks
Warrants is uncertain. Zymeworks Warrant holders should consult with their own tax advisors regarding the tax consequences of the Redomicile Transactions in their specific circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax consequences of the Redomicile Transactions and holding Delaware Common Stock will depend on a holder&#146;s specific situation. You should consult
with your tax advisor as to the tax consequences of the Redomicile Transactions and holding Delaware Common Stock in your particular circumstances, including the applicability and effect of the alternative minimum tax and any state, local, foreign
or other tax laws and of changes in those laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations of the Redomicile Transactions to U.S. Holders of
Zymeworks Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion applies only to holders of Zymeworks Common Shares that are U.S. holders. Holders of Zymeworks Common
Shares other than U.S. holders should consult with their own tax advisors regarding the tax consequences of the Redomicile Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In general
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is the opinion of Wilson Sonsini Goodrich and Rosati, P.C. that the Redomicile Transactions will qualify as an exchange described in
Section&nbsp;351(a) of the Code for U.S. federal income tax purposes. Such opinion is based on customary assumptions, representations and covenants. If any of the assumptions, representations or covenants on which the opinion is based is or becomes
incorrect, incomplete, inaccurate or is otherwise not complied with, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the validity of the opinion described above may be adversely affected and the tax consequences of the Redomicile Transactions could differ from those described herein. Zymeworks and Parent intend
for the Redomicile Transactions to be treated as an exchange described in Section&nbsp;351(a) of the Code for U.S. federal income tax purposes, and each party expects to report the Redomicile Transactions consistent with such intent. Neither
Zymeworks nor Parent has requested a ruling from the IRS in connection with the Redomicile Transactions or related transactions. The discussion below neither binds the IRS nor precludes it from adopting a contrary position. The obligation of the
parties to consummate the Redomicile Transactions is not conditioned upon the receipt of an opinion of counsel as of the date of the Redomicile Transactions (or otherwise) regarding the qualification of the Redomicile Transactions as an exchange
described in Section&nbsp;351(a) of the Code. Further, an opinion of counsel is not binding on the IRS or any court. Even if Zymeworks and Parent report the Redomicile Transactions as qualifying as an exchange described in Section&nbsp;351 of the
Code, there can be no assurance that the IRS will not assert, or that a court would not sustain, a position contrary to the position taken by Zymeworks and Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. holders of Zymeworks Common Shares should consult with their tax advisors regarding the tax consequences of the Redomicile Transactions and the
requirements that must be satisfied in order for the Redomicile Transactions to qualify as an exchange described in Section&nbsp;351 of the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax consequences if the Redomicile Transactions qualify as an exchange described in Section&nbsp;351 of the Code </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provided that the Redomicile Transactions qualify as an exchange described in Section&nbsp;351 of the Code, and subject to the discussion below under the
caption heading &#147;&#151; PFIC Considerations&#148;, the following U.S. federal income tax consequences will result to a U.S. holder of Zymeworks Common Shares in the Redomicile Transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No gain or loss will be recognized by a U.S. holder of Zymeworks Common Shares for U.S. federal income tax
purposes on the exchange of its Zymeworks Common Shares for Delaware Common Stock in the Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The aggregate tax basis of the Delaware Common Stock received in the Redomicile Transactions by a U.S. holder of
Zymeworks Common Shares will be equal to the aggregate tax basis of the Zymeworks Common Shares it exchanged in the Redomicile Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The tax holding period of the Delaware Common Stock received in the Redomicile Transactions by a U.S. holder of
Zymeworks Common Shares will include the holding period of the Zymeworks Common Shares that it surrendered in exchange therefor in the Redomicile Transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Redomicile Transactions may also qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization
under Section&nbsp;368(a) of the Code, in which case the tax consequences to U.S. holders will generally be similar. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax
consequences if the Redomicile Transactions fail to qualify as an exchange described in Section&nbsp;351 of the Code or a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization under Section&nbsp;368 of the Code </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Redomicile Transactions fail to qualify as an exchange described in Section&nbsp;351 of the Code, and subject to the discussion below under the caption
heading &#147;&#151; PFIC Considerations&#148;, U.S. holders of Zymeworks Common Shares would be treated as if they sold their Zymeworks Common Shares in a fully taxable transaction. In that case, each U.S. holder of Zymeworks Common Shares would
recognize gain or loss with respect to the disposition of each of its shares of Zymeworks Common Shares equal to the difference between (i)&nbsp;the U.S. holder&#146;s basis in each such share of Zymeworks Common Shares and (ii)&nbsp;the fair market
value of the Delaware Common Stock received in the Redomicile Transactions, determined as of the date such stock is received. Such gain or loss would be treated as capital gain or capital loss and would be treated as long-term capital gain or loss
if the Zymeworks Common Shares have been held for more than one year as of the date of the Redomicile Transactions. Long-term capitals gains of <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders generally are eligible for reduced
rates of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taxation. A U.S. holder&#146;s aggregate tax basis in the Delaware Common Stock so received would equal its fair market value as of the date such stock is received, and a U.S. holder&#146;s
holding period for such Delaware Common Stock would begin the day after such stock is received. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PFIC Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Redomicile Transactions could be a taxable event to U.S. holders of Zymeworks Common Shares if Zymeworks were treated as a passive foreign investment
corporation, or PFIC, for any taxable year during the period such U.S. holders held Zymeworks Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation will be classified as a PFIC for U.S. federal income tax purposes if either (i)&nbsp;at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of
any corporation in which it is considered to own at least 25% of the shares by value, is passive income or (ii)&nbsp;at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and averaged quarterly over the
year), including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends,
interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;1291(f) of the Code requires that, to the extent provided in Treasury Regulations, a United States person who disposes of stock of a PFIC
recognizes gain notwithstanding any other provision of the Code. No final Treasury Regulations are currently in effect under Section&nbsp;1291(f) of the Code. However, proposed Treasury Regulations under Section&nbsp;1291(f) of the Code have been
promulgated with a retroactive effective date. If finalized in their current form, those proposed Treasury Regulations may require gain recognition to U.S. holders of Zymeworks Common Shares upon the Redomicile Transactions if (i)&nbsp;Zymeworks
were classified as a PFIC at any time during such U.S. holder&#146;s holding period for such Zymeworks Common Shares and (ii)&nbsp;the U.S. holder had not timely made (a)&nbsp;a QEF Election (as described below) for the first taxable year in which
the U.S. holder owned such Zymeworks Common Shares or in which Zymeworks was a PFIC, whichever is later, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(b)&nbsp;a&nbsp;mark-to-market&nbsp;election</FONT></FONT> (as described
below) with respect to such Zymeworks Common Shares. The tax on any such recognized gain would be imposed based on a complex set of computational rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under these rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. holder&#146;s gain will be allocated ratably over the U.S. holder&#146;s holding period for such U.S.
holder&#146;s Zymeworks Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of gain allocated to the U.S. holder&#146;s taxable year in which the U.S. holder recognized the gain,
or to the period in the U.S. holder&#146;s holding period before the first day of the first taxable year in which Zymeworks was a PFIC, will be taxed as ordinary income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of gain allocated to other taxable years (or portions thereof) of the U.S. holder and included in such
U.S. holder&#146;s holding period would be taxed at the highest tax rate in effect for that year and applicable to the U.S. holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on
the U.S. holder in respect of the tax attributable to each such other taxable year of such U.S. holder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is difficult to predict
whether, in what form and with what effective date, final Treasury Regulations under Section&nbsp;1291(f) of the Code will be adopted. Therefore, if Zymeworks has ever been a PFIC, U.S. holders of Zymeworks Common Shares that have not made a timely
QEF Election or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;mark-to-market&nbsp;election</FONT></FONT> (both as defined and described below) may, pursuant to the proposed Treasury Regulations, be subject to taxation on
the Redomicile Transactions to the extent their Zymeworks Common Shares have a fair market value in excess of their tax basis therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The QEF Election is made pursuant to Section&nbsp;1295 of the Code on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">shareholder-by-shareholder</FONT></FONT> basis and, once made, can be revoked only with the consent of the IRS. Retroactive QEF Elections generally may be made only by filing a protective statement with the tax return for
the first taxation year for which the statement will apply, and if certain other conditions are met or with the consent of the IRS. U.S. holders should consult their tax advisors regarding the availability and tax consequences of a retroactive QEF
Election under their particular circumstances. A U.S. holder that makes a QEF Election may be referred to as an &#147;Electing Shareholder.&#148; An Electing Shareholder generally would not be subject to the adverse PFIC rules discussed above with
respect to their Zymeworks Common Shares. As a result, a U.S. holder that is an Electing Shareholder should not recognize gain or loss as a result of the Redomicile Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of the PFIC rules on a U.S. holder of Zymeworks Common Shares may also depend on whether the U.S. holder has made a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election under Section&nbsp;1296 of the Code. Pursuant to Section&nbsp;1296 of the Code, U.S. holders who hold (actually or constructively)
stock of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation that is classified as a PFIC may elect to mark such stock to its market value if such stock is regularly traded on an established exchange. No assurance can be given that
Zymeworks Common Shares have been considered to be regularly traded for purposes of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election or whether the other requirements of this election have
previously been satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks does not believe that it was a PFIC for its most recent taxable year ended on December&nbsp;31, 2021 or the
year that includes the Redomicile Transactions, each U.S. holder should consult with its tax advisors regarding the application of PFIC rules in their particular circumstances. WSGR expresses no opinion regarding Zymeworks&#146; status as a PFIC.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information reporting and backup withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. holders of Zymeworks Common Shares that hold 5% or more (by vote or value) of the outstanding Delaware Common Stock will be required to attach a statement
to their federal income tax returns that contains the information listed in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.351-3</FONT> and Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-3.</FONT> Such
statement, among other things, must include the fair market value of Zymeworks Common Shares surrendered by the holder in the Redomicile Transactions and the holder&#146;s tax basis in such stock, in both cases determined immediately prior to the
Redomicile Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under certain circumstances, information reporting and/or backup withholding may apply to U.S. holders with respect to the
consideration received pursuant to the Arrangement, payments of dividends on Delaware Common Stock, and certain payments of proceeds on the sale, exchange or other disposition of Delaware Common Stock. However, U.S. holders generally can avoid
backup withholding by furnishing a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> (or an acceptable substitute form) certifying that such holder is not subject to backup withholding or by otherwise establishing an exemption.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. holder&#146;s U.S. federal income tax liability if the required information is
furnished by the U.S. holder in a timely manner to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE PRECEDING DISCUSSION IS INTENDED ONLY AS A SUMMARY OF MATERIAL U.S. FEDERAL INCOME TAX
CONSEQUENCES OF THE REDOMICILE TRANSACTIONS UNDER CURRENT LAW. TAX MATTERS CAN BE COMPLICATED AND THE TAX CONSEQUENCES OF THE REDOMICILE TRANSACTIONS TO YOU WILL DEPEND ON THE FACTS OF YOUR OWN SITUATION. YOU ARE URGED TO CONSULT YOUR OWN TAX
ADVISORS TO FULLY UNDERSTAND THE TAX CONSEQUENCES OF THE REDOMICILE TRANSACTIONS TO YOU, INCLUDING THE APPLICABILITY AND EFFECT OF FEDERAL, STATE, LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> INCOME AND OTHER TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders of Ownership and Disposition of Delaware Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Parent makes distributions on Delaware Common Stock (including constructive distributions, but not including certain distributions of stock or rights to
acquire Delaware Common Stock), those payments will constitute dividends for U.S. federal income tax purposes to the extent paid from Parent&#146;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles.
To the extent those distributions exceed Parent&#146;s current and accumulated earnings and profits, the excess will constitute a return of capital and will first reduce <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s basis in
Delaware Common Stock, but not below zero, and then will be treated as gain from the sale of stock as described below under <I>&#147;&#151; Gain on Disposition of Delaware Common Stock.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding and Foreign Account Tax Compliance Act, or FATCA, withholding, any
dividend paid to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders generally will be subject to U.S. federal withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable
income tax treaty between the United States and a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s country of residence. In order to receive a reduced treaty rate, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder must provide
Parent or the applicable paying agent with an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate version of IRS Form <FONT
STYLE="white-space:nowrap">W-8</FONT> certifying qualification for the reduced rate. Under applicable Treasury Regulations, Parent may withhold up to 30% of the gross amount of the entire distribution even if the amount constituting a dividend, as
described above, is less than the gross amount. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may obtain a refund of any excess amounts withheld by filing an appropriate claim for refund with the IRS. If
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders hold Delaware Common Stock through a financial institution or other agent acting on <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s behalf, such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders will be required to provide appropriate documentation to the agent, which then will be required to provide certification to Parent or its paying agent, either directly or through other
intermediaries. Special certification and other requirements apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that are pass-through entities rather than corporations or individuals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends received by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder that are treated as effectively connected with
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, that are attributable to a permanent establishment or fixed base maintained by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder in the United States) are generally exempt from the 30% U.S. federal withholding tax, subject to the discussions below regarding backup withholding and FATCA withholding. In order to obtain this
exemption, <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder must provide Parent with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> or other applicable IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> or a
successor form properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, generally are taxed at the U.S. federal income tax rates applicable to U.S. persons, net of certain
deductions and credits. In addition, if <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder is a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, dividends such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder receives
that are effectively connected with <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an
applicable income tax treaty between the United States and <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s country of residence. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors regarding
the tax consequences of the ownership and disposition of Delaware Common Stock, including the application of any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain on Disposition of Delaware Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and FATCA withholding, <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders generally will
not be required to pay U.S. federal income tax on any gain realized upon the sale or other disposition of Delaware Common Stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s conduct
of a U.S. trade or business (and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder in the United States);
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder is an individual who is present in the United States for
a period or periods aggregating 183 days or more during the calendar year in which the sale or disposition occurs and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delaware Common Stock constitutes a United States real property interest by reason of Parent&#146;s status as a
&#147;United States real property holding corporation,&#148; or a USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s
disposition of, or holding period for, Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent believes that it is not currently and will not become a USRPHC for
U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because the determination of whether Parent is a USRPHC depends on the fair market value of Parent&#146;s U.S. real property interests relative to the fair
market value of Parent&#146;s U.S. and worldwide real property interests plus Parent&#146;s other assets used or held for use in a trade or business, there can be no assurance that Parent will not become a USRPHC in the future. Even if Parent
becomes a USRPHC, however, as long as Delaware Common Stock is regularly traded on an established securities market, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s Delaware Common Stock will be treated as U.S. real property
interests only if a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder actually (directly or indirectly) or constructively holds more than five percent of Parent&#146;s regularly traded common stock at any time during the shorter of the
five-year period preceding <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s disposition of, or holding period for, Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders described in the first bullet above generally will be required to pay tax on the gain derived from the sale (net of certain deductions and credits) at U.S. federal income tax rates applicable to
U.S. persons, and a corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax
treaty. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders described in the second bullet above will be subject to tax at 30% (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain may
be offset by U.S. source capital losses for the year, provided a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
holders should consult their tax advisors regarding any applicable income tax or other treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup
Withholding and Information Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, Parent must report annually to the IRS the amount of dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder, the name and address of such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder, and the amount of tax withheld, if any. A similar report will be sent to the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments of dividends on or of proceeds from the disposition of Delaware Common Stock made to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders may be subject to backup withholding at the applicable statutory rate unless a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder establishes an exemption, for example, by properly certifying <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status on a properly completed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or another appropriate version of IRS Form <FONT STYLE="white-space:nowrap">W-8.</FONT> Notwithstanding the foregoing, backup withholding and information reporting may apply if either Parent or
Parent&#146;s paying agent has actual knowledge, or reason to know, that a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder is a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the
amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Withholding Requirements under the Foreign Account Tax Compliance Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FATCA, including sections 1471 through 1474 of the Code and the Treasury Regulations and other official IRS guidance issued thereunder, generally imposes a
U.S. federal withholding tax of 30% on dividends (including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constructive dividends) on, and, subject to the proposed regulations discussed below, the gross proceeds from a sale or other disposition of, Delaware Common Stock, paid to a &#147;foreign
financial institution&#148; (as specially defined under these rules), unless such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax
authorities substantial information regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends (including constructive dividends) on, and the gross
proceeds from a sale or other disposition of, Delaware Common Stock paid to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as specially defined under these rules) unless such entity provides the withholding agent
with a certification identifying the substantial direct and indirect U.S. owners of the entity, certifies that it does not have any substantial U.S. owners, or otherwise establishes an exemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The withholding obligations under FATCA generally apply to dividends (including constructive dividends) on Delaware Common Stock and to the payment of gross
proceeds of a sale or other disposition of Delaware Common Stock. However, the U.S. Treasury Department has issued proposed regulations that, if finalized in their present form, would eliminate FATCA withholding on gross proceeds of the sale or
other disposition of Delaware Common Stock (but not on payments of dividends). The preamble of such proposed regulations states that they may be relied upon by taxpayers until final regulations are issued or until such proposed regulations are
rescinded. The withholding tax will apply regardless of whether the payment otherwise would be exempt from withholding tax, including under the exemptions described above under the heading &#147;Distributions.&#148; Under certain circumstances, <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders might be eligible for refunds or credits of such taxes. An intergovernmental agreement between the United States and <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s country of
residence may modify the requirements described in this section. Each <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder should consult with its own tax advisors regarding the application of FATCA withholding to ownership and disposition of
Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE PRECEDING DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE TO
HOLDERS OF DELAWARE COMMON STOCK IN THEIR PARTICULAR CIRCUMSTANCES. <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSIDERATIONS OF OWNING AND DISPOSING OF DELAWARE COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_17"></A>DESCRIPTION OF PARENT CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description summarizes certain
important terms of Parent&#146;s capital stock, as they are expected to be in effect prior to completion of the Redomicile Transactions. Parent expects to adopt the Parent Certificate of Incorporation, which will become effective at or prior to the
time of the Redomicile Transactions, and the Parent Bylaws, which will become effective at or prior to the time of the Redomicile Transactions, and this description summarizes the provisions that are expected to be included in such documents.
Because it is only a summary, it does not contain all the information that may be important to Zymeworks Securityholders. For a complete description of the matters set forth in this section titled &#147;<I>Description of Parent Capital
Stock</I>&#148;, you should refer to the Parent Certificate of Incorporation, Parent Bylaws and Certificate of Designation for the Special Voting Stock, which are included as exhibits to the registration statement of which this Proxy
Statement/Prospectus forms a part, and to the applicable provisions of Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective at or prior to the completion of the Redomicile
Transactions, Parent&#146;s authorized capital stock will consist of 1,000,000,000 shares of capital stock, $0.00001 par value per share, of which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">900,000,000 shares are designated as Common Stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100,000,000 shares are designated as Preferred Stock, of which one share is designated as Special Voting Stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record Date, there were 1,000&nbsp;shares of Delaware Common Stock outstanding, held by one stockholder of record. Assuming
the exchange of all outstanding Zymeworks Common Shares in the Redomicile Transactions for shares of Delaware Common Stock, there would be [&#9679;] shares of Delaware Common Stock outstanding following the closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Delaware Common Stock will be entitled to
receive dividends out of funds legally available if Parent&#146;s board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that Parent&#146;s board of directors may determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Preemptive or Similar Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent&#146;s
Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Delaware Common Stock will be entitled to one vote for each share held as of the applicable record date on all matters submitted to a
vote of Parent stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent stockholders do not have the ability to cumulate votes for the election of directors. As a result, the holders of a
plurality of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors can elect all of the directors standing for election, if they should so choose. With respect to
matters other than the election of directors, at any meeting of Parent stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares cast for or against a proposal shall be the act of
the stockholders and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considered for purposes of establishing a quorum, but will not be considered as votes cast for or against a proposal, except as otherwise provided by law, Parent&#146;s governing documents or the
rules of the stock exchange on which Parent&#146;s securities are listed. The holders of 33 1/3% of the voting power of the capital stock issued and outstanding and entitled to vote as of the applicable record date, present in person or represented
by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation and
Parent Bylaws will provide that members of the board of directors will be elected to one of three staggered <FONT STYLE="white-space:nowrap">three-year</FONT> terms. Only the directors serving one term will be elected at each annual meeting of its
stockholders, with the directors serving under the remaining two terms continuing for the remainder of their respective <FONT STYLE="white-space:nowrap">three-year</FONT> terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Parent becomes subject to a
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to Parent&#146;s stockholders would be distributable ratably among the holders of Delaware Common Stock and any
participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with this offering, Parent&#146;s legal counsel will opine that the shares of Delaware Common Stock to be issued in this offering will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent&#146;s board of directors will
have the authority, subject to limitations prescribed by Delaware law, to issue shares of authorized but unissued preferred stock in one or more series, and to fix the designations, powers, preferences and rights, and the qualifications, limitations
or restrictions thereof, in each case without further vote or action by Parent&#146;s stockholders. These powers, rights, preferences and rights could include dividend rights, dividend rate, conversion rights, voting rights, rights and terms of
redemption (including sinking fund provisions), redemption price(s) and liquidation preferences, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of the common
stock. The issuance of preferred stock could adversely affect the voting power of holders of Delaware Common Stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of
preferred stock could have the effect of delaying, deferring or preventing a change in control or other corporate action. Except for the share of Special Voting Stock described below, as of the closing of the Redomicile Transactions, no shares of
preferred stock will be outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Voting Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the closing of the Arrangement, one share of Special Voting Stock will be issued to the Share Trustee, as trustee for and on behalf of the holders of the
Exchangeable Shares (other than Parent and any affiliated entities of Parent). The holder of the Special Voting Stock will vote together with the holders of the Delaware Common Stock, as a single class (except as otherwise required under applicable
Law), with respect to all meetings of stockholders of Parent at which the holders of the Delaware Common Stock are entitled to vote. The Special Voting Stock entitles the holder of record to that number of votes equal to the number of Exchangeable
Shares outstanding at such time (other than those owned by Parent or any affiliated entity of Parent) multiplied by the Exchangeable Share Exchange Ratio, and in respect of each beneficial owner of the Special Voting Stock, rounded down to the
nearest whole vote (and for which the Share Trustee has received voting instructions from such holders of Exchangeable Shares in accordance with the Trust Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holder of the Special Voting Stock is not entitled to receive any dividends declared and paid by Parent
and, upon any liquidation, dissolution or winding up of Parent, whether voluntary or involuntary, shall rank senior to the Delaware Common Stock, and junior or all other or series of preferred stock of Parent, and is entitled to receive, prior to
the holders of the Delaware Common Stock, an amount equal to US$1.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At such time as the share of Special Voting Preferred Stock has no votes attached
to it, the Special Voting Preferred Stock shall be automatically cancelled for no consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options and Restricted Stock Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record Date, Zymeworks had outstanding options to purchase an aggregate of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[&#9679;] common shares, at a weighted average exercise price of C$[&#9679;] per common share; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[&#9679;] common shares, at a weighted average exercise price of $[&#9679;] per common share.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record Date, Zymeworks had [&#9679;] outstanding restricted stock units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, Parent will assume the Zymeworks Incentive Plans and each outstanding Zymeworks Incentive Award. The assumed
Zymeworks Incentive Awards will remain subject to the terms and conditions of the Zymeworks Incentive Plans, except that the security issuable upon exercise or settlement of the Zymeworks Incentive Award, as applicable, will be shares of Delaware
Common Stock rather than Zymeworks Common Shares. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#150; Effect of the Redomicile Transactions on the Zymeworks Incentive Awards</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record Date, Zymeworks had [&#9679;] outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase up to [&#9679;] common
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent will assume the Zymeworks Warrants, except that the security issuable upon exercise will be shares of Delaware Common Stock rather than
Zymeworks Common Shares. See section titled &#147;<I>The Redomicile Transactions and the Plan of Arrangement &#150; Effect of the Redomicile Transactions on the Zymeworks Warrants</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercisability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original issuance. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be exercisable, at the option of each holder, in whole or in
part by delivering to Parent a duly executed exercise notice and by payment in full in immediately available funds for the number of common stock purchased upon such exercise. As an alternative to payment in immediately available funds, the holder
may, in its sole discretion, elect to exercise the warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of common stock determined according to the formula set forth in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. No fractional common stock will be issued in connection with the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. In lieu of fractional shares, Parent will pay the holder
an amount in cash equal to the fractional amount multiplied by the fair market value of any fractional shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise Limitations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, Parent may not effect the exercise of any
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, and a holder will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, which, upon giving effect to such exercise, would cause
(i)&nbsp;the aggregate number of Parent common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of Parent common stock outstanding immediately after giving effect to the exercise, or (ii)&nbsp;the
combined voting power of Parent securities beneficially owned by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of Parent securities then outstanding immediately after giving effect to the exercise, as such
percentage to any ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 19.99%
upon at least 61 days&#146; prior notice from the holder to Parent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise Price </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price per whole common stock purchasable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is $0.0001 per
warrant share. The exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is subject to appropriate adjustment in the event of certain share dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting Parent common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Certain Provisions of Delaware, the Parent Certificate of Incorporation and
Parent Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent will be
governed by the provisions of Section&nbsp;203 of the DGCL. Section&nbsp;203 generally prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for a period of
three years after the date of the transaction in which the person became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business combination or transaction which resulted in the stockholder becoming an interested stockholder was
approved by the board of directors prior to the time that the stockholder became an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1)&nbsp;shares owned by persons who are
directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mergers or consolidations involving the corporation, or any direct or indirect majority-owned subsidiary of the
corporation, and the interested stockholder or any other entity if the merger or consolidation is caused by the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets
of the corporation or any direct or indirect majority-owned subsidiary of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation, or any direct
or indirect majority-owned subsidiary of the corporation, of any stock of the corporation or such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation, or any direct or indirect majority-owned subsidiary of the
corporation, that has the effect of increasing the proportionate share of the stock or any class or series of the corporation or such subsidiary beneficially owned by the interested stockholder; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 of the DGCL defines an &#147;interested
stockholder&#148; as an entity or person who, together with such person&#146;s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three years prior to the time of determination of interested
stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of delaying, deferring
or preventing changes in control of Parent, even though such a transaction may offer its stockholders the opportunity to sell their stock at a price above the prevailing market price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Parent Certificate of Incorporation and Parent Bylaws Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions of the Parent Certificate of Incorporation and Parent Bylaws will include a number of provisions that could deter hostile takeovers or delay or
prevent changes in control of Parent&#146;s board of directors or management. Among other things, the Parent Certificate of Incorporation and Parent Bylaws will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit Parent&#146;s board of directors to issue shares of preferred stock, with any powers, rights, preferences
and privileges as they may designate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;
provided that the size of the board of directors may not be increased by more than 1/3 of the number of directors in office at the conclusion of the most recent annual meeting of stockholders prior to the next annual meeting of stockholders, and,
prior to Parent&#146;s first annual meeting, the size of the board of directors may not be increased by more than three; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies and newly created directorships, may, except as otherwise required by law,
Parent&#146;s governing documents or resolution of Parent&#146;s board of directors, and subject to the rights of holders of Parent&#146;s preferred stock, be filled by the affirmative vote of a majority of directors then in office, even if less
than a quorum; provided that no more than 1/3 of the number of directors in office at the conclusion of the most recent annual meeting of stockholders may be appointed by the board of directors prior to the next annual meeting of stockholders, and,
prior to Parent&#146;s first annual meeting of stockholders, the size of the board of directors may not be increased by more than three; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that members of the board of directors will serve one of three staggered three-year terms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for so long as Parent&#146;s board of directors is so structured, and subject to the rights of holders of
preferred stock, provide that a director may only be removed from the board of directors by the stockholders with the affirmative vote of at least 66 2/3% of the voting power of the shares cast on such proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by Parent&#146;s stockholders must be effected at a duly called annual or
special meeting of stockholders and not be taken by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and also meet specific requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not provide for cumulative voting rights (therefore allowing the holders of a plurality of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of Parent&#146;s stockholders may be called only by the board of directors, the
chairperson of the board of directors, Parent&#146;s chief executive officer or president or the secretary of Parent upon request from holders of no less than 20% of Parent&#146;s outstanding voting stock, subject to the limitations and requirements
set forth in the Parent Bylaws; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders will be permitted to amend certain provisions of the Parent Certificate of
Incorporation and Parent Bylaws only upon receiving at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of the then outstanding voting securities, voting together as a single class. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exclusive Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that,
unless Parent consents in writing to the selection of an alternative forum, the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on Parent&#146;s behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary
duty owed by any of Parent&#146;s directors, stockholders, officers or other employees to Parent or its stockholders, (3)&nbsp;any action arising pursuant to any provision of the DGCL or the Parent Certificate of Incorporation or Parent Bylaws or
(4)&nbsp;any other action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the
federal district court for the District of Delaware), except for, as to each of (1)&nbsp;through (4) above, any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the
indispensable party does not consent to the personal jurisdiction of such court within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not
have subject matter jurisdiction. The Parent Bylaws will also provide that, unless Parent consents in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for
resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring or holding or owning (or continuing to hold or own) any interest in any of Parent&#146;s securities shall be
deemed to have notice of and consented to the foregoing bylaw provisions. This provision would not apply to any action brought to enforce a duty or liability created by the Exchange Act and the rules and regulations thereunder. Parent&#146;s
stockholders will not be deemed to have waived Parent&#146;s compliance with the federal securities laws and the rules and regulations thereunder as a result of Parent&#146;s exclusive forum provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for the shares of Delaware Common Stock and Exchangeable Shares will be Computershare. The transfer agent and registrar&#146;s address is 150 Royall Street, Canton, Massachusetts 02021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Directors and Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent
Certificate of Incorporation will contain provisions that limit the liability of Parent&#146;s directors and officers for monetary damages to the fullest extent permitted by the DGCL. In addition, if the DGCL is amended to provide for further
limitations on the personal liability of directors of corporations, then the personal liability of Parent&#146;s directors will be further limited to the greatest extent permitted by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that Parent will indemnify its directors and officers, and may indemnify its employees, agents and any other persons, to the
fullest extent permitted by the DGCL. The Parent Bylaws will also provide that it must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Parent has entered into or will enter into indemnification agreements with each of its directors and executive officers that may be broader than
the specific indemnification provisions contained in the DGCL. These indemnification agreements require Parent, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or
service. These indemnification agreements also require Parent to advance all expenses reasonably and actually incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. Parent believes that
these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent also expects to obtain and maintain insurance policies under which its directors and officers are
insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to which they are
parties by reason of being or having been Parent&#146;s directors or officers. The coverage provided by these policies may apply whether or not Parent would have the power to indemnify such person against such liability under the provisions of the
DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_18"></A>COMPARISON OF RIGHTS OF ZYMEWORKS SHAREHOLDERS AND PARENT
STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Redomicile Transactions, Zymeworks Shareholders will exchange Zymeworks Common Shares for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delaware Common Stock; and/or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of Eligible Holders that make a valid election with respect to all or a portion of their Zymeworks
Common Shares, Exchangeable Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is currently a company continued under the BCBCA and, upon completion of the Redomicile
Transactions, Parent will be a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary comparison of the significant differences between: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current rights of Zymeworks Shareholders under the BCBCA and Zymeworks&#146; Articles, each as amended to
date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights of holders of Delaware Common Stock under the DGCL and the Parent Certificate of Incorporation and
Parent Bylaws, upon consummation of the exchange of Zymeworks Common Shares for shares of Delaware Common Stock and completion of the Redomicile Transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exchangeable Shareholders will not receive shares of Delaware Common Stock as a result of the Redomicile Transactions. However, the Exchangeable Shares and
the rights of Exchangeable Shareholders as &#147;Beneficiaries&#148; under (and as defined in) the Voting Agreement that Exchangeable Shareholders receive in connection with the Redomicile Transactions are expected to hold voting rights equivalent
to a holder of Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of certain principal differences between Zymeworks&#146; Notice of Articles and
Articles, as well as the BCBCA on the one hand, and the Parent Certificate of Incorporation, Parent Bylaws and the DGCL on the other. This summary is not intended to be complete, is qualified in its entirety by reference to the Notice of Articles
and Articles of Zymeworks, the BCBCA, the Parent Certificate of Incorporation and Parent Bylaws and the DGCL and should not be considered as legal advice to any particular shareholder. To see where copies of these documents can be obtained, see
section titled &#147;<I>Where You Can Find More Information</I>&#148;. A shareholder who has any questions about such matters should consult with the shareholder&#146;s own advisors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Authorized Capital&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Zymeworks&#146; current Notice of Articles, Zymeworks has the authority to issue an unlimited number<I> </I>of Common shares and an unlimited number of Preferred Shares, both without par value.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the Parent Certificate of Incorporation, Parent will have the authority to issue a total of 1,000,000,000 shares of stock, consisting of 900,000,000 shares of Common Stock, par value $0.00001 per share and 100,000,000 shares
of Preferred Stock, par value $0.00001 per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Terms of Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Preferred Shares are issuable in one or more series, have preference over the Common Shares with respect to dividends, a return of capital and such other preferences as may be fixed by the Zymeworks Board. Prior to any
particular series being issued, the Zymeworks Board may determine any maximum number of a series to be issued (or determine that there will be no such maximum), create an identifying name for</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Parent Certificate of Incorporation will provide that the board of directors will have the power to authorize by resolution or resolutions the issuance of preferred stock from time to time, in one or more series. Subject to
limitations prescribed by law, the board of directors will have the ability to fix by resolution or resolutions the designation, powers, preferences and rights, and the qualifications, limitations or restrictions
of</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the series, and attach special rights and restrictions to the series, provided that (i)&nbsp;no series has priority over any other series in respect of dividends or a return of capital, and (ii)&nbsp;a right or special right
attached to issued shares is not prejudiced or interfered with under the Notice of Articles unless the holders of such class or series consent by special separate resolution.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the preferred stock, including, without limitation, authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund
provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dividends</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a company may declare and pay dividends out of profits, capital or otherwise by issuing shares or warrants and, unless the
company is insolvent or the payment of the dividend would render the company insolvent, by payment in property including money.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, dividends may be declared at the sole discretion of the Zymeworks Board, are subject to the rights, if any, of shareholders
holding shares with special rights as to dividends and may be paid wholly or partly in money or by the distribution of specific assets or fully paid shares or bonds, debentures or other securities of Zymeworks or any other corporation, or in any one
or more of those ways.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, a Delaware corporation may, subject to restrictions in its certificate of incorporation, declare and pay dividends out of the
corporation&#146;s surplus or, if there is no surplus, from its net profits for the fiscal year in which the dividend is declared and/or for the preceding fiscal year, and Delaware common law imposes a solvency requirement for the payment of
dividends. Dividends declared and paid out of net profits may not be paid when the capital of a Delaware corporation has diminished to an amount less than the aggregate amount of capital represented by the issued and outstanding stock of all classes
having a preference upon the distribution of assets.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The decision whether or not to
declare and pay dividends and the amount of any such dividends is subject to the discretion of the Parent Board and the existence of legally available funds.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of Directors and Size of Board</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCBCA provides that the board of directors of a public company must consist of at least three directors, and other than the first
directors of a company, must be elected or appointed in accordance with the BCBCA and the articles of the company.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; Articles provide that the number of directors (excluding additional directors appointed by the Zymeworks Board in accordance with the Articles
and the BCBCA), is the greater of (i)&nbsp;three, and (ii)&nbsp;either the number most recently (a)&nbsp;set by the Zymeworks Board, and (b)&nbsp;elected or continued into office where the place of any retiring directors who do not continue in
office are not filled. Zymeworks&#146; Articles also provide that at an annual general</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that the board of directors of a Delaware corporation must consist of one or more directors, with the precise number
thereof from time to time fixed by or in the manner provided by the certificate of incorporation or bylaws. The DGCL further permits the board of directors of a Delaware corporation to be divided into classes.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation will provide that the number of directors may
be fixed by resolution from time to time by the majority of the Parent Board; provided that (a)&nbsp;the Parent Board may not increase the number of directorships by more than 1/3 of the number of directors at the conclusion of the most recent
annual meeting of</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">meeting, the setting or changing of the number of directors is not special business, and accordingly, the number of directors may also be set
by the shareholders.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and Zymeworks&#146; Articles, between annual
general meetings the directors may appoint one or more additional directors, the number of whom must not exceed 1/3 of the number of current directors elected or appointed other than under this provision.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">stockholders prior to the next annual meeting of stockholders and (b)&nbsp;prior to the first annual meeting, the size of the Parent Board may not be increased by more than three.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Director Qualifications</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, directors must (i)&nbsp;be 18 years of age or older, (ii)&nbsp;be capable of managing the director&#146;s own affairs,
(iii)&nbsp;have no undischarged bankruptcy and (iv)&nbsp;not be convicted of an offence in connection with the promotion, formation or management of a corporation or unincorporated business or of an offence involving fraud. Under the BCBCA,
directors are not required to be residents of British Columbia or Canada.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the
BCBCA and Zymeworks&#146; Articles, a director is not required to hold share capital in Zymeworks as qualification for office.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL requires that directors of Delaware corporations be natural persons. Under the DGCL, directors are not required to be residents of Delaware or the United States.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Election of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, directors must be elected or appointed in accordance with the BCBCA and the articles of a company.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; Articles provide that directors may be elected at an annual general
meeting or at a special meeting called for that purpose, or by unanimous resolution of the shareholders.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and Zymeworks&#146; Articles, between annual general meetings the directors may appoint one or more additional directors, the number of whom
must not exceed 1/3 of the number of current directors elected or appointed other than under this provision. Under the BCBCA, unless otherwise provided under the BCBCA or the Articles, any action that must or may be taken or authorized by the
shareholders may be taken or authorized by ordinary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that directors will be elected at an annual meeting or at a special meeting called for that purpose or by majority written
consent in lieu thereof.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation will provide that
stockholders will not be permitted to cumulate votes at any election of directors. The Parent Bylaws will provide that directors will be elected by a plurality of the voting power of the shares present and entitled to vote on the election of
directors.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent expects to adopt a majority voting policy in substantively the
form of Zymeworks&#146; current majority voting policy.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that,
unless otherwise provided in the certificate of incorporation or bylaws, newly created directorships may be filled by a majority vote of the directors then in office, even if the number of
directors</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resolution (where ordinary resolution at a meeting is defined as the simple majority of the votes cast). Accordingly, except as provided
above regarding the appointment if additional directors, directors are elected by ordinary resolution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Zymeworks has adopted a majority voting policy to the effect that a nominee for election as a director of Zymeworks must receive a greater number of votes
&#147;for&#148; than votes &#147;withheld&#148; with respect to the election of directors by shareholders to be elected.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then in office is less than a quorum. Delaware common law also gives stockholders power to fill vacancies, unless the corporation&#146;s
certificate of incorporation or bylaws provide otherwise.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of
Incorporation will provide that newly-created directorships may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum or by a sole remaining
director.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Advance Notice of Director Nominations by Stockholders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; Articles provide that nominations of persons for election to the board may be made at any annual meeting of the shareholders,
or at any special meeting of shareholders if one of the purposes for which the special meeting was called was the election of directors (i)&nbsp;by or at the direction of the board, (ii)&nbsp;at the request of one or more shareholders pursuant to a
proposal made in accordance with the BCBCA or a requisition of the shareholders made in accordance with the provisions of the BCBCA, or (iii)&nbsp;by any shareholder seeking to nominate a candidate for election as a director (a &#147;Nominating
Shareholder&#148;) who has given timely notice thereof in proper written form to Zymeworks&#146; Corporate Secretary at the executive or registered office of the Company.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">To be timely, a Nominating Shareholder&#146;s notice must be made: (i)&nbsp;in the case of an annual meeting of shareholders (including an annual and special
meeting), not less than 30 days prior to the date of the annual meeting of shareholders; provided, however, that in the event that the annual meeting of shareholders is to be held on a date that is less than 50 days after the date on which the first
public announcement of the meeting was made, notice by the Nominating Shareholder may be made not later than the close of business on the 10th day following the date of such first public announcement; and (ii)&nbsp;in the case of a special meeting
of shareholders (which is not also an annual meeting) called for the purpose of electing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL does not contain any limits on or requirements for stockholders to nominate directors for annual meetings. Under the DGCL,
the&nbsp;bylaws&nbsp;of a corporation may include provisions respecting the nomination of directors, including requirements for advance notice to the corporation.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that, to be timely, a nominating stockholder&#146;s notice must be received by the secretary at the principal executive offices
of the Company no earlier than 8:00 a.m., local time, on the 120th day and no later than 5:00 p.m., local time, on the 90th day prior to the day of the first anniversary of the preceding year&#146;s annual meeting of stockholders. However, if no
annual meeting of stockholders was held in the preceding year, or if the date of the applicable annual meeting has been changed by more than 25 days from the first anniversary of the preceding year&#146;s annual meeting, then to be timely such
notice must be received by the secretary at the principal executive offices of the Company no earlier than 8:00 a.m., local time, on the 120th day prior to the day of the annual meeting and no later than 5:00 p.m., local time, on the 10th day
following the later of the day on which public announcement of the date of the annual meeting was first made by the Company and the 120th day prior to the day of the annual meeting.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In the case of the first annual meeting of stockholders of Parent as a Delaware
corporation, a nominating stockholder&#146;s</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">directors (whether or not called for other purposes as well), not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting of shareholders was made.
Zymeworks&#146; Articles also prescribe the proper written form for a Nominating Shareholder&#146;s notice.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">notice must be received by the secretary of Zymeworks at Zymeworks&#146; principal executive offices or by the secretary of Parent at Parent&#146;s principal executive offices no earlier than 8:00 a.m., local time, on [&#9679;],
2022 and no later than 5:00 p.m., local time, on [&#9679;], 2022.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Term of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCBCA does not contain specified term limits for directors.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; Articles provide that, for the purposes of facilitating staggered terms on the Zymeworks Board, beginning on the date at which Zymeworks was
continued as a British Columbia company: (i)&nbsp;three directors shall initially hold office for a <FONT STYLE="white-space:nowrap">one-year</FONT> term, (ii)&nbsp;three directors shall initially hold office for a
<FONT STYLE="white-space:nowrap">two-year</FONT> term, and (c)&nbsp;the remaining directors shall initially hold office for a three-year term. Upon expiry of each directors&#146; initial term, the directors shall be elected for three-year terms.
These provisions remain in effect until the End Date of June&nbsp;30, 2117, after which all directors are elected annually.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that directors of a Delaware corporation may, by the certificate of incorporation or by an initial bylaw, or by a bylaw
adopted by a vote of the stockholders, be divided into one, two or three classes.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Board will be divided into three classes as nearly equal in size as is practicable. At each annual meeting of stockholders, a class of directors
will be elected for a three-year term to succeed the class whose terms are then expiring.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Removal of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a director can be removed by special resolution or if the articles provide, by less than a special majority.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and Zymeworks&#146; Articles, the shareholders may remove a director by
special resolution. Zymeworks&#146; Articles also permit the directors to remove a director if the director is convicted of an indictable offense, or if the director ceases to be qualified to act as a director and does not promptly resign.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, any or all directors may be removed with or without cause by the holders of a majority of shares entitled to vote at an
election of directors unless the certificate of incorporation otherwise provides or in certain other circumstances if the corporation has cumulative voting.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation will provide that any director or the entire Parent Board may be removed by stockholders, with or without cause, with
the affirmative vote of the holders of at least 66 2/3% of the voting power of the shares cast for or against such proposal, which shall be the act of the stockholders, and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions
will be considered for purposes of establishing a quorum, but will not be considered as votes cast for or against such removal.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Filling of Board Vacancies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a vacancy that occurs among directors must be filled in accordance with the BCBCA unless the company&#146;s articles provide
otherwise.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, the shareholders may elect the directors
needed to fill any vacancies in the board of directors up to the number of directors as set by the Articles, and if the shareholders do not do so contemporaneously with setting the number of directors, then the directors may appoint, or the
shareholders may elect or appoint, directors to fill those vacancies.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
Zymeworks&#146; Articles, at every annual general meeting the shareholders are entitled to elect directors to fill vacancies created by the expiry of directors&#146; terms and vacancies created before the expiry of directors&#146; terms.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, any casual vacancy occurring in the board of directors
may be filled by the directors.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, if the Company has
no directors or fewer directors in office than the number set for quorum, then the shareholders may elect or appoint directors to fill any vacancies.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, if a director is removed by special resolution before the expiry of their term, the shareholders may contemporaneously fill the
vacancy by ordinary resolution, and if they fail to do so, then the directors may appoint, or the shareholders may elect by ordinary resolution, a director to fill the vacancy.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">If the directors remove a director who is convicted of an indictable offence or who
ceases to be qualified, then the directors may appoint a director to fill the vacancy.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that, unless otherwise provided in the certificate of incorporation or bylaws, vacancies and newly created directorships
may be filled by a majority vote of the directors then in office, even if the number of directors then in office is less than a quorum. Delaware common law also gives stockholders power to fill vacancies, unless the corporation&#146;s certificate of
incorporation or bylaws provide otherwise.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation
will provide that all vacancies, including those resulting from newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a
quorum.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Board Quorum and Vote Requirements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The BCBCA does not set out any requirements for a meeting of directors, except that minutes must be kept of all proceedings at meetings of directors or committees of directors. The articles of a company may set out requirements and
quorum for board meetings.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, a majority of the total number of directors shall constitute a quorum for the transaction of business unless the certificate or&nbsp;bylaws&nbsp;require a greater number. The&nbsp;bylaws&nbsp;may lower the number
required for a quorum <FONT STYLE="white-space:nowrap">to&nbsp;one-third&nbsp;the</FONT> number of directors, but no less.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, the quorum necessary for the transaction of business of the directors is a majority of the number of
directors. At meetings of directors, questions are to be decided by a majority of votes, and in the case of an equality of votes, the chair of the meeting does not have a second or casting vote.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and Zymeworks&#146; Articles, directors are also permitted to pass
resolutions by a unanimous written consent signed by all the directors entitled to vote on it.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that a majority of the total number of authorized directorships will constitute a quorum for the transaction
of business. It will also provide that the affirmative vote of a majority of the directors present at any meeting at which a quorum is present will be the act of the board of directors, except as may be otherwise specifically provided by statute,
the Parent Certificate of Incorporation or the Parent Bylaws.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the DGCL,
directors are also permitted to act by unanimous written consent signed by all of the members of the board of directors or of any committee thereof, as applicable.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Annual Meeting of Stockholders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In accordance with the BCBCA, Zymeworks&#146; Articles provide that an annual general meeting must be held at least once in each calendar year, and not more than 15 months after the last annual reference date (where annual reference
date generally means the date of the last annual general meeting), at such time and place as may be determined by the directors. The BCBCA provides that an annual meeting of shareholders may be held at a location outside British Columbia if
(i)&nbsp;the location for the meeting is provided for in the articles, (ii)&nbsp;the articles do not restrict the company from holding a meeting outside of British Columbia and the location is approved as required by the articles (and if not so
specified then as approved by ordinary resolution of the shareholders) or (iii)&nbsp;the location is approved in writing by the Registrar before the meeting is held.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, an annual or special stockholder meeting is held on such date, at such time and at such place, if any, as may be designated
by the board of directors or any other person authorized to call such meeting under the corporation&#146;s certificate of incorporation or&nbsp;bylaws.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">If an annual meeting for election of directors is not held on the date designated or an action by written consent to elect directors in lieu of an annual
meeting has not been taken within 30 days after the date designated for the annual meeting, or if no date has been designated, for a period of 13 months after the later of the last annual meeting or the last action by written consent to elect
directors in lieu of an annual meeting, the Delaware Court of Chancery may summarily order a meeting to be held upon the application of any stockholder or director.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Quorum for Stockholder Meetings</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, the quorum for a meeting is the quorum established by the articles. Under Zymeworks&#146; Articles, the quorum requirement for the transaction of business at a meeting of shareholders is two persons who are, or who
represent by proxy, shareholders who, in the aggregate, hold at least 30% of the shares entitled to vote at the meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, quorum for a stock corporation is a majority of the voting power of the shares entitled to vote at the meeting unless the certificate of incorporation or bylaws specify a different quorum, but in no event may a
quorum be less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the voting power of the shares entitled to vote. The stockholders may continue to transact business at the meeting even if quorum is subsequently
broken.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Parent Bylaws will provide that holders of 33 1/3% of the voting power of the capital stock of Parent will constitute a quorum for the transaction of business at all meetings of the stockholders. If, however, such quorum is not
present at any meeting of the stockholders, then either (a)&nbsp;the chairperson of the meeting or (b)&nbsp;the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting from
time to time, without notice other than announcement at the meeting, until a quorum is present.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Voting Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, subject to certain exceptions for fractional shares and a subsidiary holding shares of its British Columbia parent, and
unless the articles of the company provide otherwise, a shareholder has one vote in respect of each share held by that shareholder and is entitled to vote in person or by proxy.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, the Zymeworks Board is authorized to determine the
voting rights and restrictions attaching to each series of Preference shares before they are issued.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, on a vote (i)&nbsp;by a show of hands, every person present who is a shareholder or proxy holder and entitled to vote on the
matter has one vote, and (ii)&nbsp;by a poll, every shareholder entitled to vote on the matter has one vote for each share entitled to be voted on the matter and held by that shareholder and may be voted in person or by proxy.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL provides that each stockholder is entitled to one vote for each share of capital stock held by such stockholder, unless otherwise provided in the corporation&#146;s certificate of incorporation. Each share of Common Stock
will entitle its holder to one vote on each matter voted upon by the holders of Common Stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vote Required for Stockholder Action at a Meeting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, unless otherwise provided under the BCBCA or the Articles, any action that must or may be taken or authorized by the shareholders may be taken or authorized by an ordinary resolution.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unless the DGCL, certificate of incorporation or&nbsp;bylaws&nbsp;provide for a greater vote, generally the required vote under the DGCL is a majority of the voting power of the shares present in person or represented by proxy and
entitled to vote on the subject matter, except for the election of directors which requires a plurality of the votes cast.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stockholder Action by Written Consent</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, shareholders may act by written resolution signed by all the shareholders entitled to vote on that resolution at a meeting of shareholders.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, a majority of the stockholders of a corporation may act by written consent without a meeting unless such action is prohibited
by the corporation&#146;s certificate of incorporation.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of
Incorporation and Parent Bylaws will provide that any action required or permitted to be taken by stockholders must be effected at a duly called annual or special meeting and shall not be taken by written consent, subject to the rights of any
preferred stockholders.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Notice of Annual and Special Meetings of Stockholders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a public company must send a notice of the date and time and, if applicable, the location of a general meeting no fewer than
21 days (or such longer period as provided in the articles of the company) and no more than 2 months before the meeting. Under Zymeworks&#146; Articles, notice of the date, time and location of any meeting of shareholders, must be sent to
shareholders at least 21 days before the meeting.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and
Zymeworks&#146; Articles, the directors may also set a date as the record date for the purpose of determining shareholders entitled to notice of any meeting of shareholders between 21 days and two months (or in the case of a requisitioned meeting,
four months) before the date of the meeting. Attendance of a shareholder at a meeting of shareholders constitutes a waiver of notice of the meeting unless that person attends the meeting for the express purpose of objecting that the meeting is not
lawfully called.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, except as otherwise required by the DGCL in certain circumstances, notice of any meeting of stockholders must be sent not
less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that except as otherwise provided in the DGCL, the
Parent Certificate of Incorporation or the Parent Bylaws, the notice of any meeting of stockholders shall be given not less than 21 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting as of the
record date for determining the stockholders entitled to notice of the meeting.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Calling Special Meeting of Stockholders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the BCBCA, its regulations and the articles of a company apply to the calling, holding and conduct of shareholder meetings,
including special meetings.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Zymeworks&#146; Articles provide that the directors
may, whenever they think fit, call a meeting of shareholders and that the notice of the special meeting must (i)&nbsp;state the general nature of the special business, (ii)&nbsp;if</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that special meetings may be called by the board of directors or by such persons as may be authorized by the certificate of
incorporation or by the bylaws.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation and Parent
Bylaws will provide that special meetings of stockholders may be called at any time only by the board of directors, the chair of the board of directors, the chief executive officer, the president or by
the</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the special business includes considering any document, attach a copy of the document or state that Zymeworks&#146; has made it available at
its records office during business hours on specified days.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, the
holders of not less than 5% of the issued shares of a company that carry the right to vote at a general meeting may, subject to compliance with the requirements of, and to certain exceptions under, the BCBCA, requisition the directors to call a
meeting of shareholders for the purpose of transacting any business that may be transacted at a general meeting.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">secretary of Parent, acting in accordance with the terms of the Parent Bylaws.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will also provide that stockholders holding in the aggregate not less
than 20% of the voting power of Parent&#146;s capital stock as of the record date may request the secretary to call a meeting of stockholders, subject to compliance with the requirements for such notice set forth in the Parent Bylaws, including
timely notice and that any such proposed business must constitute a proper matter for stockholder action.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">As required by the DGCL, business transacted at all special meetings of the Parent&#146;s stockholders is confined to the purposes stated in the
notice.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stockholder Proposals</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, qualified shareholder (being a registered or beneficial owner of one or more voting shares of the company for an uninterrupted period of at least two years before the date of the signing of the proposal) may submit
a proposal to the company setting out a matter that the submitter wishes to have considered at the next annual general meeting of the Company. The proposal must be signed by shareholders who, together with the submitter, are registered or beneficial
owners of (i)&nbsp;at least 1% of the company&#146;s voting shares, or (ii)&nbsp;shares with a fair market value exceeding an amount prescribed by regulation, being CAD$2,000, and must otherwise be compliant with the requirements of the BCBCA
(including maximum word limits, time requirements for delivery to the company, and other requirements). The company must send the text of the proposal to all persons entitled to notice of its next annual general meeting, and allow the submitter to
present the proposal personally, or by proxy, at the annual general meeting, unless: (i)&nbsp;the directors have called an annual general meeting to be held after the date on which the proposal is received by the company and have sent notice of that
meeting in accordance with the BCBCA; (ii)&nbsp;the</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL does not contain any limits on or requirements for stockholders to propose business for annual meetings.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that, for nominations or other business to be properly
brought before an annual meeting, the stockholder must have given timely notice in writing to the secretary and any such nomination or proposed business must constitute a proper matter for stockholder action.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, Pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the
Exchange Act, if a stockholder would like Parent to consider including a proposal in the proxy statement to be distributed in connection with meeting, such proposal must be received at Parent&#146;s principal executive offices not less than 120
calendar days before the date of Parent&#146;s proxy statement released to stockholders in connection with the previous year&#146;s annual meeting. If Parent did not hold an annual meeting the previous year, or if the date of the annual meeting has
been changed by more than 30 days from the date of the previous year&#146;s meeting, then the deadline is a reasonable time before Parent begins to print and send its proxy materials.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">proposal is not valid within the meaning of the BCBCA or exceeds the maximum length established by the BCBCA; (iii)&nbsp;substantially the
same proposal was submitted to shareholders in a notice of meeting, or an information circular or equivalent, relating to a general meeting that was held not more than the prescribed period before the receipt of the proposal, and did not receive the
prescribed amount of support at the meeting; (iv)&nbsp;it clearly appears that the proposal does not relate in a significant way to the business or affairs of the company; (v)&nbsp;it clearly appears that the primary purpose for the proposal is
securing publicity, or enforcing a personal claim or redressing a personal grievance against the company or any of its directors, officers or security holders; (vi)&nbsp;the proposal has already been substantially implemented; (vii)&nbsp;the
proposal, if implemented, would cause the company to commit an offence; or (viii)the proposal deals with matters beyond the company&#146;s power to implement.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, Pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act, if a shareholder would like Parent to consider including a
proposal in the proxy statement to be distributed in connection with a meeting, such proposal must be received at Parent&#146;s principal executive offices not less than 120 calendar days before the date of Parent&#146;s proxy statement released to
shareholders in connection with the previous year&#146;s annual meeting. If Parent did not hold an annual meeting the previous year, or if the date of the annual meeting has been changed by more than 30 days from the date of the previous year&#146;s
meeting, then the deadline is a reasonable time before Parent begins to print and send its proxy materials.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Amendment of Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As permitted by the BCBCA, under Zymeworks&#146; Articles, any amendment to the Notice of Articles or Articles generally requires approval by a special resolution of the shareholders. A special resolution is a resolution passed by a
special majority of the votes cast by shareholders. Under Zymeworks&#146; Articles, a special majority is</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Amendment of Certificate of Incorporation</I>. Generally, under the DGCL, the affirmative vote of the holders of a majority of the outstanding stock entitled to vote is required to approve a proposed amendment to the certificate
of incorporation, following the adoption of the amendment by the board of directors of the corporation, provided that</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on the relevant resolution.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and Zymeworks&#146; Articles, if an amendment to the Articles would
prejudice or interfere with a right or special right attached to issued shares of a class or series of shares, then such amendment must be approved separately by the holders of the class or series of shares being affected by a special
resolution.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the certificate of incorporation may provide for a greater vote. Under the DGCL, holders of outstanding shares of a class or series are
entitled to vote separately on an amendment to the certificate of incorporation if the amendment would have certain consequences, including certain changes that adversely affect the powers, preferences or special rights of such class or series.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation will provide that the vote of holders of a
majority of the outstanding voting stock is required to amend the Parent Certificate of Incorporation; provided that certain provisions of the Parent Certificate of Incorporation will require 66 2/3% of the voting power to amend (see the section
below titled &#147;<I>Matters Requiring higher Threshold for Amendment of Governing Documents</I>&#148;.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of</I><I></I><I>&nbsp;Bylaws</I>. Under the DGCL, after a corporation has received any payment for any of its stock, the power to adopt, amend or
repeal&nbsp;bylaws&nbsp;shall be vested in the stockholders entitled to vote; provided, however, that any corporation may, in its certificate of incorporation, provide that&nbsp;bylaws&nbsp;may also be adopted, amended or repealed by the board of
directors.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation will provide that the board of
directors will have the power to adopt, amend or repeal the bylaws. The fact that such power has been conferred upon the board of directors will not divest the stockholders of the power nor limit their power to adopt, amend or repeal
the&nbsp;bylaws.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Matters Requiring higher Threshold for Amendment of Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The BCBCA provides that an alteration to a company&#146;s notice of articles or articles may be done by the type of resolution specified by the BCBCA, and if not so specified, then as specified in the company&#146;s articles, and if
not so specified, then by a special resolution, except that a change to the company&#146;s name may be done by either a directors resolution or an ordinary resolution of the shareholders.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Parent Certificate of Incorporation will provide that the following matters may only be amended by the affirmative vote of 66 2/3% of the voting power of the then outstanding securities of Parent, voting together as a single
class: the board of director&#146;s ability to issue preferred stock by means of a certificate of designation and related matters, classified board, removal of any directors, with or without cause,
the</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCBCA provides that a company may, by special resolution, alter
its articles to specify or change the majority required for a special resolution, which must be by a majority of not less than 2/3 and not more than 3/4 of the votes cast on the resolution.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, an amalgamation of a company by way of an amalgamation agreement
(which excludes a vertical short form and a horizontal short form amalgamation), requires the approval by way of a special resolution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, the continuation of a company into a foreign jurisdiction requires the approval by way of a special resolution.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a right or special right attached to an issued class or series of
shares must not be prejudiced or interfered with under the notice of articles or articles unless the shareholders of the class or series consent by way of a separate special resolution.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Articles provide that alterations to its authorized share structure and to
the special rights and restrictions attached to any class or series of shares require the approval by way of ordinary resolution, except where required otherwise under the BCBCA.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Zymeworks Articles also provide that where the Act or Articles do not specify the type
of resolution required, the Articles may be altered by ordinary resolution.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">board of directors&#146; ability to fill vacancies, prohibition on cumulative voting for the election of directors, prohibition on
stockholder action by written consent, denial of stockholders&#146; ability to call a special meeting, requirement to provide advance notice of stockholder nominations or proposals and the provision setting out these enhanced thresholds for
amendments.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that the following matters may only be
amended by the affirmative vote of 66 2/3% of the voting power of the then outstanding securities of Parent, voting together as a single class: the regulation of meetings of stockholders contained in Article II of the Parent Bylaws, matters relating
to the board of directors&#146; power to manage the business and affairs of Parent, the board of directors&#146; ability to fix the number of directors from time to time, director resignations and the board of directors&#146; ability to fill
vacancies, the removal of directors, provisions regarding indemnification of officers and directors, the forum selection described below under &#147;<I>Exclusive Forum</I>&#148; or these enhanced thresholds for amendments.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Fiduciary Duties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, directors and officers must (a)&nbsp;act honestly and in good faith with a view to the best interests of the company, (b)&nbsp;exercise the care, diligence and skill that a reasonably prudent individual would
exercise in comparable circumstances, (c)&nbsp;act in accordance with the BCBCA and the regulations, and (d)&nbsp;act in accordance with the articles of the company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Directors and officers of Delaware corporations have common law fiduciary duties, which generally consist of duties of loyalty and care. Under Delaware law, the duty of care generally requires that directors and officers inform
themselves, prior to making a business decision, of all material information reasonably available to them. The duty of loyalty generally requires that directors and officers act in good faith, not out of self-interest and in a manner which the
directors and officers believe to be in the best interests of the corporation and its stockholders.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Limitation on Liability of Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, a director of a company is jointly and severally liable to restore to the company any amount paid or distributed as a result of paying dividends, commissions and compensation, among other things, contrary to the
BCBCA. A director will not be found liable if the director relied, in good faith, on (i)&nbsp;financial statements of the company represented to the director by an officer of the company or in a written report of the auditor of the company,
(ii)&nbsp;a written report of a lawyer, accountant, engineer, appraiser or other person whose profession lends credibility, (iii)&nbsp;a statement of fact represented to the director by an officer of the company or any record, information, or
(iv)&nbsp;a representation that the court considers provides reasonable grounds for the actions of the director. Further, any director is not liable if the director did not know and could not reasonably have known that the act done by the director
or authorized by resolution voted for or consented to by the director was contrary to the BCBCA.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL permits a corporation to include a provision in its certificate of incorporation eliminating or limiting the personal liability of a
director to the corporation or its stockholders for monetary damages for a breach of the director&#146;s fiduciary duty as a director, except for liability: (i) for breach of the director&#146;s duty of loyalty to the corporation or its
stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law; (iii) under Section&nbsp;174 of the DGCL, which concerns unlawful payment of dividends, stock purchases or
redemptions; or (iv) for any transaction from which the director derived an improper personal benefit.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation will provide that, to the fullest extent permitted by the DGCL as the same exists or as may be amended from time to
time, a director of Parent will not be personally liable to Parent or its stockholders for monetary damages for breach of fiduciary duty as a director. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal
liability of directors, then the liability of a director of Parent will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In certain circumstances, directors may be fully protected in relying in good faith upon the records of the corporation and upon such information, opinions,
reports or statements presented to the corporation by any of the corporation&#146;s officers or employees, or committees of the board of directors, or by any other person as to matters the member reasonably believes are within such other
person&#146;s professional or expert competence and who has been selected with reasonable care by or on behalf of the corporation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Limitation on Liability of Officers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, if in a legal proceeding the court finds that an officer or director may be liable in respect of negligence, default, breach of duty or breach of trust, the court may relieve the officer or director from liability
on terms the court considers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Applicable after August 1, 2022, the DGCL is expected to permit a corporation to include a provision in its certificate of incorporation eliminating or limiting the personal liability of certain officers to the corporation or its
stockholders for monetary damages for a breach of the</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">necessary if it appears to the court that, despite the finding of liability, the officer or director acted honestly and reasonably and ought fairly to be excused.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">officer&#146;s fiduciary duty as an officer except for liability (i)&nbsp;for breach of the officer&#146;s duty of loyalty to the corporation
or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law, (iii)&nbsp;for any transaction from which the officer derived an improper personal benefit or (iv)&nbsp;in
connection with derivative actions or claims in any action by or in the right of the corporation.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Certificate of Incorporation will provide that, to the fullest extent permitted by the DGCL as the same exists or as may be amended from time to
time, an officer of Parent will not be personally liable to Parent or its stockholders for monetary damages for breach of fiduciary duty as an officer. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal
liability of officers, then the liability of an officer of Parent will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Indemnification of Directors and Officers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, as permitted under the BCBCA, and subject to certain specified prohibitions, Zymeworks must
(i)&nbsp;indemnify an eligible party against all eligible penalties to which the eligible party is or may be liable; and (ii)&nbsp;after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an
eligible party in respect of that proceeding.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and Zymeworks&#146;
Articles, an &#147;eligible party&#148; is<B> </B>an individual who (i)&nbsp;is or was a director or officer of the company, (ii)&nbsp;is or was a director or officer of another corporation at a time when the corporation is or was an affiliate of
the company, or at the request of the company, or (iii)&nbsp;at the request of the company, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity,
and includes, in most cases, the heirs and personal or other legal representatives of that individual.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, a corporation may indemnify any person who was or is made a party or is threatened to be made a party to any third-party action, suit or proceeding on account of being a director, officer, employee or agent of the
corporation (or was serving at the request of the corporation in such capacity for another corporation, partnership, joint venture, trust or other enterprise) against expenses, including attorneys&#146; fees, judgments, fines and amounts paid in
settlement actually and reasonably incurred by him or her in connection with the action, suit or proceeding through, among other things, a majority vote of a quorum consisting of directors who were not parties to the suit or proceeding, if the
person: (i) acted in good faith and in a manner he or she reasonably believed to be; (ii) or, in some circumstances, at least not opposed to the best interests of the corporation; and (iii) in a criminal proceeding, had no reasonable cause to
believe his or her conduct was unlawful.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An &#147;eligible penalty&#148;<B> </B>means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an
eligible proceeding, and an &#147;eligible proceeding&#148; means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a
director or officer of, or holding or having held a position equivalent to that of a director or officer of, the company or an associated corporation is or may be joined as a party, or is or may be liable for or in respect of a judgment, penalty or
fine in, or expenses related to, the proceeding.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a company must
not indemnify a director or officer if (i)&nbsp;the company is prohibited under its articles to provide such indemnity, (ii)&nbsp;the director or officer did not act honestly and in good faith with a view to the best interests of the company, or
(iii)&nbsp;they did not have reasonable grounds to believe their conduct was lawful. Additionally, if an associated corporation to Zymeworks brings an action against an eligible party, Zymeworks cannot indemnify the party.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL permits indemnification for derivative suits against expenses (including legal fees) if the person acted in good faith and in a
manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and only if the person is not found liable, unless a court determines the person is fairly and reasonably entitled to the indemnification.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, under the DGCL, a corporation must indemnify its present or former
directors and officers against expenses (including attorneys&#146; fees) actually and reasonably incurred to the extent that the officer or director has been successful on the merits or otherwise in defense of any action, suit or proceeding on
account of being a director, officer, employee or agent of the corporation or serving at the request of the corporation as a director, officer, employee or agent of another corporation or other entity.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will provide that Parent will indemnify its directors and officers,
and may indemnify its employees, agents and any other persons, to the fullest extent permitted by the DGCL. The Parent Bylaws will also provide that Parent must advance expenses incurred by or on behalf of a director or officer in advance of the
final disposition of any action or proceeding upon written request, subject to limited exceptions.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Transactions with Directors and Officers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to certain exceptions, the BCBCA provides that a director or senior officer of a company holds a disclosable interest in a contract or transaction if the contract or transaction is material to the company, the company has
entered, or proposes to enter, into the contract or transaction, and either of the following applies to the director or senior officer: (i)&nbsp;the director or senior officer has a material interest in the contract; or (ii)&nbsp;the director or
senior officer is a director or senior officer of, or has a material interest in, a person who has a material interest in the contract or transaction.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL generally provides that no transaction between a corporation and one or more of its directors or officers, or between a corporation and any other corporation or other organization in which one or more of its directors or
officers, are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee which authorizes
the transaction, or solely because any such director&#146;s or officer&#146;s votes are counted for such purpose, if (i)&nbsp;the material facts as to the director&#146;s or officer&#146;s interest and as
to</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA and Zymeworks&#146; Articles, a director who holds a disclosable interest in a contract or transaction may not vote on any
directors&#146; resolution to approve such contract or transaction unless all directors have a disclosable interest, in which case any or all of the directors may vote. Under the BCBCA and Zymeworks&#146; Articles, the director with the disclosable
interest may be counted in quorum at the meeting, whether or not the director votes on any or all of the resolutions considered at the meeting.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A director or senior officer is liable to account to the company for any profit that accrues to the director or senior officer under or as a result of the
interested contract or transaction unless disclosure of the interest is made, and the transaction is approved, as required under the BCBCA.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the transaction are known to the board of directors or the committee, and the board or committee in good faith authorizes the transaction by the affirmative votes of a majority of the disinterested directors, even though the
disinterested directors be less than a quorum; (ii)&nbsp;the material facts as to the director&#146;s or officer&#146;s interest and as to the transaction are disclosed or are known to the stockholders entitled to vote thereon, and the transaction
is specifically approved in good faith by vote of the stockholders; or (iii)&nbsp;the transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the board of directors, a committee or the
stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Votes on Mergers, Consolidations and Sales of Assets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, certain extraordinary corporate actions, such as continuances, certain amalgamations, sales, leases or other dispositions of
all or substantially all of the undertaking of a company (other than in the ordinary course of business), liquidations, dissolutions and certain arrangements, are required to be approved by a special majority of the company&#146;s shareholders, and
specifies that a company&#146;s articles set the requirement for a special majority between <FONT STYLE="white-space:nowrap">two-thirds</FONT> and three-quarters of the votes cast on a resolution.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, a special majority is
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on a resolution.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that, unless otherwise provided in the certificate of incorporation or&nbsp;bylaws,&nbsp;the adoption of a merger agreement
requires the approval of a majority of the outstanding stock of the corporation entitled to vote thereon.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">However, the DGCL also provides that no vote of stockholders of a corporation is required to approve (i)&nbsp;the merger of the corporation with or into
another corporation that owns 90% or more of the voting power of each class of voting stock of the corporation pursuant to a specific provision of the DGCL, (ii)&nbsp;the merger of the corporation into a direct or indirect wholly-owned subsidiary of
the corporation in a &#147;holding company reorganization&#148; meeting certain requirements, (iii)&nbsp;a merger in which the stock of the corporation remains outstanding, the certificate of incorporation is not amended in any respect and the
corporation issues less than 20% of its stock, and (iv)&nbsp;a merger meeting certain requirements following a tender offer in which the holders of sufficient shares to adopt the merger agreement if voted upon at a meeting tender their shares into
the tender offer and those stockholders who do not</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">tender (subject to certain statutory exceptions) receive the same consideration in the merger as those who tendered in the tender offer.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Anti-Takeover Provisions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The BCBCA contains no restriction on adoption of a shareholder rights plan. The BCBCA does not restrict related party transactions; however, in Canada, takeover bids and related party transactions are addressed in provincial
securities legislation and policies.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unless a corporation opts out of the provisions of Section&nbsp;203 of the DGCL, Section&nbsp;203 generally prohibits a public Delaware corporation from engaging in a &#147;business combination&#148; with a holder of 15% or more of
the corporation&#146;s voting stock (as defined in Section&nbsp;203), referred to as an interested stockholder, for a period of three years after the date of the transaction in which the interested stockholder became an interested stockholder,
except as otherwise provided in Section&nbsp;203. For these purposes, the term &#147;business combination&#148; includes mergers, asset sales and other similar transactions with an interested stockholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stockholders&#146; Rights Plan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;9, 2022, the Zymeworks Board authorized and declared a dividend distribution of one Original Right for each outstanding
Zymeworks Common Share to Zymeworks Shareholders as of June&nbsp;21, 2022. Each Original Right entitles the registered holder to purchase from the Company one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a Series A Preferred Share at an
exercise price of $74.00, subject to adjustment. The complete terms of the Rights are set forth in the Zymeworks Rights Agreement.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Zymeworks Board adopted the Zymeworks Rights Agreement to protect shareholders from coercive or otherwise unfair takeover tactics. In general terms, it
works by imposing a significant penalty upon any person or group that acquires 10&nbsp;percent or more (or 20&nbsp;percent or more in the case of certain institutional investors who report their holdings on Schedule 13G) of the Zymeworks Common
Shares without the approval of the Zymeworks Board. As a result, the overall effect of the Zymeworks Rights Agreement and the issuance of the Original Rights may be to render more difficult or discourage a merger, amalgamation, arrangement,
take-over bid, tender or exchange offer or other business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In connection with the Redomicile Transactions, the Original Rights will be terminated and Parent expects to adopt a stockholder rights plan
with respect to the Delaware Common Stock substantively similar in all material respects to the Zymeworks Rights Agreement. Parent expects that the new rights will accompany, and be evidenced by and trade with, the Delaware Common Stock upon
issuance pursuant to the Redomicile Transactions.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">combination involving the Company that is not approved by the Zymeworks Board. However, neither the Zymeworks Rights Agreement nor the Original Rights should interfere with any merger, amalgamation, arrangement, take-over bid,
tender or exchange offer or other business combination approved by the Zymeworks Board.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Dissenter&#146;s Right of Appraisal</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, a shareholder, whether or not the shareholder&#146;s shares carry the right to vote, is entitled to dissent in respect of a resolution to: (i)&nbsp;alter the company&#146;s articles to alter restrictions on the
powers of the company or on the business the company is permitted to carry on; (ii)&nbsp;adopt an amalgamation agreement; (iii)&nbsp;approve an amalgamation into a foreign jurisdiction; (iv)&nbsp;approve an arrangement; (v)&nbsp;authorize or ratify
the sale, lease or other disposition of all or substantially all of the company&#146;s undertaking; and (vi)&nbsp;authorize the continuation of the company into a jurisdiction other than British Columbia. A shareholder is also entitled to dissent in
respect of any court order that permits dissent and in respect of any other resolution if dissent is authorized by the resolution. A shareholder asserting dissent rights is entitled, subject to specified procedural requirements, including objecting
to the action giving rise to dissent rights and making a proper demand for payment, to be paid by the company the fair value of the shares in respect of which the shareholder dissents. Under the BCBCA, if the shareholder and the company do not agree
on the fair value for the shareholder&#146;s shares, the company or the dissenting shareholder may apply to a court to fix a fair value for the shares.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, a stockholder of a Delaware corporation generally has the right to dissent from and request payment for the stockholder&#146;s shares upon a merger or consolidation in which the Delaware corporation is participating,
subject to specified procedural requirements, including that such dissenting stockholder does not vote in favor of the merger or consolidation. However, the DGCL does not confer appraisal rights, in certain circumstances, including if the dissenting
stockholder owns shares traded on a national securities exchange and will receive publicly traded shares in the merger or consolidation. Under the DGCL, a stockholder asserting appraisal rights does not receive any payment for their shares until a
court determines the fair value. The costs of the proceeding may be determined by the court and assessed against the parties as the court deems equitable under the circumstances.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Derivative Actions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the BCBCA, a shareholder, defined for derivative actions to include a beneficial shareholder and any other person whom a court considers to be an appropriate person to make an application under the BCBCA, or a director of a
company may, with leave of the court, bring a legal proceeding in the name and on behalf of the company to</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, a stockholder may bring a derivative action on behalf of a corporation to enforce the corporation&#146;s rights if they were a stockholder at the time of the transaction which is the subject of the action.
Additionally, under Delaware case law, a stockholder must have owned stock in the corporation continuously until and</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">enforce an obligation owed to the company that could be enforced by the company itself, or to obtain damages for any breach of such an obligation. An applicant may also, with leave of the court, defend a legal proceeding brought
against a company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">throughout the litigation to maintain a derivative action. Delaware law also requires that, before commencing a derivative action, a stockholder must make a demand on the directors of the corporation to assert the claim, unless such
demand would be futile. A stockholder also may commence a class action suit on the stockholder&#146;s own behalf and other similarly situated stockholders where the requirements for maintaining a class action have been met.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Oppression Remedy</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The BCBCA provides an oppression remedy that enables a court to make any order, whether interim or final, to rectify matters that are oppressive or unfairly prejudicial to any shareholder, which includes a beneficial shareholder or
any other person who, in the court&#146;s discretion, is a proper person to make such an application. The oppression remedy provides the court with very broad and flexible powers to intervene in corporate affairs to protect shareholders and other
applicants.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The DGCL does not contain a statutory &#147;oppression&#148; remedy; however, stockholders may bring equitable claims against persons owing them fiduciary duties for breach of fiduciary duty.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Inspection of Corporate Records</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, specified books and records of the company must be available for inspection by any of Zymeworks&#146; shareholders at
Zymeworks&#146; registered and records office.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Zymeworks&#146; Articles, no
shareholder is entitled to inspect or obtain a copy of any accounting records of Zymeworks unless the directors determine otherwise, or unless otherwise determined by ordinary resolution.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the DGCL, any stockholder of record, in person or by attorney or other agent, shall, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper
purpose the corporation&#146;s stock ledger, a list of its stockholders, and its other books and records and to make copies or extracts therefrom.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exclusive Forum</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zymeworks&#146; Articles provide that, unless the company consents to the selection of an alternative forum, the Supreme Court of British Columbia, Canada and the appellate Courts therefrom, shall be the sole and exclusive forum for
(i)&nbsp;any derivative action or proceeding brought on behalf of Zymeworks; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee of Zymeworks to Zymeworks;
(iii)&nbsp;any action or proceeding asserting a claim arising pursuant to any provision of the BCBCA or Zymeworks&#146; Articles (as</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Parent Bylaws will provide that, unless Parent consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state
court in Delaware or the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for (a)&nbsp;any derivative action or proceeding brought on behalf of Parent, (b)&nbsp;any
action asserting a claim of breach of a fiduciary duty owed by any director, stockholder, officer or other employee of Parent to Parent or Parent&#146;s</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Parent</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">either may be amended from time to time); or (iv)&nbsp;any action or proceeding asserting a claim otherwise related to the relationships among Zymeworks, its affiliates and their respective shareholders, directors and/or officers,
but this paragraph (iv)&nbsp;does not include claims related to the business carried on by Zymeworks or such affiliates. If any action or proceeding the subject matter of which is within the scope of the preceding sentence is filed in a Court other
than a Court located within the Province of British Columbia (a &#147;<B>Foreign Action</B>&#148;) in the name of any securityholder, such securityholder shall be deemed to have consented to (i)&nbsp;the personal jurisdiction of the provincial and
federal Courts located within the Province of British Columbia in connection with any action or proceeding brought in any such Court to enforce the preceding sentence and (ii)&nbsp;having service of process made upon such securityholder in any such
action or proceeding by service upon such securityholder&#146;s counsel in the Foreign Action as agent for such securityholder.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">stockholders, (c)&nbsp;any action arising pursuant to any provision of the DGCL or the Parent Certificate of Incorporation or the Parent
Bylaws (as either may be amended from time to time) or (d)&nbsp;any action asserting a claim governed by the internal affairs doctrine, except for, as to each of (a)&nbsp;through (d) above, any claim as to which such court determines that there is
an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in the exclusive jurisdiction
of a court or forum other than such court or for which such court does not have subject matter jurisdiction.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will also provide that, unless Parent consents in writing to the selection of an alternative forum, the federal district courts of the United
States of America will be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, against any person in connection with any offering of the Company&#146;s
securities, (including without limitation and for the avoidance of doubt, any underwriter, auditor, expert, control person or other defendant).</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the selection of an alternative forum shall not apply to any action brought to enforce a duty or liability created by the 1934 Act
or any successor thereto.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_19"></A>SHARE OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
DIRECTORS OF ZYMEWORKS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below indicates information as of June&nbsp;30, 2022, regarding the beneficial ownership of Zymeworks Common Shares
for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who is known by us to beneficially own more than 5% of our common shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each named executive officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of calculating percent ownership, as of June&nbsp;30, 2022, 57,772,461 shares were issued and outstanding, and, for any individual who
beneficially owns shares represented by options exercisable, or restricted stock units vesting, within sixty days of June&nbsp;30, 2022, these shares are treated as if outstanding for that person, but not for any other person. Unless otherwise
indicated in the footnotes to the table, and subject to community property laws where applicable, the following persons have sole voting and investment control with respect to the shares beneficially owned by them. In accordance with SEC rules, if a
person has a right to acquire beneficial ownership of any common shares on or within 60 days, upon conversion or exercise of outstanding securities or otherwise, the shares are deemed beneficially owned by that person and are deemed to be
outstanding solely for the purpose of determining the percentage of our shares that person beneficially owns. These shares are not included in the computations of percentage ownership for any other person. To our knowledge, except as noted in the
table below, no person or entity is the beneficial owner of more than 5% of the voting power of our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the
address of each of the persons in this table is Suite 800 &#150; 114 East 4th Avenue, Vancouver, British Columbia, Canada, V5T 1G4. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% and Greater Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armistice Capital, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,769,533</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,218,952</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eventide Asset Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,380,200</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Advisors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,325,615</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Blue Falcons FZE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,989,498</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Astle<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,061</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy M. Cox</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diana Hausman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,377</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth Hillan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,425</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Josephson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99,281</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Klompas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">523,452</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan Mahony</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kelvin Neu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Polverino</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,407</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Priour</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,513</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings C. Renton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,425</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(17)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Natalie Sacks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,140</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(18)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ali Tehrani</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,563,874</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(19)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lota Zoth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,117</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(20)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Directors and Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (11)&nbsp;persons)<SUP
STYLE="font-size:75%; vertical-align:top">(21)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">911,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on a Schedule 13F filed May&nbsp;16, 2022 and company records, consists of 5,760,000 common shares as of
March&nbsp;31, 2022 and 9,533 shares issuable upon exercise of prefunded warrants held by Armistice Capital, LLC. The address for this entity is 510 Madison Avenue, 7th Floor, New York, New York 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on a Schedule 13F filed May&nbsp;16, 2022 and company records, consists of 23,500 common shares issuable
upon exercise of options exercisable within 60 days after June&nbsp;30, 2022, 1,708,472 common shares and 4,486,980 shares issuable upon exercise of prefunded warrants held by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker
and Julian C. Baker. The address for these entities and individuals is 860 Washington Street, 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Floor, New York, NY 10014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13F filed May&nbsp;16, 2022 and company records, consists of 5,380,200 common shares
held by Eventide Asset Management, LLC, Finny Kuruvilla and Robin C. John as of March&nbsp;31, 2022. The address for this entity is One International Place, Suite 4210, Boston MA, 02110. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13F filed May&nbsp;16, 2022 and company records, consists of 5,325,615 common shares
held by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. as of March&nbsp;31, 2022. The address for these entities and individual is 51 Astor Place, 10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>
Floor, New York, NY 10003. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13D/A filed May&nbsp;26, 2022, consists of 3,709,498 common shares directly
beneficially owned by All Blue Falcons FZE and 280,000 common shares underlying call options. Daniel Edward Llewellen Cookson may be deemed to beneficially own all of these common shares by virtue of his position as a control person of All Blue
Falcons FZE. The address for this entity and individual is Office 2301, 23<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Floor API Trio Tower, Al Bashra 1, Dubai, United Arab Emirates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Astle is not a named executive officer in this Proxy Statement/Prospectus, but he is a current
executive officer as a result of his appointment as Chief Financial Officer on February&nbsp;24, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 670 common shares and 5,391 common shares issuable upon the exercise of options exercisable within
60 days after June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 7,500 common shares and 39,000 common shares issuable upon the exercise of options exercisable
within 60 days after June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholdings are based on information available to the Company as of the date of Dr.&nbsp;Hausman&#146;s
resignation in May 2021. Consists of 5,377 shares held personally and 2,000 shares held by Dr.&nbsp;Hausman&#146;s spouse as of May&nbsp;15, 2021, Dr.&nbsp;Hausman&#146;s last day as an employee of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 50,425 common shares issuable upon the exercise of options exercisable within 60 days after
June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 11,039 common shares and 88,242 common shares issuable upon the exercise of options exercisable
within 60 days after June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 14,801 shares held personally and 700 shares held by S. Jennifer Heine, and 507,951 common shares
issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 39,000 common shares issuable upon the exercise of options exercisable within 60 days after
June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Neu was an employee of Baker Bros. Advisors LP until January 2021. Pursuant to the terms of
Dr.&nbsp;Neu&#146;s employment by Baker Brothers Advisors LP, options granted to him in 2020 were, and will continue to be, beneficially owned by Baker Bros. Advisors LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholdings are based on information available to the Company as of the date of Dr.&nbsp;Polverino&#146;s
termination in January 2022. Consists of 36,407 common shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholdings are based on information available to the Company as of the date of Mr.&nbsp;Priour&#146;s
termination in January 2022. Consists of 2,513 common shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 50,425 common shares issuable upon the exercise of options exercisable within 60 days after
June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 44,140 common shares issuable upon the exercise of options exercisable within 60 days after
June&nbsp;30, 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 260,325 common shares held personally and 55,511 common shares held by Charissa Tehrani, and
1,248,038 common shares issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 52,117 common shares issuable upon the exercise of options exercisable within 60 days after
June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Although Dr.&nbsp;Hausman, Dr.&nbsp;Polverino, Mr.&nbsp;Priour and Dr.&nbsp;Tehrani are considered named
executive officers for the purposes of this beneficial ownership table, they are no longer with the Company and are thus not included in the total of shares beneficially owned by the current directors and executive officers as a group.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_20"></A>STOCKHOLDER PROPOSALS AND NOMINATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Proposals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a stockholder would like Parent
to consider including a proposal in its proxy statement for the 2022 annual meeting pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> of the Exchange Act, then the proposal must be received by Parent&#146;s corporate secretary at
Parent&#146;s principal executive offices a reasonable time before the company begins to print and send its proxy materials. In addition, stockholder proposals must comply with the requirements of
<FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> regarding the inclusion of stockholder proposals in <FONT STYLE="white-space:nowrap">company-sponsored</FONT> proxy materials. Proposals should be addressed to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108
Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent Bylaws will also establish an advance notice procedure for stockholders who wish to present a proposal or nominate a director at an annual meeting,
but do not seek to include the proposal or director nominee in Parent&#146;s proxy statement. In order to be properly brought before the 2022 annual meeting, the stockholder must provide timely written notice to Parent&#146;s corporate secretary, at
Parent&#146;s principal executive offices, and any such proposal or nomination must constitute a proper matter for stockholder action. The written notice must contain the information specified in the Parent Bylaws. To be timely, a stockholder&#146;s
written notice must be received by Parent&#146;s corporate secretary at Parent&#146;s principal executive offices: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no earlier than 8:00 a.m., local time, on [&#9679;], and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no later than 5:00 p.m., local time, on [&#9679;]. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a stockholder who has notified Parent of his, her or its intention to present a proposal at an annual meeting of stockholders does not appear to present
his, her or its proposal at such annual meeting, then Parent will not be required to present the proposal for a vote at such annual meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Nominations to Parent&#146;s Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Parent Bylaws, stockholders may also directly nominate persons for Parent&#146;s board of directors. Any nomination must comply with the requirements
set forth in the Parent Bylaws and the rules and regulations of the SEC and should be sent in writing to the Parent&#146;s corporate secretary at the address above. To be timely for the 2022 annual meeting of stockholders, nominations must be
received by our corporate secretary observing the deadlines discussed above under &#147;<I>&#150; Stockholder Proposals</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Reports and Other Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
required to file with the securities commission or authority in each of the provinces and territories of Canada annual and quarterly reports, material change reports and other information. You may read any document Zymeworks and Parent file with or
furnish to the securities commissions and authorities of the provinces and territories of Canada through SEDAR at https://www.sedar.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation
by Reference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable securities laws allow registrants to &#147;incorporate by reference&#148; information into this Proxy Statement/Prospectus,
which means that Zymeworks can disclose important information to you by referring you to another document filed separately with Canadian securities regulatory authorities and the SEC. Due to certain differences in applicable Canadian and U.S.
securities laws, the documents incorporated by reference into this Proxy Statement/Prospectus differ for purposes of the filing of this Proxy Statement/Prospectus with Canadian securities regulatory authorities and the SEC and depending on the
residency of the person receiving or viewing this Proxy Statement/Prospectus, as outlined below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of the filing of this Proxy
Statement/Prospectus with Canadian securities regulatory authorities and for persons resident in or otherwise subject to applicable securities laws in Canada who receive or view this Proxy Statement/Prospectus, the following documents contain
important information about Zymeworks and this Proxy Statement/Prospectus incorporates them by reference: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendment No.&nbsp;1 to our annual report on Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> for the fiscal
year ended December&nbsp;31, 2021, as filed on SEDAR on May&nbsp;2, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our audited consolidated financial statements as at and for the year ended December&nbsp;31, 2021, together with
the notes thereto and the auditor&#146;s reports thereon; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our management&#146;s discussion and analysis of Zymeworks&#146; financial condition and results of operations
for the year ended December&nbsp;31, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our interim consolidated financial statements as at and for the three months ended March&nbsp;31, 2022, together
with the notes thereto; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our management&#146;s discussion and analysis of Zymeworks&#146; financial condition and results of operations
for the three months ended March&nbsp;31, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our management information circular dated March&nbsp;23, 2021, distributed in connection with Zymeworks&#146;
annual general meeting of shareholders held on May&nbsp;5, 2021, as filed on SEDAR on March&nbsp;23, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our material change report dated January&nbsp;5, 2022, regarding Zymeworks&#146; appointment of Mr.&nbsp;Kenneth
Galbraith as Chair and Chief Executive Officer of Zymeworks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our material change report dated January&nbsp;19, 2022, regarding Zymeworks&#146; announcement of its corporate
update on its key strategic priorities for 2022 and 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our material change report dated January&nbsp;31, 2022, regarding Zymeworks&#146; announcement of the closing of
an underwritten public offering of 11,035,000 common shares and 3,340,000 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for gross proceeds of US$115.0&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our material change report dated February&nbsp;25, 2022, regarding Zymeworks&#146; announcement of its financial
results for the year ended December&nbsp;31, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our material change report dated June&nbsp;10, 2022, regarding the adoption of the Preferred Shares Rights
Agreement dated as of June&nbsp;9, 2022, between the Zymeworks and Computershare Trust Company, N.A., as rights agent. and the declaration of the dividend of certain rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our material change report dated June&nbsp;27, 2022, regarding Zymeworks&#146; appointment of Dr.&nbsp;Paul Moore
as Chief Scientific Officer of Zymeworks; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our material change report dated July 15, 2022, regarding Zymeworks&#146; announcement of the Redomicile
Transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any documents of the type listed above and any other document that would be required to be incorporated by
reference in a prospectus filed by Zymeworks in Canada, including any interim financial statements and related MD&amp;A, filed by Zymeworks with the Canadian securities regulatory authorities subsequent to the date of this Proxy Statement/Prospectus
and prior to the date of the Special Meeting, are deemed to be incorporated by reference in this Proxy Statement/Prospectus for persons resident in or otherwise subject to applicable securities laws in Canada who receive or view this Proxy
Statement/Prospectus. For these purposes, upon a new document being deemed to be incorporated by reference in this Proxy Statement/Prospectus, the previous applicable document that was incorporated by reference (whether specifically in the list
above or later deemed to be incorporated by reference, as the case may be), shall be deemed no longer to be incorporated by reference in this Proxy Statement/Prospectus (for example, when new interim financial statements and related MD&amp;A are
filed by Zymeworks and deemed incorporated by reference, the previous interim financial statements and related MD&amp;A will be deemed no longer to be incorporated by reference in this Proxy Statement/Prospectus). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of the filing of this Proxy Statement/Prospectus with the SEC and for persons resident in or otherwise subject to applicable securities laws
in the United States who receive or view this Proxy Statement/Prospectus, the following documents contain important information about Zymeworks and this Proxy Statement/Prospectus incorporates them by reference (excluding any portions of such
documents that have been furnished but not filed for purposes of the U.S. Exchange Act): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000140375222000005/zyme-20211231.htm">Zymeworks&#146;
 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021, filed with the SEC on February&nbsp;24, 2022; </A> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000119312522136812/d357655d10ka.htm">Zymeworks&#146;
 Amendment No.&nbsp;1 to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021, filed with the SEC on May&nbsp;2, 2022; </A> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000140375222000013/zyme-20220331.htm">Zymeworks&#146;
 quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended March&nbsp;31, 2022, filed with the SEC on May&nbsp;4, 2022; </A> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zymeworks&#146; current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000119312522002772/d207208d8k.htm">January&nbsp;5,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001403752/000119312522012575/d461277d8k.htm">January&nbsp;
19, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001403752/000119312522019922/d302094d8k.htm">January&nbsp;
27, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001403752/000119312522023393/d299342d8k.htm">January&nbsp;
31, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001403752/000119312522054448/d295460d8k.htm">February&nbsp;
25, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001403752/000119312522070589/d497055d8k.htm">March&nbsp;
9, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001403752/000119312522136837/d212111d8ka.htm">May&nbsp;2, 2022</A> (Amendment No.&nbsp;1 to Form <FONT STYLE="white-space:nowrap">8-K</FONT> originally
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000119312522012575/d461277d8k.htm">January&nbsp;
19, 2022</A>), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000119312522161173/d322285d8k.htm">May&nbsp;
26, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000119312522172083/d319186d8k.htm">June&nbsp;
10, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1403752/000119312522194250/d373368d8k.htm">July 15, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All other reports filed pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act since the end of the fiscal
year ending December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this Proxy Statement/Prospectus incorporates by reference any future filings Zymeworks
makes with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the U.S. Exchange Act after the date of this Proxy Statement/Prospectus and prior to the date of the Special Meeting (other than information furnished pursuant to Item 2.02 or Item
7.01 of any Current Report on Form 8-K, unless expressly stated otherwise therein) for purposes of the Proxy Statement/Prospectus filed with the SEC and for persons resident in or otherwise subject to applicable securities laws in the United States
who receive or view this Proxy Statement/Prospectus. Such documents are considered to be a part of this Proxy Statement/Prospectus, effective as of the date such documents are filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained in any document incorporated by reference into this Proxy Statement/Prospectus shall be deemed to be modified or superseded to the
extent that an inconsistent statement is made in this Proxy Statement/Prospectus or any subsequently filed document. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Proxy
Statement/Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can obtain any of the documents incorporated by reference in this Proxy Statement/Prospectus from Zymeworks or from SEDAR at
www.sedar.com or the SEC&#146;s website at www.sec.gov, as applicable, at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address described above. Documents incorporated by reference are available from Zymeworks without charge at Zymeworks&#146; principal office located at 114 East 4th Avenue, Suite 800, Vancouver,
British Columbia, Canada V5T 1G4. Please be sure to include your complete name and address in your request. If you request any incorporated documents, Zymeworks will promptly mail them to you by first class mail, or another equally prompt means. To
obtain timely delivery of the documents, you must request them no later than [&#9679;], which is [&#9679;] business days before the Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial information is provided in Zymeworks&#146; audited annual consolidated financial statements as at December&nbsp;31, 2021 and 2020, and for the years
ended December&nbsp;31, 2021, 2020 and 2019, and the MD&amp;A for the year ended December&nbsp;31, 2021, and in Zymeworks&#146; unaudited interim consolidated financial statements as at and for the three months ended March&nbsp;31, 2022, and the
MD&amp;A for the three months ended March&nbsp;31, 2022. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_22"></A>APPROVAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contents and the distribution of this Proxy Statement/Prospectus have been approved by the Zymeworks Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith Chair, President&nbsp;&amp; CEO [&#9679;], 2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_23"></A>GLOSSARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified or if the context so requires, the following terms have the meanings set forth below for purposes of this Proxy
Statement/Prospectus, and any derivative of the following terms will have a corresponding meaning: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement</B>&#148; means an arrangement
under Part 9, Division 5 of the BCBCA on the terms and subject to the conditions set forth in the Plan of Arrangement, subject to any amendments or variations to the Plan of Arrangement made in accordance with the terms of the Transaction Agreement
and the Plan of Arrangement, or made at the direction of the Court in accordance with the Final Order with the prior written consent of Zymeworks; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>BCBCA</B>&#148; means the <I>Business Corporations Act </I>(British Columbia), S.B.C. 2002, c. 57, and the regulations made thereunder, as
promulgated or amended from time to time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Beneficial Shareholder</B>&#148; means a Person who holds Zymeworks Common Shares through an
Intermediary or who otherwise does not hold Zymeworks Common Shares in their own name; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Beneficiaries</B>&#148; has the meaning ascribed thereto
under &#147;<I>Description of Exchangeable Shares and Related Agreements &#150; Trust Agreement</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day on
which banks are generally open for the transaction of commercial business in Vancouver, British Columbia, and New York, New York, but does not in any event include a Saturday or Sunday or statutory holiday in Vancouver, British Columbia, or New
York, New York; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Callco</B>&#148; means Zymeworks CallCo ULC, a British Columbia unlimited liability company existing under the laws of the
Province of British Columbia and a direct, wholly-owned subsidiary of Parent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Call Rights</B>&#148; has the meaning ascribed thereto under
&#147;Material Canadian Federal Income Tax Considerations &#150; Holders Resident in Canada &#150; Call Rights&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Canadian Securities
Laws</B>&#148; means the securities laws of each province and territory of Canada, and the rules, instruments, regulations, notices and policies of each securities commission or other securities regulatory authority in each province or territory in
Canada; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call Date</B>&#148; has the meaning ascribed thereto under &#147;<I>Description of Exchangeable Shares and Related Agreements &#150;
Description of Exchangeable Shares &#150; Change of Law Call Right</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call Purchase Price</B>&#148; has the meaning
ascribed thereto in the Exchangeable Share Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call Right</B>&#148; has the meaning ascribed thereto in the Exchangeable
Share Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Computershare</B>&#148; means Computershare Trust Company of Canada, a trust company existing under the laws of Canada; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Consideration</B>&#148; means (i)&nbsp;in the case of a Zymeworks Shareholder who is an Eligible Holder and who validly elects to receive
Exchangeable Shares prior to the Election Deadline in accordance with the Plan of Arrangement, for each Designated Zymeworks Common Share, one Exchangeable Share together with the Contractual Rights,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and for each other Zymeworks Common Share (to the extent applicable), one share of Delaware Common Stock, and (ii)&nbsp;in the case of each other Zymeworks Shareholder who does not exercise the
Dissent Rights, for each Zymeworks Common Share, one share of Delaware Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Contractual Rights</B>&#148; has the meaning set forth in
the Plan of Arrangement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Court</B>&#148; means the Supreme Court of British Columbia; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CRA</B>&#148; means the Canada Revenue Agency; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Current Market Price</B>&#148; has the meaning set out in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Delaware Common Stock</B>&#148; means the shares of common stock, par value US$0.00001 per share, of Parent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Depositary</B>&#148; means Computershare, or such other Person as Zymeworks may appoint to act as depositary in relation to the Arrangement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Designated Zymeworks Common Shares</B>&#148; means the Zymeworks Common Shares of an Eligible Holder that are designated by the Eligible Holder under
a Letter of Transmittal and Election Form to be exchanged for Exchangeable Shares, as such number of Zymeworks Common Shares may be reduced as a result of the Exchangeable Share Cap, and &#147;<B>Designated Zymeworks Common Share</B>&#148; means any
one of them; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>DGCL</B>&#148; means the General Corporation Law of the State of Delaware; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissent Notice</B>&#148; has the meaning ascribed thereto under &#147;<I>The Redomicile Transactions and Plan of Arrangement &#150; Dissent
Rights</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissent Rights</B>&#148; means the rights of dissent granted to registered holders of Zymeworks Common Shares in respect of
the Redomicile Transactions under provisions of Division 2 of Part 8 of the BCBCA as modified by the Interim Order, the Plan of Arrangement and any further order of the Court; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissenting Shareholder</B>&#148; means a Registered Shareholder as of the Record Date who has duly and validly exercised its Dissent Rights in strict
compliance with Division 2 of Part 8 of the BCBCA, as modified by the Interim Order, the Plan of Arrangement, and any further order of the Court, and not withdrawn or been deemed to have withdrawn such exercise of Dissent Rights and who is
ultimately determined to be entitled to be paid the fair value of its Zymeworks Common Shares, but only in respect of the Zymeworks Common Shares in respect of which Dissent Rights are duly and validly exercised by such Registered Shareholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>DPSPs</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal Income Tax Considerations &#150; Eligibility for
Investment</I>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>EDGAR</B>&#148; means the SEC&#146;s Electronic Document Gathering and Retrieval System; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; means the date the Arrangement becomes effective, as set out in Section 2.1 of the Transaction Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Time</B>&#148; means the time at which the Arrangement becomes effective on the Effective Date pursuant to the Transaction Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Elected Amount</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal Income Tax Considerations &#150;
Section</I><I></I><I>&nbsp;85 Election</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Election Deadline</B>&#148; means 5:00 p.m. (Vancouver time) on the date before the Special
Meeting; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Eligible Holder&#148; </B>means a Zymeworks Shareholder that is (a)&nbsp;a resident of Canada for
purposes of the Tax Act and not exempt from tax under Part I of the Tax Act, or (b)&nbsp;a partnership, each member of which is a resident of Canada for purposes of the Tax Act and not exempt from tax under Part I of the Tax Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Equivalent Dividend</B>&#148; has the meaning ascribed thereto under &#147;<I>Description Of Exchangeable Shares And Related Agreements &#150;
Covenants regarding Exchangeable Shares</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Right</B>&#148;<B> </B>has the meaning ascribed thereto under &#147;<I>Description
of Exchangeable Shares and Related Agreements &#150; Trust Agreement &#150; ExchangeCo Insolvency Event &#150; Exchange Right</I>&#148;; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Cap</B>&#148; means, in respect of the number of Zymeworks Common Shares exchangeable for Exchangeable Shares under the Canadian
Share Exchange, such number of Zymeworks Common Shares that is equal to 18% of (i)&nbsp;the number of Zymeworks Common Shares issued and outstanding immediately prior to the Effective Time, less (ii)&nbsp;the number of Zymeworks Common Shares held
by any Zymeworks Shareholders who exercise their Dissent Rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Consideration</B>&#148; has the meaning set forth in the
Exchangeable Share Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Price</B>&#148; has the meaning set forth in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Exchange Ratio</B>&#148; has the meaning ascribed thereto under &#147;<I>Description of Parent Capital Stock &#150; Preferred
Stock &#150; Special Voting Stock</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Shareholders</B>&#148; means the holders of the Exchangeable Shares (excluding Parent
and its affiliates); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Shares</B>&#148; means the exchangeable shares in the capital of ExchangeCo; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Provisions</B>&#148; means the rights, privileges, restrictions and conditions attaching to the Exchangeable Shares as set forth
in the Articles of ExchangeCo, and in the form attached as Exhibit E to the Transaction Agreement, which is set forth in Appendix B to the Proxy Statement/Prospectus.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ExchangeCo</B>&#148; means Zymeworks ExchangeCo Ltd., a British Columbia company and a direct, wholly-owned subsidiary of Callco; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ExchangeCo Transfer Agent</B>&#148; means Computershare Investor Services Inc. or such other person as may from time to time be appointed by
ExchangeCo as the registrar and transfer agent for the Exchangeable Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the U.S. Food and Drug Administration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Order</B>&#148; means the final order of the Court pursuant to section 291 of the BCBCA, approving the Redomicile Transactions, after a hearing
upon the procedural and substantive fairness of the terms and conditions of the Redomicile Transactions as such order may be affirmed, amended, modified, supplemented or varied by the Court or, if appealed, then, unless such appeal is withdrawn or
denied, as affirmed or as amended on appeal; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Entity</B>&#148; means any United States, Canadian, international or other
(i)&nbsp;federal, state, provincial, local, municipal or other government entity, (ii)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other
tribunal) or (iii)&nbsp;body exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitrator or arbitral tribunal (public or private);
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Holder</B>&#148; means a beneficial owner of Zymeworks Common Shares who, for the purposes of the
Tax Act and at all relevant times, (1)&nbsp;holds Zymeworks Common Shares, and will hold Exchangeable Shares and/or Delaware Common Stock, as applicable, as capital property; and (2)&nbsp;deals at arm&#146;s length with, and is not affiliated with,
Zymeworks, Parent, Callco or ExchangeCo; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Intermediary</B>&#148; means a broker, financial institution or other nominee through which Zymeworks
Common Shares of a Beneficial Shareholder are held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Interim Order</B>&#148; means the interim order of the Court made pursuant to
Section&nbsp;291 of the BCBCA providing for, among other things, the calling and holding of the Special Meeting, as the same may be amended, modified, supplemented or varied by the Court and attached as Appendix D to this Proxy Statement/Prospectus;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Irish Sub</B>&#148; means Zymeworks Pharmaceuticals Limited, a corporation incorporated under the laws of Ireland; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Irish Sub Stock</B>&#148; means the issued and outstanding shares of Irish Sub; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>IRS</B>&#148; means the U.S. Internal Revenue Service; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>KPMG</B>&#148; means KPMG LLP, Chartered Professional Accountants; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means, with respect to any Person, any and all applicable law, constitution, treaty, convention, ordinance, code, rule, regulation,
order, injunction, judgment, decree, ruling or other similar requirement, whether domestic or foreign, enacted, adopted, promulgated or applied by a Governmental Entity that is binding upon or applicable to such Person or its business, undertaking,
property or securities, and to the extent that they have the force of law, policies, guidelines, notices and protocols of any Governmental Entity, as amended unless expressly specified otherwise; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; includes any mortgage, pledge, assignment, charge, lien, security interest, adverse interest in property, license or <FONT
STYLE="white-space:nowrap">sub-license,</FONT> charge, or other third-party interest or encumbrance of any kind (including, in the case of any equity securities, any voting, transfer or similar restrictions) whether contingent or absolute, and any
agreement, option, right or privilege (whether by law, contract or otherwise) capable of becoming any of the foregoing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation
Amount</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Call Purchase Price</B>&#148; has the
meaning ascribed thereto in the Exchangeable Share Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Call Right</B>&#148; has the meaning ascribed thereto under
&#147;<I>Description of Exchangeable Shares and Related Agreements &#150; Description of Exchangeable Shares &#150; Distribution on Liquidation and Associated Call Right</I>&#148;; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Date</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Letter of Transmittal and Election Form</B>&#148; means the letter of transmittal and election form(s) for use by registered Zymeworks Shareholders,
in the form accompanying the Proxy Statement/Prospectus or in any other form acceptable to Zymeworks, providing for, among other things, the Eligible Holder&#146;s election with respect to the Consideration (and in the case of an Eligible Holder,
setting forth the number of Designated Zymeworks Common Shares, which number may be less than the number of Zymeworks Common Shares held by that Eligible Holder), and which shall specify that delivery shall be effected, and risk of loss and title to
the applicable Zymeworks Common Shares shall pass, only upon proper delivery of such certificates or other documents to the Depositary and which shall be in such form and have such other customary provisions as Zymeworks may specify (or, if such
Zymeworks Common Shares are held in book-entry or other uncertificated form, upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entry through a book-entry transfer agent of the surrender of such Zymeworks Common Shares on a book-entry account statement, it being understood that any reference herein to
&#147;certificates&#148; shall be deemed to include references to book-entry account statements relating to the ownership of Zymeworks Common Shares); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>MD&amp;A</B>&#148; means the management&#146;s discussion and analysis accompanying the Zymeworks financial statement for the year ended December 31,
2021; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Mixed Election</B>&#148; has the meaning ascribed thereto under &#147;<I>Questions and Answers About the Redomicile
Transactions</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>New Common Shares</B>&#148; has the meaning ascribed thereto under &#147;<I>Summary of the Transaction Agreement &#150;
Post-Arrangement Matters</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>NI <FONT STYLE="white-space:nowrap">45-106</FONT></B>&#148; means National Instrument <FONT
STYLE="white-space:nowrap">45-106</FONT> &#150; <I>Prospectus and Registration Exemptions</I>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Eligible</FONT> Holders</B>&#148; has the meaning set forth in &#147;<I>Certain Canadian Federal Income Tax
Considerations &#150; Holders Not Resident in Canada</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Resident</FONT> Holder</B>&#148; means a
Holder who (i)&nbsp;for the purposes of the Tax Act and any applicable tax treaty, is neither resident nor deemed to be resident in Canada at any time while they hold Zymeworks Common Shares, Exchangeable Shares or Delaware Common Stock; and
(ii)&nbsp;does not and will not use or hold and is not and will not be deemed to use or hold the Zymeworks Common Shares, Exchangeable Shares or Delaware Common Stock in carrying on a business in Canada; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder</B>&#148; has the meaning set forth in &#147;<I>Material U.S. Federal Income Tax
Considerations</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Notice of Special Meeting</B>&#148; means the notice regarding the Special Meeting accompanying this Proxy
Statement/Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Notice Shares</B>&#148; has the meaning ascribed thereto under &#147;<I>The Redomicile Transactions and Plan of
Arrangement &#150; Dissent Rights</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>NYSE</B>&#148; means the New York Stock Exchange; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Offer</B>&#148; has the meaning ascribed thereto under &#147;<I>Description of Exchangeable Shares and Related Agreements &#150; Tender
Offers</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Original Right</B>&#148; has the meaning ascribed thereto under &#147;<I>Questions and Answers About the Redomicile
Transactions</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent</B>&#148; means Zymeworks Delaware Inc., a Delaware corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Bylaws</B>&#148; means the Amended and Restated Bylaws<B> </B>of Parent, to be effective on or prior to the Effective Time; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Certificate of Incorporation</B>&#148; means the Amended and Restated Certificate of Incorporation<B> </B>of Parent to be filed with the
Delaware Secretary of State (including any certificate of designation relating to any series of Special Voting Stock) on or prior to the Effective Time; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Control Transactions</B>&#148; has the meaning set forth in the Exchangeable Share Provisions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Dividend Declaration Date</B>&#148; has the meaning ascribed thereto under
&#147;<I>Description of Exchangeable Shares and Related Agreements &#150; Description of Exchangeable Shares &#150; Dividends and Other Distributions</I>&#148;; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Incentive Awards</B>&#148; means collectively, the stock options (together with any associated tandem stock appreciation rights), stock
appreciation rights, performance share units, restricted share units, deferred share units, restricted stock and other share-based awards to be assumed by Parent pursuant to the Parent Incentive Plans pursuant to the Arrangement, and &#147;<B>Parent
Incentive Award</B>&#148; means any one of them, as applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Incentive Plans</B>&#148; means collectively, (i) the Amended and
Restated Stock Option and Equity Compensation Plan of Parent, (ii) the Amended and Restated Employee Stock Purchase Plan of Parent, (iii) the Inducement Stock Option and Equity Compensation Plan of Parent, and (iv) the Second Amended and Restated
Employee Stock Option Plan of Parent, in each case including any schedules or appendices thereto, as amended from time to time, and &#147;<B>Parent Incentive Plan</B>&#148; means any one of them, as applicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Voting Warrants</B>&#148; means the Zymeworks Warrants assumed by Parent in connection with the Redomicile Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; includes any individual, partnership, association, joint venture, venture capital fund, association, trust, trustee, executor,
administrator, legal personal representative, estate group, body corporate, corporation, unincorporated association or organization, Governmental Entity, syndicate or other entity, whether or not having legal status; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>PFIC</B>&#148; means a passive foreign investment company as defined under Section&nbsp;1297 of the Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Plan of Arrangement</B>&#148; means the plan of arrangement in the form attached as Exhibit A to the Transaction Agreement, which is set forth in
Appendix B to the Proxy Statement/Prospectus, and any amendments or variations thereto made in accordance with the provisions of the Transaction Agreement or the Plan of Arrangement or at the direction of the Court; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Preferred Stock Rights Agreement&#148;</B> means any preferred stock rights agreement that may now or in the future be adopted and entered into by
Parent in respect of the Delaware Common Stock, to protect stockholders of Parent from coercive or otherwise unfair takeover tactics, in such form and substance as Parent may determine in its sole discretion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Proposed Amendments</B>&#148; means all specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance
(Canada) prior to the date hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Proxy Solicitor</B>&#148; means Kingsdale Advisors, or such other person as Zymeworks may appoint to act as
its strategic shareholder advisor and proxy solicitation agent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Proxy Statement/Prospectus</B>&#148; means this notice of the Special Meeting
and proxy statement/prospectus of Zymeworks dated [&#9679;], 2022, together with all appendices, schedules and exhibits hereto, sent by Zymeworks to the Zymeworks Securityholders in connection with the Special Meeting (as may be amended,
supplemented or otherwise modified from time to time); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>RDSPs</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal
Income Tax Considerations &#150; Eligibility for Investment</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Record Date</B>&#148; means the record date for determining the Zymeworks
Securityholders entitled to receive notice of and to vote at the Special Meeting, being the close of business on [&#9679;] (Vancouver Time) pursuant to the Interim Order; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Call Right</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Call Right Purchase Price</B>&#148; has the meaning ascribed thereto in the Exchangeable
Share Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Date</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Price</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Registered Plans</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal Income Tax Considerations &#150; Eligibility for
Investment</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redomicile Resolution</B>&#148; has the meaning ascribed thereto in the Transaction Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Registered Shareholder</B>&#148; means a holder of Zymeworks Common Shares as recorded in the register of Zymeworks Shareholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Statement</B>&#148; has the meaning ascribed thereto under &#147;<I>Summary of the Transaction Agreement &#150; Conditions Precedent to
the Arrangement</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redomicile Transactions</B>&#148; has the meaning ascribed thereto in the Transaction Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Required Securityholder Approvals</B>&#148; means the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes
cast at the Special Meeting on the Redomicile Resolution, in person or by proxy, by both (i)&nbsp;Zymeworks Shareholders, Zymeworks Warrantholders and Zymeworks Incentive Awardholders, voting together as a single class, and (ii)&nbsp;Zymeworks
Shareholders, voting separately; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>RESPs</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal Income Tax
Considerations &#150; Eligibility for Investment</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Resident Holder</B>&#148; means a Holder who for the purposes of the Tax Act and any
applicable tax treaty, is resident or is deemed to be resident in Canada at all times while they hold Zymeworks Common Shares, Exchangeable Shares or Delaware Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Retracted Shares</B>&#148; has the meaning ascribed thereto under &#147;<I>Description of Exchangeable Shares and Related Agreements </I><I>&#150;
</I><I>Retraction of Exchangeable Shares and Associated Call Right</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Right</B>&#148; has the meaning ascribed thereto
in the Exchangeable Share Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Right Purchase Price</B>&#148; has the meaning ascribed thereto in the Exchangeable Share
Provisions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Date</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Price</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Request</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>RRIFs</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal Income Tax Considerations &#150; Eligibility for
Investment</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>RRSPs</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal Income Tax Considerations &#150;
Eligibility for Investment</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SEDAR</B>&#148; means the System for Electronic Document Analysis and Retrieval; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Series A Preferred Shares</B>&#148; has the meaning ascribed thereto under &#147;<I>Information Concerning Parent, ExchangeCo and Callco &#150;
Material Contracts</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Share Trustee</B>&#148; means Computershare Trust Company of Canada, a trust company existing under the laws of
Canada, as share trustee under the Trust Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Shares</B>&#148; means the Zymeworks Common Shares, Exchangeable Shares and/or shares of
Delaware Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Special Meeting</B>&#148; means the special meeting of Zymeworks Securityholders to be held on [&#9679;], 2022, at the
[&#9679;], at [&#9679;],&nbsp;Pacific time, including any adjournment or postponement thereof, held in accordance with the Transaction Agreement and the Interim Order to consider the Redomicile Resolution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Special Voting Stock</B>&#148; means the share of preferred stock of Parent, issued by Parent to and deposited with the Share Trustee, which, at any
time, entitles the holder of record to that number of votes at meetings of holders of Delaware Common Stock equal to the number of Exchangeable Shares outstanding as of the record date for such meeting (excluding Exchangeable Shares held by Parent,
Callco and their affiliates) multiplied by the Exchangeable Share Exchange Ratio, and in respect of each Beneficiary, rounded down to the nearest whole vote; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Sunset Date</B>&#148; means the seventh anniversary of the Effective Date, as it may be extended from time to time by the directors of ExchangeCo;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Support Agreement</B>&#148; means the exchangeable share support agreement to be entered into among Parent, Callco and ExchangeCo, substantially
in the form attached as Exhibit C to the Transaction Agreement, which is set forth in Appendix B to the Proxy Statement/Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax
Act</B>&#148; means the <I>Income Tax Act</I>, R.S.C. 1985, c.1 (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Supplement); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>TFSAs</B>&#148; has the meaning ascribed thereto under &#147;<I>Material Canadian Federal Income Tax Considerations &#150; Eligibility for
Investment</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreement</B>&#148; means the Transaction Agreement dated July&nbsp;14, 2022 by and among Parent, Zymeworks,
Callco and ExchangeCo as the same may be amended, modified or supplemented from time to time in accordance therewith, prior to the Effective Time, providing for, among other things, the Arrangement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Transactions</B>&#148; means, collectively, the transactions contemplated by the Plan of Arrangement, the Support Agreement, the Trust Agreement, and
each other agreement, document, instrument or certificate that is necessary, desirable or useful (as determined by Zymeworks or Parent) to give effect to the Arrangement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Agreement</B>&#148; means the voting and exchange trust agreement to be entered into among Parent, Callco, ExchangeCo and the Share Trustee (as
defined therein), substantially in the form attached as Exhibit D to the Transaction Agreement, which is set forth in Appendix B to the Proxy Statement/Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S</B>.&#148; or &#147;<B>United States</B>&#148; means the United States of America; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Exchange Act</B>&#148; means the U.S. Securities Exchange Act of 1934 and, as applicable, the rules and regulations promulgated thereunder, in
each case, as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. GAAP</B>&#148; means accounting principles generally accepted in the United States; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. holders</B>&#148; has the meaning given to that term in &#147;<I>Material U.S. Federal Income
Tax Considerations</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Securities Act</B>&#148; means the U.S. Securities Act of 1933 and, as applicable, the rules and regulations
promulgated thereunder, in each case, as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ZBI</B>&#148; means Zymeworks Biopharmaceuticals Inc., a corporation incorporated under the
laws of the State of Washington; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;ZBI Stock&#148;</B> means the issued and outstand shares in the capital stock of ZBI; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B>&#148; means Zymeworks Inc. a company continued under the BCBCA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Board</B>&#148; means the board of directors of Zymeworks; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B> <B>Common Shares</B>&#148; means the common shares of Zymeworks; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B> <B>Incentive Awardholders</B>&#148; means, collectively, the holders of Zymeworks Incentive Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B> <B>Incentive Awards</B>&#148; means, collectively, the stock options (together with any associated tandem stock appreciation rights),
stock appreciation rights, performance share units, restricted share units, deferred share units, restricted stock and other share-based awards granted by Zymeworks prior to the Effective Date pursuant to the Zymeworks Incentive Plans, and
&#147;<B>Zymeworks</B> <B>Incentive Award</B>&#148; means any one of them, as applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B> <B>Incentive Plans</B>&#148; means,
collectively, (i)&nbsp;the Second Amended and Restated Employee Stock Option Plan, (ii)&nbsp;the Amended and Restated Stock Option and Equity Compensation Plan, (iii)&nbsp;the Amended and Restated Employee Stock Purchase Plan and
(iv)&nbsp;Inducement Stock Option and Equity Compensation Plan, in each case including any schedules or appendices thereto, as amended from time to time, and &#147;<B>Zymeworks</B> <B>Incentive Plan</B>&#148; means any one of them, as applicable;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Rights Agreement</B>&#148; has the meaning ascribed thereto under &#147;<I>Information Concerning Parent, ExchangeCo and Callco &#150;
Material Contracts</I>&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Securities</B>&#148; means, collectively, the Zymeworks Common Shares, Zymeworks Warrants and Zymeworks
Incentive Awards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Securityholders</B>&#148; means, collectively, the Zymeworks Shareholders, Zymeworks Warrantholders and the
Zymeworks Incentive Awardholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Shareholders</B>&#148; means (i)&nbsp;prior to the exchange of Zymeworks Common Shares for shares of
Delaware Common Stock and/or Exchangeable Shares pursuant to the Arrangement, the holders of the Zymeworks Common Shares, and (ii)&nbsp;after the exchange of Zymeworks Common Shares for shares of Delaware Common Stock and/or Exchangeable Shares
pursuant to the Arrangement, the holders of the shares of Delaware Common Stock or Exchangeable Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Warrants</B>&#148; means the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Common Shares of Zymeworks; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Warrantholders</B>&#148; means the
holders of Zymeworks Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_24"></A>APPENDIX A: REDOMICILE RESOLUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLVED THAT: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arrangement (the &#147;<B>Arrangement</B>&#148;) under Division 5 of Part 9 of the <I>Business Corporations
Act</I> (British Columbia) (the &#147;<B>BCBCA</B>&#148;) involving Zymeworks Inc. (the &#147;<B>Company</B>&#148;), pursuant to the Transaction Agreement dated July 14, 2022 among Zymeworks Delaware Inc. (&#147;<B>Parent</B>&#148;), Zymeworks
Callco ULC (&#147;<B>Callco</B>&#148;), Zymeworks ExchangeCo Ltd. (&#147;<B>ExchangeCo</B>&#148;) and the Company, as amended, supplemented or otherwise modified from time to time in accordance with its terms (the &#147;<B>Transaction
Agreement</B>&#148;), and as more particularly described and set forth in the accompanying proxy statement/prospectus of the Company (the &#147;<B>Proxy Statement/Prospectus</B>&#148;), and all transactions contemplated under the Arrangement
(collectively, the &#147;<B>Redomicile Transactions</B>&#148;), are hereby authorized, approved and adopted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The plan of arrangement involving the Company, as it has been or may be amended, modified or supplemented in
accordance with the terms of the Transaction Agreement (the &#147;<B>Plan of Arrangement</B>&#148;), the full text of which is attached as Exhibit A to the Transaction Agreement, which Transaction Agreement is attached as Appendix B to the Proxy
Statement/Prospectus, is hereby authorized, approved and adopted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Transaction Agreement and all transactions contemplated therein, including the actions of the officers and
directors of the Company in approving the Redomicile Transactions and in executing and delivering the Transaction Agreement and any modifications, supplements or amendments thereto, and causing the performance by the Company of its obligations
thereunder, are hereby ratified and approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is hereby authorized to apply for a final order from the Supreme Court of British Columbia (the
&#147;<B>Court</B>&#148;) to approve the Arrangement in accordance with and subject to the terms and conditions set forth in the Transaction Agreement and the Plan of Arrangement, as they may be, or may have been, modified, supplemented or amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding that this resolution has been passed (and the Arrangement adopted) by the Zymeworks
Securityholders (as defined in the Proxy Statement/Prospectus) or that the Arrangement has been approved by the Court, the directors of the Company are hereby authorized and empowered without further notice to, or approval of, the Zymeworks
Securityholders (i)&nbsp;to amend, modify or supplement the Transaction Agreement, or the Plan of Arrangement to the extent permitted by the Transaction Agreement, and (ii)&nbsp;subject to the terms of the Transaction Agreement, to terminate the
Transaction Agreement and not proceed with the Arrangement and any related transactions, at any time prior to the Effective Time (as defined in the Transaction Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any officer or director of the Company is hereby authorized and directed for and on behalf of the Company to
execute or cause to be executed and to deliver or cause to be delivered, all such other documents and instruments and to perform or cause to be performed all such other acts and things as in such person&#146;s opinion may be necessary or desirable
to give full effect to the foregoing resolutions and the matters authorized thereby, such determination to be conclusively evidenced by the execution and delivery of such document, agreement or instrument or the doing of any such act or thing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any and all acts performed prior to the date of these resolutions by any director or officer of the Company,
acting for and on behalf of the Company, that are within the authority conferred by the foregoing resolutions are hereby ratified, confirmed, approved, satisfied and adopted in all respects as the authorized acts and deeds of the Company.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="rom722206_25"></A><A NAME="tx722206_123"></A>TRANSACTION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY AND AMONG </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS
DELAWARE INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS CALLCO ULC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS EXCHANGECO LTD. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC.
</B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED AS OF July&nbsp;14, 2022 </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_1">ARTICLE 1 INTERPRETATION </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_2">Defined Terms</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_3">Headings and References</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_4">Time Periods</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_5">Currency</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_6">Time</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">B-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_7">Construction</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_8">Governing Law</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_9">ARTICLE 2 THE ARRANGEMENT </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_10">The Arrangement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_11">The Interim Order</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_12">U.S. Securities Laws Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_13">The Special Meeting</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_14">Information Circular</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_15">Final Order</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_16">Court Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_17">Zymeworks Incentive Awards&nbsp;&amp; Warrants</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_18">Payment of Consideration</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_19">Withholding Taxes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_20">ARTICLE 3 POST-ARRANGEMENT MATTERS </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_21">NYSE Listing</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_22">Post-Arrangement Transactions</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_23">ARTICLE 4 REPRESENTATIONS AND WARRANTIES
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_24">Organization and Qualification</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_25">Authority</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_26">No Violations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_27">ARTICLE 5 COVENANTS </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_28">U.S. Tax Treatment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_29">Section&nbsp;85 Elections</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_30">Preparation of Registration Statement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_31">Transaction Documents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_32">Post-Arrangement Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_33">ARTICLE 6 CONDITIONS TO CONSUMMATION OF THE REDOMICILE TRANSACTIONS
 </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_34">Conditions to the Obligations of the Parties </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_35">ARTICLE 7 TERMINATION </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_36">Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_37">Effect of Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx122722206_38">ARTICLE 8 MISCELLANEOUS </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>B-16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_39">Entire Agreement&nbsp;&amp; Assignment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_40">Amendment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_41">Notices</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_42">Severability</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx122722206_43">Counterparts&nbsp;&amp; Electronic Signatures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Plan of Arrangement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Redomicile Resolution</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Support Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Voting and Exchange Trust Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exchangeable Share Provisions</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSACTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS</B> <B>TRANSACTION AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;), dated as of July&nbsp;14, 2022, is made by and among <B>ZYMEWORKS DELAWARE
INC.</B>, a Delaware corporation (&#147;<B>Parent</B>&#148;), <B>ZYMEWORKS CALLCO ULC</B>, a British Columbia unlimited liability company and a direct, wholly-owned subsidiary of Parent (&#147;<B>CallCo</B>&#148;), <B>ZYMEWORKS EXCHANGECO LTD.</B>,
a British Columbia corporation and a direct, wholly-owned subsidiary of CallCo (&#147;<B>ExchangeCo</B>&#148;), and <B>ZYMEWORKS INC.</B>, a British Columbia company (&#147;<B>Zymeworks</B>&#148;). Parent, CallCo, ExchangeCo and Zymeworks are
referred to collectively as the &#147;<B>Parties</B>&#148; and each as a &#147;<B>Party</B>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BACKGROUND: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Parent is a wholly-owned subsidiary of Zymeworks and was incorporated as a Delaware corporation on June&nbsp;30, 2022 for the purpose
of consummating the transactions contemplated by this Agreement and the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;The Parties intend that, pursuant
to the Plan of Arrangement under Division 5 of Part 9 of the BCBCA, and among other things, Parent shall acquire the Zymeworks Common Shares either directly, or indirectly through ExchangeCo, as more particularly described in this Agreement and in
the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;The board of directors of Zymeworks has (i)&nbsp;determined that the Plan of Arrangement is in the
best interests of Zymeworks, (ii)&nbsp;approved the entering into of this Agreement and the Transaction Documents to which Zymeworks is a party, the performance of Zymeworks&#146; obligations under this Agreement and such Transaction Documents, the
consummation of the Redomicile Transactions contemplated by this Agreement and the Transaction Documents, and the completion of the Post-Arrangement Matters as contemplated by this Agreement, and (iii)&nbsp;resolved to recommend the approval of the
Plan of Arrangement to the Zymeworks Securityholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth in this Agreement,
Zymeworks wishes to submit the Redomicile Resolution to the Zymeworks Securityholders for approval at the Special Meeting and to submit the Plan of Arrangement to the Court for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E.&nbsp;&nbsp;&nbsp;&nbsp;The directors of each of Parent, CallCo and ExchangeCo have approved the entering into of this Agreement and the Transaction
Documents to which they are a party, respectively, and the performance of their respective obligations under this Agreement and such Transaction Documents, the consummation of the Redomicile Transactions contemplated by this Agreement and the
Transaction Documents, and the completion of the Post-Arrangement Matters to which they are a party as contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F.&nbsp;&nbsp;&nbsp;&nbsp;Each of the Parties intends for Canadian Tax purposes that the Canadian Share Exchange will occur on an income tax deferred basis
(or partially income tax deferred basis) for certain Eligible Holders under subsection 85(1) or (2)&nbsp;of the Tax Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">G.&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Parties intends for U.S. federal income tax purposes that the Parent Share Exchange and, if applicable, the Canadian Share Exchange and assumption of Zymeworks Warrants, viewed together, constitute an exchange governed by Section&nbsp;351 of
the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN CONSIDERATION of the premises and the mutual promises set forth in this Agreement and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_1"></A>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERPRETATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_2"></A><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Defined Terms</B>. In this Agreement, the following terms will have the meanings set forth
below, and any terms defined elsewhere in this Agreement will have the meanings so given to them. A derivative of a defined term will have a corresponding meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with, such Person. For purposes of this definition, the term &#147;<B>control</B>&#148; (including the correlative terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under</B> <B>common control
with</B>&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. For purposes of
this Agreement, with respect to Zymeworks, Parent, ExchangeCo or CallCo, &#147;Affiliate&#148; does not include any stockholders of Parent (other than Zymeworks), or any directors or executive officers of Zymeworks, Parent, ExchangeCo or CallCo.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning set forth in the introductory paragraph on the first page hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement</B>&#148; means an arrangement under Part 9, Division 5 of the BCBCA on the terms and subject to the conditions set forth in the Plan of
Arrangement, subject to any amendments or variations to the Plan of Arrangement made in accordance with the terms of this Agreement and the Plan of Arrangement, or made at the direction of the Court in accordance with the Final Order with the prior
written consent of Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement Effective Time</B>&#148; means the time at which the Arrangement becomes effective on the Effective
Date, as determined by Zymeworks in writing under Section&nbsp;2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>BCBCA</B>&#148; means the <I>Business Corporations Act </I>(British
Columbia) and the regulations made thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Broker</B>&#148; has the meaning set forth in Section&nbsp;2.10(c)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day on which banks are generally open for the transaction of commercial business in Vancouver, British Columbia, and
New York, New York, but does not in any event include a Saturday or Sunday or statutory holiday in Vancouver, British Columbia, or New York, New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CallCo</B>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Canadian Share Exchange</B>&#148; means the exchange of Zymeworks Common Shares for Exchangeable Shares, or for a combination of Exchangeable Shares
and Delaware Common Stock, in accordance with the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Consideration</B>&#148; means (i)&nbsp;in the case of a Zymeworks Shareholder who is an Eligible Holder and who validly elects to receive
Exchangeable Shares prior to the Election Deadline (as defined in the Plan of Arrangement) in accordance with the Plan of Arrangement, for each Designated Zymeworks Common Share, one Exchangeable Share together with the Contractual Rights, and for
each other Zymeworks Common Share (to the extent applicable), one share of Delaware Common Stock, and (ii)&nbsp;in the case of each other Zymeworks Shareholder who does not exercise the Dissent Rights, for each Zymeworks Common Share, one share of
Delaware Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Consideration Shares</B>&#148; means Delaware Common Stock and Exchangeable Shares, as the context
may require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Contractual Rights</B>&#148; means the benefit of the Support Agreement and the Voting and Exchange Trust Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Court</B>&#148; means the Supreme Court of British Columbia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Delaware Common Stock</B>&#148; means the shares of Parent&#146;s common stock, par value $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Depositary</B>&#148; means a bank or trust company selected by Zymeworks to perform the duties described in a depositary agreement in form and
substance reasonably acceptable to the parties thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Designated Zymeworks Common Shares</B>&#148; means the Zymeworks Common Shares of an
Eligible Holder that are designated by the Eligible Holder under a Letter of Transmittal and Election Form to be exchanged for Exchangeable Shares, as such number of Zymeworks Common Shares may be reduced as a result of the Exchangeable Share Cap,
and &#147;<B>Designated Zymeworks Common Share</B>&#148; means any one of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissent Rights</B>&#148; means the rights of dissent in respect
of the Arrangement described in Section&nbsp;5.1 of the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; has the meaning set forth in
Section&nbsp;2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Eligible Holder</B>&#148; means a Zymeworks Shareholder that is (i)&nbsp;a resident of Canada for purposes of the Tax Act and
not exempt from tax under Part I of the Tax Act, or (ii)&nbsp;a partnership, each member of which is a resident of Canada for purposes of the Tax Act and not exempt from tax under Part I of the Tax Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the <I>Securities Exchange Act of 1934</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Cap</B>&#148; means, in respect of the number of Zymeworks Common Shares exchangeable for Exchangeable Shares under the Canadian
Share Exchange, such number of Zymeworks Common Shares that is equal to 18% of (i)&nbsp;the number of Zymeworks Common Shares issued and outstanding immediately prior to the Arrangement Effective Time, less (ii)&nbsp;the number of Zymeworks Common
Shares held by any Zymeworks Shareholders who exercise their Dissent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Provisions</B>&#148; means the rights,
privileges, restrictions and conditions attaching to the Exchangeable Shares, substantially in the form attached as Exhibit E. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable
Shares</B>&#148; means the exchangeable shares in the capital of ExchangeCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ExchangeCo</B>&#148; has the meaning set forth in the introductory
paragraph to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Order</B>&#148; means the final order of the Court pursuant to Section&nbsp;291 of the BCBCA approving the
Arrangement, in a form acceptable to Zymeworks, as such order may be amended by the Court at any time prior to the Arrangement Effective Time, provided that any such amendment is acceptable to Zymeworks, or if appealed, then, unless such appeal is
withdrawn, abandoned or denied, as affirmed or as amended, on appeal, provided that any such amendment is acceptable to Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Governing
Documents</B>&#148; means the legal documents by which any Person (other than an individual) establishes its legal existence or which govern its internal affairs, and in the case of a U.S. corporation consists of its certificate or articles of
incorporation and its <FONT STYLE="white-space:nowrap">by-laws,</FONT> and in the case of a British Columbia company consist of its notice of articles and articles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Entity</B>&#148; means any United States, Canadian, international or other
(i)&nbsp;federal, state, provincial, local, municipal or other government entity, (ii)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other
tribunal) or (iii)&nbsp;body exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitrator or arbitral tribunal (public or private).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Information Circular</B>&#148; means the notice of the Special Meeting to be sent to the Zymeworks Securityholders, and the accompanying proxy
statement/prospectus to be prepared in connection with the Special Meeting, together with any amendments thereto or supplements thereof in accordance with the terms of this Agreement, and substantially in the form included in the Registration
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Irish Sub Stock</B>&#148; means the issued and outstanding shares of Zymeworks Pharmaceuticals Limited., a corporation incorporated
under the laws of Ireland, consisting of 100 ordinary shares, par value EUR 1.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Intended U.S. Tax Treatment</B>&#148; has the
meaning set forth in Section&nbsp;5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Interim Order</B>&#148; means the interim order of the Court contemplated by Section&nbsp;2.2 of this
Agreement and made pursuant to Section&nbsp;291 of the BCBCA, in a form acceptable to Zymeworks providing for, among other things, the calling and holding of the Special Meeting, as the same may be amended by the Court, provided that any such
amendment is acceptable to Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means any federal, state, local, provincial, foreign, national or supranational statute, law
(including common law), act, statute, ordinance, treaty, rule, code, regulation or other binding directive or guidance issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Letter of Transmittal and Election Form</B>&#148; has the meaning given to it in the Plan of Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; includes any mortgage, pledge, assignment, charge, lien, security interest, adverse interest in property, license or <FONT
STYLE="white-space:nowrap">sub-license,</FONT> charge, or other third-party interest or encumbrance of any kind (including, in the case of any equity securities, any voting, transfer or similar restrictions) whether contingent or absolute, and any
agreement, option, right or privilege (whether by law, contract or otherwise) capable of becoming any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>New Common
Shares</B>&#148; has the meaning set forth in Section&nbsp;3.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>NYSE</B>&#148; means the New York Stock Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Order</B>&#148; means any writ, order, judgment, injunction, decision, determination, award, ruling, subpoena, verdict or decree entered, issued or
rendered by any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Withholding Agent</B>&#148; has the meaning set forth in Section&nbsp;2.10(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent</B>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Share Exchange</B>&#148; means the exchange of Zymeworks Common Shares for Delaware Common Stock in accordance with the Plan of Arrangement,
but excluding any such exchange under the Canadian Share Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Party</B>&#148; and &#147;<B>Parties</B>&#148; each have the meaning set
forth in the introductory paragraph to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; includes an individual, partnership, corporation, limited liability
company, joint stock company, unincorporated organization or association, trust, joint venture, trustee, executor, administrator, legal representative, government or any other entity, whether or not a legal entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Plan of Arrangement</B>&#148; means the Plan of Arrangement in substantially the form attached as
Exhibit A with such changes as may be agreed to by Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Post-Arrangement Matters</B>&#148; means those matters to be completed or
otherwise consummated following the implementation of the Arrangement, as more particularly described in Article 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redomicile
Resolution</B>&#148; means a special resolution of the Zymeworks Securityholders in respect of the Arrangement to be considered at the Special Meeting, in substantially the form attached to this Agreement as Exhibit B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redomicile Transactions</B>&#148; means the transactions contemplated by the Plan of Arrangement, the Transaction Documents and this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Statement</B>&#148; means a registration statement of Parent on Form <FONT STYLE="white-space:nowrap">S-4</FONT> relating to the
Redomicile Transactions and containing a prospectus for the Delaware Common Stock, among other things. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Required Approval</B>&#148; has the
meaning set forth in Section&nbsp;2.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Request</B>&#148; has the meaning set forth in the Exchangeable Share Provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Laws</B>&#148; means the Exchange Act, the U.S. Securities Act and the other U.S. federal securities laws and the rules and regulations of
the SEC promulgated thereunder or otherwise, and any other applicable foreign and domestic securities or similar Laws (including the applicable Canadian provincial and territorial securities laws). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Special Meeting</B>&#148; means the meeting of the Zymeworks Securityholders, including any adjournment or postponement thereof in accordance with
the terms of this Agreement, that is to be convened as provided by the Interim Order to consider, and if deemed advisable approve, the Redomicile Resolution, and such other matters as are properly brought before the Zymeworks Shareholders at such
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Support Agreement</B>&#148; means the support agreement to be entered into among Parent, CallCo and ExchangeCo, substantially in the
form of Exhibit C, as it may be amended, supplemented or otherwise modified from time to time in accordance with its terms, and to be entered into at or prior to the issuance by ExchangeCo of any Exchangeable Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; means any and all national, supranational, multinational, federal, provincial, territorial, state, regional, local or municipal taxes,
including income, branch, profits, capital gains, gross receipts, windfall profits, value added, severance, ad valorem, property, capital, estimated, utility, recapture, net worth, production, sales, use, license, excise, franchise, environmental,
transfer, land transfer, withholding or similar, payroll, employment, employer health, government pension plan premiums and contributions, social security premiums, workers&#146; compensation premiums, employment/unemployment insurance or
compensation premiums or contributions, disability, documentary, registration, stamp, occupation, premium, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum, goods and services, harmonized sales, customs duties or other taxes,
levies, premiums, excises, fees, assessments, imposts, duties, and other similar charges of any kind whatsoever imposed, assessed, charged or collected by a Governmental Entity and any installments in respect thereof, including any interest, fines,
assessments, reassessments, penalties or additions to tax imposed in connection therewith or with respect thereto, and any interest in respect of such additions or penalties, and whether disputed or not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Act</B>&#148; means the <I>Income Tax Act</I> (Canada) and the regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Documents</B>&#148; means the Support Agreement, the Voting and Exchange Trust
Agreement, and each other agreement, document, instrument or certificate that is necessary, desirable or useful (as determined by Zymeworks or Parent) to give effect to the Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;U.S. Securities Act</B>&#148; means the <I>U.S. Securities Act of 1933</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Voting and Exchange Trust Agreement</B>&#148; means the voting and exchange trust agreement to be entered into among Parent, CallCo, ExchangeCo and
the Share Trustee (as defined therein) in connection with the Plan of Arrangement substantially in the form of Exhibit D, as it may be amended, supplemented or otherwise modified from time to time in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Withholding Shortfall</B>&#148; has the meaning set forth in Section&nbsp;2.10(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ZBI Stock</B>&#148; means the issued and outstanding shares of Zymeworks Biopharmaceuticals Inc., a corporation incorporated under the laws of the
State of Washington, consisting of 10,000 shares of Common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B>&#148; has the meaning set forth in the introductory paragraph to
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Common Shares</B>&#148; means the common shares in the capital of Zymeworks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Incentive Awards</B>&#148; means the stock options, incentive stock options, restricted stock units and all other awards and rights to
purchase Zymeworks Common Shares granted under the Zymeworks Incentive Plans that are outstanding and unexercised, whether vested or unvested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Incentive Plans</B>&#148; means collectively (i)&nbsp;the Amended and Restated Stock Option and Equity Compensation Plan of Zymeworks,
(ii)&nbsp;the Amended and Restated Employee Stock Purchase Plan of Zymeworks, (iii)&nbsp;the Inducement Stock Option and Equity Compensation Plan of Zymeworks, and (iv)&nbsp;the Second Amended and Restated Employee Stock Option Plan of Zymeworks, in
each case including any schedules or appendices thereto, as amended from time to time, and &#147;<B>Zymeworks Incentive Plan</B>&#148; means any one of them, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Securityholders</B>&#148; means holders of Zymeworks Common Shares, Zymeworks Incentive Awards and Zymeworks Warrants as at the relevant
time in question. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Shareholders</B>&#148; means, collectively, the holders of Zymeworks Common Shares immediately prior to the
Arrangement Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Warrants</B>&#148; means, as of any determination time, each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to purchase Zymeworks Common Shares that is outstanding and unexercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_3">
</A><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Headings and References</B>. The division of this Agreement into Articles and Sections and the insertion of headings are for convenience of reference only and do not affect the construction or interpretation
of this Agreement. Unless otherwise specified, references to Articles and Sections are to Articles and Sections of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_4">
</A><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Time Periods</B>. Unless otherwise specified, time periods within, or following, which any payment is to be made, or act is to be done, shall be calculated by excluding the day on which the period commences
and including the day on which the period ends and by extending the period to the next Business Day following if the last day of the period is not a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_5"></A><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Currency</B>. All sums of money which are referred to in this Agreement are expressed in the
lawful currency of the United States unless otherwise specified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_6"></A><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Time</B>. Unless otherwise indicated, all
times expressed in this Agreement are to local time, Vancouver, British Columbia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_7"></A><B>1.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Construction</B>. In this Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless the context otherwise requires, words importing the singular include the plural and vice versa and words
denoting any gender include all genders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;including&#148; or &#147;includes&#148; shall mean &#147;including (or includes) without
limitation&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reference to a statute includes all rules and regulations made pursuant to such statute and, unless otherwise
specified, the provisions of any statute or regulation or rule which amends, supplements or supersedes any such statute or any such regulation or rule. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_8"></A><B>1.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law</B>. This Agreement shall be governed by and construed in accordance with the
Laws of the Province of British Columbia and other federal Laws of Canada applicable in British Columbia without giving effect to any choice of law or conflict of law provision or rule (whether of the Province of British Columbia or any other
jurisdiction) that would cause the application of the law of any jurisdiction other than the Province of British Columbia. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_9">
</A>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE ARRANGEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_10">
</A><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>The Arrangement</B>. The Parties shall proceed to effect and implement the Arrangement under Part 9, Division 5 of the BCBCA as soon as practicable following the approval of the Final Order by the Court in
respect of the Arrangement, on such date and at such time as may be determined by Zymeworks in writing (the &#147;<B>Effective Date</B>&#148;), in accordance with the terms of, and subject to the conditions contained in, this Agreement and the Plan
of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_11"></A><B>2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>The Interim Order</B>. As soon as reasonably practicable after the
Registration Statement is declared effective by the SEC, Zymeworks shall apply under Part 9, Division 5 of the BCBCA and shall prepare, file and pursue an application to the Court for the Interim Order in respect of the Arrangement, which shall
provide, among other things, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the classes of Persons to whom notice is to be provided in respect of the Arrangement and the Special
Meeting, and for the manner in which such notice is to be provided; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the required level of approval for the Redomicile Resolution shall be by: (i)&nbsp;the Zymeworks
Shareholders by way of a special resolution passed by the Zymeworks Shareholders representing at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by the Zymeworks Shareholders, in person or by proxy, at the Special Meeting,
and (ii)&nbsp;the Zymeworks Securityholders, voting together as a single class, by way of special resolution passed by the Zymeworks Securityholders representing at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by
Zymeworks Securityholders, in person or by proxy, at the Special Meeting (collectively, the &#147;<B>Required Approval</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Special Meeting may be adjourned or postponed from time to time by Zymeworks without the need for
additional approval of the Court; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, in all other respects, other than as ordered by the Court, the terms, restrictions and conditions of the
Governing Documents of Zymeworks, including quorum requirements and all other matters, shall apply in respect of the Special Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">confirmation of the record date for the purposes of determining the Zymeworks Securityholders entitled to
receive material and vote at the Special Meeting in accordance with the Interim Order; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the record date for the Zymeworks Securityholders entitled to notice of and to vote at the Special Meeting
will not change in respect of any adjournments or postponements of the Special Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the grant of the Dissent Rights to Zymeworks Shareholders as contemplated by the Plan of Arrangement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that it is the intention of the Parent and ExchangeCo to rely upon Section&nbsp;3(a)(10) of the U.S. Securities
Act in connection with the issuance of Exchangeable Shares in accordance with the Arrangement, based on the Court&#146;s approval of the Arrangement, which approval through the issuance of the Final Order will constitute its determination of the
fairness of the Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the aggregate Designated Zymeworks Common Shares specified by Eligible Holders under the Letter of
Transmittal and Election Forms for purposes of the Canadian Share Exchange shall be no greater than the Exchangeable Share Cap, allocated proportionately among Eligible Holders participating in the Canadian Share Exchange in accordance with the
number of Designated Zymeworks Common Shares that they wish to designate, and in respect of each such Eligible Holder, rounded down to the nearest whole share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the notice requirements regarding the presentation of the application to the Court for the Final Order; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for such other matters as Zymeworks may agree are reasonably necessary to complete the Redomicile Transactions.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_12"></A><B>2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>U.S. Securities Laws Matters</B>. The Parties agree that the
Arrangement will be carried out with the intention, and the Parties will use reasonable efforts to ensure, that all Exchangeable Shares issued under the Arrangement will be issued in reliance on the exemption from the registration requirements of
the U.S. Securities Act provided by Section&nbsp;3(a)(10) thereunder. In order to ensure the availability of the exemption under Section&nbsp;3(a)(10) of the U.S. Securities Act and to facilitate Parent&#146;s compliance with other Securities Laws,
the parties agree that the Arrangement will be carried out on the following basis: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Court will be asked to approve the procedural and substantive fairness of the terms and conditions of the
Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with Section&nbsp;2.2(h), prior to the issuance of the Interim Order, the Court will be advised
of the intention of Parent and ExchangeCo to rely on the exemption provided by Section&nbsp;3(a)(10) of the U.S. Securities Act with respect to the issuance of the Exchangeable Shares pursuant to the Arrangement, based on the Court&#146;s approval
of the Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prior to the issuance of the Interim Order, Zymeworks will file with the Court a draft copy of the proposed
text of the Information Circular together with any other documents required by Law in connection with the Special Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Court will be advised prior to the hearing of the Court to give approval of the Arrangement that its
approval of the Arrangement will be relied upon as a determination that the Court has satisfied itself as to the procedural and substantive fairness of the terms and conditions of the Arrangement to all Persons who are entitled to receive
Exchangeable Shares pursuant to the Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks will ensure that each Zymeworks Shareholder and other Person entitled to receive Exchangeable Shares
pursuant to the Arrangement will be given adequate and appropriate notice advising them of their right to attend the hearing of the Court to approve the procedural and substantive fairness of the terms and conditions of the Arrangement and providing
them with sufficient information necessary for them to exercise that right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Final Order will expressly state that the Arrangement is approved by the Court as being procedurally and
substantively fair to all Persons entitled to receive Exchangeable Shares pursuant to the Arrangement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Interim Order will specify that each Person entitled to receive Exchangeable Shares pursuant to the
Arrangement will have the right to appear before the Court at the hearing of the Court to give approval of the Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Court will hold a hearing before approving the fairness of the terms and conditions of the Arrangement and
issuing the Final Order; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Person entitled to receive Exchangeable Shares will be advised that the Exchangeable Shares issued
pursuant to the Arrangement have not been registered under the U.S. Securities Act and will be issued in reliance on the exemption from registration under Section&nbsp;3(a)(10) of the U.S. Securities Act and such Exchangeable Shares will include any
appropriate legends. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_13"></A><B>2.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>The Special Meeting</B>. Subject to the terms of
this Agreement and the Interim Order, Zymeworks shall convene and conduct the Special Meeting in accordance with the Governing Documents of Zymeworks, applicable Law and the Interim Order as soon as reasonably practicable after the date of the
Interim Order to consider the Redomicile Resolution (and for any other proper purpose as may be set out in the notice for the Special Meeting, as determined by Zymeworks). Zymeworks shall use reasonable efforts to obtain the Required Approval in
respect of the Redomicile Resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_14"></A><B>2.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Information Circular</B>. Zymeworks shall prepare
and complete the Information Circular together with any other documents required by applicable Law in connection with the Special Meeting and the Arrangement and shall, as soon as practicable after obtaining the Interim Order, cause the Information
Circular and such other documents to be delivered to each Zymeworks Securityholder and any other Person as required by the Interim Order and applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_15"></A><B>2.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Final Order</B>. Zymeworks shall take all steps necessary or desirable to submit the
Arrangement to the Court and diligently pursue an application for the Final Order pursuant to Part 9, Division 5 of the BCBCA, as soon as reasonably practicable after the Required Approval is obtained for the Redomicile Resolution as provided for in
the Interim Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_16"></A><B>2.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Court Proceedings</B>. In connection with all Court proceedings
relating to obtaining the Interim Order and the Final Order, Zymeworks shall: (i)&nbsp;diligently pursue the Interim Order and the Final Order; (ii)&nbsp;ensure that all material filed with the Court in connection with the Arrangement is consistent
with this Agreement and the Plan of Arrangement; and (iii)&nbsp;subject to this Agreement, oppose any proposal from any Person that the Final Order contain any provision inconsistent with the Plan of Arrangement or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_17"></A><B>2.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Zymeworks Incentive Awards</B><B></B><B>&nbsp;&amp; Warrants</B>. The Parties acknowledge
that the outstanding Zymeworks Incentive Awards and Zymeworks Warrants shall be treated as provided under the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_18">
</A><B>2.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment of Consideration</B>. Prior to or concurrently with the Arrangement Effective Time, Parent and ExchangeCo, as applicable, shall deposit, or cause to be deposited, with the Depositary sufficient
Delaware Common Stock and Exchangeable Shares to satisfy the aggregate Consideration payable to the Zymeworks Shareholders pursuant to the terms of the Plan of Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_19"></A><B>2.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Withholding Taxes</B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of Parent, ExchangeCo, Zymeworks, the Depositary and any other Person that has any withholding obligation
with respect to any amount payable, deemed paid or consideration otherwise deliverable under this Agreement or the Arrangement to any Zymeworks Shareholder (any such other Person, an &#147;<B>Other Withholding Agent</B>&#148;), shall be entitled to
deduct and withhold, or direct Parent, ExchangeCo, Zymeworks, the Depositary or any Other Withholding Agent to deduct and withhold on their behalf, from any amount or consideration paid, deemed paid or otherwise deliverable to any Zymeworks
Shareholder (including those, if any, who exercise their Dissent Rights) such amounts as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
are required to be deducted or withheld with respect to such payment or deemed payment under the Tax Act, the Code or any other applicable Laws (including any provision of federal, provincial,
territorial, state, local, foreign or other Law relating to Taxes), in each case, as amended or succeeded. Parent, ExchangeCo, Zymeworks, the Depositary or any Other Withholding Agent may act and rely on the advice of counsel with respect to such
matters. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that amounts are so deducted or withheld, such deducted or withheld amounts shall be treated for
all purposes as having been paid to the Zymeworks Shareholder to whom such amounts would otherwise have been paid or deemed paid and such deducted or withheld amounts shall be timely remitted to the appropriate Governmental Entity as required by
applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that the amount so required to be deducted or withheld from any payment or deemed payment to a
Zymeworks Shareholder exceeds any cash otherwise payable to the Zymeworks Shareholder (such difference, a &#147;<B>Withholding Shortfall</B>&#148;), Parent, ExchangeCo, Zymeworks, the Depositary or any Other Withholding Agent are hereby authorized
to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) sell or otherwise dispose of, or direct Parent, ExchangeCo, Zymeworks, the Depositary or any Other
Withholding Agent to sell or otherwise dispose of, on their own account or through a broker (the &#147;<B>Broker</B>&#148;) and on behalf of the relevant Zymeworks Shareholder, or (B)&nbsp;require such Zymeworks Shareholder to irrevocably direct the
sale through a Broker and irrevocably direct the Broker pay the proceeds of such sale to Parent, ExchangeCo, Zymeworks, the Depositary or any Other Withholding Agent, as appropriate (and, in the absence of such irrevocable direction, the holder
shall be deemed to have provided such irrevocable direction), such portion of the amount or consideration as is necessary to provide sufficient funds (after deducting commissions payable to the Broker and other costs and expenses) to Parent,
ExchangeCo, Zymeworks, the Depositary or any Other Withholding Agent, as the case may be, to enable it to comply with such deduction or withholding requirement and Parent, ExchangeCo, Zymeworks, the Depositary or any Other Withholding Agent, as the
case may be, shall notify the Zymeworks Shareholder thereof and remit to such Zymeworks Shareholder any unapplied balance of the net proceeds of such sale, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of a Zymeworks Shareholder who is to receive Exchangeable Shares, require such Zymeworks
Shareholder to deliver a Retraction Request for a number of Exchangeable Shares that would entitle such Zymeworks Shareholder to net proceeds greater than or equal to the Withholding Shortfall and withhold the Withholding Shortfall from such net
proceeds and remit to such Zymeworks Shareholder any unapplied balance of the net proceeds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of Parent, ExchangeCo, Zymeworks, the Depositary, any Other Withholding Agent or Broker, as applicable,
shall act in a reasonable manner in respect of any withholding obligation; however, none of Parent, ExchangeCo, Zymeworks, the Depositary, any Other Withholding Agent or Broker, as applicable, will be liable for any loss arising out of any sale or
other disposal of such consideration, including any loss relating to the manner or timing of such sale or other disposal, the prices at which the consideration is sold or otherwise disposed of or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_20"></A>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POST-ARRANGEMENT MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_21">
</A><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>NYSE Listing</B>. Parent shall use reasonable efforts to cause the shares of Delaware Common Stock issuable under the Arrangement (including the Delaware Common Stock issuable pursuant to the exchange or
exercise of the Exchangeable Shares) to be listed on the NYSE under the symbol &#147;ZYME&#148; immediately prior to the Arrangement Effective Time, and in connection therewith, to satisfy any applicable initial and continuing listing requirements
of NYSE in respect of the Delaware Common Stock. Immediately following the completion of the Arrangement, Zymeworks will cause the Zymeworks Common Shares currently listed on the NYSE to cease to be traded on the NYSE and to be deregistered under
the U.S. Exchange Act, and for Canadian Tax purposes will immediately thereafter elect to be treated as a private corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_22"></A><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Post-Arrangement Transactions</B>. As soon
as practicable following the Arrangement Effective Time, the Parties shall use reasonable efforts, and shall take such corporate steps and actions, as may be necessary or desirable to effect and implement the following transactions in the order set
forth below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the authorized share structure of Zymeworks shall be reorganized to create an unlimited number of a new class
of Common shares without par value, having special rights and restrictions that are substantially similar to the Zymeworks Common Shares, and in such form and substance as may be as determined by Zymeworks (the &#147;<B>New Common Shares</B>&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ExchangeCo shall exchange all of the Zymeworks Common Shares then held by ExchangeCo for New Common Shares of
Zymeworks, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, pursuant to Section&nbsp;86 of the Tax Act, and in such form and substance as may be as determined by Zymeworks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks shall reduce the capital on the Zymeworks Common Shares (which will then be held solely by Parent),
by an amount equal to the fair market value of the ZBI Stock and the Irish Sub Stock, and in such manner and substance as Zymeworks may determine, and shall effect the same by way of a transfer of the ZBI Stock and the Irish Sub Stock from Zymeworks
to Parent free and clear of all Liens, in such form and substance as Zymeworks may determine; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks shall surrender for cancellation, free and clear of all Liens and without a return of capital, the
Delaware Common Stock held by Zymeworks. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_23"></A>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of
the Parties represents and warrants, for itself only, to the other Parties as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_24"></A><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Organization and Qualification</B>. The Party is a corporation, limited liability company or
other applicable business entity duly incorporated, organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of
good standing or any equivalent thereof) under the Laws of its jurisdiction of incorporation, organization or formation, has the requisite corporate, limited liability company or other applicable business entity power and authority to own, lease and
operate its properties, and to carry on its businesses as presently conducted, and is in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any
equivalent thereof) in each jurisdiction in which such property and assets owned, leased or operated by it, or the nature of the business conducted by it, makes such qualification or licensing necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_25"></A><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Authority</B>. The Party has the requisite corporate, limited liability company or other
applicable business entity power and authority to execute and deliver this Agreement and each Transaction Document to which it is (or will be) a party, to perform its obligations under this Agreement and, subject to obtaining the Interim Order,
Final Order and Required Approval, to consummate the Redomicile Transactions, and to complete or consummate the Post-Arrangement Matters to which it is a party. Subject to the receipt of the Interim Order, Final Order and Required Approval of the
Redomicile Resolution, the execution and delivery of this Agreement, the Transaction Documents to which the Party is (or will be) a party, and the consummation of the Redomicile Transactions and the Post-Arrangement Matters to which it is a party
have been duly authorized by all necessary corporate, limited liability company or other applicable business entity action on the part of the Party. This Agreement and each Transaction Document to which the Party is (or will be) a party has been (or
will be) duly and validly executed and delivered by that Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_26"></A><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Violations</B>. None
of the execution or delivery by the Party of this Agreement or any Transaction Documents to which it is (or will be) a party, the performance by the Party of its obligations under this Agreement or such Transaction Documents, or the consummation of
the Redomicile Transactions and the Post-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Arrangement Matters to which it is a party will, directly or indirectly (with or without due notice or lapse of time or both)&nbsp;(i) result in a breach of any provision of the Party&#146;s
Governing Documents, (ii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to which the Party or any of its properties or assets are bound or (iii)&nbsp;result in the creation of any Lien upon any of the assets or properties
of the Party. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_27"></A>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_28"></A><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>U.S. Tax Treatment</B>. The Parties intend that, for U.S. federal income tax purposes, the
Parent Share Exchange and, if applicable, the Canadian Share Exchange and assumption of Zymeworks Warrants, viewed together, will constitute an exchange governed by Section&nbsp;351 of the Code (the &#147;<B>Intended U.S. Tax Treatment</B>&#148;).
Alternatively, the Parent Share Exchange and, if applicable, the Canadian Share Exchange and assumption of Zymeworks Warrants, viewed together, are intended to constitute a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the
Code, and the Parties are hereby adopting this Agreement as a &#147;plan of reorganization&#148; for purposes of Section&nbsp;368 of the Code and U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-2(g).</FONT> No Party
will intentionally do any act or thing that could reasonably be expected to prevent the relevant Redomicile Transactions from qualifying for the Intended U.S. Tax Treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_29"></A><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Section 85 Elections</B>. Each beneficial owner of Zymeworks Common Shares who is an
Eligible Holder and who has validly elected (or for whom the registered holder has validly elected on such beneficial owner&#146;s behalf) to receive Exchangeable Shares shall be entitled to make an income tax election pursuant to subsection 85(1)
of the Tax Act, or subsection 85(2) of the Tax Act if such beneficial owner is a partnership (and in each case, where applicable, the analogous provisions of provincial income tax Law), with respect to the transfer of its Zymeworks Common Shares to
ExchangeCo and the receipt of Exchangeable Shares (or Exchangeable Shares and Delaware Common Stock, as applicable) in respect thereof, subject to and in accordance with the Plan of Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_30"></A><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Preparation of Registration Statement</B>. As soon as reasonably practicable following the
date of this Agreement, Parent and Zymeworks shall prepare and mutually agree upon, and Parent shall file with the SEC the Registration Statement. Each of Parent and Zymeworks shall use reasonable efforts to (i)&nbsp;cause the Registration Statement
to comply in all material respects with the applicable rules and regulations promulgated by the SEC; (ii)&nbsp;have the Registration Statement declared effective under the U.S. Securities Act as soon as reasonably practicable after it is filed with
the SEC; and (iii)&nbsp;keep the Registration Statement effective through the Arrangement Effective Time in order to permit the consummation of the Redomicile Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_31"></A><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Transaction Documents</B>. The Parties shall, at or before the Arrangement Effective Time,
execute and deliver the Transaction Documents to which they are a party, and take such other actions as are necessary to give effect to the Arrangement and the Redomicile Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_32"></A><B>5.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Post-Arrangement Matters</B>. Following the completion of the Arrangement, the Parties shall
execute and deliver such agreements, instruments, certificates and other documents, and take such other actions and do all such other things as are necessary, desirable or useful to complete, implement and give effect to the Post-Arrangement Matters
referred to in Article 3. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_33"></A>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO CONSUMMATION OF THE REDOMICILE TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_34"></A><B>6.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Conditions to the Obligations of the Parties</B>. The obligations of the Parties to
consummate the Redomicile Transactions under this Agreement are subject to the satisfaction of, or if permitted by applicable Law waiver by, Zymeworks of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Redomicile Resolution shall have been approved by the Required Approval at the Special Meeting in
accordance with the Interim Order; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Interim Order and the Final Order shall have been obtained on terms substantially consistent with this
Agreement and shall not have been set aside or modified in a manner unacceptable to Zymeworks, on appeal or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no Order or Law issued by any court of competent jurisdiction or other Governmental Entity or other legal
restraint or prohibition preventing the consummation of the Redomicile Transactions shall be in effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks shall have obtained such other material consents as may be desirable or useful in connection with the
consummation of the Redomicile Transactions, as determined by Zymeworks in its sole discretion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement shall have become effective in accordance with the provisions of the U.S. Securities
Act, no stop order shall have been issued by the SEC and shall remain in effect with respect to the Registration Statement, and no proceeding seeking such a stop order shall have been threatened or initiated by the SEC and remain pending; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dissent Rights shall not have been exercised for more than 10% of the Zymeworks Common Shares, or such other
amount of Zymeworks Common Shares that, as determined by Zymeworks in its sole and unfettered discretion, it is no longer in the best interests of Zymeworks to proceed with the Redomicile Transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_35"></A>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_36"></A><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination</B>. This Agreement may be terminated and the Arrangement and the Redomicile
Transactions may be abandoned at any time prior to the Arrangement Effective Time upon written notice by Zymeworks to the other Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_37">
</A><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect of Termination</B>. In the event of the termination of this Agreement pursuant to Section&nbsp;7.1, this entire Agreement shall forthwith become void and of no effect, and there shall be no liability
or obligation on the part of any of the Parties in respect of this Agreement, or the termination of the Arrangement and the Redomicile Transactions. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122722206_38"></A>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_39"></A><B>8.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement</B><B></B><B>&nbsp;&amp; Assignment</B>. This Agreement (together with the
Transaction Documents, once executed and delivered) constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, among the Parties
with respect to the subject matter hereof. This Agreement may not be assigned by any Party without the prior written approval of the other Parties. Any attempted assignment of this Agreement not in accordance with the terms of this Section&nbsp;8.1
shall be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_40"></A><B>8.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendment</B>. This Agreement may be amended or modified only by a
written agreement executed and delivered by each of the Parties. This Agreement may not be modified or amended except as provided in the immediately preceding sentence and any purported amendment by any Party or Parties effected in a manner which
does not comply with this Section&nbsp;8.2 shall be of no effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_41"></A><B>8.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices</B>. All notices, requests,
claims, demands and other communications under this Agreement shall be in writing and shall be given (and shall be deemed to have been duly given) by delivery in person, by email or by courier to the other Parties as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Zymeworks, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">114 East 4th Avenue, Suite 800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vancouver, BC, V5T 1G4 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Legal Department </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Parent, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Middletown, DE 19709 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy
to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">114 East 4th Avenue, Suite 800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vancouver, BC, V5T 1G4 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Legal Department </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to ExchangeCo or CallCo, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">114 East 4th Avenue, Suite 800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vancouver, BC, V5T 1G4 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Legal Department </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the manner set
forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_42"></A><B>8.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability</B>. Whenever possible, each provision of this Agreement will
be interpreted in such a manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, all other provisions of this Agreement
shall remain in full force and effect so long as the economic or legal substance of the Redomicile Transactions is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision of this Agreement
is invalid, illegal or unenforceable under applicable Law, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the
Redomicile Transactions are consummated as originally contemplated to the greatest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="tx122722206_43"></A><B>8.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts</B><B></B><B>&nbsp;&amp; Electronic Signatures</B>. This Agreement may be
executed in counterparts, each of which will be deemed to be an original and all of which taken together will be deemed to constitute one and the same instrument. To evidence its execution of an original counterpart of this Agreement, a Party may
send a copy of its original signature on the execution page of this Agreement to the other Parties by electronic mail or fax and transmission by electronic mail or fax will constitute delivery of an executed copy of this Agreement to the receiving
Party. This Agreement will be valid, binding and enforceable against a Party only when one copy of it has been executed by an authorised individual on behalf of the Party by means of: (i) a
DocuSign<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or other electronic signature; (ii) an original, manual signature; or (iii)&nbsp;a faxed, scanned or photocopied manual signature, and (iv)&nbsp;each DocuSign<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or other electronic, faxed, scanned or photocopied manual signature shall for all purposes have the same validity, legal effect and admissibility in evidence as an original manual signature and
the Parties hereby waive any objection to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Transaction Agreement to be duly executed on
its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS DELAWARE INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS CALLCO ULC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Neil Josephson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kenneth Galbraith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Neil Josephson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kenneth Galbraith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Secretary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt"><B>ZYMEWORKS INC.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt"><B>ZYMEWORKS EXCHANGECO LTD.</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth Galbraith</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth Galbraith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kenneth Galbraith</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kenneth Galbraith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chair, President and Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx722206_141"></A>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PLAN OF ARRANGEMENT </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Under Section&nbsp;288 of the <I>Business Corporations Act </I>(British Columbia) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">concerning </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Zymeworks Inc.
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERPRETATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this Plan of Arrangement, the following terms have the respective meanings set forth below, and any derivatives of the following terms have
a corresponding meaning: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Affected Person</B>&#148; has the meaning set forth in Section&nbsp;4.5(a) (<I>Withholding Rights</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with, such Person. For purposes of this definition, the term &#147;<B>control</B>&#148; (including the correlative terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under</B> <B>common control
with</B>&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. For purposes of
this Plan of Arrangement, &#147;Affiliate&#148;, with respect to Zymeworks, Parent, ExchangeCo or CallCo, does not include any stockholders of Parent (other than Zymeworks), or any directors or executive officers of Zymeworks, Parent, ExchangeCo or
CallCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement</B>&#148; means an arrangement under Part 9, Division 5 of the BCBCA on the terms and subject to the conditions set forth in
this Plan of Arrangement, subject to any amendments or variations to this Plan of Arrangement made in accordance with the terms of the Transaction Agreement and this Plan of Arrangement, or made at the direction of the Court in accordance with the
Final Order with the prior written consent of Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement Effective Time</B>&#148; or &#147;<B>Effective Time</B>&#148; means the
time at which the Arrangement becomes effective on the Effective Date, as determined by Zymeworks under Section&nbsp;2.1 of the Transaction Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>BCBCA</B>&#148; means the <I>Business Corporations Act </I>(British Columbia). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Broker</B>&#148; has the meaning set forth in Section&nbsp;4.5(b)(i) (<I>Withholding Rights</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day on which banks are generally open for the transaction of commercial business in Vancouver, British Columbia, and
New York, New York, but does not in any event include a Saturday or Sunday or statutory holiday in Vancouver, British Columbia, or New York, New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>CallCo</B>&#148; means Zymeworks CallCo ULC, a British Columbia unlimited liability company and a direct, wholly-owned subsidiary of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Canadian Share Exchange</B>&#148; means the exchange of Zymeworks Common Shares for Exchangeable Shares, or for a combination of Exchangeable Shares
and Delaware Common Stock, in accordance with Section&nbsp;3.1(c) (<I>Electing Zymeworks Common Shares</I>) and Section&nbsp;3.1(d) (<I>Exchangeable Share Exchange Cap</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Consideration</B>&#148; means (i)&nbsp;in the case of a Zymeworks Shareholder who is an Eligible
Holder and who validly elects to receive Exchangeable Shares prior to the Election Deadline (as defined in the Plan of Arrangement) in accordance with the Plan of Arrangement, for each Designated Zymeworks Common Share, one Exchangeable Share
together with the Contractual Rights, and for each other Zymeworks Common Share (to the extent applicable), one share of Delaware Common Stock, and (ii)&nbsp;in the case of each other Zymeworks Shareholder who does not exercise the Dissent Rights,
for each Zymeworks Common Share, one share of Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Consideration Shares</B>&#148; means Delaware Common Stock and Exchangeable
Shares, as the context may require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Contractual Rights</B>&#148; has the meaning set forth in Section&nbsp;3.1(c) (<I>Electing
</I><I>Zymeworks</I><I> Common Shares</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Court</B>&#148; means the Supreme Court of British Columbia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Delaware Common Stock</B>&#148; means the shares of Parent&#146;s common stock, par value US$0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Depositary</B>&#148; means a bank or trust company selected by Zymeworks to perform the duties described in a depositary agreement in form and
substance reasonably acceptable to the parties thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Designated Zymeworks Common Shares</B>&#148; means the Zymeworks Common Shares of an
Eligible Holder that are designated by the Eligible Holder under a Letter of Transmittal and Election Form to be exchanged for Exchangeable Shares, as such number of Zymeworks Common Shares may be reduced as a result of the Exchangeable Share Cap,
and &#147;<B>Designated Zymeworks Common Share</B>&#148; means any one of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissent Rights</B>&#148; has the meaning set forth in
Section&nbsp;5.1 (<I>Rights of Dissent</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissenting Common Shares</B>&#148; has the meaning set forth in Section&nbsp;3.1(a) (<I>Dissenting
Shareholders</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissenting Shareholder</B>&#148; means any registered Zymeworks Shareholder as of the record date for the Special Meeting who
has duly and validly exercised their Dissent Rights in respect of all Zymeworks Common Shares held by that Zymeworks Shareholder, and has not withdrawn or been deemed to have withdrawn such Dissent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; means the effective date of the Arrangement, as determined by Zymeworks under Section&nbsp;2.1 of the Transaction Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Election Deadline</B>&#148; means 5:00 p.m. (Vancouver time) on the date before the Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Eligible Holder</B>&#148; means a Zymeworks Shareholder that is: (i)&nbsp;a resident of Canada for purposes of the Tax Act and not exempt from tax
under Part I of the Tax Act; or (ii)&nbsp;a partnership, each member of which is a resident of Canada for purposes of the Tax Act and not exempt from tax under Part I of the Tax Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Cap</B>&#148; means, in respect of the number of Zymeworks Common Shares exchangeable for Exchangeable Shares under the Canadian
Share Exchange, such number of Zymeworks Common Shares that is equal to 18% of (i)&nbsp;the number of Zymeworks Common Shares issued and outstanding immediately prior to the Arrangement Effective Time, less (ii)&nbsp;the number of Zymeworks Common
Shares held by any Zymeworks Shareholders who exercise their Dissent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Document</B>&#148; means (i)&nbsp;a share
certificate representing Exchangeable Shares, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-transferable</FONT> acknowledgement of a shareholder&#146;s right to obtain a share certificate representing Exchangeable Shares, or (iii)&nbsp;a direct
registration system advice (or similar document) evidencing the electronic registration of the ownership of Exchangeable Shares, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Provisions</B>&#148; means the rights, privileges, restrictions and conditions
attaching to the Exchangeable Shares as set forth in the articles of ExchangeCo, and in the form attached to the Transaction Agreement as Exhibit E. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Shares</B>&#148; means the exchangeable shares in the capital of ExchangeCo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>ExchangeCo</B>&#148; means Zymeworks ExchangeCo Ltd., a British Columbia company and a direct, wholly-owned subsidiary of CallCo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Order</B>&#148; means the final order of the Court, as contemplated by Section&nbsp;2.6 of the Transaction Agreement and made pursuant to
Section&nbsp;291 of the BCBCA approving the Arrangement, in a form acceptable to Zymeworks, as such order may be amended by the Court at any time prior to the Arrangement Effective Time, provided that any such amendment is acceptable to Zymeworks,
or if appealed, then, unless such appeal is withdrawn, abandoned or denied, as affirmed or as amended, on appeal, provided that any such amendment is acceptable to Zymeworks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Entity</B>&#148; means any United States, Canadian, international or other (i)&nbsp;federal, state, provincial, local, municipal or
other government entity, (ii)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal) or (iii)&nbsp;body exercising or entitled to
exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitrator or arbitral tribunal (public or private). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Holders</B>&#148;, when used with reference to (i)&nbsp;the Zymeworks Common Shares, means the holders thereof shown from time to time in the central
securities registers of Zymeworks maintained by or on behalf of Zymeworks and, where the context so provides, includes joint holders of such Zymeworks Common Shares, (ii)&nbsp;the Zymeworks Incentive Awards, means the holders thereof shown from time
to time in the register or other similar records maintained by or on behalf of Zymeworks in respect of Zymeworks Incentive Awards, and (iii)&nbsp;the Zymeworks Warrants, means the holders thereof shown from time to time in the register or other
similar records maintained by or on behalf of Zymeworks in respect of Zymeworks Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Information Circular</B>&#148; means the notice of the
Special Meeting to be sent to the Zymeworks Securityholders, and the accompanying proxy statement/prospectus to be prepared in connection with the Special Meeting, together with any amendments thereto or supplements thereof in accordance with the
terms of the Transaction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Interim Order</B>&#148; means the interim order of the Court as contemplated by Section&nbsp;2.2 of the
Transaction Agreement and made pursuant to Section&nbsp;291 of the BCBCA, in a form acceptable to Zymeworks providing for, among other things, the calling and holding of the Special Meeting, as the same may be amended by the Court, provided that any
such amendment is acceptable to Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means any federal, state, local, provincial, foreign, national or supranational
statute, law (including common law), act, statute, ordinance, treaty, rule, code, regulation or other binding directive or guidance issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Letter of Transmittal and Election Form</B>&#148; means the letter of transmittal and election form(s) for use by registered Zymeworks Shareholders,
in the form accompanying the Information Circular or in any other form acceptable to Zymeworks, providing for, among other things, the Eligible Holder&#146;s election with respect to the Consideration (and setting forth the number of Designated
Zymeworks Common Shares, which number may be less than the number of Zymeworks Common Shares held by that Eligible Holder), and which shall specify that delivery shall be effected, and risk of loss and title to the applicable Zymeworks Common Shares
shall pass, only upon proper delivery of such certificates or other documents to the Depositary and which shall be in such form and have such other customary provisions as Zymeworks may specify (or, if such Zymeworks Common Shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are held in book-entry or other uncertificated form, upon the entry through a book-entry transfer agent of the surrender of such Zymeworks Common Shares on a book-entry account statement, it
being understood that any reference herein to &#147;certificates&#148; shall be deemed to include references to book-entry account statements relating to the ownership of Zymeworks Common Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; includes any mortgage, pledge, assignment, charge, lien, security interest, adverse interest in property, license or <FONT
STYLE="white-space:nowrap">sub-license,</FONT> charge, or other third-party interest or encumbrance of any kind (including, in the case of any equity securities, any voting, transfer or similar restrictions) whether contingent or absolute, and any
agreement, option, right or privilege (whether by law, contract or otherwise) capable of becoming any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT
STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares</B>&#148; has the meaning set forth in Section&nbsp;3.1(b) (<I><FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Withholding Agent</B>&#148; has the meaning set forth in Section&nbsp;4.5(a) (<I>Withholding Rights</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent</B>&#148; means Zymeworks Delaware Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Zymeworks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Incentive Awards</B>&#148; means the stock options, incentive stock options, restricted stock units, stock purchase rights, and all other
awards and rights to purchase Delaware Common Stock to be assumed pursuant to the Parent Incentive Plans pursuant to the Arrangement in full and complete exchange and substitution for the Zymeworks Incentive Awards, and &#147;<B>Parent Incentive
Award</B>&#148; means any one of them, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Incentive Plans</B>&#148; means collectively (i)&nbsp;the Amended and Restated
Stock Option and Equity Compensation Plan of Parent, (ii)&nbsp;the Amended and Restated Employee Stock Purchase Plan of Parent, (iii)&nbsp;the Inducement Stock Option and Equity Compensation Plan of Parent, and (iv)&nbsp;the Second Amended and
Restated Employee Stock Option Plan of Parent, in each case including any schedules or appendices thereto, as assumed by Parent under this Plan of Arrangement, as amended from time to time, and &#147;<B>Parent Incentive Plan</B>&#148; means any one
of them, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; includes an individual, partnership, corporation, limited liability company, joint stock company,
unincorporated organization or association, trust, joint venture, trustee, executor, administrator, legal representative, government or any other entity, whether or not a legal entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Plan of Arrangement</B>&#148;, &#147;hereof&#148;, &#147;herein&#148;, &#147;hereunder&#148;, and similar expressions refer to this plan of
arrangement and not to any particular Article, Section or other portion hereof and includes any agreement or instrument supplementary or ancillary hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Redomicile Resolution</B>&#148; means a special resolution of the Zymeworks Securityholders in respect of the Arrangement to be considered at the
Special Meeting, in substantially the form attached to the Transaction Agreement as Exhibit B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Share Trustee</B>&#148; means a trustee chosen by
Zymeworks to act as trustee under the Voting and Exchange Trust Agreement and any successor trustee appointed under the Voting and Exchange Trust Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Special Meeting</B>&#148; means the meeting of the Zymeworks Securityholders, including any adjournment or postponement thereof in accordance with
the terms of the Transaction Agreement, that is to be convened as provided by the Interim Order to consider, and if deemed advisable approve, the Redomicile Resolution, and such other matters as are properly brought before Zymeworks Securityholders
or Zymeworks Shareholders at such meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Special Voting Stock</B>&#148; means the share of preferred stock of Parent, issued by Parent to
and deposited with the Share Trustee, which, at any time, entitles the holder of record to that number of votes at meetings of holders of Parent shares equal to the number of Exchangeable Shares outstanding as of the record date for such meeting
(excluding Exchangeable Shares held by Parent, CallCo and their Affiliates) multiplied by the Exchangeable Share Exchange Ratio (as defined in the Exchangeable Share Provisions), rounded down to the nearest whole vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Support Agreement</B>&#148; means an agreement to be made among Parent, CallCo and ExchangeCo on the Effective Date and in connection with this Plan
of Arrangement, in substantially the form attached to the Transaction Agreement as Exhibit C, as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; has the meaning set forth in the Transaction Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Act</B>&#148; means the <I>Income Tax Act</I> (Canada) and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreement</B>&#148; means the Transaction Agreement dated July&nbsp;14, 2022 by and among Parent, Zymeworks, CallCo and ExchangeCo as the
same may be amended, modified or supplemented from time to time in accordance therewith, prior to the Arrangement Effective Time, providing for, among other things, the Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Voting and Exchange Trust Agreement</B>&#148; means an agreement to be made between Parent, ExchangeCo, CallCo and the Share Trustee in connection
with this Plan of Arrangement, in substantially the form attached to the Transaction Agreement as Exhibit D, as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Withholding Obligation</B>&#148; has the meaning set forth in Section&nbsp;4.5(a) (<I>Withholding Rights</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B>&#148; means Zymeworks Inc., a company existing under the BCBCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Common Shares</B>&#148; means the common shares in the capital of Zymeworks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Incentive Awards</B>&#148; means the stock options, incentive stock options, restricted stock units, stock purchase rights, and all other
awards and rights to purchase Zymeworks Common Shares granted under the Zymeworks Incentive Plans that are outstanding and unexercised, whether vested or unvested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Incentive Plans</B>&#148; means collectively (i)&nbsp;the Amended and Restated Stock Option and Equity Compensation Plan of Zymeworks,
(ii)&nbsp;the Amended and Restated Employee Stock Purchase Plan of Zymeworks, (iii)&nbsp;the Inducement Stock Option and Equity Compensation Plan of Zymeworks, and (iv)&nbsp;the Second Amended and Restated Employee Stock Option Plan of Zymeworks, in
each case including any schedules or appendices thereto, as amended from time to time, and &#147;<B>Zymeworks Incentive Plan</B>&#148; means any one of them, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Securityholders</B>&#148; means Holders of Zymeworks Common Shares, Zymeworks Incentive Awards and Zymeworks Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Shareholders</B>&#148; means Holders of Zymeworks Common Shares as of any determination time prior to the Arrangement Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks Warrants</B>&#148; means, as of any determination time, each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to purchase
Zymeworks Common Shares that is outstanding and unexercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Headings and References. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The division of this Plan of Arrangement into Articles and Sections and the insertion of headings are for convenience of reference only and do not affect the
construction or interpretation of this Plan of Arrangement. Unless otherwise specified, references to Articles and Sections are to Articles and Sections of this Plan of Arrangement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Time Periods. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified, time periods within, or following, which any payment is to be made, or act is to be done, shall be calculated by excluding the day
on which the period commences and including the day on which the period ends and by extending the period to the next Business Day following if the last day of the period is not a Business Day. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All sums of money which are referred to in this Plan of Arrangement are expressed in the lawful currency of the United States unless otherwise specified. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Time. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all times expressed in this Plan of Arrangement or in any Letter of Transmittal and Election Form are to local time, Vancouver,
British Columbia. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Construction. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Plan of Arrangement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless the context otherwise requires, words importing the singular include the plural and vice versa and words
denoting any gender include all genders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;including&#148; or &#147;includes&#148; shall mean &#147;including (or includes) without
limitation&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reference to a statute includes all rules and regulations made pursuant to such statute and, unless otherwise
specified, the provisions of any statute or regulation or rule which amends, supplements or supersedes any such statute or any such regulation or rule. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing Law. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Plan of Arrangement shall be governed by and construed in accordance with the BCBCA, and the Laws of the Province of British Columbia and other federal
Laws of Canada applicable in British Columbia. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE AND EFFECT OF THE PLAN OF ARRANGEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Plan of Arrangement. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Plan of Arrangement is made pursuant to, is subject to the provisions of and forms part of, the Transaction Agreement, except in respect of the sequence
of the steps comprising the Arrangement, which shall occur in the order set out in this Plan of Arrangement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Effectiveness. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Plan of Arrangement and the Arrangement shall become effective, and shall be binding, at and after the times referred to in Section&nbsp;3.1
(<I>Arrangement</I>) on: (i)&nbsp;Zymeworks, (ii) Parent, (iii)&nbsp;ExchangeCo, (iv) CallCo, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(v)&nbsp;all Zymeworks Securityholders (including Dissenting Shareholders), (vi) all holders of Exchangeable Shares, (vii)&nbsp;the Depositary, (viii)&nbsp;the Share Trustee, and (ix)&nbsp;all
other Persons, in each case without any further authorization, act or formality on the part of the Court or any Person from and after the Arrangement Effective Time. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE
ARRANGEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Arrangement. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing immediately following the Arrangement Effective Time, pursuant to the Arrangement, the following transactions shall occur and shall be deemed to
occur in the order in which they appear without any further act or formality, effective as at five (5)&nbsp;minute intervals (and in each case, unless otherwise specified) starting at the Arrangement Effective Time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Dissenting Shareholders</I>. The outstanding Zymeworks Common Shares held by Dissenting Shareholders (the
&#147;<B>Dissenting Common Shares</B>&#148;) shall be deemed to be transferred by the Holders thereof to Zymeworks, free and clear of all Liens, and cancelled in consideration for a debt claim against Zymeworks for the amount determined and payable
in accordance with Article 5 (<I>Rights of Dissent</I>), and without any further authorization, act or formality by such Holders or Zymeworks, and: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such Dissenting Shareholders shall cease to be the holders of such Dissenting Common Shares and to have any
rights as holders of such Dissenting Common Shares other than the right to be paid fair value by Zymeworks for such Dissenting Common Shares as set out in Article 5 (<I>Rights of Dissent</I>); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the names of such Dissenting Shareholders shall be removed from the central securities register of Zymeworks
Common Shares maintained by or on behalf of Zymeworks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">Non-Electing</FONT> </I><I>Zymeworks</I><I> Common Shares</I>. Subject to
Section&nbsp;3.4 (<I>No Fractional Shares</I>), each outstanding Zymeworks Common Share other than Zymeworks Common Shares held by (A)&nbsp;Dissenting Shareholders described in Section&nbsp;3.1(a) (<I>Dissenting Shareholders</I>), and
(B)&nbsp;Eligible Holders who have submitted a Letter of Transmittal and Election Form in accordance with Section&nbsp;3.2 (<I>Consideration Elections</I>) (collectively, the &#147;<B><FONT STYLE="white-space:nowrap">Non-Electing</FONT>
</B><B>Zymeworks</B><B> Common Shares</B>&#148;), shall be transferred by the Holders thereof to Parent, free and clear of all Liens, in exchange for an equal number of shares of Delaware Common Stock, such that one share of Delaware Common Stock
shall be issued in exchange for each <FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Share, and without any further authorization, act or formality by such Holders or Parent, and: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Holders of such <FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares shall cease to
be the holders of such <FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares and to have any rights as holders of such <FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares other than the right to
receive an equal number of shares of Delaware Common Stock in accordance with this Plan of Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the names of the Holders of the <FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares
shall be removed from the central securities register for the Zymeworks Common Shares maintained by or on behalf of Zymeworks in respect of such <FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares exchanged for Delaware
Common Stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent shall be deemed to be the legal and beneficial owner of such
<FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares so transferred, free and clear of all Liens, and shall be recorded as the registered Holder thereof on the central securities register for the Zymeworks Common Shares
maintained by or on behalf of Zymeworks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Electing </I><I>Zymeworks</I><I> Common Shares</I>. Subject to Section&nbsp;3.4 (<I>No Fractional
Shares</I>), each outstanding Zymeworks Common Share held by or for the benefit of Eligible Holders who have submitted a Letter </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of Transmittal and Election Form in accordance with Section&nbsp;3.2 (<I>Consideration Elections</I>), shall be transferred by the Holders thereof to ExchangeCo, free and clear of all Liens, as
follows: (A)&nbsp;subject to Section&nbsp;3.1(d) (<I>Exchangeable Share Exchange Cap</I>), as to the Designated Zymeworks Common Shares, in exchange for an equal number of Exchangeable Shares, such that one Exchangeable Share shall be issued in
exchange for each Designated Zymeworks Common Share, together with the benefit of the Support Agreement and the Voting and Exchange Trust Agreement to be executed and delivered under Section&nbsp;3.1(g) (<I>Documents Re Exchangeable Shares</I>) (the
&#147;<B>Contractual Rights</B>&#148;), and (B)&nbsp;as to the remaining Zymeworks Common Shares of the Eligible Holder that are not Designated Zymeworks Common Shares, in exchange for an equal number of shares of Delaware Common Stock, and in each
case, without any further authorization, act or formality by such Holders or ExchangeCo, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Holders of such Zymeworks Common Shares shall cease to be the Holders of such Zymeworks Common Shares and
to have any rights as Holders of such Zymeworks Common Shares other than the right to receive the Exchangeable Shares and Contractual Rights, and to the extent applicable the Delaware Common Stock, to which they are entitled as set forth above;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the names of the Holders of such Zymeworks Common Shares shall be removed from the central securities register
for the Zymeworks Common Shares maintained by or on behalf of Zymeworks in respect of such Zymeworks Common Shares exchanged for Exchangeable Shares and to the extent applicable the Delaware Common Stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ExchangeCo shall be deemed to be the legal and beneficial owner of such Zymeworks Common Shares so transferred,
free and clear of all Liens, and shall be recorded as the registered Holder thereof on the central securities register for the Zymeworks Common Shares maintained by or on behalf of Zymeworks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Exchangeable Share Exchange Cap.</I> If the aggregate number of outstanding Zymeworks Common Shares
specified as Designated Zymeworks Common Shares by Eligible Holders in their Letter of Transmittal and Election Forms submitted in accordance with Section&nbsp;3.2 (<I>Consideration Elections</I>) exceed the Exchangeable Share Cap, then the
following shall apply: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of outstanding Zymeworks Common Shares held by each such Eligible Holder that will be included as
Designated Zymeworks Common Shares in the Canadian Share Exchange, and thereby exchanged for Exchangeable Shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, shall be calculated based upon
the following formula, but in each case, round down to the nearest whole share: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(A/B) x C, where: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A&nbsp;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Zymeworks Common Shares specified as Designated Zymeworks Common Shares in the Letter of
Transmittal and Election Form of an Eligible Holder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B&nbsp;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the aggregate number of Zymeworks Common Shares specified as Designated Zymeworks Common Shares in all of the
Letter of Transmittal and Election Forms of the Eligible Holders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C&nbsp;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Zymeworks Common Shares comprising the Exchangeable Share Cap; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and for greater certainty, the number of outstanding Zymeworks Common Shares held by each such Eligible Holder and specified as Designated
Zymeworks Common Shares in the Letter of Transmittal and Election Form of such Eligible Holder that are not exchanged for Exchangeable Shares as a result of the application of the Exchangeable Share Cap under this provision shall be exchanged for
Delaware Common Stock under Section&nbsp;3.1(c) (<I>Electing Zymeworks Common Shares</I>); </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Exchangeable Shares</I>. Exchangeable Shares issued under Section&nbsp;3.1(c) (<I>Electing
</I><I>Zymeworks</I><I> Common Shares</I>) shall be exchangeable for Delaware Common Stock or such other securities in accordance with the Exchangeable Share Provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Special Voting Stock</I>. Contemporaneously with the step contemplated in Section&nbsp;3.1(c) (<I>Electing
Zymeworks Common Shares</I>), (i) Parent will issue one share of the Special Voting Stock to the Share </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Trustee, to be held by the Share Trustee under the terms and conditions of the Voting and Exchange Trust Agreement to be executed and delivered under Section&nbsp;3.1(g) (<I>Documents Re
Exchangeable Shares</I>), and (ii)&nbsp;Zymeworks will pay the subscription price for such Special Voting Stock to Parent on behalf of the prior Holders of the Designated Zymeworks Common Shares; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Documents Re Exchangeable Shares</I>. Contemporaneously with the steps contemplated in Section&nbsp;3.1(c)
(<I>Electing </I><I>Zymeworks</I><I> Common Shares</I>) and Section&nbsp;3.1(e) (<I>Special Voting Stock</I>), (i) Parent, ExchangeCo and CallCo shall execute the Support Agreement, (ii)&nbsp;Parent, ExchangeCo, CallCo and the Share Trustee shall
execute the Voting and Exchange Trust Agreement, (iii)&nbsp;each such prior Holder of Designated Zymeworks Common Shares shall be deemed to have the rights granted to them as Beneficiaries under, and as defined in, the Voting and Exchange Trust
Agreement in respect of the Special Voting Stock issued to the Share Trustee, and (iv)&nbsp;each such prior Holder of Designated Zymeworks Common Shares shall be deemed to have granted to CallCo the Liquidation Call Right, the Redemption Call Right,
the Retraction Call Right and the Change of Law Call Right, each as defined in the Exchangeable Share Provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Zymeworks</I><I> Incentive Plan Amendments</I>. The term &#147;Change of Control&#148; as defined in the
Inducement Stock Option and Equity Compensation Plan and the Amended and Restated Stock Option and Equity Compensation Plan forming part of the Zymeworks Incentive Plans shall be, and be deemed to be, amended (without any further action of any
person or party) to include any transaction, plan, scheme, reorganization or arrangement whereby Parent acquires, directly or indirectly, greater than 50% of the Zymeworks Common Shares, and if such is the case, Parent shall be a successor to
Zymeworks under such plans. These amendments will allow Parent to assume the obligations under such plans and issue the Parent common stock under such plans. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Zymeworks</I><I> Incentive Awards</I><I></I><I>&nbsp;&amp; Plans</I>. Zymeworks shall assign to Parent, and
Parent shall assume, all of Zymeworks&#146; rights and obligations under the Zymeworks Incentive Plans and all Zymeworks Incentive Awards granted thereunder as a successor to Zymeworks thereunder, and without any further authorization, act or
formality by Parent, Zymeworks or the Holders of the Zymeworks Incentive Awards, and consistent with the terms of the Zymeworks Incentive Plans and the Zymeworks Incentive Awards: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Zymeworks Incentive Award outstanding immediately prior to the Arrangement Effective Time shall be, and
shall be deemed to be, exchanged for a Parent Incentive Award identical to such Zymeworks Incentive Award in all material respects (and for greater certainty, in respect of Delaware Common Stock in the place and stead of Zymeworks Common Shares),
and without any further action on the part of any Holder thereof, Zymeworks or Parent (and for greater certainty, the exchange of Zymeworks Incentive Awards that are stock options for Parent Incentive Awards that are stock options shall meet the
conditions of subsection 7(1.4) of the Tax Act), section 422 of the Code, or section 409A of the Code, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Holders of such Zymeworks Incentive Awards shall cease to be Holders of such Zymeworks Incentive Awards and
to have any rights as Holders of such Zymeworks Incentive Awards, and such Holders&#146; names shall be removed as the Holders from the register or records maintained by or on behalf of Zymeworks and such Holders&#146; names shall be added as the
holders of Parent Incentive Awards in the register or records of Parent Incentive Awards maintained by or on behalf of Parent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Zymeworks Incentive Plans, and any award or grant agreement or any other document evidencing ownership of,
or a right to, a Zymeworks Incentive Award shall be assigned to, and be assumed by, Parent in their entirety as the Parent Incentive Plans and award and grant agreements or other documents evidencing ownership of rights to a Parent Incentive Award
made thereunder (including by the issuance of awards and grants by Parent to replace such Zymeworks Incentive Awards), with such administrative and ancillary amendments necessary to give the intended effect to such plans, agreements and documents,
and neither Zymeworks nor Parent shall have any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
liabilities or obligations with respect to any Zymeworks Incentive Plan or such agreements or documents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Zymeworks</I><I> Warrants</I>. Zymeworks shall assign to Parent, and Parent shall assume, all of
Zymeworks&#146; rights and obligations under the Zymeworks Warrants, and in accordance with the provisions regarding &#147;Fundamental Transactions&#148; (as that term is defined in the Zymeworks Warrants), the Holders of the Zymeworks Warrants
shall be entitled to receive Delaware Common Stock (instead of Zymeworks Common Shares) as Alternate Consideration (as that term is defined in the Zymeworks Warrants) in accordance with the terms of the Zymeworks Warrants, and without any further
authorization, act or formality by Parent, Zymeworks or the Holders of the Zymeworks Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration Elections. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the transfer and assignment of Zymeworks Common Shares pursuant to Section&nbsp;3.1(c) (<I>Electing Zymeworks Common Shares</I>): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to Section&nbsp;3.4 (<I>No Fractional Shares</I>), each Zymeworks Shareholder who is an Eligible Holder
may elect to receive Consideration Shares under this Plan of Arrangement in the form of Exchangeable Shares together with the Contractual Rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the election provided for in Section&nbsp;3.2(a) (<I>Consideration Elections</I>) shall be made by a Zymeworks
Shareholder who is an Eligible Holder by depositing with the Depositary, prior to the Election Deadline, a duly completed Letter of Transmittal and Election Form indicating such Zymeworks Shareholder&#146;s election, together with the certificates
representing their Designated Zymeworks Common Shares (or, if such Zymeworks Common Shares are held in book-entry or other uncertificated form, upon the entry through a book-entry transfer agent of the surrender of such Zymeworks Common Shares on a
book-entry account statement, it being understood that any reference herein to &#147;certificates&#148; shall be deemed to include references to book-entry account statements relating to the ownership of Zymeworks Common Shares);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Letter of Transmittal and Election Form, once deposited with the Depositary, shall be irrevocable and may
not be withdrawn by a Zymeworks Shareholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Zymeworks Shareholder who does not deposit with the Depositary a duly completed Letter of Transmittal and
Election Form (together with the certificates representing the Designated Zymeworks Common Shares, to the extent applicable) prior to the Election Deadline, or otherwise fails to comply with the requirements of this Section&nbsp;3.2
(<I>Consideration Elections</I>) or of the Letter of Transmittal and Election Form, shall be deemed to have elected to receive Delaware Common Stock under Section&nbsp;3.1(b) (<I><FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common
Shares</I>). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tax Election. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each beneficial owner of Zymeworks Common Shares who is an Eligible Holder, and who has validly elected (or for whom the registered holder has validly elected
on such beneficial owner&#146;s behalf) to receive Exchangeable Shares shall be entitled to make an income tax election pursuant to subsection 85(1) of the Tax Act, or subsection 85(2) of the Tax Act if such beneficial owner is a partnership (and in
each case, where applicable, the analogous provisions of provincial income tax Law), with respect to the transfer of the Eligible Holder&#146;s Zymeworks Common Shares to ExchangeCo and the receipt of Consideration in respect thereof by providing
two signed copies of the necessary prescribed election form(s) (or equivalent information through an alternative document or platform, at ExchangeCo&#146;s discretion) to the Depositary within sixty (60)&nbsp;days following the Effective Date, duly
completed with the details of the number of Zymeworks Common Shares transferred and the applicable agreed amounts for the purposes of such elections. Thereafter, subject to the election forms being correct and complete and complying with the
provisions of the Tax Act (and applicable provincial income tax Law), the forms shall be signed by ExchangeCo and returned to such former Eligible Holder of Zymeworks Common Shares within sixty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(60)&nbsp;days after the receipt thereof by the Depositary for filing with the Canada Revenue Agency (or the applicable provincial taxing authority) by such former Eligible Holder. ExchangeCo
shall not be responsible for the proper completion of any election form and, except for ExchangeCo&#146;s obligation to return (within sixty (60)&nbsp;days after the receipt thereof by the Depositary) duly completed election forms which are received
by the Depositary within sixty (60)&nbsp;days of the Effective Date, ExchangeCo shall not be responsible for any Taxes, interest or penalties resulting from the failure by a former Eligible Holder of Zymeworks Common Shares to properly complete or
file the election forms in the form and manner and within the time prescribed by the Tax Act (or any applicable provincial legislation). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Fractional Shares. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional Consideration Shares, or any certificates, scrip, electronic record or book entry representing fractional Consideration Shares shall be issued to
any Person under the Arrangement, and any such fractional share interests shall not entitle the owner thereof to the rights of a stockholder of Parent or a shareholder of ExchangeCo, as applicable. Any fractional Consideration Shares to be issued in
connection with the Arrangement shall be rounded down to the nearest whole number of Consideration Shares, and no payment or other adjustment shall be made with respect to the fractional interest so disregarded. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELIVERY OF
CONSIDERATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment of Consideration. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to this Section&nbsp;4.1 (<I>Payment of Consideration</I>), at or prior to the Arrangement Effective
Time, Parent and ExchangeCo shall deposit or cause to be deposited with the Depositary, for the benefit of each Zymeworks Shareholder, Delaware Common Stock and Exchangeable Shares to which each such Zymeworks Shareholder is entitled pursuant to
Section&nbsp;3.1 (<I>Arrangement</I>), as applicable, which Delaware Common Stock and Exchangeable Share Documents shall be held by the Depositary, following the Arrangement Effective Time, as agent and nominee for such former Zymeworks Shareholders
for distribution to such former holders in accordance with the provisions of this Article 4 (<I>Delivery of Consideration</I>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon surrender by a Zymeworks Shareholder to the Depositary of a certificate which immediately prior to the
Arrangement Effective Time represented one or more Zymeworks Common Shares, together with a duly completed and executed Letter of Transmittal and Election Form (if applicable) and any other documents reasonably requested by Parent, ExchangeCo or the
Depositary (or, if such Zymeworks Common Shares are held in book-entry or other uncertificated form, upon the entry through a book-entry transfer agent of the surrender of such Zymeworks Common Shares on a book-entry account statement, it being
understood that any reference herein to &#147;certificates&#148; shall be deemed to include references to book-entry account statements relating to the ownership of Zymeworks Common Shares), the registered Holder of such surrendered certificate(s)
of Zymeworks Common Shares shall be entitled to receive in exchange therefor, and the Depositary shall deliver to such Zymeworks Shareholder, as soon as practicable after the Arrangement Effective Time, the Consideration in the form of Consideration
Shares that such Zymeworks Shareholder has the right to receive pursuant to Section&nbsp;3.1(b) (<I><FONT STYLE="white-space:nowrap">Non-Electing</FONT> Zymeworks Common Shares</I>) or 3.1(c) (<I>Electing Zymeworks Common Shares</I>), as applicable,
less any amounts withheld pursuant to Section&nbsp;4.5 (<I>Withholding Rights</I>), and any certificate of Zymeworks Common Shares so surrendered shall forthwith be cancelled. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Until surrendered for cancellation as contemplated by this Section&nbsp;4.1 (<I>Payment of Consideration</I>),
each certificate that immediately prior to the Arrangement Effective Time represented one or more Zymeworks Common Shares (other than Zymeworks Common Shares held by Parent, ExchangeCo or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
any of their respective subsidiaries or Affiliates) shall be deemed at all times after the Arrangement Effective Time to represent only the right to receive upon such surrender the Consideration
that the holder of such certificate is entitled to receive in the manner contemplated by this Section&nbsp;4.1 (<I>Payment of Consideration</I>), less any amounts withheld pursuant to Section&nbsp;4.5 (<I>Withholding Rights</I>). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of the surrender of a certificate of Zymeworks Common Shares that is not registered in the
transfer records of Zymeworks under the name of the Person surrendering such certificate, the Consideration to which the registered Holder is entitled pursuant to Section&nbsp;3.1 (<I>Arrangement</I>) shall be paid to such a transferee if such
certificate is presented to the Depositary and such certificate is duly endorsed or is accompanied by all documents required to evidence and effect such transfer and to evidence to the satisfaction of Parent that (i)&nbsp;any applicable stock
transfer Taxes or any other Taxes required by reason of such payments being made in a name other than the registered Holder have been paid or (ii)&nbsp;no such Taxes are payable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any portion of the amount deposited with the Depositary that remains unclaimed by the Holders and other
eligible Persons in accordance with this Article 4 (<I>Delivery of Consideration</I>) following one year after the Arrangement Effective Time shall be delivered to Parent, and any Holder who has not previously complied with this Article 4
(<I>Delivery of Consideration</I>) shall thereafter look only to Parent for, and, subject to Section&nbsp;4.4 (<I>Extinction of Rights</I>), Parent shall remain liable for payment of such Holder&#146;s claim for payment under this Section&nbsp;4.1
(<I>Payment of Consideration</I>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No former Holder of Zymeworks Common Shares or Zymeworks Incentive Awards, or any Holder of Zymeworks Warrants,
shall be entitled to receive any consideration with respect thereto other than the consideration to which such former Holder or Holder is entitled to receive pursuant to the Arrangement, as applicable. For greater certainty, except as specifically
contemplated in this Plan of Arrangement, no such former Holder or Holder will be entitled to receive any interest, dividends, premium or other payment in connection therewith. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Distributions with respect to <FONT STYLE="white-space:nowrap">Un-Surrendered</FONT> Certificates.
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No dividends or other distributions declared or made after the Arrangement Effective Time with respect to
Zymeworks Common Shares with a record date after the Arrangement Effective Time shall be delivered to the Holder of any <FONT STYLE="white-space:nowrap">un-surrendered</FONT> certificate which immediately prior to the Arrangement Effective Time
represented outstanding Zymeworks Common Shares that were transferred pursuant to Section&nbsp;3.1 (<I>Arrangement</I>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No dividends or other distributions declared or made after the Arrangement Effective Time with respect to
Delaware Common Stock or Exchangeable Shares with a record date after the Arrangement Effective Time shall be delivered to the holder of any <FONT STYLE="white-space:nowrap">un-surrendered</FONT> certificate that, immediately prior to the
Arrangement Effective Time, represented outstanding Zymeworks Common Shares that were transferred pursuant to Section&nbsp;3.1 (<I>Arrangement</I>) unless and until the holder of such certificate shall have complied with the provisions of
Section&nbsp;4.1 (<I>Delivery of Consideration</I>) or Section&nbsp;4.3 (<I>Lost Certificates</I>). Subject to applicable Law and to Section&nbsp;4.5 (<I>Withholding Rights</I>), at the time of such compliance, there shall, in addition to the
delivery of Consideration to which such holder is thereby entitled, be delivered to such holder, without interest, the amount of the dividend or other distribution with a record date after the Arrangement Effective Time paid with respect to such
Delaware Common Stock or Exchangeable Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lost Certificates. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event any physical share certificate which immediately prior to the Arrangement Effective Time represented one or more outstanding Zymeworks Common
Shares that were transferred pursuant to Section&nbsp;3.1 (<I>Arrangement</I>) is lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such certificate to be lost, stolen or destroyed, the Depositary shall
issue in exchange for such lost, stolen or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
destroyed certificate, the Consideration that such Holder has the right to receive in accordance with Section&nbsp;3.1 (<I>Arrangement</I>), deliverable in accordance with such Holder&#146;s
Letter of Transmittal and Election Form. When authorizing such exchange for any lost, stolen or destroyed physical share certificate, the Person to whom such Consideration is to be delivered shall, as a condition precedent to the delivery of such
Consideration, give a bond satisfactory to ExchangeCo, Parent, Zymeworks and the Depositary (each acting reasonably) or otherwise indemnify ExchangeCo, Parent, Zymeworks and their respective Affiliates in a manner satisfactory to ExchangeCo, Parent
and Zymeworks (each acting reasonably) against any claim that may be made against ExchangeCo, Parent, Zymeworks or their respective Affiliates with respect to the physical share certificate alleged to have been lost, stolen or destroyed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Extinction of Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any certificate (or, if such Zymeworks Common Shares are held in book-entry or other uncertificated form, upon the entry through a book-entry transfer agent of
the surrender of such Zymeworks Common Shares on a book-entry account statement, it being understood that any reference herein to &#147;certificates&#148; shall be deemed to include references to book-entry account statements relating to the
ownership of Zymeworks Common Shares) which immediately prior to the Arrangement Effective Time represented outstanding Zymeworks Common Shares that were transferred pursuant to Section&nbsp;3.1 (<I>Arrangement</I>), and not duly surrendered, with
all other instruments required by Section&nbsp;4.1 (<I>Delivery of Consideration</I>), on or prior to the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) anniversary of the Effective Date shall cease to represent a claim or interest
of any former Zymeworks Shareholder of any kind or nature against Parent, CallCo, ExchangeCo, Zymeworks or any of their respective Affiliates. On such date, all Consideration to which the former Holder of the certificate referred to in the preceding
sentence was ultimately entitled shall be deemed to have been surrendered for no consideration to Parent or ExchangeCo, as applicable, by the Depositary and the Delaware Common Stock and Exchangeable Shares forming part of the Consideration shall be
deemed to be cancelled. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Withholding Rights. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary contained in this Plan of Arrangement, each of Parent, ExchangeCo,
CallCo, Zymeworks, the Depositary and any other Person that has any withholding obligation with respect to any amount paid or deemed paid under this Plan of Arrangement (any such Person, an &#147;<B>Other Withholding Agent</B>&#148;) shall be
entitled to deduct and withhold or direct Parent, ExchangeCo, CallCo, Zymeworks, the Depositary or any Other Withholding Agent to deduct and withhold on their behalf, from any amount or consideration paid, deemed paid or otherwise deliverable to any
Person under this Plan of Arrangement (an &#147;<B>Affected Person</B>&#148;) such amounts as are required to be deducted or withheld with respect to such payment or deemed payment under the Tax Act, the Code or any provision of any federal,
provincial, territorial, state, local or other Tax Law (a &#147;<B>Withholding Obligation</B>&#148;). Parent, ExchangeCo, CallCo, Zymeworks, the Depositary or any Other Withholding Agent may act and rely on the advice of counsel with respect to such
matters. To the extent that amounts are so deducted or withheld, such deducted or withheld amounts shall be treated for all purposes hereof as having been paid to the Affected Person to whom such amounts would otherwise have been paid or deemed
paid, and such deducted or withheld amounts shall be timely remitted to the appropriate Governmental Entity as required by applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent, ExchangeCo, CallCo, Zymeworks, the Depositary and any Other Withholding Agent shall also have the right
to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withhold and sell, or direct Parent, ExchangeCo, CallCo, Zymeworks, the Depositary or any Other Withholding
Agent to deduct and withhold and sell on their behalf, on their own account or through a broker (the &#147;<B>Broker</B>&#148;), and on behalf of any Affected Person; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">require the Affected Person to irrevocably direct the sale through a Broker and irrevocably direct the Broker
to pay the proceeds of such sale to Parent, ExchangeCo, CallCo, Zymeworks, the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Depositary or any Other Withholding Agent as appropriate (and, in the absence of such irrevocable direction, the Affected Person shall be deemed to have provided such irrevocable direction);
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">such number of Delaware Common Stock or Exchangeable Shares (or Delaware Common Stock exchanged therefor) delivered or
deliverable to such Affected Person pursuant to this Plan of Arrangement or the Exchangeable Share Provisions as is necessary to produce sale proceeds (after deducting commissions payable to the Broker and other costs and expenses) sufficient to
fund any Withholding Obligations. Any Exchangeable Shares to be sold in accordance with this Section&nbsp;4.5 (<I>Withholding Rights</I>) shall first be exchanged for Delaware Common Stock in accordance with their terms and Delaware Common Stock
delivered in respect of such Exchangeable Shares shall be sold. Any such sale of Delaware Common Stock shall be affected on a public market and as soon as practicable following the Effective Date. Each of Parent, ExchangeCo, CallCo, Zymeworks, the
Depositary, the Broker or any Other Withholding Agent, as applicable, shall act in a commercially reasonable manner in respect of any Withholding Obligation; however, none of Parent, ExchangeCo, CallCo, Zymeworks, the Depositary, the Broker or any
Other Withholding Agent shall have or be deemed to have any fiduciary duty to any stockholder of Parent or Holder of Zymeworks Common Shares (other than any Dissenting Shareholder) and shall not be liable for any loss arising out of any sale of such
Delaware Common Stock, including any loss relating to the manner or timing of such sales, the prices at which Delaware Common Stock are sold or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Liens. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any exchange or transfer of securities pursuant to this Plan of Arrangement shall be free and clear if any and all Liens or other claims of third parties of
any kind. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Paramountcy. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and after the Arrangement Effective Time: (i)&nbsp;this Plan of Arrangement shall take precedence and priority over any and all securities of Zymeworks
issued and outstanding prior to the Arrangement Effective Time, including Zymeworks Common Shares, Zymeworks Incentive Awards and Zymeworks Warrants; (ii)&nbsp;the rights and obligations of the Holders (registered or beneficial) of such securities,
Parent, CallCo, ExchangeCo, Zymeworks and their respective Affiliates, the Depositary and any transfer agent or other depositary therefor in relation to this Plan of Arrangement shall be solely as provided for in this Plan of Arrangement; and
(iii)&nbsp;all actions, causes of action, claims or proceedings (actual or contingent and whether or not previously asserted) based on or in any way relating to any securities of Zymeworks are deemed to have been settled, compromised, released and
determined without liability except as set forth herein and in the Transaction Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shares Fully Paid. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Consideration Shares issued pursuant to this Plan of Arrangement shall be fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and Parent
and ExchangeCo, respectively, shall be deemed to have received the full consideration therefor. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS OF DISSENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights of Dissent. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered Holders of Zymeworks Common Shares as of the record date for the Special Meeting may exercise rights of dissent with respect to such Zymeworks
Common Shares (&#147;<B>Dissent Rights</B>&#148;) in connection with the Arrangement pursuant to and in the manner set forth in Sections 237 to 247 of the BCBCA as modified by this Article 5 (<I>Rights of Dissent</I>), as the same may be modified by
the Interim Order; provided that, notwithstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsection 242(1)(a) of the BCBCA, the written objection to the Redomicile Resolution referred to in Subsection 242(1)(a) of the BCBCA must be received by Zymeworks c/o Blake, Cassels&nbsp;&amp;
Graydon LLP, Suite 2600 &#150; 595 Burrard Street, Vancouver, B.C., V7X 1L3, Attention: Sean Boyle and Alexandra Luchenko, not later than 11:00 a.m. (Vancouver Time) on the date that is two (2)&nbsp;Business Days immediately prior to the Special
Meeting (or any date to which the Special Meeting may be postponed or adjourned). Dissenting Shareholders who: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are ultimately determined to be entitled to be paid by Zymeworks fair value for their Zymeworks Common Shares
shall: (i)&nbsp;be deemed to have transferred such Zymeworks Common Shares (free and clear of all Liens) to Zymeworks in accordance with, and as of the time stipulated in, Section&nbsp;3.1(a) (<I>Dissenting Shareholders</I>); (ii) in respect of such
Zymeworks Common Shares, be deemed to not have participated in the transactions in Article 3 (<I>The Arrangement</I>) (other than Section&nbsp;3.1(a) (<I>Dissenting Shareholders</I>)); (iii) be entitled to be paid, subject to Section&nbsp;4.5
(<I>Withholding Rights</I>), the fair value of such Zymeworks Common Shares by Zymeworks, which fair value, notwithstanding anything to the contrary contained in the BCBCA, shall be determined as of the close of business on the day before the
Redomicile Resolution was adopted at the Special Meeting; and (iv)&nbsp;not be entitled to any other payment or consideration, including any payment or consideration that would be payable under the Arrangement had such Holders not exercised their
Dissent Rights in respect of such Zymeworks Common Shares; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are ultimately determined not to be entitled, for any reason, to be paid by Zymeworks fair value for their
Zymeworks Common Shares, shall be deemed to have participated in the Arrangement in respect of such Zymeworks Common Shares on the same basis and at the same time as a Holder of Zymeworks Common Shares that is not a Dissenting Shareholder and who
did not deposit with the Depositary a duly completed Letter of Transmittal and Election Form prior to the Election Deadline (and shall be entitled to receive the Consideration Shares in the same manner as such Holders). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recognition of Dissenting Shareholders. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In no case shall Zymeworks, ExchangeCo, Parent, the Depositary or any other Person be required to recognize
such Dissenting Shareholders as registered or beneficial Holders of Zymeworks Common Shares in respect of which Dissent Rights are sought to be exercised after the time stipulated in Section&nbsp;3.1(a) (<I>Dissenting Shareholders</I>), and the
names of such Zymeworks Shareholders shall be deleted from the register of Holders of Zymeworks Common Shares, at the time stipulated in Section&nbsp;3.1(a) (<I>Dissenting Shareholders</I>) and such Zymeworks Common Shares shall be deemed to be
cancelled. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to any other restrictions in the Interim Order or the BCBCA, none of the following shall be
entitled to exercise Dissent Rights: (i)&nbsp;beneficial and not legal Holders of Zymeworks Common Shares; (ii)&nbsp;Holders of Zymeworks Incentive Awards, or (iii)&nbsp;the Holders of the Zymeworks Warrants (in each case, in their capacity as
Holders of Zymeworks Incentive Awards or Zymeworks Warrants, as applicable); and (iv)&nbsp;any Person that has voted or instructed a proxy holder to vote such Zymeworks Common Shares in favor of the Redomicile Resolution . </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendments. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks reserves the right to amend, modify and/or supplement this Plan of Arrangement at any time and from
time to time prior to the Arrangement Effective Time, provided that any such amendment, modification, and/or supplement must be (i)&nbsp;set out in writing, (ii)&nbsp;approved by Zymeworks, (iii)&nbsp;filed with the Court and, if made after the
Special Meeting and adversely affects the economic interest of any Zymeworks Securityholder, approved by the Court subject to such conditions </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
as the Court may impose, and (iv)&nbsp;communicated to Zymeworks Securityholders if and as required by the Court or applicable Law. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any amendment, modification and/or supplement to this Plan of Arrangement may be proposed by Zymeworks at any
time prior to or at the Special Meeting, with or without any other prior notice or communication and, if so proposed and accepted by the Persons voting at the Special Meeting, shall become part of this Plan of Arrangement for all purposes.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any amendment, modification and/or supplement to this Plan of Arrangement that is approved or directed by the
Court following the Special Meeting shall be effective only if (i)&nbsp;it is consented to by Zymeworks, and (ii)&nbsp;if such consent is required by the Court, it is consented to by the Zymeworks Securityholders voting in the manner directed by the
Court. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any amendment, modification or supplement to this Plan of Arrangement may be made following the Special Meeting
without filing such amendment, modification or supplement with the Court or seeking Court approval, provided that it concerns a matter which, in the reasonable opinion of Zymeworks, is of an administrative nature required to better give effect to
the implementation of this Plan of Arrangement and is not adverse to the interest of any Holder of Zymeworks Common Shares, Zymeworks Incentive Awards or Zymeworks Warrants. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Plan of Arrangement may be withdrawn prior to the Arrangement Effective Time in accordance with the terms of the Transaction Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FURTHER
ASSURANCES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assurances. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding that the transactions and events set out in this Plan of Arrangement shall occur and be deemed to occur in the order set out in this Plan of
Arrangement without any further authorization, act or formality, each of the parties to the Transaction Agreement shall make, do and execute, or cause to be made, done and executed, all such further acts, deeds, agreements, transfers, assurances,
instruments or documents as may reasonably be required by any of them in order to further document or evidence any of the transactions or events set out in this Plan of Arrangement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REDOMICILE RESOLUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLVED THAT:
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arrangement (the &#147;<B>Arrangement</B>&#148;) under Division 5 of Part 9 of the <I>Business Corporations
Act</I> (British Columbia) (the &#147;<B>BCBCA</B>&#148;) involving Zymeworks Inc. (the &#147;<B>Company</B>&#148;), pursuant to the Transaction Agreement dated July 14, 2022 among Zymeworks Delaware Inc. (&#147;<B>Parent</B>&#148;), Zymeworks
Callco ULC (&#147;<B>Callco</B>&#148;), Zymeworks ExchangeCo Ltd. (&#147;<B>ExchangeCo</B>&#148;) and the Company, as amended, supplemented or otherwise modified from time to time in accordance with its terms (the &#147;<B>Transaction
Agreement</B>&#148;), and as more particularly described and set forth in the accompanying proxy statement/prospectus of the Company (the &#147;<B>Proxy Statement/Prospectus</B>&#148;), and all transactions contemplated under the Arrangement
(collectively, the &#147;<B>Redomicile Transactions</B>&#148;), are hereby authorized, approved and adopted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The plan of arrangement involving the Company, as it has been or may be amended, modified or supplemented in
accordance with the terms of the Transaction Agreement (the &#147;<B>Plan of Arrangement</B>&#148;), the full text of which is attached as Exhibit A to the Transaction Agreement, which Transaction Agreement is attached as Appendix B to the Proxy
Statement/Prospectus, is hereby authorized, approved and adopted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Transaction Agreement and all transactions contemplated therein, including the actions of the officers and
directors of the Company in approving the Redomicile Transactions and in executing and delivering the Transaction Agreement and any modifications, supplements or amendments thereto, and causing the performance by the Company of its obligations
thereunder, are hereby ratified and approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is hereby authorized to apply for a final order from the Supreme Court of British Columbia (the
&#147;<B>Court</B>&#148;) to approve the Arrangement in accordance with and subject to the terms and conditions set forth in the Transaction Agreement and the Plan of Arrangement, as they may be, or may have been, modified, supplemented or amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding that this resolution has been passed (and the Arrangement adopted) by the Zymeworks
Securityholders (as defined in the Proxy Statement/Prospectus) or that the Arrangement has been approved by the Court, the directors of the Company are hereby authorized and empowered without further notice to, or approval of, the Zymeworks
Securityholders (i)&nbsp;to amend, modify or supplement the Transaction Agreement, or the Plan of Arrangement to the extent permitted by the Transaction Agreement, and (ii)&nbsp;subject to the terms of the Transaction Agreement, to terminate the
Transaction Agreement and not proceed with the Arrangement and any related transactions, at any time prior to the Effective Time (as defined in the Transaction Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any officer or director of the Company is hereby authorized and directed for and on behalf of the Company to
execute or cause to be executed and to deliver or cause to be delivered, all such other documents and instruments and to perform or cause to be performed all such other acts and things as in such person&#146;s opinion may be necessary or desirable
to give full effect to the foregoing resolutions and the matters authorized thereby, such determination to be conclusively evidenced by the execution and delivery of such document, agreement or instrument or the doing of any such act or thing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any and all acts performed prior to the date of these resolutions by any director or officer of the Company,
acting for and on behalf of the Company, that are within the authority conferred by the foregoing resolutions are hereby ratified, confirmed, approved, satisfied and adopted in all respects as the authorized acts and deeds of the Company.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx722206_158"></A>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGEABLE SHARE SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS EXCHANGEABLE SHARE SUPPORT AGREEMENT </B>made as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 among <B>Zymeworks Delaware</B> Inc., a corporation existing under the Laws of the State of Delaware
(&#147;<B>Parent</B>&#148;), <B>Zymeworks CallCo</B> ULC, a company existing under the Laws of the Province of British Columbia (&#147;<B>CallCo</B>&#148;), and <B>Zymeworks ExchangeCo</B> Ltd., a company existing under the Laws of the Province of
British Columbia (&#147;<B>ExchangeCo</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RECITALS: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with a transaction agreement (the &#147;<B>Transaction Agreement</B>&#148;) dated July&nbsp;14,
2022 among Parent, CallCo, ExchangeCo and Zymeworks Inc. (&#147;<B>Zymeworks</B>&#148;), ExchangeCo is to issue exchangeable shares (the &#147;<B>Exchangeable Shares</B>&#148;) to certain holders of common shares of Zymeworks pursuant to an
arrangement under Division 5 of Part 9 of the <I>Business Corporations Act </I>(British Columbia) (the &#147;<B>Arrangement</B>&#148;) on the terms and conditions set out in the Plan of Arrangement (as defined in the Transaction Agreement).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the Transaction Agreement, Parent, CallCo and ExchangeCo are required to enter into an exchangeable
share support agreement (the &#147;<B>Agreement</B>&#148;) substantially in the form of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN CONSIDERATION of the
foregoing and the mutual agreements contained in this Agreement and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged), the parties hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
AND INTERPRETATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Defined Terms</B>. In this Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each capitalized term used and not otherwise defined in this Agreement shall have the meaning ascribed thereto
in the rights, privileges, restrictions and conditions (collectively, the &#147;<B>Exchangeable</B> <B>Share Provisions</B>&#148;) attaching to the Exchangeable Shares as set out in the articles of ExchangeCo, unless the context requires otherwise;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with, such Person. For purposes of this definition, the term &#147;<B>control</B>&#148; (including the correlative terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and
&#147;<B>under</B> <B>common control with</B>&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by
contract or otherwise. For purposes of this Agreement, &#147;Affiliate&#148; does not include any stockholders of Parent (other than Zymeworks), or directors or executive officers of Zymeworks, Parent, ExchangeCo or CallCo; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Person</B>&#148; includes an individual, partnership, association, body corporate, trustee, executor,
administrator, legal representative, government or any other entity, whether or not having legal status. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Interpretation Not Affected by Headings</B>. The division of this Agreement into Articles, Sections, subsections and
paragraphs and the insertion of headings are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. Unless the contrary intention appears, references in this Agreement to an Article,
Section, subsection, paragraph or Schedule by number or letter or both refer to the Article, Section, subsection, paragraph or Schedule, respectively, bearing that designation in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Number and Gender</B>. In this Agreement, unless the contrary intention
appears, words importing the singular include the plural and vice versa, and words importing gender shall include all genders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Date of any Action</B>. If the date on which any action is required to be taken under this Agreement by any Person is not
a Business Day, such action shall be required to be taken on the next succeeding day which is a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Statutes</B>. Any reference to a statute refers to such statute and all rules and regulations made under it, as it or
they may have been or may from time to time be amended or <FONT STYLE="white-space:nowrap">re-enacted,</FONT> unless stated otherwise. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS OF
PARENT AND EXCHANGECO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Covenants Regarding Exchangeable</B> <B>Shares</B>. So long as any Exchangeable Shares not
owned by Parent or its Affiliates are outstanding, Parent shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not take any action that will result in the declaration or payment of any dividend or make any other
distribution on the Delaware Common Stock (other than pursuant to a Preferred Stock Rights Agreement, as that term is defined in the Exchangeable Share Provisions) unless: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ExchangeCo shall (A)&nbsp;simultaneously declare or pay, as the case may be, an equivalent dividend or other
distribution economically equivalent thereto (as determined in accordance with the Exchangeable Share Provisions) on the Exchangeable Shares (an &#147;<B>Equivalent Dividend</B>&#148;), (B) in the case of a cash dividend or other distribution,
receive sufficient money or other assets from Parent (through any intermediary entities) to enable the due declaration and the due and punctual payment, in accordance with applicable Law and the Exchangeable Share Provisions, of any such Equivalent
Dividend, and (C)&nbsp;in the case of a dividend or other distribution that is a stock or share dividend or a distribution of stock or shares, have sufficient authorized but unissued securities available to enable the due declaration and the due and
punctual payment, in accordance with applicable Law and the Exchangeable Share Provisions, of any such Equivalent Dividend; provided however, for the avoidance of doubt, that in no event may ExchangeCo elect to effect a dividend or other
distribution that is a stock or share dividend or a distribution of stock or shares in the form of cash or property other than stock or shares; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the board of directors of ExchangeCo so chooses, in its sole discretion, as an alternative to taking any of
the actions described in paragraph (i)&nbsp;above, ExchangeCo shall adjust the Exchangeable Share Exchange Ratio in accordance with the Exchangeable Share Provisions, provided however that the Exchangeable Share Exchange Ratio shall only be so
adjusted to the extent that the board of directors of ExchangeCo determines in good faith and in its sole discretion that ExchangeCo would be liable for any unrecoverable tax as a result of taking any of the actions described in paragraph
(i)&nbsp;above, and determines to adjust the Exchangeable Share Exchange Ratio in lieu of taking any such action; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">advise ExchangeCo sufficiently in advance of the declaration by Parent of any dividend or other distribution on
the Delaware Common Stock (other than pursuant to a Preferred Stock Rights Agreement, as that term is defined in the Exchangeable Share Provisions) and take all such other actions as are reasonably necessary or desirable, in <FONT
STYLE="white-space:nowrap">co-operation</FONT> with ExchangeCo, to ensure that the respective declaration date, record date and payment date for an Equivalent Dividend shall be the same as the declaration date, record date and payment date for the
corresponding dividend or other distribution on the Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all such actions and do all such things as are reasonably necessary or desirable to enable and permit
ExchangeCo, in accordance with applicable Law, to pay and otherwise perform its obligations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
with respect to the satisfaction of the Liquidation Amount, the Retraction Price or the Redemption Price in respect of each issued and outstanding Exchangeable Share upon the liquidation,
dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo, whether voluntary or involuntary, or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, the delivery
of a Retraction Request by a holder of Exchangeable Shares or a redemption of Exchangeable Shares by ExchangeCo, as the case may be, including without limitation all such actions and all such things as are necessary or desirable to enable and permit
ExchangeCo to deliver or cause to be delivered Delaware Common Stock or other property to the holders of Exchangeable Shares in accordance with the provisions of Sections 26.5, 26.6 or 26.7, as the case may be, of the Exchangeable Share Provisions;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all such actions and do all such things as are reasonably necessary or desirable to enable and permit the
Share Trustee in accordance with applicable Law to perform its obligations under the Voting and Exchange Trust Agreement, including, without limitation, all such actions and all such things as are reasonably necessary or desirable to enable and
permit the Share Trustee in its capacity as trustee under the Voting and Exchange Trust Agreement to exercise such number of votes in respect of a Parent Meeting or a Parent Consent (as such terms are defined in the Voting and Exchange Trust
Agreement) as is equal to the aggregate number of Exchangeable Shares outstanding at the relevant time (other than those held by Parent and its Affiliates), multiplied by the Exchangeable Share Exchange Ratio, and rounded down to the nearest whole
vote in respect of any one Beneficiary (as that term is defined in the Voting and Exchange Trust Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all such actions and do all such things as are reasonably necessary or desirable to enable and permit
CallCo, in accordance with applicable Law, to perform its obligations arising upon the exercise by it of the Liquidation Call Right, the Retraction Call Right, the Change of Law Call Right or the Redemption Call Right (or upon the exercise by the
holder of the Exchangeable Shares of their right to require CallCo to exercise the Liquidation Call Right, the Retraction Call Right, the Change of Law Call Right or the Redemption Call Right), including without limitation all such actions and all
such things as are necessary or desirable to enable and permit CallCo to deliver or cause to be delivered Delaware Common Stock or other property to the holders of Exchangeable Shares in accordance with the provisions of the Liquidation Call Right,
the Retraction Call Right, the Change of Law Call Right or the Redemption Call Right, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all such actions and do all such things as are reasonably necessary or desirable to enable and permit
ExchangeCo in accordance with applicable Law, to perform its obligations in connection with a Retraction Request pursuant to Section&nbsp;26.6 of the Exchangeable Share Provisions and the redemption by ExchangeCo pursuant to Section&nbsp;26.7 of the
Exchangeable Share Provisions, including without limitation all such actions and all such things as are necessary or desirable to enable and permit ExchangeCo to deliver or cause to be delivered Delaware Common Stock or other property to the holders
of Exchangeable Shares in accordance with the provisions of Sections 26.6 or 26.7 of the Exchangeable Share Provisions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not, except as otherwise contemplated in the Exchangeable Shares Provisions: (i)&nbsp;exercise its vote as a
shareholder of ExchangeCo to initiate the voluntary liquidation, dissolution or winding up of ExchangeCo or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, or (ii)&nbsp;take any
action or omit to take any action that is designed to result in the liquidation, dissolution or winding up of ExchangeCo or any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, without
the approval of the holders of the Exchangeable Shares in accordance with the Exchangeable Share Provisions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Segregation of Funds</B>. Parent will cause ExchangeCo to deposit a sufficient amount of funds in a separate account of
ExchangeCo and segregate a sufficient amount of such other assets and property as is necessary to enable ExchangeCo to pay or otherwise satisfy its obligations with respect to the applicable dividend, Liquidation Amount, Retraction Price or
Redemption Price, in each case once such amounts become payable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the terms of this Agreement or the Exchangeable Share Provisions. Once such amounts become payable, Parent will transfer such funds to ExchangeCo (through any intermediary entities) and
ExchangeCo will use such funds, assets and property so segregated exclusively for the payment of dividends and the payment or other satisfaction of the Liquidation Amount, the Retraction Price or the Redemption Price, as applicable, net of any
corresponding withholding tax obligations and for the remittance of such withholding tax obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reservation of
Delaware Common Stock</B>. Parent hereby represents, warrants and covenants in favour of ExchangeCo and CallCo that Parent has reserved for issuance and shall, at all times while any Exchangeable Shares are outstanding, keep available, free from <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> and other rights, out of its authorized and unissued capital stock such number of Delaware Common Stock (or other shares or securities into which Delaware Common Stock may be reclassified or changed as
contemplated by Section&nbsp;2.7): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as is equal to the sum of (i)&nbsp;the number of Exchangeable Shares issued and outstanding from time to time
multiplied by the Exchangeable Share Exchange Ratio, and (ii)&nbsp;the number of Exchangeable Shares issuable upon the exercise of all rights to acquire Exchangeable Shares outstanding from time to time multiplied by the Exchangeable Share Exchange
Ratio; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as are now and may hereafter be required to enable and permit each of Parent, CallCo and ExchangeCo to meet its
obligations under the Voting and Exchange Trust Agreement, the Exchangeable Share Provisions and any other security or commitment relating to the Arrangement pursuant to which Parent may now or hereafter be required to issue or cause to be issued
Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notification of Certain Events</B>. In order to assist Parent to comply
with its obligations under this Agreement and to permit CallCo to exercise the Liquidation Call Right, the Retraction Call Right, the Change of Law Call Right or the Redemption Call Right, as applicable, ExchangeCo shall notify Parent and CallCo of
each of the following events at the time set forth below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of any determination by the board of directors of ExchangeCo to institute voluntary liquidation,
dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> proceedings with respect to ExchangeCo or to effect any other distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs, at least 60
days prior to the proposed effective date of such liquidation, dissolution, <FONT STYLE="white-space:nowrap">winding-up</FONT> or other distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promptly upon the earlier of (i)&nbsp;receipt by ExchangeCo of notice of, and (ii)&nbsp;ExchangeCo otherwise
becoming aware of, any threatened or instituted claim, suit, petition or other proceedings with respect to the involuntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo or to effect any other
distribution of the assets of ExchangeCo among its shareholders for the purpose of winding up its affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">immediately, upon receipt by ExchangeCo of a Retraction Request; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the same date on which notice of redemption is given to holders of Exchangeable Shares, upon the
determination of a Redemption Date in accordance with the Exchangeable Share Provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as soon as practicable upon the issuance by ExchangeCo of any Exchangeable Shares or rights to acquire
Exchangeable Shares (other than the issuance of Exchangeable Shares and rights to acquire Exchangeable Shares pursuant to the Arrangement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promptly, upon receiving notice of a Change of Law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Delivery of Delaware Common Stock</B>. Upon notice from CallCo or ExchangeCo of any event that requires CallCo or
ExchangeCo to deliver or cause to be delivered Delaware Common Stock to any holder of Exchangeable Shares, Parent shall forthwith issue and deliver or cause to be delivered the requisite number of shares of Delaware Common Stock for the benefit of
CallCo or ExchangeCo, as appropriate, and CallCo or ExchangeCo, as the case may be, shall forthwith cause to be delivered the requisite number of Delaware Common Stock to be received by or for the benefit of the former holder of the surrendered
Exchangeable Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
All such Delaware Common Stock shall be duly authorized and validly issued as fully paid, <FONT STYLE="white-space:nowrap">non-assessable,</FONT> free of preemptive rights and shall be free and
clear of any lien, claim or encumbrance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6&nbsp;&nbsp;&nbsp;&nbsp;Qualification of Delaware Common Stock. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent covenants and agrees that it shall use commercially reasonable efforts to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promptly file a prospectus supplement under a then existing and effective registration statement or a new
registration statement (such prospectus supplement or new registration statement, the &#147;<B>Registration Statement</B>&#148;) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or, if Parent is not then eligible to use Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> then such other form as Parent is then eligible to use, under the Securities Act of 1933, as amended (the &#147;<B>1933 Act</B>&#148;), to register the issuance of all shares of Delaware Common Stock to be
issued or delivered to holders of the Exchangeable Shares (including, for greater certainty, pursuant to the Exchange Right or the Automatic Exchange Right as described in the Voting and Exchange Trust Agreement); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cause the Registration Statement to become effective as soon as reasonably practicable; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cause the Registration Statement (or a successor registration statement) to remain effective at all times that
any Exchangeable Shares remain outstanding. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting the generality of Section&nbsp;2.6(1), Parent and CallCo each covenant and agree that it will
take all such actions and do all such things as are reasonably necessary or desirable to make such filings and seek such regulatory consents and approvals as are necessary so that the Delaware Common Stock to be issued or delivered to holders of
Exchangeable Shares by Parent or CallCo pursuant to the terms of the Exchangeable Share Provisions, the Voting and Exchange Trust Agreement and this Agreement will be offered, sold, issued and delivered in compliance with the 1933 Act and all
applicable state securities laws, and applicable securities laws in Canada and will use commercially reasonable efforts to ensure that the Delaware Common Stock will not be subject to any hold period as contemplated by Rule 144 under the 1933 Act or
subject to any &#147;hold period&#148; resale restriction under National Instrument <FONT STYLE="white-space:nowrap">45-102</FONT> <I>Resale of Securities</I>. Parent will in good faith expeditiously take all such actions and do all such things as
are reasonably necessary or desirable to cause all Delaware Common Stock to be delivered to holders of Exchangeable Shares pursuant to the terms of the Exchangeable Share Provisions, the Voting and Exchange Trust Agreement and this Agreement to be
listed, quoted and posted for trading on all stock exchanges and quotation systems on which outstanding Delaware Common Stock have been listed by Parent and remain listed and are quoted or posted for trading at such time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of the Exchangeable Share Provisions, or any term of this Agreement, the
Voting and Exchange Trust Agreement or the Plan of Arrangement, no Delaware Common Stock shall be issued (and Parent will not be required to issue any Delaware Common Stock) in connection with any liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of ExchangeCo, or any retraction, redemption or any other exchange, direct or indirect, of Exchangeable Shares, if such issuance of Delaware Common Stock would not be permitted by applicable Laws.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.7&nbsp;&nbsp;&nbsp;&nbsp;Economic Equivalence. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">So long as any Exchangeable Shares not owned by Parent or its Affiliates are outstanding:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent shall not without the prior approval of ExchangeCo and the prior approval of the holders of the
Exchangeable Shares given in accordance with Section&nbsp;26.11(b) of the Exchangeable Share Provisions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute Delaware Common Stock (or securities exchangeable for or convertible into or carrying
rights to acquire Delaware Common Stock) to the holders of all or substantially all of the then outstanding Delaware Common Stock by way of stock or share dividend or other distribution, other than an issue of Delaware Common Stock (or securities
exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) to holders of Delaware Common Stock (A)&nbsp;who exercise an option to receive dividends in Delaware Common Stock (or securities
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) in lieu of receiving cash dividends, (B)&nbsp;pursuant to any dividend reinvestment plan or scrip
dividend or similar arrangement, or (C)&nbsp;pursuant to a Preferred Stock Rights Agreement, as that term is defined in the Exchangeable Share Provisions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute rights, options or warrants to the holders of all or substantially all of the then
outstanding Delaware Common Stock entitling them to subscribe for or to purchase Delaware Common Stock or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock (other than pursuant to a Preferred Stock
Rights Agreement, as that term is defined in the Exchangeable Share Provisions); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute to the holders of all or substantially all of the then outstanding Delaware Common Stock
(A)&nbsp;shares or securities of Parent of any class other than Delaware Common Stock (or securities convertible into or exchangeable for or carrying rights to acquire Delaware Common Stock), (B) rights, options, warrants or other assets other than
those referred to in Section&nbsp;2.7(1)(a)(ii), (C) evidence of indebtedness of Parent, or (D)&nbsp;assets of Parent, except pursuant to a Preferred Stock Rights Agreement, as that term is defined in the Exchangeable Share Provisions;
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, ExchangeCo issues or distributes the economic equivalent of such rights, options, warrants,
securities, shares, evidences of indebtedness or other assets simultaneously to holders of the Exchangeable Shares or makes an adjustment to the Exchangeable Share Exchange Ratio in accordance with the terms of the Exchangeable Share Provisions;
provided, however, that, for greater certainty, the above restrictions shall not apply to any securities issued or distributed by Parent in order to give effect to and to consummate the transactions contemplated by, and in accordance with, the
Transaction Agreement and the Plan of Arrangement; provided, further, that the foregoing limitations and restrictions set forth in this Section&nbsp;2.7(1)(a) shall not apply to actions taken by Parent relating to a Preferred Stock Rights Agreement,
as that term is defined in the Exchangeable Share Provisions. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent shall not without the prior approval of ExchangeCo and the prior approval of the holders of the
Exchangeable Shares given in accordance with Section&nbsp;26.11(b) of the Exchangeable Share Provisions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide, redivide or change the then outstanding Delaware Common Stock into a greater number of Delaware
Common Stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce, combine, consolidate or change the then outstanding Delaware Common Stock into a lesser number of
Delaware Common Stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reclassify or otherwise change the Delaware Common Stock or effect an amalgamation, merger, combination,
reorganization or other transaction affecting the Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, the same or an
economically equivalent change is made simultaneously to, or in the rights of the holders of, the Exchangeable Shares; provided, however, that, for greater certainty, the above restrictions shall not apply to any securities issued or distributed by
Parent in order to give effect to and to consummate the transactions contemplated by, and in accordance with the Transaction Agreement and the Plan of Arrangement; provided, further, that the foregoing limitations and restrictions set forth in this
Section&nbsp;2.7(1)(b) shall not apply to actions taken by Parent relating to a Preferred Stock Rights Agreement, as that term is defined in the Exchangeable Share Provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The board of directors of ExchangeCo shall determine, in good faith and in its sole discretion (with the
assistance of such financial or other advisors as the board of may determine), &#147;economic equivalence&#148; for the purposes of any event referred to in Section&nbsp;2.7(1)(a) or Section&nbsp;2.7(1)(b) and each such determination shall be
conclusive and binding on Parent. In making each such determination, the following factors shall, without excluding other factors determined by the board of directors of ExchangeCo to be relevant, be considered by the board of directors of
ExchangeCo: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any stock or share dividend or other distribution payable in Delaware Common Stock, the number
of such shares issued as a result of such stock or share dividend or other distribution in proportion to the number of Delaware Common Stock previously outstanding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the issuance or distribution of any rights, options or warrants to subscribe for or purchase
Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock), the relationship between the exercise price of each such right, option or warrant, the number of such rights, options or
warrants to be issued or distributed in respect of each Delaware Common Stock and the Current Market Price of a Delaware Common Stock, the price volatility of the Delaware Common Stock and the terms of any such instrument; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the issuance or distribution of any other form of property (including without limitation any
shares or securities of Parent of any class other than Delaware Common Stock, any rights, options or warrants other than those referred to in Section&nbsp;2.7(2)(b), any evidences of indebtedness of Parent or any assets of Parent), the relationship
between the fair market value (as determined by the board of directors of ExchangeCo in the manner above contemplated) of such property to be issued or distributed with respect to each outstanding Delaware Common Stock and the Current Market Price
of the Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any subdivision, redivision or change of the then outstanding Delaware Common Stock into a
greater number of Delaware Common Stock or the reduction, combination, consolidation or change of the then outstanding Delaware Common Stock into a lesser number of Delaware Common Stock or any amalgamation, merger, combination, arrangement,
reorganization or other transaction affecting Delaware Common Stock, the effect thereof upon the then outstanding Delaware Common Stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in all such cases, the general taxation consequences of the relevant event to holders of Exchangeable Shares to
the extent that such consequences may differ from the taxation consequences to holders of Delaware Common Stock as a result of differences between taxation Laws of Canada and the United States (except for any differing consequences arising as a
result of differing marginal taxation rates and without regard to the individual circumstances of holders of Exchangeable Shares). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ExchangeCo agrees that, to the extent required, upon due notice from Parent, ExchangeCo shall use commercially
reasonable efforts to take or cause to be taken such steps as may be necessary for the purposes of ensuring that appropriate dividends are paid or other distributions are made by ExchangeCo, or the Exchangeable Share Exchange Ratio is adjusted, or
subdivisions, redivisions or changes are made to the Exchangeable Shares, as applicable, in order to implement the required economic equivalence with respect to the Delaware Common Stock and Exchangeable Shares as provided for in this
Section&nbsp;2.7. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tender Offers</B>. In the event that a tender offer, share exchange offer,
issuer bid, take-over bid or similar transaction with respect to Delaware Common Stock (an<B> </B>&#147;<B>Offer</B>&#148;) is proposed by Parent or is proposed to Parent or its shareholders and is recommended by the board of directors of Parent, or
is otherwise effected or to be effected with the consent or approval of the board of directors of Parent, and the Exchangeable Shares are not redeemed by ExchangeCo or purchased by CallCo pursuant to the Redemption Call Right, Parent and ExchangeCo
will use commercially reasonable efforts to take all such actions and do all such things as are necessary or desirable to enable and permit holders of Exchangeable Shares (other than Parent and its Affiliates) to participate in such Offer to the
same extent and on an economically equivalent basis as the holders of Delaware Common Stock, without discrimination. Without limiting the generality of the foregoing, Parent and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ExchangeCo will use commercially reasonable efforts in good faith to ensure that holders of Exchangeable Shares may participate in each such Offer without being required to retract Exchangeable
Shares as against ExchangeCo (or, if so required, to ensure that any such retraction shall be effective only upon, and shall be conditional upon, the closing of such Offer and only to the extent necessary to tender or deposit to the Offer). Nothing
in this Agreement shall affect the rights of ExchangeCo to redeem, or CallCo to purchase pursuant to the Redemption Call Right, Exchangeable Shares in the event of a Parent Control Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Parent</B><B></B><B>&nbsp;&amp; Affiliates Not to Vote Exchangeable</B> <B>Shares</B>. Each of Parent and CallCo
covenants and agrees that it shall appoint and cause to be appointed proxyholders with respect to all Exchangeable Shares held by it and its Affiliates for the sole purpose of attending each meeting of holders of Exchangeable Shares in order to be
counted as part of the quorum for each such meeting. Each of Parent and CallCo further covenants and agrees that it shall not, and shall cause its Affiliates not to, exercise any voting rights which may be exercisable by holders of Exchangeable
Shares from time to time pursuant to the Exchangeable Share Provisions or pursuant to the provisions of the <I>Business Corporations Act </I>(British Columbia) (or any successor or other corporate statute by which ExchangeCo may in the future be
governed) with respect to any Exchangeable Shares held by it or by its Affiliates in respect of any matter considered at any meeting of holders of Exchangeable Shares; provided however, for further clarity, that this Section&nbsp;2.9 shall not in
any way restrict the right of Parent or any of its Affiliates to vote their common shares of ExchangeCo in accordance with the articles of ExchangeCo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Ordinary Market Purchases</B>. For greater certainty, nothing contained in this Agreement, including without limitation
the obligations of Parent contained in Section&nbsp;2.8, shall limit the ability of Parent (or any of its Affiliates) to make ordinary market or other voluntary purchases of Delaware Common Stock in accordance with applicable Laws and regulatory or
stock exchange requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Ownership of Outstanding</B> <B>Shares</B>. Without the prior approval of ExchangeCo
and the prior approval of the holders of the Exchangeable Shares given in accordance with Section&nbsp;26.11(b) of the Exchangeable Share Provisions, Parent covenants and agrees in favour of ExchangeCo that, as long as any Exchangeable Shares not
owned by Parent or its Affiliates are outstanding, Parent will be and remain the direct or indirect beneficial owner of all issued and outstanding common shares in the capital of ExchangeCo and CallCo. Notwithstanding the foregoing, Parent shall not
be in violation of this Section&nbsp;2.11 if any Person or group of Persons acting jointly or in concert acquires all or substantially all of the assets of Parent or the Delaware Common Stock pursuant to any merger or similar transaction involving
Parent pursuant to which Parent is not the surviving corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reimbursement by Parent</B>. Parent shall
reimburse ExchangeCo for, and indemnify and hold ExchangeCo harmless against, any expense or liability incurred by ExchangeCo with respect to the Exchangeable Shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PARENT
SUCCESSORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Certain Requirements in Respect of Combination, etc.</B> Subject to Section&nbsp;26.7 of the
Exchangeable Share Provisions, and Article 4 with respect to a Parent Control Transaction, so long as any Exchangeable Shares not owned by Parent or its Affiliates are outstanding, Parent shall not enter into any transaction (whether by way of
reorganization, consolidation, arrangement, amalgamation, merger, combination, transfer, sale, lease or otherwise) whereby all or substantially all of its undertaking, property and assets would become the property of any other Person or, in the case
of an amalgamation or merger or combination, of the continuing corporation resulting therefrom, provided that it may do so if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other Person or continuing corporation (the &#147;<B>Parent Successor</B>&#148;) by operation of Law,
becomes bound by the terms and provisions of this Agreement or, if not so bound, executes, prior to or contemporaneously with the consummation of such transaction, an agreement supplemental hereto and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such other instruments (if any) as are necessary or advisable to evidence the assumption by the Parent Successor of liability for all moneys payable and property deliverable hereunder and the
covenant of such Parent Successor to pay and deliver or cause to be paid and delivered the same and its agreement to observe and perform all the covenants and obligations of Parent under this Agreement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such transaction shall be upon such terms and conditions as to preserve and not to impair any of the rights,
duties, powers and authorities of the other parties hereunder or the holders of the Exchangeable Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Vesting of Powers in</B> <B>Successor</B>. Whenever the conditions of Section&nbsp;3.1 have been duly observed and
performed, the parties, if required by Section&nbsp;3.1, shall execute and deliver the supplemental agreement provided for in Section&nbsp;3.1(a) and thereupon the Parent Successor and such other Person that may then be the issuer of the Delaware
Common Stock shall possess and from time to time may exercise each and every right and power of Parent under this Agreement in the name of Parent or otherwise and any act or proceeding by any provision of this Agreement required to be done or
performed by the board of directors of Parent or any officers of Parent may be done and performed with like force and effect by the directors or officers of such Parent Successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Wholly-Owned</B> <B>Subsidiaries</B>. Nothing herein shall be construed as preventing (a)&nbsp;the amalgamation or merger
or combination of any wholly-owned direct or indirect subsidiary of Parent (other than ExchangeCo or CallCo) with or into Parent, (b)&nbsp;the <FONT STYLE="white-space:nowrap">winding-up,</FONT> liquidation or dissolution of any wholly-owned direct
or indirect subsidiary of Parent (other than ExchangeCo or CallCo), provided that all of the assets of such subsidiary are transferred to Parent or another wholly-owned direct or indirect subsidiary of Parent, (c)&nbsp;any other distribution of the
assets of any wholly-owned direct or indirect subsidiary of Parent (other than ExchangeCo or CallCo) among the shareholders of such subsidiary for the purpose of winding up its affairs, and (d)&nbsp;any such transactions are expressly permitted by
this Article 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Successorship Transaction</B>. Notwithstanding the foregoing provisions of this Article 3, in the
event of a Parent Control Transaction: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which Parent merges, combines or amalgamates with, or in which all or substantially all of the then
outstanding Delaware Common Stock are acquired by, one or more other corporations to which Parent is, immediately before such merger, combination, amalgamation or acquisition, &#147;related&#148; within the meaning of the <I>Income Tax Act
</I>(Canada) (otherwise than by virtue of a right referred to in paragraph 251(5)(b) thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which does not result in an acceleration of the Redemption Date in accordance with paragraph (ii)&nbsp;of the
definition of Redemption Date in the Exchangeable Share Provisions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which all or substantially all of the then outstanding Delaware Common Stock are converted into or exchanged
for shares or rights to receive such shares (the &#147;<B>Other Shares</B>&#148;) or another corporation (the &#147;<B>Other Corporation</B>&#148;) that, immediately after such Parent Control Transaction, owns or controls, directly or indirectly,
Parent; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then all references in this Agreement to &#147;Parent&#148; shall thereafter be and be deemed to be references to &#147;Other
Corporation&#148; and all references in this Agreement to &#147;Delaware Common Stock&#148; shall thereafter be and be deemed to be references to &#147;Other Shares&#148; (with appropriate adjustments if any, as are required to result in a holder of
Exchangeable Shares on the exchange, redemption or retraction of such shares pursuant to the Exchangeable Share Provisions or the exchange of such shares pursuant to the Voting and Exchange Trust Agreement immediately subsequent to the Parent
Control Transaction being entitled to receive that number of Other Shares equal to the number of Other Shares such holder of Exchangeable Shares would have received if the exchange, redemption or retraction of such shares pursuant to the
Exchangeable Share Provisions, or the exchange of such shares pursuant to the Voting and Exchange Trust Agreement had occurred immediately prior to the Parent Control Transaction and the Parent Control Transaction was completed) but subject to
subsequent adjustments to reflect any subsequent changes in the share capital of the issuer of the Other Shares, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without limitation, any subdivision, consolidation or reduction of share capital, without any need to amend the terms and conditions of the Exchangeable Shares and without any further action
required. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN RIGHTS OF PARENT&nbsp;&amp; CALLCO TO ACQUIRE EXCHANGEABLE SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Liquidation Call Right</B>. The parties hereby acknowledge the rights and obligations of CallCo in respect of the
Exchangeable Shares as contained in Section&nbsp;26.17 of the Exchangeable Share Provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Redemption Call
Right</B>. The parties hereby acknowledge the rights and obligations of CallCo in respect of the Exchangeable Shares as contained in Section&nbsp;26.18 of the Exchangeable Share Provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Change of Law Call Right</B>. The parties hereby acknowledge the rights and obligations of CallCo in respect of the
Exchangeable Shares as contained in Section&nbsp;26.19 of the Exchangeable Share Provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Retraction Call
Right</B>. The parties hereby acknowledge the rights and obligations of CallCo in respect of the Exchangeable Shares contained in Section&nbsp;26.6(b) of the Exchangeable Share Provisions. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term</B>. This Agreement shall come into force and be effective as of the date hereof and shall terminate and be
of no further force and effect at such time as no Exchangeable Shares (or securities or rights convertible into or exchangeable for or carrying rights to acquire Exchangeable Shares) are held by any Person other than Parent and any of its
Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Changes in Capital of Parent</B><B></B><B>&nbsp;&amp; </B><B>ExchangeCo</B>. Notwithstanding the
provisions of Section&nbsp;5.4, at all times after the occurrence of any event contemplated pursuant to Section&nbsp;2.7 and Section&nbsp;2.8 or otherwise, as a result of which either Delaware Common Stock or the Exchangeable Shares or both are in
any way changed, this Agreement shall forthwith be amended and modified as necessary in order that it shall apply with full force and effect, mutatis mutandis, to all new securities into which Delaware Common Stock or the Exchangeable Shares or both
are so changed and the parties shall execute and deliver an agreement in writing giving effect to and evidencing such necessary amendments and modifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability</B>. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by
any rule or Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the
original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments, Modifications</B>. Subject to Section&nbsp;5.2, Section&nbsp;5.3 and Section&nbsp;5.5, this Agreement may not
be amended or modified except by an agreement in writing executed by Parent, CallCo and ExchangeCo and approved by the holders of the Exchangeable Shares in accordance with Section&nbsp;26.11(b) of the Exchangeable Share Provisions. No amendment or
modification or waiver of any of the provisions of this Agreement otherwise permitted hereunder shall be effective unless made in writing and signed by all of the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Ministerial Amendments</B>. Notwithstanding the provisions of
Section&nbsp;5.4, the parties to this Agreement may in writing at any time and from time to time, without the approval of the holders of the Exchangeable Shares, amend or modify this Agreement for the purposes of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding to the covenants of any or all of the parties hereto if the board of directors of each of Parent, CallCo
and ExchangeCo shall be of the good faith opinion that such additions will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evidencing the succession of Parent Successors and the covenants of and obligations assumed by each such Parent
Successor in accordance with the provisions of Article 3; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such amendments or modifications not inconsistent with this Agreement as may be necessary or desirable
with respect to matters or questions arising hereunder which, in the good faith opinion of the board of directors of each of Parent, CallCo and ExchangeCo, it may be expedient to make, provided that each such board of directors shall be of the good
faith opinion, after consultation with counsel, that such amendments or modifications will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such changes or corrections hereto which, on the advice of counsel to Parent, CallCo and ExchangeCo, are
required for the purpose of curing or correcting any ambiguity or defect or inconsistent provision or clerical omission or mistake or manifest error contained herein, provided that the boards of directors of each of Parent, CallCo and ExchangeCo
shall be of the good faith opinion that such changes or corrections will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Meeting to Consider Amendments</B>. ExchangeCo, at the request of Parent, shall call a meeting or meetings of the holders
of the Exchangeable Shares for the purpose of considering any proposed amendment or modification requiring approval pursuant to Section&nbsp;5.4. Any such meeting or meetings shall be called and held in accordance with the articles of ExchangeCo,
the Exchangeable Share Provisions and all applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Enurement</B>. This Agreement shall be binding upon and
enure to the benefit of the parties hereto and their respective successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices to Parties</B>. Any
notice and other communications required or permitted to be given pursuant to this Agreement shall be sufficiently given if delivered in Person or if sent by facsimile transmission or <FONT STYLE="white-space:nowrap">e-mail</FONT> (provided such
transmission is recorded as being transmitted successfully) to the parties at the following addresses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of Parent, at the following address: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Middletown, DE 19709 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a
copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">114 East 4th Avenue, Suite 800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vancouver, BC, V5T 1G4 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Legal Department </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of CallCo or ExchangeCo, at the following address: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">114 East 4th Avenue, Suite 800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vancouver, BC, V5T 1G4 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Legal Department </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and such notice or other communication shall be deemed to have been given and received (x)&nbsp;if delivered on a Business Day prior to
5:00 p.m. (local time in the place where the notice or other communication is received), on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date of delivery, or (y)&nbsp;otherwise, on the next Business Day. Either party may change its address for notice by giving notice to the other parties in accordance with the foregoing
provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an
original, and all of which taken together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Jurisdiction</B>. This
Agreement shall be construed and enforced in accordance with the Laws of the Province of British Columbia and the Laws of Canada applicable therein. Each party hereto irrevocably submits to the exclusive jurisdiction of the courts of the Province of
British Columbia with respect to any matter arising hereunder or related hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of this page left intentionally blank]
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be duly executed as of the date
first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS DELAWARE INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS EXCHANGECO LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS CALLCO ULC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx722206_171"></A>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING AND EXCHANGE TRUST AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS VOTING AND EXCHANGE TRUST AGREEMENT</B> (as it may be amended from time to time, the &#147;<B>Agreement</B>&#148;) made as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 among <B>Zymeworks Delaware Inc.</B>, a corporation existing under the laws of the State of Delaware
(&#147;<B>Parent</B>&#148;), <B>Zymeworks CallCo</B> <B>ULC</B>, an unlimited liability company existing under the laws of the Province of British Columbia (&#147;<B>CallCo</B>&#148;), <B>Zymeworks ExchangeCo</B> <B>Ltd.</B>, a company existing
under the laws of the Province of British Columbia (&#147;<B>ExchangeCo</B>&#148;), and <B>Computershare Trust Company of Canada</B>, a trust company existing under the laws of Canada (the &#147;<B>Share Trustee</B>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RECITALS: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with a transaction agreement (the &#147;<B>Transaction Agreement</B>&#148;) dated July&nbsp;14,
2022 among Parent, CallCo, ExchangeCo and Zymeworks Inc. (&#147;<B>Zymeworks</B>&#148;), ExchangeCo is to issue exchangeable shares (the &#147;<B>Exchangeable Shares</B>&#148;) to certain holders of common shares of Zymeworks pursuant to an
arrangement under Division 5 of Part 9 of the <I>Business Corporations Act</I> (British Columbia) on the terms and conditions set out in the Plan of Arrangement (as defined in the Transaction Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the Transaction Agreement, Parent, CallCo, ExchangeCo and the Share Trustee are required to enter
into a voting and exchange trust agreement substantially in the form of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These recitals and any statements of fact in this Agreement are made by Parent, CallCo, and ExchangeCo and not
by the Share Trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN CONSIDERATION of the foregoing and the mutual agreements contained herein and for other good and valuable
consideration (the receipt and sufficiency of which are hereby acknowledged), the parties agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS AND INTERPRETATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Agreement, each capitalized term used and not otherwise defined herein shall have the meaning ascribed thereto in the Exchangeable Share Provisions,
and the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>1933 Act</B>&#148; has the meaning ascribed thereto in
Section&nbsp;5.10; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning ascribed thereto in the introductory paragraph; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affected Person</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.13(1); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any person, any other person who, directly or indirectly, controls, is controlled by, or is
under common control with, such person. For purposes of this definition, the term &#147;<B>control</B>&#148; (including the correlative terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under</B> <B>common control
with</B>&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise. For purposes of
this Agreement, &#147;Affiliate&#148; does not include any stockholders of Parent (other than Zymeworks), or directors or executive officers of Zymeworks, Parent, ExchangeCo or CallCo; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Automatic Exchange Right</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.12(2); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Beneficiaries</B>&#148; means the registered holders from time to time of Exchangeable Shares, other than Parent, CallCo and their
Affiliates; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Beneficiary Votes</B>&#148; has the meaning ascribed thereto in Section&nbsp;4.2;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Broker</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.13(2)(a); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CallCo</B>&#148; has the meaning ascribed thereto in the introductory paragraph; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Electronic Methods</B>&#148; has the meaning ascribed thereto in Section&nbsp;13.8; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equivalent Vote Amount</B>&#148; means, with respect to any matter, proposition, proposal or question on which holders of Delaware
Common Stock are entitled to vote, consent or otherwise act, the number of votes to which a holder of one Delaware Common Stock is entitled with respect to such matter, proposition or question; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Right</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.1; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Consideration</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Document</B>&#148; means (i)&nbsp;a share certificate representing Exchangeable Shares, (ii)&nbsp;a <FONT
STYLE="white-space:nowrap">non-transferable</FONT> acknowledgement of a shareholder&#146;s right to obtain a share certificate representing Exchangeable Shares, or (iii)&nbsp;a direct registration system advice (or similar document) evidencing the
electronic registration of the ownership of Exchangeable Shares, as applicable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Exchange Price</B>&#148; has
the meaning ascribed thereto in the Exchangeable Share Provisions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Exchange Ratio</B>&#148; has the meaning
ascribed thereto in the Exchangeable Share Provisions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Provisions</B>&#148; means the rights, privileges,
restrictions and conditions attaching to the Exchangeable Shares as set out in the Articles of ExchangeCo, as they may be amended from time to time, a copy of which is attached as Exhibit A, and is current as if the date of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Shares</B>&#148; has the meaning ascribed thereto in Recital A; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ExchangeCo</B>&#148; has the meaning ascribed thereto in the introductory paragraph; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Entity</B>&#148;<B> </B>means any United States, Canadian, international or other (i)&nbsp;federal, state, provincial,
local, municipal or other government entity, (ii)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal) or (iii)&nbsp;body exercising
or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitrator or arbitral tribunal (public or private); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnified Parties</B>&#148; has the meaning ascribed thereto in Section&nbsp;8.1; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Insolvency Event</B>&#148; means (i)&nbsp;the institution by ExchangeCo of any proceeding to be adjudicated a bankrupt or insolvent or
to be dissolved or wound up, or the consent of ExchangeCo to the institution of bankruptcy, insolvency, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> proceedings against it, (ii)&nbsp;the filing by ExchangeCo of a petition,
answer or consent seeking dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> under any bankruptcy, insolvency or analogous laws, including the <I>Companies Creditors&#146; Arrangement Act</I> (Canada) and the Bankruptcy and
<I>Insolvency Act</I> (Canada), or the failure by ExchangeCo to contest in good faith any such proceedings commenced in respect of ExchangeCo within 30 days of becoming aware thereof, or the consent by ExchangeCo to the filing of any such petition
or to the appointment of a receiver, (iii)&nbsp;the making by ExchangeCo of a general assignment for the benefit of creditors, or the admission in writing by ExchangeCo of its inability to pay its debts generally as they become due, or
(iv)&nbsp;ExchangeCo not being permitted, pursuant to solvency requirements of applicable law, to redeem any Retracted Shares pursuant to Section&nbsp;26.6(a)(iii) of the Exchangeable Share Provisions specified in a retraction request delivered to
ExchangeCo in accordance with Section&nbsp;26.6 of the Exchangeable Share Provisions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Event</B>&#148; has the meaning ascribed thereto in
Section&nbsp;5.12(1)(a); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Event Effective Date</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.12(2);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>List</B>&#148; has the meaning ascribed thereto in Section&nbsp;4.6; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Officer&#146;s Certificate</B>&#148; means, with respect to Parent, CallCo or ExchangeCo, a certificate signed by any one of the
respective directors or officers of Parent, CallCo or ExchangeCo; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Corporation</B>&#148; has the meaning ascribed thereto in
Section&nbsp;10.4(c); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Shares</B>&#148; has the meaning ascribed thereto in Section&nbsp;10.4(c); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Withholding Agent</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.13(1); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent</B>&#148; has the meaning ascribed thereto in the introductory paragraph; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Consent</B>&#148; has the meaning ascribed thereto in Section&nbsp;4.2; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Meeting</B>&#148; has the meaning ascribed thereto in Section&nbsp;4.2; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Successor</B>&#148; has the meaning ascribed thereto in Section&nbsp;10.1(a); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>person</B>&#148; includes an individual, partnership, corporation, limited liability company, joint stock company, unincorporated
organization or association, trust, joint venture, trustee, executor, administrator, legal representative, government or any other entity, whether or not a legal entity, as the context requires; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Laws</B>&#148; has the meaning ascribed thereto in Section&nbsp;6.18; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Date</B>&#148; has the meaning ascribed thereto in the Exchangeable Share Provisions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Statement</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.10; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retracted Shares</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.7; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Special Voting Stock</B>&#148; means the share of preferred stock of Parent, issued by Parent to and deposited with the Share Trustee,
which, at any time, entitles the holder of record to that number of votes at meetings of holders of Delaware Common Stock equal to the number of Exchangeable Shares outstanding as of the record date for such meeting (excluding Exchangeable Shares
held by Parent, CallCo and their Affiliates) multiplied by the Exchangeable Share Exchange Ratio, and in respect of each Beneficiary, rounded down to the nearest whole vote; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Support Agreement</B>&#148; means the exchangeable share support agreement dated the date hereof between Parent, CallCo and
ExchangeCo, substantially in the form of Exhibit C to the Transaction Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreement</B>&#148; has the meaning
ascribed thereto in Recital A; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust</B>&#148; means the trust created by this Agreement under the laws of the Province of
British Columbia; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Estate</B>&#148; means the Special Voting Stock, any other securities, the Exchange Right, the Automatic
Exchange Right and any money or other property which may be held by the Share Trustee from time to time pursuant to this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Share Trustee</B>&#148; has the meaning ascribed thereto in the introductory paragraph; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Voting Rights</B>&#148; means the voting rights attached to the Special Voting Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Withholding Obligation</B>&#148; has the meaning ascribed thereto in Section&nbsp;5.13(1); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Zymeworks</B>&#148; has the meaning ascribed thereto in Recital A. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation Not Affected by Headings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The division of this Agreement into Articles, Sections, subsections and paragraphs and the insertion of headings are for convenience of reference only and
shall not affect in any way the meaning or interpretation of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement. Unless the contrary intention appears, references in this Agreement to an Article, Section, subsection, paragraph or Schedule by number or letter or both refer to the Article, Section,
subsection, paragraph or Schedule, respectively, bearing that designation in this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Number, Gender, etc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Agreement, unless the contrary intention appears, words importing the singular include the plural and vice versa, and words importing gender shall
include all genders. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Date for any Action </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the date on which any action is required to be taken hereunder by any person is not a Business Day, such action shall be required to be taken on the next
succeeding day which is a Business Day. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, all references in this Agreement to sums of money are expressed in lawful money of the United States and &#147;$&#148; refers to
United States dollars. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Statutes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any reference to a statute refers to such statute and all rules and regulations made under it, as it or they may have been or may from time to time be amended
or <FONT STYLE="white-space:nowrap">re-enacted,</FONT> unless stated otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the Exhibits attached to and incorporated in this Agreement by reference and deemed to be a part of this Agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exhibit A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exchangeable Share Provisions</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice of Exercise</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE OF AGREEMENT </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Establishment of Trust </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this Agreement is to create the Trust for the benefit of the Beneficiaries as herein provided. Parent, as the settlor of the Trust, hereby
appoints the Share Trustee as Share Trustee of the Trust and settles upon the Share Trustee the Special Voting Stock and US$1.00. The Share Trustee shall hold the Special Voting Stock in order to enable the Share Trustee to exercise the Voting
Rights and shall hold the Exchange Right and the Automatic Exchange Right in order to enable the Share Trustee to exercise or enforce such rights, in each case as Share Trustee for and on behalf of the Beneficiaries as provided in this Agreement.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL
VOTING STOCK </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue and Ownership of the Special Voting Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following execution and delivery of this Agreement, Parent shall issue to and deposit with the Share Trustee the Special Voting Stock (and shall
deliver the certificate or book-entry evidence representing such share to the Share Trustee) to be hereafter held of record by the Share Trustee as Share Trustee for and on behalf of, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and for the use and benefit of, the Beneficiaries and in accordance with the provisions of this Agreement. Parent hereby acknowledges receipt from the Share Trustee, as Share Trustee for and on
behalf of the Beneficiaries, of intangible consideration (and the adequacy thereof) for the issuance of the Special Voting Stock by Parent to the Share Trustee. During the term of the Trust, and subject to the terms and conditions of this Agreement,
the Share Trustee shall possess and be vested with full legal ownership of the Special Voting Stock and shall be entitled to exercise all of the rights and powers of an owner with respect to the Special Voting Stock; provided, however, that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Share Trustee shall hold the Special Voting Stock and the legal title thereto as Share Trustee solely for
the use and benefit of the Beneficiaries in accordance with the provisions of this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except as specifically authorized by this Agreement, the Share Trustee shall have no power or authority to
sell, transfer, vote or otherwise deal in or with the Special Voting Stock and the Special Voting Stock shall not be used or disposed of by the Share Trustee for any purpose (including for exercising dissent or appraisal rights relating to the
Special Voting Stock) other than the purposes for which this Trust is created pursuant to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legended <FONT STYLE="white-space:nowrap">Non-Transferable</FONT> Acknowledgements
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ExchangeCo shall cause each Exchangeable Share Document representing Exchangeable Shares to bear a legend notifying the Beneficiary
of such shares of his, her or its right to instruct the Share Trustee with respect to the exercise of that portion of the Voting Rights which corresponds to the number of Exchangeable Shares held by each such Beneficiary. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Safe Keeping of Certificate </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The certificate or book-entry evidence representing the Special Voting Stock delivered to the Share Trustee shall at all times be held in safe keeping by the
Share Trustee or its duly authorized agent. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE OF VOTING RIGHTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Voting Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee, as the holder of record of the Special Voting Stock, shall be entitled to exercise all of the Voting Rights, including the right to consent
to or vote in person or by proxy the Special Voting Stock, on any matter, question, proposal or proposition whatsoever that may properly come before the stockholders of Parent at a Parent Meeting or in connection with a Parent Consent. The Voting
Rights shall be and remain vested in and exercisable by the Share Trustee on behalf of the Beneficiaries as provided in this Agreement. Subject to Section&nbsp;6.15: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Share Trustee shall exercise the Voting Rights only on the basis of instructions received pursuant to this
Article 4 from Beneficiaries on the record date established by Parent or by applicable law for such Parent Meeting or Parent Consent who are entitled to instruct the Share Trustee as to the voting thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that no instructions are received from a Beneficiary with respect to the Voting Rights in respect
of which such Beneficiary is entitled to instruct the Share Trustee, the Share Trustee shall not exercise or permit the exercise of such Voting Rights; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">without prejudice to paragraph (b)&nbsp;above, under no circumstances shall the Share Trustee exercise or
permit the exercise of a number of Voting Rights which is greater than the number of Exchangeable Shares outstanding at the relevant time multiplied by the Exchangeable Share Exchange Ratio. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Number of Votes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to all meetings of stockholders of Parent at which holders of Delaware Common Stock are entitled to vote (each, a &#147;<B>Parent
Meeting</B>&#148;) and with respect to all written consents, if any, sought by Parent from holders of Delaware Common Stock (each, a &#147;<B>Parent Consent</B>&#148;), each Beneficiary shall be entitled to instruct the Share Trustee to cast and
exercise, in the manner instructed, that number of votes equal to the Equivalent Vote Amount for each Exchangeable Share owned of record by such Beneficiary at the close of business on the record date established by Parent or by applicable law for
such Parent Meeting or Parent Consent, as the case may be, multiplied by the Exchangeable Share Exchange Ratio, and in respect of each Beneficiary, rounded down to the nearest whole vote (collectively, the &#147;<B>Beneficiary Votes</B>&#148;), in
respect of each matter, question, proposal or proposition to be voted on at such Parent Meeting or consented to in connection with such Parent Consent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mailings to Stockholders </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to each Parent Meeting or Parent Consent, the Share Trustee will mail or cause to be mailed or
delivered via electronic transmission in a manner contemplated by Section&nbsp;232 of the Delaware General Corporation Law (or otherwise communicate in the same manner as Parent utilizes in communications to holders of Delaware Common Stock,
including without limitation in accordance with the notice and access rules promulgated by the U.S. Securities and Exchange Commission (&#147;<B>SEC</B>&#148;), subject to applicable regulatory requirements and to the Share Trustee being advised in
writing of such manner of communications and provided that such manner of communications is reasonably available to the Share Trustee) to each Beneficiary named in the applicable List on the same day as the mailing (or other communication) with
respect thereto is commenced by Parent to its stockholders: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of such mailing or other notice, together with any related materials, including, without limitation, any
proxy statement or notice of internet availability of proxy materials, to be provided to stockholders of Parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statement that such Beneficiary is entitled to instruct the Share Trustee as to the exercise of the
Beneficiary Votes with respect to such Parent Meeting or Parent Consent or, pursuant to Section&nbsp;4.7, to attend such Parent Meeting and to exercise personally the Beneficiary Votes thereat; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statement as to the manner in which such instructions may be given to the Share Trustee, including an express
indication that instructions may be given to the Share Trustee to give (A)&nbsp;a proxy to such Beneficiary or his, her or its designee to exercise personally such holder&#146;s Beneficiary Votes, or (B)&nbsp;a proxy to a designated agent or other
representative of Parent to exercise such holder&#146;s Beneficiary Votes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statement that if no such instructions are received from such Beneficiary, the Beneficiary Votes to which the
Beneficiary is entitled will not be exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a form of direction such Beneficiary may use to direct and instruct the Share Trustee as contemplated herein;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a statement of (A)&nbsp;the time and date by which such instructions must be received by the Share Trustee in
order for such instructions to be binding upon the Share Trustee, which in the case of a Parent Meeting shall not be earlier than the close of business on the Business Day immediately prior to the date by which Parent has required proxies to be
deposited for such meeting, and (B)&nbsp;of the method for revoking or amending such instructions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The materials referred to in this Section&nbsp;4.3 shall be provided to the Share Trustee by Parent, and the
materials referred to in Sections 4.3(1)(b), 4.3(1)(c), 4.3(1)(d), 4.3(1)(e) and 4.3(1)(f) shall (if reasonably practicable to do so) be subject to reasonable comment by the Share Trustee in a timely manner. Subject to the foregoing, Parent shall
ensure that the materials to be provided to the Share Trustee are provided in sufficient time to permit the Share Trustee to comment as aforesaid and to send all materials to each Beneficiary at the same time as such materials are first sent to
holders of Delaware Common Stock. Parent </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
agrees not to communicate with holders of Delaware Common Stock with respect to the materials referred to in this Section&nbsp;4.3 otherwise than by mail unless such method of communication is
also reasonably available to the Share Trustee for communication with the Beneficiaries. Notwithstanding the foregoing, Parent may, at its option, exercise the duties of the Share Trustee to deliver copies of all materials to all Beneficiaries as
required by this Section&nbsp;4.3 so long as, in each case, Parent delivers a certificate to the Share Trustee stating that Parent has undertaken to perform the obligations of the Share Trustee set forth in this Section&nbsp;4.3. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining the number of Beneficiary Votes to which a Beneficiary is entitled in respect of
any Parent Meeting or Parent Consent, the number of Exchangeable Shares owned of record by the Beneficiary shall be determined at the close of business on the record date established by Parent or by applicable law for purposes of determining
stockholders entitled to vote at such Parent Meeting or in respect of such Parent Consent, which number of Beneficiary Votes shall be as set forth in the List. Parent shall notify the Share Trustee of any decision of the board of directors of Parent
with respect to the calling of any Parent Meeting or any Parent Consent and shall provide all necessary information, including a certificate executed by a duly authorized officer of Parent confirming the applicable number of votes attributable to
each outstanding Exchangeable Share as of the applicable record date, and materials to the Share Trustee in each case promptly and, in any event, in sufficient time to enable the Share Trustee to perform the obligations of the Share Trustee set
forth in this Section&nbsp;4.3. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Copies of Stockholder Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent shall deliver to the Share Trustee copies of all proxy materials (including, without limitation, notices of Parent Meetings but excluding proxies to
vote Delaware Common Stock), proxy statements, reports (including, without limitation, all interim and annual financial statements) and other written communications that, in each case, are required to be distributed by Parent from time to time to
holders of Delaware Common Stock in sufficient quantities and in sufficient time so as to enable the Share Trustee to send or cause to send those materials to each Beneficiary at the same time as such materials are first sent to holders of Delaware
Common Stock. The Share Trustee shall mail or otherwise send to each Beneficiary, at the expense of Parent, copies of all such materials (and all materials specifically directed to the Beneficiaries or to the Share Trustee for the benefit of the
Beneficiaries by Parent) received by the Share Trustee from Parent contemporaneously with the sending of such materials to holders of Delaware Common Stock. The Share Trustee shall also make available for inspection, on an appointment basis, during
regular business hours by any Beneficiary at the Share Trustee&#146;s principal office in Vancouver, British Columbia all proxy materials, information statements, reports and other written communications that are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">received by the Share Trustee as the registered holder of the Special Voting Stock and made available by Parent
generally to the holders of Delaware Common Stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">specifically directed to the Beneficiaries or to the Share Trustee for the benefit of the Beneficiaries by
Parent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Parent may, at its option, exercise the duties of the Share Trustee to deliver copies of all
such materials to all Beneficiaries as required by this Section&nbsp;4.4 so long as, in each case, Parent delivers a certificate to the Share Trustee stating that Parent has undertaken to perform the obligations of the Share Trustee set forth in
this Section&nbsp;4.4. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Materials </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As soon as reasonably practicable after receipt by Parent or stockholders of Parent (if such receipt is known by Parent) of any material sent or given by or on
behalf of a third party to holders of Delaware Common Stock generally, including proxy statements with respect to contested proposals (and related information and material) and tender offers and exchange offers (and related information and
material), provided such material has not been sent to the Beneficiaries by or on behalf of such third party, Parent shall use its reasonable efforts to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and deliver to the Share Trustee copies thereof in sufficient quantities so as to enable the Share Trustee to forward such material (unless the same has been provided directly to Beneficiaries by
such third party) to each Beneficiary as soon as possible thereafter. As soon as reasonably practicable after receipt thereof, the Share Trustee shall mail or otherwise send to each Beneficiary, at the expense of Parent, copies of all such materials
received by the Share Trustee from Parent. The Share Trustee shall also make available for inspection, on an appointment basis, during regular business hours by any Beneficiary at the Share Trustee&#146;s principal office in Vancouver, British
Columbia copies of all such materials. Notwithstanding the foregoing, Parent may, at its option, exercise the duties of the Share Trustee to deliver copies of all such materials to all Beneficiaries as required by this Section&nbsp;4.5 so long as,
in each case, Parent delivers a certificate to the Share Trustee stating that Parent has undertaken to perform the obligations of the Share Trustee set forth in this Section&nbsp;4.5. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>List of Persons Entitled to Vote </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ExchangeCo shall (a)&nbsp;prior to each annual meeting of stockholders of Parent or other Parent Meeting or the seeking of any Parent Consent, and
(b)&nbsp;forthwith upon each request made at any time by the Share Trustee in writing, prepare or cause to be prepared a list (a &#147;<B>List</B>&#148;) of the names and addresses of the Beneficiaries arranged in alphabetical order and showing the
number of Exchangeable Shares (multiplied by the Exchangeable Share Exchange Ratio, and in respect of each Beneficiary, rounded down to the nearest whole share) held of record by each such Beneficiary, in each case at the close of business on the
date specified by the Share Trustee in such request or, in the case of a List prepared in connection with a Parent Meeting or Parent Consent, at the close of business on the record date established by Parent or pursuant to applicable law for
determining the holders of Delaware Common Stock entitled to receive notice of and/or to vote at such Parent Meeting or to give consent in connection with a Parent Consent. Each such List shall be delivered to the Share Trustee promptly after
receipt by ExchangeCo of such request or the record date for such meeting or seeking of consent, as the case may be, and, in any event, within sufficient time as to permit the Share Trustee to perform its obligations under this Agreement. Parent
agrees to give ExchangeCo notice (with a copy to the Share Trustee) of the calling of any Parent Meeting or the seeking of any Parent Consent, together with the record date therefor, sufficiently prior to the date of the calling of such meeting or
seeking of such consent, so as to enable ExchangeCo to perform its obligations under this Section&nbsp;4.6. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entitlement to Direct Votes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;4.8 and Section&nbsp;4.11, any Beneficiary named in a List prepared in connection with any Parent Meeting or Parent Consent shall be
entitled to (a)&nbsp;instruct the Share Trustee in the manner described in Sections 4.2 and 4.3 with respect to the exercise of the Beneficiary Votes to which such Beneficiary is entitled, (b)&nbsp;attend such meeting and personally exercise thereat
(or to exercise with respect to any written consent), as the proxy of the Share Trustee, the Beneficiary Votes to which such Beneficiary is entitled, or (c)&nbsp;appoint a third party as the proxy of the Share Trustee to attend such meeting and
exercise thereat the Beneficiary Votes to which such Beneficiary is entitled except, in each case, to the extent that such Beneficiary has transferred the ownership of any Exchangeable Shares in respect of which such Beneficiary is entitled to
Beneficiary Votes after the close of business on the record date for such meeting or seeking of consent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Voting by Share Trustee and Attendance of Share Trustee Representative at Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with each Parent Meeting and Parent Consent, the Share Trustee shall exercise, either in person
or by proxy, in accordance with the instructions received from a Beneficiary pursuant to Section&nbsp;4.2 and in the form required under Section&nbsp;4.3(1)(e), the Beneficiary Votes as to which such Beneficiary is entitled to direct the vote (or
any lesser number thereof as may be set forth in the instructions) other than any Beneficiary Votes that are the subject of Section&nbsp;4.8(2); provided, however, that such written instructions are received by the Share Trustee from the Beneficiary
prior to the time and date fixed by the Share Trustee for receipt of such instruction in the notice given by the Share Trustee to the Beneficiary pursuant to Section&nbsp;4.3. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent so instructed in accordance with the terms of this Agreement, the Share Trustee shall cause a
representative who is empowered by it to sign and deliver, on behalf of the Share Trustee, proxies for Voting Rights enabling a Beneficiary to attend a Parent Meeting. Upon submission by a Beneficiary (or its designee) named in the List prepared in
connection with the relevant meeting of identification satisfactory to the Share Trustee&#146;s representative, and at the Beneficiary&#146;s request, such representative shall sign and deliver to such Beneficiary (or its designee) a proxy to
exercise personally the Beneficiary Votes as to which such Beneficiary is otherwise entitled hereunder to direct the vote, if such Beneficiary either (i)&nbsp;has not previously given the Share Trustee instructions pursuant to Section&nbsp;4.3 in
respect of such meeting or (ii)&nbsp;submits to such representative written revocation of any such previous instructions. At such meeting, the Beneficiary (or its designee) exercising such Beneficiary Votes in accordance with such proxy shall have
the same rights in respect of such Beneficiary Votes as the Share Trustee to speak at the meeting in favour of any matter, question, proposal or proposition, to vote by way of ballot at the meeting in respect of any matter, question, proposal or
proposition, and to vote at such meeting in respect of any matter, question, proposal or proposition. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Distribution of Written Materials </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any written materials distributed by the Share Trustee to the Beneficiaries pursuant to this Agreement shall be sent by mail or delivered via electronic
transmission in a manner contemplated by Section&nbsp;232 of the Delaware General Corporation Law (or otherwise communicated in the same manner as Parent utilizes in communications to holders of Delaware Common Stock, including without limitation in
accordance with the notice and access rules promulgated by the SEC, subject to applicable regulatory requirements and to the Share Trustee being advised in writing of such manner of communications and provided that such manner of communications is
reasonably available to the Share Trustee) to each Beneficiary at its address as shown on the register of holders of Exchangeable Shares maintained by the registrar. In connection with each such distribution, ExchangeCo shall provide or cause to be
provided to the Share Trustee for purposes of communication, on a timely basis and without charge or other expense, a current List, and upon the request of the Share Trustee, mailing labels to enable the Share Trustee to carry out its duties under
this Agreement. ExchangeCo&#146;s obligations under this Section&nbsp;4.9 shall be deemed satisfied to the extent Parent exercises its option to perform the duties of the Share Trustee to deliver copies of materials to each Beneficiary and
ExchangeCo provides the required information and materials to Parent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of Voting Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the Exchangeable Share Provisions, all of the rights of a Beneficiary with respect to the Beneficiary Votes exercisable in
respect of the Exchangeable Shares held by such Beneficiary, including the right to instruct the Share Trustee as to the voting of or to vote personally such Beneficiary Votes, shall lapse and be deemed to be surrendered by the Beneficiary to Parent
or CallCo, as the case may be, and such Beneficiary Votes and the Voting Rights represented thereby shall cease immediately upon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the delivery by such holder to the Share Trustee of the Exchangeable Share Documents representing such
Exchangeable Shares in connection with the exercise by the Beneficiary of the Exchange Right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the occurrence of the automatic exchange of Exchangeable Shares for Delaware Common Stock, as specified in
Article 5 (unless Parent shall not have delivered the requisite Delaware Common Stock deliverable in exchange therefor to the Share Trustee pending delivery to the Beneficiaries); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the retraction or redemption of such Exchangeable Shares pursuant to Section&nbsp;26.6 or 26.7 of the
Exchangeable Share Provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the effective date of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of
ExchangeCo or any other distribution of the assets of ExchangeCo among its stockholders for the purpose of winding up its affairs pursuant to Section&nbsp;26.5 of the Exchangeable Share Provisions; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the purchase of such Exchangeable Shares from the holder thereof by CallCo pursuant to the exercise by CallCo
of the Liquidation Call Right, the Redemption Call Right, the Change of Law Call Right or the Retraction Call Right (unless, in any case, CallCo shall not have delivered the requisite consideration deliverable in exchange therefor).
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disclosure of Interest in Exchangeable Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee or ExchangeCo shall be entitled to require any Beneficiary or any person whom the Share Trustee or ExchangeCo, as the case may be, knows or
has reasonable cause to believe holds any interest whatsoever in an Exchangeable Share to (a)&nbsp;confirm that fact, or (b)&nbsp;give the Share Trustee or ExchangeCo such details as to whom has an interest in such Exchangeable Share, in each case
as would be required (if the Exchangeable Shares were a class of &#147;equity securities&#148; of ExchangeCo) under Section&nbsp;5.2 of National Instrument <FONT STYLE="white-space:nowrap">62-104</FONT> <I>Take-Over Bids and Issuer Bids</I> or as
would be required under the governing documents of Parent or any laws or regulations, or pursuant to the rules or regulations of any regulatory agency, if and only to the extent that the Exchangeable Shares (as multiplied by the Exchangeable Share
Exchange Ratio) were Delaware Common Stock. If a Beneficiary does not provide the information required to be provided by such Beneficiary pursuant to this Section&nbsp;4.11, the board of directors of Parent may take any action permitted under the
certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> of Parent or any laws or regulations, or pursuant to the rules or regulations of any regulatory agency, with respect to the Voting Rights relating to the Exchangeable
Shares held by such Beneficiary as if, and only to the extent that, the Exchangeable Shares (as multiplied by the Exchangeable Share Exchange Ratio) were Delaware Common Stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGE AND
AUTOMATIC EXCHANGE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Grant and Ownership of the Exchange Right and Automatic Exchange Right </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent and, in the case of the Exchange Right, CallCo hereby grant to the Share Trustee as Share Trustee for
and on behalf of, and for the use and benefit of, the Beneficiaries (i)&nbsp;the right (the &#147;<B>Exchange Right</B>&#148;), upon the occurrence and during the continuance of an Insolvency Event, to require CallCo or Parent (provided that Parent
may, in its sole discretion, cause CallCo to purchase in its place and stead to the extent permissible by applicable law) to purchase from each or any Beneficiary all or any part of the Exchangeable Shares held by such Beneficiary, all in accordance
with the provisions of this Agreement, and (ii)&nbsp;the Automatic Exchange Right. Each of Parent and CallCo hereby acknowledges receipt from the Share Trustee as Share Trustee for and on behalf of the Beneficiaries of good and valuable
consideration (and the adequacy thereof) for the grant of the Exchange Right and the Automatic Exchange Right by Parent or CallCo, as the case may be, to the Share Trustee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of the Trust, and subject to the terms and conditions of this Agreement, the Share Trustee
shall possess and be vested with full legal ownership of the Exchange Right and the Automatic Exchange Right and shall be entitled to exercise all of the rights and powers of an owner with respect to the Exchange Right and the Automatic Exchange
Right, provided that the Share Trustee shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hold the Exchange Right and the Automatic Exchange Right and the legal title thereto as Share Trustee solely
for the use and benefit of the Beneficiaries in accordance with the provisions of this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except as specifically authorized by this Agreement, have no power or authority to exercise or otherwise deal
in or with the Exchange Right or the Automatic Exchange Right, and the Share Trustee shall not exercise any such rights for any purpose other than the purposes for which the Trust is created pursuant to this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legended Exchangeable Share Document </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ExchangeCo shall cause each Exchangeable Share Document to bear a legend notifying the Beneficiary in respect of the Exchangeable Shares represented by such
Exchangeable Share Document of (a)&nbsp;his, her or its right to instruct the Share Trustee with respect to the exercise of the Exchange Right in respect of the Exchangeable Shares held by such Beneficiary and (b)&nbsp;the Automatic Exchange Right.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Exercise of Exchange Right </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchange Right shall be and remain vested in and exercisable by the Share Trustee. Subject to Section&nbsp;6.15, the Share Trustee shall exercise the
Exchange Right only on the basis of instructions received pursuant to this Article 5 from Beneficiaries entitled to instruct the Share Trustee as to the exercise thereof. To the extent that no instructions are received from any Beneficiary with
respect to the Exchange Right, the Share Trustee shall not exercise or permit the exercise of the Exchange Right. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purchase Price </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price payable by Parent or CallCo, as the case may be, for each Exchangeable Share to be purchased by Parent or CallCo, as the case may be,
pursuant to the exercise of the Exchange Right shall be an amount per share equal to the Exchangeable Share Price on the last Business Day prior to the day of the closing of the purchase and sale of such Exchangeable Share pursuant to such exercise
of the Exchange Right, which price may be satisfied only by Parent or CallCo, as the case may be, delivering or causing to be delivered to the Share Trustee, on behalf of the relevant Beneficiary, the Exchangeable Share Consideration representing
such Exchangeable Share Price. In connection with each exercise of the Exchange Right, Parent or CallCo, as the case may be, shall provide to the Share Trustee an Officer&#146;s Certificate setting forth the calculation of the Exchangeable Share
Price. Upon payment by Parent or CallCo, as the case may be, of the Exchangeable Share Price, the relevant Beneficiary shall cease to have any right to be paid any amount in respect of declared and unpaid dividends on each such Exchangeable Share by
ExchangeCo and ExchangeCo shall cease to be obligated to pay any amount in respect of such dividends. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise Instructions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth herein, a Beneficiary shall be entitled upon the occurrence and during the continuance of an Insolvency Event, to
instruct the Share Trustee to exercise the Exchange Right with respect to all or any part of the Exchangeable Shares registered in the name of such Beneficiary. In order to cause the Share Trustee to exercise the Exchange Right with respect to all
or any part of the Exchangeable Shares registered in the name of a Beneficiary, such Beneficiary shall deliver to the Share Trustee, in person or by certified or registered mail, at its principal office in Vancouver, British Columbia or at such
other place as the Share Trustee may from time to time designate by written notice to the Beneficiaries, the Exchangeable Share Documents representing the Exchangeable Shares which such Beneficiary desires Parent or CallCo to purchase, duly endorsed
in blank for transfer, and accompanied by such other documents and instruments as may be required to effect a transfer of the Exchangeable Shares under the <I>Business Corporations Act </I>(British Columbia), the articles of ExchangeCo and such
additional documents and instruments as Parent, ExchangeCo or the Share Trustee may reasonably require together with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a duly completed notice of exercise of the Exchange Right substantially in the form attached as Exhibit B,
contained on the reverse of or attached to the Exchangeable Share Documents, stating (i)&nbsp;that the Beneficiary thereby instructs the Share Trustee to exercise the Exchange Right so as to require Parent or CallCo to purchase from the Beneficiary
the number of Exchangeable Shares specified therein, (ii)&nbsp;that such Beneficiary has good title to and owns all such Exchangeable Shares to be acquired by Parent or CallCo free and clear of all liens, claims, security interests and encumbrances,
(iii)&nbsp;the names in which the Delaware Common Stock issuable in connection with the exercise of the Exchange Right are to be issued, and (iv)&nbsp;the names and addresses of the persons to whom such new certificates or book-entry evidence should
be delivered; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment (or evidence satisfactory to Parent, ExchangeCo and the Share Trustee of payment) of the taxes (if any)
payable as contemplated by Section&nbsp;5.8 of this Agreement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that if only a part of the Exchangeable Shares represented by
any Exchangeable Share Documents delivered to the Share Trustee are to be purchased by Parent or CallCo pursuant to the exercise of the Exchange Right, a new Exchangeable Share Document for the balance of such Exchangeable Shares shall be issued to
the holder at the expense of ExchangeCo. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Delivery of Delaware Common Stock; Effect of Exercise </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly after the receipt by the Share Trustee of the Exchangeable Share Document representing the Exchangeable Shares which a Beneficiary desires Parent or
CallCo to purchase pursuant to the exercise of the Exchange Right, together with a notice of exercise and such other documents and instruments specified by Section&nbsp;5.5, the Share Trustee shall notify Parent, CallCo and ExchangeCo of its receipt
of the same, which notice to Parent, CallCo and ExchangeCo shall constitute exercise of the Exchange Right by the Share Trustee on behalf of such Beneficiary in respect of such Exchangeable Shares, and Parent or CallCo, as the case may be, shall
promptly thereafter deliver or cause to be delivered to the Share Trustee, for delivery to such Beneficiary (or to such other persons, if any, properly designated by such Beneficiary) the Exchangeable Share Consideration deliverable in connection
with such exercise of the Exchange Right; provided, however, that no such delivery shall be made unless and until the Beneficiary requesting the same shall have paid (or provided evidence satisfactory to Parent, CallCo, ExchangeCo and the Share
Trustee of the payment of) the taxes (if any) payable as contemplated by Section&nbsp;5.8 of this Agreement. Immediately upon the giving of notice by the Share Trustee to Parent, CallCo and ExchangeCo of any exercise of the Exchange Right, as
provided in this Section&nbsp;5.6, the closing of the transaction of purchase and sale contemplated by the Exchange Right shall be deemed to have occurred, and the Beneficiary in respect of such Exchangeable Shares shall be deemed to have
transferred to Parent or CallCo, as the case may be, all of such Beneficiary&#146;s right, title and interest in and to such Exchangeable Shares and in the related interest in the Trust Estate and shall cease to be a holder of such Exchangeable
Shares and shall not be entitled to exercise any of the rights of a holder in respect thereof, other than the right to receive the total Exchangeable Share Consideration in respect of such Exchangeable Shares, unless such Exchangeable Share
Consideration is not delivered by Parent or CallCo, as the case may be, to the Share Trustee for delivery to such Beneficiary (or to such other person, if any, properly designated by such Beneficiary) within five Business Days of the date of the
giving of such notice by the Share Trustee, in which case the rights of the Beneficiary shall remain unaffected until such Exchangeable Share Consideration is so delivered. Upon delivery of such Exchangeable Share Consideration to the Share Trustee,
the Share Trustee shall promptly deliver such Exchangeable Share Consideration to such Beneficiary (or to such other person, if any, properly designated by such Beneficiary). Concurrently with the closing of the transaction of purchase and sale
contemplated by such exercise of the Exchange Right, the Beneficiary shall be considered and deemed for all purposes to be the holder of the Delaware Common Stock delivered to it pursuant to such exercise of the Exchange Right. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise of Exchange Right Subsequent to Retraction </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that a Beneficiary has exercised its retraction right under Section&nbsp;26.6(a) of the Exchangeable Share Provisions to require ExchangeCo to
redeem any or all of the Exchangeable Shares held by the Beneficiary (the &#147;<B>Retracted Shares</B>&#148;) and is notified by ExchangeCo pursuant to Section&nbsp;26.6(a)(iii) of the Exchangeable Share Provisions that ExchangeCo will not be
permitted as a result of solvency requirements of applicable law to redeem all such Retracted Shares, subject to receipt by the Share Trustee of written notice to that effect from ExchangeCo, and provided that CallCo has not exercised its Retraction
Call Right with respect to the Retracted Shares and that the Beneficiary shall not have revoked the retraction request delivered by the Beneficiary to ExchangeCo pursuant to Section&nbsp;26.6(a)(iv) of the Exchangeable Share Provisions, the
retraction request will constitute and will be deemed to constitute notice from the Beneficiary to the Share Trustee instructing the Share Trustee to exercise the Exchange Right with respect to those Retracted Shares that ExchangeCo is unable to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redeem. In any such event, ExchangeCo hereby agrees with the Share Trustee, and in favour of the Beneficiary, promptly to notify the Share Trustee of such prohibition against ExchangeCo and to
forward or cause to be forwarded to the Share Trustee all relevant materials delivered by the Beneficiary to ExchangeCo or to the Transfer Agent in connection with such proposed redemption of the Retracted Shares and the Share Trustee will thereupon
exercise the Exchange Right with respect to the Retracted Shares that ExchangeCo is not permitted to redeem and will require Parent or, at the option of Parent, CallCo to purchase such shares in accordance with the provisions of this Article 5. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stamp or Other Transfer Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any sale or transfer of Exchangeable Shares to Parent or CallCo pursuant to the exercise of the Exchange Right or the Automatic Exchange Right, the share
certificate or certificates or book-entry evidence representing the Delaware Common Stock to be delivered in connection with the payment of the purchase price therefor shall be issued in the name of the Beneficiary in respect of the Exchangeable
Shares so sold or transferred or in such names as such Beneficiary may otherwise direct in writing without charge to the holder of the Exchangeable Shares so sold or transferred; provided, however, that such Beneficiary (a)&nbsp;shall pay (and none
of Parent, CallCo, ExchangeCo or the Share Trustee shall be required to pay) any documentary, stamp, transfer or other taxes or duties that may be payable in respect of any sale or transfer involved in the issuance or delivery of such shares to a
person other than such Beneficiary including, without limitation, in the event that Exchangeable Shares are being delivered, sold or transferred in the name of a clearing service or depositary or a nominee thereof, or (b)&nbsp;shall have evidenced
to the satisfaction of Parent, CallCo, ExchangeCo and the Share Trustee that such taxes or duties (if any) have been paid. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice of Insolvency Event </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As soon as practicable following the occurrence of an Insolvency Event or any event that with the giving of notice or the passage of time or both would be an
Insolvency Event, Parent and ExchangeCo shall give written notice thereof to the Share Trustee. As soon as practicable after receiving notice from Parent or ExchangeCo of the occurrence of an Insolvency Event, or upon the Share Trustee otherwise
becoming aware of an Insolvency Event, the Share Trustee shall mail to each Beneficiary, at the expense of Parent (such funds to be received in advance), a notice of such Insolvency Event in the form provided by Parent, which notice shall contain a
brief statement of the rights of the Beneficiaries with respect to the Exchange Right. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>U.S. Securities Law Compliance and Listing of Delaware Common Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent covenants and agrees that it shall use its commercially reasonable efforts to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promptly file a prospectus supplement under a then existing and effective registration statement or a new
registration statement (such prospectus supplement or new registration statement, the &#147;Registration Statement&#148;) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or, if Parent is not then eligible to use Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> then such other form as Parent is then eligible to use, under the Securities Act of 1933, as amended (the &#147;1933 Act&#148;), to register the issuance of all shares of Delaware Common Stock to be issued or
delivered to holders of the Exchangeable Shares (including, for greater certainty, pursuant to the Exchange Right or the Automatic Exchange Right); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cause the Registration Statement to become effective as soon as reasonably practicable; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cause the Registration Statement (or a successor registration statement) to remain effective at all times that
any Exchangeable Shares remain outstanding </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without limiting the generality of the foregoing, Parent and CallCo each covenant and agree
that it will take all such actions and do all such things as are reasonably necessary or desirable to make such filings and seek such regulatory consents and approvals as are necessary so that the Delaware Common Stock to be issued or delivered
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to holders of Exchangeable Shares by Parent or CallCo pursuant to the terms of the Exchangeable Share Provisions, the Support Agreement and this Agreement will be offered, sold, issued and
delivered in compliance with the 1933 Act and all applicable state securities laws, and applicable securities laws in Canada and will use commercially reasonable efforts to ensure that the Delaware Common Stock will not be subject to any hold period
as contemplated by Rule 144 under the 1933 Act or subject to any &#147;hold period&#148; resale restriction under National Instrument <FONT STYLE="white-space:nowrap">45-102</FONT> <I>Resale of Securities</I>. Parent will in good faith expeditiously
take all such actions and do all such things as are reasonably necessary or desirable to cause all Delaware Common Stock to be delivered to holders of Exchangeable Shares pursuant to the terms of the Exchangeable Share Provisions, the Support
Agreement and this Agreement to be listed, quoted and posted for trading on all stock exchanges and quotation systems on which outstanding Delaware Common Stock have been listed by Parent and remain listed and are quoted or posted for trading at
such time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Delaware Common Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent hereby represents, warrants and covenants that the Delaware Common Stock deliverable as described herein will be duly authorized and validly issued as
fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and shall be free and clear of any lien, claim or encumbrance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Automatic Exchange on Liquidation of Parent </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent shall give the Share Trustee written notice of each of the following events (each, a
&#147;<B>Liquidation Event</B>&#148;) at the time set forth below: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of any determination by the board of directors of Parent to institute voluntary liquidation,
dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> proceedings with respect to Parent or to effect any other distribution of assets of Parent among its stockholders for the purpose of winding up its affairs, at least 30 days prior to
the proposed effective date of such liquidation, dissolution, <FONT STYLE="white-space:nowrap">winding-up</FONT> or other distribution; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as soon as practicable following the earlier of (A)&nbsp;receipt by Parent of notice of, and (B)&nbsp;Parent
otherwise becoming aware of any instituted claim, suit, petition or other proceedings with respect to the involuntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of Parent or to effect any other distribution of
assets of Parent among its stockholders for the purpose of winding up its affairs, in each case where Parent has failed to contest in good faith any such proceeding commenced in respect of Parent within 30 days of becoming aware thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as practicable following receipt by the Share Trustee from Parent of notice of a Liquidation Event, the
Share Trustee shall give notice thereof to the Beneficiaries. Such notice shall be provided by Parent to the Share Trustee and shall include a brief description of the automatic exchange of Exchangeable Shares for Delaware Common Stock provided for
in Section&nbsp;5.12(3) (the &#147;<B>Automatic Exchange Right</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In order that the Beneficiaries will be able to participate on a pro rata basis with the holders of Delaware
Common Stock in the distribution of assets of Parent in connection with a Liquidation Event, immediately prior to the effective date of a Liquidation Event (the &#147;<B>Liquidation Event Effective Date</B>&#148;), each of the then outstanding
Exchangeable Shares (other than Exchangeable Shares held by Parent and its Affiliates) shall be automatically exchanged for one share of Delaware Common Stock multiplied by the Exchangeable Share Exchange Ratio, and in respect of each Beneficiary,
rounded down to the nearest whole share. To effect such automatic exchange, Parent (or, if Parent so decides, in its sole discretion and to the extent permitted by applicable law, CallCo) shall exchange each such Exchangeable Share outstanding
immediately prior to the Liquidation Event Effective Date, and each Beneficiary shall transfer each Exchangeable Shares held by it at such time, free and clear of any lien, claim or encumbrance, for an amount per share equal to the Exchangeable
Share Price immediately prior to the Liquidation Event Effective Date, which amount shall be satisfied in full by Parent delivering to such holder the Exchangeable Share Consideration representing such Exchangeable Share Price. For greater
certainty, the Beneficiary shall upon delivery of the Exchangeable Share Consideration cease to have any rights to be paid by ExchangeCo any amount in respect of declared and unpaid dividends on the Exchangeable Shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The closing of the exercise of the Automatic Exchange Right shall be deemed to have occurred at the close of
business on the Business Day immediately prior to the Liquidation Event Effective Date, and each Beneficiary shall be deemed to have transferred to Parent or CallCo, as applicable, all of such Beneficiary&#146;s right, title and interest in and to
the Exchangeable Shares held by such Beneficiary free and clear of any lien, claim or encumbrance and the related interest in the Trust Estate, any right of each such Beneficiary to receive declared and unpaid dividends from ExchangeCo shall be
deemed to be satisfied and discharged, and each such Beneficiary shall cease to be a holder of such Exchangeable Shares and Parent or CallCo, as applicable, shall deliver or cause to be delivered to the Share Trustee, for delivery to such
Beneficiary, the Exchangeable Share Consideration deliverable to such Beneficiary upon such exercise of the Automatic Exchange Right. Concurrently with each such Beneficiary ceasing to be a holder of Exchangeable Shares, such Beneficiary shall be
considered and deemed for all purposes to be the holder of the Delaware Common Stock included in the Exchangeable Share Consideration to be delivered to such Beneficiary and the Exchangeable Share Documents held by such Beneficiary previously
representing the Exchangeable Shares exchanged by the Beneficiary with Parent or CallCo, as applicable, pursuant to the exercise of the Automatic Exchange Right shall thereafter be deemed to represent the Delaware Common Stock issued to such
Beneficiary by Parent pursuant to the exercise of the Automatic Exchange Right. Upon the request of any Beneficiary and the surrender by such Beneficiary of Exchangeable Share certificates or book-entry evidence deemed to represent Delaware Common
Stock, duly endorsed in blank and accompanied by such instruments of transfer as Parent or the transfer agent of Parent may reasonably require, Parent shall deliver or cause to be delivered to such Beneficiary book-entry evidence representing the
Delaware Common Stock of which the Beneficiary is the holder. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Withholding Rights </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary contained in this Agreement, each of Parent, ExchangeCo, CallCo, the
Share Trustee, and any other person that has any withholding obligation with respect to any amount paid or deemed paid under this Agreement (any such person, an &#147;<B>Other Withholding Agent</B>&#148;) shall be entitled to deduct and withhold or
direct Parent, ExchangeCo, CallCo, the Share Trustee, or any Other Withholding Agent to deduct and withhold on their behalf, from any amount or consideration paid, deemed paid or otherwise deliverable to any person under this Agreement (an
&#147;<B>Affected Person</B>&#148;) such amounts as are required to be deducted or withheld with respect to such payment or deemed payment under the <I>Income Tax Act </I>(Canada), the U.S. Internal Revenue Code of 1986, or any provision of any
federal, provincial, territorial, state, local or other tax Law (a &#147;<B>Withholding Obligation</B>&#148;). Parent, ExchangeCo, CallCo, the Share Trustee, or any Other Withholding Agent may act and rely on the advice of counsel with respect to
such matters. To the extent that amounts are so deducted or withheld, such deducted or withheld amounts shall be treated for all purposes hereof as having been paid to the Affected Person to whom such amounts would otherwise have been paid or deemed
paid, and such deducted or withheld amounts shall be timely remitted to the appropriate Governmental Entity as required by applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent, ExchangeCo, CallCo, the Share Trustee and any Other Withholding Agent shall also have the right to:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withhold and sell, or direct Parent, ExchangeCo, CallCo, the Share Trustee, or any Other Withholding Agent to
deduct and withhold and sell on their behalf, on their own account or through a broker (the &#147;<B>Broker</B>&#148;), and on behalf of any Affected Person; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">require the Affected Person to irrevocably direct the sale through a Broker and irrevocably direct the Broker
to pay the proceeds of such sale to Parent, ExchangeCo, CallCo, the Share Trustee, or any Other Withholding Agent as appropriate (and, in the absence of such irrevocable direction, the Affected Person shall be deemed to have provided such
irrevocable direction); </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">such number of shares of Delaware Common Stock or Exchangeable Shares (or shares of Delaware
Common Stock exchanged therefor) delivered or deliverable to such Affected Person pursuant to this Agreement as is necessary to produce sale proceeds (after deducting commissions payable to the Broker and other costs and expenses)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
sufficient to fund any Withholding Obligations. Any Exchangeable Shares to be sold in accordance with this Section&nbsp;5.13 shall first be exchanged for Delaware Common Stock in accordance with
their terms and Delaware Common Stock delivered in respect of such Exchangeable Shares shall be sold. Any such sale of Delaware Common Stock shall be affected on a public market and as soon as practicable. Each of Parent, ExchangeCo, CallCo, the
Share Trustee, the Broker or any Other Withholding Agent, as applicable, shall act in a commercially reasonable manner in respect of any withholding obligation; however, none of Parent, ExchangeCo, CallCo, the Share Trustee, the Broker or any Other
Withholding Agent shall have or be deemed to have any fiduciary duty to any Beneficiary and shall not be liable for any loss arising out of any sale of such Delaware Common Stock, including any loss relating to the manner or timing of such sales,
the prices at which Delaware Common Stock are sold or otherwise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Before delivering any amount or consideration to any Affected Person, the Share Trustee shall obtain from
Parent a written confirmation of the Withholding Obligations, if any. The Share Trustee shall be entitled to rely on Parent&#146;s written confirmation of any such Withholding Obligations and the Share Trustee shall not be responsible nor liable for
the calculation or determination of the same. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Fractional Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of an Exchangeable Share shall not be entitled to any fraction of a Delaware Common Stock upon the exercise of the Exchange Right or Automatic
Exchange Right hereunder and no certificates or book-entry evidence representing any such fractional interest shall be issued. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCERNING THE SHARE TRUSTEE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Powers and Duties of the Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights, powers, duties and authorities of the Share Trustee under this Agreement, in its capacity as Share
Trustee of the Trust, shall include: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">receipt and deposit of the Special Voting Stock from Parent as Share Trustee for and on behalf of the
Beneficiaries in accordance with the provisions of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">granting proxies and distributing materials to Beneficiaries as provided in this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">voting the Beneficiary Votes on the direction and behalf of the Beneficiaries in accordance with the provisions
of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">receiving the grant of the Exchange Right from Parent and CallCo, and the Automatic Exchange Right from Parent,
as Share Trustee for and on behalf of the Beneficiaries in accordance with the provisions of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercising the Exchange Right and enforcing the benefit of the Automatic Exchange Right, in each case in
accordance with the provisions of this Agreement, and in connection therewith receiving from Beneficiaries any requisite documents and distributing to such Beneficiaries the Exchangeable Share Consideration to which such Beneficiaries are entitled
pursuant to the exercise of the Exchange Right or the Automatic Exchange Right, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">holding title to the Trust Estate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">investing any moneys forming, from time to time, a part of the Trust Estate as provided in this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">taking action at the direction of a Beneficiary or Beneficiaries to enforce the obligations of Parent, CallCo
and ExchangeCo under this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">taking such other actions and doing such other things as are specifically provided in this Agreement to be
carried out by the Share Trustee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the exercise of such rights, powers, duties and authorities, the Share Trustee shall have (and is granted)
such incidental and additional rights, powers, duties and authority not in conflict with any of the provisions of this Agreement as the Share Trustee, acting in good faith and in the reasonable exercise of its discretion, may deem necessary,
appropriate or desirable to effect the purpose of the Trust. Any exercise of such discretionary rights, powers, duties and authorities by the Share Trustee shall be final, conclusive and binding upon all persons. For greater certainty, the Share
Trustee shall have only those duties as are set out specifically in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Share Trustee, in exercising its rights, powers, duties and authorities hereunder, shall act honestly and
in good faith and with a view to the best interests of the Beneficiaries and shall exercise the care, diligence and skill that a reasonably prudent Share Trustee would exercise in comparable circumstances. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Share Trustee shall not be bound to give notice or do or take any act, action or proceeding by virtue of
the powers conferred on it hereby unless and until it shall be specifically required to do so under the terms hereof; nor shall the Share Trustee be required to take any notice of, or to do, or to take any act, action or proceeding as a result of
any default or breach of any provision hereunder, unless and until notified in writing of such default or breach, which notices shall distinctly specify the default or breach desired to be brought to the attention of the Share Trustee, and in the
absence of such notice the Share Trustee may for all purposes of this Agreement conclusively assume that no default or breach has been made in the observance or performance of any of the representations, warranties, covenants, agreements or
conditions contained herein. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Conflict of Interest </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee represents to Parent, CallCo and ExchangeCo that, at the date of execution and delivery of this Agreement, there exists no material conflict
of interest in the role of the Share Trustee as a fiduciary hereunder and the role of the Share Trustee in any other capacity. If the Share Trustee has a material conflict of interest in the role of the Share Trustee as a fiduciary hereunder and the
role of the Share Trustee in any other capacity the validity and enforceability of this Agreement shall not be affected in any manner whatsoever by reason only of the existence of such material conflict of interest. If the Share Trustee contravenes
the foregoing provisions of this Section&nbsp;6.2, any interested party may apply to the Supreme Court of British Columbia for an order that the Share Trustee be replaced as Share Trustee hereunder. Notwithstanding the foregoing, if Parent
determines (acting reasonably and in good faith) that there exists a material conflict of interest in the role of the Share Trustee as a fiduciary hereunder and the role of the Share Trustee in any other capacity, then at the written request of
Parent (which written request shall set forth the nature of such material conflict of interest), the Share Trustee shall resign in the manner and with the effect specified in Article 9. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dealings with Transfer Agents, Registrars, etc. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of Parent, CallCo and ExchangeCo irrevocably authorizes the Share Trustee, from time to time, to:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consult, communicate and otherwise deal with the respective registrars and transfer agents, and with any such
subsequent registrar or transfer agent, of the Exchangeable Shares and Delaware Common Stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">requisition, from time to time, from any such registrar or transfer agent, any information readily available
from the records maintained by it which the Share Trustee may reasonably require for the discharge of its duties and responsibilities under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of Parent and CallCo irrevocably authorizes its respective registrar and Transfer Agent to comply with all
such requests and covenants that it shall supply the Share Trustee or its transfer agent, as the case may be, in a timely manner with duly executed share certificates or book-entry evidence for the purpose of completing the exercise from time to
time of all rights to acquire Delaware Common Stock hereunder, under the Exchangeable Share Provisions and under any other security or commitment given to the Beneficiaries pursuant thereto, in each case pursuant to the provisions hereof or of the
Exchangeable Share Provisions or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Books and Records </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee shall keep available for inspection during regular business hours by Parent, CallCo and ExchangeCo at the Share Trustee&#146;s principal
office in Vancouver, British Columbia correct and complete books and records of account relating to the Trust created by, and Share Trustee&#146;s actions under, this Agreement, including all relevant data relating to mailings and instructions to
and from Beneficiaries and all transactions pursuant to the Exchange Right and the Automatic Exchange Right. On or before <B>[MMM DD, YYYY]</B>, and on or before <B>[MMM DD]</B> in every year thereafter, so long as the Special Voting Stock is
registered in the name of the Share Trustee, the Share Trustee shall transmit to Parent, CallCo and ExchangeCo a brief report, dated as of the preceding December&nbsp;31, with respect to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the property and funds comprising the Trust Estate as of that date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of exercises of the Exchange Right, if any, and the aggregate number of Exchangeable Shares received
by the Share Trustee on behalf of Beneficiaries in consideration of the issuance and delivery by Parent or CallCo of Delaware Common Stock in connection with the Exchange Right, during the calendar year ended on such December 31; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any action taken by the Share Trustee in the performance of its duties under this Agreement which it had not
previously reported. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Tax Returns and Reports </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee shall, when directed by Parent, prepare and file, or cause to be prepared and filed, on behalf of the Trust appropriate Canadian income tax
returns and any other returns or reports as may be required by applicable law, by any court, tribunal, government, governmental or regulatory agency or public official, or pursuant to the rules and regulations of any securities exchange or other
trading system through which the Exchangeable Shares are traded. In connection therewith, the Share Trustee may obtain the advice and assistance of such experts or advisors (who may be experts or advisors to Parent, CallCo and/or ExchangeCo) as the
Share Trustee considers necessary or advisable. If requested by the Share Trustee, Parent shall retain or caused to be retained qualified experts or advisors for the purpose of providing such tax advice or assistance. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification Prior to Certain Actions by Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Share Trustee shall exercise any or all of the rights, duties, powers or authorities vested in it by this
Agreement at the request, order or direction of any Beneficiary upon such Beneficiary furnishing to the Share Trustee reasonable funding, security or indemnity against the costs, expenses and liabilities which may be incurred by the Share Trustee
therein or thereby, provided that no Beneficiary shall be obligated to furnish to the Share Trustee any such funding, security or indemnity in connection with the exercise by the Share Trustee of any of its rights, duties, powers and authorities
with respect to the Special Voting Stock pursuant to Article 4, subject to Section&nbsp;6.15, and with respect to the Exchange Right and the Automatic Exchange Right pursuant to Article 5. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the provisions contained in this Agreement shall require the Share Trustee to expend or risk its own
funds or otherwise incur financial liability in the exercise of any of its rights, powers, duties, or authorities unless funded, given security and indemnified as aforesaid. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Action of Beneficiaries </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Beneficiary shall have the right to institute any action, suit or proceeding or to exercise any other remedy authorized by this Agreement for the purpose of
enforcing any of its rights or for the execution of any trust or power hereunder unless the Beneficiary has requested the Share Trustee to take or institute such action, suit or proceeding and furnished the Share Trustee with the funding, security
or indemnity referred to in Section&nbsp;6.6 and the Share Trustee shall have failed to act within a reasonable time thereafter. In such case, but not otherwise, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Beneficiary shall be entitled to take proceedings in any court of competent jurisdiction such as the Share Trustee might have taken; it being understood and intended that no one or more
Beneficiaries shall have any right in any manner whatsoever to affect, disturb or prejudice the rights hereby created by any such action, or to enforce any right hereunder or the Voting Rights, the Exchange Right or the Automatic Exchange Right
except subject to the conditions and in the manner herein provided, and that all powers and trusts hereunder shall be exercised and all proceedings at law shall be instituted, had and maintained by the Share Trustee, except only as herein provided,
and in any event for the equal benefit of all Beneficiaries. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reliance Upon Declarations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee shall not be considered to be in contravention of any of its rights, powers, duties and authorities hereunder if, when required, it acts and
relies in good faith upon statutory declarations, certificates, opinions or reports furnished pursuant to the provisions hereof or required by the Share Trustee to be furnished to it in the exercise of its rights, powers, duties and authorities
hereunder if such statutory declarations, certificates, opinions or reports comply with the provisions of Section&nbsp;6.9, if applicable, and with any other applicable provisions of this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Evidence and Authority to Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent, CallCo and/or ExchangeCo shall furnish to the Share Trustee evidence of compliance with the conditions
provided for in this Agreement relating to any action or step required or permitted to be taken by Parent, CallCo and/or ExchangeCo or the Share Trustee under this Agreement or as a result of any obligation imposed under this Agreement, including in
respect of the Voting Rights, the Exchange Right or the Automatic Exchange Right and the taking of any other action to be taken by the Share Trustee at the request of or on the application of Parent, CallCo and/or ExchangeCo promptly if and when:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such evidence is required by any other Section of this Agreement to be furnished to the Share Trustee in
accordance with the terms of this Section&nbsp;6.9; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Share Trustee, in the exercise of its rights, powers, duties and authorities under this Agreement, gives
Parent, CallCo and/or ExchangeCo written notice requiring it to furnish such evidence in relation to any particular action or obligation specified in such notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such evidence shall consist of an Officer&#146;s Certificate of Parent, CallCo and/or ExchangeCo or a statutory
declaration or a certificate made by persons entitled to sign an Officer&#146;s Certificate stating that any such condition has been complied with in accordance with the terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Whenever such evidence relates to a matter other than the Voting Rights or the Exchange Right or the Automatic
Exchange Right or the taking of any other action to be taken by the Share Trustee at the request or on the application of Parent, CallCo and/or ExchangeCo, and except as otherwise specifically provided herein, such evidence may consist of a report
or opinion of any solicitor, attorney, auditor, accountant, appraiser, valuer or other expert or any other person whose qualifications give authority to a statement made by such person; provided, however, that if such report or opinion is furnished
by a director, officer or employee of Parent, CallCo and/or ExchangeCo it shall be in the form of an Officer&#146;s Certificate or a statutory declaration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each statutory declaration, Officer&#146;s Certificate, opinion or report furnished to the Share Trustee as
evidence of compliance with a condition provided for in this Agreement shall include a statement by the person giving the evidence: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">declaring that such person has read and understands the provisions of this Agreement relating to the condition
in question; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">describing the nature and scope of the examination or investigation upon which such person based the statutory
declaration, certificate, statement or opinion; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">declaring that such person has made such examination or investigation as such person believes is necessary to
enable such person to make the statements or give the opinions contained or expressed therein. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Experts, Advisers and Agents </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in relation to these presents act and rely on the opinion or advice of or information obtained from any
solicitor, attorney, auditor, accountant, appraiser, valuer or other expert, whether retained by the Share Trustee or by Parent, CallCo and/or ExchangeCo or otherwise, and may retain or employ such assistants as may be necessary to the proper
discharge of its powers and duties and determination of its rights hereunder and may pay proper and reasonable compensation for all such legal and other advice or assistance as aforesaid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">employ such agents and other assistants as it may reasonably require for the proper determination and discharge
of its powers and duties hereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pay reasonable remuneration for all services performed for it (and shall be entitled to receive reasonable
remuneration for all services performed by it) in the discharge of the trusts hereof and compensation for all reasonable disbursements, costs and expenses made or incurred by it in the discharge of its duties hereunder and in the management of the
Trust. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investment of Moneys Held by Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in this Agreement, any moneys held by or on behalf of the Share Trustee which under the terms of this Agreement may or ought to be
invested or which may be on deposit with the Share Trustee or which may be in the hands of the Share Trustee may be invested or reinvested in the name or under the control of the Share Trustee in securities in which, under the laws of the Province
of British Columbia, trustees are authorized to invest trust moneys, or as otherwise agreed upon in writing by the Share Trustee and ExchangeCo, provided that such securities are stated to mature within two years after their purchase by the Share
Trustee and the Share Trustee shall so invest such money on the written direction of ExchangeCo. Pending the investment of any money as herein provided, such moneys may be deposited in the name of the Share Trustee in any chartered bank in Canada
or, with the consent of ExchangeCo, in the deposit department of the Share Trustee or any other specified loan or trust company authorized to accept deposits under the laws of Canada or any province thereof at the rate of interest then current on
similar deposits. The Share Trustee shall not be held liable for any losses incurred in the investment of any funds as herein provided and all interest on monies held by or on behalf of the Share Trustee shall be for the account of ExchangeCo and
held by the Share Trustee for the benefit of ExchangeCo. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share Trustee Not Required to Give Security </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee shall not be required to give any bond or security in respect of the execution of the trusts, rights, duties, powers and authorities of this
Agreement or otherwise in respect of the premises. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share Trustee Not Bound to Act on Request </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as in this Agreement otherwise specifically provided, the Share Trustee shall not be bound to act in accordance with any direction or request of Parent,
CallCo and/or ExchangeCo or of the respective directors thereof until a duly authenticated copy of the instrument or resolution containing such direction or request shall have been delivered to the Share Trustee, and the Share Trustee shall be
empowered to act upon any such copy purporting to be authenticated and believed by the Share Trustee to be genuine. The Share Trustee shall have the right not to act and shall not be liable for refusing to act if, due to a lack of information or for
any other reason </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whatsoever, the Share Trustee, in its sole judgment, determines that such act might cause it to be in <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any applicable anti-money
laundering or anti-terrorist or economic sanction legislation or regulation. Further, should the Share Trustee, in its sole judgment, determine at any time that its acting under this Agreement has resulted in its being in <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with any applicable anti-money laundering, anti-terrorist or economic sanctions legislation or regulation or guideline, then it shall have the right to resign on ten days written notice to the other
parties to this Agreement, provided that (a)&nbsp;the Share Trustee&#146;s written notice shall describe the circumstances of such <FONT STYLE="white-space:nowrap">non-compliance</FONT> and (b)&nbsp;if such circumstances are rectified to the Share
Trustee&#146;s satisfaction within such ten day period, such resignation shall not be effective. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Authority to Carry on Business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee represents to Parent, CallCo and ExchangeCo that, at the date of execution and delivery by it of this Agreement, it is authorized to carry on
the business of a trust company in each of the provinces and territories of Canada but if, notwithstanding the provisions of this Section&nbsp;6.14, it ceases to be so authorized to carry on business, the validity and enforceability of this
Agreement and the Voting Rights, the Exchange Right and the Automatic Exchange Right and the other rights granted in or resulting from the Share Trustee being a party to this Agreement shall not be affected in any manner whatsoever by reason only of
such event but the Share Trustee shall, within 90 days after ceasing to be authorized to carry on the business of a trust company in any province or territory of Canada, either become so authorized or resign in the manner and with the effect
specified in Article 9. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conflicting Claims </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If conflicting claims or demands are made or asserted with respect to any interest of any Beneficiary in any
Exchangeable Shares, including any disagreement between the heirs, representatives, successors or assigns succeeding to all or any part of the interest of any Beneficiary in any Exchangeable Shares, resulting in conflicting claims or demands being
made in connection with such interest, then the Share Trustee shall be entitled, in its sole discretion, to refuse to recognize or to comply with any such claims or demands. In so refusing, the Share Trustee may elect not to exercise any Voting
Rights, Exchange Right, Automatic Exchange Right or other rights subject to such conflicting claims or demands and, in so doing, the Share Trustee shall not be or become liable to any person on account of such election or its failure or refusal to
comply with any such conflicting claims or demands. The Share Trustee shall be entitled to continue to refrain from acting and to refuse to act until: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rights of all adverse claimants with respect to the Voting Rights, Exchange Right, Automatic Exchange Right
or other rights subject to such conflicting claims or demands have been adjudicated by a final judgement of a court of competent jurisdiction and all rights of appeal have expired; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all differences with respect to the Voting Rights, Exchange Right, Automatic Exchange Right or other rights
subject to such conflicting claims or demands have been conclusively settled by a valid written agreement binding on all such adverse claimants, and the Share Trustee shall have been furnished with an executed copy of such agreement certified to be
in full force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Share Trustee elects to recognize any claim or comply with any demand made by any such adverse claimant,
it may in its discretion require such claimant to furnish such surety bond or other security satisfactory to the Share Trustee as it shall deem appropriate to fully indemnify it as between all conflicting claims or demands. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceptance of Trust </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee hereby accepts the Trust created and provided for, by and in this Agreement and agrees to perform the same upon the terms and conditions
herein set forth and to hold all rights, privileges and benefits conferred hereby and by law in trust for the various persons who shall from time to time be Beneficiaries, subject to all the terms and conditions herein set forth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Interests </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each party to this Agreement hereby represents to the Share Trustee that any account to be opened by, or interest to be held by the Share Trustee in connection
with this Agreement, for or to the credit of such party, either (a)&nbsp;is not intended to be used by or on behalf of any third party, or (b)&nbsp;is intended to be used by or on behalf of a third party, in which case such party hereto agrees to
complete and execute forthwith a declaration in the Share Trustee&#146;s prescribed form as to the particulars of such third party. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Privacy </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties acknowledge that Canadian federal and/or provincial legislation that addresses the protection of individuals&#146; personal information
(collectively, &#147;<B>Privacy Laws</B>&#148;) applies to obligations and activities under this Agreement. Despite any other provision of this Agreement, no party shall take or direct any action that would contravene, or cause the others to
contravene, applicable Privacy Laws. The parties shall, prior to transferring or causing to be transferred personal information to the Share Trustee, obtain and retain required consents of the relevant individuals to the collection, use and
disclosure of their personal information, or shall have determined that such consents either have previously been given upon which the parties can rely or are not required under the Privacy Laws. The Share Trustee shall use commercially reasonable
efforts to ensure that its services hereunder comply with Privacy Laws. Specifically, the Share Trustee agrees (a)&nbsp;to have a designated chief privacy officer, (b)&nbsp;to maintain policies and procedures to protect personal information and to
receive and respond to any privacy complaint or inquiry, (c)&nbsp;to use personal information solely for the purposes of providing its services under or ancillary to this Agreement and not to use it for any other purpose except with the consent of
or direction from the other parties or the individual involved, (d)&nbsp;not to sell or otherwise improperly disclose personal information to any third party, and (e)&nbsp;to employ administrative, physical and technological safeguards to reasonably
secure and protect personal information against loss, theft, or unauthorized access, use or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fees and Expenses of the Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent, CallCo and ExchangeCo jointly and severally agree to pay the Share Trustee reasonable compensation for all of the services rendered by it under this
Agreement and shall reimburse the Share Trustee for all reasonable expenses (including, but not limited to, taxes (other than taxes based on the net income or capital of the Share Trustee), fees paid to legal counsel and other experts and advisors
and agents and reasonable travel expenses) and disbursements, including the reasonable cost and expense of any suit or litigation of any character and any proceedings before any governmental agency, in each case reasonably incurred by the Share
Trustee in connection with its duties under this Agreement; provided, however, that Parent, CallCo and ExchangeCo shall have no obligation to reimburse the Share Trustee for any expenses or disbursements paid, incurred or suffered by the Share
Trustee in any suit or litigation or any such proceedings in which the Share Trustee is determined to have acted in bad faith or with gross negligence, fraud or willful misconduct. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AND LIMITATION OF LIABILITY </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of the Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent, CallCo and ExchangeCo jointly and severally agree to indemnify and hold harmless the Share Trustee and
each of its directors, officers, employees and agents appointed and acting in accordance with this Agreement (collectively, the &#147;<B>Indemnified Parties</B>&#148;) against all claims, losses, damages, reasonable costs, penalties, fines and
reasonable expenses (including reasonable and documented expenses of the Share Trustee&#146;s legal counsel) which, without bad faith, gross negligence, fraud or willful misconduct on the part of such Indemnified Party, may be paid, incurred or
suffered by the Indemnified Party by reason or as a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
result of the Share Trustee&#146;s acceptance or administration of the Trust, its compliance with its duties set forth in this Agreement, or any written or oral instruction delivered to the Share
Trustee by Parent, CallCo or ExchangeCo pursuant hereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Share Trustee shall promptly notify Parent, CallCo and ExchangeCo of a claim or of any action commenced
against any Indemnified Parties promptly after the Share Trustee or any of the Indemnified Parties shall have received written assertion of such a claim or action or have been served with a summons or other first legal process giving information as
to the nature and basis of the claim or action; provided, however, that the omission to so notify Parent, CallCo or ExchangeCo shall not relieve Parent, CallCo or ExchangeCo of any liability which any of them may have to any Indemnified Party except
to the extent that any such delay prejudices the defence of any such claim or action or results in any increase in the liability which Parent, CallCo or ExchangeCo have under this indemnity. Subject to (ii)&nbsp;below, Parent, CallCo and ExchangeCo
shall be entitled to participate at their own expense in the defence and, if Parent, CallCo and ExchangeCo so elect at any time after receipt of such notice, either of them may assume the defence of any suit brought to enforce any such claim. The
Share Trustee shall have the right to employ separate counsel in any such suit and participate in the defence thereof, but the fees and expenses of such counsel shall be at the expense of the Share Trustee unless (i)&nbsp;the employment of such
counsel has been authorized by Parent, CallCo or ExchangeCo and such authorization is not to be unreasonably withheld, or (ii)&nbsp;the named parties to any such suit include both the Share Trustee and Parent, CallCo or ExchangeCo and the Share
Trustee shall have been advised by counsel acceptable to Parent, CallCo and ExchangeCo that there may be one or more legal defences available to the Share Trustee that are different from or in addition to those available to Parent, CallCo or
ExchangeCo and that, in the judgement of such counsel, would present a conflict of interest were a joint representation to be undertaken (in which case Parent, CallCo and ExchangeCo shall not have the right to assume the defence of such suit on
behalf of the Share Trustee but shall be liable to pay the reasonable fees and expenses of counsel for the Share Trustee). This indemnity shall survive the termination of the Trust and the resignation or removal of the Share Trustee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This indemnity shall survive the termination of the Trust and the resignation or removal of the Share Trustee.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitation of Liability </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Share Trustee shall not be held liable for any loss which may occur by reason of depreciation of the value
of any part of the Trust Estate or any loss incurred on any investment of funds pursuant to this Agreement, except to the extent that such loss is attributable to the bad faith, gross negligence, fraud or willful misconduct on the part of the Share
Trustee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of this Agreement other than clause (1)&nbsp;above, any liability of the
Share Trustee, shall be limited to an amount of fees paid by parties to the Share Trustee under this agreement in the <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;months immediately prior to the Share Trustee receiving the first
notice of claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of this Agreement, the Share Trustee shall not be liable for any
(i)&nbsp;breach by any other party of any applicable securities legislation, and (ii)&nbsp;lost profits, punitive, consequential, special, indirect, incidental, exemplary or aggravated losses or damages of any other person under any circumstances
whatsoever, whether such losses or damages are foreseeable or unforeseeable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This limitation of liability shall survive the termination of the Trust and the resignation or removal of the
Share Trustee. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No party shall be liable to the other, or held in breach of this Agreement, if prevented, hindered or delayed in the performance or observance of any provision
contained herein by reason of act of god, riots, terrorism, acts of war, epidemics or pandemics, governmental action or judicial order, earthquakes, or any other similar causes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including, but not limited to, mechanical, electronic or communication interruptions, disruptions or failures). Performance times under this Agreement shall be extended for a period of time
equivalent to the time lost because of any delay that is excusable under this Section&nbsp;8.3. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGE OF SHARE TRUSTEE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Resignation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee, or any Share Trustee hereafter appointed, may at any time resign by giving written notice of such resignation to Parent, CallCo and
ExchangeCo specifying the date on which it desires to resign, provided that such notice shall not be given less than 30 days before such desired resignation date unless Parent, CallCo and ExchangeCo otherwise agree and provided further that such
resignation shall not take effect until the date of the appointment of a successor Share Trustee and the acceptance of such appointment by the successor Share Trustee. Upon receiving such notice of resignation, Parent, CallCo and ExchangeCo shall
promptly appoint a successor Share Trustee, which successor Share Trustee shall be a corporation organized and existing under the laws of Canada and authorized to carry on the business of a trust company in all provinces and territories of Canada,
by written instrument in duplicate, one copy of which shall be delivered to the resigning Share Trustee and one copy to the successor Share Trustee. Failing the appointment and acceptance of a successor Share Trustee, a successor Share Trustee may
be appointed by order of a court of competent jurisdiction upon application of one or more of the parties to this Agreement. If the retiring Share Trustee is the party initiating an application for the appointment of a successor Share Trustee by
order of a court of competent jurisdiction, Parent, CallCo and ExchangeCo shall be jointly and severally liable to reimburse the retiring Share Trustee for its legal costs and expenses in connection with same. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Removal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee, or any Share Trustee hereafter appointed, may (provided a successor Share Trustee is appointed) be removed at any time on not less than 30
days&#146; prior notice by written instrument executed by Parent, CallCo and ExchangeCo, in duplicate, one copy of which shall be delivered to the Share Trustee so removed and one copy to the successor Share Trustee, provided that such removal shall
not take effect until the date of acceptance of appointment by the successor Share Trustee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Successor Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any successor Share Trustee appointed as provided under this Agreement shall execute, acknowledge and deliver to Parent, CallCo and ExchangeCo and to its
predecessor Share Trustee an instrument accepting such appointment. Thereupon the resignation or removal of the predecessor Share Trustee shall become effective and such successor Share Trustee, without any further act, deed or conveyance, shall
become vested with all the rights, powers, duties and obligations of its predecessor under this Agreement, with the like effect as if originally named as Share Trustee in this Agreement. However, on the written request of Parent, CallCo and
ExchangeCo or of the successor Share Trustee, the Share Trustee ceasing to act shall, upon payment of any amounts then due to it pursuant to the provisions of this Agreement, execute and deliver an instrument transferring to such successor Share
Trustee all the rights and powers of the Share Trustee so ceasing to act. Upon the request of any such successor Share Trustee, Parent, CallCo, ExchangeCo and such predecessor Share Trustee shall execute any and all instruments in writing for more
fully and certainly vesting in and confirming to such successor Share Trustee all such rights and powers. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice of Successor Share Trustee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon acceptance of appointment by a successor Share Trustee as provided herein, Parent, CallCo and ExchangeCo shall cause to be mailed notice of the succession
of such Share Trustee hereunder to each Beneficiary specified in a List. If Parent, CallCo or ExchangeCo shall fail to cause such notice to be mailed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within ten days after acceptance of appointment by the successor Share Trustee, the successor Share Trustee shall cause such notice to be mailed at the expense of Parent, CallCo and ExchangeCo.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PARENT
SUCCESSORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Certain Requirements in Respect of Combination, etc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as any Exchangeable Shares not owned by Parent or its Affiliates are outstanding, Parent shall not enter into any transaction (whether by way of
reorganization, consolidation, arrangement, amalgamation, merger, transfer, sale for otherwise) whereby all or substantially all of its undertaking, property and assets would become the property of any other person or, in the case of an amalgamation
or merger, of the continuing corporation resulting therefrom, provided that it may do so if as a result of such transactions, and concurrently therewith, the Exchangeable Shares held by the Beneficiaries are exchanged for Delaware Common Stock in
accordance with their terms, and in any other case: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other person or continuing corporation (the &#147;<B>Parent Successor</B>&#148;), by operation of law,
becomes, without more, bound by the terms and provisions of this Agreement or, if not so bound, executes, prior to or contemporaneously with the consummation of such transaction, a trust agreement supplemental hereto and such other instruments (if
any) as are necessary or advisable to evidence the assumption by the Parent Successor of liability for all moneys payable and property deliverable hereunder and the covenant of such Parent Successor to pay and deliver or cause to be paid and
delivered the same and its agreement to observe and perform all the covenants and obligations of Parent under this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such transaction shall be upon such terms and conditions as to substantially preserve and not impair any of the
rights, duties, powers and authorities of the Share Trustee or the holders of the Exchangeable Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Vesting of Powers in Successor </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever the conditions of Section&nbsp;10.1 have been duly observed and performed, the parties, if required by Section&nbsp;10.1, shall execute and deliver
the supplemental trust agreement provided for in Section&nbsp;10.1(a) and thereupon the Parent Successor and such other person that may then be the issuer of the Delaware Common Stock shall possess and from time to time may exercise each and every
right and power of Parent under this Agreement in the name of Parent or otherwise and any act or proceeding by any provision of this Agreement required to be done or performed by the board of directors of Parent or any officers of Parent may be done
and performed with like force and effect by the directors or officers of such Parent Successor. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Wholly-Owned Subsidiaries </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing herein shall be construed as preventing (a)&nbsp;the amalgamation or merger of any wholly-owned direct or indirect subsidiary of Parent (other than
ExchangeCo or CallCo) with or into Parent, (b)&nbsp;the <FONT STYLE="white-space:nowrap">winding-up,</FONT> liquidation or dissolution of any wholly-owned direct or indirect subsidiary of Parent (other than ExchangeCo or CallCo), provided that all
of the assets of such subsidiary are transferred to Parent or another wholly-owned direct or indirect subsidiary of Parent, (c)&nbsp;the conversion of Parent as contemplated by Section&nbsp;266 of the Delaware General Corporation Law, as it may be
amended from time to time, (d)&nbsp;any other distribution of the assets of any wholly-owned direct or indirect subsidiary of Parent among the stockholders of such subsidiary for the purpose of winding up its affairs, and (e)&nbsp;any such
transactions which are expressly permitted by this Article&nbsp;10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Successor Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Article 10, in the event of a Parent Control Transaction: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which Parent merges, combines or amalgamates with, or in which all or substantially all of the then
outstanding Delaware Common Stock are acquired by, one or more other corporations to which Parent is, immediately before such merger, amalgamation or acquisition, &#147;related&#148; within the meaning of the <I>Income Tax Act</I> (Canada)
(otherwise than by virtue of a right referred to in paragraph 251(5)(b) thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which does not result in an acceleration of the Redemption Date in accordance with paragraph (ii)&nbsp;of the
definition of Redemption Date in the Exchangeable Share Provisions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which all or substantially all of the then outstanding Delaware Common Stock are converted into or exchanged
for shares or rights to receive such shares (the &#147;<B>Other Shares</B>&#148;) of another corporation (the &#147;<B>Other Corporation</B>&#148;) that, immediately after such Parent Control Transaction, owns or controls, directly or indirectly,
Parent; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, (i)&nbsp;all references herein to &#147;Parent&#148; shall thereafter be and be deemed to be references to &#147;Other
Corporation&#148; and all references herein to &#147;Delaware Common Stock&#148; shall thereafter be and be deemed to be references to &#147;Other Shares&#148; (with appropriate adjustments, if any, as are required to result in a holder of
Exchangeable Shares on the exchange, redemption or retraction of such shares pursuant to the Exchangeable Share Provisions or the Plan of Arrangement or the exchange of such shares pursuant to this Agreement immediately subsequent to the Parent
Control Transaction being entitled to receive that number of Other Shares equal to the number of Other Shares such holder of Exchangeable Shares would have received if the exchange, redemption or retraction of such shares pursuant to the
Exchangeable Share Provisions or the Plan of Arrangement, or the exchange of such shares pursuant to this Agreement had occurred immediately prior to the Parent Control Transaction and the Parent Control Transaction was completed) but subject to
subsequent adjustments to reflect any subsequent changes in the share capital of the issuer of the Other Shares, including without limitation, any subdivision, consolidation or reduction of share capital, without any need to amend the terms and
conditions of this Agreement and without any further action required, and (ii)&nbsp;Parent shall cause the Other Corporation to deposit one or more voting securities of such Other Corporation to allow Beneficiaries to exercise voting rights in
respect of the Other Corporation substantially similar to those provided for in this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS AND SUPPLEMENTAL TRUST AGREEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendments, Modifications, etc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;11.2, 11.4 and 13.1 this Agreement may not be amended or modified except by an agreement in writing executed by Parent, CallCo,
ExchangeCo and the Share Trustee and approved by the Beneficiaries in accordance with Section&nbsp;26.11(b) of the Exchangeable Share Provisions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ministerial Amendments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of Section&nbsp;11.1, the parties to this Agreement may in writing, at any time and from time to time, without the approval of
the Beneficiaries, amend or modify this Agreement for the purposes of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding to the covenants of any or all parties hereto for the protection of the Beneficiaries hereunder provided
that the board of directors of each of Parent, CallCo and ExchangeCo shall be of the good faith opinion that such additions will not be prejudicial to the rights or interests of the Beneficiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evidencing the succession of Parent Successors and the covenants of and obligations assumed by each such Parent
Successor in accordance with the provisions of Article 10; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such amendments or modifications not inconsistent with this Agreement as may be necessary or desirable
with respect to matters or questions arising hereunder which, in the good faith opinion of the board of directors of each of Parent, CallCo and ExchangeCo and in the opinion of the Share Trustee it may be expedient to make, provided that each such
board of directors and the Share Trustee shall be of the good faith opinion, after consultation with counsel, that such amendments or modifications will not be prejudicial to the rights or interests of the Beneficiaries; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such changes or corrections which, on the advice of counsel to Parent, CallCo, ExchangeCo and the Share
Trustee, are required for the purpose of curing or correcting any ambiguity or defect or inconsistent provision or clerical omission or mistake or manifest error, provided that each such board of directors and the Share Trustee shall be of the good
faith opinion that such changes or corrections will not be prejudicial to the rights or interests of the Beneficiaries. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meeting to Consider Amendments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ExchangeCo, at the request of Parent, shall call a meeting or meetings of the Beneficiaries for the purpose of considering any proposed amendment or
modification requiring approval of ExchangeCo pursuant hereto. Any such meeting or meetings shall be called and held in accordance with the articles of ExchangeCo, the Exchangeable Share Provisions and all applicable laws. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Changes in Capital of Parent and ExchangeCo </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of Section&nbsp;11.1, at all times after the occurrence of any event contemplated pursuant to Section&nbsp;2.7 or 2.8 of the
Support Agreement or otherwise, as a result of which either Delaware Common Stock or the Exchangeable Shares or both are in any way changed, this Agreement shall forthwith be amended and modified as necessary in order that it shall apply with full
force and effect, mutatis mutandis, to all new securities into which Delaware Common Stock or the Exchangeable Shares or both are so changed and the parties hereto shall execute and deliver a supplemental trust agreement giving effect to and
evidencing such necessary amendments and modifications. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Execution of Supplemental Trust Agreements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No amendment to or modification or waiver of any of the provisions of this Agreement otherwise permitted hereunder shall be effective unless made in writing
and signed by all of the parties hereto. Notwithstanding the provisions of Section&nbsp;11.1, from time to time Parent, CallCo and ExchangeCo (in each case, when authorized by a resolution of its board of directors) and the Share Trustee may,
subject to the provisions of these presents, and they shall, when so directed by these presents, execute and deliver by their proper officers, trust agreements or other instruments supplemental hereto, which thereafter shall form part hereof, for
any one or more of the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evidencing the succession of Parent Successors and the covenants of and obligations assumed by each such Parent
Successor in accordance with the provisions of Article 10 and the successors of the Share Trustee or any successor Share Trustee in accordance with the provisions of Article 9; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making any additions to, deletions from or alterations of the provisions of this Agreement or the Voting
Rights, the Exchange Right or the Automatic Exchange Right which, in the opinion of the Share Trustee relying on the advice of counsel, will not be prejudicial to the interests of the Beneficiaries or are, in the opinion of counsel to the Share
Trustee, necessary or advisable in order to incorporate, reflect or comply with any legislation the provisions of which apply to Parent, CallCo, ExchangeCo, the Share Trustee or this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for any other purposes not inconsistent with the provisions of this Agreement, including without limitation to
make or evidence any amendment or modification to this Agreement as contemplated hereby; provided that, in the opinion of the Share Trustee relying on the advice of counsel, the rights of the Share Trustee and Beneficiaries will not be prejudiced
thereby. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Trust created by this Agreement shall continue until the earliest to occur of the following events, and upon the occurrence thereof, the Share Trustee
shall surrender the electronic registration of Special Voting Stock, and the Special Voting Share shall be cancelled by Parent without a return of capital: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no outstanding Exchangeable Shares are held by a Beneficiary following the Sunset Date (as defined in the
Exchangeable Share Provisions); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each of Parent, CallCo and ExchangeCo elects in writing to terminate the Trust and such termination is approved
by the Beneficiaries in accordance with Section&nbsp;26.11(b) of the Exchangeable Share Provisions. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival of Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall survive any termination of the Trust and shall continue until there are no Exchangeable Shares outstanding held by a Beneficiary;
provided, however, that the provisions of Article 7 and Article 8 shall survive any such termination of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or law, or public policy, all other conditions
and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such
determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in
an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Enurement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall be binding upon and enure to the benefit of the parties hereto and their respective successors and assigns and, subject to the terms
hereof, to the benefit of the Beneficiaries. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices to Parties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice and other communications required or permitted to be given pursuant to this Agreement shall be sufficiently given if delivered in person or if sent
by electronic transmission to the parties at the following addresses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of Parent, CallCo or ExchangeCo, at the following address: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">114 East 4th Avenue, Suite 800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Vancouver, BC, V5T 1G4 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Daniel Dex </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
daniel.dex@zymeworks.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Bryan King </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp; bking@wsgr.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;Joseph Garcia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: joseph.garcia@blakes.com </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of Share Trustee, at the following addresses: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Computershare Trust Company of Canada </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Manager, Corporate Trust </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: corporatetrust.vancouver@computershare.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and such notice or other communication shall be deemed to have been given and received (x)&nbsp;if delivered on a Business Day prior to 4:30 p.m. (local time
in the place where the notice or other communication is received), on the date of delivery, or (y)&nbsp;otherwise, on the next Business Day. Either party may change its address for notice by giving notice to the other parties in accordance with the
foregoing provisions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice to Beneficiaries </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice, request or other communication to be given to a Beneficiary shall be given or sent (in writing or by electronic transmission) to the address of the
holder recorded in the securities register of ExchangeCo or, in the event of the address of any such holder not being so recorded, then at the last known address of such holder, in any manner permitted by the articles of ExchangeCo, and shall be
deemed received at the time specified by such articles. Accidental failure or omission to give any notice, request or other communication to one or more holders of Exchangeable Shares, or any defect in such notice, shall not invalidate or otherwise
alter or affect any action or proceeding to be taken pursuant thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same
instrument. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Jurisdiction </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall be construed and enforced in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Attornment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Parent, CallCo, ExchangeCo and the Share Trustee agrees that any action or proceeding arising out of or relating to this Agreement may be instituted in
the courts of British Columbia, waives any objection which it may have now or hereafter to the venue of any such action or proceeding, irrevocably submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of the said courts
in any such action or proceeding, agrees to be bound by any judgement of the said courts and not to seek, and hereby waives, any review of the merits of any such judgement by the courts of any other jurisdiction, and Parent hereby appoints
ExchangeCo at its registered office in the Province of British Columbia as attorney for service of process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Communications Methods </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Trustee shall be entitled to treat a facsimile, pdf or <FONT STYLE="white-space:nowrap">e-mail</FONT> communication or communication by other similar
electronic means in a form satisfactory to the Share Trustee (&#147;<B>Electronic Methods</B>&#148;) from a person purporting to be (and whom the Share Trustee, acting reasonably, believes in good faith to be) the authorized representative of a
party, as sufficient instructions and authority of the party for the Share Trustee to act and shall have no duty to verify or confirm that such person is so authorized. The parties hereto acknowledges that they are fully informed of the protections
and risks associated with the various methods of transmitting instructions to the Share Trustee and that there may be more secure methods of transmitting instructions than Electronic Methods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of this page left intentionally blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be duly executed
as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS DELAWARE INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS CALLCO ULC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZYMEWORKS EXCHANGECO LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPUTERSHARE TRUST COMPANY OF CANADA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGEABLE SHARE PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 26 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL
RIGHTS OR RESTRICTIONS ATTACHED TO THE EXCHANGEABLE SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchangeable Shares of the Company shall have the following rights, privileges,
restrictions and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.1 Interpretation </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. For the purposes of these Exchangeable Share Provisions: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>affiliate</B>&#148; means, with respect to any person, any other person who, directly or indirectly, controls, is controlled by, or is
under common control with, such person. For purposes of this definition, the term &#147;<B>control</B>&#148; (including the correlative terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under</B> <B>common control
with</B>&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise. For purposes of
this Article 26, &#147;affiliate&#148; does not include any stockholders of Parent (other than Zymeworks Inc.), or directors or executive officers of Zymeworks Inc., Parent, the Company or CallCo. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Automatic Exchange Right</B>&#148; has the meaning ascribed thereto in the Voting and Exchange Trust Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>BCBCA</B>&#148; means the <I>Business Corporations Act </I>(British Columbia) and the regulations made thereunder, as now in effect
and as they may be promulgated or amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board of Directors</B>&#148; means the board of directors of the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Broker</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.14(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day on which banks are generally open for the transaction of commercial business in Vancouver, British
Columbia, and New York, New York, but does not in any event include a Saturday or Sunday or statutory holiday in Vancouver, British Columbia, or New York, New York. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>CallCo</B>&#148; means Zymeworks CallCo ULC, a corporation existing under the laws of the Province of British Columbia. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Canadian Resident</B>&#148; means either (i)&nbsp;a person who, at the relevant time, is a resident of Canada for purposes of the
<I>Income Tax Act</I> (Canada), or (ii)&nbsp;a partnership that is a &#147;Canadian partnership&#148; for purposes of the <I>Income Tax Act</I> (Canada). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law</B>&#148; means any amendment to the <I>Income Tax Act</I> (Canada) and other applicable provincial income Tax Laws that
permits Canadian Resident holders of the Exchangeable Shares, who hold the Exchangeable Shares as capital property and deal at arm&#146;s length with Parent and the Company (all for the purposes of the <I>Income Tax Act</I> (Canada) and other
applicable provincial income Tax Laws), to exchange their Exchangeable Shares for Delaware Common Stock on a basis that will not require such holders to recognize any income, gain or loss or any actual or deemed dividend in respect of such exchange
for the purposes of the <I>Income Tax Act</I> (Canada) or applicable provincial income Tax Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call
Date</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.20(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call Purchase Price</B>&#148; has the
meaning ascribed thereto in Section&nbsp;26.20(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call Right</B>&#148; has the meaning ascribed thereto in
Section&nbsp;26.20(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Shares</B>&#148; means the common shares in the capital of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Current Market Price</B>&#148; means, in respect of Delaware Common Stock on any
date, the average closing price of a share of Delaware Common Stock on the NYSE during the period of 20 consecutive trading days ending on the third trading day immediately before such date or, if the Delaware Common Stock are not then listed on the
NYSE, on such other stock exchange or automated quotation system on which the Delaware Common Stock are listed or quoted, as the case may be, as may be selected by the Board of Directors for such purpose; provided, however, that if in the opinion of
the Board of Directors the public distribution or trading activity of Delaware Common Stock during such period does not reflect the fair market value of a share of Delaware Common Stock, then the Current Market Price of a share of Delaware Common
Stock shall be determined by the Board of Directors, based upon the advice of such qualified independent financial advisors as the Board of Directors may deem to be appropriate; and provided further that any such selection, opinion or determination
by the Board of Directors shall be conclusive and binding, absent manifest error. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Delaware Common Stock</B>&#148; means shares of
Parent&#146;s common stock, par value US$0.00001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; has the meaning ascribed thereto in the Plan
of Arrangement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Consideration</B>&#148; means, with respect to each Exchangeable Share, for any acquisition
of, redemption of or distribution of assets of the Company in respect of such Exchangeable Share, or purchase of such Exchangeable Share pursuant to these Exchangeable Share Provisions or the Support Agreement or the Voting and Exchange Trust
Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one share of Delaware Common Stock multiplied by the Exchangeable Share Exchange Ratio on the Business Day
immediately preceding the date on which the Exchangeable Share Price in respect of the Exchangeable Share Consideration being delivered is calculated; plus </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a cheque or cheques payable at par at any branch of the bankers of the payor in the amount contemplated by
clause (ii)&nbsp;and (iv) (and in respect of clause (iv), to the extent of a cash dividend that is payable), as applicable, of the definition of Exchangeable Share Price; plus </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such stock or other property contemplated by clause (iii)&nbsp;and (iv) (and in respect of clause (iv), to the
extent of a <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend that is payable), as applicable, of the definition of Exchangeable Share Price; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided that: (A)&nbsp;the part of the consideration which represents (i)&nbsp;above shall be fully paid and satisfied by the delivery of
Delaware Common Stock, such shares to be duly issued, fully paid and nonassessable; (B)&nbsp;the part of the consideration which represents (iii)&nbsp;above shall be fully paid and satisfied by delivery of such
<FONT STYLE="white-space:nowrap">non-cash</FONT> items; (C)&nbsp;in each case, any such consideration shall be delivered free and clear of any lien, claim, encumbrance, security interest or adverse claim or interest; and (D)&nbsp;in each case, any
such consideration shall be paid without interest and less any tax required to be deducted and withheld therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable
Share Document</B>&#148; means (i)&nbsp;a share certificate representing Exchangeable Shares, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-transferable</FONT> acknowledgement of a shareholder&#146;s right to obtain a share certificate
representing Exchangeable Shares, or (iii)&nbsp;a direct registration system advice (or similar document) evidencing the electronic registration of the ownership of Exchangeable Shares, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Exchange Ratio</B>&#148; means, at any time and in respect of each Exchangeable Share, an amount equal to 1.00000,
as at the Effective Date, as cumulatively adjusted from time to time thereafter by increasing the Exchangeable Share Exchange Ratio on each date after the Effective Date on which the board of directors of Parent pays any dividend or other
distribution on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement) by an amount, rounded to the nearest five decimal places, equal to (a)(i) the amount of such dividend or other
distribution (which, in the case of a <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, shall equal the fair value as determined by the Board of Directors in good faith and in its sole discretion), expressed on a per
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Delaware Common Stock per share basis, multiplied (ii)&nbsp;by the Exchangeable Share Exchange Ratio in effect on the Business Day immediately preceding the record date set for such dividend or
other distribution, divided by (b)&nbsp;the Current Market Price on the record date set for such dividend or other distribution, and any such adjustment shall be determined by the Board of Directors in good faith and in its sole discretion and any
such determination by the Board of Directors shall be conclusive and binding; provided, however, that the Exchangeable Share Exchange Ratio shall only be so adjusted to the extent that the Board of Directors determines in good faith and in its sole
discretion that the Company would be liable for any unrecoverable tax as a result of paying any such dividend or distribution and determines to adjust the Exchangeable Share Exchange Ratio in lieu of paying an equivalent dividend or other
distribution on the Exchangeable Shares in accordance with these Exchangeable Share Provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share
Price</B>&#148; means, at any time, for each Exchangeable Share, an amount equal to the aggregate of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Current Market Price of one share of Delaware Common Stock at such time multiplied by the Exchangeable
Share Exchange Ratio on the Business Day immediately preceding the date on which the Exchangeable Share Price is calculated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the full amount of all cash dividends (A)&nbsp;declared, payable and unpaid on the Exchangeable Share, plus
(B)&nbsp;to the extent a cash dividend has been declared by Parent on the Delaware Common Stock at such time for which a corresponding cash dividend on the Exchangeable Share would be required to be, but has not yet been, declared at such time, then
the undeclared and unpaid cash dividend on such Exchangeable Share of equal amount multiplied by the Exchangeable Share Exchange Ratio (but only to the extent the Company has not taken one of the alternative actions permitted under these
Exchangeable Share Provisions to account for such declaration by Parent); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the full amount of all <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends declared, payable and unpaid
at such time on such Exchangeable Share (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the full amount of all dividends declared and payable in respect of each share of Delaware Common Stock (as
adjusted by the Exchangeable Share Exchange Ratio from time to time) which have not, at such time, been paid on such Exchangeable Share in accordance herewith or adjusted for under the Exchangeable Share Exchange Ratio, or otherwise accounted for in
under clauses (ii)&nbsp;and (iii) above in this definition (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Provisions</B>&#148; means the rights, privileges, restrictions and conditions set out in this Article 26. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Shares</B>&#148; means the exchangeable shares in the capital of the Company, having the rights, privileges, restrictions
and conditions set forth in this Article 26. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; means any nation or government or any agency,
public or regulatory authority, taxing authority, self-regulatory organization (including stock exchanges), instrumentality, department, commission, court, arbitrator (public or private), ministry, tribunal or board of any nation, government or
political subdivision or delegated authority thereof, in each case, whether foreign or domestic and whether national, supranational, multinational, federal, provincial, territorial, state, regional, local or municipal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means applicable statutes, common laws, rules, ordinances, regulations, codes, orders, judgments, injunctions, writs,
decrees, governmental guidelines or interpretations having the force of Law or bylaws, in each case, of a Governmental Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Amount</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Call Purchase Price</B>&#148; has the meaning ascribed thereto in the Section&nbsp;26.18(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Call Right</B>&#148; has the meaning ascribed thereto in the
Section&nbsp;26.18(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Date</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>NYSE</B>&#148; means the New York Stock Exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Withholding Agent</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.14(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent</B>&#148; means Zymeworks Delaware Inc., a corporation existing under the Laws of the State of Delaware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Control Transaction</B>&#148; shall be deemed to have occurred if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person acquires, directly or indirectly, any voting security of Parent and, immediately after such
acquisition, directly or indirectly owns, or exercises control and direction over, voting securities representing more than 50% of the total voting power of all of the then outstanding voting securities of Parent, other than any such transaction
which would result in the holders of outstanding voting securities of Parent immediately prior to such transaction directly or indirectly owning, or exercising control and direction over, voting securities representing more than 50% of the total
voting power of all of the voting securities of the acquiring person outstanding immediately after such transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders of Parent approve a merger, combination, consolidation, recapitalization or reorganization of
Parent, other than any such transaction which would result in the holders of outstanding voting securities of Parent immediately prior to such transaction directly or indirectly owning, or exercising control and direction over, voting securities
representing more than 50% of the total voting power of all of the voting securities of the surviving entity outstanding immediately after such transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders of Parent approve a liquidation of Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent sells or disposes of all or substantially all of its assets; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other transaction or series of related transactions having a substantially similar effect.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Dividend Declaration Date</B>&#148; means the date on which the board of directors of Parent declares
any dividend or other distribution on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>person</B>&#148; includes an individual, partnership, association, body corporate, trustee, executor, administrator, legal
representative, government or any other entity, whether or not having legal status. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Plan of Arrangement</B>&#148; means the plan
of arrangement substantially in the form and content of Exhibit A to the Transaction Agreement, including any appendices thereto, and any amendments, modifications or supplements thereto made from time to time in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Preferred Stock Rights Agreement</B>&#148; means any preferred stock rights agreement that may now or in the future be adopted and
entered into by Parent in respect of the Delaware Common Stock, to protect stockholders of Parent from coercive or otherwise unfair takeover tactics, in such form and substance as Parent may determine in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Call Purchase Price</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.19(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Call Right</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.19(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Date</B>&#148; means the date for the redemption by the Company of all but not less than all of the outstanding
Exchangeable Shares (other than Exchangeable Shares held by Parent and its affiliates), which date shall be the earlier of (a)&nbsp;the Sunset Date, and (b)&nbsp;the date, if any, established by the Board of Directors following the occurrence of any
of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the aggregate number of Exchangeable Shares issued and outstanding (other than Exchangeable Shares held by
Parent and its affiliates) is less than 5% of the number of Exchangeable Shares </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
issued on the Effective Date (as such number of shares may be adjusted as deemed appropriate by the Board of Directors to give effect to any subdivision, combination or consolidation of, or stock
or share dividend on, the Exchangeable Shares, any issue or distribution of rights to acquire Exchangeable Shares or securities exchangeable for or convertible into Exchangeable Shares, any issue or distribution of other securities or rights or
evidences of indebtedness or assets, or any other capital reorganization or other transaction affecting the Exchangeable Shares), in which case the Board of Directors may accelerate such redemption date to such date as it may determine, upon at
least 30 days&#146; prior written notice to the holders of the Exchangeable Shares and the Share Trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Parent Control Transaction is proposed, in which case, provided the Board of Directors determines in good
faith that it is not practicable to substantially replicate the terms and conditions of the Exchangeable Shares in connection with such Parent Control Transaction or that the redemption of all but not less than all of the outstanding Exchangeable
Shares (other than Exchangeable Shares held by Parent and its affiliates) is necessary to enable the completion of such Parent Control Transaction in accordance with its terms, the Board of Directors may accelerate such redemption date to such date
as it may determine, upon such number of days prior written notice to the holders of the Exchangeable Shares and the Share Trustee as the Board of Directors may determine to be reasonably practicable in such circumstances; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided, however, that the accidental failure or omission to give any notice of redemption under clauses (i)&nbsp;or (ii) above to any of the
holders of Exchangeable Shares shall not affect the validity of any such redemption. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Price</B>&#148; has the meaning
ascribed thereto in Section&nbsp;26.7(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retracted Shares</B>&#148; has the meaning ascribed thereto in
Section&nbsp;26.6(a)(i)(A). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Notice</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(b)(ii). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Right</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i)(C). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Right Purchase Price</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(b)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Date</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i)(B). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Price</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Request</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Share Trustee</B>&#148; means the trustee chosen by Parent and Zymeworks Inc. to act as trustee under the Voting and Exchange Trust
Agreement, being a corporation organized and existing under the Laws of Canada or any Province thereof and authorized to carry on the business of a trust company in all the provinces of Canada, and any successor trustee appointed under the Voting
and Exchange Trust Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sunset Date</B>&#148; means the seventh anniversary of the Effective Date, as it may be extended
from time to time by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Support Agreement</B>&#148; means the support agreement to be entered into at or
prior to the issuance by the Company of any Exchangeable Shares among Parent, CallCo and the Company substantially in the form of Exhibit C to the Transaction Agreement, as it may be amended, supplemented or otherwise modified from time to time in
accordance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; means any and all national, supranational, multinational, federal, provincial,
territorial, state, regional, local or municipal taxes, including income, branch, profits, capital gains, gross receipts, windfall profits, value added, severance, ad valorem, property, capital, estimated, utility, recapture, net worth, production,
sales, use, license, excise, franchise, environmental, transfer, land transfer, withholding or similar, payroll, employment, employer health, government pension plan premiums and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
contributions, social security premiums, workers&#146; compensation premiums, employment/unemployment insurance or compensation premiums or contributions, disability, documentary, registration,
stamp, occupation, premium, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum, goods and services, harmonized sales, customs duties or other taxes, levies, premiums, excises, fees, assessments, imposts, duties, and other similar
charges of any kind whatsoever imposed, assessed, charged or collected by a Governmental Authority and any installments in respect thereof, including any interest, fines, assessments, reassessments, penalties or additions to tax imposed in
connection therewith or with respect thereto, and any interest in respect of such additions or penalties, and whether disputed or not. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Law</B>&#148; means any Law in respect of Taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreement</B>&#148; means the transaction agreement dated July&nbsp;14, 2022 among Parent, CallCo, the Company and
Zymeworks Inc., as amended, supplemented or otherwise modified from time to time in accordance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer
Agent</B>&#148; means Computershare Investor Services Inc. or such other person as may from time to time be appointed by the Company as the registrar and transfer agent for the Exchangeable Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Voting and Exchange Trust Agreement</B>&#148; means the voting and exchange trust agreement to be made among Parent, CallCo, the
Company and the Share Trustee in connection with the Plan of Arrangement substantially in the form of Exhibit D to the Transaction Agreement, as may be amended, supplemented or otherwise modified from time to time in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Withholding Shortfall</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.14(c). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Interpretation Not Affected by Headings</U>. The division of these Exchangeable Share Provisions into
sections and other portions and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation hereof. Unless otherwise indicated, all references to a &#147;Section&#148; followed by a number
and/or a letter refer to the specified section of these Exchangeable Share Provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Number and Gender</U>. In these Exchangeable Share Provisions, unless the context otherwise clearly
requires, words used herein importing the singular include the plural and vice versa and words imparting any gender shall include all genders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Date of Any Action</U>. If any date on which any action is required to be taken hereunder by any person is
not a Business Day, then such action shall be required to be taken on the next succeeding day which is a Business Day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Currency</U>. In these Exchangeable Share Provisions, unless stated otherwise, all cash payments provided
for herein shall be made in United States dollars. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.2</B><B> Ranking of Exchangeable Shares</B>. The Exchangeable Shares shall be
entitled to a preference over the Common Shares and any other shares ranking junior to the Exchangeable Shares: (a)&nbsp;with respect to the payment of dividends or other distributions as and to the extent provided in Section&nbsp;26.3 and
(b)&nbsp;with respect to the distribution of assets in the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether voluntary or involuntary, or any other distribution of the assets of the
Company among its shareholders for the purpose of winding up its affairs as and to the extent provided in Section&nbsp;26.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.3</B> <B>Dividends and
Distributions</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dividends and Distributions.</U> A holder of an Exchangeable Share shall be entitled to receive and the
Board of Directors shall, subject to applicable Law, on each Parent Dividend Declaration Date, declare a dividend or other distribution on each Exchangeable Share: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a cash dividend or other distribution declared on the Delaware Common Stock (but excluding any
dividends or distributions pursuant to a Preferred Stock Rights Agreement), in an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
amount in cash payable in United States dollars for each Exchangeable Share equal to (A)&nbsp;the cash dividend or other distribution declared on each share of Delaware Common Stock on the Parent
Dividend Declaration Date, multiplied by (B)&nbsp;the relevant Exchangeable Share Exchange Ratio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a stock or share dividend or other distribution declared on the Delaware Common Stock to be paid
in Delaware Common Stock (but excluding any dividends or dividends or distributions pursuant to a Preferred Stock Rights Agreement), by the issue or transfer by the Company of such number of Exchangeable Shares for each Exchangeable Share as is
equal to the number of Delaware Common Stock to be paid on each share of Delaware Common Stock multiplied by the relevant Exchangeable Share Exchange Ratio; provided, however, that the Company may, in lieu of such stock or share dividend or other
distribution, elect to effect a corresponding, contemporaneous and economically equivalent (as determined by the Board of Directors in accordance with Sections 26.3(e) and 26.3(f)) subdivision of the outstanding Exchangeable Shares; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a dividend or other distribution declared on the Delaware Common Stock in property other than
cash or Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement), in such type and amount of property for each Exchangeable Share as is the same as or economically equivalent (as determined
by the Board of Directors in accordance with Section&nbsp;26.3(e)) and adjusted for the relevant Exchangeable Share Exchange Ratio to the type and amount of property declared as a dividend or other distribution on each share of Delaware Common
Stock; and </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">such dividends or other distributions shall be paid out of money, assets or property of the Company properly
applicable to the payment of dividends or other distributions, out of authorized but unissued shares of the Company or through the subdivision of outstanding Exchangeable Shares, as applicable; provided, that the Board of Directors may determine, in
its sole discretion, to adjust the Exchangeable Share Exchange Ratio as provided herein in lieu of paying any such dividend or other distribution on the Exchangeable Shares, and provided further, however, that the Exchangeable Share Exchange Ratio
shall only be so adjusted to the extent that the Board of Directors determines in good faith and in its sole discretion that the Company would be liable for any unrecoverable tax as a result of paying any such dividend or distribution. The holders
of Exchangeable Shares shall not be entitled to any dividends or other distributions other than or in excess of the dividends or other distributions referred to in this Section&nbsp;26.3(a). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payments of Dividends and Distributions</U>. Cheques of the Company payable at par at any branch of the
bankers of the Company shall be issued in respect of any cash dividends or other distributions contemplated by Section&nbsp;26.3(a)(i) and the sending of such cheque to each holder of an Exchangeable Share shall satisfy the cash dividend or other
distribution represented thereby unless the cheque is not paid on presentation. An Exchangeable Share Document registered in the name of the registered holder of Exchangeable Shares shall be delivered in respect of any stock or share dividends or
other distributions contemplated by Section&nbsp;26.3(a)(ii) or any subdivision of the Exchangeable Shares under Sections 26.3(a)(ii) and 26.3(f) and the sending of such Exchangeable Share Document to each holder of an Exchangeable Share shall
satisfy the stock or share dividend or other distribution represented thereby. Such other type and amount of property in respect of any dividends or other distributions contemplated by Section&nbsp;26.3(a)(iii) shall be issued, distributed or
transferred by the Company in such manner as it shall determine, and the issuance, distribution or transfer thereof by the Company to each holder of an Exchangeable Share shall satisfy the dividend or other distribution represented thereby. Subject
to the requirements of applicable Law with respect to unclaimed property, no holder of an Exchangeable Share shall be entitled to recover by action or other legal process against the Company any dividend or other distribution that is represented by
a cheque that has not been duly presented to the Company&#146;s bankers for payment or that otherwise remains unclaimed for a period of three (3)&nbsp;years from the date on which such dividend was payable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Record and Payment Dates</U>. The record date for the determination of the holders of Exchangeable Shares
entitled to receive payment of, and the payment date for, any dividend or other distribution declared on the Exchangeable Shares under Section&nbsp;26.3(a) shall be the same dates as the record date and payment date, respectively, for the
corresponding dividend or other distribution declared on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement). The record date for the determination of the holders of Exchangeable
Shares entitled to receive Exchangeable Shares in connection with any subdivision of the Exchangeable Shares under Sections 26.3(a)(ii) and 26.3(f), and the effective date of such subdivision, shall be the same dates as the record and payment date,
respectively, for the corresponding stock or share dividend or other distribution declared on the Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Partial Payment</U>. If on any payment date for any dividends or other distributions declared on the
Exchangeable Shares under Section&nbsp;26.3(a) the dividends or other distributions are not paid in full on all of the Exchangeable Shares then outstanding, any such dividends or other distributions that remain unpaid shall be paid on a subsequent
date or dates determined by the Board of Directors on which the Company shall have sufficient moneys, assets or property properly applicable to the payment of such dividends or other distributions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Economic Equivalence</U>. The Board of Directors shall determine, in good faith and in its sole discretion
(with the assistance of such financial or other advisors as the Board of Directors may determine), &#147;economic equivalence&#148; for the purposes of the Exchangeable Share Provisions and each such determination shall be conclusive and binding on
the Company and its shareholders. In making each such determination, the following factors shall, without excluding other factors determined by the Board of Directors to be relevant, be considered by the Board of Directors: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any stock or share dividend or other distribution payable in Delaware Common Stock (but
excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement), the number of such shares issued as a result of such stock or share dividend or other distribution in proportion to the number of Delaware Common Stock
previously outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the issuance or distribution of any rights, options or warrants to subscribe for or purchase
Delaware Common Stock or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement), the relationship between the
exercise price of each such right, option or warrant, the number of such rights, options or warrants to be issued or distributed in respect of each share of Delaware Common Stock and the Current Market Price of a share of Delaware Common Stock, the
price volatility of the Delaware Common Stock and the terms of any such instrument; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the issuance or distribution of any other form of property including, without limitation, any
shares or securities of Parent of any class other than Delaware Common Stock, any rights, options or warrants other than those referred to in Section&nbsp;26.3(e)(ii), any evidences of indebtedness of Parent or any assets of Parent (but excluding
any dividends or distributions pursuant to a Preferred Stock Rights Agreement), the relationship between the fair market value (as determined by the Board of Directors in the manner above contemplated) of such property to be issued or distributed
with respect to each outstanding share of Delaware Common Stock and the Current Market Price of a share of Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any subdivision, redivision or change of the then outstanding Delaware Common Stock into a
greater number of Delaware Common Stock or the reduction, combination, consolidation or change of the then outstanding Delaware Common Stock into a lesser number of Delaware Common Stock or any amalgamation, merger, arrangement, reorganization or
other transaction affecting the Delaware Common Stock, the effect thereof upon the then outstanding Delaware Common Stock; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in all such cases, the general taxation consequences of the relevant event to holders of Exchangeable Shares to
the extent that such consequences may differ from the taxation consequences to holders of Delaware Common Stock as a result of differences between taxation Laws of Canada and the United States (except for any differing consequences arising as a
result of differing marginal taxation rates and without regard to the individual circumstances of holders of Exchangeable Shares). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Subdivision on Stock or Share Dividend</U>. In the case of a stock or share dividend declared on Delaware
Common Stock to be paid in Delaware Common Stock, in lieu of declaring the stock or share dividend contemplated by Section&nbsp;26.3(a)(ii) on the Exchangeable Shares, the Board of Directors may, in good faith and in its discretion and subject to
applicable Law and to obtaining any required regulatory approvals, subdivide, redivide or change each issued and unissued Exchangeable Share on the basis that each Exchangeable Share before such subdivision becomes a number of Exchangeable Shares
equal to the sum of (i)&nbsp;one share of Delaware Common Stock, and (ii)&nbsp;the number of Delaware Common Stock to be paid as a share dividend on each share of Delaware Common Stock. In such instance, and notwithstanding any other provision
hereof, such subdivision shall become effective on the effective date specified in Section&nbsp;26.3(c) without any further act or formality on the part of the holders of Exchangeable Shares. For greater certainty, subject to applicable Law, no
approval of the holders of Exchangeable Shares to an amendment to these Articles shall be required to give effect to such subdivision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Share Consolidation</U>. In the case of a consolidation of shares of Delaware Common Stock, the Board of
Directors may, in good faith and in its discretion and subject to applicable Law and to obtaining any required regulatory approvals, consolidate each issued and unissued Exchangeable Share on the same basis concurrently with, or as soon as
practicable following, the consolidation of the shares of Delaware Common Stock (and to ensure that the Exchangeable Share Exchange Ratio does not decrease as a result of the consolidation of the shares of Delaware Common Stock). For greater
certainty, subject to applicable Law, no approval of the holders of Exchangeable Shares to an amendment to these Articles shall be required to give effect to such consolidation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.4</B> <B>Certain Restrictions</B>. So long as any of the Exchangeable Shares are outstanding, the Company shall not at any time without, but may at any
time with, the approval of the holders of the Exchangeable Shares given as specified in Section&nbsp;26.11(b): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pay any dividends or other distributions on any shares ranking junior to the Exchangeable Shares with respect
to the payment of dividends or other distributions (other than the Common Shares), other than stock or share dividends payable in Common Shares or any such other shares ranking junior to the Exchangeable Shares, as the case may be;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">redeem or purchase or make any capital distribution in respect of any shares ranking junior to the Exchangeable
Shares with respect to the payment of dividends or other distributions (other than the Common Shares) in the event of the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or any other distribution of the
assets of the Company among its shareholders for the purpose of winding up its affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">redeem or purchase or make any capital distribution in respect of any other shares of the Company ranking
equally with the Exchangeable Shares with respect to the payment of dividends or other distributions in the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether voluntary or involuntary,
or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue any Exchangeable Share or any other shares ranking equally with, or superior to, the Exchangeable Shares,
other than, in each case, by way of stock or share dividends to the holders of such Exchangeable Shares or pursuant to a shareholders rights plan adopted by the Company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that the restrictions in this Section&nbsp;26.4 shall not apply if, in connection with
all dividends or other distributions declared and paid on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement): (i) all dividends or other distributions on the outstanding
Exchangeable Shares shall have been declared and paid in full on the Exchangeable Shares, or (ii)&nbsp;the Exchangeable Share Exchange Ratio shall have been adjusted in accordance with these Exchangeable Share Terms, in each case, prior to or as at
the date of any such event referred to in this Section&nbsp;26.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.5</B> <B>Liquidation</B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Liquidation Amount</U>. Subject to applicable Laws and the due exercise by CallCo of the Liquidation Call
Right (which shall itself be subject to the sale and purchase contemplated by the Automatic Exchange Right), in the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other distribution
of the assets of the Company among its shareholders for the purpose of winding up its affairs, a holder of Exchangeable Shares shall be entitled to receive from the assets of the Company in respect of each Exchangeable Share held by such holder on
the effective date of such liquidation, dissolution, <FONT STYLE="white-space:nowrap">winding-up</FONT> or other distribution (the &#147;<B>Liquidation Date</B>&#148;), before any distribution of any part of the assets of the Company among the
holders of the Common Shares or any other shares ranking junior to the Exchangeable Shares with respect to dividends or other distributions an amount per share (the &#147;<B>Liquidation Amount</B>&#148;) equal to the Exchangeable Share Price
applicable on the last Business Day prior to the Liquidation Date, which price shall be satisfied in full by the Company delivering or causing to be delivered to such holder the Exchangeable Share Consideration representing the Liquidation Amount
for each Exchangeable Share held by such holder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment of Liquidation Amount</U>. In the case of a distribution pursuant to Section&nbsp;26.5(a), and
provided that the sale and purchase contemplated by the Automatic Exchange Right has not occurred and that the Liquidation Call Right has not been exercised by CallCo, on or promptly after the Liquidation Date, the Company shall deliver or cause to
be delivered to the holders of the Exchangeable Shares the Liquidation Amount for each such Exchangeable Share, upon presentation and surrender of the Exchangeable Share Documents representing such Exchangeable Shares, together with such other
documents and instruments as may be required to effect a transfer of Exchangeable Shares under the BCBCA and these Articles, as applicable, together with such additional documents, instruments and payments as the Transfer Agent or the Company may
reasonably require, at any office of the Transfer Agent as may be specified by the Company by notice to the holders of the Exchangeable Shares. Payment of the Liquidation Amount for such Exchangeable Shares shall be made by delivery to each holder,
at the address of such holder recorded in the securities register of the Company for the Exchangeable Shares or by holding for <FONT STYLE="white-space:nowrap">pick-up</FONT> by such holder at the registered office of the Company or at any office of
the Transfer Agent as may be specified by the Company by notice to the holders of the Exchangeable Shares, the Exchangeable Share Consideration such holder is entitled to receive pursuant<U> </U>to Section&nbsp;26.5(a). On and after the Liquidation
Date, the holders of the Exchangeable Shares shall cease to be holders of such Exchangeable Shares and shall not be entitled to exercise any of the rights of holders in respect thereof (including, without limitation, any rights under the Voting and
Exchange Trust Agreement) other than the right to receive, without interest, their proportionate part of the aggregate Liquidation Amount, unless payment of the aggregate Liquidation Amount for such Exchangeable Shares shall not be made upon
presentation and surrender of Exchangeable Share Documents and other required documents in accordance with the foregoing provisions, in which case the rights of the holders shall remain unaffected until the Liquidation Amount has been paid in the
manner so provided. The Company shall have the right at any time after the Liquidation Date to transfer or cause to be issued or transferred to, and deposited in a custodial account with, any chartered bank or trust company the Liquidation Amount in
respect of the Exchangeable Shares represented by Exchangeable Share Documents that have not at the Liquidation Date been surrendered by the holders thereof, such Liquidation Amount to be held by such bank or trust company as trustee for and on
behalf of, and for the use and benefit of, such holders. Upon such deposit being made, the rights of a holder of Exchangeable Shares as of the date of such deposit shall be limited to receiving its proportionate part
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of the aggregate Liquidation Amount for such Exchangeable Shares so deposited, without interest, and all dividends and other distributions with respect to the Delaware Common Stock to which such
holder is entitled with a record date on or after the date of such deposit and before the date of transfer of such Delaware Common Stock to such holder against presentation and surrender of the Exchangeable Share Documents for the Exchangeable
Shares held by them in accordance with the foregoing provisions. Upon such payment or deposit of the Liquidation Amount, the holders of the Exchangeable Shares shall thereafter be considered and deemed for all purposes to be holders of the Delaware
Common Stock delivered to them or the custodian on their behalf. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Right to Participate in Further Distributions</U>. After the Company has satisfied its obligations to pay
the holders of the Exchangeable Shares the aggregate Liquidation Amount per Exchangeable Share pursuant to this Section&nbsp;26.5, such holders shall not be entitled to share in any further distribution of the assets of the Company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.6</B> <B>Retraction of Exchangeable Shares</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Retraction at Option of Holder</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to applicable Laws and the due exercise by CallCo of the Retraction Call Right, a holder of
Exchangeable Shares shall be entitled at any time to require the Company to redeem (at the holder&#146;s discretion) any or all of the Exchangeable Shares registered in the name of such holder for an amount per share equal to the Exchangeable Share
Price applicable on the last Business Day prior to the Retraction Date (the &#147;<B>Retraction Price</B>&#148;), which price shall be satisfied in full by the Company or CallCo, as applicable, delivering or causing to be delivered to such holder
the Exchangeable Share Consideration representing the Retraction Price. A holder of Exchangeable Shares must give notice of such request to redeem or purchase by presenting and surrendering to any office of the Transfer Agent as may be specified by
the Company by notice to the holders of the Exchangeable Shares, the Exchangeable Share Documents representing the Exchangeable Shares that such holder desires to have the Company redeem or CallCo purchase, as applicable, together with (A)&nbsp;such
other documents and instruments as may be required to effect a transfer of Exchangeable Shares under the BCBCA and these Articles, as applicable, together with such additional documents, instruments and payments as the Transfer Agent or the Company
may reasonably require, and (B)&nbsp;a duly executed request (the &#147;<B>Retraction Request</B>&#148;) in the form of the Appendix attached hereto or in such other form as may be acceptable to the Company: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">specifying that such holder desires to have all or any number specified therein of the Exchangeable Shares
represented by such Exchangeable Share Documents (the &#147;<B>Retracted Shares</B>&#148;) redeemed by the Company or purchased by CallCo, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">stating the Business Day on which the holder desires to have the Company redeem or CallCo purchase the
Retracted Shares (the &#147;<B>Retraction Date</B>&#148;), provided that the Retraction Date shall not be less than 10 Business Days nor more than 15 Business Days after the date on which the Retraction Request is received by the Transfer Agent on
behalf of the Company and further provided that, in the event that no such Business Day is specified by the holder in the Retraction Request, the Retraction Date shall be deemed to be the 15th Business Day after the date on which the Retraction
Request is received by the Transfer Agent on behalf of the Company, subject to Section&nbsp;26.6(a)(v); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acknowledging the overriding right (the &#147;<B>Retraction Call Right</B>&#148;) of CallCo to purchase all but
not less than all the Retracted Shares directly from the holder and that the Retraction Request shall be deemed to be a revocable offer by the holder to sell the Retracted Shares to CallCo in accordance with the Retraction Call Right on the
Retraction Date for the Retraction Call Right Purchase Price and on the other terms and conditions set out in Section&nbsp;26.6(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of a redemption or purchase of Exchangeable Shares pursuant to this Section&nbsp;26.6(a), upon
receipt by the Transfer Agent in the manner specified in Section&nbsp;26.6(a)(i) of one or more </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Exchangeable Share Documents representing the number of Exchangeable Shares which the holder desires to have the Company redeem or CallCo purchase, together with a duly executed Retraction
Request and such additional documents and instruments specified in Section&nbsp;26.6(a)(i) or that the Company or the Transfer Agent may reasonably require, and provided that (A)&nbsp;the Retraction Request has not been revoked by the holder of such
Retracted Shares in the manner specified in Section&nbsp;26.6(a)(iv), and (B)&nbsp;CallCo has not exercised the Retraction Call Right, the Company shall redeem or CallCo shall purchase, as applicable, the Retracted Shares effective at the close of
business on the Retraction Date. On the Retraction Date, the Company or CallCo shall deliver or cause to be delivered to such holder, at the address of the holder recorded in the securities register of the Company for the Exchangeable Shares or at
the address specified in the Retraction Request or by holding for <FONT STYLE="white-space:nowrap">pick-up</FONT> by the holder at any office of the Transfer Agent as may be specified by the Company by notice to the holders of the Exchangeable
Shares, the Exchangeable Share Consideration representing the Retraction Price and such delivery of such Exchangeable Share Consideration by or on behalf of the Company by the Transfer Agent shall be deemed to be payment of and shall satisfy and
discharge all liability for the Retraction Price to the extent that the same is represented by such Exchangeable Share Consideration, unless any cheque comprising part of such Exchangeable Share Consideration is not paid on due presentation. If only
a part of the Exchangeable Shares represented by any Exchangeable Share Document is redeemed or purchased, a new Exchangeable Share Document for the balance of such Exchangeable Shares shall be issued to the holder at the expense of the Company. On
and after the close of business on the Retraction Date, the holder of the Retracted Shares shall cease to be a holder of such Retracted Shares and shall not be entitled to exercise any of the rights of a holder in respect thereof (including, without
limitation, any rights under the Voting and Exchange Trust Agreement), other than the right to receive the aggregate Retraction Price in respect thereof, unless payment of the aggregate Retraction Price payable to such holder shall not be made upon
presentation and surrender of the Exchangeable Share Documents and other required documents in accordance with the foregoing provisions, in which case the rights of such holder shall remain unaffected until such aggregate Retraction Price has been
paid in the manner so provided. On and after the close of business on the Retraction Date, provided that presentation and surrender of the Exchangeable Share Documents and payment of such aggregate Retraction Price has been made in accordance with
the foregoing provisions, the holder of the Retracted Shares so redeemed by the Company shall thereafter be considered and deemed for all purposes to be a holder of the Delaware Common Stock delivered to such holder. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of this Section&nbsp;26.6, the Company shall not be obligated to redeem
Retracted Shares specified by a holder in a Retraction Request if and to the extent that such redemption or purchase of Retracted Shares, as applicable, would be contrary to solvency requirements or other provisions of applicable Laws. If the
Company believes, after due enquiry, that on any Retraction Date it would not be permitted by any of such provisions to redeem the Retracted Shares tendered for redemption on such date, and provided that (A)&nbsp;CallCo has not exercised the
Retraction Call Right with respect to such Retracted Shares, and (B)&nbsp;the holder has not required that CallCo purchase such Retracted Shares as contemplated under Section&nbsp;26.6(a)(i), then the Company shall only be obligated to redeem
Retracted Shares specified by a holder in a Retraction Request to the extent of the maximum number that may be so redeemed (rounded down to a whole number of shares) as would not be contrary to such provisions and shall notify the holder and the
Share Trustee at least two Business Days prior to the Retraction Date as to the number of Retracted Shares which will not be redeemed by the Company. In any case in which the redemption by the Company of Retracted Shares would be contrary to
solvency requirements or other provisions of applicable Laws, the Company shall redeem Retracted Shares in accordance with Section&nbsp;26.6(a)(ii) on a pro rata basis in proportion to the total number of Exchangeable Shares tendered for retraction
and shall issue to each holder of Retracted Shares a new Share Exchange Document, at the expense of the Company, representing the Retracted Shares not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
redeemed by the Company pursuant to Section&nbsp;26.6(a)(ii). If the Company would otherwise be obligated to redeem Retracted Shares pursuant to Section&nbsp;26.6(a)(ii) but is not obligated to
do so as a result of solvency requirements or other provisions of applicable Laws, the holder of any such Retracted Shares not redeemed by the Company pursuant to Section&nbsp;26.6(a)(ii) as a result of solvency requirements or other provisions of
applicable Laws shall be deemed, by delivery of the Retraction Request, to have instructed the Transfer Agent to require CallCo to purchase such Retracted Shares from such holder on the Retraction Date or as soon as practicable thereafter on payment
by CallCo to such holder of the aggregate Retraction Price in respect of such Retracted Shares, all as more specifically provided for in the Voting and Exchange Trust Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A holder of Retracted Shares may, by notice in writing given by the holder to any office of the Transfer Agent
as may be specified by the Company by notice to the holders of the Exchangeable Shares, before the close of business on the Business Day immediately preceding the Retraction Date, withdraw its Retraction Request, in which event such Retraction
Request shall be null and void and, for greater certainty, the revocable offer constituted by the Retraction Request to sell the Retracted Shares to CallCo shall be deemed to have been revoked. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of this Section&nbsp;26.6(a), if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise of the rights of the holders of the Exchangeable Shares, or any of them, to require the Company to
redeem any Exchangeable Shares pursuant to this Section&nbsp;26.6(a) on any Retraction Date would require listing particulars or any similar document to be issued in order to obtain the approval of the NYSE to the listing and trading (subject to
official notice of issuance) of the Delaware Common Stock that would be required to be delivered to such holders of Exchangeable Shares in connection with the exercise of such rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a result of (A)&nbsp;above, it would not be practicable (notwithstanding the reasonable endeavours of
Parent) to obtain such approvals in time to enable all or any of such Delaware Common Stock to be admitted to listing and trading by the NYSE (subject to official notice of issuance) when so delivered; the Retraction Date shall, notwithstanding any
other date specified or otherwise deemed to be specified in any relevant Retraction Request, be deemed for all purposes to be the earlier of (i)&nbsp;the second Business Day immediately following the date the approvals referred to in
Section&nbsp;26.6(a)(v)(A) are obtained and (ii)&nbsp;the date which is 30 Business Days after the date on which the relevant Retraction Request is received by the Company, and references in these Exchangeable Share Provisions to such Retraction
Date shall be construed accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Retraction Call Rights</U><U> </U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that a holder of Exchangeable Shares delivers a Retraction Request pursuant to
Section&nbsp;26.6(a), and subject to the limitations set forth in Section&nbsp;26.6(a)(ii), the Retraction Call Right will be available to CallCo, notwithstanding the proposed redemption of the Exchangeable Shares by the Company pursuant to
Section&nbsp;26.6(a), to purchase from such holder on the Retraction Date all but not less than all of the Retracted Shares held by such holder on payment by CallCo of an amount per share equal to the Exchangeable Share Price applicable on the last
Business Day prior to the Retraction Date (the &#147;<B>Retraction Call Right Purchase Price</B>&#148;), which price shall be satisfied in full by CallCo delivering or causing to be delivered to such holder the Exchangeable Share Consideration
representing the Retraction Call Right Purchase Price. Upon the exercise of the Retraction Call Right in respect of Retracted Shares, the holder of such Retracted Shares shall be obligated to sell all of such Retracted Shares to CallCo on the
Retraction Date on payment by CallCo of the aggregate Retraction Call Right Purchase Price in respect of such Retracted Shares as set forth in this Section&nbsp;26.6(b)(i). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon receipt by the Transfer Agent of a Retraction Request, the Transfer Agent shall immediately notify the
Company and CallCo thereof and shall provide CallCo with a copy of the Retraction </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Request. In order to exercise its Retraction Call Right, CallCo must notify the Transfer Agent in writing of its determination to do so (a &#147;<B>Retraction Call Notice</B>&#148;) within five
Business Days after the Transfer Agent notifies CallCo of the Retraction Request. If CallCo does not so notify the Transfer Agent within such five Business Day period, then the Transfer Agent shall notify the holder as soon as possible thereafter
that CallCo will not exercise the Retraction Call Right. If CallCo delivers a Retraction Call Notice within such five Business Day period and duly exercises its Retraction Call Right in accordance with this Section&nbsp;26.6(b)(ii), the obligation
of the Company to redeem the Retracted Shares shall terminate and, provided that the Retraction Request is not revoked by the holder of such Retracted Shares in the manner specified in Section&nbsp;26.6(a)(iv), CallCo shall purchase from such holder
and such holder shall sell to CallCo on the Retraction Date the Retracted Shares for an amount per share equal to the Retraction Call Right Purchase Price. Provided that the aggregate Retraction Call Right Purchase Price has been so deposited with
the Transfer Agent as provided in Section&nbsp;26.6(b)(iii), the closing of the purchase and sale of the Retracted Shares pursuant to the Retraction Call Right shall be deemed to have occurred as at the close of business on the Retraction Date and,
for greater certainty, no redemption by the Company of such Retracted Shares shall take place on the Retraction Date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of completing a purchase of Retracted Shares pursuant to the exercise of the Retraction Call
Right, CallCo shall deliver or cause to be delivered to the holder of such Retracted Shares, at the address of the holder recorded in the securities register of the Company for the Exchangeable Shares or at the address specified in the holder&#146;s
Retraction Request or by holding for <FONT STYLE="white-space:nowrap">pick-up</FONT> by the holder at any office of the Transfer Agent as may be specified by the Company by notice to the holders of Exchangeable Shares, the Exchangeable Share
Consideration representing the Retraction Call Right Purchase Price to which such holder is entitled, and such delivery of Exchangeable Share Consideration on behalf of CallCo shall be deemed to be payment of and shall satisfy and discharge all
liability for the Retraction Call Right Purchase Price to the extent that the same is represented by such Exchangeable Share Consideration, unless any cheque comprising part of such Exchangeable Share Consideration is not paid on due presentation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent in accordance with Section&nbsp;26.6(b)(ii) of its intention to
exercise the Retraction Call Right in the manner and timing described therein, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Transfer Agent) that CallCo exercise the
Retraction Call Right in respect of the shares covered by the notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On and after the close of business on the Retraction Date, the holder of the Retracted Shares shall cease to be
a holder of such Retracted Shares and shall not be entitled to exercise any of the rights of a holder in respect thereof (including, without limitation, any rights under the Voting and Exchange Trust Agreement), other than the right to receive the
aggregate Retraction Call Right Purchase Price in respect thereof, unless payment of the aggregate Retraction Call Right Purchase Price payable to such holder shall not be made upon presentation and surrender of Exchangeable Share Documents and
other required documents in accordance with the foregoing provisions, in which case the rights of such holder shall remain unaffected until such aggregate Retraction Call Right Purchase Price has been paid in the manner so provided. On and after the
close of business on the Retraction Date, provided that presentation and surrender of Exchangeable Share Documents and payment of such aggregate Retraction Call Right Purchase Price has been made in accordance with the foregoing provisions, the
holder of the Retracted Shares so purchased by CallCo shall thereafter be considered and deemed for all purposes to be a holder of the Delaware Common Stock delivered to such holder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.7</B> <B>Redemption of Exchangeable Shares by the Company</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Redemption Amount</U>. Subject to applicable Laws and the due exercise by CallCo of the Redemption Call
Right, the Company shall on the Redemption Date redeem all but not less than all of the then </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
outstanding Exchangeable Shares (other than Exchangeable Shares held by Parent and its affiliates) for an amount per share (the &#147;<B>Redemption Price</B>&#148;) equal to the Exchangeable
Share Price on the last Business Day prior to the Redemption Date, which price shall be satisfied in full by the Company delivering or causing to be delivered to each holder of Exchangeable Shares the Exchangeable Share Consideration for each
Exchangeable Share held by such holder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice of Redemption</U>. In the case of a redemption of Exchangeable Shares pursuant to
Section&nbsp;26.7(a), the Company shall, at least 30 days before the Redemption Date (other than a Redemption Date established in connection with a Parent Control Transaction), send or cause to be sent to each holder of Exchangeable Shares a notice
in writing of the redemption by the Company or the purchase by CallCo under the Redemption Call Right of the Exchangeable Shares held by such holder. In the case of a Redemption Date established in connection with a Parent Control Transaction, the
written notice of the redemption by the Company or the purchase by CallCo of the Exchangeable Shares under the Redemption Call Right will be sent on or before the Redemption Date, on as many days&#146; prior written notice as may be determined by
the Board of Directors to be reasonably practicable in the circumstances. In any such case, such notice shall set out the formula for determining the Redemption Price or the Redemption Call Purchase Price, as the case may be, the Redemption Date
and, if applicable, particulars of the Redemption Call Right. In the case of any notice given in connection with a possible Redemption Date, such notice will be given contingently and will be withdrawn if the contingency does not occur.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment of Redemption Price</U>. On or promptly after the Redemption Date, and provided that the Redemption
Call Right has not been exercised by CallCo, the Company shall deliver or cause to be delivered to the holders of the Exchangeable Shares to be redeemed the Redemption Price for each such Exchangeable Share, upon presentation and surrender of the
Exchangeable Share Document representing such Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable Shares under the BCBCA and these Articles, as applicable, together with
such additional documents, instruments and payments as the Transfer Agent or the Company may reasonably require, at any office of the Transfer Agent as may be specified by notice to the holders of the Exchangeable Shares. Payment of the Redemption
Price for such Exchangeable Shares shall be made by delivery to each holder, at the address of the holder recorded in the securities register of the Company for the Exchangeable Shares or by holding for
<FONT STYLE="white-space:nowrap">pick-up</FONT> by the holder at the registered office of the Transfer Agent as may be specified by the Company by notice to the holders of Exchangeable Shares, the Exchangeable Share Consideration representing the
Redemption Price. On and after the Redemption Date, the holders of the Exchangeable Shares called for redemption shall cease to be holders of such Exchangeable Shares and shall not be entitled to exercise any of the rights of holders in respect
thereof (including, without limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive, without interest, their proportionate part of the aggregate Redemption Price, unless payment of the aggregate
Redemption Price for such Exchangeable Shares shall not be made upon presentation and surrender of Exchangeable Share Documents in accordance with the foregoing provisions, in which case the rights of the holders shall remain unaffected until the
Redemption Price has been paid in the manner so provided. The Company shall have the right at any time after the sending of notice of its intention to redeem the Exchangeable Shares as provided to deposit or cause to be deposited the aggregate
Redemption Price (in the form of Exchangeable Share Consideration) of the Exchangeable Shares so called for redemption, or of such of the said Exchangeable Shares represented by Exchangeable Share Documents that have not at the date of such deposit
been surrendered by the holders thereof in connection with such redemption, in a custodial account with any chartered bank or trust company in Canada named in such notice and any interest earned on such deposit shall belong to the Company. Provided
that such aggregate Redemption Price has been so deposited prior to the Redemption Date, on and after the Redemption Date, the Exchangeable Shares in respect of which such deposit shall have been made shall be redeemed and the rights of the holders
thereof after the Redemption Date shall be limited to receiving, without interest, their proportionate part of the aggregate Redemption Price for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such Exchangeable Shares so deposited, against presentation and surrender of the Exchangeable Share Documents for the Exchangeable Shares held by them, respectively, in accordance with the
foregoing provisions. Upon such payment or deposit of the Redemption Price, the holders of the Exchangeable Shares shall thereafter be considered and deemed for all purposes to be holders of the Delaware Common Stock delivered to them or the
custodian on their behalf. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.8</B> <B>Purchase by Private Agreement</B>. Subject to applicable Laws and the articles of the Company,
and notwithstanding Section&nbsp;26.7(b), the Company may at any time and from time to time purchase for cancellation all or any part of the Exchangeable Shares by private agreement with the holder thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.9</B> <B>Voting Rights</B>. Except as required by applicable Laws and by Section&nbsp;26.11, the holders of the Exchangeable Shares shall not be
entitled as such to receive notice of or to attend any meeting of the shareholders of the Company or to vote at any such meeting. Without limiting the generality of the foregoing, the holders of the Exchangeable Shares shall not be entitled to class
votes except as required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.10</B> <B>Specified Amount</B>. The &#147;specified amount&#148; for the purposes of subsection 191(4)
of the <I>Income Tax Act </I>(Canada) in respect of each Exchangeable Share shall be the amount specified by a director or officer of the Company in a resolution that is entered into in connection with the issuance of the Exchangeable Shares of the
Company (expressed as a dollar amount). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.11</B> <B>Amendment and Approval</B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment</U>. The rights, privileges, restrictions and conditions attaching to the Exchangeable Shares may
be added to, changed or removed only with the approval of the holders of the Exchangeable Shares given as specified below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Approval</U>. Any approval given by the holders of the Exchangeable Shares to add to, change or remove any
right, privilege, restriction or condition attaching to the Exchangeable Shares or any other matter requiring the approval or consent of the holders of the Exchangeable Shares either in accordance with applicable Laws or as expressly provided under
these Exchangeable Share Provisions shall be deemed to have been sufficiently given if it shall have been given in accordance with applicable Laws, subject to a minimum requirement that such approval be evidenced by resolution passed by not less
than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on such resolution at a meeting of holders of Exchangeable Shares duly called and held at which the holders of at least 10% of the outstanding Exchangeable Shares at that time
are present or represented by proxy; provided, however, that if at any such meeting the holders of at least 10% of the outstanding Exchangeable Shares at that time are not present or represented by proxy within
<FONT STYLE="white-space:nowrap">one-half</FONT> hour after the time appointed for such meeting, then the meeting shall be adjourned to such date not less than five days thereafter and to such time and place as may be designated by the Chair of such
meeting. At such adjourned meeting, the holders of Exchangeable Shares present or represented by proxy thereat may transact the business for which the meeting was originally called and a resolution passed thereat by the affirmative vote of not less
than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on such resolution at such meeting shall constitute the approval or consent of the holders of the Exchangeable Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.12</B> <B>Reciprocal Changes</B><B> in Respect of Delaware Common Stock</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acknowledgement in Respect of Issuances or Distributions</U>. The Company and each holder of an Exchangeable
Share acknowledges that the Support Agreement provides, in part, that Parent will not, except as provided in the Support Agreement, without the prior approval of the Company and the prior approval of the holders of the Exchangeable Shares given in
accordance with Section&nbsp;26.11(b): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute Delaware Common Stock (or securities exchangeable for or convertible into or carrying
rights to acquire Delaware Common Stock) to the holders of all or substantially all of the then outstanding Delaware Common Stock by way of stock or share dividend or other distribution,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
other than an issue of Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) to holders of Delaware Common Stock who
exercise an option to receive dividends in Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) in lieu of receiving cash dividends, or pursuant to any dividend reinvestment
plan or scrip dividend or similar arrangement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute rights, options or warrants to the holders of all or substantially all of the then
outstanding Delaware Common Stock entitling them to subscribe for or to purchase Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute to the holders of all or substantially all of the then outstanding Delaware Common Stock:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares or securities of Parent of any class other than Delaware Common Stock (or securities convertible into or
exchangeable for or carrying rights to acquire Delaware Common Stock); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">rights, options or warrants other than those referred to in Section&nbsp;26.12(a)(ii) above;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evidence of indebtedness of Parent; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">assets of Parent; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, the Company issues or distributes the economic equivalent of such rights, options, warrants, securities, shares,
evidences of indebtedness or other assets simultaneously to holders of the Exchangeable Shares; provided, however, that, for greater certainty, the above restrictions shall not apply to any securities issued or distributed by Parent in order to give
effect to and to consummate the transactions contemplated by, and in accordance with, the Transaction Agreement and the Plan of Arrangement; provided, further, that the foregoing limitations and restrictions set forth in this Section&nbsp;26.12(a)
shall not apply to actions taken by Parent relating to a Preferred Stock Rights Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acknowledgement in Respect of Corporate Changes</U>. Each holder of an Exchangeable Share acknowledges that
the Support Agreement further provides, in part, that for so long as any Exchangeable Shares not owned by Parent or its affiliates are outstanding, Parent will not without the prior approval of the Company and the prior approval of the holders of
the Exchangeable Shares given in accordance with Section&nbsp;26.11(b): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide, redivide or change the then outstanding Delaware Common Stock into a greater number of Delaware
Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce, combine, consolidate or change the then outstanding Delaware Common Stock into a lesser number of
Delaware Common Stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reclassify or otherwise change the Delaware Common Stock or effect an amalgamation, merger, reorganization or
other transaction affecting the Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, the same or an economically equivalent
change is made simultaneously to, or in the rights of the holders of, the Exchangeable Shares; provided, however, that, for greater certainty, the above restrictions shall not apply to any securities issued or distributed by Parent in order to give
effect to and to consummate the transactions contemplated by, and in accordance with the Transaction Agreement and the Plan of Arrangement; provided, further, that the foregoing limitations and restrictions set forth in this Section&nbsp;26.12(b)
shall not apply to actions taken by Parent relating to a Preferred Stock Rights Agreement. The Support Agreement further provides, in part, that the above noted provisions of the Support Agreement shall not be changed without the approval of the
holders of the Exchangeable Shares given in accordance with Section&nbsp;26.11(b). Accordingly, and notwithstanding any provision to the contrary contained elsewhere in these Articles, the Company may, by way of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
resolution of the Board of Directors (i)&nbsp;subdivide, redivide or change the then outstanding Exchangeable Shares into a greater number of Exchangeable Shares, or (ii)&nbsp;reduce, combine,
consolidate or change the then outstanding Exchangeable Shares into a lesser number of Exchangeable Shares, to give effect to an economically equivalent change in the rights of the holders of the Exchangeable Shares to any similar change made to the
Delaware Common Stock under Sections 26.12(b)(i) or 26.12(b)(ii) respectively, as applicable. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Successorship Transaction</U>. Notwithstanding the foregoing provisions of this Section&nbsp;26.12, in the
event of a Parent Control Transaction: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which Parent merges or amalgamates with, or in which all or substantially all of the then outstanding
Delaware Common Stock are acquired by one or more other corporations to which Parent is, immediately before such merger, amalgamation or acquisition, related within the meaning of the <I>Income Tax Act </I>(Canada) (otherwise than by virtue of a
right referred to in paragraph 251(5)(b) thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which does not result in an acceleration of the Redemption Date in accordance with paragraph (ii)&nbsp;of the
definition of such term in Section&nbsp;26.1(a); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which all or substantially all of the then outstanding Delaware Common Stock are converted into or exchanged
for shares or rights to receive such shares (the &#147;<B>Other Shares</B>&#148;) of another corporation (the &#147;<B>Other Corporation</B>&#148;) that, immediately after such Parent Control Transaction, owns or controls, directly or indirectly,
Parent; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">then all references herein to &#147;Parent&#148; shall thereafter be and be deemed to be references to
&#147;Other Corporation&#148; and all references herein to &#147;Delaware Common Stock&#148; shall thereafter be and be deemed to be references to &#147;Other Shares&#148; (with appropriate adjustments, if any, as are required to result in a holder
of Exchangeable Shares on the exchange, redemption, retraction or purchase of shares pursuant to these Exchangeable Share Provisions, the Support Agreement and the Voting and Exchange Trust Agreement (as applicable) immediately subsequent to the
Parent Control Transaction, being entitled to receive that number of Other Shares equal to the number of Other Shares such holder of Exchangeable Shares would have received if the exchange, redemption, retraction or purchase of such shares pursuant
to these Exchangeable Share Provisions, the Support Agreement and the Voting and Exchange Trust Agreement (as applicable), had occurred immediately prior to the Parent Control Transaction and the Parent Control Transaction was completed), but
subject to subsequent adjustments to reflect any subsequent changes in the share capital of the issuer of the Other Shares, including without limitation, any subdivision, consolidation or reduction of share capital, without any need to amend the
terms and conditions of the Exchangeable Shares and without any further action required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.13 Actions by the Company under Support Agreement and the
Voting and Exchange Trust Agreement </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Actions by the Company</U>. The Company will take all such actions and do all such things as shall be
necessary or advisable to perform and comply with and to ensure performance and compliance by Parent, CallCo and the Company with all provisions of the Support Agreement and the Voting and Exchange Trust Agreement applicable to Parent, CallCo and
the Company, respectively, in accordance with the terms thereof including taking all such actions and doing all such things as shall be necessary or advisable to enforce to the fullest extent possible for the direct benefit of the Company all rights
and benefits in favour of the Company under or pursuant to such agreements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Changes to Support Agreement or Voting and Exchange Trust Agreement</U>. The Company shall not propose,
agree to or otherwise give effect to any amendment to, or waiver or forgiveness of its rights or obligations under, the Support Agreement or the Voting and Exchange Trust Agreement without the approval of the holders of the Exchangeable Shares given
in accordance with Section&nbsp;26.11(b) other than such amendments, waivers and/or forgiveness as may be necessary or advisable for the purposes of: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding to the covenants of any or all of the other parties to the Support Agreement or the Voting and Exchange
Trust Agreement if the board of directors of each of Parent, CallCo and the Company shall be of the good faith opinion that such additions will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evidencing the succession of successors to Parent either by operation of Law or agreement to the liabilities
and covenants of Parent under the Support Agreement (&#147;<B>Parent Successors</B>&#148;) and the covenants of and obligations assumed by each such Parent Successor in accordance with the provisions of Article 3 of the Support Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such amendments or modifications not inconsistent with the Support Agreement and the Voting and Exchange
Trust Agreement as may be necessary or desirable with respect to matters or questions arising thereunder which, in the good faith opinion of the board of directors of each of Parent, CallCo and the Company, it may be expedient to make, provided that
each such board of directors shall be of the good faith opinion, after consultation with counsel, that such amendments and modifications will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such changes in or corrections to the Support Agreement and the Voting and Exchange Trust Agreement
which, on the advice of counsel to Parent, CallCo and the Company, are required for the purpose of curing or correcting any ambiguity or defect or inconsistent provision or clerical omission or mistake or manifest error contained therein, provided
that the board of directors of each of Parent, CallCo and the Company shall be of the good faith opinion that such changes or corrections will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.14</B> <B>Legend; Call Rights; Withholding Rights</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Legend</U>. The Exchangeable Share Documents evidencing the Exchangeable Shares shall contain or have
affixed thereto a legend in form and on terms approved by the Board of Directors with respect to the Support Agreement, including provisions relating to the Liquidation Call Right, the Redemption Call Right and the Change of Law Call Right, the
Voting and Exchange Trust Agreement (including the provisions with respect to the voting rights and automatic exchange thereunder) and the Retraction Call Right. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Call Rights</U>. Each holder of an Exchangeable Share, whether of record or beneficial, by virtue of
becoming and being such a holder shall be deemed to acknowledge each of the Liquidation Call Right, the Redemption Call Right, the Change of Law Call Right and the Retraction Call Right, in each case, in favour of CallCo, and the overriding nature
thereof in connection with the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, or
the retraction or redemption of Exchangeable Shares, as the case may be, and to be bound thereby in favour of CallCo as provided herein and in the Support Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Withholding Rights</U>. Each of Parent, the Company, CallCo, the Transfer Agent and any other person that
has any withholding obligation with respect to any amount paid, deemed paid or otherwise deliverable to any holder of Exchangeable Shares (any such person, an &#147;<B>Other</B> <B>Withholding Agent</B>&#148;) shall be entitled to deduct and
withhold or direct Parent, the Company, CallCo, the Transfer Agent, or any Other Withholding Agent to deduct and withhold on their behalf, from any amount or consideration paid, deemed paid or otherwise deliverable to any holder of Exchangeable
Shares such amounts as are required to be deducted or withheld with respect to such payment or deemed payment under the <I>Income Tax Act </I>(Canada) or United States Tax Laws or any provision of federal, provincial, territorial, state, local,
foreign or other Tax Law, in each case, as amended or succeeded. Parent, the Company, CallCo, the Transfer Agent, or any Other Withholding Agent may act and rely on the advice of counsel with respect to such matters. To the extent that amounts are
so deducted or withheld, such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
deducted or withheld amounts shall be treated for all purposes as having been paid to the holder of the Exchangeable Shares to whom such amounts would otherwise have been paid or deemed paid and
such deducted or withheld amounts shall be timely remitted to the appropriate Governmental Authority as required by applicable Law. To the extent that the amount so required to be deducted or withheld from any payment or deemed payment to a holder
exceeds the cash portion of the amount or consideration otherwise payable to the holder (such difference, a &#147;<B>Withholding Shortfall</B>&#148;), Parent, the Company, CallCo, the Transfer Agent, and any Other Withholding Agent are hereby
authorized to (A)&nbsp;(i) sell or otherwise dispose of, or direct Parent, the Company, CallCo, the Transfer Agent or any Other Withholding Agent to sell or otherwise dispose of, on their own account or through a broker (the
&#147;<B>Broker</B>&#148;) and on behalf of the relevant holder or (ii)&nbsp;require such holder to irrevocably direct the sale through a Broker and irrevocably direct the Broker pay the proceeds of such sale to Parent, the Company, CallCo, the
Transfer Agent or any Other Withholding Agent, as appropriate (and, in the absence of such irrevocable direction, the holder shall be deemed to have provided such irrevocable direction), such portion of the amount or consideration as is necessary to
provide sufficient funds (after deducting commissions payable to the Broker and other costs and expenses) to Parent, the Company, CallCo, the Transfer Agent or any Other Withholding Agent, as the case may be, to enable it to comply with such
deduction or withholding requirement and Parent, the Company, CallCo, the Transfer Agent or any Other Withholding Agent, as the case may be, shall notify the holder thereof and remit to such holder any unapplied balance of the net proceeds of such
sale or (B)&nbsp;require such holder to deliver a Retraction Request for a number of Exchangeable Shares that would entitle such holder to net proceeds greater than or equal to the Withholding Shortfall and withhold the Withholding Shortfall from
such net proceeds and remit to such holder any unapplied balance of the net proceeds. Each of Parent, CallCo, the Company, the Transfer Agent, the Broker or any Other Withholding Agent, as applicable, shall act in a commercially reasonable manner in
respect of any withholding obligation; however, none of Parent, the Company, CallCo, the Transfer Agent, the Broker or any Other Withholding Agent, as applicable, will be liable for any loss arising out of any sale or other disposal of such
consideration, including any loss relating to the manner or timing of such sale or other disposal, the prices at which the consideration is sold or otherwise disposed of or otherwise. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.15</B> <B>Notices</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. Subject to applicable Laws, and except as otherwise provided herein, any notice, request or
other communication to be given to the Company or the Transfer Agent by a holder of Exchangeable Shares shall be in writing and shall be valid and effective if given by first class mail (postage prepaid) or personal delivery or delivery by courier
to the registered office of the Company or Transfer Agent, as applicable, and in each case, addressed to the attention of the Secretary of the Company. Any such notice, request or other communication, if given by mail or delivery, shall only be
deemed to have been given and received upon actual receipt thereof by the Company or the Transfer Agent, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exchangeable Share Documents</U>. Any presentation and surrender by a holder of Exchangeable Shares to the
Company or the Transfer Agent of Exchangeable Share Documents representing Exchangeable Shares in connection with the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or the retraction. redemption or
purchase of Exchangeable Shares shall be made by first class mail (postage prepaid) or by personal delivery or delivery by to such office of the Transfer Agent as may be specified by the Company, in each case, addressed to the attention of the
Secretary of the Company. Any such presentation and surrender of Exchangeable Share Documents shall only be deemed to have been made and to be effective upon actual receipt thereof by the Transfer Agent. Any such presentation and surrender of
Exchangeable Share Documents made by first class mail (postage prepaid) shall be at the sole risk of the holder mailing the same. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice to Shareholders</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to applicable Laws, any notice, request or other communication to be given to a holder of Exchangeable
Shares by or on behalf of the Company shall be in writing and shall be valid and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
effective if given by first class mail (postage prepaid) or by personal delivery or delivery by courier to the address of the holder recorded in the register of shareholders of the Company or, in
the event of the address of any such holder not being so recorded, then at the last known address of such holder. Any such notice, request or other communication, if given by mail, shall be deemed to have been given and received on the third
Business Day following the date of mailing and, if given by delivery, shall be deemed to have been given and received on the date of delivery. Accidental failure or omission to give any notice, request or other communication to one or more holders
of Exchangeable Shares shall not invalidate or otherwise alter or affect any action or proceeding to be taken by the Company pursuant thereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any interruption of mail service immediately prior to a scheduled mailing or in the period
following a mailing during which delivery normally would be expected to occur, the Company shall make reasonable efforts to disseminate any notice by other means, such as publication. Except as otherwise required or permitted by Law, if post offices
in Canada are not open for the deposit of mail, any notice which the Company or the Transfer Agent may give or cause to be given hereunder will be deemed to have been properly given and to have been received by holders of Exchangeable Shares it is
published once in the national edition of <I>The Globe and Mail </I>and in a daily newspaper of general circulation in the French language in the City of Montreal, provided that if the national edition of <I>The Globe and Mail </I>is not being
generally circulated, publication thereof will be made in the National Post or any other daily newspaper of general circulation published in the City of Toronto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provisions of these Exchangeable Share Provisions, notices, other communications and
deliveries need not be mailed if the Company determines that delivery thereof by mail may be delayed. Persons entitled to any deliveries (including Exchangeable Share Documents and cheques) which are not mailed for the foregoing reason may take
delivery thereof at the office of the Transfer Agent to which the deliveries were made, upon application to the Transfer Agent, until such time as the Company has determined that delivery by mail will no longer be delayed. The Company will provide
notice of any such determination not to mail made hereunder as soon as reasonably practicable after the making of such determination and in accordance with this Section&nbsp;26.15(c). Such deliveries in such circumstances will constitute delivery to
the persons entitled thereto. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.16</B> <B>Disclosure of Interests in Exchangeable Shares</B>. The Company shall be entitled to
require any holder of an Exchangeable Share or any person whom the Company knows or has reasonable cause to believe holds any interest whatsoever in an Exchangeable Share to (a)&nbsp;confirm that fact, or (b)&nbsp;give such details as to whom has an
interest in such Exchangeable Share, in each case as would be required (if the Exchangeable Shares were a class of &#147;equity securities&#148; of the Company) under section 5.2 of National Instrument <FONT STYLE="white-space:nowrap">62-104</FONT>
<I>Take-Over Bids and Issuer Bids </I>or as would be required under the constating documents of Parent or any Laws or regulations, or pursuant to the rules or regulations of any regulatory agency, if and only to the extent that the Exchangeable
Shares were Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.17</B> <B>Fractional Shares</B>. A holder of an Exchangeable Share shall not be entitled to any fraction of a
share of Delaware Common Stock upon the exchange, redemption or purchase of such holder&#146;s Exchangeable Share pursuant to Sections 26.5, 26.6 and 26.7 or otherwise, and no Exchangeable Share Certificates representing any such fractional interest
shall be issued and such holder otherwise entitled to a fractional interest shall be entitled to receive for such fractional interest from the Company, Parent or CallCo, as the case may be, a cash payment equal to such fractional interest multiplied
by the Current Market Price as part of the Exchangeable Share Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.18</B> <B>Liquidation Call Right</B>. CallCo shall have the following
rights and obligations in respect of the Exchangeable Shares: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CallCo shall have the overriding right (the &#147;<B>Liquidation Call Right</B>&#148;), in the event of and
notwithstanding the proposed liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs,
pursuant to these Exchangeable Share Provisions, and subject to the purchase and sale contemplated by the Automatic Exchange Right, to purchase from all but not less than all of the holders of the Exchangeable Shares (other than any holder of
Exchangeable Shares which is Parent or any of its affiliates) on the Liquidation Date all but not less than all of the Exchangeable Shares held by each such holder upon payment by CallCo to each such holder of the Exchangeable Share Price (payable
in the form of the Exchangeable Share Consideration) applicable on the last Business Day prior to the Liquidation Date (the &#147;<B>Liquidation Call Purchase Price</B>&#148;) in accordance with Section&nbsp;26.18(c). In the event of the exercise of
the Liquidation Call Right by CallCo each such holder of Exchangeable Shares (other than Parent and its affiliates) shall be obligated to sell all of the Exchangeable Shares held by the holder to CallCo on the Liquidation Date upon payment by CallCo
to such holder of the Liquidation Call Purchase Price (payable in the form of Exchangeable Share Consideration) for each such share, and the Company shall have no obligation to pay any Liquidation Amount to the holders of such shares so purchased.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To exercise the Liquidation Call Right, CallCo must notify the Transfer Agent, as agent for the holders of the
Exchangeable Shares, and the Company of its intention to exercise such right (i)&nbsp;in the case of a voluntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other voluntary distribution of the
assets of the Company among its shareholders for the purpose of winding up its affairs, at least fifteen (15) Business Days before the Liquidation Date, or (ii)&nbsp;in the case of an involuntary liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other involuntary distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, at least five (5)&nbsp;Business Days before the
Liquidation Date. The Transfer Agent will notify the holders of the Exchangeable Shares as to whether or not CallCo has exercised the Liquidation Call Right forthwith after the expiry of the period during which CallCo may exercise the Liquidation
Call Right. If CallCo exercises the Liquidation Call Right, then on the Liquidation Date, CallCo will purchase and the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its affiliates) will
sell, all of the Exchangeable Shares held by such holders on such date for a price per share equal to the Liquidation Call Purchase Price (payable in the form of Exchangeable Share Consideration). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;26.18(d), for the purposes of completing the purchase and sale of the Exchangeable
Shares pursuant to the exercise of the Liquidation Call Right, CallCo shall deposit or cause to be deposited with the Transfer Agent, on or before the Liquidation Date, the Exchangeable Share Consideration representing the aggregate Liquidation Call
Purchase Price for all holders of the Exchangeable Shares (other than Parent and its affiliates). Provided that such Exchangeable Share Consideration has been so deposited with the Transfer Agent, the holders of the Exchangeable Shares (other than
Parent and its affiliates) shall cease to be holders of the Exchangeable Shares on and after the Liquidation Date and, from and after such date, shall not be entitled to exercise any of the rights of holders in respect thereof (including, without
limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive their proportionate part of the aggregate Liquidation Call Purchase Price, without interest, upon presentation and surrender by the holder of
Exchangeable Share Documents representing the Exchangeable Shares held by such holder and the holder shall on and after the Liquidation Date be considered and deemed for all purposes to be the holder of the Delaware Common Stock which such holder is
entitled to receive. Upon surrender to the Transfer Agent of Exchangeable Share Documents representing Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable Shares under the
BCBCA and these Articles, as applicable, and such additional documents, instruments and payments as the Transfer Agent may reasonably require, the holder shall be entitled to receive, in exchange therefor, and the Transfer Agent on behalf of CallCo,
shall deliver to such holder the Exchangeable Share Consideration such holder is entitled to receive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent and the Company in accordance with Section&nbsp;26.18(b) of its
intention to exercise the Liquidation Call Right in the manner and timing described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that CallCo exercise
the Liquidation Call Right in respect of the shares covered by the notice, in which case, CallCo shall be deemed of have exercised the Liquidation Call Right and will be bound thereby. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.19</B> <B>Redemption Call Right</B>. CallCo shall have the following rights and obligations in respect of the Exchangeable Shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the proposed redemption of the Exchangeable Shares by the Company pursuant to these
Exchangeable Share Provisions, CallCo shall have the overriding right (the &#147;<B>Redemption Call Right</B>&#148;) to purchase from all but not less than all of the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares
which is Parent or any of its affiliates) on the Redemption Date all but not less than all of the Exchangeable Shares held by each such holder upon payment by CallCo to each such holder of the Exchangeable Share Price (payable in the form of the
Exchangeable Share Consideration) applicable on the last Business Day prior to the Redemption Date (the &#147;<B>Redemption Call Purchase Price</B>&#148;) in accordance with Section&nbsp;26.19(c). In the event of the exercise of the Redemption Call
Right by CallCo, each such holder of Exchangeable Shares (other than Parent and its affiliates) shall be obligated to sell all of the Exchangeable Shares held by the holder to CallCo on the Redemption Date upon payment by CallCo to such holder of
the Redemption Call Purchase Price (payable in the form of Exchangeable Share Consideration) for each such share, and the Company shall have no obligation to redeem, or to pay the redemption price otherwise payable by the Company in respect of the
Exchangeable Shares so purchased. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To exercise the Redemption Call Right, CallCo must notify the Transfer Agent, as agent for the holders of the
Exchangeable Shares, and the Company of its intention to exercise such right (i)&nbsp;in the case of a redemption occurring in connection with a Parent Control Transaction, on or before the Redemption Date, and (ii)&nbsp;in any other case, at least
fifteen (15)&nbsp;Business Days before the Redemption Date. The Transfer Agent will notify the holders of the Exchangeable Shares as to whether or not CallCo has exercised the Redemption Call Right forthwith after the expiry of the period during
which CallCo may exercise the Redemption Call Right. If CallCo exercises the Redemption Call Right, CallCo will purchase and the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its
affiliates) will sell, on the Redemption Date, all of the Exchangeable Shares held by such holders on such date for a price per share equal to the Redemption Call Purchase Price (payable in the form of Exchangeable Share Consideration).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;26.19(d), for the purposes of completing the purchase and sale of the Exchangeable
Shares pursuant to the exercise of the Redemption Call Right, CallCo shall deposit or cause to be deposited with the Transfer Agent, on or before the Redemption Date, the Exchangeable Share Consideration representing the aggregate Redemption Call
Purchase Price for all holders of the Exchangeable Shares (other than Parent and its affiliates). Provided that such Exchangeable Share Consideration has been so deposited with the Transfer Agent, the holders of the Exchangeable Shares (other than
Parent and its affiliates) shall cease to be holders of the Exchangeable Shares on and after the Redemption Date and, from and after such date, shall not be entitled to exercise any of the rights of holders in respect thereof (including, without
limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive their proportionate part of the aggregate Redemption Call Purchase Price, without interest, upon presentation and surrender by the holder of
Exchangeable Share Documents representing the Exchangeable Shares held by such holder and the holder shall on and after the Redemption Date be considered and deemed for all purposes to be the holder of the Delaware Common Stock which such holder is
entitled to receive. Upon surrender to the Transfer Agent of Exchangeable Share Documents representing the Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable Shares under
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the BCBCA and these Articles, as applicable, and such additional documents, instruments and payments as the Transfer Agent may reasonably require, the holder shall be entitled to receive, in
exchange therefor, and the Transfer Agent on behalf of CallCo shall deliver to such holder the Exchangeable Share Consideration such holder is entitled to receive. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent and the Company in accordance with Section&nbsp;26.19(b) of its
intention to exercise the Redemption Call Right in the manner and timing described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that CallCo exercise
the Redemption Call Right in respect of the shares covered by the notice, in which case, CallCo shall be deemed of have exercised the Redemption Call Right and will be bound thereby. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.20</B> <B>Change of Law Call Right</B>. CallCo shall have the following rights and obligations in respect of the Exchangeable Shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CallCo shall have the overriding right (the &#147;<B>Change of Law Call Right</B>&#148;), in the event of a
Change of Law, to purchase from all but not less than all of the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its affiliates) on the Change of Law Call Date all but not less than all of
the Exchangeable Shares held by each such holder upon payment by CallCo to each such holder of the Exchangeable Share Price (payable in the form of the Exchangeable Share Consideration) applicable on the last Business Day prior to the Change of Law
Call Date (the &#147;<B>Change of Law Call Purchase Price</B>&#148;) in accordance with Section&nbsp;26.20(b). In the event of the exercise of the Change of Law Call Right by CallCo each such holder of Exchangeable Shares (other than Parent and its
affiliates) shall be obligated to sell all of the Exchangeable Shares held by the holder to CallCo on the Change of Law Call Date upon payment by CallCo to such holder of the Change of Law Call Purchase Price (payable in the form of Exchangeable
Share Consideration) for each such share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To exercise the Change of Law Call Right, CallCo must notify the Transfer Agent, as agent for the holders of
the Exchangeable Shares, and the Company of its intention to exercise such right at least fifteen (15)&nbsp;Business Days before the date (the &#147;<B>Change of Law Call Date</B>&#148;) on which CallCo shall acquire the Exchangeable Shares pursuant
to the exercise of the Change of Law Call Right. The Transfer Agent will notify the holders of the Exchangeable Shares as to CallCo exercising the Change of Law Call Right forthwith after receiving notice of such exercise from CallCo. If CallCo
exercises the Change of Law Call Right, then on the Change if Law Call Date, CallCo will purchase and the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its affiliates) will sell, all of
the Exchangeable Shares held by such holders on such date for a price per share equal to the Change of Law Call Purchase Price (payable in the form of Exchangeable Share Consideration). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;26.20(d), for the purposes of completing the purchase and sale of the Exchangeable
Shares pursuant to the exercise of the Change of Law Call Right, CallCo shall deposit or cause to be deposited with the Transfer Agent, on or before the Change of Law Call Date, the Exchangeable Share Consideration representing the aggregate Change
of Law Call Purchase Price for all holders of Exchangeable Shares (other than Parent and its affiliates). Provided that such Exchangeable Share Consideration has been so deposited with the Transfer Agent, the holders of the Exchangeable Shares
(other than Parent and its affiliates) shall cease to be holders of the Exchangeable Shares on and after the Change of Law Call Date and, from and after such date, shall not be entitled to exercise any of the rights of holders in respect thereof
(including, without limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive their proportionate part of the aggregate Change of Law Call Purchase Price, without interest, upon presentation and surrender
by the holder of Exchangeable Share Documents representing the Exchangeable Shares held by such holder and the holder shall on and after the Change of Law Call Date be considered and deemed for all purposes to be the holder of the Delaware Common
Stock which such holder is entitled to receive. Upon surrender to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Transfer Agent of a Exchangeable Share Documents representing Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable
Shares under the BCBCA and these Articles, as applicable, and such additional documents, instruments and payments as the Transfer Agent may reasonably require, the holder shall be entitled to receive, in exchange therefor, and the Transfer Agent on
behalf of CallCo shall deliver to such holder the Exchangeable Share Consideration such holder is entitled to receive. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent and the Company in accordance with Section&nbsp;26.20(b) of its
intention to exercise the Change of Law Call Right in the manner and timing described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that CallCo exercise
the Change of Law Call Right in respect of the shares covered by the notice, in which case, CallCo shall be deemed of have exercised the Change of Law Call Right and will be bound thereby. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is the intention of the Company, CallCo and Parent that the Exchangeable Shares are treated as shares of
Parent for U.S. federal income tax purposes and the provisions of these Articles shall be interpreted in a manner consistent with the foregoing. The Company shall not take any position for U.S. federal income tax purposes that is inconsistent with
the foregoing except to the extent otherwise required by a change in law (it being understood that this Section&nbsp;26.20(e)shall not prevent the Company from taking any action that is explicitly contemplated in these Articles).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[TO
BE PRINTED ON EXCHANGEABLE SHARE DOCUMENTS] </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Computershare Trust Company of Canada</B> (the &#147;<B>Share Trustee</B>&#148;) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left">COPY&nbsp;TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Zymeworks CallCo</B> ULC (&#147;<B>CallCo</B>&#148;) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice is given pursuant to Section&nbsp;5.1 of the Voting and Exchange Trust Agreement (as defined in the special rights or restrictions (the
&#147;<B>Exchangeable Share Provisions</B>&#148;) attaching to the Exchangeable Shares of Zymeworks ExchangeCo Ltd. (&#147;<B>ExchangeCo</B>&#148;) represented by this Exchangeable Share Document and all capitalized words and expressions used in
this Notice of Exercise that are defined in the Voting and Exchange Trust Agreement have the meanings ascribed to such words and expressions in such Voting and Exchange Trust Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby notifies the share Trustee that the undersigned desires to have CallCo (and failing CallCo, Parent, subject to Parent&#146;s right to
cause CallCo to fulfill Parent&#146;s obligations hereunder) to purchase the following pursuant to the Exchange Right as a result of the continuance of an Insolvency Event: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all share(s) represented by this Exchangeable Share Document </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share(s) represented by this
Exchangeable Share Document </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Notice of Exercise may not be revoked and withdrawn by the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants to CallCo, Parent and the Share Trustee that the undersigned: (select one) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a resident of Canada for purposes of the <I>Income Tax Act </I>(Canada). THE UNDERSIGNED ACKNOWLEDGES THAT IN THE ABSENCE OF AN INDICATION THAT THE UNDERSIGNED
IS A RESIDENT OF CANADA, WITHHOLDING ON ACCOUNT OF CANADIAN TAX MAY BE MADE FROM AMOUNTS PAYABLE TO THE UNDERSIGNED ON THE PURCHASE OF THE EXCHANGEABLE SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants to CallCo, Parent and the Share Trustee that the undersigned has good title to, and owns, the share(s)
represented by this Exchangeable Share Document to be acquired by CallCo or Parent, as the case may be, free and clear of all liens, claims and encumbrances. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Date)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Signature of Shareholder)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Guarantee of Signature)</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please check box if the securities and any cheque(s) resulting from the purchase of the Exchangeable Shares are
to be held for <FONT STYLE="white-space:nowrap">pick-up</FONT> by the shareholder from the Transfer Agent, failing which such Exchangeable Share Document and cheque(s) will be mailed to the last address of the shareholder as it appears on the
register. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Note</U>: This panel must be completed and this Notice of Exercise, together with the Exchangeable Share Documents and
such additional documents and payments (including, without limitation, any applicable stamp taxes) as the Transfer Agent, CallCo, Parent of the Share Trustee may require, must be deposited with the Share Trustee. The securities and any cheque(s)
resulting from the purchase of the Exchangeable Shares will be issued and registered in, and made payable to, respectively, the name of the shareholder as it appears on the register of ExchangeCo and the securities (or evidence of the electronic
registration thereof) and any cheque(s) resulting from such purchase will be delivered to such shareholder as indicated above, unless the form appearing immediately below is duly completed. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;person&nbsp;in&nbsp;Whose&nbsp;Name&nbsp;Securities&nbsp;or&nbsp;Cheque(s)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Are to be Registered, Issued or Delivered
(please print):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Street Address or P.O. Box:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature of Shareholder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">City,&nbsp;Province&nbsp;and&nbsp;Postal&nbsp;Code:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature Guaranteed by:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Note</U>: If this Notice of Exercise is for less than all of the shares represented by this Exchangeable Share Document,
an Exchangeable Share Document representing the remaining share(s) of ExchangeCo represented by this Exchangeable Share Document will be issued and registered in the name of the shareholder as it appears on the register of ExchangeCo. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGEABLE SHARE PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 26 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL
RIGHTS OR RESTRICTIONS ATTACHED TO THE EXCHANGEABLE SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exchangeable Shares of the Company shall have the following rights, privileges,
restrictions and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.1 Interpretation </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. For the purposes of these Exchangeable Share Provisions: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>affiliate</B>&#148; means, with respect to any person, any other person who, directly or indirectly, controls, is controlled by, or is
under common control with, such person. For purposes of this definition, the term &#147;<B>control</B>&#148; (including the correlative terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under</B> <B>common control
with</B>&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise. For purposes of
this Article 26, &#147;affiliate&#148; does not include any stockholders of Parent (other than Zymeworks Inc.), or directors or executive officers of Zymeworks Inc., Parent, the Company or CallCo. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Automatic Exchange Right</B>&#148; has the meaning ascribed thereto in the Voting and Exchange Trust Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>BCBCA</B>&#148; means the <I>Business Corporations Act </I>(British Columbia) and the regulations made thereunder, as now in effect
and as they may be promulgated or amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board of Directors</B>&#148; means the board of directors of the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Broker</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.14(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day on which banks are generally open for the transaction of commercial business in Vancouver, British
Columbia, and New York, New York, but does not in any event include a Saturday or Sunday or statutory holiday in Vancouver, British Columbia, or New York, New York. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>CallCo</B>&#148; means Zymeworks CallCo ULC, a corporation existing under the laws of the Province of British Columbia. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Canadian Resident</B>&#148; means either (i)&nbsp;a person who, at the relevant time, is a resident of Canada for purposes of the
<I>Income Tax Act</I> (Canada), or (ii)&nbsp;a partnership that is a &#147;Canadian partnership&#148; for purposes of the <I>Income Tax Act</I> (Canada). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law</B>&#148; means any amendment to the <I>Income Tax Act</I> (Canada) and other applicable provincial income Tax Laws that
permits Canadian Resident holders of the Exchangeable Shares, who hold the Exchangeable Shares as capital property and deal at arm&#146;s length with Parent and the Company (all for the purposes of the <I>Income Tax Act</I> (Canada) and other
applicable provincial income Tax Laws), to exchange their Exchangeable Shares for Delaware Common Stock on a basis that will not require such holders to recognize any income, gain or loss or any actual or deemed dividend in respect of such exchange
for the purposes of the <I>Income Tax Act</I> (Canada) or applicable provincial income Tax Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call
Date</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.20(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call Purchase Price</B>&#148; has the
meaning ascribed thereto in Section&nbsp;26.20(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Law Call Right</B>&#148; has the meaning ascribed thereto in
Section&nbsp;26.20(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Shares</B>&#148; means the common shares in the capital of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Current Market Price</B>&#148; means, in respect of Delaware Common Stock on any
date, the average closing price of a share of Delaware Common Stock on the NYSE during the period of 20 consecutive trading days ending on the third trading day immediately before such date or, if the Delaware Common Stock are not then listed on the
NYSE, on such other stock exchange or automated quotation system on which the Delaware Common Stock are listed or quoted, as the case may be, as may be selected by the Board of Directors for such purpose; provided, however, that if in the opinion of
the Board of Directors the public distribution or trading activity of Delaware Common Stock during such period does not reflect the fair market value of a share of Delaware Common Stock, then the Current Market Price of a share of Delaware Common
Stock shall be determined by the Board of Directors, based upon the advice of such qualified independent financial advisors as the Board of Directors may deem to be appropriate; and provided further that any such selection, opinion or determination
by the Board of Directors shall be conclusive and binding, absent manifest error. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Delaware Common Stock</B>&#148; means shares of
Parent&#146;s common stock, par value US$0.00001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; has the meaning ascribed thereto in the Plan
of Arrangement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Consideration</B>&#148; means, with respect to each Exchangeable Share, for any acquisition
of, redemption of or distribution of assets of the Company in respect of such Exchangeable Share, or purchase of such Exchangeable Share pursuant to these Exchangeable Share Provisions or the Support Agreement or the Voting and Exchange Trust
Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one share of Delaware Common Stock multiplied by the Exchangeable Share Exchange Ratio on the Business Day
immediately preceding the date on which the Exchangeable Share Price in respect of the Exchangeable Share Consideration being delivered is calculated; plus </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a cheque or cheques payable at par at any branch of the bankers of the payor in the amount contemplated by
clause (ii)&nbsp;and (iv) (and in respect of clause (iv), to the extent of a cash dividend that is payable), as applicable, of the definition of Exchangeable Share Price; plus </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such stock or other property contemplated by clause (iii)&nbsp;and (iv) (and in respect of clause (iv), to the
extent of a <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend that is payable), as applicable, of the definition of Exchangeable Share Price; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided that: (A)&nbsp;the part of the consideration which represents (i)&nbsp;above shall be fully paid and satisfied by the delivery of
Delaware Common Stock, such shares to be duly issued, fully paid and nonassessable; (B)&nbsp;the part of the consideration which represents (iii)&nbsp;above shall be fully paid and satisfied by delivery of such
<FONT STYLE="white-space:nowrap">non-cash</FONT> items; (C)&nbsp;in each case, any such consideration shall be delivered free and clear of any lien, claim, encumbrance, security interest or adverse claim or interest; and (D)&nbsp;in each case, any
such consideration shall be paid without interest and less any tax required to be deducted and withheld therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable
Share Document</B>&#148; means (i)&nbsp;a share certificate representing Exchangeable Shares, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-transferable</FONT> acknowledgement of a shareholder&#146;s right to obtain a share certificate
representing Exchangeable Shares, or (iii)&nbsp;a direct registration system advice (or similar document) evidencing the electronic registration of the ownership of Exchangeable Shares, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Exchange Ratio</B>&#148; means, at any time and in respect of each Exchangeable Share, an amount equal to 1.00000,
as at the Effective Date, as cumulatively adjusted from time to time thereafter by increasing the Exchangeable Share Exchange Ratio on each date after the Effective Date on which the board of directors of Parent pays any dividend or other
distribution on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement) by an amount, rounded to the nearest five decimal places, equal to (a)(i) the amount of such dividend or other
distribution (which, in the case of a <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, shall equal the fair value as determined by the Board of Directors in good faith and in its sole discretion), expressed on a per
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Delaware Common Stock per share basis, multiplied (ii)&nbsp;by the Exchangeable Share Exchange Ratio in effect on the Business Day immediately preceding the record date set for such dividend or
other distribution, divided by (b)&nbsp;the Current Market Price on the record date set for such dividend or other distribution, and any such adjustment shall be determined by the Board of Directors in good faith and in its sole discretion and any
such determination by the Board of Directors shall be conclusive and binding; provided, however, that the Exchangeable Share Exchange Ratio shall only be so adjusted to the extent that the Board of Directors determines in good faith and in its sole
discretion that the Company would be liable for any unrecoverable tax as a result of paying any such dividend or distribution and determines to adjust the Exchangeable Share Exchange Ratio in lieu of paying an equivalent dividend or other
distribution on the Exchangeable Shares in accordance with these Exchangeable Share Provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share
Price</B>&#148; means, at any time, for each Exchangeable Share, an amount equal to the aggregate of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Current Market Price of one share of Delaware Common Stock at such time multiplied by the Exchangeable
Share Exchange Ratio on the Business Day immediately preceding the date on which the Exchangeable Share Price is calculated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the full amount of all cash dividends (A)&nbsp;declared, payable and unpaid on the Exchangeable Share, plus
(B)&nbsp;to the extent a cash dividend has been declared by Parent on the Delaware Common Stock at such time for which a corresponding cash dividend on the Exchangeable Share would be required to be, but has not yet been, declared at such time, then
the undeclared and unpaid cash dividend on such Exchangeable Share of equal amount multiplied by the Exchangeable Share Exchange Ratio (but only to the extent the Company has not taken one of the alternative actions permitted under these
Exchangeable Share Provisions to account for such declaration by Parent); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the full amount of all <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends declared, payable and unpaid
at such time on such Exchangeable Share (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the full amount of all dividends declared and payable in respect of each share of Delaware Common Stock (as
adjusted by the Exchangeable Share Exchange Ratio from time to time) which have not, at such time, been paid on such Exchangeable Share in accordance herewith or adjusted for under the Exchangeable Share Exchange Ratio, or otherwise accounted for in
under clauses (ii)&nbsp;and (iii) above in this definition (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Share Provisions</B>&#148; means the rights, privileges, restrictions and conditions set out in this Article 26. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchangeable Shares</B>&#148; means the exchangeable shares in the capital of the Company, having the rights, privileges, restrictions
and conditions set forth in this Article 26. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; means any nation or government or any agency,
public or regulatory authority, taxing authority, self-regulatory organization (including stock exchanges), instrumentality, department, commission, court, arbitrator (public or private), ministry, tribunal or board of any nation, government or
political subdivision or delegated authority thereof, in each case, whether foreign or domestic and whether national, supranational, multinational, federal, provincial, territorial, state, regional, local or municipal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means applicable statutes, common laws, rules, ordinances, regulations, codes, orders, judgments, injunctions, writs,
decrees, governmental guidelines or interpretations having the force of Law or bylaws, in each case, of a Governmental Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Amount</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Call Purchase Price</B>&#148; has the meaning ascribed thereto in the Section&nbsp;26.18(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Call Right</B>&#148; has the meaning ascribed thereto in the
Section&nbsp;26.18(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation Date</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>NYSE</B>&#148; means the New York Stock Exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Other Withholding Agent</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.14(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent</B>&#148; means Zymeworks Delaware Inc., a corporation existing under the Laws of the State of Delaware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Control Transaction</B>&#148; shall be deemed to have occurred if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person acquires, directly or indirectly, any voting security of Parent and, immediately after such
acquisition, directly or indirectly owns, or exercises control and direction over, voting securities representing more than 50% of the total voting power of all of the then outstanding voting securities of Parent, other than any such transaction
which would result in the holders of outstanding voting securities of Parent immediately prior to such transaction directly or indirectly owning, or exercising control and direction over, voting securities representing more than 50% of the total
voting power of all of the voting securities of the acquiring person outstanding immediately after such transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders of Parent approve a merger, combination, consolidation, recapitalization or reorganization of
Parent, other than any such transaction which would result in the holders of outstanding voting securities of Parent immediately prior to such transaction directly or indirectly owning, or exercising control and direction over, voting securities
representing more than 50% of the total voting power of all of the voting securities of the surviving entity outstanding immediately after such transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders of Parent approve a liquidation of Parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent sells or disposes of all or substantially all of its assets; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other transaction or series of related transactions having a substantially similar effect.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Dividend Declaration Date</B>&#148; means the date on which the board of directors of Parent declares
any dividend or other distribution on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>person</B>&#148; includes an individual, partnership, association, body corporate, trustee, executor, administrator, legal
representative, government or any other entity, whether or not having legal status. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Plan of Arrangement</B>&#148; means the plan
of arrangement substantially in the form and content of Exhibit A to the Transaction Agreement, including any appendices thereto, and any amendments, modifications or supplements thereto made from time to time in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Preferred Stock Rights Agreement</B>&#148; means any preferred stock rights agreement that may now or in the future be adopted and
entered into by Parent in respect of the Delaware Common Stock, to protect stockholders of Parent from coercive or otherwise unfair takeover tactics, in such form and substance as Parent may determine in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Call Purchase Price</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.19(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Call Right</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.19(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Date</B>&#148; means the date for the redemption by the Company of all but not less than all of the outstanding
Exchangeable Shares (other than Exchangeable Shares held by Parent and its affiliates), which date shall be the earlier of (a)&nbsp;the Sunset Date, and (b)&nbsp;the date, if any, established by the Board of Directors following the occurrence of any
of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the aggregate number of Exchangeable Shares issued and outstanding (other than Exchangeable Shares held by
Parent and its affiliates) is less than 5% of the number of Exchangeable Shares </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
issued on the Effective Date (as such number of shares may be adjusted as deemed appropriate by the Board of Directors to give effect to any subdivision, combination or consolidation of, or stock
or share dividend on, the Exchangeable Shares, any issue or distribution of rights to acquire Exchangeable Shares or securities exchangeable for or convertible into Exchangeable Shares, any issue or distribution of other securities or rights or
evidences of indebtedness or assets, or any other capital reorganization or other transaction affecting the Exchangeable Shares), in which case the Board of Directors may accelerate such redemption date to such date as it may determine, upon at
least 30 days&#146; prior written notice to the holders of the Exchangeable Shares and the Share Trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Parent Control Transaction is proposed, in which case, provided the Board of Directors determines in good
faith that it is not practicable to substantially replicate the terms and conditions of the Exchangeable Shares in connection with such Parent Control Transaction or that the redemption of all but not less than all of the outstanding Exchangeable
Shares (other than Exchangeable Shares held by Parent and its affiliates) is necessary to enable the completion of such Parent Control Transaction in accordance with its terms, the Board of Directors may accelerate such redemption date to such date
as it may determine, upon such number of days prior written notice to the holders of the Exchangeable Shares and the Share Trustee as the Board of Directors may determine to be reasonably practicable in such circumstances; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided, however, that the accidental failure or omission to give any notice of redemption under clauses (i)&nbsp;or (ii) above to any of the
holders of Exchangeable Shares shall not affect the validity of any such redemption. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Redemption Price</B>&#148; has the meaning
ascribed thereto in Section&nbsp;26.7(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retracted Shares</B>&#148; has the meaning ascribed thereto in
Section&nbsp;26.6(a)(i)(A). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Notice</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(b)(ii). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Right</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i)(C). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Call Right Purchase Price</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(b)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Date</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i)(B). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Price</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Retraction Request</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.6(a)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Share Trustee</B>&#148; means the trustee chosen by Parent and Zymeworks Inc. to act as trustee under the Voting and Exchange Trust
Agreement, being a corporation organized and existing under the Laws of Canada or any Province thereof and authorized to carry on the business of a trust company in all the provinces of Canada, and any successor trustee appointed under the Voting
and Exchange Trust Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sunset Date</B>&#148; means the seventh anniversary of the Effective Date, as it may be extended
from time to time by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Support Agreement</B>&#148; means the support agreement to be entered into at or
prior to the issuance by the Company of any Exchangeable Shares among Parent, CallCo and the Company substantially in the form of Exhibit C to the Transaction Agreement, as it may be amended, supplemented or otherwise modified from time to time in
accordance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; means any and all national, supranational, multinational, federal, provincial,
territorial, state, regional, local or municipal taxes, including income, branch, profits, capital gains, gross receipts, windfall profits, value added, severance, ad valorem, property, capital, estimated, utility, recapture, net worth, production,
sales, use, license, excise, franchise, environmental, transfer, land transfer, withholding or similar, payroll, employment, employer health, government pension plan premiums and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
contributions, social security premiums, workers&#146; compensation premiums, employment/unemployment insurance or compensation premiums or contributions, disability, documentary, registration,
stamp, occupation, premium, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum, goods and services, harmonized sales, customs duties or other taxes, levies, premiums, excises, fees, assessments, imposts, duties, and other similar
charges of any kind whatsoever imposed, assessed, charged or collected by a Governmental Authority and any installments in respect thereof, including any interest, fines, assessments, reassessments, penalties or additions to tax imposed in
connection therewith or with respect thereto, and any interest in respect of such additions or penalties, and whether disputed or not. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Law</B>&#148; means any Law in respect of Taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Agreement</B>&#148; means the transaction agreement dated July&nbsp;14, 2022 among Parent, CallCo, the Company and
Zymeworks Inc., as amended, supplemented or otherwise modified from time to time in accordance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer
Agent</B>&#148; means Computershare Investor Services Inc. or such other person as may from time to time be appointed by the Company as the registrar and transfer agent for the Exchangeable Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Voting and Exchange Trust Agreement</B>&#148; means the voting and exchange trust agreement to be made among Parent, CallCo, the
Company and the Share Trustee in connection with the Plan of Arrangement substantially in the form of Exhibit D to the Transaction Agreement, as may be amended, supplemented or otherwise modified from time to time in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Withholding Shortfall</B>&#148; has the meaning ascribed thereto in Section&nbsp;26.14(c). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Interpretation Not Affected by Headings</U>. The division of these Exchangeable Share Provisions into
sections and other portions and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation hereof. Unless otherwise indicated, all references to a &#147;Section&#148; followed by a number
and/or a letter refer to the specified section of these Exchangeable Share Provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Number and Gender</U>. In these Exchangeable Share Provisions, unless the context otherwise clearly
requires, words used herein importing the singular include the plural and vice versa and words imparting any gender shall include all genders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Date of Any Action</U>. If any date on which any action is required to be taken hereunder by any person is
not a Business Day, then such action shall be required to be taken on the next succeeding day which is a Business Day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Currency</U>. In these Exchangeable Share Provisions, unless stated otherwise, all cash payments provided
for herein shall be made in United States dollars. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.2</B><B> Ranking of Exchangeable Shares</B>. The Exchangeable Shares shall be
entitled to a preference over the Common Shares and any other shares ranking junior to the Exchangeable Shares: (a)&nbsp;with respect to the payment of dividends or other distributions as and to the extent provided in Section&nbsp;26.3 and
(b)&nbsp;with respect to the distribution of assets in the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether voluntary or involuntary, or any other distribution of the assets of the
Company among its shareholders for the purpose of winding up its affairs as and to the extent provided in Section&nbsp;26.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.3</B> <B>Dividends and
Distributions</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Dividends and Distributions.</U> A holder of an Exchangeable Share shall be entitled to receive and the
Board of Directors shall, subject to applicable Law, on each Parent Dividend Declaration Date, declare a dividend or other distribution on each Exchangeable Share: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a cash dividend or other distribution declared on the Delaware Common Stock (but excluding any
dividends or distributions pursuant to a Preferred Stock Rights Agreement), in an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
amount in cash payable in United States dollars for each Exchangeable Share equal to (A)&nbsp;the cash dividend or other distribution declared on each share of Delaware Common Stock on the Parent
Dividend Declaration Date, multiplied by (B)&nbsp;the relevant Exchangeable Share Exchange Ratio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a stock or share dividend or other distribution declared on the Delaware Common Stock to be paid
in Delaware Common Stock (but excluding any dividends or dividends or distributions pursuant to a Preferred Stock Rights Agreement), by the issue or transfer by the Company of such number of Exchangeable Shares for each Exchangeable Share as is
equal to the number of Delaware Common Stock to be paid on each share of Delaware Common Stock multiplied by the relevant Exchangeable Share Exchange Ratio; provided, however, that the Company may, in lieu of such stock or share dividend or other
distribution, elect to effect a corresponding, contemporaneous and economically equivalent (as determined by the Board of Directors in accordance with Sections 26.3(e) and 26.3(f)) subdivision of the outstanding Exchangeable Shares; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a dividend or other distribution declared on the Delaware Common Stock in property other than
cash or Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement), in such type and amount of property for each Exchangeable Share as is the same as or economically equivalent (as determined
by the Board of Directors in accordance with Section&nbsp;26.3(e)) and adjusted for the relevant Exchangeable Share Exchange Ratio to the type and amount of property declared as a dividend or other distribution on each share of Delaware Common
Stock; and </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">such dividends or other distributions shall be paid out of money, assets or property of the Company properly
applicable to the payment of dividends or other distributions, out of authorized but unissued shares of the Company or through the subdivision of outstanding Exchangeable Shares, as applicable; provided, that the Board of Directors may determine, in
its sole discretion, to adjust the Exchangeable Share Exchange Ratio as provided herein in lieu of paying any such dividend or other distribution on the Exchangeable Shares, and provided further, however, that the Exchangeable Share Exchange Ratio
shall only be so adjusted to the extent that the Board of Directors determines in good faith and in its sole discretion that the Company would be liable for any unrecoverable tax as a result of paying any such dividend or distribution. The holders
of Exchangeable Shares shall not be entitled to any dividends or other distributions other than or in excess of the dividends or other distributions referred to in this Section&nbsp;26.3(a). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payments of Dividends and Distributions</U>. Cheques of the Company payable at par at any branch of the
bankers of the Company shall be issued in respect of any cash dividends or other distributions contemplated by Section&nbsp;26.3(a)(i) and the sending of such cheque to each holder of an Exchangeable Share shall satisfy the cash dividend or other
distribution represented thereby unless the cheque is not paid on presentation. An Exchangeable Share Document registered in the name of the registered holder of Exchangeable Shares shall be delivered in respect of any stock or share dividends or
other distributions contemplated by Section&nbsp;26.3(a)(ii) or any subdivision of the Exchangeable Shares under Sections 26.3(a)(ii) and 26.3(f) and the sending of such Exchangeable Share Document to each holder of an Exchangeable Share shall
satisfy the stock or share dividend or other distribution represented thereby. Such other type and amount of property in respect of any dividends or other distributions contemplated by Section&nbsp;26.3(a)(iii) shall be issued, distributed or
transferred by the Company in such manner as it shall determine, and the issuance, distribution or transfer thereof by the Company to each holder of an Exchangeable Share shall satisfy the dividend or other distribution represented thereby. Subject
to the requirements of applicable Law with respect to unclaimed property, no holder of an Exchangeable Share shall be entitled to recover by action or other legal process against the Company any dividend or other distribution that is represented by
a cheque that has not been duly presented to the Company&#146;s bankers for payment or that otherwise remains unclaimed for a period of three (3)&nbsp;years from the date on which such dividend was payable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Record and Payment Dates</U>. The record date for the determination of the holders of Exchangeable Shares
entitled to receive payment of, and the payment date for, any dividend or other distribution declared on the Exchangeable Shares under Section&nbsp;26.3(a) shall be the same dates as the record date and payment date, respectively, for the
corresponding dividend or other distribution declared on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement). The record date for the determination of the holders of Exchangeable
Shares entitled to receive Exchangeable Shares in connection with any subdivision of the Exchangeable Shares under Sections 26.3(a)(ii) and 26.3(f), and the effective date of such subdivision, shall be the same dates as the record and payment date,
respectively, for the corresponding stock or share dividend or other distribution declared on the Delaware Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Partial Payment</U>. If on any payment date for any dividends or other distributions declared on the
Exchangeable Shares under Section&nbsp;26.3(a) the dividends or other distributions are not paid in full on all of the Exchangeable Shares then outstanding, any such dividends or other distributions that remain unpaid shall be paid on a subsequent
date or dates determined by the Board of Directors on which the Company shall have sufficient moneys, assets or property properly applicable to the payment of such dividends or other distributions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Economic Equivalence</U>. The Board of Directors shall determine, in good faith and in its sole discretion
(with the assistance of such financial or other advisors as the Board of Directors may determine), &#147;economic equivalence&#148; for the purposes of the Exchangeable Share Provisions and each such determination shall be conclusive and binding on
the Company and its shareholders. In making each such determination, the following factors shall, without excluding other factors determined by the Board of Directors to be relevant, be considered by the Board of Directors: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any stock or share dividend or other distribution payable in Delaware Common Stock (but
excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement), the number of such shares issued as a result of such stock or share dividend or other distribution in proportion to the number of Delaware Common Stock
previously outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the issuance or distribution of any rights, options or warrants to subscribe for or purchase
Delaware Common Stock or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement), the relationship between the
exercise price of each such right, option or warrant, the number of such rights, options or warrants to be issued or distributed in respect of each share of Delaware Common Stock and the Current Market Price of a share of Delaware Common Stock, the
price volatility of the Delaware Common Stock and the terms of any such instrument; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the issuance or distribution of any other form of property including, without limitation, any
shares or securities of Parent of any class other than Delaware Common Stock, any rights, options or warrants other than those referred to in Section&nbsp;26.3(e)(ii), any evidences of indebtedness of Parent or any assets of Parent (but excluding
any dividends or distributions pursuant to a Preferred Stock Rights Agreement), the relationship between the fair market value (as determined by the Board of Directors in the manner above contemplated) of such property to be issued or distributed
with respect to each outstanding share of Delaware Common Stock and the Current Market Price of a share of Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any subdivision, redivision or change of the then outstanding Delaware Common Stock into a
greater number of Delaware Common Stock or the reduction, combination, consolidation or change of the then outstanding Delaware Common Stock into a lesser number of Delaware Common Stock or any amalgamation, merger, arrangement, reorganization or
other transaction affecting the Delaware Common Stock, the effect thereof upon the then outstanding Delaware Common Stock; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in all such cases, the general taxation consequences of the relevant event to holders of Exchangeable Shares to
the extent that such consequences may differ from the taxation consequences to holders of Delaware Common Stock as a result of differences between taxation Laws of Canada and the United States (except for any differing consequences arising as a
result of differing marginal taxation rates and without regard to the individual circumstances of holders of Exchangeable Shares). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Subdivision on Stock or Share Dividend</U>. In the case of a stock or share dividend declared on Delaware
Common Stock to be paid in Delaware Common Stock, in lieu of declaring the stock or share dividend contemplated by Section&nbsp;26.3(a)(ii) on the Exchangeable Shares, the Board of Directors may, in good faith and in its discretion and subject to
applicable Law and to obtaining any required regulatory approvals, subdivide, redivide or change each issued and unissued Exchangeable Share on the basis that each Exchangeable Share before such subdivision becomes a number of Exchangeable Shares
equal to the sum of (i)&nbsp;one share of Delaware Common Stock, and (ii)&nbsp;the number of Delaware Common Stock to be paid as a share dividend on each share of Delaware Common Stock. In such instance, and notwithstanding any other provision
hereof, such subdivision shall become effective on the effective date specified in Section&nbsp;26.3(c) without any further act or formality on the part of the holders of Exchangeable Shares. For greater certainty, subject to applicable Law, no
approval of the holders of Exchangeable Shares to an amendment to these Articles shall be required to give effect to such subdivision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Share Consolidation</U>. In the case of a consolidation of shares of Delaware Common Stock, the Board of
Directors may, in good faith and in its discretion and subject to applicable Law and to obtaining any required regulatory approvals, consolidate each issued and unissued Exchangeable Share on the same basis concurrently with, or as soon as
practicable following, the consolidation of the shares of Delaware Common Stock (and to ensure that the Exchangeable Share Exchange Ratio does not decrease as a result of the consolidation of the shares of Delaware Common Stock). For greater
certainty, subject to applicable Law, no approval of the holders of Exchangeable Shares to an amendment to these Articles shall be required to give effect to such consolidation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.4</B> <B>Certain Restrictions</B>. So long as any of the Exchangeable Shares are outstanding, the Company shall not at any time without, but may at any
time with, the approval of the holders of the Exchangeable Shares given as specified in Section&nbsp;26.11(b): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pay any dividends or other distributions on any shares ranking junior to the Exchangeable Shares with respect
to the payment of dividends or other distributions (other than the Common Shares), other than stock or share dividends payable in Common Shares or any such other shares ranking junior to the Exchangeable Shares, as the case may be;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">redeem or purchase or make any capital distribution in respect of any shares ranking junior to the Exchangeable
Shares with respect to the payment of dividends or other distributions (other than the Common Shares) in the event of the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or any other distribution of the
assets of the Company among its shareholders for the purpose of winding up its affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">redeem or purchase or make any capital distribution in respect of any other shares of the Company ranking
equally with the Exchangeable Shares with respect to the payment of dividends or other distributions in the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether voluntary or involuntary,
or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue any Exchangeable Share or any other shares ranking equally with, or superior to, the Exchangeable Shares,
other than, in each case, by way of stock or share dividends to the holders of such Exchangeable Shares or pursuant to a shareholders rights plan adopted by the Company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that the restrictions in this Section&nbsp;26.4 shall not apply if, in connection with
all dividends or other distributions declared and paid on the Delaware Common Stock (but excluding any dividends or distributions pursuant to a Preferred Stock Rights Agreement): (i) all dividends or other distributions on the outstanding
Exchangeable Shares shall have been declared and paid in full on the Exchangeable Shares, or (ii)&nbsp;the Exchangeable Share Exchange Ratio shall have been adjusted in accordance with these Exchangeable Share Terms, in each case, prior to or as at
the date of any such event referred to in this Section&nbsp;26.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.5</B> <B>Liquidation</B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Liquidation Amount</U>. Subject to applicable Laws and the due exercise by CallCo of the Liquidation Call
Right (which shall itself be subject to the sale and purchase contemplated by the Automatic Exchange Right), in the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other distribution
of the assets of the Company among its shareholders for the purpose of winding up its affairs, a holder of Exchangeable Shares shall be entitled to receive from the assets of the Company in respect of each Exchangeable Share held by such holder on
the effective date of such liquidation, dissolution, <FONT STYLE="white-space:nowrap">winding-up</FONT> or other distribution (the &#147;<B>Liquidation Date</B>&#148;), before any distribution of any part of the assets of the Company among the
holders of the Common Shares or any other shares ranking junior to the Exchangeable Shares with respect to dividends or other distributions an amount per share (the &#147;<B>Liquidation Amount</B>&#148;) equal to the Exchangeable Share Price
applicable on the last Business Day prior to the Liquidation Date, which price shall be satisfied in full by the Company delivering or causing to be delivered to such holder the Exchangeable Share Consideration representing the Liquidation Amount
for each Exchangeable Share held by such holder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment of Liquidation Amount</U>. In the case of a distribution pursuant to Section&nbsp;26.5(a), and
provided that the sale and purchase contemplated by the Automatic Exchange Right has not occurred and that the Liquidation Call Right has not been exercised by CallCo, on or promptly after the Liquidation Date, the Company shall deliver or cause to
be delivered to the holders of the Exchangeable Shares the Liquidation Amount for each such Exchangeable Share, upon presentation and surrender of the Exchangeable Share Documents representing such Exchangeable Shares, together with such other
documents and instruments as may be required to effect a transfer of Exchangeable Shares under the BCBCA and these Articles, as applicable, together with such additional documents, instruments and payments as the Transfer Agent or the Company may
reasonably require, at any office of the Transfer Agent as may be specified by the Company by notice to the holders of the Exchangeable Shares. Payment of the Liquidation Amount for such Exchangeable Shares shall be made by delivery to each holder,
at the address of such holder recorded in the securities register of the Company for the Exchangeable Shares or by holding for <FONT STYLE="white-space:nowrap">pick-up</FONT> by such holder at the registered office of the Company or at any office of
the Transfer Agent as may be specified by the Company by notice to the holders of the Exchangeable Shares, the Exchangeable Share Consideration such holder is entitled to receive pursuant<U> </U>to Section&nbsp;26.5(a). On and after the Liquidation
Date, the holders of the Exchangeable Shares shall cease to be holders of such Exchangeable Shares and shall not be entitled to exercise any of the rights of holders in respect thereof (including, without limitation, any rights under the Voting and
Exchange Trust Agreement) other than the right to receive, without interest, their proportionate part of the aggregate Liquidation Amount, unless payment of the aggregate Liquidation Amount for such Exchangeable Shares shall not be made upon
presentation and surrender of Exchangeable Share Documents and other required documents in accordance with the foregoing provisions, in which case the rights of the holders shall remain unaffected until the Liquidation Amount has been paid in the
manner so provided. The Company shall have the right at any time after the Liquidation Date to transfer or cause to be issued or transferred to, and deposited in a custodial account with, any chartered bank or trust company the Liquidation Amount in
respect of the Exchangeable Shares represented by Exchangeable Share Documents that have not at the Liquidation Date been surrendered by the holders thereof, such Liquidation Amount to be held by such bank or trust company as trustee for and on
behalf of, and for the use and benefit of, such holders. Upon such deposit being made, the rights of a holder of Exchangeable Shares as of the date of such deposit shall be limited to receiving its proportionate part
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of the aggregate Liquidation Amount for such Exchangeable Shares so deposited, without interest, and all dividends and other distributions with respect to the Delaware Common Stock to which such
holder is entitled with a record date on or after the date of such deposit and before the date of transfer of such Delaware Common Stock to such holder against presentation and surrender of the Exchangeable Share Documents for the Exchangeable
Shares held by them in accordance with the foregoing provisions. Upon such payment or deposit of the Liquidation Amount, the holders of the Exchangeable Shares shall thereafter be considered and deemed for all purposes to be holders of the Delaware
Common Stock delivered to them or the custodian on their behalf. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Right to Participate in Further Distributions</U>. After the Company has satisfied its obligations to pay
the holders of the Exchangeable Shares the aggregate Liquidation Amount per Exchangeable Share pursuant to this Section&nbsp;26.5, such holders shall not be entitled to share in any further distribution of the assets of the Company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.6</B> <B>Retraction of Exchangeable Shares</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Retraction at Option of Holder</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to applicable Laws and the due exercise by CallCo of the Retraction Call Right, a holder of
Exchangeable Shares shall be entitled at any time to require the Company to redeem (at the holder&#146;s discretion) any or all of the Exchangeable Shares registered in the name of such holder for an amount per share equal to the Exchangeable Share
Price applicable on the last Business Day prior to the Retraction Date (the &#147;<B>Retraction Price</B>&#148;), which price shall be satisfied in full by the Company or CallCo, as applicable, delivering or causing to be delivered to such holder
the Exchangeable Share Consideration representing the Retraction Price. A holder of Exchangeable Shares must give notice of such request to redeem or purchase by presenting and surrendering to any office of the Transfer Agent as may be specified by
the Company by notice to the holders of the Exchangeable Shares, the Exchangeable Share Documents representing the Exchangeable Shares that such holder desires to have the Company redeem or CallCo purchase, as applicable, together with (A)&nbsp;such
other documents and instruments as may be required to effect a transfer of Exchangeable Shares under the BCBCA and these Articles, as applicable, together with such additional documents, instruments and payments as the Transfer Agent or the Company
may reasonably require, and (B)&nbsp;a duly executed request (the &#147;<B>Retraction Request</B>&#148;) in the form of the Appendix attached hereto or in such other form as may be acceptable to the Company: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">specifying that such holder desires to have all or any number specified therein of the Exchangeable Shares
represented by such Exchangeable Share Documents (the &#147;<B>Retracted Shares</B>&#148;) redeemed by the Company or purchased by CallCo, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">stating the Business Day on which the holder desires to have the Company redeem or CallCo purchase the
Retracted Shares (the &#147;<B>Retraction Date</B>&#148;), provided that the Retraction Date shall not be less than 10 Business Days nor more than 15 Business Days after the date on which the Retraction Request is received by the Transfer Agent on
behalf of the Company and further provided that, in the event that no such Business Day is specified by the holder in the Retraction Request, the Retraction Date shall be deemed to be the 15th Business Day after the date on which the Retraction
Request is received by the Transfer Agent on behalf of the Company, subject to Section&nbsp;26.6(a)(v); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acknowledging the overriding right (the &#147;<B>Retraction Call Right</B>&#148;) of CallCo to purchase all but
not less than all the Retracted Shares directly from the holder and that the Retraction Request shall be deemed to be a revocable offer by the holder to sell the Retracted Shares to CallCo in accordance with the Retraction Call Right on the
Retraction Date for the Retraction Call Right Purchase Price and on the other terms and conditions set out in Section&nbsp;26.6(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of a redemption or purchase of Exchangeable Shares pursuant to this Section&nbsp;26.6(a), upon
receipt by the Transfer Agent in the manner specified in Section&nbsp;26.6(a)(i) of one or more </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Exchangeable Share Documents representing the number of Exchangeable Shares which the holder desires to have the Company redeem or CallCo purchase, together with a duly executed Retraction
Request and such additional documents and instruments specified in Section&nbsp;26.6(a)(i) or that the Company or the Transfer Agent may reasonably require, and provided that (A)&nbsp;the Retraction Request has not been revoked by the holder of such
Retracted Shares in the manner specified in Section&nbsp;26.6(a)(iv), and (B)&nbsp;CallCo has not exercised the Retraction Call Right, the Company shall redeem or CallCo shall purchase, as applicable, the Retracted Shares effective at the close of
business on the Retraction Date. On the Retraction Date, the Company or CallCo shall deliver or cause to be delivered to such holder, at the address of the holder recorded in the securities register of the Company for the Exchangeable Shares or at
the address specified in the Retraction Request or by holding for <FONT STYLE="white-space:nowrap">pick-up</FONT> by the holder at any office of the Transfer Agent as may be specified by the Company by notice to the holders of the Exchangeable
Shares, the Exchangeable Share Consideration representing the Retraction Price and such delivery of such Exchangeable Share Consideration by or on behalf of the Company by the Transfer Agent shall be deemed to be payment of and shall satisfy and
discharge all liability for the Retraction Price to the extent that the same is represented by such Exchangeable Share Consideration, unless any cheque comprising part of such Exchangeable Share Consideration is not paid on due presentation. If only
a part of the Exchangeable Shares represented by any Exchangeable Share Document is redeemed or purchased, a new Exchangeable Share Document for the balance of such Exchangeable Shares shall be issued to the holder at the expense of the Company. On
and after the close of business on the Retraction Date, the holder of the Retracted Shares shall cease to be a holder of such Retracted Shares and shall not be entitled to exercise any of the rights of a holder in respect thereof (including, without
limitation, any rights under the Voting and Exchange Trust Agreement), other than the right to receive the aggregate Retraction Price in respect thereof, unless payment of the aggregate Retraction Price payable to such holder shall not be made upon
presentation and surrender of the Exchangeable Share Documents and other required documents in accordance with the foregoing provisions, in which case the rights of such holder shall remain unaffected until such aggregate Retraction Price has been
paid in the manner so provided. On and after the close of business on the Retraction Date, provided that presentation and surrender of the Exchangeable Share Documents and payment of such aggregate Retraction Price has been made in accordance with
the foregoing provisions, the holder of the Retracted Shares so redeemed by the Company shall thereafter be considered and deemed for all purposes to be a holder of the Delaware Common Stock delivered to such holder. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of this Section&nbsp;26.6, the Company shall not be obligated to redeem
Retracted Shares specified by a holder in a Retraction Request if and to the extent that such redemption or purchase of Retracted Shares, as applicable, would be contrary to solvency requirements or other provisions of applicable Laws. If the
Company believes, after due enquiry, that on any Retraction Date it would not be permitted by any of such provisions to redeem the Retracted Shares tendered for redemption on such date, and provided that (A)&nbsp;CallCo has not exercised the
Retraction Call Right with respect to such Retracted Shares, and (B)&nbsp;the holder has not required that CallCo purchase such Retracted Shares as contemplated under Section&nbsp;26.6(a)(i), then the Company shall only be obligated to redeem
Retracted Shares specified by a holder in a Retraction Request to the extent of the maximum number that may be so redeemed (rounded down to a whole number of shares) as would not be contrary to such provisions and shall notify the holder and the
Share Trustee at least two Business Days prior to the Retraction Date as to the number of Retracted Shares which will not be redeemed by the Company. In any case in which the redemption by the Company of Retracted Shares would be contrary to
solvency requirements or other provisions of applicable Laws, the Company shall redeem Retracted Shares in accordance with Section&nbsp;26.6(a)(ii) on a pro rata basis in proportion to the total number of Exchangeable Shares tendered for retraction
and shall issue to each holder of Retracted Shares a new Share Exchange Document, at the expense of the Company, representing the Retracted Shares not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
redeemed by the Company pursuant to Section&nbsp;26.6(a)(ii). If the Company would otherwise be obligated to redeem Retracted Shares pursuant to Section&nbsp;26.6(a)(ii) but is not obligated to
do so as a result of solvency requirements or other provisions of applicable Laws, the holder of any such Retracted Shares not redeemed by the Company pursuant to Section&nbsp;26.6(a)(ii) as a result of solvency requirements or other provisions of
applicable Laws shall be deemed, by delivery of the Retraction Request, to have instructed the Transfer Agent to require CallCo to purchase such Retracted Shares from such holder on the Retraction Date or as soon as practicable thereafter on payment
by CallCo to such holder of the aggregate Retraction Price in respect of such Retracted Shares, all as more specifically provided for in the Voting and Exchange Trust Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A holder of Retracted Shares may, by notice in writing given by the holder to any office of the Transfer Agent
as may be specified by the Company by notice to the holders of the Exchangeable Shares, before the close of business on the Business Day immediately preceding the Retraction Date, withdraw its Retraction Request, in which event such Retraction
Request shall be null and void and, for greater certainty, the revocable offer constituted by the Retraction Request to sell the Retracted Shares to CallCo shall be deemed to have been revoked. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provision of this Section&nbsp;26.6(a), if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise of the rights of the holders of the Exchangeable Shares, or any of them, to require the Company to
redeem any Exchangeable Shares pursuant to this Section&nbsp;26.6(a) on any Retraction Date would require listing particulars or any similar document to be issued in order to obtain the approval of the NYSE to the listing and trading (subject to
official notice of issuance) of the Delaware Common Stock that would be required to be delivered to such holders of Exchangeable Shares in connection with the exercise of such rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a result of (A)&nbsp;above, it would not be practicable (notwithstanding the reasonable endeavours of
Parent) to obtain such approvals in time to enable all or any of such Delaware Common Stock to be admitted to listing and trading by the NYSE (subject to official notice of issuance) when so delivered; the Retraction Date shall, notwithstanding any
other date specified or otherwise deemed to be specified in any relevant Retraction Request, be deemed for all purposes to be the earlier of (i)&nbsp;the second Business Day immediately following the date the approvals referred to in
Section&nbsp;26.6(a)(v)(A) are obtained and (ii)&nbsp;the date which is 30 Business Days after the date on which the relevant Retraction Request is received by the Company, and references in these Exchangeable Share Provisions to such Retraction
Date shall be construed accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Retraction Call Rights</U><U> </U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that a holder of Exchangeable Shares delivers a Retraction Request pursuant to
Section&nbsp;26.6(a), and subject to the limitations set forth in Section&nbsp;26.6(a)(ii), the Retraction Call Right will be available to CallCo, notwithstanding the proposed redemption of the Exchangeable Shares by the Company pursuant to
Section&nbsp;26.6(a), to purchase from such holder on the Retraction Date all but not less than all of the Retracted Shares held by such holder on payment by CallCo of an amount per share equal to the Exchangeable Share Price applicable on the last
Business Day prior to the Retraction Date (the &#147;<B>Retraction Call Right Purchase Price</B>&#148;), which price shall be satisfied in full by CallCo delivering or causing to be delivered to such holder the Exchangeable Share Consideration
representing the Retraction Call Right Purchase Price. Upon the exercise of the Retraction Call Right in respect of Retracted Shares, the holder of such Retracted Shares shall be obligated to sell all of such Retracted Shares to CallCo on the
Retraction Date on payment by CallCo of the aggregate Retraction Call Right Purchase Price in respect of such Retracted Shares as set forth in this Section&nbsp;26.6(b)(i). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon receipt by the Transfer Agent of a Retraction Request, the Transfer Agent shall immediately notify the
Company and CallCo thereof and shall provide CallCo with a copy of the Retraction </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Request. In order to exercise its Retraction Call Right, CallCo must notify the Transfer Agent in writing of its determination to do so (a &#147;<B>Retraction Call Notice</B>&#148;) within five
Business Days after the Transfer Agent notifies CallCo of the Retraction Request. If CallCo does not so notify the Transfer Agent within such five Business Day period, then the Transfer Agent shall notify the holder as soon as possible thereafter
that CallCo will not exercise the Retraction Call Right. If CallCo delivers a Retraction Call Notice within such five Business Day period and duly exercises its Retraction Call Right in accordance with this Section&nbsp;26.6(b)(ii), the obligation
of the Company to redeem the Retracted Shares shall terminate and, provided that the Retraction Request is not revoked by the holder of such Retracted Shares in the manner specified in Section&nbsp;26.6(a)(iv), CallCo shall purchase from such holder
and such holder shall sell to CallCo on the Retraction Date the Retracted Shares for an amount per share equal to the Retraction Call Right Purchase Price. Provided that the aggregate Retraction Call Right Purchase Price has been so deposited with
the Transfer Agent as provided in Section&nbsp;26.6(b)(iii), the closing of the purchase and sale of the Retracted Shares pursuant to the Retraction Call Right shall be deemed to have occurred as at the close of business on the Retraction Date and,
for greater certainty, no redemption by the Company of such Retracted Shares shall take place on the Retraction Date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of completing a purchase of Retracted Shares pursuant to the exercise of the Retraction Call
Right, CallCo shall deliver or cause to be delivered to the holder of such Retracted Shares, at the address of the holder recorded in the securities register of the Company for the Exchangeable Shares or at the address specified in the holder&#146;s
Retraction Request or by holding for <FONT STYLE="white-space:nowrap">pick-up</FONT> by the holder at any office of the Transfer Agent as may be specified by the Company by notice to the holders of Exchangeable Shares, the Exchangeable Share
Consideration representing the Retraction Call Right Purchase Price to which such holder is entitled, and such delivery of Exchangeable Share Consideration on behalf of CallCo shall be deemed to be payment of and shall satisfy and discharge all
liability for the Retraction Call Right Purchase Price to the extent that the same is represented by such Exchangeable Share Consideration, unless any cheque comprising part of such Exchangeable Share Consideration is not paid on due presentation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent in accordance with Section&nbsp;26.6(b)(ii) of its intention to
exercise the Retraction Call Right in the manner and timing described therein, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Transfer Agent) that CallCo exercise the
Retraction Call Right in respect of the shares covered by the notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On and after the close of business on the Retraction Date, the holder of the Retracted Shares shall cease to be
a holder of such Retracted Shares and shall not be entitled to exercise any of the rights of a holder in respect thereof (including, without limitation, any rights under the Voting and Exchange Trust Agreement), other than the right to receive the
aggregate Retraction Call Right Purchase Price in respect thereof, unless payment of the aggregate Retraction Call Right Purchase Price payable to such holder shall not be made upon presentation and surrender of Exchangeable Share Documents and
other required documents in accordance with the foregoing provisions, in which case the rights of such holder shall remain unaffected until such aggregate Retraction Call Right Purchase Price has been paid in the manner so provided. On and after the
close of business on the Retraction Date, provided that presentation and surrender of Exchangeable Share Documents and payment of such aggregate Retraction Call Right Purchase Price has been made in accordance with the foregoing provisions, the
holder of the Retracted Shares so purchased by CallCo shall thereafter be considered and deemed for all purposes to be a holder of the Delaware Common Stock delivered to such holder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.7</B> <B>Redemption of Exchangeable Shares by the Company</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Redemption Amount</U>. Subject to applicable Laws and the due exercise by CallCo of the Redemption Call
Right, the Company shall on the Redemption Date redeem all but not less than all of the then </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
outstanding Exchangeable Shares (other than Exchangeable Shares held by Parent and its affiliates) for an amount per share (the &#147;<B>Redemption Price</B>&#148;) equal to the Exchangeable
Share Price on the last Business Day prior to the Redemption Date, which price shall be satisfied in full by the Company delivering or causing to be delivered to each holder of Exchangeable Shares the Exchangeable Share Consideration for each
Exchangeable Share held by such holder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice of Redemption</U>. In the case of a redemption of Exchangeable Shares pursuant to
Section&nbsp;26.7(a), the Company shall, at least 30 days before the Redemption Date (other than a Redemption Date established in connection with a Parent Control Transaction), send or cause to be sent to each holder of Exchangeable Shares a notice
in writing of the redemption by the Company or the purchase by CallCo under the Redemption Call Right of the Exchangeable Shares held by such holder. In the case of a Redemption Date established in connection with a Parent Control Transaction, the
written notice of the redemption by the Company or the purchase by CallCo of the Exchangeable Shares under the Redemption Call Right will be sent on or before the Redemption Date, on as many days&#146; prior written notice as may be determined by
the Board of Directors to be reasonably practicable in the circumstances. In any such case, such notice shall set out the formula for determining the Redemption Price or the Redemption Call Purchase Price, as the case may be, the Redemption Date
and, if applicable, particulars of the Redemption Call Right. In the case of any notice given in connection with a possible Redemption Date, such notice will be given contingently and will be withdrawn if the contingency does not occur.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment of Redemption Price</U>. On or promptly after the Redemption Date, and provided that the Redemption
Call Right has not been exercised by CallCo, the Company shall deliver or cause to be delivered to the holders of the Exchangeable Shares to be redeemed the Redemption Price for each such Exchangeable Share, upon presentation and surrender of the
Exchangeable Share Document representing such Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable Shares under the BCBCA and these Articles, as applicable, together with
such additional documents, instruments and payments as the Transfer Agent or the Company may reasonably require, at any office of the Transfer Agent as may be specified by notice to the holders of the Exchangeable Shares. Payment of the Redemption
Price for such Exchangeable Shares shall be made by delivery to each holder, at the address of the holder recorded in the securities register of the Company for the Exchangeable Shares or by holding for
<FONT STYLE="white-space:nowrap">pick-up</FONT> by the holder at the registered office of the Transfer Agent as may be specified by the Company by notice to the holders of Exchangeable Shares, the Exchangeable Share Consideration representing the
Redemption Price. On and after the Redemption Date, the holders of the Exchangeable Shares called for redemption shall cease to be holders of such Exchangeable Shares and shall not be entitled to exercise any of the rights of holders in respect
thereof (including, without limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive, without interest, their proportionate part of the aggregate Redemption Price, unless payment of the aggregate
Redemption Price for such Exchangeable Shares shall not be made upon presentation and surrender of Exchangeable Share Documents in accordance with the foregoing provisions, in which case the rights of the holders shall remain unaffected until the
Redemption Price has been paid in the manner so provided. The Company shall have the right at any time after the sending of notice of its intention to redeem the Exchangeable Shares as provided to deposit or cause to be deposited the aggregate
Redemption Price (in the form of Exchangeable Share Consideration) of the Exchangeable Shares so called for redemption, or of such of the said Exchangeable Shares represented by Exchangeable Share Documents that have not at the date of such deposit
been surrendered by the holders thereof in connection with such redemption, in a custodial account with any chartered bank or trust company in Canada named in such notice and any interest earned on such deposit shall belong to the Company. Provided
that such aggregate Redemption Price has been so deposited prior to the Redemption Date, on and after the Redemption Date, the Exchangeable Shares in respect of which such deposit shall have been made shall be redeemed and the rights of the holders
thereof after the Redemption Date shall be limited to receiving, without interest, their proportionate part of the aggregate Redemption Price for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such Exchangeable Shares so deposited, against presentation and surrender of the Exchangeable Share Documents for the Exchangeable Shares held by them, respectively, in accordance with the
foregoing provisions. Upon such payment or deposit of the Redemption Price, the holders of the Exchangeable Shares shall thereafter be considered and deemed for all purposes to be holders of the Delaware Common Stock delivered to them or the
custodian on their behalf. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.8</B> <B>Purchase by Private Agreement</B>. Subject to applicable Laws and the articles of the Company,
and notwithstanding Section&nbsp;26.7(b), the Company may at any time and from time to time purchase for cancellation all or any part of the Exchangeable Shares by private agreement with the holder thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.9</B> <B>Voting Rights</B>. Except as required by applicable Laws and by Section&nbsp;26.11, the holders of the Exchangeable Shares shall not be
entitled as such to receive notice of or to attend any meeting of the shareholders of the Company or to vote at any such meeting. Without limiting the generality of the foregoing, the holders of the Exchangeable Shares shall not be entitled to class
votes except as required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.10</B> <B>Specified Amount</B>. The &#147;specified amount&#148; for the purposes of subsection 191(4)
of the <I>Income Tax Act </I>(Canada) in respect of each Exchangeable Share shall be the amount specified by a director or officer of the Company in a resolution that is entered into in connection with the issuance of the Exchangeable Shares of the
Company (expressed as a dollar amount). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.11</B> <B>Amendment and Approval</B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment</U>. The rights, privileges, restrictions and conditions attaching to the Exchangeable Shares may
be added to, changed or removed only with the approval of the holders of the Exchangeable Shares given as specified below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Approval</U>. Any approval given by the holders of the Exchangeable Shares to add to, change or remove any
right, privilege, restriction or condition attaching to the Exchangeable Shares or any other matter requiring the approval or consent of the holders of the Exchangeable Shares either in accordance with applicable Laws or as expressly provided under
these Exchangeable Share Provisions shall be deemed to have been sufficiently given if it shall have been given in accordance with applicable Laws, subject to a minimum requirement that such approval be evidenced by resolution passed by not less
than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on such resolution at a meeting of holders of Exchangeable Shares duly called and held at which the holders of at least 10% of the outstanding Exchangeable Shares at that time
are present or represented by proxy; provided, however, that if at any such meeting the holders of at least 10% of the outstanding Exchangeable Shares at that time are not present or represented by proxy within
<FONT STYLE="white-space:nowrap">one-half</FONT> hour after the time appointed for such meeting, then the meeting shall be adjourned to such date not less than five days thereafter and to such time and place as may be designated by the Chair of such
meeting. At such adjourned meeting, the holders of Exchangeable Shares present or represented by proxy thereat may transact the business for which the meeting was originally called and a resolution passed thereat by the affirmative vote of not less
than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on such resolution at such meeting shall constitute the approval or consent of the holders of the Exchangeable Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.12</B> <B>Reciprocal Changes</B><B> in Respect of Delaware Common Stock</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acknowledgement in Respect of Issuances or Distributions</U>. The Company and each holder of an Exchangeable
Share acknowledges that the Support Agreement provides, in part, that Parent will not, except as provided in the Support Agreement, without the prior approval of the Company and the prior approval of the holders of the Exchangeable Shares given in
accordance with Section&nbsp;26.11(b): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute Delaware Common Stock (or securities exchangeable for or convertible into or carrying
rights to acquire Delaware Common Stock) to the holders of all or substantially all of the then outstanding Delaware Common Stock by way of stock or share dividend or other distribution,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
other than an issue of Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) to holders of Delaware Common Stock who
exercise an option to receive dividends in Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock) in lieu of receiving cash dividends, or pursuant to any dividend reinvestment
plan or scrip dividend or similar arrangement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute rights, options or warrants to the holders of all or substantially all of the then
outstanding Delaware Common Stock entitling them to subscribe for or to purchase Delaware Common Stock (or securities exchangeable for or convertible into or carrying rights to acquire Delaware Common Stock); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue or distribute to the holders of all or substantially all of the then outstanding Delaware Common Stock:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares or securities of Parent of any class other than Delaware Common Stock (or securities convertible into or
exchangeable for or carrying rights to acquire Delaware Common Stock); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">rights, options or warrants other than those referred to in Section&nbsp;26.12(a)(ii) above;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evidence of indebtedness of Parent; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">assets of Parent; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, the Company issues or distributes the economic equivalent of such rights, options, warrants, securities, shares,
evidences of indebtedness or other assets simultaneously to holders of the Exchangeable Shares; provided, however, that, for greater certainty, the above restrictions shall not apply to any securities issued or distributed by Parent in order to give
effect to and to consummate the transactions contemplated by, and in accordance with, the Transaction Agreement and the Plan of Arrangement; provided, further, that the foregoing limitations and restrictions set forth in this Section&nbsp;26.12(a)
shall not apply to actions taken by Parent relating to a Preferred Stock Rights Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Acknowledgement in Respect of Corporate Changes</U>. Each holder of an Exchangeable Share acknowledges that
the Support Agreement further provides, in part, that for so long as any Exchangeable Shares not owned by Parent or its affiliates are outstanding, Parent will not without the prior approval of the Company and the prior approval of the holders of
the Exchangeable Shares given in accordance with Section&nbsp;26.11(b): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide, redivide or change the then outstanding Delaware Common Stock into a greater number of Delaware
Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce, combine, consolidate or change the then outstanding Delaware Common Stock into a lesser number of
Delaware Common Stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reclassify or otherwise change the Delaware Common Stock or effect an amalgamation, merger, reorganization or
other transaction affecting the Delaware Common Stock; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">unless, in each case, the same or an economically equivalent
change is made simultaneously to, or in the rights of the holders of, the Exchangeable Shares; provided, however, that, for greater certainty, the above restrictions shall not apply to any securities issued or distributed by Parent in order to give
effect to and to consummate the transactions contemplated by, and in accordance with the Transaction Agreement and the Plan of Arrangement; provided, further, that the foregoing limitations and restrictions set forth in this Section&nbsp;26.12(b)
shall not apply to actions taken by Parent relating to a Preferred Stock Rights Agreement. The Support Agreement further provides, in part, that the above noted provisions of the Support Agreement shall not be changed without the approval of the
holders of the Exchangeable Shares given in accordance with Section&nbsp;26.11(b). Accordingly, and notwithstanding any provision to the contrary contained elsewhere in these Articles, the Company may, by way of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
resolution of the Board of Directors (i)&nbsp;subdivide, redivide or change the then outstanding Exchangeable Shares into a greater number of Exchangeable Shares, or (ii)&nbsp;reduce, combine,
consolidate or change the then outstanding Exchangeable Shares into a lesser number of Exchangeable Shares, to give effect to an economically equivalent change in the rights of the holders of the Exchangeable Shares to any similar change made to the
Delaware Common Stock under Sections 26.12(b)(i) or 26.12(b)(ii) respectively, as applicable. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Successorship Transaction</U>. Notwithstanding the foregoing provisions of this Section&nbsp;26.12, in the
event of a Parent Control Transaction: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which Parent merges or amalgamates with, or in which all or substantially all of the then outstanding
Delaware Common Stock are acquired by one or more other corporations to which Parent is, immediately before such merger, amalgamation or acquisition, related within the meaning of the <I>Income Tax Act </I>(Canada) (otherwise than by virtue of a
right referred to in paragraph 251(5)(b) thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which does not result in an acceleration of the Redemption Date in accordance with paragraph (ii)&nbsp;of the
definition of such term in Section&nbsp;26.1(a); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in which all or substantially all of the then outstanding Delaware Common Stock are converted into or exchanged
for shares or rights to receive such shares (the &#147;<B>Other Shares</B>&#148;) of another corporation (the &#147;<B>Other Corporation</B>&#148;) that, immediately after such Parent Control Transaction, owns or controls, directly or indirectly,
Parent; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">then all references herein to &#147;Parent&#148; shall thereafter be and be deemed to be references to
&#147;Other Corporation&#148; and all references herein to &#147;Delaware Common Stock&#148; shall thereafter be and be deemed to be references to &#147;Other Shares&#148; (with appropriate adjustments, if any, as are required to result in a holder
of Exchangeable Shares on the exchange, redemption, retraction or purchase of shares pursuant to these Exchangeable Share Provisions, the Support Agreement and the Voting and Exchange Trust Agreement (as applicable) immediately subsequent to the
Parent Control Transaction, being entitled to receive that number of Other Shares equal to the number of Other Shares such holder of Exchangeable Shares would have received if the exchange, redemption, retraction or purchase of such shares pursuant
to these Exchangeable Share Provisions, the Support Agreement and the Voting and Exchange Trust Agreement (as applicable), had occurred immediately prior to the Parent Control Transaction and the Parent Control Transaction was completed), but
subject to subsequent adjustments to reflect any subsequent changes in the share capital of the issuer of the Other Shares, including without limitation, any subdivision, consolidation or reduction of share capital, without any need to amend the
terms and conditions of the Exchangeable Shares and without any further action required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.13 Actions by the Company under Support Agreement and the
Voting and Exchange Trust Agreement </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Actions by the Company</U>. The Company will take all such actions and do all such things as shall be
necessary or advisable to perform and comply with and to ensure performance and compliance by Parent, CallCo and the Company with all provisions of the Support Agreement and the Voting and Exchange Trust Agreement applicable to Parent, CallCo and
the Company, respectively, in accordance with the terms thereof including taking all such actions and doing all such things as shall be necessary or advisable to enforce to the fullest extent possible for the direct benefit of the Company all rights
and benefits in favour of the Company under or pursuant to such agreements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Changes to Support Agreement or Voting and Exchange Trust Agreement</U>. The Company shall not propose,
agree to or otherwise give effect to any amendment to, or waiver or forgiveness of its rights or obligations under, the Support Agreement or the Voting and Exchange Trust Agreement without the approval of the holders of the Exchangeable Shares given
in accordance with Section&nbsp;26.11(b) other than such amendments, waivers and/or forgiveness as may be necessary or advisable for the purposes of: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adding to the covenants of any or all of the other parties to the Support Agreement or the Voting and Exchange
Trust Agreement if the board of directors of each of Parent, CallCo and the Company shall be of the good faith opinion that such additions will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evidencing the succession of successors to Parent either by operation of Law or agreement to the liabilities
and covenants of Parent under the Support Agreement (&#147;<B>Parent Successors</B>&#148;) and the covenants of and obligations assumed by each such Parent Successor in accordance with the provisions of Article 3 of the Support Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such amendments or modifications not inconsistent with the Support Agreement and the Voting and Exchange
Trust Agreement as may be necessary or desirable with respect to matters or questions arising thereunder which, in the good faith opinion of the board of directors of each of Parent, CallCo and the Company, it may be expedient to make, provided that
each such board of directors shall be of the good faith opinion, after consultation with counsel, that such amendments and modifications will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making such changes in or corrections to the Support Agreement and the Voting and Exchange Trust Agreement
which, on the advice of counsel to Parent, CallCo and the Company, are required for the purpose of curing or correcting any ambiguity or defect or inconsistent provision or clerical omission or mistake or manifest error contained therein, provided
that the board of directors of each of Parent, CallCo and the Company shall be of the good faith opinion that such changes or corrections will not be prejudicial to the rights or interests of the holders of the Exchangeable Shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.14</B> <B>Legend; Call Rights; Withholding Rights</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Legend</U>. The Exchangeable Share Documents evidencing the Exchangeable Shares shall contain or have
affixed thereto a legend in form and on terms approved by the Board of Directors with respect to the Support Agreement, including provisions relating to the Liquidation Call Right, the Redemption Call Right and the Change of Law Call Right, the
Voting and Exchange Trust Agreement (including the provisions with respect to the voting rights and automatic exchange thereunder) and the Retraction Call Right. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Call Rights</U>. Each holder of an Exchangeable Share, whether of record or beneficial, by virtue of
becoming and being such a holder shall be deemed to acknowledge each of the Liquidation Call Right, the Redemption Call Right, the Change of Law Call Right and the Retraction Call Right, in each case, in favour of CallCo, and the overriding nature
thereof in connection with the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, or
the retraction or redemption of Exchangeable Shares, as the case may be, and to be bound thereby in favour of CallCo as provided herein and in the Support Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Withholding Rights</U>. Each of Parent, the Company, CallCo, the Transfer Agent and any other person that
has any withholding obligation with respect to any amount paid, deemed paid or otherwise deliverable to any holder of Exchangeable Shares (any such person, an &#147;<B>Other</B> <B>Withholding Agent</B>&#148;) shall be entitled to deduct and
withhold or direct Parent, the Company, CallCo, the Transfer Agent, or any Other Withholding Agent to deduct and withhold on their behalf, from any amount or consideration paid, deemed paid or otherwise deliverable to any holder of Exchangeable
Shares such amounts as are required to be deducted or withheld with respect to such payment or deemed payment under the <I>Income Tax Act </I>(Canada) or United States Tax Laws or any provision of federal, provincial, territorial, state, local,
foreign or other Tax Law, in each case, as amended or succeeded. Parent, the Company, CallCo, the Transfer Agent, or any Other Withholding Agent may act and rely on the advice of counsel with respect to such matters. To the extent that amounts are
so deducted or withheld, such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
deducted or withheld amounts shall be treated for all purposes as having been paid to the holder of the Exchangeable Shares to whom such amounts would otherwise have been paid or deemed paid and
such deducted or withheld amounts shall be timely remitted to the appropriate Governmental Authority as required by applicable Law. To the extent that the amount so required to be deducted or withheld from any payment or deemed payment to a holder
exceeds the cash portion of the amount or consideration otherwise payable to the holder (such difference, a &#147;<B>Withholding Shortfall</B>&#148;), Parent, the Company, CallCo, the Transfer Agent, and any Other Withholding Agent are hereby
authorized to (A)&nbsp;(i) sell or otherwise dispose of, or direct Parent, the Company, CallCo, the Transfer Agent or any Other Withholding Agent to sell or otherwise dispose of, on their own account or through a broker (the
&#147;<B>Broker</B>&#148;) and on behalf of the relevant holder or (ii)&nbsp;require such holder to irrevocably direct the sale through a Broker and irrevocably direct the Broker pay the proceeds of such sale to Parent, the Company, CallCo, the
Transfer Agent or any Other Withholding Agent, as appropriate (and, in the absence of such irrevocable direction, the holder shall be deemed to have provided such irrevocable direction), such portion of the amount or consideration as is necessary to
provide sufficient funds (after deducting commissions payable to the Broker and other costs and expenses) to Parent, the Company, CallCo, the Transfer Agent or any Other Withholding Agent, as the case may be, to enable it to comply with such
deduction or withholding requirement and Parent, the Company, CallCo, the Transfer Agent or any Other Withholding Agent, as the case may be, shall notify the holder thereof and remit to such holder any unapplied balance of the net proceeds of such
sale or (B)&nbsp;require such holder to deliver a Retraction Request for a number of Exchangeable Shares that would entitle such holder to net proceeds greater than or equal to the Withholding Shortfall and withhold the Withholding Shortfall from
such net proceeds and remit to such holder any unapplied balance of the net proceeds. Each of Parent, CallCo, the Company, the Transfer Agent, the Broker or any Other Withholding Agent, as applicable, shall act in a commercially reasonable manner in
respect of any withholding obligation; however, none of Parent, the Company, CallCo, the Transfer Agent, the Broker or any Other Withholding Agent, as applicable, will be liable for any loss arising out of any sale or other disposal of such
consideration, including any loss relating to the manner or timing of such sale or other disposal, the prices at which the consideration is sold or otherwise disposed of or otherwise. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.15</B> <B>Notices</B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. Subject to applicable Laws, and except as otherwise provided herein, any notice, request or
other communication to be given to the Company or the Transfer Agent by a holder of Exchangeable Shares shall be in writing and shall be valid and effective if given by first class mail (postage prepaid) or personal delivery or delivery by courier
to the registered office of the Company or Transfer Agent, as applicable, and in each case, addressed to the attention of the Secretary of the Company. Any such notice, request or other communication, if given by mail or delivery, shall only be
deemed to have been given and received upon actual receipt thereof by the Company or the Transfer Agent, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exchangeable Share Documents</U>. Any presentation and surrender by a holder of Exchangeable Shares to the
Company or the Transfer Agent of Exchangeable Share Documents representing Exchangeable Shares in connection with the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or the retraction. redemption or
purchase of Exchangeable Shares shall be made by first class mail (postage prepaid) or by personal delivery or delivery by to such office of the Transfer Agent as may be specified by the Company, in each case, addressed to the attention of the
Secretary of the Company. Any such presentation and surrender of Exchangeable Share Documents shall only be deemed to have been made and to be effective upon actual receipt thereof by the Transfer Agent. Any such presentation and surrender of
Exchangeable Share Documents made by first class mail (postage prepaid) shall be at the sole risk of the holder mailing the same. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice to Shareholders</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to applicable Laws, any notice, request or other communication to be given to a holder of Exchangeable
Shares by or on behalf of the Company shall be in writing and shall be valid and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
effective if given by first class mail (postage prepaid) or by personal delivery or delivery by courier to the address of the holder recorded in the register of shareholders of the Company or, in
the event of the address of any such holder not being so recorded, then at the last known address of such holder. Any such notice, request or other communication, if given by mail, shall be deemed to have been given and received on the third
Business Day following the date of mailing and, if given by delivery, shall be deemed to have been given and received on the date of delivery. Accidental failure or omission to give any notice, request or other communication to one or more holders
of Exchangeable Shares shall not invalidate or otherwise alter or affect any action or proceeding to be taken by the Company pursuant thereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any interruption of mail service immediately prior to a scheduled mailing or in the period
following a mailing during which delivery normally would be expected to occur, the Company shall make reasonable efforts to disseminate any notice by other means, such as publication. Except as otherwise required or permitted by Law, if post offices
in Canada are not open for the deposit of mail, any notice which the Company or the Transfer Agent may give or cause to be given hereunder will be deemed to have been properly given and to have been received by holders of Exchangeable Shares it is
published once in the national edition of <I>The Globe and Mail </I>and in a daily newspaper of general circulation in the French language in the City of Montreal, provided that if the national edition of <I>The Globe and Mail </I>is not being
generally circulated, publication thereof will be made in the National Post or any other daily newspaper of general circulation published in the City of Toronto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provisions of these Exchangeable Share Provisions, notices, other communications and
deliveries need not be mailed if the Company determines that delivery thereof by mail may be delayed. Persons entitled to any deliveries (including Exchangeable Share Documents and cheques) which are not mailed for the foregoing reason may take
delivery thereof at the office of the Transfer Agent to which the deliveries were made, upon application to the Transfer Agent, until such time as the Company has determined that delivery by mail will no longer be delayed. The Company will provide
notice of any such determination not to mail made hereunder as soon as reasonably practicable after the making of such determination and in accordance with this Section&nbsp;26.15(c). Such deliveries in such circumstances will constitute delivery to
the persons entitled thereto. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.16</B> <B>Disclosure of Interests in Exchangeable Shares</B>. The Company shall be entitled to
require any holder of an Exchangeable Share or any person whom the Company knows or has reasonable cause to believe holds any interest whatsoever in an Exchangeable Share to (a)&nbsp;confirm that fact, or (b)&nbsp;give such details as to whom has an
interest in such Exchangeable Share, in each case as would be required (if the Exchangeable Shares were a class of &#147;equity securities&#148; of the Company) under section 5.2 of National Instrument <FONT STYLE="white-space:nowrap">62-104</FONT>
<I>Take-Over Bids and Issuer Bids </I>or as would be required under the constating documents of Parent or any Laws or regulations, or pursuant to the rules or regulations of any regulatory agency, if and only to the extent that the Exchangeable
Shares were Delaware Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.17</B> <B>Fractional Shares</B>. A holder of an Exchangeable Share shall not be entitled to any fraction of a
share of Delaware Common Stock upon the exchange, redemption or purchase of such holder&#146;s Exchangeable Share pursuant to Sections 26.5, 26.6 and 26.7 or otherwise, and no Exchangeable Share Certificates representing any such fractional interest
shall be issued and such holder otherwise entitled to a fractional interest shall be entitled to receive for such fractional interest from the Company, Parent or CallCo, as the case may be, a cash payment equal to such fractional interest multiplied
by the Current Market Price as part of the Exchangeable Share Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.18</B> <B>Liquidation Call Right</B>. CallCo shall have the following
rights and obligations in respect of the Exchangeable Shares: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CallCo shall have the overriding right (the &#147;<B>Liquidation Call Right</B>&#148;), in the event of and
notwithstanding the proposed liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs,
pursuant to these Exchangeable Share Provisions, and subject to the purchase and sale contemplated by the Automatic Exchange Right, to purchase from all but not less than all of the holders of the Exchangeable Shares (other than any holder of
Exchangeable Shares which is Parent or any of its affiliates) on the Liquidation Date all but not less than all of the Exchangeable Shares held by each such holder upon payment by CallCo to each such holder of the Exchangeable Share Price (payable
in the form of the Exchangeable Share Consideration) applicable on the last Business Day prior to the Liquidation Date (the &#147;<B>Liquidation Call Purchase Price</B>&#148;) in accordance with Section&nbsp;26.18(c). In the event of the exercise of
the Liquidation Call Right by CallCo each such holder of Exchangeable Shares (other than Parent and its affiliates) shall be obligated to sell all of the Exchangeable Shares held by the holder to CallCo on the Liquidation Date upon payment by CallCo
to such holder of the Liquidation Call Purchase Price (payable in the form of Exchangeable Share Consideration) for each such share, and the Company shall have no obligation to pay any Liquidation Amount to the holders of such shares so purchased.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To exercise the Liquidation Call Right, CallCo must notify the Transfer Agent, as agent for the holders of the
Exchangeable Shares, and the Company of its intention to exercise such right (i)&nbsp;in the case of a voluntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other voluntary distribution of the
assets of the Company among its shareholders for the purpose of winding up its affairs, at least fifteen (15) Business Days before the Liquidation Date, or (ii)&nbsp;in the case of an involuntary liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company or any other involuntary distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, at least five (5)&nbsp;Business Days before the
Liquidation Date. The Transfer Agent will notify the holders of the Exchangeable Shares as to whether or not CallCo has exercised the Liquidation Call Right forthwith after the expiry of the period during which CallCo may exercise the Liquidation
Call Right. If CallCo exercises the Liquidation Call Right, then on the Liquidation Date, CallCo will purchase and the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its affiliates) will
sell, all of the Exchangeable Shares held by such holders on such date for a price per share equal to the Liquidation Call Purchase Price (payable in the form of Exchangeable Share Consideration). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;26.18(d), for the purposes of completing the purchase and sale of the Exchangeable
Shares pursuant to the exercise of the Liquidation Call Right, CallCo shall deposit or cause to be deposited with the Transfer Agent, on or before the Liquidation Date, the Exchangeable Share Consideration representing the aggregate Liquidation Call
Purchase Price for all holders of the Exchangeable Shares (other than Parent and its affiliates). Provided that such Exchangeable Share Consideration has been so deposited with the Transfer Agent, the holders of the Exchangeable Shares (other than
Parent and its affiliates) shall cease to be holders of the Exchangeable Shares on and after the Liquidation Date and, from and after such date, shall not be entitled to exercise any of the rights of holders in respect thereof (including, without
limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive their proportionate part of the aggregate Liquidation Call Purchase Price, without interest, upon presentation and surrender by the holder of
Exchangeable Share Documents representing the Exchangeable Shares held by such holder and the holder shall on and after the Liquidation Date be considered and deemed for all purposes to be the holder of the Delaware Common Stock which such holder is
entitled to receive. Upon surrender to the Transfer Agent of Exchangeable Share Documents representing Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable Shares under the
BCBCA and these Articles, as applicable, and such additional documents, instruments and payments as the Transfer Agent may reasonably require, the holder shall be entitled to receive, in exchange therefor, and the Transfer Agent on behalf of CallCo,
shall deliver to such holder the Exchangeable Share Consideration such holder is entitled to receive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent and the Company in accordance with Section&nbsp;26.18(b) of its
intention to exercise the Liquidation Call Right in the manner and timing described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that CallCo exercise
the Liquidation Call Right in respect of the shares covered by the notice, in which case, CallCo shall be deemed of have exercised the Liquidation Call Right and will be bound thereby. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.19</B> <B>Redemption Call Right</B>. CallCo shall have the following rights and obligations in respect of the Exchangeable Shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the proposed redemption of the Exchangeable Shares by the Company pursuant to these
Exchangeable Share Provisions, CallCo shall have the overriding right (the &#147;<B>Redemption Call Right</B>&#148;) to purchase from all but not less than all of the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares
which is Parent or any of its affiliates) on the Redemption Date all but not less than all of the Exchangeable Shares held by each such holder upon payment by CallCo to each such holder of the Exchangeable Share Price (payable in the form of the
Exchangeable Share Consideration) applicable on the last Business Day prior to the Redemption Date (the &#147;<B>Redemption Call Purchase Price</B>&#148;) in accordance with Section&nbsp;26.19(c). In the event of the exercise of the Redemption Call
Right by CallCo, each such holder of Exchangeable Shares (other than Parent and its affiliates) shall be obligated to sell all of the Exchangeable Shares held by the holder to CallCo on the Redemption Date upon payment by CallCo to such holder of
the Redemption Call Purchase Price (payable in the form of Exchangeable Share Consideration) for each such share, and the Company shall have no obligation to redeem, or to pay the redemption price otherwise payable by the Company in respect of the
Exchangeable Shares so purchased. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To exercise the Redemption Call Right, CallCo must notify the Transfer Agent, as agent for the holders of the
Exchangeable Shares, and the Company of its intention to exercise such right (i)&nbsp;in the case of a redemption occurring in connection with a Parent Control Transaction, on or before the Redemption Date, and (ii)&nbsp;in any other case, at least
fifteen (15)&nbsp;Business Days before the Redemption Date. The Transfer Agent will notify the holders of the Exchangeable Shares as to whether or not CallCo has exercised the Redemption Call Right forthwith after the expiry of the period during
which CallCo may exercise the Redemption Call Right. If CallCo exercises the Redemption Call Right, CallCo will purchase and the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its
affiliates) will sell, on the Redemption Date, all of the Exchangeable Shares held by such holders on such date for a price per share equal to the Redemption Call Purchase Price (payable in the form of Exchangeable Share Consideration).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;26.19(d), for the purposes of completing the purchase and sale of the Exchangeable
Shares pursuant to the exercise of the Redemption Call Right, CallCo shall deposit or cause to be deposited with the Transfer Agent, on or before the Redemption Date, the Exchangeable Share Consideration representing the aggregate Redemption Call
Purchase Price for all holders of the Exchangeable Shares (other than Parent and its affiliates). Provided that such Exchangeable Share Consideration has been so deposited with the Transfer Agent, the holders of the Exchangeable Shares (other than
Parent and its affiliates) shall cease to be holders of the Exchangeable Shares on and after the Redemption Date and, from and after such date, shall not be entitled to exercise any of the rights of holders in respect thereof (including, without
limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive their proportionate part of the aggregate Redemption Call Purchase Price, without interest, upon presentation and surrender by the holder of
Exchangeable Share Documents representing the Exchangeable Shares held by such holder and the holder shall on and after the Redemption Date be considered and deemed for all purposes to be the holder of the Delaware Common Stock which such holder is
entitled to receive. Upon surrender to the Transfer Agent of Exchangeable Share Documents representing the Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable Shares under
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the BCBCA and these Articles, as applicable, and such additional documents, instruments and payments as the Transfer Agent may reasonably require, the holder shall be entitled to receive, in
exchange therefor, and the Transfer Agent on behalf of CallCo shall deliver to such holder the Exchangeable Share Consideration such holder is entitled to receive. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent and the Company in accordance with Section&nbsp;26.19(b) of its
intention to exercise the Redemption Call Right in the manner and timing described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that CallCo exercise
the Redemption Call Right in respect of the shares covered by the notice, in which case, CallCo shall be deemed of have exercised the Redemption Call Right and will be bound thereby. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.20</B> <B>Change of Law Call Right</B>. CallCo shall have the following rights and obligations in respect of the Exchangeable Shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CallCo shall have the overriding right (the &#147;<B>Change of Law Call Right</B>&#148;), in the event of a
Change of Law, to purchase from all but not less than all of the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its affiliates) on the Change of Law Call Date all but not less than all of
the Exchangeable Shares held by each such holder upon payment by CallCo to each such holder of the Exchangeable Share Price (payable in the form of the Exchangeable Share Consideration) applicable on the last Business Day prior to the Change of Law
Call Date (the &#147;<B>Change of Law Call Purchase Price</B>&#148;) in accordance with Section&nbsp;26.20(b). In the event of the exercise of the Change of Law Call Right by CallCo each such holder of Exchangeable Shares (other than Parent and its
affiliates) shall be obligated to sell all of the Exchangeable Shares held by the holder to CallCo on the Change of Law Call Date upon payment by CallCo to such holder of the Change of Law Call Purchase Price (payable in the form of Exchangeable
Share Consideration) for each such share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To exercise the Change of Law Call Right, CallCo must notify the Transfer Agent, as agent for the holders of
the Exchangeable Shares, and the Company of its intention to exercise such right at least fifteen (15)&nbsp;Business Days before the date (the &#147;<B>Change of Law Call Date</B>&#148;) on which CallCo shall acquire the Exchangeable Shares pursuant
to the exercise of the Change of Law Call Right. The Transfer Agent will notify the holders of the Exchangeable Shares as to CallCo exercising the Change of Law Call Right forthwith after receiving notice of such exercise from CallCo. If CallCo
exercises the Change of Law Call Right, then on the Change if Law Call Date, CallCo will purchase and the holders of the Exchangeable Shares (other than any holder of Exchangeable Shares which is Parent or any of its affiliates) will sell, all of
the Exchangeable Shares held by such holders on such date for a price per share equal to the Change of Law Call Purchase Price (payable in the form of Exchangeable Share Consideration). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;26.20(d), for the purposes of completing the purchase and sale of the Exchangeable
Shares pursuant to the exercise of the Change of Law Call Right, CallCo shall deposit or cause to be deposited with the Transfer Agent, on or before the Change of Law Call Date, the Exchangeable Share Consideration representing the aggregate Change
of Law Call Purchase Price for all holders of Exchangeable Shares (other than Parent and its affiliates). Provided that such Exchangeable Share Consideration has been so deposited with the Transfer Agent, the holders of the Exchangeable Shares
(other than Parent and its affiliates) shall cease to be holders of the Exchangeable Shares on and after the Change of Law Call Date and, from and after such date, shall not be entitled to exercise any of the rights of holders in respect thereof
(including, without limitation, any rights under the Voting and Exchange Trust Agreement) other than the right to receive their proportionate part of the aggregate Change of Law Call Purchase Price, without interest, upon presentation and surrender
by the holder of Exchangeable Share Documents representing the Exchangeable Shares held by such holder and the holder shall on and after the Change of Law Call Date be considered and deemed for all purposes to be the holder of the Delaware Common
Stock which such holder is entitled to receive. Upon surrender to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Transfer Agent of a Exchangeable Share Documents representing Exchangeable Shares, together with such other documents and instruments as may be required to effect a transfer of Exchangeable
Shares under the BCBCA and these Articles, as applicable, and such additional documents, instruments and payments as the Transfer Agent may reasonably require, the holder shall be entitled to receive, in exchange therefor, and the Transfer Agent on
behalf of CallCo shall deliver to such holder the Exchangeable Share Consideration such holder is entitled to receive. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If CallCo does not notify the Transfer Agent and the Company in accordance with Section&nbsp;26.20(b) of its
intention to exercise the Change of Law Call Right in the manner and timing described above, each holder of Exchangeable Shares will, at the holder&#146;s discretion, be entitled to demand (by way of notice given to the Company) that CallCo exercise
the Change of Law Call Right in respect of the shares covered by the notice, in which case, CallCo shall be deemed of have exercised the Change of Law Call Right and will be bound thereby. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is the intention of the Company, CallCo and Parent that the Exchangeable Shares are treated as shares of
Parent for U.S. federal income tax purposes and the provisions of these Articles shall be interpreted in a manner consistent with the foregoing. The Company shall not take any position for U.S. federal income tax purposes that is inconsistent with
the foregoing except to the extent otherwise required by a change in law (it being understood that this Section&nbsp;26.20(e)shall not prevent the Company from taking any action that is explicitly contemplated in these Articles).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RETRACTION REQUEST </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[TO
BE PRINTED ON EXCHANGEABLE SHARE DOCUMENTS] </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks ExchangeCo Ltd. (the &#147;<B>Company</B>&#148;) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left">COPY&nbsp;TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zymeworks CallCo ULC (&#147;<B>CallCo</B>&#148;) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice is given pursuant to Section&nbsp;26.6 of the special rights or restrictions (the &#147;<B>Exchangeable Share Provisions</B>&#148;) attaching to the
Exchangeable Shares of the Company represented by this Exchangeable Share Document and all capitalized words and expressions used in this Retraction Request that are defined in the Exchangeable Share Provisions have the meanings ascribed to such
words and expressions in such Exchangeable Share Provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby notifies the Company that, subject to the Retraction Call Right
referred to below, the undersigned desires to have the Company redeem in accordance with Section&nbsp;26.6 of the Exchangeable Share Provisions: (select one) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all share(s) represented by this Exchangeable Share Document </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
share(s) represented by this Exchangeable Share Document </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby notifies the Company that the Retraction Date shall be
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTE: The Retraction Date must be a Business Day and must not be less than
10 Business Days nor more than 15 Business Days after the date upon which this Retraction Request is received by the Company. If no such Business Day is specified above, the Retraction Date shall be deemed to be the 15th Business Day after the date
on which this Retraction Request is received by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges the overriding Retraction Call Right of CallCo to purchase all
but not less than all the Retracted Shares from the undersigned and that this Retraction Request is and shall be deemed to be a revocable offer by the undersigned to sell the Retracted Shares to CallCo in accordance with the Retraction Call Right on
the Retraction Date for the Retraction Call Right Purchase Price and on the other terms and conditions set out in Section&nbsp;26.6(b) of the Exchangeable Share Provisions. If CallCo does not exercise the Retraction Call Right, the Company will
cause the undersigned to be notified of such fact as soon as possible. This Retraction Request, and this offer to sell the Retracted Shares to CallCo, may be revoked and withdrawn by the undersigned only by notice in writing given to the Transfer
Agent at any time before the close of business on the Business Day immediately preceding the Retraction Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges that if, as a
result of solvency provisions of applicable Law, the Company is unable to redeem all Retracted Shares, and provided that CallCo has not exercised the Retraction Call Right with respect to the Retracted Shares, and that the undersigned has not
exercised its right to demand CallCo to exercise its Retraction Call Right under Section&nbsp;26.6(b)(iv) of the Company&#146;s Articles, then the Retracted Shares will be automatically exchanged pursuant to the Voting and Exchange Trust Agreement
so as to require Parent to purchase the unredeemed Retracted Shares (subject to Parent&#146;s option of delegating such obligation to CallCo). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
undersigned hereby represents and warrants to CallCo and the Company that the undersigned: (select one) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a resident of Canada for purposes of the <I>Income Tax Act </I>(Canada). THE UNDERSIGNED ACKNOWLEDGES THAT IN THE ABSENCE OF AN INDICATION THAT THE
UNDERSIGNED IS A RESIDENT OF CANADA, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
WITHHOLDING ON ACCOUNT OF CANADIAN TAX MAY BE MADE FROM AMOUNTS PAYABLE TO THE UNDERSIGNED ON THE REDEMPTION OR PURCHASE OF THE RETRACTED SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants to CallCo and the Company that the undersigned has good title to, and owns, the share(s) represented by this
Exchangeable Share Document to be acquired by CallCo or the Company, as the case may be, free and clear of all liens, claims and encumbrances. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Date)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Signature of Shareholder)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Guarantee of Signature)</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please check box if the securities and any cheque(s) resulting from the retraction or purchase of the Retracted
Shares are to be held for <FONT STYLE="white-space:nowrap">pick-up</FONT> by the shareholder from the Transfer Agent, failing which such Exchangeable Share Document and cheque(s) will be mailed to the last address of the shareholder as it appears on
the register. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Note</U>: This panel must be completed and this Retraction Request, together with the Exchangeable Share Documents
and such additional documents and payments (including, without limitation, any applicable stamp taxes) as the Transfer Agent or the Company may require, must be deposited with the Transfer Agent. The securities and any cheque(s) resulting from the
retraction or purchase of the Retracted Shares will be issued and registered in, and made payable to, respectively, the name of the shareholder as it appears on the register of the Company and the securities (or evidence of the electronic
registration thereof) and any cheque(s) resulting from such retraction or purchase will be delivered to such shareholder as indicated above, unless the form appearing immediately below is duly completed. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Person in Whose Name Securities or Cheque(s) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Are to be Registered, Issued or Delivered (please print):
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Street Address or P.O. Box:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature of Shareholder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">City, Province and Postal Code:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature Guaranteed by:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Note</U>: If this Retraction Request is for less than all of the shares represented by this Exchangeable Share Document,
an Exchangeable Share Document representing the remaining share(s) of the Company represented by this Exchangeable Share Document will be issued and registered in the name of the shareholder as it appears on the register of the Company, unless the
Share Transfer Power on the Exchangeable Share Document is duly completed in respect of such share(s). </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_26"></A>APPENDIX C: DIVISION 2 OF PART 8 OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE </B><B><I>BUSINES CORPORATIONS ACT </I></B><B>(BRITISH COLUMBIA) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definitions and Application </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>237</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) In this Division: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>dissenter</B>&#148; means a shareholder who, being entitled to do so, sends written notice of dissent when and as required by section
242; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>notice shares</B>&#148; means, in relation to a notice of dissent, the shares in respect of which dissent is being exercised
under the notice of dissent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>payout value</B>&#148; means, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(a) in the case of a dissent in respect of a resolution, the fair value that the notice shares had immediately before the passing of the
resolution, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(b) in the case of a dissent in respect of an arrangement approved by a court order made under section 291 (2) (c) that
permits dissent, the fair value that the notice shares had immediately before the passing of the resolution adopting the arrangement, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(c)
in the case of a dissent in respect of a matter approved or authorized by any other court order that permits dissent, the fair value that the notice shares had at the time specified by the court order, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(d) in the case of a dissent in respect of a community contribution company, the value of the notice shares set out in the regulations, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">excluding any appreciation or depreciation in anticipation of the corporate action approved or authorized by the resolution or court order
unless exclusion would be inequitable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) This Division applies to any right of dissent exercisable by a shareholder except to the extent
that </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the court orders otherwise, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a right of dissent authorized by a resolution referred to in section 238 (1) (g), the court
orders otherwise or the resolution provides otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right to Dissent </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>238</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) A shareholder of a company, whether or not the shareholder&#146;s shares carry the right to vote, is
entitled to dissent as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) under section 260, in respect of a resolution to alter the articles
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) to alter restrictions on the powers of the company or on the business the company is permitted to carry on, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) without limiting subparagraph (i), in the case of a community contribution company, to alter any of the company&#146;s community purposes
within the meaning of section 51.91, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) without limiting subparagraph (i), in the case of a benefit company, to alter the
company&#146;s benefit provision; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) under section 272, in respect of a resolution to adopt an amalgamation agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) under section 287, in respect of a resolution to approve an amalgamation under Division 4 of Part 9; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(d) in respect of a resolution to approve an arrangement, the terms of which arrangement permit dissent; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(e) under section 301 (5), in respect of a resolution to authorize or ratify the sale, lease
or other disposition of all or substantially all of the company&#146;s undertaking; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(f) under section 309, in respect of a resolution to
authorize the continuation of the company into a jurisdiction other than British Columbia; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(g) in respect of any other resolution, if
dissent is authorized by the resolution; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(h) in respect of any court order that permits dissent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1.1) A shareholder of a company, whether or not the shareholder&#146;s shares carry the right to vote, is entitled to dissent under section
51.995 (5) in respect of a resolution to alter its notice of articles to include or to delete the benefit statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) A shareholder
wishing to dissent must </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) prepare a separate notice of dissent under section 242 for </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the shareholder, if the shareholder is dissenting on the shareholder&#146;s own behalf, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) each other person who beneficially owns shares registered in the shareholder&#146;s name and on whose behalf the shareholder is
dissenting, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) identify in each notice of dissent, in accordance with section 242 (4), the person on whose behalf dissent is being
exercised in that notice of dissent, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) dissent with respect to all of the shares, registered in the shareholder&#146;s name, of
which the person identified under paragraph (b)&nbsp;of this subsection is the beneficial owner. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Without limiting subsection (2), a
person who wishes to have dissent exercised with respect to shares of which the person is the beneficial owner must </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) dissent with
respect to all of the shares, if any, of which the person is both the registered owner and the beneficial owner, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) cause each
shareholder who is a registered owner of any other shares of which the person is the beneficial owner to dissent with respect to all of those shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Waiver of Right to Dissent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>239</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) A shareholder may not waive generally a right to dissent but may, in writing, waive the right to dissent
with respect to a particular corporate action. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) A shareholder wishing to waive a right of dissent with respect to a
particular corporate action must </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) provide to the company a separate waiver for </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the shareholder, if the shareholder is providing a waiver on the shareholder&#146;s own behalf, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) each other person who beneficially owns shares registered in the shareholder&#146;s name and on whose behalf the shareholder is providing
a waiver, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) identify in each waiver the person on whose behalf the waiver is made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) If a shareholder waives a right of dissent with respect to a particular corporate action and indicates in the waiver that the right to
dissent is being waived on the shareholder&#146;s own behalf, the shareholder&#146;s right to dissent with respect to the particular corporate action terminates in respect of the shares of which the shareholder is both the registered owner and the
beneficial owner, and this Division ceases to apply to </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) the shareholder in respect of the shares of which the shareholder is both the
registered owner and the beneficial owner, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) any other shareholders, who are registered owners of shares beneficially owned by the
first mentioned shareholder, in respect of the shares that are beneficially owned by the first mentioned shareholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) If a shareholder
waives a right of dissent with respect to a particular corporate action and indicates in the waiver that the right to dissent is being waived on behalf of a specified person who beneficially owns shares registered in the name of the shareholder, the
right of shareholders who are registered owners of shares beneficially owned by that specified person to dissent on behalf of that specified person with respect to the particular corporate action terminates and this Division ceases to apply to those
shareholders in respect of the shares that are beneficially owned by that specified person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice of Resolution </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>240</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) If a resolution in respect of which a shareholder is entitled to dissent is to be considered at a meeting
of shareholders, the company must, at least the prescribed number of days before the date of the proposed meeting, send to each of its shareholders, whether or not their shares carry the right to vote, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) a copy of the proposed resolution, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) a notice of the meeting that specifies the date of the meeting, and contains a statement advising of the right to send a notice of dissent.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) If a resolution in respect of which a shareholder is entitled to dissent is to be passed as a consent resolution of shareholders or as
a resolution of directors and the earliest date on which that resolution can be passed is specified in the resolution or in the statement referred to in paragraph (b), the company may, at least 21 days before that specified date, send to each of its
shareholders, whether or not their shares carry the right to vote, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) a copy of the proposed resolution, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) a statement advising of the right to send a notice of dissent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) If a resolution in respect of which a shareholder is entitled to dissent was or is to be passed as a resolution of shareholders without the
company complying with subsection (1)&nbsp;or (2), or was or is to be passed as a directors&#146; resolution without the company complying with subsection (2), the company must, before or within 14 days after the passing of the resolution, send to
each of its shareholders who has not, on behalf of every person who beneficially owns shares registered in the name of the shareholder, consented to the resolution or voted in favour of the resolution, whether or not their shares carry the right to
vote, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) a copy of the resolution, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) a statement advising of the right to send a notice of dissent, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) if the resolution has passed, notification of that fact and the date on which it was passed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) Nothing in subsection (1), (2) or (3)&nbsp;gives a shareholder a right to vote in a meeting at which, or on a resolution on which, the
shareholder would not otherwise be entitled to vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice of Court Orders </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>241</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If a court order provides for a right of dissent, the company must, not later than 14 days after the
date on which the company receives a copy of the entered order, send to each shareholder who is entitled to exercise that right of dissent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) a copy of the entered order, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) a statement advising of the right to send a notice of dissent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice of Dissent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>242</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>(1) A shareholder intending to dissent in respect of a resolution referred to in section 238 (1) (a),
(b), (c), (d), (e) or (f)&nbsp;or (1.1) must, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) if the company has complied with section 240 (1) or (2), send written
notice of dissent to the company at least 2 days before the date on which the resolution is to be passed or can be passed, as the case may be, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if the company has complied with section 240 (3), send written notice of dissent to the company not more than 14 days after receiving the
records referred to in that section, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) if the company has not complied with section 240 (1), (2) or (3), send written notice of
dissent to the company not more than 14 days after the later of </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the date on which the shareholder learns that the resolution was
passed, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) the date on which the shareholder learns that the shareholder is entitled to dissent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) A shareholder intending to dissent in respect of a resolution referred to in section 238 (1) (g) must send written notice of dissent to the
company </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) on or before the date specified by the resolution or in the statement referred to in section 240 (2) (b) or (3) (b) as the
last date by which notice of dissent must be sent, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if the resolution or statement does not specify a date, in accordance with
subsection (1)&nbsp;of this section. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) A shareholder intending to dissent under section 238 (1) (h) in respect of a court order that
permits dissent must send written notice of dissent to the company </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) within the number of days, specified by the court order, after the
shareholder receives the records referred to in section 241, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if the court order does not specify the number of days referred to in
paragraph (a)&nbsp;of this subsection, within 14 days after the shareholder receives the records referred to in section 241. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) A notice
of dissent sent under this section must set out the number, and the class and series, if applicable, of the notice shares, and must set out whichever of the following is applicable: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) if the notice shares constitute all of the shares of which the shareholder is both the registered owner and beneficial owner and the
shareholder owns no other shares of the company as beneficial owner, a statement to that effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if the notice shares constitute all
of the shares of which the shareholder is both the registered owner and beneficial owner but the shareholder owns other shares of the company as beneficial owner, a statement to that effect and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the names of the registered owners of those other shares, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) the number, and the class and series, if applicable, of those other shares that are held by each of those registered owners, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a statement that notices of dissent are being, or have been, sent in respect of all of those other shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) if dissent is being exercised by the shareholder on behalf of a beneficial owner who is not the dissenting shareholder, a statement to that
effect and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the name and address of the beneficial owner, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a statement that the shareholder is dissenting in relation to all of the shares beneficially owned by the beneficial owner that are
registered in the shareholder&#146;s name. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5) The right of a shareholder to dissent on behalf of a beneficial owner of shares,
including the shareholder, terminates and this Division ceases to apply to the shareholder in respect of that beneficial owner if subsections (1)&nbsp;to (4) of this section, as those subsections pertain to that beneficial owner, are not complied
with. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice of Intention to Proceed </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>243</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) A company that receives a notice of dissent under section 242 from a dissenter must, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) if the company intends to act on the authority of the resolution or court order in respect of which the notice of dissent was sent, send a
notice to the dissenter promptly after the later of </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the date on which the company forms the intention to proceed, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) the date on which the notice of dissent was received, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if the company has acted on the authority of that resolution or court order, promptly send a notice to the dissenter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) A notice sent under subsection (1) (a) or (b)&nbsp;of this section must </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) be dated not earlier than the date on which the notice is sent, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) state that the company intends to act, or has acted, as the case may be, on the authority of the resolution or court order, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) advise the dissenter of the manner in which dissent is to be completed under section 244. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Completion of Dissent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>244</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) A dissenter who receives a notice under section 243 must, if the dissenter wishes to proceed with the
dissent, send to the company or its transfer agent for the notice shares, within one month after the date of the notice, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) a written statement that the dissenter requires the company to purchase all of the notice shares, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) the certificates, if any, representing the notice shares, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) if section 242 (4) (c) applies, a written statement that complies with subsection (2)&nbsp;of this section. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) The written statement referred to in subsection (1) (c) must </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) be signed by the beneficial owner on whose behalf dissent is being exercised, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) set out whether or not the beneficial owner is the beneficial owner of other shares of the company and, if so, set out </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the names of the registered owners of those other shares, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) the number, and the class and series, if applicable, of those other shares that are held by each of those registered owners, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) that dissent is being exercised in respect of all of those other shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) After the dissenter has complied with subsection (1), </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) the dissenter is deemed to have sold to the company the notice shares, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) the company is deemed to have purchased those shares, and must comply with section 245, whether or not it is authorized to do so by, and
despite any restriction in, its memorandum or articles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) Unless the court orders otherwise, if the dissenter fails to comply with
subsection (1)&nbsp;of this section in relation to notice shares, the right of the dissenter to dissent with respect to those notice shares terminates and this Division, other than section 247, ceases to apply to the dissenter with respect to those
notice shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5) Unless the court orders otherwise, if a person on whose behalf dissent is being
exercised in relation to a particular corporate action fails to ensure that every shareholder who is a registered owner of any of the shares beneficially owned by that person complies with subsection (1)&nbsp;of this section, the right of
shareholders who are registered owners of shares beneficially owned by that person to dissent on behalf of that person with respect to that corporate action terminates and this Division, other than section 247, ceases to apply to those shareholders
in respect of the shares that are beneficially owned by that person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(6) A dissenter who has complied with subsection (1)&nbsp;of this
section may not vote, or exercise or assert any rights of a shareholder, in respect of the notice shares, other than under this Division. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment for
Notice Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>245</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) A company and a dissenter who has complied with section 244 (1) may agree on the amount of the payout value
of the notice shares and, in that event, the company must </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) promptly pay that amount to the dissenter, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if subsection (5)&nbsp;of this section applies, promptly send a notice to the dissenter that the company is unable lawfully to pay
dissenters for their shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) A dissenter who has not entered into an agreement with the company under subsection (1)&nbsp;or the
company may apply to the court and the court may </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) determine the payout value of the notice shares of those dissenters who have not
entered into an agreement with the company under subsection (1), or order that the payout value of those notice shares be established by arbitration or by reference to the registrar, or a referee, of the court, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) join in the application each dissenter, other than a dissenter who has entered into an agreement with the company under subsection (1), who
has complied with section 244 (1), and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) make consequential orders and give directions it considers appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Promptly after a determination of the payout value for notice shares has been made under subsection (2) (a) of this section, the company
must </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) pay to each dissenter who has complied with section 244 (1) in relation to those notice shares, other than a dissenter who has
entered into an agreement with the company under subsection (1)&nbsp;of this section, the payout value applicable to that dissenter&#146;s notice shares, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if subsection (5)&nbsp;applies, promptly send a notice to the dissenter that the company is unable lawfully to pay dissenters for their
shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) If a dissenter receives a notice under subsection (1) (b) or (3) (b), </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) the dissenter may, within 30 days after receipt, withdraw the dissenter&#146;s notice of dissent, in which case the company is deemed to
consent to the withdrawal and this Division, other than section 247, ceases to apply to the dissenter with respect to the notice shares, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) if the dissenter does not withdraw the notice of dissent in accordance with paragraph (a)&nbsp;of this subsection, the dissenter retains a
status as a claimant against the company, to be paid as soon as the company is lawfully able to do so or, in a liquidation, to be ranked subordinate to the rights of creditors of the company but in priority to its shareholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5) A company must not make a payment to a dissenter under this section if there are reasonable grounds for believing that </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) the company is insolvent, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) the payment would render the company insolvent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Loss of Right to Dissent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>246</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The right of a dissenter to dissent with respect to notice shares terminates and this Division, other than
section 247, ceases to apply to the dissenter with respect to those notice shares, if, before payment is made to the dissenter of the full amount of money to which the dissenter is entitled under section 245 in relation to those notice shares, any
of the following events occur: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) the corporate action approved or authorized, or to be approved or authorized, by the
resolution or court order in respect of which the notice of dissent was sent is abandoned; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) the resolution in respect of which the
notice of dissent was sent does not pass; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) the resolution in respect of which the notice of dissent was sent is revoked before the
corporate action approved or authorized by that resolution is taken; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(d) the notice of dissent was sent in respect of a resolution
adopting an amalgamation agreement and the amalgamation is abandoned or, by the terms of the agreement, will not proceed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(e) the
arrangement in respect of which the notice of dissent was sent is abandoned or by its terms will not proceed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(f) a court permanently
enjoins or sets aside the corporate action approved or authorized by the resolution or court order in respect of which the notice of dissent was sent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(g) with respect to the notice shares, the dissenter consents to, or votes in favour of, the resolution in respect of which the notice of
dissent was sent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(h) the notice of dissent is withdrawn with the written consent of the company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) the court determines that the dissenter is not entitled to dissent under this Division or that the dissenter is not entitled to dissent
with respect to the notice shares under this Division. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders Entitled to Return of Shares and Rights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>247</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, under section 244 (4) or (5), 245 (4) (a) or 246, this Division, other than this section, ceases to apply
to a dissenter with respect to notice shares, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) the company must return to the dissenter each of the applicable share
certificates, if any, sent under section 244 (1) (b) or, if those share certificates are unavailable, replacements for those share certificates, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) the dissenter regains any ability lost under section 244 (6) to vote, or exercise or assert any rights of a shareholder, in respect of the
notice shares, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) the dissenter must return any money that the company paid to the dissenter in respect of the notice shares under,
or in purported compliance with, this Division. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_27"></A>Appendix D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX D: INTERIM ORDER </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>&#9679;<B></B><B>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_28"></A>Appendix E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX E: NOTICE OF HEARING OF PETITION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>&#9679;<B></B><B>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_29"></A>APPENDIX F: AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>a Delaware corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zymeworks Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;<B>Company</B>&#148;), does hereby
certify as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;The Company was originally incorporated under the name of Zymeworks Delaware Inc., and the
original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on June&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;This Amended and Restated Certificate of Incorporation was duly adopted in accordance with Sections&nbsp;242 and 245
of the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;) by the Board of Directors of the Company (the &#147;<B>Board of Directors</B>&#148;) and has been duly approved by the written consent of the stockholder of the
Company in accordance with Section&nbsp;228 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;The text of the Amended and Restated Certificate of
Incorporation is hereby amended and restated in its entirety to read as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Company is Zymeworks Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address
of the Company&#146;s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nature
of the business or purposes to be conducted or promoted by the Company is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;This Company is authorized to issue two classes of stock, to be designated, respectively, Common Stock
and Preferred Stock. The total number of shares of stock that the Company shall have authority to issue is 1,000,000,000 shares, of which 900,000,000 shares are Common Stock, $0.00001 par value per share, and 100,000,000 shares are Preferred Stock,
$0.00001 par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Each share of Common Stock outstanding as of the applicable record
date shall entitle the holder thereof to one (1)&nbsp;vote on any matter submitted to a vote at a meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or
resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any series of
Preferred Stock, including, without limitation, authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price
or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing. The Board of Directors is further authorized to increase (but not above the total
number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series of Preferred Stock, subject to the powers, preferences and rights, and the
qualifications, limitations and restrictions thereof stated in this Amended and Restated Certificate of Incorporation or the resolution of the Board of Directors originally fixing the number of shares of such series. Except as may be otherwise
specified by the terms of any series of Preferred Stock, if the number of shares of any series of Preferred Stock is so decreased, then the Company shall take all such steps as are necessary to cause the shares constituting such decrease to resume
the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise required by law or provided in this Amended and Restated Certificate of
Incorporation, holders of Common Stock shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that
relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law
or pursuant to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The number of authorized shares of Preferred Stock or Common Stock may be increased or decreased (but
not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all the then-outstanding shares of capital stock of the Company entitled to vote thereon, without a separate vote of
the holders of the class or classes the number of authorized shares of which are being increased or decreased, unless a vote of any holders of one or more series of Preferred Stock is required pursuant to the terms of any certificate of designation
relating to any series of Preferred Stock, irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of holders of Preferred Stock, the number of directors that constitutes the
entire Board of Directors of the Company shall be fixed only by resolution of the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board. Notwithstanding the foregoing, the size of the Board of Directors may not
be increased by more than 1/3 of the number of directors in office at the conclusion of the most recent annual meeting of stockholders prior to the next annual meeting of stockholders, and, prior to the Company&#146;s first annual meeting of
stockholders, the size of the Board of Directors may not be increased by more than three. For the purposes of this Amended and Restated Certificate of Incorporation, the term &#147;<B>Whole Board</B>&#148; shall mean the total number of authorized
directorships whether or not there exist any vacancies or other unfilled seats in previously authorized directorships. At each annual meeting of stockholders, directors of the Company shall be elected to hold office until the expiration of the term
for which they are elected and until their successors have been duly elected and qualified or until their earlier resignation or removal; except that if any such meeting shall not be so held, such election shall take place at a stockholders&#146;
meeting called and held in accordance with the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;From and after the effectiveness of this
Amended and Restated Certificate of Incorporation until the End Date, the directors of the Company (other than any who may be elected by holders of Preferred Stock under specified circumstances) shall be divided into three classes as nearly equal in
size as is practicable, hereby designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Directors already in office shall be assigned to each class at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time such classification becomes effective in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following the date hereof,
the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following the date hereof, the term of office of the Class&nbsp;II
directors shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following the date hereof, the term of office of the Class&nbsp;III directors shall expire and
Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such
annual meeting. If the number of directors is changed, any newly created directorships or decrease in directorships shall be so apportioned hereafter among the classes as to make all classes as nearly equal in number as is practicable, <I>provided
that</I> no decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. Commencing with the first annual meeting of stockholders held on or after the End Date, all directors shall be
elected annually for <FONT STYLE="white-space:nowrap">one-year</FONT> terms. For the purposes of this Amended and Restated Certificate of Incorporation, the term &#147;<B>End Date</B>&#148; shall mean June&nbsp;30, 2117. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;From and after the effectiveness of this Amended and Restated Certificate of Incorporation and subject
to the rights of holders of Preferred Stock, any director or the entire Board of Directors may be removed from office at any time, with or without cause, but only by the affirmative vote of at least 66 2/3% of the voting power of the shares cast for
or against such proposal, which shall be the act of the stockholders, and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be considered for purposes of establishing a quorum, but will not be considered as votes cast for
or against such removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided for or fixed by or pursuant to the
provisions of ARTICLE IV hereof in relation to the rights of the holders of Preferred Stock to elect directors under specified circumstances or except as otherwise provided by resolution of a majority of the Whole Board, newly created directorships
resulting from any increase in the number of directors, created in accordance with the Bylaws of the Company, and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause may be filled by
the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director. A person so elected by the Board of Directors to fill a vacancy or newly created
directorship shall hold office until the next election of the class for which such director shall have been chosen until his or her successor shall have been duly elected and qualified, or until such director&#146;s earlier death, resignation or
removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;The Company is to have perpetual existence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;The business and affairs of the Company shall be managed by or under the direction of the Board of
Directors. In addition to the powers and authority expressly conferred upon them by statute or by this Amended and Restated Certificate of Incorporation or the Bylaws of the Company, the directors are hereby empowered to exercise all such powers and
do all such acts and things as may be exercised or done by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;In furtherance and not in
limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, alter, amend or repeal the Bylaws of the Company. The affirmative vote of at least a majority of the Whole Board shall be required in order for
the Board of Directors to adopt, amend, alter or repeal the Company&#146;s Bylaws. The Company&#146;s Bylaws may also be adopted, amended, altered or repealed by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders of the Company.<B> </B>Notwithstanding the above or any other provision of this Amended and Restated Certificate of Incorporation, the Bylaws of the Company may not be amended,
altered or repealed except in accordance with the provisions of the Bylaws relating to amendments to the Bylaws. No Bylaw hereafter legally adopted, amended, altered or repealed shall invalidate any prior act of the directors or officers of the
Company that would have been valid if such Bylaw had not been adopted, amended, altered or repealed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The election of directors need not be by written ballot unless the Bylaws of the Company shall so
provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;No stockholder will be permitted to cumulate votes at any election of directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of holders of Preferred Stock, any action required or permitted to be taken by
the stockholders of the Company must be effected at a duly called annual or special meeting of stockholders of the Company and may not be effected by any consent in writing by such stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms of any series of Preferred Stock, special meetings of stockholders of the Company
may be called only by the Chairperson of the Board of Directors, the Chief Executive Officer, the President, the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board, or, subject to and in compliance with this
Article VIII and the Bylaws of the Company, and only if so permitted pursuant to the Company&#146;s Bylaws, by the Secretary of the Company upon the written request of one or more holders of record of shares in the aggregate entitled to cast not
less than 20% of the voting power of the Company&#146;s then-outstanding capital stock, but a special meeting may not be called by any other person or persons and any power of stockholders to call a special meeting of stockholders is specifically
denied. Only such business shall be considered at a special meeting of stockholders as shall have been stated in the notice for such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Advance notice of stockholder nominations for the election of directors and of business to be brought
by stockholders before any meeting of the stockholders of the Company shall be given in the manner and to the extent provided in the Bylaws of the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended from time
to time, a director or officer of the Company shall not be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. If the DGCL is amended to authorize corporate
action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Subject to any provisions in the Bylaws of the Company related to indemnification of directors of the
Company, the Company shall indemnify, to the fullest extent permitted by applicable law, any director of the Company who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (a &#147;<B>Proceeding</B>&#148;) by reason of the fact that he or she is or was a director of the Company or is or was serving at the request of the Company as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by such person in connection with any such Proceeding. The Company shall be required to indemnify a person in connection with a Proceeding (or part thereof) initiated by such person only if the Proceeding (or part
thereof) was authorized by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the power to indemnify, to the
extent permitted by applicable law, any officer, employee or agent of the Company who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of
the Company or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against
expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;Neither any amendment nor repeal of any Section of this ARTICLE IX, nor the adoption of any provision
of this Amended and Restated Certificate of Incorporation or the Bylaws of the Company inconsistent with this ARTICLE IX, shall eliminate or reduce the effect of this ARTICLE IX in respect of any matter occurring, or any Proceeding accruing or
arising or that, but for this ARTICLE IX, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings of
stockholders may be held within or outside of the State of Delaware, as the Bylaws may provide. The books of the Company may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such
manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reserves the right to amend or repeal any provision contained in this Amended and Restated Certificate of Incorporation in the
manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation; <I>provided</I>, <I>however</I>, that notwithstanding any other provision of this Amended and Restated
Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote, the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board and the affirmative vote of 66&nbsp;2/3% of the voting
power of the then outstanding voting securities of the Company, voting together as a single class, shall be required for the amendment, repeal or modification of the provisions of Section&nbsp;3 of ARTICLE IV, Section&nbsp;2 of ARTICLE V,
Section&nbsp;1 of ARTICLE VI, Section&nbsp;2 of ARTICLE VI, Section&nbsp;5 of ARTICLE VII, Section&nbsp;1 of ARTICLE VIII, Section&nbsp;2 of ARTICLE VIII, Section&nbsp;3 of ARTICLE VIII, or this ARTICLE XI of this Amended and Restated Certificate of
Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Zymeworks Inc. has caused this Amended and Restated Certificate of
Incorporation to be signed by the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the Company on this &nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL VOTING
PREFERRED STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Section&nbsp;151 of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zymeworks Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that the following resolution was adopted by the
Board of Directors of the Company (the &#147;<B>Board</B>&#148;) pursuant to the authority of the Board as required by Section&nbsp;151 of the Delaware General Corporation Law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that pursuant to the provisions of the Amended and Restated Certificate of Incorporation of the Company (as such may be
amended, modified or restated from time to time, the &#147;<B>Amended and Restated Certificate of Incorporation</B>&#148;) (which authorizes 100,000,000 shares of Preferred Stock, par value $0.00001 per share (the &#147;<B>Preferred
Stock</B>&#148;)), and the authority vested in the Board, a series of Preferred Stock be, and it hereby is, created, and that the designation and number of shares of such series, and the voting and other powers, preferences and relative,
participating, optional or other rights, and the qualifications, limitations and restrictions thereof are as set forth in the Amended and Restated Certificate of Incorporation and this Certificate of Designations, as it may be amended from time to
time (the &#147;<B>Certificate of Designations</B>&#148;) as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL VOTING PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;<U>Designation, Amount and Par Value</U>.&nbsp;The series of Preferred Stock shall be designated as Special Voting
Preferred Stock and the number of shares so designated shall be one (1).&nbsp;The sole authorized share of Special Voting Preferred Stock shall have a par value of $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;<U>Dividends</U>.&nbsp;The holder of record of the share of Special Voting Preferred Stock shall not be entitled to
receive any dividends declared and paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;<U>Voting Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The holder of record of the share of Special Voting Preferred Stock, except as otherwise required under applicable law or
as set forth in subparagraph (b)&nbsp;below, shall not be entitled to vote on any matter required or permitted to be voted upon by the stockholders of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to all meetings of the stockholders of the Company at which the holders of the Company&#146;s common stock,
par value $0.00001 per share, are entitled to vote (each, a &#147;<B>Stockholder Meeting</B>&#148;) and, if applicable, with respect to any written consents sought by the Company from the holders of such common stock (each, a &#147;<B>Stockholder
Consent</B>&#148;), the holder of the share of Special Voting Preferred Stock shall vote together with the holders of such common stock as a single class except as otherwise required under applicable law, and the holder of the share of Special
Voting Preferred Stock shall be entitled to cast on such matter a number of votes equal to (1)&nbsp;the Exchangeable Share Exchange Ratio, multiplied by (2)&nbsp;the number of Exchangeable Shares (the &#147;<B>Exchangeable Shares</B>&#148;) of
Zymeworks ExchangeCo Ltd., a British Columbia corporation (&#147;<B>ExchangeCo</B>&#148;), outstanding as of the record date for determining stockholders entitled to vote at such Stockholder Meeting or in connection with the applicable Stockholder
Consent (i)&nbsp;that are not owned by the Company or its affiliated entities and (ii)&nbsp;as to which the holder of the share of Special Voting Preferred Stock has received voting instructions from the holders of such Exchangeable Shares in
accordance with the Voting and Exchange Trust Agreement, as it may be amended from time to time (the &#147;<B>Trust Agreement</B>&#148;) to be entered into among the Company, ExchangeCo and the trustee thereunder (the &#147;<B>Trustee</B>&#148;),
and (3)&nbsp;rounded down to the nearest whole vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Exchangeable Share Exchange Ratio</B>&#148; has the meaning
ascribed thereto in the rights, privileges, restrictions and conditions attaching to the Exchangeable Shares as set out in the articles of ExchangeCo, as they may be amended from time to time, a copy of which shall be maintained in the books and
records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;<U>Liquidation</U>.&nbsp;Upon any liquidation, dissolution or winding up of the Company,
whether voluntary or involuntary, the holder of record of the share of Special Voting Preferred Stock shall rank senior to the Common Stock of the Company, and junior to all other series of Preferred Stock of the Company, and shall be entitled to
receive, prior to such shares of Common Stock, an amount equal to $1.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.&nbsp;<U>Other Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The holder of record of the share of Special Voting Preferred Stock shall not have any rights hereunder to convert such
share into, or exchange such share for, shares of any other series or class of capital stock of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The
Trustee shall exercise the voting rights attached to the share of Special Voting Preferred Stock pursuant to and in accordance with the Trust Agreement.&nbsp;The voting rights attached to the share of Special Voting Preferred Stock shall terminate
pursuant to and in accordance with the Trust Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At such time as the share of Special Voting Preferred Stock
has no votes attached to it, the Special Voting Preferred Stock shall be automatically cancelled for no consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
The effective date of this Certificate of Designations shall be [____] [_], 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[this space left blank intentionally&#151;signature
page&nbsp;follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Certificate of Designations to be signed by
[______], its [______], this [_]th&nbsp;day of [____], 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ZYMEWORKS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_30"></A>APPENDIX G: AMENDED AND RESTATED BYLAWS OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(initially
adopted on June&nbsp;30, 2022) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(as amended on [&#9679;]) </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B><I>Page</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><A HREF="#f722206_100">ARTICLE I&#151;CORPORATE OFFICES </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">G-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_101">REGISTERED OFFICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_102">OTHER OFFICES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><A HREF="#f722206_103">ARTICLE II&#151;MEETINGS OF STOCKHOLDERS </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_104">PLACE OF MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_105">ANNUAL MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_106">SPECIAL MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_107">ADVANCE NOTICE PROCEDURES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_108">NOTICE OF STOCKHOLDERS&#146; MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">G-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_109">QUORUM</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_110">ADJOURNED MEETING; NOTICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_111">CONDUCT OF BUSINESS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_112">VOTING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_113">STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_114">RECORD DATES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_115">PROXIES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_116">LIST OF STOCKHOLDERS ENTITLED TO VOTE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_117">INSPECTORS OF ELECTION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_118">ARTICLE III&#151;DIRECTORS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_119">POWERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_120">NUMBER OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_121">ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_122">RESIGNATION AND VACANCIES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_123">PLACE OF MEETINGS; MEETINGS BY TELEPHONE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_124">REGULAR MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_125">SPECIAL MEETINGS; NOTICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_126">QUORUM; VOTING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_127">BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_128">FEES AND COMPENSATION OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_129">REMOVAL OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_130">ARTICLE IV&#151;COMMITTEES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_131">COMMITTEES OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_132">COMMITTEE MINUTES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_133">MEETINGS AND ACTION OF COMMITTEES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_134">SUBCOMMITTEES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_135">ARTICLE V&#151;OFFICERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_136">OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_137">APPOINTMENT OF OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_138">SUBORDINATE OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_139">REMOVAL AND RESIGNATION OF OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_140">VACANCIES IN OFFICES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_141">REPRESENTATION OF SECURITIES OF OTHER ENTITIES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_142">AUTHORITY AND DUTIES OF OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B><I>Page</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_143">ARTICLE VI&#151;STOCK </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">G-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_144">STOCK CERTIFICATES; PARTLY PAID SHARES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_145">SPECIAL DESIGNATION ON CERTIFICATES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_146">LOST CERTIFICATES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_147">DIVIDENDS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_148">TRANSFER OF STOCK</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_149">STOCK TRANSFER AGREEMENTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_150">REGISTERED STOCKHOLDERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_151">ARTICLE VII&#151;MANNER OF GIVING NOTICE AND WAIVER
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_152">NOTICE OF STOCKHOLDERS&#146; MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_153">NOTICE TO STOCKHOLDERS SHARING AN ADDRESS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_154">NOTICE TO PERSON WITH WHOM COMMUNICATION IS UNLAWFUL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_155">WAIVER OF NOTICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_156">ARTICLE VIII&#151;INDEMNIFICATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_157">INDEMNIFICATION OF DIRECTORS AND OFFICERS IN THIRD PARTY PROCEEDINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_158">INDEMNIFICATION OF DIRECTORS AND OFFICERS IN ACTIONS BY OR IN THE RIGHT OF THE COMPANY</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_159">SUCCESSFUL DEFENSE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_160">INDEMNIFICATION OF OTHERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_161">ADVANCED PAYMENT OF EXPENSES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_162">LIMITATION ON INDEMNIFICATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_163">DETERMINATION; CLAIM</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_164"><FONT STYLE="white-space:nowrap">NON-EXCLUSIVITY</FONT> OF RIGHTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_165">INSURANCE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_166">SURVIVAL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_167">EFFECT OF REPEAL OR MODIFICATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_168">CERTAIN DEFINITIONS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_169">ARTICLE IX&#151;GENERAL MATTERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_170">EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_171">FISCAL YEAR</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_172">SEAL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_173">CONSTRUCTION; DEFINITIONS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_174">FORUM SELECTION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_175">ARTICLE X&#151;AMENDMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS OF ZYMEWORKS INC. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_100"></A>ARTICLE I&#151;CORPORATE OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_101"></A>1.1&nbsp;&nbsp;&nbsp;&nbsp;REGISTERED OFFICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registered office of Zymeworks Inc. (the &#147;<B>Company</B>&#148;) shall be fixed in the Company&#146;s certificate of incorporation, as
the same may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_102"></A>1.2&nbsp;&nbsp;&nbsp;&nbsp;OTHER OFFICES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may at any time establish other offices. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_103"></A>ARTICLE II&#151;MEETINGS OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_104"></A>2.1&nbsp;&nbsp;&nbsp;&nbsp;PLACE OF MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings of stockholders shall be held at a place, if any, within or outside the State of Delaware, determined by the board of directors of
the Company (the &#147;<B>Board of Directors</B>&#148;). The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as
authorized by Section&nbsp;
211(a)(2) of the Delaware General Corporation Law or any successor legislation (the &#147;<B>DGCL</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_105"></A>2.2&nbsp;&nbsp;&nbsp;&nbsp;ANNUAL
 MEETING </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual meeting of stockholders shall be held each year. The Board of Directors shall designate the date and time of the
annual meeting. At the annual meeting, directors shall be elected and any other proper business, brought in accordance with Section&nbsp;2.4 of these bylaws, may be transacted. The Board of Directors acting pursuant to a resolution adopted by a
majority of the Whole Board may cancel, postpone or reschedule any previously scheduled annual meeting at any time, before or after the notice for such meeting has been sent to the stockholders. For the purposes of these bylaws, the term
&#147;<B>Whole Board</B>&#148; shall mean the total number of authorized directorships whether or not there exist any vacancies or other unfilled seats in previously authorized directorships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_106"></A>2.3&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL MEETING </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A special meeting of the stockholders, other than as required by statute, may be called at any time by (i)&nbsp;the
Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board, (ii)&nbsp;the chairperson of the Board of Directors, (iii)&nbsp;the chief executive officer, (iv)&nbsp;the president or (v)&nbsp;the secretary of the
Company upon written request from stockholders pursuant to and subject to the requirements set forth in Section&nbsp;2.4(b)(ii), but a special meeting may not be called by any other person or persons, and, except as expressly set forth herein, any
power of the stockholders to call a special meeting of stockholders is specifically denied. Except for a meeting called pursuant to Section&nbsp;2.4(b)(ii), the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole
Board may cancel, postpone or reschedule any previously scheduled special meeting at any time, before or after the notice for such meeting has been sent to the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The notice of a special meeting shall include the purpose for which the meeting is called. Only such business shall
be conducted at a special meeting of stockholders as shall have been brought before the meeting by or at the direction of a majority of the Whole Board, the chairperson of the Board of Directors, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chief executive officer or the president, or pursuant to Section&nbsp;2.4(b)(ii). Nothing contained in this Section&nbsp;2.3(b) shall be construed as limiting, fixing or affecting the time when a
meeting of stockholders called by action of the Board of Directors may be held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_107"></A>2.4&nbsp;&nbsp;&nbsp;&nbsp;ADVANCE NOTICE PROCEDURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Annual Meetings of Stockholders</I><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Nominations of persons for election to the Board of Directors or the proposal of other business to be transacted
by the stockholders at an annual meeting of stockholders may be made only (1)&nbsp;pursuant to the Company&#146;s notice of meeting (or any supplement thereto); (2)&nbsp;by or at the direction of the Board of Directors (including a committee
thereof); (3)&nbsp;as may be provided in the certificate of designations for any class or series of preferred stock; or (4)&nbsp;by any stockholder of the Company (or, in the case of the first annual meeting of stockholders of the Company as a
Delaware corporation, any stockholder of Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia) (the &#147;<B>Redomiciling</B><B> Entity</B>&#148;)) who (A)&nbsp;is a stockholder of record at the time of
giving of the notice contemplated by Section&nbsp;2.4(a)(ii) or, in the case of the first annual meeting of stockholders of the Company as a Delaware corporation, was a stockholder of record of the Redomiciling Entity at the time of giving such
notice; (B)&nbsp;is a stockholder of record on the record date for the determination of stockholders entitled to notice of the annual meeting; (C)&nbsp;is a stockholder of record on the record date for the determination of stockholders entitled to
vote at the annual meeting; (D)&nbsp;is a stockholder of record at the time of the annual meeting; and (E)&nbsp;complies with the procedures set forth in this Section&nbsp;2.4(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For nominations or other business to be properly brought before an annual meeting of stockholders by a
stockholder pursuant to clause (4)&nbsp;of Section&nbsp;2.4(a)(i), the stockholder (or in the case of the first annual meeting of stockholders of the Company as a Delaware corporation, such stockholder in their capacity as a stockholder of the
Redomiciling Entity) must have given timely notice in writing to the secretary of the Company and any such nomination or proposed business must constitute a proper matter for stockholder action. To be timely, a stockholder&#146;s notice must be
received by the secretary of the Company at the principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on the 120th day and no later than 5:00 p.m., Eastern time, on the 90th day prior to the day of the first anniversary
of the preceding year&#146;s annual meeting as first specified in the Company&#146;s notice of such annual meeting (without regard to any adjournment, rescheduling, postponement or other delay of such annual meeting occurring after such notice was
first sent). However, if no annual meeting was held in the preceding year, or if the date of the annual meeting for the current year has been changed by more than 25 days from the first anniversary of the preceding year&#146;s annual meeting, then
to be timely such notice must be received by the secretary of the Company at the principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on the 120th day prior to the day of such annual meeting and no later than 5:00
p.m., Eastern time, on the 10th day following the later of the day on which public announcement of the date of such annual meeting was first made by the Company and the 120th day prior to the day of the annual meeting and in the case of the first
annual meeting of stockholders of the Company as a Delaware corporation, notice must be received by the secretary of the Redomiciling Entity at the principal executive offices of the Redomiciling Entity or by the secretary of the Company at the
principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on [&#9679;], 2022 and no later than 5:00 p.m., Eastern time, on [&#9679;], 2022). In no event will the adjournment, rescheduling, postponement or other delay of any
annual meeting, or any announcement thereof, commence a new time period (or extend any time period) for the giving of a stockholder&#146;s notice as described above. In no event may a stockholder provide notice with respect to a greater number of
director candidates than are subject to election by stockholders at the annual meeting. If the number of directors to be elected to the Board of Directors is increased and there is no public announcement (as defined below) naming all of the nominees
for director or specifying the size of the increased Board of Directors at least 10 days before the last day that a stockholder may deliver a notice of nomination pursuant to the foregoing provisions, then a stockholder&#146;s notice required by
this Section&nbsp;2.4(a)(ii) will also be considered timely, but only with respect to any nominees for any new positions created by such increase, if it is received by the secretary of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company at the principal executive offices of the Company (or, in the case of the first annual meeting of stockholders of the Company as a Delaware corporation, the secretary of the
Redomiciling Entity at the principal executive offices of the Redomiciling Entity) no later than 5:00 p.m., Eastern time, on the 10th day following the day on which such public announcement is first made. &#147;<B>Public announcement</B>&#148; means
disclosure in a press release reported by a national news service, in a document publicly filed by the Company or the Redomiciling Entity with the Securities and Exchange Commission pursuant to Section&nbsp;13, Section&nbsp;14 or Section&nbsp;15(d)
of the Securities Exchange Act of 1934 (as amended and inclusive of rules and regulations thereunder, the &#147;<B>1934 Act</B>&#148;) or by such other means as is reasonably designed to inform the public or stockholders of the Company in general of
such information including, without limitation, posting on the Company&#146;s investor relations website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;A
stockholder&#146;s notice to the secretary of the Company must set forth: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;as to each person whom the
stockholder proposes to nominate for election as a director: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;such person&#146;s name, age, business address,
residence address and principal occupation or employment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;the class and number of shares of the Company that
are held of record or are beneficially owned by such person and any (i)&nbsp;Derivative Instruments (as defined below) held or beneficially owned by such person, including the full notional amount of any securities that, directly or indirectly,
underlie any Derivative Instrument; and (ii)&nbsp;other agreement, arrangement or understanding that has been made the effect or intent of which is to create or mitigate loss to, manage risk or benefit of share price changes for, or increase or
decrease the voting power of such person with respect to the Company&#146;s securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;all information
relating to such person that is required to be disclosed in connection with solicitations of proxies for the contested election of directors, or is otherwise required, in each case pursuant to the Section&nbsp;14 of the 1934 Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;such person&#146;s written consent to being named as a nominee of such stockholder in such stockholder&#146;s
proxy statement and to serving as a director of the Company if elected; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;any direct or indirect compensatory,
payment, indemnification or other financial agreement, arrangement or understanding that such person has, or has had within the past three years, with any person or entity other than the Company (including, without limitation, the amount of any
payment or payments received or receivable thereunder), in each case in connection with candidacy or service as a director of the Company (such agreement, arrangement or understanding, a &#147;<B>Third-Party Compensation Arrangement</B>&#148;); and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(F)&nbsp;&nbsp;&nbsp;&nbsp;any other material relationships between such person and such person&#146;s respective affiliates and
associates, or others acting in concert with them, on the one hand, and such stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made, and their respective affiliates and associates, or others acting in
concert with them, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> if such stockholder, beneficial owner,
affiliate or associate were the &#147;registrant&#148; for purposes of such rule and such person were a director or executive officer of such registrant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;as to any other business that the stockholder giving the notice proposes to bring before the annual meeting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;a brief description of the business desired to be brought before the annual meeting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;the text of the proposal or business (including the text of any resolutions proposed for consideration and, if
applicable, the text of any proposed amendment to these bylaws); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;the reasons for conducting such business at the annual meeting;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;any material interest in such business of such stockholder giving the notice and the beneficial owner, if
any, on whose behalf the proposal is made, and their respective affiliates and associates, or others acting in concert with them; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;all agreements, arrangements and understandings between such stockholder and the beneficial owner, if any, on
whose behalf the proposal is made, and their respective affiliates or associates or others acting in concert with them, and any other persons (including their names) in connection with the proposal of such business by such stockholder; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or
proposal is made: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the name and address of such stockholder (as they appear on the Company&#146;s books), of
such beneficial owner, or of their respective affiliates or associates or others acting in concert with them; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;for each class or series, the number of shares of stock of the Company that are, directly or indirectly, held of
record or are beneficially owned by such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;any agreement, arrangement or understanding between such stockholder, such beneficial owner or their respective
affiliates or associates or others acting in concert with them, and any other person or persons (including, in each case, their names) in connection with the proposal of such nomination or other business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;any (i)&nbsp;agreement, arrangement or understanding (including, without limitation, and regardless of the form of
settlement, any derivative, long or short positions, profit interests, forwards, futures, swaps, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions and borrowed or loaned shares) that has been
entered into by or on behalf of such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them with respect to the Company&#146;s securities (any of the foregoing, a &#147;<B>Derivative
Instrument</B>&#148;), including the full notional amount of any securities that, directly or indirectly, underlie any Derivative Instrument; and (ii)&nbsp;other agreement, arrangement or understanding that has been made the effect or intent of
which is to create or mitigate loss to, manage risk or benefit of share price changes for or increase or decrease the voting power of, such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert
with them with respect to the Company&#146;s securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;any proxy, contract, arrangement, understanding or
relationship pursuant to which such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them has a right to vote any shares of any security of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(F)&nbsp;&nbsp;&nbsp;&nbsp;any rights to dividends on the Company&#146;s securities owned beneficially by such stockholder, such beneficial
owner or their respective affiliates or associates or others acting in concert with them that are separated or separable from the underlying security; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(G)&nbsp;&nbsp;&nbsp;&nbsp;any proportionate interest in the Company&#146;s securities or Derivative Instruments held, directly or
indirectly, by a general or limited partnership in which such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them, is a general partner or, directly or indirectly, beneficially owns
an interest in a general partner of such general or limited partnership; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(H)&nbsp;&nbsp;&nbsp;&nbsp;any performance-related fees (other than an asset-based fee)
that such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them is entitled to based on any increase or decrease in the value of the Company&#146;s securities or Derivative Instruments,
including, without limitation, any such interests held by members of the immediate family of such persons sharing the same household; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(I)&nbsp;&nbsp;&nbsp;&nbsp;any significant equity interests or any Derivative Instruments in any principal competitor of the Company that are
held by such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(J)&nbsp;&nbsp;&nbsp;&nbsp;any direct or indirect interest of such stockholder, such beneficial owner or their respective affiliates or
associates or others acting in concert with them, in any contract with the Company, any affiliate of the Company or any principal competitor of the Company (in each case, including, without limitation, any employment agreement, collective bargaining
agreement or consulting agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(K)&nbsp;&nbsp;&nbsp;&nbsp;any material pending or threatened legal proceeding in which such
stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them is a party or material participant involving the Company or any of its officers, directors or affiliates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(L)&nbsp;&nbsp;&nbsp;&nbsp;any material relationship between such stockholder, such beneficial owner or their respective affiliates or
associates or others acting in concert with them, on the one hand, and the Company or any of its officers, directors or affiliates, on the other hand; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(M)&nbsp;&nbsp;&nbsp;&nbsp;a representation and undertaking that the stockholder is a holder of record of stock of the Company as of the date
of submission of the stockholder&#146;s notice and intends to appear in person or by proxy at the annual meeting to bring such nomination or other business before the annual meeting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(N)&nbsp;&nbsp;&nbsp;&nbsp;a representation and undertaking as to whether such stockholder, such beneficial owner or their respective
affiliates or associates or others acting in concert with them intends, or is part of a group that intends, to (x)&nbsp;deliver a proxy statement or form of proxy to holders of at least the percentage of the voting power of the Company&#146;s
then-outstanding stock required to approve or adopt the proposal or to elect each such nominee; or (y)&nbsp;otherwise solicit proxies from stockholders in support of such proposal or nomination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(O)&nbsp;&nbsp;&nbsp;&nbsp;any other information relating to such stockholder, such beneficial owner, or their respective affiliates or
associates or others acting in concert with them, or director nominee or proposed business, that, in each case, would be required to be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies
in support of such nominee (in a contested election of directors) or proposal pursuant to Section&nbsp;14 of the 1934 Act; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(P)&nbsp;&nbsp;&nbsp;&nbsp;such other information relating to any proposed item of business as the Company may reasonably require to
determine whether such proposed item of business is a proper matter for stockholder action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;In addition to
the requirements of this Section&nbsp;2.4, to be timely, a stockholder&#146;s notice (and any additional information submitted to the Company in connection therewith) must further be updated and supplemented (1)&nbsp;if necessary, so that the
information provided or required to be provided in such notice is true and correct as of the record date(s) for determining the stockholders entitled to notice of, and to vote at, the annual meeting and as of the date that is 10 business days prior
to the annual meeting or any adjournment, rescheduling, postponement or other delay thereof; and (2)&nbsp;to provide any additional information that the Company may reasonably request. Any such update and supplement or additional information
(including if requested pursuant to Section&nbsp;2.4(a)(iii)(3)(P)), must be received by the secretary of the Company at the principal executive offices of the Company (A)&nbsp;in the case of a request for additional information, promptly following
a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
request therefor, which response must be received by the secretary of the Company not later than such reasonable time as is specified in any such request from the Company; or (B)&nbsp;in the case
of any other update or supplement of any information, not later than five business days after the record date(s) for the annual meeting (in the case of any update and supplement required to be made as of the record date(s)), and not later than eight
business days prior to the date for the annual meeting or any adjournment, rescheduling, postponement or other delay thereof (in the case of any update and supplement required to be made as of 10 business days prior to the meeting or any
adjournment, rescheduling, postponement or other delay thereof). The failure to timely provide such update, supplement or additional information shall result in the nomination or proposal no longer being eligible for consideration at the annual
meeting. For the avoidance of doubt, the obligation to update and supplement, or provide additional information, as set forth in this Section&nbsp;2.4(a)(iv) or any other Section of these bylaws shall not limit the Company&#146;s rights with respect
to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines pursuant to these bylaws or enable or be deemed to permit a stockholder who has previously submitted notice pursuant to these bylaws to amend or update any
nomination or to submit any new nomination. No disclosure pursuant to these bylaws will be required with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is the stockholder
submitting a notice pursuant to this Section&nbsp;2.4 solely because such broker, dealer, commercial bank, trust company or other nominee of has been directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Special Meetings of Stockholders</I>. Except to the extent required by the DGCL, special meetings of
stockholders may be called only in accordance with the Company&#146;s certificate of incorporation and these bylaws. Only such business will be conducted at a special meeting of stockholders as has been brought before the special meeting pursuant to
the Company&#146;s notice of meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;If the election of directors is included as business to be brought
before a special meeting in the Company&#146;s notice of meeting, then nominations of persons for election to the Board of Directors at such special meeting may be made by any stockholder who (i)&nbsp;is a stockholder of record at the time of giving
of the notice contemplated by this Section&nbsp;2.4(b)(i); (ii)&nbsp;is a stockholder of record on the record date for the determination of stockholders entitled to notice of the special meeting; (iii)&nbsp;is a stockholder of record on the record
date for the determination of stockholders entitled to vote at the special meeting; (iv)&nbsp;is a stockholder of record at the time of the special meeting; and (v)&nbsp;complies with the procedures set forth in this Section&nbsp;2.4(b)(i) (with
such procedures deemed to be applicable to such special meeting). For nominations to be properly brought by a stockholder before a special meeting pursuant to this Section&nbsp;2.4(b)(i), the stockholder&#146;s notice must be received by the
secretary of the Company at the principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on the 120th day prior to the day of the special meeting and no later than 5:00 p.m., Eastern time, on the 10th day following the day
on which public announcement of the date of the special meeting was first made. In no event will any adjournment, rescheduling, postponement or other delay of a special meeting, or any announcement, thereof commence a new time period (or extend any
time period) for the giving of a stockholder&#146;s notice as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The secretary of the Company
will call a special meeting upon a written request from one or more stockholders of record who have (or who are acting on behalf of beneficial owners who have) an aggregate net long position (as determined below) of not less than 20% of the voting
power of the Company&#146;s then-outstanding stock as of the Ownership Record Date (as defined below), it being understood that each such stockholder of record (or beneficial owner directing such stockholder of record) (each such beneficial owner
and each record stockholder who is not acting solely as a nominee, a &#147;<B>Disclosing Party</B>&#148;) must have held such individual&#146;s net long position included in such aggregate amount continuously for the
<FONT STYLE="white-space:nowrap">one-year</FONT> period ending on the Ownership Record Date and must continue to hold such net long position through the date of the conclusion of the special meeting (such aggregate net long position held for the
requisite period, the &#147;<B>Required Percentage</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;2.4(b)(ii) and for determining the
Required Percentage, net long position shall be determined in accordance with Rule <FONT STYLE="white-space:nowrap">14e-4</FONT> under the 1934 Act with respect to each stockholder requesting a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special meeting and each beneficial owner who is directing a stockholder to act on such owner&#146;s behalf (each stockholder and beneficial owner, a &#147;<B>party</B>&#148;), provided that
(i)&nbsp;for purposes of such definition, in determining such party&#146;s &#147;short position&#148;, the reference in Rule <FONT STYLE="white-space:nowrap">14e-4</FONT> to &#147;the date that a tender offer is first publicly announced or otherwise
made known by the bidder to holders of the security to be acquired&#148; shall be the Ownership Record Date (as defined below), and the reference to the &#147;highest tender offer price or stated amount of the consideration offered for the subject
security&#148; shall refer to the closing sale price of the Company&#146;s common stock on The New York Stock Exchange (or such other securities exchange designated by the Board of Directors if the common stock is not listed for trading on The New
York Stock Exchange) on such record date (or, if such date is not a trading day, the next succeeding trading day) and (ii)&nbsp;the net long position of such party shall be reduced by the number of shares of the Company&#146;s common stock as to
which the Board of Directors determines that such party does not, or will not, have the right to vote or direct the voting of at the special meeting or as to which the Board of Directors determines that such party has entered into any derivative or
other agreement, arrangement or understanding that hedges or transfers, in whole or in part, directly or indirectly, any of the economic consequences of ownership of such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;Such stockholder request to call a special meeting (a &#147;<B>Requisition</B>&#148;) must (A)&nbsp;include the
information required by Section&nbsp;2.4(a)(iii)(2), which information shall be supplemented by each Disclosing Party not later than 10 days after the record date for determining the record stockholders entitled to notice of the special meeting
(such record date, the &#147;<B>Meeting Record Date</B>&#148;) to disclose the foregoing information as of the Meeting Record Date and as of the date that is 10 days prior to the special meeting or any adjournment or postponement thereof, which
shall be received by the secretary of the Company not later than the fifth day before the special meeting); (B) include any additional information necessary to verify the net long position of such Disclosing Party (including such information for the
<FONT STYLE="white-space:nowrap">one-year</FONT> period prior to the Ownership Record Date); (C) be signed by, and include the information required by Section&nbsp;2.4(a)(iii)(3) with respect to all the requisitioning stockholders; (D)&nbsp;be
delivered in a written record, which may consist of a single record or several records, in substantially the same form and content, each of which is signed by one or more of the requisitioning stockholders; provided that, in the event the
Requisition consists of more than one record, the Requisition will be deemed received by the secretary on the first date by which the secretary has received a sufficient number of Requisition records that comply with this Section&nbsp;2.4(b)(ii)(1);
(E) be delivered to the secretary at the principal executive offices of the Company and (F)&nbsp;be amended or supplemented from time to time as described in Section&nbsp;2.4(a)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;A beneficial owner who wishes to deliver a written request to call a special meeting must cause the nominee or
other person who serves as the stockholder of record of such beneficial owner&#146;s stock to sign the written request to call special meeting. If a stockholder of record is the nominee for more than one beneficial owner of stock, then the
stockholder of record may deliver a written request to call a special meeting solely with respect to the common stock of the corporation owned by the beneficial owner who is directing the record stockholder to sign such written request to call a
special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder of record (whether acting for him, her or itself, or at the direction of a
beneficial owner) shall, by written notice to the secretary of the Company, demand that the Board of Directors fix a record date to determine the stockholders who are entitled to deliver a written request to call a special meeting (such record date,
the &#147;<B>Ownership Record Date</B>&#148;). A written demand to fix an Ownership Record Date shall include all of the information that must be included in a written request to call a special meeting as of the date of the demand for the record
date, as set forth in this Section&nbsp;2.4(b)(ii). The Board of Directors may fix the Ownership Record Date within 10 days of the secretary&#146;s receipt of a valid demand to fix the Ownership Record Date. The Ownership Record Date shall not
precede, and shall not be more than 10 days after, the date upon which the resolution fixing the Ownership Record Date is adopted by the Board of Directors. If an Ownership Record Date is not fixed by the Board of Directors, then the Ownership
Record Date shall be the date that the first written request to call a special meeting is received by the secretary with respect to the proposed business to be submitted for stockholder approval at a special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;Upon receiving a request for a special meeting that complies with Section&nbsp;2.4(b)(ii), the secretary must,
subject to Section&nbsp;2.4(b)(ii)(7), (A) call a meeting of stockholders, to be held not more than 120 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
days after the date on which the Requisition is received by the Company, to transact the business stated in the Requisition, (B)&nbsp;send notice of the date and time and, if applicable, the
location of the meeting at least the prescribed number of days, but not more than 120 days, before the meeting to each stockholder entitled to attend the meeting and (C)&nbsp;send, in accordance with Section&nbsp;2.4(b)(ii)(6), a notice to the
persons entitled to notice of the meeting, of the text of the proposal or business referred to in Section&nbsp;2.4(a)(iii)(2)(B). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;If the requisitioned meeting is an electronic or a virtual meeting, the notice referenced in
Section&nbsp;2.4(b)(ii)(4) must also contain instructions for attending and participating in the meeting by telephone or other communications medium, including, if applicable, instructions for voting at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(6)&nbsp;&nbsp;&nbsp;&nbsp;The text referenced in Section&nbsp;2.4(b)(ii)(1)(A) must be sent (A)&nbsp;in, or within the time set for the
sending of, the notice of the requisitioned meeting or (B)&nbsp;in the Company&#146;s proxy statement or equivalent, if any, sent in respect of the requisitioned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(7)&nbsp;&nbsp;&nbsp;&nbsp;The secretary need not comply with Section&nbsp;2.4(b)(ii)(4) and (5)&nbsp;if (A) the directors have called a
meeting of stockholders to be held after the date on which the Requisition is received by the Company and have sent notice of that meeting in accordance with Section&nbsp;2.3, (B) notices relating to an identical or substantially similar item (such
item, a &#147;<B>Similar Item</B>&#148;) sufficient to meet the 20% threshold are received by the secretary (i)&nbsp;more than 60 days following receipt of the first such written request and (ii)&nbsp;before the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the receipt of such first written request regarding a Similar Item; (C)&nbsp;if a Similar Item has been presented at the most recent annual meeting or at any special meeting held within
five years prior to receipt by the secretary of such written request to call a special meeting; (D)&nbsp;the secretary reasonably determines that the business proposed to be transacted is not proper for stockholder action; (E)&nbsp;it clearly
appears that the business stated in the stockholder Requisition does not relate in a significant way to the business or affairs of the Company; (F)&nbsp;it clearly appears that the primary purpose for the Requisition is securing publicity or
enforcing a personal claim or redressing a personal grievance against the Company or any of its directors, officers or security holders; (G)&nbsp;the business stated in the Requisition has already been substantially implemented; (H)&nbsp;the
business stated in the Requisition, if implemented, would cause the Company to violate or be in violation of the law or (I)&nbsp;the Requisition deals with matters beyond the Company&#146;s power to implement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(8)&nbsp;&nbsp;&nbsp;&nbsp;A stockholder may revoke its request to call a special meeting at any time before the special meeting by sending
written notice of such revocation to the secretary of the Company. All written requests for a special meeting shall be deemed revoked: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;upon the first date that, after giving effect to revocation(s) and notices of net long position decreases
(pursuant to Section&nbsp;2.4(b)(ii)), the aggregate net long position of all of the Disclosing Parties who are listed on the unrevoked written requests to call a special meeting with respect to a Similar Item decreases to a number of shares of the
corporation&#146;s common stock less than the Required Percentage; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;if any Disclosing Party who has provided a
representation pursuant to Section&nbsp;2.4(b)(ii)(1)(C) and Section&nbsp;2.4(a)(iii)(3)(K) does not act in accordance with the representations set forth therein; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;if any Disclosing Party does not timely provide the supplemental information required pursuant to
Section&nbsp;2.4(b)(ii)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a deemed revocation of all written requests to call a special meeting has occurred after the special
meeting has been called by the secretary, then the Board of Directors shall have the discretion to determine whether or not to proceed with the special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(9)&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors may vary from the requirements in this Section&nbsp;2.4(b)(ii) if reasonably necessary to
comply with applicable law, including U.S. securities laws and the rules and regulations thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Other Requirements</I><I> and Procedures.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;To be eligible to be a nominee by any stockholder for election as a director of the Company, the proposed nominee
must provide to the secretary of the Company, in accordance with the applicable time periods prescribed for delivery of notice under Section&nbsp;2.4(a)(ii) or Section&nbsp;2.4(b): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;a signed and completed written questionnaire (in the form provided by the secretary of the Company at the written
request of the nominating stockholder, which form will be provided by the secretary within 10 days of receiving such request) containing information regarding such nominee&#146;s background and qualifications and such other information as may
reasonably be required by the Company to determine the eligibility of such nominee to serve as a director of the Company or to serve as an independent director of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and undertaking that, unless previously disclosed to the Company, such nominee is not,
and will not become, a party to any voting agreement, arrangement, commitment, assurance or understanding with any person or entity as to how such nominee, if elected as a director, will vote on any issue; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and undertaking that, unless previously disclosed to the Company, such nominee is not,
and will not become, a party to any Third-Party Compensation Arrangement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and
undertaking that, if elected as a director, such nominee would be in compliance, and will continue to comply, with the Company&#146;s corporate governance guidelines, conflict of interest, confidentiality, stock ownership and trading, and other
policies and guidelines applicable to directors and in effect during such person&#146;s term in office as a director (and, if requested by any candidate for nomination, the secretary of the Company will provide to such proposed nominee all such
policies and guidelines then in effect); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and undertaking that such nominee, if
elected, intends to serve a full term on the Board of Directors; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(6)&nbsp;&nbsp;&nbsp;&nbsp;consents to being named on the
Company&#146;s form of proxy pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the 1934 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;At the request of the Board of Directors, any person nominated by the Board of Directors for election as a
director must furnish to the secretary of the Company the information that is required to be set forth in a stockholder&#146;s notice of nomination pertaining to such nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;No person will be eligible to be nominated by a stockholder for election as a director of the Company, or to be
seated as a director of the Company, unless nominated and elected in accordance with the procedures set forth in this Section&nbsp;2.4. No business proposed by a stockholder will be conducted at a stockholder meeting except in accordance with this
Section&nbsp;2.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;The chairperson of the applicable meeting of stockholders will, if the facts warrant,
determine and declare to the meeting that a nomination was not made in accordance with the procedures prescribed by these bylaws or that other proposed business was not properly brought before the meeting. If the chairperson of the meeting should so
determine, then the chairperson of the meeting will so declare to the meeting and the defective nomination will be disregarded or such business will not be transacted, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Section&nbsp;2.4, unless otherwise required by law, if the
stockholder (or a qualified representative of the stockholder) does not appear in person at the meeting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to present a nomination or other proposed business, such nomination will be disregarded or such business will not be transacted, as the case may be, notwithstanding that proxies in respect of
such nomination or business may have been received by the Company and counted for purposes of determining a quorum. For purposes of this Section&nbsp;2.4, to be considered a qualified representative of the stockholder, a person must be a duly
authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting, and such
person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Without limiting this Section&nbsp;2.4, a stockholder must also comply with all applicable requirements of the
1934&nbsp;Act with respect to the matters set forth in this Section&nbsp;2.4, it being understood that (1)&nbsp;any references in these bylaws to the 1934&nbsp;Act are not intended to, and will not, limit any requirements applicable to nominations
or proposals as to any other business to be considered pursuant to this Section&nbsp;2.4; and (2)&nbsp;compliance with clause&nbsp;(4) of Section&nbsp;2.4(a)(i) and with Section&nbsp;2.4(b) are the exclusive means for a stockholder to make
nominations or submit other business (other than as provided in Section&nbsp;2.4(c)(vii)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary in this Section&nbsp;2.4, the notice requirements set forth in these bylaws with respect to the proposal of any business pursuant to this Section&nbsp;2.4 will be deemed to be satisfied by a stockholder if (1)&nbsp;such
stockholder has submitted a proposal to the Company in compliance with <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> under the 1934&nbsp;Act; and (2)&nbsp;such stockholder&#146;s proposal has been included in a proxy statement that has
been prepared by the Company to solicit proxies for the meeting of stockholders. Subject to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> and other applicable rules and regulations under the 1934&nbsp;Act, nothing in these bylaws will be
construed to permit any stockholder, or give any stockholder the right, to include or have disseminated or described in the Company&#146;s proxy statement any nomination of a director or any other business proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_108"></A>2.5&nbsp;&nbsp;&nbsp;&nbsp;NOTICE OF STOCKHOLDERS&#146; MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever stockholders are required or permitted to take any action at a meeting, a notice of the meeting shall be given which shall state the
place, if any, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders
entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Except as
otherwise provided in the DGCL, the certificate of incorporation or these bylaws, the notice of any meeting of stockholders shall be given not less than 21 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at
such meeting as of the record date for determining the stockholders entitled to notice of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_109"></A>2.6&nbsp;&nbsp;&nbsp;&nbsp;QUORUM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of 33 1/3% of the voting power of the capital stock of the Company issued and outstanding and entitled to vote, present in person
or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. Where a separate vote by a class or series or classes or series is required, 33 1/3% of the voting power of the outstanding
shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter, except as otherwise provided by law, the certificate of
incorporation or these bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, however, such quorum is not present or represented at any meeting of the stockholders, then either
(a)&nbsp;the chairperson of the meeting, or (b)&nbsp;the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at
the meeting, until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the original meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_110"></A>2.7&nbsp;&nbsp;&nbsp;&nbsp;ADJOURNED MEETING; NOTICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting
if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are provided in the manner described in
Section&nbsp;222(c) of the DGCL. At the adjourned meeting, the Company may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given
to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such
adjourned meeting in accordance with Section&nbsp;213(a) of the DGCL and Section&nbsp;2.11 of these bylaws, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date
fixed for notice of such adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_111"></A>2.8&nbsp;&nbsp;&nbsp;&nbsp;CONDUCT OF BUSINESS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such
regulation of the manner of voting and the conduct of business and discussion as seem to the chairperson in order. The chairperson of any meeting of stockholders shall be designated by the Board of Directors; in the absence of such designation, the
chairperson of the Board of Directors, if any, or the chief executive officer (in the absence of the chairperson of the Board of Directors) or the president (in the absence of the chairperson of the Board of Directors and the chief executive
officer), or in their absence any other executive officer of the Company, shall serve as chairperson of the stockholder meeting. The chairperson of any meeting of stockholders shall have the power to adjourn the meeting to another place, if any,
date or time, whether or not a quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_112"></A>2.9&nbsp;&nbsp;&nbsp;&nbsp;VOTING </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section&nbsp;2.11 of
these bylaws, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section&nbsp;218 (relating to voting trusts and other voting agreements) of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be otherwise provided in the certificate of incorporation or these bylaws, each stockholder shall be entitled to one vote for
each share of capital stock held by such stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by law, the certificate of incorporation, these bylaws
or the rules of the stock exchange on which the Company&#146;s securities are listed, in all matters other than the election of directors, the affirmative vote of a majority of the voting power of the shares cast for or against a proposal shall be
the act of the stockholders, it being understood that broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be considered for purposes of establishing a quorum at the meeting but will not be considered as votes cast for or
against a proposal. Except as otherwise required by law, the certificate of incorporation or these bylaws, directors shall be elected by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and
entitled to vote on the election of directors. Except as otherwise provided by law, the certificate of incorporation, these bylaws or the rules of the stock exchange on which the securities of the Company are listed, where a separate vote by a class
or series or classes or series is required, in all matters other than the election of directors, the affirmative vote of the majority of the voting power of the outstanding shares of such class or series or classes or series cast for or against such
proposal shall be the act of such class or series or classes or series, it being understood that broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will not be considered as votes cast for or against a proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_113"></A>2.10&nbsp;&nbsp;&nbsp;&nbsp;STOCKHOLDER ACTION BY WRITTEN CONSENT
WITHOUT A MEETING </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights of holders of preferred stock of the Company, any action required or permitted to be taken by the
stockholders of the Company must be effected at a duly called annual or special meeting of stockholders of the Company and may not be effected by any consent in writing by such stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_114"></A>2.11&nbsp;&nbsp;&nbsp;&nbsp;RECORD DATES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Company may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the
Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which record date shall not be more than 60 nor less than 10 days before
the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record
date, that a later date on or before the date of the meeting shall be the date for making such determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed
by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is
waived, at the close of business on the day next preceding the day on which the meeting is held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A determination of stockholders of
record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however</I>, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at
the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with
the provisions of Section&nbsp;213 of the DGCL and this Section&nbsp;2.11 at the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Company may
determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose
of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such
action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_115"></A>2.12&nbsp;&nbsp;&nbsp;&nbsp;PROXIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder entitled to vote at a meeting of stockholders, or such stockholder&#146;s authorized officer, director, employee or agent,
may authorize another person or persons to act for such stockholder by proxy authorized by a document or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted
upon after three years from its date, unless the proxy provides for a longer period. The authorization of a person to act as a proxy may be documented, signed and delivered in accordance with Section&nbsp;116 of the DGCL; <I>provided </I>that such
authorization shall set forth, or be delivered with information enabling the Company to determine, the identity of the stockholder granting such authorization. The revocability of a proxy that states on its face that it is irrevocable shall be
governed by the provisions of Section&nbsp;212 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_116"></A>2.13&nbsp;&nbsp;&nbsp;&nbsp;LIST OF STOCKHOLDERS
ENTITLED TO VOTE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall prepare, in accordance with Section&nbsp;219 of the DGCL, a complete list of the stockholders entitled
to vote at the meeting; <I>provided, however,</I> if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before
the meeting date, arranged in alphabetical order, and showing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address of each stockholder and the number of shares registered in the name of each stockholder. The Company shall not be required to include electronic mail addresses or other electronic contact
information on such list. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting during the period contemplated by Section&nbsp;219 of the DGCL: (a)&nbsp;on a reasonably accessible electronic network,
<I>provided</I> that the information required to gain access to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the Company&#146;s principal place of business. In the event that the Company
determines to make the list available on an electronic network, the Company may take reasonable steps to ensure that such information is available only to stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_117"></A>2.14&nbsp;&nbsp;&nbsp;&nbsp;INSPECTORS OF ELECTION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before any meeting of stockholders, the Company shall appoint an inspector or inspectors of election to act at the meeting or its adjournment.
The Company may designate one or more persons as alternate inspectors to replace any inspector who fails to act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such inspectors shall:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;ascertain the number of shares outstanding and the voting power of each; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;determine the shares represented at the meeting and the validity of proxies and ballots; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;count all votes and ballots; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;determine and retain for a reasonable period a record of the disposition of any challenges made to any
determination by the inspectors; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;certify their determination of the number of shares represented at the
meeting, and their count of all votes and ballots. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inspectors of election shall perform their duties impartially, in good faith, to
the best of their ability and as expeditiously as is practical. If there are multiple inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all. Any report or
certificate made by the inspectors of election is <I>prima facie</I> evidence of the facts stated therein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_118"></A>ARTICLE III&#151;DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_119"></A>3.1&nbsp;&nbsp;&nbsp;&nbsp;POWERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The business and affairs of the Company shall be managed by or under the direction of the Board of Directors, except as may be otherwise
provided in the DGCL or the certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_120"></A>3.2&nbsp;&nbsp;&nbsp;&nbsp;NUMBER OF DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors shall consist of one or more members, each of whom shall be a natural person. Unless the certificate of incorporation
fixes the number of directors, the number of directors shall be determined from time to time by resolution of a majority of the Whole Board. No reduction of the authorized number of directors shall have the effect of removing any director before
that director&#146;s term of office expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_121"></A>3.3&nbsp;&nbsp;&nbsp;&nbsp;ELECTION, QUALIFICATION AND TERM OF
OFFICE OF DIRECTORS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;3.4 of these bylaws, each director, including a director elected to fill a vacancy
or newly created directorship, shall hold office until the expiration of the term for which elected and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until such director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal. Directors need not be stockholders unless so required by the
certificate of incorporation or these bylaws. The certificate of incorporation or these bylaws may prescribe other qualifications for directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so provided in the certificate of incorporation, the directors of the Company shall be divided into three classes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_122"></A>3.4&nbsp;&nbsp;&nbsp;&nbsp;RESIGNATION AND VACANCIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice given in writing or by electronic transmission to the Company. A resignation is effective when
the resignation is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events. A resignation which is conditioned upon the director failing to receive a specified vote
for reelection as a director may provide that it is irrevocable. Unless otherwise provided in the certificate of incorporation or these bylaws, when one or more directors resign from the Board of Directors, effective at a future date, a majority of
the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation or these bylaws or permitted in the specific case by resolution of the Board of
Directors, and subject to the rights of holders of Preferred Stock, vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single
class may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and not by stockholders. Notwithstanding the foregoing, no more than 1/3 of the number of directors in office at the
conclusion of the most recent annual meeting of stockholders may be appointed by the Board of Directors prior to the next annual meeting of stockholders, and, prior to the Company&#146;s first annual meeting of stockholders, the size of the Board of
Directors may not be increased by more than three. If the directors are divided into classes, a person so chosen to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall
have been chosen and until his or her successor shall have been duly elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_123"></A>3.5&nbsp;&nbsp;&nbsp;&nbsp;PLACE OF MEETINGS; MEETINGS BY TELEPHONE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may hold meetings, both regular and special, either within or outside the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the Board of Directors may participate in a
meeting of the Board of Directors by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in
person at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_124"></A>3.6&nbsp;&nbsp;&nbsp;&nbsp;REGULAR MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regular meetings of the Board of Directors may be held without notice at such time and at such place as shall from time to time be determined
by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_125"></A>3.7&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL MEETINGS; NOTICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the chairperson of the Board of Directors,
the chief executive officer, the president, the secretary or a majority of the Whole Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of the time and place of special
meetings shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;delivered personally by hand, by courier or by telephone; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;sent by United States first-class mail, postage prepaid; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;sent by facsimile; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;sent by electronic mail; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;otherwise given by electronic transmission (as defined in Section&nbsp;232 of the DGCL), </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">directed to each director at that director&#146;s address, telephone number, facsimile number, electronic mail address or other contact for notice by
electronic transmission, as the case may be, as shown on the Company&#146;s records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the notice is (i)&nbsp;delivered personally by
hand, by courier or by telephone, (ii)&nbsp;sent by facsimile, (iii)&nbsp;sent by electronic mail or (iv)&nbsp;otherwise given by electronic transmission, it shall be delivered, sent or otherwise directed to each director, as applicable, at least 24
hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall be deposited in the United States mail at least four days before the time of the holding of the meeting. Any oral notice of the time and place
of the meeting may be communicated to the director in lieu of written notice if such notice is communicated at least 24 hours before the time of the holding of the meeting. The notice need not specify the place of the meeting (if the meeting is to
be held at the Company&#146;s principal executive office) nor the purpose of the meeting, unless required by statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_126">
</A>3.8&nbsp;&nbsp;&nbsp;&nbsp;QUORUM; VOTING </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At all meetings of the Board of Directors, a majority of the Whole Board shall constitute a
quorum for the transaction of business. If a quorum is not present at any meeting of the Board of Directors, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a
quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the directors present at any meeting at which a quorum is present shall be the
act of the Board of Directors, except as may be otherwise specifically provided by statute, the certificate of incorporation or these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the certificate of incorporation provides that one or more directors shall have more or less than one vote per director on any matter,
except as may otherwise be expressly provided herein or therein and denoted with the phrase &#147;notwithstanding the final paragraph of Section&nbsp;3.8 of the bylaws&#148; or language to similar effect, every reference in these bylaws to a
majority or other proportion of the directors shall refer to a majority or other proportion of the votes of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_127">
</A>3.9&nbsp;&nbsp;&nbsp;&nbsp;BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of
incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or committee, as the case may
be, consent thereto in writing or by electronic transmission. Any person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action will be effective at a future time (including a
time determined upon the happening of an event), no later than 60 days after such instruction is given or such provision is made and such consent shall be deemed to have been given for purposes of this Section&nbsp;3.9 at such effective time so long
as such person is then a director and did not revoke the consent prior to such time. Any such consent shall be revocable prior to its becoming effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_128"></A>3.10&nbsp;&nbsp;&nbsp;&nbsp;FEES AND COMPENSATION OF DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board of Directors shall have the authority to fix the
compensation of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_129"></A>3.11&nbsp;&nbsp;&nbsp;&nbsp;REMOVAL OF DIRECTORS </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director or the entire Board of Directors may be removed from office by stockholders of the Company in the manner specified in the
certificate of incorporation and applicable law. No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration of such director&#146;s term of office. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_130"></A>ARTICLE IV&#151;COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_131"></A>4.1&nbsp;&nbsp;&nbsp;&nbsp;COMMITTEES OF DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may, by resolution passed by a majority of the Whole Board, designate one or more committees, each committee to consist
of one or more of the directors of the Company. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or
disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of
Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of Directors or in these bylaws, shall have and may exercise all the powers and
authority of the Board of Directors in the management of the business and affairs of the Company, and may authorize the seal of the Company to be affixed to all papers that may require it; but no such committee shall have the power or authority to
(a)&nbsp;approve or adopt, or recommend to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (b)&nbsp;adopt, amend or repeal any
bylaw of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_132"></A>4.2&nbsp;&nbsp;&nbsp;&nbsp;COMMITTEE MINUTES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each committee and subcommittee shall keep regular minutes of its meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_133"></A>4.3&nbsp;&nbsp;&nbsp;&nbsp;MEETINGS AND ACTION OF COMMITTEES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified by the Board of Directors, meetings and actions of committees and subcommittees shall be governed by, and held and
taken in accordance with, the provisions of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.5 (place of meetings and meetings by telephone);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.6 (regular meetings); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.7 (special meetings and notice); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.8 (quorum; voting); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.9 (action without a meeting); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.4 (waiver of notice) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with such changes in the context of those bylaws as are necessary to substitute the committee or subcommittee and its members for the Board of Directors and
its members. <I>However</I>, (i)&nbsp;the time and place of regular meetings of committees or subcommittees may be determined either by resolution of the Board of Directors or by resolution of the committee or subcommittee; (ii)&nbsp;special
meetings of committees or subcommittees may also be called by resolution of the Board of Directors or the committee or the subcommittee; and (iii)&nbsp;notice of special </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meetings of committees and subcommittees shall also be given to all alternate members who shall have the right to attend all meetings of the committee or subcommittee. The Board of Directors may
also adopt other rules for the government of any committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision in the certificate of incorporation providing that one or more
directors shall have more or less than one vote per director on any matter shall apply to voting in any committee or subcommittee, unless otherwise provided in the certificate of incorporation or these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_134"></A>4.4&nbsp;&nbsp;&nbsp;&nbsp;SUBCOMMITTEES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation, these bylaws or the resolutions of the Board of Directors designating the
committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_135"></A>ARTICLE V&#151;OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_136"></A>5.1&nbsp;&nbsp;&nbsp;&nbsp;OFFICERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of the Company shall be a president and a secretary. The Company may also have, at the discretion of the Board of Directors, a
chairperson of the Board of Directors, a vice chairperson of the Board of Directors, a chief executive officer, a chief financial officer or treasurer, and any such other officers as may be appointed in accordance with the provisions of these
bylaws. Any number of offices may be held by the same person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_137"></A>5.2&nbsp;&nbsp;&nbsp;&nbsp;APPOINTMENT OF
OFFICERS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors shall appoint the officers of the Company, except such officers as may be appointed in accordance with
the provisions of Section&nbsp;
5.3 of these bylaws, subject to the rights, if any, of an officer under any contract of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_138"></A>5.3&nbsp;
&nbsp;&nbsp;&nbsp;SUBORDINATE OFFICERS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may appoint, or empower any officer to appoint, such other officers as the
business of the Company may require. Each of such officers shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as determined from time to time by the Board of Directors or any duly
authorized committee or subcommittee thereof or by any officer who has been conferred such power of determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_139"></A>5.4&nbsp;&nbsp;&nbsp;&nbsp;REMOVAL AND RESIGNATION OF OFFICERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by
the Board of Directors or, for the avoidance of doubt, any duly authorized committee or subcommittee thereof or by any officer who has been conferred such power of removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any officer may resign at any time by giving notice, in writing or by electronic transmission, to the Company. Any resignation shall take
effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation
is without prejudice to the rights, if any, of the Company under any contract to which the officer is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_140"></A>5.5&nbsp;&nbsp;&nbsp;&nbsp;VACANCIES IN OFFICES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any vacancy occurring in any office of the Company shall be filled by the Board of Directors or as provided in Section&nbsp;5.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_141"></A>5.6&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATION OF SECURITIES OF OTHER ENTITIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the Board of Directors, the chief executive officer, the president, any vice president, the treasurer, the secretary or
assistant secretary of the Company or any other person authorized by the Board of Directors or the chief executive officer, the president or a vice president, is authorized to vote, represent and exercise on behalf of the Company all rights incident
to any and all shares or other securities of, or interests in, or issued by, any other entity or entities, and all rights incident to any management authority conferred on the Company in accordance with the governing documents of any entity or
entities, standing in the name of the Company, including the right to act by written consent. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly
executed by such person having the authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_142"></A>5.7&nbsp;&nbsp;&nbsp;&nbsp;AUTHORITY AND DUTIES OF OFFICERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each officer of the Company shall have such authority and perform such duties in the management of the business of the Company as may be
designated from time to time by the Board of Directors or, for the avoidance of doubt, any duly authorized committee or subcommittee thereof or by any officer who has been conferred such power of designation and, to the extent not so provided, as
generally pertain to such office, subject to the control of the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_143"></A>ARTICLE VI&#151;STOCK
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_144"></A>6.1&nbsp;&nbsp;&nbsp;&nbsp;STOCK CERTIFICATES; PARTLY PAID SHARES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of the Company shall be represented by certificates, provided that the Board of Directors may provide by resolution or resolutions
that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Company. Unless otherwise provided
by resolution of the Board of Directors, every holder of stock represented by certificates shall be entitled to have a certificate signed by, or in the name of, the Company by any two officers of the Company representing the number of shares
registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such
officer, transfer agent or registrar before such certificate is issued, it may be issued by the Company with the same effect as if such person were such officer, transfer agent or registrar at the date of issue. The Company shall not have power to
issue a certificate in bearer form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may issue the whole or any part of its shares as partly paid and subject to call for the
remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly-paid shares, or upon the books and records of the Company in the case of uncertificated partly-paid shares, the
total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully-paid shares, the Company shall declare a dividend upon partly-paid shares of the same class, but only
upon the basis of the percentage of the consideration actually paid thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_145"></A>6.2&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL
DESIGNATION ON CERTIFICATES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company is authorized to issue more than one class of stock or more than one series of any class, then
the powers, the designations, the preferences and the relative, participating, optional or other special rights of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the
certificate that the Company shall issue to represent such class or series of stock; <I>provided, however</I>, that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the
face or back of the certificate that the Company shall issue to represent such class or series of stock, a statement that the Company will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated
stock, the registered owner thereof shall be given a notice, in writing or by electronic transmission, containing the information required to be set forth or stated on certificates pursuant to this Section&nbsp;6.2 or Sections&nbsp;156, 202(a),
218(a) or 364 of the DGCL or with respect to this Section&nbsp;6.2 a statement that the Company will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other
special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated
stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_146">
</A>6.3&nbsp;&nbsp;&nbsp;&nbsp;LOST CERTIFICATES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in this Section&nbsp;6.3, no new certificates for shares shall be
issued to replace a previously issued certificate unless the latter is surrendered to the Company and cancelled at the same time. The Company may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore
issued by it, alleged to have been lost, stolen or destroyed, and the Company may require the owner of the lost, stolen or destroyed certificate, or such owner&#146;s legal representative, to give the Company a bond sufficient to indemnify it
against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_147"></A>6.4&nbsp;&nbsp;&nbsp;&nbsp;DIVIDENDS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors, subject to any restrictions contained in the certificate of incorporation or applicable law, may declare and pay
dividends upon the shares of the Company&#146;s capital stock. Dividends may be paid in cash, in property, or in shares of the Company&#146;s capital stock, subject to the provisions of the certificate of incorporation. The Board of Directors may
set apart out of any of the funds of the Company available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_148"></A>6.5&nbsp;&nbsp;&nbsp;&nbsp;TRANSFER OF STOCK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers of record of shares of stock of the Company shall be made only upon its books by the holders thereof, in person or by an attorney
duly authorized, and, if such stock is certificated, upon the surrender of a certificate or certificates for a like number of shares, properly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_149"></A>6.6&nbsp;&nbsp;&nbsp;&nbsp;STOCK TRANSFER AGREEMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of
the Company to restrict the transfer of shares of stock of the Company of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_150"></A>6.7&nbsp;&nbsp;&nbsp;&nbsp;REGISTERED STOCKHOLDERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to
receive dividends and notices and to vote as such owner; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;shall not be bound to recognize any equitable or other claim to
or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_151"></A>ARTICLE VII&#151;MANNER OF GIVING NOTICE AND WAIVER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_152"></A>7.1&nbsp;&nbsp;&nbsp;&nbsp;NOTICE OF STOCKHOLDERS&#146; MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any meeting of stockholders shall be given in the manner set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_153"></A>7.2&nbsp;&nbsp;&nbsp;&nbsp;NOTICE TO STOCKHOLDERS SHARING AN ADDRESS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise prohibited under the DGCL, without limiting the manner by which notice otherwise may be given effectively to stockholders,
any notice to stockholders given by the Company under the provisions of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the
stockholders at that address to whom such notice is given. Any such consent shall be revocable by the stockholder by written notice to the Company. Any stockholder who fails to object in writing to the Company, within 60 days of having been given
written notice by the Company of its intention to send the single notice, shall be deemed to have consented to receiving such single written notice. This Section&nbsp;7.2 shall not apply to Sections&nbsp;164, 296, 311, 312 or 324 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_154"></A>7.3&nbsp;&nbsp;&nbsp;&nbsp;NOTICE TO PERSON WITH WHOM COMMUNICATION IS UNLAWFUL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given, under the DGCL, the certificate of incorporation or these bylaws, to any person with whom
communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting
which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the Company is such as to require
the filing of a certificate under the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_155"></A>7.4&nbsp;&nbsp;&nbsp;&nbsp;WAIVER OF NOTICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a written waiver,
signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a
person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not
lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so
required by the certificate of incorporation or these bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_156"></A>ARTICLE VIII&#151;INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_157"></A>8.1&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF DIRECTORS AND OFFICERS IN THIRD PARTY PROCEEDINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article&nbsp;VIII, the Company shall indemnify, to the fullest extent permitted by the DGCL, as now or
hereinafter in effect, any person who was or is a party or is threatened to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;<B>Proceeding</B>&#148;) (other than an action
by or in the right of the Company) by reason of the fact that such person is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection
with such Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to
believe such person&#146;s conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of <I>nolo contendere</I> or its equivalent, shall not, of itself, create a presumption that the person did
not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person&#146;s
conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_158"></A>8.2&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF DIRECTORS AND OFFICERS IN ACTIONS BY OR IN
THE RIGHT OF THE COMPANY </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article&nbsp;VIII, the Company shall indemnify, to the fullest extent
permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed Proceeding by or in the right of the Company to procure a judgment in its favor by
reason of the fact that such person is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such Proceeding if such person acted in good
faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been
adjudged to be liable to the Company unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the
circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_159"></A>8.3&nbsp;&nbsp;&nbsp;&nbsp;SUCCESSFUL DEFENSE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that a present or former director or officer (for purposes of this Section&nbsp;8.3 only, as such term is defined in
Section&nbsp;145(c)(1) of the DGCL) of the Company has been successful on the merits or otherwise in defense of any Proceeding described in Section&nbsp;8.1 or Section&nbsp;8.2, or in defense of any claim, issue or matter therein, such person shall
be indemnified against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection therewith. The Company may indemnify any other person who is not a present or former director or officer of the Company
against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person to the extent he or she has been successful on the merits or otherwise in defense of any suit or proceeding described in Section&nbsp;8.1 or
Section&nbsp;8.2, or in defense of any claim, issue or matter therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_160"></A>8.4&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF OTHERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article&nbsp;VIII, the Company shall have power to indemnify its employees and agents, or any other
persons, to the extent not prohibited by the DGCL or other applicable law. The Board of Directors shall have the power to delegate to any person or persons identified in subsections (1)&nbsp;through (4) of Section&nbsp;145(d) of the DGCL the
determination of whether employees or agents shall be indemnified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_161"></A>8.5&nbsp;&nbsp;&nbsp;&nbsp;ADVANCED PAYMENT OF EXPENSES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses (including attorneys&#146; fees) actually and reasonably incurred by an officer or director of the Company in defending any
Proceeding shall be paid by the Company in advance of the final disposition of such Proceeding upon receipt of a written request therefor (together with documentation reasonably evidencing such expenses) and an undertaking by or on behalf of the
person to repay such amounts if it shall ultimately be determined that the person is not entitled to be indemnified under this Article&nbsp;VIII or the DGCL. Such expenses (including attorneys&#146; fees) actually and reasonably incurred by former
directors and officers or other employees and agents of the Company or by persons serving at the request of the Company as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be
so paid upon such terms and conditions, if any, as the Company deems appropriate. The right to advancement of expenses shall not apply to any Proceeding (or any part of any Proceeding) for which indemnity is excluded pursuant to these bylaws, but
shall apply to any Proceeding (or any part of any Proceeding) referenced in Section&nbsp;8.6(b) or 8.6(c) prior to a determination that the person is not entitled to be indemnified by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless otherwise determined pursuant to Section&nbsp;8.8, no advance shall be made by the Company to an officer
of the Company (except by reason of the fact that such officer is or was a director of the Company, in which event this paragraph shall not apply) in any Proceeding if a determination is reasonably and promptly made (a)&nbsp;by a vote of the
directors who are not parties to such Proceeding, even though less than a quorum, or (b)&nbsp;by a committee of such directors designated by the vote of the majority of such directors, even though less than a quorum, or (c)&nbsp;if there are no such
directors, or if such directors so direct, by independent legal counsel in a written opinion, that facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad
faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_162">
</A>8.6&nbsp;&nbsp;&nbsp;&nbsp;LIMITATION ON INDEMNIFICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirements in Section&nbsp;8.3 and the DGCL, the Company
shall not be obligated to indemnify any person pursuant to this Article&nbsp;VIII in connection with any Proceeding (or any part of any Proceeding): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;for which payment has actually been made to or on behalf of such person under any statute, insurance policy,
indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;for an
accounting or disgorgement of profits pursuant to Section&nbsp;16(b) of the 1934 Act, or similar provisions of federal, state or local statutory law or common law, if such person is held liable therefor (including pursuant to any settlement
arrangements); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;for any reimbursement of the Company by such person of any bonus or other incentive-based or
equity-based compensation or of any profits realized by such person from the sale of securities of the Company, as required in each case under the 1934 Act (including any such reimbursements that arise from an accounting restatement of the Company
pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the &#147;<B>Sarbanes-Oxley Act</B>&#148;), or the payment to the Company of profits arising from the purchase and sale by such person of securities in violation of Section&nbsp;306 of
the Sarbanes-Oxley Act), if such person is held liable therefor (including pursuant to any settlement arrangements); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;initiated by such person, including any Proceeding (or any part of any Proceeding) initiated by such person against
the Company or its directors, officers, employees, agents or other indemnitees, unless (i)&nbsp;the Board of Directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii)&nbsp;the Company provides the
indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii)&nbsp;otherwise required to be made under Section&nbsp;8.7 or (iv)&nbsp;otherwise required by applicable law; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;if prohibited by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_163"></A>8.7&nbsp;&nbsp;&nbsp;&nbsp;DETERMINATION; CLAIM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a claim for indemnification or advancement of expenses under this Article&nbsp;VIII is not paid in full within 90&nbsp;days after receipt
by the Company of the written request therefor, the claimant shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of expenses. The Company shall indemnify such
person against any and all expenses that are actually and reasonably incurred by such person in connection with any action for indemnification or advancement of expenses from the Company under this Article&nbsp;VIII, to the extent such person is
successful in such action, and to the extent not prohibited by law. In any such suit, the Company shall, to the fullest extent not prohibited by law, have the burden of proving that the claimant is not entitled to the requested indemnification or
advancement of expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_164"></A><FONT STYLE="white-space:nowrap">8.8&nbsp;&nbsp;&nbsp;&nbsp;NON-EXCLUSIVITY</FONT> OF
RIGHTS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification and advancement of expenses provided by, or granted pursuant to, this Article&nbsp;VIII shall not be deemed
exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the certificate of incorporation or any statute, bylaw, agreement, vote of stockholders or disinterested directors or otherwise,
both as to action in such person&#146;s official capacity and as to action in another capacity while holding such office. The Company is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees
or agents respecting indemnification and advancement of expenses, to the fullest extent not prohibited by the DGCL or other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_165"></A>8.9&nbsp;&nbsp;&nbsp;&nbsp;INSURANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company,
or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person
in any such capacity, or arising out of such person&#146;s status as such, whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_166"></A>8.10&nbsp;&nbsp;&nbsp;&nbsp;SURVIVAL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights to indemnification and advancement of expenses conferred by this Article&nbsp;VIII shall continue as to a person who has ceased to
be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_167">
</A>8.11&nbsp;&nbsp;&nbsp;&nbsp;EFFECT OF REPEAL OR MODIFICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A right to indemnification or to advancement of expenses arising under a
provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to or repeal or elimination of the certificate of incorporation or these bylaws after the occurrence of the act or omission that is the
subject of the Proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has
occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_168"></A>8.12&nbsp;&nbsp;&nbsp;&nbsp;CERTAIN DEFINITIONS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article&nbsp;VIII, references to the &#147;<B>Company</B>&#148; shall include, in addition to the resulting company, any
constituent company (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents, so
that any person who is or was a director, officer, employee or agent of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such constituent company, or is or was serving at the request of such constituent company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or
other enterprise, shall stand in the same position under the provisions of this Article&nbsp;VIII with respect to the resulting or surviving company as such person would have with respect to such constituent company if its separate existence had
continued. For purposes of this Article&nbsp;VIII, references to &#147;<B>other enterprises</B>&#148; shall include employee benefit plans; references to &#147;<B>fines</B>&#148; shall include any excise taxes assessed on a person with respect to an
employee benefit plan; and references to &#147;<B>serving at the request of the Company</B>&#148; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director,
officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries
of an employee benefit plan shall be deemed to have acted in a manner &#147;<B>not opposed to the best interests of the Company</B>&#148; as referred to in this Article&nbsp;VIII. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_169"></A>ARTICLE IX&#151;GENERAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_170"></A>9.1&nbsp;&nbsp;&nbsp;&nbsp;EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by law, the certificate of incorporation or these bylaws, the Board of Directors may authorize any officer or
officers, or agent or agents, or employee or employees, to enter into any contract or execute any document or instrument in the name of and on behalf of the Company; such authority may be general or confined to specific instances. Unless so
authorized or ratified by the Board of Directors or within the agency power of an officer, agent or employee, no officer, agent or employee shall have any power or authority to bind the Company by any contract or engagement or to pledge its credit
or to render it liable for any purpose or for any amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_171"></A>9.2&nbsp;&nbsp;&nbsp;&nbsp;FISCAL YEAR </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fiscal year of the Company shall be fixed by resolution of the Board of Directors and may be changed by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_172"></A>9.3&nbsp;&nbsp;&nbsp;&nbsp;SEAL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may adopt a corporate seal, which shall be adopted and which may be altered by the Board of Directors. The Company may use the
corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_173"></A>9.4&nbsp;&nbsp;&nbsp;&nbsp;CONSTRUCTION; DEFINITIONS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the
construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term &#147;<B>person</B>&#148; includes a corporation, partnership, limited
liability company, joint venture, trust or other enterprise, and a natural person. Any reference in these bylaws to a section of the DGCL shall be deemed to refer to such section as amended from time to time and any successor provisions thereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_174"></A>9.5&nbsp;&nbsp;&nbsp;&nbsp;FORUM SELECTION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the
Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a)&nbsp;any derivative
action or proceeding brought on behalf of the Company, (b)&nbsp;any action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asserting a claim of breach of a fiduciary duty owed by any director, stockholder, officer or other employee of the Company to the Company or the Company&#146;s stockholders, (c)&nbsp;any action
arising pursuant to any provision of the DGCL or the certificate of incorporation or these bylaws (as either may be amended from time to time) or (d)&nbsp;any action asserting a claim governed by the internal affairs doctrine, except for, as to each
of (a)&nbsp;through (d) above, any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court
within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, against any person in connection with any offering of the Company&#146;s securities,
(including without limitation and for the avoidance of doubt, any underwriter, auditor, expert, control person or other defendant). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
person or entity purchasing or otherwise acquiring any interest in any security of the Company shall be deemed to have notice of and consented to the provisions of this Section&nbsp;9.5. This provision shall be enforceable by any party to a
complaint covered by the provisions of this Section&nbsp;9.5. For the avoidance of doubt, nothing contained in this Section&nbsp;9.5 shall apply to any action brought to enforce a duty or liability created by the 1934&nbsp;Act or any successor
thereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_175"></A>ARTICLE X&#151;AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These bylaws may be adopted, amended or repealed by the stockholders entitled to vote; provided, however, that the affirmative vote of the
holders of at least 66&nbsp;2/3% of the total voting power of outstanding voting securities, voting together as a single class, shall be required for the stockholders of the Company to alter, amend or repeal, or adopt any bylaw inconsistent with,
the following provisions of these bylaws: Article II, Sections 3.1, 3.2, 3.4 and 3.11 of Article III, Article VIII, Section&nbsp;9.5 of Article&nbsp;IX or this Article X (including, without limitation, any such Article or Section as renumbered as a
result of any amendment, alteration, change, repeal, or adoption of any other Bylaw). The Board of Directors shall also have the power to adopt, amend or repeal bylaws; provided, however, that a bylaw amendment adopted by stockholders which
specifies the votes that shall be necessary for the election of directors shall not be further amended or repealed by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc722206_31"></A>APPENDIX H </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n13.jpg" ALT="LOGO">
 </P> <P ALIGN="center" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Computershare8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.comSecurity ClassHolder Account
NumberFoldForm of Proxy - Special Meeting to be held on XXX, 2022This Form of Proxy is solicited by and on behalf of Management.Notes to proxy1.Every holder has the right to appoint some other person or company of their choice, who need not be a
holder, to attend and act on their behalf at the meeting or any adjournment or postponement thereof. If you wish to appoint a person or company other than the Management Nominees whose names are printed herein, please insert the name of your chosen
proxyholder in the space provided (see reverse).2.If the securities are registered in the name of more than one owner (for example, joint ownership, trustees, executors, etc.), then all those registered should sign this proxy. If you are voting on
behalf of a corporation or another individual you may be required to provide documentation evidencing your power to sign this proxy with signing capacity stated.3.This proxy should be signed in the exact manner as the name(s) appear(s) on the
proxy.4.If a date is not inserted in the space provided on the reverse of this proxy, it will be deemed to bear the date on which it was mailed to the holder by Management.5.The securities represented by this proxy will be voted as directed by the
holder, however, if such a direction is not made in respect of any matter, and the proxy appoints the Management Nominees listed on the reverse, this proxy will be voted as recommended by Management.6.The securities represented by this proxy will be
voted in favour, or withheld from voting, or voted against each of the matters described herein, as applicable, in accordance with the instructions of the holder, on any ballot that may be called for. If you have specified a choice with respect to
any matter to be acted on, the securities will be voted accordingly.7.This proxy confers discretionary authority in respect of amendments or variations to matters identified in the Notice of Meeting and Management Information Circular or other
matters that may properly come before the meeting or any adjournment or postponement thereof, unless prohibited by law.8.This proxy should be read in conjunction with the accompanying documentation provided by Management.VOTE USING THE TELEPHONE OR
INTERNET 24 HOURS A DAY 7 DAYS A WEEK!Proxies submitted must be received by XXX, Pacific Time, on XXX, 2022. * Call the number listed BELOW from a touch tone telephone.1-866-732-VOTE (8683) Toll FreeIf you vote by telephone or the Internet, DO NOT
mail back this proxy.Voting by mail may be the only method for securities held in the name of a corporation or securities being voted on behalf of another individual.Voting by mail or by Internet are the only methods by which a holder may appoint a
person as proxyholder other than the Management Nominees named on the reverse of this proxy. Instead of mailing this proxy, you may choose one of the two voting methods outlined above to vote this proxy.To vote by telephone or the Internet, you will
need to provide your CONTROL NUMBER listed below.CONTROL NUMBER </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g13n04.jpg" ALT="LOGO">
 </P> <P ALIGN="center" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Appointment of Proxyholderl/We being holder(s) of securities of Zymeworks Inc. (the "Company) hereby appoint: Kenneth
Galbraith, President, Chief Executive Officer and Chair of Board of Directors of the Company, or failing him, Neil Klompas, Chief Operating Officer of the Company, or failing him, Christopher Astle, Senior Vice President, Chief Financial Officer of
the Company (the Management Nominees) as my/our proxyholder with full power of substitution and to attend, act and to vote for and on behalf of the holder in accordance with the following direction (or if no directions have been given, as the
proxyholder sees fit) and on all other matters that may properly come before the Special Meeting of shareholders of the Company to be held at XXX on XXXX, 2022 at XXXX, Pacific Time, and at any adjournment or postponement thereof. For Against
Abstain1. Redomicile ResolutionTo consider and, if deemed advisable, to pass, with or without variation, a special resolution, the full text of which is set forth in Appendix A to the management information circular of the Company dated XXX, 2022
(Management Information Circular), approving a plan of arrangement under the Business Corporations Act (British Columbia), all as more particularly described in the Management Information Circular. FoldSignature of ProxyholderSignature(s) l/We
authorize you to act in accordance with my/our instructions set out above. I/We hereby revoke any proxy previously given with respect to the Special Meeting. If no voting instructions are indicated above, and the proxy appoints the Management
Nominees, this Proxy will be voted as recommended by Management. DateDD/MM/YY 34417599999+ </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Parent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General
Corporation Law authorizes a corporation&#146;s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent expects to adopt an amended and restated certificate of incorporation (the &#147;<B>Parent Certificate of Incorporation</B>&#148;), which will become
effective at or prior to the Effective Time of the Redomicile Transactions, and which will contain provisions that limit the liability of Parent&#146;s directors and officers for monetary damages to the fullest extent permitted by the Delaware
General Corporation Law. Consequently, Parent&#146;s directors, and, if applicable, its officers, will not be personally liable to Parent or its stockholders for monetary damages for any breach of fiduciary duties as directors or officers, as
applicable, except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to Parent or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which they derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain amendments have been proposed to the Delaware General Corporation Law that, if adopted, would permit similar exculpation of certain specified officers
from liability for breaches of fiduciary duties beginning in August 2022. If such amendments are adopted, certain of Parent&#146;s officers will have similar exculpation benefits, other than with respect to the above list of exclusions (except in
respect of Section&nbsp;174 of the DGCL, which applies only to directors) and with respect to derivative actions or other claims by or in the right of Parent, to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or elimination of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim
that occurred or arose prior to that amendment, repeal or elimination. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal
liability of Parent&#146;s directors and officers will be further limited to the greatest extent permitted by the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, Parent expects to adopt amended and restated bylaws (the &#147;<B>Parent Bylaws</B>&#148;), which will become effective at or prior to the time of the Redomicile Transactions, and which will provide that Parent will indemnify its directors
and officers, and may indemnify its employees, agents and any other persons, to the fullest extent permitted by the Delaware General Corporation Law. The Parent Bylaws will also provide that Parent must advance expenses incurred by or on behalf of a
director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Parent has entered into or
will enter into indemnification agreements with each of Parent&#146;s directors and executive officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification
agreements require Parent, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require Parent to advance all expenses
reasonably and actually incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. Parent believes that these agreements are necessary to attract and retain qualified individuals to serve as
directors and executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions that are expected to be included in the Parent
Certificate of Incorporation, the Parent Bylaws and the indemnification agreements that Parent has entered into or will enter into with Parent&#146;s directors and executive officers may discourage stockholders from bringing a lawsuit against
Parent&#146;s directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against Parent&#146;s directors and executive officers, even though an action, if successful, might
benefit Parent and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that Parent pays the costs of settlement and damage awards against directors and executive officers as required by these
indemnification provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parent expects to obtain and maintain insurance policies under which its directors and officers are insured, within the
limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to which they are parties by reason of
being or having been Parent&#146;s directors or officers. The coverage provided by these policies may apply whether or not Parent would have the power to indemnify such person against such liability under the provisions of the Delaware General
Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of Parent&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their
employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of Parent&#146;s board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zymeworks </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BCBCA, Zymeworks may
indemnify an individual who: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is or was Zymeworks&#146; director or officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is or was a director or officer (1)&nbsp;at Zymeworks&#146; request, or (2)&nbsp;of another corporation at the
time when such corporation is or was an affiliate of Zymeworks; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at Zymeworks&#146; request, is or was, or holds or held a position equivalent to that of a director or officer of
a partnership, trust, joint venture or other unincorporated entity, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">in each case against a judgment, penalty or fine
awarded or imposed in, or an amount paid in settlement of, any legal proceeding or investigative action, whether current, threatened, pending or completed, in which such eligible party is involved because of that association with Zymeworks or other
entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, indemnification is prohibited under the BCBCA if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such eligible party did not act honestly and in good faith with a view to Zymeworks&#146; best interests (or the
other entity, as the case may be); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a proceeding other than a civil proceeding, such eligible party did not have reasonable grounds
for believing that such person&#146;s conduct was lawful; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that
the agreement to indemnify or pay expenses was made, Zymeworks was prohibited from giving the indemnity or paying the expenses by Zymeworks&#146; articles; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at
the time that the indemnity or payment is made, Zymeworks was prohibited from giving the indemnity or paying the expenses by Zymeworks&#146; articles. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure of a director or officer of Zymeworks to comply with the BCBCA or our articles does not invalidate any indemnity to which he or she might be
entitled. However, we may not indemnify or pay the expenses of an eligible party in respect of an action brought against an eligible party by or on behalf of us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCBCA allows Zymeworks to pay, as they are incurred in advance of a final disposition of a proceeding,
the expenses actually and reasonably incurred by the eligible party, provided that Zymeworks receives from such eligible party an undertaking to repay the amounts advanced if it is ultimately determined that such payment is prohibited. Following the
final disposition of an eligible proceeding, the BCBCA requires Zymeworks to pay the expenses actually and reasonably incurred by the eligible party in respect of that proceeding if the eligible party has not been reimbursed for those expenses and
is wholly successful, on the merits or otherwise, in the outcome of the proceeding, or is substantially successful on the merits in the outcome of the proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the foregoing, on application by Zymeworks or an eligible party, a court may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order Zymeworks to indemnify an eligible party in respect of an eligible proceeding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order Zymeworks to pay some or all of the expenses incurred by an eligible party in an eligible proceeding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order enforcement of or any payment under an indemnification agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order Zymeworks to pay some or all of the expenses actually and reasonably incurred by a person in obtaining the
order of the court; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any other order the court considers appropriate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCBCA provides that Zymeworks may purchase and maintain insurance for the benefit of an eligible party (or their heirs and personal or other legal
representatives of the eligible party) against any liability that may be incurred by reason of the eligible party being or having been a director or officer, or in an equivalent position of ours or that of an associated corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our articles provide that Zymeworks will indemnify any of Zymeworks&#146; directors, former directors, officers, and former officers and other parties
specified by the articles against all judgments, penalties or fines awarded or imposed in, or an amount paid in settlement of, any legal proceeding or investigative action, whether current, threatened, pending or completed, to which they are or may
be made a party by reason of having been a director or officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks has entered into indemnity agreements with certain of Zymeworks&#146; officers
and directors, pursuant to which Zymeworks is obligated to indemnify and hold harmless such persons against all costs, charges, and expenses, including any amounts paid to settle actions or satisfy judgments, reasonably incurred by them in respect
of any civil, criminal, administrative, investigative, or other proceeding to which they are made a party by reason of being or having been an officer or director. However, such indemnification obligations arise only to the extent that the party
seeking indemnification was acting honestly and in good faith with a view to Zymeworks&#146; best interests, and, in the case of criminal or administrative actions or proceedings enforced by monetary penalties, that such person had reasonable
grounds for believing that his or her conduct was lawful. Under the indemnity agreements, Zymeworks may advance to the indemnified parties the expenses incurred in defending any such actions or proceedings, but if the director or officer does not
meet the conditions to qualify for indemnification, such amounts shall be repaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the BCBCA, the Registrant has purchased directors&#146;
and officers&#146; liability insurance that, under certain circumstances, insures its directors and officers against the costs of defense, settlement, or payment of a judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">***** </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such
indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits listed in the exhibit index, appearing elsewhere in this registration statement, have been filed as part of this registration statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx722206_123">Transaction Agreement (included as Appendix B to the Proxy Statement/Prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx722206_141">Plan of Arrangement (included as Exhibit A to the Transaction Agreement included as Appendix B to the Proxy Statement/Prospectus). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx722206_158">Form of Exchangeable Share Support Agreement, dated [&#9679;], 2022 by and between Zymeworks Delaware Inc., Zymeworks CallCo ULC, and Zymeworks ExchangeCo Ltd. (included as Exhibit C to the Transaction Agreement).
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx722206_171">Form of Trust Agreement, dated [&#9679;], 2022 by and between Zymeworks Delaware Inc., Zymeworks CallCo ULC, Zymeworks ExchangeCo Ltd. and Computershare Trust Company of Canada (included as Exhibit D to the Transaction
 Agreement). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex31.htm">Form of Amended and Restated Certificate of Incorporation of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex32.htm">Form of Certificate of Designation of Special Voting Stock of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex33.htm">Form of Amended and Restated Bylaws of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex34.htm">Notice of Articles of the Company. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex35.htm">Form of Articles of the Company.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522172083/d319186dex41.htm#EXA">Resolutions of the Board of Directors of the Company (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form
 <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June&nbsp;10, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1&plusmn;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen common stock certificate of Zymeworks Delaware Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312519177515/d663729dex992.htm">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Shares (incorporated by reference to Exhibit 99.2 to the
Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June&nbsp;20, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312520013371/d868443dex41.htm">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Shares (incorporated by reference to Exhibit 4.1 to the
 Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;24, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312520073718/d900170dex41.htm">Registration Rights Agreement dated March&nbsp;
16, 2020, by and among Zymeworks, Baker Brothers Life Sciences, L.P. and 667, L.P. (incorporated by reference to Exhibit 4.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;
16, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522019922/d302094dex41.htm">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Shares (incorporated by reference to Exhibit 4.1 to Zymeworks&#146;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522172083/d319186dex41.htm">Preferred Shares Rights Agreement, dated as of June&nbsp;
9, 2022, by and between Zymeworks and Computershare Trust Company, N.A., as rights agent (incorporated by reference to Exhibit 4.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June&nbsp;
10, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1&plusmn;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex81.htm">Form of tax opinion of Blake, Cassels &amp; Graydon LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex82.htm">Form of tax opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex102.htm">Amended and Restated Employment Agreement, dated January&nbsp;17, 2017, by and between Zymeworks and Dr.&nbsp;
Ali Tehrani (incorporated by reference to Exhibit 10.2 to Zymeworks Inc.&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522002772/d207208dex102.htm">Separation Agreement and Release by and between Zymeworks and Ali Tehrani, dated January&nbsp;
5, 2022 (incorporated by reference to Exhibit 10.2 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> originally filed with the SEC on January&nbsp;5, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex104.htm">Amended and Restated Employment Agreement, dated January&nbsp;
17, 2017, by and between Zymeworks and Neil Klompas (incorporated by reference to Exhibit 10.4 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522002772/d207208dex103.htm">Promotion Letter from Zymeworks to Neil Klompas, dated January&nbsp;
5, 2022 (incorporated by reference to Exhibit 10.3 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> originally filed with the SEC on January&nbsp;5, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex106.htm">Amended and Restated Employment Agreement, dated January&nbsp;
18, 2017, by and between Zymeworks and Diana Hausman (incorporated by reference to Exhibit 10.6 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517125105/d293184dex1013.htm">Form of Indemnity Agreement between Zymeworks and its officers and directors (incorporated by reference to Exhibit 10.13 to Zymeworks&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217100),</FONT> originally filed with the SEC on April&nbsp;17, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517125105/d293184dex1014.htm">Second Amended and Restated Employee Stock Option Plan and forms of agreements thereunder (incorporated by reference to Exhibit 10.14 to Zymeworks&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217100),</FONT> originally filed with the SEC on April&nbsp;17, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1016.htm">Amended and Restated Research and License Agreement, effective as of December&nbsp;
3, 2014, by and between Zymeworks Inc. and Merck Sharp&nbsp;&amp; Dohme Research GmbH (incorporated by reference to Exhibit 10.16 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1017.htm">Licensing and Collaboration Agreement, effective as of December&nbsp;
17, 2013, by and between Zymeworks and Eli Lilly and Company (incorporated by reference to Exhibit 10.17 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1018.htm">First Amendment to Licensing and Collaboration Agreement, effective as of May&nbsp;
30, 2014, by and between Zymeworks and Eli Lilly and Company, as amended February&nbsp;25, 2014 and June&nbsp;
16, 2014 (incorporated by reference to Exhibit 10.18 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1019.htm">Licensing and Collaboration Agreement, effective as of October&nbsp;
22, 2014, by and between Zymeworks and Eli Lilly and Company (incorporated by reference to Exhibit 10.19 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1020.htm">First Amendment to Licensing and Collaboration Agreement, effective as of June&nbsp;
4, 2015, by and between Zymeworks and Eli Lilly and Company (incorporated by reference to Exhibit 10.20 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1021.htm">Second Amendment to Licensing and Collaboration Agreement, effective as of January&nbsp;
24, 2017, by and between Zymeworks and Eli Lilly and Company (incorporated by reference to Exhibit 10.21 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1022.htm">Collaboration Agreement, effective as of December&nbsp;
23, 2014, by and among Zymeworks, Celgene Corporation and Celgene Alpine Investment Co. LLC (incorporated by reference to Exhibit 10.22 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000134100417000445/ex99-1.htm">First Amendment to Collaboration Agreement, effective as of May&nbsp;
29, 2017, by and between Zymeworks, Celgene Corporation and Celgene Alpine Investment Co. LLC (incorporated by reference to Exhibit 99.1 to a Report of Foreign Private Issuer on Form <FONT STYLE="white-space:nowrap">6-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally furnished to the SEC on July&nbsp;18, 2017 and deemed filed under the Exchange Act). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375220000004/zyme-20200331xex991.htm">Second Amendment to Collaboration Agreement, effective as of March&nbsp;
31, 2020, by and between Zymeworks, Celgene Corporation and Celgene Alpine Investment Co. LLC (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;7,
 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375220000012/zyme-20200630xex102.htm">Third Amendment to Collaboration Agreement, dated June&nbsp;
22, 2020, by and between Zymeworks, Celgene Corporation and Celgene Alpine Investment Co. LLC. (incorporated by reference to Exhibit&nbsp;
10.2 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;5, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex994.htm">Letter Agreement, effective April&nbsp;
20, 2021, by and between Zymeworks and Celgene Corporation and Celgene Alpine Investment Co. LLC. (incorporated by reference to Exhibit 99.4 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on
 August&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000020/zyme-20210930xex991.htm">Fourth Amendment to Collaboration Agreement, dated August&nbsp;
4, 2021, by and between Zymeworks, Celgene Corporation and Celgene Alpine Investment Co. LLC (incorporated by reference to Exhibit&nbsp;
99.1 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on November&nbsp;3, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1023.htm">Collaboration and License Agreement, effective as of December&nbsp;
1, 2015, by and between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited (incorporated by reference to Exhibit 10.23 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312519065609/d662324dex992.htm">Side Letter Agreement effective as of January&nbsp;
11, 2019, by and between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited (incorporated by reference to Exhibit&nbsp;99.2 to Zymeworks&#146;s 2018 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally filed with the SEC on March&nbsp;6, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312520058902/d829510dex994.htm">First Amendment to Collaboration and License Agreement, effective as of April&nbsp;
30, 2019, by and between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited (incorporated by reference to Exhibit 99.4 to Zymeworks&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally filed with the SEC on March&nbsp;2, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312520058902/d829510dex995.htm">Side Letter Agreement effective as of September&nbsp;
30, 2019, by and between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited. (incorporated by reference to Exhibit&nbsp;99.5 to Zymeworks&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally filed with the SEC on March&nbsp;2, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312520058902/d829510dex996.htm">Side Letter Agreement effective as of February&nbsp;
20, 2020, by and between Zymeworks Inc. and GlaxoSmithKline Intellectual Property Development Limited. (incorporated by reference to Exhibit&nbsp;99.6 to Zymeworks&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally filed with the SEC on March&nbsp;2, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000005/zyme-20201231xex9911.htm">Fifth Amendment to Collaboration and License Agreement, effective as of March&nbsp;
30, 2020, by and between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited (incorporated by reference to Exhibit 99.11 to Zymeworks&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally filed with the SEC on February&nbsp;24, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1024.htm">Platform Technology Transfer and License Agreement, effective as of April&nbsp;
21, 2016, by and between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited (incorporated by reference to Exhibit 10.24 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> <FONT
STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000134100419000364/ex99-1.htm">First Amendment to Platform Technology Transfer and License Agreement between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited,
 dated May&nbsp;15, 2019 (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on May&nbsp;17, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex997.htm">Letter Agreement, effective June&nbsp;
4, 2021, by and between Zymeworks and GlaxoSmithKline Intellectual Property Development Limited (incorporated by reference to Exhibit 99.7 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;4,
2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1025.htm">Collaboration and Cross License Agreement, effective as of September&nbsp;
26, 2016, by and between Zymeworks and Daiichi Sankyo Co., Ltd (incorporated by reference to Exhibit 10.25 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312519065609/d662324dex991.htm">Side Letter Agreement effective as of September&nbsp;
25, 2018, by and between Zymeworks and Daiichi Sankyo Co., Ltd. (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s 2018 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on March&nbsp;6, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex998.htm">Second Amendment to Collaboration and Cross License Agreement, effective July&nbsp;
2, 2021, by and between Zymeworks and Daiichi Sankyo Company, Limited (incorporated by reference to Exhibit&nbsp;99.8 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;
4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312517107264/d293184dex1026.htm">Lease of Office Space Agreement dated as of April&nbsp;
6, 2015, by and between Poplar Properties Ltd. and Zymeworks and the Amendment thereto dated August&nbsp;
28, 2015 (incorporated by reference to Exhibit 10.26 to Zymeworks&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217100),</FONT> originally filed with the SEC on April&nbsp;3, 2017). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312518165311/d527862dex991.htm">Amended and Restated Employee Stock Purchase Plan (incorporated by reference to Schedule &#147;B&#148; to Exhibit 99.1 to Zymeworks&#146;s Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally filed with the SEC on May&nbsp;16, 2018). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.34&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000114420417060772/tv480196_ex99-1.htm">Collaboration and License Agreement, effective as of November&nbsp;
13, 2017, by and between Zymeworks and Janssen Biotech, Inc., (incorporated by reference to Exhibit 99.1 to a Report of Foreign Private Issuer on Form <FONT STYLE="white-space:nowrap">6-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally furnished to the SEC on November&nbsp;24, 2017 and deemed filed under the Exchange Act). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.35&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312519065609/d662324dex993.htm">First Amendment to the Collaboration and License Agreement, effective as of January&nbsp;
14, 2019, by and between Zymeworks and Janssen Biotech, Inc. (incorporated by reference to Exhibit 99.3 to Zymeworks&#146;s 2018 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on March&nbsp;6, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.36&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312518167931/d591104dex991.htm">License Agreement, effective as of May&nbsp;
14, 2018, by and between Zymeworks and Daiichi Sankyo Company, Limited (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on May&nbsp;18, 2018). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.37&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000134100418000595/ex99_1.htm">Research and License Agreement, effective as of October&nbsp;
23, 2018, by and between Zymeworks and LEO Pharma A/S (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on October&nbsp;26, 2018). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.38&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000134100418000648/ex99-1.htm">License and Collaboration Agreement, effective as of November&nbsp;
26, 2018, by and between Zymeworks and BeiGene Ltd. (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on December&nbsp;6, 2018). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.39*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000010/zyme-20210331xex992.htm">First Amendment to Collaboration Agreement, effective March&nbsp;
29, 2021, by and between Zymeworks and BeiGene, Ltd. (incorporated by reference to Exhibit 99.2 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;5, 2021).
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.40*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex991.htm">Letter Agreement, effective October&nbsp;
7, 2020, by and between Zymeworks and BeiGene, Ltd. (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.41*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000020/zyme-20210930xex992.htm">Second Amendment to License and Collaboration Agreement, dated August&nbsp;
10, 2021, by and between Zymeworks and BeiGene Ltd. (incorporated by reference to Exhibit 99.2 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on November&nbsp;3, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.42&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000134100418000648/ex99-2.htm">License and Collaboration Agreement, effective as of November&nbsp;
26, 2018, by and between Zymeworks and BeiGene Ltd. (incorporated by reference to Exhibit 99.2 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on December&nbsp;6, 2018). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.43*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375220000012/zyme-20200630xex101.htm">First Amendment to Collaboration Agreement, dated May&nbsp;
25, 2020, by and between Zymeworks and BeiGene, Ltd. (incorporated by reference to Exhibit 10.1 to Zymeworks&#146;s Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> filed with the SEC on August&nbsp;5, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.44*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex996.htm">Second Amendment to License and Collaboration Agreement, effective June&nbsp;
2, 2021, by and between Zymeworks and BeiGene, Ltd. (incorporated by reference to Exhibit 99.6 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.45*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex992.htm">Letter Agreement, effective October&nbsp;
7, 2020, by and between Zymeworks and BeiGene, Ltd. (incorporated by reference to Exhibit 99.2 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.46&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000134100418000648/ex99-3.htm">Research and License Agreement, effective as of November&nbsp;
26, 2018, by and between Zymeworks and BeiGene Ltd. (incorporated by reference to Exhibit 99.3 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on December&nbsp;6, 2018). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.47*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex993.htm">Letter Agreement, effective October&nbsp;7, 2020, by and between Zymeworks and BeiGene, Ltd.&nbsp;
(incorporated by reference to Exhibit 99.3 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312519065609/d662324dex1029.htm">Indenture of Lease dated as of January&nbsp;25, 2019, by and between 5th&nbsp;
&amp; Main Partnership and Zymeworks (incorporated by reference to Exhibit 10.29 to Zymeworks&#146;s 2018 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on March&nbsp;6, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375220000004/zyme-20200331xex992.htm">Notice and Acknowledgement of Exercise of Expansion Option under Lease, dated as of June&nbsp;27, 2019, by and between 5th&nbsp;
&amp; Main Partnership and Zymeworks (incorporated by reference to Exhibit&nbsp;99.2 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;7, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375220000004/zyme-20200331xex993.htm">Lease Expansion and Modification Agreement, dated as of April&nbsp;16, 2020, by and between 5th&nbsp;
&amp; Main Partnership and Zymeworks (incorporated by reference to Exhibit 99.3 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;7, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000010/zyme-20210331xex991.htm">Third Lease Modification Agreement, dated February&nbsp;17, 2021, by and between Zymeworks and 5th&nbsp;
&amp; Main Partnership (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;5, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex995.htm">Fourth Lease Modification Agreement, dated May&nbsp;7, 2021, by and between Zymeworks and 5th and Main Partnership&nbsp;
(incorporated by reference to Exhibit 99.5 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.53#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312519065609/d662324dex1030.htm">Employment Agreement effective September&nbsp;
17, 2018, by and between Zymeworks and Anthony Polverino (incorporated by reference to Exhibit 10.30 to Zymeworks&#146;s 2018 Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on March&nbsp;6, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.54*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000134100419000356/ex99-1.htm">License Agreement between Zymeworks and Iconic Therapeutics, Inc., dated May&nbsp;
13, 2019 (incorporated by reference to Exhibit 99.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on May&nbsp;15, 2019). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.55*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312520058902/d829510dex997.htm">Amendment No.&nbsp;1 to License Agreement effective as of February&nbsp;
26, 2020, by and between Zymeworks and Iconic Therapeutics, Inc. (incorporated by reference to Exhibit 99.7 to Zymeworks&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on March&nbsp;2, 2020).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000005/zyme-20201231xex9912.htm">Amendment No.&nbsp;2 to License Agreement effective as of December&nbsp;
10, 2020, by and between Zymeworks and Iconic Therapeutics, Inc. (incorporated by reference to Exhibit 99.12 to Zymeworks&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-38068),</FONT> originally filed with the SEC on February&nbsp;24, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.57#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312520058902/d829510dex1033.htm">Employment Agreement effective October&nbsp;14, 2019, by and between Zymeworks and Kathryn O&#146;Driscoll&nbsp;
(incorporated by reference to Exhibit 10.33 to Zymeworks&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38068),</FONT> originally filed with the SEC on March&nbsp;
2, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312519286057/d828966dex11.htm">Open Market Sale AgreementSM, dated November&nbsp;
5, 2019, between Zymeworks and Jefferies LLC (incorporated by reference to Exhibit 1.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on November&nbsp;6, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312521289906/d237389dex11.htm">Amendment No.&nbsp;1 to the Open Market Sale AgreementSM, dated October&nbsp;
1, 2021, by and between Zymeworks and Jefferies LLC (incorporated by reference to Exhibit 1.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;1, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.60#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375220000004/zyme-20200331xex101.htm">Amended and Restated Stock Option and Equity Compensation Plan (incorporated by reference to Exhibit 10.1 to Zymeworks&#146;s Quarterly
 Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;7, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.61#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000010/zyme-20210331xex101.htm">Employment Agreement, effective April&nbsp;
1, 2020, by and between Zymeworks and James Priour (incorporated by reference to Exhibit 10.1 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;5, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.62#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000010/zyme-20210331xex102.htm">Letter, dated March&nbsp;3, 2021, from Zymeworks to James Priour (incorporated by reference to Exhibit&nbsp;
10.2 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;5, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.63#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375222000005/zyme-20211231xex1063.htm">Separation and Release Agreement by and between Zymeworks and James Priour, dated February&nbsp;
4, 2022 (incorporated by reference to Exhibit 10.63 to Zymeworks&#146; Annual Report on Form 10-K, originally filed with the SEC on February 24, 2022).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.64#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex101.htm">Employment Agreement, effective April&nbsp;
29, 2019, by and between Zymeworks and Neil Josephson (incorporated by reference to Exhibit 10.1 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August 4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.65#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375221000015/zyme-20210630xex102.htm">Letter, dated May&nbsp;
16, 2021, from Zymeworks to Neil Josephson (incorporated by reference to Exhibit 10.2 to Zymeworks&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on August&nbsp;4, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.66#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000140375222000005/zyme-20211231xex1066.htm">Letter, dated November&nbsp;
9, 2021, from Zymeworks to Neil Josephson (incorporated by reference to Exhibit 10.66 to Zymeworks&#146; Annual Report on Form 10-K, originally filed with the SEC on February 24, 2022).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.67#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522002772/d207208dex101.htm">Employment Agreement by and between Zymeworks and Kenneth Galbraith, dated January&nbsp;
5, 2022 (incorporated by reference to Exhibit 10.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> originally filed with the SEC on January&nbsp;5, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.68#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522002772/d207208dex104.htm">Inducement Stock Option and Equity Compensation Plan (incorporated by reference to Exhibit 10.4 to Zymeworks&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> originally filed with the SEC on January&nbsp;5, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.69#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522136812/d357655dex1070.htm">Separation Agreement and Release by and between Zymeworks and Kathryn O&#146;Driscoll, dated March&nbsp;
4, 2022 (incorporated by reference to Exhibit 10.70 to Zymeworks&#146;s Amendment No.&nbsp;1 to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> originally filed with the SEC on May&nbsp;2, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.70#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522136812/d357655dex1069.htm">Separation Agreement and Release by and between Zymeworks and Anthony Polverino, dated March&nbsp;
14, 2022 (incorporated by reference to Exhibit 10.69 to Zymeworks&#146;s Amendment No.&nbsp;1 to Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> originally filed with the SEC on May&nbsp;2, 2022).
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.71#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522054448/d295460dex101.htm">Amended and Restated Employment Agreement by and between Zymeworks and Christopher Astle, dated February&nbsp;
24, 2022 (incorporated by reference to Exhibit 10.1 to Zymeworks&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> originally filed with the SEC on February&nbsp;25, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.72#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1403752/000119312522070589/d497055dex101.htm">Executive Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to Zymeworks&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> originally filed with the SEC on March&nbsp;9, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.73</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex1073.htm">Form of Indemnification Agreement between the Company and its officers and directors. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex211.htm">Subsidiaries of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex231.htm">Consent of KPMG LLP, an Independent Registered Public Accounting Firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2&plusmn;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex81.htm">Consent of Blake, Cassels &amp; Graydon LLP (included in Exhibit 8.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex82.htm">Consent of Wilson Sonsini Goodrich &amp; Rosati, P.C. (included in Exhibit 8.2) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (contained on signature page). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex991.htm">Consent of Troy M. Cox to be named as a director of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex992.htm">Consent of Kenneth Hillan to be named as a director of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex993.htm">Consent of Susan Mahony to be named as a director of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex994.htm">Consent of Kelvin Neu to be named as a director of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex995.htm">Consent of Hollings C. Renton to be named as a director of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex996.htm">Consent of Natalie Sacks to be named as a director of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dex997.htm">Consent of Lota Zoth to be named as a director of Zymeworks Delaware Inc. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.8&plusmn;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter of Transmittal</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d722206dexfilingfees.htm">Filing Fee Table. </A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has omitted portions of the referenced exhibit pursuant to a request for confidential treatment
under Rule <FONT STYLE="white-space:nowrap">24b-2</FONT> promulgated under the Securities Exchange Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain portions of this exhibit (indicated by &#147;[&#133;***&#133;]&#148;) have been omitted in accordance
with Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> because the omitted information is not material and the Company customarily and actually treats such omitted information as private or confidential.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&plusmn;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i)&nbsp;to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; (ii)&nbsp;to reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
registration statement (notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
of the estimated maximum offering range may be reflected in the form of a prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate
offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement); and (iii)&nbsp;to include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act of 1933, each prospectus filed pursuant to Rule 424(b) as part of a
registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or
prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) That, for the
purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned
Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the
undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i)&nbsp;any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to
be filed pursuant to Rule 424; (ii)&nbsp;any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii)&nbsp;the portion of any other free
writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv)&nbsp;any other communication that is an offer in the
offering made by the undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) That, for purposes of determining any liability under the Securities Act, each filing
of the Registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Securities Exchange Act of
1934, as amended) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial <I>bona fide</I> offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(7) That prior to any public reoffering of the securities registered hereunder through use of a prospectus
which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the Registrant undertakes that such reoffering prospectus will contain the information called for by the
applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(8) That every prospectus (i)&nbsp;that is filed pursuant to paragraph (5)&nbsp;above, or (ii)&nbsp;that purports to meet the requirements of
Section&nbsp;10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to this registration statement and will not be used until such amendment has become
effective, and that for the purpose of determining liabilities under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(9) To respond to requests for information that is
incorporated by reference into the prospectus pursuant to Items 4, 10(b), 11 or 13 of this form, within one (1)&nbsp;business day of receipt of such request, and to send the incorporated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date
of responding to the request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(10) To supply by means of a post-effective amendment all information concerning a transaction, and the company being
acquired involved therein, that was not the subject of and included in this registration statement when it became effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(11) Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the
opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of
expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer, or controlling person in connection with the securities
being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Middletown, Delaware, on July 15, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ZYMEWORKS DELAWARE INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kenneth Galbraith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chair, President and Chief Executive&nbsp;Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kenneth Galbraith and Christopher Astle with full
power of substitution and resubstitution, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agent to act in his or her name, place and stead and to execute in the name
and on behalf of each person, individually and in each capacity stated below, and to sign any and all amendments to this registration statement, including post-effective amendments, and to file any and all documents in connection therewith, with the
Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and
thing, ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents or any of them or their and his or her substitute or substitutes, may lawfully do or cause to
be done by virtue thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by or on
behalf of the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Capacity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kenneth Galbraith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kenneth Galbraith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, President and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July 15, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Christopher Astle</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Christopher Astle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July 15, 2022</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d722206dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_29"></A>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>a
Delaware corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zymeworks Inc., a corporation organized and existing under the laws of the State of Delaware (the
&#147;<B>Company</B>&#148;), does hereby certify as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;The Company was originally incorporated under the
name of Zymeworks Delaware Inc., and the original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on June&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;This Amended and Restated Certificate of Incorporation was duly adopted in accordance with Sections&nbsp;242 and 245
of the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;) by the Board of Directors of the Company (the &#147;<B>Board of Directors</B>&#148;) and has been duly approved by the written consent of the stockholder of the
Company in accordance with Section&nbsp;228 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;The text of the Amended and Restated Certificate of
Incorporation is hereby amended and restated in its entirety to read as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Company is Zymeworks Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address
of the Company&#146;s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nature
of the business or purposes to be conducted or promoted by the Company is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;This Company is authorized to issue two classes of stock, to be designated, respectively, Common Stock
and Preferred Stock. The total number of shares of stock that the Company shall have authority to issue is 1,000,000,000 shares, of which 900,000,000 shares are Common Stock, $0.00001 par value per share, and 100,000,000 shares are Preferred Stock,
$0.00001 par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Each share of Common Stock outstanding as of the applicable record
date shall entitle the holder thereof to one (1)&nbsp;vote on any matter submitted to a vote at a meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or
resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any series of
Preferred Stock, including, without limitation, authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price
or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing. The Board of Directors is further authorized to increase (but not above the total
number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series of Preferred Stock, subject to the powers, preferences and rights, and the
qualifications, limitations and restrictions thereof stated in this Amended and Restated Certificate of Incorporation or the resolution of the Board of Directors originally fixing the number of shares of such series. Except as may be otherwise
specified by the terms of any series of Preferred Stock, if the number of shares of any series of Preferred Stock is so decreased, then the Company shall take all such steps as are necessary to cause the shares constituting such decrease to resume
the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise required by law or provided in this Amended and Restated Certificate of
Incorporation, holders of Common Stock shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that
relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law
or pursuant to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The number of authorized shares of Preferred Stock or Common Stock may be increased or decreased (but
not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all the then-outstanding shares of capital stock of the Company entitled to vote thereon, without a separate vote of
the holders of the class or classes the number of authorized shares of which are being increased or decreased, unless a vote of any holders of one or more series of Preferred Stock is required pursuant to the terms of any certificate of designation
relating to any series of Preferred Stock, irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of holders of Preferred Stock, the number of directors that constitutes the
entire Board of Directors of the Company shall be fixed only by resolution of the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board. Notwithstanding the foregoing, the size of the Board of Directors may not
be increased by more than 1/3 of the number of directors in office at the conclusion of the most recent annual meeting of stockholders prior to the next annual meeting of stockholders, and, prior to the Company&#146;s first annual meeting of
stockholders, the size of the Board of Directors may not be increased by more than three. For the purposes of this Amended and Restated Certificate of Incorporation, the term &#147;<B>Whole Board</B>&#148; shall mean the total number of authorized
directorships whether or not there exist any vacancies or other unfilled seats in previously authorized directorships. At each annual meeting of stockholders, directors of the Company shall be elected to hold office until the expiration of the term
for which they are elected and until their successors have been duly elected and qualified or until their earlier resignation or removal; except that if any such meeting shall not be so held, such election shall take place at a stockholders&#146;
meeting called and held in accordance with the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;From and after the effectiveness of this
Amended and Restated Certificate of Incorporation until the End Date, the directors of the Company (other than any who may be elected by holders of Preferred Stock under specified circumstances) shall be divided into three classes as nearly equal in
size as is practicable, hereby designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Directors already in office shall be assigned to each class at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time such classification becomes effective in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following the date hereof,
the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following the date hereof, the term of office of the Class&nbsp;II
directors shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following the date hereof, the term of office of the Class&nbsp;III directors shall expire and
Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such
annual meeting. If the number of directors is changed, any newly created directorships or decrease in directorships shall be so apportioned hereafter among the classes as to make all classes as nearly equal in number as is practicable, <I>provided
that</I> no decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. Commencing with the first annual meeting of stockholders held on or after the End Date, all directors shall be
elected annually for <FONT STYLE="white-space:nowrap">one-year</FONT> terms. For the purposes of this Amended and Restated Certificate of Incorporation, the term &#147;<B>End Date</B>&#148; shall mean June&nbsp;30, 2117. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;From and after the effectiveness of this Amended and Restated Certificate of Incorporation and subject
to the rights of holders of Preferred Stock, any director or the entire Board of Directors may be removed from office at any time, with or without cause, but only by the affirmative vote of at least 66 2/3% of the voting power of the shares cast for
or against such proposal, which shall be the act of the stockholders, and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be considered for purposes of establishing a quorum, but will not be considered as votes cast for
or against such removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided for or fixed by or pursuant to the
provisions of ARTICLE IV hereof in relation to the rights of the holders of Preferred Stock to elect directors under specified circumstances or except as otherwise provided by resolution of a majority of the Whole Board, newly created directorships
resulting from any increase in the number of directors, created in accordance with the Bylaws of the Company, and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause may be filled by
the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director. A person so elected by the Board of Directors to fill a vacancy or newly created
directorship shall hold office until the next election of the class for which such director shall have been chosen until his or her successor shall have been duly elected and qualified, or until such director&#146;s earlier death, resignation or
removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;The Company is to have perpetual existence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;The business and affairs of the Company shall be managed by or under the direction of the Board of
Directors. In addition to the powers and authority expressly conferred upon them by statute or by this Amended and Restated Certificate of Incorporation or the Bylaws of the Company, the directors are hereby empowered to exercise all such powers and
do all such acts and things as may be exercised or done by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;In furtherance and not in
limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, alter, amend or repeal the Bylaws of the Company. The affirmative vote of at least a majority of the Whole Board shall be required in order for
the Board of Directors to adopt, amend, alter or repeal the Company&#146;s Bylaws. The Company&#146;s Bylaws may also be adopted, amended, altered or repealed by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders of the Company.<B> </B>Notwithstanding the above or any other provision of this Amended and Restated Certificate of Incorporation, the Bylaws of the Company may not be amended,
altered or repealed except in accordance with the provisions of the Bylaws relating to amendments to the Bylaws. No Bylaw hereafter legally adopted, amended, altered or repealed shall invalidate any prior act of the directors or officers of the
Company that would have been valid if such Bylaw had not been adopted, amended, altered or repealed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The election of directors need not be by written ballot unless the Bylaws of the Company shall so
provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;No stockholder will be permitted to cumulate votes at any election of directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of holders of Preferred Stock, any action required or permitted to be taken by
the stockholders of the Company must be effected at a duly called annual or special meeting of stockholders of the Company and may not be effected by any consent in writing by such stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms of any series of Preferred Stock, special meetings of stockholders of the Company
may be called only by the Chairperson of the Board of Directors, the Chief Executive Officer, the President, the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board, or, subject to and in compliance with this
Article VIII and the Bylaws of the Company, and only if so permitted pursuant to the Company&#146;s Bylaws, by the Secretary of the Company upon the written request of one or more holders of record of shares in the aggregate entitled to cast not
less than 20% of the voting power of the Company&#146;s then-outstanding capital stock, but a special meeting may not be called by any other person or persons and any power of stockholders to call a special meeting of stockholders is specifically
denied. Only such business shall be considered at a special meeting of stockholders as shall have been stated in the notice for such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Advance notice of stockholder nominations for the election of directors and of business to be brought
by stockholders before any meeting of the stockholders of the Company shall be given in the manner and to the extent provided in the Bylaws of the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended from time
to time, a director or officer of the Company shall not be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. If the DGCL is amended to authorize corporate
action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Subject to any provisions in the Bylaws of the Company related to indemnification of directors of the
Company, the Company shall indemnify, to the fullest extent permitted by applicable law, any director of the Company who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (a &#147;<B>Proceeding</B>&#148;) by reason of the fact that he or she is or was a director of the Company or is or was serving at the request of the Company as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by such person in connection with any such Proceeding. The Company shall be required to indemnify a person in connection with a Proceeding (or part thereof) initiated by such person only if the Proceeding (or part
thereof) was authorized by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the power to indemnify, to the
extent permitted by applicable law, any officer, employee or agent of the Company who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of
the Company or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against
expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;Neither any amendment nor repeal of any Section of this ARTICLE IX, nor the adoption of any provision
of this Amended and Restated Certificate of Incorporation or the Bylaws of the Company inconsistent with this ARTICLE IX, shall eliminate or reduce the effect of this ARTICLE IX in respect of any matter occurring, or any Proceeding accruing or
arising or that, but for this ARTICLE IX, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings of
stockholders may be held within or outside of the State of Delaware, as the Bylaws may provide. The books of the Company may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such
manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reserves the right to amend or repeal any provision contained in this Amended and Restated Certificate of Incorporation in the
manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation; <I>provided</I>, <I>however</I>, that notwithstanding any other provision of this Amended and Restated
Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote, the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board and the affirmative vote of 66&nbsp;2/3% of the voting
power of the then outstanding voting securities of the Company, voting together as a single class, shall be required for the amendment, repeal or modification of the provisions of Section&nbsp;3 of ARTICLE IV, Section&nbsp;2 of ARTICLE V,
Section&nbsp;1 of ARTICLE VI, Section&nbsp;2 of ARTICLE VI, Section&nbsp;5 of ARTICLE VII, Section&nbsp;1 of ARTICLE VIII, Section&nbsp;2 of ARTICLE VIII, Section&nbsp;3 of ARTICLE VIII, or this ARTICLE XI of this Amended and Restated Certificate of
Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Zymeworks Inc. has caused this Amended and Restated Certificate of
Incorporation to be signed by the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the Company on this &nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>d722206dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL VOTING
PREFERRED STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Section&nbsp;151 of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zymeworks Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that the following resolution was adopted by the
Board of Directors of the Company (the &#147;<B>Board</B>&#148;) pursuant to the authority of the Board as required by Section&nbsp;151 of the Delaware General Corporation Law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that pursuant to the provisions of the Amended and Restated Certificate of Incorporation of the Company (as such may be
amended, modified or restated from time to time, the &#147;<B>Amended and Restated Certificate of Incorporation</B>&#148;) (which authorizes 100,000,000 shares of Preferred Stock, par value $0.00001 per share (the &#147;<B>Preferred
Stock</B>&#148;)), and the authority vested in the Board, a series of Preferred Stock be, and it hereby is, created, and that the designation and number of shares of such series, and the voting and other powers, preferences and relative,
participating, optional or other rights, and the qualifications, limitations and restrictions thereof are as set forth in the Amended and Restated Certificate of Incorporation and this Certificate of Designations, as it may be amended from time to
time (the &#147;<B>Certificate of Designations</B>&#148;) as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL VOTING PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;<U>Designation, Amount and Par Value</U>.&nbsp;The series of Preferred Stock shall be designated as Special Voting
Preferred Stock and the number of shares so designated shall be one (1).&nbsp;The sole authorized share of Special Voting Preferred Stock shall have a par value of $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;<U>Dividends</U>.&nbsp;The holder of record of the share of Special Voting Preferred Stock shall not be entitled to
receive any dividends declared and paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;<U>Voting Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The holder of record of the share of Special Voting Preferred Stock, except as otherwise required under applicable law or
as set forth in subparagraph (b)&nbsp;below, shall not be entitled to vote on any matter required or permitted to be voted upon by the stockholders of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to all meetings of the stockholders of the Company at which the holders of the Company&#146;s common stock,
par value $0.00001 per share, are entitled to vote (each, a &#147;<B>Stockholder Meeting</B>&#148;) and, if applicable, with respect to any written consents sought by the Company from the holders of such common stock (each, a &#147;<B>Stockholder
Consent</B>&#148;), the holder of the share of Special Voting Preferred Stock shall vote together with the holders of such common stock as a single class except as otherwise required under applicable law, and the holder of the share of Special
Voting Preferred Stock shall be entitled to cast on such matter a number of votes equal to (1)&nbsp;the Exchangeable Share Exchange Ratio, multiplied by (2)&nbsp;the number of Exchangeable Shares (the &#147;<B>Exchangeable Shares</B>&#148;) of
Zymeworks ExchangeCo Ltd., a British Columbia corporation (&#147;<B>ExchangeCo</B>&#148;), outstanding as of the record date for determining stockholders entitled to vote at such Stockholder Meeting or in connection with the applicable
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Stockholder Consent (i)&nbsp;that are not owned by the Company or its affiliated entities and (ii)&nbsp;as to which the holder of the share of Special Voting Preferred Stock has received voting
instructions from the holders of such Exchangeable Shares in accordance with the Voting and Exchange Trust Agreement, as it may be amended from time to time (the &#147;<B>Trust Agreement</B>&#148;) to be entered into among the Company, ExchangeCo
and the trustee thereunder (the &#147;<B>Trustee</B>&#148;), and (3)&nbsp;rounded down to the nearest whole vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
&#147;<B>Exchangeable Share Exchange Ratio</B>&#148; has the meaning ascribed thereto in the rights, privileges, restrictions and conditions attaching to the Exchangeable Shares as set out in the articles of ExchangeCo, as they may be amended from
time to time, a copy of which shall be maintained in the books and records of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;<U>Liquidation</U>.&nbsp;Upon any liquidation, dissolution or winding up of the Company, whether voluntary or
involuntary, the holder of record of the share of Special Voting Preferred Stock shall rank senior to the Common Stock of the Company, and junior to all other series of Preferred Stock of the Company, and shall be entitled to receive, prior to such
shares of Common Stock, an amount equal to $1.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.&nbsp;<U>Other Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The holder of record of the share of Special Voting Preferred Stock shall not have any rights hereunder to convert such
share into, or exchange such share for, shares of any other series or class of capital stock of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The
Trustee shall exercise the voting rights attached to the share of Special Voting Preferred Stock pursuant to and in accordance with the Trust Agreement.&nbsp;The voting rights attached to the share of Special Voting Preferred Stock shall terminate
pursuant to and in accordance with the Trust Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At such time as the share of Special Voting Preferred Stock
has no votes attached to it, the Special Voting Preferred Stock shall be automatically cancelled for no consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
The effective date of this Certificate of Designations shall be [____] [_], 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[this space left blank intentionally&#151;signature
page&nbsp;follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Certificate of Designations to be signed by
[______], its [______], this [_]th&nbsp;day of [____], 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ZYMEWORKS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>d722206dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom722206_30"></A>AMENDED AND RESTATED BYLAWS OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(initially
adopted on June&nbsp;30, 2022) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(as amended on [&#9679;]) </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B><I>Page</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><A HREF="#f722206_100">ARTICLE I&#151;CORPORATE OFFICES </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">G-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_101">REGISTERED OFFICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_102">OTHER OFFICES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><A HREF="#f722206_103">ARTICLE II&#151;MEETINGS OF STOCKHOLDERS </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_104">PLACE OF MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_105">ANNUAL MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_106">SPECIAL MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_107">ADVANCE NOTICE PROCEDURES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_108">NOTICE OF STOCKHOLDERS&#146; MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">G-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_109">QUORUM</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_110">ADJOURNED MEETING; NOTICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_111">CONDUCT OF BUSINESS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_112">VOTING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_113">STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_114">RECORD DATES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_115">PROXIES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_116">LIST OF STOCKHOLDERS ENTITLED TO VOTE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_117">INSPECTORS OF ELECTION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_118">ARTICLE III&#151;DIRECTORS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_119">POWERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_120">NUMBER OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_121">ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_122">RESIGNATION AND VACANCIES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_123">PLACE OF MEETINGS; MEETINGS BY TELEPHONE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_124">REGULAR MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_125">SPECIAL MEETINGS; NOTICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_126">QUORUM; VOTING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_127">BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_128">FEES AND COMPENSATION OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_129">REMOVAL OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_130">ARTICLE IV&#151;COMMITTEES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_131">COMMITTEES OF DIRECTORS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_132">COMMITTEE MINUTES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_133">MEETINGS AND ACTION OF COMMITTEES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_134">SUBCOMMITTEES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_135">ARTICLE V&#151;OFFICERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_136">OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_137">APPOINTMENT OF OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_138">SUBORDINATE OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_139">REMOVAL AND RESIGNATION OF OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_140">VACANCIES IN OFFICES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_141">REPRESENTATION OF SECURITIES OF OTHER ENTITIES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_142">AUTHORITY AND DUTIES OF OFFICERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B><I>Page</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_143">ARTICLE VI&#151;STOCK </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">G-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_144">STOCK CERTIFICATES; PARTLY PAID SHARES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_145">SPECIAL DESIGNATION ON CERTIFICATES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_146">LOST CERTIFICATES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_147">DIVIDENDS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_148">TRANSFER OF STOCK</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_149">STOCK TRANSFER AGREEMENTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_150">REGISTERED STOCKHOLDERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_151">ARTICLE VII&#151;MANNER OF GIVING NOTICE AND WAIVER
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_152">NOTICE OF STOCKHOLDERS&#146; MEETINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_153">NOTICE TO STOCKHOLDERS SHARING AN ADDRESS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_154">NOTICE TO PERSON WITH WHOM COMMUNICATION IS UNLAWFUL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_155">WAIVER OF NOTICE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_156">ARTICLE VIII&#151;INDEMNIFICATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_157">INDEMNIFICATION OF DIRECTORS AND OFFICERS IN THIRD PARTY PROCEEDINGS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_158">INDEMNIFICATION OF DIRECTORS AND OFFICERS IN ACTIONS BY OR IN THE RIGHT OF THE COMPANY</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_159">SUCCESSFUL DEFENSE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_160">INDEMNIFICATION OF OTHERS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_161">ADVANCED PAYMENT OF EXPENSES</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_162">LIMITATION ON INDEMNIFICATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_163">DETERMINATION; CLAIM</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_164"><FONT STYLE="white-space:nowrap">NON-EXCLUSIVITY</FONT> OF RIGHTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_165">INSURANCE</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_166">SURVIVAL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_167">EFFECT OF REPEAL OR MODIFICATION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>8.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_168">CERTAIN DEFINITIONS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_169">ARTICLE IX&#151;GENERAL MATTERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_170">EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_171">FISCAL YEAR</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_172">SEAL</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_173">CONSTRUCTION; DEFINITIONS</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>9.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#f722206_174">FORUM SELECTION</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#f722206_175">ARTICLE X&#151;AMENDMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS OF ZYMEWORKS INC. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_100"></A>ARTICLE I&#151;CORPORATE OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_101"></A>1.1&nbsp;&nbsp;&nbsp;&nbsp;REGISTERED OFFICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registered office of Zymeworks Inc. (the &#147;<B>Company</B>&#148;) shall be fixed in the Company&#146;s certificate of incorporation, as
the same may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_102"></A>1.2&nbsp;&nbsp;&nbsp;&nbsp;OTHER OFFICES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may at any time establish other offices. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_103"></A>ARTICLE II&#151;MEETINGS OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_104"></A>2.1&nbsp;&nbsp;&nbsp;&nbsp;PLACE OF MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings of stockholders shall be held at a place, if any, within or outside the State of Delaware, determined by the board of directors of
the Company (the &#147;<B>Board of Directors</B>&#148;). The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as
authorized by Section&nbsp;
211(a)(2) of the Delaware General Corporation Law or any successor legislation (the &#147;<B>DGCL</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_105"></A>2.2&nbsp;&nbsp;&nbsp;&nbsp;ANNUAL
 MEETING </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual meeting of stockholders shall be held each year. The Board of Directors shall designate the date and time of the
annual meeting. At the annual meeting, directors shall be elected and any other proper business, brought in accordance with Section&nbsp;2.4 of these bylaws, may be transacted. The Board of Directors acting pursuant to a resolution adopted by a
majority of the Whole Board may cancel, postpone or reschedule any previously scheduled annual meeting at any time, before or after the notice for such meeting has been sent to the stockholders. For the purposes of these bylaws, the term
&#147;<B>Whole Board</B>&#148; shall mean the total number of authorized directorships whether or not there exist any vacancies or other unfilled seats in previously authorized directorships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_106"></A>2.3&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL MEETING </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A special meeting of the stockholders, other than as required by statute, may be called at any time by (i)&nbsp;the
Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board, (ii)&nbsp;the chairperson of the Board of Directors, (iii)&nbsp;the chief executive officer, (iv)&nbsp;the president or (v)&nbsp;the secretary of the
Company upon written request from stockholders pursuant to and subject to the requirements set forth in Section&nbsp;2.4(b)(ii), but a special meeting may not be called by any other person or persons, and, except as expressly set forth herein, any
power of the stockholders to call a special meeting of stockholders is specifically denied. Except for a meeting called pursuant to Section&nbsp;2.4(b)(ii), the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole
Board may cancel, postpone or reschedule any previously scheduled special meeting at any time, before or after the notice for such meeting has been sent to the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The notice of a special meeting shall include the purpose for which the meeting is called. Only such business shall
be conducted at a special meeting of stockholders as shall have been brought before the meeting by or at the direction of a majority of the Whole Board, the chairperson of the Board of Directors, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chief executive officer or the president, or pursuant to Section&nbsp;2.4(b)(ii). Nothing contained in this Section&nbsp;2.3(b) shall be construed as limiting, fixing or affecting the time when a
meeting of stockholders called by action of the Board of Directors may be held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_107"></A>2.4&nbsp;&nbsp;&nbsp;&nbsp;ADVANCE NOTICE PROCEDURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Annual Meetings of Stockholders</I><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Nominations of persons for election to the Board of Directors or the proposal of other business to be transacted
by the stockholders at an annual meeting of stockholders may be made only (1)&nbsp;pursuant to the Company&#146;s notice of meeting (or any supplement thereto); (2)&nbsp;by or at the direction of the Board of Directors (including a committee
thereof); (3)&nbsp;as may be provided in the certificate of designations for any class or series of preferred stock; or (4)&nbsp;by any stockholder of the Company (or, in the case of the first annual meeting of stockholders of the Company as a
Delaware corporation, any stockholder of Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia) (the &#147;<B>Redomiciling</B><B> Entity</B>&#148;)) who (A)&nbsp;is a stockholder of record at the time of
giving of the notice contemplated by Section&nbsp;2.4(a)(ii) or, in the case of the first annual meeting of stockholders of the Company as a Delaware corporation, was a stockholder of record of the Redomiciling Entity at the time of giving such
notice; (B)&nbsp;is a stockholder of record on the record date for the determination of stockholders entitled to notice of the annual meeting; (C)&nbsp;is a stockholder of record on the record date for the determination of stockholders entitled to
vote at the annual meeting; (D)&nbsp;is a stockholder of record at the time of the annual meeting; and (E)&nbsp;complies with the procedures set forth in this Section&nbsp;2.4(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For nominations or other business to be properly brought before an annual meeting of stockholders by a
stockholder pursuant to clause (4)&nbsp;of Section&nbsp;2.4(a)(i), the stockholder (or in the case of the first annual meeting of stockholders of the Company as a Delaware corporation, such stockholder in their capacity as a stockholder of the
Redomiciling Entity) must have given timely notice in writing to the secretary of the Company and any such nomination or proposed business must constitute a proper matter for stockholder action. To be timely, a stockholder&#146;s notice must be
received by the secretary of the Company at the principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on the 120th day and no later than 5:00 p.m., Eastern time, on the 90th day prior to the day of the first anniversary
of the preceding year&#146;s annual meeting as first specified in the Company&#146;s notice of such annual meeting (without regard to any adjournment, rescheduling, postponement or other delay of such annual meeting occurring after such notice was
first sent). However, if no annual meeting was held in the preceding year, or if the date of the annual meeting for the current year has been changed by more than 25 days from the first anniversary of the preceding year&#146;s annual meeting, then
to be timely such notice must be received by the secretary of the Company at the principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on the 120th day prior to the day of such annual meeting and no later than 5:00
p.m., Eastern time, on the 10th day following the later of the day on which public announcement of the date of such annual meeting was first made by the Company and the 120th day prior to the day of the annual meeting and in the case of the first
annual meeting of stockholders of the Company as a Delaware corporation, notice must be received by the secretary of the Redomiciling Entity at the principal executive offices of the Redomiciling Entity or by the secretary of the Company at the
principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on [&#9679;], 2022 and no later than 5:00 p.m., Eastern time, on [&#9679;], 2022). In no event will the adjournment, rescheduling, postponement or other delay of any
annual meeting, or any announcement thereof, commence a new time period (or extend any time period) for the giving of a stockholder&#146;s notice as described above. In no event may a stockholder provide notice with respect to a greater number of
director candidates than are subject to election by stockholders at the annual meeting. If the number of directors to be elected to the Board of Directors is increased and there is no public announcement (as defined below) naming all of the nominees
for director or specifying the size of the increased Board of Directors at least 10 days before the last day that a stockholder may deliver a notice of nomination pursuant to the foregoing provisions, then a stockholder&#146;s notice required by
this Section&nbsp;2.4(a)(ii) will also be considered timely, but only with respect to any nominees for any new positions created by such increase, if it is received by the secretary of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company at the principal executive offices of the Company (or, in the case of the first annual meeting of stockholders of the Company as a Delaware corporation, the secretary of the
Redomiciling Entity at the principal executive offices of the Redomiciling Entity) no later than 5:00 p.m., Eastern time, on the 10th day following the day on which such public announcement is first made. &#147;<B>Public announcement</B>&#148; means
disclosure in a press release reported by a national news service, in a document publicly filed by the Company or the Redomiciling Entity with the Securities and Exchange Commission pursuant to Section&nbsp;13, Section&nbsp;14 or Section&nbsp;15(d)
of the Securities Exchange Act of 1934 (as amended and inclusive of rules and regulations thereunder, the &#147;<B>1934 Act</B>&#148;) or by such other means as is reasonably designed to inform the public or stockholders of the Company in general of
such information including, without limitation, posting on the Company&#146;s investor relations website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;A
stockholder&#146;s notice to the secretary of the Company must set forth: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;as to each person whom the
stockholder proposes to nominate for election as a director: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;such person&#146;s name, age, business address,
residence address and principal occupation or employment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;the class and number of shares of the Company that
are held of record or are beneficially owned by such person and any (i)&nbsp;Derivative Instruments (as defined below) held or beneficially owned by such person, including the full notional amount of any securities that, directly or indirectly,
underlie any Derivative Instrument; and (ii)&nbsp;other agreement, arrangement or understanding that has been made the effect or intent of which is to create or mitigate loss to, manage risk or benefit of share price changes for, or increase or
decrease the voting power of such person with respect to the Company&#146;s securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;all information
relating to such person that is required to be disclosed in connection with solicitations of proxies for the contested election of directors, or is otherwise required, in each case pursuant to the Section&nbsp;14 of the 1934 Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;such person&#146;s written consent to being named as a nominee of such stockholder in such stockholder&#146;s
proxy statement and to serving as a director of the Company if elected; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;any direct or indirect compensatory,
payment, indemnification or other financial agreement, arrangement or understanding that such person has, or has had within the past three years, with any person or entity other than the Company (including, without limitation, the amount of any
payment or payments received or receivable thereunder), in each case in connection with candidacy or service as a director of the Company (such agreement, arrangement or understanding, a &#147;<B>Third-Party Compensation Arrangement</B>&#148;); and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(F)&nbsp;&nbsp;&nbsp;&nbsp;any other material relationships between such person and such person&#146;s respective affiliates and
associates, or others acting in concert with them, on the one hand, and such stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made, and their respective affiliates and associates, or others acting in
concert with them, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> if such stockholder, beneficial owner,
affiliate or associate were the &#147;registrant&#148; for purposes of such rule and such person were a director or executive officer of such registrant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;as to any other business that the stockholder giving the notice proposes to bring before the annual meeting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;a brief description of the business desired to be brought before the annual meeting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;the text of the proposal or business (including the text of any resolutions proposed for consideration and, if
applicable, the text of any proposed amendment to these bylaws); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;the reasons for conducting such business at the annual meeting;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;any material interest in such business of such stockholder giving the notice and the beneficial owner, if
any, on whose behalf the proposal is made, and their respective affiliates and associates, or others acting in concert with them; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;all agreements, arrangements and understandings between such stockholder and the beneficial owner, if any, on
whose behalf the proposal is made, and their respective affiliates or associates or others acting in concert with them, and any other persons (including their names) in connection with the proposal of such business by such stockholder; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or
proposal is made: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the name and address of such stockholder (as they appear on the Company&#146;s books), of
such beneficial owner, or of their respective affiliates or associates or others acting in concert with them; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;for each class or series, the number of shares of stock of the Company that are, directly or indirectly, held of
record or are beneficially owned by such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;any agreement, arrangement or understanding between such stockholder, such beneficial owner or their respective
affiliates or associates or others acting in concert with them, and any other person or persons (including, in each case, their names) in connection with the proposal of such nomination or other business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;any (i)&nbsp;agreement, arrangement or understanding (including, without limitation, and regardless of the form of
settlement, any derivative, long or short positions, profit interests, forwards, futures, swaps, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions and borrowed or loaned shares) that has been
entered into by or on behalf of such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them with respect to the Company&#146;s securities (any of the foregoing, a &#147;<B>Derivative
Instrument</B>&#148;), including the full notional amount of any securities that, directly or indirectly, underlie any Derivative Instrument; and (ii)&nbsp;other agreement, arrangement or understanding that has been made the effect or intent of
which is to create or mitigate loss to, manage risk or benefit of share price changes for or increase or decrease the voting power of, such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert
with them with respect to the Company&#146;s securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;any proxy, contract, arrangement, understanding or
relationship pursuant to which such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them has a right to vote any shares of any security of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(F)&nbsp;&nbsp;&nbsp;&nbsp;any rights to dividends on the Company&#146;s securities owned beneficially by such stockholder, such beneficial
owner or their respective affiliates or associates or others acting in concert with them that are separated or separable from the underlying security; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(G)&nbsp;&nbsp;&nbsp;&nbsp;any proportionate interest in the Company&#146;s securities or Derivative Instruments held, directly or
indirectly, by a general or limited partnership in which such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them, is a general partner or, directly or indirectly, beneficially owns
an interest in a general partner of such general or limited partnership; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(H)&nbsp;&nbsp;&nbsp;&nbsp;any performance-related fees (other than an asset-based fee)
that such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them is entitled to based on any increase or decrease in the value of the Company&#146;s securities or Derivative Instruments,
including, without limitation, any such interests held by members of the immediate family of such persons sharing the same household; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(I)&nbsp;&nbsp;&nbsp;&nbsp;any significant equity interests or any Derivative Instruments in any principal competitor of the Company that are
held by such stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(J)&nbsp;&nbsp;&nbsp;&nbsp;any direct or indirect interest of such stockholder, such beneficial owner or their respective affiliates or
associates or others acting in concert with them, in any contract with the Company, any affiliate of the Company or any principal competitor of the Company (in each case, including, without limitation, any employment agreement, collective bargaining
agreement or consulting agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(K)&nbsp;&nbsp;&nbsp;&nbsp;any material pending or threatened legal proceeding in which such
stockholder, such beneficial owner or their respective affiliates or associates or others acting in concert with them is a party or material participant involving the Company or any of its officers, directors or affiliates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(L)&nbsp;&nbsp;&nbsp;&nbsp;any material relationship between such stockholder, such beneficial owner or their respective affiliates or
associates or others acting in concert with them, on the one hand, and the Company or any of its officers, directors or affiliates, on the other hand; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(M)&nbsp;&nbsp;&nbsp;&nbsp;a representation and undertaking that the stockholder is a holder of record of stock of the Company as of the date
of submission of the stockholder&#146;s notice and intends to appear in person or by proxy at the annual meeting to bring such nomination or other business before the annual meeting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(N)&nbsp;&nbsp;&nbsp;&nbsp;a representation and undertaking as to whether such stockholder, such beneficial owner or their respective
affiliates or associates or others acting in concert with them intends, or is part of a group that intends, to (x)&nbsp;deliver a proxy statement or form of proxy to holders of at least the percentage of the voting power of the Company&#146;s
then-outstanding stock required to approve or adopt the proposal or to elect each such nominee; or (y)&nbsp;otherwise solicit proxies from stockholders in support of such proposal or nomination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(O)&nbsp;&nbsp;&nbsp;&nbsp;any other information relating to such stockholder, such beneficial owner, or their respective affiliates or
associates or others acting in concert with them, or director nominee or proposed business, that, in each case, would be required to be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies
in support of such nominee (in a contested election of directors) or proposal pursuant to Section&nbsp;14 of the 1934 Act; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(P)&nbsp;&nbsp;&nbsp;&nbsp;such other information relating to any proposed item of business as the Company may reasonably require to
determine whether such proposed item of business is a proper matter for stockholder action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;In addition to
the requirements of this Section&nbsp;2.4, to be timely, a stockholder&#146;s notice (and any additional information submitted to the Company in connection therewith) must further be updated and supplemented (1)&nbsp;if necessary, so that the
information provided or required to be provided in such notice is true and correct as of the record date(s) for determining the stockholders entitled to notice of, and to vote at, the annual meeting and as of the date that is 10 business days prior
to the annual meeting or any adjournment, rescheduling, postponement or other delay thereof; and (2)&nbsp;to provide any additional information that the Company may reasonably request. Any such update and supplement or additional information
(including if requested pursuant to Section&nbsp;2.4(a)(iii)(3)(P)), must be received by the secretary of the Company at the principal executive offices of the Company (A)&nbsp;in the case of a request for additional information, promptly following
a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
request therefor, which response must be received by the secretary of the Company not later than such reasonable time as is specified in any such request from the Company; or (B)&nbsp;in the case
of any other update or supplement of any information, not later than five business days after the record date(s) for the annual meeting (in the case of any update and supplement required to be made as of the record date(s)), and not later than eight
business days prior to the date for the annual meeting or any adjournment, rescheduling, postponement or other delay thereof (in the case of any update and supplement required to be made as of 10 business days prior to the meeting or any
adjournment, rescheduling, postponement or other delay thereof). The failure to timely provide such update, supplement or additional information shall result in the nomination or proposal no longer being eligible for consideration at the annual
meeting. For the avoidance of doubt, the obligation to update and supplement, or provide additional information, as set forth in this Section&nbsp;2.4(a)(iv) or any other Section of these bylaws shall not limit the Company&#146;s rights with respect
to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines pursuant to these bylaws or enable or be deemed to permit a stockholder who has previously submitted notice pursuant to these bylaws to amend or update any
nomination or to submit any new nomination. No disclosure pursuant to these bylaws will be required with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is the stockholder
submitting a notice pursuant to this Section&nbsp;2.4 solely because such broker, dealer, commercial bank, trust company or other nominee of has been directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Special Meetings of Stockholders</I>. Except to the extent required by the DGCL, special meetings of
stockholders may be called only in accordance with the Company&#146;s certificate of incorporation and these bylaws. Only such business will be conducted at a special meeting of stockholders as has been brought before the special meeting pursuant to
the Company&#146;s notice of meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;If the election of directors is included as business to be brought
before a special meeting in the Company&#146;s notice of meeting, then nominations of persons for election to the Board of Directors at such special meeting may be made by any stockholder who (i)&nbsp;is a stockholder of record at the time of giving
of the notice contemplated by this Section&nbsp;2.4(b)(i); (ii)&nbsp;is a stockholder of record on the record date for the determination of stockholders entitled to notice of the special meeting; (iii)&nbsp;is a stockholder of record on the record
date for the determination of stockholders entitled to vote at the special meeting; (iv)&nbsp;is a stockholder of record at the time of the special meeting; and (v)&nbsp;complies with the procedures set forth in this Section&nbsp;2.4(b)(i) (with
such procedures deemed to be applicable to such special meeting). For nominations to be properly brought by a stockholder before a special meeting pursuant to this Section&nbsp;2.4(b)(i), the stockholder&#146;s notice must be received by the
secretary of the Company at the principal executive offices of the Company no earlier than 8:00 a.m., Eastern time, on the 120th day prior to the day of the special meeting and no later than 5:00 p.m., Eastern time, on the 10th day following the day
on which public announcement of the date of the special meeting was first made. In no event will any adjournment, rescheduling, postponement or other delay of a special meeting, or any announcement, thereof commence a new time period (or extend any
time period) for the giving of a stockholder&#146;s notice as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The secretary of the Company
will call a special meeting upon a written request from one or more stockholders of record who have (or who are acting on behalf of beneficial owners who have) an aggregate net long position (as determined below) of not less than 20% of the voting
power of the Company&#146;s then-outstanding stock as of the Ownership Record Date (as defined below), it being understood that each such stockholder of record (or beneficial owner directing such stockholder of record) (each such beneficial owner
and each record stockholder who is not acting solely as a nominee, a &#147;<B>Disclosing Party</B>&#148;) must have held such individual&#146;s net long position included in such aggregate amount continuously for the
<FONT STYLE="white-space:nowrap">one-year</FONT> period ending on the Ownership Record Date and must continue to hold such net long position through the date of the conclusion of the special meeting (such aggregate net long position held for the
requisite period, the &#147;<B>Required Percentage</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;2.4(b)(ii) and for determining the
Required Percentage, net long position shall be determined in accordance with Rule <FONT STYLE="white-space:nowrap">14e-4</FONT> under the 1934 Act with respect to each stockholder requesting a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special meeting and each beneficial owner who is directing a stockholder to act on such owner&#146;s behalf (each stockholder and beneficial owner, a &#147;<B>party</B>&#148;), provided that
(i)&nbsp;for purposes of such definition, in determining such party&#146;s &#147;short position&#148;, the reference in Rule <FONT STYLE="white-space:nowrap">14e-4</FONT> to &#147;the date that a tender offer is first publicly announced or otherwise
made known by the bidder to holders of the security to be acquired&#148; shall be the Ownership Record Date (as defined below), and the reference to the &#147;highest tender offer price or stated amount of the consideration offered for the subject
security&#148; shall refer to the closing sale price of the Company&#146;s common stock on The New York Stock Exchange (or such other securities exchange designated by the Board of Directors if the common stock is not listed for trading on The New
York Stock Exchange) on such record date (or, if such date is not a trading day, the next succeeding trading day) and (ii)&nbsp;the net long position of such party shall be reduced by the number of shares of the Company&#146;s common stock as to
which the Board of Directors determines that such party does not, or will not, have the right to vote or direct the voting of at the special meeting or as to which the Board of Directors determines that such party has entered into any derivative or
other agreement, arrangement or understanding that hedges or transfers, in whole or in part, directly or indirectly, any of the economic consequences of ownership of such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;Such stockholder request to call a special meeting (a &#147;<B>Requisition</B>&#148;) must (A)&nbsp;include the
information required by Section&nbsp;2.4(a)(iii)(2), which information shall be supplemented by each Disclosing Party not later than 10 days after the record date for determining the record stockholders entitled to notice of the special meeting
(such record date, the &#147;<B>Meeting Record Date</B>&#148;) to disclose the foregoing information as of the Meeting Record Date and as of the date that is 10 days prior to the special meeting or any adjournment or postponement thereof, which
shall be received by the secretary of the Company not later than the fifth day before the special meeting); (B) include any additional information necessary to verify the net long position of such Disclosing Party (including such information for the
<FONT STYLE="white-space:nowrap">one-year</FONT> period prior to the Ownership Record Date); (C) be signed by, and include the information required by Section&nbsp;2.4(a)(iii)(3) with respect to all the requisitioning stockholders; (D)&nbsp;be
delivered in a written record, which may consist of a single record or several records, in substantially the same form and content, each of which is signed by one or more of the requisitioning stockholders; provided that, in the event the
Requisition consists of more than one record, the Requisition will be deemed received by the secretary on the first date by which the secretary has received a sufficient number of Requisition records that comply with this Section&nbsp;2.4(b)(ii)(1);
(E) be delivered to the secretary at the principal executive offices of the Company and (F)&nbsp;be amended or supplemented from time to time as described in Section&nbsp;2.4(a)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;A beneficial owner who wishes to deliver a written request to call a special meeting must cause the nominee or
other person who serves as the stockholder of record of such beneficial owner&#146;s stock to sign the written request to call special meeting. If a stockholder of record is the nominee for more than one beneficial owner of stock, then the
stockholder of record may deliver a written request to call a special meeting solely with respect to the common stock of the corporation owned by the beneficial owner who is directing the record stockholder to sign such written request to call a
special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder of record (whether acting for him, her or itself, or at the direction of a
beneficial owner) shall, by written notice to the secretary of the Company, demand that the Board of Directors fix a record date to determine the stockholders who are entitled to deliver a written request to call a special meeting (such record date,
the &#147;<B>Ownership Record Date</B>&#148;). A written demand to fix an Ownership Record Date shall include all of the information that must be included in a written request to call a special meeting as of the date of the demand for the record
date, as set forth in this Section&nbsp;2.4(b)(ii). The Board of Directors may fix the Ownership Record Date within 10 days of the secretary&#146;s receipt of a valid demand to fix the Ownership Record Date. The Ownership Record Date shall not
precede, and shall not be more than 10 days after, the date upon which the resolution fixing the Ownership Record Date is adopted by the Board of Directors. If an Ownership Record Date is not fixed by the Board of Directors, then the Ownership
Record Date shall be the date that the first written request to call a special meeting is received by the secretary with respect to the proposed business to be submitted for stockholder approval at a special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;Upon receiving a request for a special meeting that complies with Section&nbsp;2.4(b)(ii), the secretary must,
subject to Section&nbsp;2.4(b)(ii)(7), (A) call a meeting of stockholders, to be held not more than 120 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
days after the date on which the Requisition is received by the Company, to transact the business stated in the Requisition, (B)&nbsp;send notice of the date and time and, if applicable, the
location of the meeting at least the prescribed number of days, but not more than 120 days, before the meeting to each stockholder entitled to attend the meeting and (C)&nbsp;send, in accordance with Section&nbsp;2.4(b)(ii)(6), a notice to the
persons entitled to notice of the meeting, of the text of the proposal or business referred to in Section&nbsp;2.4(a)(iii)(2)(B). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;If the requisitioned meeting is an electronic or a virtual meeting, the notice referenced in
Section&nbsp;2.4(b)(ii)(4) must also contain instructions for attending and participating in the meeting by telephone or other communications medium, including, if applicable, instructions for voting at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(6)&nbsp;&nbsp;&nbsp;&nbsp;The text referenced in Section&nbsp;2.4(b)(ii)(1)(A) must be sent (A)&nbsp;in, or within the time set for the
sending of, the notice of the requisitioned meeting or (B)&nbsp;in the Company&#146;s proxy statement or equivalent, if any, sent in respect of the requisitioned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(7)&nbsp;&nbsp;&nbsp;&nbsp;The secretary need not comply with Section&nbsp;2.4(b)(ii)(4) and (5)&nbsp;if (A) the directors have called a
meeting of stockholders to be held after the date on which the Requisition is received by the Company and have sent notice of that meeting in accordance with Section&nbsp;2.3, (B) notices relating to an identical or substantially similar item (such
item, a &#147;<B>Similar Item</B>&#148;) sufficient to meet the 20% threshold are received by the secretary (i)&nbsp;more than 60 days following receipt of the first such written request and (ii)&nbsp;before the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the receipt of such first written request regarding a Similar Item; (C)&nbsp;if a Similar Item has been presented at the most recent annual meeting or at any special meeting held within
five years prior to receipt by the secretary of such written request to call a special meeting; (D)&nbsp;the secretary reasonably determines that the business proposed to be transacted is not proper for stockholder action; (E)&nbsp;it clearly
appears that the business stated in the stockholder Requisition does not relate in a significant way to the business or affairs of the Company; (F)&nbsp;it clearly appears that the primary purpose for the Requisition is securing publicity or
enforcing a personal claim or redressing a personal grievance against the Company or any of its directors, officers or security holders; (G)&nbsp;the business stated in the Requisition has already been substantially implemented; (H)&nbsp;the
business stated in the Requisition, if implemented, would cause the Company to violate or be in violation of the law or (I)&nbsp;the Requisition deals with matters beyond the Company&#146;s power to implement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(8)&nbsp;&nbsp;&nbsp;&nbsp;A stockholder may revoke its request to call a special meeting at any time before the special meeting by sending
written notice of such revocation to the secretary of the Company. All written requests for a special meeting shall be deemed revoked: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;upon the first date that, after giving effect to revocation(s) and notices of net long position decreases
(pursuant to Section&nbsp;2.4(b)(ii)), the aggregate net long position of all of the Disclosing Parties who are listed on the unrevoked written requests to call a special meeting with respect to a Similar Item decreases to a number of shares of the
corporation&#146;s common stock less than the Required Percentage; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;if any Disclosing Party who has provided a
representation pursuant to Section&nbsp;2.4(b)(ii)(1)(C) and Section&nbsp;2.4(a)(iii)(3)(K) does not act in accordance with the representations set forth therein; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;if any Disclosing Party does not timely provide the supplemental information required pursuant to
Section&nbsp;2.4(b)(ii)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a deemed revocation of all written requests to call a special meeting has occurred after the special
meeting has been called by the secretary, then the Board of Directors shall have the discretion to determine whether or not to proceed with the special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(9)&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors may vary from the requirements in this Section&nbsp;2.4(b)(ii) if reasonably necessary to
comply with applicable law, including U.S. securities laws and the rules and regulations thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Other Requirements</I><I> and Procedures.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;To be eligible to be a nominee by any stockholder for election as a director of the Company, the proposed nominee
must provide to the secretary of the Company, in accordance with the applicable time periods prescribed for delivery of notice under Section&nbsp;2.4(a)(ii) or Section&nbsp;2.4(b): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;a signed and completed written questionnaire (in the form provided by the secretary of the Company at the written
request of the nominating stockholder, which form will be provided by the secretary within 10 days of receiving such request) containing information regarding such nominee&#146;s background and qualifications and such other information as may
reasonably be required by the Company to determine the eligibility of such nominee to serve as a director of the Company or to serve as an independent director of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and undertaking that, unless previously disclosed to the Company, such nominee is not,
and will not become, a party to any voting agreement, arrangement, commitment, assurance or understanding with any person or entity as to how such nominee, if elected as a director, will vote on any issue; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and undertaking that, unless previously disclosed to the Company, such nominee is not,
and will not become, a party to any Third-Party Compensation Arrangement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and
undertaking that, if elected as a director, such nominee would be in compliance, and will continue to comply, with the Company&#146;s corporate governance guidelines, conflict of interest, confidentiality, stock ownership and trading, and other
policies and guidelines applicable to directors and in effect during such person&#146;s term in office as a director (and, if requested by any candidate for nomination, the secretary of the Company will provide to such proposed nominee all such
policies and guidelines then in effect); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and undertaking that such nominee, if
elected, intends to serve a full term on the Board of Directors; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(6)&nbsp;&nbsp;&nbsp;&nbsp;consents to being named on the
Company&#146;s form of proxy pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the 1934 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;At the request of the Board of Directors, any person nominated by the Board of Directors for election as a
director must furnish to the secretary of the Company the information that is required to be set forth in a stockholder&#146;s notice of nomination pertaining to such nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;No person will be eligible to be nominated by a stockholder for election as a director of the Company, or to be
seated as a director of the Company, unless nominated and elected in accordance with the procedures set forth in this Section&nbsp;2.4. No business proposed by a stockholder will be conducted at a stockholder meeting except in accordance with this
Section&nbsp;2.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;The chairperson of the applicable meeting of stockholders will, if the facts warrant,
determine and declare to the meeting that a nomination was not made in accordance with the procedures prescribed by these bylaws or that other proposed business was not properly brought before the meeting. If the chairperson of the meeting should so
determine, then the chairperson of the meeting will so declare to the meeting and the defective nomination will be disregarded or such business will not be transacted, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Section&nbsp;2.4, unless otherwise required by law, if the
stockholder (or a qualified representative of the stockholder) does not appear in person at the meeting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to present a nomination or other proposed business, such nomination will be disregarded or such business will not be transacted, as the case may be, notwithstanding that proxies in respect of
such nomination or business may have been received by the Company and counted for purposes of determining a quorum. For purposes of this Section&nbsp;2.4, to be considered a qualified representative of the stockholder, a person must be a duly
authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting, and such
person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Without limiting this Section&nbsp;2.4, a stockholder must also comply with all applicable requirements of the
1934&nbsp;Act with respect to the matters set forth in this Section&nbsp;2.4, it being understood that (1)&nbsp;any references in these bylaws to the 1934&nbsp;Act are not intended to, and will not, limit any requirements applicable to nominations
or proposals as to any other business to be considered pursuant to this Section&nbsp;2.4; and (2)&nbsp;compliance with clause&nbsp;(4) of Section&nbsp;2.4(a)(i) and with Section&nbsp;2.4(b) are the exclusive means for a stockholder to make
nominations or submit other business (other than as provided in Section&nbsp;2.4(c)(vii)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary in this Section&nbsp;2.4, the notice requirements set forth in these bylaws with respect to the proposal of any business pursuant to this Section&nbsp;2.4 will be deemed to be satisfied by a stockholder if (1)&nbsp;such
stockholder has submitted a proposal to the Company in compliance with <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> under the 1934&nbsp;Act; and (2)&nbsp;such stockholder&#146;s proposal has been included in a proxy statement that has
been prepared by the Company to solicit proxies for the meeting of stockholders. Subject to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> and other applicable rules and regulations under the 1934&nbsp;Act, nothing in these bylaws will be
construed to permit any stockholder, or give any stockholder the right, to include or have disseminated or described in the Company&#146;s proxy statement any nomination of a director or any other business proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_108"></A>2.5&nbsp;&nbsp;&nbsp;&nbsp;NOTICE OF STOCKHOLDERS&#146; MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever stockholders are required or permitted to take any action at a meeting, a notice of the meeting shall be given which shall state the
place, if any, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders
entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Except as
otherwise provided in the DGCL, the certificate of incorporation or these bylaws, the notice of any meeting of stockholders shall be given not less than 21 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at
such meeting as of the record date for determining the stockholders entitled to notice of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_109"></A>2.6&nbsp;&nbsp;&nbsp;&nbsp;QUORUM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of 33 1/3% of the voting power of the capital stock of the Company issued and outstanding and entitled to vote, present in person
or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. Where a separate vote by a class or series or classes or series is required, 33 1/3% of the voting power of the outstanding
shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter, except as otherwise provided by law, the certificate of
incorporation or these bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, however, such quorum is not present or represented at any meeting of the stockholders, then either
(a)&nbsp;the chairperson of the meeting, or (b)&nbsp;the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at
the meeting, until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the original meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_110"></A>2.7&nbsp;&nbsp;&nbsp;&nbsp;ADJOURNED MEETING; NOTICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting
if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are provided in the manner described in
Section&nbsp;222(c) of the DGCL. At the adjourned meeting, the Company may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given
to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such
adjourned meeting in accordance with Section&nbsp;213(a) of the DGCL and Section&nbsp;2.11 of these bylaws, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date
fixed for notice of such adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_111"></A>2.8&nbsp;&nbsp;&nbsp;&nbsp;CONDUCT OF BUSINESS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such
regulation of the manner of voting and the conduct of business and discussion as seem to the chairperson in order. The chairperson of any meeting of stockholders shall be designated by the Board of Directors; in the absence of such designation, the
chairperson of the Board of Directors, if any, or the chief executive officer (in the absence of the chairperson of the Board of Directors) or the president (in the absence of the chairperson of the Board of Directors and the chief executive
officer), or in their absence any other executive officer of the Company, shall serve as chairperson of the stockholder meeting. The chairperson of any meeting of stockholders shall have the power to adjourn the meeting to another place, if any,
date or time, whether or not a quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_112"></A>2.9&nbsp;&nbsp;&nbsp;&nbsp;VOTING </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section&nbsp;2.11 of
these bylaws, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section&nbsp;218 (relating to voting trusts and other voting agreements) of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be otherwise provided in the certificate of incorporation or these bylaws, each stockholder shall be entitled to one vote for
each share of capital stock held by such stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by law, the certificate of incorporation, these bylaws
or the rules of the stock exchange on which the Company&#146;s securities are listed, in all matters other than the election of directors, the affirmative vote of a majority of the voting power of the shares cast for or against a proposal shall be
the act of the stockholders, it being understood that broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will be considered for purposes of establishing a quorum at the meeting but will not be considered as votes cast for or
against a proposal. Except as otherwise required by law, the certificate of incorporation or these bylaws, directors shall be elected by a plurality of the voting power of the shares present in person or represented by proxy at the meeting and
entitled to vote on the election of directors. Except as otherwise provided by law, the certificate of incorporation, these bylaws or the rules of the stock exchange on which the securities of the Company are listed, where a separate vote by a class
or series or classes or series is required, in all matters other than the election of directors, the affirmative vote of the majority of the voting power of the outstanding shares of such class or series or classes or series cast for or against such
proposal shall be the act of such class or series or classes or series, it being understood that broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions will not be considered as votes cast for or against a proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_113"></A>2.10&nbsp;&nbsp;&nbsp;&nbsp;STOCKHOLDER ACTION BY WRITTEN CONSENT
WITHOUT A MEETING </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights of holders of preferred stock of the Company, any action required or permitted to be taken by the
stockholders of the Company must be effected at a duly called annual or special meeting of stockholders of the Company and may not be effected by any consent in writing by such stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_114"></A>2.11&nbsp;&nbsp;&nbsp;&nbsp;RECORD DATES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Company may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the
Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which record date shall not be more than 60 nor less than 10 days before
the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record
date, that a later date on or before the date of the meeting shall be the date for making such determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed
by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is
waived, at the close of business on the day next preceding the day on which the meeting is held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A determination of stockholders of
record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however</I>, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at
the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with
the provisions of Section&nbsp;213 of the DGCL and this Section&nbsp;2.11 at the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Company may
determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose
of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such
action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_115"></A>2.12&nbsp;&nbsp;&nbsp;&nbsp;PROXIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder entitled to vote at a meeting of stockholders, or such stockholder&#146;s authorized officer, director, employee or agent,
may authorize another person or persons to act for such stockholder by proxy authorized by a document or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted
upon after three years from its date, unless the proxy provides for a longer period. The authorization of a person to act as a proxy may be documented, signed and delivered in accordance with Section&nbsp;116 of the DGCL; <I>provided </I>that such
authorization shall set forth, or be delivered with information enabling the Company to determine, the identity of the stockholder granting such authorization. The revocability of a proxy that states on its face that it is irrevocable shall be
governed by the provisions of Section&nbsp;212 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_116"></A>2.13&nbsp;&nbsp;&nbsp;&nbsp;LIST OF STOCKHOLDERS
ENTITLED TO VOTE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall prepare, in accordance with Section&nbsp;219 of the DGCL, a complete list of the stockholders entitled
to vote at the meeting; <I>provided, however,</I> if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before
the meeting date, arranged in alphabetical order, and showing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address of each stockholder and the number of shares registered in the name of each stockholder. The Company shall not be required to include electronic mail addresses or other electronic contact
information on such list. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting during the period contemplated by Section&nbsp;219 of the DGCL: (a)&nbsp;on a reasonably accessible electronic network,
<I>provided</I> that the information required to gain access to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the Company&#146;s principal place of business. In the event that the Company
determines to make the list available on an electronic network, the Company may take reasonable steps to ensure that such information is available only to stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_117"></A>2.14&nbsp;&nbsp;&nbsp;&nbsp;INSPECTORS OF ELECTION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before any meeting of stockholders, the Company shall appoint an inspector or inspectors of election to act at the meeting or its adjournment.
The Company may designate one or more persons as alternate inspectors to replace any inspector who fails to act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such inspectors shall:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;ascertain the number of shares outstanding and the voting power of each; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;determine the shares represented at the meeting and the validity of proxies and ballots; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;count all votes and ballots; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;determine and retain for a reasonable period a record of the disposition of any challenges made to any
determination by the inspectors; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;certify their determination of the number of shares represented at the
meeting, and their count of all votes and ballots. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inspectors of election shall perform their duties impartially, in good faith, to
the best of their ability and as expeditiously as is practical. If there are multiple inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all. Any report or
certificate made by the inspectors of election is <I>prima facie</I> evidence of the facts stated therein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_118"></A>ARTICLE III&#151;DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_119"></A>3.1&nbsp;&nbsp;&nbsp;&nbsp;POWERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The business and affairs of the Company shall be managed by or under the direction of the Board of Directors, except as may be otherwise
provided in the DGCL or the certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_120"></A>3.2&nbsp;&nbsp;&nbsp;&nbsp;NUMBER OF DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors shall consist of one or more members, each of whom shall be a natural person. Unless the certificate of incorporation
fixes the number of directors, the number of directors shall be determined from time to time by resolution of a majority of the Whole Board. No reduction of the authorized number of directors shall have the effect of removing any director before
that director&#146;s term of office expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_121"></A>3.3&nbsp;&nbsp;&nbsp;&nbsp;ELECTION, QUALIFICATION AND TERM OF
OFFICE OF DIRECTORS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;3.4 of these bylaws, each director, including a director elected to fill a vacancy
or newly created directorship, shall hold office until the expiration of the term for which elected and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until such director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal. Directors need not be stockholders unless so required by the
certificate of incorporation or these bylaws. The certificate of incorporation or these bylaws may prescribe other qualifications for directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so provided in the certificate of incorporation, the directors of the Company shall be divided into three classes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_122"></A>3.4&nbsp;&nbsp;&nbsp;&nbsp;RESIGNATION AND VACANCIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice given in writing or by electronic transmission to the Company. A resignation is effective when
the resignation is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events. A resignation which is conditioned upon the director failing to receive a specified vote
for reelection as a director may provide that it is irrevocable. Unless otherwise provided in the certificate of incorporation or these bylaws, when one or more directors resign from the Board of Directors, effective at a future date, a majority of
the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation or these bylaws or permitted in the specific case by resolution of the Board of
Directors, and subject to the rights of holders of Preferred Stock, vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single
class may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and not by stockholders. Notwithstanding the foregoing, no more than 1/3 of the number of directors in office at the
conclusion of the most recent annual meeting of stockholders may be appointed by the Board of Directors prior to the next annual meeting of stockholders, and, prior to the Company&#146;s first annual meeting of stockholders, the size of the Board of
Directors may not be increased by more than three. If the directors are divided into classes, a person so chosen to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall
have been chosen and until his or her successor shall have been duly elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_123"></A>3.5&nbsp;&nbsp;&nbsp;&nbsp;PLACE OF MEETINGS; MEETINGS BY TELEPHONE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may hold meetings, both regular and special, either within or outside the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the Board of Directors may participate in a
meeting of the Board of Directors by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in
person at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_124"></A>3.6&nbsp;&nbsp;&nbsp;&nbsp;REGULAR MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regular meetings of the Board of Directors may be held without notice at such time and at such place as shall from time to time be determined
by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_125"></A>3.7&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL MEETINGS; NOTICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the chairperson of the Board of Directors,
the chief executive officer, the president, the secretary or a majority of the Whole Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of the time and place of special
meetings shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;delivered personally by hand, by courier or by telephone; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;sent by United States first-class mail, postage prepaid; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;sent by facsimile; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;sent by electronic mail; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;otherwise given by electronic transmission (as defined in Section&nbsp;232 of the DGCL), </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">directed to each director at that director&#146;s address, telephone number, facsimile number, electronic mail address or other contact for notice by
electronic transmission, as the case may be, as shown on the Company&#146;s records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the notice is (i)&nbsp;delivered personally by
hand, by courier or by telephone, (ii)&nbsp;sent by facsimile, (iii)&nbsp;sent by electronic mail or (iv)&nbsp;otherwise given by electronic transmission, it shall be delivered, sent or otherwise directed to each director, as applicable, at least 24
hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall be deposited in the United States mail at least four days before the time of the holding of the meeting. Any oral notice of the time and place
of the meeting may be communicated to the director in lieu of written notice if such notice is communicated at least 24 hours before the time of the holding of the meeting. The notice need not specify the place of the meeting (if the meeting is to
be held at the Company&#146;s principal executive office) nor the purpose of the meeting, unless required by statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_126">
</A>3.8&nbsp;&nbsp;&nbsp;&nbsp;QUORUM; VOTING </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At all meetings of the Board of Directors, a majority of the Whole Board shall constitute a
quorum for the transaction of business. If a quorum is not present at any meeting of the Board of Directors, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a
quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the directors present at any meeting at which a quorum is present shall be the
act of the Board of Directors, except as may be otherwise specifically provided by statute, the certificate of incorporation or these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the certificate of incorporation provides that one or more directors shall have more or less than one vote per director on any matter,
except as may otherwise be expressly provided herein or therein and denoted with the phrase &#147;notwithstanding the final paragraph of Section&nbsp;3.8 of the bylaws&#148; or language to similar effect, every reference in these bylaws to a
majority or other proportion of the directors shall refer to a majority or other proportion of the votes of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_127">
</A>3.9&nbsp;&nbsp;&nbsp;&nbsp;BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of
incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or committee, as the case may
be, consent thereto in writing or by electronic transmission. Any person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action will be effective at a future time (including a
time determined upon the happening of an event), no later than 60 days after such instruction is given or such provision is made and such consent shall be deemed to have been given for purposes of this Section&nbsp;3.9 at such effective time so long
as such person is then a director and did not revoke the consent prior to such time. Any such consent shall be revocable prior to its becoming effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_128"></A>3.10&nbsp;&nbsp;&nbsp;&nbsp;FEES AND COMPENSATION OF DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board of Directors shall have the authority to fix the
compensation of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_129"></A>3.11&nbsp;&nbsp;&nbsp;&nbsp;REMOVAL OF DIRECTORS </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director or the entire Board of Directors may be removed from office by stockholders of the Company in the manner specified in the
certificate of incorporation and applicable law. No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration of such director&#146;s term of office. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_130"></A>ARTICLE IV&#151;COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_131"></A>4.1&nbsp;&nbsp;&nbsp;&nbsp;COMMITTEES OF DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may, by resolution passed by a majority of the Whole Board, designate one or more committees, each committee to consist
of one or more of the directors of the Company. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or
disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of
Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of Directors or in these bylaws, shall have and may exercise all the powers and
authority of the Board of Directors in the management of the business and affairs of the Company, and may authorize the seal of the Company to be affixed to all papers that may require it; but no such committee shall have the power or authority to
(a)&nbsp;approve or adopt, or recommend to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (b)&nbsp;adopt, amend or repeal any
bylaw of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_132"></A>4.2&nbsp;&nbsp;&nbsp;&nbsp;COMMITTEE MINUTES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each committee and subcommittee shall keep regular minutes of its meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_133"></A>4.3&nbsp;&nbsp;&nbsp;&nbsp;MEETINGS AND ACTION OF COMMITTEES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified by the Board of Directors, meetings and actions of committees and subcommittees shall be governed by, and held and
taken in accordance with, the provisions of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.5 (place of meetings and meetings by telephone);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.6 (regular meetings); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.7 (special meetings and notice); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.8 (quorum; voting); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.9 (action without a meeting); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.4 (waiver of notice) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with such changes in the context of those bylaws as are necessary to substitute the committee or subcommittee and its members for the Board of Directors and
its members. <I>However</I>, (i)&nbsp;the time and place of regular meetings of committees or subcommittees may be determined either by resolution of the Board of Directors or by resolution of the committee or subcommittee; (ii)&nbsp;special
meetings of committees or subcommittees may also be called by resolution of the Board of Directors or the committee or the subcommittee; and (iii)&nbsp;notice of special </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meetings of committees and subcommittees shall also be given to all alternate members who shall have the right to attend all meetings of the committee or subcommittee. The Board of Directors may
also adopt other rules for the government of any committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision in the certificate of incorporation providing that one or more
directors shall have more or less than one vote per director on any matter shall apply to voting in any committee or subcommittee, unless otherwise provided in the certificate of incorporation or these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_134"></A>4.4&nbsp;&nbsp;&nbsp;&nbsp;SUBCOMMITTEES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation, these bylaws or the resolutions of the Board of Directors designating the
committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_135"></A>ARTICLE V&#151;OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_136"></A>5.1&nbsp;&nbsp;&nbsp;&nbsp;OFFICERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of the Company shall be a president and a secretary. The Company may also have, at the discretion of the Board of Directors, a
chairperson of the Board of Directors, a vice chairperson of the Board of Directors, a chief executive officer, a chief financial officer or treasurer, and any such other officers as may be appointed in accordance with the provisions of these
bylaws. Any number of offices may be held by the same person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_137"></A>5.2&nbsp;&nbsp;&nbsp;&nbsp;APPOINTMENT OF
OFFICERS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors shall appoint the officers of the Company, except such officers as may be appointed in accordance with
the provisions of Section&nbsp;
5.3 of these bylaws, subject to the rights, if any, of an officer under any contract of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_138"></A>5.3&nbsp;
&nbsp;&nbsp;&nbsp;SUBORDINATE OFFICERS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may appoint, or empower any officer to appoint, such other officers as the
business of the Company may require. Each of such officers shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as determined from time to time by the Board of Directors or any duly
authorized committee or subcommittee thereof or by any officer who has been conferred such power of determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_139"></A>5.4&nbsp;&nbsp;&nbsp;&nbsp;REMOVAL AND RESIGNATION OF OFFICERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by
the Board of Directors or, for the avoidance of doubt, any duly authorized committee or subcommittee thereof or by any officer who has been conferred such power of removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any officer may resign at any time by giving notice, in writing or by electronic transmission, to the Company. Any resignation shall take
effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation
is without prejudice to the rights, if any, of the Company under any contract to which the officer is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_140"></A>5.5&nbsp;&nbsp;&nbsp;&nbsp;VACANCIES IN OFFICES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any vacancy occurring in any office of the Company shall be filled by the Board of Directors or as provided in Section&nbsp;5.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_141"></A>5.6&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATION OF SECURITIES OF OTHER ENTITIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the Board of Directors, the chief executive officer, the president, any vice president, the treasurer, the secretary or
assistant secretary of the Company or any other person authorized by the Board of Directors or the chief executive officer, the president or a vice president, is authorized to vote, represent and exercise on behalf of the Company all rights incident
to any and all shares or other securities of, or interests in, or issued by, any other entity or entities, and all rights incident to any management authority conferred on the Company in accordance with the governing documents of any entity or
entities, standing in the name of the Company, including the right to act by written consent. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly
executed by such person having the authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_142"></A>5.7&nbsp;&nbsp;&nbsp;&nbsp;AUTHORITY AND DUTIES OF OFFICERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each officer of the Company shall have such authority and perform such duties in the management of the business of the Company as may be
designated from time to time by the Board of Directors or, for the avoidance of doubt, any duly authorized committee or subcommittee thereof or by any officer who has been conferred such power of designation and, to the extent not so provided, as
generally pertain to such office, subject to the control of the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_143"></A>ARTICLE VI&#151;STOCK
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_144"></A>6.1&nbsp;&nbsp;&nbsp;&nbsp;STOCK CERTIFICATES; PARTLY PAID SHARES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of the Company shall be represented by certificates, provided that the Board of Directors may provide by resolution or resolutions
that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Company. Unless otherwise provided
by resolution of the Board of Directors, every holder of stock represented by certificates shall be entitled to have a certificate signed by, or in the name of, the Company by any two officers of the Company representing the number of shares
registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such
officer, transfer agent or registrar before such certificate is issued, it may be issued by the Company with the same effect as if such person were such officer, transfer agent or registrar at the date of issue. The Company shall not have power to
issue a certificate in bearer form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may issue the whole or any part of its shares as partly paid and subject to call for the
remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly-paid shares, or upon the books and records of the Company in the case of uncertificated partly-paid shares, the
total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully-paid shares, the Company shall declare a dividend upon partly-paid shares of the same class, but only
upon the basis of the percentage of the consideration actually paid thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_145"></A>6.2&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL
DESIGNATION ON CERTIFICATES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company is authorized to issue more than one class of stock or more than one series of any class, then
the powers, the designations, the preferences and the relative, participating, optional or other special rights of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the
certificate that the Company shall issue to represent such class or series of stock; <I>provided, however</I>, that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the
face or back of the certificate that the Company shall issue to represent such class or series of stock, a statement that the Company will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated
stock, the registered owner thereof shall be given a notice, in writing or by electronic transmission, containing the information required to be set forth or stated on certificates pursuant to this Section&nbsp;6.2 or Sections&nbsp;156, 202(a),
218(a) or 364 of the DGCL or with respect to this Section&nbsp;6.2 a statement that the Company will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other
special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated
stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_146">
</A>6.3&nbsp;&nbsp;&nbsp;&nbsp;LOST CERTIFICATES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in this Section&nbsp;6.3, no new certificates for shares shall be
issued to replace a previously issued certificate unless the latter is surrendered to the Company and cancelled at the same time. The Company may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore
issued by it, alleged to have been lost, stolen or destroyed, and the Company may require the owner of the lost, stolen or destroyed certificate, or such owner&#146;s legal representative, to give the Company a bond sufficient to indemnify it
against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_147"></A>6.4&nbsp;&nbsp;&nbsp;&nbsp;DIVIDENDS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors, subject to any restrictions contained in the certificate of incorporation or applicable law, may declare and pay
dividends upon the shares of the Company&#146;s capital stock. Dividends may be paid in cash, in property, or in shares of the Company&#146;s capital stock, subject to the provisions of the certificate of incorporation. The Board of Directors may
set apart out of any of the funds of the Company available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_148"></A>6.5&nbsp;&nbsp;&nbsp;&nbsp;TRANSFER OF STOCK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers of record of shares of stock of the Company shall be made only upon its books by the holders thereof, in person or by an attorney
duly authorized, and, if such stock is certificated, upon the surrender of a certificate or certificates for a like number of shares, properly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_149"></A>6.6&nbsp;&nbsp;&nbsp;&nbsp;STOCK TRANSFER AGREEMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of
the Company to restrict the transfer of shares of stock of the Company of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_150"></A>6.7&nbsp;&nbsp;&nbsp;&nbsp;REGISTERED STOCKHOLDERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to
receive dividends and notices and to vote as such owner; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;shall not be bound to recognize any equitable or other claim to
or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_151"></A>ARTICLE VII&#151;MANNER OF GIVING NOTICE AND WAIVER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_152"></A>7.1&nbsp;&nbsp;&nbsp;&nbsp;NOTICE OF STOCKHOLDERS&#146; MEETINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any meeting of stockholders shall be given in the manner set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_153"></A>7.2&nbsp;&nbsp;&nbsp;&nbsp;NOTICE TO STOCKHOLDERS SHARING AN ADDRESS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise prohibited under the DGCL, without limiting the manner by which notice otherwise may be given effectively to stockholders,
any notice to stockholders given by the Company under the provisions of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the
stockholders at that address to whom such notice is given. Any such consent shall be revocable by the stockholder by written notice to the Company. Any stockholder who fails to object in writing to the Company, within 60 days of having been given
written notice by the Company of its intention to send the single notice, shall be deemed to have consented to receiving such single written notice. This Section&nbsp;7.2 shall not apply to Sections&nbsp;164, 296, 311, 312 or 324 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_154"></A>7.3&nbsp;&nbsp;&nbsp;&nbsp;NOTICE TO PERSON WITH WHOM COMMUNICATION IS UNLAWFUL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given, under the DGCL, the certificate of incorporation or these bylaws, to any person with whom
communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting
which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the Company is such as to require
the filing of a certificate under the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_155"></A>7.4&nbsp;&nbsp;&nbsp;&nbsp;WAIVER OF NOTICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a written waiver,
signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a
person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not
lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so
required by the certificate of incorporation or these bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_156"></A>ARTICLE VIII&#151;INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_157"></A>8.1&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF DIRECTORS AND OFFICERS IN THIRD PARTY PROCEEDINGS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article&nbsp;VIII, the Company shall indemnify, to the fullest extent permitted by the DGCL, as now or
hereinafter in effect, any person who was or is a party or is threatened to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;<B>Proceeding</B>&#148;) (other than an action
by or in the right of the Company) by reason of the fact that such person is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection
with such Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to
believe such person&#146;s conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of <I>nolo contendere</I> or its equivalent, shall not, of itself, create a presumption that the person did
not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person&#146;s
conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_158"></A>8.2&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF DIRECTORS AND OFFICERS IN ACTIONS BY OR IN
THE RIGHT OF THE COMPANY </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article&nbsp;VIII, the Company shall indemnify, to the fullest extent
permitted by the DGCL, as now or hereinafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed Proceeding by or in the right of the Company to procure a judgment in its favor by
reason of the fact that such person is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such Proceeding if such person acted in good
faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Company; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been
adjudged to be liable to the Company unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the
circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_159"></A>8.3&nbsp;&nbsp;&nbsp;&nbsp;SUCCESSFUL DEFENSE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that a present or former director or officer (for purposes of this Section&nbsp;8.3 only, as such term is defined in
Section&nbsp;145(c)(1) of the DGCL) of the Company has been successful on the merits or otherwise in defense of any Proceeding described in Section&nbsp;8.1 or Section&nbsp;8.2, or in defense of any claim, issue or matter therein, such person shall
be indemnified against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection therewith. The Company may indemnify any other person who is not a present or former director or officer of the Company
against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person to the extent he or she has been successful on the merits or otherwise in defense of any suit or proceeding described in Section&nbsp;8.1 or
Section&nbsp;8.2, or in defense of any claim, issue or matter therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_160"></A>8.4&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF OTHERS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the other provisions of this Article&nbsp;VIII, the Company shall have power to indemnify its employees and agents, or any other
persons, to the extent not prohibited by the DGCL or other applicable law. The Board of Directors shall have the power to delegate to any person or persons identified in subsections (1)&nbsp;through (4) of Section&nbsp;145(d) of the DGCL the
determination of whether employees or agents shall be indemnified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_161"></A>8.5&nbsp;&nbsp;&nbsp;&nbsp;ADVANCED PAYMENT OF EXPENSES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses (including attorneys&#146; fees) actually and reasonably incurred by an officer or director of the Company in defending any
Proceeding shall be paid by the Company in advance of the final disposition of such Proceeding upon receipt of a written request therefor (together with documentation reasonably evidencing such expenses) and an undertaking by or on behalf of the
person to repay such amounts if it shall ultimately be determined that the person is not entitled to be indemnified under this Article&nbsp;VIII or the DGCL. Such expenses (including attorneys&#146; fees) actually and reasonably incurred by former
directors and officers or other employees and agents of the Company or by persons serving at the request of the Company as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be
so paid upon such terms and conditions, if any, as the Company deems appropriate. The right to advancement of expenses shall not apply to any Proceeding (or any part of any Proceeding) for which indemnity is excluded pursuant to these bylaws, but
shall apply to any Proceeding (or any part of any Proceeding) referenced in Section&nbsp;8.6(b) or 8.6(c) prior to a determination that the person is not entitled to be indemnified by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless otherwise determined pursuant to Section&nbsp;8.8, no advance shall be made by the Company to an officer
of the Company (except by reason of the fact that such officer is or was a director of the Company, in which event this paragraph shall not apply) in any Proceeding if a determination is reasonably and promptly made (a)&nbsp;by a vote of the
directors who are not parties to such Proceeding, even though less than a quorum, or (b)&nbsp;by a committee of such directors designated by the vote of the majority of such directors, even though less than a quorum, or (c)&nbsp;if there are no such
directors, or if such directors so direct, by independent legal counsel in a written opinion, that facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad
faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_162">
</A>8.6&nbsp;&nbsp;&nbsp;&nbsp;LIMITATION ON INDEMNIFICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirements in Section&nbsp;8.3 and the DGCL, the Company
shall not be obligated to indemnify any person pursuant to this Article&nbsp;VIII in connection with any Proceeding (or any part of any Proceeding): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;for which payment has actually been made to or on behalf of such person under any statute, insurance policy,
indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;for an
accounting or disgorgement of profits pursuant to Section&nbsp;16(b) of the 1934 Act, or similar provisions of federal, state or local statutory law or common law, if such person is held liable therefor (including pursuant to any settlement
arrangements); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;for any reimbursement of the Company by such person of any bonus or other incentive-based or
equity-based compensation or of any profits realized by such person from the sale of securities of the Company, as required in each case under the 1934 Act (including any such reimbursements that arise from an accounting restatement of the Company
pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the &#147;<B>Sarbanes-Oxley Act</B>&#148;), or the payment to the Company of profits arising from the purchase and sale by such person of securities in violation of Section&nbsp;306 of
the Sarbanes-Oxley Act), if such person is held liable therefor (including pursuant to any settlement arrangements); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;initiated by such person, including any Proceeding (or any part of any Proceeding) initiated by such person against
the Company or its directors, officers, employees, agents or other indemnitees, unless (i)&nbsp;the Board of Directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii)&nbsp;the Company provides the
indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii)&nbsp;otherwise required to be made under Section&nbsp;8.7 or (iv)&nbsp;otherwise required by applicable law; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;if prohibited by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_163"></A>8.7&nbsp;&nbsp;&nbsp;&nbsp;DETERMINATION; CLAIM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a claim for indemnification or advancement of expenses under this Article&nbsp;VIII is not paid in full within 90&nbsp;days after receipt
by the Company of the written request therefor, the claimant shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification or advancement of expenses. The Company shall indemnify such
person against any and all expenses that are actually and reasonably incurred by such person in connection with any action for indemnification or advancement of expenses from the Company under this Article&nbsp;VIII, to the extent such person is
successful in such action, and to the extent not prohibited by law. In any such suit, the Company shall, to the fullest extent not prohibited by law, have the burden of proving that the claimant is not entitled to the requested indemnification or
advancement of expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_164"></A><FONT STYLE="white-space:nowrap">8.8&nbsp;&nbsp;&nbsp;&nbsp;NON-EXCLUSIVITY</FONT> OF
RIGHTS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification and advancement of expenses provided by, or granted pursuant to, this Article&nbsp;VIII shall not be deemed
exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the certificate of incorporation or any statute, bylaw, agreement, vote of stockholders or disinterested directors or otherwise,
both as to action in such person&#146;s official capacity and as to action in another capacity while holding such office. The Company is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees
or agents respecting indemnification and advancement of expenses, to the fullest extent not prohibited by the DGCL or other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_165"></A>8.9&nbsp;&nbsp;&nbsp;&nbsp;INSURANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company,
or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person
in any such capacity, or arising out of such person&#146;s status as such, whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_166"></A>8.10&nbsp;&nbsp;&nbsp;&nbsp;SURVIVAL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights to indemnification and advancement of expenses conferred by this Article&nbsp;VIII shall continue as to a person who has ceased to
be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_167">
</A>8.11&nbsp;&nbsp;&nbsp;&nbsp;EFFECT OF REPEAL OR MODIFICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A right to indemnification or to advancement of expenses arising under a
provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to or repeal or elimination of the certificate of incorporation or these bylaws after the occurrence of the act or omission that is the
subject of the Proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has
occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_168"></A>8.12&nbsp;&nbsp;&nbsp;&nbsp;CERTAIN DEFINITIONS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article&nbsp;VIII, references to the &#147;<B>Company</B>&#148; shall include, in addition to the resulting company, any
constituent company (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents, so
that any person who is or was a director, officer, employee or agent of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such constituent company, or is or was serving at the request of such constituent company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or
other enterprise, shall stand in the same position under the provisions of this Article&nbsp;VIII with respect to the resulting or surviving company as such person would have with respect to such constituent company if its separate existence had
continued. For purposes of this Article&nbsp;VIII, references to &#147;<B>other enterprises</B>&#148; shall include employee benefit plans; references to &#147;<B>fines</B>&#148; shall include any excise taxes assessed on a person with respect to an
employee benefit plan; and references to &#147;<B>serving at the request of the Company</B>&#148; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director,
officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries
of an employee benefit plan shall be deemed to have acted in a manner &#147;<B>not opposed to the best interests of the Company</B>&#148; as referred to in this Article&nbsp;VIII. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_169"></A>ARTICLE IX&#151;GENERAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_170"></A>9.1&nbsp;&nbsp;&nbsp;&nbsp;EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by law, the certificate of incorporation or these bylaws, the Board of Directors may authorize any officer or
officers, or agent or agents, or employee or employees, to enter into any contract or execute any document or instrument in the name of and on behalf of the Company; such authority may be general or confined to specific instances. Unless so
authorized or ratified by the Board of Directors or within the agency power of an officer, agent or employee, no officer, agent or employee shall have any power or authority to bind the Company by any contract or engagement or to pledge its credit
or to render it liable for any purpose or for any amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_171"></A>9.2&nbsp;&nbsp;&nbsp;&nbsp;FISCAL YEAR </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fiscal year of the Company shall be fixed by resolution of the Board of Directors and may be changed by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_172"></A>9.3&nbsp;&nbsp;&nbsp;&nbsp;SEAL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may adopt a corporate seal, which shall be adopted and which may be altered by the Board of Directors. The Company may use the
corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_173"></A>9.4&nbsp;&nbsp;&nbsp;&nbsp;CONSTRUCTION; DEFINITIONS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the
construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term &#147;<B>person</B>&#148; includes a corporation, partnership, limited
liability company, joint venture, trust or other enterprise, and a natural person. Any reference in these bylaws to a section of the DGCL shall be deemed to refer to such section as amended from time to time and any successor provisions thereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="f722206_174"></A>9.5&nbsp;&nbsp;&nbsp;&nbsp;FORUM SELECTION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the
Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a)&nbsp;any derivative
action or proceeding brought on behalf of the Company, (b)&nbsp;any action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asserting a claim of breach of a fiduciary duty owed by any director, stockholder, officer or other employee of the Company to the Company or the Company&#146;s stockholders, (c)&nbsp;any action
arising pursuant to any provision of the DGCL or the certificate of incorporation or these bylaws (as either may be amended from time to time) or (d)&nbsp;any action asserting a claim governed by the internal affairs doctrine, except for, as to each
of (a)&nbsp;through (d) above, any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court
within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, against any person in connection with any offering of the Company&#146;s securities,
(including without limitation and for the avoidance of doubt, any underwriter, auditor, expert, control person or other defendant). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
person or entity purchasing or otherwise acquiring any interest in any security of the Company shall be deemed to have notice of and consented to the provisions of this Section&nbsp;9.5. This provision shall be enforceable by any party to a
complaint covered by the provisions of this Section&nbsp;9.5. For the avoidance of doubt, nothing contained in this Section&nbsp;9.5 shall apply to any action brought to enforce a duty or liability created by the 1934&nbsp;Act or any successor
thereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="f722206_175"></A>ARTICLE X&#151;AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These bylaws may be adopted, amended or repealed by the stockholders entitled to vote; provided, however, that the affirmative vote of the
holders of at least 66&nbsp;2/3% of the total voting power of outstanding voting securities, voting together as a single class, shall be required for the stockholders of the Company to alter, amend or repeal, or adopt any bylaw inconsistent with,
the following provisions of these bylaws: Article II, Sections 3.1, 3.2, 3.4 and 3.11 of Article III, Article VIII, Section&nbsp;9.5 of Article&nbsp;IX or this Article X (including, without limitation, any such Article or Section as renumbered as a
result of any amendment, alteration, change, repeal, or adoption of any other Bylaw). The Board of Directors shall also have the power to adopt, amend or repeal bylaws; provided, however, that a bylaw amendment adopted by stockholders which
specifies the votes that shall be necessary for the election of directors shall not be further amended or repealed by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-28 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>5
<FILENAME>d722206dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g14a08.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">BRITISH COLUMBIA BC Registry Servies Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca
Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 Notice of Articles BUSINESS CORPORATIONS ACT CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies T.K. SPARKS This Notice of Articles
was issued by the Registrar on: June 10, 2022 01:32 PM Pacific Time Incorporation Number: C1117210 Recognition Date and Time: Continued into British Columbia on May&nbsp;2, 2017 09:30 AM Pacific Time NOTICE OF ARTICLES Name of Company: ZYMEWORKS
INC. REGISTERED OFFICE INFORMATION Mailing Address: SUITE 2600, THREE BENTALL CENTRE 595 BURRARD STREET, P.O. BOX 49314 VANCOUVER BC V7X 1L3 CANADA Delivery Address: SUITE 2600, THREE BENTALL CENTRE 595 BURRARD STREET, P.O. BOX 49314 VANCOUVER BC
V7X 1L3 CANADA RECORDS OFFICE INFORMATION Mailing Address: SUITE 2600, THREE BENTALL CENTRE 595 BURRARD STREET, P.O. BOX 49314 VANCOUVER BC V7X 1L3 CANADA Delivery Address: SUITE 2600, THREE BENTALL CENTRE 595 BURRARD STREET, P.O. BOX 49314
VANCOUVER BC V7X 1L3 CANADA Page: 1 of 3 </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g14a09.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">DIRECTOR INFORMATION Last Name, First Name, Middle Name: Cox, Troy Mailing Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4
CANADA Delivery Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Last Name, First Name, Middle Name: Sacks, Natalie Mailing Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Delivery Address: 114 EAST 4TH AVENUE,
SUITE 800 VANCOUVER BC V5T 1G4 CANADA Last Name, First Name, Middle Name: Zoth, Lota Mailing Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Delivery Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Last Name,
First Name, Middle Name: Galbraith, Kenneth Mailing Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Delivery Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Last Name, First Name, Middle Name: Renton, Hollings
C, Mailing Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Delivery Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Last Name, First Name, Middle Name: Mahony, Susan Mailing Address: 114 EAST 4TH AVENUE, SUITE
800 VANCOUVER BC V5T 1G4 CANADA Delivery Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Page: 2 of 3 </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g15a00.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Last Name, First Name, Middle Name: Neu, Kelvin Mailing Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Delivery
Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Last Name, First Name, Middle Name: Hillan, Kenneth J. Mailing Address: 114 EAST 4TH AVENUE, SUITE 800 VANCOUVER BC V5T 1G4 CANADA Delivery Address: 114 EAST 4TH AVENUE, SUITE 800
VANCOUVER BC V5T 1G4 CANADA RESOLUTION DATES: Date(s) of Resolution(s) or Court Order(s) attaching or altering Special Rights and Restrictions attached to a class or a series of shares: June 9, 2022 AUTHORIZED SHARE STRUCTURE 1. No Maximum Common
Shares Without Par Value Without Special Rights or Restrictions attached 2. No Maximum Preferred Shares Without Par Value With Special Rights or Restrictions attached 1. No Maximum Series A Participating Preferred Special Rights or Restrictions are
attached Page: 3 of 3 </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>6
<FILENAME>d722206dex35.htm
<DESCRIPTION>EX-3.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>BUSINESS CORPORATIONS ACT</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>ARTICLE 1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>INTERPRETATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business Corporations Act and Interpretation Act Definitions Applicable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 2</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SHARES AND SHARE CERTIFICATES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized Share Structure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Share Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholder Entitled to Certificate or Acknowledgement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delivery by Mail</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replacement of Worn Out or Defaced Certificate or Acknowledgement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replacement of Lost, Stolen or Destroyed Certificate or Acknowledgement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Splitting Share Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of Trusts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 3</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ISSUE OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors Authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commissions and Discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brokerage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditions of Issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Purchase Warrants and Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 4</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SHARE REGISTERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Central Securities Register</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Register</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 5</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SHARE TRANSFERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registering Transfers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Instrument of Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferor Remains Shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signing of Instrument of Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Enquiry as to Title Not Required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>TRANSMISSION OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Personal Representative Recognized on Death</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rights of Legal Personal Representative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 7</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PURCHASE OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Authorized to Purchase or Otherwise Acquire Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase When Insolvent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale and Voting of Purchased, Redeemed, or Otherwise Acquired Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>BORROWING POWERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowing Powers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ALTERATIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alteration of Authorized Share Structure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Rights and Restrictions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Interference with Class&nbsp;or Series Rights without Consent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Alterations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>MEETINGS OF SHAREHOLDERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Resolution Instead of Annual General Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calling of Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice for Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record Date for Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record Date for Voting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure to Give Notice and Waiver of Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Special Business at Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;Meetings and Series Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings by Telephone or Other Communications Medium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance Notice of Nominations of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 11</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PROCEEDINGS AT MEETINGS OF SHAREHOLDERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Majority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Shareholder May Constitute Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Persons May Attend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Requirement of Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lack of Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lack of Quorum at Succeeding Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selection of Alternate Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjournments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Adjourned Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decision by Show of Hands or Poll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Declaration of Result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Motion Need Not be Seconded</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casting Vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manner of Taking Poll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demand for Poll on Adjournment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair Must Resolve Dispute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casting of Votes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Demand for Poll on Election of Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demand for Poll Not to Prevent Continuance of Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retention of Ballots and Proxies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 12</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>VOTES OF SHAREHOLDERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Votes by Shareholder or by Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Votes of Persons in Representative Capacity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Votes by Joint Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Personal Representatives as Joint Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representative of a Corporate Shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proxy Provisions Do Not Apply to All Companies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Proxy Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alternate Proxy Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">When Proxy Holder Need Not Be Shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Validity of Proxy Vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revocation of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revocation of Proxy Must Be Signed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair May Determine Validity of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Production of Evidence of Authority to Vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 13</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in Number of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- iii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors&#146; Acts Valid Despite Vacancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qualifications of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reimbursement of Expenses of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Remuneration for Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gratuity, Pension or Allowance on Retirement of Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 14</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ELECTION AND REMOVAL OF DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staggered Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Election at Annual General Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Election or Appointment between Annual General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Election at Annual General Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consent to be a Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure to Elect or Appoint Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Places of Retiring Directors Not Filled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors May Fill Casual Vacancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining Directors Power to Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders May Fill Vacancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ceasing to be a Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Removal of Director by Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Removal of Director by Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>POWERS AND DUTIES OF DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Powers of Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Attorney of Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 16</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>DISCLOSURE OF INTEREST OF DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligation to Account for Profits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restrictions on Voting by Reason of Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interested Director Counted in Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure of Conflict of Interest or Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director Holding Other Office in the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Disqualification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional Services by Director or Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director or Officer in Other Corporations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- iv - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 17</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PROCEEDINGS OF DIRECTORS</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting at Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings by Telephone or Other Communications Medium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calling of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">When Notice Not Required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meeting Valid Despite Failure to Give Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver of Notice of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Validity of Acts Where Appointment Defective</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consent Resolutions in Writing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 18</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>EXECUTIVE AND OTHER COMMITTEES</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment and Powers of Executive Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment and Powers of Other Committees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligations of Committees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Powers of Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 19</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>OFFICERS</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors May Appoint Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Functions, Duties and Powers of Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qualifications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration and Terms of Appointment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 20</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>INDEMNIFICATION</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatory Indemnification of Directors and Former Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification of Other Persons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Compliance</FONT> with <I>Business Corporations
Act</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company May Purchase Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 21</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>DIVIDENDS</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of Dividends Subject to Special Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Declaration of Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Notice Required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manner of Paying Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- v - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of Difficulties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">When Dividend Payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends to be Paid in Accordance with Number of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receipt by Joint Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Bears No Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fractional Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization of Surplus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unclaimed Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 22</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>DOCUMENTS, RECORDS AND REPORTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recording of Financial Affairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inspection of Accounting Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 23</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>NOTICES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Method of Giving Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed Receipt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of Sending</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice to Joint Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice to Legal Personal Representatives and Trustees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Undelivered Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 24</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SEAL AND EXECUTION OF DOCUMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Who May Attest Seal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sealing Copies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mechanical Reproduction of Seal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Execution of Documents Generally</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 25</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PROHIBITIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consent Required for Transfer of Shares or Designated Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 26</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FORUM SELECTION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forum for Adjudication of Certain Disputes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 27</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SPECIAL RIGHTS OR RESTRICTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Participating Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- vi - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Continuation number: C1117210 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>BUSINESS CORPORATIONS ACT </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERPRETATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.1
</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Definitions.</B> In these Articles (the &#147;<B>Articles</B>&#148;), unless the context otherwise requires: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Securities Laws</B>&#148; means the applicable securities legislation of each relevant province and territory of Canada,
as amended from time to time, the written rules, regulations and forms made or promulgated under any such statute and the published national instruments, multilateral instruments, policies, bulletins and notices of the securities commissions and
similar regulatory authorities of each province and territory of Canada; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>appropriate person</B>&#148; has the meaning set forth
in the <I>Securities Transfer Act</I>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>board of directors</B>&#148;, &#147;<B>directors</B>&#148; and &#147;<B>board</B>&#148;
mean the directors of the Company for the time being; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Corporations Act</I></B>&#146;&#146; means the <I>Business
Corporations Act</I> (British Columbia) from time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>Interpretation Act</B>&#148; means the <I>Interpretation Act</I> (British Columbia) from time to time in force and all amendments
thereto and includes all regulations and amendments thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>legal personal representative</B>&#148; means the personal or other
legal representative of a shareholder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>protected purchaser</B>&#148; has the meaning set forth in the <I>Securities Transfer
Act</I>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>registered address</B>&#148; of a shareholder means the shareholder&#146;s address as recorded in the central
securities register; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>seal</B>&#148; means the seal of the Company, if any; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B></B><B><I>Securities Act</I></B><B></B>&#148; means the <I>Securities Act</I> (British Columbia) from time to time in force and all
amendments thereto and includes all regulations and amendments thereto made pursuant to that Act; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Transfer
Act</I></B>&#146;&#146; means the <I>Securities Transfer Act</I> (British Columbia) from time to time in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2 </B><B>&nbsp;&nbsp;&nbsp;&nbsp;Business Corporations Act and Interpretation Act Definitions Applicable.</B> The definitions in the <I>Business
Corporations Act </I>and the definitions and rules of construction in the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Interpretation Act,</I> with the necessary changes, so far as applicable, and unless the context requires otherwise, apply to these Articles as if they were an enactment. If there is a
conflict between a definition in the <I>Business Corporations Act</I> and a definition or rule in the <I>Interpretation Act </I>relating to a term used in these Articles, the definition in the <I>Business Corporations Act</I> will prevail in
relation to the use of the term in these Articles. If there is a conflict between these Articles and the <I>Business Corporations Act</I>, the <I>Business Corporations Act</I> will prevail. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES AND
SHARE CERTIFICATES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Authorized Share Structure.</B> The authorized share structure of the Company consists of
shares of the class or classes and series, if any, described in the Notice of Articles of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2 &nbsp;&nbsp;&nbsp;&nbsp;Form of Share
Certificate.</B> Each share certificate issued by the Company must comply with, and be signed as required by, the <I>Business Corporations Act</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3 &nbsp;&nbsp;&nbsp;&nbsp;Shareholder Entitled to Certificate or Acknowledgement.</B> Unless the shares of which the shareholder is the registered owner
are uncertificated shares within the meaning of the <I>Business Corporations Act</I>, each shareholder is entitled, without charge, to (a)&nbsp;one share certificate representing the shares of each class or series of shares registered in the
shareholder&#146;s name or (b)&nbsp;a <FONT STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of the shareholder&#146;s right to obtain such a share certificate, provided that in respect of a share held jointly by several
persons, the Company is not bound to issue more than one share certificate and delivery of a share certificate for a share to one of several joint shareholders or to one of the shareholders&#146; duly authorized agents will be sufficient delivery to
all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4 &nbsp;&nbsp;&nbsp;&nbsp;Delivery by Mail.</B> Any share certificate or <FONT STYLE="white-space:nowrap">non-transferable</FONT> written
acknowledgement of a shareholder&#146;s right to obtain a share certificate may be sent to the shareholder by mail at the shareholder&#146;s registered address and neither the Company nor any director, officer or agent of the Company (including the
Company&#146;s transfer agent or legal counsel) is liable for any loss to the shareholder because the share certificate or acknowledgement is lost in the mail or stolen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.5 &nbsp;&nbsp;&nbsp;&nbsp;Replacement of Worn Out or Defaced Certificate or Acknowledgement.</B> If the directors are satisfied that a share certificate
or a <FONT STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of the shareholder&#146;s right to obtain a share certificate is worn out or defaced, they must, on production to them of the share certificate or acknowledgement,
as the case may be, and on such other terms, if any, as they think fit: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">order the share certificate or acknowledgement, as the case may be, to be cancelled; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue a replacement share certificate or acknowledgement, as the case may be. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6 &nbsp;&nbsp;&nbsp;&nbsp;Replacement of Lost, Stolen or Destroyed Certificate or Acknowledgement.</B> If a share certificate or a <FONT
STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of a shareholder&#146;s right to obtain a share certificate is lost, stolen or destroyed, a replacement share certificate or acknowledgement, as the case may be, must be
issued to the person entitled to that share certificate or acknowledgement, as the case may be, if the directors receive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">proof satisfactory to them that the share certificate or acknowledgement is lost, stolen or destroyed; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any indemnity the directors consider adequate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.7 &nbsp;&nbsp;&nbsp;&nbsp;Splitting Share Certificates.</B> If a shareholder surrenders a share
certificate to the Company with a written request that the Company issue in the shareholder&#146;s name two or more share certificates, each representing a specified number of shares and in the aggregate representing the same number of shares as the
share certificate so surrendered, the Company must cancel the surrendered share certificate and issue replacement share certificates in accordance with that request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.8 &nbsp;&nbsp;&nbsp;&nbsp;Certificate Fee.</B> There must be paid to the Company, in relation to the issue of any share certificate under Articles 2.5,
2.6 or 2.7, the amount, if any and which must not exceed the amount prescribed under the <I>Business Corporations Act</I>, determined by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.9 &nbsp;&nbsp;&nbsp;&nbsp;Recognition of Trusts.</B> Except as required by law or statute or these Articles, no person will be recognized by the Company
as holding any share upon any trust, and the Company is not bound by or compelled in any way to recognize (even when having notice thereof) any equitable, contingent, future or partial interest in any share or fraction of a share or (except as by
law or statute or these Articles provided or as ordered by a court of competent jurisdiction) any other rights in respect of any share except an absolute right to the entirety thereof in the shareholder. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ISSUE OF
SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1 &nbsp;&nbsp;&nbsp;&nbsp;Directors Authorized.</B> Subject to the <I>Business Corporations Act</I> and the rights of the holders of
issued shares of the Company, the Company may issue, allot, sell or otherwise dispose of the unissued shares, and issued shares held by the Company, at the times, to the persons, including directors, in the manner, on the terms and conditions and
for the issue prices (including any premium at which shares with par value may be issued) that the directors may determine. The issue price for a share with par value must be equal to or greater than the par value of the share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2 &nbsp;&nbsp;&nbsp;&nbsp;Commissions and Discounts.</B> The Company may at any time, pay a reasonable commission or allow a reasonable discount to any
person in consideration of that person purchasing or agreeing to purchase shares of the Company from the Company or any other person or procuring or agreeing to procure purchasers for shares of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3 &nbsp;&nbsp;&nbsp;&nbsp;Brokerage.</B> The Company may pay such brokerage fee or other consideration as may be lawful for or in connection with the
sale or placement of its securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4 &nbsp;&nbsp;&nbsp;&nbsp;Conditions of Issue.</B> Except as provided for by the <I>Business Corporations
Act</I>, no share may be issued until it is fully paid. A share is fully paid when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consideration is provided to the Company for the issue of the share by one or more of the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">past services performed for the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">money; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the value of the consideration received by the Company equals or exceeds the issue price set for the share
under Article 3.1. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.5 &nbsp;&nbsp;&nbsp;&nbsp;Share Purchase Warrants and Rights.</B> Subject to the <I>Business Corporations
Act</I>, the Company may issue share purchase warrants, options and rights upon such terms and conditions as the directors determine, which share purchase warrants, options and rights may be issued alone or in conjunction with debentures, debenture
stock, bonds, shares or any other securities issued or created by the Company from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE REGISTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp; Central Securities Register. </B>As required by and subject to the<I> Business Corporations Act</I>, the Company must maintain
in British Columbia a central securities register, which may be kept in electronic form. The directors may, subject to the <I>Business Corporations Act</I>, appoint an agent to maintain the central securities register. The directors may also appoint
one or more agents, including the agent which keeps the central securities register, as transfer agent for its shares or any class or series of its shares, as the case may be, and the same or another agent as registrar for its shares or such class
or series of its shares, as the case may be. The directors may terminate such appointment of any agent at any time and may appoint another agent in its place. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Closing Register.</B> The Company must not at any time close its central securities register. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE
TRANSFERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1 &nbsp;&nbsp;&nbsp;&nbsp;Registering Transfers. </B>A transfer of a share of the Company must not be registered unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a duly signed instrument of transfer in respect of the share has been received by the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a share certificate has been issued by the Company in respect of the share to be transferred, that share
certificate has been surrendered to the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a <FONT STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of the shareholder&#146;s
right to obtain a share certificate has been issued by the Company in respect of the share to be transferred, that acknowledgement has been surrendered to the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2 &nbsp;&nbsp;&nbsp;&nbsp;Form of Instrument of Transfer.</B> The instrument of transfer in respect of any share of the Company must be either in the
form, if any, on the back of the Company&#146;s share certificates or in any other form that may be approved by the directors from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3
&nbsp;&nbsp;&nbsp;&nbsp;Transferor Remains Shareholder.</B> Except to the extent that the <I>Business Corporations Act</I> otherwise provides, the transferor of shares is deemed to remain the holder of the shares until the name of the transferee is
entered in a securities register of the Company in respect of the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.4 &nbsp;&nbsp;&nbsp;&nbsp;Signing of Instrument of Transfer. </B>If a
shareholder, or other appropriate person or an agent who has actual authority to act on behalf of that person, signs an instrument of transfer in respect of shares registered in the name of the shareholder, the signed instrument of transfer
constitutes a complete and sufficient authority to the Company and its directors, officers and agents to register the number of shares specified in the instrument of transfer or specified in any other manner, or, if no number is specified, all the
shares represented by the share certificates or set out in the written acknowledgements deposited with the instrument of transfer: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the name of the person named as transferee in that instrument of transfer; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if no person is named as transferee in that instrument of transfer, in the name of the person on whose behalf
the instrument is deposited for the purpose of having the transfer registered. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enquiry as to Title
Not Required.</B> Neither the Company nor any director, officer or agent of the Company is bound to inquire into the title of the person named in the instrument of transfer as transferee or, if no person is named as transferee in the instrument of
transfer, of the person on whose behalf the instrument is deposited for the purpose of having the transfer registered or is liable for any claim related to registering the transfer by the shareholder or by any intermediate owner or holder of the
shares, of any interest in the shares, of any share certificate representing such shares or of any written acknowledgement of a right to obtain a share certificate for such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer Fee.</B> There must be paid to the Company, in relation to the registration of any transfer, the amount, if any,
determined by the directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSMISSION OF SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal Personal Representative Recognized on Death. </B>In case of the death of a shareholder, the legal personal
representative, or if the shareholder was a joint holder, the surviving joint holder, will be the only person recognized by the Company as having any title to the shareholder&#146;s interest in the shares. Before recognizing a person as a legal
personal representative, the directors may require proof of appointment by a court of competent jurisdiction, a grant of letters probate, letters of administration or such other evidence or documents as the directors consider appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rights of Legal Personal Representative. </B>The legal personal representative has the same rights, privileges and
obligations that attach to the shares held by the shareholder, including the right to transfer the shares in accordance with these Articles, provided the documents required by the <I>Business Corporations Act</I> and the directors have been
deposited with the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE OF SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company Authorized to Purchase or Otherwise Acquire Shares.</B> Subject to Article 7.2, the special rights and
restrictions attached to the shares of any class or series, the <I>Business Corporations Act</I> and the Applicable Securities Laws, the Company may, if authorized by the directors, purchase or otherwise acquire any of its shares at the price and
upon the terms determined by the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase When Insolvent.</B> The Company must not make a payment or
provide any other consideration to purchase or otherwise acquire any of its shares if there are reasonable grounds for believing that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is insolvent; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making the payment or providing the consideration would render the Company insolvent. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sale and Voting of Purchased, Redeemed, or Otherwise Acquired Shares.</B> If the Company retains a share redeemed,
purchased or otherwise acquired by it, the Company may sell, gift or otherwise dispose of the share, but, while such share is held by the Company, it: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not entitled to vote the share at a meeting of its shareholders; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must not pay a dividend in respect of the share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must not make any other distribution in respect of the share. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BORROWING
POWERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowing Powers.</B> The Company, if authorized by the directors, may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">borrow money in the manner and amount, on the security, from the sources and on the terms and conditions that
the directors consider appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue bonds, debentures and other debt obligations either outright or as security for any liability or
obligation of the Company or any other person and at such discounts or premiums and on such other terms as the directors consider appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">guarantee the repayment of money by any other person or the performance of any obligation of any other person;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mortgage, charge, whether by way of specific or floating charge, grant a security interest in, or give other
security on, the whole or any part of the present and future assets and undertaking of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALTERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alteration of Authorized Share Structure.</B> Subject to Articles 9.2 and 9.3, the <I>Business Corporations Act</I> and
the special rights and restrictions attached to the shares of any class or series, the Company may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by ordinary resolution: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">create one or more classes or series of shares or, if none of the shares of a class or series of shares are
allotted or issued, eliminate that class or series of shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increase, reduce or eliminate the maximum number of shares that the Company is authorized to issue out of any
class or series of shares or establish a maximum number of shares that the Company is authorized to issue out of any class or series of shares for which no maximum is established; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company is authorized to issue shares of a class of shares with par value: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">decrease the par value of those shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if none of the shares of that class of shares are allotted or issued, increase the par value of those shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">change all or any of its unissued, or fully paid issued, shares with par value into shares without par value or
any of its unissued shares without par value into shares with par value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">alter the identifying name of any of its shares; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise alter its shares or authorized share structure when required or permitted to do so by the <I>Business
</I><I>Corporations Act</I>; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and, if applicable, alter its Notice of Articles and Articles accordingly, or </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by resolution of the directors, subdivide, or consolidate all or any of its unissued, or fully paid issued,
shares and, if applicable, alter its Notice of Articles and Articles accordingly. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special Rights
and Restrictions.</B> Subject to Article 9.3, the special rights or restrictions attached to any class or series of shares and the <I>Business Corporations Act</I>, the Company may by ordinary resolution: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">create special rights or restrictions for, and attach those special rights or restrictions to, the shares of
any class or series of shares, whether or not any or all of those shares have been issued; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vary or delete any special rights or restrictions attached to the shares of any class or series of shares,
whether or not any or all of those shares have been issued; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and alter its Articles or Notice of Articles accordingly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.3&nbsp;&nbsp;&nbsp;&nbsp; No Interference with Class&nbsp;or Series Rights without Consent.</B> A right or special right attached to issued shares
must not be prejudiced or interfered with under the <I>Business Corporations Act</I>, the Notice of Articles or these Articles unless the holders of shares of the class or series of shares to which the right or special right is attached consent by a
special separate resolution of the holders of such class or series of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.4&nbsp;&nbsp;&nbsp;&nbsp; Change of Name.</B> The Company may by
director&#146;s resolution or ordinary resolution authorize an alteration of its Notice of Articles in order to change its name. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.5&nbsp;&nbsp;&nbsp;&nbsp; Other Alterations. </B>If the <I>Business Corporations Act</I> does not specify the type of resolution and these Articles do
not specify another type of resolution, the Company may by ordinary resolution alter these Articles. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEETINGS OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp; Annual General Meetings.</B> Unless an annual general meeting is deferred or waived in accordance with the <I>Business
</I><I>Corporations Act</I>, the Company must hold an annual general meeting at least once in each calendar year and not more than 15 months after the last annual reference date at such time and place as may be determined by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.2&nbsp;&nbsp;&nbsp;&nbsp; Resolution Instead of Annual General Meeting.</B> If all the shareholders who are entitled to vote at an annual general
meeting consent by a unanimous resolution under the <I>Business Corporations Act</I> to all of the business that is required to be transacted at that annual general meeting, the annual general meeting is deemed to have been held on the date of the
unanimous resolution. The shareholders must, in any unanimous resolution passed under this Article 10.2, select as the Company&#146;s annual reference date a date that would be appropriate for the holding of the applicable annual general meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.3&nbsp;&nbsp;&nbsp;&nbsp; Calling of Meetings of Shareholders. </B>The directors may, whenever they think fit, call a meeting of shareholders, to
be held at such time and place as may be determined by the directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.4&nbsp;&nbsp;&nbsp;&nbsp; Notice for Meetings of Shareholders.</B> The Company must send notice of the
date, time and location of any meeting of shareholders, in the manner provided in these Articles, or in such other manner, if any, as may be prescribed by ordinary resolution (whether previous notice of the resolution has been given or not), to each
shareholder entitled to attend the meeting, to each director and to the auditor of the Company, unless these Articles otherwise provide, at least the following number of days before the meeting: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if and for so long as the Company is a public company, 21 days; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise, 10 days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.5&nbsp;&nbsp;&nbsp;&nbsp; Record Date for Notice.</B> The directors may set a date as the record date for the purpose of determining shareholders
entitled to notice of any meeting of shareholders. The record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general meeting requisitioned by shareholders under the <I>Business
Corporations Act</I>, by more than four months. The record date must not precede the date on which the meeting is held by fewer than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if and for so long as the Company is a public company, 21 days; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise, 10 days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If no record date is set, the record date is 5 p.m. on the day immediately preceding the first date on which the notice is sent or, if no notice is sent, the
beginning of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.6&nbsp;&nbsp;&nbsp;&nbsp; Record Date for Voting.</B> The directors may set a date as the record date for the purpose of
determining shareholders entitled to vote at any meeting of shareholders. The record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general meeting requisitioned by shareholders under
the <I>Business Corporations Act</I>, by more than four months. If no record date is set, the record date is 5 p.m. on the day immediately preceding the first date on which the notice is sent or, if no notice is sent, the beginning of the meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.7&nbsp;&nbsp;&nbsp;&nbsp; Failure to Give Notice and Waiver of Notice.</B> The accidental omission to send notice of any meeting to, or the <FONT
STYLE="white-space:nowrap">non-receipt</FONT> of any notice by, any of the persons entitled to notice does not invalidate any proceedings at that meeting. Any person entitled to notice of a meeting of shareholders may, in writing or otherwise, waive
or reduce the period of notice of such meeting. Attendance of a person at a meeting of shareholders is a waiver of entitlement to notice of the meeting unless that person attends the meeting for the express purpose of objecting to the transaction of
any business on the grounds that the meeting is not lawfully called. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.8&nbsp;&nbsp;&nbsp;&nbsp; Notice of Special Business at Meetings of
Shareholders.</B> If a meeting of shareholders is to consider special business within the meaning of Article 11.1, the notice of meeting must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">state the general nature of the special business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the special business includes considering, approving, ratifying, adopting or authorizing any document or the
signing of or giving of effect to any document, have attached to it a copy of the document or state that a copy of the document will be available for inspection by shareholders: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the Company&#146;s records office, or at such other reasonably accessible location in British Columbia as is
specified in the notice; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">during statutory business hours on any one or more specified days before the day set for the holding of the
meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.9&nbsp;&nbsp;&nbsp;&nbsp; Class&nbsp;Meetings and Series Meetings of Shareholders.</B> Unless otherwise specified in
these Articles, the provisions of these Articles relating to a meeting of shareholders will apply, with the necessary changes and so far as they are applicable, to a class meeting or series meeting of shareholders holding a particular class or
series of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.10&nbsp;&nbsp;&nbsp;&nbsp; Meetings by Telephone or Other Communications Medium.</B> The directors may determine that a meeting
of shareholders shall be held entirely by means of telephonic, electronic or other communication facilities that permit all participants to communicate with each other during the meeting. A meeting of shareholders may also be held at which some, but
not necessarily all, persons entitled to attend may participate by means of such communications facilities, if the directors determine to make them available. A person participating in a meeting by such means is deemed to be present at the meeting.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.11&nbsp;&nbsp;&nbsp;&nbsp; Advance Notice of Nominations of Directors. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Nomination Procedures</U> - Subject only to the <I>Business Corporations Act</I>, Applicable Securities Law
and these Articles, only persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the Company. Nominations of persons for election to the board may be made at any annual meeting of
shareholders, or at any special meeting of shareholders if the election of directors is a matter specified in the notice of meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by or at the direction of the board, including pursuant to a notice of meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by or at the direction or request of one or more shareholders pursuant to a proposal made in accordance with
the provisions of the <I>Business Corporations Act</I>, or a requisition of the shareholders made in accordance with the provisions of the <I>Business Corporations Act</I>; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by any person (a &#147;<B>Nominating Shareholder</B>&#148;) who (A) at the close of business on the date of the
giving of the notice provided for in this Article 10.11 and on the record date for notice of such meeting, is entered in the securities register as a holder of one or more shares carrying the right to vote at such meeting or who beneficially owns
shares that are entitled to be voted at such meeting and provides evidence of such beneficial ownership to the Company, and (B)&nbsp;has given timely notice in proper written form as set forth in this Article 10.11. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Manner of timely notice</U> - To be timely, a Nominating Shareholder&#146;s notice must be received by the
corporate secretary of the Company at the principal executive office or registered office of the Company: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an annual meeting (including an annual and special meeting) of shareholders, not later than the
close of business on the 30th day prior to the date of the meeting; provided, however, that in the event that the meeting is to be held on a date that is less than 50 days after the date (the &#147;<B>Notice Date</B>&#148;) on which the first public
announcement of the date of the meeting was made, notice by the Nominating Shareholder may be made not later than the close of business on the tenth (10th) day following the Notice Date; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a special meeting (which is not also an annual meeting) of shareholders called for the purpose
of electing directors (whether or not called for other purposes), not later than the close of business on the fifteenth (15th) day following the day on which the first public announcement of the date of the meeting was made. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Proper form of notice</U> - To be in proper written form, a Nominating Shareholder&#146;s notice must comply
with this Article 10.11 and must set forth: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to each person whom the Nominating Shareholder proposes to nominate for election as a director:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">their name, age, business and residential address, and principal occupation or employment for the past five
years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">their direct or indirect beneficial ownership in, or control or direction over, any class or series of
securities of the Company, including the number or principal amount; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other information that would be required to be disclosed in a dissident proxy circular or other filings
required to be made in connection with the solicitation of proxies for election of directors pursuant to the <I>Business </I><I>Corporations Act</I> or Applicable Securities Laws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to each Nominating Shareholder giving the notice: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">their name, business and residential address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any direct or indirect beneficial ownership in, or control or direction over, any class or series of securities
of the Company, including the number or principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any proxy, contract, arrangement, agreement or understanding pursuant to which such person, or any of its
Affiliates or Associates, or any person acting jointly or in concert with such person, has any interests, rights or obligations relating to the voting of any securities of the Company or the nomination of directors to the board; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other information relating to such person that would be required to be included in a dissident proxy
circular or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to the <I>Business Corporations Act</I> or as required by Applicable Securities Laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">References to &#147;Nominating Shareholder&#148; in this Article 10.11 shall be deemed to refer to each shareholder that nominates a person for
election as a director in the case of a nomination proposal where more than one shareholder is involved in making such nomination proposal. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Currency of information</U> - All information to be provided in a timely notice pursuant to this Article
10.11 shall be provided as of the record date for determining shareholders </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
entitled to vote at the meeting (if such date shall then have been publicly announced) and as of the date of such notice. The Nominating Shareholder shall update such information to the extent
necessary so that it is true and correct as of the date that is ten (10)&nbsp;business days prior to the date of the meeting, or any adjournment or postponement thereof. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Power of the chair</U> - The chair of the meeting shall have the power and duty to determine whether a
nomination was made in accordance with the procedures set forth in the foregoing provisions and, if any proposed nomination is not in compliance with such foregoing provisions, to declare that such defective nomination shall be disregarded.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Delivery of notice</U> - Notwithstanding any other provision of these Articles, notice given to the
corporate secretary of the Company pursuant to this Article 10.11 may only be given by personal delivery, facsimile transmission or by email (at such email address as may be stipulated from time to time on the Company&#146;s website for general
inquiries), and shall be deemed to have been given and made only at the time it is served by personal delivery to the corporate secretary at the address of the principal executive offices of the Company, email (at the address as aforesaid and
provided that confirmation of receipt of such email has been received) or sent by facsimile transmission (provided that receipt of the confirmation of such transmission has been received); provided that if such delivery or electronic communication
is made on a day which is not a business day or later than 5:00 p.m. (Vancouver time) on a day which is a business day, then such delivery or electronic communication shall be deemed to have been made on the subsequent day that is a business day.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusive Means</U> - For the avoidance of doubt, this Article 10.11 shall be the exclusive means for any
person to bring nominations for election to the board at or in connection with any annual or special meeting of the shareholders of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver</U> - Notwithstanding the foregoing, the board may, in its sole discretion, waive any requirement in
this Article 10.11. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U> - For purposes of this Article 10.11, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148;, when used to indicate a relationship with a specific person, shall mean a person that directly, or indirectly
through one or more intermediaries, controls, or is controlled by, or is under common control with, such specified person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Associate</B>&#148;, when used to indicate a relationship with a specified person, shall mean (i)&nbsp;any body corporate or trust of
which such person beneficially owns, directly or indirectly, voting securities carrying more than 10% of the voting rights attached to all voting securities of such body corporate or trust for the time being outstanding, (ii)&nbsp;any partner of
that person, (iii)&nbsp;any trust or estate in which such person has a substantial beneficial interest or as to which such person serves as trustee or in a similar capacity, (iv)&nbsp;a spouse of such specified person, (v)&nbsp;any person of either
sex with whom such specified person is living in conjugal relationship outside marriage or (vi)&nbsp;any relative of such specified person or of a person mentioned in clauses (iv)&nbsp;or (v) of this definition if that relative has the same
residence as the specified person; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>beneficially owns</B>&#148; or &#147;<B>beneficially owned</B>&#148; means, in connection with
the ownership of shares in the capital of the Company by a person, (i)&nbsp;any such shares as to which such person or any of such person&#146;s Affiliates or Associates owns at law or in equity, or has the right to acquire or become the owner at
law or in equity, where such right is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
exercisable immediately or after the passage of time and whether or not on condition or the happening of any contingency or the making of any payment, upon the exercise of any conversion right,
exchange right or purchase right attaching to any securities, or pursuant to any agreement, arrangement, pledge or understanding whether or not in writing; (ii)&nbsp;any such shares as to which such person or any of such person&#146;s Affiliates or
Associates has the right to vote, or the right to direct the voting, where such right is exercisable immediately or after the passage of time and whether or not on condition or the happening of any contingency or the making of any payment, pursuant
to any agreement, arrangement, pledge or understanding whether or not in writing; (iii)&nbsp;any such shares which are beneficially owned, directly or indirectly, by a Counterparty (or any of such Counterparty&#146;s Affiliates or Associates) under
any Derivatives Contract (without regard to any short or similar position under the same or any other Derivatives Contract) to which such person or any of such person&#146;s Affiliates or Associates is a Receiving Party; provided, however that the
number of shares that a person beneficially owns pursuant to this clause (iii)&nbsp;in connection with a particular Derivatives Contract shall not exceed the number of Notional Securities with respect to such Derivatives Contract; provided, further,
that the number of securities owned beneficially by each Counterparty (including their respective Affiliates and Associates) under a Derivatives Contract shall for purposes of this clause be deemed to include all securities that are owned
beneficially, directly or indirectly, by any other Counterparty (or any of such other Counterparty&#146;s Affiliates or Associates) under any Derivatives Contract to which such first Counterparty (or any of such first Counterparty&#146;s Affiliates
or Associates) is a Receiving Party and this proviso shall be applied to successive Counterparties as appropriate; and (iv)&nbsp;any such shares which are owned beneficially within the meaning of this definition by any other person with whom such
person is acting jointly or in concert with respect to the Company or any of its securities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>close of business</B>&#148; means
5:00 p.m. (Vancouver time) on a business day in British Columbia, Canada; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Derivatives Contract</B>&#148; shall mean a contract
between two parties (the &#147;<B>Receiving Party</B>&#148; and the &#147;<B>Counterparty</B>&#148;) that is designed to expose the Receiving Party to economic benefits and risks that correspond substantially to the ownership by the Receiving Party
of a number of shares in the capital of the Company or securities convertible into such shares specified or referenced in such contract (the number corresponding to such economic benefits and risks, the &#147;<B>Notional Securities</B>&#148;),
regardless of whether obligations under such contract are required or permitted to be settled through the delivery of cash, shares in the capital of the Company or securities convertible into such shares or other property, without regard to any
short position under the same or any other Derivatives Contract. For the avoidance of doubt, interests in broad-based index options, broad-based index futures and broad-based publicly traded market baskets of stocks approved for trading by the
appropriate governmental authority shall not be deemed to be Derivatives Contracts; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>public announcement</B>&#148; shall mean
disclosure in a press release reported by a national news service in Canada, or in a document publicly filed by the Company under its profile on the System for Electronic Document Analysis and Retrieval at <U>www.sedar.com</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROCEEDINGS AT MEETINGS OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp; Special Business. </B>At a meeting of shareholders, the following business is special business: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at a meeting of shareholders that is not an annual general meeting, all business is special business except
business relating to the conduct of or voting at the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at an annual general meeting, all business is special business except for the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">business relating to the conduct of or voting at the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consideration of any financial statements of the Company presented to the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consideration of any reports of the directors or auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the setting or changing of the number of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the election or appointment of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the appointment of an auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the setting of the remuneration of an auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">business arising out of a report of the directors not requiring the passing of a special resolution or an
exceptional resolution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other business which, under these Articles or the <I>Business Corporations Act</I>, may be transacted at a
meeting of shareholders without prior notice of the business being given to the shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp; Special
Majority. </B>The majority of votes required for the Company to pass a special resolution at a meeting of shareholders is <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on the resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp; Quorum.</B> Subject to the special rights and restrictions attached to the shares of any class or series of shares and Article
11.4, the quorum for the transaction of business at a meeting of shareholders is two persons who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 30% of the issued shares entitled to be voted at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp; One Shareholder May Constitute Quorum.</B> If there is only one shareholder entitled to vote at a meeting of shareholders:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the quorum is one person who is, or who represents by proxy, that shareholder, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that shareholder, present in person or by proxy, may constitute the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp; Other Persons May Attend.</B> In addition to those persons who are entitled to vote at a meeting of shareholders, the only
other persons entitled to be present at the meeting are the directors, the officers, any lawyer for the Company, the auditor of the Company, any other persons invited to be present at the meeting by the directors or by the chair of the meeting and
any persons entitled or required under the <I>Business Corporations Act</I> or these Articles to be present at the meeting; but if any of those persons does attend the meeting, that person is not to be counted in the quorum and is not entitled to
vote at the meeting unless that person is a shareholder or proxy holder entitled to vote at the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.6&nbsp;&nbsp;&nbsp;&nbsp; Requirement of Quorum.</B> No business, other than the election of a chair
of the meeting and the adjournment of the meeting, may be transacted at any meeting of shareholders unless a quorum of shareholders entitled to vote is present at the commencement of the meeting, but such quorum need not be present throughout the
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.7&nbsp;&nbsp;&nbsp;&nbsp; Lack of Quorum.</B> If, within <FONT STYLE="white-space:nowrap">one-half</FONT> hour from the time set for the
holding of a meeting of shareholders, a quorum is not present: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a general meeting requisitioned by shareholders, the meeting is dissolved, and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any other meeting of shareholders, the meeting stands adjourned to the same day in the next week
at the same time and place. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.8&nbsp;&nbsp;&nbsp;&nbsp; Lack of Quorum at Succeeding Meeting. </B>If, at the meeting to which the
meeting referred to in Article 11.7(b) was adjourned, a quorum is not present within <FONT STYLE="white-space:nowrap">one-half</FONT> hour from the time set for the holding of the meeting, the person or persons present and being, or representing by
proxy, one or more shareholders entitled to attend and vote at the meeting constitute a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.9&nbsp;&nbsp;&nbsp;&nbsp; Chair. </B>The following
individual is entitled to preside as chair at a meeting of shareholders: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chair of the board, if any; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the chair of the board is absent or unwilling to act as chair of the meeting, the president, if any.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.10&nbsp;&nbsp;&nbsp;&nbsp; Selection of Alternate Chair.</B> If, at any meeting of shareholders, there is no chair of the board
or president present within 15 minutes after the time set for holding the meeting, or if the chair of the board and the president are unwilling to act as chair of the meeting, or if the chair of the board and the president have advised the
secretary, if any, or any director present at the meeting, that they will not be present at the meeting, the directors present must choose one of their number to be chair of the meeting or if all of the directors present decline to take the chair or
fail to so choose or if no director is present, the shareholders entitled to vote at the meeting who are present in person or by proxy may choose any person present at the meeting to chair the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.11&nbsp;&nbsp;&nbsp;&nbsp; Adjournments. </B>The chair of a meeting of shareholders may, and if so directed by the meeting must, adjourn the meeting
from time to time and from place to place, but no business may be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.12&nbsp;&nbsp;&nbsp;&nbsp; Notice of Adjourned Meeting.</B> It is not necessary to give any notice of an adjourned meeting of shareholders or of the
business to be transacted at an adjourned meeting of shareholders except that, when a meeting is adjourned for 30 days or more, notice of the adjourned meeting must be given as in the case of the original meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.13&nbsp;&nbsp;&nbsp;&nbsp; Decision by Show of Hands or Poll.</B> Subject to the <I>Business Corporations Act</I>, every motion put to a vote at a
meeting of shareholders will be decided on a show of hands, or the functional equivalent of a show of hands by means of electronic, telephonic or other communications facility unless </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a poll, before or on the declaration of the result of the vote by show of hands or the functional equivalent of a show of hands, is directed by the chair or demanded by at least one shareholder
entitled to vote who is present in person or by proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.14</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Declaration of Result.</B> The chair of a meeting of
shareholders must declare to the meeting the decision on every question in accordance with the result of the show of hands (or its function equivalent) or the poll, as the case may be, and that decision must be entered in the minutes of the meeting.
A declaration of the chair that a resolution is carried by the necessary majority or is defeated is, unless a poll is directed by the chair or demanded under Article 11.13, conclusive evidence without proof of the number or proportion of the votes
recorded in favour of or against the resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.15</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Motion Need Not be Seconded.</B> No motion proposed at a meeting
of shareholders need be seconded unless the chair of the meeting rules otherwise, and the chair of any meeting of shareholders is entitled to propose or second a motion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.16</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Casting Vote.</B> In the case of an equality of votes, the chair of a meeting of shareholders does not, either on a
show of hands or on a poll, have a second or casting vote in addition to the vote or votes to which the chair may be entitled as a shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.17</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Manner of Taking Poll.</B> Subject to Article 11.18, if a poll is duly demanded at a meeting of shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the poll must be taken: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting, or within seven days after the date of the meeting, as the chair of the meeting directs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the manner, at the time and at the place that the chair of the meeting directs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the result of the poll is deemed to be the decision of the meeting at which the poll is demanded; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the demand for the poll may be withdrawn by the person who demanded it. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.18 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Demand for Poll on Adjournment.</B> A poll demanded at a meeting of shareholders on a question of adjournment must be
taken immediately at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.19</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Chair Must Resolve Dispute.</B> In the case of any dispute as to the admission
or rejection of a vote given on a poll, the chair of the meeting must determine the dispute, and his or her determination made in good faith is final and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.20</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Casting of Votes.</B> On a poll, a shareholder entitled to more than one vote need not cast all the votes in the same
way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.21</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>No Demand for Poll on Election of Chair.</B> No poll may be demanded in respect of the vote by which a chair
of a meeting of shareholders is elected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.22</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Demand for Poll Not to Prevent Continuance of Meeting.</B> The demand
for a poll at a meeting of shareholders does not, unless the chair of the meeting so rules, prevent the continuation of a meeting for the transaction of any business other than the question on which a poll has been demanded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.23</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Retention of Ballots and Proxies.</B> The Company or its agent must, for at least three months after a meeting of
shareholders, keep each ballot cast on a poll and each proxy voted at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting, and, during that period, make them available for inspection during normal business hours by any shareholder or proxy holder entitled to vote at the meeting. At the end of such three
month period, the Company may destroy such ballots and proxies. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTES OF SHAREHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.1</B>
&nbsp;&nbsp;&nbsp;&nbsp;<B>Number of Votes by Shareholder or by Shares.</B> Subject to any special rights or restrictions attached to any shares and to the restrictions imposed on joint shareholders under Article 12.3: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a vote by show of hands, every person present who is a shareholder or proxy holder and entitled to vote on
the matter has one vote; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a poll, every shareholder entitled to vote on the matter has one vote in respect of each share entitled to
be voted on the matter and held by that shareholder and may exercise that vote either in person or by proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.2</B>
&nbsp;&nbsp;&nbsp;&nbsp;<B>Votes of Persons in Representative Capacity.</B> A person who is not a shareholder may vote at a meeting of shareholders, whether on a show of hands or on a poll, and may appoint a proxy holder to act at the meeting, if,
before doing so, the person satisfies the chair of the meeting, or the directors, that the person is a legal personal representative or a trustee in bankruptcy for a shareholder who is entitled to vote at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.3 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Votes by Joint Holders.</B> If there are joint shareholders registered in respect of any share: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any one of the joint shareholders may vote at any meeting of shareholders, personally or by proxy, in respect
of the share as if that joint shareholder were solely entitled to it; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if more than one of the joint shareholders is present at any meeting of shareholders, personally or by proxy,
and more than one of them votes in respect of that share, then only the vote of the joint shareholder present whose name stands first on the central securities register in respect of the share will be counted. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.4 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Legal Personal Representatives as Joint Shareholders.</B> Two or more legal personal representatives of a shareholder
in whose sole name any share is registered are, for the purposes of Article 12.3, deemed to be joint shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.5</B>
&nbsp;&nbsp;&nbsp;&nbsp;<B>Representative of a Corporate Shareholder.</B> If a corporation, that is not a subsidiary of the Company, is a shareholder, that corporation may appoint a person to act as its representative at any meeting of shareholders
of the Company, and: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for that purpose, the instrument appointing a representative must be received: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the registered office of the Company or at any other place specified, in the notice calling the meeting, for
the receipt of proxies, at least the number of business days specified in the notice for the receipt of proxies, or if no number of days is specified, two business days before the day set for the holding of the meeting or adjourned or postponed
meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting or any adjourned or postponed meeting, to the chair of the meeting or adjourned or postponed
meeting or by a person designated by the chair of the meeting or adjourned or postponed meeting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a representative is appointed under this Article 12.5: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the representative is entitled to exercise in respect of and at that meeting the same rights on behalf of the
corporation that the representative represents as that corporation could exercise if it were a shareholder who is an individual, including, without limitation, the right to appoint a proxy holder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the representative, if present at the meeting, is to be counted for the purpose of forming a quorum and is
deemed to be a shareholder present in person at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evidence of the appointment of any such representative may be sent to the
Company or its transfer agent by written instrument, fax or any other method of transmitting legibly recorded messages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.6</B>
&nbsp;&nbsp;&nbsp;&nbsp;<B>Proxy Provisions Do Not Apply to All Companies.</B> Articles 12.7 to 12.15 do not apply to the Company if and for so long as it is a public company or a <FONT STYLE="white-space:nowrap">pre-existing</FONT> reporting
company which has the Statutory Reporting Company Provisions as part of its Articles or to which the Statutory Reporting Company Provisions apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.7</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Appointment of Proxy Holders.</B> Every shareholder of the Company, including a corporation that is a shareholder but
not a subsidiary of the Company, entitled to vote at a meeting of shareholders of the Company may, by proxy, appoint one or more (but not more than five) proxy holders to attend and act at the meeting in the manner, to the extent and with the powers
conferred by the proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.8</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Alternate Proxy Holders.</B> A shareholder may appoint one or more alternate proxy holders
to act in the place of an absent proxy holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.9</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>When Proxy Holder Need Not Be Shareholder.</B> A person must not be
appointed as a proxy holder unless the person is a shareholder, although a person who is not a shareholder may be appointed as a proxy holder if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the person appointing the proxy holder is a corporation or a representative of a corporation appointed under
Article 12.5; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company has at the time of the meeting for which the proxy holder is to be appointed only one shareholder
entitled to vote at the meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders present in person or by proxy at and entitled to vote at the meeting for which the proxy
holder is to be appointed, by a resolution on which the proxy holder is not entitled to vote but in respect of which the proxy holder is to be counted in the quorum, permit the proxy holder to attend and vote at the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.10 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Deposit of Proxy.</B> A proxy for a meeting of shareholders must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be received at the registered office of the Company or at any other place specified, in the notice calling the
meeting, for the receipt of proxies, at least the number of business days specified in the notice, or if no number of days is specified, two business days before the day set for the holding of the meeting or any adjourned meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless the notice provides otherwise, be provided, at the meeting or any adjourned meeting, to the chair of the
meeting or to a person designated by the chair of the meeting; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be received in any other manner determined by the board or the chair of the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proxy may be sent to the Company by written instrument, fax or any other method of transmitting legibly recorded messages or by using such available
internet or telephone voting services as may be approved by the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.11</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Validity of Proxy Vote.</B> A vote
given in accordance with the terms of a proxy is valid notwithstanding the death or incapacity of the shareholder giving the proxy and despite the revocation of the proxy or the revocation of the authority under which the proxy is given, unless
notice in writing of that death, incapacity or revocation is received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the registered office of the Company, at any time up to and including the last business day before the day
set for the holding of the meeting or any adjourned meeting at which the proxy is to be used; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting or any adjourned meeting by the chair of the meeting or adjourned meeting, before any vote in
respect of which the proxy has been given has been taken. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.12 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Form of Proxy.</B> A proxy, whether
for a specified meeting or otherwise, must be either in the following form or in any other form approved by the directors or the chair of the meeting: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Zymeworks Inc.</I> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the
&#147;Company&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned, being a shareholder of the Company, hereby appoints <I>[name]</I> or, failing that person,
<I>[name]</I>, as proxy holder for the undersigned to attend, act and vote for and on behalf of the undersigned at the meeting of shareholders of the Company to be held on <I>[month, day, year]</I> and at any adjournment of that meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Number of shares in respect of which this proxy is given (if no number is specified, then this proxy if given in respect of all shares
registered in the name of the shareholder): &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Signed this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Signature of shareholder)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Name of shareholder - printed)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.13</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Revocation of Proxy.</B> Subject to Article 12.14, every proxy may be revoked by
an instrument in writing that is received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the registered office of the Company at any time up to and including the last business day before the day
set for the holding of the meeting at which the proxy is to be used; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting or any adjourned meeting, by the chair of the meeting or any adjourned meeting, before any vote
in respect of which the proxy has been given has been taken. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.14 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Revocation of Proxy Must Be Signed.</B> An instrument referred to in
Article 12.13 must be signed as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the shareholder for whom the proxy holder is appointed is an individual, the instrument must be signed by
the shareholder or his or her legal personal representative or trustee in bankruptcy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the shareholder for whom the proxy holder is appointed is a corporation, the instrument must be signed by
the corporation or by a representative appointed for the corporation under Article 12.5. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.15 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Chair
May Determine Validity of Proxy.</B> The chair of any meeting of shareholders may determine whether or not a proxy deposited for use at the meeting, which may not strictly comply with the requirements of this Article 12 as to form, execution,
accompanying documentation, time of filing or otherwise, shall be valid for use at the meeting, and any such determination made in good faith shall be final, conclusive and binding upon the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.16</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Production of Evidence of Authority to Vote.</B> The directors or the chair of any meeting of shareholders may, but
need not, inquire into the authority of any person to vote at the meeting and may, but need not, demand from that person production of evidence as to the existence of the authority to vote. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1 &nbsp;&nbsp;&nbsp;&nbsp;Number of Directors.</B> The number of directors, excluding additional directors appointed under Article 14.13, is
set at: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company is a public company, the greater of three and the most recently set of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set by the board of directors of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set under Article 14.9; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company is not a public company, the most recently set of: <B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set by the board of directors of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set under Article 14.9. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Change in Number of Directors.</B> If the number of directors is set under Article 13.1(a)(i) or 13.1(b)(i): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders may elect the directors needed to fill any vacancies in the board of directors up to that
number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the shareholders do not elect the directors needed to fill any vacancies in the board of directors up to
that number contemporaneously with the setting of that number, then the directors may appoint, or the shareholders may elect or appoint, directors to fill those vacancies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.3 &nbsp;&nbsp;&nbsp;&nbsp;Directors&#146; Acts Valid Despite Vacancy.</B> An act or proceeding of the directors is not invalid merely because fewer than
the number of directors set or otherwise required under these Articles is in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.4</B> &nbsp;&nbsp;&nbsp;&nbsp;<B>Qualifications of
Directors.</B> Notwithstanding any other provision of these Articles, a director is not required to hold a share in the capital of the Company as qualification for his or her office but must be qualified as required by the <I>Business Corporations
Act</I> to become, act or continue to act as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.5 &nbsp;&nbsp;&nbsp;&nbsp;Remuneration of Directors.</B> The directors are entitled to the
remuneration for acting as directors, if any, as the directors may from time to time determine. If the directors so decide, the remuneration of the directors, if any, will be determined by the shareholders. That remuneration may be in addition to
any salary or other remuneration paid to any officer or employee of the Company as such, who is also a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.6
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reimbursement of Expenses of Directors.</B> The Company must reimburse each director for the reasonable expenses that he or she may incur in and about the business of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.7 &nbsp;&nbsp;&nbsp;&nbsp;Special Remuneration for Directors.</B> If any director performs any professional or other services for the Company that in
the opinion of the directors are outside the ordinary duties of, or not in his or her capacity as, a director, or if any director is otherwise specially occupied in or about the Company&#146;s business, he or she may be paid remuneration fixed by
the directors, or, at the option of that director, fixed by ordinary resolution, and such remuneration may be either in addition to, or in substitution for, any other remuneration that he or she may be entitled to receive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.8 &nbsp;&nbsp;&nbsp;&nbsp;Gratuity, Pension or Allowance on Retirement of Director.</B> Unless otherwise determined by ordinary resolution, the
directors on behalf of the Company may pay a gratuity or pension or allowance on retirement to any director who has held any salaried office or place of profit with the Company or to his or her spouse or dependants and may make contributions to any
fund and pay premiums for the purchase or provision of any such gratuity, pension or allowance. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION AND REMOVAL OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.1
&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</B> For purposes of this Article 14, the following defined terms shall apply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B>Continuation Date</B><B>&#148;</B> means the date that the Company is continued as a British
Columbia company, as indicated on a Certificate of Continuation for the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B>End Date</B><B>&#148;</B> means the first to occur of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if and for so long as the Company is listed on the Toronto Stock Exchange, the later of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date of the third annual general meeting of the Company following the Continuation Date; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such date as may be determined by the Toronto Stock Exchange in writing and notified to the Company prior to
the date of such third annual general meeting of the Company following the Continuation Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company ceases to be listed on the Toronto Stock Exchange before the occurrence of an &#147;End
Date&#148; under Article 14.1(b)(i), or does not list on the Toronto Stock Exchange, then June&nbsp;30, 2117. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.2 &nbsp;&nbsp;&nbsp;&nbsp;Application.</B> The provisions of this Article 14 will be automatically
applied as follows, without any further act or formality: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">from and after the Continuation Date and up to and including the End Date, the provisions of Articles <FONT
STYLE="white-space:nowrap">14.3-14.5</FONT> will govern and apply and the provisions of Article 14.6 will have no force or effect; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commencing on the first day after the End Date, the provisions of Article 14.6 will govern and apply and the
provisions of Articles <FONT STYLE="white-space:nowrap">14.3-14.5</FONT> will have no force or effect, and the term of every director in office on the first day after the End Date shall expire and be deemed to expire on the first annual general
meeting of the Company following the occurrence of the End Date notwithstanding any terms or conditions to the contrary that were in effect prior to the End Date and at the time of their election or appointment, and thereafter the terms of office of
the directors shall expire at the times contemplated in Article 14.6(a). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.3 &nbsp;&nbsp;&nbsp;&nbsp;Staggered Terms.</B> Subject
to Article 14.2(b), and for purposes of facilitating staggered terms on the board, the following provisions shall apply from the Continuation Date to the End Date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective on the Continuation Date, three directors (or such lesser number if the number of directors as
determined under Article 13.1 is less than three) shall initially hold office for a <FONT STYLE="white-space:nowrap">one-year</FONT> term expiring on the first annual general meeting of the Company following the Continuation Date, as approved by
ordinary resolution of the shareholders of the Company prior to the Continuation Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective on the Continuation Date, three directors (or such lesser number if the number of directors as
determined under Article 13.1 is less than six) shall initially hold office for a <FONT STYLE="white-space:nowrap">two-year</FONT> term expiring on the second annual general meeting of the Company following the Continuation Date, as approved by
ordinary resolution of the shareholders of the Company prior to the Continuation Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective on the Continuation Date, the remaining number of directors (if the number of directors as determined
under Article 13.1 is more than six) shall initially hold office for a three-year term expiring on the third annual general meeting of the Company following the Continuation Date, as approved by ordinary resolution of the shareholders of the Company
prior to the Continuation Date, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and upon the expiry of the directors&#146; initial terms of office as set forth above, the directors
shall be elected in the manner provided in Article 14.4 to hold office for three-year terms expiring on the third annual general meeting following their election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.4 &nbsp;&nbsp;&nbsp;&nbsp;Election at Annual General Meeting.</B> From the Continuation Date to the End Date, and subject to Article 14.2(b), at every
annual general meeting and in every unanimous resolution contemplated by Article 10.2: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all of the directors whose terms expire shall cease to hold office immediately before the election or
appointment of directors under Article 14.4(b) below, but are eligible for re-election or <FONT STYLE="white-space:nowrap">re-appointment;</FONT> and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders entitled to vote at the annual general meeting for the election of directors may elect, or in
the unanimous resolution appoint, the number of directors required to fill the following vacancies, such that the staggered terms are maintained as contemplated in Article 14.3: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the vacancies created by the expiry of any directors&#146; terms under these Articles, to hold office for
three-year terms expiring on the third annual general meeting following their election; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any vacancies created before the expiry of any directors&#146; terms under these Articles, to hold office until
the remainder of the unexpired portion of the term of the departed directors for whom the new directors are replacing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.5
&nbsp;&nbsp;&nbsp;&nbsp;Election or Appointment between Annual General Meetings.</B> From the Continuation Date to the End Date, and Subject to Article 14.2(b), a director may be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elected or appointed under Articles 14.10, 14.12, 14.15, and 14.16 to hold office until the remainder of the
unexpired portion of the term of the departed director for whom the new director is replacing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appointed under Article 14.13 for a three-year term expiring on the third annual general meeting of the Company
following the director&#146;s appointment under Article 14.13. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For greater certainty, following the expiry of the term of any director
appointed under Articles 14.10, 14.12, 14.13, 14.15, and 14.16, that director is eligible for <FONT STYLE="white-space:nowrap">re-election</FONT> or <FONT STYLE="white-space:nowrap">re-appointment</FONT> under these Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.6 &nbsp;&nbsp;&nbsp;&nbsp;Election at Annual General Meeting.</B> Following the End Date, at every annual general meeting and in every unanimous
resolution contemplated by Article 10.2: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all the directors cease to hold office immediately before the election or appointment of directors under
Article 14.6(b), but are eligible for <FONT STYLE="white-space:nowrap">re-election</FONT> or <FONT STYLE="white-space:nowrap">re-appointment;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders entitled to vote at the annual general meeting for the election of directors may elect, or in
the unanimous resolution appoint, a board of directors consisting of the number of directors for the time being set under these Articles. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.7 &nbsp;&nbsp;&nbsp;&nbsp;Consent to be a Director.</B> No election, appointment or designation of an individual as a director is valid unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that individual consents to be a director in the manner provided for in the <I>Business Corporations Act</I>;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that individual is elected or appointed at a meeting at which the individual is present and the individual does
not refuse, at the meeting, to be a director. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.8 &nbsp;&nbsp;&nbsp;&nbsp;Failure to Elect or Appoint Directors.</B> If: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company fails to hold an annual general meeting, and all the shareholders who are entitled to vote at an
annual general meeting fail to pass the unanimous resolution contemplated by Article 10.2 on or before the date by which the annual general meeting is required to be held under the <I>Business Corporations Act</I>; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders fail, at the annual general meeting or in the unanimous resolution contemplated by Article
10.2, to elect or appoint any directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">then each director then in office continues to hold office until the earlier of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which his or her successor is elected or appointed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which he or she otherwise ceases to hold office under the <I>Business Corporations Act</I> or these
Articles. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.9 &nbsp;&nbsp;&nbsp;&nbsp;Places of Retiring Directors Not Filled.</B> If, at any meeting of shareholders at which
there should be an election of directors, the places of any of the retiring directors are not filled by that election, then those retiring directors who are not <FONT STYLE="white-space:nowrap">re-elected</FONT> and who are asked by the newly
elected directors to continue in office will, if willing to do so, continue in office to complete the number of directors for the time being set pursuant to these Articles until further new directors are elected at a meeting of shareholders convened
for that purpose. If any such election or continuance of directors does not result in the election or continuance of the number of directors for the time being set pursuant to these Articles, then the number of directors of the Company is deemed to
be set at the number of directors actually elected or continued in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.10 &nbsp;&nbsp;&nbsp;&nbsp;Directors May Fill Casual Vacancies.</B> Any
casual vacancy occurring in the board of directors may be filled by the directors, subject to these Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.11 &nbsp;&nbsp;&nbsp;&nbsp;Remaining
Directors Power to Act.</B> The directors may act notwithstanding any vacancy in the board of directors, but if the Company has fewer directors in office than the number set pursuant to these Articles as the quorum of directors, then the directors
may only act for the purpose of appointing directors up to that number or of summoning a meeting of shareholders for the purpose of filling any vacancies on the board of directors or, subject to the <I>Business Corporations Act</I>, for any other
purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.12 &nbsp;&nbsp;&nbsp;&nbsp;Shareholders May Fill Vacancies.</B> If the Company has no directors or fewer directors in office than the
number set pursuant to these Articles as the quorum of directors, then the shareholders may elect or appoint directors to fill any vacancies on the board of directors, subject to these Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.13 &nbsp;&nbsp;&nbsp;&nbsp;Additional Directors.</B> Notwithstanding Articles 13.1 and 13.2, between annual general meetings or unanimous resolutions
contemplated by Article 10.2, the directors may appoint one or more additional directors subject to these Articles, but the number of additional directors appointed under this Article 14.13 must not at any time exceed
<FONT STYLE="white-space:nowrap">one-third</FONT> of the number of the current directors who were elected or appointed as directors other than under this Article 14.13. Except as provided otherwise under these Articles or the <I>Business
Corporations</I> Act, any director so appointed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">before the End Date shall cease to hold office at the end of a three-year term expiring on the third annual
general meeting of the Company following the director&#146;s appointment, subject to Article 14.2(b); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after the End Date shall cease to hold office immediately before the next election or appointment of directors
under Article 14.6(b); </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">but is eligible for <FONT STYLE="white-space:nowrap">re-election</FONT> or
<FONT STYLE="white-space:nowrap">re-appointment.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.14 </B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Ceasing to be a Director.</B> A director ceases to be a
director when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the term of office of the director expires; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director dies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director resigns as a director by notice in writing provided to the Company or a lawyer for the Company; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director is removed from office pursuant to Articles 14.15 or 14.16. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.15 &nbsp;&nbsp;&nbsp;&nbsp;Removal of Director by Shareholders.</B> The Company may remove any director before the expiration of his or her term of
office by special resolution. In that event, the shareholders may elect, or appoint by ordinary resolution, a director to fill the resulting vacancy, subject to these Articles. If the shareholders do not elect or appoint a director to fill the
resulting vacancy contemporaneously with the removal, then the directors may appoint or the shareholders may elect, or appoint by ordinary resolution, a director to fill that vacancy, subject to these Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.16 &nbsp;&nbsp;&nbsp;&nbsp;Removal of Director by Directors.</B> The directors may remove any director before the expiration of his or her term of
office if the director is convicted of an indictable offence, or if the director ceases to be qualified to act as a director of a company and does not promptly resign, and the directors may appoint a director to fill the resulting vacancy, subject
to these Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.17 &nbsp;&nbsp;&nbsp;&nbsp;Amendment.</B> An amendment to these Articles providing for the deletion of Articles <FONT
STYLE="white-space:nowrap">14.1-14.5</FONT> may be effected by a directors&#146; resolution or by an ordinary resolution of the shareholders. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 15 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWERS AND
DUTIES OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.1 &nbsp;&nbsp;&nbsp;&nbsp;Powers of Management.</B> The directors must, subject to the <I>Business Corporations Act</I> and
these Articles, manage or supervise the management of the business and affairs of the Company and have the authority to exercise all such powers of the Company as are not, by the <I>Business Corporations Act</I> or by these Articles, required to be
exercised by the shareholders of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.2 &nbsp;&nbsp;&nbsp;&nbsp;Appointment of Attorney of Company.</B> The directors may from time to
time, by power of attorney or other instrument, under seal if so required by law, appoint any person to be the attorney of the Company for such purposes, and with such powers, authorities and discretions (not exceeding those vested in or exercisable
by the directors under these Articles and excepting the power to fill vacancies in the board of directors, to remove a director, to change the membership of, or fill vacancies in, any committee of the directors, to appoint or remove officers
appointed by the directors and to declare dividends) and for such period, and with such remuneration and subject to such conditions as the directors may think fit. Any such power of attorney may contain such provisions for the protection or
convenience of persons dealing with such attorney as the directors think fit. Any such attorney may be authorized by the directors to <FONT STYLE="white-space:nowrap">sub-delegate</FONT> all or any of the powers, authorities and discretions for the
time being vested in him or her. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCLOSURE OF INTEREST OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.1 &nbsp;&nbsp;&nbsp;&nbsp;Obligation to Account for Profits.</B> A director or senior officer who holds a disclosable interest (as that term is used in
the <I>Business Corporations Act</I>) in a contract or transaction into which the Company has entered or proposes to enter is liable to account to the Company for any profit that accrues to the director or senior officer under or as a result of the
contract or transaction only if and to the extent provided in the <I>Business Corporations Act</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.2 &nbsp;&nbsp;&nbsp;&nbsp;Restrictions on
Voting by Reason of Interest.</B> A director who holds a disclosable interest in a contract or transaction into which the Company has entered or proposes to enter is not entitled to vote on any directors&#146; resolution to approve that contract or
transaction, unless all the directors have a disclosable interest in that contract or transaction, in which case any or all of those directors may vote on such resolution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.3&nbsp;&nbsp;&nbsp;&nbsp;Interested Director Counted in Quorum.</B> A director who holds a disclosable
interest in a contract or transaction into which the Company has entered or proposes to enter and who is present at the meeting of directors at which the contract or transaction is considered for approval may be counted in the quorum at the meeting
whether or not the director votes on any or all of the resolutions considered at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.4&nbsp;&nbsp;&nbsp;&nbsp;Disclosure of Conflict of
Interest or Property.</B> A director or senior officer who holds any office or possesses any property, right or interest that could result, directly or indirectly, in the creation of a duty or interest that materially conflicts with that
individual&#146;s duty or interest as a director or senior officer, must disclose the nature and extent of the conflict as required by the <I>Business Corporations Act</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.5&nbsp;&nbsp;&nbsp;&nbsp;Director Holding Other Office in the Company.</B> A director may hold any office or place of profit with the Company, other
than the office of auditor of the Company, in addition to his or her office of director for the period and on the terms (as to remuneration or otherwise) that the directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.6&nbsp;&nbsp;&nbsp;&nbsp;No Disqualification. </B>No director or intended director is disqualified by his or her office from contracting with the
Company either with regard to the holding of any office or place of profit the director holds with the Company or as vendor, purchaser or otherwise, and no contract or transaction entered into by or on behalf of the Company in which a director is in
any way interested is liable to be voided for that reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.7&nbsp;&nbsp;&nbsp;&nbsp;Professional Services by Director or Officer.</B> Subject to
the <I>Business Corporations Act,</I> a director or officer, or any person in which a director or officer has an interest, may act in a professional capacity for the Company, except as auditor of the Company, and the director or officer or such
person is entitled to remuneration for professional services as if that director or officer were not a director or officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.8&nbsp;&nbsp;&nbsp;&nbsp;Director or Officer in Other Corporations.</B> A director or officer may be or become a director, officer or employee of, or
otherwise interested in, any person in which the Company may be interested as a shareholder or otherwise, and, subject to the <I>Business Corporations Act,</I> the director or officer is not accountable to the Company for any remuneration or other
benefits received by him or her as director, officer or employee of, or from his or her interest in, such other person. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 17
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROCEEDINGS OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.1&nbsp;&nbsp;&nbsp;&nbsp;Meetings of Directors. </B>The directors may meet together for the conduct of business, adjourn and otherwise regulate their
meetings as they think fit, and meetings of the directors held at regular intervals may be held at the place, at the time and on the notice, if any, as the directors may from time to time determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.2&nbsp;&nbsp;&nbsp;&nbsp; Voting at Meetings.</B> Questions arising at any meeting of directors are to be decided by a majority of votes and, in the
case of an equality of votes, the chair of the meeting does not have a second or casting vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.3&nbsp;&nbsp;&nbsp;&nbsp;Chair of Meetings.</B> The
following individual is entitled to preside as chair at a meeting of directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chair of the board, if any; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the absence of the chair of the board, the president, if any, if the president is a director; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other director chosen by the directors if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the chair of the board nor the president, if a director, is present at the meeting within 15 minutes
after the time set for holding the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the chair of the board nor the president, if a director, is willing to chair the meeting; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chair of the board and the president, if a director, have advised the secretary, if any, or any other
director, that they will not be present at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.4&nbsp;&nbsp;&nbsp;&nbsp; Meetings by Telephone or Other Communications
Medium.</B> A director may participate in a meeting of the directors or of any committee of the directors in person or by telephone if all directors participating in the meeting, whether in person or by telephone or other communications medium, are
able to communicate with each other. A director may participate in a meeting of the directors or of any committee of the directors by a communications medium other than telephone if all directors participating in the meeting, whether in person or by
telephone or other communications medium, are able to communicate with each other and if all directors who wish to participate in the meeting agree to such participation. A director who participates in a meeting in a manner contemplated by this
Article 17.4 is deemed for all purposes of the <I>Business Corporations Act </I>and these Articles to be present at the meeting and to have agreed to participate in that manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.5&nbsp;&nbsp;&nbsp;&nbsp; Calling of Meetings. </B>A director may, and the corporate secretary or an assistant corporate secretary of the Company, if
any, on the request of a director must, call a meeting of the directors at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.6 &nbsp;&nbsp;&nbsp;&nbsp;Notice of Meetings.</B> Other than
for meetings held at regular intervals as determined by the directors pursuant to Article 17.1, reasonable notice of each meeting of the directors, specifying the place, day and time of that meeting must be given to each of the directors by any
method set out in Article 23.1 or orally or by telephone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.7 &nbsp;&nbsp;&nbsp;&nbsp;When Notice Not Required.</B> It is not necessary to give
notice of a meeting of the directors to a director if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the meeting is to be held immediately following a meeting of shareholders at which that director was elected or
appointed, or is the meeting of the directors at which that director is appointed; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director has waived notice of the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.8 &nbsp;&nbsp;&nbsp;&nbsp;Meeting Valid Despite Failure to Give Notice.</B> The accidental omission to give notice of any meeting of directors to, or
the <FONT STYLE="white-space:nowrap">non-receipt</FONT> of any notice by, any director does not invalidate any proceedings at that meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.9
&nbsp;&nbsp;&nbsp;&nbsp;Waiver of Notice of Meetings. </B>Any director may send to the Company a document signed by him or her waiving notice of any past, present or future meeting or meetings of the directors and may at any time withdraw that
waiver with respect to meetings held after that withdrawal. After sending a waiver with respect to all future meetings and until that waiver is withdrawn, no notice of any meeting of the directors need be given to such director and all meetings of
the directors so held are deemed not to be improperly called or constituted by reason of notice not having been given to such director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attendance of a director at a meeting of the directors is a waiver of notice of the meeting, unless that
director attends the meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.10 &nbsp;&nbsp;&nbsp;&nbsp;Quorum. </B>The quorum necessary for the transaction of the business of the directors is a majority of the number of
directors in office or such greater number as the directors may determine from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.11&nbsp;&nbsp;&nbsp;&nbsp; Validity of Acts Where
Appointment Defective.</B> Subject to the <I>Business Corporations Act, </I>an act of a director or officer is not invalid merely because of an irregularity in the election or appointment or a defect in the qualification of that director or officer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.12 &nbsp;&nbsp;&nbsp;&nbsp;Consent Resolutions in Writing.</B> A resolution of the directors or of any committee of the directors consented to in
writing by all of the directors entitled to vote on it, whether by signed document (which may include an electronic signature, as permitted by the <I>Electronic Transactions Act </I>(British Columbia), fax, email or any other method of transmitting
legibly recorded messages, is as valid and effective as if it had been passed at a meeting of the directors or of the committee of the directors duly called and held. Such resolution may be in two or more counterparts which together are deemed to
constitute one resolution in writing. A resolution passed in that manner is effective on the date stated in the resolution or on the latest date stated on any counterpart. A resolution of the directors or of any committee of the directors passed in
accordance with this Article 17.12 is deemed to be a proceeding at a meeting of directors or of the committee of the directors and to be as valid and effective as if it had been passed at a meeting of the directors or of the committee of the
directors that satisfies all the requirements of the <I>Business Corporations Act</I> and all the requirements of these Articles relating to meetings of the directors or of a committee of the directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 18 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE
AND OTHER COMMITTEES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.1 &nbsp;&nbsp;&nbsp;&nbsp;Appointment and Powers of Executive Committee. </B>The directors may, by resolution, appoint an
executive committee consisting of the director or directors that they consider appropriate, and this committee has, during the intervals between meetings of the board of directors, all of the directors&#146; powers, except: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to fill vacancies in the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to remove a director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to change the membership of, or fill vacancies in, any committee of the directors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other powers, if any, as may be set out in the resolution or any subsequent directors&#146; resolution.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.2&nbsp;&nbsp;&nbsp;&nbsp; Appointment and Powers of Other Committees.</B> The directors may, by resolution: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint one or more committees (other than the executive committee) consisting of the director or directors
that they consider appropriate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delegate to a committee appointed under paragraph (a)&nbsp;any of the directors&#146; powers, except:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to fill vacancies in the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to remove a director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to change the membership of, or fill vacancies in, any committee of the directors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to appoint or remove officers appointed by the directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make any delegation referred to in paragraph (b)&nbsp;subject to the conditions set out in the resolution or
any subsequent directors&#146; resolution. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.3 &nbsp;&nbsp;&nbsp;&nbsp;Obligations of Committees. </B>Any committee appointed under
Articles 18.1 or 18.2, in the exercise of the powers delegated to it, must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conform to any rules that may from time to time be imposed on it by the directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">report every act or thing done in exercise of those powers at such times as the directors may require.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.4 &nbsp;&nbsp;&nbsp;&nbsp;Powers of Board. </B>The directors may, at any time, with respect to a committee appointed under
Articles 18.1 or 18.2: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">revoke or alter the authority given to the committee, or override a decision made by the committee, except as
to acts done before such revocation, alteration or overriding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terminate the appointment of, or change the membership of, the committee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fill vacancies in the committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.5 &nbsp;&nbsp;&nbsp;&nbsp;Committee Meetings.</B> Subject to Article 18.3(a) and unless the directors otherwise provide in the resolution appointing the
committee or in any subsequent resolution, with respect to a committee appointed under Articles 18.1 or 18.2: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the committee may meet and adjourn as it thinks proper; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the committee may elect a chair of its meetings but, if no chair of a meeting is elected, or if at a meeting
the chair of the meeting is not present within 15 minutes after the time set for holding the meeting, the directors present who are members of the committee may choose one of their number to chair the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a majority of the members of the committee constitutes a quorum of the committee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">questions arising at any meeting of the committee are determined by a majority of votes of the members present,
and in case of an equality of votes, the chair of the meeting does not have a second or casting vote. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 19 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.1
&nbsp;&nbsp;&nbsp;&nbsp;Directors May Appoint Officers. </B>The directors may, from time to time, appoint such officers, if any, as the directors determine and the directors may, at any time, terminate any such appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.2 &nbsp;&nbsp;&nbsp;&nbsp;Functions, Duties and Powers of Officers.</B> The directors may, for each officer: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine the functions and duties of the officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entrust to and confer on the officer any of the powers exercisable by the directors on such terms and
conditions and with such restrictions as the directors think fit; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">revoke, withdraw, alter or vary all or any of the functions, duties and powers of the officer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.3&nbsp;&nbsp;&nbsp;&nbsp; Qualifications. </B>No officer may be appointed unless that officer is qualified in accordance with the
<I>Business Corporations Act</I>. One person may hold more than one position as an officer of the Company. Any person appointed as the chair of the board or as the managing director must be a director. Any other officer need not be a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.4 &nbsp;&nbsp;&nbsp;&nbsp;Remuneration and Terms of Appointment.</B> All appointments of officers are to be made on the terms and conditions and at the
remuneration (whether by way of salary, fee, commission, participation in profits or otherwise) that the directors think fit and are subject to termination at the pleasure of the directors, and an officer may in addition to such remuneration be
entitled to receive, after he or she ceases to hold such office or leaves the employment of the Company, a pension or gratuity. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
20 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.1
&nbsp;&nbsp;&nbsp;&nbsp;Definitions. </B>In this Article 20: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>eligible party</B>&#148;, in relation to a Company, means an individual who: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director or officer of the Company, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director or officer of another corporation (A)&nbsp;at a time when the corporation is or was an
affiliate of the Company, or (B)&nbsp;at the request of the Company, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the request of the Company, is or was, or holds or held a position equivalent to that of, a director of
officer of a partnership, trust, joint venture or other unincorporated entity, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and includes, to the extent permitted by
the Act, the heirs and personal or other legal representatives of that individual; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;eligible penalty&#148;</B> means a judgment, penalty or fine awarded or imposed in, or an amount paid
in settlement of, an eligible proceeding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;eligible proceeding&#148;</B> means a legal proceeding or investigative action, whether current,
threatened, pending or completed, in which a director or former director of the Company </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(an &#147;eligible party&#148;) or any of the heirs and legal personal representatives of the eligible party, by reason of the eligible party being or having been a director of the Company:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or may be joined as a party; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the
proceeding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>expenses</B>&#148; has the meaning set out in the <I>Business Corporations Act.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.2 &nbsp;&nbsp;&nbsp;&nbsp;Mandatory Indemnification of Directors and Former Directors.</B> Subject to the <I>Business
Corporations Act</I>, the Company must indemnify an eligible party against all eligible penalties to which such person is or may be liable, and the Company must, after the final disposition of an eligible proceeding, pay the expenses actually and
reasonably incurred by such person in respect of that proceeding. Each director is deemed to have contracted with the Company on the terms of the indemnity contained in this Article 20.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.3&nbsp;&nbsp;&nbsp;&nbsp; Indemnification of Other Persons. </B>Subject to any restrictions in the <I>Business Corporations Act,</I> the Company may
indemnify any person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.4 <FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;Non-Compliance</FONT> with </B><B><I>Business Corporations
Act</I></B><B>.</B> The failure of a director or officer of the Company to comply with the <I>Business Corporations Act</I> or these Articles does not invalidate any indemnity to which he or she is entitled under this Article 20. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.5 &nbsp;&nbsp;&nbsp;&nbsp;Company May Purchase Insurance.</B> The Company may purchase and maintain insurance for the benefit of any person (or his or
her heirs or legal personal representatives) who: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director, officer, employee or agent of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director, officer, employee or agent of a corporation at a time when the corporation is or was an
affiliate of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the request of the Company, is or was a director, officer, employee or agent of a corporation or of a
partnership, trust, joint venture or other unincorporated entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the request of the Company, holds or held a position equivalent to that of a director or officer of a
partnership, trust, joint venture or other unincorporated entity; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">against any liability incurred by him or her as such director,
officer, employee or agent or person who holds or held such equivalent position. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 21 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.1&nbsp;&nbsp;&nbsp;&nbsp;
Payment of Dividends Subject to Special Rights. </B>The provisions of this Article 21 are subject to the rights, if any, of shareholders holding shares with special rights as to dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.2 &nbsp;&nbsp;&nbsp;&nbsp;Declaration of Dividends. </B>Subject to the <I>Business Corporations Act </I>and the rights of the holders of issued shares
of the Company, the directors may from time to time declare and authorize payment of such dividends as they consider appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.3
&nbsp;&nbsp;&nbsp;&nbsp;No Notice Required. </B>The directors need not give notice to any shareholder of any declaration under Article 21.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.4 &nbsp;&nbsp;&nbsp;&nbsp;Record Date.</B> The directors may set a date as the record date for the
purpose of determining shareholders entitled to receive payment of a dividend. The record date must not precede the date on which the dividend is to be paid by more than two months. If no record date is set, the record date is 5 p.m. on the date on
which the directors pass the resolution declaring the dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.5 &nbsp;&nbsp;&nbsp;&nbsp;Manner of Paying Dividend.</B> A resolution declaring a
dividend may direct payment of the dividend wholly or partly in money or by the distribution of specific assets or of fully paid shares or of bonds, debentures or other securities of the Company or any other corporation, or in any one or more of
those ways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.6&nbsp;&nbsp;&nbsp;&nbsp; Settlement of Difficulties.</B> If any difficulty arises in regard to a distribution under Article 21.5, the
directors may settle the difficulty as they deem advisable, and, in particular, may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">set the value for distribution of specific assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine that cash payments in substitution for all or any part of the specific assets to which any
shareholders are entitled may be made to any shareholders on the basis of the value so fixed in order to adjust the rights of all parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vest any such specific assets in trustees for the persons entitled to the dividend. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.7&nbsp;&nbsp;&nbsp;&nbsp; When Dividend Payable.</B> Any dividend may be made payable on such date as is fixed by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.8 &nbsp;&nbsp;&nbsp;&nbsp;Dividends to be Paid in Accordance with Number of Shares. </B>All dividends on shares of any class or series of shares must be
declared and paid according to the number of such shares held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.9&nbsp;&nbsp;&nbsp;&nbsp; Receipt by Joint Shareholders. </B>If several persons are
joint shareholders of any share, any one of them may give an effective receipt for any dividend, bonus or other money payable in respect of the share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.10 &nbsp;&nbsp;&nbsp;&nbsp;Dividend Bears No Interest.</B> No dividend bears interest against the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.11 &nbsp;&nbsp;&nbsp;&nbsp;Fractional Dividends.</B> If a dividend to which a shareholder is entitled includes a fraction of the smallest monetary unit
of the currency of the dividend, that fraction may be disregarded in making payment of the dividend and that payment represents full payment of the dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.12 &nbsp;&nbsp;&nbsp;&nbsp;Payment of Dividends. </B>Any dividend or other distribution payable in money in respect of shares may be paid by cheque,
made payable to the order of the person to whom it is sent, and mailed to the address of the shareholder, or in the case of joint shareholders, to the address of the joint shareholder who is first named on the central securities register, or to the
person and to the address the shareholder or joint shareholders may direct in writing. The mailing of such cheque will, to the extent of the sum represented by the cheque (plus the amount of the tax required by law to be deducted), discharge all
liability for the dividend unless such cheque is not paid on presentation or the amount of tax so deducted is not paid to the appropriate taxing authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.13 &nbsp;&nbsp;&nbsp;&nbsp;Capitalization of Surplus. </B>Notwithstanding anything contained in these Articles, the directors may from time to time
capitalize any surplus of the Company and may from time to time issue, as fully paid, shares or any bonds, debentures or other securities of the Company as a dividend representing the surplus or any part of the surplus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.14 &nbsp;&nbsp;&nbsp;&nbsp;Unclaimed Dividends.</B> Any dividend unclaimed after a period of three years from the date on which the same has been
declared to be payable shall be forfeited and shall revert to the Company. The Company shall not be liable to any person in respect of any dividend which is forfeited to the Company or delivered to any public official pursuant to any applicable
abandoned property, escheat or similar law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 22 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS, RECORDS AND REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.1&nbsp;&nbsp;&nbsp;&nbsp; Recording of Financial Affairs. </B>The directors must cause adequate accounting records to be kept to record properly the
financial affairs and condition of the Company and to comply with the <I>Business Corporations Act.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.2&nbsp;&nbsp;&nbsp;&nbsp; Inspection of
Accounting Records. </B>Unless the directors determine otherwise, or unless otherwise determined by ordinary resolution, no shareholder of the Company is entitled to inspect or obtain a copy of any accounting records of the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 23 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.1 &nbsp;&nbsp;&nbsp;&nbsp;Method of Giving Notice. </B>Unless the <I>Business Corporations Act</I> or these Articles provide otherwise, a
notice, statement, report or other record required or permitted by the <I>Business Corporations Act </I>or these Articles to be sent by or to a person may be sent by any one of the following methods: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mail addressed to the person at the applicable address for that person as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record mailed to a shareholder, the shareholder&#146;s registered address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record mailed to a director or officer, the prescribed address for mailing shown for the director or
officer in the records kept by the Company or the mailing address provided by the recipient for the sending of that record or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other case, the mailing address of the intended recipient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delivery at the applicable address for that person as follows, addressed to the person: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record delivered to a shareholder, the shareholder&#146;s registered address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record delivered to a director or officer, the prescribed address for delivery shown for the director or
officer in the records kept by the Company or the delivery address provided by the recipient for the sending of that record or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other case, the delivery address of the intended recipient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sending the record by fax to the fax number provided by the intended recipient for the sending of that record
or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sending the record by email to the email address provided by the intended recipient for the sending of that
record or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">physical delivery to the intended recipient; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">creating and providing a record posted on or made available through a generally-accessible electronic source
and providing written notice by any of the foregoing methods of the availability of such record; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as otherwise permitted by any securities legislation (together with all regulations and rules made and
promulgated thereunder and all administrative policy statements, blanket orders, and rulings, notices, and other administrative directions issued by securities commissions or similar authorities appointed thereunder) in any province or territory of
Canada or in the federal jurisdiction of the United States or in any state of the United States that is applicable to the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.2 &nbsp;&nbsp;&nbsp;&nbsp;Deemed Receipt.</B> A notice, statement, report or other record that is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mailed to a person by ordinary mail to the applicable address for that person referred to in Article 23.1 is
deemed to be received by the person to whom it was mailed on the day, Saturdays, Sundays and holidays excepted, following the date of mailing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">faxed to a person to the fax number provided by that person referred to in Article 23.1 is deemed to be
received by the person to whom it was faxed on the day it was faxed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">e-mailed</FONT> to a person to the
<FONT STYLE="white-space:nowrap">e-mail</FONT> address provided by that person referred to in Article 23.1 is deemed to be received by the person to whom it was <FONT STYLE="white-space:nowrap">e-mailed</FONT> on the day it was <FONT
STYLE="white-space:nowrap">e-mailed;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delivered in accordance with Article 23.1(f), is deemed to be received by the person on the day such written
notice is sent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.3 &nbsp;&nbsp;&nbsp;&nbsp;Certificate of Sending. </B>A certificate signed by the corporate secretary, if any, or
other officer of the Company or of any other corporation acting in that capacity on behalf of the Company stating that a notice, statement, report or other record was sent in accordance with Article 23.1 is conclusive evidence of that fact. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.4&nbsp;&nbsp;&nbsp;&nbsp; Notice to Joint Shareholders. </B>A notice, statement, report or other record may be provided by the Company to the joint
shareholders of a share by providing such record to the joint shareholder first named in the central securities register in respect of the share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.5&nbsp;&nbsp;&nbsp;&nbsp; Notice to Legal Personal Representatives and Trustees. </B>A notice, statement, report or other record may be provided by the
Company to the persons entitled to a share in consequence of the death, bankruptcy or incapacity of a shareholder by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mailing the record, addressed to them: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by name, by the title of the legal personal representative of the deceased or incapacitated shareholder, by the
title of trustee of the bankrupt shareholder or by any similar description; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the address, if any, supplied to the Company for that purpose by the persons claiming to be so entitled; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if an address referred to in paragraph (a)(ii) has not been supplied to the Company, by giving the notice in a
manner in which it might have been given if the death, bankruptcy or incapacity had not occurred. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 33 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.6 &nbsp;&nbsp;&nbsp;&nbsp;Undelivered Notices. </B>If, on two consecutive occasions, a notice,
statement, report or other record is sent to a shareholder pursuant to Article&nbsp;23.1 and on each of those occasions any such record is returned because the shareholder cannot be located, the Company shall not be required to send any further
records to the shareholder until the shareholder informs the Company in writing of his or her new address. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 24 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAL AND EXECUTION OF DOCUMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.1
&nbsp;&nbsp;&nbsp;&nbsp;Who May Attest Seal.</B> Except as provided in Articles 24.2 and 24.3, the Company&#146;s seal, if any, must not be impressed on any record except when that impression is attested by the signatures of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any two directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any officer, together with any director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company only has one director, that director; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any one or more directors or officers or persons as may be determined by the directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.2 &nbsp;&nbsp;&nbsp;&nbsp;Sealing Copies.</B> For the purpose of certifying under seal a certificate of incumbency of the directors or officers of the
Company or a true copy of any resolution or other document, despite Article 24.1, the impression of the seal may be attested by the signature of any director or officer or the signature of any other person as may be determined by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.3 &nbsp;&nbsp;&nbsp;&nbsp;Mechanical Reproduction of Seal. </B>The directors may authorize the seal to be impressed by third parties on share
certificates or bonds, debentures or other securities of the Company as they may determine appropriate from time to time. To enable the seal to be impressed on any share certificates or bonds, debentures or other securities of the Company, whether
in definitive or interim form, on which facsimiles of any of the signatures of the directors or officers of the Company are, in accordance with the <I>Business Corporations Act </I>or these Articles, printed or otherwise mechanically reproduced,
there may be delivered to the person employed to engrave, lithograph or print such definitive or interim share certificates or bonds, debentures or other securities one or more unmounted dies reproducing the seal and such persons as are authorized
to attest the Company&#146;s seal may in writing authorize such person to cause the seal to be impressed on such definitive or interim share certificates or bonds, debentures or other securities by the use of such dies. Share certificates or bonds,
debentures or other securities to which the seal has been so impressed are for all purposes deemed to be under and to bear the seal impressed on them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.4 &nbsp;&nbsp;&nbsp;&nbsp;Execution of Documents Generally. </B>The Directors may from time to time by resolution appoint any one or more persons,
officers or Directors for the purpose of executing any instrument, document or agreement in the name of and on behalf of the Company for which the seal need not be affixed, and if no such person, officer or Director is appointed, then any one
officer or Director of the Company may execute such instrument, document or agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 34 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 25 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROHIBITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25.1
&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</B> In this Article 25: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>designated security&#148;</B> means: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a voting security of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a security of the Company that is not a debt security and that carries a residual right to participate in the
earnings of the Company or, on the liquidation or winding up of the Company, in its assets; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a security of the Company convertible, directly or indirectly, into a security described in paragraph
(i)&nbsp;or (ii); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>security</B>&#148; has the meaning assigned in the <I>Securities Act</I> (British Columbia); <B>
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>voting security</B>&#148; means a security of the Company that: <B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not a debt security, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">carries a voting right either under all circumstances or under some circumstances that have occurred and are
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25.2&nbsp;&nbsp;&nbsp;&nbsp;Application.</B> Article 25.3 does not apply to the Company if and for so long as it is a
public company or a <FONT STYLE="white-space:nowrap">pre-existing</FONT> reporting company which has the Statutory Reporting Company Provisions as part of its Articles or to which the Statutory Reporting Company Provisions apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25.3&nbsp;&nbsp;&nbsp;&nbsp;Consent Required for Transfer of Shares or Designated Securities.</B> No share or designated security may be sold, transferred
or otherwise disposed of without the consent of the directors and the directors are not required to give any reason for refusing to consent to any such sale, transfer or other disposition. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 26 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORUM
SELECTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.1&nbsp;&nbsp;&nbsp;&nbsp;Forum for Adjudication of Certain Disputes.</B> Unless the Company consents in writing to the selection of
an alternative forum, the Supreme Court of British Columbia, Canada and the appellate Courts therefrom, shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf
of the Company; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee of the Company to the Company; (iii)&nbsp;any action or proceeding asserting a claim arising pursuant
to any provision of the <I>Business Corporations Ac</I><I>t</I> or these Articles (as either may be amended from time to time); or (iv)&nbsp;any action or proceeding asserting a claim otherwise related to the relationships among the Company, its
affiliates and their respective shareholders, directors and/or officers, but this paragraph (iv)&nbsp;does not include claims related to the business carried on by the Company or such affiliates. If any action or proceeding the subject matter of
which is within the scope of the preceding sentence is filed in a Court other than a Court located within the Province of British Columbia (a &#147;<B>Foreign Action</B>&#148;) in the name of any securityholder, such securityholder shall be deemed
to have consented to (i)&nbsp;the personal jurisdiction of the provincial and federal Courts located within the Province of British Columbia in connection with any action or proceeding brought in any such Court to enforce the preceding sentence and
(ii)&nbsp;having service of process made upon such securityholder in any such action or proceeding by service upon such securityholder&#146;s counsel in the Foreign Action as agent for such securityholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 35 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 27 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL RIGHTS OR RESTRICTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.1&nbsp;&nbsp;&nbsp;&nbsp; Preferred Shares.</B> The special rights or restrictions attached to the Preferred Shares shall be as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Issuable in Series </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Preferred Shares may at any time and from time to time be issued in one or more series.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Article 9.3 and the <I>Business Corporations Act,</I> the board may from time to time, by
directors&#146; resolution, if none of the Preferred Shares of any particular series are issued, alter these Articles and authorize the alteration of the Notice of Articles of the Company, as the case may be, to do one or more of the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine the maximum number of shares of any of those series of Preferred Shares that the Company is
authorized to issue, determine that there is no such maximum number, or alter any determination made under this paragraph (i)&nbsp;or otherwise in relation to a maximum number of those shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">create an identifying name by which the shares of any of those series of Preferred Shares may be identified, or
alter any identifying name created for those shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">attach special rights or restrictions to the shares of any of those series of Preferred Shares or alter any
special rights or restrictions attached to those shares, including, but without limiting or restricting the generality of the foregoing, special rights or restrictions with respect to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rate, amount, method of calculation and payment of any dividends, whether cumulative, partly cumulative or <FONT
STYLE="white-space:nowrap">non-cumulative,</FONT> and whether such rate, amount, method of calculation or payment is subject to change or adjustment in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights upon a dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company
or upon any other return of capital or distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights of redemption, retraction or purchase for cancellation and the prices and terms and conditions of
any such rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights of conversion, exchange or reclassification and the terms and conditions of any such rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any voting rights and restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms and conditions of any share purchase plan or sinking fund; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other special rights or restrictions, not inconsistent with these share provisions, attaching to such
series of Preferred Shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 36 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No special rights or restrictions attached to any series of Preferred Shares will confer upon the shares of
that series a priority over the shares of any other series of Preferred Shares in respect of dividends or a return of capital in the event of the dissolution of the Company or on the occurrence of any other event that entitles the shareholders
holding the shares of all series of the Preferred Shares to a return of capital. The Preferred Shares of each series will, with respect to the payment of dividends and the distribution of assets or return of capital in the event of dissolution or on
the occurrence of any other event that entitles the shareholders holding the shares of all series of the Preferred Shares to a return of capital, rank on a parity with the shares of every other series. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Class&nbsp;Rights or Restrictions </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Holders of Preferred Shares will be entitled to preference with respect to payment of dividends over the Common
Shares and any other shares ranking junior to the Preferred Shares with respect to payment of dividends. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the
Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, the holders of the Preferred Shares will be entitled to preference over the Common
Shares and any other shares ranking junior to the Preferred Shares with respect to the repayment of capital paid up on and the payment of unpaid dividends accrued on the Preferred Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Preferred Shares may also be given such other preferences over the Common Shares and any other shares
ranking junior to the Preferred Shares as may be fixed by directors&#146; resolution as to the respective series authorized to be issued. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATED May 2, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SIGNATURE OF A DIRECTOR OF THE COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g722206g28g07.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Approved at Meeting of Board of Directors held on June&nbsp;9, 2022</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 37 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 27.2 Special Rights and Restrictions for Series A Participating Preferred
Shares</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>&nbsp;&nbsp;&nbsp;&nbsp;Designation and Amount</I>. The shares of this series will be designated as &#147;<B>Series A
Participating Preferred Shares</B>&#148;, will be without par value, and will be unlimited in number. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<I>&nbsp;&nbsp;&nbsp;&nbsp;Dividends and Distributions</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;Subject to the prior and superior rights of the
holders of any shares of any other class of shares ranking prior and superior to the Series A Participating Preferred Shares with respect to dividends, the holders of Series A Participating Preferred Shares, in preference to the holders of Common
Shares (the &#147;<B>Common Shares</B>&#148;), of the Company, and in parity with any other series of Preferred Shares, will be entitled to receive, when, as and if declared by the Board out of funds legally available for the purpose, quarterly
dividends payable in cash on the last day of March, June, September and December in each year (each such date being referred to as a &#147;<B>Quarterly Dividend Payment Date</B>&#148;), commencing on the first Quarterly Dividend Payment Date after
the first issuance of a Series A Participating Preferred Share or fraction of a Series A Participating Preferred Share, in an amount per share (rounded to the nearest cent) equal to the greater of (i)&nbsp;US$1.00 and (ii)&nbsp;subject to any
provision for adjustment in this Article 27.2, 1,000 times the aggregate per share amount of all cash dividends, and 1,000 times the aggregate per share amount (payable in kind) of all <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends or
other distributions other than a dividend payable in Common Shares or a subdivision of the outstanding Common Shares (by reclassification or otherwise), declared on the Common Shares since the immediately preceding Quarterly Dividend Payment Date,
or, with respect to the first Quarterly Dividend Payment Date, since the first issuance of a Series A Participating Preferred Share or fraction of a Series A Participating Preferred Share. If the Company at any time after June&nbsp;9, 2022 (the
&#147;<B>Rights Dividend Declaration Date</B>&#148;) (A) declares and pays any dividend on the Common Shares payable in the form of Common Shares, (B)&nbsp;subdivides the outstanding Common Shares or (C)&nbsp;combines or consolidates the outstanding
Common Shares into a smaller number of shares, then in each such case the amount to which holders of Series A Participating Preferred Shares were entitled immediately prior to such event under clause (ii)&nbsp;of the preceding sentence will be
adjusted by multiplying such amount by a fraction, the numerator of which will be the total number of Common Shares outstanding immediately after the occurrence of such event and the denominator of which will be the total number of Common Shares
that were outstanding immediately prior to the occurrence of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;The Company will declare a dividend
or distribution on the Series A Participating Preferred Shares as provided in Section&nbsp;2(a) immediately after it declares a dividend or distribution on the Common Shares (other than a dividend payable in Common Shares), except that if no
dividend or distribution has been declared on the Common Shares during the period between any Quarterly Dividend Payment Date and the next subsequent Quarterly Dividend Payment Date, then a dividend of US$1.00 per share on the Series A Participating
Preferred Shares will nevertheless be payable on such subsequent Quarterly Dividend Payment Date (it being understood that the actual payment of such dividend may be deferred if prohibited under any of the Company&#146;s debt instruments). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 38 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;Dividends will begin to accrue and be cumulative on outstanding
Series A Participating Preferred Shares from the Quarterly Dividend Payment Date next preceding the date of issue of such Series A Participating Preferred Shares, unless the date of issue of such shares is prior to the record date for the first
Quarterly Dividend Payment Date, in which case dividends on such shares will begin to accrue from the date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the
determination of holders of Series A Participating Preferred Shares entitled to receive a quarterly dividend and before such Quarterly Dividend Payment Date, in either of which events such dividends will begin to accrue and be cumulative from such
Quarterly Dividend Payment Date. Accrued but unpaid dividends will not bear interest. Dividends paid on the Series A Participating Preferred Shares in an amount less than the total amount of such dividends at the time accrued and payable on such
shares will be allocated pro rata on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">share-by-share</FONT></FONT> basis among all such shares at the time outstanding. The Board may fix a record date for the determination of
holders of Series A Participating Preferred Shares entitled to receive payment of a dividend or distribution declared thereon, which record date will be no more than 60 days prior to the date fixed for the payment thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>&nbsp;&nbsp;&nbsp;&nbsp;Voting Rights</I>. The holders of Series A Participating Preferred Shares will have the following voting rights:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; Subject to the provision for adjustment hereinafter set forth, each share of Series A Participating Preferred
Shares will entitle the holder thereof to 1,000 votes on all matters submitted to a vote of the shareholders of the Company. If the Company at any time after the Rights Dividend Declaration Date (i)&nbsp;declares any dividend on the Common Shares
payable in Common Shares, (ii)&nbsp;subdivides the outstanding Common Shares or (iii)&nbsp;combines or consolidates the outstanding Common Shares into a smaller number of shares, then in each such case the number of votes per share to which holders
of Series A Participating Preferred Shares were entitled immediately prior to such event will be adjusted by multiplying such number by a fraction the numerator of which is the number of Common Shares outstanding immediately after such event and the
denominator of which is the number of Common Shares that were outstanding immediately prior to such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;
Except as otherwise provided in this Article 27.2, in the special rights and restriction for any other Preferred Shares or any similar shares, the Notice of Articles or the Articles of the Company, or by law, the holders of Series A Participating
Preferred Shares and the holders of Common Shares and any other share in the capital of the Company having general voting rights will vote together as one class on all matters submitted to a vote of shareholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in this Article 27.2 or as required by law, the holders of Series A Participating Preferred
Shares will have no special voting rights and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 39 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their consent will not be required (except to the extent that holders of Series A Participating Preferred Shares are entitled to vote with holders of Common Shares as set forth in this Article
27.2) for taking any corporate action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>&nbsp;&nbsp;&nbsp;&nbsp;Certain Restrictions</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; The Company will not declare any dividend on, make any distribution on, or purchase or otherwise acquire for
consideration any Common Shares after the first issuance of a Series A Participating Preferred Share or fraction of a Series A Participating Preferred Share unless concurrently therewith it will declare a dividend on the Series A Participating
Preferred Shares as required by Section&nbsp;2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;Whenever quarterly dividends or other dividends or
distributions payable on the Series A Participating Preferred Shares as provided in Section&nbsp;2 are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on Series A Participating Preferred
Shares outstanding will have been paid in full, the Company will not: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp; declare or pay dividends on, make any
other distributions on, or redeem or purchase or otherwise acquire for consideration any shares ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Participating Preferred Shares, other than
(A)&nbsp;redemptions or purchases that may be deemed to occur upon the exercise of share options, warrants or similar rights or the grant, vesting or lapse of restrictions on the grant of any performance shares, restricted shares, restricted share
units or other equity awards to the extent that such shares represent all or a portion of (1)&nbsp;the exercise or purchase price of such options, warrants or similar rights or other equity awards and (2)&nbsp;the amount of withholding taxes owed by
the recipient of such award in respect of such grant, exercise, vesting or lapse of restrictions; or (B)&nbsp;the repurchase, redemption, or other acquisition or retirement for value of any such shares from employees, former employees, directors,
former directors, consultants or former consultants of the Company, or their respective estate, spouse, former spouse or family member, pursuant to the terms of the agreements pursuant to which such shares were acquired; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp; declare or pay dividends, or make any other distributions, on any shares ranking on a parity (either as to
dividends or upon liquidation, dissolution or winding up) with the Series A Participating Preferred Shares, except dividends paid ratably on the Series A Participating Preferred Shares and all such parity shares on which dividends are payable or in
arrears in proportion to the total amounts to which the holders of all such shares are then entitled; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;
redeem or purchase or otherwise acquire for consideration shares ranking junior (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Participating Preferred Shares, it being understood that the Company may at any
time redeem, purchase or otherwise acquire any such junior shares in exchange for shares of the Company ranking junior (either as to dividends or upon dissolution, liquidation or winding up) to the Series A Participating Preferred Shares; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 40 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp; redeem or purchase or otherwise acquire for consideration any
Series A Participating Preferred Shares, or any shares ranking on a parity with the Series A Participating Preferred Shares, except in accordance with a purchase offer made in writing or by publication (as determined by the Board) to all holders of
such shares upon such terms as the Board, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and classes, will determine in good faith will result in fair and equitable
treatment among the respective series or classes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;The Company will not permit any subsidiary of the Company
to purchase or otherwise acquire for consideration any shares of the Company unless the Company could, pursuant to Section&nbsp;4(a), purchase or otherwise acquire such shares at such time and in such manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>&nbsp;&nbsp;&nbsp;&nbsp;Reacquired Preferred Shares.</I> Any Series A Participating Preferred Shares purchased or otherwise acquired by
the Company in any manner whatsoever will be retired and canceled promptly after the acquisition thereof. All such shares will upon their cancellation become part of the authorized but unissued share capital of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>&nbsp;&nbsp;&nbsp;&nbsp;Liquidation, Dissolution or Winding Up.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;Upon any liquidation, dissolution or winding up of the Company, voluntary or otherwise, no distribution will be
made to the holders of shares ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Participating Preferred Shares unless, prior thereto, the holders of Series A Participating Preferred Shares will
have received an amount per share (the <B>&#147;</B><B>Series</B><B> A </B><B>Liquidation Preference&#148;)</B> equal to the greater of (i)&nbsp;US$1.00 plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not
declared, to the date of such payment or (ii)&nbsp;the Adjustment Number multiplied by the per share amount of all cash and other property to be distributed in respect of the Common Shares upon such liquidation, dissolution or winding up of the
Company. The <B>&#147;</B><B>Adjustment</B><B> Number&#148; </B>will initially be 1,000. If the Company at any time after the Rights Dividend Declaration Date (A)&nbsp;declares and pays any dividend on the Common Shares payable in the form of Common
Shares, (B)&nbsp;subdivides the outstanding Common Shares or (C)&nbsp;combines or consolidates the outstanding Common Shares into a smaller number of shares, then in each such case the Adjustment Number in effect immediately prior to such event will
be adjusted by multiplying such Adjustment Number by a fraction the numerator of which is the number of Common Shares outstanding immediately after such event and the denominator of which is the number of Common Shares that were outstanding
immediately prior to such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; If there are not sufficient assets available to permit payment in full of
the Series A Liquidation Preference and the liquidation preferences of all other classes and series of Preferred Shares, if any, that rank on a parity with the Series A Participating Preferred Shares, then the assets available for distribution will
be distributed ratably to the holders of the Series A Participating Preferred Shares and such parity shares in proportion to their respective liquidation preferences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 41 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;None of the merger, amalgamation, arrangement or consolidation
of the Company into or with another entity or the merger, amalgamation, arrangement or consolidation of any other entity into or with the Company will be deemed to be a liquidation, dissolution or winding up of the Company within the meaning of this
Section 6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>&nbsp;&nbsp;&nbsp;&nbsp;Consolidation, Merger, etc</I>. If the Company enters into any consolidation, merger,
amalgamation, arrangement, combination, conversion, share exchange or other transaction in which the Common Shares are exchanged for or changed into other shares, securities, cash or any other property (payable in kind), then in any such case the
Series A Participating Preferred Shares will at the same time be similarly exchanged or changed in an amount per share (subject to the provision for adjustment hereinafter set forth) equal to the Adjustment Number multiplied by the aggregate amount
of shares, securities, cash and/or any other property (payable in kind), as the case may be, into which or for which each share of Common Shares is changed or exchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>&nbsp;&nbsp;&nbsp;&nbsp;No Redemption</I>. The Series A Participating Preferred Shares will not be redeemable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>&nbsp;&nbsp;&nbsp;&nbsp;Ranking</I>. The Series A Participating Preferred Shares will rank in parity to all other series of the
Preferred Shares as to the payment of dividends and the distribution of assets,, and will rank senior to the Common Shares as to such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>&nbsp;&nbsp;&nbsp;&nbsp;Amendment</I>. At any time when any Series A Participating Preferred Shares are outstanding, neither the
Articles nor this Article 27.2 will be amended in any manner that would materially alter or change the special rights and restrictions of the Series A Participating Preferred Shares so as to affect them adversely without the affirmative vote of the
holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding Series A Participating Preferred Shares, voting separately as a class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>&nbsp;&nbsp;&nbsp;&nbsp;Fractional Preferred Shares</I>. Series A Participating Preferred Shares may be issued in fractions of a share
that will entitle the holder, in proportion to such holder&#146;s fractional shares, to exercise voting rights, receive dividends, participate in distributions and to have the benefit of all other rights of holders of Series A Participating
Preferred Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 42 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>7
<FILENAME>d722206dex81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g722206g0714173424359.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="right">Blake, Cassels &amp; Gradyon LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="right">Barristers &amp; Solicitors</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="right">Patent &amp;
Trademark Agents</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="right">595 Burrard Street, P.O. Box 49314</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="right">Suite 2600, Three Bentall Centre</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="right">Vancouver
BC V7X 1L3 Canada</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Arial Narrow" ALIGN="right">Tel: 604-631-3300 Fax; 604-631-3309</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;], 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks
Delaware Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown,
Delaware </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19709 U.S.A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Zymeworks Delaware Inc. Form <FONT STYLE="white-space:nowrap">S-4</FONT> Registration Statement - Canadian
Federal Income Tax Considerations </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Zymeworks Delaware Inc., a Delaware corporation (the &#147;<B>Parent</B>&#148;), in connection with the transactions contemplated
by (i)&nbsp;the Transaction Agreement, dated as of July&nbsp;14, 2022 (the &#147;<B>Agreement</B>&#148;), entered into by and among Zymeworks Inc., a British Columbia company (&#147;<B>Company</B>&#148;), Zymeworks CallCo ULC, a British Columbia
unlimited liability company and a direct, wholly-owned subsidiary of Parent (&#147;<B>Callco</B>&#148;), Zymeworks ExchangeCo Ltd., a British Columbia corporation and a direct-wholly owned subsidiary of Callco (&#147;<B>ExchangeCo</B>&#148;), and
the Company, and (ii)&nbsp;the Plan of Arrangement Under Section&nbsp;288 of the Business Corporations Act (British Columbia) concerning the Company as filed with the Supreme Court of British Columbia (the &#147;<B>Plan of Arrangement</B>&#148;).
Pursuant to the Agreement and the Plan of Arrangement, among other transactions, Parent will issue to Company Shareholders, at their election and subject to applicable eligibility criteria, for each Company Common Share, either (a)&nbsp;one share of
Parent common stock, par value $0.00001 per share (the &#147;<B>Delaware Common Stock</B>&#148;) or (b)&nbsp;one exchangeable share (the &#147;<B>Exchangeable Share</B>&#148;) in the capital of ExchangeCo, subject to a cap on the aggregate number of
Exchangeable Shares that is equal to 18% of (1)&nbsp;the number of Company Common Shares issued and outstanding, less (2)&nbsp;the number of Company Common Shares held by any Company Shareholders who exercise their dissent rights as described in the
Plan of Arrangement (the &#147;<B>Exchangeable Share Cap</B>&#148;) (such transactions, together, the &#147;<B>Share Exchange</B>&#148;). At your request, and in connection with the filing of the Registration Statement (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-[&#9679;])</FONT> of the Parent on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed on [&#9679;], 2022 with the Securities and Exchange Commission (the &#147;<B>Registration Statement</B>&#148;), we are
rendering our opinion concerning certain Canadian federal income tax matters. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being delivered in connection with the Registration Statement and certain Canadian federal income tax aspects of the Redomicile Transactions
as defined therein, and will appear as an exhibit to the Registration Statement. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g0714173424812.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g722206g0714173424359.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"> Page
 2
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering our opinion, we have reviewed the Registration Statement and such other documents and
information, and have made such other investigations, as we have considered necessary or relevant for purposes of rendering our opinion. In our examination, we have assumed, without independent verification, (i)&nbsp;the authenticity of original
documents, (ii)&nbsp;the accuracy of copies and the genuineness of signatures, (iii)&nbsp;that the execution and delivery by each party to a document and the performance by such party of its obligations thereunder have been authorized by all
necessary measures and do not violate or result in a breach of or default under such party&#146;s certificate or instrument of formation and <FONT STYLE="white-space:nowrap">by-laws</FONT> or the laws of such party&#146;s jurisdiction of
organization, (iv)&nbsp;that each agreement represents the entire agreement between the parties with respect to the subject matter thereof, (v)&nbsp;that the parties to each agreement have complied, and will comply, with all of their respective
covenants, agreements and undertakings contained therein, (vi)&nbsp;that the transactions provided for by each agreement were and will be carried out in accordance with their terms, and (vii)&nbsp;the statements concerning the Redomicile
Transactions provided in the Registration Statement (including, without limitation, their respective exhibits) are true, correct and complete and will remain true, correct and complete at all times up to and including the Effective Time. In
addition, in rendering our opinion, we have relied upon, without independent verification, facts and representations that have been provided or made to us by you and your agents which we assume are, and will continue to be, true, correct and
complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion set forth below is based on the Income Tax Act (Canada), as amended, the regulations thereunder, all specific proposals to amend
the Income Tax Act (Canada) publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof, and our understanding of the current published administrative practices and assessing policies of the Canada Revenue Agency.
Each of these authorities is subject to change, and such changes could apply retroactively. Any changes in law or the facts regarding the Redomicile Transactions, or any inaccuracy in the facts or representations on which we relied, could affect the
continuing validity of the opinion set forth below. We assume no responsibility to inform you of any such changes or inaccuracy that may occur or come to our attention. We express our opinion below only as to those matters specifically provided
below and no opinion should be inferred as to tax consequences under any provincial or foreign law, or with respect to other areas of Canadian federal taxation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, and subject to the limitations and qualifications set forth herein and in the Registration Statement (including those
under the heading &#147;Certain Canadian Federal Income Tax Considerations&#148; therein), the discussion set forth under the heading &#147;Certain Canadian Federal Income Tax Considerations&#148; in the Registration Statement, insofar as it
expresses conclusions as to the application of Canadian federal income tax law, is our opinion. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g0714173424812.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g722206g0714173424359.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"> Page
 3
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are furnishing this opinion in connection with the filing of the Registration Statement and this opinion
is not to be relied upon for any other purpose without our prior written consent. We hereby consent to the filing of the opinion as an exhibit to the Registration Statement and to the reference to our name in the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours very truly, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BLAKE, CASSELS&nbsp;&amp; GRAYDON LLP </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g722206g0714173424812.jpg" ALT="LOGO">
 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>8
<FILENAME>d722206dex82.htm
<DESCRIPTION>EX-8.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g722206g0714111013875.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professional Corporation</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650 Page Mill Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, California 94304-1050</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SMALL>O</SMALL>: 650.493.9300 </P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><SMALL>F</SMALL>: 650.493.6811</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;], 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Zymeworks Delaware Inc., a Delaware corporation (the &#147;<U>Parent</U>&#148;), in connection with the
transactions contemplated by (i)&nbsp;the Transaction Agreement, dated as of [&#149;], 2022 (the &#147;<U>Agreement</U>&#148;), entered into by and among Zymeworks Inc., a British Columbia company (&#147;<U>Company</U>&#148;), Zymeworks CallCo ULC,
a British Columbia unlimited liability company and a direct, wholly-owned subsidiary of Parent (&#147;Callco&#148;), Zymeworks ExchangeCo Ltd, a British Columbia corporation and a direct-wholly owned subsidiary of Callco
(&#147;<U>ExchangeCo</U>&#148;), and the Company, and (ii)&nbsp;the Plan of Arrangement Under Section&nbsp;288 of the Business Corporations Act (British Columbia) concerning the Company as filed with the Supreme Court of British Columbia (the
&#147;<U>Plan of Arrangement</U>&#148;). Pursuant to the Agreement and the Plan of Arrangement, among other transactions, Parent will issue to Company Shareholders, at their election and subject to applicable eligibility criteria, for each Company
Common Share, either (a)&nbsp;one share of Parent common stock, par value $0.00001 per share (the &#147;<U>Delaware Common Stock</U>&#148;) or (b)&nbsp;one exchangeable share (the &#147;<U>Exchangeable Share</U>&#148;) in the capital of ExchangeCo,
subject to a cap on the aggregate number of Exchangeable Shares that is equal to 18% of (1)&nbsp;the number of Company Common Shares issued and outstanding, less (2)&nbsp;the number of Company Common Shares held by any Company Shareholders who
exercise their dissent rights as described in the Plan of Arrangement (the &#147;<U>Exchangeable Share Cap</U>&#148;) (such transactions, together, the &#147;<U>Share Exchange</U>&#148;). At your request, and in connection with the filing of the
Registration Statement (File No.&nbsp;333-[&#149;]) of the Parent on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed on [&#149;], 2022 with the Securities and Exchange Commission (the &#147;<U>Registration Statement</U>&#148;), we are
rendering our opinion concerning certain U.S. federal income tax matters. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In providing our opinion, we have examined the Agreement, the Registration Statement, and the other documents described therein and such other
documents as we have deemed necessary or appropriate for purposes of our opinion. In addition, we have assumed that (i)&nbsp;the Share Exchange will be consummated in accordance with the provisions of the Agreement and as described in the
Registration Statement (and no transaction or condition described therein and affecting this opinion will be waived by any party), (ii) the statements concerning the Share Exchange and the parties thereto set forth in the Agreement and in the
Registration Statement are true, complete and correct, (iii)&nbsp;the statements and representations made by Parent and the Company in their respective officer&#146;s certificates dated as of the date hereof and delivered to us for purposes of this
opinion (the &#147;<U>Officer&#146;s Certificates</U>&#148;) are true, complete and correct as of the date hereof and will remain true, complete and correct at all times up to and including the effective time of the Share Exchange, (iv)&nbsp;any
such statements and representations made in the Officer&#146;s Certificates &#147;to the knowledge of&#148; any person or similarly qualified are and will be true, complete and correct without such qualification, and (v)&nbsp;Parent, Callco,
ExchangeCo, the Company and their respective subsidiaries will treat the Share Exchange for U.S. federal income tax purposes in a manner consistent with the opinion set forth below. If any of the above described assumptions is untrue for any reason
or if the Share Exchange is consummated in a manner that is different from the manner described in the Agreement and the Registration Statement, our opinion as expressed below may be adversely affected. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g722206g0714111014188.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;],
2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing and
subject to the assumptions, exceptions, limitations and qualifications set forth herein and in the Registration Statement, we are of the opinion that the statements in the Registration Statement under the heading &#147;Material U.S. Federal Income
Tax Considerations,&#148; insofar as they relate to statements of U.S. federal income tax law and legal conclusions, are accurate in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion on the Company&#146;s status as a &#147;passive foreign investment company&#148; within the meaning of Section&nbsp;1297
of the Internal Revenue Code of 1986, as amended, and on any issue relating to the tax consequences of the transactions contemplated by the Agreement or the Registration Statement other than the opinion set forth above, and our opinion does not
address tax consequences to&nbsp;any Company Shareholders acquiring Exchangeable Shares or Special Voting Stock as a result of the Share Exchange, as well as any holders of Company Warrants and Company Incentive Awards. Our opinion is based on
current provisions of the Code, Treasury Regulations promulgated thereunder, published pronouncements of the Internal Revenue Service and case law, any of which may be changed at any time with retroactive effect. Any change in applicable laws or the
facts and circumstances surrounding the transaction, or any inaccuracy in the statements, facts, assumptions or representations upon which we have relied, may affect the continuing validity of our opinion as set forth herein. We assume no
responsibility to inform the Company of any such change or inaccuracy that may occur or come to our attention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are furnishing this
opinion in connection with the filing of the Registration Statement, and this opinion is not to be relied upon for any other purpose without our prior written consent. We hereby consent to the filing of this opinion with the Securities and Exchange
Commission as an exhibit to the Registration Statement, and to the references therein to us. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act
of 1933, as amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#149;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">WILSON SONSINI GOODRICH&nbsp;&amp; ROSATI</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Professional Corporation</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.73
<SEQUENCE>9
<FILENAME>d722206dex1073.htm
<DESCRIPTION>EX-10.73
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.73</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.73 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indemnification Agreement (this &#147;<B><I>Agreement</I></B>&#148;) is dated as of [<I>insert date</I>], and is between Zymeworks Inc.,
a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and [<I>insert name of indemnitee</I>] (&#147;<B><I>Indemnitee</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Indemnitee&#146;s service to the Company substantially benefits the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Individuals are reluctant to serve as directors or officers of corporations or in certain other capacities unless
they are provided with adequate protection through insurance or indemnification against the risks of claims and actions against them arising out of such service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;Indemnitee does not regard the protection currently provided by applicable law, the Company&#146;s governing
documents and any insurance as adequate under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;In order to induce Indemnitee to continue to provide services to the Company, it is reasonable, prudent and
necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee as permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is a supplement to and in furtherance of the indemnification provided in the Company&#146;s
certificate of incorporation and bylaws, and any resolutions adopted pursuant thereto, and this Agreement shall not be deemed a substitute therefor, nor shall this Agreement be deemed to limit, diminish or abrogate any rights of Indemnitee
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties therefore agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<B>Definitions.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;A &#147;<B><I>Change in Control</I></B>&#148; shall be deemed to occur upon the earliest to occur after the date of
this Agreement of any of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Acquisition of Stock by Third Party.</I> Any Person (as
defined below) becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&#146;s then outstanding securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Change in Board Composition.</I> During any period of two consecutive years (not including any period prior to
the execution of this Agreement), individuals who at the beginning of such period constitute the Company&#146;s board of directors, and any new directors (other than a director designated by a person who has entered into an agreement with the
Company to effect a transaction described in Sections&nbsp;1(a)(i), 1(a)(iii) or 1(a)(iv)) whose election by the board of directors or nomination for election by the Company&#146;s stockholders was approved by a vote of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute
at least a majority of the members of the Company&#146;s board of directors; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Corporate Transactions.</I> The effective date of a merger
or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by
remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and
with the power to elect at least a majority of the board of directors or other governing body of such surviving entity; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<I>Liquidation.</I> The approval by the stockholders of the Company of a complete liquidation of the Company or
an agreement for the sale or disposition by the Company of all or substantially all of the Company&#146;s assets; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<I>Other Events.</I> Any other event of a nature that would be required to be reported in response to Item 6(e) of
Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended, whether or not the Company is then subject to such reporting requirement,
<I>except</I> the completion of the transactions contemplated by the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-[&#9679;]),</FONT> including the Transaction
Agreement, the Plan of Arrangement, the Support Agreement, and the Trust Agreement, shall not be considered a Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
purposes of this Section&nbsp;1(a), the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Person</I></B>&#148; shall have the meaning as set forth in Sections&nbsp;13(d) and 14(d) of the
Securities Exchange Act of 1934, as amended; <I>provided, however,</I> that &#147;<B><I>Person</I></B>&#148; shall exclude (i)&nbsp;the Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the
Company, and (iii)&nbsp;any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Beneficial Owner</I></B>&#148; shall have the meaning given to such term in <FONT
STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> under the Securities Exchange Act of 1934, as amended; <I>provided, however,</I> that &#147;<B><I>Beneficial Owner</I></B>&#148; shall exclude any Person otherwise becoming a Beneficial Owner by
reason of (i)&nbsp;the stockholders of the Company approving a merger of the Company with another entity or (ii)&nbsp;the Company&#146;s board of directors approving a sale of securities by the Company to such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Transaction Agreement</I></B>&#148; shall mean the Transaction Agreement dated [&#9679;], 2022 by and
among the Company, Zymeworks Inc., a company continued under the Business Corporations Act (British Columbia), Zymeworks CallCo ULC, an unlimited liability company existing under the laws of the Province of British Columbia
(&#147;<B><I>Callco</I></B>&#148;), and Zymeworks ExchangeCo Ltd., a company existing under the laws of the Province of British Columbia (&#147;<B><I>ExchangeCo</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Plan of Arrangement</I></B>&#148; shall mean the plan of arrangement and any amendments or variations
thereto made in accordance with the provisions of the Transaction Agreement or the Plan of Arrangement or at the direction of the Supreme Court of British Columbia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Support Agreement</I></B>&#148; shall mean the Exchangeable Share Support Agreement dated [&#9679;],
2022 by and among the Company, CallCo and ExchangeCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(6)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Trust Agreement</I></B>&#148; shall mean
the Voting and Exchange Trust Agreement dated [&#9679;], 2022 by and between the Company, CallCo, ExchangeCo, and Computershare Trust Company of Canada, a trust company existing under the laws of Canada. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Corporate Status</I></B>&#148; describes the status
of a person who is or was a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>DGCL</I></B>&#148; means the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Disinterested Director</I></B>&#148; means a director of the Company who is not and was not a party to
the Proceeding in respect of which indemnification is sought by Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Enterprise</I></B>&#148; means the Company and any other corporation, partnership, limited liability
company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Expenses</I></B>&#148; include all reasonable and actually incurred attorneys&#146; fees, retainers,
court costs, transcript costs, fees and costs of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types
customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also include (i)&nbsp;Expenses incurred in
connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond or other appeal bond or their equivalent, and (ii)&nbsp;for purposes of
Section&nbsp;12(d), Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#146;s rights under this Agreement or under any directors&#146; and officers&#146; liability insurance policies
maintained by the Company. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Independent Counsel</I></B>&#148; means a law firm, or a partner or member of a law firm, that is
experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i)&nbsp;the Company or Indemnitee in any matter material to either such party (other than as Independent Counsel with
respect to matters concerning Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the
foregoing, the term &#147;<B><I>Independent Counsel</I></B>&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or
Indemnitee in an action to determine Indemnitee&#146;s rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Proceeding</I></B>&#148; means any threatened, pending or completed action, suit, arbitration,
mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature,
including any appeal therefrom and including without limitation any such Proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be involved as a party, a potential party, a
<FONT STYLE="white-space:nowrap">non-party</FONT> witness or otherwise by reason of (i)&nbsp;the fact that Indemnitee is or was a director or officer of the Company, (ii)&nbsp;any action taken by Indemnitee or any action or inaction on
Indemnitee&#146;s part while acting as a director or officer of the Company, or (iii)&nbsp;the fact that he or she is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or
fiduciary of the Company or any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification or advancement of expenses can be provided under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Reference to &#147;<B><I>other enterprises</I></B>&#148; shall
include employee benefit plans; references to &#147;<B><I>fines</I></B>&#148; shall include any excise taxes assessed on a person with respect to any employee benefit plan; references to &#147;<B><I>serving at the request of the
Company</I></B>&#148; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its
participants or beneficiaries; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner
&#147;<B><I>not opposed to the best interests of the Company</I></B>&#148; as referred to in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnity in Third-Party Proceedings.</B> The Company shall indemnify Indemnitee in accordance with the
provisions of this Section&nbsp;2 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this
Section&nbsp;2, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in
connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal
action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnity in
Proceedings by or in the Right of the Company.</B> The Company shall indemnify Indemnitee in accordance with the provisions of this Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in
the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on
Indemnitee&#146;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No
indemnification for Expenses shall be made under this Section&nbsp;3 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the
extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and
reasonably entitled to indemnification for such expenses as the Delaware Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</B> To the extent that Indemnitee is
a party to or a participant in and is successful (on the merits or otherwise) in defense of any Proceeding or any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by
Indemnitee or on Indemnitee&#146;s behalf in connection therewith. For purposes of this section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as
to such claim, issue or matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification for Expenses of a Witness.</B> To the extent that Indemnitee
is, by reason of his or her Corporate Status, a witness in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified to the extent permitted by applicable law against all Expenses actually and reasonably incurred by
Indemnitee or on Indemnitee&#146;s behalf in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Indemnification.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any limitation in Sections&nbsp;2, 3 or 4, the Company shall indemnify Indemnitee to the fullest
extent permitted by applicable law if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with
the Proceeding or any claim, issue or matter therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of Section&nbsp;6(a), the meaning of the
phrase &#147;<B><I>to the fullest extent permitted by applicable law</I></B>&#148; shall include, but not be limited to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional
indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the
date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<B>Exclusions.</B> Notwithstanding any provision in this Agreement, the Company shall not be obligated under this
Agreement to make any indemnity in connection with any Proceeding (or any part of any Proceeding): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;for which
payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;for an accounting or disgorgement of profits pursuant to Section&nbsp;16(b) of the Securities Exchange Act of 1934,
as amended, or similar provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based
compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting
restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the &#147;<B><I>Sarbanes-Oxley Act</I></B>&#148;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in
violation of Section&nbsp;306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against
the Company or its directors, officers, employees, agents or other indemnitees, unless (i)&nbsp;the Company&#146;s board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii)&nbsp;the Company
provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii)&nbsp;otherwise authorized in Section&nbsp;12(d) or (iv)&nbsp;otherwise required by applicable law; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;if prohibited by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<B>Advances of Expenses.</B> The Company shall advance the Expenses incurred by Indemnitee in connection with any
Proceeding prior to its final disposition, and such advancement shall be made as soon as reasonably practicable after the receipt by the Company of a written statement or statements requesting such advances from time to time (which shall include
invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditure made that would cause Indemnitee to waive any privilege
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accorded by applicable law shall not be included with the invoice). Advances shall be unsecured and interest free and made without regard to Indemnitee&#146;s ability to repay such advances.
Indemnitee hereby undertakes to repay any advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. This Section&nbsp;8 shall not apply to the extent advancement is prohibited by law and
shall not apply to any Proceeding (or any part of any Proceeding) for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding (or any part of any Proceeding) referenced in Section&nbsp;7(b) or 7(c) prior to a
determination that Indemnitee is not entitled to be indemnified by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<B>Procedures for Notification
and Defense of Claim.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Indemnitee shall notify the Company in writing of any matter with respect to which
Indemnitee intends to seek indemnification or advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof. The written notification to the Company shall include, in reasonable detail, a description
of the nature of the Proceeding and the facts underlying the Proceeding. The failure by Indemnitee to notify the Company will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this
Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay materially prejudices the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If, at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has
directors&#146; and officers&#146; liability insurance in effect that may be applicable to the Proceeding, the Company shall give prompt notice of the commencement of the Proceeding to the insurers in accordance with the procedures set forth in the
applicable policies. The Company shall thereafter take all commercially-reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall
be entitled to assume the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, conditioned or delayed, upon the delivery to Indemnitee of written notice of its election to do so. After
delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to
the same Proceeding. Notwithstanding the Company&#146;s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the fees and expenses of Indemnitee&#146;s separate counsel to the extent (i)&nbsp;the employment of
separate counsel by Indemnitee is authorized by the Company, (ii)&nbsp;counsel for the Company or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense
such that Indemnitee needs to be separately represented, (iii)&nbsp;the Company is not financially or legally able to perform its indemnification obligations or (iv)&nbsp;the Company shall not have retained, or shall not continue to retain, counsel
to defend such Proceeding. The Company shall have the right to conduct such defense as it sees fit in its sole discretion. Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at
Indemnitee&#146;s personal expense. The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be
reasonably appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not be liable to indemnify Indemnitee for any settlement of any
Proceeding (or any part thereof) without the Company&#146;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not settle any Proceeding (or any part thereof)
in a manner that imposes any penalty or liability on Indemnitee without Indemnitee&#146;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<B>Procedures upon Application for Indemnification.</B><B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To obtain indemnification, Indemnitee shall submit to the Company a written request, including therein or therewith
such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the Proceeding. Any delay
in providing the request will not relieve the Company from its obligations under this Agreement, except to the extent such failure is prejudicial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Upon written request by Indemnitee for indemnification pursuant to Section&nbsp;10(a), a determination with respect
to Indemnitee&#146;s entitlement thereto shall be made in the specific case (i)&nbsp;if a Change in Control shall have occurred, at Indemnitee&#146;s written request by Independent Counsel in a written opinion to the Company&#146;s board of
directors, a copy of which shall be delivered to Indemnitee or (ii)&nbsp;if a Change in Control shall not have occurred, (A)&nbsp;by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#146;s board of
directors, (B)&nbsp;by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#146;s board of directors, (C)&nbsp;if there are no such Disinterested
Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company&#146;s board of directors, a copy of which shall be delivered to Indemnitee or (D)&nbsp;if so directed by the Company&#146;s board of
directors, by the stockholders of the Company. If it is determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days after such determination. Indemnitee shall cooperate with the person, persons or
entity making the determination with respect to Indemnitee&#146;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information that is not privileged or
otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys&#146; fees and disbursements) actually and reasonably incurred by
Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company, to the extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to
Section&nbsp;10(b), the Independent Counsel shall be selected as provided in this Section&nbsp;10(c). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Company&#146;s board of directors, and the Company
shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request
that such selection be made by the Company&#146;s board of directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In
either event, Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection;
<I>provided</I>, <I>however</I>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#147;Independent Counsel&#148; as defined in Section&nbsp;1 of this Agreement, and
the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the
Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after the later of (i)&nbsp;submission by Indemnitee
of a written request for indemnification pursuant to Section&nbsp;10(a) hereof and (ii)&nbsp;the final </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disposition of the Proceeding, the parties have not agreed upon an Independent Counsel, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any
objection which shall have been made by the Company or Indemnitee to the other&#146;s selection of Independent Counsel and for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall
designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&nbsp;10(b) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant
to Section&nbsp;12(a) of this Agreement, the Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to pay the reasonable fees and expenses of any Independent Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<B>Presumptions and Effect of Certain Proceedings.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity
making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof
to overcome that presumption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The termination of any Proceeding or of any claim, issue or matter therein, by
judgment, order, settlement or conviction, or upon a plea of <I>nolo</I> <I>contendere</I> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself create a presumption that Indemnitee did not act in good
faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Neither the knowledge, actions nor failure to act of any other director, officer, agent or employee of the
Enterprise shall be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<B>Remedies of Indemnitee.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;12(e), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;10 of
this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;8 or 12(d) of this Agreement, (iii)&nbsp;no determination of entitlement to
indemnification shall have been made pursuant to Section&nbsp;10 of this Agreement within 90 days after the later of the receipt by the Company of the request for indemnification or the final disposition of the Proceeding, (iv)&nbsp;payment of
indemnification pursuant to this Agreement is not made (A)&nbsp;within ten days after a determination has been made that Indemnitee is entitled to indemnification or (B)&nbsp;with respect to indemnification pursuant to Sections&nbsp;4, 5 and 12(d)
of this Agreement, within 30 days after receipt by the Company of a written request therefor, or (v)&nbsp;the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes
any litigation or other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of competent
jurisdiction of his or her entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration with respect to his or her entitlement to such indemnification or
advancement of Expenses, to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within
180 days following the date on which Indemnitee first has the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commence such proceeding pursuant to this Section&nbsp;12(a); <I>provided, however,</I> that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his
or her rights under Section&nbsp;4 of this Agreement. The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication or award in arbitration in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Neither (i)&nbsp;the failure of the Company, its board of directors, any committee or subgroup of the board of
directors, Independent Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii)&nbsp;an actual determination by the
Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct, shall create a presumption that Indemnitee has or has not met
the applicable standard of conduct. In the event that a determination shall have been made pursuant to Section&nbsp;10 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to
this Section&nbsp;12 shall be conducted in all respects as a <I>de novo</I> trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced
pursuant to this Section&nbsp;12, the Company shall, to the fullest extent not prohibited by law, have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent not prohibited by law, the Company shall be precluded from asserting in any judicial
proceeding or arbitration commenced pursuant to this Section&nbsp;12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company
is bound by all the provisions of this Agreement. If a determination shall have been made pursuant to Section&nbsp;10 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial
proceeding or arbitration commenced pursuant to this Section&nbsp;12, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s statements not materially misleading, in
connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To the extent not prohibited by law, the Company shall indemnify Indemnitee against all Expenses that are incurred
by Indemnitee in connection with any action for indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company to the extent
Indemnitee is successful in such action, and, if requested by Indemnitee, shall (as soon as reasonably practicable, but in any event no later than 90 days, after receipt by the Company of a written request therefor) advance such Expenses to
Indemnitee, subject to the provisions of Section&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in this Agreement to the
contrary, no determination as to entitlement to indemnification shall be required to be made prior to the final disposition of the Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<B>Contribution.</B> To the fullest extent permissible under applicable law, if the indemnification provided for in
this Agreement is unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether for Expenses, judgments, fines or amounts paid or to be paid in settlement, in connection
with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)&nbsp;the relative benefits received by the
Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding; and (ii)&nbsp;the relative fault of Indemnitee and the Company (and its other directors, officers, employees and agents) in connection with such events
and transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-exclusivity.</FONT></B>
The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company&#146;s certificate
of incorporation or bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of
Expenses than would be afforded currently under the Company&#146;s certificate of incorporation and bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by
such change, subject to the restrictions expressly set forth herein or therein. Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy
shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. Except as expressly set forth herein, the assertion or employment of any right or remedy hereunder, or
otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<B>[Primary
Responsibility.</B> The Company acknowledges that Indemnitee has certain rights to indemnification and advancement of expenses provided by [<I>insert name of fund</I>] [and certain affiliates thereof] ([collectively,] the &#147;<B><I>Secondary
Indemnitor[s]</I></B>&#148;). The Company agrees that, as between the Company and the Secondary Indemnitor[s], the Company is primarily responsible for amounts required to be indemnified or advanced under the Company&#146;s certificate of
incorporation or bylaws or this Agreement and any obligation of the Secondary Indemnitor[s] to provide indemnification or advancement for the same amounts is secondary to those Company obligations. [[To the extent not in contravention of any
insurance policy or policies providing liability [or other] insurance for [the Company or] any director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, the][The] Company
waives any right of contribution or subrogation against the Secondary Indemnitor[s] with respect to the liabilities for which the Company is primarily responsible under this Section&nbsp;15.] In the event of any payment by the Secondary
Indemnitor[s] of amounts otherwise required to be indemnified or advanced by the Company under the Company&#146;s certificate of incorporation or bylaws or this Agreement, the Secondary Indemnitor[s] shall be subrogated to the extent of such payment
to all of the rights of recovery of Indemnitee for indemnification or advancement of expenses under the Company&#146;s certificate of incorporation or bylaws or this Agreement or, to the extent such subrogation is unavailable and contribution is
found to be the applicable remedy, shall have a right of contribution with respect to the amounts paid]; <I>provided, however,</I> that the foregoing sentence will be deemed void if and to the extent that it would violate any applicable insurance
policy. The Secondary Indemnitor[s] [are][is an] express third-party [beneficiaries][beneficiary] of the terms of this Section&nbsp;15.] [<B>Reserved.</B>] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<B>No Duplication of Payments.</B> The Company shall not be liable under this Agreement to make any payment of
amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract, agreement or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance.</B> To the extent that the Company maintains an insurance policy or policies providing liability
insurance for directors, trustees, general partners, managing members, officers, employees, agents or fiduciaries of the Company or any other Enterprise, Indemnitee shall be covered by such policy or policies to the same extent as the most
favorably-insured persons under such policy or policies in a comparable position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<B>Subrogation.</B> In the
event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights,
including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<B>Services to the Company.</B> Indemnitee agrees to serve as a
director or officer of the Company or, at the request of the Company, as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected or appointed or
until Indemnitee tenders his or her resignation or is removed from such position. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in
which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and
Indemnitee. Indemnitee specifically acknowledges that any employment with the Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, with or without
notice, except as may be otherwise expressly provided in any executed, written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies adopted by the
Company&#146;s board of directors or, with respect to service as a director or officer of the Company, the Company&#146;s certificate of incorporation or bylaws or the DGCL. No such document shall be subject to any oral modification thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<B>Duration.</B> This Agreement shall continue until and terminate upon the later of (a)&nbsp;ten years after the
date that Indemnitee shall have ceased to serve as a director or officer of the Company or as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other Enterprise, as applicable; or (b)&nbsp;one year
after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to
Section&nbsp;12 of this Agreement relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<B>Successors.</B> This Agreement shall be binding upon
the Company and its successors and assigns, including any direct or indirect successor, by purchase, merger, consolidation or otherwise, to all or substantially all of the business or assets of the Company, and shall inure to the benefit of
Indemnitee and Indemnitee&#146;s heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business or
assets of the Company, by written agreement, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability.</B> Nothing in this Agreement is intended to require or shall be construed as requiring the
Company to do or fail to do any act in violation of applicable law. The Company&#146;s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. If
any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including without
limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and
shall remain enforceable to the fullest extent permitted by law; (ii)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto;
and (iii)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not
itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&nbsp;&nbsp;&nbsp;&nbsp;<B>Enforcement.</B> The Company expressly confirms and agrees that it has entered into this Agreement and assumed
the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement.</B> This Agreement constitutes the entire
agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; <I>provided</I>,
<I>however</I>, that this Agreement is a supplement to and in furtherance of the Company&#146;s certificate of incorporation and bylaws and applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.&nbsp;&nbsp;&nbsp;&nbsp;<B>Modification and Waiver.</B> No supplement, modification or amendment to this Agreement shall be binding unless
executed in writing by the parties hereto. No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate
Status prior to such amendment, alteration or repeal. No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor shall any waiver constitute a continuing waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices.</B> All notices and other communications required or permitted hereunder shall be in writing and shall
be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;if to Indemnitee, to Indemnitee&#146;s address, facsimile number or electronic mail address as shown on the
signature page of this Agreement or in the Company&#146;s records, as may be updated in accordance with the provisions hereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>(b)</I>&nbsp;&nbsp;&nbsp;&nbsp;if to the Company, to the attention of the Chief Executive Officer or Chief Financial Officer of the Company
at 108 Patriot Drive, Suite A, Middletown, DE 19709, with a copy to 114 East 4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Avenue, Suite 800, Vancouver BC, Canada V5T 1G4, or at such other current address as the Company shall have
furnished to Indemnitee, with a copy (which shall not constitute notice) to Tony Jeffries and Bryan King, Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C., 650 Page Mill Road, Palo Alto, CA 94304-1050. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i)&nbsp;if
delivered by hand, messenger or courier service, when delivered (or if sent <I>via</I> a nationally-recognized overnight courier service, freight prepaid, specifying <FONT STYLE="white-space:nowrap">next-business-day</FONT> delivery, one business
day after deposit with the courier), (ii)&nbsp;if sent <I>via</I> mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed
as aforesaid, or (iii)&nbsp;if sent <I>via</I> facsimile, upon confirmation of facsimile transfer or, if sent <I>via</I> electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal
business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#146;s next business day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.&nbsp;&nbsp;&nbsp;&nbsp;<B>Applicable Law and Consent to Jurisdiction.</B> This Agreement and the legal relations among the parties shall
be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;12(a) of this
Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any
other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in
connection with this Agreement, (iii)&nbsp;appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, 19801, as
its agent in the State of Delaware as such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party&#146;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party
personally within the State of Delaware, (iv)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action
or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts.</B> This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in counterparts, each of which shall for all purposes be deemed
to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.&nbsp;&nbsp;&nbsp;&nbsp;<B>Captions.</B> The headings of the paragraphs of this Agreement are inserted for convenience only and shall not
be deemed to constitute part of this Agreement or to affect the construction thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>signature page follows</I>) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties are signing this Indemnification Agreement as of the date stated in the
introductory sentence. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZYMEWORKS INC.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><I>(Signature)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><I>(Print name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><I>(Title)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>[INSERT INDEMNITEE NAME]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><I>(Signature)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>(Print name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">108 Patriot Drive, Suite A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Middletown, DE 19709</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">United States</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">with copies to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">114 East 4th Avenue, Suite 800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Vancouver, BC, V5T 1G4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Canada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Attn: Legal Department</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Signature page to Indemnification Agreement</I>) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>d722206dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Subsidiaries of the Company</U></B>* </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Subsidiary</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>State or Jurisdiction of Incorporation or Organization</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zymeworks ExchangeCo Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Province of British Columbia</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zymeworks CallCo ULC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Province of British Columbia</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inclusion on the list above is not an admission that any of the above entities, individually or in the
aggregate, constitutes a significant subsidiary within the meaning of Rule <FONT STYLE="white-space:nowrap">1-02(w)</FONT> of Regulation<I>&nbsp;S</I>-<I>X</I>&nbsp;and Item 601(b)(21)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT>
</P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>d722206dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 10426 777 Dunsmuir Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vancouver BC V7Y 1K3 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone (604) <FONT STYLE="white-space:nowrap">691-3000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax (604) <FONT STYLE="white-space:nowrap">691-3031</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our reports dated February&nbsp;24, 2022, with respect to the consolidated financial statements of Zymeworks Inc. and the
effectiveness of internal control over financial reporting, incorporated herein by reference and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chartered Professional Accountants</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vancouver, Canada</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>12
<FILENAME>d722206dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent to Reference in Proxy Statement/Prospectus </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the
&#147;Registration Statement&#148;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to
the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such service to commence upon the effective time of the redomicile transaction described in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sincerely,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Troy M. Cox</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy M. Cox</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Director Consent to Reference </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>13
<FILENAME>d722206dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent to Reference in Proxy Statement/Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the
&#147;Registration Statement&#148;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to
the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such service to commence upon the effective time of the redomicile transaction described in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth Hillan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kenneth Hillan</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Director Consent to Reference </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>14
<FILENAME>d722206dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent to Reference in Proxy Statement/Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the
&#147;Registration Statement&#148;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to
the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such service to commence upon the effective time of the redomicile transaction described in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Susan Mahony</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Susan Mahony</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Director Consent to Reference </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>15
<FILENAME>d722206dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent to Reference in Proxy Statement/Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the
&#147;Registration Statement&#148;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to
the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such service to commence upon the effective time of the redomicile transaction described in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kelvin Neu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kelvin Neu</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Director Consent to Reference </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>16
<FILENAME>d722206dex995.htm
<DESCRIPTION>EX-99.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent to Reference in Proxy Statement/Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the
&#147;Registration Statement&#148;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to
the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such service to commence upon the effective time of the redomicile transaction described in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hollings C. Renton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hollings C. Renton</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Director Consent to Reference </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>17
<FILENAME>d722206dex996.htm
<DESCRIPTION>EX-99.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent to Reference in Proxy Statement/Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the
&#147;Registration Statement&#148;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to
the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such service to commence upon the effective time of the redomicile transaction described in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Natalie Sacks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Natalie Sacks</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Director Consent to Reference </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>18
<FILENAME>d722206dex997.htm
<DESCRIPTION>EX-99.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;15, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">108 Patriot Drive, Suite A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middletown, Delaware 19709 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent to Reference in Proxy Statement/Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks Delaware Inc. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the
&#147;Registration Statement&#148;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to
the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such service to commence upon the effective time of the redomicile transaction described in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lota Zoth</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lota Zoth</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Director Consent to Reference </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>19
<FILENAME>d722206dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZYMEWORKS DELAWARE
INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Table 1 &#150; Newly Registered Securities </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Security Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Class&nbsp;Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calculation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>Rule</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount<BR>Registered<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Maximum<BR>Aggregate<BR>Offering Price<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Amount of<BR>Registration<BR>Fee</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common<BR>Stock,<BR>$0.00001<BR>par value<BR>per<BR>share<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">457(c),(f)(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">70,897,339</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$5.78</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$409,786,619.42</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$92.70 per<BR>$1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">$37,987.22</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Warrants<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">457(i)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">8,581,961</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common<BR>Stock,<BR>$0.00001<BR>par value<BR>per<BR>share<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">457(c),(f)(1),<BR>(i)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">8,581,961</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$5.79</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$49,689,555.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$92.70 per<BR>$1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">$4,606.23</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$459,476,174.42</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">$42,593.45</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">&#150;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$42,593.45</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All securities being registered will be issued by&nbsp;Zymeworks Delaware Inc., a Delaware corporation
(&#147;<B>Parent</B>&#148;). The reorganization transactions described in this registration statement and the enclosed proxy statement/prospectus (the &#147;<B>Reorganization</B>&#148;), will include, among others, (i)&nbsp;the issuance to Zymeworks
Shareholders (as defined in the registration statement), at their election and subject to applicable eligibility criteria, for each Zymeworks Common Share (as defined in the registration statement), either (a)&nbsp;one share of Parent common stock,
par value $0.00001 per share (the &#147;<B>Delaware Common Stock</B>&#148;) or (b)&nbsp;one exchangeable share (the &#147;<B>Exchangeable Shares</B>&#148; and recipients thereof, the &#147;<B>Exchangeable Shareholders</B>&#148;) in the capital of
Zymeworks ExchangeCo Ltd., a company existing under the laws of the Province of British Columbia and a direct, wholly-owned subsidiary of Callco (&#147;<B>ExchangeCo</B>&#148;), subject to a cap on the aggregate number of Exchangeable Shares that is
equal to 18% of (1)&nbsp;the number of Zymeworks Common Shares issued and outstanding, less (2)&nbsp;the number of Zymeworks Common Shares held by any Zymeworks Shareholders who exercise their Dissent Rights, (the &#147;<B>Exchangeable Share
Cap</B>&#148;); (ii) the entry by Parent, Zymeworks CallCo ULC, an unlimited liability company existing under the laws of the Province of British Columbia and a direct, wholly-owned subsidiary of Parent (&#147;<B>Callco</B>&#148;) and ExchangeCo
into the Exchangeable Share Support Agreement (the &#147;<B>Support Agreement</B>&#148;); and (iii)&nbsp;the entry by Parent, ExchangeCo, Callco and Computershare Trust Company of Canada, a trust company existing under the laws of Canada (the
&#147;<B>Share Trustee</B>&#148;) into the Voting and Exchange Trust Agreement (the &#147;<B>Trust Agreement</B>&#148;) for the benefit of the Exchangeable Shareholders. After the Reorganization is complete, Zymeworks Shareholders will hold one
share of </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Delaware Common Stock for each Zymeworks Common Share owned immediately prior to the
Reorganization, or, in the case of the Exchangeable Shareholders to the extent of their election, one Exchangeable Share for each Zymeworks Common Share owned immediately prior to the Reorganization, up to an aggregate number of Exchangeable Shares
that is equal to or less than the Exchangeable Share Cap. If the Exchangeable Share Cap is reached, then the Exchangeable Shares shall be allocated proportionally among the applicable Exchangeable Shareholders and rounded down to the nearest whole
share in respect of each Exchangeable Shareholder, and any other Zymeworks Common Shares held by them will be exchanged for Delaware Common Stock. The Share Trustee will hold one share of Parent preferred stock, par value $0.00001 per share, (the
&#147;<B>Special Voting Stock</B>&#148;), which will be held by the Share Trustee under the terms of the Trust Agreement, and which shall have certain variable voting rights as further described in the proxy statement/prospectus contained in this
Registration Statement. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a), there are also being registered an indeterminable number of additional securities as
may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with Rule 457(f)(1), Rule 457(c) and Rule 457(i) under the Securities Act of 1933, as amended
(the &#147;<B>Securities Act</B>&#148;), as applicable, solely for purposes of calculating the registration fee, based on (i)&nbsp;in respect of the shares of Delaware Common Stock issuable upon exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants of Zymeworks (the &#147;<B>Zymeworks Warrants</B>&#148;), the sum of (a) $5.79, the average of the high and low prices of each Zymeworks Common Share on the New York Stock Exchange (the
&#147;NYSE&#148;) on July&nbsp;12, 2022 and (b)&nbsp;the $0.0001 exercise price of the Zymeworks Warrants and (ii)&nbsp;with respect to the remaining shares of Delaware Common Stock, $5.78, the average of the high and low price of each Zymeworks
Common Share as reported on the NYSE on July&nbsp;12, 2022. Pursuant to Rule 457(i), no separate fee is required for the registration of the&nbsp;Zymeworks Warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents a maximum aggregate amount of up to 70,897,339 shares of Delaware Common Stock issuable pursuant to
the Transaction Agreement (as defined in the registration statement), consisting of (i)&nbsp;up to 57,891,885 shares of Delaware Common Stock to be issued (a)&nbsp;in exchange for Zymeworks Common Shares and (b)&nbsp;upon exchange of the
Exchangeable Shares; (ii)&nbsp;up to 8,188,908 shares of Delaware Common Stock issuable upon exercise of outstanding options and settlement of outstanding restricted stock units under the Zymeworks Incentive Plans (as defined in the Registration
Statement), and (iii)&nbsp;up to 4,816,546 shares of Delaware Common Stock reserved for issuance under the Zymeworks Incentive Plans. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents&nbsp;the Zymeworks Warrants that will be assumed by Parent in connection with the Reorganization and
thereafter will be exercisable for shares of Delaware Common Stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents a maximum aggregate amount of up to 8,581,961 shares of Delaware Common Stock issuable upon exercise
of outstanding Zymeworks Warrants. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g722206g0714111013875.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g0714111013875.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  S 'X# 2(  A$! Q$!_\0
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'RFE[)(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g722206g0714111014188.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g0714111014188.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 $ # 2(  A$! Q$!_\0
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&M=_XC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g722206g0714173424359.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g0714173424359.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ ,\# 2(  A$! Q$!_\0
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MM9^BZ)IWAW2H=,TJU2VM(1\J)W/<D]23ZFI]0O[32M/GO[Z=+>U@0O+*YP%
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7C6-%"HH 4#L!3J* "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g722206g0714173424812.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g0714173424812.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  7 B # 2(  A$! Q$!_\0
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M49N8%:-3,@,GW!N'S?2@"6BFEU#JA8!F!('KBHWN[>/SM\R+Y(#2Y;[@/<T
M<_J-]>+/J%LC7"@7$1W1QG*P%4WE3CKDM[]<5FM=Z_$KS0-=36JKY:*R?.RM
M*0LG3.0 ,_[)SUKM6FB1XT9U#2'" G[QQGC\!3Z .(6ZU;#A9K\Q%R+QF3F(
M>;@>7QG[N<XSQ@CFD-WK\0::%KJ6U"^4BLGSE6F8+)TSD #/^R<]:[BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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'Q^!10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g722206g13n03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g13n03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19F4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     8 00!0 $0
M+0 R       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F
M       .             #^    X0DE-! T       0   !:.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      -!
M    !@             !!0   M     & &< ,0 S &X ,  S     0
M                   !              +0   !!0
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   !!0    !29VAT;&]N9P
M M     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   04     4F=H=&QO;F<   +0     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1"  Z * # 2(  A$! Q$!_]T !  *_\0!/P
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M)V NV_VEYO\ \^OK*+SD>M663N^S&ML
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M.LD3=?M4H@C2.IHMSY.LBPTY4AJQM)X('2*4QQ%RR1-+(G=UC!Z)_*>@ ]
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M;%:&>K'R!YIZ%NO?CK@MZ#6#6\"$E5#R*695!(L;-4Y+^+N58O\ NR1AHAR
M&DB=944D^@'9 I)]#GD^M<KEG5V5'8SZ>Y@3*JUK91X=A6V,<T.="F1GJ(\:
M7%D,&:,<)6JP@RL81KT5'(BISYRSP359I:UF&6"Q7D>&>"=&BFAFC8I)%+&X
M5XY(W4JZ,H9&!4@$$:I!T>%GCD1DD1B&1P592/1#*>"I!X/L D^AQJX_TJ]3
M9-7R<YW':0Y%?CEU2CPW&7R6E%^=>VUC65Q8Q!O1&E@5YJV)7LFM5PRS"SXP
MG>2%*:WJ7].&V;\5C,;KL120T+%(XC'LX91=9K4-BY-$" 'BK/4B@\PY4S/-
M$C=HIE%A;(HSH;60D5EAE000EN?[WAP[NH/Y5.BJ'_=BZ_E#K[_K@;#S77O0
M3-DPJ785SLWS3"L"RBSK'G#)AX?=29TVW"Z4#V?&B71:F%C<]7.8.7!NI%<]
M7-F^-_T1^"L;1R/R%1^N2.44:5[(58I0K*]R!8TA(1N0[P"9[4? Y1X%E'\G
M(TGS=D;N/V#=^B:2,WKM*A:EB+*R4YW=Y@67VJ3&)*TG) =)FC/\_!X5N=[:
MX8)(_'/]/? '^_[#_;]N1Z]>CUG?TXN>Y=9ZT[):WGA.7"L1S#!<JQV<1'J.
M->YI57]=DE6$CF*U1K%P^@GI'&5&QS29!U$CIZD=Q_\ J3Q.-K9;;V7KI#%D
M<G5O09 1QHDEB.@U3Z2S.5X:20+9EKB20,QBABB#=(55>LOTZ9"Y+C-QXV3L
MU&G<HVJKG^5)[T5A+,2G^A6G!+U!X5G9N.9.3TI<YGUTCIQIIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIKE$[145_CW8;<D#)1G;9F
MV'E%LA#M<BRJV[MI-M3S0_-7HL>553(A@(CGHP3FB1W_ "U1/FK\@5+M+>^Z
MH,@KK9.>R=@E^09(;5J6U5F7DD^*:M-#+$ QX215_ (U1V<BEBRV068'N;<T
MOOD%HY79XF'KCJ4=>/;$?CGT=8]HC'LBRG<VL:3%!R'W\C-\<-")%1_SAMK[
M./83+%[F(JCCUD2*>?*+_L$".0CD^+5]\+:-&[DMT[>I8Y7:[-EJ!@*%N8S%
M8CF><E0S*E>.)YY) #XXXGD/I3KQQ44T^2HQ5^WE-F%E*\\J$=7=S_0(JEB?
MY0%)(X).NMSGTWU>^G&FG&FL"R'6>L<CL&W^58#@UY:1&H5+J^QBBL9T=@&J
MY"+83X1CC8%J*J.4J-&U%5%:GOS19#;6V<A8&0RF!PEVU"H87;V,HV)XUC^X
M$V)X7=53CMR7X7CGUQK&EJ5)F\D]:M*Z\'R2PQ.PZ^Q]SJ2 /?[^O>J0R]\Y
M^B<KV5A>A:?'<FU=)V#<Y!B;\NB6:1Z:/9L$ZZJ\:B4]Q6J+&I%\.;8T22"M
M<&%*3Y00%,1K>/T^8K.RLCN'%;)KX^_MN?.V[^*.5AM%*D5A5^J@H1U;E8I0
M>VKS4U=^1 03#')+)UKAMT/C;%NMBXXIZ1M22P?4*X6(/P98X5B= (6F#O%S
MQU#<%020-L!W?*]2C$Y?53(\6QK!*G+*\MEM:Y)8-N36&*T-A53(\;7%5/A>
M6!E1;=8LMDZ=*E_IZ/7K9QCS3*H06]\;_.F]-R[FV_6VN<=M'.XRR<MDLNT@
MO)9QU-HA/C\9C;41\DF1CFDKW(YIY1%1\\B2]C_=^\]F+?=&?;=RM%!7MQ%L
M@_?NS0121LOT2NA\=D3=661BP@Z"12[?:*Y\B_IP<W7-#CQ/LQBC==FF?.-,
MR#![A<R@0"&>OUC5E=:?A+67%C^-B3&W%0*<5'$6%7L5!\^FU;]2]#Z%3<VO
M<.25.&2O?A^BDD"C[Q+)%YX4=N3T,$QC' \DA]ZIRQ^G*]]:PJ;EJ?P\O]CS
MTIOK8XBW/0Q1R^&5E' #B:$.>2$B' UT%]-NH&LNE&F:_4&M5F6+26!LAR_+
M;9K&W.9Y9,BPX<V\G"$YX((4BP(<*MJ8CEBUL&*(2/D2GRYLOG;>N\LIOC-R
M9G*=(^(UK4J<))@I4T=WC@C) :1N\CR2S. \LCL>%0)&G0.SMH8S96&CQ&,[
MR<R&Q<MS<>>[;=$1YY "5C7I&B10H>D4:@<LY>1Y7<B.I7IQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK0FY>LVF=].@2-CXD.QM
MJP2QX%_73)=->!BJY7_3)85Y0OFPFD<\@8E@V7'C%(4L882&,Y\(W9\=[3WJ
MT$N=QOEMUEZ0WJTTM2X(B>?#)-"R^>$,2R1V%E6)F=HA&9)"VLR&'QV4ZFY7
M#N@(256:.50??7NA4LH/L*W90>2 .3SZNF.K>E-"GEV&O,32)=S@?5DY#;39
M5U=K$54<^+'F3B$;7QC.1'20UPHC)3F#62A?$)&?G:?QQM+9<DMC"8WI=F0Q
MO?MRO;N>(\$PQRRGB")BH,B0)$)2%\G?JG7\X["XW%EFIUPDC#JTKLTDI7_*
M&<GH#^6"!0WKL#P.)"\G.MKIQIIQIK%,\I9V28/F>.UDCZEE?XID5+7ROE\/
MK3K2HF08DCY(J*WPR#C)\D5/;X^_NGM[\U6=ISY#"9FA5<1V;V*R%.NY)4)/
M9J30PN6!!4+(ZDD$$<<\C\Z\;,;35[$2-U>6&6-6_P K.C*K?\$@ZY#+ZCM\
M8NK7'K^ODU=U23Y59:UTP;@R84Z$9\>1',)Z?P(,K'-]T]T<B(YO\7>_/F%:
MJV:5FQ3MPR5K56:6O9KS*4E@GA<I+%(OY#1NI5EY_P!CQQS0DT4L$LD,RE98
MG=)$?D%60E>""/7O\?U''['W.STU\*R+(NR=+E-;'D-H<#I<BL<BLD&](K$N
M:2QH*VL>9&J'[<Z98I(#&<]"$BU\Z0-JMC/5+C^!,1?O?(%+(UT?Z/#5KUC(
M3A2(T6U1LT:T+/P5,MB:?E8R0SQ0SNGJ%M2;9U:6;,1SH#XJL4SS/QP.98VB
M1/7KLS-VX/Y5&('KD]&7.[]6WIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK0VSNL6A]Q60[K8>N
M*6\NAM:QUR UE1VTD;&-&,4^QH)U7+L1B&U&!9/-):!B?$*#3WY"=P?'.RMT
M6?K<W@*EJZ>.]R)[%&U,%4(OU$]&:M)9Z(H1/J&EZ* J=1K67<-C,BP>W4CE
MD'KR O%(1QQPSQ,C. /0#E@!^ -;%P/76#:PH0XQK_%ZC%*,+_+]&IC-"DB1
MXQB=+G27*278SGC$-A9T^1)F%:-B%._XI[;_  N!PVW*2X_!XVKC*:GL8JT?
M4R2=0IEGD8M+8F*JJM-/))*P4!G/ UEUJE:G$(:L,<$0_P ,:\<G\=F;VSL?
MW=RS']R=9IS;ZR-.--.--.--.--.--.--:IRG>.IL)V1@.H<JSFFI-E;2'9E
MU_B$Q97Y3*!TP22+-]=XHQ(R)$"$KR?9D ^2,<@_FY/;FWJ8'+WL9D<S4H33
MXO$F)<C<3IXJIG8+$).6#?>S #JK<<CG@:U-K.8FCDJ&(MWH8,EE!*<?3?OY
M;0A!:4Q\*5^P D]F7\>N=;6YJ-;;3C33C33C33C357W83U%I^C=OY?JT.I8>
M2BQ=],QMV7-35+YOY;'JJ\570&8O8MC^!UDL5/:8;R(%"^[%(HV<[;U^=YMH
M[IRVW%VQ%?7&254%MLN]8S?4T*ETDPC&SA.ALF/@2OR$#'CMU$,RV[&QE^>D
M*"S"'Q?WILF/MY(ED]H('X +=>>Q_K_IK2__ !;[3W1/]"('_O8LA/W7W]O_
M *5^_P#9?[?^O?D6_P#*;L?^QL/_ ,^?_P#D:UQWX_\ ZK7_ )N$>_?KW6_T
M_.M]Z<[\97N;%MPW6/Z8A,N-68?%R^-0LS>5*?DD9)A&V<,,AN)#+$E1JR-+
MF0F#B373Y0PP4:!3H=DPVS\UY/=&/W1;H[1C^IVYBDRJU%S$DAO1+.%M1HZX
ML-')%6$L\2K'*T[QB *ID#C:8[=$^1@R$D6.7R4JXG6(6F8S#D]E!^G!5@BL
M5X5NS +ZYYU[_6#U!(?8+9H]:W6 1<%EV--93Z&</*WWB6EE5M%*-4?6+05"
MB*^J;8V RM,7^-:43A(I&N;D?'OS?%O7<4>W[>$CPTEFK8EI3+DFN_46JRK,
MU7QM1J]"U5;$ZR=S_P!CIT)<$?K"[J7+7/HY*HJLT;O&PG\O=TX8Q\&*/@E.
M[@\GTA! )U)#M%V'K.M6M4SB53MR2UL+RNQ_'\=6Q_%I9S97FES"&G-B6!8L
M6!4PYTIYV09+72FPX;T%]QIF3SY&WW6^/\"F6DJ_Q"U9N0TJ-#SBMYY'#RS.
M\WCF:.&"M%*[2+#(#,8(2%\P<;?-99,/3^I,?F=I4ABA[].[MRS<OU<JJQJ[
M$]6]A5/';D:"TKW:RO;FN=S;/+J"'08UJ;%+*W$=,T/8+D600*R1<?I\2KB\
M-(8V5\=IIT]/M.BK-@(V&9#N4<&VO\PY/<>W]W;C.U8J>/VMBK%P/_&'F-Z_
M# UE:"\XV(Q*($+SS\2&+R0 1/Y"4UN,W%-D*E^X:"PPTH7<$V"WFE5&D\0_
MN%"@(H+-]Q'=/M]ZT3CWJPU4N)D<G)=1OJ30*;[&.0ZS,'V9;Z])80XP:R20
M^-0!U,!D$LZQEVB_<<)D)L8,*0>6)J1"G^I>O(ETWMKFO)%3:2C%7RK6#;NF
M>NB5I7;'0K5@$,D]B2R?*P$ B2&2250-5#OJ-EF,U QLD?:)$L&0RR%U 0\P
MIT4*6=G^\@* %8L!K"Q^K7DOW$>72M%^/\J?*.S,[!)OB7_I;+?C_A\B?LOD
M6"C7>RIXVI_)-2/U,97SACM3'FMVY,0R5@3]./Y?J#6,??G_ !?3=>.1T'YU
MX#?<G/O&)QSP0+3<^_P!S /?X]E0/S^PUO;._4_UI2Z_P_),*Q6;E679,Z6V
MUPZPMP4RX;^.<P,O\S8@AV;I3Y4@@W4C8<)HK*#YYDB17%!](DRRWZB<#6PF
M+O8G%SW\K?\ *+6+L65JKBC!U60V+*0SFP)I&!I&&%%L0"265ZLJ?3G96MZ4
MHJE>>O T\\Y;O7:01_3]#P_D<+)R22/&%7AUY8LO'4Z2J/5JNFRQ)?:6JRP7
M$8AW5.92H\P0ODGE>(<RBDAD$1GNHQO)&8Y41'&8B_)(A5_4QD%D'UVU*<L1
M9 ?I<G/!(JE@&(\M6RKMUYZJ?&.>.6 YXUR;[?L/+C5"<\'I:/8>QSQVAX)X
M/H$J/_>X_%I6+[VUWE6G&;TA6CXN",H+#()\B:P8YU6*I0[;2NG11&,UMI#D
MQC0UBB,7[$GQ)%(9APO)T;C=Z8+)[4&\HK!BPZTY[EAIN@GJ_3=Q8K3QI(ZB
MU'(AB$2NWD<IXBZR(6FL.3J3X\9-7*U?$TS,P^Y G(=64$_>K*5*@GEAPI/(
MYK0L_57NK6XE5^O=$2+:,PY%@$LLCER+:7"8OQ0TBFI:*2R&9WR8\C V<\0$
M51^8WNTO.?K?ZDKD]AX<'M 3)Y#X7MWI9;$D '':2K4J\12$\$A;,Z)_)V<G
MN(<^^'>1DJXMY5#$*6G/=@#^6CCA?J>/9 =POXY/(.O _P!4W.J$@FYAUW6O
M88C/'\\GN*0KQ(ON;PCM,3D(8B-5%:J/8UJHOS147W;Y+^H_,4V5<KLJ)"Y!
M0+D+=%N@_GX%BA8[M['L,H7]P>1K^'>UF)E$^'9 Q'',\B'CCD\=ZP!/_(XX
M/.I5Y-Z@&J\9ZM7':]<1V#DN&8C:UU+GN-8C H[++L.ES9D"O-*G0[.]I(4R
MIA2;:I*6?"FD)^.L@6+X@0Q[%L'J;X>O5?F<4H]OVJN,N6WLUGK9B62,09"I
M MF6B9:L%D.\M<^:K+T1)XRJGQ3L8%V&4WKCL5MN?<\M2_:I5)(H[L-*."2U
M6,DD<1=TFGKHT4;RQ%W20D)()"H57*3&P?,\=V+AN*9]B-B*VQ;-<=ILIQVS
M"J*.=37U?'LZZ2B(J_!Q(LD3GB<OS$3Y">B/8Y$V]^E9QMVWCKD9AMT;,]2S
M$WYCGKR-%*O[<@.IX/X(X(]'4GHW*^1IU+]202U;M>&U7E'XDAGC66-O].48
M$C\@\@^QJ .]O5+ZX=?.R=)UBS2NV!.RZQG8%67.58]58_-P;"[#8LEHZ&)E
MMG*R>#:5IA0#0[N>T-+*<*GF@E1TDJA1CL+ ?%&YMQ[8GW31EQT=.*/(2P5+
M$UE+]Z/&KS8>G$E22*53('@C)G7M,A1NG()@.=^4=N;?W)!MB['D'MRR4(IK
M5>&N]&G)D6 @2W*]J.6,A&2:0+ Y$3JRACR!9-RLM61J)NCNXNL]_P"==@<0
MPBJRJ/2]<<I-AF:[+O 4,'75MD,)9_Y>'BUV"_F2K =&RMDGMY<VNK8T.*^'
M)<50SHSB2_/;,RFW:&W;EZ:HT^Y:BWJ.+KM8DR4-:3Q^%[<#5T2,V#*JPI'+
M*SN'4#F-@(G@]X8S/WMP4Z,5I8=N6C3NY.=:Z8Z6PGD\R59UL.\@@$3M,SQQ
MK&I1B>)$)C!(]634V17%["T+U^[:]H<?QRT/2V>P=%:9-D> .M(R-^Q$K[^U
MNJ0D]XE<U?(."P$@+Q2X99,(X)))4OQ#EZT,#[@W%L_:MBS"L\6.SV;6MD1$
M_P#*\E>&"<1@_C@R%E8,CJKJRB+M\L8FQ-8CP.W]V;G@K3&"7(8/#-8H>51R
MR1SRS0F0CU[$85@5="R,K'TY_JI,H(<BXRWH1ZAF+8W7A)*N,BL] 0UKJ>"$
M;B'GSWBS%5##CL:KY!W?$81HXA'(UJKS]Q_$QL.L-3Y!^.+5F1@D%:/<3^2>
M1CPL<8-+[G<^D Y[-P![.OP_RH($::WL+Y"JUHU+S6), ACA102TDA%S[44#
MEF)X4>SZU/C0N_\ 4_9C6]3M?3&61<OPRV-(A),$"3"FUMM":);"DNZN<*//
MJ;BO\X%E09@!D01X\H*FB28T@U?;@V[E]KY.;$9NHU.["JOT+))'+"_/CG@E
MC+1S0R=6ZR(Q'*LC=71E$^P.?Q.Y<;%E<-;6Y2E+)W"LCQ2IQY()XI LD,T?
M9>T;J#PRNO9&5FK_ *'U@-%9U7''JC3/9O<6<0LAR&EM]8ZPUC"R[,<>K<>F
MAKG9;DJUN3%H*/'+B<^1%HGS;IMK.)!EO)5Q@($QK#L?#6?H2*<OF]K86A)6
MKSPY3*Y5Z=*S+81I/HZOEJK8GLPQA7G"0&%!(@69V[*L K_+^"OQ-_"<-N;,
M7DL6(9<9C,6ENY7BKN(S<L^*RU>"M,Y98"\WED,;DQ*O#']/ZN>K,/O<:K]\
M=;>WW6O&\IN8U!7[%W5IX..X'&M);G>(-C<0LCLY F-&PL@[XL&:\$41I91,
MB!,<8?#N6N5[4FW]S;-W/:J0-8DQF#S)LY!XDXY:*%ZT2DDD*H>2,,[*BDNR
MJ1^6\74GK1YW;>[]M5K4RUXLCFL.*]$2MSP))DL2,  "S%4<JH+LH168:D[G
MD87U;/3!*)["")3;:(,@W(]A&/H[AS'L>U5:YCFJCFN:JHY%14547FWV2"/A
M_P"4P001/AP01P018A!!!]@@^B#^-:G>A!^6OC$@@@PY8@CV#S#,001Z]CG@
M\^Q_7]K5=\=B-,]9L$F['W;GE+@N,1?F*,2Q,XMK>3VC4C*C&J.(T]OD5P5J
M*]E=4PY1V!0DJ0T,,)Y JFV_MO-[HR$>,P6/GOVWX+")0(H(R>#-:L.5AK0@
M^C+,Z*6(12SLJFU,]N'#;9H/D<W?AHU4Y"F0\RSR <B&M @::Q,1[$<*.P7E
MV"HK,,3ZS=DA=G</?L"ET]N+66&RE"3&+;;M'CF,2<S@G8TPK?'J.NRF]O/P
MQ0/$>-:6L"LASQF8ZM+-:TSA9>Z-LG:UT8Z?-87*74["W#AK%FVM&125,-F>
M2I7@\X8$-%#)*\9!$H0E><3;.Y!N>F<A!A\QC*;\&K-EX*U5KL;#D35X([5B
M?PE2&666.)) P,9<!B(Z;.]3/56&[=S+1VM=.]C>RVPM;D!&V/"T!K-N7U6"
MSY#WC;67]O8W5'''/85C@F2*V3#')')A+-6=!GQ8LEQ7Q=EKN'I9[)YG;6V,
M;DPS8Q]PY0TYK\:@,9:\,4%AC&001W*.5*N(_')&S1W)_)F*IY>Y@\9A]Q;E
MR&.*KD4V_C?K(J,C-U$5B:2:!5D!]'J&3L&3OW1U7'C^I1E$<3S$].SU#/@-
MJN=X]*8Z<GLG_P"1!STA2+_XL8YR_P"$YDK\8U&(4?)'QSR3P.<Y94>_ZEL>
M !_4D@#]SK&;Y)M*"Q^._D'@?TPM<G_@"\2?^!SZ.I,]4.X.INX>)9-DVLP9
M;166#9-(PW/<%V#0IC6<87DD9BD=77U.R98@"I48=@2QYTAGGB389_!.@RXH
M(MN[9F7V9<JU<HU.Q%?JK=Q]_'6/JJ%ZJQX$M>8I&S<<J6#1J>KHZ]HY$=I-
MM3>&)WA4M6<8MN"2C::G?HY" 5KU*RH[>.>$/(J\CL%*R,.R.C=71U7$^U7:
M;477V$6/84U)F^T+*.U]9B PP"2@C</XAL\GL'@D$JJQC&M0 GM+8V"? <*-
M]9#S8G.7R7\B[5V7'+%)0H9K<T\:F'&F*!VB5EX2QD[!BD:"!4 ,</#V;'V)
M&B0L]B')S><HXE2KHEFXXY2LO7MQQZ>9N#XX^...07?\(I'++2YB&O\ >_>/
M:4ZU& +FN,,=UD;H*U6#X15(JD#70016>$3FL>YT*GA^>TL3D?,FO)\Y]FSE
M#$X+>'RUN.>Q%$CL[CZR_P"$5,/B*_)9($2).D:JK<05(1+:G8M-+W8V+.J[
M@JY7<UYI/7H]9)R"E:JGY"(J_OQ[5%Y=R27]=G%]77;K%KKKEBQ:?&8JVF06
M\:.S+<OL1)^1R(XF+[B2.XAPUM.(CRK#J([WB"UZODFFRW%E%[1V)\=8/8F.
M:M23ZO(6XD3*92= );S*/<:Q%I%KTPQ8QU49P >99)I.9#9^)P]3$0^.!>\K
M@>>PP^^9A_IR0D8/\D:GA1^2S$L:,NQ6#7/4;M6R[Q4*0JJ)D,#9>O\ QHY(
MRTDNR*<E$Y5]T\$"8"QQXX'*]Y:X8BE]VR_WXYWQA[?QC\C--C5^G@KWH,_@
M2I"QFC).TJ5N%Y/BKR1V,<Z..9(8.S#I*"U:Y>L^ SJS0#B,2K=JCC[?&SGO
M"??)"L&B(]DIP21V/&5=\>P,'L)L;!:3 9,JTQ:CQFE?610HXBS,MS6/#M)X
MA@&Y5)-AQC4U 4+QMD1K2%9Q%:B_)';/YDWS#OG.XBOAFEGQM''5#7A7[O-D
M\K'%8LJB(26EA5ZE"167O'9KSQA03[]=T95,K<K0U2TD,<,?C _Q3V5#L  ?
M;*IBB((Y5UD4CD<:M%%IV-HSHCGN!H".RZ#IW-[;+9 /W2;E5MC4V5;D<56H
MXS(A%'5PR.:URP*^(WXM^/LG0DFU4V=\(Y_#E%6Y_9/,7,HZ^_)DK6/EDL\M
MP.RP?95B;@<PUX^1SSS.$QZXW;=BKZ\BT+#SL!_/8>%FD//[@'B-2?\  JC]
MM57>G%A&*9UV)6+E]%69%!I,%R._A5US#!85Z6@9U'5@D'@RF%BREC1[:4\#
M9(BL#(\,D;&G" @^>/@K#8S,[[2'*4JU^O4Q-^]%7MQ+/7-F.2K7C>2"0&&0
MQK9=XQ(CJLH65566-'6"[/K06<LPGB258ZLTJI(BLHD$D,8+*05/42-P"/3<
M-P"!JQ_U$=::\@=:,DR&NPC%*N]I;[$B5EQ5T-76647[E[#K)0F3844$A8TB
M%+,(T5Y'1R+XB.&I0 >.]OG7;N!K;#LWJN&QE6[5R.-\%JK1K5K"+)-X)(_+
M#'&[1/'(0T3,8RRQN5[1HRS#=E.HN&L3+6@26-ZY21(T1UYF1" ZJ#P58CJ>
M0>1ZY (B;Z6&O\+RZ\W!<Y5B]%D<['8.$1:1UY5P[9E:VY/E!; L0,\)Q!D'
M6IA,^R-B&:,3QC(UA2(^N/TYX/#Y:]NFUD\;2R$N/KXB.H;M:*RL'UKY/ZAH
MTG1T61Q3B3N%[J@9 P5V!T.R*M:>3(2S012O$M9(_(BR>,.9B_4.#PQ*(.WY
M^W@$#D'/O5)US@N-X=K#)<<Q+'<>N9&56M/,FT=-7U)9\$M5]UH9RP 1TEH"
M1&0D=QT(\"FD>)S$,5'[C]16WL)CL;MV_CL70Q]J6]<JS24:D%0SPM LRK.*
MZ1B4QR(6C9P63R2=2.[<Y>]JE:*M2FB@BBE:PT;-'&B%E,98!NH7MPRCJ2>5
MY/!]G6LM8&L7^EWO%D1Q5>#83!JUGR565[[W6)K%B(U45!K'+*<]/]J->]7)
M\5=R/;?:<_IWWD(BQ*[AB!Z_D0&[MIIO_A\9<M^W')_WPJ1D.RLEU)Y%GUQS
MZ3RTV8#^@X+$C\>SQZX&HV=0*SLS89+F+NLUK6560@I("Y(:>/#G%?3EGO2,
M.,[+JVQ&UOW&(IT@M"YZH!9"O:T:-@/QE#\@2Y'(GX]DBBR"4X_KW<8;O]&T
MP"A#EXY%"F;KY/I^&)"=R0$UI]OQYIYK/\'ECBE$2>8OX/<98]57S1RC\_Y0
MOO@GGC4E]W:G[_YSA?X[>F7Z_=A,.U@S_L9+D&GL4@1;5B%BP2-O(]=2&CF,
MV24+ )/&V3Y7"<(BN^*3O>&WOFS,8I8=YVL5_"H;45A9<CD=G8R"&WU>*$BY
M&U1T9A(\8C$X63L05;UK=9.ANFS6Z9*U2^F5T<M-)1@17!*J?*L414L3P!W'
M//7]^!(CH_U]B'T9OG5&RI^"9CBVRC%H+B%AV:XYFT):BYQB13V(Y<K'IL\-
M9/>(J%B>8HY37A%+ C'!8_EN_IOIY;9\65O+>Q;VZ^9QE^G)B<SC,ND,U6-W
M!F?%VK4<)=E0>*9U,J!AT*<D[+ X6*QALMBL@]2W5R DK3I6L164,4]?PR!F
MC+!'(/*\_<" XX]<:E],'<4G1F%]E^F&\\@063=%<@RFTK[:>)L5UKU[E"D9
M-29*!K_9YH=<Q\JP^93/^E1Y)BL%JH,;/;N7Y3PJYZ]M?>V!K<U=_5ZD4D,;
M%Q#N-2M6Q58@D*TA"1\ #O/6MN1V)U#_ (QS#8.EN79F<L$6MBV+<L<T@"^7
M;S!K,%E>?;)&"\GL_97LU(QZ'J)&ENJ-IW9Z,][.R65T)G;<[?; R7:.HW26
M.+95-!IJQFR]6T=03XE?$6;9AR/#WEB(QTVC? $0CQC$K)CG-W1;&W[L';%2
MPHPVS<=5Q68"$".:QFXXTRUB8>@_2(U;H5^>D_D*@%CS$L-M27>NQM];DM0-
M_%]W9"UE,06!,D4&'=VQ<$)/)3O*MFF2A'> Q@D@#4K0>I VL])''NR@;3\G
MNFPQ&)HVLKPN9^:F=@F-)AJR$@^%WFL CBEV:2M#'<LBH8@PC1#C:D1;XS,O
MS!9VPT/BP<=Q\]+(P/@3;A(N]3)SZB8L,4)2PZS'DG[2=2H?(_B^)8-RK+Y,
MT]1,'%&./,VX>#3[",*>9%"G)F-5/:(< >QK[-?USG]/?1UW/@S6FA[-MNOV
MRL^VK9B.:183-CYQB1"92DB9Y/(<E-7+%Q9DICF--$I!2E3R%*Y_C)N6/>?S
M1A+YZOBX=Q8O'XF)E58TQE"Z!4ZIQPHGD[VRAYZO.4_  'M'MV3:'P]FJ/!C
MR<VW\E?RLH8L[Y&]4/U79^>6\,?6J&''9( WHL3J6_IG4]12]".JD>EA184>
M7I[%KB6R*$86GM[J,MI=33>-K?)*F6DN6>09_P B$*]RN<Y?WY#OE"::?Y!W
M:T[L[)FK<*%R6*PP/X8$7DGA4A1%4#T /0&I;\:0PP;"VJL*)&KX>K,X10H:
M:=3+.[=0.7>5W9V/)+$DDG4YE1'(K7(CFN14<U4145%3V5%1?V5%3]E1?V5.
M0/\ 'XU.=4N^DI$BT6SO4OQ&DCCK\3QWNMG \>J(:N95U@RV.01"QZZ*UWUH
MPV1*RL!\ ,8B CQA*GC"%K+O^8':?%_%]R=S+<L['H&S,_!FE(BK.&E?CLQ+
MRRGEB?N9V_+,33'Q,BP9/Y*J0JL=6OO6\*\*<B*(-).I6-/Y4 2.)>%'\JJ/
MP% ^#Z$-77 Z[]A;@,&**UL.W.S8,ZP''$V9+A5F,8"6NB'E-:A31X);*P)%
M"]RC ^;*<)K7'(KO?Y^EE;<FW(6D<Q1[.Q<B1%B4226WD1*ZH20KR+%$'(]L
M(T!)"CC'^"8HUV[N"8(@EDW;DHY) !W=(JM QHS <E4,DA522%+N1_,2;%>[
M'6*-W#ZVY_U_/DP<*-F1L5E0,N-1?J3\!,QK+J/)?LCITM*5THDR+52JGW;:
M1%".Q(97%:-0%K;8VZ6V9N?';B6JUY:0MI)36Q]-]0EJG8J]#/XIP@1IEF]Q
M/R8PO Y["Q=Z[97>&W+^ :RM(W#5>.VT'U/T[UK<%GL(?+!V+K$T7/E7J)"W
MOCJ:=/4#Q[=.&]Z/3$Q/15CA%YNK%=7YKCN'6VS@6\;"[>YI,=6LGV611J22
M6UCCGUT6QE #&EF4-B6*PYRQVF>ZZ/CNS@[NPOE.YGX[]?!V\K1LW8L4T+WH
M89[/ECBK-840L8Y7B1F=!S$'*J&*@4]\@5\U2WS\8U,%)1GS57&7*U.7)B9*
M4TT%<QR26%@8S*)(TD951R5D*AF*ACK#>I,W65IVQN8_JNLS!O=T6024U+!W
MLE8'KH&A-(^%./2L6&K<#)9%F(<5>:R2362I(*Y^,2393]I5S=X1Y6+:,#?$
M9IG8IKI_&), 96W(;"IS.<X[\Y 1A"ID6(I*B-+]6BU.FL+:3XR7=<P^5OK!
MO86'_A,>=\0VZM<MQ",*J'Z$RE^P0R=HF98C6=K7;730U&HUJ-1$:B(C4:B(
MU&HGLB-1/V1$3V1$3]D3^W.7?S^==,#CCU^/VX_'&J&<"U]W)ZX]I^Y&R>I6
M,=?>V6L=[;4/D.74X]OTF*YEK'/J^7<SIF(Y$7SR@UEI4&R.QA3:>4V9(/'9
M637,I)"S(A+_ ,AD=E;EVGLK&;OM;BVAE<!B5JTYSA9[E+*8Z1(42Y6 5#+%
M,M:)TF4HJN9$!G7JXH:AC]Y;;W3O+);2K;?W;C,]E6L7(!F(:MS%WXWF=Z=E
MNSK%+";,J20N'=E\3\0-Y$,D'=A?5::U[D]/O4SU:U51C>T&,_)_M_TM^4!K
M5<J?V^2M3_NB_LL:&W/B4GC_ *BY<?ZG:EOC_P#(=20[A^50.?\ I_B3_H-S
MU>?_ +-?2]/WL/@FU]F=I,'L>L%?U9[.8AEM+;=@,:K[.BR46;3KA;<E3E9<
MOIH-5^H9K9![,DIY8!HPH]S7S8%Q:"M2?5\OD3;E_$8O:E^+=4F[-K7:<\.W
M;4D5BJU&. 0K-4%*>2;Z>/JL00"16+0R1R0Q&$=_78&X:&5R>Z*$FV(]K;GI
MVX)MP58Y8+0NO-YC#;-R&.'ZAPS2ER8RH6:.2.643-TP7?/IQ['VWM_/-CU>
MPL+K:_++QUI#@V8+TDZ(!8L>.P$A\>$4"N8@$1OB(YC6?%&JGQ]N<";S^"-Q
M[EW1F\[6S&%AKY2ZUF*&R;WGCC*1HJ2>.I(G8!./M=AP  >/0V65VA;R%^U<
M2Y719Y.ZHZ2%E'15 8@<?X?V_ X'O\#7M9Z8F^Z,!(U)N_&*J.4JF)'K9V9U
MP'F5C6*9XXD1C'%<UC&.>K/G\&-3Y*C4;S01?I\W[4C,=+=.'@5F+LD5W,UD
M+\ !BL-$ACP "2 > !R0-8L>RLE$"J9.) ??5/.H)_J>O'^GX]G\<^O<O.I'
M5';6A,ZR')L^V=!S>JML5-1PZZ+99-,)%G$MJN>R:X=T)D=K4!"D 5PG*9%,
MUJ>[%>O+/^+_ (UW9LS.W<EGL[3RE2QBY:4,%>[DK+I.]NI.LS1W:L$2@1UY
M$[*[."_ '4L1O\#@KF*LS36;JV4D@\:H#,2K>1'[?WA(XX4CU['/^_.$^HU&
MZ^Y)C])2;#V(W"-E8O"EY1B\:!BT_)KJ_I9X9\)U T8"5\&+%MKBNC/'.G6P
M10"UQB/ X9R/34_/:[*OU:=/,9X8?<>-@ER./CBQ-G)V+]*PLT/T',;UJ\*V
M;D$;1SV+BK7,,K>%ED9AC;M7%30QQ7+8K6X5:>!5B:666-@RF( %%"R2(OW,
MX"E.3ZY.H)^G!I%=E[J;G-S#<;%=5!#>*XHW.BS<MDO</&H/R5$8Y8;ARKY_
MQ>JM)5PQ%$X4I5Y4'P3M#^T.[DRMJ$OC-MJE]RR$QRY)V(QL!)X',<BR72/?
MNHJ.O67G48V?C/K,A]5(G,%$"0$\]7G;GPKQ^_7[I3[XY100>QU?-MG$)NP-
M8;!P6NE18-AE^'9%C<*9-\WTXLFYJY4 ,B5]=A3^ 1#M>7Q#(3X-7XL<OLB]
ME;LQ$^?VQN#"59(8;.6Q&0Q\$M@N((YK=:2&-YC&DD@C5G!<I&[!>2J,> ;0
MN0&S4LUU8*T\$L2L>>%,B%03Q[X!/)X]\:@5T_Z-9UUQVI.S[),RQ._KY6&V
MV-,A4@[ADULJPLZ.<.0Y9\*,#P,'5E8]$(I/D\7Q:K?FK:7^+/A_<&Q=S2YK
M*9'#VJSXNU16*A+=>?RSSU)$9A8HUD$:K!(&(D+!BH"D$E8O@-LSX>Z]J6S#
M,K5G@ZHKAN6DB<-RPXX C(X]GV/V&I7]IM.76^M,Y#K3'[:KI+.XGT$L-C<)
M+=!"RHN8=F5I&P@R)"O*.,X0_B-41[T<Y4:B^]E_)>U+^]-J6\#C;%2M;GLT
MITEO-,E<+6G65U9H(;$@+*"%XB8<_D@>];S-8^3)XZ:E%(L3RM$1(X)4>.5)
M#R%]^PI X_!/.M*=*>IN6]82[(?E&3XYD29HS%&P4H!V;%B?I]V1+(67^0BQ
M47S_ )D" 0/D5/"7R*GNSWB/Q!\:9KX]?<+9:[C+8RZXI:XQTEN0QFB<B9?-
M]54J\=_K(_'T[_ROV"\#MKMNX.;"_5^:>*;ZGP=?&KKU\7EY[=OSSY!QQ^ .
M#SZUE/<SK1D?9G$</QW&\CI<<D8WD<FZD2+L,XP9 3UAH+0A2 $ST*TA$>JD
M:C%8BI[^_P"R[/Y:^/\ )_(&-Q-+&7*-.3'WIK4C7S85'22N80J&O!.W8,02
M&4+Q[YY'&O?<&'ES->"&*=(##,92SJS!@49. %_?WS[]>OW_ !KQ]<>JBZLT
M'E^CMCV-/E]=F-SD,JR)3,FQXSJN^IZBL4+%G!$<,Z.2N))#(8QR!*L<HW>0
M:HGYV%\;2;?V3EMG[CFIY&'+W;TLYH-.(_IKE2I7"J\\,,B6(GKF1'"$(XC=
M26! _F(P@HXN?&6G2RD\DS.4#*"DL:(5]^PPZD@C\'@CV-0=G>F-N;#<FEVF
MF=W5-3#)Y10[&=897A^2A@F*I$@S)6+0K44SQM8!I#C+$#+(SS+ C(U@DIVS
M^GO>6+R$D^U-TXZ.$ADBLV+65PV0$+L6:"0XVI>5PH6(,ZS(D[!F,$055,;;
M9E^O,TF.R8B4DA69IX)E0GD*S0!@Y X!;[0W /0>@/6N/3K[89F./79WO['\
M@IQR1R%CV^8[)R<8"L]QI)!6V]*&(^2(1"M&Y3@?[.4?E8TCG)XV/@GY0R82
M#+[MQ-NJ'1RD^<W#D C*2OD2O:Q,<9D5&?J?(A]]>RABP_,NTLY:"I:RZ31A
MN>LDUN8 _CL$D4+V )X]C^G/!.K)>KW7"DZT:_D8C77$C([:YM'7N27QXHX+
M)MBZ)&A#!!A,(=T2MA@C(V,$TF29Q2R9!"HIT$+H/XYV#5^/\++C8K;Y"W<L
M_67[C1B%9)O%'"D4$(9S'7A1/L#R2.TCRR%E#B-)?AL1%AZAKI(TSR2&6:5@
M%[.55>%0<]44*. 2QY+$DD^H#^H%Z:6R.SNU1;=T'N"BTQDN8:BM]([J%:5U
MJ:-G^#R;&+/K1&=2L>^1)0*&K+/[S$4U?68\&/(&V K>=4?'?R?C-K8DX?<.
M&L9NK2S$.=P;121!\=?6-XY643D!5[<2Q>/^626RS*3(#JM=_P#QKD=S949?
M Y>##6;F(FPF:$L<I7(46D5XU8P@EFZ\Q2^3\QQ5PK#QG5HFGM94&F-5:ZU+
MBPU'C^N,,QW#:I7(U"GC4%7&KON2%:UC7RYQ /FRR(UOEE2#$5$5Z\JK,Y2Q
MF\MDLQ;/-C)W;-V7\\*UB5I.B\DD)&&$:#D\(JC]M6?A\97PV*QV)JCBOCJ=
M>G%SQRRP1+'W;@ %W*EW/ Y9B?WU3CB/I$992]J8F9W&T<5F=1<?[&9=V:QC
M0,*LM!S(^P+VI@AITF-+$2D2#26595!8(<@P$HJY\&+&CNM)/@NBY\Q4Y]I/
M1AQ-M-XV-M4]K6MPO+$4;'5YI#-T(?S]YXI96)*JQL2B1V80KVIZG\1VX-U)
M=FRE5]HU]Q7-S5< D<H9<A8B00AP4\'CAEBB '9AX(S&JJ96ZW79KA^/;#P[
M*\"RV RTQ;-<<NL4R.M>YS&SJ3(*Z356D7R,5'B4\*48;2C5I!.<A!N:]K52
MCJ-VSC;M3(4Y##;HV8+=:4 $QSUI5FB?@^CUD120>00."""=75=IU\A3MT+<
M8EJW:T]2S&3P)(+$;12IR/8[([#D>QSR/8U4C@'3OU&NJV-,U3U6[1:/S/2U
M/8V)<%Q_L=@>2?JG!:.=*D31XY%R'"QV2W<2,>21R%E"@1VD1SZZMJHI5KV7
M#D=Y_&N[;)R^[-JYZCG)HXA?L[9R%7Z6_/&BH;+UKQB$#NJ $*9'(_[DLSCR
M&I*&S_D;:U88K:NZ,'<PL,LC4:^XZ%GZJC [LZUEL4A+YT4L?;+&O;W'%$A,
M8RXNNO6:O02*BR[ ]*,-AV$<T0N38=K_ &+=9+3H=BL^]45V250*61.CHY7Q
MTGO6.A&M5['_ .,)<E\)UV6:+;V^;SQLKBK=R&-@JS=3SXYI:LS3K&WX;QCM
MQSP1K+..^9IPT4NX-E4DD5D:S3H9&>S%V]=X8[,2PEU')7R$KSQR#^=2FZ5=
M/\9Z:ZLM,(K<KN]B9CFF6VFP]H[)R0;0V^;YU=BBALK5T5)$TE? 1D0?U(!K
M&SD,,69,E6$N9.DF=%-\;RM;URT5^6I!C:5&G%C<5C*Q+0T<? SM%#WZH)).
M7/>18XE("(D:)&BB5;+VA5V;BY:,5J?(W+MN7(93)60%FO7IPJR2E>SF.,!!
MTC:25@Q=VD=Y'8X!Z='47,^FFI=D:]S?)L8RJQS3>>:[4@3\5_*I"BU&3TN)
M5L6MEI;P*^0EC&-C\EYU$PT91'!XSN=Y&MV'R3O&EO7,8S(T:MJI%1P-'$R1
MV_#Y'FJSW)7E3PR2+XF6R@4'JW*MRH'!.N^.MHW=FXG)8^]:JVY+N=NY6.2I
MY>BPVH:D:1OYHXV\JM78MU#*0RD,3R!8!RO-6!JOC?G4'-=M=V>HW9VFR?%J
MW$^O$+-(N28_9K;?J&\?E$"?#CNH_JUTBM1L5TH;S_?FQ5<UKT&BJC?E8NW]
MY4<1L;>.UIZMN6WN-Z+U;,7A^F@%22-V$_>19?O"$+XT?@\<_OQ7V?VA>RV]
M=H[FALU8ZFWDN+9KRF;ZB<V4D13 $B:+A>X+>21.??'X',BNQ/6'2/:K!).O
M=W8/6Y;3.\A:JP<BPLEQ>P>U$9;8KD47X6='8C<T:O=%.D6:-GU+.+.@O-%)
M&]M[ISNTL@N2P5^6G..!+'ZDK6HP?<-NL_,4\9Y/ =>\9/>)XY '$BW%MC";
MJH-CLW1CN0>VBD/*6:LG[35;"<2P2 @<E&ZN!TE5XR4,:.IO7'MKU>R&=KVY
MWYCN_P#K* AF8.#90L@A[QP&N<]BP*L63Q(EM3Y35UL=JPOQUFZ (OL$],7&
M(05IC2C=^YMH;KK1Y&#;UG;NZ&"F^V+:N^!R$@!#RM4=X9JLLK</Y8@Y'W"<
M6Y&\XC6T]N;LVQ8DQ\V?KY_;*DBBN2%A,W0C]>.);*)-#:BB4=/'*8PWIH6J
MH#"=13>E?<31VY]Y[*Z6[_U-1X;V%SF5LS,]7;RP:[N:RBSJU>8UY=XW>XR4
M]@[\C(*3_P",2/ "D1X(LMLY];!E-W";XV9GL)@<7O?;V8GN[<H+BZ.6P-^"
M&6>A"%6O!9KV@L8\2J/N#2'N&=.@ED36H?9>\,'F<YDMEY_$P4]PWFR=S%YR
ME/-%!>E):>>M/6+2$R,Q^TK&O0JCAS$C#[KL*]9-R>R;JZ*L_P#)N ;654_?
M_"/$YO\ V_=/\_X7V5,<7OA4?^A-_'^H.0Q '_@0?_IKW^B^9/WS>Q1_MC\K
M_P#M3Q_X_P"^MF]-.EV5Z#S_ 'AO[=.T(>V^PO82PIS9I?4&/)BN&X_24(G#
MJ\<Q>H>>3+( 7N%A["8^.XT2OJH[( 31IDRRU>]M[U-PX_!;>P>*?#[<VY',
MM&O8L_5W;$]@@RV;<P54#'V5C0,%>25C(RLB1;/9NS+6!R&<S^:RB9;<.X)(
M3=GKU_I*=>" <15JL)9G91]H:5^I*1Q((U*/)+8/RNM6#IQIIQIJ+^ZNH.FM
M^Y579CL.%D$FYK*:-01UJKX]7%=6Q)L^P$(H!"?\B?8L97R,QXR*QS6HY/@B
M\K?=WQ7M;>V4AR^;&1-J"G%145+@KQ&"&:>=.R&&1B_>Q("P< KUX 8=CILC
M@<=E)DL6TE:2.,1@I*\8**S. 0O[\NWL<'@_G\:VWK#4^O\ 36,"Q#7&.1,<
MHV'?+,$!)$F7/G$8,99]G8S2R)UA,>,0A>>7(*X81"CA\8!"$R5;=VQ@]J8\
M8S T(Z%3N99 K22RSS, K36)YFDFGE*JJAI';HBK&@6-549].E5Q\(KU(5AB
M!+=5Y)9B "SNQ9W8@ =F8G@ #T !L7F^UE:<::<::<::<::<::<::<::<::<
C::<::<::<::<::<::<::<::<::<::<::<::<::<::<::_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g722206g13n04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g13n04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Y2^8#8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]       $@ U     0 M    !@
M 3A"24T#]P      '   _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #-0    8             "HP   A#          $
M             0             (0P  "HP                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P  "HP     4F=H=&QO;F<   A#
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   J,     %)G:'1L;VYG   (0P    -U<FQ415A4     0
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M[GJ.*U^>^TL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M              #_X@.F24-#7U!23T9)3$4  0&^S/[^'@   Y!!1$)% A
M '!R=')'4D%96%E:( ?/  8  P       &%C<W!!4%!,     &YO;F4
M               !  #VU@ !     -,M041"10
M                                        !6-P<G0   #     ,F1E
M<V,   #T    9W=T<'0   %<    %&)K<'0   %P    %&M44D,   &$   "
M#'1E>'0     0V]P>7)I9VAT(#$Y.3D@061O8F4@4WES=&5M<R!);F-O<G!O
M<F%T960   !D97-C          U$;W0@1V%I;B R,"4
M
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M1?B\+$VA@;V=X5I]SLAVLVM$XY.6K'+5AO4;$M\OCU7M;\IW/'0OF.;O/+Y
M3X+\>T$D?79#S!!;7,D!N'3PRU \>@2!CB;6)%+%)6U;BW$[D_)$@[O6LZ7;
MGN;<W95KVXXW0YU^OS@V5?(!*@O("[OSE2-.5RII?VA)'C'&LS,TR(RT?4-V
M_<\.KHX,ZA1K9%+>XX)TFA'NRQS5:MN6_&WPZ[WK?:E*4KDSYM>#I7\DWCUE
M#DR%"0!%)!-2V+7YK>I+<']K$4Z0(/F,I=-2Y8-#I4[ZU"A V[]*''0S*->Q
M7GJPW[$^J^6[#JLTI-B!J;$.W+#+:B;T23;EKO>^O+8F3:].>6%\L<<KX7RP
MO?&^6.-[XWM[QM?Z5<*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5
MHKW,X;V^W'MM..O*R_NKGQOW?,QRR^'1OR+,\\M?PYX?#LM?5C;'++XL;6O?
MWA?W;U_G@^6-\5J.J.]]FS7HME;@KK%KM;'#9:WR,_.9)UKY_79E^^_ON7K*
MU_@^EOS/TVO'76+\LV2ES=GEK3VNI\4_;=]EL<-EK6NY>/$UMO\ A][;W_-^
MRZ_E>[Y?#\67Q7S]VMCV?Y")UZ7P7FGR]26_V>6.,V_#X\-M_>C9X\.;[Y99
M>MUO>SVFP]96^''ZY?F7]V]7W@5X4[_W0)$F[/#1;+\G]WOJ]8XYVQ^''R)]
MD+K?2^=[^_FX6QO>]_[G[M],O65N0,/D*V\W=?N'RTWSG2"^,;*,?@V_*P]^
M#[KW._RK?.^/'ZX6M^?GG]+W_7Z]=)N B):W^-;RMJ=.M-EL_+=NRGULPV7Q
M^8H>XX4YV]8[<;_!;8@TVQM\7NV&6RU[WOECECR]C5_68^$I*T6UI_LU^)WS
M"^?P[/G>L^N_*9LO?XOF?![^+5CZ_>_T>[7]W]7MNIYGW93K\7?BNVXX:;Y*
M>-O&SEG;+'.^-KZD1ZKQMCZV6O:WS$>K&_N][WPOG:U[7OCECD3F]*G#R9>)
MI'OPT8ZTGE=DC9KRU8YVSROO1PCNSMG?+9E:]K9;LK8^L<?6-K>_=_=[Y#U0
M\JM'GA$-6&&B^.,1]8IK7RQSO?Y>ORD=1..-_=MEO6?ST6K&][6]7U7V8VM;
M*^.>.(<!/:O.3/.XY98:/G_D+N?M_P -L-GROC3\.11JUV^&^V^?PWQSO?*W
MQ^[W]>KXV^E8+QX0K4DM=YZ=6M-?'?Y-^B%^5\\-E\K;K=]^,#\VWP[<;?+_
M #+?FWM?+ZW_ #_T>KA';RJ3?N6+F%%KPT7U*"_R1HME\\,[YVU?BEZV4?%C
M>VS'&VSXU>VWN^.6/PVPM\/NU[Y:#]=OJO?XRA]/GKT6UIQCC+5A?'#9;*^*
M/BOQ8;=7Q7OMO:^5\MF7QWMC:U[>OAMC7=+S?OBO3Y0_'GKPUI[XZ^U.35EK
MY8;+WOMUQL$WQM?UMM^9?[QW^[6]7O\ !K_.^F?QX!P \JG/SI^)[-1AHPOK
MY'ZG;L?E8YXVOHT"4SJ,,LOBV9^]M\_IEE],;X^K6PM?ZUS*97Y6G[5[PSPU
MI[W2\&<\;M=LL-E[99-G)HK\BV?K;;WCG=5LOMM;X?B]8?#?#U?XNP'C.=5&
M /YQW*V&GY^?FQY$O?'X<[ZK74=V1IHS]8_,^/Z897OC:^=_67Z;Y6^E<.N9
M7]9CXEM:&VM/\G5%W3NC'+X-GS/@4\W^9_+9>][;?A]VNY;[8^L+6M\.KW:_
MPY?'N'Y,'51L\"_C+;\L--M-_&==3\5L<_F?&E[ X%1:[>[YWQ^&^K&V6=OA
M]WV>[VOCC^;;O-S^1KMT"]=.N6M-91_92\DI_@QPV?)^#9YP>IVS*_PWW99?
M%9/A;.U[;/7S?SKVOA^97XP>3GY8BV<+9:L$^5V_G7S"6T_,PSO;+[;"T^Y[
M?F?#MP]^K_37\/P^OU_%7^P#2E<>X,\?,OQEYFNVO(H^$\>+(;Z4YXAR)0H6
M:W(AVR.TD,>,\:MSPM)6Q4-)!Q*T*MP:Y9MVYL)W59LU[T5U")-EGNQT=A*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6@_>>.65^,?AQO
ME\/?'.V67JU[^L;6,?>5_7Z+6]V]WO\ 2WNO\[GRNX9VZE[XM\&5O?#75V5O
MS;V]XV\YDD^\K?3^UM>U_>7Z/I>WZ:C?JW7LM*',]KX9VO;Q3=F>[7QR^GP^
M/$]^+W]/I\/NWQ>_T>[>_P!-J[,<EZME_!<=^M>=_<S<7Y6]897]XV\=_.WO
M*WJWUM];?7]'UM_#:LJX PSMY_XDM?'*U_[ +OB_UQO:_J_D'[+Q]^KVM]+Y
M?3_']/T_2N/$/Z]GXX.L,?@S^+&"^,/BQ^'*^6/OP=]@?IMZ]V^M_7J_K^"N
MD_!VO/+QG^5JUL,\K_EM'"WK'&][_%9T!+>O5K?IM?+&U[?IM[M;]-[5R_C?
M7L_(NI,_@S^#^PJ>?SOAR^'Z=<^4_P!_G>O7T]V_7^NMV_-'AE?Q;^*>UL<K
MWMQIXWK7M\-_=O;3(]K>[?JO>][6]?PWM;]-[5?]^&>/D\\4=\L<K8W\K<A_
M#>^-[6O?[N@RU_5[V]7]7MZOZO\ 2]KUD75^&=_/*)>L<OK%?6E[?FY7]VOY
M.NK,;7^EOK;XLK6]_6WN]K6^M[5AW &&=C[SN8WPRME^0H@2WPWQO\7N_$$3
M7M;UZ]^[V_16 \BZ]F4O]W7QPSO:WDKZ*M>]L<KVM?\ L^_&%]+WM;Z7_9^F
MKL!X9W_<MG+=[8Y7M8Z\D>5[VM?U:WXG^K;>[W]>K6]VO;W^CZ7M^J]:"=;8
M9V\:+->^&5K7'>//5[XY6M>V7$WBLMC>WNWZ,KVOZ_A]7]5W1\X>&=_*/X]_
M6&5_?97*%O?PWO\ G?BUCOU:WT_3?X<OI^G\V_\ !>L#\>.&>/G1\4/Q8Y8^
M^5>K,K?%C>WO&X7,]K9?6UOI>_T]_H]_2N8[9AG?M/OCUAG>]^!X'M;UC>_N
M^7)@9\-K?3Z_%ZO\/K]/J_KWZ]UV&\:..5XZ\XN-L<OB_+8<>6OC\-_?T[RC
M/W]/7OZ?6]_V?7]%<,^9M>S\E#\5L,_A_%ITM?W\.7KU;FWS(^[^_7KU;X,O
M?\'PY?P7];F>2S'*W@D\967PY6Q_)C*;>_5_7N_9? ][6]^O7N]O65K>_K;Z
M_P %=VN>M6RW.G76'R\_B_LJ^1KVQOCE\7JWG1ZIR]^O7OU\/YU[^O7P_7]'
MUK\8O+&O/++B/X<,\OBYV\O7P_#C>_Q?#"D^^_7JWUM;]?K]'Z+U_L,TI2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K2[L[^TY4_RT8'
M_P#'$E?YZ7EOOZZN[V_VNSK:W_\ O*E:H^ZW]?C6Y\_VJCO;W_C_ ">!/7:S
MC/\ O%Y-_P#/_CK^&WK_ *7CS#^C^'_G^NU>W"'_ %P;$G^U[=Z?^4I[$KD?
M$'O^R&[=_A_$5QI_C]_D0^N:Z3^.J_\ TN7RM_[>21?UE,0_R?\ Z?ZJY<1G
M?_I$R?\ R)2#WZ_RP?*+Z]_LO?U^S^']NY'F8O\ ]+#\7?\ D<>-']G_ &97
M_P _?ZZR@M_OD'B*^O\ [+%*7T_^HAK_ )_SU?\ IW^_LAWZO_,5ZJ^O_P#5
MCZ-_\%8GP/\ ]6?SM_[1SSC_ ,1:+JP_BO\ ZJ'?O^VG=#?\?KQ>UZ1;[_\
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M<<2TZ?>=E5_M[.%[';-<V-_V71O].:NSAKLDNH^2E_,V?.WZ_P WW^8OM?\
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MGY4+RF_Q ?1W]+[F'_.*?E0O*;_$!]'?TON8?\XI^5"\IO\ $!]'?TON8?\
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MF7Q%+(\)! \SI][/NV;'-.5L<H #.C2L.Y2ZX6D0&Q^4FW%PW=PY^2KQ%X^
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MC+U9\!DP6N0@LH=.S3%([>1W06WLYCU%!W0D;'25.\";L)OP_L2D;-"I:Q/
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M-3I$XG!TYF!TYF),/(6EK8&7=H<;9YJDN_$1;R 1[*L92!*45"<@[Q $,^?
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M$.;$B<P18Y9,6A85#N\V$&IPE6./(E$,C3:!<\X@TK!DKF[<>+58L;IXQ0.
M4ICPGD82?FPA0LTH/SF_9X.D9/5U#Y&*"0@\;3O8'<W)152?"29VAK=Y78Y!
MAB7'>88KDP971;(DGCJ10A_%BT"1Z$A$XSA$B4X&2^0)8$AQC0-N,,+DY3^-
M!WCG>XE[BU,,>(3'<3"FEVN\D>7WD:,!MJ)'Y0;9ZGER4-"5#OT@ AM3.&:V
M1=@XD>7>2I#!A,?4GP;$<DR7'R5](VY67!@INTM6C:9/0P(OD@R)Y!0.+Y+'
MDQ$-$SCS\3PE#TN7GL=:TZP8!4\RGI*#AJJ14[@]-C^@'REQ2BC</9C R3O&
MER>URXB0,XTT.;VW0:)^;OA<Q61NUMQ4Z:'F1CW&/\&G>10PM4"[DL414G8U
M[LL8I=>&<GT/N<V1OEJ8HJ<Y%.![!W>KFXD*Y D@8BV['+'6 1UF)O!8&ATE
M FMGR#E5V.4F5@9']P')# !B30,N0)QLH+D'W$4B!8V+4>E<XH2%N5ZG!L(&
M%G<$>2?+:*E*4I2HEGU#%#I!,TML\;$6F#G")I&0S+M<UKDW-VJ*E8>\:)#V
M+W!FW)WA BP$=CODJ6-6_0Y)=%L]Z';K58:L\>1 &6^,@9EI00YODJ#[K&SR
M\2T_;YD+>P&M[U2X#!,J'1 X23%DILZ%GV.8+',7')F)N#WL5;=7V1T1C(\C
M2)1W-PSTMGSQHC[B2$"=T+L#QO/7K>U_98KZ<,5#F>LLNR]U2XDS$(C(_P#>
M9V%C,P0G+1:3O E?:+(DX*\"REZ;V54SHUF<I.4>1.8N5XJ;#3(^=T@HS1^@
M8)"@I'-* ^5E;1KF$OL316R0@O?#\,0K]4TSBN5IA]>KT(8^+GUC(WER9$N6
M^^$Q8*^,_P"TR#,D##D@D^CG&.]!^VMPQLZ,O%C2Q!39%DB8-<,,3[LTQ6X/
MV_?#D5*"1B DRM[5O#:@3$J/-0[N.M; 03*G"$WR=-DYSTFFA*5&TAAI< Q.
M]"/2F#8F<!('A.%6YRC@38&1(,'LN_,(V!$5[!4?5R( CDB. @79(Q]*][$\
M_P EQYXLW3$#(9#2%)@+=7LS_*X9;);T87QE@%'A.EW$A6L;6S8X"$) :V3^
ME&(V=-Y&G!V-@E)]#SK?9J(8W&G00B"/SCQLO3+,!T?EQL>M_2+_ "M-6XHP
M@OJ("8<([..8B*,D8LC<%C(K6N1&4\L1><23A?8[X$$E.;L=3: C;4B,AS5;
MYE];XHDX4X2?H'2N7<'N44#2+,+0_P#1BS'5KF7=,C,_E\&MZ#%QNUQN\L4K
M3K(0>11,WZ0TW++,'XNGE05IHNR;J"0G;Q>LT;F6YH33@>+'H!EMD*@U^/.N
MA-!)9.37Z(,3N+YJ*2G=J'\)X;<3/HLI1 TF[KR4%I-C@[M3 VI&,,VMTB]"
M]#^,OJ<B=FSHX2(BL'C"-=&X(D-4"3VDT/89-6L_5207BS8-"#>[;XF'1CG]
MF)]_0B'8XQQ]W.Z2S$7(5&[9@[R(_P"CQN8-COT&YM,G[&S?,TQP(FW-XQTZ
MHL>2R_.'4.R5$,?1RW-.Q5)%DZR>NHD:8U!QM\84?VHH:AM\_P"@UK2L]-,D
MD^,^0B+<B-WR2-QR!688K$]D=M73[$>/&R,7>3AA>Q0PLC5L0$<AK@E2YRV(
M2HLC/<_KAQLS*&D]5($.G'Y>(_@QP.;<H]QQWRRO,-#"^<F%X.:&XH-367-"
MX'0",DOK;^+<A?,4S(?O[ HD\D5;6T )MY)9<]-R%=O3WP:;IX/@,VY//"J+
M5;WS[("(K<=4*$LN.2Z9.DR\*5.<V3K,\<1?>6E4HB<?:YJDH'GPALD1LLG#
M.IQ 4Y^H>0[=O;H[;DR:9R")_%5SPL)81T#$OQH^#&$9(5:B,D?7R(F*;LH!
M"O(HL#!LDQ[JV/,EJE@A*T0 A2(!9&0JW,A+\"TB2;#IN?2)HE5BECBF?7"(
M.9XE02$0,)B=GDVMAP(Y3G%JN(Y+(V%XZ0>5""4?NL=<1>4'=),&]0_1;H+F
M0O&PZ1MK.]BV@55JV;'!MLV^+B-8?+HT8'F2P*-7AW#S93KCL-ZJ:G/!CB6+
MFL9%9:"2$4'<B*T)LT5\L[D^4FC:_;$Q*P1P4YN+R^8.CU9XP[I:(/'!R SO
MVE4%S(TE@C""PNBT2#)&ZE'@9MO#H:QRV'C8?(C$Z.,9Q,=%N'#HNONNR<6\
MC)5$=74OR9[R)U:4IO"8(\=8+&0E,<@B4EQPV;5IN'##.R'?1\F8@0[RO)XG
M@22=H1ABU]V@ XA4<PQ:;RO)BUO9V?+8B3V/B)R=C)_4ED' 1MXOD4G*=9."
MSC"37$NYO+Q\E)B'JENCIT5\[R#*;&W-1>A288 Z5(QZ_&DW2V*")PJ4Y&KN
MUNN]M8'$I5DV)%L)!L0>+\M+VX*B9CE[:5#(P.GI8Q.N_K-GUMH[#*H3CJ/&
M2>/PJS0MFM0$.?/ PIC "E7=9WV;A':7B#,O;R)U=7SW$9K\94D1V71B$8S7
M<<=]\)'ZA(U1-UV-E"TCAP9YD209O!G92%-Q$K-&T-5\SEC$/"RG<\O8J^LI
MP\-:YD=7]TSUY&)+\5J/&\2,,93BFBO$D22@T2M]AZE5XX'&OGZ)L!9^8";8
MF5R&GDY*RO $#BC3I7X'[=,;0@T)4&B2%;3]Y3452=XKWR,H_@<@43<3"0J6
M'9:.MB$-[.(#+5(\K?V1#?)#,3&+.P*SIQE'?GCT2[$801/BD[&%XB_$-F=K
M=!1E6)*?J<KXNA\CC+D>3XLZ&(!AE,-$OJ)(#7KI4E,$3UT+%7=KN;%6\PC;
M2_RC(3\]L$1RB.ES)K?-F] +R'D^-V+:TQYNQ:;.2M_C29Y/CX0$F3H-?)1-
M)@:(@3P#OO5HO@Q9R 5Z1U7)L<'6M0W,>P3%R9$]M1:5@SJI:F-?(AVT.ZQ(
M@DLIQ=)")E?C#9Y+30&MT2LR2 'FUP]I>AY@ZP2Z0\Y(#3F!I4N#5-[.UYL;
M6M:S=BY?9GDQP-[H6)P*1]G>W?1J.2)(YW&.S3Q\/,5/G-#8>3+KCIM>(:Q"
MHY-F[I<2*XZO$5N3&&'D4=N)NU-T@:MZHS.( .F;<D7;U1D42"O>UFIW4W.-
M^O!BL2\5T-D<@QDZXSBT/$5%88@(F4=4]F$R%9."U?"Q0#N BXCGWRW2=TSH
M13%"NIM=1%<52YJ#WUG:5.W-@9'1.U^DD'WBI-Y#=IG-5DONA8_'#8;;D#4*
M=?V92PC&HJ-1/7,#'&HXP8L12/MT4\[FK&KE)F'7 6TM,7N.K4]8*UOQOM>Z
MRGXP@:74<IC2^1WB7!28) >PP?"TG3SN+25-I/MZ@R,3 ?$QYL<H^E#[A5$_
M1HR02:D9288C)K^-L=WMD96,)UI,XB'7X^3%4FZ52+209(V@:..J9'9'B1)I
MS!PC:'2)(!B8/QZ++W)*!K4D?2Y(\MF<=:GA@^[]KD]D<B1JU[FQ.A=6_$Y2
M/O%V^O4ER!(5I8CLS-EC9,\JG:8,ZVALV#W2/HDE6'QW86$C,P"SS$[F3Q )
M2\(B@:N5#2J4&S>\[1YG(7@H9ECK80Z1/%D*'&HK#=T]@Q:SEFG:VQXD#NU@
MO\,'\2+TGR0,>AE2/M>B2V^-#;5F=[8Z91=_:(_6E1$<+6AJ:RTE7+<QE9SX
M#4=%Q$0EPX5KDW3 TP]&-4S"!%-6V-C!0I-^9 2-$<KMX5CF()P%W(VF#W,;
MWR?M; =O)6_1K^Q:]Y459KX6F&<?'7,#)S/S_I$I4*X99XYD&--+LRI.N8X?
MQ:'U<=Q""#H*UM@F"6.I8U=!ZI1AL7"6QR<&YG/]:K;K;25Y*].H3>KV>EWB
M.,&9>WO6V9;:4+5O%G%T ACL]B(&I*^M/0$AF@&K( !D0/S8](167Y_7RP#[
MUN@A%F-8Y(#)I:5(V-IVS)>TI!XN:9ZC.-9<AZ9Y"2%T:Q.QN;Y&BF?'P$>X
MR=&/JDDC&SL#Q&D>F^7B&.GF,S-^#D*QN<"(2W'>V2&12EP%E[@AV%&%O"O2
M:J08ECA[-7IU>RD>Z55.0*[3;'V\E+HA&8CCU&815*J/:,-S\J $+%% B7M(
M"5JV]D(5&AF-6[4\N;XFW:#<W3#P.B$[2(:1NMB-@9"&+\!J/(>F[H#I =!"
MZ)Q(4ES)JEB#A0;;'V!IZAD/Y:"7^<=1Q&"=HS869&N2R,;[C8]U+963H/$6
M+&C@],NZ2G D&95:R)K&!/'K$P;C22P) O'U9S&X".IG=JERPFT<S.+66EH,
MRE+,Q-$4J\G5:D0N._>0^LP2MX_T,'1Z'NX<5OR6&0J3(LB0+$WWH4="C8"
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MKZR*(R9!2Q^B7FK24BH_E(0)U_M,9 F.)E+^2A+XEP%%R!&O5GRYI9Q ZB=
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M]X_ITM1(F:'H7E6/_%DR"R-UQ*9U+CAU<05LCC2Y; T5'M2 4'&_DEB&]&A
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MVWU##N)'I0PX>\LDES'3IM;'?J4[LIY ?!(2V#":%I>4<J$,/F<WH9*D!Z$
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MK63[,<]8KBTR8J#) 4.EFEZW*L@E.T:="+)QR<T7)AG_ '.U(:;4A#W_ *"
M"J,6P8%Q5*D(8DW.A_O9(LC?H2(8>'EAGF=Z-:D79@"?%39(;5DS:59]^#.O
M0U.H,E(W[6HD-H\$O0#$-CZ1NZ^'\R=(&KP]\>'H DA]VYL^'2@=T Q#(T:+
M)Y_'<S#B5,Q/8BXO*R7764K[71O>V"16#2TZF;9&;3^YR2UL$7015SP(OME<
M&KH<:7A9'.S'<PK%4!<N00E-DB=46.&[!S;T/-NU\P3Z%NI1M_#M6U8NFG6U
M;%;O^EF,P)Z$5>_>Z7;[X;4.]/C]CV[-F5MFQ0BV6ME\>G7^;\*?.][VO?\
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M.[$6^8_*J2(1GFH]=H_D/7,4L]4RP?<8GQ(YC!R%;E<6JF @?W=3I)'=PCQ
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M-Y5JS1G2.9T]RDD1NC<4JE.#6_X6X$@OO_2<#AH@'.C4YPB<'L!C([(RN7$
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M!UT9K0.(_P"^4=P_Y+?C^_X;=V5OY7/2;_[Y)P'_ /05WE_X[E*NA=<VM/\
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MZ?J]>J],&Q-A;UCM<;V_V;N[;+_S[%N5_P"NOG8U)=EO66URM_\ !O+OJO\
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M]M;B@96+6E+KV+D^DC8,MFG'[Y;K*<M,^D^>HY;W9U/IPB<,;F):\-KRK)Y
M%V72V.0\Z"K&^-RV[@YZ+IW!I>CL):7!#LM94E<C 71;=6*E^:]:K)&&8HE*
M5&I*,2: $:E0A=G-/I8B]@=]BAM8FP2>WIPT8MZ]1?>A:6<^!G5Q5ZOC3HVX
MQ%UN_9@F?6S8IBN".R>9.DT +NA^9X^*WR0XM8)E8 1(6#^R0M4?$21N5)'I
MV#$[FH>VS!'DZH$3O@H3?_@M>ITI%>6O9NT_,]=W9O(J=,XK5'3L!Z$;3(">
M*7-5NEH&U)T$E*]3AO3 JK=F^8Z])1N3L[PHQ9\\K+/L[,\;[ZK:FIPS36)A
M[?YI((LCN<M$HA[5#$EHBEP8Y/)S$(%A%&F$GW4+K\G-<_DZ#=;+>2;M3'HU
MMB9SS2NFW2C>;-6Y1HPVY\^=0<W#(*!2@1SU#[%&\IJ&M+&IX[R,)MP@>*'E
M+L7->H2(5;KJ:G[)8AT[ENN[:J48XI-&]3LOAIT[<\+.M[!Y0;5S@UN'2D%H
M7%ID5-$3FA5RH$IU;?**O8Y:4\?J]&UZPVZ"[9O97I-]Q;,<7#%4RO*;/1CO
M:7'6FMF[MSC=.FR6[^JN>-"/ G(@O-7NF./]2; M$&G6_E0[EOS?\=6+L.L.
M[4^/2.^=MK:S;=;JKQU(,\5%\7"/(%QR=-Z%Q1=#1&RZGMSE-*+Z262 5J4E
M[/#KT7LQH9"^JY'O^]@U)8#+772]ZLL<+,X^\JUNE%FSNVA#F[7V/R4]ZPS<
MT=-0*Y:9$4%20#W(I9!E&HP4 VS/49:AS9K?,L':XQMUY:WRZ++;BVYWUXJK
MZ[[=5L\D;>E>>'@!995:ISB1PC,C5$B%AD!+(0KN#7A:&L)04ER-N(\'2[2J
M5C T$&1 0)M2O+<SLHH1.;A@G1L[AN3ZYSEY+.2N?7->U'$CLBU2C8\GS188
M+([>=B_6D&I','M)K17-DKHV;AX<C)Y<W-:0H&9DWZU[=J9W9UWI"34/SH]]
M;<MC,8C$UD?14)L$0&KJI8A"3GJ30YK!"9[16?+KV9C*5SQH9G)U;K#!+DY-
MR17M6-V(Z_9+=.BS.XW3>C-UAS&2#"TS&9_AXF%F_0F4JGL=D05>T&.M<]%X
MXWVPWMCHIPV['(A #AC;-6J^>QP=A$C0(\=REF7Z]%$ ];<[2'L1M+3+L=H3
MC*P^E?HR=3H-PD4,)"$2?#70%%HR@?G!0U%Z%@%3!4Y,^&U3DG_ TLRU[=VD
M?<]J>JT=4\_O#*0OH9+,<2&A#BN,@\SR"I$ '/$/=)9)F ;$/PF5JB= VM%U
MMR)$\)6U4NP?GQKQ^4*,Y"]K6=G<\:0=S<8NS0ROS-U7ST]M!([/K ..#-+X
M$ZI2!\&6UE>'UG9-R%]WZW-R;FLF&%^Y(CRV[KI2@8W88YZR)FR7>,9=S\@R
MZQ??H/T;#;G9+'(_*Q"S7D@,L1!8,2L#(3-ST;,^I[W*1=/@S$;&L6['6VC2
MDU.K?LV;?DKD>W?8B#R <ELYZ-Q>TS7')M(!.8O $D%@^0X[6N"$K&2L%$2E
MA=]CF7-") ^CJ^06;>L',U69(OU)'="Q,[N^H];.HRY-VSQTLUL6Y)U1STJU
M$YLIC<;V)YA =V#\?H]@YK4AK/EK?LK.)'IN8"6S)I27VK/LY2.JK:KIGMMV
MJ<J;>G^<'@'.),:)XB)UCR,WS<,2$;MDABJ\6"R/1DVX9,)*^)73:W,[QLS>
M6;%*VK5&E6MN\-7V/3O^\D7SX^,>[N/@ANS<73HV'5MM;9%Y!M1,<CAKPY:A
M*8RX'"P UV(TCWELUACTZR0%*<2;*]FG!F(FEW^TY(G)OV*I2(NB($$#G?&)
M7-,6#4C)1]&5J05]/1AI+$XRXN>AF;WW>P+G/0YZFI<ZJ4[>D6YIL="A5NU:
MM.>>6>-KXZS]6<]OIO, "VRP#[GB! UO.Y=6W*&'!A!!]222:).FXD>KN7V-
MFWB+]$9JA-=3IDBL+;4&K!VV:-NW9KTX,,]Z<BE\DH8O89\BM:]OT?M,D!;E
MC(01]PR$Q+"*9!E_2@BW$AR4D3O'SC!1Y>1$29#C@*:4Z;[:HR48.J=KD(9Z
MIYE,QW,O$N@X7(Q;7@R;=Q$S26'N#-HUDI.[!0]FH<4SQL2I\7LP87H8:[[M
MNNRY^:7%K3_,6(]^G#-@:78QE("PD^+3P3DT!W:G?8C+ $A:"M@7YL.]4E=D
MJ)V9UBIOWJT"U&I0JD]E-LTRS3L3J+:MF&5K:(E'E=YH#Q8I,WIEE? ?$H;C
M2:5ZM,,,*K8K9I*PA99B+MB?66_-5F82R]#0X1'+=ZUM;8RFS>I;'EYW:E2?
M3M0$]7P,<F6N.D4BBS-(;D5R8*"@"2$HPUFQWG$985 YL_A8K9[4/CV-H"@$
M.&S2XX(=.U1D&DRBR7!*SK-VK$6?O#DA>@E%:]3Y%0+OA4Z*(^E5G/)#"!M[
M GH<DXLBA"H*FY01;-K"W&I&'N*L&VNUT:H@95;8LQ1IE"O)'IRW+L'E#$HU
MA-^E8)_##:6,8)K&+2L#Y/N9J3:=2@=$[->+W=9^$+[I4)=C2T?*^W.&*YO^
MRZ-MW!%;?B<*]V<HSS&;5*81-\;:F56&J3=^:'H\"DI* MK2S"CX5(9 ;$1$
MXZ1EV!TIN*Z31,I6[-(\K?&S2L4VLN2Y[MN:4K\_4I,75G5?EGZ?YL">^>C>
M48C@WE/E^3!X8@UEA-=I=BN4R:7FDG7/*B3XN/%E_C3AS1=/@B4I=>&>.WXL
M,K96MC.OY,?K3^.J\AG^]KC_ /T;Z?DQ^M/XZKR&?[VN/_\ 1OI^3'ZT_CJO
M(9_O:X__ -&^GY,?K3^.J\AG^]KC_P#T;Z?DQ^M/XZKR&?[VN/\ _1OI^3'Z
MT_CJO(9_O:X__P!&^GY,?K3^.J\AG^]KC_\ T;Z?DQ^M/XZKR&?[VN/_ /1O
MI^3'ZT_CJO(9_O:X_P#]&^GY,?K3^.J\AG^]KC__ $;Z?DQ^M/XZKR&?[VN/
M_P#1OI^3'ZT_CJO(9_O:X_\ ]&^GY,?K3^.J\AG^]KC_ /T;Z?DQ^M/XZKR&
M?[VN/_\ 1OI^3'ZT_CJO(9_O:X__ -&^GY,?K3^.J\AG^]KC_P#T;Z?DQ^M/
MXZKR&?[VN/\ _1OI^3'ZT_CJO(9_O:X__P!&^GY,?K3^.J\AG^]KC_\ T;Z?
MDQ^M/XZKR&?[VN/_ /1OK'_%86="-O3'E$YGG#IF4.HV;EN:>?12,3B7&Z/V
MXO3,LA\]CLFD"19:.0X*8MV.3\0[M>C*S3;9@D2),<L\MOSMFWMA2E*4I2E*
M4I2E*4I2E1_+(DB/XKDL$<WC =;36/S(2<"#9AIV:V-$1CCDSJWC9K4*$NC9
M@V:%NQ;EAO5)M.>.B^.Q1IPOELQYL/GC^Y\EB\;M;Y-364J0X7ZO9G%*R*!V
MZDW:NR6TT&658ZZM#ZO4VU1\)$I.P 6S7DHU._R=BO5FFR;[:-.'1EQ-"/-\
MRPG+671=RS1'FJ!1U:-;=3\]O93-)+$^[D8/DE6WL,C+ (5;I12E^QY=G#.(
MU)3^%"QX5(Y90@[D0#2G$=WC$7F9I(A8.=LH'TZ)]"I2C5.(:Z2-FP1U(0MU
ML)ZLUC"YSRK0(U3D']8$^0<M D4:16D=@<;>FR+E2):3M;OE"KQXPP7"\Q!1
M#U .NPQ.CLU@+7<>1##40-&ACFV69B)0] ];31\3OQHI+9Q*&/3O1M37M8&[
M0-IU0XYN:98K=,O1\#HTA%*$ZE_3H>KDJ2'N#9)*31JCAG%HX:%\22%S<6Q^
MY- JJDIZW-@R0,G+P0PN6A>;KK/3LY/Y V.B1#9I&6N-1/Q[CC&;PJ=R#V#'
M1621Z[QR]F"]N'B0(W3!L;IL:.A0\Q*&W^R7?AIUDR0IC7/CR\EQ6/&PLZMY
M0S(8O (_>1@=(,<_(N/4YSUM-O2++((]%!>T%,7R!""HJ5#,FB6XH"03;'L[
M2@ZQTQ&HLZXA!\*L<<QJ\-B\P$G]H-(*Q,K9H\-3?F[9ARWQ,*\@2@,W3]'L
M9 (Q[$9"Q"\;$ XP,!LFU/H'RX!&1T1E6@QR3N##ACS<,N;6W-@$-MP\H-WA
M K=7-'H8<$EFY&XF%H**(VP;>G ^41>--XL3CXNSBK(S$ZX\PY+"^7 YZ<R=
M#(A)98+.G.$9-I!K%-8WJ4OIML?)"0$R<13LH4/PM%O!&(Z2.\EL?;B);(!"
M'D$7X$4D1HJ*MSA$82IDX3D8B:1&6IA)&'<[*-Q6B>& L&65OYS'M+3JS8(/
M5QR8[1O*<)-YVB*,H0B!#*G03.D8.-5Q5-RM4D%DRA]((]AJ5P_H)S0[PY(3
M/+TN<144CML'B=Q8$RW8Y+E>\@1#3+]K0#.KPGO@!MFGFYI@ACZ?V@HBU,?0
MRLN?$:1WN@>@WH1\*7[>\+T@;+$>X[- 7FM=$;+I,W<PBI]T:7966QX]N2!A
M6#%B%^1MR-XU) 7K<32-L>@9>*"*U; P>0-+=S?+)F0$QCHR+WDMW,4B2HVO
M2!K0:I*<KN\?AJ1H0W(H/6N9V2N)/BS3XXHQQ95308=4C;WL;^=MO" &O9QH
M3&M@\&B:!I&HV0/:52;D",IF47<W!;@<J-&D>;CK8_M;!H!@Y"FP2.5CE+Q:
M.4H;'_"1.RVY-=YWR2^FS,P@KX*"R4R.WV=#1]=VD%_'\I$T2)(Q]#8:MES]
MFD$R0H14:=&<Y84A&6)B+#7*">;.C)8Z*CL%Z^TC"OL4,4A<UQNOB70C-VX5
M:HJAA2T!<?/YJN;T4=R0D:YA&G\@Q6"Q22K&\PVM@ZTAQA'RXG:=CW;@N(%_
M-Y5R_*,\CZDD,YT$93.BC4H6IW58J?;BP0\ >AKE24I2/;)I>A-F>H65*RZ1
MB]Y5M)L^YL-\&G2S"K="OY+J*6H''P))UPTWV#;8TQ 8/!.QC#LZD#Q=7U(J
M<&M?JT';-K:C1W<^L4&I"W*\7'<A;A)J:L6I=D3:%+/M5+7(\6R'%2F-W6=6
M)A1"LW==&;P][=([ONSE/9X9T\&Y!SHF4D:;4UNHOJZPV+676J4:G$GS8&Q-
M="@Q(\MJ/2HZY>@V5)V WUNFM*@C29W+K*,$!T@W-&IN/9T>!XNCC?$S4.:5
MV;NI=H4C(0ZY>D)H]78A9"]&[3O'MI&[;$J?7E4[<MQ?&N\+Z3?>RA (8!&1
MIP?^9GFT3W.&-/LZ"7SG+TRC1-D-R'IWS*\*6HM/+Q>Y,VX%U"ND8;,71L/'
M9:^_A'M1''+,3).2Q+G$?G1D>FHLDX'D(<-DR9@U.)6[17*(/*BUC;F/4_YV
M<E^%HYQ8'JVA;O7L2?)5N5(\<VRZ2^E&OF:"V;J05C]FZ1-18TC8ZC5C*7S1
M!\ACHKM>8RY:Y0=7*$4D],9(-QYH=C:%^=F"1C2.3Y7(X8I#S+8I1A*8_!A@
MO:950>.-G5Q>/1Z,]<!&;\?"IJ/NA,BCAH<TQ_&1%#_,\4E^P&'=$M6W)'I)
MKYD W7697?2]I:$C\_M"H?WY[69U;/C5Q0'..B+!EQZZ%U,=0VBBT; 5&N+Q
M]F:7F']<Q(#<##,);U'F*<VF-P-8.3L1&4HW)8TZ69+[:X<$B,K5$KU&C=S1
M!*;7%* ZZGVNY#T((R+X]H1=&B"G,0:UNN'48SH2MCL@L_/*9&:#VKE@ZTO!
MBZN P+R \OK:V";2.)4@JQ.LJ\S\\1')W)<GQS&?4 \?!DXG[NX1GFY Y4/C
M SKYIEG6'%.P2BYXE5&2,[9^,.-G#[V?8$(H-!6)?M;3J 1^)7/<V$:V#Q7A
MR' *5FIH1]O*C^2B-GB2:!Y>1#Y])UDY:#H8L8V^6"5PQF=8!?BD>[\?JVES
M4[DK)).YS=%[45SZ_8YC*.^V4\\4!70AV\$S3TZ)#K%)LD:.BP1A2#P^3N^_
MH41@=JY::R=M)M9ZUV+XC:0UO9LWZ+FQD1/2LYSWK,90:43CBPZ]?IC30YQ6
MQ] 1M-W7CNPR5U% )#MNY!$!&:HDT$LC]HS I1E4<,PF3DJM9GNECO%CCUHC
M5"Z9&^+6TI"Q(;H<$SN[L]SV>*89>&N0X3-.M&]Q'9J&%N$LB"034_C6<,VF
M2>@9E9G<.-Y$F21SAA;V AZ8W??^PWU26]/S"PL6IT)DJI_=G)9FY3XQ8JGV
MSC(DH]&)BM^G'*<D)V1Q,TLP,!24Y2MSJ-\UB&L09=IB=YH]\/!D>V+11+F5
M%^]3)"DM*<]B%*JLT-TT16S11P["LK/$I]11TX@ZYN=I<E8F^RDZE;H5&6D/
MC@5-$JTKEV9I(7#63",L0JWIB B-ES\0[L<6(A:F5,T![;#<4<2<YEXSS>S+
MY?6D2V(S>:A(C:BH1L /70+2U!:SFW :<0PI5ZGRXV+X\]QH1AQ2SZ'EG,T4
M)LY0/;E(R[:7)/7\_>-< #Y!@&31/I+;*^B%A@(:9 W99.3MODJ3@=9-3]MD
M+?8<E'&.AEX+2R="LD*DKY'1P0I]R5,E$2H5P="+<[Y'-'BT:Y2>@PN9YH>!
M$MCR0)[D@54Z60K1-6Q]GJ:I.E-W3D6R-I4BPZ6MK$RRP2B2+6/2 *JUZU,T
MD#@LV-V#F).F-KO$&$?=$0,;)+3TVMT:;#5C>$VQD?TB,MCT\?84?7ACVM 9
M(H2Q9D:.\%B[8T.AHU2""Z&]>X_>$7N:M"/*F;'$GC$+1IPY2859Y:1T<6F4
M"#A2;LPNQ1>T-_-'+0A)JX/C$J$E!49.9Z^RE(AR@_#=S9<V=D=$+.S*%C*P
M:A;1I).UE*5Q:@;^_P 'D+_R$N%?^'71-=I:4I2E*4I2E*4I2E*5Q3\=?]\P
M\ZG^49R%_P 36/:[65:WIVT,;6K=E6I3OT(\,-FS4CUX;5.>.>W#5;Y6O9LU
M897M?9;+*U]F/YMLKV]WM:U[ UG+4Z[-&O!([(_M-[8Z<UJ+'7AEGEGCACC>
M^C>HO:^5\[7ME?'Y=K?7+/&J(ID9I$U>2-:U$"[;AKT;+W:4"=5A\*B^5L/K
MM6I[V^&^/K9>^-K8WOC:U[_%;WD8\1-Q,@LX-WVG'7\7R]NE6GS3*-&WX<<\
MM6S#+WAEEC;*WO/1LW:;W]VQV9>K^M7^J>S([Y,(>6A,R&C8O(^MNE0SF.-V
M@$2,2Y:W%!>T$#[O,2;4]OS%DE A-I'%BPJ=6RSJX-^K>COJ:E/S_P W:IW=
M=#,D^V*-2G=K^;AJ^!+KPV;?BV?%ZO\ #GLU8_#:V-[Y7^/Z?JM>K:X%3<W,
M-B'=I7;$F5]>.*?0GQR799[-OR;Z[:<]NO7\6N]L\L[WW6P^##++#/.]\+96
M7*16;%(Q+,D#WCI?]:S:FM='HOL38(5%DVVZW#%9?Y5\\[_'JMINHOGK_.O;
M'+UC>^OA,A8<$^:G0N4V4XWRPLBT8;<L<;7PQM?.VW=H]?%?/\VUKY7_ #<O
MBMC^;\60WRQMC?/*]L<;8_%>^5[6MCC:WN]\KW^EK6M];WO]+?KK4;B7LB/^
M[H 0=(12+G ['KX:2:'C-CA(PHW4FU1>=O\ 'KF4-&E@("%#L''I^&G6[ HW
MK]"Q4CTX*%*));9AC?9A"4-BYH6O..*I,G;\E6"S0KT?)5Z-J3'XL]5]7QY8
M9Y[,,M=]-M>W.V>6S'5>^.ZVS7A\-A0C=,D..*-S1_>27-4DS6IM>O#9CAMS
MUWU7RT[U%L-U[87VVQR]8VU7POEGCEGAAE4?A CR?_P=UZ%VU9BDR5[U&M->
MZ!+A:V&6&O>IRSQO;;MQVZ[Z[:]>S7>^=L,MF.?O&U]I2E*5 75PH@.^6^E
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M?]F@_CB4&+B20 P?!M;X8'_8<$&4=19,[>W9M8'S3!G5T*-D+QL9-[6[/.K
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M<7K1?6L4MA*XXC+SI.LF87K9Z\:4FSRKDN-6R2>/8PD4^AUJ3EL0QD'+&=O
MAQ[QZR#&&3&WTU*3?>E<W&5EMEBMM2QE^,EZ'S%A6D2)E:%K8^SCU!SNS!,%
M1.!D74$50U)T3R-./1D?%13K5J?E$!-/>))'I#I&="M.0.0R&RA+43B)XK1X
MZM"BQ*G:L5J+:0H/C@TR\'S\^9KQ<=EP>'@9<#3<$,CK?(^N61NVFQ9V:Y B
M47:V5\86E^T:1OJQ&R%N;Z[I4^O0P'")(UOFN0$2X/U0?^1X2/=ZZ*4W7/+3
M0=GTB] \9D@BF6R,7.K7T^XQ;T3JWPRQ+B31BN=]R8;Z%R.I#3Y- >T;W=HW
MJVIDS5ORQ36[QIQ)+8#V !;8JB<+(P0FEF/Y8Q.%$>LB85@UKCF:^@9>VLH>
M1)3%M=0QU(?QI8M)VD;P=1B5:%[&C&MCK9:9N -L1V9XWGCL2<H,EXN>HNV-
M\9B$2LQ((D@DI)VYS> GLSF+I<MW,>MSU*=&AL(@J$S:-D^*_7DJSU&^O6Y?
M.:=CLGW0)VIX:7#K.9YOEYKDL+CDCE]X4I4YNE#E2^0QZ/EW ,V\B+@O)Z3*
M&Y6X,*X\E!ED-S'-3PWM#JR,:QOW;-#QM1+=&5)/%A)=N#Y>Y_:I)B>'I_..
MCL^JXE)H2 W8?@SF:3VUW"MC"T1&#K5MW=&(K&@0=LR_1?-#F^/LFR.LP1ID
MSS;1?22=?!8P?A.:Q^-2QS.%!TMLKJ(<V-I\!*M\REY>S<XP<$L7/YV09.V6
MH^@.,Q3E)9,(\+#31F_,KOIQ?L6])K"%#F_8XE\;D3R#*+SN9^EH%(9E;N@3
MR/AIOCUC4)Y& I'C_JSN7N";8; 7=VRT?@<6:H@ZX$!_>G5.+2U[L!'[U=M^
MY@7-GP;S>"WFZ=.?XMZ+6SA!;3STJ/I+A_0'@K6"B,98KF*)>58-AIS+E(*%
MR7+30T+2(J"'W<Z.&1HJW%#]H>"A*B3,SNU;57:4>/! K?CL7'GU(Z/\9/[8
M+'C8GQ48[QH@>1$=/&QL79;M.O5GO6"):./FO)+L4:K)'5/CGLP48[M.K+J4
MI2N+4#?W^#R%_P"0EPK_ ,.NB:[2TI2E*4I2E*4I2E*4KBGXZO[YAYU/\HSD
M+_B:Q[7:RL9,;:\AEWMM^'X+I\/?Q7]6]_/U7Q^ONWYWQ>OA^O\ ;>O\5?+K
MJT;![1GN^&U]*='GJRV7Q^*V=\=6-\?BRM[]Y8WO?*V-[7R^'Z^[6O:O!%\.
M18JV>_>W,?1WV7^GN][[\;VOG:WZ,K_IM;U:WP^O7\%?UETITI 0Z$EM>&K/
M)-OVZ]6.O'#'?GJUYY?%;7:UL<OBV[+_  ^K7O\ %?+/XL_>5<2>T+9S/YQ?
M$?!NM1=0R<\Q/V'VJ<,N.&*G5M4[QD?@J)WA;I^5E=%]TE9 0[&U?LV6U;%6
MS<GU8V4X:L\>WQ7;"[7C;9_:?:]/OW?UC_:;?7Q?6WT]^O7U_MOAK$7?#3M:
MM[/E>V6M)L<U>>%MNV^&K0G0[=^F^VULK?F_:,KVQO>]L;;\+6RME\S\ZPZT
MB92@!D]OAO;)$\XZ?S\K8VSNI^++._J][_F[+6RW7_.]6ME]/5O57YYV:7!N
MP4[+VRLE2MJ:V66S9>WSL\MV6WX?=[6MM]:[8[/?O++X;9VR^&]JB_MV:=7.
M7&G5$];%6"/9$'/,O2$AW9[M:>]W<7 GUU9$^O;MU[L,5"MW3(4B:U].^^:C
M?JPQT;LLL=6>M/A>AK= GBHX-CA;HV)W;5SH"FI!JWZL]*G GE9)LE0FQ58;
M+8[KJL7XS<,=^>_''?LVXY9[L,-E\L,=W2!GOB4H69)NQ1MQ;MNJ<4^J]T]]
MV;5KNH4VUYZOS[Y9Z,,[_+SQR3Y;-]\MF'Q8Z]FJ0WA)KNW_ !ZO6G)NMBH3
M7Q^*UM7V>UKVMCCCEC;U;#'X<?=KVQ]?2WZ:I1Q%JQT[W;.V&:UVVYJ-V^V-
M[96U?%?'7HQOEEEZU8WQOLM;&V-K_%:U[9?!C>LDI2E*5"_2 01R9SO/4;A[
MDA9BV0(7E((%G=S7JFIM:B,K!WUA9')P=$*=4M;4*%S7I52M>C2J52/1JV*$
MZ?=MUX:\OS!GWBTF%T$YU+V_H&#,[/Z4_"YH?M?4"IJ:+.#Q/'#<SP*%F2TV
MC&4HR;M#2#!LE[OP$/0!U&G[&9FMH6-"YDE=U($&9!WAYF&/39!+73Y-S2,Q
M^,LT329,DJMLP20-,FDLAGQ_N?/C*K(FHJ9FIN4",4SFQC$N-9$5&NEO=$"A
M0[+V!C4,"5DWT, <"]>3"@BF:]ICQWTB%-YF!)T@R%]CS.41&,/L:<Z\9P<W
M=&"TFQ($C;L42D"$/.,M+VL!2*QW1HTS.MT[CG2MQ?-CC0(/"AV$*QJ-1^Q-
M?/SW'@0SC(RMY^4]!3*%QS+V+ <>1ES0%Q$3#47*7@86#[AU) 4PM;'J9GO4
ML+XM6M"AP2K1\4(MV7E7A6[!7,,F*54N#Y_)$CC)@'GL@+)D,!@@E5A2J^ 7
MD"UOZ<EBR509/IWDG/G1#^]B1$!%X6OW2?M8R! \L\@F6ULSWL_B[ILRXO\
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M><LN#1,D/.2&9)%>@./U^EYB5+A'^ICA >2H1%0RZ(68;[2)\,-<EW)GEPD
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MNU/R WC7_P!9?1?].#L[_EVI^0'\:_\ K+Z*_IO]F_\ +M_S_DM3\@/XU_\
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M!QP]7_AO>U_\5>^O!_\ 7[ZH9[W]?^MI%N-O?^+);E]/T_3W_+7GNP);VO\
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M_P /[*I;:RKYE_:H?^5]/AM9 XVV?[+WE=ROC_B]8_3]?NJOX7SU_=VKXO\
MXJL]?S?;/?Z/VU2YZRGX[?+5#]M?OZVS0.-\_7Z_66+CCC[_ ,>-ZNB2R^V.
M?V_8CV9^[?!=)JW:L;6^OQ?';=NW7O?]'KU>WKZ^_?TJKI2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*5Y[=VI/JV;]^W7ITZL,MFW=MSQUZM>&-O>6>S9G?'###&W
MURRRO:UK?6]ZM7X1CW_[]9O^^B'_ /[U]ZWYBW;->G2]-.W;MSQUZM6MQ1Y[
M-FS/*V.&&O#'=?+///*]L<<<;7RRRO:UK7O>KM2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*I\5:7-1L28*4^:O3ACL
MW)<=VO)1JUY_#?#/9HME?;AAE;+&^.66-L<OBQ]7O[M512E*5R^\V']Z.\C7
M^2%-O_ QRK_%(KH!XGO[Z1XW?\O#D?\ ^SX U_M\4J)=$\0XHV3/JM(XKIV<
M[;ODSG@M<]3?>++?@4WR-BJ,_M]DUF=MV@CHA*]#KOO9M4,N[);H5[->A1?5
MG8F4L!P+#9J*N.MW%R]A:"<<=M6E2GU.C"_-Z=U:''5H6:4RO5J7-ZI.IUZU
M*?1OPPVXX[=6O.V6-M+8D\GO <[R@,PK$74L8G4JF6U[T"H,SK73%]?MPXRN
M)&^ZFW0M:TFM1L:V)H<W17CCM]ZT:+?M]7MCZOLU+TZ1! ;,,$4SR(,1JQ&9
M^)1:+NY6X8-C>\R$>+\FP/%$JK9C?59U?U^&:9!KW9:M6>S'+YFW7C:^552N
M9XJ03 S0 L/!W1-)" /,J,L:YKL?PK<8Z'GUL&7DQT-ML;Y_<2 @>6UHW+,\
ML,<EJK'3JMLOAM^7[RU+T7P-'A-+,S'HM&4:AJ/4N)C4R=TC(P-&A0JT($>*
MA<LV:\,E;BXJT;8UH-%MJ]U=%B-L;DRI>K3I]N'<_=/0!U2).1QSU*HI*@VQ
MOJD7(5(XKW6<!@F2)DJW>.E; XZ$) +/F*!<A<<6DA:VU?M;%Z%RTI]B%:E4
M;9WI2E*4K7Q5UAS4BGM)RXKG"-D_0R]!K<4D0[BANP-=^O<RJB;0CQ:K[?BL
M]J1=$M*DH[EGB_J15&J)M#;L8D^UPPV#K!P*2X_E)O?':.B]A-&L:,BV/7YP
M'7#2Y(VLW GM6-&8PJ4)\LM6#N,D"%:S/"6V66:)Q2*$FWUNT[,<?D^DZ/8L
M0CSE(IB/AB$M. V-1A00..AOQ(#^0GY(,A0@SX[LK;'!_)'U<F;VQN38;-^[
M/+9NRQP3)U&[5G582)R0!';N?L :6L9,\167:@&1F]F7ZER@--=PJ-&^ P_6
MTWRQ1/5A,Q%WW8ASRONTH7M#ENQU[-E]>,'=(=O\C<?J!))T_P!"Q?!JD\T/
M:H-T2(2)F#82)QS-LU/NYJQ4?55K:MCTU8+<L/IIR7IK9?W2U3M'DA!$L@@?
M)\:E#.;1[( XT%X48#RS6X,1.,/Z'2Y,KZSKM7[VK;7- HT*T:G7^9NT;<-F
M/TRM4$@G;_(LGSJ7<R1YT/%ICT !;R9,9Q(P$Z-P-AI0&+]+65IW=HTWRVI-
MP\Y;]*%VU9W^-&JSMIVXX[+7QMM/2E*4I2E*PDLD@#!'0#9#$L8QMXE M_ .
M/&QU7:DJXR,;#S^6Y#@^FSO\UQ=-8R+$3[M3Z,<KZFQG7JMM\-6C*]7LF)&(
M-'" O*'1(QC(JR.I(1/2_.^I"T,3&@4.;NZ+=EK97UI&]O2J%:C.V.5\-.G/
M+U?UZK57G?R"\4]9%+D#\Y=+15+1HT#]RQ<(C!#AD38BV*M(W[21,Q.&I"Z+
MV%,N<&Y$L=T"52WHE3BWIU:C3M7),-TI= =+P/RL&-LA=#2>-10&/).WA;40
M%&Y5J1N)6ZH'5T;F%'BC2JU&]Q6-S&[K-.C7HROEH;U.=[VMKO7GS]T_SWU4
M*.QOSI+X/, P/D"@4(7(*>=+GD.DZ5$B<MP^0H+VU.3"\6;7)N<\&]V1HU6Y
MM<$+AIU;$:M/NV3O2E*4I2E*C22IEBN'?P"_&D>C('^-&2!F(([_  E<M+;^
M&,GF=EUQ4&8OG7M]M(GZS:O^[4&O]\4?9=WPW_-J2ZT6;_)IP*YR[A Z;JR(
M\);VR*OB/0%KW[8U+E,H-KXK&%0 E6N:5&T*BS\)$*I@3,B=PVKE[UJ^ZT.E
M2MSUZ,]Y-V[2FT[E"C=J3IT^K9NW[]VS#5ITZ=6%]FW=NV[+XX:]6O#'+/9L
MSRQPPPQOEE>UK7O4%0'U'SMU*RD1#SM,L?S&RB3WK'B1P R!&^:&=U4($[L@
MU+/L^?S,$KNTJTSLQ.6.&38_-6_4Y,RQ<BSMOO/5*4I2E*4I6O>GK'FE1/BC
MEK1.,:[>B$C?BXJ8@UE+;D;:->3)B461;&JV[XL7S\%,\"VXY\?X08B66)3D
MV68+V<;RE(4A@D2@Y3)<GEXZ 1\$,JTB+S,M=D3$-C;&W:K[EKH\.SANT(T2
M31KM^=LW;<?BSRPU86RVYX898_#<VQ)T(!MTG0E((Q)@$ZJW-N2$PHY:W%!9
MT95VYM>6A9CC\"EM>&AP3[D3JT..A(Y-RK7EH6)=.RWPUATA=8<U1-+$?P7)
M4X1N$3!*F*/8 1V1D[<VDY)K='>X\R[$K?OVXY)]9"1XYC8SL7Y),"8DU[!]
M@R<7C7FBQGM8L2-Z14O7JDZ%"B3[UBU:LWZDR1(D3:LMRE4J4[LL-*=.GTX9
M[=^_;GAJU:L,MFS+''&][07 /4O.G5#$^DO.<SQ],K$,.VED('$"(43[I:7!
M4BU.3?@MQ3Y_-U)7AKWZ75B<;Z[MK\U;=;FS*UR'/%1?SGKJSF[EQ*)K>B)L
MCF&TITZ+&<2W'Y*WL&+XK;$VM:\[DEE>S'+%J8$6[0M)'W?CI8QQ(I2JGQQ;
M]"G1LV3YJVZM^K7OT;->[3NUX;=.[5GCLU;=6S&V>O9KV87OAGKSPO;+#/&]
M\<L;VRQO>U[7KTK5#H+NWB_D\@8A3IKJ>!8#)B=GS(1U@EJ4!($=GMBU+=[;
ML=VM 1.B!2M;L'!,H19*]&O/193HVZ;Y_,PRQM^6KF'R-\#C7[HU\EO0A#V/
MS<RP7(_(O.XH R\YR\$HX[,B8?'H93OC -EN]XP9GAV:=[.ZZG% B5[E"78W
M+,-VO#)/MMC^K[GOK;E_K-J(WWF+H"(I^9@]P1-)4Z1&>CAX@'7-Q3;%B!O>
M5(ZO7ZF]6L2:=JA-H4Y:]F[3JSV:\<L<<KVV&I2E<OO-A_>CO(U]?7_G0IL_
MX&.7T_E_17^*170#Q/?WTCQN_P"7AR/_ %SX ^J_V^*5PZ\AW,K.?]K\<MR<
ME<!P#[D=GCF+L<#0I=>;1.L1<]A9]US'C&];,-Z;8B5;'>/"V(BE?;!7N((:
ME\Z$-WR<?NE2A[;+U[8Q-:US<E:-I9F9 I7KURO;I1M[8V-Z?-0J5J=^R^O0
ME1HTNG9NW;=F6&G1HUY9Y7QPQO>W$;A#HWGGMSIIY[4?Y\A5V*RAJ*(<X)YZ
MURL$+9(".>$2F[P:2XZQGB_;B5JEWI)<,V-'=+=IUO0C!0S'(VYZ6QR_#I/N
MROS>PIIZ/Y]YT@?8LNV*)9['CH&:'K#/Y:@<(WV*YM2"Y2AW?#G\AR%B/-K(
M6Q3\&?V9P;$V_P"#/Y?PWTOX)E]X[ \D4!]T$3%N']\Q<<='P^*-BQ-DF7-(
M] .SA7\93$JTYY9_(6CO64D],B"[#5GEJW8"J#.VW=CKU9UT?\F#L/!9;X\)
M8E96WM?.$3]R,A1.9(09:M(4#Y/$!3R#PF>R N5Y8M;,)C?017&-L2-ZSTM
MR5. L0K5:'%LP7)HOY#GN'.HO*#UG*G,!)I*HU#>7H9A6?B!L:G9A:W+HL.F
MV=[#;6L3NZ%LV$+^,1KBLW:RI$F7-S@$%0-L;7IP9U+3;5V>I2E*4K@1UJ?0
MHKZMY]0Q >QRA*(Y\HL)(>C.5]8586F>9)XD&'6,0'IP0DVY?I)G@?B.#"\;
MDU<O;116)& /&#ZUKC72G&UK3?J)W&3]!B?+LI+^60$FD6<G)"S"X:TAJ@&T
M%3#J+2)I&R601W1))6$A+L_QJ*.CV>,+ 0D[0V$+V/M[*L5ZDR[=GCHIX/\
M#6P\X3E&S7 ,H<^BL:=C=*#@L,RDZQP\O>Q#>1G;<H;E3E'DAR)H<2,958YL
MYL[N3E;[Z*<7!T;'$A1*OOE1J?Y>"6?]G1D*D+SR%/,HP3S]T)P$^0(5Q\^<
M^6"B">"WL&'E1X0.B([FP+-41SB')6_GV(;[1+2/('"3917DQ*V#3\G>6?\
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2V;,L<+88VQM;X;>JRE*4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g722206g13n07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g13n07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-^4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     8 00!0 $0
M+0 R       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+  &         *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F
M       .             #^    X0DE-! T       0   !:.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      -!
M    !@              90   >,    & &< ,0 S &X ,  W     0
M                   !              'C    90
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    90    !29VAT;&]N9P
M >,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   &4     4F=H=&QO;F<   'C     W5R;%1%6%0
M   !        ;G5L;%1%6%0    !        37-G951%6%0    !       &
M86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E
M;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO
M<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E
M5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453
M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $    !#A"24T$#      (Z     $   !S    &
M 5P  ""@   (S  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ & !S P$B  (1 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                      #_XO__24-#7U!23T9)3$4  0F^S/[^'@ (@'!!
M1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,     $%$
M0D4                    !  #VU@ !     -,M041"10
M                                                "F1E<V,   #\
M    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P  "B!D$R0C(
M  &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT  (XM$(R
M03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N4RX@5V5B($-O
M871E9" H4U=/4"D@=C(
M
M    =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US+"!);F,N
M  !865H@        M5H  +QG  "2,&UF=#(     ! ,)   !
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MFO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ. 8V.HGYN
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MQ(N YH&VOO-_^''"N9!_2F%*M&U^XE -KYY^Q#VMJU]^Y2E=J&9_,@^%J<.
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M@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F S(8C@4.
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MX@  AQF  ),JL+><^8/+K&::2W/4J#B7U6,OI$&5K5'.H)23Y3]FG5F2PRM
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MIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^ M4GVJTR
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MC7/?F@)L-&/$E^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P  @ !]T)!
MG8UQ8X)(FQ!R47,\F,-S.F,FEJ-T(E'PE+9U##]EDRIUZ2K3DG5V>A XE/5U
M\@  @ "  (^8G"%YV8%UF;IZ$G)]EVUZ36)@E5-ZE5$]DVIZZ3[+D>%[0"I9
MD1Q[<1 &DR][)0  @ "  ([/FLR"/8"2F&Z!VW&$EBV!>6&0E!.!)E![DC>
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MNC&#?UTUMB."VE!6LA6"2T*TKBN!US04JK>!FB.4J(6!G@^IJ3"!K@  FFR
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MI0^6$%]4HB:4]5*<GS.3GT3SG%^2639 F?21LR7IF&&1O!*"F*V,@P  D">
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MK]V9H%2[K"R8O4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*')@  C "
M    @ "  ,$39Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW<+ELT4;'
M<D5O$"S/<R9PW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)ORW)&;,]Q
M8%RH;K%RZT7)<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'9GUV\X5S
M:+-WI7#X:M)X7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN 7:FX8?6
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MDUN#6F)\D=:#/E7<D$B"^T@[CLJ"H3F$C8:"5BDPC+Z"-Q5VC62": #@B2>
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MF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR 5E=QG!:
M84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2     @ "  &(F
MG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RLE'2%#0  A<Z
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MI]*+0TP3I3**_4"JHH.*9S0RG_Z)SR9=GB&)RA7_GA&)-@5-F:N#E@  @A:
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M77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2 =S;H:@. 2QYK:'2
M'0#J?G5_U*!C6Y"+>Y$K7D**EH$)8+B)DF_I8PF(@UWF94"'@DK)9S6&HS9#
M:%B%^!WN9JN%V@#9?I& DY]?6?F5=) R7+R3S( :7SZ1^V\&89N0)%T18^*.
M;TH39=R,\S6_9N6+X1V/93.+C #,?JB BIZ=6+N?88]S6XB<]W]97@V:6VY*
M8&R7OUQ:8KB584EH9+F3:34W9;*2-QTZ9 20-@#!?KJ @IX=5]BI-H[J6J6F
M#'[#72.BIVVR7WN?3EO08<2<6$CU8\*:!S3#9**8Y1S+8PV3> "X?LF ?)LV
M<+)8]XS5<<Q<8'UG<O%?D&R\=!MBC%KA=41E9$?!=F=H$S+R=VAJ8!E>=\UK
M6@  @ !R'9GA;8=BC8NC;NYE#WPQ<$%G:6NC<8QIH5GE<M%KOD;F= =MNC(X
M=/5O8!C2=,EOW   @ !VR)B%:J%L((H_;$!MQWL1;;UO56J%;R9PQECN<(-R
M*$88<<ES=#&9<J5T?!AC<B9TDP  @ !ZXI<$: 5UF8C!:<MV?GF#:V=W1FDZ
M;.QW^5>^;FQXHT46;\)Y03#'<(EYMQ?*;^QYC   @ !^<96@9<9_#H=G9Z9_
M/'@S:5Y_1F?X:OE_.5;&;(A_+$0Y;>U_*# :;IY_'A=2;@9^\   @ "  )1[
M8^J(DH9,9=^("G<F9Z:'5F;W:5.&C%76:NV%S$-_;$Z%*R^(;.>$OQ;I;'*$
MP   @ "  )./8F*2$H5E9&:0V'9&9C:/9F8A9^V-XE4-:9*,?4+6:O2+5B\5
M:VJ*K!:=:R.)QP  @ "  )+>82Z;B82R8SN9H76.90Z7=65N9L.5.E1>:&V3
M/4(O:=*1LBZ3:BZ1)196:A6-Y0  @ "  ))F8$VD\X0N8EVB9W3[9"F?A&39
M9=:<G%/89WJ:%T'!:-F84RXB:1B78!7E:4R.S@  @ "  (Y\>.=8L8$G>5)<
M"7*W>>%?*&+^>H1B$U(!>S%DU#^=>^]G7BL\?,5I6Q#>?E!I8   @ !V"8U2
M=>%ANH 0=IED0'&<=U)FFV']> ]HTU$?>,]JZS[=>95LTRJ?>D=N0!"(>X5M
M]@  @ !Z'XP=<QMJM7Z]= EL>7![=.-N'6#E=;MOHE R=H]Q$CX:=UUR72H+
M=^US11 ]>1!RRP  @ !]M8K5<)-SLGUK<:ATP&\I<J%UK5_H<XUVAT]/='IW
M2SUG=4]W^RF.=;UX:1 #=NQW\   @ "  (F3;FM\KGQ0;YE]%FX+<*E]5UZX
M<:5]>DY=<IY]FCR*<WU]NBC=<\9]PP^A=25]G@  @ "  (B);*2%MGM';>.%
M>FT.;O^%#%W'< F$@DU_<0>#_SOC<=N#F2A;<?^#90]:<Z&"^@  @ "  (>R
M:RR.NGIU;'F-WFQ!;9R,PUT";JN+D4S&;["*>SM(<'Z)IB?Z<'"):0\N<EF'
M<   @ "  (<,:@*7N7G-:UB61&N5;'R4@5Q=;8F2J4PC;HZ1#SJJ;UN/]B>
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ME+=YR$\&DWUZ0T.QDBYZE3=1D.EZPRF8D 1ZWQEQD"UZS <[C?A[T0  @ "
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M^   @ "  $\]IE-A[T4MI)9CCCI!HNME&"X1H7YF>2 3H0=G5@[1HN%G"@
MFMYI[@  @ !Z/   @ "  $['I MHIT2CHEEIWCFDH+9K 2VAGTEL !_ GK]L
MD0[&H#]L*   F'=O*P  @ !]_P  @ "  $Y+H@MO<40KH&MP3CDSGL5Q$2TK
MG4QQI!^,G*5Q]@[ G=EQC@ UE@!U"0  @ "     @ "  $W7H&IV8$/*GM-V
M\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "     @ "  $US
MGQ-]54-_G8-]HCBKF\]]L"RWFC=]GA\FF5U]C [1F>5]M0"PD@E^S@  @ "
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MU0-6>ER"0IWB1%^EAH\/2/"B27]530F?%6Z;4,Z<%ESK5%.9<DHU5S^72#9
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M<4F)FELT<DV)54]B<P&(O4*"<W2(!31G<[N'BR1R<XF'FQ%+=&J&P0  @ "
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M>DJ-;% %>M>-*T39>O^,;3BG>LV+DBLG>G6+2!MB>=F+,@E,>RJ&20  @ "
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M>@  @ "  $='G^94_CWXGNQ7=S-XGAI9Q2>/G:];O!E%GJ%<V BGGW-=60
MCMQD?@  @ !U40  @ "  $:;G0U;G3TTG"U=K#+"FV]?CB;;FOEA)!C#F[UA
MZ@B7F\YB4   C$-I40  @ !YJ0  @ "  $8'FCQB.CR$F6]CW#'VF+QE5B9
MF$=FBQA'F.UG!@B F$QG7P  B=YN?   @ !]@   @ "  $5DE[AHZ#O=EPQJ
M*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "     @ "  $3%
ME9-OOCM*E0IPIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER9   AA!Y9P  @ "
M    @ "  $0[D\)VG#K/DUIW.3""DJYWEB3XD@%WO!=HDAYWF0B"C])XFP
MA+)]R@  @ "     @ "  $/)DD%]D#IMD?9][3 RD4]]^"3#D(A]VA="D'-]
MR A2C?!^>   @T6     @ "     @ "  $. D02$QCHED,Z$]"_QD#*$LR29
MCUF$91=*CP6$APB%C%F#6   @G&     @ "     @ "  )[[4]5-U8_(5PA2
M'8 $6B)64&]<72Q:8UVE8!E>44J_8K5B$39Q9&-E@1Y?8Y9G] %[?8!K&9S1
M3H58"(X44BY;;WZ$5;)>OFX(61%A\EQO7$-E!DFK7P=G]C6 8)AJGQVM8#)L
M=@&+?61OSYK:2:QB/HP[3<!DN7SO49QG(FR*54%I>UL@6*AKODB-6XIMZ#2:
M7/-OVAT.74IQ) &:?4MTXICH13QL9(IK2;-M^7LR3=1OB&L?4;EQ#5G:559R
MA4=^6$YS\#/(685U-!Q_6MIV!@&F?39YBY<*039V>(C+1@IW.'F^2GEW]6F]
M3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F ?H=K0M2
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M9)-[>%-+9I5[\T@;:#-\.CO2:5]\8BXS:>A\BQYZ:1U\K O7;\)]/0  @ "
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M;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<>** )P  @ "
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MZP  @ "  $B;?O%F/#\G?X]GSC3"?_YI-RD>@$]J5QN5@,%J^ L[@6!J_0
M@ !P>0  @ !^O@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O:"AQ?7UP(AK[?:9P
M; L3?H9PAP  @ !V50  @ "     @ "  $;X>3%T73V5>BUU'3-<>LMUIR?F
M>P5V QIR>N=V$PK4?#9V;   @ ![1P  @ "     @ "  $9/=M![;#SK> -[
MT#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "     @ "  $73
M=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@  @ "     @ "
M    @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2F;Y48
MA+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!69A%NF*%7
M+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>DCY: A\Z
MDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;_310CI]=
M]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6   @ "  #R:
MBQ1BFC-TBVED)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5HAP  @ !T!   @ "
M    @ "  #O+A_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1KU@*FAP-N,
M@ !Y.P  @ "     @ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-AK]QM [GAJYQ
MA@*6A,5T4P  @ !]F   @ "     @ "  #I\@KMW"C%=@\]W?"=VA&5WKAPN
MA)=WJ ZCA$EWD@)N@P)Z*P  @ "     @ "     @ "  #H-@*I^)S#G@?9^
M3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "     @ "
M__\  /__  #__P  ;69T,@     $ PD   $                    !
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M*ZLLGRV3+H<O?#!P,60R63---$$U-C8K-R$X%CD+.@ Z]COM/.,]VS[3/\M
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MY9GFY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^N____P"
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M,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N +J-<7BF
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M>$6U%']<::ZO#W\'6Q6H\W[\3*:BIW\L/KV<$W^ ,9.5%H ?)=R-G8$!E-G
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M,WR"!'YUX.&"CH*IS%R"%X'FMQ*!LX$_H2B!98#!BNF!*X!K=*"!"8 Y7G.
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M9ZJT4Y4%6Q.MSI(03JFG*X\U0J2@6HQD-V690XF7+3.2 8;=)*>*K(1<@)_
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MHHO51]MZ0XA?,GI\)(1>WD%P$ZI5R5EQ/Z77M )R;J%AGDYSK)T&B'!U!)C
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M&YD94%B<"93K1 R6_9#*.(.1SXRU+>*,FXBF),V';83A>1K ,&YE;7VZRV^
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M*:Z F(-?J;:#ZJ#'FG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B IY B2%F
M5(R#.&^ .(BB*:6 ,(1WJ26#9*F F=N"E:6XB=2!PZ&*>4B!"9T<:)^ @YBJ
M6 R +I0H1_-_Z8^&.$%_THJ7*9Y_VX5EJ,2#!K(7F62"/*U]B46!8*A5>+.
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M5PV!Y78T1NJ!P7?\-R.!P'GY*&N!Z'P^H["!P'=%E6B!<'@)AG^!(WB[=L"
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MVVAO6IB%4FM83$6$SVYI/EN$5W&F,.6#_74\)*6#RWE"CLN%R6@0@K*%+FI
M=;B$IFQ>:!:$+&Y[6?^#NG"J2]&#6'+Z/@^# W5L,-""T7@@)-:"PWLAC>F#
MP'!1@:R#5G' =-6"ZW,A9SR"C72!64V".W7Q2TN!_7=Y/;J!SWD:,+:!Q'KE
M)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B VGLE2L: P7O>/6F
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M@6^DH\Y?N7$!DW%BU7)<@E9EZW/%<--I&W4\7RML>G;(3=)P"GAL/.=S[7I
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M$G=9)J>"''GL']^"/7R(9<> QW$L7/& XW*@4\* X'0-2E> RG5Z0-^ OG<
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M'E*#<7BE8$-\'5Z06 Q\X6&>3X1]D&2Y1H]^+F?L/8!^T&M#-)A_C&[)+%J
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M?'45-KY^W';-+XA_37BG*/-_TGJ+(QR ='QT'G.!%WX[4\5ZLW9Y3)1[N'>
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M/96"KWJ?-U:"7GM8,2V!ZGPR*T6!BWT@)AJ!,GX6(82!&7[Y'=J!+'^T2?N
M?'ZE0Y>!4G[;/56!G7[F-S&!;'[Y,22!#W\P*U2 RG]\)BB EG_1(9J GH ;
M'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
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MGXC:CY^(VH^?B-K_IS@R_Z-$2_ZC25_SJ49OZ*Y$@-VS0Y#3MDB?S+=1JLK
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MA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>LA\G_JC0R_Z9
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M/GF&WDZ#@=A?BW_4:Y!ZT7"4=\]TEW7.=YASS7F:<LU[FW',?9MPRW^<;\N
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M0?^G0U#_KC]=][<\:?#".W/FT#]YT]D_BK[+49VOP&&LI;ENMJ"U>;R<LH'
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MH[1\O9JO@<.2K(7(BZF*S(2GDL^ IIS0@*.ESX"AILZ H:;.@*&FSH"AILZ
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MI6C%D:7_IRP:_[4E'^S)&AS0XADAO_ B.*_]*TV@^#5>D^Y!;(GF37>!X%B
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MA"@)_X0Y%_^(123_D4PP_Y51._^65D?_E5Q2_Y-B7/F/:F;SBG)P[85[>.F
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MAL&HB(;!J(B&P:C_BB<)_XPW%_^;/1__HCTG_Z@_+_^N0C;WM$<\[;I-0>3
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M9]F)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G_>2,&_WDT$/^
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M>.9ALGKD8+M[XE_'?.!?VGW48N%]RF/@?L-DX'^]9M^ MV??@+=GWX"W9]^
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MBI=TV(K_<R $_WHJ"?^++P__ECD6_YT_'/^A0R/ZI$@J\:9.,>BG5#CAIUQ
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M/37_FCXT_Z$^,_^J/S/_JC\S_ZH_,_^J/S/_JC\S_ZH_,_^J/S/_JC^QN@$
MH\@  );6  "+] D!@_\6 GG_( 9O_R@,9_\P$E__-Q=8_SX;4O]$'TS_2B)(
M_U D1/]5)D'_6B<^_U\I._]D*CK_:2LX_VXL-O]T+33_>BXS_X$O,?^(,##_
MCS N_Y8Q+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC*DP@  EL\
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M44+NO%%![\Q20>_E4D#M\5% [?%10.WQ44#M\5% [?%10.WQ44#M\5'4I0
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M)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F)?^G)B7_IR:?P   D<T  (/;  !X]@(
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M[#R_J@  L;,  *2_  "8R@$ C-@$ (3Z#@!\^QL"=/LF!6S\, IE_#@07OU
M%5C^1QE3_DT=3_]4($O_6B)(_V$E1?]G)D+_;2A _W4J/?]]*SK_ABTX_Y$N
M-O^;+S3_IC S_[(Q,O^^,C'_T#(Q_]8R,?_6,C'_UC(Q_]8R,?_6,C'_UC*R
MKP  I;H  )C&  "+T@  ?]\" 'G_$0%O_QD"9_\B!&#_+ =:_S0,5/\\#T__
M0Q-*_TD51_]/%T/_51E _UL;/O]A'#O_9AXY_VT?-O]T(#3_?2$Q_X8C+_^1
M)"W_FR4L_Z4F*_^O)BK_NR<I_[XG*?^^)RG_OB<I_[XG*?^^)RG_OB>FM@
MF,(  (O.  !^VP  =?D' &O_#P%B_Q8"6_\> U3_)@5._RX&2?\U"$7_/ M!
M_T,-/O](#CO_3A X_U,1-?]8$C/_7A,Q_V04+O]J%2S_<A8J_WH7)_^#&"7_
MCADD_Y@:(_^@&B+_JALA_ZT;(?^M&R'_K1LA_ZT;(?^M&R'_K1N:O@  B\H
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M O]\&@'_B!X!_Y$D O*9*P3GGC$%W: V"=&<017'ETTAOY%6+;>,7S>QAV=
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M8V2,]&-DC/1C9(ST8V2,]&/_<1 !_X(/ /^1#0#>GPD TZH) ,RS"0#$N!,
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M-D#DN#<_Y<LW/^7D-S_C\S8]XOLX/>+[.#WB^S@]XOLX/>+[.#WB^SC&H0
MMZL  *JT  ">O@  D\D" (C4!@!_[@X >>T; 7'M)P-J[C((9.X[#5[N0Q-8
M[DL74^Y2&E#O61Y,[V @2>]G(T?O;R5$\'<G0?" *3_PBBH]\94L._&A+3GR
MKBXX\KXO-_/0+S?SYR\V\?,O-O'S+S;Q\R\V\?,O-O'S+S;Q\R^YIP  J[
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M$![_J!$=_[$1'?^Q$1W_L1$=_[$1'?^Q$1W_L1&5O   AL<  'G3  !KX
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M6(EK_5>':_U6AVO^5H=K_E:':_Y6AVO^5H=K_E;_7A<!_VP2 ?]X% '_@Q<
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MHA< QJ$I [V>-PNTFD,6K)9-(*225BJ=CEXREXME.9*(;$"-A7-%B(-Z2H2
M@4Z ?XI2?'V357A\G5AU>ZA;<WJV7'%ZQUQQ>N)<<7OS6G%[^UER>OQ8<GK\
M6')Z_%AR>OQ8<GK\6')Z_%C_9Q$!_W4/ /^##@#TC@T VYD* -2A"P#,I!4
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M2$JSN4A)M,Y(2;/I2$BQ]DE(L/]*2+#_2DBP_TI(L/]*2+#_2DBP_TKBA@
MSI0  ,*A  "VJ0  J[$  *&Z 0"8PP4 D,D0 (K)( &#R2\%>\@[#73'111N
MQDX;:,56(6/$72=>PV0K6L)K+U;!<C-3P7LV3\"$.4S CSQ*P)L^1\"H/T;
MN$!%P,U 1<#H/T2^]D%#O?]"0[S_0T.\_T-#O/]#0[S_0T.\_T/6C0  QIL
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M(S3NYB,TZ_4C-.OX(S3K^",TZ_@C-.OX(S3K^".SI0  IJT  )FW  "-P0
M@,L  '75 0!IX08 9/,1 %[S' %9]"8"5/0P!$_U. 9+]4 (1_9'"D3V3@Q!
M]U4./_=<#SSW8Q$Z^&H3-_AS%#7X?18S^8@7,?F4&"_ZH1DN^J\:+?N^&BS[
MSQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  " R0  =-,
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M1YU;_T>;7/]&FES_1II<_T::7/]&FES_1II<_T;_51<!_V 2 ?]K% '_=!<
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M%P#=BQP T(LL \>(.PJ_A$<3N']1'+%[6B2L=V(KIW1J,:-Q<C:?;WD[FVV
M/YAKB$*5:9!%DFB92(]FHDJ,9JU,BF6Z38AES$Z'9N9.AF?V3(9G_TN%:/]+
MA&C_2H1H_TJ$:/]*A&C_2H1H_TK_7!(!_V@/ /]T$ #_?1  \X40 .2+$0#6
MCQ< RXXJ L*,. FZB$02LX1/&ZQ_6".G?& KH7AH,9UU;S:9<W8[E7%]/Y)O
MA4*.;8U%BVR62(AKH$N%:JI-@VFW3H%IR$^ :N-/@&OT3G]K_TQ_:_]+?VO_
M2W]K_TM_:_]+?VO_2W]K_TO_7A !_VL. /]V#@#[@ T ZH@- -N/# #0DA4
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M@J!-98&L3F.!O$]B@=%/8H'K3F.!^4UC@?],9(#_2V2 _TMD@/]+9(#_2V2
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M2UB0N$Q7D,Q,5Y#G2U>/]TI7CO]*6([_25B._TE8CO])6([_25B._TG_<0$
MX(   ,^,  #$E@( NYX" +*D  "IJ@4 HJP5 )NL)@*4JS0'C*H_#X6H2!=^
MIE >>*18)7.B7BMNH64P:I]L-&6><SEAG7L\7IN$0%J:CD-7F9I%5)FG1U*9
MMDA1F<I(49CF2%&7]4A1E_]'49;_1U&6_T=1EO]'49;_1U&6_T?V=P  V(4
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M-$*Y\S5!N/TW0+?_-T"W_S= M_\W0+?_-T"W_S?.BP  OY@  +*A  "GJ0
MG+   )&X  "&P ( >\@' '3+$@!PS"(!:\LP V;+/ =ART4,7,I.$5C*5A54
MRET94<ED'$[);!]+R70B2,A^)$7(B"=#R)4H0<BB*C_(L2L^R<0K/LGA*C['
M\BL]QOPM/,7_+CS%_RX\Q?\N/,7_+CS%_R[$DP  MI\  *FF  "=K@  DK<
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M$2?U\1$G]?$1)_7Q$2?U\1&CJ   EK(  (B[  ![Q0  ;\X  &+7  !6W@
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M/(]<_SR/7/\\CUS_/(]<_SS_51$ _U\- /]I#@#_<0X ]7<0 .9[$0#9?1@
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M0V9XN$1E>,Q%97CG1&5X]T-F>/]"9GC_069X_T!F>/] 9GC_0&9X_T#_9 ,
M[G$  -A\  #+A0( PXP# +N1 P"SE D K)88 *66* *=E#8'EI)!#I"/2A6*
MC5(<A(M:(G^)8"=[AV<L=X5N,'.#=31O@GTW;(&&.VE_D#YF?IM!8WZH0V%]
MMD1@?<E$7WWE0V!]]D)@??]!87W_0&%]_T!A??] 87W_0&%]_T#_9P  XW0
M -)_  #'B $ OH\" +:5 0"NF 8 IIH5 )^:)@*8F3,&D9<_#(N52!2%DU :
M?Y%8('J/7R5VC64J<HML+FZ*<S)JB'LV9H>$.6.&CCQ@A9D_782F05N$M$):
MA,=#6H3C0EJ#]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@  WG@  ,V#
M  #"C   N9,  +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_F4X8>I=6
M'G6672-PE&,H;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+LD!4B\5
M5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP  ,B'  "]
MD0  M)@  *J<  "@H@  F:00 ).E( &,I"X#A:,Y"7^B0P]YH$P6=)]3&V^=
M6B!JG&$E9IIH*6.9;RU?F'<P6Y> -%B6BC=5E94Y4I6B.U"4L#U/E,,]3Y3?
M/$^3\CQ/DOT\3Y+_/$^1_SQ/D?\\3Y'_/$^1_SSD=   SX$  ,*,  "XE@
MK9P  *.A  "8J   D*H- (NK&P"%JRH"?JHV!GBI00QRJ$D2;:=1&&FF6!QD
MI%\A8*-F)5VB;2E9H74L5J%^+U.@B#)/GY,U39^@-TN>KSA*GL$X29[=.$F=
M\#A)G/PX29O_.4F;_SE)F_\Y29O_.4F;_SG;>@  R(<  +R2  "QF@  IJ
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M)#B__R0XO_\D.+__)#B__R2]D0  L)L  *2B  "8J@  C+$  ("Y  !UOP
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M!!;_Y 23K@  A;<  'C   !JR0  7=(  %#9  !$WP  .N0  #7W P R_PP
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M*Z=+_RNG2_\KITO_*Z=+_RO_21( _U . /]9$ #_7Q( _V,6 /)E'0#G924
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M.'1FN3ES9LLZ<F;F.7)G]SAR9_\W<FC_-G)H_S5R:/\U<FC_-7)H_S7_60(
M]F4  -UN  #/=@$ QWL# ,!_! "Y@ P L8(: *J"*@*C@#<%G7U""Y=[2Q&2
M>%07C79;&XET8B"%<FDD@7%P)WYO=RM[;G\N>&V(,79LDC1S:YPV<&JH.&YJ
MMSIM:LDZ;&KD.FUK]3AM:_\W;6O_-FUK_S9M:_\V;6O_-FUK_S;_6P  ZV<
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M.5UY\3A=>/XW7GC_-EYX_S5>>/\U7GC_-5YX_S7U9   W'   ,IZ  # @P
MMHD  *Z-  "DCP  G9$0 )>2( "1D2X#BI Y!X2.0PQ_C4P2>HM3%W6)6AMQ
MB&$@;H9H(VJ%;R=GA'<K8X-_+F""B3%=@90S6X"A-EE_KS=7?\ X5W_:-U=_
M\#=8?OTV6'[_-5A^_S58?O\U6'[_-5A^_S7I:   U'0  ,9^  "[AP  LHT
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M+D:6_RY&EO\N1I;_+D:6_R[1=P  P80  +:.  "JE0  H)L  )6?  "*I
M?:D  '>K$ !SJQX ;ZPL 6JK-P1EJT$'8:I)"UVI40]:J5@35ZA?%E.G9AE0
MIVX<3:9V'TJE@2%(I8PD1:69)D.DJ"="I+@H0:3.)T&CZB= HO@H0*'_*4"@
M_RE H/\I0*#_*4"@_RG)?@  NHL  *^4  "CF@  F*   (VE  ""J@  =;
M &RS# !IM!@ 9;0G 6&T,P)>M#T$6K1&!U:S3@I3LU4-4+-<$$VR8Q-*LFL6
M1[%T&$6Q?AI"L(H=0+"7'CZPIB \L+<@/+#,(#ROZ" [KO<A.JW_(CJL_R,Z
MK/\C.JS_(SJL_R/ A@  LY(  *>9  "<GP  D*8  (2L  !YL0  ;;<  &&\
M!0!=O1( 6KX@ %B^+0%4OC@"4;Y"!$Z^2@9,OE((2;Y9"D:^8 Q$OF@.0;UQ
M$3^]?!,\O8@5.KV5%CB]I!<WO;48-KW*&#>\YQ<UN_89-;K_&C2Y_QLTN?\;
M-+G_&S2Y_QNXCP  JI@  )^?  "3I@  AZP  'NS  !ON0  8[X  %C$! !0
MR P 3<@7 $S))0!*RC$ 1\H[ 47*1 )#RDP#0<I4!#[*7 8\RF0'.LMN"3C+
M> HVRX4,-,N2#3++H@XQR[(/,,S'#S#+Y0XOR?4/+LC]$2['_Q(NQ_\2+L?_
M$B['_Q*NEP  H9X  )6E  ")K0  ?+0  '"[  !DP0  6<8  $[+ P!%T @
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M 13Y@0$3^9(!$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[Z0*/JP
M@;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X* "'_$  ?
M_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8 "_]B  G_
M;P (_W\!!_^0 07_H $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_QP&#M   =;T
M &?&  !:SP  2]4  #_<   SX0  *>4  "'L   >_0  &O\% !?_#  5_Q
M$O\4 !#_&0 ._QX #?\C  O_*  (_RX !O\U  /_/0  _T8  /]1  #_70
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M*X56NBR#5LPL@E?F+(%7]RN 6/\J@%C_*H!8_RF 6/\I@%C_*8!8_RG_3P(
M_5D  .)@  #59P  S&H# ,9L!0# ; X MVT= +!N+ &J;#D$I6I$"*!H3@V;
M9E<1EV1>%91B91F18&P<CE]S'HM>>R&)78(DAER+)H1;E"B!6YXJ?UJJ+'U:
MMRU\6LDN>EKC+GI;]2UZ7/\L>5S_*WI<_RIZ7/\J>ES_*GI<_RK_40  \EL
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M,&EG\"]I9_TM:6?_+&IG_RMJ9_\K:F?_*VIG_RO^6   X6,  ,]L  #$<P
MNW@  +-Z  "K>@0 I'L2 )Y\(@"8?"\"DGH[!8QX10J'=TT.@W55$G]S7!9[
M<F(:>'!I'75O<"!R;G@C;VV!)FULBREJ;)8K:&NA+F9KKR]D:K\P8VO8,&-K
M[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  # =@  MWL
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MA@  E(@, (Z)&0")B2@!@XDT WZ'/@=YAD<+=(5/#W"$5A-M@ET7:8%C&F:
M:AUC?W(@8'YZ(UU]A"9:?(\I6'N<*U9[J2Q4>[DM4WO.+51ZZBU4>ODL5'G_
M*U5Y_RI5>?\J57G_*E5Y_RKA90  S'$  +]Z  "T@@  JX<  *&*  "5BP
MC8T) (>.%@""CR0!?8\Q GB..P5SC40);XQ,#6N*5!%GB5H59(AA&&&':!M>
MAG >6X5X(5B$@B15A(TF4H.:*5""IRI/@K<K3H+,*TZ"Z"M.@?@J3X#_*D^
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M(#R;_R#"?   M8@  *F0  ">E@  DYL  (>?  ![I   ;Z@  &.L! !?K1$
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M!BW%F@<KQ:H(*L6^""K%V@@JQ/ (*<+["2C!_PHHP?\+*,'_"RC!_PNHE0
MG9L  )&B  "$J0  >*\  &NU  !?NP  5+\  $G#   _R 0 -LT) #/.$0 R
MSQP ,<\G ##0,0 OT#H +M%# "W13  KTE4 *M)? 2C3:0$GTW8!)=.$ B34
ME (BU*8"(=6Y B'5T@(@T^L"(-+V Q_1_P0?T?\$']'_!!_1_P2?FP  E*(
M (>I  !YL0  ;;@  &"^  !4PP  2<<  #[+   UT $ +=4& "7;"P DWA(
M(]X< "+?)0 AX"X (. W !_A0  >X4H '>)3 !SC7@ ;XVH &N1X !CDB $7
MY9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@  B:D  'NQ
M  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <[!  &^T7
M !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS>  ,](H
M"_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(  &^Z  !B
MP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T $OL2 !#\
M%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@  _W<  /^)
M  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#  !6RP
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M&IQ%OQJ:1=$;F$7I&Y9&^!R51O\;E$;_&Y-&_QN31_\;DT?_&Y-'_QO_0@4
M_TH! /)0  #A5 $ V58% --5"0#,51( PU8B +Q7,@&W5C\"LE1*!:U35 BJ
M45T+IU!D#J1.;!"B37,2GTQZ%)U,@1:;2XD7F4J1&9=*F1J52:,;DTFN'9))
MNQZ02<P>CDKE'HU*]AZ+2_\>BTO_'8I+_QV*2_\=BDO_'8I+_QW_10  _TT
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M)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_30  Y5<  --?  #(9
MOV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E1P>09$\*C&)7#8AA7A"%
M7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):KR1Q6K\E<%K5)6];
M[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B  #$9P  NVL
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M(V!F_R-A9O\B86;_(F%F_R+H6   TV,  ,1K  "Y<0  L'4  *=W  ">=0
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M;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T  )]_  "2?@  BG\' (2
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M($M[_R#09P  P'(  +1[  "J@@  H(8  )6(  "'B   ?(H  ':,#@!RC1H
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M$SR:FQ0ZFJL5.9J]%3F:V14YF.\6.9?\%CB6_Q<XE?\7.)7_%SB5_Q>[>@
MKX4  *2,  "8D0  C94  (&:  !UG0  :*   %ND  !6I0P 4Z87 %&G(P!/
MIR\ 3*<X 4JG00%(ITD"1J=0!$.G6 5!IU\&/Z9H"#VF<@HZIGT+.*:*#3:E
MF0XTI:D/,Z6[#S.EU \SI.X/,J+[$#*A_Q$RH?\1,J'_$3*A_Q&T@@  J(P
M )V2  "2EP  AIP  'FA  !MI0  8:D  %6L  !+KP4 1[ 0 $6P' !$L2<
M0K$R $&R.P _LD,!/;)+ 3NR4P(YLEL#-[)D!#6R;@4SLGD&,;*'!R^QE@@N
MLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP  H)(  )68
M  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P WO!X -;PI
M #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_D0,FOZ(#
M)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@  (R>  "
MI0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!, )\D= ";)
M)P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;S9P &<ZN
M 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F  !UK0
M:+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0 !78&0 5
MV2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$ #N"D  W@
MN  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !JM0  7;P
M %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G$@ -Z!D
M#.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4  #JIP
MZ[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@  4<4  $/)
M   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %]A(  _88
M  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #VE0  ]Z<
M />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T  #?1   K
MUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_"   _PT  /X0  #^
M%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@   _Y(  /^A
M  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2< _Q$N /\0.@#_#D<!
M_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*E0'_"IL!_PF@ ?\)I0#_
M":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV /,)_P#R"O\ \0K_ ?$+
M_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20 _Q<L /\5-P#_$T0 _Q%0
M ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!_PZ= ?\.HP'^#J@!
M_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P._P'K#_\!Z@__ >H0_P'I
M$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I /\<- #_&D  _Q=, ?\5
M6 '_%&,!_Q-N ?\3=P'^$X !_!.( ?H2C@'Y$I4!^!*: ?82H 'U$J8!]!*L
M ?,2LP'Q$KP!\!+' >T2V 'I$^@!YA/U >04_P'B%/\"X17_ N$5_P+@%?\"
MX!7_ N 5_P+_)1L _R87 /\D%@#_)1P _R8E /\D, #_(3L _Q]( /\=5 ']
M&U\!^1II ?<:<P'T&7P!\AF$ ?$9BP'O&9$![AF7 >P9G0'K&:,!Z1FJ >@9
ML0'G&;H!Y1G% >,9U0'?&N@!W!OU M@;_P+5'/\#U!S_ ],<_P32'/\$TAS_
M!-(<_P3_*1< _RH3 /\I$@#_+!@ _RPA /\L*P#_*3< _2=# /<E3P'S(UH!
M[R)D >PA;@'I(7<!YR%_ >4AA@'D(8T!XB"4 >$@F@'?(* !WB"G =PAKP':
M(;@"V"'# M4ATP+1(N<"S2+T \HC_P3((_\%QR/_!L8C_P;&(_\&QB/_!L8C
M_P;_+!( _RX/ /\P$ #_,Q0 _S,; /\R)0#Z,#  \BX\ .PL20#G*E4!XRI?
M > I:0'=*7(!VBAZ =<H@@+5*(D"TRB0 M$HE@//*)P#SBBC \PHJP/**+,#
MR2B^!,<HS 3%*>($P2KQ!KXJ_@>\*O\(NBK_"+HJ_PBY*O\)N2K_";DJ_PG_
M, \ _S(+ /\V#0#_.!  _SD5 /DW'@#O-2@ YS,U . R0@#;,D\ U3%: = Q
M9 +-,&T"RS!U \DP? /'+X,$Q2^*!,0OD07"+Y<%P2^>!K\OI@:]+Z\&O"^Y
M![HOQP>X,-T'M3#N";(P^PJP,/\+KC#_"ZXP_PNM,/\+K3#_"ZTP_PO_,PP
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M%HA&\!:&1OT6AD;_%H5'_Q6%1_\5A4?_%85'_Q7_/P  [$@  -U/  #/4P
MQE4  ,!3 P"[40P LU(9 *U3*0"H4S8!HU)" I]12P2<4%0&F4]<")9.8PJ4
M36H,D4QQ#H]+> ^-2W\1BTJ'$HE*D!2'29H5A4FE%X-)L1B"2< 8@4K6&7]*
M[1A^2_P8?DO_%WU+_Q=]2_\6?4O_%GU+_Q;_0P  YDP  -93  #)6   P%D
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M&FI7_QEK5_\9:U?_&6M7_QGK3   V%8  ,A>  "\8@  LV4  *ME  "C8@
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M&E=F_QK;60  QV(  +IJ  "O<   IG,  )IS  "/<   AW$% (%R$0!\<QX
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M%DEYG!=(>*L81GB]&49XU1E&=^\81W;\&$=V_QA'=?\71W7_%T=U_Q?)90
MNF\  *YW  "D?0  F'\  (M_  !^?P  <X$  &R#"0!HA!, 984@ &*&+ !?
MAC8!7(8_ EF%1@-7A4X%5(55!U*$7 E/@V,+38-K#4N"= ](@G\11H&,$T2!
MFA5"@*D608"Z%D" TA9!?^T607[[%D%]_Q9!??\607W_%D%]_Q;":@  M74
M *I]  "?@@  DH,  (6$  !YA0  :HD  &2* P!@C!  78T; %N.)P!8CC(
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M""Z@R0@NG^<(+9WW"2V<_PHMF_\*+9O_"BV;_PJO@   HXD  )>.  "-DP
M?Y4  '*8  !FG   6Z   $^D  !%IP  /JD, #RJ%  ZJA\ .:HI #BK,@ W
MJSL -:M# #2L2P RK%,!,:Q< 2^L9@(MK'$"*ZQ_ RJLC@,HK)X$)ZRP!":L
MQ00FJ^0#):GU!"6H_P4EI_\%):?_!26G_P6GB0  FX\  )&4  "$F0  >)X
M &NB  !?I@  4ZH  $BM   ]L   -+,# "^U#@ MM18 ++4@ "NV*0 JMC(
M*;<Z "BW0P GMTP )KA5 "2X7P CN&L (KAX 2"XB $?N)D!';FK 1RYP $<
MN-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0  ;J8  &*K
M  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;PR8 &L,O
M !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'N0 /Q]0
M$,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\  %BT  !+
MN   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D #=$A  S1
M*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #U<   =7<
M  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]   _P
M-,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8  '>(
MWB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X  .7!  #E
MU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   SR   *,P
M !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1  #H%@  Z1T
M .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M  #TNP
M],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0  '=8  !3<
M   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q#@  \Q(  /08
M  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_I@  _[
M /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1 /\ 70#_
M &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8 ^P"L /D
MLP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M /\ [0#_
M .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%60#_!&0
M_P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J /,!L #Q
M ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\ Y@;_ .8&
M_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_"V  _PMJ
M /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)K@#K";8
MZ G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_ =L-_P'_
M'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L ]1!F /,0
M;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A#[0 X ^^
M -X/S #:$.$ U1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3_P'_(A(
M_R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@ .<6:@#D
M%G( XA9Z . 6@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$ T!>[ ,X7
MR0#,&-X R!GN <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_)@X _R4+
M /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>90#5'FT
MTA]U - ??0#.'X, S!^* <L?D ')'Y<!R!^> <8?I0'%(*T!PR"W <$@Q '
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M!J$P\P>?,/\(GC'_")TQ_PB<,?\(G#'_")PQ_PC_,   _S4  .\X  #B.@
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M$'A&_Q!X1O\/>$;_#WA&_P_P/P  WTD  ,U/  #!4P  N%0  +%2  "K3@4
MI$X1 )Y/( "94"T E5 Y 9)/0P&.3DP#BTU3!(E-6@6&3&$&A$MH"()+;@F
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M$F%6_Q+@30  RU8  +U=  "R80  J&,  )UA  "570  C5X) (=>$P"#7R
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M$E1BG!-38JH54F*[%5%BTA518>T54F'[%%)A_Q-38?\24V'_$E-A_Q+15@
MP%\  +-F  "I:P  G&L  )!J  "%9P  ?6D  '=J#0!S:Q< ;VLD &QL+P!I
M;#@!9FM! F-K20-A:U $7FI7!EQJ70=::64)6&EM"U5H=@U3:($/46>-$4]G
MFA).9ZD436>Y%$QGSQ1,9NL436;[$TUF_Q).9?\23F7_$DYE_Q+,6@  O&,
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M#CQ[R X\>N8./'GW#CQX_PX\>/\./7?_#CUW_PZ\:   KW(  *1Y  "6>@
MB'H  'QZ  !P?   8W\  %R"  !7A L 4X44 %&&( !/ABH 3H<T $R'/ %*
MAT0!2(=+ D:'4P)$AEH#0H9B!$"&; 8^A78'.X6#"#F%D0HXA* +-H2Q"S:$
MQ@LV@^0+-H+V"S:!_PPV@/\,-H#_##: _PRV;P  JG@  )]_  "0?@  @W\
M '>   !K@@  7H<  %6*  !.C 8 2HX0 $B/&@!'CR4 19 O $20. !"D$
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M 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8  !7G0
M3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q !ZP.@ =
ML4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX $['K !.O
M^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0J   1:P
M #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]+@ 0O3<
M$+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?  B^\  (
MO?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP  /+8  #&X
M   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $RBP  \HV
M  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,X@  S.\
M ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X  ";!   =
MQ   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@  UB(  -<J  #9
M-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R   WMX  -[B
M  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+   3SP
M#=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<  .4>  #F)P
MZ#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(  .[&  #N
MQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6   +VP   ]X
M  #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3  #R&@  ]",
M /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO  #^KP#_
M$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4 _P!N /\
M=P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S +4 \@"]
M /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H _P#_$QP
M_Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K /T <P#Z
M 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +( Z@"Z .@
MQ@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_%1@ _Q,4
M /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8 ;P#R '<
M[P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X -\ PP#=
M -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!, _Q40 /\2
M#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I!7( Y@5Z
M .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&P #0!\\
MS@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD, /\8#0#_
M&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T VPUU -@-
M? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&#L\ PQ#F
M , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?" #_'PT
M_QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O ,D4=P#'
M%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L MQCB +,9
M\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\) < ]R$,
M .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?<0"Z'W@
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M!8TQ_P6,,?\%C#'_!8PQ_P7_+0  ZC4  -PZ  #./0  QCP  , W @"[,PT
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M"FM&_PKE0   STD  ,%/  "U4@  JU(  *%/  ";2@  E$H, (]+%P"+3"0
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M"UY0FPU=4*D.6U&Y#EM1S@]:4>H.6U'Z#5M1_PQ;4?\,6U'_"UM1_PO62@
MPU,  +99  "K7   GEH  )-9  "+5   A%8# 'Y6$ !Z5QH =E<F '-8,0!P
M5SH ;5=" 6I720)H5E "9E97 V167@1B564%8%5M!UY5=@A=58$*6U6-"UE4
MF@U85*<.5E6X#U95S ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS130  P%8
M +-<  "G7@  FET  (]<  "&6   ?UD  'E:#0!T6Q< <5LC &Y;+@!K6S<
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M#4=BQPU'8N0-2&'V#$AA_PQ(8/\+26#_"TE@_PO$6   M6   *IF  ";9@
MC68  ()E  !V9   ;F4  &AF!0!C9Q  8&@: %UI)0!;:B\ 66HX %=J0 %5
M:D<!4VI. E%J50-/:5T$36ED!4MI;09):'@'1VB$"49HD@I$9Z$+0V>Q#$)G
MQ0Q"9^(,0F;U#$-F_PM#9?\+0V7_"T-E_PN_7   L60  *9J  "6:0  B6D
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M<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T 08!% #^
M3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P?MH&,'WP
M!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW  !C>0
M5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E  #>)2  V
MB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#*8;N RF%
M_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=@0  4H4
M $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V300 LDTH
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M  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G   KJ@
M(ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y  >W0P &
MMT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$  +7W  "U
M]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   CM0  &K@
M !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##.0  Q$0
M ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N  #$[@"&
MF   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9OP  $<(   S%
M   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0  TC@  -1$
M  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8W0![H
M;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0  "LP   +0
MU    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH  .4V  #G
M0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!PJ   8J\
M %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D   #=    X0
M .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G  #V,P
M]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL _P<9 /\
M&0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#] 'L ^P""
M /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X PP#L -$
MZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5 /\!% #_
M !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '< \P!^ /(
MA #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C ,P X0#B
M -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&$ #_ A4
M_P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y .@ ?P#G
M (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@ T@#= -$
M[0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_"Q( _P<9
M /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T >P#; ($
MV0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7 ,4 Z@##
M /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X _PX4 /\*
M'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,!7P R@6"
M ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)Z0"W"_@
MM0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$. /(.%0#H
M#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7< OPU] +T.
M@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K$OH J1+_
M *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40#@#9#A<
MSQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X +$6?@"O
M%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O< G1O_ 9P;
M_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*%Q$ PAH@
M +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?>0"C'X
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M WPQ_P/M+P  VS<  ,D]  "^/@  LSP  *PX  "G,P0 HC(1 )TT'0"9-2H
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M.0  S$(  +Y'  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$ A4 M ()
M-P!_0$  ?4!( 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N/X0$;#^0
M!6L_G 9I/ZD&:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65 _P7</@
MQT8  +E+  "L3   H$H  )='  "10P  BT,( (9#$@""1!X ?D0I 'M%- !Y
M13T =D5% '1$3 %R1%,!<$19 6Y$8 )L0V<":T-O VE#=P1G0X$%9D.-!F1#
MF09B0Z<'842V"&!$R@A@1.8(7T7X!U]%_P=@1?\&8$3_!F!$_P;600  PTD
M +9.  "G3P  FTT  ))+  ",1P  A4<$ (!'$ !\2!H >$@F '5), !S23H
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M"5!0Q E04.$)4%#T"%%0_P=13_\'44__!E%/_P;)2P  N5,  *M7  "<5@
MCU4  (54  !\4   =5$  '!2"0!K4Q( :%0= &54)P!B5#$ 8%0Y %Y400!<
M5$@!6E1/ 5E45@%75%T"5E1E U14;@125'@%452$!D]4D0=.5* (3%2O"$Q4
MP@E+5-\)3%3S"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8  *=:  "860  BU@
M (%7  !W5   <%4  &I6!@!F5Q  8E<: &!8) !=6"X 6UDW %E9/P!7648
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M!CUA_08^8/\&/F#_!CY@_P:Y60  JV$  )IA  "+80  ?V$  '1A  !I80
M7V(  %ED  !49@D 46<1 $YG&@!,:"0 2VDM $EI-@!(:3X 1FI% $5J3 !#
M:E0!0FI< 4!I90(^:6\"/&E[ SMIB00Y:9@%.&BH!3=HN@4W:=,%-VCN!3=G
M_ 4X9O\%.&;_!3AF_P6T7@  IV4  )5E  "&9   >F4  &]E  !D9@  66@
M %)J  !-; 0 26X. $=N%@!%;R  1' I $)P,@!!<#H 0'%" #]Q20 ]<5$
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M B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.    [@P
M,X8  "V)"@ JBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 CC$( (HU* "&-5  @
MC5X 'XUK !V->0 <C8H &XV< !F-K@ 8C,0 &(SC !F*]0 9B?\!&8C_ 1F(
M_P&==P  C'8  'UV  !R=P  97D  %I\  !0@   1H0  #R)   TC   +9
M "63 @ ?E0P '982 !R6&@ ;ER( &I<J !F7,@ 8F#H %YA# !:830 5F%@
M%)AD !.8<P 1F(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0E?P $)3_ !"4_P"5
M?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP  )IH  !Z=
M   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +I%  "J1<
M  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A^P"-@P
M?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4  !>H   1
MJP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<  +!3  "P
M80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'B0  >(H
M &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T   +M@
M!;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(  "^5@
MOF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@  <)4  &*:
M  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_   "P@   ,0
M  #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.20  SUD
M ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$  %NG  !.
MK@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*    S@   -    #1
M    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B/   XTL  .1<
M  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R  !$N0
M-;P  "C    <Q   $L@   S+   #SP   -,   #8    W    -\   #?
MX0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP  /1-  #U
M7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_ !@ _P C
M /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@ @P#V (@
M]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A .< \0#F
M /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4 _P ? /\
M*P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M (0 ZP"*
M .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #: -H [ #8 /D
MU@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P : /\ )@#\
M #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (  X "% -X
MBP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#) /4 R #_
M ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P ( #Q "P
M[  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "  ,X A@#,
M (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /( NP#] +L
M_P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F "4 X0 R
M -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$ @0#  (<
MO@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[ *X"_P"M
M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT T@,K ,P#
M-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S!H, L@:)
M + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-_P"A#?\
MH0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB , ,, "\
M#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX IP^% *4/
MC0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5%/\ E13_
M )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03*0"P%#4
MK!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>  )D7B "8
M%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\ B1S_ (D<
M_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D'2\ H1XZ
M )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@A ",((T
MBB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_ 7\D_P'L
M)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H EB8U ),F
M/P"1)D< CR9/ (TF5@"+)UP B2=B (@G:0"&)V\ A2=W (,G?P"!)XD!@"B3
M 7XHG@%]*:L!>RFY 7HIS0%X*N@!=ROY 78K_P%V*_\!=2O_ 74J_P'E+
MT#0  ,$X  "S.   J#4  *(Q  "=+0  F2H. )0K& "0+"0 C2TP (HM.@"'
M+4, A2U* (,M40"!+E@ @"Y> 'XN9 !]+FL >RYS 7DN>P%X+H4!=BZ/ 70O
MFP%S+Z@"<2^V G PR0)O,.4";C'W FTQ_P)M,?\";3'_ FTQ_P+?,@  R3D
M +L^  "L/0  H3H  )HW  "5,P  D#$* (PQ% "',B  A#,K ($S-0!_,SX
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M!%H_P01:/]T$63_R!%D__P-9/_\#63__ UD__P/,/P  O$8  *M(  "<1P
MD48  (A$  ""0   ?#\  '= # !S0!4 ;T$@ &Q!*@!J03, :$$[ &9"0P!D
M0DH 8T%0 &%!5P!@0EX!7D)E 5U";@);0G@"6D*$ UA"D -70IX$5D.M!%5#
MOP140]H$5$/Q!%1#_@-40_\#5$/_ U1#_P/(0@  N$D  *=+  "82@  C4D
M (-'  !]0P  =D,  '%$"@!M1!( :D4= &=%)P!D13  8D4X &!%/P!?14<
M745- %M%5 !:1EL!649C 5=&; %61G8"5$:! U-&C@-21YP$4$>K!%!'O01/
M1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53   B4L  ']*
M  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T 74DU %M)/0!9240 5TE*
M %9)40!52ED!5$IA 5)*:0%12G0"3TI_ TY*C --2IL$3$NJ!$M+O 1*2],%
M2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P  A4X  'M-  !S
M20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!434$ 4TY( %).
M3P!03E<!3TY? 4Y.9P%,3G("2TY] DE.BP-(3ID$1T^H!$9/N@1&3]$$1D_M
M!$9._ 1&3O\#1T[_ T=._P.]3   KE(  )Q1  "-40  @5$  '=0  !N3
M9TX  &)/  !=4 T 6E 4 %=1'@!542< 4U$P %%2. !04C\ 3E)& $U230!,
M4U4 2E-= 4E390%(4V\"1E-[ D53B0-#4Y<#0E.G!$%3N 1!4\\$05/L!$%2
M^P-"4O\#0E+_ T)1_P.Z3P  JE0  )A4  ")5   ?5,  '-3  !I40  8E(
M %Q3  !85 H 5%42 %)5&P!/5B0 3E8M $Q7-0!+5SP 2E=$ $A72P!'6%(
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M C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB  !%90
M068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2 #-J6P Q
M:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"*V?_ BMG
M_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8  $=H  ! :P  .FX%
M #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR5P J<F$
M*7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_ 2-N_P&A
M90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O   [<@  -'4  "YX
M"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A>UP ('MH
M !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW_P&9:0
MB&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT  ">! P B
M@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8 %H9C !6&
M<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1;@  @6T
M '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<  "&*   :C08
M%8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<  R1:@ +
MD7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P  >W,  &]S
M  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5   3EP  #IH(
M  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=8@  G'(
M )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD  &AZ  !<
M?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .HP  ":8%  .G
M#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I60  J6@  *EZ
M  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$  !5B0
M28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP   +(   "S!P
MLPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T  +AN  "X
M@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.E@  0IP
M #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X   "^    OP8
M , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB  #)=0
MR8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I   .JL  "^P
M   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*    S    ,T#
M  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?9P  X'P
M ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@  "2\   8
MOP  $,,   C'    R@   ,T   #1    U0   -@   #9    VP   -T   #?
M    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6   \VL  /.
M  #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\ + #_ #D
M_P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@") /$ C@#P
M ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L X@#_ .$
M_P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_ #0 _@!!
M /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8 B@#E (\
MXP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_ -$ _P#0
M /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\ ]  [ /
M1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5 (L TP"1
M -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,( _P#! /\
MP@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V ., 00#?
M $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8 Q0", ,,
MDP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T /\ M #_
M +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "( UP O -$ .P#- $4
MR@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"' +4 C@"S
M )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *< _P"G /\ I@#_ *8
M_P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_ #X O !(
M +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P J@"" *D B0"G )$
MI0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_ )D%_P#_
M"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#< L 5" *T&
M2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";"8X F@F7
M )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T._P#V$0
MYA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[ *(.1 "?
M#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H CQ&4 (T1
MGP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M&@  W"$
M ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86/@"4%D<
MDA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0 ($9FP"
M&J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@  T"D  +\L
M  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")'D$ AQ])
M (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<AEP!U(J0
M="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#   +<R  "H
M,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E- " )CT ?29$ 'PF
M2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L**$ :RFO
M 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V  "A-0
MEC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q  ',L1P!Q
M+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!8B^L 6$O
MO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";.@  D#@
M (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ0P!J,4H
M:#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J 5HUNP%:
M-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0  BSP  (,Z
M  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C-D8 839-
M & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<XC %6.9D!53FH E0YN0)3.L\"
M4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!   "20   AC\  'X]  !X
M.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP 8#HT %XZ/ !=.T, 6SM* %H[
M4 !8.U< 5SM? %8\9P!4/'$!4SQ\ 5(]B0%1/9<!3SVF DX^MP)./LT"3C[I
M DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P  @D(  'I   !S/0
M;3P  &@]!0!D/0X 83X7 %X^(0!</BD 6CXQ %@^.0!7/D  53]& %0_30!3
M/U4 4D!< %! 90!/0&\!3D%Z 4U!AP%+098!2D&E DE"M0))0LL"24+H DE"
M^0))0?\"24'_ 4E!_P&]0P  JD4  )A%  "*10  ?T4  '9#  !O0   :$
M &-! 0!?00T 7$$4 %E"'0!70B8 54(N %-"-@!10CT 3T)# $]#2P!.0U(
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M 3Q,_P&S30  GDP  (U,  !_3   =$P  &I,  !@2@  64L  %1,  !0304
M3$X. $E/%0!'3QX 14\F $10+@!"4#4 05 ] $!11  _44L /E%3 #U27  \
M4F8 .E)R #E2?P$X4HX!-U*> 392KP$U4L0!-5+B 392]0$V4?\!-E#_ 3=0
M_P&N3P  F4\  (E/  ![3P  <$\  &9/  !<3@  5$\  $]1  !*4@$ 1E,,
M $-4$@!!5!L 0%4C #Y5*P ]5C( /%8Z #M600 Z5DD .5=1 #A76@ V5V,
M-5=O #17? $S5XP!,5>< 3!7K0$P5\(!,%?@ 3!6] $Q5O\!,57_ 3%5_P&H
M4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P  0%D( #U:
M$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P76$ +UUL
M "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:_P&C50
MCU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$ #9@#0 T
M81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T *&1I "=D
M=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<6   B5@
M 'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H"@ L:1
M*FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE !]L<@ >
M;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57   @UP  '5<
M  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C<@T (7(2
M "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U;@ 5=7X
M%'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6   &]A  !E
M80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X   <>P< %WT. !9]
M$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -?W@ #'^*
M  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE  !A9@
M5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5A   $(<(  V)#@ ,
MB10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$  8F#  ")
ME@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;;   4'
M $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3#  "DQ$
M )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z  "5C@
ME*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R  !4=0  27D  #]^
M   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0  GPX  )\2
M  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "CA   HID
M **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4  #B+   N
MD   ))4  !N:   4G@  #J$   FD   "IP   *H   "K!   JPH  *P-  "M
M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0  LHX  +&C
M  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9   FG@
M'*,  !.G   -JP  !ZX   "R    M0   +<   "X    N0(  +D(  "Z#
MNQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((  ,27  #$
MJP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =K0  %+$
M  VV   &N0   +P   "_    PP   ,0   #%    Q@   ,<   #)!   R@D
M ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*  #;G@
MVZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W   5NP  #;X   3"
M    Q0   ,D   #-    T    -(   #2    U0   -8   #9    VP   -X%
M  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4  .]Z  #OCP  \)\
M /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!! /\ 30#^
M %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\ ZP"5 .H
MFP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#= /\ W@#_
M -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@ 2 #T %(
M\ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0 -P E@#:
M )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\ RP#_ ,L
M_P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G $P Y !5
M .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L D@#) )D
MQP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_ +P _P#_
M    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $< T@!0 ,X
M5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z )0 N0"<
M +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T _P#_
M_P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!* +\ 4@"\
M %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X B "M (\ JP"8 *D
MH0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_    ]@
M .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H M !# +$ 3 "N %,
MK !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3 )P G0":
M *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0  Z@L  -P-
M  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B $T H !3
M )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !F0". J0
MC *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0  ,H5  "\
M$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4< E0E. ),)
M5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"##*( @0VP
M ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=  "O'
MIAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!( (@03P"'
M$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J  =Q.N '43
MO@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E(P  G"$
M )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X72@!\%U
M>A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK &L<NP!J
M'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@  DR@  (TE
M  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R'TL <1]1
M &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(CN !A(\T
M8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T  (4J  "
M*   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4< :"5- &8E
M5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:*LH 62KG
M %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O  !Y+0
M=2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I* %\K4 !>
M*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\< 4B_E %(O
M]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S,0  ;R\
M &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O30!7,%,
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M 4([_P&S/0  GCX  (T^  !_/@  =3X  &P]  !F.@  8#D  %LZ  !7.@@
M4SL0 %$[& !..R  3#LH $L[+P!)/#8 1SP] $<\1 !&/4L 13U3 $0^7 !#
M/F8 0C]Q $$_?@! /XT /T"< #Y K0$]0, !/4#= 3U \@$]0/\!/C__ 3X_
M_P&N0   FD   (E!  !\00  <4$  &A   !A/   6ST  %8^  !2/@4 3C\.
M $P_%0!)/QT 1T E $9 + !$0#, 0T Z $)!0@!!04D 0$%1 #]"6@ ^0F,
M/4-O #Q#?  [0XL .D2; #E$JP$Y1+X!.$3; 3E$\0$Y0_X!.4/_ 3E#_P&J
M0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@( 24,, $9#
M$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y1V$ .$=L
M #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&_P"F1
MDD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(1P  1$<* $%($  _
M21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\ ,TQJ #),
M=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A1P  CD@
M 'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-#@ Y3A4
M-TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G "Q1=0 K
M480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@  B4H  'I+
M  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5(" #53#  S5!( ,509
M #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97<@ E5X$
M)%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X  '5.  !I
M3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\ *EL5 "A<
M'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >7GX '5Z/
M !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1  !D4@
M6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1 "%C&  ?
M9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H %66+ !1E
MG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@5@  5U8
M $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@< &6P. !AL$P 6;1H
M%6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'  UNF@ ,
M;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@  5%H  $I<
M  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .=Q0 #G<;
M  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -WE  !=J<
M ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F   $5C   \
M9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$  X$6  *!
M'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0  @:   ("T
M  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K   V<
M+70  "5X   >?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3  ",&
MC!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID  (VM  ",
MPP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O>P  )G\
M !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP  )</  "8$P  F1@
M )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P  G)   )NE  ";N@
MFM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP  'HP  !:1
M   0E0  "ID   2<    H    *(   "C 0  HP8  *0+  "E#@  IA(  *<7
M  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "KKP  J\,
M *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL  !"?   )
MHP   :<   "J    K@   +    "P    L0   +(#  "T"   M0T  +80  "W
M%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I   O;<  +W&
M  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I   $*D   FN    L@
M +8   "Y    O0   +\   "_    P    ,$   ##    Q 4  ,8*  #'#@
MR1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD  -*X  #2
MQ !5C   29,  #V:   PH@  ):@  !JN   1M   ";D   "]    P0   ,0
M  #(    RP   ,T   #-    SP   -    #2    U    -@   #:!@  W0P
M . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH  #LL@#_
M  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %( ^ !: /8
M8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D )T X@"E
M .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0 _P#_  @
M_P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5 .H 70#G
M &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D T0"@ ,\
MJ@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_    _P
M /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D 6 #5 %\
MT@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"< +\ I0"]
M +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_    _P   /T
M  #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$ %D P@!?
M ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +  H "N *H
MK0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_    _@   /$   #E
M    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %, L@!9 +$
M7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@ *4 G@"R
M )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]    \    .$   #1
MQ@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4 *, 60"A
M %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$ D0"M (\
MNP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_!   MP
M +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8 5 "5 %D
MDP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I (, N "!
M ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@  J T  *,(
M  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@") E0 AP)9
M (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&M0!V!\@
M=0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,  )81  "4
M#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\ ?0Q4 'L,
M6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L#LD :P_F
M &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9  "(%0
MAQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0 '$15@!P
M$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8 8A;C &$6
M]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^'0  ?!D
M 'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@840!F&%@
M91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@ %@>] !8
M'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P  <R   '$<
M"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>'E0 7!];
M %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D\@!1)/\
M423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4  &DB!0!F
M(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%  5217 %,E
M7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!**?\ 2RG_
M $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G 0!?)PP
M7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4 $TJ7 !,
M*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX 12[_ $4M
M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9+ D 5BP0
M %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N60!&+V,
M13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_ $ R_P"J
M,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8 43 . $XP
M%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P! ,V  /S1K
M #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV_P"F-@
MDC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0, $DT$@!&
M-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X .CAI #DY
M=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B.   CCD
M 'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y$ !!.1<
M/SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG #0]=  S
M/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P  BSP  'L\
M  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \/14 .CX<
M #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!<@ N0H$
M+4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX  '<_  !K
M/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A( -4,9 #-#
M(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I1GX *$:/
M "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"  !G0@
M7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6 "Y)'@ L
M224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP (DN- "%,
MGP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D10  6D4
M %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/&@ F3R$
M)4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&* !M1G  :
M4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2   5D@  $Y(
M  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?5AX 'E8D
M !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18F@ 35ZP
M$E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL  $M,  !$
M30  /$\  #51   O5   *58  "19   >6P< &ET- !A=$@ 771D %EX@ !5>
M)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -7ZD #%Z^
M  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0  ! 4@
M.%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;  YG(@ -
M9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,  F:W  -E
MSP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [6   ,UL
M "M>   E80  'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P'0 $<"0
M W L  )P-0  <#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R  !NR
M;>4  &WR  !M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)3$4 ! E15P
M1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$  5X"P !
M> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\  'IP  !Z
M@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,7   0F
M #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"  """   @PT
M (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H  "'>P
MAY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&9   /&D  #)M
M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".!   C@D  (\-
M  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?  "5<@  E8@
M )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70  "MY   A
M?P  &80  !&)   ,C0  !I$   "4    F    )H   ";    G (  )T'  ">
M"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F:   IGT  *:4
M  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$  ".'   9C0
M$9(   N7   $G    *    "C    I@   *@   "I    J@   *P   "M!
MK@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$  +B(  "X
MG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7   2G0  #*(
M  .G    JP   *X   "R    M@   +@   "X    N@   +L   "]    O@
M , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ  #-D0
MS:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,K    [$   "V
M    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-    S@   -
M  #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F@@  YY8
M .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X /T 0P#Y
M $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4 Y "+ .,
MD0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1 /\ SP#_
M ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S /  /@#L $@
MZ !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"% -  C #.
M ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\ OP#_ +X
M_P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .  . #; $( U0!+
M -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\ A@"] (X
MNP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_ +  _P#_
M    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P P@!% +\
M30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M (@ K "1
M *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$ _P#_
M]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _ *\ 1P"L
M $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@"> (( G "+ )L
ME0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W    YP
M -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X *  0 "> $<
MG !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"% (T CP"+
M )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L    TP   ,$!
M  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1 $$ CP!(
M (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (  B@!^ )8
M?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L  +(,  "F
M"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L @P!" ((
M2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S )( <0"?
M '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82  ":$0
MD1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\ '<$0P!U
M!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")  9PF= &4)
MK !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0&   AQ8
M ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,/@!L#$0
M:PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^< %P0JP!;
M$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@  ?AT  '@;
M  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C$3\ 8A%%
M & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5J0!2%KH
M41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(  ' A  !L
M'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL 61=! %@8
M1P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*'+@ 2AW/
M $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE  !F(P
M8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T] % =0P!/
M'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8 0R+, $,C
MZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@)P  7"4
M %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB0 !((D8
M1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?* #THZ  ]
M*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P  6"@  %0F
M  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!)T, 0"=+
M #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<LY@ X+/@
M."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@  4RL  % J  !,
M*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T  .RQ( #HL
M4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S,/< ,S#_
M #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM  !'+@
M1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #4Q3@ T
M,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8 +S/_ "\S
M_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !",@  /S(%
M #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U3  O-E4
M+C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_ "HW_P"2
M-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@  .C8" #<W
M"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J.E, *3M>
M "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[_P"--@
M?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L  #(["  O
M/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U  (T!; ")
M:  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P").0  >#H
M &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!!0 J0@P
M)T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459 !Q%90 ;
M170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/   <ST  &8^
M  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D1PH (4@/
M "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+8@ 52W$
M%$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T   &%!  !7
M0@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >308 &T\- !A0
M$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /4FT #E)^
M  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$  !310
M2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P  %%8) !%7#@ 0
M6!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@ !UAY  98
MC  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !02   2$@
M $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@#  *8!
M"6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S  !@A@
M7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,3   14P  #U.
M   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG"P #9PX  &@3
M  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I@   :90
M &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$  #A4   P
M5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T  '$0  !Q
M%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S>0  <XX  '.C
M  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<   J8
M(F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H  'L.  !\$0
M?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8  ("=  !_
ML@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE   C:@  &V\
M !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*  ")#0  BA
M (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5  ".JP
MC<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <=P  %'P   Z!
M   (A0   (D   "-    D    )(   "3    E    )8#  "7"   F P  )H/
M  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?H@  G[<
M )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0  #8L   :0
ME    )@   "<    GP   *$   "B    I    *4   "G    J 0  *H)  "L
M#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "RF   L:P  +*_
M  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?    I
M *@   "L    KP   +$   "Q    LP   +4   "V    N    +H   "\!@
MO@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\  ,BO  #(
MO !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O    LP   +<
M  "\    OP   ,$   #"    Q    ,4   #'    R0   ,L   #-    SP,
M -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B  #BK0#_
M  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@ \P!0 /
M5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #< ), V0"<
M -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$ _P#_
M_P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+ .  4@#=
M %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X Q@"6 ,0
MH #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_    _P
M /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H 30#' %,
MQ0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0 +( F@"Q
M *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_    _0   .X
M  #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U $X L@!3
M +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "* *, E "A )\
MGP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^    [@   -X   #+
M    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@ H@!- *$
M4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2 )D D "F
M (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<   "Z
ML    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !( )( 30"1
M %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0 @@"@ (
MKP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J    H@
M )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4 1P"# $T
M@@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"< '0 J@!R
M +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";!@  DP0  (X
M  "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W $< =@!,
M '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@ I@!G +8
M9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T  ($+  !^
M!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L $( :P!' &H
M30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!< [, 7 /'
M %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81  !S#@
M<@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=# &$'20!?
M!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[, 4@S' %(,
MY !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J%   9Q$
M &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-10!7#4L
M5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'( $D1Y0!)
M$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@  7Q<  %X4
M 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/$D< 3A).
M $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7XP!"%_8
M0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P  %<9  !5
M%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T, 1A=* $48
M4@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 ['?4 .QS_
M #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>  !/' (
M31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU' #X=3P ]
M'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?, -B'_ #8A
M_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)(   1R )
M $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B3  W(E4
M-B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_ #$E_P"1
M)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)   020% #\D
M#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q)U, ,"==
M "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI_P"-*
M?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*   /"@" #DH"P W
M*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$ *RQ; "HL
M9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"**P  >"T
M &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L"0 R+ X
M,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9 "4Q90 D
M,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0  =2\  &<P
M  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M,0T *S$1
M "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U8P ?-7$
M'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(  &,S  !9
M-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L )3<0 "0W
M%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9.FX &#I_
M !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U  !5-@
M338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P. !X]$@ =
M/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP $T!\ !)
MCP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2.0  2CD
M $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#$  70Q4
M%40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y  U%C  -
M19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P  1SP  $ \
M   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*#0 12A( $$H8
M  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+AP %2YH
M!$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X  #T^   W
M/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +41  "E$4  E1
M&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0  498  %&I
M  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"   T0P
M+44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2  !9%P
M61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?   69   %FE  !8
MN@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='   O20  *$P
M ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A%   81D
M &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@  !AM@
M8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J4   (U,  !Q7
M   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J$0  :Q4  &P;
M  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !LL   :\@
M &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6   '5P  !9@   0
M9   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@  =A$  '<6  !X
M'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@  >,$  '??
M  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K   +;P
M!7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT  (01  "&%0
MB!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D  (?1  "&
MZ !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY   "?0   ($
M  "%    B    (H   ",    C0   (\   "0!   D@@  ),,  "5$   EQ4
M )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'  "7W@!+
M7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(    C    )$   "5
M    F    )H   ";    G0   )\   "@    H@   *0%  "F"@  J X  *H4
M  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "KRP!%9@
M.6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0   *$   "E
MJ    *L   "K    K@   *\   "Q    LP   +4   "W 0  N0<  +P-  "_
M$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^<@  ,G@
M ">    <B   $I    J7    G0   *,   "H    K0   +(   "V    N0
M +L   "\    O@   ,    #"    Q    ,8   #(    RP   ,X%  #1#0
MUA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_    _P   /\
M  #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J %D YP!?
M .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\ H0#, *P
MR@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P   /\   #^
M  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4 %, T0!9 ,X
M7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[ *8 N0"T
M +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@   #M
MY0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3 +P 60"Z
M %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I *  J "M *8
MO@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7    RP &
M ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!. *D 4P"G %@
MI@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F )8 M@"5
M ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!    MP " *\
M"P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7 %( E@!7
M )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (< KP"% ,(
MA0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O    I@   )X !P":
M  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P AP!1 (8
M5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W +H =@#3
M '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP   )   @"+  L
MB  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+ '@ 4 !W
M %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0 :@#) &D
MZ !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,   !_  8 >P -
M 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P 2P!K %
M:@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@## %X X0!>
M /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T!   <0 ) &\
M#P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@ $P 7P!2
M %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0 V@!3 .\
M5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD# &8$"P!D
M !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4< 5@%. %4"
M5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*!^T 2@?Y
M $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-!0!="0T
M6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E* $P)40!+
M"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X 0@W[ $(-
M_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4#@@ 4PT.
M %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.3P!$#E<
M0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+] #L1_P"3
M&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P, 3!$+ $H0
M$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \$U0 .Q->
M #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06_P".&P
M?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&   118' $,5#@!!
M%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$ -!A; #,9
M9@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*'@  >"
M &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:#  [&1$
M.1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9 "T=9  L
M'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(   =",  &<D
M  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U'@X ,QX3
M #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B8@ F(F\
M)2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24  &,F  !9
M)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T +B(1 "PB
M%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A)VT ("=]
M !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I  !6*0
M32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0 "<G%  E
M)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL &RM[ !HL
MC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3+   2BP
M $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L$@ @+!@
M'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y !4PBP 4
M,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@  2"X  $$N
M   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;,A4 &C(<
M !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$UB0 0-9P
M$#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13   #XP   X
M,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q, %#@9 !,X
M'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,.ID "SFL
M  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS   V,P
M,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5  X^'  .
M/B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0 !#^H  ,^
MO  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T-0  +C4
M "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$&0 (1"
M!T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19   $2D  !$N0
M1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.   *SD  "4[
M   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+%@  2QP  $LC
M  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+M0  2LX
M $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX  ")!   <
M0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@  %,?  !3
M)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2L0  4<H  %'G
M  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'   72@
M$DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:  !<(0
M7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4  %KD  !9
M\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/   24P  #E8
M  I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46  !F'   9R,
M &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>  !D\ !/
M1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -7   "&    )C
M    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R%P  <QT  '0F
M  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P[ !,2@
M14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':    &L   !O
M<@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0  @A8  (0>  "$
M*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*3@  /U
M #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D   !]    @0
M (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA   )06  "6(
MEBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$50  .5D  "]=
M   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-    D0   ),
M  "4    E@   )@   ":    G    )X   "@!@  H@L  *40  "H%P  J2,
M *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,  "=J   =
M<   $W@   Q_   #A0   (L   "1    E@   )L   "?    H@   *0   "E
M    IP   *D   "K    K0   +    "R    M0(  +<)  "[$   OA@  +XF
M  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X   6@
M#8@   6/    E@   )P   "B    IP   *P   "P    LP   +8   "W
MN0   +L   "]    OP   ,(   #%    R    ,H   #."   TA   -4;  #5
M+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\   #_  4 _P .
M /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$ 7@#> &,
MW !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W ,( S #
M .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z  $ \P + .T
M$@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#& %X Q !C
M ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +  P@"N .,
MK@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F    W0 ' -( #@#-
M !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@ L0!= +
M8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0"> -( G0#R
M )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 " +H # "V !(
ML@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %( G@!7 )T 6P"<
M &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8 C #H (L
M_0", /\ C #_ (P _P#M    V    ,4   "W    K    *8 " "A  X GP 5
M )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T 50"+ %H
MB@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #< 'P ]0!\
M /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0  P C0 1 (L
M& ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\ %0 >P!:
M 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X [0!N /X
M;@#_ &X _P#$    KP   *    "4    C    (8   "!  @ ?@ . 'P % ![
M !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\ ;0!4 &P
M6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$ Y !A /@ 80#_
M &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 + &\ $ !M !8
M;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/ &  5@!?
M %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$ 5@#_ %8
M_P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C !$ 80 8
M &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8 40!5 %@
M4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z $P _P"=
M"0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:  X 6  3 %<
M&0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+ %4 2@!=
M $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $, _P"5#0
M@P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0 $\!%0!.
M 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$ 0@1: $ %
M9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".$   ?!(
M &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D($0!'"!8
M10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8 #D+8P X
M#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P  =Q4  &D7
M  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@! #1( /PT8
M #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/8@ Q$&X
M+Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD  &0:  !9
M&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!  .! 5 #<0
M&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J%&P *11[
M "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =  !6'@
M31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02 # 4%P O
M%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H (QEY "(9
MB@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3(   2B
M $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8%  I&!H
M)Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW !T=B  <
M'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@  2"(  $$B
M   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C'1< (1T=
M "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@BAP 7(ID
M%B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124  #XD   Y
M)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >(14 '2(; !LB
M(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2)I@ $2:K
M !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF   V)@
M,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8 !<G'P 6
M)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8 #BJI  TJ
MO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH   T*   +R@
M "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L'  1+2,
M$"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E  DNN0 (
M+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@  +2H  "DJ
M   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -,B  #3(G
M  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (SM@ ",\T
M S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP  "8L   B
M+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T !S@D  8X
M+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP  .,H  #CF
M   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P   ?,0
M&C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA   ^*
M/C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<  #WD   ]
M\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T   ;-@  %C@
M !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%)   12T
M $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C  !#\@!5
M-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/   $C\   ]!
M   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.(   3B@  $XR
M  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*\@!0.
M1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P  #T8   M)   '
M2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P  5R,  %<L  !7
M.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+/   0CP
M #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\   51    5
M %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F  !B,0
M8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'0   /S\  #H_
M   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;    7@   &$
M  !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O*@  ;S8
M &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,  #5$   K
M1P  (TL  !M/   35   #E@   A<   "8    &0   !G    :P   &T   !O
M    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@  ?RX  '\]
M  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],   E4
M'%4  !1;   .8   !V4   !J    ;@   '(   !V    >0   'P   !^
M?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0  DB4  )(S  "2
M1   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >7   %6(
M  YH   ';@   '0   !Y    ?@   ((   "&    B0   (P   ".    D
M )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL  *8I  "F.@
MI4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0  #W    =W
M    ?@   (0   "*    CP   )0   "8    FP   )X   "?    H@   *0
M  "F    J    *L   "M    L    +,$  "W#   NQ(  +L?  "[,   NT,
M +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>   "8    "(
MCP   )8   ";    H0   *8   "J    K@   +    "Q    M    +8   "X
M    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2)0  TC@  -%.
M  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P + /P $0#Y !L
M]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C -, : #0
M &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H N0#_ +@
M_P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .< #P#B !8 WP @
M -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P 8@"Z &<
MN0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y *4 _P"C
M /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #% !( PP ; ,
M) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G &$ I@!G
M *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0 _P"5 /\
MD #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \ J@ 6 *@ '@"H
M "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H DP!@ )$
M9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$ /\ @P#_
M ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1 )0 &0"3 "$
MD@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!: ($ 8 !_
M &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\ = #_ '0
M_P#+    M@   *8   ":    D@   (H   "&  @ @P . ($ % "! !L @  C
M '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$ 6@!P &$
M;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_ &< _P"X
M    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q !8 <  = '
M) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C %L 80!C
M &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H _P"H
ME0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8 &, 'P!B
M "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8 5@!> %0
M: !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<    B0
M 'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4 %< &0!7 "
M5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!: $H 8P!)
M &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!   @ <  '$*
M  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!- !L 3  @
M $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$ 7P!  &L
M/@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@  > P  &H.  !?
M#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8 1  < $,
M(0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X &@ -@!U
M #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00  !9$0
M41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8 #L"'0 Z
M R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8 +P=S "X'
M@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4%   3!0
M $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(&0 T"1\
M,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS "<,@P F
M#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P  2!<  $(6
M   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M#1L + TA
M "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0A  ?$)8
M'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D  #\9   Z
M&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@ )A > "40
M)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9%)4 &!2G
M !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;   V&P
M,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,: !\3(0 >
M%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&), $QBF !(8
MN@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T'0  +QP
M "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8'@ 9&"0
M&!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE  \<N0 .
M'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P  +1X  "D=
M   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4'2( $QTI
M !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@M0 +(,H
M"R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B   "8?   C
M'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\ #R(F  XC
M+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &),< !B/C
M  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A   A(0
M'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C  HG*P )
M*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4  2CA  $G
M\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C   ?(P  &R0
M !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L*  #+3
M BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@   L\ !:
M)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@  &2<  !4I
M   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0  ,BT  #(V
M   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q\ !6)P
M2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP  !(N   /
M,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@  ."H  #DS   Y
M/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1*P  1BP
M #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S   --0
M"3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O  ! .@
M0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@  0B\  #DO
M   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ   )/   !3X
M  !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(-0  2$$
M $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(  #8R   P
M,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #1    $8   !(
M @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,   4CP  %%*
M  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U   O-
M)S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30   $\   !1
M4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@  738  %Q$  !<
M5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K.0  (SP
M !P_   50P  $$<   M*   %3@   %$   !4    5P   %H   !<    70
M %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\  !J30
M:5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0   '40  !9)
M   030  "E$   15    6@   %T   !@    8P   &8   !H    :@   &L
M  !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y10  >%D
M 'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX  !!4   *
M60   EX   !C    9P   &L   !O    <@   '4   !W    >0   'L   !]
M    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  "..P  C4X  (MC
M  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA   !9P
M &T   !R    =P   'L   !_    @P   (8   "(    B@   (T   "/
MD0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0  HT0  *)9  "@
M<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P    =P   'T
M  "#    B    (T   "1    E0   )@   ":    G    )\   "A    HP
M *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D  +A.  "W90
MMGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!    B0   (\   "6
M    FP   *    "D    J    *L   "L    KP   +(   "T    M@   +D
M  "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/6P  S7,
M ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !< ]  @ /$ *@#K
M #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@ R0!N ,8
M=0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E /\ G@#_
M )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ; -8 ) #2 "T
MS  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G +$ ;@"O
M '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\ D@#_ (\
M_P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W "< LP O
M *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X 9P"< &\
MF@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_ (( _P#G
M    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@ "( GP I )L
M, "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"( &@ AP!P
M (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8 _P#6
MP    *\   "C    F0   ),   "/  D C0 . (L % "* !P B@ C (@ *@"%
M #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$ =@!I '4
M<P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#     JP
M )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  > '< ) !U "H
M<P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C &4 ;0!D
M '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L    F0   (H
M  !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G "4 90 J
M &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@ 9P!7 '(
M50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP   'P   !Q
M    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\ 60 E %<
M*@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+ &T 2@!Z
M $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@   '    !F
M7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @ $T )0!,
M "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@ 0 !U #\
MA0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=!P  508
M % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $, ( !" "4
M00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q #8 @0 U
M ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6#   3@P  $@+
M  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z "$ .0 E
M #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X ?0 M (\
M+ "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@  20X  $,.   ^
M#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T ,0 B #
M)P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F 8P )0"?
M "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1   Y$
M-@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,> "D#(P H
M!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL '@>= !X'
ML  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U$@  ,1$
M "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)(  B"28
M(0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R> !<,L  6
M#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q%   +1,  "H2
M   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =#2, ' TJ
M !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0LP 0#\D
M$ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4  "<4   D
M$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$ %A H !41
M,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -$L4 #!+A
M  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<  "06   A%@
M'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F !$4+0 0
M%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$ "!;=  D5
M[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?&   '!<
M !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8*@ ,&3,
M#!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:  09[ !<
M&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =&0  &AD  !<8
M 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P ('2\ !QXY
M  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =[ !8&@
M2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L  !8; 0 3
M&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP  2(U   B
M0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5'0  2!\
M #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT  !,>   1'P(
M#B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R   G/0
M)TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1(   12$  #LB
M   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B   /(P  #24#
M  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO   M.0  +48
M "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@  020  #@D   P
M)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -*   "BH"  8L
M!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S-@  ,T(  #-0
M   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G   M)P
M*"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@  !C !  (R!
M- <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX  #I,   Z
M7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K*0  )B@
M "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<    Y @  .P4
M #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'  !"5P
M0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J*P  )2H  !\K
M   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!    0P(  $4%
M  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"  !,40  2V0
M $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\  !LQ   5
M-   $#<   TZ   (/0   D    !#    1@   $@   !*    3    $X!  !/
M!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P  5EX  %9S
M  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X   1/
M#$    =$    1P   $H   !-    4    %,   !5    5P   %D   !:
M7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1   9%<  &1K  !B
MA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,1@  !DH
M  !/    4P   %8   !9    7    %\   !A    9    &4   !G    :0
M &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C  !S>P
M<I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@   %<   !<
M    8    &0   !H    :P   &X   !Q    <P   '4   !W    >@   'P
M  !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&<@  A8L
M (.E  ""O  O0   )40  !Q)   33@  #50   1:    80   &8   !K
M;P   '0   !Y    ?0   (    "#    A0   (<   "*    C    (\   "2
M    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P  FH$  )J9
M  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<   !]    @@
M (8   "+    CP   ),   "5    EP   )H   "=    H    *,   "F
MJ@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7   M'0  +&.  "O
MI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0    E0   )H
M  "?    HP   *8   "H    JP   *X   "P    LP   +8   "Z    O0
M ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!  #*E@#\
M    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H "X X@ V -X
M/@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^ '@ O "!
M +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\ _P#T
M[    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P ,  -P"\
M #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$ IP!Z *4
MA0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H    WP
M -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D ,0"F #@
MI  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R )$ ?0"/
M (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9    S0   +L
M  "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1 #$ C@ W
M (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X =0!\ ((
M>@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0   *4   "9
M    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^ "L ?  Q 'H
M-@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L 'H :@"*
M &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )    "%
M?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J &D , !H
M #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ', 6P"" %D
MDP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U    ;
M &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P *@!; "\
M60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![ $T C !,
M )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G    7P   %H
M  !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !. "D 30 N
M $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $( A@!! )@
M0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=    50   $\   !,
M    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0 0P I $(
M+0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W ), -@"G
M #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#  !# 0
M00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D #@ *0 W
M "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X +0"B "T
MN  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [!P  . 4
M #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #  )  O "D
M+@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D )@"= "4 LP E
M ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V"P  ,@H  # (
M   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@ (  G "4 )@ K
M "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X K@ > ,<
M'@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0  +0T  "H,   H
M"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "( (  H !\
M+@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8 ,$ & #A
M !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X  "8.   C#0
M(@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E !D%*P 8
M!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P $@39 !(#
M[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0   @#P  '0X"
M !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0**0 3"C$
M$@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2  T*Z@!<
M#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$   &A " !@/
M!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /#3  #@X[
M  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.Z !8$0
M2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$" !41!0 3
M$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T "Q$V  H1
M00 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5$@  210
M #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(# !,2!0 2$0<
M$!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S  44/@ $
M%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2%   1A8  #L7
M   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1$@@ #Q((
M  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P  $8.P  &4<
M !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@  #D9   P
M&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8 #A4'  P6
M"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.   '40  !U2
M   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;   M&P
M)AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%  H:!P '
M' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0  (D$  ")/   B
M7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K'0  )!T
M " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?!0 #(0@
M "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX  "=+   G7
M)VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H'P  (QX  !X=
M   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D!   )@8  "@(
M   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M6   +6H
M "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0  (2   !T?   :
M'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @  +00  "\&   P
M"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U4P  -&8  #1\
M   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA   7(0
M$R,  ! E   -)P  "2D   4K   !+@   #     R    - $  #8$   X!@
M.@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$  #QW   [
MD0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4)@  $"@
M  TK   )+@  !3     S    -0   #@    Z    /    #X!  !  P  0@<
M $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q  !$BP
M0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1+0  #3    DS
M   #-@   #D    \    /@   $$   !#    1@   $@   !*    3 ,  $X&
M  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J  !0@P  3YX
M $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0  "#D   (]
M0    $,   !&    20   $P   !.    40   %,   !5    5P   %D!  !<
M!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P  7)8  %NP
M  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40   !(    3
M $\   !2    50   %@   !;    70   &    !B    9    &8   !I
M;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L  &NF  !J
MP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5    60   %T
M  !A    90   &@   !K    ;0   &\   !R    =    '<   !Z    ?@
M (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;  !^L@ I
M.@  (#T  !9"   /2   "$X   !4    6@   &    !D    :0   &X   !R
M    =@   'H   !]    @    ((   "%    B    (L   ".    D@   )8
M  "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5IP C0P
M&4@  !%.   )50   %P   !C    :@   '$   !V    >P   (    "&
MB@   (X   "1    DP   )8   "9    G    *    "C    IP   *L   "P
M    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <3@  $U0
M  M<   !9    &P   !T    ?    (,   ")    CP   )0   ":    GP
M *(   "D    IP   *H   "N    L0   +0   "X    O    ,$   #'
MS0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
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MZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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MYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O\
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
M%C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#N9N(QK>8B,JUE8G-LY**
MT+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C %C'Y
MO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#N9N(QK>8B,JUE8G-LY**T+&/
MB]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C %C'YO2!3
MZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#N9N(QK>8B,JUE8G-LY**T+&/B]*P
MC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ /%?C %C#YO2!3ZK@G
M?,RH1*O&I5VTPJ1PNKZB?[^\H(C#N9N(Q[>8B,JUE8G.LY**T+&/B].PC8W5
MKXJ/UZV(D]FMAIC:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JK
MAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:]\$/%??!%C#XOA]3ZK@F?,NI
M0ZO&IERTPJ1ONKZB?K^[H(C#N9V'R+::A\RSEXC/L92)TK"2BM6NCXS7K8V.
MV:R*DMRKB9G=IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;
MIXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;]L$.%/?!%3#XOQY3ZKDE?,NI0JO&
MIUNSPJ5NNKZC?K^[H8C$N)Z'R;6<A\VRF8?1L):(U*Z4B=>MDHO:JY"-W*F-
MDM^HC9K?HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<
MW*.+G-RCBYS<HXN<W*.+G-RCBYS<]L$.%/;"%3#WOQY3ZKHD?,NI0:S&IUJS
MPJ5MNKZC?;^[HXC$MZ"'R;2=A\ZQFX?3KYF(UJV7B=JKE8K<J9.-WZ>2D>*D
MD9G@H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".
MG-R@CIS<H(Z<W*".G-R@CIS<]<(.%/7"%##VP!U3ZKHC?,NJ0:S&J%FSPJ9M
MNKZD?;^ZI(?%MZ&'RK.?A\^PG8?4KIN(V*N9B=RIF(O?IYB.XJ67DN:@EIG@
MG).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<
MDYO=G).;W9R3F]V<DYO=],(-%/7#%##VP!Q3ZKLB?,JJ0*S&J%BSPJ9LNKZD
M?+^ZI87%MJ.'R[.AA]"PGX?5K9V(VJJ=BMVGFXS@I)J.XI^8C^.=FICAF9>;
MW9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=
MF9>;W9F7F]V9EYO=\L,-%/3#$S#UP1M3ZKPA?,JK/ZW&J5>SPJ=KNKZE>[^Z
MIH3%MJ6'R[*CA]&OH8?6JY^(VJ>=B=VDG(K?H)N+X)N:C>*7FI/AEYR;WI><
MF]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;
MWI><F]Z7G)O>\,,-%/3$$R_UPAI2ZKT@?,JK/JS&JE:SPJAKNKZG>;^ZJ(/%
MMJ>'S+*EA]&LHH?6J*"'V:2>B-RAG8C=G)R)WI>;B^"3FX_@DIV7WI*=E]Z2
MG9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=
ME]Z2G9?>[<0,$_/%$B_TPAE2ZKT??,JL/*S&JU6SPJAJN;ZI=[^ZJH#%M:F'
MS*^EA]*JHH?6I:"&V*&?AMJ=GH?;F9V'W92=B=Z0G(W>CIV3W8Z=D]V.G9/=
MCIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.
MG9/=ZL4,$_+%$2_SPQA2ZKX=?,NM.JS&K%2SPJEIN;ZL<[^ZK7[%LJF'S*RE
MAM&GHX;5HJ&%UYZ@A=B:H(7:EI^&VY&>B-R-GHO<BYZ/W(N>C]R+GH_<BYZ/
MW(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<
MYL4+$_'&$2_RQ!=2ZL ;?,NO.*S&K5*RPJMFN;^P;[ZWK7[&L*F'S:JFAM&D
MI(73GZ.$U9NBA-:7H878DZ"%V8^@A]F+GXK:B)^-VHB?C=J(GXW:B)^-VHB?
MC=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:X<8*
M$_#'$"[PQA91ZL$9?,NP-:O'KT^RP[!@N+RR;+^RK7['K:F&S*>GA<^AI832
MG*2$TYBCA-24HX35D**%UHVAAM>)H8C8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'
MH8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8V\<)$N[)
M#R[NR!11Z\06?,RS,*O'L4RQQ+A6M[:Q;L&NK7_'J:J&RZ.HA,Z>IX//F::#
MT96E@]*1I(33CJ2%U(NCAM2(HXC5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5
MA:.*U86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5VL@)$NO+#2WK
MRA%0Z\<2?,RV*JK(MT2PNK99NJ^Q<,*JK7_'IJN%RJ"JA,R:J(/-EJB#SI*G
M@\^/IH30C*:%T8FEAM&'I8?2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)
MTH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2V,D)$=_-"RSGS0]/
MZ,L.>\V\(JC"O#RQL;5>O*FQ<L*FKG_%HJV$QYRK@\F7JH/*DZJ$RY"IA,R-
MJ83-BZB%S8BHALZ&IX?.A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2G
MB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/U<D)$-C/"BO:TPM.V- +
M>LW#%JBSND:UJ;1BO:2Q=,&AL'_#GJZ$Q9FMA,>4K(3(D*N$R8ZKA,J+JH7+
MB:J&RX>IA\R%J8C,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#
MJ8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,TLL)#]31"BG5U0M,T- *?KB_
M):ZHN$^XH;1FO)ZR=;^=L7_!F["$PY:NA,61KH3&CJV%QXNLA<>)K(;(AZR'
MR8:KA\F$JXG)@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*
M@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*S\P)#=#2"BC.U I2Q=$*@ZK#+:B>
MMU>XF[5HNYJT=;Z9LG^_E[&$P9.PA<*/KX7#C*^%Q(JNAL6(KH?%AJZ(QH2M
MB,:#K8K&@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+
MQX&MB\>!K8O'@:V+QX&MB\>!K8O'S,T)#,O3"BW'U I9LM@+@)[-*YJ8P5"K
MEKAGMY6U=;R4M'Z^E+.%OY"RA<",L8;!BK&'PHBPA\*&L(C"A;")PX.PBL."
MKXO#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&O
MC,.!KXS#@:^,PX&OC,.!KXS#Q\\($,74"32XV0I;HN<2=I?:)8F0ST68CL==
MHXW!;JN-O7FQC+J!M(FX@[>&MX6YA+:&NH.UA[N"M8B\@;2)O8"TBKU_M(N^
M?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^
MLXR^?K.,OGZSC+Y^LXR^PM$'%KW6"#JG\0Y5F_$;:)'F+7B)W4"%A=56CX//
M9Y>"RW.=?LAXH7O&?*1YQ'^F=\."J'7"A*ETPH6J<\&'JW+!B*MRP(JL<<"+
MK'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL
M<<"+K'' BZQQP(NL_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MC*:%T(FFAM&&I8?2A*6*TH&EC=* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]*
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MILZ<A:;._[04"/^T'QW_L2PZ_ZTX6>NF17O5G5><QYMGLL2>;K;"H'>ZOZ&
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MEU]^W)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V
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MK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
MJL1QP*K$<<"J_Y(2 ?^6)PK_ECL<_Y1+,/^064/_CV-4^HYI9/&-<'+IBWI^
MXHF"B=R%B9+8@HZ9U'^3GM%]EZ+/>YNFS7F>J,QWHJK+=J6LRG2IK<ESK:[)
M<K*OR7&WK\AQO*_"<[VNOG2]K[YTO:^^=+VOOG2]K[YTO:^^=+VOOG2]K[YT
MO:^^=+VO_Y,2 ?^7)PK_F#L<_Y5+,/^1643_D6!5^I!F9/"/;7/HC7> X8R
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MTI'.:-*1_X,3 ?^$(@;_A344_X-&)/]_533_@5Y"_X%F4/]_;ESY?'=F\WJ
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M;ZNING*EM;IWG;6Y>IFVMWV6M[9^D[FT?Y&ZLH"0N[& D+NQ@)"[L8"0N[&
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MP*IMHL"J_Y4- /^:'@7_HBP0_ZTH%?N[(QCHS2 7U=\E'<CH,#&\[SE$L.Q
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M;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=LW:\  ,6\! "UR@0
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MR)^,@<B?C('(GXR!R)^,@<B?_X(1 ?^!&@/_ABT-_Y8T%?^@.1W_ICPF_ZM
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M?U+&WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!_Y(, /^@#0#;MP8
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MA,N8A(/.EH2#T)2$@M*2A('3D(2!U(Z$@-:,A(#6C(2 UHR$@-:,A(#6C(2
MUHR$@-:,_W<2 ?]T&P/_@AX$_Y0G"/^@,@W_IS03^JXX&.^U/1SFO$8AW+],
M+,ZY5#_#L5U0MZIE7ZVD;&RCG71WF9A\@9&3AHJ)CY*1@HR?EGV*KYAZB\>8
M?(G.EGV(T)1^AM*2?X73D'^$U(Z @]:,@(/6C("#UHR @]:,@(/6C("#UHR
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MAV&AVX9CG=N%8YW;A6.=VX5CG=N%8YW;A6.=VX5CG=N%_WX0 ?^'$0'_FA$
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M_VH5 ?]K&P+_>Q<"_XH< O^8)@7_HC (]:@S#.NN.1#BLT$4UK%'(\JK4C3
MI%Q#MIYD4:V8;%REDG1FG8U];Y:(AG:/A9%]BH*<@H6 JH6!?[R&@(#;A8"
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M<%FCZW!9H^MP6:/K<%FCZW!9H^MP_W</ ?^-" #>H ( SZX% ,2Y!0"[Q08
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MA X5_Y(/%/^@$!/_K1$3_[H1$__#$A/_PQ(3_\,2$__#$A/_PQ(3_\,2E[X
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M:&F)\&AIB?!H:8GP:&F)\&AIB?!H_V<2 ?]Y# #_B@H WYH$ -.F!P#,L0@
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M0.FR/C_JRSX^Z.\^/>;_/SW@_T(_U_]$0,[_1D#._T9 SO]&0,[_1D#._T9
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ML"@N_\@I+?_J*BS__RHL__\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RHO^?\JN:8
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M&O^R$1G_R!(8_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,  )"_  "
MS   <MH  &3D  !8]0  4?\! $K_"P!$_Q !/O\7 3G_'@(T_R4",/\L RS_
M,@0H_S@$)?\^!2+_1 4?_TH%'/]1!AK_6087_V,'%/]N!Q+_? @0_XP(#_^<
M" [_K D._[L)#?_3"0W_TPD-_],)#?_3"0W_TPD-_],)D;P  (')  !RUP
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M6W5Y^UIU>?M:=7G[6G5Y^UIU>?M:_UT3 ?]L#0#_>PL ]H@) -R3!@#5G0D
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MQCM#T.HZ0,W]/C[+_T! P_]"0;W_0T*Y_T1"N?]$0KG_1$*Y_T1"N?]$W8@
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M'2K\^ATJ^O\=*O?_'"KW_QTJ]_\=*O?_'2KW_QTJ]_\=LZ,  *2K  "7M@
MB<$  'O+  !OU@  8]\  %OU!@!5_Q  4/\9 4O_(P)&_RP#0O\T!#[_/ 4Z
M_T,&-_]+!S3_4P@Q_UL)+O]D"BO_;PPH_WP-)O^+#B3_G! B_ZX1(?_%$B#_
MZ1,?__P3'O__$Q[__Q,>__\3'O__$Q[__Q,>__\3IJD  )BS  "*OP  >\H
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M2*%:_TB=6_]'FUS_1IE<_T697/]%F5S_19E<_T697/]%_TL: ?]7$P'_81
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M3(!K_TJ :_]*@&O_2H!K_TJ :_]*_U02 ?]A# #_;@H _7@) .B"" #<B0D
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MNDI.HME)3J#U24Z?_TE0F?])4I;_2%22_T=4DO]'5)+_1U22_T=4DO]'_VX
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M,#W$_S,[P_\U/+[_-CVX_S<]N/\W/;C_-SVX_S<]N/\WT88  ,"5  "RGP
MI:<  )JO  ".MP  @[\  'C' P!NSP< 9=<- &/8'0!@V"T"6]@Z!%?81@E3
MV% -3]A9$4O78A5'UVP81-=W&T'7A!X^V),@/-BC(3O9MR(ZVM4B.M;R(S?4
M_R<VTO\I--'_*S;*_RTVRO\M-LK_+3;*_RTVRO\MQ9   +:=  "HI0  G*T
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M"1G__PD9__\)&?__"1G__PD9__\)HJ<  ).Q  "%NP  =L8  &G0  !;V@
M3N   $/E   ^^P$ .O\, #;_$P R_QL +_\C "O_*@$H_S$!)/\W 2'_/P(?
M_T8"'/]. AG_6 ,6_V,#$_]P Q+_@001_Y,$$/^G! __O04._^ %#O_V!0[_
M_P4.__\%#O__!0[__P4.__\%E:\  (:Z  !WQ0  :-   %K;  !,X0  0.<
M #?S   R_P  +O\' "K_#@ F_Q, (_\: !__(  ;_R8 &/\K 17_,@$2_S@!
M$/]  0[_2 $,_U(!"?]= @;_:P($_WT" O^0 @'_HP( _[8" /_- P#_[ ,
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M.X];_SJ/6_\ZCUO_.H];_SJ/6_\Z_TP2 /]6#0#_8 D _V@* /IO# #S<PX
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MMD=>@<U'7H'O1E^!_T1@?_]"87W_06)[_S]C>O\_8WK_/V-Z_S]C>O\__UX
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M/$R9_SQ,F/\\397_/$^1_SM0C_\[4(__.U"/_SM0C_\[ZVT  --\  ##B0
MMY,  *R:  "BGP  F:4  (ZK  "%L L @;$; 'RQ*P)WL#@'<:]##6NN311F
MK5498:Q='EVK92-9JFXG5:EW*U&H@B]-IX\R2J>>-4BGKS9'I\8V1J;I-D6D
M_C=%H_\W1J#_-TB<_S=)FO\W29K_-TF:_S=)FO\WXG0  ,J#  "\CP  L)@
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M'S#)_R$OR/\A+\C_(2_(_R$OR/\AOH\  *^:  "BH0  EJD  (JP  !]N
M<;\  &;&  !;S ( 4-(' $?:# !&W!@ 1=PG $3=-0%!W4 "/]Y+ SW>500Z
MWU\&.-]I!S7?=@DSX(0+,>"4#"_AI@TNX;P.+>+@#BW>^ \KW?\2*MS_%"G:
M_Q8HVO\6*-K_%BC:_Q8HVO\6LY@  *6@  "9IP  B[   'ZX  !QP   9<@
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M @?__P('__\"D:T  (*X  !SP@  9,P  %;5  !(W0  .^(  ##G   G[@
M(_\  "#_!  <_PP &?\1 !;_%@ 3_QL $?\A  [_)P -_RX "O\V  ?_/@ $
M_T@  /]4  #_8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_Z@$ __,! /_S 0#_
M\P$ __,!A+<  '3!  !ES   5M@  $??   YY0  +>H  "/N   <_0  &/\
M !7_   1_P0 #_\+  W_#@ )_Q$ !O\5  /_&@  _R   /\F  #_+@  _S<
M /]!  #_30  _UP  /]M  #_@@  _Y8  /^H  #_N@  _\,  /_#  #_PP
M_\, _R0O ?\E+P'_*"\!_R<Q ?\D-@+_(#X"_QI) _\75@/_%60#_Q-R!/\2
M?P3_$HH$_Q*4!/\2G07_$J0%_Q*L!O\2LP;_$KH&_Q+#!O\3S@?_$]\'_Q/K
M!_\3]@?_$_\'_Q/_!O\3_P;_%/\'_Q3_"/\3_PC_%?\)_Q7_"?\5_PG_%?\)
M_R4N ?\I+0'_*RP!_RLN ?\I,P+_)#L"_Q]& _\=4P/_&V$$_QEN!/\7>P3_
M%X<%_Q>1!?\7F@;_%Z$&_Q>I!_\7L ?_%[<(_Q? "/\8R@C_&-L(_QCH"/\8
M] C_&/T(_QG_"/\9_PC_&?\)_QG_"O\8_PO_&O\+_QK_"_\:_PO_&O\+_R8M
M ?\L*0'_+B@!_R\J ?\M+P+_*3<"_R=# _\D4 /_(ET$_R!J!?\>=P7_'H,&
M_QZ-!_\>E@?_'IX(_QZE"?\>K G_'K,)_QZ\"O\>Q@K_'M,*_Q[E"O\>\0K_
M'_P*_A__"OT?_PO\'_\,_![_#?P?_P[W(?\.]R'_#O<A_P[W(?\._RHJ ?\O
M)@'_,B0!_S,E ?\R*@'_,30"_R\_ _\M3 /_*ED$_RAF!?\F<@;_)7X'_R6)
M"/\ED@G_)9H*_R6A"_\EJ O_)+ ,_R2X#/\EP0S_)<X-_R7A#?PE[PWY)OH,
M]B;_#?4F_P_T)?\0]"7_$?(F_Q+M)_\2[2?_$NTG_Q+M)_\2_RXF ?\T(@'_
M-R !_SDA ?\X)0'_.2\"_S@[ O\U1P/_,U0%_S%A!O\O;0?_+GD)_RV$"O\M
MC0S_+)8-_RR=#?\LI0[]+*P/_"RT#_LLO0_Y+,D0]BS=$/,M[ _O+?@/[2W_
M$NLL_Q3J+/\5Z2S_%N4M_Q;@+O\6X"[_%N N_Q;@+O\6_S(C ?\X'0'_/!L!
M_SX; ?] (@'_02L!_T V O\^0@/_/$\%_SE<!O\X: C]-G,+^S5^#/@UB [W
M-)$/]329$/,TH!'R,Z@2\#.P$N\SN1/N,\43ZS37$^<TZA+C-/<4X33_%]XS
M_QG<,_\:VS/_&M0T_QK.-?\:SC7_&LXU_QK.-?\:_S8? ?\\&0'_018 _T06
M /]''@'_22<!_T@R O]&/0/_1$D%^D)6!_9 8@GR/VX,[SUY#^T\@Q#J/(P2
MZ#N4$^<[G!3E.Z05XSJM%>(ZMA;@.\(6WSO2%MH[Z!?4.O8:T#K_',TZ_Q[+
M.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?] %0#_11$ _TH3 /].
M&0#_4"(!_U L ?U.-P+V2T,$\$E0!^M(70KG1FD-XT5T$.!$?A/=0X<5VT*0
M%]A!F!C50* 9TT"I&]% LAS/0+T=S4#,'<I!Y![&0/0@PD#_(K] _R.]0/\C
MNT#_([9!_R.S0O\BLT+_(K-"_R*S0O\B_ST7 /]$$0#_2@X _U 0 /]4%0#_
M5AT _58F ?-5,0'K4ST#Y5)+!M]06 K:3F,.U$QN$]!*>!;-28$9RTB*&\A'
MDAW&1YH?Q$:C(<)&K"+ 1;<COD7%)+Q%W"2X1O EM4;_)[)&_R>P1O\GKD;_
M)ZI'_R:G2/\FITC_)J=(_R:G2/\F_T 4 /](#@#_3@L _U4. /]9$0#_7!8
M]%T? .I<*@'B6S<"VEI&!=)74PO,55X0R%-H%<11<AG!4'L<OD^$'[Q-C"*Y
M394DMTR=)K5+IR>S2[$IL4J_*J]*T2JL2^LKJ4O\+*9+_RRE3/\KHTS_*I]-
M_RJ=3?\IG4W_*9U-_RF=3?\I_T,1 /]+# #_4P@ _UH+ /]>#0#Y8!  ZV$6
M .%B(0#68C$!SF%!!<=?3@O"7%D1O5ID%[E8;1NV5G8?LU5^(K!3AR6N4H\H
MJU&8*JE0HBRG4*PMI4^Y+Z-/RR^@4.8OGE#Y,)Q0_R^:4?\NF%'_+992_RR4
M4O\KE%+_*Y12_RN44O\K_T80 /]."0#_5@4 _EX& .]B!P#G90H Y&8. -9G
M&0#-:"T!Q6<]!;]E2@NY8U42M&!?%[!>:1RL7'$AJ5IZ)*99@BBD6(LKH5:4
M+9]5G2^<5:@QFE2T,YA4Q3.65.$TDU7V,Y)5_S*15O\QCU;_,(U6_RZ,5_\M
MC%?_+8Q7_RV,5_\M_TD. /]1!0#_6@$ [F(  -]G P#8:@8 U6L* ,UM%0#%
M;BD!OFTY!+=K1PNQ:%(1K&9<&*AD91VD8FTBH6!U)IY>?BF;788MF%R/+Y5:
MF3*36:0TD%FP-HY9P#:,6=LWBEGS-HE:_S2(6_\SAUO_,89;_S"%6_\OA5O_
M+X5;_R^%6_\O_TL, /]4  #[7@  XF4  -AK 0#/;@4 S' ( ,9R$@"^<R8!
MMW,V!+%P1 JK;D\1IFM9&*%I81V=9VHBF65R)Y9C>BJ38H,ND&",,8U?E32*
M7J VAUZM.(5=O#F#7=0Y@E[P.(%?_S: 7_\T@%__,W]?_S%^7_\P?E__,'Y?
M_S!^7_\P_TT) /]6  #N80  W6D  -%O  #*<P, Q74& ,!V$ "X>", L7@S
M ZMV00FE<TP0GW!6%YMN7QV6;&<BDVIO)X]H=RN,9W\OB66(,H5DDC6"8YTW
M@&*J.7UBN3I[8L\[>F+N.7IC_SAZ8_\V>6/_-'EC_S)Y8O\Q>6+_,7EB_S%Y
M8O\Q_T\' /]9  #F9   UVP  ,QS  #$=P( OWD$ +EZ#@"R?"  K'PQ Z5Z
M/@F?>$H0FG53%Y5S7!V1<60BC6]L)XEM="N%;'PO@FJ%,G]ICS5\:)LX>6>G
M.G9FMCMT9LP\<V?K.W-G_SAS:/\V<VC_-7-G_S-S9O\R<V;_,G-F_S)S9O\R
M_U$$ /]<  #B9P  TG   ,=V  # >@  NGT" +1_# "M@1T IX$N J!_/ B:
M?4</E7I1%I!X6AR+=F(AAW1I)H-R<2M_<7HO?&^#,GANC35U;9@X<FRE.W!K
MM#QN:\D\;6OI.VUL_CEM;/\W;FS_-6YK_S1N:O\R;FK_,FYJ_S)N:O\R_U,
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M.EM\^CA<>_\W77O_-5YY_S1?=_\S7W?_,U]W_S-?=_\S_EP  .%J  #-=0
MP'X  +:&  "NBP  I8X  )N1  "5DQ$ D)0B 8N3,0.%DCT)?Y%(#WJ/419U
MC5D;<8Q@(&R*:"5HB7 I9(=Y+6&&@S%=A8\T6H2<-E>#K#A5@[\Y58/A.%6"
M^3=6@O\U5H'_-%A__S-9??\R67W_,EE]_S)9??\R[V   -MN  #'>@  NX,
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M+$*;_RQ$E_\K1)?_*T27_RM$E_\KUW(  ,.   "VC   JI0  )^9  "4G@
MB:,  'ZH  !PK@  :K . &BQ'0!EL2P!8;$X UVP0P99L$P*5:]4#E*O71%.
MKF452ZYO&$BM>1M%K88>0JR5(#^LI2(^K;DC/:W8(CVK]2,\J?\E.Z?_)CNF
M_R8[I/\F.Z3_)CND_R8[I/\FS'H  +N(  "ND@  HID  )>>  ",I   @*H
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M#2/0_PTCT/\-KI8  *"=  "4I   AJP  'FT  !LNP  8,(  %3&  !(RP
M/M   #75!  MW0H +.$3 "OB'P IXRH *.0U "?D/P FY4H ).95 "/F80$A
MYVX!(.=^ A[HD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD_P08X_\%&./_!1CC
M_P48X_\%HYT  ):D  "(K   >K4  &R]  !?Q   4\H  $?.   \TP  ,MH
M "K?   E[@D (_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X %_1( !7U4@ 3]E\
M$O9N 1'W@ $0^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-\_\!#?/_ 0WS_P$-
M\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@  )N(  !_J
M   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )_TX !O]<
M  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__  #__P  __\
MC:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H  !7Y   2
M_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST  /])  #_
M5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@  __H @+4
M '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_   +_P
M"/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V  #_0P
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M$-$L_Q#/+/\0SBW_$,XM_Q#.+?\0_S(9 /\W% #_.A$ _SP2 /\_&0#_0"(
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M'II'_QZ:1_\>_T - /]&! #_3   ^%(" .A5! #A50@ XE4- -55&0#,5RP
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MM"U_6<<N?5GF+7Q:^BQ[6O\J>UO_*'M;_R=[6O\F>EK_)7I:_R5Z6O\E_TD
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M,&EG]2YI9_\L:6?_*FIG_REJ9O\H:F;_)VIF_R=J9O\G_U   .=;  #39@
MQ6X  +MS  "S=P  JWD  *1X P"=>A0 F'LE 9-[- ..>D 'B7A*#81V4Q*
M=5L7?'-B&WAR:A]U<7(B<F][)F]NA2EL;9 L:6R<+F9LJC!D;+PQ8VS9,&-L
M]"]C;/\M9&S_*V1K_REE:O\H96K_*&5J_RAE:O\H_5,  .-?  #.:0  P7$
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M*5-[_RA4>O\G5'K_)U1Z_R=4>O\GZ%X  -!K  # =@  M'X  *N%  "AB0
MEXL  (F-  "#CP@ ?I 7 'N1)P%VD30#<I _!FV/20MICE$/98U9$V*,8!=>
MBV@;6XIQ'E>)>R%4B(8D48>4)T^&HBE-AK0J2X;,*DN%[BE,A/\I3(/_*$R#
M_R=-@?\F3H'_)DZ!_R9.@?\FX6,  ,EP  "[>P  L(0  *:*  ";C@  D9$
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M'#>?_QPWG_\<Q'@  +6%  "ICP  G94  )*:  "&GP  >J,  &ZH  !BK
M5;   %"R#@!.LAL 3;,H $NS-0!)LS\!1K-) D2S4@1!LUL&/[-D"#RS;PHZ
MLWL,-[.*#C6RF@\SLZT0,K/%$#*RZ1 QL/X2,*[_%"^M_Q4OK/\6+ZS_%B^L
M_Q8OK/\6NX$  *Z.  "AE0  EIH  (F@  !]I@  <:L  &6O  !9M   3K<
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MA0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1V_\"GIH
M )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=   "35   <VP
M%=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B  GP=  (
M\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\ E:$  (:I
M  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@   2Y   #_ !
M  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\80  _74
M /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D  'FR  !J
MNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *\0  "/T   7_
M P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30  _U\  /]U
M  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\  !=Q@
M3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P   /\   #_
M_P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH  /]=  #_
M<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_&2@ _Q4K
M /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\ E '_ )P
M_P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#] /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4 _QDG /\3
M+ #_#C0 _PM  ?\(3@'_!5L!_P-H ?\"= '_ G\!_P*( ?\"D0'_ I@!_P*?
M ?\!I0#_ :P _P&R /\!N@#_ <0 _P'1 /\ Y #_ /$ _P#\ /P!_P#\ O\
M_ /_ /P$_P'\!?\!_ 7_ ?P%_P'\!?\!_Q\F /\A(@#_("$ _QXC /\8)P#_
M$S  _Q$\ ?\.2@'_#5<!_PMC ?\*;P'_"GH!_PJ$ ?\*C0'_"I0!_PJ; ?\*
MH@'_"J@!_PJO ?\*MP'_"L  _PK, /\*X #["N\ ]PKZ /4+_P'U#/\!] W_
M ?0-_P+T#?\"] W_ O0-_P+T#?\"_R(B /\D'0#_)!P _R(= /\>(@#_'"P
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M#+LL_PR[+/\,_S$1 /\U# #_-@< _SH+ /\\$ #_.Q4 ^#D? .\W*P#G-CD
MX35' -PU5 '5-6 "T35J \XT<P3,-'P%RC2%!L@TC0?&,Y0(Q#.<"<(SI0G!
M,ZX*OS.Y"[TSR N[-.$+MS3S#;0T_P^Q-/\/L#3_$*\T_Q"N-/\/KC3_#ZXT
M_P^N-/\/_S4. /\X!P#_/ ( _T & /]!"P#Z00\ [3\6 .,\(@#:/3$ TCY!
M ,P^3P+(/EH#Q#UD!<$];@>_/'8(O#Q^"KH[APNX.X\,MSN7#;4ZGPZS.JD/
ML3JT$*\ZPA&N.MD1JCOO$J<[_Q.E._\4I#O_$Z,[_Q.B._\3HCO_$J([_Q*B
M._\2_S@* /\\  #_00  ]44  .9& @#A10< XT(- -5#&0#,12P QD<\ <%'
M20*\1E4$N45?!K5$: FS0W$+L$-Y#:Y"@0^L0HD0JD&1$JA!FA.G0*04I4"O
M%:- O!:A0- 6GD'J%YQ!_!>:0?\7F$'_%YA!_Q:70?\5ET'_%9=!_Q670?\5
M_SL& /\_  #Y1@  Y4L  -Q.  #3300 T4H) ,I*% #"32< O$XW ;=.10*R
M35 %KTQ:"*M+8PJH2FP-IDET#Z1)?!&A2(03GT>,%9U'E1>;1I\8F4:J&9=&
MN!J61LH;DT;F&Y%'^1N/1_\:CD?_&8Y'_QB-1_\8C4?_%XU'_Q>-1_\7_SX"
M /]#  #K2P  W5$  -%4  #*5 $ QE(% ,%1$0"Y4R( LU4S :Y400*J5$P%
MIE-6"*)17PR?4&</G4]O$9I.=Q283G\6EDV(&)-,D1F13)L;CTNF'8U+LQZ+
M2\4>B4OB'H=,]QZ&3/\=A4S_'(5-_QJ%3/\9A4S_&85,_QF%3/\9_T   /Q'
M  #E4   U58  ,I9  #"6@  O5@# +A7#@"Q61X K%HO :=:/0*B64D%GEA3
M"9M76PR75F00E55K$I)4<Q6/4WL7C5*$&HM1C1R(49<>AE"C'X10L"""4,$A
M@%#=(7Y1]"!]4?\??5'_'7U1_QQ]4?\;?5'_&GU1_QI]4?\:_T(  /!*  #?
M5   SEH  ,1>  "\7P  MEX  +%<"P"K7AH I6 K *!@.@*<7T4%EUY0"91<
M6 R06V 0C5IH$XM9<!:(6'<8A5> &X-6B1V 5I0??E6?(7M5K2)Y5+TC>%77
M(W=5\B)V5O\@=E;_'W96_QUV5O\<=E;_&W96_QMV5O\;_T4  .Q.  #:6
MR5X  +]B  "W9   L6,  *MA" "D8Q< GV0H )IE-P*69$,%D6--"(YA50R*
M8%T0AU]E$X1>;!:!7709?EQ]''Q;AAYY6I$@=UJ=(G19JB1R6;HE<5G2)7!:
M\"-O6O\B;UK_('!:_QYP6O\=<%K_''!:_QQP6O\<_T@  .=2  #36P  Q6(
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M(5]F_Q]@9O\>8&;_'F!F_QY@9O\>[T\  -I<  #&90  NFT  +!R  "G=0
MG70  )1S  "-= T B78< (5W*P&!=S@#?'9#!GAU3 ET=%0-<7-;$6YR8Q1K
M<6L7:'!S&F5O?!UB;H<@7VV4(EULHB1:;+(E66S')5ALZ"59;/TC66O_(5IK
M_Q];:_\>6VK_'EMJ_QY;:O\>ZU,  --@  #":0  MG$  *QV  "C>0  F7D
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M'$E\_QQ)?/\<UF$  ,)N  "T>   JH   )^%  "4AP  B(<  'N)  !PC
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MD0<NK*,(+:RX"2RLV0@LJO4**ZC_"RJF_PPJI?\-*J7_#2JE_PTJI?\-M8
M *B+  "<D0  D98  (6<  !XH   :Z4  %^H  !3K   2*\  #VR   VM0L
M-+45 #.V(0 RMBP ,;<W #"W00 ON$L +KA5 "RX8 $JN&T!*;E[ B>YC0(E
MN9\#)+FT R.YT@,CM_0$(K7_!2&T_P8AL_\'(;+_!R&R_P<ALO\'K8H  *"1
M  "5EP  B)T  'NC  !NJ   8:T  %6Q  !*M   /[<  #2[   KO@, ),(,
M "+"%  BPQ\ (<,J "#$-  ?Q#\ 'L5* !W&5@ <QF, &\=S !K'A0 9QYD
M&,BN !?(RP 7QO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$  )B8  "+
MG@  ?:4  '"K  !BL0  5K8  $JY   ^O0  -,   "K$   BR   &<P$ !/0
M"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,UHT "]BD
M  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?  " I@
M<JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8   S;!0 (
MW@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L  .:2  #F
MJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !TKP  9;<
M %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0  ">$   +E    Z08
M .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^  #TEP
M];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN   6,$  $K(
M   [S   +M$  "/6   9W   $>    SC   $YP   .H   #U    ]    /4%
M  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_@0  _YH
M /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L  #O1   M
MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_    _P   /\   #_
M    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3  #_:0  _X$  /^9
M  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&+0#_ #4
M_P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"= /\ I #_
M *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_ #  _P ]
M /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\ H #_ *8
M_P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_ /@ _P#X
M /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP _P<Y /\#
M1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_ *, _@"I
M /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\ _P#O /\
M\ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT /\,00#_
M"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\ ]@:F /0&
MK0#R!K4 \ 7  .T%S@#K!>0 Z0;S .8(_P#E"O\ Y O_ .0+_P'D"_\!Y O_
M >0+_P'D"_\!_R$8 /\A$P#_(!$ _QL2 /\<&@#_&B0 _Q8O /\3/ #_$4D
M_Q!5 /P.80#Y#FL ]@YU /0.?@#R#H8 \ Z. .X.E0#M#IL ZPZB .H.J@#H
M#K, Y@^] .4/S #A#^, W1#S -D1_P'6$O\!U!/_ =,3_P+2$_\"TA/_ M(3
M_P+2$_\"_R43 /\E$ #_) T _R,. /\C% #_(AX _Q\I /\<-0#Y&4, ]!A/
M .\76P#L%V8 Z1=P .87>0#D%X$ XA>) . 7D0#?%Y@ W1>? -L7IP#9&+$
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M$HM!\1*)0O\2B$+_$8A"_Q"'0O\0AT+_#X="_P^'0O\/_S@  /,]  #C1P
MTDP  ,A.  # 30  NTH" +9'#@"P21T JTLM *9,.P&B3$<"GDM1!)M+6@:9
M2F((EDEJ"I1)<0R22'D.CTB"#XU'BQ&+1Y42B4:@%(=&K!6%1KL6A$;1%H)'
M[A: 1_\5?T?_%']'_Q)_1_\1?T?_$7]'_Q%_1_\1_SL  .Y#  #<3   S%$
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M%VI5_Q9J5?\5:U7_%&M5_Q1K5?\4\D,  -]/  #+6   O5T  +-A  "K8@
MHF   )M<  "57A  D& ? (QA+@"(83H"A&!%!(%@3@9^7U8)>UY="WA=90YV
M7&P0<UQT$W!;?15N6H@7:UJ4&6E9H1MG6; <95G#'&19XQQD6?H:9%G_&&19
M_Q=E6?\595G_%&59_Q1E6?\4[T8  -I2  #&6P  NF$  +!E  "F9@  G6,
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M%59E_Q569?\5XE$  ,I=  "[9@  KVP  *9Q  "9<   CF\  (-N  !]< 4
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MDA$_A*(2/82U$SR$SQ,\@O 2/('_$CV _Q(]?_\2/7[_$3U^_Q$]?O\1Q68
M +5Q  "J>P  GX(  )*"  "%@@  >8,  &V&  !?B@  6(T! %2.#P!2CQL
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M!":EQ@,FI.L$):+_!26@_P8DG_\&))[_!R2>_P<DGO\'KWX  *.(  "7C@
MC9,  'Z5  !PF   8YL  %>?  !,H@  0J8  #BI   OK , *JX. "FN&  H
MKR, )Z\M ":P-P EL$$ )+!+ ".Q5@ BL6, (;%Q !^Q@@ >LI0!'+*I 1NR
MP0$;L><!&Z_^ AJM_P(:K/\#&JO_ QJK_P,:J_\#J(@  )N/  "1E   A)H
M ':?  !HH@  6Z4  $^I  !$K0  .;   "^S   FM@  'KD% !B[#@ 7NQ8
M%[P@ !:\*@ 5O34 %+U  !.^2P 2OE@ $KYG !&_>  0OXP $,"B  [ N@ .
MP.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP  >:$  &NG
M  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +R@T "<H4
M  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,JP  S<@
M ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH  &"P  !2
MM@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1   !U D  -0.  #5
M%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP  W[0  -[9
M  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z  !%OP
M.,(  "S&   AR0  &,T  !#1   +U0  !-H   #>    X $  .$)  #B#@
MY!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(  /"\  #P
MXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   WR   *LP
M !_0   5U0  #MH   ?>    X@   .8   #I    Z@   .P   #N!0  [PP
M /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F  #_P
M_^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-   JT@  '=@  !/=
M   ,X@   ^8   #I    [    /    #S    ]    /8   #X    ^@   /T'
M  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_I@  _[H
M /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^ /\ 3 #_
M %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4 _P"K /\
ML@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^ /\ _@#_
M /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\ 2 #_ %4
M_P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G /X K@#]
M +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\ ]0#_ /4
M_P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_ %  _P!<
M /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4 J@#T +(
M\@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_ .H _P#J
M /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L _P!7 /\
M8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I *X YP"W
M .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T _P#= /\
M_QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1 /<"7 #R
M F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L VP2T -@%
MP #6!=  TP;G - (^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+_P#+"_\ _Q\0
M /\>"P#_&@< _QD+ /\8$0#_%AD _Q(D /H0, #S#CX [@U* .D,5@#E#&$
MX@QJ -X-<P#;#7L V0V# -8-B@#4#9$ T@V9 - .H #/#JD S0ZS ,L.OP#*
M#]  QA'I ,(2^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3_P&[$_\!_R(, /\A
M! #_(   _R$% /\?# #_'!$ ]A@< .P5* #E$S8 WQ)# -D33P#3%%H T!5D
M ,T6;0#+%G4 R1=] ,<7A0#%&(P Q!B4 ,(9G # &:4 OAFO +T:NP"[&LL
MN!OE ;0<]@&R'?\"L!W_ J\=_P*N'?\"KAW_ JX=_P*N'?\"_R8& /\E  #_
M)@  ^R<  /$E P#P(0L Z!P2 -X9'0#4&RT S1T\ ,@?20#%(%4 P2%? +\B
M: "\(G  NB-X +DC?P&W(X<!M2./ ;0DEP&R)* !L22J J\DM@*M)<8"JR7?
M J@F\P.E)O\#HR;_ Z(F_P2A)O\#H2;_ Z$F_P.A)O\#_RD  /\H  #V+0
MYS   -\O  #9*P0 UB(* ,XC%@#&)B< P"@V +LJ1 "X*T\ M2Q9 +(L8@&P
M+&H!KBUR :PM>@*J+8$"J2V* J<MD@.E+9L#I"VE!*(ML02@+< $GRW8!)PN
M[P69+O\&ER__!I8O_P:5+O\%E2[_!94N_P65+O\%_RP  /\N  #J-0  W3D
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M#'A"_PMX0O\+>$+_"GA!_PIX0?\*]C8  .9   #12   PTT  +E.  "Q30
MJ4D  *1%!@"?1A, FD@C )9),@"22CX!CTI( HQ*40.*25D$ATE@!85): >#
M2&\(@4AW"G]'@ M]1XH->D>5#GA&H@]V1K 0=4;"$'-&X!!R1_</<4?_#G%'
M_PUQ1_\,<4?_"W%&_PMQ1O\+\SD  .!$  #,3   OE$  +13  "J4@  HDX
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M#5]3_PU?4_\-YT0  ,]0  "_6   LUT  *A?  "<70  DEL  (M8  "%6@H
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MDA!,9Z$22V>R$DEGR1))9^L226;_$$IF_P]*9?\.2V7_#4MD_PU+9/\-T50
M +Y>  "Q9P  IFT  )=L  "*:P  ?VL  '-K  !M;0  :&X, &5P%P!B<20
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M"S=^PPLW?>8+-WO\"S=Z_PLW>?\*.'C_"CAX_PHX>/\*OF0  +!O  "E>
MEGD  (=Y  ![>0  <'H  &1\  !8@   4(,  $N%"@!(AA0 1X<@ $6(*P!$
MB#4 0X@^ $&)1P% B4\!/HA8 CR(80,ZB&P$-XAX!36(AP8SB)@',H>J!S"(
MP <PA^0',(7["#"#_P@P@O\(,('_"#"!_P@P@?\(MVL  *IV  "@?P  D'X
M ()^  !V?P  :H   %Z#  !3AP  2HL  $&. @ ]D X .Y 8 #J1(P YD2T
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M !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0  ?9(  &V5  !@F
M5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /M1  #K47  ZU(0 -
MM2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :VJ@ %ML4 !K;J  >U
M_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7I   2Z@
M $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L  L 1  '!&0  P2(
M ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:  #$]@
MP_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0  0;4  #6W
M   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,  #-$0  SA@  ,XA
M  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6Z0  UOT
M -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T  "C!   =
MQ   %,<   W+   &S@   -(   #7    V0   -H%  #<"P  W1   -\5  #A
M'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@  Z^\  .O^
M  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+   2SP
M"],   +8    W0   .$   #D    Y0   .<   #I    ZP<  .T-  #O$0
M\1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(  /WM  #]
M]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (W0   .$
M  #E    Z    .P   #O    \0   /,   #U    ]P   /D!  #["   _@X
M /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*  #_U
M_]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8 _P!B /\
M;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_ +4 _P"^
M /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D _P#Y /\
M_PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!> /\ : #_
M '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +  ^0"Y /@
MQ@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S /\ _Q 9
M /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\ 8P#^ &T
M_ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T .T P #K
M ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ _Q(4 /\0
M$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T &< \0!P
M .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\ N@#= ,D
MVP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40 /\2# #_
M#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$ Y0!J .(
M<@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#, ,0 R@#9
M ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5!0#_$
M_Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D -(#; #/
M W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$ O0C5 +L)
M[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_%P  _Q8
M /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-9P#"#F\
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M H\H_P*.)_\"CB?_ HXG_P*.)_\"_R8  /(I  #C,0  TC0  ,@T  # ,
MNRD" +@C#@"Q)AP K"@K *@J. "D*T0 H2Q. )\M5P"=+5\ FRUG 9DM;@&8
M+G4!EBY] I0NA@*3+I "D2Z: X\NI@.-+K,#C"[% XHOX02'+_8$A2__!(0O
M_P.$+_\#@R__ X,O_P.#+_\#^RD  .LQ  #9.   R3P  +\\  "V.0  L#(
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M!FI!_P5J0?\%[3<  -9"  #$20  MTT  *M-  "@2@  F$<  )-"  ".0PT
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MD0M75* ,55.P#513Q0U34^8,4U/\"U-3_PE44O\(5%+_"%12_P=44O\'VD8
M ,-0  "U6   J%L  )E:  "-6   A%<  'M4  !V5@$ <5</ &Y9&P!L6B@
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M"T1BOPM$8N$+1&'Y"D1@_PE$8/\(15__!T5?_P=%7_\'R%(  +A<  "K9
MFV0  (QC  " 8P  =F,  &IB  !C9   7V8& %MG$0!9:!T 5VDI %9J,P!4
M:CP 4FI% 5!J3 %.:E0"3&I< TIJ901(:6\%1FEZ!T1IB A":)@)0&BI"C]H
MO0H^:-X)/F?W"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<  +-A  "G:0  EF@
M (=G  ![9P  <6<  &5H  !<:@  6&P! %1N#@!2;Q@ 4&\D $YP+@!-<#@
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M RE]_P,I?/\#*7O_ RE[_P,I>_\#L6H  *5T  "5=@  A74  'AU  !M=0
M87<  %=Z  !,?@  0X$  #N%   UB D ,HD1 #&)&P PB24 +XHO "Z*.  M
MBT$ +(M* "J+5  IBU\ *(MK ":+>@$DBXL!(XN> 2*+LP$AC,X!(8KQ 2"(
M_P(@AO\"((7_ B&%_P(AA?\"JW(  *%\  "/>P  @'H  '-Z  !F?   6W\
M %""  !&A@  /(H  #2-   LD0  )I,, "24$P CE!P (I4F "&5+P @E3@
M'Y9" !Z63  =EE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5E\D %I7N !:3_P$6
MDO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A   5(@  $F+
M   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2H2X $:(X
M !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@_@ -G_\
M#9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(  $&7   W
MFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20 !*XN  *N
M.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]   K?\  *S_
M  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC   OIP
M):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%   N1P  +HE  "Z+P
MNSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X  +O_  "[
M_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   EM   &[<
M !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #()   RBX
M ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_  #-_P
MS?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP  $<(   K%
M   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1  #:&   W"$  -\L
M  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E_P  Y?\
M>J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /R@  !\X   #1
MU@   -P   #?    X    .(   #D    Y@,  .@)  #I#@  [!4  .X>  #Q
M*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P  ^?, ;:H
M %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V    -T   #A    Y
M .@   #K    [0   .\   #Q    \P   /8   #X P  ^@L  /T1  #_&P
M_RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8 _P0< /\
M&0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_ '( _P!Z
M /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\ Q0#_ -D
M_@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8 /\!%0#_
M !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T _P!U /\
M?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T ,X \P#F
M /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&$0#_ !
M_P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P /< > #U
M '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,< Y0#> .,
M\ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_ 0P _P ,
M /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H <@#H 'D
MY@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3 -  Z@#.
M /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P( _P ( /\
M#@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7 ', U !Z
M -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,  Y0"^ /4
MO0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@! /\$"@#X
M !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X Q !T ,(
M>P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q ?( KP+_
M *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*  #I PD
MW0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O +4&=@"T
M!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0 H@[_ * .
M_P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2$ ( SPD+
M ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1<0"H$7@
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M 7PH_P%\*/\!]20  .,N  #/-0  P3@  +0V  "K,0  I2P  *(F!@">)A,
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MD05C09\%84&N!F!!P@9>0>(&7D'Y!5U!_P1=0/\#74#_ UU _P-=0/\#WSD
M ,A#  "Y2@  J4L  )M)  "01P  B$0  (-!  !^008 >D(1 '9#'@!T12H
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M!TY.NP=-3MD'34[U!DU._P5-3?\$34W_!$Y,_P-.3/\#SD0  +Q.  "N5
MG%,  (Y2  "#40  >E   ')-  !L3P  :% + &51%0!C4B$ 85,L %]3-@!=
M5#\ 6U1' %I43@%85%8!5E1= E149@-24V\#4%-[!$Y3B 5,4Y<&2U.G!TE3
MN@=(4]4'2%+S!DA2_P5(4?\$25'_!$E0_P-)4/\#RD@  +E2  "J5P  F%8
M (I5  !_5   =E,  &Q1  !G4P  8E0( %]6$@!=5QX 6U<I %E8,P!86#P
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M!#AA_P0X8/\#.%__ SE>_P,Y7O\#O%4  *U?  "<8   BU\  'U?  !R7P
M:%\  %U@  !58@  3V0  $MF"@!)9Q( 1V@= $5H)P!$:3$ 0VDY $)J0@!
M:DH /VI2 #UJ6P$\:F4!.FIP CAJ?@(V:8T#-&F? S-IL@,Q:<L#,6CM S%G
M_P,Q9O\#,F7_ S)D_P,R9/\#MUL  *ED  "69   AF,  'AC  !M8P  9&0
M %EE  !0:   26L  $-M! ! ;@X /F\8 #UO(@ \<"L .G T #EQ/0 X<44
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M 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P  5'8  $EY   _?0
M-X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7CC  %HXY !6.0P 4
MCT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\ $(K_ !")
M_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X  $*"   YA@  +XH
M ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:.P )FD8
M")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_  66_P %
MEO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@  *)8  !^9
M   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H  "F,@  IST  *=*
M  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D_P  I/\
MD8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(  !>F   0
MJ0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S*   M#(  +4_  "U
M30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P  M/\ BX\
M 'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T   )MP
M ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R  #&0
MQE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\ @Y<  '&:
M  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT   ;     PP   ,<
M  #)    R@   ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;,@  W4(
M -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\  &BF  !9
MK0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,    T    -4   #9
M    V@   -P   #>    X    .(%  #D"P  YQ   .H8  #M)   \#(  /%$
M  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO  !,MP
M/;T  "W!   ?Q@  $\H   O.    T@   -<   #<    X    .4   #G
MZ0   .L   #M    [P   /$   #S    ]@<  /D.  #\%@  _R(  /\S  #_
M1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_ !4 _P 8
M /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0
M_P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G /H ^ #Y
M /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$ _P 2 /\
M%P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #] 'X _ "%
M /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X \@#L /\
M[ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P - /\ $P#_
M !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D [P!_ .X
MA@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#< /L VP#_
M -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\ #P#_ !@
M^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z -X @ #<
M (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8 Q@#_ ,4
M_P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T !( [P ?
M .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H >@#( (
MQ@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_ +8 _P"U
M /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8  P#H  T X  7 -D
M) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y 'L MP""
M +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L IP#[ *8 _P"F /\
MI0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1 ,@ ' #"
M "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4 J0!] *@
MA "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8"/\ EPC_
M )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P % "W 2$
ML@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX )P+@ ":
M#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\ BQ#_ (L0
M_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K#1D IPXF
M *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4? "/%(4
MC16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_ '\8_P!_
M&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!, FQ8A )<8
M+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#'X  @A^+
M ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A_P!T(?\
M[R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ; (TA* ")
M(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP >"B' '8H
MDP!T** !<BBO 7$IP0%O*> !;2GW 6PI_P%K*?\!:RG_ 6LH_P%K*/\!Z"@
M - R  # .   KC<  *$U  "8,@  DBT  (XI  "+)PP AR@7 (,J(P" *R\
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M ED[N -8.](#5SOQ E8[_P)6._\"5CK_ 58Z_P%6.?\!U#<  ,!!  "O1
MG4,  )!"  "%0   ?CX  'D[  !T.@  <3H. &T\& !K/20 :3XO &<_. !E
M/T  9$!( &) 3P!A0%< 7T!> 5U 9@%<0&\!6D!Z EA AP)60)4"5$"D U-
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M@@)+29$#2DFA TA)LP-'2<H#1DGL T9(_P)&2/\"1T?_ D=&_P)'1O\"QD,
M +9,  "B3   D4P  (1+  !Y2@  <$D  &E&  !D1P  7TD& %Q*$ !:2QL
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M CA7K0(W5\0"-U?G C=6_0(W5?\"-U3_ C=3_P(X4_\"ND\  *E6  "550
MA50  'A4  !M5   9%0  %A4  !25@  3E<  $I9"0!'6A$ 1EH; $1;)0!#
M6RX 0EPV $%</@ _7$8 /EU/ #U=5P [76$ .EUL 3A=>0$V78@!-%V9 C-=
MJP(Q7<(",5SE C%;_ (Q6O\",5G_ C)9_P$R6/\!ME0  *19  "06   @%@
M '-7  !I5P  8%@  %19  !.6P  2%T  $-?! ! 8 X /F$7 #UA(  [8BD
M.F(R #EB.@ X8T( -V-+ #9C5  T8UT ,V-H #%C=@$O8X4!+F.6 2QCJ0$K
M8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7   >UL  &];
M  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S:20 ,FDM
M #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1KIP C:[T
M(FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\  &I?  !A
M8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X *'$F "=R
M+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :<[D &7/<
M !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D  !=9
M4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L? !M[*  :
M>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4 #WW5 !![
M]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7:@  3&T
M $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"''P 0AR@
M#H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)  :%[  '
MA/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@  1G4  #QY
M   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "DB   9(I
M  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1Y0  D/H
M (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?   /X   #2$   K
MB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P  GAH  )XB  "?
M*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@  G?8  )W_
M  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1   CE@
M&IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9  "M(@
MKBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\  *W_  "M
M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :I   $J@
M  RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2  "[&   O2$
M +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y  # _P
MP/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1LP  "[@   *[
M    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,#P  SA4  - ?
M  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL  #9^P  V/\
M<)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0   ,4   #(
MRP   ,\   #2    TP   -8   #8    VP   -T   #?!P  X@T  .43  #H
M'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P[   \/0 9Z8
M %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(   #6    W
M .    #C    Y    .8   #H    ZP   .T   #O    \@(  /4*  #X$0
M_!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$ _P 4 /\
M$@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_ &@ _P!P
M /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P N0#Z ,@
M^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1 /\ #@#_
M  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &, _@!K /P
M<P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M ,$ ZP#6
M .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\ "@#_  @
M_P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F .X ;0#L
M '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D V@#* -<
MY@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_    _P #
M /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X 9P#; &T
MV0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#" ,, W #!
M /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_    _P   /8
M" #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#& &< Q !M
M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$ S@"P .H
MKP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@   .@   #>
M  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$ M !G +(
M;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A ., GP#V
M )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4   #+  8
MPP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B *0 : "B
M &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P D@#R )$
M_P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[!P  MP *
M +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!8P"6 FD
ME )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP (0*_P"#
M"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@  J T  *8'
M#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+#64 B0UL
M (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2_P!W$O\
M=Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<  )D1! "8
M#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6  ?A9H 'T6
M;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M&_\ ;1K_
M &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"   (T<  ",%PP
MB!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C ',?:P!Q
M('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\ 9"+_ &0B
M_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""( @ ?B 2
M 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG: !I*'$
M9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_ %PI_P!<
M*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* , =B<0 '(I
M&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A+VX 7R]X
M %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N_P!5+O\
MT#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX- &LO%@!I
M,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L 635U %<U
M@@!5-9 !5#6? 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_ 4\T_P%/,_\!RS8
M +@]  "C/   DCP  (4[  ![.@  =#<  &\U  !L,P  :#0* &4U$P!B-AX
M8#<H %XW,0!=.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4.F@ 4SIS %$Z?P%/
M.HT!3CJ= 4PZK@%+.L,!2CKE 4DZ_ %).?\!23G_ 4DX_P%*./\!QSH  +-
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M 4)#JP% 0\ !/T/A 3]#^0$_0O\!/T'_ 4!!_P% 0/\!OT$  *I%  "610
MAD4  'E$  !O1   9T(  & _  !;00  5T(  %1##0!11!4 3T4? $Y%* !,
M1C$ 2T8Y $I'00!)1T@ 2$=0 $9'6 !%1V$ 0TAL $)(> % 2(<!/DB7 3Q(
MJ0$[2+X!.DC? 3I'^ $Z1O\!.D7_ 3M%_P$[1/\!NT4  *9(  "21P  @D<
M '9'  !K1P  8T8  %M#  !610  4D<  $Y("@!,21( 2DD< $A*)0!'2BX
M1DLV $5+/@!#2T8 0DQ- $%,5@! 3%\ /DQJ #Q,=@ [3(4!.4R5 3=,IP$V
M3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@  ?DH  ')*
M  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!3RL 0% S
M #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1I0$P4;H!
M+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT  &Y-  !D
M30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52< .54O #A5
M-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J5[@ *5?6
M "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0  !@4
M6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK #%;,P O
M7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4 (EW2 ")<
M\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<5   5%4
M $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB+@ G8S8
M)F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63. !IC\0 ;
M8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96   4%D  $=;
M   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =:S  '&LY
M !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K[P 2:?\
M$VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX  $)A   Y
M9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D $74R !%U
M.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *<_T "W'_
M  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164  #QH   S;
M*V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J  9_-  %
M?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<  'S_  ![
M_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q   L=0  )'D
M !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC  "++   BS<
M (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_  "'_P
MA_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E@   '80  !6(
M   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8)   F"X  )DY
M  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_  "5_P  E?\
M>W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(   Z6   )
MF0   9P   "@    H0   *(&  "B#   I!   *44  "E'   IR0  *@O  "H
M/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P  I?\ =WL
M &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D    J
M *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL  +@D  "Z,0
MND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\ ;X,  %^&
M  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T    MP   +L
M  "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-)   SC,
M ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\  %>4  !)
MF@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##    Q@   ,L   #-
M    S@   -    #1    U    -8   #: @  W D  -\/  #C%P  YB0  .<V
M  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D  !"JP
M-+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V    -L   #?
MX    .(   #D    Y@   .D   #K    [@   /$%  #U#0  ^18  /PE  #]
M.0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_  \ _P 1
M /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\ <P#_ 'H
M_P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#: /4 \0#T
M /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H _P + /\
M$0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W '0 ]0!Z
M /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#- .4 Z0#D /L
MXP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $ /\ #@#_
M !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X Y@!T .0
M>@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#. /0 S #_
M ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P   /T "P#W !,
M\0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M ,X <P#,
M 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T N0#^ +@
M_P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X !0#E  X W@ 8
M -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L ;0"Y ',
MMP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X *8 _P"F
M /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0  H R  2 ,(
M'0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H &T IP!S
M *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8 _P"6 /\
MEP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0 N  . +, %@"O
M "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &< F !N )<
M=0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"( /\ B #_
M (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8 $ "B !H
MG@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I (H < "(
M '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\ >P3_ 'L$
M_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7 !, DP >
M ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(; !]"'0
M? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_ &\-_P!O
M#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X B0L7 (8,
M(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S$'$ <1%[
M ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43_P!E$_\
MWQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2 'P2'0!Y
M%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T :!EW &89
M@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<&_\ U24
M +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:& !O'",
M;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S %TA?P!<
M(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\ S2L  +8N
M  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G(Q\ 920I
M &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H? !4*(H
M4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#   + R  "<
M,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P 7BHE %PK
M+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.+H@ 3"^7
M $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU  "7-0
MAS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B %8P*P!5
M,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4 1S25 $4T
MI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3.   @S@
M '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U* !/-C
M3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3 $ YI  ^
M.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P  ?SL  ',[
M  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*.BT 2#LU
M $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]HP Y/;8
M.#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X  &\^  !F
M/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH 0S\R $)
M.@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T0K0 ,D+.
M #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!  !B0
M6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O #Q$-P [
M13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K, +4;, "U&
M[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?0P  5T,
M %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)-  U2CL
M-$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO* "=+[0 G
M2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@  5$8  $Q'
M  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O3S@ +D]
M "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0ZP A3_\
M(D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H  $E+  !
M3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53, )E4\ "56
M10 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :5?\ &U3_
M !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X  $5/   \40
M-E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW !Q=0  ;
M74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X $UK_ !-:
M_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3   X5@  ,ED
M "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E.@ 2940
M$650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_  UA_P -
M8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T7   +%\  "9B
M   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *;CX "&Y*
M  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J_P #:O\
MA5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<  !]J   9
M;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<  'A#  !X
M4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T_P  =/\ ?E\
M &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W   !AT   2=P
M#7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[  "$2
MA%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\ =V4  &ED
M  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,@P  !H<
M  "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2/P  DDX
M ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L  &9J  !8
M:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $D0   )4   "8
M    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B-0  HT0  *-5
M  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R  !1=0
M1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H    *0   "G
MJ    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0  M#D  +1*  "U
M70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)@@  /(<
M "^.   CE   &)H  !"?   )I    *D   "M    L    +0   "W    N
M +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P  ,D]  #*4
MRF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0  ,Y@  ">?
M   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(    R0   ,L
M  #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N  #C0@  Y%<
M .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D  !^P   3
MM@  "[P   #!    Q0   ,D   #-    T@   -8   #:    VP   -X   #@
M    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y,@  ^D@  /M?
M  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\ $P#_ !X
M_P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z /\ @0#]
M (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X [P#_ .\
M_P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_ !D _P E
M /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$ >@#O ($
M[@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_ -T _P#4
M /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0 _0 @ /H
M*P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #< 'H V@"!
M -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0 _P#$ /\
MNP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !  ZP : .< )0#D
M #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ', PP!Z ,$
M@0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P /\ K@#_
M *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4 ,T 'P#* "H
MQP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T L !S *X >@"L
M (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P"> /\ GP#_ )T
M_P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D &0"U ", LP N
M +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T <P"; 'L
MF@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_ (X _P"/
M /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E !T H@ G *
M,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"- '4 BP!^
M (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (  _P"  /\
M] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A )( *@"/
M #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '  ?@!Y 'P
MA ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S /\ Z0T
M ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 : (8 ) "# "X
M@0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U '$!@ !O
M HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\ WQ0  ,,7
M  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y!R@ =P@P
M '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,?@!F#(L
M9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P  +D=  "D
M'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B( ;@\K &P0
M,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<$X@ 6Q.7
M %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B  "=(P
MC2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G &,6+P!A
M%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4 4AN4 %$;
MI !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6)P  AR@
M 'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>*P!:'C,
M6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1 $DBH@!(
M(K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P  @BP  '8K
M  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3)#  4B4W
M % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,HH !!*+(
M0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\  '$O  !H
M+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP 2RHT $HK
M.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \+;  .BW(
M #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR  !D,@
M73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q $4P. !#
M,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\ -3+' #0R
MZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@-0  630
M %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U-@ ^-3T
M/35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?% "\WZ  O
M-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P  5C<  % V
M  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y.CH .#I"
M #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[Y@ J.OT
M*CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH  $TZ  !&
M.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C< ,C\_ #$_
M1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D/_P )3[_
M "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]  !"/0
M/#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\ "M$1  J
M1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L 'T/_ "!"
M_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9    ^00  .$,
M #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)00 C2DH
M(DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_ !I'_P :
M1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [10  -4<  #!)
M   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <4$< &E!1
M !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--_P 43?\
MCT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P  "M.   F
M4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 35T( $E=- !%7
M60 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .4_\ B$D
M '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94   A5@
M&UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(  I>5  (
M7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\ @4X  '!.
M  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;70  %6
M !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G3@  9UP
M &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(  &I3  !=
M4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   490  $&@   QK
M 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2   <58  '%F
M  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57  !:5P
M458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(   1V
M> 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X  'U>  !]
M<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !77   2UT
M $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX   ""    @P$
M (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6  "+:0
MBX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@  1&4  #AI
M   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0    D@   )(
M  "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<7P  G'8
M )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$  #!V   E
M?   &X$  !*'   ,C   !)$   "5    F0   )T   "@    H0   *(   "D
M    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O5   KVL  *Z%
M  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%   =C
M$Y(   R8   #G0   *(   "F    J@   *X   "P    L0   +,   "T
MM@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X  ,5W  #%
MDP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4G0  #:,
M  .I    K@   +(   "W    NP   +\   #"    P@   ,4   #&    R
M ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H  #@A
MX:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP  !;4   "Z
M    OP   ,0   #(    S@   -$   #4    U0   -@   #:    W0   -\
M  #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X<@  ^9
M /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F /\ ,@#_
M #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($ ^P"( /D
MCP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#= /\ S@#_
M ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A /\ + #_ #@
M_P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@"" .@ B0#G
M )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\ P0#_ +L
M_P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T #( \  \
M .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -  @@#- (H
MRP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_ *X _P"K
M /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#= "L VP V -,
M/P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X (( M@"+
M +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$ _P"? /\
M_P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O +P . "X
M $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L HP"$ *$
MC@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2 /\ _P
M /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@ ,@"E #H
MH@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!] )  AP".
M ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\ ^    .4
M  #-    O0   +,   "J    HP * )\ $0"; !D F0 C )< + "5 #0 D@ \
M )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($ @0!_ (T
M?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0   -$"  "[
M @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"& "X A  V ((
M/0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R (@ <0"6
M &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,  "N#
MG@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P '8 . !T
M #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0 90"2 &0
MH0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B$@  DQ(
M (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!,P!J CD
M:0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/ %H'GP!9
M![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&   BA@  '\7
M  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B##4 8 P\
M %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.GP!0#K$
M3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX  '<=  !O
M'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$ 6!(X %<2
M/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'%:X 1A7%
M $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B  !H(0
M8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T $\8.P!.
M&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP /QO" #X<
MY0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C)0  720
M %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?-P!''SX
M1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+  #<BXP W
M(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0  6"@  %0F
M  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!)3L 0"5#
M #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$GX0 Q)_D
M,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L  % J  !,
M*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD .RI  #DJ
M2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L+/@ +"O_
M "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN  !(+
M12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^ #0O10 S
M+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/< )R__ "@O
M_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$,   0"\
M #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T0P M-$P
M+#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_ ",S_P C
M,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  ! -   .C,  #<T
M   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H.4D )CE3
M "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX_P >-_\
MDS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@  #(Y   O
M.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8 (#Y0 !\^
M7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8//\ CC<
M 'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^   I0
M)D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1- !A$60 7
M1&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\ B3L  '8\
M  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"   E1   (48#
M !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*5@ 02F0
M#TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX  '$_  !B
M0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A20  '$L  !9.
M!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *45\ "5%O
M  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#  !=1
M4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$  !)4 P .
M5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83   6%H  %AI  !8
M?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !92   3T<
M $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@   U; @ )7@D
M!%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C  !@=@
M8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53   3$L  $1+
M   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC   "9@<  &<,
M  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J;P  :H4
M &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\  #]0   U
M4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N    ;P,  ' (  !Q
M#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V:   =GX  ':7
M  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8   O6P
M)E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?    'P#  !^"
M?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74  (6/  "$
MJ0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G9@  'FL
M !5P   .=0  "7D   %^    @0   (4   "(    B@   (L   "- 0  C@8
M ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&  "5H@
ME,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=   %7D   Y_
M   'A    (D   ".    D@   )8   "8    F@   )L   "=    GP   *$#
M  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "HF0  J+4
M *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH   >0
ME@   )H   "?    HP   *<   "J    JP   *T   "O    L0   +,   "U
M    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^BP  OJ@  +[)
M  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B    IP
M *P   "P    M0   +D   "\    O0   +\   #!    PP   ,8   #(
MR@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH  -NU  #;
MV0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T    N0   +X
M  #"    R    ,L   #.    SP   -(   #4    U@   -H   #=    WP
M .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E  #UOP
M]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D _P!$ /\
M30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U )( \P";
M /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\ _P"[ /\
M_P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^ /P 1P#X
M $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L WP"5 -P
MGP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P /\ _P
M /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .< 0 #B $D
MWP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"- ,( F #
M *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\ _P   /\
M  #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#( $( Q !*
M ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T D "J )P
MJ "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P   /X   #O
M    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L K0!# *L
M20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8 )0 E@"B
M )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P   #9
MQP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4 FP \ )@ 0P"6
M $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P A ": ((
MJ@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"    LP
M *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (< /0"% $,
MA !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4 '0 HP!R
M +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P    H@   )<
M  "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X #T =@!#
M '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ". &< G0!E *\
M90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @  (D'  ""
M P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@ :@ ^ &D
M1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!; *H 60"_
M %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.  !V#0
M<0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y %\ /P!=
M $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *< 4 "[ $\!
MVP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L$@  9Q
M &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'.P!5!T(
M5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ $8*V !%
M"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P  7Q8  %P3
M  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.#CX 30Y%
M $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0W  ]$?8
M/1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L  %49  !3
M%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL 11-" $03
M20!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U%O4 -A;_
M #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >  !-&P
M3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_ #T91@ \
M&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/, +QO_ # ;
M_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB  !((   1AT
M $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?1  V'TP
M-"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_ "H@_P K
M(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$)   0B$  #\A
M   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P)$H +R53
M "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D_P E)/\
ME"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28  #HE   W
M)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4< *2E1 "@J
M7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A*/\ D"@
M 'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J   R*P,
M,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/ ",N6@ A
M+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\ C"L  '@M
M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M+P  *S *
M "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS5P ;,V0
M&C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX  '0O  !E
M,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-   )34& ",V
M#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5.6( %#EQ
M !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R  !A-
M530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0  (#H" !T["P ;
M/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\ #SYO  X^
M@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=-P  43<
M $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!!@ 40PT
M$D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J  =$?  &
M1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@  3CH  $4Z
M   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-& P /20H #4H/
M  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*=P  2HL
M $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX  $(]   \
M/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +3PD !U -  -1
M$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1<@  48<  %&=
M  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!    Y0
M,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,  !8$
M6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$  %F9  !9
ML0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$   U10  +4<
M "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)  !@#0  81
M &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3  !CK0
M8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3   )T\  !]2
M   850  $ED   U=   (8    F,   !F    : $  &D%  !J"@  :PT  &T1
M  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !OIP  ;L8
M &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@  !A<   1
M8   #&0   9H    :P   &\   !R    =    '4   !W!   > D  'H-  !\
M$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^H   ?;X  'SI
M  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H   +;0
M W(   !V    >@   'T   "     @P   (0   "&    AP(  (D'  "+#
MC1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0  ([A  ",
M^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW   "?0   ((
M  "&    BP   (X   "1    DP   )4   "7    F0   )L   "=!   GPH
M *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0  "@]0
MG_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")    C@   ),   "8
M    G0   *$   "D    I0   *<   "I    JP   *T   "P    L@   +4(
M  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "WZ@  M_P
M1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0   *8   "K
ML    +,   "W    MP   +H   "\    OP   ,$   #$    QP   ,H   #-
M!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2TP  TO( /GD
M #&    CB   %Y$   V9   #H    *<   "N    LP   +@   "]    P@
M ,8   #*    R@   ,T   #/    T@   -4   #9    W0   -\   #C
MYP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@ _P   /\
M  #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_ %  _P!8
M /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X H@#K *\
MZ #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P   /\   #_
M    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H \@!2 .X
M6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1 *< S@"V
M ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\   #_
M_P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+ -, 40#0
M %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\ MP"M +4
MP0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[    [@
M .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H 2P"W %$
MM0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E )\ M@"=
M -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G    TP   ,8
M  "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A $H GP!/
M )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P K0"* ,,
MB0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,    O    +    "G
M    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $, C !) (L
M3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y +@ > #8
M '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J    )X   "6
MCP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !# 'H 2 !Y
M $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\ :0#( &@
M[0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T   "&    @0
M 'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P 0P!K $@
M:@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^ %P Y !<
M /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X    =    '
M! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!? $, 7@!)
M %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$ U@!1 /4
M40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <  &4#  !C
M  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\ 5 !% %,
M2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !' .\ 1@#_
M $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X  %L,  !:"0(
M600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %! $H"2 !)
M D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H /07\ #T&
M_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1#@  4 P%
M % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*10!""DT
M0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W] #4-_P V
M#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P  21$  $D.
M!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [$$L .A!4
M #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1_P O$/\
MEQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4  $(3 @!!
M$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@ ,Q11 #$4
M7  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I%?\ D1H
M 'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8   [%P<
M.18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/ "L:60 J
M&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\ C1T  'D?
M  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;   U' 0 -!P-
M #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?5P D'V0
M(A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2   '4B  !E
M(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P( $ +B$* "PA
M$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?)&$ '21P
M !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D  !B)@
M5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0  *24' "<F#@ E
M)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\ &"EN !8I
M@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?*   4RD
M $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K#  @*Q$
M'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL !$N?@ 0
M+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P  4"P  $8L
M   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :,0X &3$3
M !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS>@ ,,XX
M"C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\  $,O   \
M+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P $C<1 !$W
M%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %.(H  SB?
M  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q   Y,0
M-#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.  P]$P +
M/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8  #V<   ]
ML@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W-   ,C,
M "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$$0 #1!8
M D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28  !#KP
M0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@  ,#8  "DW
M   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)#P  2A,  $L9
M  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*K   2LH
M $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H  "4\   ?
M/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0  41   %(5  !4
M&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3J   4L8  %+M
M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#   91@
M$TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1  !=%@
M7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$  %OK  !:
M_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+   33@  #E(
M  I5   #60   %L   !>    8    &("  !C!@  90H  &8.  !H$0  :A<
M &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G  !F_P
M9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .60  "%T   %A
M    9    &<   !J    ;    &X   !P    <@4  ',)  !U#0  =Q$  'H8
M  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T_   <_\
M3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@   &H   !O
M<@   '8   !Y    ?    'T   !_    @0   (,"  "&!P  B P  (L1  ".
M&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&]P  A?\ 35$
M $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L   !_    @P
M (<   "*    C0   (X   "1    DP   )4   "8    F@4  )T,  "@$0
MHQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\ 1ED  #E<
M   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2    E@   )H
M  "=    GP   *$   "D    I@   *@   "K    K@   +$#  "T"P  N!$
M +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0  #%I   E
M;P  &'<   ]_   &AP   (X   "4    F@   *    "E    J@   *X   "Q
M    L@   +4   "W    N@   +P   "_    PP   ,8   #)    S@H  -(3
M  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX   =@
M$8D   B1    F@   *$   "G    K0   +,   "Y    O@   ,(   #%
MQ@   ,D   #,    S@   -(   #5    V@   -X   #A    Y0   .H+  #K
M%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_  $ _P '
M /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\ 6@#] &
M^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\ ., W #?
M /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_    _P   /\
M!@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H %D Y0!?
M ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4 R0#" .T
MP #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]    ^@   /@   #P
M  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %( R !8 ,4
M70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L .$ J@#\
M *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP   -L   #1  0
MR@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1 *P 5@"J
M %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P E0#Q )0
M_P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P   "T    KP *
M *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !* )8 3P"4 %4
MDP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D (  _P"
M /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=    EP % )0
M#0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (, 2 "! $X ?P!4
M 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\ ]@!O /\
M;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",    A0   (( "0!_
M  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@ ;P!- &X
M4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A /\ 80#_
M &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P   '( !0!P  P
M;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!( &  3@!?
M %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L 5 #_ %4
M_P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8  0!C  D 80 .
M &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4 20!3 %
M4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_ $D _P!*
M /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9  4 5P , %8
M$ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!* $P 2 !4
M $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $  _P!  /\
MH @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@  3P(( $X #0!,
M !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@ 0 !0 #X
M6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W /\ F T
M (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'"@!%! X
M1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05. #<%5P V
M!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\ D1   'T1
M  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -!@! "@P /@D0
M #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,5@ O#&$
M+0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(  '<4  !G
M%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@ . X- #<.
M$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H$&$ )A!O
M "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7  !C&0
M5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+ #$2$  O
M$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\ (!5M !\5
M?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?'   4QT
M $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6#@ I%Q,
M*!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK !D:?  7
M&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P  4"   $<@
M   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D'!$ (AP6
M "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?>@ 2'HT
M$1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(  $0B   \
M(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >(0\ '2$4 !PA
M&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .(XL #2.?
M  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D   Z)
M-"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81 !8F%P 5
M)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(< "2B;  <G
ML0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W)@  ,28
M "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L%  0+!L
M$"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8   LK@
M+,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U*0  +R@  "LH
M   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,,1< "S$>
M  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   QK   ,<<
M ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L  "DJ   E
M*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0  S<;  (W
M(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   WJ0  -L4  #;J
M   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M   B+0
M'2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7   ^'@
M/B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,  #SI   \
M_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >,@  &30
M !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04  !%&@  1B(
M $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H  !#_@
M0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :.   %#H  ! ]
M   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.%0  3QP  $\E
M  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+_@  2O\
M4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(   Q%   '
M2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0  61<  %H?  !9
M*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4_0  5/\ 3CT
M $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL   5.    40
M %0   !7    60   %L   != @  7@8  & +  !B#@  9!(  &<8  !G(@
M9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_   7_\ 24(  $%!
M   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:    70   &
M  !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42  !W&P  =B8
M '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8  $!%   U
M1@  *D@  "!,   740  $%8   E:   !7P   &,   !H    :P   &\   !R
M    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")$P  BAT  (HK
M  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,   N3P
M(U,  !A8   07@  "60   !I    ;P   '0   !X    ?    ($   "$
MAP   (@   "+    C@   )    "3    E@   )D'  "=#0  H10  * A  "@
M,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F6@  &V
M !%G   );0   '0   ![    @0   (8   "+    D    )0   "7    F0
M )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T  +@6  "W)@
MMCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:   $W    MX
M    @    (<   ".    E0   )H   "?    I    *@   "L    K0   +
M  "S    M0   +@   "[    OP   ,,   #'    RP4  -$.  #1&P  T"X
M ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$   &+
MDP   )L   "B    J    *X   "T    N    +T   #     P@   ,4   #(
M    RP   ,X   #1    U@   -L   #?    Y    .@&  #K$0  ZB,  .HZ
M  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $ /\ "P#_ !
M_P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A /@ 9@#V
M &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /< U@#_ ,
M_P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P  P#^  L _P 1
M /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\ 7P#< &4
MV !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_ +  _P"D
M /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J  4 YP . .(
M%0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "] %X NP!D
M +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\ _P"5 /\
MCP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(    P0 * +\ $0"\
M !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8 H0!< )\
M8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"& /\ @ #_
M 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ % *( #0"A !,
MH  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5 (H 6P"(
M &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\ <@#_ '
M_P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L "@") !  B  5
M (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8 5 !U %L
M<P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_ &0 _P!C
M /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V  P =0 1 '0
M& !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8 3@!E %4 8P!=
M &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@ _P!8 /\
MN0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D 90 . &0 $P!C
M !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\ 5@!7 %0
M8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!- /\ J@
M )0   ""    =0   &L   !D    8    %T   !:  4 6  , %< $ !6 !4
M5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2 $D 6P!(
M &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\ G@   (D
M  !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!, !$ 2P 7
M $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!- #\ 5@ ^ &$
M/0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,  ( '  !O
M"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \ 0@ 3 $$
M& !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V %T - !J
M #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,  !H#0
M7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0 #H %0 Y
M !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N %H +0!G "L
M=P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C$   5A$
M $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%$@ R!!<
M,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E "0'=0 C
M!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@  4A,  $@3
M  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M"A0 + L9
M "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-=0 <#8@
M&@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8  $46   ]
M%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$ )@X6 "4/
M'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5$(D %!">
M !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9   Z&0
M-!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4 " 2&@ >
M$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(< $!2<  X4
ML0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W&P  ,AH
M "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7%P 9%QT
M&!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8  H9K0 )
M&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0  +QT  "H<
M   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4'!L $QPB
M !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=J@ #'<(
M QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\  "@>   D
M'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@ #B$?  XB
M)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ   (<   "'E
M   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@   B(
M'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<  DF(@ (
M)BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\  "7D   E
M^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B   A(@  'B$
M !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K'P !+"<
M "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD   J^@
M*?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?)   &R0  !<E
M   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'   ,2,  #(L
M   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O^P  +_\
M6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P  &"@  !0J   1
M+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&   ."   #@H   X
M,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U_   -?\ 52H
M $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O   -,0
M"C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D  ! +@
M0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_   //\ 4"\  $,O
M   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV   ).   !3L
M   ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>  !**   2C0
M $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,  #\S   V
M,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #00   $,   !&
M    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5(@  5"X  %0\
M  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW   U-@
M+S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@   $T   !0
M4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P  8B<  &(T  !A
M10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T.0  *CH
M "$\   80   $4,   Q'   &2P   $\   !3    5@   %D   !<    7P
M &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M  !Q/0
M<$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P  )$(  !I&
M   22@  #$\   14    6    %T   !A    90   &@   !K    ;@   '$
M  !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%-   A$8
M ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P  !-2   ,
M5P   UT   !C    :    &T   !Q    =@   'H   !^    @0   (,   "&
M    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=*0  G#P  )I2
M  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@   #9P
M &X   !T    >@   (    "$    B@   (X   "2    E0   )<   ":
MG0   *    "C    IP   *L   "O    M D  +@0  "W'@  M3   +-&  "Q
M8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q    >0   ($
M  "(    CP   )0   ":    GP   *0   "H    J0   *P   "O    LP
M +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24  - [  #-5
MRG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$    C0   )4   "=
M    HP   *D   "O    M    +D   "\    O@   ,(   #%    R    ,P
M  #0    U    -H   #?    Y    .H   #N#   [1H  .PO  #J20  Z&4
M .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X _P 4 /\ '0#_
M "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@ \@!O /
M=@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H /\ GP#_
M )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ . /T %@#[ "
M]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G ,\ ;@#,
M '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P": /\ D@#_ (T
M_P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L $0#: !H VP C
M -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +, 9@"Q &X
MK@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_ (  _P!^
M /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T !0 M  = +,
M)0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7 &4 E0!N
M ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ', _P!R /\
MX    -    #&    M@   *D   "A    G0 ! )D "@"8 !  F  6 )< '@"4
M "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X @ !F 'X
M<0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E /\ S
M +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1 '\ & "  "
M?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !> &H : !H
M '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\ O0   *D
M  "7    B0   'X   !X    <P   &\  0!M  D ;  . &L $P!K !D :@ @
M &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H 80!9 &T
M5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0   )@   "&
M    >    &X   !G    8P   &    !=  4 7  + %L $ !; !4 6P ; %H
M(0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+ &8 2@!T
M $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D   !X
M;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6 $T ' !,
M "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &  /P!N #X
M?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N    80
M %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2 $, %P!" !T
M0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H #0 >  S
M (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0  60<  % '
M  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y !D -P >
M #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D "P <P K (<
M*@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL  $H+  !"
M"P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4 ,  : "\
M'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C (( (@"7
M "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.   ]#@
M. T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7 "@!'  G
M "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\ &P"4 !H
MJ@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y$   ,Q
M "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&&0 A!A\
M( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1 !0'IP 3
M!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@  ,!(  "L1
M   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <#!P &PPB
M !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-IP -#+X
M#0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10  "@3   E
M$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH %@\A !40
M*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 ($+P !Q#?
M  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85   B%0
M'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,> !$3)0 0
M$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L  A/=  $2
M]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7   @%P  '18
M !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7(@ ,%RD
M"Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=   6]0
M%O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >&   &Q@  !@7
M   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P ''"8 !1PO
M  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>   :]@  &O\
M7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@  &1D  !<9 0 4
M&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,  "$K   A
M-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >^   'O\ 6AL
M $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;   2'
M$!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H   F,@
M)CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0  (_\ 51X  $<@
M   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>   0(   #B$
M  PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE   L+@  +#H
M "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\ 42(  $0C   X
M)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .)   "R8   @H
M   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S*@  ,S4  #-#
M   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F   U)P
M+28  "<E   B)   'B,  !DC   4)   $28   XH   +*@  !RP   ,O
M,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$  #L^   [
M3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R*@  *RD
M "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30    V    .
M #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P  $0Y  !$2
M1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0  *2L  "0J
M   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _    00   $0
M  !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/0P  3U4
M $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X  " N   9
M,0  $C,   XW   ).@   CT   !     1    $<   !)    3    $\   !1
M    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=/   7$X  %MC
M  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV   3.0
M#CT   A!    10   $D   !,    4    %,   !6    60   %L   !=
M8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48  &M;  !J
M=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .1   !TD
M  !-    4@   %8   !:    7@   &(   !E    :    &L   !M    <
M ',   !V    >0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4  !^:P
M>XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+   '40   %<   !<
M    8@   &8   !K    ;P   '0   !X    >P   'X   "     @P   (8
M  "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "48@  DW\
M )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:    80   &@   !N
M=    'D   !_    A    (D   "-    D0   ),   "6    F0   )T   "@
M    I    *@   "L    L@,  +<-  "W%P  M2@  +(^  "P5@  K',  *J4
M  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P   'L   ""    B0
M (X   "4    F@   )\   "D    I@   *D   "M    L    +,   "W
MNP   ,    #%    RP   -$$  #5#@  TQT  - R  #-2P  RF8  ,:'  #"
MJ0  P<L (EL  !9B   ,:P   70   !]    AP   )    "7    G@   *0
M  "K    L0   +8   "Z    O    ,    #$    R    ,L   #/    U
M -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z  #DFP
MX+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "( _P L /\
M-0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L 'H Z0"%
M .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )  _P", /\
M^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E /  +@#K
M #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '( Q0!\ ,(
MB "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"  /\ \
M .4   #>    V@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L )P#% "\
MP  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S *< ?P"D
M (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\ X@   -,
M  #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H "@ I  O
M *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P =0"* (,
MB "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP   ,$   "Y
M    K0   *    "8    E    )$ !@"0  T D  2 (\ &0". "$ BP H (@
M+P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T 'D <@")
M '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$   "@
MD@   (D   ""    ?    'H  0!X  D =P . '@ % !W !H =  A '( )P!P
M "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '  7P!_ %X
MDP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-    ?P
M '0   !N    :@   &8   !E  0 8P + &, $ !C !4 8P ; &$ (0!? "<
M70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W $\ B0!.
M )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T   !\    ;@   &4
M  !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1 "$ 3P F
M $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $( @0!! )<
M0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O    8P   %D   !1
M    30   $H   !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P 1  A $(
M)@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I #< >@ V (\ -0"G
M #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E    6    $\   !(
M0P   #\    ]    /  " #P !P [  P .P / #L $@ Z !< .0 < #< (0 V
M "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@ + "@ "L
MNP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(  $@#  !  P  .P(
M #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\ '0 M "(
M+  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9 ", LP B
M -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((   Z"   -0<  # &
M   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F !X )0 D
M "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L K  ; ,T
M&P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L  "L*   H
M"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L '@ @ !T
M)@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4 ,, % #N
M !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-   C#
M(0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00> !@$(P 7
M!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P #P#E  \
M_@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \  "0.   @#@  '0X
M !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)(0 2"2@
M$@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;  H%]@ *
M!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0   =$   &@\  !@/
M 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /#"< #@TO
M  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,\0 ""_\
M7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$  !40 @ 4
M$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0 "A L  D0
M-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4   .\P  #O\ 7!
M $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@  %A(  !01 P 2$08
M$1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I  43,P #
M$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1]0  $?\ 6!(  $D4
M   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1$@< $!()
M  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7,   %SL
M !=(   76   %VH  !:    6F0  %;0  !79   4]P  $_\ 510  $86   Z
M%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P< #Q,'  T4
M!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD   ;+0  &S@  !M&
M   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8   W&0
M+AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$  L7!0 )
M&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A*@  (34  "%"   A
M4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T'   *QP
M "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @< P %'00
M A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_   F3@
M)F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P  *!X  "(>
M   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\   0A   !(P(  "4$
M   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX  "X[   N2@  +5P
M "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$  " @   <
M'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G    *0   "P!   N
M P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V   V10  -5<  #5M
M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)   )",  !\A   ;(
M%B   !$A   .(P  "B4   8H   "*@   "T    O    ,@   #0    W
M.0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(  #YG   ]
M@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4  !\C   8)   $B4
M  XH   **@  !2T    P    ,P   #8    X    .P   #X   !     0@
M $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA  !(?
M1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@  #BT   HP
M   $,P   #<    Z    /0   $    !#    1@   $@   !+    30   %
M  !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5=   5),
M %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8   ,Z
M/P   $(   !&    20   $P   !/    4@   %4   !8    6@   %T   !@
M    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@  9(D  &&K
M  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0   D(   !'    3
M %    !4    6    %L   !?    8@   &4   !H    :P   &X   !Q
M=0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\  ':?  !S
MQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$   !6    6P   &
M  !E    :0   &X   !R    =@   'D   !\    ?@   ((   "%    B0
M (X   "3    F 8  )P.  ";&@  F"L  )9   "260  D7,  (V5  "+M0
MB.@ *SX  "!!   51P  #4T   )4    6P   &$   !H    ;@   ',   !Y
M    ?@   (,   "(    C    (\   "2    E0   )D   "=    H0   *4
M  "J    L    +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "FJ   HM$
M(T@  !A.   .5   !%P   !D    ;0   '4   !\    @P   (D   "/
ME0   )L   "@    HP   *8   "I    K0   +$   "U    N0   +X   #$
M    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\  #"G0  P;T '%4
M !%<   '90   &X   !W    ?P   (@   "0    F    )\   "E    K0
M +,   "X    N@   +X   #"    Q@   ,H   #.    TP   -H   #@
MYP   .T   #S    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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MY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
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MK$8E_[-/-/^T64;_M&-8]K%L:^JM=7W?HWN-U9N!G,V2AJC'BXJQPH6/N;^
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MMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NO^@'@3_H2@(_[$P"_O
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M_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3___XO__24-#7U!23T9)3$4
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MQ+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PI_^8%P+_GB $_Z\F!?C
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M)3O_GB8[_YXF._^>)CO_GB8[_YXF._^>)CO_GB8[_YXF._^>)JO!  "=T
MC^$  (;_#@)Z_Q4#;O\<!F3_(PE<_RL,5?\S#T__.Q%)_T(31O])%$+_3Q9
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M1DK_T$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1]&N  "_N0,
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M7?A;T5WX6_]I'@/_92@%_VXK!_]X+@K_?S8._X,_%/^%2!S_AU,E_X1@+_^
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MN[^ 5;S9?U:XXWI8LN=U6++G=%BRYW18LN=T6++G=%BRYW18LN=T6++G=/^
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M;$W8[&I.S_!G3L_P9T[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P9_^/"P#II 0
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M@*" A'^K@H%_N(-_?\J$@8'A?8&!YG:!@.MO@(#O:H" [VJ @.]J@(#O:H"
M[VJ @.]J@(#O:O]H' +_>!<"_X<8 O^4'0+_GR,#^*DJ!.RQ,0?BMSD-U;="
M',FP3BV^JE<]M*-?2JN>9U6CF&Y?G)1U9I:0?&V0C8-SBXJ+>(:(E'R!AIZ
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M>5JKZ'-<I^QN7:3O:EVD[VI=I.]J7:3O:EVD[VI=I.]J7:3O:O]Y$0'_C X
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M3TCA_$](X?Q/2.'\3TCA_$](X?Q/2.'\3^&9  #-J0  OK," +.^ P"HRP4
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M!/]K* ;_<3 (_W0Y#?]U0Q/_=4T9_W59(?]Q9RG_;70P_6J -OIFBCSX8Y1
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M6U:M^UI6K?M:5JW[6E:M^UI6K?M:5JW[6O]^"0#RD0( UJ$" ,JM!0# MP4
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M4<]9L%/-6+I4RUC&5<E7VE;%5^Q5PUOY3\)>_TK 7_]&O6#_0KI@_T"Z8/]
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M5V>1_U)GD?]29Y'_4F>1_U)GD?]29Y'_4O]N#@#_?PD \8X% -F;!0#/I@<
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MH?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00 N;8# ++
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M24ZY_TE.N?])3KG_2>^%  #4E0  QZ,  +JL 0"PM   I[\# )[)!@"5U L
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M"1;_E D5_Y\*%/^J"A3_LPH4_[,*%/^S"A3_LPH4_[,*%/^S"I.[  "$QP
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M6HUL\E./;O],D'#_1X]Q_T./<?]!CW'_08]Q_T&/<?]!CW'_0?];% '_: \
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M3'> _T=W@/]&=X#_1G> _T9W@/]&=X#_1O]D#P#_<@D _W\( .6,!0#8E@<
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M1F"6_T9@EO]&8);_1O]P P#K@0  UH\  ,J: 0#!HP, N:H" +&R 0"JMQ$
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M&3+UQ1HQ]>(:,?3Q&3'Q_ADQ\?\9,?'_&3'Q_QDQ\?\9,?'_&;*D  "EJP
MF+8  (O   !^R@  <=4  &7>  !>]0H 6?P3 %/\'@%._"<"2OTP T7].05!
M_4 &/OY(!SO^3PDX_U<*-O]>"S/_9PPQ_W -+O]\#BS_B0\K_Y80*?^D$"C_
MM!$G_\<1)__A$2;_\A$F__81)O_V$2;_]A$F__81)O_V$:>I  "9LP  B[X
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M1J1;]D"C7O\[HU__-Z-@_S.C8?\QHV'_,:-A_S&C8?\QHV'_,?]3%0'_71
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M/X5P_SN&<?\XAG'_.(9Q_SB&<?\XAG'_./];#P#_9P@ _W,( /-]" #>A@<
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MG!8 LYPJ ZJ9.0NBE444FY%.'92.5R:.BU\MB8AF,X2&;3B A'0]>X)[07>
MA$5T?XU(<'V72VU\HTYJ?+!/:'S!4&=\W5!J?O-);8#_0VZ!_S]O@?\\;X'_
M/&^!_SQO@?\\;X'_//]D" #_<@  X7\  -.) 0#*D@, PY@$ +V>! "VH!,
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M,4' TC%!ONXP0;W]+T&\_RY!O/\M0;S_+4&\_RU!O/\M0;S_+<Z*  "_F
ML:   *:H  ";L   D+@  (6_  !ZQP0 ;\\) &O1%0!GT28!8]$T!%[00 A9
MT$H,5<]3$%'/6Q1.SV,82\YK&TC.=1Y%SG\@0LZ,(D#.F20^SJ@F/,ZZ)CS/
MU"8\S>\E.\S[)3O+_R4[RO\E.\K_)3O*_R4[RO\E.\K_)<.3  "UG@  J*8
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M"R']\@H@_/P*(/S\"B#\_ H@_/P*(/S\"J*G  "5L0  A[L  'G&  !LSP
M7]D  %+?  !(Z   0_\( #__$  [_QD -_\A #3_*0$P_S !+?\W BK_/@(G
M_T0")?]+ R+_4P,@_UP#'?]F!!O_<@09_X %%_^/!1;_GP85_Z\&%/_ !A3_
MU@83_^D&$__I!A/_Z083_^D&$__I!I>O  "(N@  >L4  &S/  !>V@  4.
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M/^@?XD#T'M] _AW=0?\;VT+_&ME"_QC80O\7V$+_%]A"_Q?80O\7V$+_%_]
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M,99?_RV68/\JEF#_*I9@_RJ68/\JEF#_*O]2#P#_7 H _V8) /]N"@#V= P
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M,'QP_S!\</\P?'#_,/];" #_9@  YW(  -I[  #/@@, R8<% ,2*!@"\C!4
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M/$Z6R3Q.EN@Z3Y;Y-E&6_S-2EO\P4I;_,%*6_S!2EO\P4I;_,.9R  #0@
MPHP  +B6  "MG   HZ$  )FF  ".K0  B*X1 (.N(@%]K3$$=ZP]"G*J1Q!L
MJ4\69ZA7&V.G7A]?IF4D6Z1M)UBD=2M4HW\N4:*),4ZAEC1+H:0V2:&T-DBA
MR#=(H.<U2:#Y,DJ?_S!+G_\N2Y__+4N?_RU+G_\M2Y__+=UY  #)A@  O)(
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M'#?%_QPVQ/\<-L3_'#;$_QPVQ/\<-L3_'+Z1  "PFP  I*,  )BJ  ",L@
M@+D  '3   !HQP  7<T% %/3"@!/UQ( 3=@B $O8, !)V#P"1MA& T393P1!
MV5@&/]EA"#S9:PHZV78,-]F"#C7:D \TVJ 0,MJQ$3';QQ$QVN<1,-CV$C#6
M_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  " N@  =,$
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M P[_\ ,.__ ##O_P Y.N  "$N   =L(  &?,  !:U0  3-P  #_A   UY@
M+?0  "K_ @ F_PL (_\1 "#_%P =_QT &?\C !;_*0 4_R\ $O\U !#_/0 .
M_T4!#/]. 0K_6 $'_V4!!?]T 0/_A0$"_Y8! ?^F 0#_M0$ _\8! /_* 0#_
MR@$ _\H! /_* 8:W  !WP0  :,P  %K7  !+W@  /N0  #+I   G[0  (_\
M !__   ;_P4 %_\, !3_$  1_Q0 #_\8  W_'0 +_R( "/\H  7_+@ "_S4
M /\]  #_1P  _U(  /]>  #_;0  _WX! /^. 0#_FP$ _ZD! /^K 0#_JP$
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M'ZY,_QVM3/\;K4W_&JU-_QJM3?\:K4W_&O]'$0#_3PT _U8, /]<#@#_8!(
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M(XE?_R.)7_\CB5__(_]1"0#_6@  ]60  .!L  #7<0, T'0& ,UU"0#$=A<
MO'8J ;1T.@6N<48,IVY1$J)K6AB>:6(=FF=I(99E<2639'@HD&* *XUAB"Z+
M8)$QB%^:,X9>I36#7K(W@E["-X!>W#B 7_(S@6'_+8)B_RF"8_\F@F3_)8)D
M_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= ( RG@% ,9Y!P"^>A4 MGHH
M :]X-P6H=D0+HG-.$IQP5QB8;5\=E&MG(9!J;B6-:'4HBF=]*X=EA2Z$9(XQ
M@6.7-']BHC9\8J\X>F*^.7EBU3EY8^\T>F7^+WMF_RM\9_\H?&?_)GQG_R9\
M9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $ Q7L# ,!]!0"Y?A( L7XE :I]
M-02C>D$*G7=,$9=T51>2<ET<CG!D((IN:R2';'(HA&MZ*X%J@BY^:8LQ>V>5
M-'AGH#9V9JPX=&:\.7-FT3IS9^TV=&G],'5J_RQV:_\I=VO_)W=K_R=W:_\G
M=VO_)_]7  #V8P  WVT  -%U  #(>P  P7\" +N  P"T@1  K((C :6!,@2>
M?C\)F'M*$))Y4Q:-=EL;B71B((5R:22!<7 G?F]W*WMN?RYX;8@Q=6R2-'-K
MGC=P:JHY;FJY.FUJSCIM:^LW;VW\,7!N_RUQ;O\J<6__*'%O_RAQ;_\H<6__
M*/]9  #K90  VW   ,UX  #$?@  O((! +:$ 0"NA0X IX8@ *"%, .:@CT(
MDX!(#XY]416)>UD:A'E@'X!W9R-\=6XG>71U*G9S?2YS<H8Q<'&0-&UPG#=J
M;Z@Y:&^W.F=ORSIG<.DW:7'Z,FMR_RUL<_\J;'/_*&QS_RAL<_\H;'/_*/]<
M  #G:   U7,  ,E[  # @@  N(8  +&(  "IB0T HHH= )R)+@*5ASL'CX5%
M#HF"3Q2$@%<9?WY>'GM\92)X>VPF='ES*G%X>RUN=X0P:W:.,VAUFC9E=*8X
M8W2U.6%TR3IA=.<X8W;Y,F5V_RYF=_\K9W?_*6=W_REG=_\I9W?_*?]?  #C
M;   T'8  ,5_  "\A0  M(H  *R,  "CC@H G8X: )>.*P*0C#@&BHI##(2'
M3!)_A548>H1<'7:"8R%S@&HE;W]Q*6Q^>2QH?8(O97R,,F)[F#5?>J0W77JS
M.%QZQSE<>N4W7GOX,E][_RY@?/\K87S_*6%\_REA?/\I87S_*?5B  #>;P
MS'H  ,"#  "WB0  KXX  *:1  "=D@8 EY,7 )&3* &+DC8%A9!!"W^.2A%Z
MC%(6=8I:&W&(81]MAV@C:H9O)V:$=RMC@X N8(**,5V!EC1:@:,V6("R-U:
MQ3=6@.,V6('W,5F!_RU;@O\J6X+_*5N"_RE;@O\I6X+_*>QF  #8<P  QWX
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M*4::_R='FO\E1YK_)$>:_R1'FO\D1YK_)-1W  #"A   MH\  *N6  "AG
MEJ   (NE  !_J@  =*X% &^O% !LKR0 :*\R F2N/05?K48)6ZQ/#5BL5A%4
MJUX44:IF%TZJ;AI+J7@=2*F#($6HCR)#J)TD0:BM)4"HP"4_J-\E/Z;T(T"E
M_R) I?\A0*3_($"D_R! I/\@0*3_(,I^  "[BP  KY4  *2;  "9H0  CJ8
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M#2G-_PTIS?\-*<W_#:Z8  "BGP  EJ8  (FN  !\M@  ;[T  &/#  !7R
M3,T  $+2 P YV0D -=\0 #3?&P RX"< ,>$R ##A/0 NXD< +>)0 2OB6@$J
MXV4"*.-Q B;D?P,EY(\#(^6A!"+EM 0AY<T$(.3L!"#B^P0?X?\%'^#_!1_@
M_P4?X/\%'^#_!:2>  "8I0  BZX  'VV  !PO@  8\8  %;+  !+T   0-4
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M (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0  &NT  !7]   2_P
M$/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)   _RL  /\S  #_/0
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M#,XS_PS--/\+S#3_"\PT_PO,-/\+S#3_"_\Y%@#_/A( _T$0 /]%$P#_2!L
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M%IU,_Q:=3/\6G4S_%O]'"P#_30( _U0" /=:! #K70< YUT+ .%<$ #371X
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M+VEFQC!H9N0O:FCW*6MI_R5L:?\B;&K_(&QJ_R!L:O\@;&K_(/]7  #D8@
MTFP  ,9S  "]>   M7L  *U\  "E? H GWT: )E\*@&3>S@$C7E#"8AW3 Z#
M=502?W-;%GMR8AEX<&D==6]P(')N>"-O;8$F;&R+*6ILERQG:Z,N96NR+V1K
MQ#!B:^$O9&SV*F9M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99  #@90  SF\
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M*55\_R56?/\B5WS_(%=\_R!7?/\@5WS_(.5D  #/<   P7H  +:#  "MB0
MHXP  )F.  "-CP  AI . (&1'0!]D"P!>(\X!'..0@ANC4L,:HQ3$&>*6A1C
MB6$78(AH&UV'<!Y:AGDA5H6#)%2%CR91A)PH3X2J*DV$O"I-A-<J38/Q)T^#
M_R10@_\B4(/_'U"#_Q]0@_\?4(/_']YI  #)=0  O(   +*(  "HC0  G9$
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M&#R?_Q@\G_\8/)__&,1\  "VB0  JI(  )^7  "5G   B:$  'VF  !QJ@
M9*X  %JQ" !7L10 5;(C %.R, %0LCL"3;)$ TNQ305(L54'1;%="4.Q90M
ML&\-/K!Z#SNPAQ$YKY83-Z^F%#:ON!0UL-$4-:[O%#2M_A0TK/\4-*O_%#2K
M_Q0TJ_\4-*O_%+N%  "OD   HY<  )B=  ",HP  @*@  '2M  !HL@  7+8
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M J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3   IV0
M(=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ: !'M9P 0
M[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\ #.O_ )>C
M  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =X0  &.P"
M !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\5P #_68
M OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S] (NK  !]
MM   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@  $/H   [_
M!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10  _U,  /]B
M  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4  /_E '^T  !PO0
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M ?$3_P+P%/\"\!3_ O 4_P+P%/\"\!3_ O\J'P#_+!P _RP; /\K'0#_*20
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M";HS_PFZ,_\)NC/_"?\Y$ #_/0L _T ) /]$#0#_1A$ _T49 /=$(P#N02\
MYC\\ > ^2@':/5<"TSQB!,\[; ;,.G4'R3I]"<<YA0K%.8P+PSB4#,$XFPW
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M(W=6QR1V5N0D=E?W'W=8_QMW6?\9=UG_%W=9_Q9W6?\6=UG_%O],  #I5@
MV5\  ,ME  #!:   NFD  +1H  "M9PT IF@< *!H+0&:9SH#E65%!I!C3@J,
M8E<-B6%>$(9?91.#7FP6@%US&'Y<>QI[7(,=>5N-'W9:F"%T6J0C<EJR)'%:
MQ"5O6N$E<%OV('%<_QQQ7?\:<5W_&'%=_Q=Q7?\7<5W_%_U/  #E60  TV(
M ,=H  "];   MFT  *]L  "G:PL H&P9 )ML*@&5:S<"D&E#!8MH3 F'9E0,
M@V5;$(!C8A-]8FD5>F%P&'AA>!IU8($=<U^+'W!>EB)N7J(D;%ZP)6M>P29I
M7MXF:E_T(6M@_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7   SV4  ,-K
M  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY !89L20B":E(,?FE9
M#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D9F*N)65BOR9D8MHF
M9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=7P  RV@  +]O  "V
M<P  KG4  *9U  "=<P4 EG,4 )%T) "+<S("AG(^!(%P1PA];T\+>6U7#G9L
M7A%S:V04<&IL%VUJ<QIK:7P<:&B&'V9GD2)C9YXD86:L)6!FO29?9]8F7V?Q
M(F!H_QYA:/\<8FC_&F)H_QEB:/\98FC_&>Q7  #98@  QVL  +QR  "S=P
MJGD  *%Y  "7=P$ D'@1 (MX(0"&>"\!@7<[!'QU10=X=$T*=')5#G%Q7!%N
M<&,4:V]J%FAN<1EF;GH<8VV$'F!LCR%>;)PC7&NJ)5IKNR99;-,F6FSO(UML
M_Q]<;?\<76W_&EUM_QE=;?\976W_&>A:  #29@  PV\  +AV  "O>P  IGX
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M&4Q^_QA,?O\83'[_&-5G  ##<P  MGP  *R$  "BB0  F(L  (V-  !\C0
M=8X$ &^/$@!MD"$ :9 N 66/.0)BCD($7HY+!UN-4@I8C%D,5HMA#U.+:!)0
MBG$438E[%TJ)AQE(B)4;1HBC'42(M!U#B,H=0X?J'$2&^QI$AO\818;_%T6%
M_Q=%A?\7187_%\UM  "]>   L8(  *>*  "<C@  DI   (:3  !YE0  ;)<
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M#;:$  "JC@  GI0  )29  "'G@  >Z,  &^H  !CK   5Z\  $NR  !!M08
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M !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:  "1H0
M@Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4  !7:!0 0
MX@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT !N:   7F
ME0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%J0  =[$
M &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP  $M\   WC   +\0@
M"?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M  #R@@
M\I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@  :KH  %S"
M  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@   7S   #_0$  /P(
M  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^;0  _X(
M /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0  $_-  !
MT@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_    _P   /\   #_
M!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6   _VL  /^
M  #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5)P#_$"T
M_PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P": /\ H #_
M *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\ ^ #_ /\ _0#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA /\9(P#_$RD _PXR
M /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6 /\"G #_ J(
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M >$2_P'A$O\!X1+_ ?\I%@#_*A, _RD2 /\G$P#_*!P _R<G /\C,P#_(#\
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M%8U#S16+1.@5BD7Z$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]   #R1P
MXT\  -13  #+50  Q%0  ,!0! "Y3Q$ LE B *Q1,@"G43\"HE!* YY/4P6;
M3EP(F$UC"I5,:@R32W$-D4IY#XY*@!&,28D2BDF2%(A(G!6&2*@6A4BU%X-(
MQQB!2.08@4KW%8!*_Q* 2_\0@$O_#X!+_PZ 2_\.@$O_#O]#  #L2P  W5,
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M&FM7_Q=K6/\4;%C_$FQ8_Q%L6/\1;%C_$?%+  #?5@  S%X  ,!D  "W9P
MKF@  *=F  "?8@8 F&,4 ))D) "-8S(!B6(] H1A1P2!8$\'?5]6"7I>70MW
M760-=5QK$'-<<Q)P6WL4;EN%%VQ:D!EJ6IP;:%FJ'&9:NAUE6M$=95KN&V5;
M_A=F6_\59ES_$V=<_Q)G7/\29US_$NU.  #:60  R&$  +QG  "S:@  JVP
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M%%AG_Q-89_\36&?_$^%8  #+8P  O6L  +)R  "I=@  H'@  )9W  "(<P
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M$,9K  "W=@  K'\  **%  "7B0  C(L  (&-  !SC@  98\  %V/"0!:D!0
M6) A %:1+0!3D#@!49!! DZ020-,D% $2H]8!4>/8 =%CFD)0HYS"T"-?PT^
MC8T//(V<$#J-K!$YC<$1.(WA$#B+]A XBO\/.8G_#SF)_PXYB?\..8G_#K]R
M  "R?0  IX8  )R*  "1C@  AI$  'J3  !ME0  7Y<  %29 0!/F0\ 3IH:
M $R:)P!*FC( 2)H\ 4::1 %$FDP"0II4 T"97 0^F68%.YEP!SF8? @WF(H*
M-9B:"S.8JPLRF+\,,IC?"S&6]0LQE?\+,93_"S&3_PLQD_\+,9/_"[AZ  "L
MA0  H8L  ):0  "+E   ?Y<  '*;  !FG0  6J   $ZB  !%I D 0J03 $"D
M'P _I"H /J4T #RE/@ [I4<!.:5/ 3>E6 (UI6$",Z5L S&E>00OI(<%+:27
M!BRDJ08KI+T&*J3>!BJB]0<IH?\'*:#_""F?_P@IG_\(*9__"+&"  "EBP
MFI$  )"6  "#F@  =I\  &JB  !>I@  4JD  $:K   \K0  -:\, #.P%0 R
ML"$ ,; K "^P-0 NL3X +;%( "RQ40 KL5L *;%G 2>Q= $FL8,!)+&4 B.Q
MI@(BLKL"(;+; B&O\P,@KO\#(*W_!!^L_P0?K/\$'ZS_!*J+  "=D0  DY<
M (><  !ZH@  ;:<  &"K  !5KP  2;$  #ZT   SMP  *KH# "2\#0 BO14
M(;T@ "&]*@ @O3, '[X] !Z^1P =OE( '+]> !J_;  9OWP &+^. !? H0 6
MP+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F   BIX  'VD
M  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3RPL $<P2
M !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.EP )SJP
M",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4  '&L  !D
MLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4 "-D,  ;9
M$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B   WYT  -^S
M  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U  !8O0
M2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #X0   .,'  #C#0
MY!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP  .ZA  #O
MMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+Q@  /,H
M "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP   .L   #M!0  [@L
M / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-  #]HP
M_K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*   \SP  +M0  "+:
M   7W@  $.(   GF    Z0   .P   #P    ]@   /8   #W    ^    /H'
M  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_C0  _Y\
M /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S /\ 00#_
M $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *( _P"H /\
MK@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[ /\ ^P#_
M /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\ J@#_
M +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\ \P#_ /,
M_P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_!48 _P)3
M /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H IP#X *X
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M /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.BP#I#I(
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M ZXD_P.N)/\#KB3_ _\O!@#_+P  _S(  /\S @#Y,@@ ]R\. .LK%@#A)R(
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M"/\\  #K0P  W$H  ,Q/  ##4   O$X  +=) 0"Q1@X JD@< *1)+ "@23H
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M$VY-N11L3<X4;$WK$VQ._1!L3_\.;$__#&Q/_PML3_\+;$__"^Y%  #<4
MR5<  +U<  "T7@  K%X  *1;  "<5@0 E582 )!7(0"+6"\ AU<[ 8-61 )_
M5DT#?%54!7I46P9W5&((=5-H"7-3< MQ4G@-;U*"#VU1C1%K49D2:5&F%&=1
MMA5F4<L595+I%&52^Q%F4_\/9E/_#693_PQF4_\,9E/_#.I)  #54P  Q5H
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M%59>]Q)67O\05U[_#E=>_PU77O\-5U[_#=Y3  #(70  NV0  +!J  "F;0
MG6X  )-M  "%9P  ?F<) 'AG%0!T9R, <6@O &YG.0%K9T(":&9* V5F4@5C
M95@&8&5?"%YD9PI<9&\,6F-Y#EACA!!58I$24V*?$U)BKA518L(54&+A%5%B
M]A)18O\04F+_#E)B_PU28O\-4F+_#=E6  #$8   MV@  *QN  "C<0  FG,
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M#4%S_PQ!<_\,07/_#,9D  "W;@  JW8  *)\  "7?P  C($  (&!  !R@
M97\  %U_" !9?Q, 5X @ %6 *P!3@38 48 ^ 4^ 1@)-@$X"2W]5 TE_705&
M?V8&1'YP"$)^>PD_?H@+/7V7##Q]IPTZ?;H..G[6#3I\\0TZ>_\,.GO_"SIZ
M_PLZ>O\+.GK_"\!I  "R=   IWP  )V!  "2A   AX8  'N'  !NAP  8(<
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M!*R!  "@B   E8X  (N2  !_E@  <IH  &6=  !9H   3J,  $*D   WI@
M+J@% "FI#P HJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  BJU, (:M> ""K:@ >
MJWD ':N+ !NKG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF_P(8IO\"&*;_ J6)
M  "9CP  CY0  (.9  !UG@  :*(  %RF  !0J0  1*P  #FN   OL   )K,
M !ZU!@ 9MP\ &+<7 !>W(0 6MRH %;<T !2X/@ 3N$D $KA4 !*Y8@ 1N7$
M$+F#  ^YEP .N:P #;G$  VXYP .MOL #K7_  ZT_P .M/\ #K3_ )R0  "2
ME0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@  ';T  !7
M   0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #QF8  L9W
M  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66  ")G
M>Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<   [*   (
MS@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520  UE@  -9I  #6
M?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^I   ;ZL
M &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(   75    VP
M -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9  #H:P
MZ8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0  8[4  %6\
M  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C    Y0   .<
M  #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X6@  ^6T
M /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX  $C&   Y
MRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M    [P   /$   #S
M    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P  _UH  /]N
M  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$(0#_ "<
M_P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_
M )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L ^P#_ /L
M_P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_ "$ _P M
M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E #_ )H
M_@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_ /( _P#Q
M /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T _P H /\
M-@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W )8 ]0"<
M /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8 _P#E /\
MY0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD /\%, #_
M 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$ ZP"7 .D
MG@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6 /\ U0'_
M -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.*@#_"S@
M_0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23 -T%F@#;
M!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\ Q0S_ ,4,
M_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V$3  [PX^
M .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.E@#+#IT
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M O\L  #_+0  [3(  .(T  #:,P  TRX# -(E"@#))1< P2<G +LI-@"V*D,
MLBM. *\K5P"L*V  JBMG :@K;P&F*W8!I"M] :,KA *A*XT"GRN5 IXKGP*<
M*ZH#FBNV YDLQP.7+.(#E"WU!)(M_P.1+?\#D"[_ Y M_P.0+?\#D"W_ _\P
M  #R,P  Y#H  -8]  #,/   QSD  ,,Q!0"]+A$ M3 A + R, "K,ST IS-)
M *0S4@"A,UH!GS-B 9PS:0*:,W "F3-W I<R?P.5,H<#DS*0!)(RF@20,J4%
MCC*Q!8TSP@:+,]P&B33R!H<T_P6&-/\%AC3_!(4T_P2%-/\$A33_!/PS  #K
M.@  W$$  ,U$  ##1   O4$  +@[ 0"R-PX JS@< *4Y*P"A.C@ G3M$ )H[
M30&7.E8!E#I= I(Z9 *0.FL#CCER XPY>@2*.8(%B3F+!8<YE0:%.: '@SFM
M!X(YO B!.=,(?SKN"'TZ_@=\._\&?#O_!7P[_P5\._\%?#O_!?0W  #E0
MTD<  ,5*  "\2P  M4D  *]#  "I/@L HC\7 )U )@"8030 E$$_ )%!20&.
M05$!BT!9 HE 8 .'0&<#A3]M!(,_=06!/WT&?SZ'!WT^D0A[/IP)>CZI"7@^
MN IW/\T*=3_J"G1 _ AT0/\'=$#_!G- _P9S0/\&<T#_!O$[  #?10  S$P
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M#F!-]@Q@3O\*8$[_"6!._PA@3O\(8$[_".-'  #-4   OE<  +-;  "J70
MH5T  )A:  "-4P  AE(, (!3& !\4R4 >50Q '54/ !S4T0!<%-, FU24P)K
M4ED#:5)@!&=1: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0K0Y;4< .6E'>#UI1
M]0Q:4O\*6U+_"5M1_PA;4?\(6U'_"-]*  #)4P  NUH  +!?  "F80  G6$
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M"DQ=_PE,7?\(3%W_",]4  "^7@  L64  *=J  "=;0  E&T  (EL  !X90
M;V0  &ED#@!E9!D 8F0E &!E, !>93H 7&5" 5IE2@)89%$"5F18 U1D7P12
M9&<%4&-Q!TYC>PE,8X@*2F.7"TACI@Q'8[@-1F/1#49C[PQ&8O\*1V+_"4=B
M_PE'8O\(1V+_",I8  "Z8@  KFD  *-N  ":<0  D'(  (1Q  !T:P  :6D
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M!KEH  "M<0  HGD  )A^  "-@   @H$  ':"  !I@0  6X$  %&!  !(@ H
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M !^8F0$=F*P!')C# 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_  "<A@
MD8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP  *J$  "&C"@ ?
MHQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5I7  %*6! !.E
ME  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5C   C)$
M '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN   2L D
M$+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X  >QBP %
ML:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP  @I@  '6=
M  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -O , ![X,
M  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_@   OI4
M +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*   &JF  !<
MJP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $QP   ,D'  #)
M#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@  SX<  ,^=
M  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO  !0M0
M0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP   -4   #6!@
MV P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<  .2.  #D
MI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#O@  -<(
M "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(   #D    Y0,
M .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\  #VDP
M]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP  )\P  !O0
M   1U0  "ML   #?    X@   .4   #I    [    .T   #P    \0   /,
M  #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_@   _Y8
M /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N /\ / #_
M $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\
MI@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y /\ ^@#_
M /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\ -P#_ $4
M_P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"< /P H0#[
M *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\ [P#_ .\
M_P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_ $  _P!-
M /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$ G0#P *,
M[@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_ .$ _P#@
M /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H _P!' /D
M4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C )\ X0"F
M -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X _P#. /\
MS@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !! .T 30#I
M %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H SP"A ,T
MJ@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_ _\ OP/_
M /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #1@#< U$
MU@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:= +\&I@"]
M!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\ KP[_ /\>
M  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+#4H QPU5
M ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0HP"P$:T
MKQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_ /\B  #_
M(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0 N1=. +47
M5P"S&&  L!AG *X8;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:G@"C&Z@ H1NT
M )\<Q0">'-\ FAWS 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__ ?\F  #T)P
MYBT  -HO  #/+0  RB<  ,<?" #!'!, NAXB +0?,0"O(#T JR%( *@B4@"F
M(EH HR-B *$C:0"@(V\ GB-W )PC?@";(X8 F22/ 9<DF0&6)*,!E"2P 9(E
MOP&1)=8!CB;O 8PG_P*+)_\"BB?_ HDG_P*))_\!B2?_ ?HI  #L,   W38
M ,TX  #$-P  OC(  +HK @"U)0X KB<= *@I*P"D*C@ H"I# )TK3 ":*U4
MF"M< )8K8P"4*VH!DBMQ 9 L> &/+($!C2R* 8LLE **+)\"B"RK H8LN@*%
M+<X#@R[J X$N_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P  TCT  ,4_
M  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C, EC(^ )(S2 "0,U  C3-8
M (LS7@&),V4!AS-L 88S<P&$,WP"@C.% H SCP-_,YH#?3.G WPSM01Z,\D$
M>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=/0  RD,  +Y%  "U
M1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY0P"'.4P A#E3 8(Y
M6@& .6$!?CEH GPY;P)Z.7<">3F  W<YBP1U.98$=#FC!7(YL05Q.<0&;SKB
M!FXZ]P5N._\$;3O_!&T[_P-M.O\#;3K_ ^HY  #50@  Q$@  +E+  "O2P
MITD  )]$  "8/@$ D3P0 (P]'0"(/BH A#\U ($_/P!^/T@ ?#]/ 7H_5@%X
M/UT!=CYD G0^:P)R/G,#<#Y\ V\^AP1M/I,%:SZ@!FH^K@9I/\ '9S_>!V<_
M]09F0/\%9D#_!&9 _P1F/_\$9C__!.4]  #/1@  OTP  +1/  "J4   HD\
M )E*  "11   BD$- (1"&0" 0R8 ?40R 'I$/ !W1$0 =41, 7)$4P%P0UD!
M;T-@ FU#9P)K0V\#:4-Y!&A#@P5F0X\&9$.=!V-#JP=A0[T(8$39"&!$\P=@
M1/\&7T3_!5]$_P1@1/\$8$3_!.!!  #*2@  NU   +!3  "G50  GE,  )5/
M  "+20  @T<+ 'U'%0!Y1R( =D@N '-(. !Q2$$ ;DA) 6Q(4 %J2%8!:$A=
M F9'9 )E1VP#8T=V!&%'@ 5@1XT&7D>:!UQ'J0A;2+L(6DC4"%I(\0=:2?\&
M6DG_!5I(_P5:2/\$6DC_!-M$  #&30  N%,  *U7  "C60  FE@  )%4  "&
M3@  ?4L( '=+$@!S3!\ <$PK &U,-0!K3#X :$Q& &9,30%D3%,!8DQ: F%,
M8@)?3&H#7DQS!%Q+?@5:2XH&6$N8!U=,IPA63+D)54S1"51,[PA43?\&54S_
M!E5,_P553/\%54S_!=5(  #"40  M5<  *I;  "@7   EUP  (U9  "!4P
M=T\$ '%/$ !N4!P :E H &A0,@!E4#L 8U!# &%02@%?4%$!75!8 EQ07P):
M4&<#6%!Q!%=0>P554(@&4U"6!U)0I0A04+<)4%#."4]0[0A04/\'4%#_!E!0
M_P504/\%4%#_!=!+  "_5   LEH  *=>  "=8   E&   (E=  !\5P  <E0
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M!<-6  "T7P  J&8  )YJ  "5;0  BFT  ']L  !O9P  9&0  %MB!0!68A
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M S%RF@,O<JP#+G+! RYRXP,N<?@#+G#_ RYO_P,N;_\#+F__ [-F  "G;P
MG78  )-Z  "(?   ?GT  ')]  !D?   5WL  $QZ  !">0, /'D. #IZ%P Y
M>B$ .'HJ #=[,P V>SL -'M$ #-[3  R>U4 ,'M? "][:@$M>W<!*WN' 2I[
MF (H>ZH")WN_ B9[X0(F>O<")GC_ B9X_P(G=_\")W?_ JYL  "C=@  F7P
M (Y_  "$@@  >(,  &R$  !?A   480  $>$   \A   ,X0) #"$$0 OA!H
M+80D "R%+0 KA34 *H4^ "F%1P HAE  )X9: ":&9@ DAG, (X:# "&&E0 @
MAJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0  DX(  (F%
M  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60#  CD!, (I <
M "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2D  5DJ0
M%)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@  (2,  !W
MCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P %9T3 !2=
M&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +G9X "IVR
M  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2  !ME@
M8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-  BJ$P '
MJAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4  *FJ  "I
MP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !CG@  5J(
M $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V#P  MA4
M +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@  "WM@
MM],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP  2ZP  #ZO
M   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #""P  PQ   ,05
M  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(J@  R,,
M ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4  #&X   E
MN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P  T D  -$.  #3
M$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G   W[(  -[+
M  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!   9Q0
M$,@   G,    SP   -,   #9    W    -T   #?    X0   .(%  #D"P
MYA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(  /.V  #S
MR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .T   !M4
M  #:    W@   .(   #F    Z0   .H   #L    [@   /    #R    ] 8
M /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C  #_LP
M_\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $< _P!4 /\
M7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_ *@ _P"O
M /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8 _P#S /\
M\0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/ /\ 6P#_
M &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *, ]P"K /8
MLP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L /\ ZP#_
M /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\ 50#] &
M^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F .D K@#G
M +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\ W0#_ /\/
M#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R %H [@!C
M .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D J0#5 +(
MT@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_ /\1" #_
M#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0 X != -T
M90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$ *T P@"X
M ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4  #_#P
M_PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7 ,H 7P#'
M &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@ LP"S +$
MP@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_$@  ]Q(
M .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&6 "Y!F
MMP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP *4+OP"C
M#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0  ZAX  -\>
M  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L$%H JA!A
M *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3O "7%-
ME!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@  - J  #'
M)P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50 G!I< )H:
M8@"9&FD EQMP )4;=P"4&W\ DAR( ) <D@"/')T C1VI (L=MP"*'LH B!_G
M (8@^@"$(/\!@R#_ 8,@_P&"(/\!@B#_ ?4D  #E+   TS$  ,8S  "\,0
MMBT  + E  "L'0P IAX8 *$@)@"<(3( F2(] )4B1P"3(T\ D2-6 (\C70"-
M)&0 BR1K (DD<@"()'H AB2# (0EC0"#)9@!@26D 8 FL@%^)L4!?2?B 7LG
M]P%Y*/\!>"C_ 7@H_P%X*/\!>"C_ >\K  #=,P  RCD  +X[  "T.@  K38
M *8O  "A* < FR<3 )8H( "1*2T CBHX (LK0@"(*TH ABM2 (0K6 ""+%\
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M E\Z_P)?.O\"7SK_ MT[  #'0P  N4D  *Y+  "D3   FTH  ))%  ")/P
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M \A)  "X40  K%<  *%;  "87   CEP  (-9  !V4P  :TX  &1-"@!?3!,
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M CU8F0,\6*H#.UF_ SI9X ,Z6/<#.EC_ SM7_P,[5_\#.U?_ [Q4  "N7
MHV,  )EG  "0:0  A6D  'EG  !K8@  8&   %5=  !.6PP 2UL4 $E<'P!'
M7"@ 1ETQ $5=.0!#74$ 0EU( $%>4 ! 7E@ /EYA 3Q>; $[7G@".5Z' C=>
MEP(V7JD#-5Z] S1?W0,T7O4#-5W_ C5=_P(U7/\"-5S_ KA9  "J80  H&<
M )9L  ",;@  @6X  '9L  !G:0  7&8  %%D  !(8@D 1&(1 $)B&P!!8R0
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M !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\  " ?@
M='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T< "-^)0 B
M?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\ %G^S !5_
MS@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![A   ;88
M &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)'0 7BB8
M%HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO  R*R  ,
MB>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP  98T  %F/
M  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,EQT #)<F
M  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5O@  E.
M )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@  794  %"8  !$
MF@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<  *,?  "C
M)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@  H=(  *'P
M  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A   YHP
M+:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$  + 8  "P(
ML2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK   L,8  +#H  "O
M]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   MK   (JX
M !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1  "^%@  OQX
M , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7  #"[P
MPOH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@  %KD   Z[
M   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-#P  SA0  - <
M  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#  #9X0  V?
M -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P   #<0   7'
MR@   ,X   #2    U0   -8   #9    VP   -T   #?!P  X0P  .,1  #F
M&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@  []T  ._D
M &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M    #4    V0
M -X   #B    Y0   .8   #H    Z0   .P   #N    \ (  /()  #U#P
M^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\   /_& /\
M%0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_ &8 _P!O
M /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\ M #^ +\
M_0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_ /\#$@#_
M !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$ _P!J /\
M<@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R +D \ #&
M .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'#@#_  T
M_P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E /4 ; #S
M '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C +, X0"_ -\
MT #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_ 04 _P #
M /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .< 9P#D &X
MX@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X ,H QP#(
M .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P  _P   /\
M P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1 &@ S@!N
M ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D P "W -0
MM0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,  /<   #T
M  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$ O@!H +P
M;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H ,L I@#F
M *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-  #?"0
MV@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B *T : "K
M &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8 F07B )@&
M] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,%0  QQ
M ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *8@">"VD
MG MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B (L0]@")
M$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@  N1P  +04
M 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1$F, D!-I
M (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8] !]&?\
M?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<  *@@  "C
M%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X A!QD ((<
M:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R(?\ <2+_
M '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M-0  I3$  )XK  "8(P(
MDAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21? '<D9@!V
M)6X ="5W ',E@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!:"G_ 6@I
M_P%H*/\!:"C_ >$N  #+-@  O#L  +$]  "G/0  GSD  )<S  "/+0  B"<,
M (,G%@!_*"( ?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK8@!L*VH
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M <T\  "\1   KTD  *1,  ":3   D4L  (=&  !]0   <SL  &PX#0!H.1<
M93DB &,Z*P!@.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V  5CMH %4\<P%3
M/'\!4CR- 5 ]G %//:P"3C[! DT^X0)-/O@"33[_ 4T^_P%-/?\!33W_ <E
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M 49%F )%1JD"1$:] D-&W )#1O4"0T;_ D-&_P%#1?\!0T7_ <%'  "R3P
MIE0  )Q7  "26   B%@  'Y5  !Q3P  9DH  %Q&!0!71@\ 5$88 %%&(@!/
M1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(2%@ 1TAA $5); !$27@!0DF& 4%)
ME@% 2J<"/TJ[ CY+V (^2O,"/DK_ CY)_P$_2?\!/TG_ ;U*  "O4@  HU@
M )E;  "070  AEP  'M9  !M4P  8D\  %=, 0!12@T 3DH5 $Q+'P!*2R@
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M 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I  "':@
M?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF #5=+@ T
M738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z  *%^S 2=?
MS  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#;P  >6\
M &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD*0 M9#$
M+&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q !]FR0 ?
M9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0  =74  &ET
M  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D;2P (VTT
M ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9OQ@ 6;ND
M%VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L  &1[  !7
M>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8 &7<N !AW
M-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .=^8 #G;Z
M  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"  !0@@
M1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G  Z#,  -
M@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L !('R  6
M_P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)BP  /8P
M #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/*0  CS(
M ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN  ",^P
MB_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  ! E0  -)8  "B6
M   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<(@  G2L  )TU
M  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9^0  F?\
M )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@  *9\  !^A   5
MH@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@  JB(  *LK  "L
M-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I]   J?T  *G_
M (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K   -K@
M!K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D  +HA  "[*P
MO#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<  +O^ 'Z5
M  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW   #N0   +P
M  "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6  #,(   SRL
M - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V '.=  !D
MHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##    Q@   ,D   #-
M    SP   -    #2    U    -8   #9 @  VP@  -X.  #A$P  Y!T  .@J
M  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F  !8K
M2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP   -D   #=
MX    .$   #C    Y0   .<   #J    [    .X$  #Q"P  ]1(  /@<  #[
M*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_ !  _P 1
M /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\ <P#_ 'H
M_P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#) /D X0#X
M /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T _P - /\
M#@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\ '4 ^P![
M /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L U0#J .P
MZ #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P & /\ "0#_
M !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\ [0!V .P
M? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7 .0 U #V
M -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\ ! #_  T
M^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O -H =@#8
M 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@ P #O +\
M_@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\   #T  < [0 1
M .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8 ;P## '4
MP0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G *X ^ "L
M /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G    WP , -8
M%0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S &\ L0!U
M *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X \@"= /\
MG #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ % ,8 $ #
M !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@ H@!O *$
M=0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/ /P C@#_
M (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H""@"T !(
MK@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I ),#;P"1
M!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P @0S_ ( ,
M_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H"0T H@<6
M )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-:@"%#G$
M@PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_ '03_P!T
M$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";$P, E@\0 ) 0
M&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y%6P =Q5T
M '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;_P!J&_\
M:AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<, (48%@"!
M&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6< ;1YP &L>
M>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A(O\ 82+_
M -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@$@!W(1T
M="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K &(E=0!A
M)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\ 62C_ ,\R
M  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N)QD :R@C
M &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK<@!9+'T
M6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_ ,HV  "Z
M/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G+14 9"T? &$N
M* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2,7H 43&(
M % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z  "V0@
MJ48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(< %HR)0!8
M,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G< 2S:% $HW
ME0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R10  IDH
M )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W(@!2-RH
M4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N# $0[DP!#
M/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20  HTX  )E0
M  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-.R< 2SLO
M $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^! #\_D0 ^0*(
M/4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3   H5$  )=4  "-
M50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'0"0 1D L $1
M,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$CP Y1*  .$6S
M 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18  "+60
M@%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"( 044I #]%,0 ^
M13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X ,TFQ #))
MR0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(70  ?ET
M '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*+@ Y2C4
M.$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO "Q.QP L
M3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@  >V$  '!?
M  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S4#( ,E Z
M #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93Q0 F4^<
M)E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8  &UE  !@
M80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L5B\ *U<V "I7
M/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?6>4 'UCZ
M "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK  !=:
M464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR ")>.@ A
M7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.( %U_Y !A>
M_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8;@  3&P
M $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG-0 89SX
M%V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W !!F_P 1
M9?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@  1G0  #MS
M   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0<3@ #G%"
M  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO_P );O\
M"6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T  #5]   J
M?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#( !'P]  -\
M2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@  >?\  'C_
M )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'   CAP
M&H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV  ")0@
MB$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\  (3_ )!^
M  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :D@  $I,
M  V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N  "6.0  ED8
M )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_ (N&  "#
MB@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2G0  #)\   2@
M    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P  ICP  *9+
M  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-  !XD0
M:I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0   :L   "M
MKP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)   MS   +<_  "W
M4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !MF   7YT
M %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<   "Z    O
M +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20  ,HR  #+0P
MRU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0  4J8  $2K
M   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(    RP   ,L
M  #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D  #C-0  Y$@
M .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@  1K   #BU   H
MN0  &KP   _    %Q    ,<   #+    SP   -0   #8    W    -T   #?
M    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X)0  ^3@  /E-
M  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\ $ #_ !8
M_P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\ /\ @@#_
M (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /  ] #_ /,
M_P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_ !( _P >
M /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /< ?0#V (,
M] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z ., _P#B
M /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X _P 9 /\
M)0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F 'T Y "#
M .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P _P#+ /\
MR@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3 /$ ( #M
M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8 S@!\ ,P
M@P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W /\ MP#_
M +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP / .$ &0#; "4
MU0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V +D ? "X
M (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\ I0#_ *0
M_P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P $P#' !\ P@ J
M +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O *D =0"G 'P
MI0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_ )4 _P"5
M /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !< LP C *\
M+@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8 '8 E@!]
M )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8 _P"& /\
MA@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ; *$ )@">
M #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '  B !W (8
M@ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X!O\ > ;_
M .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4 'P"1 BD
MC0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR 'H(? !X
M"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\ ;0[_ .$<
M  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$#"( @0TL
M 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0=P!L$((
M:Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_ -8D  ##
M*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP =A,G ',4
M, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B%WX 81B+
M %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ  "],0
MKS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB &D;*P!G
M&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD 6!^' %8@
ME@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X-@  JSH
M * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A)@!?(B\
M72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6# $\FDP!.
M)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P  IS\  )Q!
M  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7)RL 52@R
M %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@KD !'+*$
M1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,  )E%  "/
M10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"< 3RPO $TM
M-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!,9X 0#*Q
M #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)  ",20
M@T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K $<Q,@!&
M,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP .S:O #HW
MQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*3@  @$P
M '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U+P! -38
M/S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM #4[Q  T
M.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@  ?E   '--
M  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [.C0 .CH[
M #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_P@ O/^0
M+S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4  '%2  !D
M3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$ -3\X #0_
M0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I1.( *D/Y
M "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7  !A4@
M5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V "]%/0 M
M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.  )$CW "5'
M_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?6   554
M $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*.P G2T,
M)DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV !Y,_P ?
M3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@  4EL  $=8
M   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A44  (%%)
M !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2_P 84?\
M&5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99   36$  $)?   X
M7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P &%A% !99
M4  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 16/\ $5C_
M )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF   S90
M*6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%   ]A2P .
M85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\ "U__ )MF
M  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M;@  )&P
M !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K1P %:U,
M!&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_ )=M  "-
M<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P  '78  !5V
M   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U00  =4X  '5<
M  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U  ")>@
M@'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$  !""   *
M@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<  ()5  "!
M90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$@0  >X0
M &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T   F.   "CP
M ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-  "070
MCW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  " B   <HL  &2-
M  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";    G0   )T
M  "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@5   H&8
M )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(  %F6  !+
MF0  /9P  #">   CGP  %Z    ZB   'I    *8   "H    J@   *H   "J
M    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q2   L5H  +%O
M  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?   _HP
M,:8  ".G   7J0  #JL   6N    L    +(   "U    MP   +<   "X
MN0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/   QDX  ,9B  #&
M>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   RK   )*\
M !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8   #(    R0
M ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT   .!4  #A:P
MX84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0  %[D   V\
M   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:    W    -\
M  #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W7   ^'0
M /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ? /\ + #_
M #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0 _@"* /T
MD #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P /\ Y@#_
M -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\ )P#_ #,
M_P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$ .\ B@#M
M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\ V0#_ ,P
M_P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P (@#Y "X ]@ Y
M /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T A #; (L
MV "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_ +X _P"X
M /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G "@ Y  S .$
M/@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$ (0 P@",
M ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +  _P"L /\
MJ0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "( S0 M ,H -P#&
M $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T KP"% *T
MC0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P"> /\ G #_
M /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F +< ,0"T #H
ML0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^ )P A@":
M )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\ C0#_ /@
M  #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D #0 H0 \
M )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T @ "+ (H
MB0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_ .X*  #<
M#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P DP U )
M/@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!] (0 >P"/
M 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1  #-%P
MOQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O (, -P"
M #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\ ;@*+ &P#
MF !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$(   MB,
M *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(, !T"#@
M<@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR' &(,E0!@
M#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*   KRL  *0K
M  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I#S( 9Q Y
M &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2D@!6$Z(
M51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(  )\R  "5
M,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T 714T %P5
M.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.&I\ 3!JP
M $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX  "0-P
MAS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP %0<-P!2
M'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P 12&N $0A
MQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-/0  @SH
M 'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA,P!+(CH
M22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K #TGP0 ]
M)^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@  @#\  '8[
M  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$)C8 0R8]
M $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<LOP W+.
M-RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40  '-   !H
M.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S, /2LY #PK
M00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q,=X ,3'W
M #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%  !E0
M6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V #8P/@ U
M,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L +#7U "TU
M_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B10  6$
M $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T/  P-40
M+S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT "@Y_P H
M./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20  5D8  $Q"
M  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K.D$ *CI*
M "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]_P C/?\
M(SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP  $I(  !
M1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\ )#]( "-
M4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =0?\ 'D'_
M *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(  $A.   ]2@
M,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5% !U%3P <
M1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\ %T;_ *)2
M  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@  $14   Y40  +TX
M "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,3  53%<
M%$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_ )Y7  "4
M70  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];   U6   *U8  ")4
M 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /4U0 #E-B
M  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=  "19
MB&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P8   )EX  !U=   5
M6P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$ !EM>  1;
M;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".:P  A&X
M 'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF   19@$
M#&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:  !D:0
M9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0  @'4  'AW
M  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -<0  !G$(
M  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O9   ;W4
M &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L  '-]  !E
M?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\   &?0   'T%  !\
M"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@  >V\  'J$
M  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#  !=A0
M3X8  $*'   UB   *8<  !V'   4AP  #8@   :)    B@   (H   ")!@
MB0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@  (E\  "(
ME   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3C0  18\
M #B1   KD0  'Y(  !22   -DP  !)0   "6    EP   )@   "7    EP4
M )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES  "8BP
MF*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3  !(E@  .ID  "R:
M   ?FP  %)P   R>   #GP   *$   "C    I0   *4   "E    I0   *8"
M  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K@   JIH
M *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \GP  +:(  ""C   3
MI0  "Z<   &I    JP   *X   "Q    L@   +(   "S    M    +4   "V
M    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@  P(T  ,&F
M  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M   +L
M +,   "U    N    +P   "_    P0   ,$   ##    Q    ,8   #'
MR0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;9   VWX  -R9  #<
ML   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4   JX    NP   +\
M  ##    Q@   ,L   #.    T0   -$   #4    U@   -D   #;    W@
M .    #D    YP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(  #TH0
M]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0 _P!! /\
M3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y )( ]P"9
M /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -( _P#) /\
MQ #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [ /T 1@#Z
M %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P YP"3 .4
MG #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"] /\ N0#_
M /\   #_    _P   /\   #_  L _  3 /< '@#T "H \@ U .X 0 #I $H
MY@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "- ,X E0#,
M )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\ K0#_ /\
M  #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3 $, SP!,
M ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D C@"W )@
MM0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_ /\   #_
M    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T NP!% +@
M30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E )$ HP"<
M *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T   #Q
MY0   -D   #-    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^ *< 1@"D
M $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8 @ "4 (H D0"5 (\
MH@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C    T0
M ,4   "]    M@   *X "P"H !( I  < *  )@"< "\ F@ W )< /P"5 $8
MD@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/ '\ FP!^
M *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#   PPT  +@,
M  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"& $  A !&
M (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$ E0!P *0
M;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8  *T5  "D
M$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D =P!  '4
M1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C )\ 8@"O
M &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?  ";'
MDQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z &D"0 !G
M T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP 5PBM %8(
MP0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4)0  BR$
M (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+.@!="T
M6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL $P/P@!,
M$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0  ABD  'TD
M  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3$#L 4A%"
M % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04O@!#%=\
M0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$  '@K  !O
M)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C< 218^ $@6
M1 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [&]L .QSV
M #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R  !J+0
M82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ $$<00!
M'$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8 -2'T #4B
M_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G,@  72T
M %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA/0 Y(44
M.")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R "\F_P P
M)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.   6C,  %$N
M  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S)D( ,B9*
M #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK_P J*O\
M*RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@  $XS  !$
M+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M( "PK
M4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E+_\ )B[_
M *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY  !!-
M."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]& "<P3P E
M,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\ (3+_ *9#
M  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _.P  -C8"
M "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U30 @-5@
M'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_ *-'  "8
M30  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%   ]00  ,ST  "HY
M"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :.E8 &3MC
M !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+  "540
MBU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,  "= !0 @
M/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%, $T!@ !)!
M<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "35@  B5H
M (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(   ;10D
M%T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>  U';0 ,
M1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P  AV   'UB
M  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(  !]0   73@0 $4P,
M  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.:0 $3GL
M DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8  'IH  !Q
M:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8   25P$ #58)  E5
M#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97  !690  57<  %6+
M  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N  !O;P
M8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .80  "6 (  -@#0
M7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(  %Z'  !=
MG   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J=0  770
M $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;    FL&  !K"P  :@\
M &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"  !HF
M9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P  57L  $AZ
M   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"  !W"   =@T  '80
M  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !TD@  <ZH
M '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((  #^#   R
MA   )8,  !J#   1@P  "H,   *#    A    (4   "$ P  @P@  (,-  "#
M$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U  ""C   @:0  ("]
M  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-   GC0
M&XT  !&.   *C@   (\   "1    D@   )(   "2    D@$  )('  "2#
MDA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP  )&V  "0
MV   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <EP  $9@
M  F9    FP   )P   ">    H    *    "@    H    *$   "A!   H@D
M *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L  "DR0
MH^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@   1H0  "*,   "E
M    IP   *D   "L    K@   *X   "N    KP   +    "Q    L@   +,&
M  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "YNP  NMX
M +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   'K    *\   "Q
MM    +@   "[    O    +P   "^    OP   ,    #"    Q    ,8   #(
M P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22  #5JP  U<0  -3B
M %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N    +L   "^    P@
M ,<   #*    S    ,P   #.    T    -(   #5    V    -L   #?
MX@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(  /'% /\
M P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_ %$ _P!9
M /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /( G0#P *<
M[@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_ /\   #_
M    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L \@!3 /
M6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#= *  VP"L
M -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\   #_
M_P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !- -P 50#9
M %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H PP"E ,
ML@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_    _@
M /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4 3@#" %4
MP !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@"> *P J@"I
M +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[    \    .4
M  #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N $X K !4
M *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D HP"7 +(
ME@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K    W0   ,\   #&
M    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@ FP!. )D
M4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "& *H A "\
M (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X   "V
MK@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!' (D 30"'
M %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *, =0"T ',
MS !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H!   H0
M )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L 1P!Y $P
M=P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N &4 PP!D
M .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$   E0L  (\#
M  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L $8 :@!,
M &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D O !8 -P
M6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10  (4/  !^
M"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $  7P!& %T
M3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !. M( 303P
M $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8  !U$@
M;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9! %,&1P!1
M!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]  1 SO $,-
M_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N&P  9A0
M %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-0@!(#4D
M1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q #L1_P [
M$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P  81T  %D6
M  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@! $44 /A)-
M #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06_P T%O\
M-!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0  %0>  !,
M& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D( -Q9* #87
M4P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N&_\ +AO_
M *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P  62H  % E  !''P
M0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M' "\<4  N
M'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\ *"#_ *DV
M  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$)0  .R '
M #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA3@ I(5@
M)R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_ *8Z  ":
M/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+   ."8# #$C
M#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C)E8 (B9C
M "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^  "80P
MC4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T  "PH"0 H
M)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0 '2M@ !LK
M;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "51P  BTL
M ()-  !X30  ;DP  &1)  !81   3T   $8]   ].   ,S0  "HO!@ D+ T
M(2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!> !8P;0 5
M,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P  B4\  (!1
M  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H  "<V P ?,@L '#(0
M !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U:P 0-GT
M#S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,  'Y6  !U
M5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]   <.@@ %C@. !4X
M$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +.WH "CN-
M  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;  !R6P
M:%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   80@, $D + ! _$  .
M/Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!90 $078  T&*  %!
MGP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P8   9F
M %U>  !16P  15<  #I4   O40  )4\  !Q,   42@  #D@(  M'#@ (1Q(
M!T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&  !(FP
M2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@  968  %ED
M  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('  51#0 !4!$  % 6
M  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\  %"#  !/F   3ZX
M $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L  %-I  !&
M9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;"P  6@\  %H3  !:
M&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^  !8E   5ZL  %?%
M  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP   _;@
M,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0  90T  &41  !D%0
M9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<  &#!  !?
MY@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<  $5W   X=@  *W8
M "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H  '$.  !P$0  <!<
M ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\  !KX@
M:O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_   O@   (G\  !=^
M   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*  !^#0  ?A$  'X7
M  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !YV@  >/4
M '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D   ^)   '
MB@   (L   ",    C0   (T   ",    C    (P#  ","   C0T  (T1  "-
M%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN  "*S0  B>\  (G_
M 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5    E@
M )@   ":    FP   )L   ";    FP   )L   "<    G04  )T+  ">$
MGQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@  )SY '",
M  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\   "A    HP   *4
M  "H    J0   *D   "I    J@   *L   "L    K0   *X!  "P"0  L@\
M +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P &23  !5
MEP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M    L    +0   "V
M    N    +@   "Y    N@   +P   "]    OP   ,    ##    Q0<  ,D/
M  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;  !)H
M.J4  "RI   <JP  #ZX   2Q    M    +<   "Z    O@   ,,   #&
MR    ,@   #*    RP   ,T   #/    T@   -4   #9    W0   .$%  #F
M#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_    _P
M /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L 6P#Z &(
M^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M .< O0#E
M -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_    _P   /\
M  #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H %P Y@!B
M .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\ M #, ,D
MR0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P   /\   #X
M  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8 S@!< ,P
M8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V +X M #=
M +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\   #F
MWP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6 +8 6P"U
M &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0 H #+ )\
M[@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/    QP &
M ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *, 50"B %H
MH !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_ (P X@"+
M /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@   "_    M0 ! *X
M"P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0 %, C@!9
M (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L SP!Y /$
M> #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O    J    *  !@":
M  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" (( 1P"  $T ?P!2 'T
M6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J .< :0#]
M &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B    FP   )0   "-  H
MB  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !, &\ 4@!M
M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X NP!= -P 7 #V %P
M_P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""  4 >P -
M '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$ 8P!& &( 3 !@ %(
M7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O %  _P!0
M /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@  <0 ( &L
M#@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5 $T 4P!4
M %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8 ^P!& /\
M10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O$   : L  &$$"@!=
M !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@ 20!/ $<!
M5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \!_\ / ?_
M +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&   81(  %H- P!3" P
M3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+ #X)4P ]
M"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\ - W_ *TG
M  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H  %04  !,#P8 1@P-
M $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.4  T#EH
M,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_ *HL  "=
M,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@  0!$) #L0
M#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M$E< +!)C
M "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q  ":-@
MCSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<% #44#0 R
M$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0 )A=@ "08
M;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8.@  C3T
M (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9"@ L& \
M*A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q> !\=;  =
M'7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0  BT$  (%"
M  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G'0T )1T2
M ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA:@ 8(GL
M%B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40  ']&  !U
M1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF P C(@L ("$0 !XA
M%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3)GD $B:-
M !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*  !T2@
M:DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<. !DG$@ 8
M)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W< #BN+  TL
MGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S3P  :4X
M %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L$  3+14
M$BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(  @QG  &
M,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5   9U(  %U0
M  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .,Q, #3,9
M  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   VF0  -J\
M #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O60  95@  %M5  !1
M4@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$ "#L7  8[
M'@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP  /*P  #O%
M   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<  !.6
M0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5  !#&P
M0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#E   0JH  $+#  !!
MY@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)70  /5H
M #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+&   2Q\
M $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G   !(Y
M2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F  !#9   -V$  "Q?
M   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40  !5%0  5!L  %0C
M  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0X@  4/@
M $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D  "5H   :
M9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<  %\>  !>
M*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY  !:WP  6?<  %C_
M (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P  *'(  !UP   3;P
M#&X   1N    ;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9  !J(@
M:BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4  &3_ (!U
M  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL  !1Z   ->@  !'H
M  !Z    >@   'H   !Y    >0$  '@&  !X"P  > X  '@3  !X&@  >"4
M '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_ 'Y]  !U
M@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%   #A0   (8   "'
M    B    (@   "'    AP   (<   "'!   APD  (<.  "($P  B!P  (@I
M  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$  !JA@
M7(@  $V*   _C   ,8X  "./   6CP  #9    *1    D@   ),   "5
ME@   )8   "6    E@   )8   "7    EP   )<'  "8#0  F1,  )H?  ":
M+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X &V*  !?C0  4)
M $&3   SE@  ))<  !:8   -F0   9L   "=    GP   *$   "D    I0
M *0   "E    I0   *8   "G    J    *D   "J!   K P  *X3  "N(0
MKC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0  1)@  #6<
M   FGP  %Z$   VC    I0   *<   "J    K    +    "R    M    +,
M  "T    M0   +<   "X    N0   +L   "]    OP$  ,,+  #%%0  Q24
M ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(  "FF   9
MJ   #:L   "M    L0   +0   "W    N@   +\   #!    Q    ,,   #%
M    Q@   ,@   #*    S0   ,\   #2    U@   -L   #@#   X1@  .,K
M  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_    _P   /\  0#_  H
M_P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C /( :0#P
M &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T W #N -D
M_P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P   /\   #_  8 _P /
M /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@ X != -X 8P#< &@
MV0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C ,  ^P#
M /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L   #S  $ [0 , .@
M$P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#" &( P0!G
M +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +< K0#0 *L \@"J /\
MJ0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@    U0 ( ,X $ #)
M !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L K !A *H
M9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6 /\ E0#_
M )( _P"- /\ B@#_ /P   #P    XP   -0   #(    OP # +D #0"S !,
MKP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!: )< 7P"6
M &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8 @@#_ ($
M_P!^ /\ ? #_ .T   #=    S    ,$   "X    K@   *< "0"B !  G@ 7
M )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X B !3 (8 60"$ %\
M@@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_ '  _P!P
M /\ ;@#_ -T   #)    O    +$   "I    H0   )D  P"3  P C@ 2 (H
M&0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T %@ <@!?
M '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$ _P!A /\
M80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&  @ @0 . 'P % !X
M !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %( 9 !9 &,
M8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R %4 _P!4 /\ 50#_
M ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  ( =0 + '  $ !L !8
M:  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3 %8 6P!4
M &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\ 20#_ +D2
M  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A !$ 70 8
M %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L 5@!) %\
M1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_ +(9  "D
M'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X 4P 3 %
M&0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _ %H /@!E
M #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@  "?)
ME"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/ $< % !$
M !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8 -01A #,$
M;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";*@  D"P
M (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'$  [!A4
M.0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I> "L+;  I
M"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P  C3(  (,R
M  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S#!$ ,0P6
M "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/:@ B#WL
M(!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8  ( W  !V
M-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X *A 2 "@0
M&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;$W@ &A.+
M !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[  !T.P
M:S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0 "(3%0 @
M$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8 %!B) !,8
MG@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S/P  :3T
M %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7$@ :%Q<
M&1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'  \=G  .
M';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P  :$(  %X^
M  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5'!4 %!T;
M !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LBF0 *(JX
M"2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8  %Q$  !2
M/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A#@ 1(1, $"(9 ! B
M(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $)JP  R;$
M  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(  !01
M1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6  PH'0 +
M*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD  "O!   K
MXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/2@  1T<
M #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A  !RX5  8O&P %+R,
M R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_   PX0
M,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3  !.4   14T  #I)
M   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383   V&0  -B   #8I
M   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4  #:]   VX   -?4
M #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(  #5.   J
M2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT  #XF   ^
M+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[   \W@  ._4  #O_
M (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5   E4@
M&U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B  !&+
M1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#W   0O4  $+_ (A=
M  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?6@  %5<
M  Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/)P  3S(
M $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_ (5E  !\
M:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D   88@  $&    E?
M    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9  !9(@  62T  %DZ
M  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L  !Y<
M<W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H   !J
M:0   &D   !H    9P,  &8(  !F#   9@\  &44  !E'   92<  &0T  !D
M0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W=P  ;GD
M %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0   '4   !U    =@
M '4   !T    =    ',"  !S!P  <PP  '(0  !R%0  <B   '(L  !R.P
M<4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@  9'X  %5_
M  !'@   .8$  "N"   >@0  $H$   J!    @0   ((   "#    @P   (,
M  ""    @@   ((   ""    @@4  ((*  ""#P  @A<  ((C  "",@  @D,
M (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684  $N'   \
MB0  +HH  ""+   3BP  "HL   ",    C0   (\   "1    D@   )$   "1
M    D0   )$   "1    D@   )("  "3"0  E \  )09  "4)P  E#@  )1,
M  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0   PD@
M(90  !25   *E@   )<   "9    FP   )T   "?    H    *    "@
MH    *$   "B    HP   *0   "E    I@<  *@0  "H'   J"T  *E   "I
M5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098  #.9   CG   %)T
M  J?    H0   *,   "F    J    *P   "N    KP   *\   "P    L
M +(   "S    M    +8   "W    N@   +T'  "_$   OQ\  , S  # 20
MP&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0  "Z<   "J
M    K0   +    "S    M@   +L   "]    P    +\   #!    P@   ,0
M  #&    R    ,H   #,    SP   -,   #:!P  VQ,  -TE  #>.P  WU,
M .!N  #?C   W:D  -W" /\   #_    _P   /\   #_  < _P 0 /\ &0#_
M "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D Z0!O .<
M=0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/ /\ Q #_
M +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  ( ^P - /< %0#S !\
M[P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I ,X ;@#,
M '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\ M #_ *D
M_P"B /\ G0#_ /\   #_    _P   /8   #N    YP * .$ $0#< !H UP C
M -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@ : "V &X
MM !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_ )L _P"5
M /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8 #@#! !4 O0 > +D
M)P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A &< GP!N
M )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L _P"& /\
M@P#_ /@   #I    W    ,P   #!    N    +( "@"L !$ J  8 *4 (0"B
M "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &  C0!G (L
M;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W /\ =0#_
M .8   #3    Q@   +L   "Q    IP   *$ !0";  T EP 3 ), &P"0 ",
MC  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@ 'D : !W
M '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\ 9P#_ -,
M  ##    M0   *L   "C    FP   )(   ",  H AP 0 (, %@!_ !T ?0 D
M 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H 80!H &H
M9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_ ,4   "V
M @  J0(  )\   "6    C@   (<   "   4 >@ , '4 $0!Q !@ ;@ > &L
M)0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!: &0 6 !N
M %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*  "L#0
MH T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9 %\ 'P!=
M "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X 3 !H $H
M=0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E%   F14
M (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0 &@!1 !\
M3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C #\ ;P ^
M 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P  DQT  (D<
M  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0 $H %0!' !H 10 @
M $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8 :P T 'H
M,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0  (0D  !Z
M(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8 /  ; #H
M(0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K '8 *@"(
M "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J  !W*
M;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7 #$!'  P
M 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0 (@:& " &
MF@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T+@  :BL
M &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'%P H"!T
M)P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R% !@,F0 7
M#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P  :#$  %\L
M  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A#!D 'PP?
M !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0F  1$*X
M$!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8  %TR  !3
M+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4 &! ; !<0
M(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -$ZL "Q/"
M  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW  !2,@
M22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8 !(3'P 1
M%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@ !AB_  <8
MX  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0.   1S,
M #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8'  .&",
M#1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\  (<W0 "
M'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!  !//0  1CD  #XV
M   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *'B( "!XJ
M  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   AVP  (?(
M "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\  #T\   U
M.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"   B0H  $E
M,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y   FV0  )?(  "7^
M (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"   Q/0
M)SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF   K+P
M*SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(  "K_ (Q)
M  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL  #='   M0P  (S\
M !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q+   ,C<
M #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__ (E/  "
M5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),   H2   'D4  !5"
M   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0  .30  #E
M   Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5  !_6@
M=ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B3P  &$P  !!*   *
M2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!)@  03$  $$]  !!
M2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\8   <V,
M &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2   $40
M $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY  !*1P
M2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P  <FH  &ML
M  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T   9;    6@   %D
M  !8    5P0  %8(  !6#   51   %04  !4'0  5"<  %0T  !40@  4U(
M %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$  &9Q  !8
M<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E    90   &4   !C
M    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N  !?/   7TT  %Y>
M  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV  !/=@
M074  #-U   F=   &7,  !!R   '<0   '$   !Q    <0   '$   !O
M;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8  &M8  !K
M;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$?0  -GX
M "A^   ;?0  $'T   =]    ?0   'T   !^    ?P   'X   !]    ?0
M 'P   !\    ?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/  ![90
M>WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@  *X<  !V'
M   1AP  !X@   "(    B0   (H   ",    C0   (T   ",    C    (P
M  ",    C    (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".6P  C70
M (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   MCP  'I   !&1   '
MD@   ),   "5    EP   )D   ";    G    )L   ";    G    )P   "=
M    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z  "C3P  HV@  **&
M  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;    G0
M *    "B    I    *@   "J    JP   *H   "K    K    *T   "N
MKP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL  +IW  "[
ME   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0   "G    J@   *P
M  "O    L@   +<   "Y    NP   +H   "\    O0   +\   #     P@
M ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI  #7A@
MUZ,  -:] /\   #_    _P   /\   #_  , _P - /\ %0#_ "  _  K /@
M-0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #? '8 W0!^
M -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$ _P"I /\
MHP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M !L Z0 E .0 , #?
M #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\ PP!W ,
M?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"< /\ EP#_
M /\   #_    ^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@ *0#$ #(
MP  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O *H > "H
M (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\ B@#_ /\
M  #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N "L J@ T
M *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )< < "5 'H
MD@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_ /(   #C
M    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X ' ": "4 EP M )0
M- "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0"" '( ?P!]
M 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\   #,
MOP   +0   "K    H0   )H  @"4  L D  0 (P %P"( !X A0 F (, +0"!
M #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L ;@!U &P
M@P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\    KP
M *4   "=    E    (P   "&  < @0 - 'P $@!X !D =0 ? ', )@!Q "T
M;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N %T >P!;
M (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P    I    )D
M  "0    B    ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C "8 80 L
M %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %  = !. (,
M3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP  ) *  "&
M!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@ &@!6 "$ 5  F %,
M+ !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!" 'T 0 ".
M #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1  !_#P
M=@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A $@ )@!&
M "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@ -@") #0
MG  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z%@  <!(
M &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T (0 \ "8
M.@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "% "L F  J
M *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A  !U'P  ;!H  &,6
M  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S "$ ,0 G
M #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "( E0 A *D
M( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(  %\=  !7
M&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T *0 B "<
M*  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9 *< & "]
M !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD  !4'P
M2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(> " ")  >
M RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4 $0>[ ! '
MVP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1)0  22
M $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@((  7"2<
M%@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[  L-V0 +
M#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P  1R8  #XA
M   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1#2, $ TK
M  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40U  %$.\
M!A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P  #TG   U
M(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"  #! H  L1
M,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0  $^X  !/[
M ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN   T*@
M+"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F  85+P $
M%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7T   %^T  !?[ (XZ
M  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S,   +"P
M "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :+0  &S@
M !M$   <40  '&   !UR   =AP  ')T  !RS   <S@  &^T  !O\ (P^  ""
M0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ   S-P  *C(  " M
M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B   @*P  (38  "%!
M   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#  " 2
M>$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O.P  )3<  !PS   3
M+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,  "<_   G
M30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_3   =E
M &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y   0-@
M"C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P  +3$  "T]   M2@
M+5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@  =54  &Q7
M  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,  !,_   -/0  !CH
M   X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X  #0Z   T1P  -%<
M #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL  &I=  !B
M70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'   (1    $(   !!
M P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW   \1   /%,  #QE
M   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC  !B9
M5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !30   $P   !*
M200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%0   15   $1A  !$
M=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=:0  3V8
M $)D   T80  *%\  !U=   26P  "UD   )8    5@   %8   !4    4P
M %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=  !.<@
M38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0  1VP  #EJ
M   L:0  (&<  !1E   -9    V(   !B    80   &    !?    7@   %T
M  !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9;0  6(4
M %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,  #!R   C
M<0  %F\   UN   $;0   &T   !M    ;0   &P   !K    :@   &D   !I
M    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@  97\  &2:
M  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[   8>@
M#GD   1Y    >0   'D   !Z    >@   'H   !X    >    '<   !W
M=P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<  '23  !S
MKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0  !J$   .@P  !(0
M  "$    A0   (8   "(    B0   (@   "'    AP   (<   "'    AP
M (@   "(    B <  (D0  ")'   B2P  (@_  "(50  B&T  (>)  "&IP
MA<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-   $C@   )    "1
M    DP   )4   "7    F    )8   "7    EP   )<   "8    F    )D
M  ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<G   G+D
M )OB %J+  !+C@  /)$  "V3   >E0  $)8   28    F@   )P   ">
MH0   *0   "F    IP   *8   "G    IP   *@   "I    J@   *P   "M
M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@  M*P  +3,
M $V2   _E@  +YH  ""=   1GP  !:$   "C    I@   *D   "L    KP
M +,   "U    MP   +8   "W    N    +H   "[    O0   +\   #!
MQ    ,<   #+    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T  -"X
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M______________________________________\
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MX.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,!(0
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M________X(,\       NA^W_____________________________K%,0
M   7;=;____________________________[@#$        )8<S_________
M___________________26@(         7<S_________________________
M__^H-0          7-/___________________________]]#0
M5-;__________________________^Y]10          1-3_____________
M______________RJ9"\"   $(C=)6,[____________________________I
MI&M!*#]C?Y6GNMK______________________________]6RK++,Y/K_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^6[EW=BR/______________________
M___________;GF<V"@ "C/_______________________________\A_/P4
M    7L______________________________V8$Y        /*K_________
M____________________GDP         (Y#_________________________
M___<;QH         $'WY__________________________^O2
M &_N__________________________^$$P           &3F____________
M_____________^Q1             %?>_________________________[@5
M             $C6_________________________W04             #C/
M________________________^:):$P           "/%________________
M_________]^;7"P           VZ___________________________OL7U5
M.2(1!P$"$2*R_______________________________?OZ69F)J@K+W:____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________C
MOIV ?/O________________________________RMX17, X ':S_________
M_____________________]**3!4      '+S________________________
M____UG\V         $O)___________________________ZD3X
M "^K___________________________ 6@           !J5____________
M______________^-)             B$_________________________^=>
M              !W_________________________[0E              !J
M_________________________WT               !;]/______________
M_________2L               !,Z_______________________I0
M           \X?______________________, P                MV?__
M__________________^9BF$G               GU___________________
M____[;Z)52<            EW/_________________________^RIUV74H\
M,BTL,#E'WO_______________________________>;=UM+0T]GD________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^_4N];_________________________
M________Y[B/:DLO%6_______________________________^2A9S0'
M #S)____________________________UH([         !*7____________
M_______________MA3$           !O__________________________^F
M0@            !0X?_______________________^QI               W
MR?_______________________[,O               BMO______________
M_________WD                0I_______________________\C0
M            F?______________________J0                  C/__
M____________________1@                  ?___________________
M___?                    =/____________________^7
M        :O_____________________.                    8_______
M________________*2(!                8?______________________
MN:. 5S<7            :/__________________________^M.NE(9\=7%P
M<G>!E/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________;NIV":6G3____________
M___________________(DV4]&0   !V>____________________________
MVXY,$P        !N___________________________;?"P           !%
MU_________________________^+*@             BM/______________
M_________\)$               #E________________________WT!
M            ?_______________________YS8                 :O__
M____________________G0                  6/__________________
M____1@                  1_C____________________I
M        ->G___________________^6                    )=O_____
M______________^\                    &,[____________________K
M                    #\+_____________________
M    "KG_____________________)P                  "K7_________
M____________<                   #;G_____________________X)R,
M<%5",R8;% \-#A(:)K_____________________________YY-C2SLS+S,_6
MX/S_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________KT[SC________________________________TJF%94@L$@&%
M____________________________\:MQ/ \       !/X/______________
M___________5?S4            ?LO_______________________^-U'0
M            B?_______________________Y C                9___
M____________________U4,                 2/;_________________
M____B@                  +MW_____________________.
M        %\C___________________^^                    !+;_____
M______________^<                     *7___________________^Z
M                     )/____________________<
M     (+_____________________                     '3_________
M____________$P                   &C_____________________0@
M                 &#_____________________>@
M %W_____________________T0                   &'_____________
M_________R0                  &;______________________\FLF8E]
M=G%L:6=F9VMP>HS_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________BQ:J1>6%W_____________________________]VF
M=U L#      QQ/_________________________@DDX3            C___
M_____________________])P'0              8/__________________
M____[F\/                -^+_____________________EAP
M        %,#_____________________0                    */_____
M______________^N                     (G___________________^>
M                     '+___________________^\
M     %_____________________:                     $W_________
M___________Z                     #O_____________________#@
M                 "KY____________________,P
M !OI____________________7@                    _;____________
M________CP                    ;0____________________T
M              #*_____________________RL                   #(
M_____________________X                    #+________________
M______<6 04% P$       $&#1C+_______________________\Z^'8S\S-
MS]#2U-?<XNK_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________\=K&____
M___________________________QQJ.$:$TR&  5J___________________
M________N7Q&&           <?_______________________]=\+P
M        .^/_____________________WV0)                #+7_____
M________________= ,                  (W____________________%
M%0                   &K___________________^9
M     $O___________________^V                     ##]________
M___________7                     !GG___________________V
M                  73____________________#@
M  #!____________________+P                    "O____________
M________4@                    ">____________________>0
M              ".____________________I0                    "
M____________________V                     !T________________
M_____S8                   !M_____________________WP
M          !I_____________________]<-                  !H____
M__________________]P                  !A____________________
M____4#Q&3E1976%D:&QP=GZ)____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________O
MU;NCBW-:E?__________________________^+^.9$$A!0      4OS_____
M__________________>=5A@             %\'_____________________
MY6P6                 (W_____________________8P
M     %[___________________^=                     #7\________
M__________^A                     !'9___________________*
M                  "[___________________N
M  "A____________________#                     "*____________
M________+0                    !V____________________30
M              !D____________________;P                    !2
M____________________E                     ! ________________
M____O                      P____________________Z@X
M           B_____________________T0                    5____
M_________________X$                    +]?__________________
M_\@+                   "[/____________________]>
M        Y?_____________________)'                   VO______
M________________G0$             !PX7Q?______________________
M_]6YO,''SM7;X>;M]/O_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________C?S_______________________
M_______LQJ6(;50[(0< ,M[________________________7DEDI
M     *#______________________XDV                 &?_________
M____________9@                   #+V__________________^5
M                  /(__________________^G
M  "@___________________7                      !\____________
M________                      !>____________________)0
M              !#____________________2                      L
M____________________:@                     8________________
M____BP                     %\___________________KP
M            X?__________________U0                      S___
M_________________R0                     OO__________________
M_U0                     KO___________________XL
M        G____________________\L.                    DO______
M______________]7                    AO____________________^J
M"@                  >?______________________;0
M    9O______________________]U4                 1?__________
M______________]J(RLU/TI58&IU?H>1G/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________Z,^VG8-I3KG_________
M________________[+*#7#H= @       'O______________________\5M
M*0               $#_____________________@QL
M  ?+__________________^2                      "8____________
M______^D                      !J___________________=
M              !!____________________#@                     =
M____________________.0                      Z/______________
M____8                       SO__________________A0
M            M___________________J                       H___
M________________RP                      D/__________________
M[Q8                     ??___________________SX
M        ;/___________________VD                     6O______
M_____________YD                     2?___________________](6
M                    .?____________________]8
M    *?____________________^B                    &?__________
M___________U5@                  !/______________________NR\
M                 /C______________________ZLI
M ,_________________________)1P     '$R N/E)HA.W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________TU<G____________________________ZTK"2=UU"* P
M $K________________________%?447             !'8____________
M________Q%                    "?__________________^B#
M              !H__________________^4                       V
M___________________:                       '[/______________
M____%0                      Q/__________________2
M            HO__________________=0                      @___
M________________G0                      :?__________________
MPP                      4O__________________YP\
M        /O___________________S,                     *_______
M_____________U@                     &/___________________X$
M                    !?___________________ZP
M     /___________________]XB                     /+_________
M__________]<                     -____________________^?
M                 ,S____________________H2@
M +?_____________________H!8                  )S_____________
M_________WH"                 '?_______________________]Z"P
M            !4S_________________________HE=H=("-G*N\T.?_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________[>/__________________________]*C
M>E@Z*2,<%@X&  "?_____________________ZQ2#@                !I
M___________________D0P                     T________________
M__]Y                        X__________________-
M            LO__________________$P                      A?__
M________________3P                      7?__________________
M@P                      .O__________________L@
M        '/__________________VP,                      O______
M_____________RH                      /O__________________T\
M                     .?__________________W0
M     -3__________________YL                      ,#_________
M_________\0'                     *W___________________ S
M                 )K___________________]G
M (;___________________^C                     '+_____________
M_______C1                    %S_____________________D08
M             $'_____________________ZU\                  !W_
M_____________________\I+                  #_________________
M_______+5P  #!@D,3].8'2+I\?__________________________]?G\O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^O4S<?"OKJWL["MJ:BE____________________W7Y3/S C&1$)
M @          V_________________]V                        I___
M______________^Z                        =?__________________
M!P                      1O__________________3@
M        &O__________________C                        /W_____
M____________P0                       -O_________________\1D
M                     +[__________________T0
M     *3__________________VL                      (W_________
M_________Y$                      'G__________________[<
M                 &;__________________]XA
M %/___________________]*                     #______________
M______]W                     "O___________________^L"@
M             !;____________________G10                    #_
M____________________B@                    #_________________
M____UDT                   #]_____________________Z<N
M          #5______________________^8*@          !A@M16#@____
M____________________J&-T@8^<J[O-XOK_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M&0H
M        ,?__________________                         _______
M____________0@                       -S_________________C@
M                     ++_________________S@
M     (W__________________RD                      &O_________
M_________UH                      $[__________________X8
M                 #3__________________ZX
M ![__________________]07                      K_____________
M______H]                      #___________________]E
M              #___________________^.                      #_
M__________________^\&0                    #O________________
M___Q3@                    #8____________________BP
M          "_____________________S$,                   "A____
M_________________Y$9                  !Z____________________
M__)T"@               !%?_______________________H=!,?+#A%4V)R
MA9NTTO7__________________________]?H]/______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________^_?S\>[LZ^OL\?__________________V;*9
MAWEM9%U644M&03PX,BTH(\3_________________2R4+
M     )+_________________B                        &;_________
M________UP                       #W__________________S,
M                 !C__________________VP
M  #__________________YT                       #_____________
M_____\D,                      #V__________________$U
M              #?__________________];                      #+
M__________________^"                      "W________________
M__^I!@                    "C___________________3+P
M          "-____________________7@                    !W____
M________________DP<                   !>____________________
MS4,                   ! _____________________X<0
M       <_____________________]A>                    ________
M______________^_3@      #APL/E)JAJ7(________________________
MPGR,FJ>VQ=;H_?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[N'7S\G#OKJVL:VIIZ:FIZ[_________________OH9M6TQ
M-R\H(AP6$ L$     !3_________________UP4
M  #__________________S0                       #V____________
M_____W8                       #2_________________[
M              "R_________________^$D                      "6
M__________________]1                      !\________________
M__]Y                      !F__________________^@
M          !1___________________'(P                     \____
M_______________N2P                     G____________________
M=                      0____________________HQ8
M        ____________________V$P                     ________
M_____________X@/                    _____________________\M3
M                    ______________________^E.           "1TT
M3FN,________________________F3E#45]N?8Z@M<OE________________
M_____________^OY____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^O,N:RAF9&+AH%\>'1P:VAF9FCQ_________________V%%,B,8#@8
M              ">_________________WX                       !U
M_________________\,                       !2________________
M__LW                       R__________________]J
M           6__________________^6                        ____
M______________^_&P                      ___________________F
M0@                      ____________________:0
M        ____________________D (                     ________
M____________N2P                     ]/__________________Z%P
M                    V?___________________Y$8
M    O/___________________\I3                    G?__________
M__________^8+@             0*49FQ/_____________________N?QT,
M&B@W1E=I?I6OS.[_________________________YZ"JN<C8Z?S_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________]]?#KYN+?V]C4TM'0TM?@________________
M_\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ_________________](E$0,
M            __________________]"                        ____
M______________]]                        __________________^P
M"P                      ]O_________________=.0
M        W/__________________8@                      Q?______
M____________B0                      K___________________KR(
M                    F?__________________UD@
M    @O___________________W(                     :?__________
M_________Z$H                    3O___________________]-<
M                ,_____________________^6+@              %3)2
M=______________________@<A,   $/'R]"6'"+J,CL________________
M________RF]N?HZ>L,/8[_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________YX-+(P+JUL*RHI:*?G9N;G*"G__________________^"
M9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M        K?_________________,'@                      B_______
M___________[4@                      ;?__________________@
M                    4?__________________J1L
M    .O__________________T$(                     (___________
M________]6@                     #/___________________X\4
M                 /___________________[@^
M /___________________^5M P                   /______________
M______^?-P              $"]0=/_____________________=<A0
M!A<J05IUE+;:________________________O%A$5&1UAIJOR./_________
M_____________________]+-X?'_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________S[^OO]____________
M___________NN:B=EH^*AH)_>WAV=')S=7A_D/_________________K3SHP
M*"$;%1 +!P(         (___________________:0
M     /__________________FPH                      /__________
M________R#D                      /__________________\&,
M                 /___________________XH.
M /___________________[ T                     /______________
M_____]5;                     /____________________^%&@
M             ^S___________________^Q20              &#E=@?__
M___________________E>QX       PA.%)OC[/9____________________
M____NU@I.4E:;("7L,WM_____________________________[.>M,77Z___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________KOY^'<V=;4TM#0T-'3V>#K]___________
M________N(I^=W%L:&1A7EM96%=765YE<?__________________OS$?%A *
M!0               /__________________[58
M .C__________________X($                     ,S_____________
M_____ZLO                     +/__________________])7
M             )O___________________=\$                    (7_
M__________________^B-P                 %*Y3_________________
M___+80(            ,+%!VGM'____________________UC3        TC
M.U=VF;[E________________________PV,8*CM,7W2-I\;G____________
M_________________ZA_EJB[T.?_________________________________
M___]________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________]W.Q;^\N;:TL[&RLK6YP,G5X_______________
M_____Y=L9%Y955%/3$I(1T9(2U!99J'__________________Z<F#@<"
M             %;__________________\Y0                     #K_
M__________________1Y"P                   "'_________________
M__^?,@                    [____________________$6
M      @Q6H3____________________I?Q\           8G2W&:PNG_____
M________________ITD      A<O2FB*KM7\________________________
MTW4>)CA*7G6/J\OO_____________________________ZYRA9BLPMOV____
M_______________________________?[___________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_________________
M__^*6E-/2TA&1$-"04)#1TY9:7W___________________^>+@8
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M__________________________________________________\
M
M
M                                         /__________________
M____________________________________________________________
M____________________________________________________________
M________________________________     /_A/UQH='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC
M,# U(#<Y+C$V-#4Y,"P@,C R,"\Q,B\P.2TQ,3HU-SHT-" @(" @(" @(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @
M(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIP:&]T
M;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,BTP-RTQ,E0Q-#HU-3HR.2LP
M-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T
M93XR,#(R+3 W+3$R5#$U.C X.C W*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*
M(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,BTP-RTQ,E0Q-3HP.#HP
M-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY-:6-R;W-O9G0Z(%!R:6YT(%1O(%!$1CPO<&1F.E!R;V1U8V5R/@H@
M(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^9&5L=&$\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O
M<F0@+2!0<F]J96-T($-H<F]N;W,@4R T(%)E9VES=')A=&EO;B!3=&%T96UE
M;G0@-R Q,2 R,BYD;V-X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z,F-A-C0Y-C4M83!C9"UD-31D+3@Y9#4M.6$R.6(U,#)E
M-F4U/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z-3%B86-E,#8M,60Y."UD931F
M+3AA,V,M9#4P-C!A9#@W8S-B/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z8F,R-CDQ864M
M9# R8BTY8C1A+6)C.3(M-#)D-#1E.6$U-#9D/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#IB8S(V.3%A92UD,#)B+3EB-&$M8F,Y
M,BTT,F0T-&4Y834T-F0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,#<M,3)4,34Z,#<Z,C4K,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXQ("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z9F$Y8F1A8C,M8F5A92UC9C1C+6)C.#0M.3AD-S(X.3<U
M9F%E/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(R+3 W+3$R5#$U.C X.C W*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @,C(N,2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,F-A-C0Y-C4M83!C
M9"UD-31D+3@Y9#4M.6$R.6(U,#)E-F4U/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 W+3$R5#$U.C X
M.C W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N,2 H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#IF83EB9&%B,RUB96%E+6-F-&,M8F,X-"TY.&0W
M,C@Y-S5F864\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z8F,R-CDQ864M9# R8BTY8C1A+6)C.3(M
M-#)D-#1E.6$U-#9D/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z8F,R-CDQ864M9# R
M8BTY8C1A+6)C.3(M-#)D-#1E.6$U-#9D/"]S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T
M960@*%-73U I('8R/"]P:&]T;W-H;W Z24-#4')O9FEL93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1"  @ )L# 1$  A$! Q$!_\0 '0   @,! 0 #
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M2)2X70Y!JD^<<]O$QZ^4Q$Q^OYZ4CT%T,HO'TE[.UO\ 5SN+N[A-+4KA.JY
M5:%:76LZ@AH(Q[L*M6X\.FUZWF-_72@>L/Q[ "CBA=F,7\;BW*LUPRX(U=$>
M43$1/U\^O/S\YTRL2[]-:X^ _8-N>=YU/JVQU!)89]%]3:%V9;C[PKI4;>DP
MA(;=?)@:W<@MC5]E,\P.S//,L(2MJ&L8,Y<!HL/#5L\=T>7'IS'RY_+0<:ZX
M4[E8_+ZG_233GU:[C]WHHY^-Z3]U=?=MVJXZR;159,TL-BJ4 +VR&#$2DHU9
MV*?RSKK I,9># -0,!"LS@C5>8YF)&..>/JGU]>=-]TE]:3[%\0F'TCV/!7P
MMHU355_5,U>$6*]#8MYU6R-];4\84+&3/T<*\VZ.M-"%XOF7BX9T7"/'_CA8
M^^&J2/Q=L?KRY_AI8WPAZ0[%TQU]%ROW7MK8^Q/.T^5=>=9<^M-MWZXW%BM+
MEA.<Y5&M^W!D=ZGG=59C:B;$E7^0CPG:^!QABQ]D\QS-7%$<<Q'I/$\1HW=X
M[CVZK_XD[D'3"S:FR%^GK#R-9[ _U0#>+.)K5V_@1]!2PO'%%':1U=FWAE4*
M9(F1JJ8R.18OSPF\R"&]C-4B([)GCSY]?PTZ/M)VYK7'765CKK=F@L"#FC>[
MM$]2GE*G*5RJU;:CEC=2T!E@-6LUIL$!@!X<\)094,1 \L<T>&>)JV/6/OC^
M>L'''.Z>7]F<]TFY==_?OZ):!WZS*M,5SU77+]TO:D]>'7VMT!6)Q':NO68(
MOUU5ADSN?&%T9_C$L)AI/!Y8LQH3628GGR$>/W?TUOFY=K"ZF\Y:0K:?:5SW
M<G6:PIN"?;^Q#CV=YV4I)1AFK+I:CVF.#(IU8 21V)LK".,SV6?WPF/";S/#
MPUBUDUTQ\MMR]E];;HM5B5N=<\[P;[VL2^V.Q%\#,M(8NQ'V!*/6X9T?N;ID
M;EA*)G8?1IJVB]C*F+(.8C#HF#&TMHWLYFK[F@=7&1DKDLLG':3A&TWE=42C
M]H4S$C+>)4O@I*2,8676C=OM';4Z4=,=I8VA9J9[?9[*VTNE@4,EJ<:UF"I2
MNYGVI*(J5U00M&CX@9"[W+!0)0QEU#HNW.W=)_,_02S1'-R>M^;/ 3Q5RATE
M5!*S2:Z&FB]DGN-]*QSDQ);Y_JY,!ES=A(_M#HR-JTC)7>L"9-ZSV>H;5QH8
M_& KWL5PNK7 9-=8?F^R7/F7GW0)E+7,*#.)'O+42ND'2#=WM";VL;SW];OS
MMU]HK^:S%E@UKF>8!0(8K"KX&5U8[80RQ40-+&U%36K$NQ"%CB_M=KLMZLKR
MXW%XRLEILK(IP^?."Y3F;1D;+E*2665-EE))))GE_IY[[YC'AYC%'CA'AAAB
MQ;G-L-8][#:YIR;&',D9F4\R13/K,_A$>4<1&NL^,QF/PV/IXK%4Z^/QN/KJ
MJTJ558IKUJZ1@5J4L(@1$8C[RF9(IDIF9(KA?_S1Y0_]Q&GO_OJ+\5-O?Y=P
M_P#M*G_U"]:'UE_S2=3?]P]U_P#9+NMNGTNU+L+>_ G6NG-45V2V[)V/I*Y5
M2EUF$]4KE=OV@/Z0*^-B\/6)P\B)/]OD[%@&+A_WEGP\_P!?R3&N$4>4Q]\:
MSZ6[X77QU\E>4\=1ZT T%]-^5A2=K)CJNWJZFVW/8!%F*;6.GV/8*9[(B,>L
MA@J^UI=D.L!8-?<H5"*%BFKK%Q^B:N[O.>9Y&>8_=\OZ_GJW_IMS_P#1SZ+_
M "PY9J-BY595_K^F=,:_LVZ]:#7C4HZS-;3M?[/KK?9=9<_\Q2JYE7+$=8D9
M@]?_ 'Z6Q*361JSU<4$LQ:DFB)B"GZOE_"?O^S1/]/<<]&;"^Y?SUZSJVLYW
M?.VF-"76F;1V%_(*@.)6K W1] !!*B*ZP?C6II_DS7.MQ>S*$+$/'QIC[-/A
M@.;Z.:I$QVS'SF?RTM>?XF=#\Y_:KGO=W.E&+L/!RS<\V]?8Q;;5 %>@W-U"
M("V+51ZDX>*G4Z_]S2IBTDE52-L/*K)74Y<\QJ$G/\-7=W(SSZ^GS^S^OY:*
M#??+?T!^?'T@WGW_ ,&: KO8&F>N*^O@WSH'^7+Z-=:Q:P/%,Y;M$>S/SE/S
M;/ #WJYNJ2VGP/"UVE$UI\,<":Q9&J1,3$1,\3'I.J ^?_ G:B_ZP:7[IO?
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MG*U6C;EL.IE1"&VEW%^":DD!&+O(C TE ,B& 91)+,?\0S&DS*=/,_1?MQ=
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-T:GX:-3\-&I^&C7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g722206g13n13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g13n13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1R84&AO=&]S:&]P(#,N,  X0DE-! 0
M    ''R^<I(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]       $@ U     0 M    !@
M 3A"24T#]P      '   _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #-0    8             "HP   A(          $
M             0             (2   "HP                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P  "HP     4F=H=&QO;F<   A(
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   J,     %)G:'1L;VYG   (2     -U<FQ415A4     0
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MR^RO_GYOV-W^E]/8[=_-_P"FGT_^BNH24I))))2DDDDE*22224I))))3'U&
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M:DIMI)))
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         /_B Z9)0T-?4%)/1DE,10 ! ;[,_OX>   #D$%$0D4"$   <')T
M<D=205E865H@!\\ !@ #        86-S<$%04$P     ;F]N90
M          $  /;6  $     TRU!1$)%
M                                   %8W!R=    ,     R9&5S8P
M /0   !G=W1P=    5P    48FMP=    7     4:U120P   80   (,=&5X
M=     !#;W!Y<FEG:'0@,3DY.2!!9&]B92!3>7-T96US($EN8V]R<&]R871E
M9    &1E<V,         #41O="!'86EN(#(P)0
M
M                        6%E:(        /;6  $     TRU865H@
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M-Q[-SGS:\).W;3U5J^-3,Q?]7_T!E#UYF.DKIHSZ.XR@]XL02TLN0$OMHII
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M_"T[6@4!<@RL2VAH\[->#ZSG0E[^GWZV41E442MZ^4WA7(H$MD7P]: /0"G
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MNKO+3E_GI_[DWZ=_ZCWLG_L/QQ_Z;_Z'[_Z?G]_W)OT[_P!1_P!D?]A^-_\
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MJT1W;,-N*],[P[7E"<J/4-C+==_^X8B2G,NF;M_+IV!IV.7>G+_/%_JMW_\
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MG'EJF4<7WU^YVXL,7>)[QP[ZF:L]/YNN_P#/P_OF4_S_ /RRM2__ 'KX0_\
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MX$Z+MA["\6)G(VLG<--PE?O>A45O)#E\F0@D96O3WJYYP^PE?^DR'EY\7I]
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MOSUK 'W)S9IISV\T*&<?O+J7VZUEY$:+,2\M&6'7YOW&34GA^]?Y.OS99_\
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M'[Q[!=:^^^\!.&?_  ^3/U%Y'\V>U:ND4OZGIY0NJM-Q> P:EMMC2O\ T&,
MS"1I@'P!D5+&GULY&C3)T' POE1A'L<0(C<Y.4 A,C[X4H> /&B D>>JW2//
M2 JHWE-ZRL[SZM@HA ; K>P]D0U"DN@[]L0U[RS)/TL1S,H58]QF66EDY<\E
MLE3MG[CJV;-\[TI<K?5+[:%> W-OH\LU'*I-ENYW<A,*NZM,2FR6.TQID>)O
MR.*L^8$F:R,>;I[B2-GZ6O7M_#9UKVH?,GP2AK:,G*OE^M1BI6U66_226N9Q
M2Q$*&JF_#4QBN-'['%2LV*3#6":GS)Y[$OJGR=FV3MPCR(^GO]/JJD3XN?+J
MLE5Z2D3QQ6:ZN6=6LNG[%A1)SKNDO%;3&L$[9JC26FM4HP<A1V197I@V00G[
MR B*%'!Q4R&%BZA^-_VIX \;7?+L>=;7G]'?)5MTPK>>[%VG\2\C^IJ=2&7)
MR3TN3AK*:M<2,L-G>+&#+#,(1\:9TQB$4MJDQ8VS5H'Z2^,-(CO(-XT3\\:C
M\U>?G:Y\:DC/8VV$ A9E/76NU(PDS E1N(8:V-![*5MP8#LR!:B]K_NF$8LX
M!N(PYRH^.W75_P ^?B(EU53WLU#]NU3Y,;@OM!XJ8DQ><?.JRZC/-M:(U#I
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M@8B4BTI !U\IU^PB-KU5[0&(I<_>TU^O/0$K,)^AP:PS[R6AWTD4<Q:)OS"
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M!H$G-\.+6BCUL7BAS223[[^@]Z7>C@%B\$!<7F$AY^!T^T(E.V6OU1?6H/\
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MM_[$!M]=JP19I>Q!Q*1>F&3X$HRS%E'O%)53M]*];7%5$L[?,AD"@L66L%T
MV+,=7LD7E.G];YECJ>%@UK");"U]]-_H!LL&JZJ?J^HLR?N;TBN>;%5I4:OM
M)>7Q369JOQ?ZP,SRPPQ:+%*VB%OS!;7K'7JG8E(V!1XH)=G;L1V@\36],'^F
MWT1]NK3Q[5\S4A@MH.:M6M@BDW>!KFUY=]*B(,\Q*5S1_8@JR0KD(3<$!EM
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M(:_  G99?0.WQ FL!#*Y] ]L>)-*Z^HGB.PM&Z?E>J&B!2=PJ5)UF<LAN4U
M?=C6\471?H):E5/U//=S&,202_0U>0/SRH@PCH99>X3(&Z\9 :25YCGU'\#0
MH+WK6/55$6,Z(:E:#9(K!(MZM93\<QJ%$/V*Z!0PXRUA!FLJ.6E@[)W[39<,
M%'9"#&9DN,B@CDD=,-OT4\+PXUC;BWK&@0TFG(P_?;PPE:J5K)5CO)M?2'&'
M.D;09D?Q!/\ KCO6H90L\]FW)@D0AVKK9M(C_P!UF37O?Q,NR76&9]74!"EU
MRKICL\1LK33]N];4[$V+6I$/$-4<KMSQ'M^QT3,5[;JQV]E?ZR4>XF.WIG!]
MSYX3]3>;0HY",%;VJB 'M1<5G"M"TEZ7=8M^5'=K1D5/8U CW/\ V;"$9G&S
MJZ6@A(7NDQ")EW5X,;;LW&X&._6ZM_JAX1LQIO54&^C:K RZ U9G6@@TV$B"
M13!6>FK*GMF5=*?+Q99.12I(@6XED/N<)ND9H[8H9J)JC[84:(0G6D,]]^(C
M,M2@B_67GV;*?*Z,6XGZM-K)O?\ /UHOQ&P@==8&>1;'7F #04%]F$YN>>O&
M#&1G/?)ZUZU4]D/RAGV_X]7:36O2)[TQ2@>A'(O)7U6W25A+D-"8&*%K8LY:
MX*8M\_"!+8HN2DSZ) '5MR+:9@ M V0\9L'?'PCQ?Z&^$P,MQ@F/7OG4?*KY
M?3VQVUR+:3,<5I:L':K:$DX5VXE\M,<8S[GE(UAY?ZF6J9DY*G6O+O\ J(/^
M\ZH7Z->!V,$#9P/LCS:776:P0E4KQN!<"1)%F;&8PL%C!IHZ;K,9:)1PF#)P
M"4:)JSR[RCRM7>66.7?>/5B+GK_RNW*MO/*QZ'IPZFT!)+Q+L:1E@K4H!5FT
M#'F2RV3P5UD>X:_&B1QY#;E,G[M,/;U G=1]^W*')ZU5;-^E?S\&C(AB?[*\
MY0QLY TVG#DR+64M74BO)#KMK;0VZ]61+K?V(VV)HWH>O?WKZRR<M&Y8ZU_S
M6K9"QM%]]?\ E6K=E1:[']%4PD_W^UPMU(;66QE83&MJ.2DK$,?*KV5+)ZXS
M9$FR'51PBRPNZ7&W],@;9KVY:I\?/.@^_J?X-Q8G"!M],TQI3$0+#EM%M;+8
MK+JN135+8"B]E6LJ;BWY']+[%WB\Y.X;M7M8W;C)CC(9:4?PEAXO=5/J/X#<
M&AL4QWJ6G84]6L^NJ?CS33XKB@KJ\6Q7:[9Z!#KPK)+=1G(>RK++$P&EQ/>P
M?++0R@V-OW;H666?4D?3;RM*(^RH".V_W8U>%J(DWO>9.KB:@VBX44;(NZ*=
MK45+C-&K'JTU[?0[3@:73V(*!#[+K779G/\ >3_XVPU?Z#>(7*'6TM>]64(1
M_N[/;!%<QHUIIDF4VFT+"/D[!0NN*8WXSR2MG,AZ"^B+LW=:9$X?JU9[LB,#
M]S7C#]3?!T-%971'],TK<$L#5;=<HY*K6W:LFM;@A)! P(83*O\ U$YK:[(A
M0RBZ?@YDB; +$:]@0OMW$=449-WZ-DJL]/>=+P;[%K^G;OJZSGBHY_\ %6@I
M([J!9&% )?S1]<[@MHD7-DS0<K ^JL@79IGZ=.>HF$)0MG6,B+MUXZH^FO8G
MS_;ENS/.5G.M;7[,_K^F:5M_STJLRNRO:\2N?T+6GG];(MBK_48@N &IMI6&
MESV,QHD1SBCAC!+#-.PWM7XL_,4QZS^9E05G5]=4EZ0\Q+%9%+'-TQ5PA:MI
M5G##MJ[S0PNQJHTEN/3Y9]S+L-A@C1F=.G3BA\Q8 (Q-(3YCD+E$[(@_0CPN
M2'!RT#UUYWE"V"T=%* B&FV4S*&8M:5#A$8B*-D?RWZ4T[-'DQ9"#HCY;-<V
M"4&3(NW='(PMF^(>AO8WB]2F7)07J^T*\J55Q6557:)EJV:FH@)W&W$M.,G-
M> 2HKI#<Q\^*O+!N24DSAZQNU0N^RJZ0GQQY.<,[@?V7\\*)2&*O@OI'S16:
M%Y:Q3*?95:+9"6#"4UAHS()*4C$('\GKU@<(FY/-K<&!ECUC#D*3! W]Z=ZZ
M8PA<^GZ/>*R/I=&\A+?H&NW/T$]EWX%$K]-9@C$47B];+4AL9AC?A!(YYKY+
M 1&W;1XN1KV$R'6O=(T0^X$:7-T514OU[\'W-=,>BU2Z5V"UE=[()5)[0<5E
M\,[MJI;MD4V825']XQ?S)=GZ.UF1/P8>(?3'(*+&F%8LK.4QQ!V.[5+7Y2/H
M]/VV#05L5]<B-I-$%W<VULUAG!?U'1>$;;.%;"@27,B83=$:; F]:<MG66X<
M0'D='ZD&?#D;K<XXXXXXXYK=ZSH CZ=H]@IT79[/44HX?0S?;@J8RMLS.,E/
M2ZYS%<M&@&%PG.57.*!VJC8/&,8&;/7BY&)K)Z<-VS7M\%K5^ C&E4-H0/.]
M[F'R8$#*8A?KVQPR<GKLUPE^=$'Q@V6B=?Q(<PRQ((>C4A?;(R )';81!R!F
MM,63JU-([6L[33?B$O\ 1R(S /4]D CB W;I]!2^J^KXAKJA ,NWH9V:T8OH
MW1]7=G$BLKTU88X2[,VV,1!1!J?(S&EB,-HF-^3&?$&K1M&94?A=;EN@91K6
MC]L>Q27>B7?=J?.I;^=LS;W'ZE=Z>\PR:N86%"_XW_CC\W>#V]X"\>M^68F?
M%*H2DZ1(*VZ[R(A!H)L12-& @8,F7J,>V"7M$@.TDM>S9(B=[#1+97VJ?ACL
MWZ0.G06ZPR(:^M'*VK/X,5I7BEFN[_0;PQ%-Z:42)K)(2%J%.FC-CQXM9P,V
M7UB0ES)980%\3(RY*ESB<O7*_JDYL#QUI=#JB@%V&9OEAB6\U4G0@#T:UJS%
MYYLN['.KK3PKE)/2X:M>BQ=E=-"0QI1S*4N,&Z#6]ZLX84TXY#9NIC&!&7:/
MV0<2:R2P%@?,#<D?/7T-XX\UN&_(M;-EK#\J'7C(?KW*N UUJ"5W$ES]HXQ&
M/R5Y4K3#.#,,BI&)PGAIC$HFN+OSZPKK#XAJTLMO(GO3;X6BOATA8=^B^JMJ
M7.%:UOXVOZ9NM8<A,8^#9(*$L@'[U,\[I]:806A8;5\$K+C#E)A;&_-MIEG^
M&[XBU$J+U'^IF@T]+[#5XO3K?@,6:FK:,']O^4O39'^W0UJ-/<Y1'5Q H,X9
M6*]G%&9;9V9BGB>LU9?G1AXV;$O@;7Q90,H$WTY9>U0=03RP6.,Z1$'3(:_0
MSQ5/H^I)-RCRL>/I(*:["">G7DCJI\/O[7-A(,JX=&=$#4R0V6:-OPUJAIOZ
M3?.-W/(V:<L*0\-:GBM Y@$K'@3Z\94L0-T;IN$05+5W2O8QS,]+&FY4V(6D
M1AD9=/"P+4,PQWX.5(;K_8BXWM8([O0+1M0@U 7 D.4//5K4?ABLDPONP@SH
M<B1$AD?"2(V$Q<2>-WS_ .KV4)$+"L(PTGKYYOPDJ8A6F=;;[R=],><(.P"Y
M> G*D"5-GM/CCU!Y&8"4:)HSZB0NI<?U(U6/&BYXS,M)H$,$RY1'7-(E-FUU
MT?.;3>;]25AMUV&=1BL*[HM'<8D!% X#;*G43Z>HGU,$8L8^XEMS3^S;A2V\
M(4$0MI>+K"MVW]MOQD ]'<_13+_#S4OE--Y]W]8&X2PITD41$S5)?(8:W7>$
MEHV#D,RFD-T$/#ZK27DJ20 T9&GS)F&938TXC)I):FW&P?%A1WWS;7HM+]#N
MJ?8K7<FN_*DWS$54<AU06.4L<79[O^Z@GY66IY4&D^/D1M*KC_2&L1!(?NLR
M!5A#KIX1LYXR^>(SP]UB(JBZ7$DED]U=9.JTT+*E-E.>JM?.ZI18;"2=C0XN
M\!LD%U.'9<O)9ABHV)/?M5X\32MX:X_6"I;YU*GFH'Z1G "9.\)%UTN;K6?6
M[9V)3PK#$VW1ZYO7H!N8-&@MB-TLI3U@>1II&6/F1QXA>&%LHN_?*FQL=-//
M?Q(VK-1^9!UL7HRQ;!7TFLM7K@4OP5UO@WFWUUZ@W^SUKJ%8AT&)9UF0MW?.
MWB2;8&%Q93K7D.(!S$KV^,+("[_IKY$K%8>4/17E5@O]Z?Q5\5)6%."7K:IJ
MZJQ56OT=58ZIZ=,J\4-GLB$&E,&KRNTYFB>SO83=1.\MCK'P9D<2-U^"_P"'
MQH%2JPU5:C;K=$#3S=HE1/3,F*;D/#"[#@T-I&IV HKGKZ_I9/(T=_+"/XF:
M#9H)%\932NS*3;$!- [9FA_D\KTDW4&[R;]LVQV*BGRMGW05=X^@L7;)5<^8
M_27F>"$*'B10F=Q"9 _2!4P-ZG$C)47H3ET')*%_U9Y?="BGQQ7BUJG'R3Z.
M>=:JXW.PV.[U_H1$SK \E3O7PWW4M5K";-_>\VN;5ST1@P3)3N(PUE6"OF/M
M0DCH10&";85=^Y_D)8/H2U+;]$UWZ,9M]CO$^LAZ*B/$&'-3JL78-J>2&=YQ
M5YQ"06&ZH(R'YFQ>%E9Q3XT8PYM+7%;IYW0:$RUNL-'PCE.%C66MVYZ 9#'G
MEU6%@^V1UM=30#O;MWGCGN9HL=IWRM C?G4BX :O8AHTIK2U+-Q"4/2. $-V
MB&&(;F/8)3^+ZQ L$1;S[Z+=+#M#.PE"QW@]G7J2J F\TB6[X8L59C0U !W@
M*5A\=;\$UBCSM,+9-V$-[(V-F>W7,VP1D:R:B^5^JE*5]#4DA^E[( ";ZH9)
MI_2V E\.!=Z[8TD*WKD:R%8^-(ZY&$N:%8AL;L'A^RV#Y(;?/&'XTDGJR%U*
M]_*JS WG+R!YOI"]- K*EO9UV^B'&WV!-#$"H9<O*N?8>MEC+Z$=EL IGD17
MCT9!7AT V=USL53N28E'Y!\7U*GX:DO@W2-"V&%:T^YK#(K"<U4>THBBT! !
MN: V5+8E$V6;'3&G;GKWSH+TP>?4[+9I%"EW6(QED-L[4S;QZML7L/K^$P(7
M'?-BIZULY4)MC]8S"$CCZ_1I:"GJ5QUK;=2VT&#5,2V2J\".KXFV].Q*.R$#
M05_4:3$<KIKCK'2WPW';[S_\OZM\_6"8<@;RU&Q)A#]2USN62$2%%SQ7?4-L
MUU:!;\S#&W9$]Y!0UUU 614_9A^N0BS]Y&7WIE:-6KN!>3ODRL>9+5JBXB=Z
MM]LN%/J>RME;8;2$I3@]5D!IA&HNM%Z1!5=$:/D>4$U,W2C;AUK_ 'SD;8B.
MS9#!A88@) QK;\H"I=P;VU2]9/*;A']&,7JBBE[;4U5- >H+?L)N;W"SB!Z4
M5&:V2UP#),L!V'@5PT? P% <<TYQOY,L%"E(-2KGP7HY0K_;6Z]<UAZP.L&=
M #)94$LDS4**;I;P[2V<K=-PP@Z)$[2+\0KAOO./"'Q<IS^PPH\.(.%B]'=#
MK_P5=K%I2>L7;ZU>DQR8@QZMR2[60,!FBP*1DNWKMH@U^9S@]J\^R)>PUZM+
MOL$TUY]C [$GHT HJM.D(9FLL_\ 3'Q<.%*:L,/0]BD#=OOVRP Z^R'IHRO(
M]9%+C]CUKZM(7! ,#Q+01(EJB+U_'' UC3$PW-X??*'2"@_9(RR[W:]*_+VN
M;]QI,2NV(QTZF593'7F=B4%9<63<)X\Z].]+V#A7PZ6?C[M]?&HARB4Z&-=U
MS#:1A 9IZ%U VD<P!A>ULQ^&58DEEF36^^7U@ ,0U+5>OV*JM@#(Y%1F;W$:
M% 8Y:/)F=["F\9[?9@\UARB8=[=R,$*8"]?96=!C[!^%_ERH^)K"E6G$M@]9
MKL7K9BKUB(%E00O:"G9]U7&CL[K[C$"Y?&7H&)ZT!D:RIDW(G=P,I^9'1'Z@
M"1M*!OBPL",2>6GTO9$,AUB@PD]A!*:R$94D36EH>W;-4>Q977)E8;V.!,]L
M'X>3#LAZ<,Y%?KQ3$5KR)3H>B,U)\,$>M-1+>3]%O+@;,-"8W$C$Q2@Z=^\J
MJ^D/-'I:7WW(+,K(:DXG6OS>/#RI98X5+?QC5,FSB14R,USI]W^B/DXL>B+>
MO.S#=WM $1=H]VSWID)-7YV"LSV%XH:O#[,P#F"3-U3)\?;7Y9:98 :7$PUP
MF-:F8=SM\!BW:AWYI?Y'U[2^_P!G="[<;S<#UP@V]7D6.5 !\YU6AKQ<;.L9
M^R&F-LJ3,8NLWJTC!$$.[Z7PHT4.'19HTLP2#346U0@?X>FLUB-<6BO_ %+<
M*7E=C@>97+& ('=Q)X9E8H98DA3=4$T)FS4B*.@#QX9>_D8PN/+#A9!>&<!Z
M"JP:LX9\05I:KD.EIOJ"S%(Z%@-$+0Y UR&)G3]+;H\-PC@XM@#8PY?8 -"?
M$ %>/C1;&(GE5RR&H7@9@]P1\G/1R1\!+.WV2JT!JLV=&\3 U/82,OV#*I_W
M).63'\5%?((-G'I&FLM!1?9!D'0AS)(;&Q"-:D0JJ9,?LHS&V8A0&]*W\.*Q
M"Z=6^?=[:5.2LEXB?)ZTM?A1RC&+A_03 L7CQ)!$G-BX'"7T$<B>SHD7.F\]
MU?+<H\Q,AXXR'Y?]I7X:U72MGQ+$&7@\GXX:Q:LLE; &E@!OS$EDFR*_MAS@
M9&MLN1)R$/SI7(25I@B8H/0NPMFW1,UM4R&'(C;&J7Y$*]3>8+_\IP;W;3"#
M?-.T-5\LC,3@$8ZJE:3J!4I?<XCM\<AEI(=."NAI\K>O2]6N,#*P2>^&0EZ2
MW6B#3VSX)TN&E6;$K>\+#KM+N&V[V:GI)@+"B='84SZ&R\M3W:A4F6;TR=Z(
M*!%_)Z'JKMR":^BJ8I$R:G%&2M8]=)B,J=^%U4&UHDN97@\Q,"2+'1=D[2J+
M>4C7%TUE]!JTRGX]92.NLI&^+] V\OMU=Y?IY3:]7M7>7>LN3SU?VQOAM6SW
MJRFPKZ>UIH@-]N/RR=A+D#](8TVOZ76O1LC<6B##@,@;%AMP&2C:H.@V&ERQ
M)7LQJ*#BH^)WU7VG_#WTP'%OJ^MWBU:UQG1D!66@317:@PP5,LI8^:,#AC1V
M-E+&\8.9^O+:/(B#ZNVU,QJ) J5G G7'8OUOBB;$^F/CM7?J*@/)M(OE^W/D
M9\G5JP5Z#M^3-AF;&?MY6MPRX&;70I.SQSF,"I:R/5%]")'ZVW9L?*P7>I>_
M;CGOF=5^=^%U)S%G)26+>>4H,).CF1%U"EQ7G;4\JI^?O(-&5W^.)77*A'QR
MGO\ &Z&YS!I2%W&9=QX^NS^HX_+3)[@K5\"*[>V FPM7I^U\)[]7WH18NP@E
MK"O7Y>TF7TD7]&M+V3G[UK?&#Y($1T](G6U9K!R 6!&52R2EY*S,"PDO73IM
MTK?+Y0!T+2]*E;5.FYE5^D'STX8<<%89!V.SR_IMRII*!(#R29:1 %PHEP;I
M<6>3/L[/-E+<*2>/F"!$@1SU<K7X4*R$_P!:NA?U9;#]%J=?\]*Z8#:5X5*Q
M%@//M@^/K($ H<K:;D1!0 H=\B"<- <&(%1A&E_9IN[LT=U_S$[!DO\ #\T_
M- T^#TW_ &#&PJI.K6M9.6:BM2(+?7J;7"K7+2(*A^Y>H=T6=HB6OE<"D[49
M%@9NF;IVKAZ/,_+IV6J3Y2Z:;IWVA4:;Z@MD!&];R)4@2448$)*'TE+WS6F?
MO/H*>NE8JT":V7-GZ@OY"N8E7 6(:  9@59-/QYS 0I )\*Z_ U6]H4#T([:
MF1GFU&<7G?0IQ(.:HPU'ZE].^I!TC,8/:(A,R'-'/436GD1>#2'(: 8(*2@G
MM![O9/PF%Z_* M:,CQ732K:LI'\X>=_'=B^7++*05U,DO=@+$]Z\:&E]4%A\
MP$==3-+6'\],.TJUJ$<5M29N(J&N ]D"=UH@S)?^0-;KQRAS<>VFO;G105.#
MC8F2T"PC,7:A;URW!KG$>L9'>4641+W*3@2LH_ZG6&D/#EX=]R)._K#6>-_A
M]JXC"JQ7^O2]@[P-;#J@!8#9:(KR-9U?1/-?F[S18 \CKR)=0I&RRUSRE4;%
M"[*P#0M)-:6;7B&9HQJ+T)V8JKY(+M9(?KJM]U_.;4K^FO+$WQXL:IZ4I#2%
M.T[@:](FEW1&GBLM&;^R@]OI5FTR#[%A#D&M8(3LEZ].W=+SRK)O^&=2-=\R
M+U[NIX'S#5C;WMK5.EH'- EHP\C6K.DA1T;?,Q@BY*JZUO'.=GI@PW*FPS,J
M,-BKQ\6!:QD4<O@54+?'71O=\OHX,#\D('F/:/Q4UV?WO-5SYP/>6PEK#,IL
MS.&OD)5:,9#LJ '#_P!UO,8:OVC7! SF,"?V[J?YZG//=S@;<I^Y)6O,J:<!
M-IA&%7!?MS]9/GI7T]ZJ8PPS=A!)R=9KM[] CUF!,T;PDC2#4M!?86SW2IX,
MCJ9'^-IRU+>NBRKYN<@. $_7+Q>-+U\E!%_=%!K;+Z9\G^BR\QC:?V@Q@(E7
MC/R6D*68.7G(CH\<JS&(!$W)E@XB_#US_#\**K7U9UH*]<VWTK5TZ*;%F,WJ
MXKL>V!ZPQ\^:*BB,X^,PQ8YMK1Q_GH8(P:3W\R)P$O[]!3DQ$PV*.2E^Q_\
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MI6=/%)[NM=T.R*2]ZY@5<B61/*6.;B;F^^6^FJ<+5[#[C+LXP-?NUY>$,?\
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MY!YM]ON(%XSK%C JIG9:LI:K0^O-=MNI1B@C5(H$DMZW.TR%=>(DV<ASUQ\
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M/&NKLIACJPW38I"=BKL\/4;FQQ1B-"$EI1#'*9MACM @QG,EZ>A!/]IPU/\
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MK/A!$VR=>TV.D6VTJU%@V#"6GLP8O&6B6B^0J\\]X$>ATFN+(SALD$@L.4>
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MRD^[?'HH<;G,7I&EUG<J8K6MQ%F;+2\2"F2;1TLF$"F>H!R=$_E9>L<3C:M
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M_DU[.L)GY]],5)Z?$O[)3#'&<5.O[&E5G);A4L616V,W"3$IUESE8F*(D-9
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MQZIA-55.<N,/W;"4;6@MTXS4@:)@S1-+#&A CC%'U LSF*TQK6/O#YQQ+?\
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M,6<>/E/6E@JEG)A^S''6&M,01"&\Q0P3 )0816X_7=PS,Q<W]3?UIE]D/7+
M(U[MVC=KZT)P:9NT;]A&?HPQ:E\HTX&'LJ,9M@L0-VUA5F;@2 J$8) PF598
M5D.T"0$C'&-R8NNBL%^CKTS:UM[>6UX+\>;_ "^^/(T"1L:B_)XOO.[&MH]0
MLC.SZP?0$<1FHT_;"A0)UDU78IJ%I!E[-."Q0C3U7$E34 :?H4A@ (9AE#^A
MT=(!YI<+*2OF<'57"JCI"Y#9]<H@[;9JI%GM*!C)0KN_C3(Y6_';&#21D;6W
M(F\FX11-WZ1J_BG  ^(#?H8R!(@R;<BP_-!%/L?ET[N?2>[1YXJJDZ?-#2R_
M@7BV(KT&T W=&E80>ST-?7#<EE%3.C\TNOO.C8%,;M:Y#66D4!<1=0Q/C\IK
M"TOCZ_OAO"MBRI'$F"ZM:< >9I(&QB/2B+/V,T"00"XGBXBJ?2$I%426V;'[
M#=UJA3RFAB$:SRN9DJ'\FT5&LZ)8>JU3I&.!?+)>541(6=.TA"W6^-NS^O!A
MH^483'4R'DQ75.)K>A5$) X<)6@PYB%MQ_9*<,L;,^3L,E7J-3Q#T.R[JHJX
MX]LB"LZJW3]1:,;M=&M1:L:8T-F<K>59-4P_;)YA4X$7 ! 7!N/2X6CMF> T
MZ)[43Q#<29['K1R130_=0>BZWOTI:! U-"9%R#PV2/:)#0L@@_07,\+[$D/4
M $=IVQR\D,P EJ09DS%(R-G@K)ZF[YK&G5L]+ODQZW5,=MZVK=$JFG0/"V='
M$>:;/02ZP\*>J!,U@(@0^[VS85[>AU8A^\-]I#':F(U@'M W^H5:79]7_.6#
M7GH16O29<9=DBUTX'#M<I&26+%Z0@ WW[)F9@CK'_,D9[&5CD_:+IU@QZH8/
M7L")B>,S!_R6QB/FHK#^?]E&K48[E,W,*5&Q,O*Z[+\WCX-?#V8$GQ[@=$LX
MT2[)U=L "?8VIA"H0J .!:)Z?+3=Y4U*P8CLC4M9+5,_[Q;Y[_=9Y=6G:6 _
M?3^=*S8&K!<C=S53OS?IH;7OV[(@Z/&TD-+)JSO+#&+ T#O[D[]N?4#H3WU%
MYN1Y7\) /-)VUFOMYW-['<J6KJ;CG#6NEH1HVK#A<+-I) ]1)A<V;O\ <P[8
MQ"[<6QN;BW>*S#F;STK&7C"@17RM\]L?,Y)/RVW*1?%Y 0F-64PVQ##+DV*P
MO*C3J<[,Y4ST8.XFH4V%2P(@O+$D9KC 23$TXSR+$)Q4!2CJ"Q?*NRZ?4TUI
MH>S9EB6S6K"QYUR%+:A:0@(@!TJ29316*I)K)/=UT8$U@YI4O,0PY!31@K,Z
M-3C7RT#%!5^GR>Z/E[P*'\]J-?!YKW/8BRO4MS5N:SBBXL*!.D7H:J!B9R$#
M=GWE)PU )]31H0+J3H[SEPBVW;/PU;HVO5E5@_Y6K72"K)AVY"Y6: A%HLXY
MHKQ2ZBFMQ>3Y8W[Y,A59-S:O;].&/EH%IR$G(K &FZ6DI&)P)T&%IAR>Z0\&
M6TJ5'YQJNL+NC9E:P],.%M&'EN6BS*#24ALH*_:PR4ZXK]M?&8QT $3K)!P%
MI8,661C+FF82G#9>M=$BTO4#?+933%1$1$"VV $I+,F9!8X9I5%LI1J3HGH!
M<]&)P",8_E!&U<, &]7@@"S3HCD9#(H$#$?H:&9,5IG6<)4?S:V4O;WF/L(W
M%FNLJ*,7Y:!@\=P5@Y)I>+FBIY(DI%EE="PHY09+O'6Y>D Q7#(8/KPY(@H2
MR,_IF('T"?[8GR)J:P[GL*Z)EGO0\H[G+4.P5_1 ";@:QNL]660^<2)^?7KF
MD("NS2[[?P,:7)QQTLWI&P]N7Y=>F%WMNRFO! 2HV5!9O[DE6*77EP&+1%:]
MBT/%83(&^BGSS\OJQ'/21F9[,@J>YZ"$XWI_1[,GQ&R5K%"8A/*##U>:OF0Y
M(&9BT:ELXJZV,M.V+K5E>;8 =)0 ,V==%16@8+QUPB3,I6AIGZ:VV8-@=0A5
M!7;_ "MT;>*"U0S[R3S+R]2_*[,?2%.JUG6C-U6*LLM36D^;UD4(FA9#^DI'
ME=?-A!DWJ"O8S $HCYC'[M!/ $%RSULL[..$':84&%C"[+^:%FK!JGQE!-<8
MB$E:J&1;>8FO8!@:AE;T3+\9:HN Y<V#)TC838@WE65-U%@)#N7!,L.*O("9
MCB0^PJXVQN'PPTV,S6N44_0S!7*Q:[XK6P94("EMW;)%A@0-,I1' J\K+JC6
M#G7AM&I,"*W)2@S(Q+87.,<XVX,*Y)A)T'4.L?D@]*2N<KB3Z.*A4NOF"M>J
M&G UN2,:"4))H?R'5)T]:# C.B$QR![E!\\'5(FC)AQ*E:!307,ZG7=A+ !5
M>XZ\^6$.O46%4L'T$T3*KULU=6"67]E?J&MA.V)7NBG@4<O);]NZ7)'KLU/I
M58'ZU@*.';HS&1.L,L\5&;QBJ*DWG+P40KJ9ZJZ=3.K9_>6L:XH8"4U#UDV-
MWKZ72@JNG&U8%>GQS*K+<VU36N$09J\8<W0(1VHH>6>_D8Q:4-PI8K\@")-<
MWKV'K%^@PCJW#4FP3'"MVU<EK(N9Z&S J2WA,N*0[B$58B>CFB2NHS-8#RM1
MCRLD=DX)=&$S*])<A7XQ5^QF#&QFN=D*K+6"DJ+8'U*FF&3D*NH^^/0*,O$.
MVB4N!V =8-J6 6E,QE+:I?:_*5A"U&4F58VO!OT#\YT$\4G+L0FVVY#LPG:C
MT5L=RVQ*V&H,3<U24NK*_$;0\(>Q'/XP8)6:RUZ]\';(G[2A(Y(G;)L7"#HB
M[=I................4-7GH=.L>TK*J$>!?%ULK31')[\G)6W+PUO6][0V(
M^3:E;M\G;,(K6#FC-B_'G%H 3:9Z%:F->BF$PTO,I?.7O;\*A:I<+<*)+X_A
M485)/G@-;#P!1JU@!VK9+-&8T%D9%0;(A@QNF24)8=%\)G<*-NZ@1)TK]*+L
MH1+]\42U9'09G>4K"TET4 8"-%VB;K)8N/)99<@?8QH@JNBQ"D,DM]QF0%+E
MFH)F1!A?R<4?)VZS6SH7R\-'I#SO)0F6U8U]4O(J],.;5APLC1:2/M0E1ET3
M!X[<O,KAK.Y+P(YI(%Q4':)*$8L_7,)CXN<?K?-C8;<!(]=^3XA".)E>GO/$
M8K+VHFF*,D756VDA)W6D+VG*RTQX6QEQD[MMBA=.XPB:]>O+-N%ZMI!?Z(1-
M>6[J8:;YHV1LEZH]SU1OVCUJ>YS]>FQ5#;LA)XLK_!$VN7A@8RRC+0XYUV&G
MG=W6 N(5_P#0=(E:YG_$\@=N^O\ S51N\U!LFZ*U7C"K/KW0[+TQ\3HC"@A[
M-<%U(671\#$3T&<HHO9EI#[)[8<TPQ,4?(ZEX[]WYM6O;,AGH>@#9W4KAKRI
MXNS;@*8TZ5T99B7/.[5BQR0,-7K'J$Q3>V?L OA=G6Q287PC]CV@DP@X(21.
ME%H&J13AWWGY=7)AD<3M%:UD8%UUU0($?@P*^4VQ;#LL739D1&K")D>PWO@X
M..O1(E-<H#KD[P&G YMDQ,M0SK.3,XWKOSCVZWE7IJX*]36_SIOT;+7".[LH
MJT];6MZ57SUU8,N$5.Z)L2N=0ZRUH7O=2<8<#U,7<\/E)_7BX9;Y^3O&E@HZ
MNRY>WJO&"[?F"AU2D2#^IPH%I$3L?1+!CZYF2B^J,[3C463&DB(JUM);R.B3
MHW0\-VO=KRRK.![0\I;@?9HUZ)HY-W04-1LIG M]QU<(/HJB\#UH@N%W:)BW
MRHP& 1P<5>/$+;INT&1DGPW0DJ0TEAFZ7+9GIWS8.Z.Y$/0M'0<5='"V:S93
M+80HW2[6S)T/R7;!.][C^'0E(/XEA785KG_MP)7HF/[@S]_4V-^I# OLOSR3
MKFN[?*V(LHU6V97QRS0+_8K4F)"M%50;"D+'<LL5/,L6/'Z*%[ 7(XJ7$[G"
M=N<O1HEDX4PD#BENK;_MWS!1O=<96';R8*BVP!&MZ&5P8P&0$ZD$+%I^M-CU
M&8=Y2,"R3AA>\44V2/8$<X>M.R/-$7*6- $<]5N*MY4F], Q32;AJUQ:3:*-
MM ,M*M@J3"P%ZS,YQ]8>Q!@807F$9Z*6V3(FL:VQ(VT!.SE1\(I#;EOU=98J
M+Z/\\S^SO4&^:8F=JQIA6V;J+:*/([76)1S&:VL"=ZTG,^Q!I8V&@VMA%D/V
M\X+F6&8DM$;*?%ZVXG'U=Y;RA]$,?2=!90,K"SJ3&=C<5=]P^[6PC]3,ZRZD
M],?>GNPL(F6,K-+ZS_J3&/WUO[&]:N^LN8(-[-\IEZMJ*YY'H.H5BN+X PV.
MI&-YL-22([R/EZ(&_O4!P9RXO9/)P.R<"*8$1\=A(,0DZQY.-%F]_H<S67K+
MRQAC'SS]+>?\,92!"M>+EG<E=8XR:M)2HD$=96CO)CZZW($^;/@PX3CK_,NR
MI4V)'T$=FZ1IPSY1_JOR\6D0X@KTC0A*411)EI#XP^X:\F2)U9#H7\D0L:'I
MC,6S9)1(([_T(3&[3CFOQH7_ "O<0PT?\9S.*_H.@W@C"#I=WU WEB2#MM8<
M+5[*3& C/J[02UAMUDPH0DU+DRD'28W:16UQT:MB[K);=<'(CU*SQU=XQ5]/
M>:WJ:CC$CT+1SB1L[MBZK8>JVRA,,VPNU#N3BV=(\40?F;VSM7RA3,6+H#KG
M]A>XDKHE^V[C[?R5JE^\/)[[;Q^C %U(75D )Y\)VOE6M:$3330H.5H)#JH+
M0\@8T%SS2ED:B;"K2'@#=N\2K; ;/M[R#&8LOEH[/2GG/56&-W;;^I372^<K
M=!PMW9:B+A6&<V/,WCI$/!^R.]*F4K00BR8.Z/B6[W:YD??%SPQWZ=F&.-,^
MKO+:YM:M##Z3H(#O102\T.VDS<5=B]J<LMO8K%48FG7-8]&:^"9LCH3%>+%L
M8D UV8%=#9$GLA$_6YP_J3S(PX@<P'HNB#F#4\2*R6,P]NU^3Q8[)B1!\^57
MP'*$P[^C#Q&@EA<V0IC^Y![3$)#Y.R!CIF1L]D'R]K^<.EC:S=6.O;-F@!D^
M[%+4=6]K_C3^#_\ T#W>O21K.9,65,]Y?@X8O.,'N%FE=XE<-.4_+$3W:SC?
M5&5VS8)5@714Z,Y;50N^:U)QL5/66;8C (Q.:=<\ )HQ"*YJ@6&$,RR[%C$[
M$#8P@GOF3-.J!*SU803Z@\T'R"J)!>B*,-%7I>*MR0,$VT@D2#BJ LF# VSJ
ML*&P;I+"O!\U-JP*FA&J8-'Y++!C+DZ>PQ'J-UHWJSR[-T)DJ'Z2H.7&L<:R
MF:\D1KAKS?H? Z7K([7$LF;=3%GK:!JGJ$%MC+.!Y3HH+6+(YE-L7&%)[U8)
M?]C>9&DC^R!7;5\^!.9EI$46778J)BK63832MCG ?7]8FMC)A'?&[4L'E0U*
M&+W4S#J*W =<63+EYD8PZ2C_ $I2&VMZUM5CL=2KA4MF0$$I>=HL8! GD6X]
MJW]QJ^_:L1.'CG8,:7")"IRA$W2S&DJ)*0L(^[.%N[QQISUGYJ!U[<EI?WQJ
MXZD^?(!B=<Y92>5EM_MSF#A2)\\6V1U\H0W@SOZ$7=C'"$\(I.3OZQT:8V>W
M+K'D<5/;WDMM6&YNC^AJ;"!D%Z(UP\;&>T$ %M4&V,X,R4'%L^$MD_( WNI-
M2,34/06V0Y3:&PTDA,;=KV9X:[6:[SI-$:AJ*\7#5B:[F0)!I$)S78*DNM15
M8$PC1,JQC5XN7AEYP$8.6V(@0+Q8>T?#A 34N3(UZ!<[9HC:QZE\QNTS^.3/
M1E$-I#]FK$>H*Q;M?GIG8]X(0A*5.ZC"F&7N_9N!0F-&J\K\GZ#!/(088G.7
M(EQ]>R=*%JU?848)-0;(0GB&RCC9A<EJ#@O,L8^(6IX@4QE F\*1FZBHY?)G
MP0TW.@Y[XPJ>:$0Y^W1()0]>Z>\<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<<<<<<<<<<TM0O,5@IOI2R/0\JTDLI,L#5 59HZ!3VA8.':U&,[,T !5C
ML@)UBPWYYKJ*<'UY5;[+7!^:S6PLB,-A&I@9R#%'V1MI$QM*JK-K',GV%QL:
MOG-$R,8Q>IV0G%O7"2_V3QA=[XO4SN!T0[E=1>Y4;J1WJ_1[WZ?S_J8Z)W-\
MZH%N%,"O=GY )/5HUQ8^W9@FZ9^_=HKWSZ7HK2O9[_Z@A[.XQ#LML:\9&7YL
M(4C#,=C#W][LB&,!#^#+BJ#S"=IRN;.5G=LE^F_*]IHF;$GLG=>5NH4K;M E
MY</4G-5PGC.\.+5ZL),O]#I]@)*B%V;-*=3BF@!AX07A%(7R6W *Q>$)9O$1
MI*VIW9H"Q&,_4$<S#WH=Z>>*/HFV(*<O1WP7I66R/OI?0T56>GD60$C"V$@C
MEE)P%];"$GKD/FJQ@;00I8EBS; =A^UROKN_F:"O**8/$Z=XDFPN58=C^SDP
M\SUS:CPG^>(L)2_C3A"%*K]O;GAW*2637"W7LZ_/\BX^J#_H/JW-(55.N-16
M!,K4>IGL])=LJQS\\,\8FQ9RK%W(4HIE!\]BPHYR!5DN6)G!/0A;<WN"W7Z0
M!'44J?*-J0P:P 5/0"SU"K<]6%H5OL,TO*E3]%QUQ_N8M74AW(#+1$;F:J"D
M3R^N:,$(7BM,(_MDD_E?9,=55XT7'H/R.8J]+0C0[T4&+SC3O4#%9>9RF,I.
MHV$J0_Y3=(T!&C:;,TZT4^=;_+L+=-.S<FV%'".'[3$'O+J 0WNLZ]_FJP7=
M8=O-NV[QZP"=;63[]1!()';EYN6+:30/E\!#P:K-1;?2VQAKV5%\PA=NT(G[
M:W<HLMHD3AS_ !)BPN[M$H9_GH7)UKY515BX^DXQYY+$)YMT' [ D&F>.S.Z
MK83G$ 29-R9EL!YT^K81]BQ<QJ]D@I%EP#+JL.3BHJ;&,U3\]_..Y*_N.MZ_
M89$/3Y]\R+P60A6&464C>=L]QZLKQK:$W=$E";(,MG\7**>:C\?:-<$5(SK7
MLHNB%X[< R!$,!9#6?QUGU+,'$%7T)T1FJ$:H&5 R;52RS@<5:-4=>9,=<\P
MC=7Y$K;<@'</,"WC*"JR6H6)JQ/=:L[3E:4Y8UZMHA?S[UQ4_P A+!&SHL[?
MY8 B16V9#08XL:[S1GH'S3?7<^(#Z9)>E0C?OO.^H# &Z99O$9I9]<[3*VY
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M+BS(VW;@]7J^@]I=-7L[!$13[[8=LUDN@YV?[$SM8*0FVZ.LB?.%RN]4X8I
M9]&V-#_K*=HT+4R2*AZ8I+;F7&XR9D4O2H!BT4:\;%3S D57!NW<NEMA$L9
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M[3#%3Y),$(4.T--A5-M**U(PZ)3\U"IY@(3#@*$CS#H2K1F#YK*4W:;3(B:
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ME@D'$'L&81]N.O4R]AMA/?\ IQA.,^1NTZME_P#\L*_ CW_)C_P$;.M1;O\
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MVY=]==:HNK;LPV2-G???776&K'/+OOOKKKK\>=+!D7=F6O'6?"YY;NY>.G'
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MGY+=8;B15M*P4TGMAB=2/HV%PYO.?/\ ^0[%XVN6L+G,-55G&Y63FY$>&=5
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MI.T(BO/M[Q14K=U#%KJ,51##/")^XDB4N8#W'<N%8]?MN_,SUK- ,<:U4O\
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MP35P@=B<V8;[XC)Z9CW8'G=.P%RI>VCMVYIQL38@E-0UJC%JV%6B/$_N"_\
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M+UA*B"R#/Z<D8:'])KJ+6NTT<*\[U7L?$<_7%>,YR5Z 8<:T[LNW7-N$I$<
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MM&.E]%_8>WG&F$DAM\\R[#=Y%.UA,Z:>Y[N#U/ME1Q7GR)<)#%74*48.BL+
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MW-ZD15,< >K%Z*ET,GO9@.T^3",NL5@3*P#H?/7!Z>OS5XJN/=6]NP*II@U
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M0URFR</1",$BG\:1T"60NWPQ=52,28MG#P8%\7+C7ZV(I<IKH2Q2,M:+UO\
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M)V*C'K@LZEDWA2"'N-ZD^=3'?LU*S"6K%!PAGG5@J:QM!Z 9,]VHXJR([J%
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M%(ZT9]R\E@QKC8[=D/9CUS/%EI5<QE>4WF,QN#HX+R"J:(HHR<('FUHV;L1
M@>+ #BA+=WW'BSBI*;^TZ' 0 PNQ'9@T"()D8DZXY"D.QDBSPN#)7[' :UW=
MJ#R81\1^OO"%83"M W (2"%<M.$ X**+;(%*0RH>1.';M<WK1C*_=1Y6C1S/
MS^F5:FL-@V&QBU)+5!^PH?83&_\ 0@CXF&>&G#\W>..>Z1*E2=NB$/@1-6^>
M3(28HX?&E3I4>/MAE37[4]XP]\VL6C:PX0NIF!:)*7&I:+K\\:8G 28%H!M8
M,&:56H65'2HQ518X MG&8]1Y,\1'B386^18S.R DQ;87!H)1PRTJ RS(Q&)?
MZG[44"!0)!0N2D_I8;-O[>"/BR)6[]/7LV?IZLOR899?ACWEH\C3*CZ)4?9C
MMCR=.J1HVX_C^79IW88[-6S'\>NN_P N>&6.77X]==_AW_GUUWSFY@69I7$L
M),96TX,7  _*)A-,&)FF /C9SYL8;!U[I,C/#7CLFD9D2#$U_F_/(ER=$?3C
MGNVX89<*@WK3ZM"'!/+Q3ZR>C=S YB%^I^UGQ>MNS1WNT_K:]6W\O6W5LU]_
MGUX=_FP[_P N23G5G388R%,(D94>"/'Q9$V=-E;<-$6'#BZL]\F5)W[,L=>F
M/'TZ\]N[;LRQPUZ\,L\\NL>N^^1=(L-&LD7(-(+6#;Q,63%AR2 &?H(Q8\N<
M##LL2+NVZ,LL=<C>!8 I7#3GWUL_9DXFW+'KK;UUR9=]]===]]]_AUU_GWWW
M_P W77_I>^5]75K5Q;@J:=K)Q!NX4?O"1Y)=>E=3QGYV1+5;% 9QYVO']M-C
MET=W4V:!+A;9$62+.P=VO=WEGGAA)A[( +%6 $,,#YYA4DP(;*-BR=6Z8#EE
M1L<R.BE-.&7><.1-$S(A*/IW=8[-D*5'DXX_I;]6>6;XXXXXXYK.@UE8B;:=
MZ661Z4V6?<-MI> W?(.%84Q,\_H]4K:Z#6HGX+,O&>9'V9U93KH6^]T4/ENL
MLW._J75)_-"VV->204LVD[AK<'(@Q#5@U;8*0'EE-F_4-BE&Q2+@1\@CMBQY
M<G7!TRY^G9+V1XLG?A'QV9:8^[9UCKR\O+U^;3S8UE;;83Y=5A; EN=6:)[M
M-W&H39*IM+\_;40[7.9L>L2Y^08E;<-<>M2Y^YQ"3L@ DZ0SUG XR+IKI9\(
MW937B&PZ&+UU45NRW#USY9>QE6Q"^T@GM20%N?S;E9N-L-@ND%*87"F!Z4W&
MF@PV5Q9KGN2\<I=NO5S,6]C-D*TU?'^U8" WX;87GASM5UR( 8# RG7:)'J(
M9EY?I:IJ>>D%FPK\NSSVCQ_8:=9TRAP7Z"KGVMV!.9QSG7SN2FZM$RD^"[N5
M+231\G:*G1+S]9,3.]2T?78A]:K[QV<_F+0L[S*;-&!\4&MH>YMK:JHJ1OAR
M0&!UJMVU1*J@+0*+ME\O"^O!EGV1>%QV+I0/.%H G]ZK=QZE6NSN@]H<ZO3X
M/GB"5\@.4 ?7C4O1J/G,-3.=LZMQ+^O 4MX:HD&55\; NZL1;7U+^/+;$'!]
MMC8T2]L\QWI24^&CD4RTYGJNJZ3\_"L>L=LII4)DX^L*A+S!;>M&"G\LH'73
M4",2^AI5N<^QL$K3XQVL'KUB5[4-UM9A/53]NJR]D=;H&44K=CJL4LJ?W]ZD
MJOFE"AJ;K88A.L2"[,+<KWJ]:HYT;B].%X1BS(/SV&N;YSW79?C:FJ EB?/3
MNR(-;WY7G:PYD9JU6:(9L[=UIJ:YTO\ H:FHX639U$+4/-9%15BJJC5)O;HZ
MR4D?62__ !:EU4L'Y5^A1CZW,\S&@'L"S!TZ*WJCDSDIHRW@2G<]*V'NJ-HE
MS:%+N"RBLJ[7;2'9!FYV?JD*2#(S=C0D$V=LQM;^H8^0%LSIU9LX@G4B.SCW
MV0PND6OF.3'@+VN&-\[CJU8$UJM:C[D>R4^CA57V8L5Y"$F*L=8XJR26T/;R
M?H:GX4<_-<?)6]D$8D HW7GF.,4R8*$H=B6!N'ZZ*(+N/EZ'UZ$J(7$JZ'#Z
MMX\,H]]PF@<,E/J)G8^P5OL0L$)NVA@Q+#\@KX%(5-HE63:!7(B2%J-I8Y>B
M;D-G:O0Z.CT$!;KB#3F"B[)V9'6\I6+CO*.JUIK>Z2DHNND=5J+HZ6]+C%L=
MY%\.,GG[T-1JQK$0QJ'4OF=;?+=E*JZ>%(KC[0RPL.K8%CA6X@,#Q'X\T559
M]P:;'QV1MQL=F)JDDPXPMLP-KVZ\Z/F)[6!Y7\87C/G7^?NX$]+4V!B\G5-:
MP,V:@>B4UMMK9_1?G 4>(,6N78M:SHXVPBMI60Q0 )*&W>@">8)8ZZEK5\AW
MDA/L9C1(5!5@\E&^Y-:&Z*NU@%&85:V=+^@A.6M39Z^B@2:U&;9?J>IXSV"7
MILV-NQ1IY;49*$U-([V_PY\BW5Q@6?,(+GG1.WNR/LK^OZ\"2#; B477C V^
ML3[M4J/(DUNOZ<$!DSMVI39L:)4UL48.+9<;FOQ0BFG?OK8J3QU:9RM/H0C:
MA\&N=#T@L_FWS4MD8K.!1T&(UH92PK7(JLV8K@BY&MY?IFWWM?67 2CAHIY!
MK-1G+@'L-H$929,N?.)O6*:]A5F$DUH%E>H_/FU%*;@DP^-B'+B*63Z@.L-A
MNTR&O1R$J840;8JQ1S:=>!)E[@HVL!UIU@U=7_6U$?\ XVV])+WGI0I]4ZTM
ML;",] 49; C+:E)5<6\X:JA=8D/5XW;U_,;YV4Y@6MT );4GTF-A)PR3IJ;.
MA3$9,+IT>-?+;TU<XAI+;Q=35ENSOV]#5@@(QS,9+]@CI%R^E,$EIN.%:7GJ
M]D\"+KR,[I;I1_\ -I5X3)  8-DAS5=E]"J97=JJQ^;MHIUU4-8S<J>=; )T
MOZ!D6PTW@Q,CP7OF\AIBN+W0 $YS[(H&:] 9Z"@VZ$A5OLFS6H@<')L74(;:
MFA;LP^[-#?FXZS_4(&XVY>H64OJ7HMFNZ8Q=[B[&_P!R3RMG6:]5LWOHLP@1
M1J^_^<TUS'U!54V*S-DC2JR3F L^GA((18Y7;I\MK6M'U7:-J6-HH@_4%EM9
MT@V*,S*'.SL1?AO0@_6L=X :Z0%FF.6KJT3<#F1;-MRW1,&?G.AUW$0$,GTF
MQ*N"_'B]5EWJ(L L)&"*B(>JYCZ!K+%"$X*+D!KSR5 N"RE_)H\_V >GMEU/
M%-6WM>92:W4NSN<%TTDGEY8HSU82MUGHWR(L=5AUR#50/G0PLK)FFCND(;,M
M06%6+ZH"/#NZS;TKN/"K8WT3M2P#/F^VH!>;*VJQ5ET63J.,#;UL:[&"DHSA
M\67]?IX6L($VETNQMX2H0EALZSLZ'RK)65*I_-HZW*^/&F:H7P226KKMFH'@
MXV].M>/0 _K<\&YU26PM*,+FS)D/CI9$VK.A4W31K;8FPKKAS9#T4W%XI2GA
MM&Q@ZY0!-E$4HOC<J\ W:%5#0T0$JU?3!@I57FL,@C2P$.J0]C:I^?ET(GG?
MTS3Y+33$S3;%V5_:85(S/3):M8 =;L-5<;.1[:<Q--*!Z>LW8M+>ZNRV]U5[
MLL>&NF2>BQ;1N2'G"'P)Q07SGV)U6^G5NQ8-<!GB_E4JBJA^N=Q4I(IJMIP3
M=N3:G3V4PO+1;2E4FQS-$.O-$ :(@[1JLO&.@("3UJ"C-*K.^3GJVT65+9&-
MOHG>=G5U8L&X62 8(BY1]JO.L_1NRW%$3(WT@7L[97>N^[QB-*? AW,HI&A,
M7QNXS3A"Q HMKQY;J^/MS6 V:QRKK\XAJJ"+WJ)030>[5#AZPE?W9W[?C*5:
M; VVA6-@AJB_J]#5%+V!4RT$Q @ZTDW#)UR]% 2(QQ,^^?*>_'6,W0-6GSZ$
MF-\Z]B YXC.#QBUUJ@6EAZET0O+JCI'5>,U[Z:E$;N27<]/P* X6EE7"GZ-=
MD9P-%8!NP%+_ #KL:F/8%4W&JQ::7ZFK[9>X+ *$VZ," "JGRT?5;U7M:UZI
M]U#'GI45;TW/6^N3&5;@7*SZ'KC"#+50VEE^LG<#C*%^<MDU!Z*3K#CJ_GU?
M5%.Y[.?QCNF&#T.R%VM6IB]1D\:97%:-6 ,!J5+#FW6D/-@1MKAJ'1&X";ZS
M'-\P&ALP^OG+Y//FQKN*TZ^C4$+MYTF/)Q1=#.+3J(Z&-^M/WF;:2#(8#+>D
M[UM:JH]"T#7#'.@39$^8 J_M3V;-ZPD).F;0P;XR7G#U_NN]/F\:S0>C,>NG
MB/)$:W&DHDQK]#E5W>@;47S%5R@+G*.[T;+L$7%14RLPD=[K>!&'#8&;9VVK
M,@!?&:Q<*^L,<UCZ@839%>31M4*Y%H29XBJ,H-M '-]$I\N)XT7Z6!@7,6O]
MFB03+RJ756@^=/@WQ78])LZV$]K+Y\!WE;"MY8BEO[%6=E2]#"*YMNIGDNXK
MM17$VZDS:LY9;_TTU[F1E10;I8ZVD_:7 %BG377RCIZAB2&>AD ZX4Y\=;3!
M.</N[&&L;4K^1(3M-@@SQ(,?!VHM@BJ06"JS2G=>>5AA.#:C%JLNOJ^T6G<-
MOBLU(A(U+(:K11H^K28\!^--O9@-8ETP\XGBL40JF,V65N.FR1VVAGGCS56I
M&QRG92LM4G0U1'JIGLB-;\IQ)DF"#HXQND#2I0L)@]R?\B?0^QIM-C,G*BM\
M0XO[HT&*VLYUUP*_O >U1_0T5"_N?H4_,41F@E/.>=MH)2LIKVR^AB74VL8$
M%0+U4('J,8!M+?7S8<;T(TU":-U6,R17U (5;,*NV[C9$83>T6@O85>"6&*'
MV+4L;-AA[%O6LFX%/G]:"(_-2G'HT.*=!+^F;V?2GS5G>C?05264\J=$V I@
MJ;04"R=UAQ)!AI+$Z[3_ $Z.AC8L&6CEHC(KG'.^5=NW9&&$3V+(5[JG]A"9
M#>/VCX]Y-^=-_P!*.=]M=E64#<S%KT@]UY(9];4/(R79C<]BQ*5Y+I#C4*F/
M6^'38X,204TR_P!QW9,UJQ67L3 M9#RQ=4VT06^0MT SC9J6R='6?4Q.NZ2
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MJ&"6=\OG4_D?(-/C>W6I6'F0>C'F:BI*'0*]D4<ZTI"NTZ[^G^YJK1M9JM%
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M>UL=7C7?&O:=<795)RZ+7%1V:=$V *.4I&EG+*E8(\H=+"*^)ZL-4HR/Z#7
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M3;<L1IJ8#OSB#R$S4D,+OHB1^XNL#AV%GZD&CQJ(M3?-DH.PAFBE(-FP=EO
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M,X(-;MP*KU#T0:.-_9]TK<")-EA<CS]-G1$=%)NP0S =TC42L=:W]O>*'?\
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MCKS ^L4MU8:-K'?8,C+.3&L;4E+?3T*,8X:<1S&+8MXN1,C,0+;'U20!;/\
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M=F<8R)NUXYG@8K-BV8&.OS]6I\_*45KT\,?43Y%O-:7[Y>P\_.$?U5XW6K_
MPU>\J8K^QH\BSZA;A$$<P,L?K*NO15;/)"02",4GLB';=8Z9,T2#,[1A[(?!
MFMI)?P,#]:VJ8CV-Z%^C)@IZL]'.TT7%C:39=UT_T^H(@X?^7;U"1:[KH0#5
M "[GND#X>WL[*AZ]&DOLCX0+Y.>8?-D?U[](O7-+T#3=(!U:]3'S^IE<J"M$
MVMP@VNO-D9>E7"TYPDP.'A%#]I7^99-1HU-U2)VQ=K%##Z]VN((ZZW^!GL'/
MQILIG[HQ3NSS[W](._K;WL\8:-FQ Z]C_P!7Y;_)6NO]E,Z\<NKB_I_MFZ;L
M=N:[U_37XXMG4SO\>BG778]U^J["_P!]=L'Z4"*/]'-U??,_TGYP\NQ[[1E.
M,0\Z)].H@5[7/H,J6&Q],T67":S3?Z/CQ@N\<K&8\2.B"M),G!UD=FJ)Z=W/
MXD MWW?K&IA+QLT^0/2R8,^JEW4!'BZY"C8?J#RN2CT^H,NO9KSZB:UYTGV)
M6ED/(C./*A-[36D,D5ZWR-T'=#\Y:V/T=4'T7JUQ2#GDSU?7%K?9NTA\&L6Q
M;8*7^KODWTW8S>[!'H[-V)Q\>8MCS\EE<ITDGJM*.85S21+68^X+#WQH.T5N
M]_B2"+#ZDMGS7\\$>EO1?H#6$J2^?8-H)OF5;A,SNL,>Q%;Z%\B.IC1.95B+
M&5%^[&AC:#_ZQ#N1NTK$&/ @$=LK+#3M!<MEGOIS_AJWJV=?YLK@)^1-C^TQ
MOTOVY$-Z0\E&8K2\0OV7?64D:0C6W3)C&)$VX:I>$??%_P"#CUNQR[^:G5JL
MR][&K2Y9H<_J4/\ $HWI)5YHB5EGMS5DSS-]$*@,+.AAT=[]NF'HR\P"&F#'
MQU=R=$N/LS[QZ[B[-NWKTO\ G3&5M/OGU/.9;*^+P&!H^R/KO7@G>EDQ6F?1
MPC.[OB1J!X4DV%W0=,'[9QG9 T53A'69N[0?P)=0/W4O=KPP@_Q7C+6@&B$3
MEF?%:/\ C8/M33%1#J6KX?5S(S)L3T## Z8;G,=<2W9F05VP9H+#4I?N]E-;
M(8J%AGWEIFY1;_#_ $9ZK#T#\\&[WB+560#ZA\#LM9_+%PA2ILA=H["K6MDE
M7%5.T?,UXB@]QWBB3XUBD7/3ND%B 7ONNQI'7$W2EP?].OQ"1Q];_*?Q<E##
MJ\RQ E9D\>C:HR@7%>G29[XW%)V0QE6")8"6TZ9TV3&V;QI&5HUR-.Z/WLZV
MZ=F&/JKQQQQQQQQQQQQQQQQQQQQQQQQQQQQQR#S*RK8A8 >V9]?(\ZU%Y=(*
M "S)BF!DV #4RTK"<55P[GN@9L8Q=)S<,)A )"):!LV5AA(DQMFW'K/J F_+
MGF=EN$)Z&8_/%'G[]6M$>,NW<:JA$*6V!T1->6F'J#V+. [VX;A#TYYZ8G4,
MOI_:Z=FS5H_3U[,\<K(SK]"VO<>TMJ0H[+.AJDI#B6-FM!LWN*CS2T8_-3([
M?E"[8-"I+.PX9J4NZB&(B06BQB.V'G,T:MV%"*OA3Q$B/ VSDCQQY63;)#%M
MI\182KYZJ->>!1V1WO[WFAK8(4(9Z"6W=R9/>TE%GZIFSN1O[SW9=[=GYIM<
MWF'S9Z-R6,O0?GVD[SR29^91.RN"K$>R<E0EMRTY;IRYDX@S.063NRCQ\M^X
M=W'SW=Z-'>WO/]+7^7KVUY5\P7Y,3"%Y^<Z*N6?7.[J17\VU*E0K EI&[K+3
MGUFI2&L 6VKW?YXT;/OH3G$Q[V1H^??7>6C5WA(25!44999SH7I6I2KB39D%
MU)-A*N$Z<RD'*J-.Z-5K;..R@VTI+9JVCR-\=!/;Y6PJG:=^[4NRQVO9GCED
M.J9I_&79D_JJ*UZG75JA:+DF](JOU+MK0-#9+@[39DCH7^L^:H"]GF!A:VG,
MKA%#9Y"]'6N#EWH[PM+>=//WFX!/5//%&U!1*P5(9%BB]3M;)U:!"93/KO'(
MD1%IH8-"FS^\.^]?4N5IVR.M?X:^MG6'76/4SZKNO\78A9>**G=6,75(B(5?
M^E@)T[$T> 2F&(*:0:NH/\[-5(1<B0*Q%V3/VB(Q*=,G:8>$J3OVYQ490%$!
M U;+@:E*D$+U-3I)2H (RMTZ &JDG,@DQ<PC6PN(&U04:=*&&C Z3+5] N1O
M@EB<3;LSCSY6O;6=>>&/$M1.0:Q:G\=^6*PL%=SF[%][KSSY4J4Y LR0Z8'(
MYAF=;41AL9F0$D)XN;E"G:.Y0Z=,A;^]D:3NU9WR:K]#9&A,=V))43SI7.T]
MOKUO-+88HT(F]J%?P;/N3#\Z%O+*^UC"=]ASVP)+@YF!7_H/(=R(G_$\H4OX
M6\2,#_*M<]XZ\KF[2G,N+I-LHOY[J0D_S''"?@4P;)3C,4=S%(9<">O61Q.[
M2.93&?KPF=2NI&..SK\0O"7B 8Y3+%&^-O*@^P2,P^1(/<+SS441RGD&N.1B
M-,Z8SZ%#6;E3&6(7+1C\G?.SWF8Y0CI(YR=<V3CMZ"Y\_/!:?M+[U+Q)Y$5M
M[ NFU ]N7/-E-!-IM398>8YC5R^P8EQ<R2ZP#]F< V$F=[AI6'GG%GQM^C+O
M#O8!IJZLWE#D56ZUTBN%83!PP/+KAI45]@0Y0D)OA20PN0H%A\M>WCA$D:.D
M#(6T=E&@;X$+;%U:MD71EKY=U:UU(<B%C2$!*WV$63L*[*O>Y5!;7(G7^HE)
M,ZT4@T9P,C<U.UEYLPK@L29VT)@2ER9V,'J5OV[<ZF0O'?DBJU2PT2L?+GG>
MNTBW-,Z-:R<D4M6ZJJV9%)Q9,$C$?UX&MP1+A$G09LR%*BL,0A'WQ)<J-LU9
M:)&W#.8L/GVA6Z3C,;*1J)GEX5L7IK"4PULF&I.%0,&.G ]56.\D%D[<:V-X
M1X^!=&ZRZ6"6.C3C,%[NM6'6,1J3Q_Y*H%DF.5$>7/.E*-Y +)6Y[74E)5I6
M[).79DT>2E@9AU.60Q22%E$1(J?)%[I6<'?-&#Y6W1EOAQMFO*O/ESS/9]E*
M%S63YXH^P;>K[K1BB6F[52BM-B)F,7?LEQ,59T. IS&!ZB2]VZ5$Z%D8O465
MMVR(_P"GNV9YY2_?3E12I-FS)-5UQ)EW7 ABKEE;T=8W2;;%C@&Q5'C;-W[!
M>6U]@0%?;M6X<-JR*QXH#9L#Z-> [/*/WPY4I362W7*=E4M99*%/%UE@J15R
M0U7M;JT\EP]XY.-UR#[%=C$@NICY4J"LDEF*,F 8<G?&%[HNG=LPRQL3SU04
M -7RY!H^GX:]4K7M>ZJ Q*T2XX:LGC?)*S=[E7PO2%P@IC7NF'CDO:PKF@:7
MV23)7?G,RVD9F>[,;Z<J*5)LV;)JNN),RZQ\,3<LO>CK&Z3;8H< V*@\99N_
M8+RVOH^"K[=JW#A-696-% ;=@?1JP'9Y1NZ.7O '@Y1U,>A3\3>1UC2X+DQ.
M;=*]YNIL+J:5$A-'$IZJQZQJ9&P-KDXB($SY@,GU*&29HP=*W1<]\*-LU6H_
M>=//EK3XQ6T:)INR2D)3*(4,D_5@DN,^(C&\]6PREQIC"#(R-"F7V:-&PFN:
MMF(>?LTZ<Y</;EJP[QY7'SW05ADSAI_H^H'DPSU]_:1E+.-:);,38:J_FM3)
M_;(Y/-!9LHM7W]1:-![^C)^V0N?S6G44_C?WVO#?U%JK\A^3J*G'2E(^7_.]
M.$VD+L6V8C5=*5M7LYC7=N[7(V@3LM16A$@N%VR-6K?L%D-DB#GNUZ]N6CO/
M#'+JT =95LL5_%J9;KU'7JKA+N]0A5F#4P(FOXBG*B[H,E7BID"!'7(Z[(A2
M-\/>$U#<!NV+OW1]D;+5MSPRKBHO)_EGS^9)L5#>:J I)@-C.@ID[45-UU6Q
MDN&ZE:)W0DF335P+-GC.IT:-,Z@2]^V+U*CZ)'Z7ZVK7GC80BJJO7TXU78&M
MT()7[+L;=S$BB$]>&IQ_<_3B11ZVFEB&.TA"NQU)&C!%MV3H._)CG%B4LQW,
MD3Y6S;TX-,T^,EUC/&U36P^?28(BKTS-@HJO$EU(LF P]<+KM8R= O7N0@11
M>$B@1$0JYBA\X,,'BY,?;!A1M&N)5]Y<\SU+8+G;-5^>:/K6T[%RWY6!9*#5
M**H/COE*EX3Y?;8W+X(>?8?W<_7KG2OY:?+_ ',W#&7O_4D8];.OPI>5_,:#
M:#A=R+YUHQ,N:PM4W0^6RJU,AK]E.FDENPDDM34\"0,1E8-9*1JU2".)4G*Z
MG[]6K=+ZW;->&6.6Q\Z^?<%2NT3"BJ<P1ZA9!KE4R;A6*3BJ5>WA=T^0':J[
M7L0G0A)9!,@H3WC#BU#&%(&XC/VQ96K.7(RV8I!\M>9:JL=RN*L/.]'5S;5B
M=R<GZST6J$13L%V[FRL)\WMK<@(& PL'[V?KUSIO\H1E?NYN&$N1^K(QQV=6
M"&K.N%PN]L"]7Z0"/6C.B$[--AE0$,+V*2@"-2_ (/9*% T3&Z;" Q] 2)*8
M-Q#?&$:-(W3LPA:L-&,**>:?.1NIAU!FJ I,O10?J'T)I8I52+/J87T.GYE1
M_0ZN98':GPNH!/9L)0^HP;5U%G[,YFC\DC++9WQ+_F+S6I+Z4I*OGJCEE5K9
MTU6172ROU,A!E]!L33'DP]+ZE!AH",-5735$FS(NII!1H!S7'ER=&,[K5OVX
MYSC=6%:274E94BO$:18QE+PK8N_[E(!M=2M=ZB<DUK0235L'Y'9R7K,39A;!
M6E3]H/ G+DS\8/4K?MVYY-,2DVN%4"BUXI+"&D*P[0(6$Y, BE=57!,;KOJ,
M+ KP.)!$"!T?KOOK1"'PX\;5UWWUKU8_CWSB441'K^&5'(::J)(\ZR'W(W!4
M5T0MPS+>UD=I=I:BL4-#A:"#(R%M^\H?.2\-Q0P1W;9I&5)D[,]N551/)OE<
M?:DB]8'FCS_"NZ65DG95QQ*:KF-:DDW,U]Z99B186E<P;MQ65J[[U22&POE+
MWZ^^\-N[+'OOKDKU432$=&<JPT4W56FM;%(,Q:P:\U5XHZT9Z*NLG.:Y$W)2
MP#X@&<@VS-NR6S338^=)/2=F>\KLE[<\L^\Q"JNL!K*N.8ZN$* X)R9NKE1:
MX2>O1655KV1O'2I"(N'= [64!IF^4'$R=RN,E10FW>+';LX.6R#&RU02'Y9\
MR#[IE^D('G:C87H6?&V0YUZQ*H1(]P3(NV%_&[=$FR=('!QWZ]PW\!VWK89R
M_5']=0MGYHV/6KJQXE=U^/>3%GP$5.A66Q !:HP6'$60D9Y.JP.5+G!%HPVZ
M8.!\F #S9\Z8+#32&\</E39<B)&T[I&[//HK-3U8EKC G)U:H"FHMI1F.-2J
MLIJZ!7&8VZ;MTAQ,, ,6-BC#)1LD29&]F($8LF6>W;]VTINE9[<\LL /\^T(
M(AU8.%4C4(P?1FZ5)I."/K5,A0Z>D3H6X;-D59%C!=6BOMTP=(WCY6U2P$;)
M$+?NB[<L]&S/7E6V?A?Q)LL/*W=GCKROLM?-P[L+.S\_/=296'F_=F/ZA[>,
MG7)1[9,G#L__ .ASMF[)=FNS'_H3[F_O?^/YP+O@WPVH.,2Q%/QEY15[ @$I
M1B"]+OG:H0CC"+SL9&,TK$9QJ?&-QB4S&7*QE3M,["5(QDR.MVW/K=LZRLK'
MSIY\P 5BIX433>*M29J R4TM8U@DX@*D8A76_H6>K$-T#Z'(1H;U*D]0"BK&
M%3H?4C?U'WZ_U=GYITD(B/62H&1*W352OD=<C;(:\FI"\(4U0#$VR-TS;%#+
MP&' $"XVR7)D2MFB##T:LY&_=ORQ[V[<\LI5QQQQQQQQQQQQQQQQQQQQQQQQ
MQQQQQSQS^@/N\NE6P-\9T@PN\"Z6-(@N)[JDT@):OH@E 9)!L>MUY0J6S]]U
MVO/1/2$(M#M==W;8U-4.C8 S;=H($WY/ZC?,CN]4^C_ OI:E;Y!CK_:3PX)Z
M7[];5\_>D76WV-^+UI[,]1IK34[U#;FUH3&8JL4HB5RLTG8B+'6OX^TRM,=1
M<2Z1:S,,Z]3%3_&*_(L\%C$3L3U*D$]N6>,A?.4V')SHO>'?7Y<^YJJ_'Q&[
M5MZ[_'7WKG_J]=XY=;=.O_@]Y2/_ $OSXZ?](O1O^PV7_P!Y./\ 2_/CI_TB
M]&_[#9?_ 'DX_P!+\^.G_2+T;_L-E_\ >3C_ $OSXZ?](O1O^PV7_P!Y./\
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M^'$3WAV744P&F)5@P)\K,7DN]:OT]P"3?]%O ,:/)>1L_P"E?D=<ZVZB;VF
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M3]!^:8!N>&T+'6K'$-(O7)VBP)$F=^&:_L$:I<?85_E8.U1W_$"9RFB8WKM
MMH M,OXE<LC5G:5?$L)8YDL 3=9P',9-] 8V1I-AK<@;,$0X!?  P-6D)843
M2VPE <UC-T)2_P!HS5;@T-8;ZI8;!$+5>5A6YJ02LD:0)28*I3?N^GW9I7HC
MS7KTK0&YOC^VYC1&WLBVUB=)9#_:L8MHA-$G$;J#[R]W9>X-5:$C"BV+K6@-
M/HB=*(F7=?80YM9N:YCMR -6*\MUT@"A#H"(MS((<F45%B!7;1'7)T%35)$
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MS6).&K//5A+7CPR3CJSV:L=O6O//'+Y&_5_P@L>]+[N.F?+OHIU0/4OSU5*
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M"Z^J?_7!X<_VIW3_ .7?C_0NOJG_ -<'AS_:G=/_ )=^/]"Z^J?_ %P>'/\
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MA<E9V %5I>D8H#+4I$@\;-(&?8'HFR#3J?[F67'@$;P$G?0YB.BO<*"-' 8
MB;^\ DI;9-DBY5W\IE^%Y:G^9UUW5%R!O=Z\<Q)D95\2,/7"*WY)1/++89"K
MT1AB:X3:PY+[39T!BCS],B&T,V.HGB7RUDB1.NW#X]1W,%MD;'^M%1VF-NEF
MF[4>GI2XGZ5K68] -<ND1(Z"]:6,;2AYGN0)M952.R8:RL-4GR,=<4F:@2%_
MU7\\U-A1-'U=3VN=")85VG"5CJ8,CF80G/L?I_+EJ"CV%A:S(T'&RR[BA1<]
MC,;1@K3$@83-FJ-KZQN7CCCCE->@?/5+>J:D;:(]"UV M:HGK6*UM:*S:Y68
M@Q_!&QK(&V[<X,F%.CR!9X0,*P94*7&DQID+1MU;<>\>_P :A]">:&5_@(,B
MDG-?J1@049YJ0;JFB7S%>U5=8L=(Z,B0$BI+,IQ]2V($2K1$(JC&JO W9 @B
MBR]G%_;G_P"1%:IJ?S#( JZ])(!ZW0#M)O&EF"I\'=AK79*;VLLQ,S:[]V%Z
M"GR7&7_=YA5SK5V 2?T\EK<OH\+<)QGR99']W!S2O\W98&D+'J66[UU.F-KU
M034**Z*HVQ0Y';0=G![&BNUF@]KA+VNUV61^QW"+%LN,1!]ENH2S,U!=?\+E
M&F06FODN%I7T96UT++TJ:E2O.T_L+7PU#-K&A/R4*ABUW.WUMFL/PE?795EG
MI!QAL_,NLL,1D&[H G=!SG_OC4G"M_R(CGCIZ0 LM'4 YJURUOXS1%1:X[UH
MF%+:G/\ E5>;-";H,7=2.,29BP[$GH3KW;+EC:;([)=:NN@&,-:/C.;/PSO8
M;T0.0F.02B;1#DF5=M',9"(#>;?O55*/DO)XR[9VT'Z$<*;9]IC5V.CE$GS^
MO)TJ'CK99<D-^WCY%PDA!@SZJVK3HTUPWA&%26)U>+4@DY5PM.U[.42AF DS
MO2H-/HA:3;X7^J%8XVJZTYXI.Z%.(+6]BBG5J3G_ )5G+BH3QLIM5A1J0=**
MJL>J/P2N5V)N!F]LW>(C2U6-A$/]P("^K(#)>M=@($.49@#\[6D&(4^=J QL
M"G6K;Y!2*[<JZ8]=H(9C6D/Q-BE&"=9LY)^(PL[#\WV)#<A;(7M(D*6+N/[_
M #QH67]]!KD,<R &^7UT TYAHVB;G+0^3I&QKBMBS]=JH@46_6HA6J-5,ZBW
M&<OYU)<SCS^Z;&,N[RCQ??.(&(XZ,-&S12> Z&R&%;50QED.X[]G/!WB/+Q<
MF;4_LU7K9WNW3MVUD"HS.#9\^_Z6JM-BX:BK-8SSD/'FX-8Z&1O A]0T,1:Y
M\0CHBZY@R>48?0+GQ^?0KS?/)>CO>=J&(UV&*%B^@_-S0XC%[RE\\_>BU&M9
M\JKSG19YC4*I?$^\_1R*31:IBK3J[BCB&LSBRF)FE54>7A' L@KYX%_)]5>Q
M'VP/,\*S#;<49F;TBT(]R>IZ(5U#5:UX>M_-%4^3:HBUIYXI.O=C/1Y3S-/H
MM2L&P@MBU;5[I4B 84K:F" Z0RJ306USK_W0LVEYRNGT9GBA=7:_F/<%;5M0
M,8+7EZL9OUS?5<^3TZ>KEO-+7#>F=^HEZ7*+2]--GY==,0;^LQ5P"[<D 8>5
M=8F-Z-WB5#(_5/TCX#\ZN3Y0E.,GFGT_ZNW6'Y 9CM';9=\$W^C],KSN?'T6
M93U-S$^81'9],5JQ:-9/?7D2^&/N0N")YL?GOU$5?/-8476%/>Z6OYH6,@^9
M:TK:O7VX[DVU10H8AYZ]"0K#J]:3P ZI_0^\==5HUS1",RV?3;>?9T)PG7HV
M&%:_3&^R+)3%.QP=PV%@-#T!Z/\ I+J7_3P3QI6-Q6A?GG>UK5\5?,.RC#5.
MO[V=&E1MM"[/0R&R^E5!:,N-J2[;2RSV+5X&Q9'=3A\C43F"=$GZR/BYNIB=
M\TO-IV@+5;;KK)PQMU^A60]J\-,;S3;85[6<[V<//+8T6%$CIRM9Y]P4N^P@
M[2"FZ@>L@#V2A,J'+W^I''''''''''''''''''''''''''''''''''''''''
M'-4O:->VA9=%;P%,Y3,;)&6E0KJN?LV'6M88](%XUZYF-Y"9O(BHLT5! A"A
M$B#DR_R'8L/8*TQYDN5&B;O(\)YT^KT6:*;<'=I'L!B'5ZR5)SB->RWL;&4R
M-XSHN35^'H$P,,(BZZO&+J7U9V#8\@PM,@ 7'JD]" 3ZL _NIJ1^C5DJM<7O
M!9K72K*BTZ%T)6VX+!5=Q3IR?FKR;/M$FZK$'LCGC5IQ>5K</+58,T'(TIRX
MNW*4LA&W>GCA<\8*4^IDX<<.5P^VBF8:XVD17B39-L5VY- 10(5OZ>TN^E]F
MAS\E;;+(F6E(HDG7S)K<]^*R!E+ WID!Q0M@XZ/5/RS$N$13:JOWEI/[GX/'
MF=3C;'(6]Q,D.(F2Q)>&$,5U[LCK^:4EB2$5F"7/=&W>3,BY9#IS=.Y&QG);
M%\<<<<<<<<<<<<<<<<<<<\^_>+3[?38=:&/&BCJ?=NS>TZ["6<HZAEMRUK^Y
M4L,'GA*:I,#]MBY!$=[I2/M@S/Q'GK<7V/?IU?T_J*#-(RY?[20RUKKH;N 3
M@IO<U:J9VFJ].:L;-EL+L'J,$^M$#5IC80!R6ML!CT@=#BH"YF1Z2(2O'TR(
M962JSKE,2_H'8R_YRGZQKY3=AG$&YIMT'0 &GRT^M)#X_4V[UX@B.FH:Y)Q0
MHI)<8X@&B_:V:UR":X7G]39DS;%*2JX9'#Z[='4S9!"28(:$_" !G6'6*I)_
MU1U+)B;#@EB<*9$D[Q]79I%GSZ9=<NF!!9(#QYWS/B741';>I#O1*Z9^O>F5
ML:C_ 'Z-S*RD<>K_ *\%8\Y389A@615^M0LQ_;J:HBP:)DRW Q4?5;I^GK+2
M==606 B*L5E7P4"\!^SQ"3]/!6K5%),=@S%DU#'6&VM:DF4"3L-%ZD7_ )H+
ME3M:+<E.[$%XH*@3,:XT0LS 79L(,RE-%E"3+T2CIDZHZ 8/K"JW:NS+A"6B
M7K<TPAGBP@^T14I^%-DSZ+K_ &V$F"\1L?\ .LKRR8'9XUN/57M:C[+9GO<*
M?)L0+C"&86NY.'TDU-<GI-BW7MQ[L%^V:QT^OO/'=>XD-=U*@A'3(9C]CTXY
MT;_N:MK@_P IPG[M3IG9<4,'R?99G9(JCN_O&43W *?&&'Z<<7-Y3IB5JVB9
MS>L4RO\ 8EKAXI)'+ =E52DI;]V9.4U/0B3J+:R434*1UO"'^U(ZC)9I](>.
M.?Y_?M!HNEI^O'UXJ11]-WE1JX!:O*,.M@E/9UV.%$+T]R4IYF\-?U/9T]I2
M64^11Q"ZZ!Y)2$O3X# "T"MS"@20;QK@F]5!^W?1EC>3_1?AZJ/!]$-ONUL\
MGVW<-F(CVD.4OTC65C61-IZGUJQE&*U^1V2'=K*X5DS5Z4LI[KCT@^-EHAE)
MV5(CX.RI<B@KVG72O_"='@Z?J^T"/@&_K4N!1H9<AWGK\)7H5W>YJ']A6\_6
M=LV,=\^823ZWV=4'5;*:$K3ZKWZJ;15/?,:FSM[Z;MG:SJ"?0-Z&]_S/#GIY
MN\C^;*I6?/-A^:?)C]NJ1-NT..M('?.^Y["JJ"H^F+)]-QNR;#3JPJ@:Z8X;
MUW?5T)Y)_>WVL13''9V >'AQ=)+XQ 7$QFK)O!M^@-\7G9WGSSCX]3K(1@<<
M=YR??=[4B@^GH:O>/R5982P]E(2BCW.5] J]L5M*7Z9EA&46864.X<*YDB,I
MYL\KC?%5'>E//[_ZK\N79,HJC7+9>'I%MM>X+@\)[T2/8P6LR'ASU"F&'XQ"
MJ?T6MSR8INH=?\^Z*6NO6?0$L/W*,QYS")._4S\<WT_9GS9\ON##3:G0>Z8N
MN@H%62*B/=;*(Y%5[1>%>N&4"HV?+GV!#@V+7X99L?$FV3IAAEV-FQFDRI'\
MQCNS],^.........................................=31/@RH6LE&F
MQ) [='ZEZI^B3IW0ML7O#]3J3KE:\\M&<?O7_P 9UNQV=Z^\/^'UE^7_ #YP
MXEQ.>D=(Q*#LHYC/5K$[\9L;+24SWZ-DK3@.V];>\)N>Z-JVR-6,;+;WLT:]
MFW#KO7AEEUV-,V'(WRHNB7&WRH.6K"=&T[]6S?#SWZL=^C"5IPSRV1\MVC+'
M=JQW8X=[-66.S#KO#OKOOJ=&PO?[K\"XOO\ 8Z=\B;^$^)W^ST1O_<G?*_XW
M_D^F/_\ /]FW\F&K_P">98\YNR@SK,?K[(P.MA?'+(5AW+C]9D\<-'[K/(?C
M^I^,W'"+_P IR[C=;>L='_'=_AK_ .%S^Y$AV$B3$SGPL)4.+A.EQLI6C&1%
M@[,MN.N9)T][.MFB+LRC[\<)&W''3EEIV]8Y]]Z\_P O2P95S9.&#,#X7,D:
MA9DPX_ K!RG%ANO#K9L(#(G6_O?/A8:^^L\Y<77MT8X=]99;.L>_QYC\7M(S
MSW:\')5SV1\-NR1KQ81&6>C7H_']?/=AU,[RU8:?P[_5RSZQQU_AW^?OK\.9
M44>!GM>W<#,BC.G1LZU;]HHC#(Z].W+'\^.O;G#W;L=>S+#OK+K#/O'+O'O\
MW77X?Y\_L,V%(9QM< N+G;)D/,A$PAD(DG.5 U[L8VR=&QT[L\M\/7(RQT9R
M=766G#=ECJRSZS[ZQ[_N1L-A&RF9%QF,3";_ !F<K*?%QC8$NI74'L?EO[V]
M:L9O4WOJ'^T[RZW_ +KOJ/\ I_K=_DXEFPT#*5A.+C(6<&+IFS<)<^+'RAPY
M&[./'ERL=VW#N/%WR->S1ID;>L-6W=KSU89Y9XY8]<99A  >M&1TX'"XRN]G
M4;(L3A#NI'>GK#O;UH[F;]/6[O5ULU][.M?YN\.MF'YOP_-C^/>B38<^+IG0
M9<69!D:^MVB9$D:I$7?I[_'\-NF1ISST[-??X=_AGAGECW^'?^?^7.O$,")^
MO/; *#INK5'T3-FR).C2=>N)*UY[8LK//3MSQPCR=6O9MT;\N^M6[7AGGKRR
MQQR[ZZPEE7#^6_ $?"&LXV.O.3@)*P2.4?#;WGUJRWXP]^[O5CL[PSZUY;.L
M>L^\,^L>^^\>_P ,UQQQQQQS4+WC[/K?Y\>5+3]<VVM/S<@5-I5MAQ?K(+!/
M.,_MO=%U%&?QT(J5!B=>B.698,DG-)F!\2$-TRY'>[9NPTQM]6>M?H]5_D=0
M\W.C4@O[,+],L(T(I81Y]=H&0+L@NPV;3"8)]N.Z"$P=R,&=JB*U9P2LMX<C
M,8F)7!,V8-DZ^LC!^I/@THPLJH-OZ!/8E/!HR+"8:':DB3NVI^Z?&-P0'Z2-
MGK;2G[L,PP0PA4V&BC.05'& LPR\Q.:- FMSWV7^>0,^I!M=X;CH]E&2#Q-S
M (-@ST5#7\*,V^B8A9Z:<EG0/#Y$:QR%E] .-D09H>TZ*U&0@O7G*W1<^,^M
M?AB:ZGU$A<,=:@B*]UV*/;V9?: BZ>@0<K?P<EK3^_":"H&PD/91UB:&"N6T
M< >),M<.P@*^7F+C%H%2O/ZD^!]6V'HW^C%N-(G*))TT1Y2S8$61B-$=,V,\
M-*CR5'5N@/\ KD)3F/U5;.PCV9++)[4'AJ6\HNF(<+-5U[QKBU+\1Z72TQ]*
MK5IU6<M>K;MUZU;%!>@2M!0Y[1E!7LF7JU @P%ML4 L3FAKK\"M:;#BG:[WD
MM#8,UCIF\?'''''/E$^H?R^=;R]C/5A>/8GE&)[.LJO+P9K([-E7&%81'S@Y
M>02GF^KR%@)YFYH@DLT2;S!F@576LF+JDLU\5BJ)AD L$Q.89IWS@0KK\LP?
M&%O^ +GK\D2$N:\VK_DVHO-UGKMS.&7L:N$()(L&KZ1]FU0!EHX.U'1FT*AE
M5\V6 K6=<0QV=(Q%N,.%>6+6Z2NZ^^_ODPH(0SQ9Z#;WOWR=,>UO<S!!NQI#
MT+8P;V28I]Z5*D7D.L+%#+J\.30]SU^52[+)UX#RJ 41M+0\$M@H%NUJ4WO9
MMG7?D?S-Y>@[85/_ $4W34*&I61>*W7OTDJ7:TC//#/2^"W7'I[=?Q%$G4-8
M"U>"J9O&C %>5*]-,=95MAEV[::^:6&<K%%72_Y.VNFY3;6GV.S6TZ_/#1YQ
MEA;EOKT)<E5U/&(G/.C>DJ%7>R/+592JU4[+PC5V?RBUD75-KA8K+I<[G4 -
MF.#'-F2(1^,UN/K+SC[06K7+^Y$#S@3]ZNJN_,C%/NFCLT\5YTD]#O0ZD\^W
M?.=B W)IEV;[9K))5;(+N:<PTNI(-Q7.* AT\8,@QDS9]EWPP9!KA\T*?9PA
MJ,Q #5N>SIRV;@S<2(XBL;/;?HGI:WB9FO/9IW!OX+$?K#_ML^XFL7A$U1.L
M8V&K''UQXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXY1GI>L,[FH:T
M*PZ?[#K#2WK$B!/=:H/:E6P1HG1(CD#,!<9MD$CM7][&)AS5F:9':-1L:,,3
M98">*-Z1Y2'\LK-8E_1?\.S1U30/,A<YYV-_+;SF5;O3T*UEV/!26J::2 Y5
M6<Z-AAR=DM-9KRSCK=K<)B/TQQBK_P"KESK;!D][R$?R=UE):[(\BER"O45C
MTX@%/3._QNIQD2WM-*>D+V_WUI;*;!OSM[1WE-/4#-+5@=7"%*$8I=Y(K5?H
MYQ=U;VU$)MAF1Z(_+*U?2=.^F?5LFK_**-[!]C&85Z$/4X=>;COG"VJ]<X?N
MFQ!2ZJ^A[,M%Q8*@LHRTU\3U6-39",B+C4'JP/I556;-2^L)$O:<GY,^<"Q9
M?V(]3VE0B/6-&)KE4WCAJW U5YFJ1I@F%*5]*W';EW":[*C&9HK\W>]I5D+N
M'7L*QU?.JZ?,Z#>G2NF6KN;Y?5>X^*)L3X^44WG@2/Z;'-\5@3_3SD==QZDD
M>9*5^@5G,58R?'2KOB=;T\Y[8:Q45)JH=O$:LESS'NU#'4^>"K:K(,[^_3UM
M]I:SU1784\O&O,MX_1NI;4^-)^O15J*%S_TN3N%Y5&SSS<<UZ0-$$)I[$!I_
MHC+#3GC^]7M,KO=OS_+EUGKU6]%5UYKJIP]L4A*3R,#Z[+/LCS&K_*C+4MM^
MVVAWFU'#>;@'G'_<]LPT?_#"*84EL!:\>X=8HA 6XO<%WUO.K(AG!QRF?O/Q
M)Y)JP%_B+6RN?-U,HS#5],>1NZW/A*_##Y"5C;M=9$;7R [X$71)@QWR=MVS
M'37!VZLS>S/9E,RSV9?FZ]"_#;]4]=_,KZ3N_C!J^?;98U?5?<#S D_."D'V
MDDF&Y!:%/E*\UN:^[MK@6-O?1@--WCR@\C&B?Q/4&%A"PDZ=N^1XZOZG,0??
M]3A/,XK5C;B;YJIJOO/"F$',6WTNPJF7R#O> OW)5#UI@9"(OC8+8)0$(LQ
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MB*U0(_/27Y&(SFEBO?UCMOI;UI?A"J?7_JWSDD@?17H9\N!6"UY1K1#S3),
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M''''''*37?-M!*+SLLU8I^O@-A;66Q7+8YBU@9$8\VJW="M&M!@[*ZM&,O\
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M8VJ.TE**L]@^L"5\4_YE7BU6DA6Z[R]2V:?)UM;#8U4@K58!];D8B?89QEO
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M]WSY.HJG$9#'BZWGNS/ZD\]>,FY2@L,QF;6%;4<=MH^CSF\R6D,$Z NJ<2/
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M%S^ZP"JM[GC;OD&XDF.G0MXS;LA/-9-TJ=9\SSU6WI56K;7 !%\]VN2:0;.
MQ"++JSE! 3#ET/ZS*:.Y4R#-ZE^@<7VAJ]:JEQ^9Y:CYGK#R0FW"T!+ 91RL
MT'S&RP_2";8R:S;&4XFAXZ$5D>?)^:BPG\E1?*J\>6<=)4-?;H0\;F8?V %R
MH!OJ%YL?9!%5EJBT>T1"1_;"T.3]:ANLT02%$85MU:!H 5AKQ5XGL&BK(\R
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MOA1(=E0MSC"4Q4MX.5_)37U&UZC"L%4O/3&W;[58K3$TC+U66B0ACZ'H^5;
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M:U>H&,&UFA5R@ZEAFF)/8XS!9GG\HIJ%\B",98,2L-(VFFAC/%I&[LCK[L=
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MB)2DI<L=@L%<%MBIJT5\+\_VK8]572:&M<[='SL3#>51\YJ,*TKBM+*1]@[
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M=MB@3:TX_P![FX,&+VC4-5)KC.#D\>LV&<29;2T=&%<1K@8# < B6TEIA"#
M"'[UKWZ&R;*\Y%KR!>=+,',D>W*?J !6#?G)19;(6O E5,)--Q69U7%^/BOB
ML;:%Z'0G##$X0XPLMX]6E.D"&#,L%1(?V#KMW%!#O]B;B A;!DIP^FRYL&7"
M#+0.VYNQ_L>I"9S,NKL;MJL >-;C)/4$V,RNI"UV/)S;#?\ -QL8^*2/K_$L
MY>'L->>3+T8]1FLFV\@D3>/*@)QFG RRBL"X> #S:E#*NK:P2;#7P4Q*K@:[
M_L"&S/8OGW*-)%[2-N4%].$V_KD2*B7*E?.]3/U-7SE@!-!=J0E"QQJ.S6+-
M62K/"5X8"&'TK:QLA;IK&75W\6Z&P22RU6 -]GM8"*Q_H'8-G7[YJI^MJVC)
M8*V+-%'BS:UF1A^2S^<2=>>LV!>+@1([]'-1=V9F\OEMA,*;[(YKJ@3#XZI,
MIG-E82/41/Z<W<I&_16M^I\# 2Z]7;?CK+BG&H9F0MLJ!8OT2 *\PTL&YPB6
MWZF1;\<@8Y2#"(+\<0QDLYFJ9(#L$C2G;5COH4+(('I-O_L^SQF/SS8"PC]U
MM/8!H1R:=;U8.=<HIJ2/9H '>L#6DIHD%@S#G'-UVPK_ .F22K!;?VQ[2"KC
M#Z<F)QTDJ O,C*79 C4Y5N6TY6>F#1']SJO%WBPV:MB2LZ'KW3PX8!YZ?MZT
MT3!@K4T%"R$/DC%V(7:BR/CM'UTK*7T[SX=2/DA=2F :D[#6!Q2SW&7]YI9_
M] 4PHP F@CO*Q9-L5VL), 1.+:!\0=9MJKE8;.YK,%:]8?8CV_ZM8/)@JD7&
M L8-P-G?K)$O"O#RC8,!D&F>6_0%RP!*D5(SQ@D2;GM]9+4'HD8_4'?QF\CH
MWZXV4G";$U#M[ZPLZ8(90 'SUM$V>. VL/%9/3IUHKDG:M0/5M)KFG+#7' C
M1MA1@\.G3[5+'@"L"S="^P*)V964-2V-K0H\;']GT8$IOS=AY\M3>/3YLXH%
MS(:#0'4_5Z(&707+L*5@22\"C8S1!U'G2.Y;2Q#6KA [<A'7BQ4P+,;YZ7MS
MYQ]7.-^>A;@3<T:.IU(J5FH--;&)12$39'.5OO'T?4+,P%-$+=C_ $W!F;J7
M@30BS*C29T49.C$"!7HJ2)+:SOAQQQQQSR5NVW?!K)8CA5>FBE"\+2]8VU6W
MEZ\!Y>H'F"(L0.CF7U<WFVE\V56?$V*IT(127I<VFP&\TOH-C0("NS-E?;L\
MCHB+D]'QP@6'#J0G2U806:O@?5 0\=GF.RHB*MJZ\1L6H<T_78&%:ZJUUKHY
M@M"PJSDE^F78+[:+,E*<@KL-ND2$1T.]K!OFS;UL4)8, 05 =5C9CC9+DKQJ
MY'U 5Z=ZSJU>]$[RMIA[E\NLMUH,<JD^8JD!36:JS*2ZL=<,0./J@,*]M'2=
M.Z-V6/\ *IYEW3?V<^/7-\E$5N2&'U"I^6'@_>JNER$5O36*R5OMOHITUL%<
MK"35[XJS[5WJ;-58" NLZU//1OY"= (9JV[+\(>2XOGOPI95%LC14U!UVB*:
M<:)U,[V>"1$@_P"8?7:KO-:<%)&99[,5SIRC+25++EB8>.W2KV(>.&=FL+ ;
M,HDY0J^^7UX77"@1//=)L%Z*#@^&1)\?3AXY!"'*[LHPDQB>5L;T$8FBWV3N
MHG49'J^X_P!,<4<O$)"W_.*V.YB,QW^\_P B-5(-U,;55'B4-8&(PDW5U*\X
M6U"3V('7*0.#@[)F I-9:<<J_24N@X(\'<.K3J2@6%0?HBFR.13<_P!E,EZ_
M_EM5">PUN#@(E6++V@25%SJW.B;#0I<FN*J37-(-@'2N9E>"3(%<JY!0F 0W
M1&$(,BHJK)5I#)T*%OZ-)9.*'Y)\$UQ(IST>@1 5.4;XWM.]6T17M;5^M*]1
MQ;Z+='_,K]:39&@5]L?)A1 '_P!6(,*6,8H* *%18AN5#E"$Q:*!^5VL;Y7-
M-A6%T]@JS/N3PQM=;6,TF*>=B 9K>9?]"U\TUL7?NTO:I&7PH!HJNY6U&UGM
M[.5K.NEFP8@J37@V$R=QRW:^^054B]%Y6A1E+1HAMM]/J';E#\_-+H2Q.Y$+
M6A^J]Q.,I(S 7$@H>S3<\Y]:B<*$K# T][.:#$<,?*32/(]69\GC<263LZO5
M"0,?H]D$&>:_>8K9TBOWRE5#]2EC@[%VL-7:X*FYP:7\[OZ1/2G?L,W24.LI
MVJ(%WBXD'=OL24O?-&@4WL[#JJM5U2:5BPO&TV.ETJU-79ZOJY:+)*VQ6YY<
M3T\\2(ULHM$6T3M@M!L9M3X4R0QFC['W_+YRINN-4W;\J#%%EMY2H U8";#@
M B]H5^0I.V21O4/5B["]P;1/EQM?Y$3%?)S*O,;B0]*PM^=>KSI *&B5BQ&C
M';)V; $_0/S4V2JP69 Y<DR*--ADJE00:A;1EX* X(5E&!)VK!P&N]NF;3((
MWYND$NK04M,^GA)6G8TK<TZ):T/SU26LFWYUKTZRO0M9+Z&L%:83-0QM?QU6
MMRZ3P0",V>%$&D?7,5(,RR5=RGHLU34':LX37 L+<H:U!7-G^@D,7'J,1;7R
M82\V-?AK"*E:7U;M*>\QR?G^T585I&2PMG9V<CO<TO74 4EL,@+YSMG1NIYD
MD@F?/56+/!#*'ZL7/1(LA2<?&5*;#_K* ?9(0BV80'S6L*D>E736S)8ZD-MR
M/;#4X&H%FJX]UPI8<S(NVT[%C.8 D1"C8!<U)VATU?A_M]<6J^O%$'S[8#R2
M\D#SU0#;W</,J&/ (;!.T/&5/5-#&0GG++>ABX*FC:0OGL&IIK^O$FQ:"A4I
M ,Y-X0C"E"%FV*QL/Y>'92V!4*^4EQ@?E,'0A%4ET%9:M+6UDU+2P"O7]I1#
M%?"-%;A'HN400*$1LG6KP+8FRE6*GD&?+(9AC B+%\DR#A=M$VG355HA%/\
M28M1-A+'J4H'#6!9K<A1#,$^H$)2]T(,+T\>ZLP+?$&3\@4'#,L0(P(0EJ&S
M3%RI3+\SF^OO1X1434??6Q%?,W#?HJ?2[\'77984#YN8R,D"$P)4#38@=#=P
MS)$8!=?:S\9'L' R')#!#82E1)E<S[Q\!^3[#LNTEDV?GGZK\_&*M U[7]1,
MT].1U*KB5MV.PHJN[KE;:PG3C;+LAO'>,9YL0EL<7&NIT-6PP+06+J?E%7TE
M\T59AFF"2PC5D\2)ST>*E-=*V5$TP>ZXMSU%<&&+0Z;*L#"5^P)STD>EK7BU
MR8FQVZ6\:+'S 0&4AW_(E/PTR/E OU&EW.TU F0:^VL]B4FL:I/F>U<VV&QH
M=>-J_9:.6JO16VRQQ>M$K:AV_ Y@S)\86I@:\F%<) _")HF[>_9?I/YHOR(>
M$.*U%L$1J.,UP&4<C05LX$H#]&A-2QH(N8\Q7X[97C9;.@6SH-?Z+!V*V=W0
MB9!04=;>+8=XXAAZ[]@> K$7NM3)6!12**<11KM1KXYY^MU@9V11J-_7"E;K
MU=K\"L9,]]FHC7/5&@C7R5#96.KI$N$2=!@33JW2M=9;K+^1,26'J!=I5#:J
MM8:^.OW;4DT58;6KF)^#IY<"JZ<B[UJORTVV6ECW7?6<;>)K>>RDT$$N#TYK
M&A0_485!V@GX_-N@W=&9^T*MTMPL!;KMI668!431,P#K$>:KJ]7'&,T 4YXF
MJH3">@IRHI3'.2HYO+:& KL+(XQ (D*!6U\^K/$H!S)#=E4P+59'D=@P/;-F
MB,(]6CZW#7XF3MO3BY3U*7$V$"]6W#YW8]\*)J(S<U5-$A)6C0;BC1F5<B6;
MY;@F5$+(F/=<[Z?MF*^;JUK/SW8LV':]I)8"Y:O :U?1JI<DV6U"\_;--MYQ
MO[%2=HZN8JAL_JKL8C+<<3ID3X!^<OMBZVU+TUZOMYTZ@[[I>_1@1,(00Y@9
M2#[2 <F! /S HY*5BPV,;$ H5DFD N>VP02'I1&F; -K:SI 58HM/RB'7P=6
MO[30LH5F(<5$*%+$H2P5Q9J6$,'4Y5PFJ&A:;ZK"%*E#O0>T$-C%NUFYA!C#
M+LW1_"L6_IXPTR=D$JS_ )8[5F9K7@=?K@'0E:TB?!9Z8L%&FRZ_>FBH(>,:
M6.=4<(9*K;HP7)31^0<W1Y<1BCOH!WF$I8R?+-8_EY9/G0^^>@;+/I4795.J
MU]+-;=)I"CWL3,2'CU(\IFPN3.UVV* 1F"*;-'N==M4MD47]*TPKQ9>8Q&N?
MLW*^WF<"C/GKZ <GCUF7%A;'G.$>J/-I"?:U4LX[6)B6*,DJR (&K#^BA3^*
M_<*]Z&U#13E.A3E5@5[!EZ@)V.!8V;$A312W?D_/KD:BJ]9+]C)#":I(1!%K
M5'V;)$'(SM;*O$%,PIRE)D>"U2TH_P"ONG>R,PC"6;1D.WSG;9H[ENDZ)/L6
M$[_.< @MGJBK*3"L>KJUJ?5SQ!0HAQ!.N]@NPH+K=+:@RH930S',33JUZ.+M
M41D5@F]8<@+LV'@DHZ8-D=LFIE[TQ\U?0:?0]OV'2RWI(0:D1=@57<*6LL^_
MI4?^2IG*K41&2M%5;I]N@,62\0XI!;$N$87)$XF?U(>PM"+N^8RT;=4/FL-2
M_.%'.(<<J5<<;!GHY#1@U:/<E(:OZ@%[ZF#'[5,QDLM&5!10Y=2H$&S'XXHE
MMK;)25R--ZPCXA<L?C?/R>?!""SS0:A@M)T@G:""R,OGFVTU96"#3TN6>3(0
MC#!6H(.&+$EZ$E>A=JW-D1R&JL1"9Z2Q#Z:]!+]@0935R5\^+LL.LIU.]J\L
M0K+E@1UFHUZLL59(-[R_G.AT.78LZ.5011[?H%^3[/J6O%LC&/1$8Y7%FKX[
MN&>(#EW: V_/^2_,[4U0GACHVM3+</*;S49AGJX[>3_E) !76.YLB1EJ_&;M
MT!4E.BPNIO4C =N5E\A PC$1$&7HB9+PEXX+;VF7/\W5-MF.L85$9INI3@19
MI*.$F#B(O#J9$QT28/<0D*B$\=@[;$V;"?<PCNSV321+?+LW?YWHO?6QRG>Z
MG1--6L<S61+H4)>'CUB01CRQI"$1T"X.J/''D19$,'(AYX[&)+#$!(N<*W0Y
M0^)NTQ<9Y!\O!.Y70>A:O%:YR"-JZ7''*0N%$D5Z(CA(@Y3V0X^C7%R$1H:R
MMQ.M/Z/Y]L1?"1MVS9H%0-<?-5[YD\^5.PSVVM:>0$EF)$CI:6<7EZ"/)92V
M3J/_ #6&B5JU];(<"9W&UY]"8?>@5&V9R=L.%'V3)>6_'S/*'FHCC8&LA1];
M3]-K$,RMD1IRN.EQ'0AMG.Y/?)8(DC5LC$,I!.RK")R<=NKO7)).S1/WX;)9
MLANW\2)Y*\T5CW+R0:2KU7W$"JP>)2A@&-A.)GDQAEMRR>*3]OZLPD<%-A @
MT:S$[?()2&(A/-RY4@G-E2MN;Z\VT'TR.3AW42'DS6$P+S4[F<U^#LF-#&ID
M5@PN&3&6>O+"7/$%DM5*1-V>'X]$0<"=G^>3KRVY<2+YF\_5DD]UN@4^@J:)
MDX!'_-5#+\**'V.2U*7I:TQ;8O6OO'<16\E%3BKVS;WG@#%JZZ&%X1!(,9"B
MP7?X9\>R8J7 V^;JB_85UH!Q4B#J3A<>$M15@0A UN(-B:-6J/KB+P^K*TZ!
MQ<]6R.)F5^FE(&N.46A$R)VC_B?R4TP548P^>JL+#D@$%5U2#+58&<4(M+@L
M*' +T31CACK["!82RL=C!6[';!A35=8*1]&LHNA9D&C*O^7GE%"_K?8V)(:Y
MI;J]B'O;*L5(K*+T*FK\4]"$18T! 1TD22RSC-+)J8RQ^ 5,N,<OM',\XD(B
M#1L+9PKY;\YG1V8@U2=:EQ6R'L'[!A-4%3A^V!M$V<!VP]T.5'VQ]L;8&NBV
M!F>G9KRUY0K":]&6/>!>5UGBAWD+R^)7<U*#1-:8+FX?F,EBMRQ F1R4/=HL
MR/+Q+Y3-<C<8WD==SVUD5FE-LN:6WV.Y224B5)8".W?+3?GVD6800 LE6I;"
M'+*5?H92 <"1"V@DGU4>(--;@)W1#"1G+@)#*6)'UO#?EGL%F9N\E&V83,_U
MN0\9X\\M!LFK,50E80,W>4RRVO*,JC=?9K-PA3A[)'E=]:O^".*Q"A;5N$Z/
MT1>K(N8VQX>G<5(;).;D>8?/,J<QDY--5[O(-XQU#-$S:MC\Y!X38S$6;GP>
M4V=ZN\I<5M9SIDZ=U;>\L2!,E,E[^LMN_/+N$$_"_CLUI/1RWFVH2.EG=.[!
M/X2TT7NZ)MF>MBTR)\CO/3WEU$F:'!RT$ FOO6!(QW-QT3QDC2UL&!&< O,7
MGM9B6%  4\A"H5K,45KL6+$7X>&EN/0#\IK@32VOO#+';K'M) HRP(.OK4/A
M,!@T9BQ-1$R4DRXJ7\5>3#S;O>S/GNK"3?)E-$_>>EJL#;.VDG:0YR7 MEEW
MA^GV89L[#=]1POUKZ)DH;*4@2I6R#NZCX]]V\?>7+'BSH3W0M8M4<D1FEIV!
MA6'2LI)$HSV&Y%Y.S=EKZW?F-L=MVE/.Z\=F.HWA8KL/*ZY@UG,0YF<7O,?G
ME48+,:5VF*Y$GKF'30]JD(BL+QR?@Q.24G$PK+'SCYQ"08H2.L!8F)VZ/XX@
M88F(Q,C;R9\Q+F]1'\J^<:UAZ8"'2]?J\?1)7)O78L!%U2=\Y0<"+^L$)L[/
MK9-($ ;H6(LHZ?/D29D<K+V2,=WX]8=8Y#/S50.UE<G#;4*%M9K"/+;2[F=B
M]!V3&AB3RR>>63)G+/7EA,(!3=?I1>%(V8?GP)K0F=EWG)C8[._R@>:* JM.
MQKVN:A0TQ)P<05@8+( !#@"<7-5E+TM58<8NO#\O4]6R4E2,LY==_I+XQ870
MX?7"$A!D*+T5?RIYM2MTB0JTA6H/=(L0?;.6R"JB]>6BQA&HKI#-D'O+1G_&
MD@>LZ=Q!]#_VT4+V;,9"X\3(I.[WX0-XQ\H+PQI"A?/=4CA#J.;@S2-C)XK&
M&8"/>M=TM0/?'RT9:]0(GI4EC3B%C8Z!8[2!%ZA<2%KAZ<<<FE^2_-%=MRP_
M)%(UVM.J8 E+2RTC%V'J."1<[89VS\])'+'.1N,$,F1DZ(,<K/>Q3]3(QZ99
M7=I/%L)F34O,?GM#;"#VFTY7ZVY%'.=8<UF$KL&(9VN9(4YA9Q["=AK_ %H\
MF0.L>P]>>F-EIAX[WQSG81\9[0;DSNEO\I^;I6#OKDTI7F_79!,J9?-6Y<A;
M-344.=V#F9G&-6>'>N3O*;+8LS?.R[QZZDR7QJD[>LMYJ=LW0IU\/^;6ZLK=
MJB%6X!*6;V8 ;':O:>)%0)CC+"N<9Y_9E>YL$A%VAR)C IU,#]1<1VO!E9Y$
M"-"(G)\W;GB'C/RH61<:S)4%6,Y$QE!YW:U)6(.V!LG@H!@3!G[LLL>Y,B?M
M$L;***S=^_9*/BV9F''=Q*$Q&M$[#-OBVA68JH$AZ8"3-:_9R?:;'"5%=0B8
MV,9KZQ62ZT@>XD)Z^0,?QZU>C)(M\?O $ ACILQFZ,RF0%A91!>UV.AZ:;P0
MI8::U4&!?!'FQH#B"X>-.@C&%[@-PMQ,0],C'/K1/8QK\Z0"LC#\,Y41F,:,
M_P#BYFS'NO6/Q=Y/;SYEI9_/E5G6%A$N@4X5)*8V3**P+$DN4MS[G=YZN\)$
MX]NL6P>I!;/#LKHT/+A%AS8T5E,Z9L>-> O%;'J8M)[S'3I;6VL$MG9L9Z<-
MD?SA8C%98A+HEELU]Y2A1/6YN&THO[.^U\E-;&<C.&2)Y\M)EVW7OGRD:F;G
MQ^K6KTU)<[0WQI%@,J\&C#RS9MB%#QV/_+RM6/6>_7@?:FIART8_DT;&%H9#
MNW7F6/%IDRXN.....:- O E4A;D%71N=;4-EU*QG2R:Y52Y=0_H^MR%FM#\]
MV:$6M Q(&L,X ^/=B%VHQBW,;,9'R1:V'6C()8$]@Y/X<_GW2SQTU?R3':([
M8W%C1HA) - L1.A3COHB'Z9E;0I&.M_OQ>V-8,'1#'2X\GJ?!7.OV^F7T9PT
MG-6L 3XE^40P@L)Z;[@V8&]KWNGY"O[*HP_#;8=#RO/!S^+5:WI5-2PFK4CR
M]A"#I$+</#)KZR.%?Y3*3.CR^/U#\O"KJ@:USS999>OVT[697S^UN30U1X,Z
M%3#)'O#<=BC<!U8-L0[OGFKM)3&!=V#U,FP0EM5U*MH56:$RV SN/<OBBL[Q
MM#9:3:UV- G[Z_V5[)6U\DJQ%B1"RKST96&@[GB03RC!@?B*WJ&R]6C+0P:@
MV<[4MRY063V+D:R$.K?YX4S5]Y)=] &:PYC,A:;8Q7Q1?*O-T'7ON5WLA[<,
M)+- KP=9LA<S+6@<[AUUV^XUCW/$JC>03"%@K\9OSIZHOEHA@ZWP7[KLJQK.
M<RE-,%&&">@PMB0BY6Y^ XPXZ6@]!D1<*1!"C*?FTRI&V/8:<]!,OC@<83@P
M2$'CL^Q_-A-Q[8K#@OME6O=\E1ML1C/MYU KJ58TRY5]E!60 LX56=6CPL5,
MLR%*K<2XQE5'U9CAU%4U.51XTTJDYK)90;R8T(GDIL\T FT99PJ=Y?!42% 6
MCE)%+QEOZ4FQ?LBQ'=K "33A-FW 29M1YQS_ &Q63'(C]TL7CJDEYVSJI,_E
M!24M05DV795SQ ZL"2",$8%,).H=JOU#I>!0@7U%KW'D1B8IEO85S P%2!["
MQ'JL*2\]AT]7)=CW23&^Z3'@NK66F1=+-3M:K(,A1/26HBXD3"AI=6,CZJC6
M-IM8Z9WBT@<LZR>R1:+.07M057$" \KH;J[%RX$3.%OI&Q_EA3+!9I"_0\QA
M:[+%9W$S*B+8)!#TUH7;[9Q]#R#0)B<(M/,EP*U<&=OI)Z$G5I)9M0.5!T+;
M"45V5O78Y69;J_X5""?/OFZFHUQ6\G-?GY6P";+CK8\&#V$]3V52EKUP3SY=
MJ7'#O3OM@L4)N)L\)T#'<.W9#V17:P1B#C+V0DW\O:1)BQ@P18MW)^<2EX'G
M,P26V!$Z)-=%]['K8V5N=VG*Y-1] Y_[>MF3*<7(P!N@2%A4F)C"J2H93<8B
MSG\D:">PLU</6/=,@#V068RR)VR*A)1:^KQ-+V:P*E7(?9RH"N\ ,53]M-1E
M/LO'=O\ 0"80C+6Y5N$/BO1,,K!K/YF^=ZFKB\*N3-[2)7;M_A-6Z6+'5@ML
M"#%4#IAI0.E4RI5LOR&0LALQK<9!-MOXV@Y$=L$1";6%F&#\(6S"L?RT\]O*
M<>4+#9[6>\7$FQL#R<.%TF.5<FAN6?3RTQL1:*#01"Y$E$?]UG99C 8# B5X
M>2&)D<<'B@@TX,8F4?Y\UF*H^OJ74K"LJOI%:/[K92S9U=BJ52W*,RV,NV&E
MNV.M6!T_%I2 ',I-H-:OI$"*G'1 \?(.;#8P6T) 8=>3._/^DRM P_. HQ8*
MA7XRPF"PA$A;,+V1\5O:MS1J/K$.6P*IX=FL3EYR8U''7,$RSL,'/QDP3T9C
MB0SVB&$/F)YUG^A0WI?.6V]V(-<E!SF_OA]6L$(K*K\77L))&1B;/69MQ28
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MZ82T17UE<'[1N./>C#$"&D:.M4L;#D::MM_YL^0;JK_SA33;42KJHGS&_E;
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M?+/I.C:[2_&U%&:K1*BLZVK5JJS*[O>KE)GG&X:^Y)\U0<LVC?IDZ-33L:Y
MZ7$DB##%HF^]OG=8M%(HFHDNZSB8SVPH5ZK*[\RUX'WKR2Q,B^)C"9YY<7I&
MB-F '&,HF)' 'JT:X@C9)V#H/7<*-'R[N+O]3]3'KKK#]'\FS\_?>67ZG6S\
MVO\ 2ZQQZQ_+WAWC^KWLR[RZRZRZU]8XY=99=X_OCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
LCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g722206g13n44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g13n44.jpg
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MHL+2LO_:  P# 0 "$0,1 #\ _P!_
M                                 "8J%Y'J'G"?]'V56VLPQ)>I[2S;
M]J9DLR>I,V9EV4.Z#/JLV.9YB:-M7B&G[80H]=LZ%;I6PL_1D9H^UM)9F9J^
M$5&(TU^U.@@
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ML87(]M-MR<(W0M/NQO4?=78LQ,1$SI,7'>E.@@
M                                        )CBGZ9E]^['R/]JO;(+P
MCK/UZ5. @      /SPX\/B^''C>#P^+X<>'P>'P>'P?C\'AQG'A_%X0'Z  )
MCY'_ #52OWG.V/XS+[!9U]O3]0IP$
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MF;;2& J)9-$D<1R-:2?W]_;C*L@1,?(_YJI7[SG;'\9E]@LZ^WI^H4X"
M         "8J%UZ[UG_2&>DC*0WK3:TO#RQK56LJUE9=1>8;>+K;69!C#?M+
M/+>8^4RQYV3>D_6#)>V&C9BTT+-8J[K-UKMMU4Z"
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M]M2*#EB-].*:%!);@9HGV(U(    !,?(_P":J5^\YVQ_&9?8+.OMZ?J%. @
M            ?]OQ@
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M4.Z#/JLV.9YB:-M7B&G[80H]=LZ%;I6PL_1D9H^UM)9F9J^$5&(TU^U.@@
M
M)CBGZ9E]^['R/]JO;(+PCK/UZ5. @          )CY'_ #52OWG.V/XS+[!9
MU]O3]0IP$             $Q4+UO4G1\_P"CZVKC6::R3EBT\U!:.91#'F,M
M6\NP@V7YVBCHY%:)I*T^3*.QA<CVTVW)PC="T^[&]1]U=BS$Q$3.DQ<=Z4Z"
M
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MO<B=3=-2$OI!S4:(4B)%JG2$$=[
M                                                     $QT)^=7
MMCWG(I_!GR."SIZ>GYE3@(                    F*A=>N]9_TAGI(RD-Z
MTVM+P\L:U5K*M96747F&WBZVUF08PW[2SRWF/E,L>=DWI/U@R7MAHV8M-"S6
M*NZS=:[;=5.@@
M                      F.A/SJ]L>\Y%/X,^1P6=/3T_,J<!
M          #_ +?C
M                           !,="?G5[8]YR*?P9\C@LZ>GI^94X"
M                )BH7D>H><)_T?95;:S#$EZGM+-OVIF2S)ZDS9F790[H,
M^JS8YGF)HVU>(:?MA"CUVSH5NE;"S]&1FC[6TEF9FKX148C37[4Z"
M
M  "8Z$_.KVQ[SD4_@SY'!9T]/3\RIP$                    3%0O6]2='
MS_H^MJXUFFLDY8M/-06CF40QYC+5O+L(-E^=HHZ.16B:2M/DRCL87(]M-MR<
M(W0M/NQO4?=78LQ,1$SI,7'>E.@@
M                                     F.A/SJ]L>\Y%/X,^1P6=/3T
M_,J<!
M                                     $QT)^=7MCWG(I_!GR."SIZ>
MGYE3@(                    F*A=>N]9_TAGI(RD-ZTVM+P\L:U5K*M967
M47F&WBZVUF08PW[2SRWF/E,L>=DWI/U@R7MAHV8M-"S6*NZS=:[;=5.@@
M
M      F.A/SJ]L>\Y%/X,^1P6=/3T_,J<!                    #_ +?C
M
M           !,="?G5[8]YR*?P9\C@LZ>GI^94X"
M)BH7D>H><)_T?95;:S#$EZGM+-OVIF2S)ZDS9F790[H,^JS8YGF)HVU>(:?M
MA"CUVSH5NE;"S]&1FC[6TEF9FKX148C37[4Z"
M                                              "8Z$_.KVQ[SD4_
M@SY'!9T]/3\RIP$                    3%0O6]2='S_H^MJXUFFLDY8M/
M-06CF40QYC+5O+L(-E^=HHZ.16B:2M/DRCL87(]M-MR<(W0M/NQO4?=78LQ,
M1$SI,7'>E.@@
M                     F*A-M<VKVUC&<9SKT[%-=L8SC.==O8RY&V\&V,?
MBSXNVNW@S^'Q=L9_%G +.GIZ?F5.@@
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MB%5$&AQCK2SN#M*5+V+O_&/B/WXJO 0
M      !._7OZ)O4'N[W7]FLF!?3K'6/MNC'\BL__ .EM_P#_ %"01R@
M                  )DZ/\ EKF3WFXA^X-F *;              $Q](?+/
M,GO.0[]P[,!8T]73\PIP$ #_ +?C         3"_?IGU5[L-_P#VK<T@*>
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MT?=\Q28<Z5$V.+&AD4F:C9%NEF&KPB9O/5S0RORU.4U*1CA,^\?YE6P(
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MMS(9(8\[Q:71MZ;7!='XZZEZ..[>\,#0Z(E:(HC7@
M     $Q\5?H?\N_V U+^XS( W&=EJ#87*M$LTWK@[,?=<_& 60P*3845JB.V
M42D@F5HW&+94,2?4UR3F25M=(^2<F+.>6MR;BU*%0'S3K/I>V66OY_UY-)/*
M9MS+(Y) $5-0Z9)*YATH9^;DDL;8W8/:<F41BKV!\5L3L3*B;)1PQ5A$B8*"
MC;'*ENR2:RI>P(#4QPX\>O+6?]S55%M'E?=3W'9&4S(Z92.J ]#R*\DNIME;
M-IA[%VOT=/\ FZF7$EMV@*LS4TA^BL>E\T0*E*4]BBDE<M$&SW(HV2QR ?QG
M_P#J_P#VQ$SQW]WG@7<[U9KRABT(HMR?Y2SK4+7:Z%//FI&U5ZI<[FO&A4CL
MB>G9@;<2J*E3VAY0L5N9J&-OJB(K$:Z.Q:0RLA;"2"56OMVB?S'!G4<^%'@[
MI%+&E;S6SJT8J6E4=[6!&T,B,>94QQ-DJ>QIU<3/JW&1=I1+I=3,]KHZF98V
M)'/=M3S23Q+#N]1[=^0-YXJ?Q%?'2]8YM5=NRI8FN5FYY14XWJK.>Y<U1W"L
MFT,%P4EC?J=E-QMLI;96972M6Y*,-4"F\?.8CHHF-(D3?'C35!D:DN'UN+45
M=S73>MHX\)EC'/'?;J[\?1>Z9FW+;#6Q'2%PJW);J2X-S^T3-=%R9/*IK/:[
M@=:.+M#J[;VQRCSP5*8[$W- KC3WBQ,,#)4*36>G"8J9CKVX9G]ZSA]2V%W2
M2!C9GYO/1JD#VU-SNB4MZ]*Z(%"1R1DK4QZ%S0F&HG%&<2=H8F7HS3$JLG;1
M0G,W*,TVR93OU]^9<C^VOEO^)^G@%.@                 "9.C_EKF3WFX
MA^X-F *;              $Q](?+/,GO.0[]P[,!8T]73\PIP$ $Q4+UO4G1
M\_Z/K:N-9IK).6+3S4%HYE$,>8RU;R["#9?G:*.CD5HFDK3Y,H[&%R/;3;<G
M"-T+3[L;U'W5V+,3$1,Z3%QWI3H(F)[_ $S:S]V*\OM5YX!>$]8^O4IT$?.S
MHF77*XWI%^?Z'OF7QRPIX>P65.#443IUUAO-7-<9.;VR5RUU]:ZVDKL\SFWY
M(TOL-J5ND3V8D4OCE)I40T*HI3TH;W$U&DS,8TO.9Y8KWU^8>])^[,1=CZ(6
MG5;Z0?N9_7A;8$<1SHG8[>.MNM?O=3R!O<LQ3",Q)=T!G9LMBQN^NC<A6Q.6
M14US7.L??-VHE:3>)K_/:7673X1#6'.S\VV+4A3$G9)'<T!PX1VPMI.4LL*J
M)15["A;]2U\&BV4D1EJ*VHTMQ+5AA*R.N")^;W"+J&Q&BD+F*TKC7S\ZQ,:<
M,:OV??"#.]0K$""WJ&75ZJ7)U#N06XV&D==UD3BET1N VS,FXACB*]7ACJ^I
M9S"^D'LA^31Y_P!JS62<QP9&3:%NR[<1%Z3_ +JZ[Q6KO"GN)"2K<MRJX4K&
M6.S+FV)29<GD^?2B4GK:QB*_I*1,C";&BSWMF5ZR&"2.:><*V==&F]^?VUH2
M2M^AJUL<!5]IGM%^?CGC 8QWG/)+;G'#L[1YO@D%Z[HFQ7VNJX<Y>@<V)QE'
MK+RHM@\EFEBDUBG7P%_*9K%M:(-<5U6/+#,W[2$LS9L=,I@T-S;.,=)Z\%K$
M[3$3\]^"Z:7Z#;+@F%OP?#"HB4FI^298WN-OA[FFE)C:KDLV98O,MF9RC[.0
M?")ZU0[,E@LQC3G*HK(DJMT92'LJ2Q"5-#94K]_>//\ RH<$3#SW^7_8GO/)
MOX9^;@%/                         )CXJ_0_Y=_L!J7]QF0!HML.M++&
MQKJ>[%U?J&6]E+G6+1 ;%-93&BUUK@PN;DZP!(Q/V<H9:K<HTW/2Q5%]2%I[
MBS('4W9">C2+,EC/#AGINPR25%SG,G^5T9 'ZO('8B.%-**VXK"&: .E@&T#
M.S'%L5P:0M[LVN[C$(397H=6F0N2=*W*E"B.[J6(_8YJ.W)+F,S&MU,\^>]3
MKJWI^I.H)0[G/\BK2$O3TH*KX@]T<HZV*EQI%32E3.*M)W4&I]C-BJWFJU9+
MX)IG;Q8G*%:I_8<('50<KW)<\^?SB>\8EP;;S9SXSR6.S-KI2KD$NB.7S:,2
M9-"(\4_,.TEDKC,W_9K==4'GJ/9VF#R\RM;L2=KDZ2O+P^YSZ4=5ZI0+GF[F
MDK&MT!RA0B@,-2GJTTX1JS2(TSE;JDEFR3$QL9*IVT1XRH33N6:XDLO(.\<J
M1/OA=7;54MSD[(<"UT33+(=&53/5\':U<,7JG6)+$$<;4JR-N*R+E08]:R*R
M4^BEM49@Y">%%&)32MDT/3IXLF\DQ$$H- X9IYHY\8="]&*F*W8\$M#/'R=F
M:),[6:2Q1XB0I&%G).0)4YI+8RHI=*V]J0E[ZID#=)Y$WI2RD3VY$*1<\VS(
M4B%N1I6YM2I4*!N3D(4:!"22F1H$B4DLI*C2I4^NA*5.F3ZE%$)RB]"R2=2]
M"]-=,:X 39U]^9<C^VOEO^)^G@%.@                 "9.C_EKF3WFXA^
MX-F *;              $Q](?+/,GO.0[]P[,!8T]73\PIP$    3$]_IFUG
M[L5Y?:KSP"\)ZQ]>ISAW5_,B8N5F*K^J%'B#$3=3+RUD_C20^.DUF;DBQMW1
M,I<2E";$"/QA/,<;%>-&E.Y:=XPC.-*TW%3RGMST[N:D?.="R]\F,FE%.UR_
M2"PT#<U3YY=8DRK'*;-C.UF,C2VRQ6<DV.D*!M9SCVM"C=ME:=*@//2$EZ$'
M&Z;DN>>FFSC6CG^)G(;0269E#;^ULKRTTHQ,8G$2&\^ L:YP40*LSF=E9F]N
M=(O!T[FX:(#'LER='%P='AR<%AF%Y:1('O.G-O/SYZ8P]TO63WK(=YUO("WF
M&,+J2^[6>VH&:R,O!"]$H)<_7QI:FMME^%NA^)$B;6].[85%(DVI0N>;EDU%
MTNCBS5"$U4UZ5$&-KDK(T1O$18\LS>TS-N5-$Q0)D.R+8@M/+&Q<M0R;3&G_
M *\F6*BW7*O50=XXN>>_OS<PY596SO(DTO<X)$ULH1H&AL3R!0Q-V[L6WQU6
MX.$;297>;X4&$1IP=WA?&M#=]\1U<\.RME\Q4.:\Q0&7J*)Y:6GQ^KU-45&J
M,B=>[-$7A)L28#B8[6)4RCSUEG9&G9%LG:XD5.XC$G7#6B*(;RY%%8VMU3ZK
M&%K-2"YYM98H1 X&8]O$?CD>C!KF5D]_=$2)(W[J4J5Q?9!G"Y9C73;"%.\R
M64R#8C<S5(6]222/>2\.+Z[JU8<K$Y7&IW%HW-X8^M4IA\Q8&>4Q23,2TAR9
M)%&Y WIW9C?&=Q2[F)E[6[-BM*O;UJ<PPA4D4$GD[[%F:[9&FK .>_R_[$]Y
MY-_#/S< IX                        !,?%7Z'_+O]@-2_N,R ,K[YY]F
M'2D$K>"P9O6H97&;%5VM";/)51TE!3EJUY74\<:6GKDF<GQMD#FD06XJA>CB
MV11L>5;E']GYN=-$;2L4F&EB:G:JG>)U]^R5&JE>M(O<]X7293L@7S&\*8X!
M235SKRTX"Q>-/X'TO?$WO2(1YT<+#ATC>HS450VK#X,UFNJBO?C1A,*<F)K?
MVUY6ILJBW%1&F?5KRF/3$>^/:7\5M5W>Z9_J:33-'=_I&(M?%[&_HW+H"-J8
M\YJ(G+^AF/J!\D<7:K?=(U*R9#7#M4"Y8M>FA\?GQP*:GMG1&3=D=3T3]_?@
MFL]9^XKAUY?+&YC+>NJW@D:9K>VO"N76QI9!BV:)*^AZ;S*EY>O(5D0^UFQL
MM1TZ?AVI9E<VT5#;7..:);%2)^_-[:YQN"LR602]'#1C.>>:QK$Q6)JXB=8]
MFR/5;=@S&%WLNASQUD<^N'/,R2\P29'>55Q2OI1I->6(HRP-'-(ZX2_:RHY?
ML;O5"MD:R5&*VJ/-ZU4HD2&W7!C<G*#G2;S7+'4N+C37-1O]5I'7&DO=G%/=
MUMC[:SE31UPI%BVTK:UJTV;]#$R"+MU6R7X/YA;XP2O9Y-9LR3I3T_=2=U<&
M%P6Q5^D4,).-5MR0FL-BV@^F,7,:9J,W_*=N7+:-G&6/2O9+I&%*^J_;(;EB
MFBNM'F.1RS^GJR+F,4Z$D;US"[\\LCLMK6UD,/>8RS.44N]0S(WJ2V+'VIB?
MWF/R5X3QJ2-,&:RW%_\ 3K&8C%9NKBXX1I'W*^N4H'-J]:+I;)TQ29J6OW2=
M[3QA7O\ +T<M2/T+GMAO<KAJQA\WEDE5,*!!''1N9%+ X(XV<WN+:J)3-1[?
MJD<EAF>%<H^L_+W>OOS+D?VU\M_Q/T\"*=                  $R='_+7,
MGO-Q#]P;, 4V              )CZ0^6>9/><AW[AV8"QIZNGYA3@( )BH77
MKO6?](9Z2,I#>M-K2\/+&M5:RK65EU%YAMXNMM9D&,-^TL\MYCY3+'G9-Z3]
M8,E[8:-F+30LUBKNLW6NVW53H(F)[_3-K/W8KR^U7G@%X3UCZ]3YI3/@FR[#
MYU[:Q*(E.EULO$[^$@D_+-8*I=4"2)G/?4\.LZNX=/"'5G7EJ$SF^PFQ7AC.
M0V-/B6R.D2%X5J(RC<TK4L1&OY1?IY1_&YXXF)QT^_9WJPH#W0QN-C,M81*^
M':,Z6G8<JJ=Z4=%15V<FN+E-O(K]'(\[$SB[V]Z>&N3RUGZ21Q_65R*0-4/;
MM5T1=($3$Y['GR*$Q6L7CA.\?$5PS.;N,^=SH'K)QBS8?@[I$B4/EO\ >RZ7
MITW5CZW91U<\N_2JWC9$V:MMZD-#)A(V2ZFD" B*&)'1G/84&D\,3)XYHH+%
MQRC_ *=8VSOF?S7!TZ;UQ\(<DJVRXQ"X]>;A+I5'2'6'R3VBXALX1*SG'B@^
M,N*DLQYN=M5%1,KI4D@_T&@D!<3C<G-)FK' )1'3URM&7^FXG%7F*F+C^6F(
M_P#3F]==FS2!@[,=XU:+D5 [V;;0:[#7+&=>P7M5S7$+-H*2]%UY-\0RM8FK
MLARC,'O6%\WLKG4Y+_+6&O(SM.BI8N26*]M\ZUG2,F+UBO?6M9Q=7G&:X6Z[
MM5'8L=EL;017?IV1P)QQQ0X$.MBW]6SG+(:17'85RS#HYBLC=BL*/-[RODW.
M,]@$5-]3FN=))O'X&FC\ME4FEC$V/4B%Q7"_ZN&MQ%5C&8VUTB'3(/4G<-9U
MQ63%%H7;!VT%I**L$^BRN^(BI.GTE8>JH!)+);X4\.EO+B&N;V-S^BLE#!)J
M[KH@6A.?VQH?Y77[EOE4QDC>NW&L<-(G6/B6SJX[U<V733#A#:\Z"350Q/$
M>Y;K+;]KZ8K-XZ_+NG=)U#9<TN5R%%.3O"O7>I5:E1J5:!3NR,\52Q:<J'FM
MS,2$8SI?"KX5]_>NWK<<U#U54S?R+&IBTO39 X)RS2M1VG!WV8,AB& 3VN*0
M(95\@A2F"V4\1Z8H7B8:YBLBCDA@2Y5JI1L\_B]HIVI =#5Q?5,3/JF.,S,;
MQ,W[3TY5UJWGO\O^Q/>>3?PS\W RIX                        !,?%7Z
M'_+O]@-2_N,R *<  'YMXV==L:9QKMG&?%SMKG;7&W@_!G;7&VF=L8SX,YUQ
MOKG./P8VU\/AP'SDKKOFL7&M&.2]"831:1.\GZ85(&B+U]8LSC[;!N6NF-N<
M)+8KL]MK!(6]B1('UPA<F>E+LL;/5M),B""\N"5E5/JM&?GXFEJ?KYBZ6;$;
M@@TYD;E&8PK>G)4VZ2+;+MZJR=-%%YD0E:J#2I(TS!4T$QAS<(_*T2EG<&Y&
MZFKO*%;JTJ=2W:;K-2-/   !,77WYER/[:^6_P")^G@%.@
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MH9+<+C>3-:=I5].W*J4E.&G0[XLE+81$D4D=)8G.2HIQ6DTV*>M'MV4J?/\
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MD&&MO/'/30XE%FEYV+W,0.S>O:UNFNV=DKBA6(C\%J4QQ6@5$
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M0:E-.;7IGCJ-R0FFICSDYAB525ON0<:3MG)9F^N1<\Y[MZ!
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M3'+#=@0                      $R='_+7,GO-Q#]P;, 4V
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MUCHZK'1]<W5U7%F;F\1B(J,1AY>N.58!V;2CQ1%F26S(G$WI^B<A4O-2S57
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M RUP5B0YA<OF'E#/6F31?)'H1\D.-_ \.2)2X8UT\X\343F9XYG:_;@W8$
M  ?/?>[;:5N?PE3:FE21'GFE4Q$U ;B-LRC9KPKY@@-X*-G\LPC7$C+/E<K<
M6?Q3,H]](RE2(RCM7HM0^J"U'].^O>8T_P LIC_6=AOW;5V<>.,_,AQD>N&(
MMM:3=\A#.6T/T*:^;J0NR=U>POAC1I'97>4@7VE(E[2S&&-BB-U;%E<UT99-
MO%GI)(2SZ<1.MQ<QQC,Q?2XCWFGU>!D  'A(3ITNFQ:8@E.7N<>HWT(*T*TV
M/4G;J%)^VI>NNNQRA0:8>>9G&=S3C-S3-MM]]MLAY@         !,G1_RUS)
M[S<0_<&S %-@             "8^D/EGF3WG(=^X=F L:>KI^84X"
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MFXA^X-F *;              $Q](?+/,GO.0[]P[,!8T]73\PIP$
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M^6N9/>;B'[@V8 IL              3'TA\L\R>\Y#OW#LP%C3U=/S"G 0
M                    $6R.$V9"NQI%?D=KQULF(3WF2!T]NFC+_"6AUBTN
MK&SK2FR12_)YO)XKH?'92VVOLF2N$=,?G%L61I;JO9M25R XTN*WB9^8CQ\I
MY4\Q7-$+0I>65,RO\7F,+/YBJZW925+XB[<^] 4%6S;&\S)985:2%UWE3);%
M=FGSS-'S:$1!'*B)$GA*222=5 %STUL!;B==/ZL<IG3EBZ^<<_JP#(
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MD/EGF3WG(=^X=F L:>KI^84X"
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MSS)[SD._<.S 6-/5T_,*<!
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M@_J6!"\QY0]'M#4Z+EC:W>G&Q.>Z%HLK3]T6BA.>'5OBKZ2^E7_\J,@?@_\
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M5(=%9C')X^L+7L[J6@<%;4L,0K"O"6HT3N*%8C,WTSG7!Z<W7&<^+X0'<@
M =8E4TB<(3-"R7R!KCJ5_D\;A;*H=51:0ISEDP=DS#%X^CV,SC!SH^O*Q*VM
MJ77PF*59Y96F,[; .S@ "8GO],VL_=BO+[5>> 7A/6/KU*=!
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MT\0QSJ8J>?#XUC\Q-ZW=OH.")B>_TS:S]V*\OM5YX!>$]8^O4IT$
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M:,);2@7.*DQ 22I^OG_7MQ4V")B>_P!,VL_=BO+[5>> 7A/6/KU*=!
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MT82W5 ^Z,;BX-R98M9]7MKVW;'C5M4'&(]71NVV0N&I.%B3;*<XO.3+G@
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MQQ*:4>K1L2!O2K%S@I)-6'D8 ]_IFUG[L5Y?:KSP"\)ZQ]>I3H(
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MTC<<-<$D*UX(CV[GF.DZ-7I_+;N_,FB\:1PUCC$Z7RZK*!
M                          &?RV+.REQ;Y;#5:1NF#9A(B.*<##D[!*X]
MA;G=4PROS%*H7J-&Y*M>5\/7D>,=&9(N,6ZDKFARD;&^#;]_?WA#VH?/&B8:
MJT99*EAE+.F:U$I@CXI9=I?$,O12@]K)D*)B=WQN*PX%(U>[>O;G1R:'+5(J
MV;7%7JF/R6'=@ !TF33QHCCBW1\HA3(9>[DDN#;"V)2R^LRN/ER:,1A^E)2)
MY=V9/F.Q%1+6EQDJ[SORR5LV-\P2N3ELE;50_?WJ]6"Q9U:"ELAERM*Y3R4%
MM*N2FH##E+"QJ4C"T-A\7@YB],0[)(0E<&]8\HD3AMNH4O;T^OJC1.I>#DJ<
M-          3%R@Y=<NE?R<_LZ.4K&+,*M&=I8DAHIRDSI%5-2$+R-("XO!\
MI/4KM)6K3>?9<]"#"DQB'1J5&H&ES4N+2A+-8J](N^?&JX<E.@@
M                F+JO\CZN]YWE[[=(, IT
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M
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M4B=EPW-[#@HC<]/C21%:ZO8+BHJ[S?+:E.@@
M          )HY7ZXI'LR R6RZ%?GF0Q*)67-*E>ECY%9#$%1,R@:E*G?4Q+=
M)6]M6J47DUZ%2E7E$[$F%JO-3_-G-(X($99B?3-3%8OVE2X(
M        \.5!&,YQD\G&<?@SC)FGAQG_ &9_T@#SA/\ [\G_ )NG_D ><)_]
M^3_S=/\ R /.$_\ OR?^;I_Y )CZK4$9A]7> XK/_P")SE[/X#-,_@Q>D&SG
M/_YOQ8Q^'.?]6 %.><)_]^3_ ,W3_P @#SA/_OR?^;I_Y 'G"?\ WY/_ #=/
M_( \X3_[\G_FZ?\ D \NNVN^,;:;:[:Y\/@VUSC;&?!GP9\&<>'&?!G&<9_X
MX\ #]
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M:F-=XGQ"U@9
M        $Q<H.77+I7\G/[.CE*QBS"K1G:6)(:*<I,Z1534A"\C2 N+P?*3U
M*[25JTWGV7/0@PI,8AT:E1J!I<U+BTH2S6*O2+OGQJN')3H(
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M3@O<PE?MQ/TTX!,3W^F;6?NQ7E]JO/ +PGK'UZE.@@
M
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M!%EQ:-SQC]"/&TF]91>N_#A'3ZZ*Z!$Q/?Z9M9^[%>7VJ\\ O">L?7J4Z"
M              (_LVW9LMZMJ7E>&.I,'22VDK9OR:3_ -%M[O(S&*N)I54
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M9+W>3*&EH9%CTK=)H_2%SV7N"%C;<N9VBO3+FX%J'APPI=U[@N5$_#20
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MF;6?NQ7E]JO/ +PGK'UZE.@@
M                     \)"=.ETV+3$$IR]SCU&^A!6A6FQZD[=0I/VU+UU
MUV.4*#3#SS,XSN:<9N:9MMOOMMD/,                   #&+XKF069"$#
M9$G5G:)9%Y]6UDQHZ1I%JR/+G:MIPQ3,EB?-&P].Y)6Z0DLY[&:[(,J5+$8O
M*>]&M\U;]F1Q'5TKUB[,_4]S'G_C[2-J8\/_ ,/94SX/_=X<^#_;D ]8NS/U
M/<Q_62M3^E, ]8NS/U/<Q_62M3^E, ]8NS/U/<Q_62M3^E,!GMBW-UY7".*K
M7&CN;W#25V%"*\2:(NE+.UV2N$Y?DK A7J,G\K:8RC1'JM3U6I>=C]BM=L$Z
M;[YQ@!H7K%V9^I[F/ZR5J?TI@'K%V9^I[F/ZR5J?TI@'K%V9^I[F/ZR5J?TI
M@'K%V9^I[F/ZR5J?TI@/- X';KQ;I5QW GKB,+&"N'VM8I#*VD$GFR;9++)-
M%I/))%()C*(G #3E&YT*CC>R,+=#$Q;87J\K5S\\[.:)&R%O%;WV_P!RI8$
M                                                        $Q<H
M.77+I7\G/[.CE*QBS"K1G:6)(:*<I,Z1534A"\C2 N+P?*3U*[25JTWGV7/0
M@PI,8AT:E1J!I<U+BTH2S6*O2+OGQJN')3H(
M )CZD^0J;]YSGO[1V@!3@
M                                                     "8^I/D*
MF_><Y[^T=H 4X
M                  F+E#E"ON/*_D];UO)K0E3)++1G=M.#A;,[7V!($TAL
M%>0X.[:VN[@0G-21U(:F+]'-WDS#\GF+71T6NCXZ.KJM+,WG&D1B*TBE.@@
M                        F/J3Y"IOWG.>_M': %.
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M5)E2M*2<2J_W$_380
M              !X2$Z=+IL6F()3E[G'J-]""M"M-CU)VZA2?MJ7KKKL<H4&
MF'GF9QG<TXS<TS;;??;;(>8                   $Q=5?DI5'O.\S?;/$
M%.@           F)[_3-K/W8KR^U7G@%X3UCZ]2G00
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MSP"\)ZQ]>I3H(
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M $S:S]V*\OM5YX!>$]8^O4IT$
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MW.F$\E:\QB1R0DMD=?*;Y;R7@UJ?],$&^DF-O\)/EB<)ZQ_]E? @
M                                                 FCE?KBD>S(#
M);+H5^>9#$HE9<TJ5Z6/D5D,05$S*!J4J=]3$MTE;VU:I1>37H5*5>43L286
MJ\U/\V<TC@@1EF)],U,5B_:5+@@                  )BZJ_)2J/>=YF^V
M>( *=     <>WM#2TY69:FQN;,N"PYQ<,MZ),CRN<%'@RH7+/-BB_.5A^==<
MG*CO'/-\&/'WV\& '(     )B>_TS:S]V*\OM5YX!>$]8^O4IT$
M                                                'A(3ITNFQ:8@
ME.7N<>HWT(*T*TV/4G;J%)^VI>NNNQRA0:8>>9G&=S3C-S3-MM]]MLAY@
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MMOW]U;@"
M
(       __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g722206g13n45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g13n45.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"BP(T P$1  (1 0,1 ?_$ (<  0$  @(# 0$
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M/>G0[5*T-!DOL6&Q>*I71Y7;Z)D2<Y86:L5&:$$Z[FF::;!7@
M
M        (JC\-+G_ '59=B2]LU=$?/U/5?!*0T<B"E"2(2JU5%AR2\II'L&'
M;83R*919)$6,U5Y#4]*WM1Y!!_DG%<3D+5           !P,IBT9G$9D$,F<
M?999$)8RN<<E$7D;8C>H_(H^](SFYX8WQG<25"!T:71 H,(4)SR]RCBM]M=M
M<ZYS@!+W"9[F5S<S15Q=G!\)J>T^E*"C3J\+%SH^*X#SKTM;M$UMM(7ES5KW
M-_DA=?UVV:.+BI.,4.*W4U2;GQS=@%?@
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M
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M=Y%+L>A<4YVF-]M<[%'E[X\.N^N<ARP  D#A[^YB:_J_]X3_ (^NE@%?@
M                CKF'D4[FJQ.J[ ,Z(Z%NPOI^ZG&XD\/NJ=?&Z)4:6Y&.
M2C>O:6;LHDVT5@J0YVV)3I/'WU*0(T*?&/"FV-."Q0
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MK:=1R"SM>6J6+XU73+A&DU@L?UV?=SO,#=U*DLDQ.3Y7"1.C(("TP
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M':>D/%QKA*6D)("Z0
M             $_UW_?MT7_XB_Z.7 *    !J<VCZK5R%TDCI"8V_+'.>,5K
M%II$Q,K\B9+78(G\0DEG1G5V;U:F.S@Z$DIVLQ:D-*SA*G_U>I9BA88I#)(9
M6]=URF5(Z]@4+@:1;YOYZEAD68XNF5^:8.PD\Z(9$*$I1YKA29Y/Q\9\3RFW
M@\'C9\(:_<^7^:'N#$5@\\[T6[UJF41Q6FKQSJ2 +X,G5P_7.D25$1)5'S6
MI1%M-LX;M]4^-D.,^ G.@#.IY/:^IF OD]L"1,, KJ#M.BQ\D#N<4UL$=9T^
MQ*,G<_?77!25*7N8647IKK_3MKKKC]N, ,Z   !('#W]S$U_5_[PG_'UTL K
M\                   $'<>5A[OZ VCVB^\8F5,;:]@]"O$C[:VKJQ54ZD!
M/0YV[DM>4EA-:N4R+$!?BU[JX&F-"8EM1E.!R[;";53E4 O$
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M2-MM<;;$FY(-/(R87G/B[9TWWT\./V;9Q^T![  !('#W]S$U_5_[PG_'UTL
MK\                   $'<?.WN^7&U>TD_%^::^EQLZ"<T?;V*Q;\(9+GH
M/79T]*[V2;LE3[.+]Z2U=-#3R-C4F771RT\?SW1=C 7B
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M3.X76
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M:,BL]BSC9B-W;<A:X  D#A[^YB:_J_\ >$_X^NE@%?@
M  ACD7K_ ):Z8M'LNO>>F-T:9OR[?[G3W1JU=6*B!)9!;#=HN1.3JWOIB)-I
M/BRU+&J2Y<-]LJ-]4^AV-<HU")0H"YP
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M>[5N8G7;EHS34IZ91Y'!2DG;8+!
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M]U54^*T"LHE6W*)%6T]:E^Z8W34U-E3Y/?'C:Y 66
M"..7^K9/T78W5T"D',-]T DYGNQQJ%AFEQ1C+!%N@6Q%EPR19U.K<ZZZOT'<
MTJ(E6G4:9,UV1.*,S.^##3"20L<
M                       !IVYZ#J?H%B9F&U(N<]:1A^)E4.D#'))7 I[
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MFFA>FI9>NNFFFNNFFFFN-=---<8UUUUUUQC&NNN,>#&,?LQ@!Y
M          CKF+H6^;JL?JV'W!R'-N:HK1-TKJVIJPY5.&66-?4$#3X7FI+>
MB+:V,K0HBK*O2$I3\)#37'4O"[0G95YVG6IDP6*
M                                          "/^_?8UZ%^K]9\.0 +
M                            !''+UK=<6+8G5[!TIS2QT3 :RO!RA_,4
MV:+&9YJHO^GB=59C;9#JQMIZA5#%BI+HD.W3*?);ZFK3$ODL&(C3#0L<
M                                                           $
M?]^^QKT+]7ZSX<@ 6                            "..7I1W'(;$ZO1]
M;5G2$ K"-W>Y,W';Q5$C>WN56%0Q6JO=LEEMHW-X=T;/,%1>4F=RTVC=C53L
MJ)\SP2G(6+0L<
M                $?\ ?OL:]"_5^L^'( %@
M    CCEY#W2CL3J_?KIYH!VJY9>#DIXW)IU-*2)@TT+OJK]%MUR;OJ)&VG3
ME+YCY39%D_&7#S_/E<I=D6N@6.
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M;6C!!">;JN/RX:-M5)7=H5JE<T+;VXU"EV6J<%;';MV5>=,*5JK.0L<
M       !('N]O8%X>_2!S3]S$* 5^
M      C]R]ON&_H_LO[Z*F 6           (_P"_?8UZ%^K]9\.0 +
M      !('N]O8%X>_2!S3]S$* 5^              (XY@YFM.A;&ZMF]A]9
MW!T<R]#W6X6E74!LK5/I&N:(FJRX825+5NA3@OW+B;>F5D$:XUU1D[Z(2C,I
M\*C%:E2%C@            ) ]WM[ O#WZ0.:?N8A0"OP
M                    $?N7M]PW]']E_?14P"P          !'_ '[[&O0O
MU?K/AR !8            ) ]WM[ O#WZ0.:?N8A0"OP             !'W,
M?(^_-=@]33W;H3H6ZL=.W4Z7&7$[KGN9A%*1T=#7)1FO*5;,HDF(E 4&[IL0
MF1XV,P4A2(R/#GS?RA@6"             D#W>WL"\/?I YI^YB% *_
M                                1^Y>WW#?T?V7]]%3 +
M $?]^^QKT+]7ZSX<@ 6   -?VK9\.I:MIO;%@N"AKA=?1MTE,B5HFUP>G++>
MUIMS]DC.QM"9:\/[XXF8U3H6]&2<L7*S2R""S#3--,A-C3;/<<M38?H[Q]3<
M-CJ_P',S)>W7CW#+7(1;XSL5M,(C3_+O0M?QYPW+SKG*9%,'CR><YUWWUVU\
M&0Y3XZ]]?EIY _?AN?\ R]@#XZ]]?EIY _?AN?\ R]@#XZ]]?EIY _?AN?\
MR]@#XZ]]?EIY _?AN?\ R]@#XZ]]?EIY _?AN?\ R]@&J:(8.[:+H^FJ2;:
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M8:O>84ZH#,.+4P/R!6ASA:U)25"$Y6%(@
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MPZ&EZ;Z[:X#E $@-WM]3'](%:_?/:X"OP
M  !'[E[?<-_1_9?WT5, L           1_W[[&O0OU?K/AR !8   C_N_P!F
M:4?6!0'^(6K %@  #X7-&:X-K@@3N*YG/7(5:,EV;,(LN36:I3F$EN+?AR1.
M+=E<AWWP:3YPG/(\IKCQR]]?#KD(>BW&;;1?/3/1M.K7RSXI'F>4LZRL+ML!
MHC$1N%5:BQQ3VW,;QL2'4G*Y],99)B9B_OJS)R90F>Y"L\=5J3MDA8A#$W?W
M9U.26"UQ#)'.[7-,@'.B;G)4]M3U']%\P9U-AUE;4MG4D5RJ-3)Z7V!-[&JI
MO<G%>>N/W.W.4YW\<U08=L&:17@:M8+/LV5"K-O"*2ERFESRF9*6*511"18#
M)>UFZW!-*[E!>D%R8GB:"P-CUC,M:=VN4,VBU60F=]"%1Y9@9.V\)\U-=I.E
MODP8Q3+7=XNUW4Z.3LN<F4K3HIJBB&XF%$U+3#BD<3FCM%MWM0U:9PAU?WEU
M<-"M3W _;8,29?=Z4DQO](2@B06<MD'/9U0(ZX=W>0L+HY)H30\2N&%5?7#V
MO610Q:_1EA9+XDWG"U09M)'90L*.<'148E3;%!B,']V)0M>,UCQ>-RFS,PVY
MW"1/-T0-^UJB5U_;K]*)K-9D[O\ 8,%D]4.\4?GA41.U3(<=E&7YXPHFM*KP
MHV9VLU(%UU[!V6LH!!ZVC1KP='*]A\9@[ =(7MSDK^:RQ-E1,+4:^2-[4K7F
M0/!B% 7E2N5G&JE9V=C3=]C-MMLAF   D#C?_AV_/U?]/?>D\@*_      $'
M<?5K[OV"6KVD]\8FU$;;<^Z!<Y'VYK6]B'3>1)^@SLNBEU3V*SGRB08@#]Y^
MO<C3&I,0VI-'(U?OYOA7E9D!>(    "0+U]ICAW_ )_N[_#Y/0%?@/2H*W/3
MGDE*#D9AQ)I1:M/JGV4)=S--M-%!&JLA4EV.(VSXVN#2C"\[8QXVNV/#C(1!
M ./D_.E+(JWI1]E5F$L;E84J7P>[)_'8['KVF]M*Y.KLF1] 67%J+F4VDCE*
M7:<.;PJ/RW+2U#KY#QT_DBB<$AKEP]U[24AJ*JJFD,QM E%6?)EK\B;N$=?6
M<L^10F^9'2,TN.1N:J8Q^;/9\PEDOH-D5EK#EIVZ;7=3C^ON?L8 V$V\"5LP
M6*IM:*V?>,1G+M/;:F4G>HU*8DV&2QCO!P@CQ8]9/)6L#,+3PIS>*V:%2)6@
MPBE+*>09LVO"3"E3@X,UCG$?.T5N(Z\VB'J-9\9)+CDY*A8[K7%J0*;^01 F
MV6EN:UVYY**+RY]B6SZ<UZ9P@UD#PZN&A6I[@HVV#733[N6A63Z%/1[O96NW
M/&U-ME0FJY Q.:N)P"A%\H75E5I:]SBJQ>Y0UHQ*C"51ZLT]_="D:/SUR/W3
M%[@.)A_NTJ+@>MOI8U*;,3LG0<LL6:7M%'+-72*&6\_6=T%+^B9(IGD/D56N
ML<>?*/M@/<<VV\VT-6PM?HSK]UA#>U;( M.KJZCU0UO!*LB1CP;%Z[B;##(]
MO('A<_O.6>.MJ=K;L.+NXF&JEBC5*FUQG/AU+TQC&I>FA>NNFH9X D!N]OJ8
M_I K7[Y[7 5^                              (_<O;[AOZ/[+^^BI@%
M@          "/^_?8UZ%^K]9\.0 +   $?\ =_LS2CZP* _Q"U8 SOK=.G5\
MK](I%)!*K5515KIR4QY6AVJA:=!GPMO(+),UVP:J-7[%ZDZXQG?8[.N-<>-X
M '0[")#/J*B\B/@\-K5VB2_G;W22PPF+P1TVJAMG>_2A$:M_-DPTITU9DW3J
M"+R?#YN[)W$\[1GCR!2]-VA2-)E0%4W%WWU?7\3Q,FZ&U_'"<RR4Q>S6VR(!
M,"RN<%S;WM17,]>HI2J2SN,E2 NX:.M-WE#&X'JD*9VWC_IMMT5,:G9*E#2=
MI=+=0P3H5NO)<R0_>3UY0_3<+1[D0>6H(E>E8,G>W-L,KV0MT?.F1SI&GR75
MIL\K6U?YTZHU>J1:[-A&[4JUTU#;#W[P?J ^PS8I"VJ'E1>3VA1$8C$TL&A[
M+83FILG':MP\X6XT&Q%38,>5$.E8UE%HY(]]E[CE;C16:Z+D;>B=43<U!ALH
M]XCVE"DUB['H*6F2N$1+WB\H2E--.V$S^G5_&72G/574Q%DA.MR/YJ5=T=7-
ML/COIOXRHT[1BR>V%&$EJ-L!M&<>\6NJ)W8YQQ##5D@I$^263'I-9)%*V(WK
MJ6;ZOZFJ^EI!+CF4M6^*I=$TU93P]_\ 3)FNJ9:F+(DQ*4F+YTV6!GCGUIT^
MLDDQKN.%1\Z<PF!JY5%RU%!W.T'])1%TH65OK18M3QQ2F?4T56-%])T+0I1N
MSTH+2HVT\A2EV.D;"H3!IZM^Q>H;7N6A$ST[.4*J5TN&(,TK>"*G4H8>],,]
M]VBINTYMG+E(F8P]-'8]T\8N:,>;+V@\D]OV:U2K*PC??4'-?=%SJ^::E<Y7
M$TM/26#\'4'=JFMF/E^X;*1666Z<@J)[91=:,$$>VM;'3JANQO*B_P 4=5)[
MNCT:%#<?H8M?F,U$&N3.G;]G'2D6E>[?$T$UJ&$=XP*M)#)6:5Q>!S=O>ZPX
M-LRF959&[$EDNA+6N>9R^$86-);@A+;VM6H2Y5Z$J5!P=U'--DR"W*6B,^E4
M<DT2D#JJES>Z1^7((\B?$*B+S:1Q3&QBB(/DCATD;5I3)JH0/K,K,9Y$@-)=
M$.I218226&MN-_\ AV_/U?\ 3WWI/("OP     !!G'CQ[OATM3M,GB[Z'/I<
M:^A'9#V]BM&S+=)L]"%&.I;OO9!AJ1+NY/F7,MTUW4$9-1[.FCEKC?*S5=C
M7F     D"]?:8X=_Y_N[_#Y/0& ^]0*4'^[L[!(1$[*7(ZDI44SIR\;Y4GOI
MA9&C$2AP46:HRY&O&2-4WDM-CO.,Z>3QG?Q< .M/J*)7)RI=9'1]9/$#1NTD
M:^T+[K:I(PT2.:4[%\P'CB&-47CNJ)$X0,]X?+VFT*V<7#9L(:$QC@ZX+2D*
MG'50ZN(;%MKWDO2L??Y7O6D4C*Z.[5[<+H@43JF+*1)HC8]8VSQ#%([""O(R
M^/J):EGU=]$S9Z0.QRA!A^TBI:YK;]6A&<K>0Y*;]P=G02Q;DKW9THN4$P"[
M+=J:-29'2$]:RWR,P;W8U9]>,5C90ZWJ[D*"UO1#ZZ0@SR)^4.YI6Z/7;"\K
MR>@>R6>\GZ.;W(E[@=/++#;%4 DJMU@C=3]E$N\5FB+E"G+_ (ZE8STZ]:]6
ML6I?I/*\>,A3MWQC0L^S2S)MG)F='%8&]3.NK>7V/ J^BTGC+K&9^3&9K5ER
M.]$W"TQJY(Z=;VS78E5,[<W-[Z7](T,IO9,J2NV3VAM7KW4MYU2F-#(\H30D
MR.]M=GV!'H)B0$R:O#4K;[J626@YQJG5[:O89?<'8O1%,=N5VX:RN-R-*W,,
M$AU7Q0QS(\CZ1CQKT:8>KPF6)BR@W/S!U];#MF'UY*&-AJ\E2Y363QA[BW/U
MDRR'7<H;NXNA*ZM.OHPS1)Y6*(/*H[1\2C4G*5*5ZK90KG:5]-U5-#6Y)5@3
MD^==79<SWS:^REJ1I_B'T?S_ &I"I7M6,_@13['+2X4Z=>I61*(1AQE+\V1>
M/W2UZM&6@E<YNC:JU*95RE8^(CC-P[C.0K:L"X:K6/EH1U5&YS'Y<Z1%^(+]
M!.45=%C6V,BTQ^KF:Q=>MCUBUZZ[NF=VYV)+0+"\>.@<T#>\(7!$0'#-WM]3
M'](%:_?/:X"OP                             !'[E[?<-_1_9?WT5,
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MWT5, L           1_W[[&O0OU?K/AR !8   C_ +O]F:4?6!0'^(6K %@
M     #I8M?W6\RM;2TBW6:5KIFQ)+W\](SUD?=70UA1=K4NAJ=L1[:J4^OGY
MU>J$F5ZC?3=/HYZ[8*TU39QY0!5%+\K7/3;E.7-/9]/S1:X.DPE5;R.=TR_2
M&S8:]V<G@N\]B3Y9NEHMJR0UIHX0@C5"C0-[(L,;T;,E4';Z,VN5H7^
M ) XW_X=OS]7_3WWI/("OP     !#'(O7_+73%H]EU[STQNC3-^7;_<Z>Z-6
MKJQ40)+(+8;M%R)R=6]],1)M)\66I8U27+AOME1OJGT.QKE&H1*% 7.
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M$VRY7DGQ_$\L9X/&R&QP !(#=[?4Q_2!6OWSVN K\
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MR%2G6H5J<E6C6)#BU*56E4EZG)U*903MN2>G/)WQOIOIG.NVN<9QG.,@/H
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MX.WCY*SE5A"9N02<%C@                     "/W+V^X;^C^R_OHJ8!8
M          C_ +]]C7H7ZOUGPY  L
M                                                  !'[E[?<-_1
M_9?WT5, L           1_W[[&O0OU?K/AR !8
M                                                           "
M/W+V^X;^C^R_OHJ8!8           C_OWV->A?J_6?#D "P
M                   3/U5T25S;7T5D22,_'2969<E/4%6,5-=M8^V.UC79
M/6:"1T^12'9$Y[,<3CFKH>[NR@I*K5X;6\[1(F4J]R$YH<;,;W<.>LS&2=-2
M&&ME4-T91/D7GT&A%DJG#)T8B5BS>Y#)M#V;%D*(Q&83$X22YD.^ZSS0TM5N
MG,SHH+*PI#B2^\^5CI5*8459#H9((=](A;P3I6%N;-RE=544@D[F[+&9!B"9
MC\UDC?"[+9'5*V,RI>XNK>LR>@)4ED*=B0UET)[PVJZXH^9674C@AM*7Q=^7
M1TV%&LT_;E#,X1:[6RC)_B=)TT14NL"UB\Q.6HR]GHIL3."Q"860?MKKN9J%
M3P+H*H[-FTKKB&RDY?-X4TIY!(8ZXQJ61I:3'EDUGE=HY$V;2=B9TTBCJV9U
MD^(25[=NK2';H,[Z&;%&D&&!N8
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M$GW//2M6%:@A/IL:9IJ7C.P"H    1_W[[&O0OU?K/AR !8
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M9IX%T:GM<P%^G%?S6/+B\Z*V660F9L"%U:7%-N4K;W%(2H(,T-+UVP%I@
MC_OWV->A?J_6?#D "P
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M6?#D "P
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M2!TM]S$U 5^   "/^_?8UZ%^K]9\.0 +
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M1.A6E=($2%$WJ6@PR1QDQ,^F;JE"O1S,#M< 2![PGV!>X?T@=+?<Q-0%?@
M C_OWV->A?J_6?#D "P
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MF)J K\   $?]^^QKT+]7ZSX<@ 6
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MR !8
M                         "/W+V^X;^C^R_OHJ8!8           C_OWV
M->A?J_6?#D "P
M                                  $?N7M]PW]']E_?14P"P
M   !'_?OL:]"_5^L^'( %@
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MDR?%>^I2!G)<-W->;MC1.09MG&,A6H   (_[]]C7H7ZOUGPY  L
M
M      1G[OAO1H>.J1/2IRR5$@8WN8OJG&,[*7F6367R&62^2.JG?.Q[@^2:
M3/*M>N5&[;G*5:@PTS;;?;.<A9@           (V]XHB1K^ ^V-%B8E3A'RE
MT \HLFEZ[[HGF/U9*7U@>$1F<>41NS$^-R=:B4EYU/2*TY9Q6VAA>FV LD
M $?]^^QKT+]7ZSX<@ 6
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M_   !'_?OL:]"_5^L^'( %@
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MXH6WS5"JV38"HP$@>\)]@7N']('2WW,34!7X   (_P"_?8UZ%^K]9\.0 +
M
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M^QKT+]7ZSX<@ 6
M                             (_X"]C7GKZOT?PY> L    '!R>-LDRC
M<AB$F0%NL;E3&[1N0-9IAY)3DR/B!0UNJ TU*:0I*+6(%1A>VQ>^AFN-O#KM
MC/@R Q.N:GA55-_HZ($R3;3T6SLFSA+YY/+(D!C-']G+=D:C9/8TEE<C.;VH
MQX5[$$[*LEE[*#,XQX=\YR&R     $@>\)]@7N']('2WW,34!7X   (_[]]C
M7H7ZOUGPY  L
M                           =<%+S"Z>5HDGY\FO+UP65':Y6/;56%S4>
MHK&5Q*P*ZW>UJ^)9DL<DEDQ"?P2S&1B<$Z-]2'M1K(J7$&*6Q>>2;LF2!N#U
MKY%^3WK_ /L35OXQ@'K7R+\GO7_]B:M_&, ]:^1?D]Z__L35OXQ@'K7R+\GO
M7_\ 8FK?QC 8J9W*05-TE<&<J]<ZS9=%7";)&',#K?*@Z+-3NV,3@[ZJ,6YE
M#@E,[/*8G.F3<&YV-QG&N=<;9P&5>M?(OR>]?_V)JW\8P#UKY%^3WK_^Q-6_
MC& >M?(OR>]?_P!B:M_&, ]:^1?D]Z__ +$U;^,8#2_0DTNSJ>F;+YKK?ENY
MX$=?$#EM22JV[L.JR&5_5,+L)D51*6S QO9;*E\]FTL;8P[K3V)H:V10D7.Q
M!)#DN:DAN5FH=DX   (_[]]C7H7ZOUGPY  L
M                                                         !'[
ME[?<-_1_9?WT5, L           1_P!^^QKT+]7ZSX<@ 6
M
M        C]R]ON&_H_LO[Z*F 6           (_[]]C7H7ZOUGPY  L
M
M                !'[E[?<-_1_9?WT5, L           1_W[[&O0OU?K/A
MR !8
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MZDJ%,<<E*=U;C4ZM)IOD.T8   $?]^^QKT+]7ZSX<@ 6
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M%0AKBCZRPJ<SG9B>T^KMA_8UA:+=R:T9+PW;FA6P"0/>$^P+W#^D#I;[F)J
MK\   $?]^^QKT+]7ZSX<@ 6
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M$EXQC&--? &> ) ]X3[ O</Z0.EON8FH"OP   1_W[[&O0OU?K/AR !8
M
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M; '=QIC?&FN#-M=M\:ZXWVTUSIIMOX,>-MKIMN9G37.?Z,9VVSC'^G/](#R
M2![PGV!>X?T@=+?<Q-0%?@   C_OWV->A?J_6?#D "P
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MX+\IMGP:Y =I0
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M0 !('O"?8%[A_2!TM]S$U 5^
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M*=UCI(&=X:'16CW2F.+>[-#"J;F_#B%X@) ]X3[ O</Z0.EON8FH"OP
M
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M?%TW3/BN%-+@[H-=?*Z*4;,Y9WR1LG*PI#8@  D#WA/L"]P_I Z6^YB:@*_
M
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M#^D#I;[F)J K\
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ME<0:D9Y;L12DVPV^58GA]>9"E,:F-8JV2-ZI8<2:D#L1
M
M          $?N7M]PW]']E_?14P"P
M
M  $?N7M]PW]']E_?14P"P
M                                                      $?N7M]
MPW]']E_?14P"P
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M=F20(4C<ZY2JER%R2EJ$2D.RD
M                                            $?\  7L:\]?5^C^'
M+P%@ .L;NF1R.13R!<M4).;"CW4/3T57,Y4BBE@S!K9>8N<X2\^"X^JUL08G
MUN8OCDV8FB6/1$UP(,],3%<T$;XW;D#EY,/8S]-S:'V(Y<_P@J.SJ)Q2F8Y;
M]+V8]O<^GQEF\]Q&NIW&)F]2>TG:1/!\PLV-WE$HXW.KD8J5&K6B9-[M_MQY
MZG"<)@C7O;+,UBD(F<JHEA>TDC8:"?UL7KAZ?W*6+M[^X,M3L)NCL43.+?@M
MQ>HO)*E-CI>=]/"^$O92C4I :@R0XALJ4^\$O-5!F"PJ6B]%W3%K+?)3 *;=
M:W?W&Q,2:T)#0#7;7/T;GNT0E:F-U6V3R=M#[%EZU8\J]4)*V.NJK5!JYGHD
M8<[(_>22%)!5MC1:NDKLRG<U23KRN(])T3O"YG>]:1^5M\02UC6;:I<G1+FW
MI/LJ3."'QC596V91&D&$F^[F:L2A-%S=\76A7\NWX[,^L-@S1VK[P;G>11BO
M9'84F8%D8YD4]JT*^VI>$;;B6+:35C#7*D6B?+$Z)"O<FA"B7&)L;&%Z9 =E
MM-]2N=@=$32C'I&Q[HVJ'N,RKR<15$:ZQ"UXU&BJI;Y5)X]*624S!F8%C'*K
M*T1KHR^Y:GM,E.;G!!EY;%V5Q 6N D#WA/L"]P_I Z6^YB:@*_
M
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MX!('O"?8%[A_2!TM]S$U 5^
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MJ K\
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M"?8%[A_2!TM]S$U 5^
M                                     "-?=]+4BOCVDTJ922<JCK*^
MPQ^3E[Z['LTMA$PD42F$;<BL9\=&]1F3LRM M3F8U-3JDYA>^,;:YP LH
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M-,@;T9&IBE:N4E)R=-S3---@LL
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MO:V;%B<?FC5A1OYH\)$)+FD\;/D3]/" J\
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M.4+2""L[G&Z%[!N&7RV-0&)RB=S-Y0QR'PJ.O<ME<A<S?(-K#&HXVJ7A]>7
M[P;>10M;6C-/-V\&?%+TSD!KCG?HJE>L:;A?07.\_:;1IRPR7D^&SIC3NB1M
M>]([(WB(OFI*5Z0-;LE.:I,P+41Y9Z<HS0]-OKG7]@#'5'6_."3I]!Q>IMF-
MD=0.M8&W,W4^9HZ:R%96Q+HI9S)(0LRW^@=_%6HCO]C\\\_R03N?@C)&FQF
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MTMZ8O4LA,G*+)*+UQKKKC&,8 <2CK*MF^P'>V$%>P=#:<@CZ*)OUEHXFPIK
M>XLVJ-%;=&G>9$H-)$Y1] J+U-)1G*=TQ1FN-M=,9QC(#V6%6]=VW$76 6M
MH79L#??,_3D)L*+,<SB+SZ.7IG1O]*QN1H7)F<?,7-$2I)\L3OY(\K0S7P;Z
MZYP&8$DE)RBB""BR"""]"222=-2RB2B]<:%E%%Z8UT+++TUQC77&,8QC'@P
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M*)O;F]$3HF1H4*--H4G2(TB<K4LHHO770O37&NN,8QC #%8]6E<Q&3S>;Q.
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M/QQ"VM*50ZNRTY4IW+)UV/4';F;YVWWVVR&:
M          "(J_MWK-[[AN^K9K4U.L?%\>KF)K*%NUBM-K>[7LBV2RF3:TX9
M)JW*>-G.-)8.>O4:&9V;BR]"=41VJM1NM-3H MT
M
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MA10
M                             FBUX^KN^7[T2YMKH73Z*/MT@O$Q>Q/2
M>/VI'I>DG3,Q5!%[ CD\C3FROC0_QU&]2Q'LA7IU4=4HF]3KE,]&8 4N
M QV7Q..SR*26$2YK)>XK,&%VC,D9U!B@DET8WU >V.J PY(<G5D:JD2G?3QR
MC"S=/#XVFVNV,9P&L:J?9:VO<JJFP#'AW?XL8JDL9G)\<)88O,JZD\ME>8>R
MQ]<;-IB\RB655'$;<SRM8MP@5'KS$SALF+)=$V=PW@
M                        (B=>MI.FV[N(:ZK85ROBK9I\AHX68X-B>SM%
M]&1*^56QQZ>LW<R#[)(W+-$9>-2GG!RXG;&<EE;8,P&+UOV^ZVO<5T<_PNN(
M2Y6]1M[)ZVF\8Q<*_)+%5>D#@TX77?)EB>J5"F,I70V<E,T=8SDQBJ1NR-9Y
M!06B0.*Q$'8*                                       "=^8&HG:K
M4]D'M:=NDE]O"Z]929F(/D%?%1T_3(#88BF,9DZA1(FR80RJF^/QM<4MR6>7
MNRX+R21C3!)840 A;KM\D;!=GNW-FJ62:+1>3=JR&%V<4T3%[BT?DT1<.(.R
M9/$XQ,TK>[-K;(&UQO6'PS*)(KT.\X=2TR;37;"DPDX(%ZEM#HFIIO1,IYY1
M6A<<G?\ M/KMOQ59ERSPQEG\5@G-EMO"F-M,>?)RV1B8IX!+8&8K:(?EQ8VQ
M<_M66SS]IV4*%9(=J/(TNJR?\]5S.*:L>;6Q I6VJW=%.+'D4MD,\<WDQR6$
M2I'+RIL9A_B,F8Y.G5H7".;IFXN.K$YK<6A1ZIL)BPI(!/\ <S66RRFFK@0-
MWEWN%SQNKAU4M5?JIU+G"M[[>HY7[[%VE0WJ2%\.C9=EZPV52%WQJ<F1-,1,
M-4Z83Z&&%A0                                           DMZY72
MKIW?C^V3=0VPOJ1'%$]YP=1'$2]8[G1>$):R5J(7+TZ]K71/XZ5RUH6=WPJ3
M/&^A"+0YLW;%>QBC<)Z<O=OI=+;D/0T+MO6!7^OZ=7] ,EH,=?[8<$T*DM>U
MQ6U@\XS-!I.4NEBT]8+)53.I7)%QI>4SLGT<46$J],A4I [-],;XTUP9MKMO
MC77&^VFN=--M_!CQMM=-MS,Z:YS_ $8SMMG&/].?Z0'D
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M\OK@F2($9.FVKDN.)1FX\B>8 WT
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M30IL<&V"UG@U])421B?CE$G>87)9^6S,JGT2CVWUW6X\HI3ZX\!H;\
M
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M2&DX:AC[5HAH[6Q8,UZ&S)K9)1Z4>U6QCD[(BGY\7X0*-T?D-]@H
M
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M]T"([5O*#=0
M
K                                                      /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g722206g14a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g14a08.jpg
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M(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X #D%D;V)E &3
M     ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,#_\  $0@#P +2 P$1  (1 0,1 ?_$ ,@  0 " @,! 0$!           '
M" 8)! 4* P(!"P$!  ,! 0$! 0            $" P0%!P8($   !00!  ,)
M"PD$" 0% P4#! 4&!P ! @@)$1(3%-05%E87UQ@*(9/3E%65UI=8F%E1D=%2
MDM+5&1HQ(B-X0;(S)'6W.#FT-;5Y<8$R=C=AL<%"H24F-A$!  (" @$!!@,'
M P$)      $" P01!1(A,4$B$P8'42,487&!T3(5")&Q0O"AP>%B,T,T%A?_
MV@ , P$  A$#$0 _ /?Q0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!05LDK;O7J*3 R>ZI&3!E@"^>.:&W #KH5<10^CKEQ@4(N>
M!)F,.M;IP'$"O;_300WAR/ZY7*EE :TAEDXT9N5#/C,HQD!VELL\;WR#+G1S
M75MV=_[ [Y>Y_906/C+8B%IBZ0X[D)!7CV-ND1'R%'2UX/HPMGGUD-8 (*F6
M(5K_ -[+$++"WY:":*!0*#HSCA3R*^B-L?M_"*^26CY#J!=8OV"!=,L?[<;K
M6[+/I5PNI;HOUO[W]G1[H=Y0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*#BGCQ-,)'%)1-%R*>GE3!X\=-BX%RI,F4"S
M'-&C(XN6(8)<N 'EGGGE>V..-KWO?HH-(FQNTTA;%@+R'":BJ)$1H)D8LX<D
M3(4B[GHG!Y9!F%,<<.^!Y.;HH6.68),.^&1D#^^/>_N@AA&;#@,);8>6 Y7
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M=15CQ9.(@7$SQ##L,;."@EP[B"96QQZV5NF][6M[M!A)>8HB-' DXK*<<&5
M;/$,$B7?#9&."B9?_3@$5#5,AQ,\O]%K8WO>@D:U[96MEC>V6.5K7QRM>U[7
MM>W3:]KV]R]KVH.A<;K:S/3[JSN<B UDJPF(-U-QK"<B)]A<_P#Z KG%,R5+
M6$S_ -&/6Z;T&'HDW0RY%$)';TM1HN*XW^Q2DE]-A04AO=Z/\(@55!30MKW_
M -..%Z#(WF_F+'"/9PR&]&FPT#(V"0Q7'FXT=KH]SQC 40N2LIKAPB2N;'#
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MSSN4+JSM;,I)"T.%A>_9X&39-E)^.=[6Z<\0,.GW,;4'NVH(K<?_ .7(O_\
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M+:KBP"SL,'SK7+KZPNF#1TN /W,*8R[2P>.=\[Y!"YOB)T[*[)21L^P$A]1
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M6B*$T87DUB2ZPF2XUQV,<B]XVGJ,)39)EQL-=<RD*C*X!, T7P4!@C'=0-@
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M/W8R8Y,1X^@-8UMB )0:T&,[*.HT<:O%RHOX"CQ_%;://YPJ <.(1;$VX!U
M, ,(P)@#8R9S'L'7-;AOA=LR4\9,\[\KJJJ[%,N=$"-(4+IZAV!3:J(-N"^3
MI>R#%J3(DHKX;\AXDE65W2KK"A@WA\BH>88N&)BX9L^>*6(7Y)S9DQ0DZ3")
MIO3\Z-AK)Q)*BH8^ ZW+)J5*HY%F/]2CL_)T5$QEE'#3%$9L+24:7&_GF1/Y
MCVL$*$'6OCB6B%YQ_'[#M*DFI8,:QRG1PAFATN,74D+24FS&2F</%^L1YL-?
M83^1SBX2Q*&4=33ATD<MB'G<"QD $? .RCWBBAN-XK78L191E_(!2CYELI&=
MV D=([F:"Q&VTLL;?QY(+<)MR/T=E$W,T)>E7,4L4\#^ ;D4HF6R3[A=OB,$
M^1]IL39D(S%$"M/$[.E?G!^NZ3W=-Y9Q-Q@2\DOIVXH.=UQD*L;M=K-QJX-H
MVW"F244#3!"80 .)8R$:+W$#$""CO&&WW .X':\]B9>=,PNQ]MAW.>5_%."&
ML=64AKQ3-D)EV<;9;+B9O,(0JI1[L*Z03:MFGYN$0V;+BXGL B)(N 'Z,\4>
MOPLQP],X:F>%7XN9$#,=6+N&-H#?QI[E-;0K!QBJA.^0XE=;\B]8RM;$-9%9
MRHA65  0;= (P6(]!A,:<.<$0\G'"$;/MSM+-,>\2/"-E="C'6]#<K$ AV44
MN4V^@+#O0(72'?,!50.I026;-O,^N'\TP(++$;$_AD>$#;O0*!0*!0*!0*!0
M*!0*!0:3.0]CANOD7XM2R,Q(<>;O76MONB@)LR)W=+47"!"&&2IE4Q:[D0UY
M24B:<<&$,!%^P$P#MF-GCU,LKWN&OS6279&8T6:$PVT4Z?7@Y()V]Y(]5)KB
MAE3@II+?G!S0?#>Q4M -*(7?FY&JEK\1-9VXIY%A64Q2:DAE4@NDG1<1B!F^
M06ZC*3I6=L)\+B^:V9?D@7V#V>DM,>[M;+G7FX><D;+>NVX<L,V'9*#L$DFG
M.[H-/,AO(2R95B("H;76H9S/@!B&#Q;,+-LJ-E11W?G;78>:]D_-U'&H6EC[
M:N.4_2:97BCS7I@VJ2W6YCRT>7S8ZP>?"7%R045 S>(Q0R 5SQP!#[02^05O
MCYR[6O&%'"J1(]%&;7TP^2#?K!R:\/Z?U^-WW/.M\/3=,L-I<61?+1P^8468
M8B 16:Q\F$/F52%$5-!(JQXM@>$-7#NXGV/=#_V"T)=&NHFPLEQ9)^D^X#W5
M(JF:7C+5<Q5SQY/.N+-(G)1+. XK)CI>L4'7VOMK$:XQ[,<,7 QD</6! -7"
MW''8\I%>QC=\W):B\,U=M;SR<RD-JNM_FY! CMHI,;Q M)++;:B(.(GDT$J>
M<ALX&"7PPMA<[</*][!X6Q#8]016X_\ \N1?_P#;,G?Z[%H(:W\D:7X?T>VZ
ME77]+S69MCK7*8GG%A$).P61[OANL1<5&^;+H@@0V"X933Y; R&1OAG8Z(%8
M#JW[3HN&E_CUU6XPN4GBXCU<3$QI3%,3_B9&+SSL<N'PG#N*PMK3[7#N^7NY
MY3-'19.:S_1)#N84DD'NTNE9D,"^),#)*S"#N'H!C]/SA>$& ARA(I%;-1G&
MC-;CYE5SCEFV1<*HUVVEHJX]E@5341RR/9?42@AP3$8T)8+(?JW$SO;K7#-T
M-VM1S-TL[VVYF\X&F=)BJ!-T(:TFJS=-D .T[8\66R!DPFCDP>RSZPN M\,>
MK?IO[EZ#IDZ4(S6/%_P3(C%5/&QOEG:UO!SM0#OC*U3@@(1-S-_N90%\,M\V
M*8#Q#.ENT+"99XVQSO?*W2&3^&T:P AKPNF=S!&\" ICN\KV 9X2X=@R8@O:
M]G@;SN-AT!WO;._7M[GNVH* S[&D^NC<W3.9&#O2C0OKHS3<@M24-7S"(VCH
M6S[M64-7R0DQ(<AU6*FAUI#P)9C9$P@C(Q(-.$' PMGD-?$+W.MXM%B(IAR/
MATMQFMTGD'@;7G6N)C=12N8M[V"Q,*BN:)D0,A+VZ,;9"6O?_10?='<[;<*$
M7=" X4-<;)PKF>*.)'5B"FA&B077N*<+JY(P.GCE0[!Y=83$2^%NK?IO[EZ#
M6(M\87%QLW+3NVC;T<-I5DYWJ8A62I*UPG^5HN ?BR4ZF1L&2,->959K<=ZS
M?/+KF\E,$<T/GGED/?.^>72%V8&0M9XO1#4%:Y81&V$R/!S/AF-HT4VUD>;B
MD;'Z5(^ZT=(.&%?!P*AV]Q#IU2MD=.&<KB#B""97RN$_4"@4$+SWKI!.TD>F
M(GV+B9BS1&QI81E\PR9$;Y%RMX5:;YNQU'4\DY0"%!L;(C]/5RMT7N'GF'ET
MAYYXY!,!,F43RA4@0*ER)$B7 )DB1, (L4)E"P6()8J5+ XX ERY<'#'####
M&V.&-K6M:UK4'(H% H% H% H% H% H% H%!6O;Z*'7-&N,H,>/%HZW)0Q2"+
MRB->(J0Z3FER_&RTF2)%9@X=+B!9^!!'ZUT\)2 ROV1M.$' %MD&)GC<-,Z_
M,FS[N[BWKB2(Y -/R;52>B,'PZ_&(Z%-:9;(UQT=GKS9H"DRS0"6>::](NT@
MKB.9WQN1-N)/44PAB->V9>]!@<C[%;/66XJE:%=B]DIY :$>;CM)G.=PZ;&X
M^;LH/$TU-6G/D(JQBC,5O#28MP\W!GVMM_N5.:HBBH-,=M!>$#F"F,J!WB[L
M!NO)S3GY$:,Q23(\#L+63?618SE=<U6;#9<.W8L=Q7K39@,UUMI4B]#)D4I)
MDJ6'LA!"MM$03#P 0,+E;7L6,&3 3C#6W^U3AY,DF#% 9[^84XK3*R'(QW5$
MHB*49&,?QNE.*/7DEN!)A4@"AHC]5$TX(C'U:2%W-T)YG(0NA)=P;V!"FB\5
M>2=R;OM>:H!)1E('D88 9%M(#%V>(S\K0BMQ/%K975/*522F>UXPUH;&"L<6
MG FJ"2&7-I"4H%0#@"R,3%P"X?'QA#11[:]!J;;V[&Y ;,QS$MW%MPE9J(ML
M%_V:)L22%/8-3? I2)'"PSLG%L,8U";^1R^ (Y+-!##0\%#(,,[>;.EHCM<X
MM.T=.DA1A^5I^:_((([RHSA$0DN+&62*N*3X#"?!L8)*1C[MW 939.60^Z<.
MZ&N]5+# *Y0J-CB&L373.:(NC*59W 3IK?ZQKJE:D;120VFVQM@FLX_.NS'U
M,R%M-!TAHLH*RV/.^TRA!DCGPW&Y&T53D=;&3$>]D,EU"&8P7RT:B/89D[2L
MB$)>,RD?;L/,YS;R+#S7U%RJ+6<$Q;?L5LL=QQJ O'!?!JB Q)?M,2J"B]J-
M@CIZFCWQ!!PL5RH*\R#"$SS3O+-L),Y6=J:Y7F^-E3\E3_BM;+MYV-R*%J"S
MJUJZW%!KN!FHT$IK#A?8,)G#M53;;D5S"[=*,"!DBHHCEM<)?5G$4V2B&4-J
MMO6E*\8-Q^GXQUS9#36HYGAR1U$[AA1F/DZ_7[-\214[6*]'7%"SMJYW BAC
MB#@IRS@VVL;R'P*B%S(8;7M!A7\)I;K(%*":]DQ^I\.LQ&<>,CG%DZ^E0TA)
M82*7<[IS<A4DYRBN\") )6$**H6"J1[M[G.V[J"%O<+=4"@4"@4"@4"@U3[Z
M*<TP;)K4G.!TMXN9R3O$[ITLQ0T0NM+Z&V9K>"I=QZG3 X4(D":((328KR4'
M*1<2R+@$$$16R]S(M@RX?5"E2Y(LXZFJ;CA5J/F6(:@>.)6>+'0IH;&L*QLN
M_I-=45Z?:.XPK&CC2QT1=-NC.<W0XGJ9/+. A)16E)!LC$EI,-7L)01:%LGN
M3$+"=B&GS//Z<OE)&Y!W4T_&#5G*5W))>S:9LB>4X!TV72:?'BK9I1P\HL<!
M!83<R!HL;/E5S,)+<94BB9 XA+SLG[=9IE%2;WJ/(J^XKI')\"W6@V(#::N;
M@1/B*>HSBV)4UH&B;5#4'62-->PRV=4UL57P6"*=F?*DS0!;(J9#MF_.&R>P
M?$7R.*4J*+E=4@- ALE'T9NXDS'8@N%\,("(VJYVFX4\% AW7I8>X(AMV'"I
M=70&<@8*I8IC<F$();NH8*@Q<45B1"3$PL7="[HE;8/5EQ[!JFHS&VR8$0B1
M<<CC8U"?3.;D>R H.683)A(EY*CM8E8ZSE(RD'F8?)@FBP/<ZU<T&_#1/.&?
M-B] -=4.:46#@)27?-U>6PWN40#Z>.WVL86#,$)4F#7?B3!X3F$.A)P)LN5)
M9*8:@(EAW2LR0F879H% H% H% H% H% H% H% H% H% H% H% H*"3]L1(/K
M=Z\Z01 H);.=,LQ7,6PTERHK(X#B.,B'8;7XW95T5@MU0RQ0U*0W\^Y33@ C
M:E@:3TA+)'1LR9H<0MAB$-['L%HL:6XT5I[:\9[DNV8WDSX.TY;\LQ9%*3)\
M=2@?09.?$O&LY8;['(AHT0VBIG"K2AF52158"R09+AXG\SY8M@$*[5[$,O4)
M0\"R-I3 *S(<"Z_O[9W4)1:ZH306$I->+G2SVS.C,92H-&9E?A.4FCA*:2=[
M,BFGD]=1U43+NH/((Z6""STRMB)HEE[2%FE-4=>UI8G;9>036;C[D*(F40S$
M/#<FSP_9A8Q4M'Y_)7=KO+QNK$C)^PB*HG#:GB,9'RP%-XW#!IXG8[KV^MOY
MQ9>HD82')L2)T"(AI<;+JS1)KG=@OGNE04&K@HWC@[D$L,!. -FD5''/'2:D
M8L(&&(2$,7RR#&W0\M0R<M:.0=!VKL&/]D;<+S]F%(DQ,)([5;T?9NN#'G,A
M&0DDJCM(^IKKQGEGLY4Q,BAF$X4R7QN.?%&Q&QPS"(-7=T8_F:<-:$TIJEK8
MCR\X<]UX(81R,WXE+S]UI;.I+]D"/#^3L218U:RXT8(EM<CXN$7NE]3,J>4T
MLN(GFK=8R6">8@VJ9L?\=JER ,_4E)0'A-*"HS@JP! 9A.67K*CR-Y'KY=LX
MA&JS/'!^CMM'&.J!XP0[;$F2$MUA< ,.D-H3"?+5DYC,R2F*L%7$R9":C=?#
M.<!'*^9)<:SK2":\WU@IE>UKY%E))/@C!WO:U^KG:@Q=Q_\ Y<B__P"V9._U
MV+0=^^)%8T;%&\>?CF2VN2=CU:4<MTRK"Y  *SX?JR6;C-;)82V&>-U-R+QP
M$F4PRZMA3 N&%K];*UKAY/\ E<XDS/'Z!+W,3Q'R*IZDSE"R8?F"?('11A+Z
M[SQ'B :P77^1-,,,0%-1L[IV!@\82,<<T8[V>7<8"<?O@<N&;!S?)O*7R70+
M&N2Y"C%8;$XM8"WD8&O^QD/KT]1@Z95V4-(BBY),SC]/EB(23F=4,MI9(H*(
M;5,U0%'S/*)@N6!-C6,!!E^T'& X-7M N<:0I%F5A/\ 8FS&L;LEA.UTAF#5
M#76"(=EB&8I7CH$BQ^TB\O2.,0<+T64)+4EOL1BP*HI$>V-8#VS[/ ,^XQ^'
M?CFF?CYTHG.5]:VS(LR2IQZQ4P7E(CV6G:[%@XW9"B=LX'PR">XE]3;B,H-D
MI? JW3A0D":;A,(,!.$+A88XV#7QIVD$3?'3.? 4ZVVS;[0,W>Q;T><IL!KM
MK-<5('D535IS-;KC)1TIF(97DG6)NN 5 71@L31=:2T2UQ<!12_2%RMV]9H&
MUZYB?9SD.$XP;,:(J$>W0C1-1VF6&2T<%G,:" UYM$,D<$>R6*>)KKQ53HRA
MD#=0.FCXPIH<;/*U[!,F@16+N2'<SE1E/;%HMB9W)JGN.Z=-X*A26T5+>K%@
MF$XX;R84#>C5C9R%U%M)CNGMW>%SJJOBE15,V"G!DPC.!,O8"P5]WC@B,M>]
ML^.#BHU318PUIUMW>G+:C:>7V&[&R\'O DF2+$\8M)1:4+J,6(TE1N#C%3B<
MA<!3-,Y/5DYNFE,F1P$(#@"#%1PLVM<0&PR3*&Q,^Q]MO".O[VF+1J4]0TED
MZMZOJ.L49G'V\"2P!$,TOP0E.<C&%608U<RT$"G*A8F&J@$<0RI87"UNIF%6
M>)!UPJT]D];=)-O=&0=&N473F G6@QL]F4G(Y2,]R(;#;H;'?CX09%;!<.\G
M!KXJ/@YCZ<L#'A %LN.H &[F<#Y<$/5Q0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*#AJ*BGHZ>>5E8\32TI+)FE%34U$T 23TY/) 9F3IX\=,YA%BA,
MH6"R$%%$RQP#PQOEE>UK7O6^KJ[.[LX]+2QWS;F:]:8\=*S>][WF*UI2M8FU
MK6M,16L1,S,Q$1,RBUHK$VM,16(YF9]S[%S!<X7 -E!P314T"$8+&2XN Q<P
M7'PQ%!' &#RR#%!&#RMECEC>^.6-[7M?HK/+BR8,EL.:MJ9J6FMJVB8FLQ/$
MQ,3ZQ,3Z3$^L21,3',>Q]JHEB15^L<\YSK*).]M''>FBG0%%KE5I.,+Y =-2
MVNN* !U)",9G2HQ)&>R,;%P$PQRP+*I02]K8& KY>SF^G._U^IQ]]L:6U3I,
MM:33/;%>,-XODSXJ37),>%HMEU=G'68F8F^OFK'Q8[Q&<9L4Y)Q1:LY(]L<Q
MSZ1$^S]UJS^Z8_%EM>,T*!0=*ON-OM1.LL.=<26\DW445(LIK:@42R%U5R+)
M!N-]-L;.B@@=WKC@52I$H%UNT,&S 80=LA,\<;]W6]7V7<;7Z+J=?-L[GRLN
M3PQ4MDO\O!BOGS7\:Q,^&+#CR9<EN.*8Z7O:8K69BM[TQU\LDQ6O,1S/IZS/
M$1_&9B(_&9=U7"L4"@4"@4&/.%W-1HV1<G4YD!M8N1PI31;MU]83TCP\ZUP0
M0)%;*+X0,%_"B^K"!9V+$P.N8'ZF74POU;] 8?(<WPQ$:DRT:599C:-E>1UJ
MS;C]+?;V;;34'LOW$*@V1FJ375(B87U+MSY</L2N(N?:F L.CK"AVR"(\][-
M*PUM\-H3;'7<-Q1F27U*0T'.8&)@L,A.:JZG-AS'W2F9+ECB(3;SD6"A Z*8
MP#P*G#0((E\1!,,;A(3'V2UZDR-G/,<=SA$[XB5E7<%GC)C5?[776(U+M-*!
M7'1BXW4FJ9A$1+MQ&,8&SUC(P=RA?.P@O5PO:]!A1?=S3@RVV@\0=J=>;M.0
M'0<9#%<F<PL$%$>#P3LB&"@V6RIC+P91;6R BJ5Q'+%\Q!0LC0-L[6N+A;()
M/3YOAA6E):@Y*EJ-5*:&XC N%P1*0?#9-R2B((^!(0)8560 IB.0@FY!*17.
MXPI;$.V!H#*][8C!7S#+5%Y-!'7TIJJSI;J6Z%Y)7U]$;B@M)I-=6$)JY)>#
MH6TQ),&0SYY(;F:X2Q/F0@\@2F1P"PN6%Q0^L%>R.\VERE'BK+A#;'70W%:&
MX2#25Y' F2/\V.G.E5*>$$QNFG19?\"AK2@GVN8!+7&[84"UQ,<;X6OE8))"
MV$@4Q(#6B@":XG'D]\M@)ZLN.P)#:0SV=K/')C*)=T-IKAJV2TN(!I.*C&0C
M98$4 4N"*+AEE@'GEB$OT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%1M@]4",Q
M2="6P+)?BK$.P^OF3Q3&!(J<CE'2AK+ DL)#+R9%$F,<^<2R[TC]W^+2:<L&
M$=35-,5DPH<(G0,PQ<!PCF6M-I$GM9;STDW805,?D2OF.I2UL.QA'19KMN&)
M(9)5ZH[C<:@C.-VO14DLK+3-?9YMN(@>4"A6[=&$+D;$S8F2A08EM!Q^+&VJ
M+(0\E30139!<L#//7=@.%LQAABU8E9DHN1E.65U]!:"R^5127'R_AXX0BPIP
M\L9%21%-P +E<>V.9F@D:7M599F)?C%]K&PR:WY!@>26?*D)'6Q#Y<LST%RD
M&?)4<265?+85I!6%M^(,KQW*1]*,%@EI)R2>P+&20F!G#,04.],:P/!140W<
MJRLC&9 5YNCV77PL@QN, WE5&C%)LC-.-VPW/'W(ZVD4D!UC&1TTHJQP0\.,
M+?\ P\\  @AU@\;+.B%SZL'XJD=<1&=JY,4\RV@L]T(N+N&5BTTL)^1<C1JG
MK^"X@W:D=PW'CWP1VP3!*&<RI%()!"""8X"]J&$QQQ?^*C<@=J/";@7DDZY;
M9S/N5'!Q)BLNR7+E*4MO.7GX&@N%R%'VLGS<<-]=FI6#,)I'P::6T\$L4.F\
MP,3&)@)*A70$O&T1:N04_I!;LS1CK,TW.C%4!S199.P>SH5 326V'RJ! OQ1
M24]49S;5%$@$!W(9!'Q4S O2$)<*X039ICK.8U!@E&U_+O[-^LUDN5\"1?B*
MV\FYDP8S<;N6'.T(D)AYN%QBJ3<BM.6+(:(.*-@-@B$B@ EL\P;BB!810;(:
M@ZVTZ<C@@0C;37*G!DL0L<@S>+CNB7$%S&OG;,+(IX%MU;6M>V?:7Z>CHMTA
M!>XNJD?[KZ[/_7"2EIYM9O/C)KJ9)Z1NMAMJ1&&\&&[T&0&$^V,X12:A@C.E
MH/1KD#Y0:X(F/7 ZN6-\<LK4%,7AQT;!3W%.6N>W7(#($YZ[+19/2),:;6A*
M-80DF;&HFF2QJ[*E"6F<=4#&#:<F9(,)>LV$ELG54I<4OW2"$.+CD' W?X?H
MDVND#7^?8AEN4=)MIM7FR$P89GK7>Z(3/)<8 !&02T6NAF+!09NNI@)X1\SB
M63\^Y\, C9@#.XI880#(.S=?&2_Y-UDFZ"ICWUV.E20-DF/>)YAG1P-J'DX_
ME#YE*<B.L1S%T2H#'3(@BTJO%7,/F=5RR4;<)H?JYC'Q,02F!8+4:0:LK&F&
MOK#UOSFQVS8R(E:[78,6*3X:S';KD:\?L]!)-]!;*@=8R.A$G*(2*$<+6/&2
M^)L3&UK"99Y=.>08>@<?$&-WD0?_ "3DB@WGQD'7-J:ZJ)6Y0E9)*IK>=!E;
M4GJ"/;"YT5UN-$)(:*,)E>U@4U#"##OT##6N$-[8\:*WM+MQK;M[EMM*L7.O
M4,\[E77]E--@1 LLUM*DD-=-:4E''+XUM%77GEXX(Z9B%U#!P+$AAE?N7LA+
MW$N$13KPU$E_;UV;U:;[@SMH/L7*Z2FHT]'HG1&!(,838&D%RI1.6WE$DEHR
MJTQ787+%;6[LZH@/:WN8Q+XFQ#!@<.QV)X3H-VA@-OQU+<[;(N#89I2V5V$:
MF[OCLE)FQ#8G$HB)#>+N=L7;R"AL)G,TJCM]/*EFLB)*8D% B!<<''!1PN?R
M#GA<4DBR'#;ZC+;+D;VVV7<:XS[M..'Y<M%L,XPR?).%KNYO2,V6E&#/34MX
MRLWW*S4\<NNNH9<, !!BA%L2W=1O,<)IC'0%R8;+Q1MQM+L<N;/35K]&SYC"
M"C@47,:&&FQR$IA)A23GBI-UFYJ1ET2$]$M$*$A#(ATLCDBN(MB:8 (-F)0;
M):!0*!0*!0*!0*!0*!0*!0*!0*!0*"!MF6J_W9"[N"B88QC*S8R0I$C0B"MB
M-XLXWS&S@2WVW&2M*EC10N V7^?;^*&JV,97*Y)RB-87&^'3:OHGVI[CZ;Z;
MZ[TK_65:S]'[<9=+>O.*,UL&IO8<FIFVL6/QM:<^G3-.WK^$?,C-AQ^$Q;AR
M;V/-DU;?I_\ Y%>+5]>.;5F+169_"W'C//IQ,M7B7K#OTCMMQ.0=[N-Q29&;
MD14B$RQZ6S6)!Y-"?++S@V26GH#=:P0\S45+4TF2#4#.X"#%RL9)MR5L,#F/
M7_K;;^[/^.6]VFKU>/K]75^E.UU<N3M+4ZZOGK;/4?)P])BU9^5.6*]ABZO'
MF["V*:UOD[W:_4>5L$\>#70[>M+7F]K9Z6B*?'_5&3F<DV]>/@F\Q3GW8J\>
MUQ[Z=;Q&6*FI(DMOH@]G.JN'5!V/(K+:F*HMK4YGI*.AQKL8G!"+?< DY.53
MB[!</YE@_#/:R =!&$O8GU<-8^]_^/\ B^H<NY7I>NR=#J8</U#KZUNNQQ3/
M]0[.3+EWNEO,8O..JP8]^=3#%Y_3>/3X,F.O.?FS^V]K.**_,O&6TSBFWG/,
M8HB(KDCU_KF:^4\?%^9,3[$^*C VX6-.EQJ+3<>UMD)5.H<SRV39DMI2"F$"
MZA+K+4I)UEBZ2LW:25&:NCP:GG&VBJ9/ DD8&,,C5U(F./<>WSG4^I/LOH_>
M_7[C0VM#_P#+NGQY>LZZVUUV3-DO:G7;5-'O=_1C6MCV<4=K?'O;6#+.79FD
MQAC5SX\?RYZ[8>QMULX[5O\ K<DQ>_C>(CUO6;8JVYYK/AS6LQQ'O\HF>59D
MZ -P!'VVE)&BW89E)(+GAD;6\RX-PPW@FZNL!LSJX%V;DK8!#M)M\)'49+B4
MP 6*)8(,C!A)V99"NJ%;$N[;_5]K[D?9*OT]MZN]V_TSO[MM3LX[NN'Z:G6O
MWVYGZG#BZK)T^7]!SI4T>QB]\F>UNEM;-&7L/TF:<_R'#73[+YM;5QYJU\J?
M+YS<QBK&29O&2/+XIM3TB/S/3BGE''*!%J MD$-UQS$"8B[)N6>7/JK-,B=W
M)6VKA1DB+-AUB?6TE1I-<@F%26":0Z&='J!D 'BDI8:V"73@Q">"*:[KSN']
M%T/N/]KNPZ?M/K;;S_2VK]N]3ZPZO2\,GT[ARY.PZ;'U&?)O=7IQCZZV37V=
MS-YS.QGMJVOFM7/;?P_)K%N2VINTR4UJQGMMVU[V],TQ%,DY(BM[<WXF*Q[H
M\O3T\9Y3#).L&\3H<$ED4--G)+=;A=$O8R=,1'9RZ8P9FBQV32V%2$&O#+!*
M2;=1B)T1?&F-PS!L-);(J8$E'RP!M5S5^US_ !'TM]V?\?\ J>MZK8[#+]/Y
MNGUM3K?T'6WZ+YFYUG8:_5Y\?:Y^SW+:/AV6OO[WQ4QVV-ZN>VQKY<F'3KI>
M%>C/H=KDO>*1EC)-K^5_F\5O2;Q-(I7RYI-:^_BO'$Q$V\F-2[I[N2]9SEUJ
MMIB2"EP4Y8TV1A,ID9GA65X^=46N#5QPLR"BBF<>&QKG>)I5%E,LFYG2H#*;
MN"$;MF8S/JF)@P;$]7Z+^]WV.Z'[?=+W':]CUN;[A:O:])VEO'J,>/<U]_#W
M^':[:U*ZW28-:N..OMGC%DMVF[.WC\<4:VI.+'AK39ZWLLNWDQTI>-2U,E/_
M %)FLTG%-<?/.2;<^?',>%?&?7FW,R^[3U7Y!BL@KZBSEN7HC"O#ZXWX;\*/
M-M+3"8+4&U/"8\<1$^E#/8YZF;.1A3E8,^9&36"K7S4RME;%QFPAQBV>?<_=
M_P#QKR_36MJ]WK]+W5_[WBS=G\O5SXMO<V(^H9V]WL=2D=)JU^1N=5SAI7/V
M^OQ@R?HYZO#?'CRUG'H=Q&:;8YR8_P N8IS:)K6/E>-:6_,MZUOZSQCGUCR\
MYYF&0H&G&QC^=:2FJK+V9B'7$,-XG;12[MRG$XI#*2.% ZH@FW>JO]BS2OKI
MEFO&5#B:.EIF"\8"P5D<9:')D.[KAY^9V/WQ^V'TYT^;:T]_Z4[O[H3.M3^X
M:WTSAPZ5M*>WQYJZV/3V^KPXJ[.MU]<]-C/.I2TZ^S30QY]G]/%HO3K=W-DB
MMJY\>E\7P3FF;>7RYCF;5O,^-K\<1Y3ZQ-IB.7 .ZE;RN0P3S6PI#2C#\O"9
MB8EUIS209SB6E,DSN)YM2>M&EMI/)*4KKN!6#Y3*]VE<[&+@@&;%L^JI%NZ>
MG!]YO\?NKQWKH3UF;%UW]TKUN+8ZN^SAQ8[;/W"SZ&*N+8ULE/E3;M>@R?*R
M1X>5\4Y:\ZN7Y59Z[M;S'EYQ-_#SF+^,S/CJ1:>8M$\_!ECF/7V\?U1SPI:U
M&WRQ&:C2CUR3<0BYEOG95.BL%J2<4=CU862_,1)PP5("\O/O9.+C2NV4"/!A
MR::(L#O8RBEP!"8R 8"-=6M_HS[T?X[33<[KZEU>@R?5V_U_1W["=C0MKZNW
M\GK+8>VT\.'4Z/?KCSYMV*9<\:U.KQ[5[UST[''?#RC8Z[MN:X\-LL8*WRQ3
MBW-J\WYQVF;9:\Q%?2.?.:^R:3R['EPDQQHH)<@N7E]-&6==]E&Q"#'8L]%(
M#>)C8])76>BL&9DL1M24V@93(J26=N&BMTD8670#B?RP\6\[GA\RG-_A?]*=
M7O7ML=?_ &3+3!]3='G[7:V^HMV^M7I,F'9R[G69(SZ.>>OO3)7RVMW+35T+
M3ABW]TB-?'7-;ZBSWK'%_F1,X<L4K7)\N?F1,16\<6CSYC^FL>5O7^CUGC-4
M[5[<YR/)_E!3,P,-XJ*+LP=>,]*>P1E5C"5513=I5V:7DHRB@B_54ZPC42BI
MR6"K8B(#: +D""@GYBJX2N*/EX.S]V_L7U?1];FI3I.QZ/%GZ*NMU&/IZX]_
MK\>/6MK_ %/?>["^ICIN5[&+[%M>:[F]>^;-K;-::5]*F.-:Z'9WRWC\RF28
MR^62<G-;S,\X?&GE/CX<1S\-?2+5^+RY29($0[.R5HRXV*^8HD!9V!F.0XXV
M,D!H(,R-1,(LDP%M/&+^4(!8<H&GH3S;B[&D/MK B044_ !)S,)8AH YB:,8
MVS_*?3?UK]IOI7_(+5^H?I_N>MP?;;H^LW>ET]G-UFQDOM5GH-_3IW&WH5U;
M1GQ;W99YRYL.:;[$4V*X<F"<..?'?-K;V?JK8LN.\[F6]<EHB\1X_FUM\NMO
M+TFM(XB8].8YB>91$U=?-ODAW,A85XOV$<,:EW NFM>XUQW(#:J]JUD9FDJM
M@G]B72#(3EO*Z&?C6V=RI0OE(ETE,P%;N)>^!KNFOVG<?<K[*;O2[^CI=O\
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MZ%Z!_6]2_P#AM-#[Q#H]"] _K>I?_#::'WB'1Z%Z!_6]2_\ AM-#[Q#H]"]
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M0/%5L>3B#\SI_>] \56QY.(/S.G][T#Q5;'DX@_,Z?WO0/%5L>3B#\SI_>]
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M0/%5L>3B#\SI_>] \56QY.(/S.G][T#Q5;'DX@_,Z?WO0/%5L>3B#\SI_>]
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M-\\J"&V9OUO,E:5;9;*>N3O>\W]&>@#WG)K).R?%A'.LD%I$C=P,H9+<3&F
M>'T-)D=00CRV)DEI-S!PJL)F0QO((4,"^6(7V@38+?'6K<GCAAC97;,IN=$7
M)C#<RK:1FX($BZ&9#@64H<A]K39<PEJ40$45%>+ <R LCIHH*@1N;)F\ AK&
M.KE</()HV%FG=#9'D@>.@.JFR"'IBTH#U98NQ4E3%C";)G619'>$JO9Q-9FL
M1O-J3!O$Q"C]NIS7$.*I[ $53-F1K% A"V/^-B$0/;8/DM?>P6F'&D4V(@6"
M-BGCJ]+>T&T6W4,1<3EUNKS8C:3"<5,MM0.P9>+EFLE.=Z&E,NH.7)3)G@$G
M/M<"&.006/;!KSV>Y5-Y('07[JY)VVR3'DFZR\INK^J\N;SQKK0T76=>VL&R
MNMTH3@DN@;7TXW));H$M-,1MEP%0HWR&88N8(>)8&ULA>V"78EW3Y6'7JEL_
MLO&$K.796-M']G6P^6%(4@ZJM_6QP<BFF*.QTU?V08A*.W$S&X>93NC2^9L1
MLNE$)I5EDV2$+9@"YB=D"&WOBSG/9K<%A29NM,:H=:<";(.\%=TAU\.MEI)B
MS'.LJ$7%2FA)+[7TD@(XEA_S[?&[C'(FE-0(I">*4#)Y6Q%$QQ#:C0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!08B]'^PXW20E^0WLT6$
MA#'RJ6"M/1R(S6215,[?.Q)."45PZ1)B'S=P\NR!MG<03JWZMK]%Z#FBNYJ%
MUY':P[G;P+G<2:?66^W!5I-#7EU(2^YK*:JCI&9G%04TU.N=![<< /,('ML.
MOE;K8](9#01PTICB)_.!<:;%E2.'HZFQVWC*VFD^&PXW WNYC?@\QX<1D=4.
M**3V!_\ P,^Z P^H-_<OT9>Y09@X6^ANQ 7&JYDE/7VVY4=2;[A0E8J">2EI
M#620R<K)*F2,8Y@'$]1(&1 1@L\;X"!YWQO:]KWH-44#\+6J$ RO$4DHS\VD
MD)M:WJ2\L:MP',,_N:0M?]9E1P)YU&'/1$PE$J =+&$I#4C!),NM**S9*+"]
M4I8&^.&6(=? 7#BQ-9G,U%"'MX^1ML1VT94598):_A;!,OS$'U-QR(HR>[6N
MK,H"'2YXTRG@Z5D[DID\#X0ID(X-;ML<\[YT&2WX;M3 =9]==94E9F5OI^IL
M[K.QVODQHCT0B<[1K)CBE)V2RNF$=Z9LX9'%;RTM/0Z1.)@Z4*3-IE@0QL!!
M@ C&(6T3]5HB*[H.?>$LLN8:;E#6UN:KKR5=?2LV20C=!D-8EU+."-T-*Q5"
M3L'77 +?(T(>[#,CU,<2^-^D3(*<ZJ<=NB\12'KY)L$2ZX7RXH!OMZ)&P.$M
M,)Y):K;;Q\(TG3/X;+-U +#K.**L"%+I?<XI?P>4,86,=TY9X"4$M[4<<FM&
MR,B2W/$R.1_MY4D+1"6-#7T<1W@WVXU$C7V3G2 _7HO@766VI62'JGGR'2"J
MCF<R)<K;*PI43HZ]@@!(X8(YM$\AP6]=X^1R9(3DN#7% 2C%TL;",AULI%9+
MA2"2(54&NEEH<2K$'*V$TB'@E&A<S )>U[]<$6U^B@S?63C&UHU8G!OS.O[#
M[(;*37%$7F(XBA7VYGU-DLW L9O((4!4(QBTTUOLE 9P3T(,84L.IYD!3QLD
MEC%\3/8!#!V"0]I.."!MPY%9FQJ?*VP>O\VI,<F(V);!:?S2;B-]/:%UX_XS
M81ZZ%PBG.%!>#&NKF<E)/N*4S,$3(UQR9@'/+K4$0JG$%HNX(MUPB2&EZ5(!
M<VG2*MY07-.M,WJC0V%8R%,1I167T,K/L6[FN[$::%BQM14\%PB?)J)JXX@&
M.%KB6H,E9G#MJ,QFO#J&E'YH4W%$^Y;7WV6)5=LFF7E+DX[)M-NN5J)[KG9\
MN=*5#SR3!D)T#@9D"F"8 %B&'W/V'2+VH755'9 >S;1E6$F_+C$? 3D9#J8[
M^2HUD-I+SK;R"[4M0::L., D'5D=#.A8'Q P13)>^ 9BUK7QRO:^-P[;7&!V
M5J[ 4-:X1P87S; @R-6=%;,-.D^55'(8;3'0R;?1AEU1(IZ22.JHA$CA<<4(
MJ7#S$Z;XAX6Z,;!+(BNE!*I5"%4T\-;/$#RJ21A#I;!5.):883RBDI%4_(2Q
MLP03S2L5"'&PPN&$(9"QSO:XF%KAV% H.E<3D;K00U-SNU>16NVT4KF>67"X
ME0BB(:22#O:PAQ35E,<L0(%0[Y6ZP@HF&%NGW;T'; C F00C!<4(<N.$&, .
M")B*","+C;,(4(7"^6 @0F&5KXY6O>U[7Z;4'TH% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H%!JLVUCPRF[;QW/TEZQ.K;Z"$_7AX1*@LIFLMFRNLP
M[+J\^TI>5WC>+WNL))<VGRXR"P"(.O)^)@PD61,2QJP)%2&&Q"#>._2N0X8V
M%2I6E".G<RS*3I]=B,!M')"&=K*AMNO';K9.2VKKJDER2TIM;PY"\)KC.0C
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M$-S62F)(R-,C=62:J F@IN0&%T[+#/,MW-<,*8C:I;XQ<VDU(U\CZ16N>BF
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MCQ#NMH0@=B%C"KEFE!AN.H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M>S&@F+"P50@35[A743F!5/N-CD%8>XF-\*#@:$\LVA7): YP=19S3WVYV23
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M "N$H3N^TWK%S@_7%\6DJXN65KF>D,+6*Q2(O;^$?C^_]C*TSDGPKZ1$^O\
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MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ML/<DED+#C&Q?\8V,9.G#9TZ9%,&3 XHI@R8%S%%SRSSRROFU230?0/\ T_\
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MEN]\3=*!E<,!(;>!NE@& 4E0%#-C9E>YQ0^LJ\A6TT#ZQE'3.NO450QL 8W
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MTE)[PG+6";W>W1!#3S(("ZXL!$4,.RF2*#%PKFPM=,L-;D1K"Z;IFQ1)*7Y
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MLYU0],"@[Q,TQY.8EC)Z;F X$4%,(#G2:@7L2M@&"/F%L)X=4L,J)7>X8+C
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M @)SA0Y2>27+BWGFG$"]E'N!"-)*MD<41@BQ>Y@)DA_=U&7^/['>V9F^492
MVHRDR0WPGLLZ<<3?6T^+5]V-W)P10I*Q=.47$T)7NU@E!HBF@PACA%7)=>^5
M\^OD&!Q-M/M,D2VBQMM1$<9DE*5=4Y!VRC=@:Z"/5V2?'Y:,7+'R&Y(&?X+O
M.%D21Y%.@R@F!IZNC>!DXRL%CI.Y?$+$(UD&2:Q[H/N9&5M1*,L0$\(@;<$[
M!J4&M>-&X4,33-"EXJ-YA9NLZY4J+17,DJCG!>#Y[D'34"YPNBAD#.(YLQ<
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MBA^2(M593=RJFNG(=K)!)+15)O% @"0MAS8V8=W'.B&Y,,Y:H.1@3' ;D=$
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M7@$T,Z;[,V9Q"_RAI-L@K[KL[8D=\Z\MY*CR9#ST0)VC]LR PMKG;KSV*M9
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MXPH@V?1:W7%SR$RZ+?V6ZV=[WZ+4'SH% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H%!1SDY_[;V^W^4*?_P#E
MNOT'FX:7_DWLAW_$'5_J1[0;M?9_?^NCV@3_ #ZH'^O+E!ZC:!0*#7)S _\
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M#K4S1F1=ILN:26J]UPN+FI9%\[@#*)$6P>%Q+C8AYA%6S<>Z0[<<+>U,PPI
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M LCXA%@L;9F<1<K8A86Z>C''H#Z!(Z. .$:+HR.7-EQC!@N;+I2> :+F3A<
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M+7; 3A;#/>4LG5?9]<!0H/6&,#&3W>#0D!!>AFQR]LDQ4&-EQ$HZ (!8<&V
M@0]*')H\@ 6:RHOU1GTI.ZCO#&>I;ZBEV(46+SE:2<L,=#GYU+9(9MS&(S%5
M8<NNQDV?0\0U<8-// CV4\ +EL<# 9ZC<BS5$4\4!FLB>-F7O**WM,\H<C^-
M(VCMJ'$V*=8Y92H)==E5TN62T=I@M,5]ECYA%="Z?(9K@'6"N7 ,6*E1PG2)
M]Y(1F4)AFFGB\"R>^M/".\.2DOHA1,(LZ%U-;NWT\N]!/"HXJ8\3Q\FHY E
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MKSR*/*TF-D-P;OPONK&K?U?F;8+;@G'.N $)*FL25%<>ICJ(.! =N#IR(/\
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MS(701&2=>K$E)0DUFN-@0J>R<"LNJZ* 13#! :Q["P=KVN&UTOR"Q_;8QK0
MXH@FJ/T^1)$?L5QC+K]!C)#:KS>D=-YV.Q<#%C_&1C4ZLQIGFZQU,TFN!=:R
M<DGP@,,\1< S!?,0(M5>4%AC1@^I9PA':%C0>+#,GRE"NT"K%C5<$;2RFL<L
M 5)*K0;15_8N=',NHVK%#C/*/0JURST+WMB5'QL);I"!SN[NR2KN2XX%S4Y!
MBV+HPD;5_4NSU,ZSQ*\<IRVIEE,+OM['3RN9G(F)%[;%C <NMDBA!*/8)Z&(
M>.&;XF "9,4+OPWO4V)UD%L(C)@78L"&Y*./]/A[:539J")!4G'8YLHYK0B8
M82W4IR$TVNMAHQWQ<7G&AI"2Y;EN@B.)D,7L,$4\BCRVYBXI$CHUMV-:,<C2
ME.6O>M3>BQRZZ-*4L5QXS!)5D9QOL5ZK3O2%8B6:<==WJEDP$GD#G=&OUAL;
M#YY!AUKGVX4-1'"]FQLC.;YV+5HD8\/++Q*1?JTS&>?=J_MM.^$.Z[H#426S
M(*LIF7NG'&<M9#(A<++%03CECF0]QBX!7,/X7Y4&B&N.! <6IVW#/'CK8>-=
M:YN4EUN1,.A0N^9I56$DQ"(X5=#EA7+//-YYR8CC#)K5\.*R$7,7S4P"W^'8
M4,X*\EL*GIB2XX3V5)IZ.EJ=QM7DS94OE'&4/G]@ EI0:?B,01<I QF,\@"O
MI*';V#I#;%VWDN8=SXF[AWL/0;$J!0*!0*!0*"CG)S_VWM]O\H4__P#+=?H/
M-PTO_)O9#O\ B#J_U(]H-VOL_O\ UT>T"?Y]4#_7ER@]1M H%!KDY@?^U3R,
M_P"2S9#_ )4.B@\;C2_VWLA?_#W;_P"FQS0;(N&O_K6YX?\ W  ?_$RO0;=S
M4"FE#<1K;5GG:&(58>M3O@-EL0-)%#'2%B19.;#\?;\$<%U#((:ZRCL9&2@R
M>)3#(/ L()D-G82P>(4=DKBV+O5B+L>D)!C<^S6CN2YMO-9XSF.#2$S0K& ,
MDLM;094@A_1@L.I((ON*5IVO9Q+Z'BGF40TVS:D%8K>]BUNN'/;G&JX8I9L)
M+$"RM#48;%0U+4JRW9X)>I[$;&OSG,35'YB,'FR!=?(K<,=F$QKMYG6* MT[
MFXSJ^6%)=)T\<P,C!V#+E'2G9UNNUORI$&\9I/FY;@4KK].LIS1!B'*QQ[(Z
M=([TE%NO^,FVC/-@(T5/!B+TBJY)$3A?#+?"2.X@#)8P(3L,,&L2<M3]CX+%
MG'3K0Q"V1:S7V&A"!=?EY[N6!VW)K!?8"*SS+$>,\%=L2\E-Y-@93LTWDM8/
MA.7FVHJI]2*W,MXN&(>#%P#:0\^/,!QQINI%Z7)A-#2]NU. F?B=+M ?/Q!U
MQ@F/HLBLM#Q4K9="NJFG S&>X0['[9E@2PSGSR[F$L!E88/RDZ(OEKR^QYG;
M$T-8%P-_;+;S9MRI2Y&!]625O'91A)\4,9!0<RKX2C+=<D&Q>@$40@IB]VEC
M9<0WEW&%<0+' (Q8O&Y-<$MYD)NLNW*/%*^<U4B_5N=W4Y('*22HNF\9K$@N
M4K-D.X&I!;H4:2D><$MN0?(-6LY$?+,V7&$+9CEKYBAF)+C336?$>UT119*
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M,H28>U\71Y#VTS>+1B5=L@K+1C<N[T(FH07(PSK10(F=;I8;Y4$%2-'DI?"
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M9.["PRC;5=&B*:Y>#FN)7!$@\ISI/.+^>+MD&:"*0Y#0Y@[F& ECFQQC.)3
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M!0*!0*!0*"CG)S_VWM]O\H4__P#+=?H/-PTO_)O9#O\ B#J_U(]H-VOL_O\
MUT>T"?Y]4#_7ER@]1M H%!KDY@?^U3R,_P"2S9#_ )4.B@\;C2_VWLA?_#W;
M_P"FQS06MXR]HM:=>=X><-/GS8*&84/.G?<T<;).5)':C$-.$HE'9-!5#**
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M)%7T4H'J2Z9?9&UB^H2*OHI0/4ETR^R-K%]0D5?12@>I+IE]D;6+ZA(J^BE
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MV'%Q"OEC;K"8AN\H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M,'"U;H@HBD>N80P<B^>!H +"^6=\PQ+WM?$+4C)R>8N2N.0)#W3AL#"?<8J
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M0MQ0;WSZ+6M[H:OM;N+[D&T.:7&!L[#D:Q5-^QNJ6J$IZ:[0ZPJ$O)[#+O\
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M1"+P14\Z84FR<6$G*QHJ$=" S,%[V$#MEA_>H,NH% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H-1_-IKO,&T.C><4P>P3LEO<38S51X
M"M4@>1$\89IL.?V$[7FHYF'"II*=<ND-I),F!,+C=H)@'?$/'/.]L;AYQ&KP
MT;U-/8+%QJL1K;FCO7'EMTN0-1#!=?8^!AK\<D<[8;+[02(]@<!G3W4$F(:M
M,R8$(6RQP4\[$,00B@F &-[!,C$T<Y%UGD%U1F.3-*ST<I$-<F4MRQ)CJA@O
MI6R==O-A*!1])S?DMAI3$)D=I9*6%XH8)G'JLO19,&,!QL< 4T0847N0,HU(
MXWMV8[>'&VH/'7]PH2?"W\]BTH"C.!B#X-"VU:F9,:^V.X$G49R.6DD"^/<O
M<EC'<O3;NON>W]@9-HKQ93NDR#Q+Y[/:H)2JS=;N+?8V'90)R&7C1Z(;!GAX
MRD*<:K<-(XJTN%SZVIM%4/7"-E0314($R)CD-AGE>U!0R(H7>W'Y_)\RW3U_
MAV9'8TM#]R=>%_2Z>IWUFC];C-T._8UYR$GS>0/3T]"42KS15(Z-%T)?,)*D
M=4T=&%MGF5%MV9<0-PO!LJS)%_LY,?.B#(P./F;"3%W <4&QJBCII0)UO54G
MV;18T*)J@Y#J0FW;)U8,E!<3I@8/ 5-M<>U\NMC;(*31?Q <F^E\?\46P+7E
M= V0?>F$QEW@^=76A";(CN3D1E[B&Q#>[Q%0V&4YC.@S.LI@Z^.'A<\2*X'.
MY<# '5[ (',(VV7XT=V0FWMGKVC<<9:>WW)/+20WN8^_!%]0.&9'@ITRZSW*
M&W,;.QTIDPEY#9S=P.(AQ$P+!I 24*=,@#7M8+ X'ZW2XTMV#S3Y$H";''*!
ML4_MBN3A/WEB3>Q,?,"%S:#"#ADZ/5\M&P(;T="/+1%\1N@)BDWK)   25='
M4#QD$3'#'# Z%E)GX>=@INAOGZQ;,*M5F;)[:;8%71K');E&8I-R2C S;&BE
MW*S"0W]B95#[%:TH#("XD#EU#,B5,C'+640LB=\[V"/6WQ=3?(.MW(6Y'7H_
MMW@Y9R T_3&]$#[VET&AB5I"4]<5[!QEI*C]NZV:XI&N;+=$.&;Y%43!SB'0
MGNGX=B:P(7L%E<.C+<?&^<@:D2PES9J%++S3FSO/!.P6LEV4X-#M9>0M&+,I
M@.IMO>=973(T;3GU)V!<[8.+F"8B-]S&BJDJIF8XXQP'(,IA0;)]!X<VLBG4
M1JMK<C05ESFLJ/(TF/6(&6#&^GT?RC$D6J9Y/':VX^P[<B_,O!&$YQTLECI\
M^;:.9IQ9 #ENS$$,8B7P#T54"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4&CGF(BK8IRRMQ?SG 6NL@[*EM4]PS\QR<QXR6H[1G:&S[1BXF\".F9R6\
MF0@&3!A54P\,<+G,;_VWOU;>[0:L-O.-_D$Y$T;DYVH%@(_K8]=@(ST\AW7[
M5E^R=%*A)4FQMK3,"/+TFVD]>;JB_(A9JK(QQ-N40$\\<4B660.."I; KG?,
M0,$+<9.V3BC>2I(;6KVS+.>$O<C?&9)ZRR9XE#2\9U*T;:M.%1S?<PB15JC'
M,1PQ$^:&EJ]R ^)8^L*SD)D"YD0 $7"W;A/SDXWMP\(DY(9=840&$W:B+N;U
MX<E^@J2I+C5+!S&WD)/BU,.HME,FOY!I;8FIAE'"C#$E(<CD,8L7N:"QQQQR
ML$$R1Q&;H,&)>,B;0F!(TNRFS'GN+L1O]'4&'M63$T#;+;S)R(X5.0&JD;8M
MQ]ZZR"=C0<@$RC^9PN,= 1BN!A,&Z;B#8A.6M/$4_6Q,7"0D2YJDH+$%:P1+
MR"+4NLJ;GU"VPR;!C]G1:3';%3-7%)NLR.V6[,R:L;,C)82(V!4Y -6Q""'S
ML5 -9!@4#0&7D'FVD+2&.EV/9#T1U<VG7^9!4P9[B37228.R4H, &+&OKXOE
M484VCM%59,_Y.-])Z1G? 4L6"M>X(>71>@V=\MNJ^Y&[^Q''K"<!'B\10I#D
MM+NX,M;).=G-F4F6UI8AE+L'K@S#$1J3Y9JE()@\ZU0^;,ELQ R!?&Q<QGGG
MF#V5PU!R)Q3\E38BCD6U0.-A$VWCIW;D:S<F$<*Q-)84$Q=M8YA7LE.G;W6,
MS'A]_.U.C(POJ:(0/)9,X)FA'!R.8F0H.1BV&(8_+/&INKLLI\MLC,?CL):P
M-C8\+C1DN*-8G0^8+24[8$AJR^%9P3'%3S$B]SKS 9SH?Y(@&:$+F<^X1#(A
M3$T8N,(9$"#']G..W='95N\RSOCKC,6=84?<:"N.MMPO"!5V:]@+KT6X6V78
MZY*YQ=)QP^QF*U'039[>,*(H-SF-\T\ OEVN1X3,# +3\H7%1,^&V#<D;6;6
M![25JBM<?CGT]0X&U0'TFC@2+9 6I&<CP5P5EO[7QJ]F(THNEU/<ML%ET- @
M&ZR)TG<43,3#LPQPKSM#Q9;IQPN,@MJIJ/,CEE SJ7IY"V;Y>4KZ,[<ZQR>M
MP4@)J""R=MXYV>C"/W"TB\2)P6) !T,DJ,"XBQ; X$0*G,L\<0E7>W03?L[N
MA*4M:KZDK1Z7)K5]3W&X9 <Z[IU/O'I+SJC!N,YN.UU2U$^Q#8(;$ZYCQNG(
MHP"3@T#"X8/6*%S!3,N8$RM8/3?!I0N7G;:X>VI)2#5$XY8N%5=A2A:.0+;@
M&PV#@#9V9B-4P,^#'FMPP\ 87<^.)G$/JV*WR Z>@+7T"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$.SW/47:S16Y)EF-P#MUBM@5$
M)&3">B+CH75===*\F-1HM1JM-KIRNYG:[W>ZEHFF)26G%#)T\>-! A!Y996H
M*<)?*[JC@SIO=,D SA *KKQ&Q.9I.C2?X%DZ+Y7)0^HK([<3Y/;+%6$#-3?;
M,,.$J(0$-(ES_<9W&P!K$ 7,/#,+E21.L:1,[(29#Y6S*6X]AY&/13%),!'5
ME(-?>Z='CVE(VF&C:<3,E4, -E1XJF;&3N8!?+,OB#;.XHH>&04=DWE]TVB>
M.2TP./+897B44\_TH_)[#U1V,D-@-M6C*8G9 KM2G<[69&RTAM13*R:S#A$N
M ?&+B' LBY@"PA<R ((':.+E<UD:B9&1I?8^X*>X9A6Y+18[C071[:Z\PN*T
M1)3)67\O%XDPB7*006@BDY"2[65Q$_!.'%%$#"&SS &QP"56T-JKR*L#)5DC
M6 ^^FHRG8:3$UK;J:?N=DJ9!<LFI2@.MM=B[*1NCJPR>.6. AV5")2Y<0<',
M&PMQ ,\<0P>-N1S1I1E9N:Q1R[SZ,/9ZN"!XY64^%I/:FN+BD^-RZJ7<4)1;
M.(K$3((<CV:0+9/E[HB0LBB6%3C!8##,8 0+$,CB?DHTZFN7/,NP).4S;G4"
M\@&F.XEZ.)+9\5S !$AO(C*XD'S&[6DBQ=,N,;&<,O#%VXK*-BP.&9BU\RP0
M@V =)#_*7I#-YEYALZ6E-*369%#IGSQIDF,I2B5DO6!&.9!*/"<(J><F,UJM
MF58G;1@T!W8NM\TH$0 S)<7+.P)@ 00)$U?WPUMV_5'6WX9<;TLZ&>@-9YJ;
M0DZ(Y7A)WG8\?>:J&Q9.;C7E]F,E;=$;/$5#.8$%M/ ,$!12^8>0F EK87"6
M)[GEJZZL@!_/!J3"\DHPO$&[@DPA"TH3P\L#BB54#8)P9DQ(UG>Z0$0$--SQ
M'/YE+% !,PL!!,<A0[9!2:..8/3.4(T5YG0<MB4>($@1H%L91?6INQ\?Q^MJ
M#XF-J0(@)#5=KQC1&0W4LYR@\2A P4(#&#!3 ,R.-C@ 4,"!A="4-D8BAQ_1
M;&<@.$VD/"94V55:/TX!"6U0!6(PLS+/^0Q3*@FD#1!*NCM>_;AXFA LC>7^
M&!803^[04GCKF-TJD>T4*)<78YD,><55D(<52_+&G^T$60>\E63AB):-2I"9
MGO%*-&Y<.032F6"1C!E2!*GQ3(6 0N60H=L@[Y:Y7M8DU]2='Z$R-P9,5H>D
M9RQ*_P!8AK1[:^7V4D2&SQ2X3E; +YCN)7$U%)01\S87;6+&Q;8V$QOT]&5J
M#O)'Y/M;8UEIXP@.U-J) DB/$1A+[^185TZV:FL!E%)-;WC2RBKI5HPC!T):
M$KK*);,7$D9&#-!W#$QSPQRPRM8+&.S:&*6!K&X]NG]D]V)#;.BY6F%VB/.-
MWTV'\V64A) ZXK"+T6K*"3D)*72*>6SR$2QD[!0MG;J=CU[VM00S"/(WK3.S
M[#C!%\]<<2(?9:_(K89^P6M\\Z\+#]933R2\78OQS:98]9A1_ -?PX2R4 DH
M4T9*!&PA1 [!9=>@CV#^5S6C8LY&5HE8&Y;B;<OFFX$PI('T6VT1HE5DUU#%
MPD5T#RFL1$28B8S# 9K ?-8,GPDX(MTC9C8AVOE02PS.0_4:0]>)^VD9DJ N
M"'M75B9V].ZN1;SES7H]7H"Q4!Y,1U5GY).#H%4$M.3^["H8!06ZD2' '*]J
M&,'ED$1RURR:N0M):+$ST9^W0[O=JR90&!9HZ2;5/E!D]6(M,P^SY2+70THG
M5V_(V2>SR1E1,71S!RP)0H.)G>V((E\0G60-ZM;8F2]75&5G<NQF9W$?#3CB
M#FV_6$^&J\U-YO-,P44=$>#/5T JXHW'!%,EB1[-?+IP:<IG2I,SD$8,!!Y!
M+UYWC.T_8:QW6S/GD$A\6=\&YX&5^X[QF"] 8^$6_&#N+P#8S9TCX@=Q]T=U
MWQOVG9]G_>H/TVITC5VS/*>OZ$M&34I0PTXO>TA(0B.K%BJ0W)B$? 3 .%UH
MR3"1E416SCI6L("5'%%*]SX]MCAVH?6#NY:EF-H(C1[3%,#S0X]C&.6\?=3V
M>;C-=R(Z A)H7:&3AH3'$0883*]\0P0 <!#!D?/ $$,07/##(*:Q/R<:VRF]
M?-VHHL^PD\%9C.V3HZ1MD=>I6@@Q,T>L-.!6'FYH@\X+;2;/7-KHYL Z?2@^
MS7BA(? R*1Q ZPF(=3!G*;KEL8I1D6BN/-RU9!E_!OFV%(JOHQMDUXF5D1TE
M 5! =0TIN*(TUAIK/4T\R&8#53!\(A<N)B)VO4O:]!(#.Y'=/Y U6E;<YG2K
MBOP#"!Z3$F57(1;+HS764LQ"I&$U]HJPR<DC%W@JZ9<' R"7L2N(<(F2YHO8
M0 P")F$82URQ:P0K+A6#WNRMP<Y#65]T-QF)[6T=VP>B7):@RTP1<= L6.%K
M1(K(<DIB,A Y'AC:,8.%L26-QNOV?]Z@_KGY8=7FP]W+'5F=MZ[7@QVW'#GD
M%'CC2#:^21HZ*RJP4>3&>DR!=D1(NXLUU#LY< ,FD@_V"D1SZX)@$,4//#$.
MP=/*[INAI$!K;67Y;FLILS'KSE2'2NN^NT[3PN.!A1VMMIL/A?56S&,?.-R-
M -JN9W$$U0!5RA$R341KEA@\!\! \0MM D[M;8ECC/\ :#4F!G)(*Z?;V23-
MT+R? [RR-IQ<@9&.!,B6VLT72*BC8*&&(![$I<H.)@)@&)ED$);$)KH% H%
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MGW+N4U.0*$XGE4-Z1+#B%"@$>[(0!)<*QDOM4-G-)U*R6BJ,IZ[%$D\35PS
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M9KRF,JH*LVK@FQ,QRP-Q Q95T,VX2A8]T0D-.F&4H8C;EBBG;EG[20F2.ZZ
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M\-7ML(E@26Y 4./O;R13SYA(TC(S<?4R14\H*D*#7S(^OY1>72:*^5%JEY/
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MOLFK0.R0MNVDUFIL,@A*+4D8PQ%I.6F&^U)L*1I%*2JRK$1,C2"VY0328*V
MC'@P5!%N=R(CXY7 L*(&MZ>]+M@WXR>=]$;371C:AO1&R*V];0QW6B$\'8K$
M]&&A"!@%<%',8X,\/"1D@<I80_V>-P,;&+?X65KT$I-B9.3)9A]7:;-T*;D&
M2;'4?LM18RI.VQ,32!'$J*+0<S))NV)[B0HXU9VL5P/R/<%G!&<1LD92DE3P
M+BG"XP72#F'PXX]:Y4B.4MIY@<.O3)TEBB<O-'BQ].8^?+;>Z.W7VQB3V#E"
M?7!C'Q4K%36>LS8N1'3S1)O7'L:*-8J=4!LSIC/ (-LE H% H% H% H% H%
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M)]?*#:^.*'\,H'JY/KY0;7QQ0_AE ]7)]?*#:^.*'\,H'JY/KY0;7QQ0_AE
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M/&C./9YBA@B7M8,:UK].-O=Z:#,Z!0*!0>6[<;E8V!C+DBVUU4#WTT$T5BN
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M;L^D6P882#LWRF[/PQ-FC$&"<BW'9';$V"U*D;8%U;M/^$E4:"9!64N21R#
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M=JVR5T3!&=":D+0!<%P-XT&$(*7PQ'#PQ%#ZP>>.5PTOZ1\T$N[+\@%H0?\
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M(!325((D<)Y$CG:X8V*C7Q"6T+E*TQ<49,654Z0W%X$D7;+#1MMM\U&T@E)
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MJ,^+ER[D4DB77/,LQCRPL&'4N7Q-HYI)L3.,<T%88D.=SOCV08"SN"_;!(U
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M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%;-M-FFMJ/"BO,;G;3G?
MN+ICJ.V8PF;=$"<S^DV7W^VXNC)E)9]SJR UD7-R/EVD2PJ@IGBA @!GF8&%
MM@'>UPI*[>3Q]P7&.QSUVST@FF"G)KY"-M@P$1#>#"E]A2G'N#E#:2BG,F9&
MN:3F:G2.WEDP!X0;JUBF'L2IH$T5[K*Y9C!A=Z;=E&W!\AZM1TN-U>6E':J:
M56$FJH)&:=B1;"VE0U*4T"K+BL=-%S B2*BQ6;)XV*XC#=U&0;WP[.V>6(:Z
M)4Y?EQAZTGMO6CHW.<J0 VG'+31?SQ09.UW;1]EN*)]E7MK,;3S#5>DFH3D7
M<'"Y&B"IE!DXL9!#3U(*PV08X0X882*]^1F?&$O0%&"QQP3H+L%L0<G4TSH3
M*3IJ@(H$61 B-&"JY'TL/Z\PVC<N15A9/!+$R.*GDI7$)#99@XX9!99A>;7J
M3I?E1IJZY,VM3RU?<1%P#)::RGM(<120I+B,&G)YL-SEEB&WF]V\3)#G30Q6
MQ8R9".8YE<L[AV#S#RR"F:+R@(IJ5V4W'5JULG'$!RK/2_K%$^U3Y2X]1X^>
MLSH2DZ4,JG&(Z\?19S9[&>:^RE(BWG&K-HJG*AC #/\ P2YHN/F'(A3D_:,Q
M.=".FM=]@HXUWD9EO^0X6VM>*0RSD32(R8W1S;G576X4EHO%R2-";<>3-3S"
MZSSCU1T,%TI &0A6^(^0184,"8?,/%*DAGGU-D!3_K)%B_K!)NY<&2+*Y&.E
M!/GC7F(TUN+ST76X@1\_W@Z&>_2S8>:,K%VHX"B<LFDY2#S##N*&8!!"PNKF
M] D_2<XH0DS6Z;-4)E3HN;<[MB/YJ,QDK''W";J6S;9)O-#5XI?T@(I!8;CC
M*AD7"@J Q551#)TI80// QAG06*GV194C!C@.2']>W9LNZQ5\@EBQVS'Y%D=
MJY9'-%5 8XY<U^7W:S&J(233!4$',O@;R."9&L<@P\L,!+XAK!C+F"7WMK&9
MW$=VBL[1?KZ;6(^;+-=ZW)^NKE4GHZ'[LTS-7L$0DTF9)RXY4;-#=CI,*!@P
MH%BQ<5/2Q; YYC#%PQ0OS/>V[2@"78#B%P-1SKJK/Z+L"MH*RBYI.*4WP=>X
MQ\Z#@ 6\3YXJ<S'<"7TEB/<X8MK&+=(M\,/[U!0QC<O#N4HK@G9.6./W8V&]
M3)_,05BV=ASLDZROU';27LJM-)MPRZ'Q'K'F%3E%#:[D<#[1RIH?!),&4W,_
MA<<O:UL^J$@I/([/4D/F=VYKWQP3I.30@.>)#UX<$D)LZ:GQ\CKC[C(<@ Y<
MD5OR7,+8=MDK"ZF#<(8<F'82V5[6]W&_0'>.[D*F7+8F9]<H+T"FC81QZ_(<
M.J4JN%O3+K+'J$@*DTLL9[MQOE,94E9I*"X<(IY0<(T.3"&*XBA?W1+XY87N
M%EIDVC,:^:8R5M[,,1.]I&(BA)SS*_H6 7V2XGLC^*;?-KZLRP'&WEY18*HM
MX8%+@X&"RB*0S$O:]A;X^[005%7(*ZEJ7&5">Q>GTU:HO27&!(DAPF;>CV@F
M3FK)A&)TQ"7'^W05R%I-?([2=J.A.0J>!*K!4F"<*V'N$/<0'(*X85JMR'[%
M;8-F"I3:7&K.K9@.>4UE.Q F-RSUJ3<DB1P]@R9XD_%ABILR&Y"R*DD4Y8X*
MG@)PBGEAC</ #(6]L;A^(OY>=?)9U9W5V9;34?X!C1(2<KS##ZN BILAGDV&
M\'D:3'*T^Z%/%%56A*A!D'KH"K<P&3%-E3A03/ <B:Q##@S?R53=$$Q1'$J5
MQT3G) 6Q+H6&IKV]&_.&JJ(BRDH-Z*UN8US/%-=DO(Z^R@2#(;"F/TKA8AVH
MI/LL.L(*#CF$I;%<D#"U/+:D$YZC!_L]Z;/N-$2'(SD\\SG5GKHWC!]EM=X2
M-+[F;R^>:UH[CF1).;" JJJ6:.ENZEP 4'(0&V6=@L1ELNVL=P M.O%M?\<!
M=;!]E[._KIGBM9M%Y0+1;DV[A=V>&?#^2H9L:MEW/W-W/:]NTZ_]V@_;'V4;
M;ZV>G_5PBW%\BY]?(]@:1' YCF:;=NKZ=/H\J@(*>B!@'!%3 \A910;N=N8!
M"#O8T#V66?0)U0[?9K8Z-=2X0?$^RR.MV9K'+I >24U4<9Q/%VN5T+Z6T60P
MV0W ! 1G ]GX\UX@CI!*P@5C"@="PS$#POD)B%1&-OS,)-])['V>T3FG6>SX
M8DC/V)71D]XUFUIN+S7-89ZN=@2,NQ2JJI"&I,$:P(AL@55!!T13[F, %%48
MT#8#,.KU<WZV0VA18*D9'XV9Q9$$3RVV*_F_,CFGK4PTGHT;2&AI[F;[U5V*
MAS$H2)D (@J@!C,@"FYJ.'7ZEP>O:^-@Q:+^8S7F6M)-G]T6PSY!"+:CY21A
M+<**H:"G2B3Q8@R@.BJ26$.JXH1]MR6WB>*B@JF)FQ V'D*#VEC!0T&$'(G3
MDBGF&-A([U\)<<$Z2&IS@Y)'0H!=S?G34]'0)7*1<T3#]<ZX"5=$PI"TR2F+
M0*YFP05TN0,"7MV-L.UO;"@^AKD>GE8F&785B;C>GJ7G7K^C0R)-5T.;]3VJ
M59;QF.(V[+Q5@D\WW,C<Q=JLV4IP6)&CB9D83!C8&5P#&866&>0= 3Y;RLG%
M]7 =6=19SV,=.T$2SI+Y!D .R$HA<$9H^N,GLV&):07^9EB1FXVK.9KR>\@D
MC,!,/GPAA2PHH @H%L1;AL8@.193D]C#.28-?'9K2[ UX^F!QV\GW%LB*XZ0
M5+$!B;DQ7XA=KS:F!-3',C!8%\CEC8>1;+(0/'',.^0390*!0*!0*!0*!04Y
MVXVT'UJSAEELN(W+/<[;&OU:CJ$HC;KF:3# <2RU6$YY.>"PZ)!?2@GMIGM9
MK,AH'31@:]CI\P+V0!0F9%$Z,0@1/Y*#+?3V8C3KJO-4&RVO;@0KITO1\M&V
MHYF\0<T\(F;C8\H,>5T50P9,J11FE87P-&4O/%6(J (Y(V0+F ;X7"6-D=\&
M+K5(+WCQR,=Y.-08VCVQN]!Y00!4' B=8^MRJRTEQL@G924BABSP<0KU!S(9
MB88D<<01.V&#OU;7"MTZ<GTKPZ>@<XB<>\Y2BP=G7)#S$@N06Y,VKZ 0>DA3
M'%AF4TIHF6Z\991'4UA$0DC*I(V>4RA5/R,IN600V80Y?,0.[6^1>?0YB"U[
M9/'!.D@30A0'&\^RPS$Z=-4$ "*4B57Y+3$:+94W0Z9A26R[5TT/#Y\V)FB&
M3Y4$ <+'(2PG6QQ"^S,E5QCPC>79FBAU04LI+:=#I>L7*JLUY-=C13FP(KCB
MA]W1"JO1 =)Y00TS$Z7+I!@Z-G8Q@!U>Z+9!V#7PU^7-AI^)A5V4UJV.U 9J
M]KG*.U\0NN:$Z.%2\J0Q#::VER0+8M>,)!?;MCZ4D9 >:2=Q:+@)D5<<,[8(
M+'(T&*7P#(B'*0AM>/IV?^R.J6T6L(,*QJWY=(H;Y;S!>YV46D\'#DS6HUF4
MM1(_GRSB4YGGP*21CC$6%-,7TX\K$<A@^YA[F PZK/E;;[4:\NDIJU9V'AO8
M>+EG7Q"1M6E<>(7A),PGML'>KQ_KOE$[H8DFKT6KI1[/ANJB6HC&ULB&W#*0
M=R4;@@ XC"A:K5#;,ELT%++<78ID" IJ@)]D(\FB$9.-LI6<K/5UYH(#_:*T
MFN2.G0\60[V6]&:YBIQ-4T\^(&)EB. )@$.7%#Q#']W]KY'T^C-8F%L:J2+L
M?'K$8DDR7+ZW'\BPNR1XP9L9M\)T*:F<295?+05':*HH8!\8 NBA'A[7(989
MX8YB@6$"'XXY$G:N^JW:8-/I;@+/<"84F*H8P<<B0<_LE,@JZ_RGL+9^J_FM
M?[MLAH15N1<*2$*F;AJ/=AX&]@;A8#9X!V>W?);'6H3@V";;HC.0'F?U]U(9
MFW*Q=K&6N7!<[9>\Q.B&$QEH6:VL)_8ND%>:^9D40U8$C8J/AT"WSMEC8.&R
MN021B<Y0K!NSNCTZ:J'=C5QULR%GVYI#UWEEAN>1&>PW+)R@PEL]"LKO5:9R
MTI,9G*IU.&/$<2)NY 4'M\!>SQS#!]7^1[8;;!K0]*T=\:4\$H%F8=#4$*8%
MZ>M1RA-,8BPL631WVIL;"9LY [A2R6 IP0@$G9J0H0?4" S%RQPN'[;O(YL#
M*+HF8A '&S.TT,6&I\E_7A0DHC.^I;"27$\H5>:@QW><1FY(LQMMW@H_A=.S
MN7$,D@LA0[VO:W]M!:O<;:_+4>)F?(>,1O&8'3(4PP[!3*BYEKK*05];D2;7
M>G,AHIN3B>Z\@,Y+)X+RF'@8-&3H0 >'3GUNK:]Z"J3@Y6$^+HWVX7]AM5IN
M@:6=0(#1MFG7"+B<<./13D"&G,H/1";KICA_QE(3PC]1S,.:/E5--E#QP@<(
MF@,+YAY BABW"2$7=+9E.27R\9KXY)G@N-8^BZ1).7GVOSUJ@]B^ #!9ZJ[<
M&^$W8YF!S.C-3<=DNY0N)W)W, ,);(QF&';+*P=5''*A TKZB:_;@,IO/8\U
M)TG&"-=U!AG2Z4ER'$<IS7*[5B TW)*1CJ@'@F'(]<+J"-* 868N9Q,[,V1L
M8!,ELQ B\[R9;+%-D<=5P^+;8$U*IB-%6:D\H'L1IJ&DGHB2'XG1R:>F*J--
M^!,#*[C5BV.*:)EBI7#%Z_8]7'*]@LS('(%#\<[O1#HPMI#J%?<LL^R_B_"9
M=/$CEDN==3Y$6XRC5XJ^9[ PFO>66]#+R.H9:P67= ;>%M>_6' MD$O13LHV
MY9G7:B!TEN+Z4NZI.B*6LZEQ2S3<D9TFI8B-M2^DFFW@4-CGPRR4D.8,H9L;
M" SN:"SN';(/JY7#\:Z;+-K8\UL(4;C<7V[GKOLE(.M+AR7LTS/%P.6/$9H+
M*@XT/P:<-WP0% %X X 8F.R,VS!SZX>-NK>X=)MGMBV]5&NP1A6.]9?E2:)%
M38?@>#XVP0[OF5Y+5$9<<MTDB><ZL@M=L-MN-1LJ2RNKBJ=*IJ.DD!AQ<\L^
MR!%"FKOY3G)!\5[+.O:;2^:H2DO6Z+6W-(D=I;G8LH,^7([=CPP8::<BV<6\
M<3H_,.=)=67<JPAK/@=43\1 #&(0Y,<,S029Z[^R#19DP29/''1,\&QM#<)R
MI,RV[EB>-47WBIX1>T%%X9L]-0XVE]SKV*TY2B6*"5,"E\" (MK7,"AXWZ:#
M[LOD]@V1M:-5=GF4WWHKM;:2=X@UQ :1DNE)+YB.5)1=HK%66O*B*H* 7@98
MB]V%!RBT5!S&&RN%VA6PX(@0F80\G\F.RQW9'/5<7BWV!)2H5C5&FE3*B[$:
M:BI*=$2X_%2.BCTS52\WB%#.5G&B&\<DT'+-2L&#U^QZN>%[AU"ERSR*$U]@
M)B;?'5LF_-:-;9,V%C^1)N:<H:MV'&3=8'V[&)+;S;44N2:&Y)*TEI!ME*!H
M K8D&>-E@?\ "#RSOCA<)!4N3!Y/.8G1%&IVEDO;9DF=#NODVKS^:4J:^14W
M0&CLTA.QRQ78J1FV2&(O*!Q31F6>%'L"6SL6ZN.(G5RSQM<-CT7N=WO-@-=T
M/V-5F'GBM)MC:_&;@<+1=:RSCUQQ@[I*@XF&LN%GJP]@@\1.U('3 '0):W6Z
MULK6#/:!0*!0*!0*!0*!0*!0*!0*!0*!04IY!6N_'GK"[FXRM=(ZVX2E)<9H
M4KZV2*"FY>=V%+.5.RD]O1X9<"\VFHGS GMRPBFUAE<X"G^&" .&8@.>88X0
M:);Z6SE.T1;S07J)#VYNM>JDJZ.2"P6Q"&^TH*RNDJ.X>3K;"W%F,#MY^R?,
M;]BF.B;12%A*=!S-4)MTX854S,@4$[@,#T%]3+UGK>W:#C_4<M+]D]9&EJ1,
M#ZV"GIW[&)4?ME$ 7C6MLO0DVHKBH9K/]XF964E1VRWD;'6"((:*624K,7NG
M(8P"!00PXM0ME#G"!L-K(6B5<%GEW3CLFYVW&UE-L65U9!>?(L]Y@:ZF ?R7
M<6^$"L1HI@*X>(IP,3  6V&>. ]KA6"4N6* 7#*.S6@4FJ&LNS^S$+Q(W=OD
MN3434J3?-5*;<<$DHL&E8W.W<9">]=7$(@'C#54\30!1=R"S[''MP!+6#H+Q
M<?Q%L(,3.-L,[6O;G69!2WN<.A-C<61QY4?SA.JR2E9'%UONM2V*V46O%;#$
MH&7Q*CK)0, R&+D$5QL)D((&MU"6]E]K-OO#FX&DVYC,8+"?[]96H#;;R5K^
M;UWA\LXD1PQP'N).+FPV'L_G_,RJT%X[9)*%FYFF,-+41@B1<^J#C*=@IYJS
MQ=RNC(VNFNZ9IRM:I2!#NN>QFN^Z^Z>3_8:PS=Q&H_M<'Q"$?IC8,M9^+\H2
MZB+TC++??Y4L[T1&PCX!NXI93$//(,#(,RD'4#=S>B"XC@%Z:MN;6-?U%XX-
MD]>#;RDI_P 4J[%FC9V18GBZ)6 E1$:CIYO)>-PP/YO#RLH+ZV113 !<\3+X
MD<Q\3%@PN@C2S.(>P$C\F>PVGDV:YQ?K-H>MPB/%;C<$(.^8I-?[VEQDRA*1
M^.TQCRPM-(\Q&$3C9-)I)Y25TLXXAU :Y8EC<''$4-Y^&77QQSM;*ULL;96M
ME:^.5NM:U^C+&_NXY6Z?=M_HH/.,/I-L&N\"3/TZ<,-KIJ9#,GQP([HENMH1
M19NRPN1EORF[1<UM/<I9,+A!1!@95<LRJE@:P+VO8&]C5L<*#/93XK(\A+;[
M424M.X 7$I!1X\W?;4S.7&3'L[RJ5X]:\#-J*T\R2E*15_,OFX7B:$+!")I?
MK=I?_><\ K6O050CKB2=.NFL?%QL:T82E689RUB:VLRAM-I!*$^2'*#-<ZEX
MJM%&?CYB)@25+JO"[&V$UF>&0CB:829F0;PH! TG@!XBYIPY8/XV]8"K!G?=
MI;GOCGY0Y?7I*WAG67X]D+5?913C>)'%%3O.H!AD' V@V-]X#3\%S/N Q<YF
M;;F!L6U\+#"BVM:V 9M,VNYE1Y ]O9SFGC^Y'II8DVLC4DS$"]JA/><0@(MF
M7#YM'D-L26E,G=G7K)2=2&XCP);$0R$LAAW"&L6-6"RO<4-E.WT:/:>.'K8N
M&X;A67&R^G_IC)$81I!<LKZ2J3*55A6"J--K-%XN@](S]3E1V'NP!L(H&W.H
MYF,Q;#&#F0N0F5@UW:RZLO,EM[KQ*6O>E6Z^L389$63>P=H7MN]/Z9,))\L!
MXQF*$S(UA%LNK:'9]V-YVG9O1T!7-*J1DUR 2.E&"QW(WW07+AA'?%YKRG:Y
M,'2IH2;QJ\K+:V#C1N14SW]) ^RIQ7UJ;[\+DB#?<SQ&C4'D%-LH6*TDV8&.
M9$2[($!"(A_X"7?/$,&@ZF;>-7;@'C+<KG@*->X]ULF+R%:YR;"2NM-X@%L9
MJGM#LGL.XT%JGEG!4$0"[YC3"0$V06&=,&L<B8@BDDB6"Q6S>. ;?Y[A&573
ML)Q%.QNLQ05FWK[+$JKLRJX!M)" 8:.NZ2S1&:0H*81E1 -'0C[[<A%-QQ)!
MFL\1C..66-@K9"8A3O83CEV,Y!ME-V'O(DV/K5.&%V(P=!XK:B9&4&2:>EK7
MI20$N0I@E"QA_I#S/L*SZF%TYD$\9,%2%C,NRT\V+U,@B>081I##CWTAG8C6
MS9+8W1_92:7LD<<BQI_,AR QH.<R@:FF-MFQQ\)&.!2!-T<EKM69F6TP781%
M+F#(P&"R&7'""&P$PP"<&_+,_P -;U[(;-F>/+=A_L#:76;2Y.;";'J5K<>=
MD?NF(3NQF;Y9<H)CFV2:J>E.-.PDA,OAX*.+!(6V6?08_N^Z%P^0F%I4VITX
M2\X=:5RLW,:1M9=K8VBJ1U-);5UY\:^3!'L[EX;>RP2.KC>;ZHZ@6D80!#F)
MHTG$%(Q@/D-F7"N)<(L#VEVWVE7B\<QUHQ-D!Q7C&LOY;$O3;1%9[.7Q5L]&
MJ\C1M%.O:4RI0=@#X=*I(Q\L95G$8QS:Y1"(C!@C#FS@%P UU\8,"H>OC:TE
M:CWXW.5=E3U&\?P]'L@2>Y-E%!QZT-N0"C)264^GB9C;/D"<#0SBL@I"G#1<
MF68P@9,CB'<HF!B!!!8!#DR<9>X:=Q7(:O L6F ]Q3\"S]JGL/KXI+K=)#3M
MKI*TYR<YF:'95R7;-,*48!5W>&[V@<&.X8^"U)=2,\K75,<0@W@;&PW)SPW?
MXMY-;+0/J["@U>VL-2RY0#24$39)=]ZSJS*: JB7-* "@;Q7728P)A=Q@F;X
M"9=83J!_WZ"B$J\3AG;/:7E5?$AJ\]P0HS!ZNB5JY.463Q*# 2A!6QK"TVNX
M%U3C:-Y,0&M("4@R$FB$%(JYDO(R;)6&+E1P0\PQ\ J:[-7Y*4E;C:<4T<9&
MQR:Q]<M3]KM<),@SC]EDG%)5@S )*NO6+3>+&<;8V=@)PK4%2LB1XO+R6&87
MCIR^)XOX5+YJ 68V(;[M#2C=2(/%;K3U[VEUM0$%XKI8DQ]NW\+)DHJ69X!.
M5S3D*.X[/>QBL=:QPTH9ERH1I?PS %*C88%0@;!Y"!=2@4"@4"@4"@4"@U?<
MGS!49!9<0)SMTQ)[P:VD'VJ*4\QRSL>SV:CX<!OCVC"9];38C_C?.S@9SFN.
M36P$Q3+N01)5<A4W/*X!@N8#5@EZT[BJ4/K;]C6)-LEB -=M]-,MKM3M4=M)
M22G=MRJQ["_=I?9IOMERR+(CI4T!#7@U_NUAMIY.O)1N;2#6&8A(!1* AA-<
MV,W8K?%[;>3NS]4YWAAGI7$7M]IM%K7V#2&?'LJ35/.PIU!=)9.:C&+/1P"H
MK0;1>.")"ZJM&$P(^I+/5+XYERHIBX6OG37V9G1$'$ WF^P5136M>MK=3WY-
M">"=1 Q6 T&%KE+;.>"ZJ9F%0$ Z60G,ODR8N!',T-F(/CD'AGA;+/$*A[M:
MXFUGDTD"<),TMWJV5A]S:;:\1JPW/I?-YJ(,T:0&1+>R+A?B,^L6]MGK&MK(
M>""^$,4EW5X4+!7%%['LL\A>N&WJ '!XH:D):RR==MBV)XA,MYB-37J;G6EN
MW813%:@RZ,E-M2>*S,,M$5A<?!DICX,-*;N-_P"$< [I& MCE@$&A%9@K;GD
M/A_;LELMJUM%$>[>P6KDC1?#[KD$*&VUI_JPV+JB"^DG7V*W"Q9U?LE*"S*#
MQ:J1XW2 ?;F"DO&$\#(,!,32!).P#X*6@<X2HW-F5G5[1%9T):)O7:!0!-<)
M&D2+2 .T.XVO6TL=;(H3G&%C.09(:68:>VHW.M'SC. R36'/FZ[#' [ET_M;
M!,$UPIN)M5,;MW\3-/9,BY6@Q>X[\XAUBE%\PLFS/.B3JS/<V2Y/IH RU)&>
M$9- T<;\XBI[-#5' #9644;,0Q<D7- YW"V6N;RD*+)KV0W"GO7R6H<+;\[/
MZKZ_P[#JP:B]Q2DS&PR8MQCI E"8R30D9;;#=3G(]#*N,8(I"HO*28C E#(P
M-[9&;%@O7OJPGA*NC&Z$7QZA&70_Y(U.V+83';)(8D7..)X/"'WBWFRA%#"B
M9))X!E76E$ N'F.,"#CF):^>>.-KY6#7UM?I(X=E(XX@HDD")55ZQ]#\T,E<
MV602[H,MD1EME!TDG5BV4%);;#I;S@M@0E1<1R5_!!L4408;'K6S+7%O040W
M-XFEUEJ/(0TM*]<7/:.YZXTH@C)N@$I&5G$(\9U2=J'RXW.UTU5E"15-P(ZF
MGQJ,GG+Y6')I^.&=L@A.Z>O:@N<1XXR>H'(3KKLI!,;2//\ #CR0G5"3]2I8
MFN3IV?.F+I7450,(.QT'+$_2@ZE5+9D@E@QVI(1$D,*IX%C*><(VN7P4BPP4
M;XS]<R^MT?:GM>7.-+E8([#QJ:;!!XR&C;*&#6MJ:\,',-<5V81D5Y!23$'C
M5.P-8&C"<&R;ELBH>>-DT3+_  \@Y+ UG*1E+VW"K.O&_P IDK/)Y;W[43&R
MY"UDV64&)#3HC1]2^LNF-%9-9+>W\@]$P-FT$8(0[B:; !@?/+_>;C97RH-H
M_+S$#YV%U-BA):4+2S+8:'MAJ/+4BQ/%CE365,AF+6%*S?=DDDFBY0Y$CW!"
M>R8VBP^)<<@Y$\P$;QMD7.896Q%L&HUZ:/; O.(>4@KJ]IWL[!L1;&Z "Q00
MBG;:9FQ+6P<W;4(C@6+,U48SC<,^S\[65';7C=94$\8JKO$DEG512!&)$ !
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MLW%&]'^TTX3P/)S:6G $SVB5DL\A,6*VI'R2,!B;7ATY45ELWCF3N"5*9"F
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M>FW#/?DF/Y5F HW[/,QBY'!,+Z>K)<R.J.I))Y .9 :ZTG!AG,"(!@B; R[
M3^YB+D$[[7:_[,3B+$TUQLF1"Q-D-,]F71)VN:2Z'JYG%&TV1.X(X<L1O!GR
MLM)[#35N*%J3F!("I8,1.(.3%N+">GF;"* &0X%!@K+AO<O8/:6*=M-H(MB&
M!4K5*/9F2M>-?&1-"K,*\])?F=!26HY))E>5 HT9#?;;51F4DC(Z&DIB4IFN
MLLG#YP:V0)8G035O'!$T[?\ '#L!KZ428^9<^3OKHLLH5!-/%86XR;<BN9O
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MAD_LZ16D8RK'/5<=#U(L*7W&V!BQ\CDCK\;ISK+NK(UG8<'P>AF@<PKV%Z^
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MD=JLU726-,VNFSD:*TI,J4FJS3[H4S<92&JHQ?-,54^ZBK$DY7230A;(4J9
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M21WZ0KI1;=3<?S3DE*>,T+H#5&G=;?DJN9Q/YUS0*]"S:+E )0M)#F'7R9O
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@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g722206g14a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g14a09.jpg
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M(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X #D%D;V)E &3
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MDJ_IZ/\ ]XX_.,!^I25?T]'_ .\<?G& _4I*OZ>C_P#>./SC ?J4E7]/1_\
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MU^_ >L'R@_Q:_?@/6#Y0?XM?OP'K!\H/\6OWX#U@^4'^+7[\!ZP?*#_%K]^
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MLQ&OZ>8__$H/F^ ^S$:_IYC_ /$H/F^ ^S$:_IYC_P#$H/F^ ^S$:_IYC_\
M$H/F^ ^S$:_IYC_\2@^;X#[,1K^GF/\ \2@^;X#[,1K^GF/_ ,2@^;X#[,1K
M^GF/_P 2@^;X#[,1K^GF/_Q*#YO@/LQ&OZ>8_P#Q*#YO@/LQ&OZ>8_\ Q*#Y
MO@/LQ&OZ>8__ !*#YO@/LQ&OZ>8__$H/F^ ^S$:_IYC_ /$H/F^ ^S$:_IYC
M_P#$H/F^ ^S$:_IYC_\ $H/F^ ^S$:_IYC_\2@^;X#[,1K^GF/\ \2@^;X#[
M,1K^GF/_ ,2@^;X#[,1K^GF/_P 2@^;X#[,1K^GF/_Q*#YO@/LQ&OZ>8_P#Q
M*#YO@/LQ&OZ>8_\ Q*#YO@/LQ&OZ>8__ !*#YO@/LQ&OZ>8__$H/F^ ^S$:_
MIYC_ /$H/F^ ^S$:_IYC_P#$H/F^ ^S$:_IYC_\ $H/F^ ^S$:_IYC_\2@^;
MX#[,1K^GF/\ \2@^;X#[,1K^GF/_ ,2@^;X#[,1K^GF/_P 2@^;X#[,1K^GF
M/_Q*#YO@/LQ&OZ>8_P#Q*#YO@/LQ&OZ>8_\ Q*#YO@/LQ&OZ>8__ !*#YO@/
MLQ&OZ>8__$H/F^ ^S$:_IYC_ /$H/F^ ^S$:_IYC_P#$H/F^ ^S$:_IYC_\
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MDOQ:>48H9I2<TPH!QU>-ON2A&  (&C3=A]@0[W[1;_Z8'75JNG[HY YN\*T
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MKT^GV%?L_P"WKTZ]G[/9^S \M  $0AA #0Q^GUCT'6A#].O8'U"UKVB].O\
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M)4;H8]M9S2UBV->F=7+T 3&C*-+.$&PW 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M%X4WMAL=FFZ2_(^4W,GFEFWE?2,">M%I 2HM*ZS25ZEH8D\,S$64XM.DOO\
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MG<3WGR+7W+-4P*]Z<#!8!(+:E'5K5$N2JPIM#?CI.VTT<-+KB-5.IC45I1-
MWX1.S3OA'MP>4"4HM4IV;ZSA!LSP& P& P& P& P& P& P& P& P& P& P&
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MM5#4<J<R'^QVU@5RNYI4GWH9<SO>RWISLF\IH STA&,F5VQ+'A<5H7MV60>
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M;\ULLAFO)N\?!5?!9798N.YOZ/MRS[+*7D ) UB(BTOHV",@V42H[059XW
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MP+MZZMF^8%=MX7%!V*R44#G(8[J-PIT;)=Q[;CHV_9HQF.,++*>C4X!*A>[
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M]:.-7'16Y+9K6.$+752[ZFL0K^8N48C=GMQB^-QH]"@G"%#I86DVG4%)A;$
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MRK&WHRE+$[9G;\[,Z>1"8.2ZZI<B0MY6T7QJ4MHDEAW/9L)82#S-B$0FTZ[
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M;FT*&OBIZO=7= D.T:8B,=SB #^'+)++"T> P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&! SAT[0
MS4O7-;A9+*E7MBU4WKDPT[ML:9:B/,2JDX]@;A V,D\H0=^S>]>W7[-X'R?J
MLYZ_-!C_ ,L\_5F _59SU^:#'_EGGZLP'ZK.>OS08_\ +//U9@/U6<]?F@Q_
MY9Y^K,!^JSGK\T&/_+//U9@/U6<]?F@Q_P"6>?JS ?JLYZ_-!C_RSS]68#]5
MG/7YH,?^6>?JS ?JLYZ_-!C_ ,L\_5F _59SU^:#'_EGGZLP'ZK.>OS08_\
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MC+=M@&,HX\ ='^P6P[%[-X'+_AK77] PK[JL7S# ?AK77] PK[JL7S# ]!<
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M:UU_0,*^ZK%\PP,4;4- O$D>H<T)*?=9=&RBSY%%6U/"UTD8"#?<[*.>F-*
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ME'%M]E5+%J%E[*= (I[F;TI7+5]$P^JGM&8@_P#QZ PUF'[A$UFZ,2(R-^D
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M2@S8A[]8O:'#2+AWC67UU,*BEG+- R>KK LQ[NB;5](*HA3S$91;TD4Z5O\
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M>\5%F%+8W+FU* E:B4@.3F%[%KT:]8_4%>ZF\9'C^HMU5/M1\D4I!7E=$YG
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M\ANF31]6VN1?(,9NRN&M%35^1RQB9"4WI)1&R$\F<5"<P*8.M%@]8=C[ 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# ZZ/G6.JA/T1X5#KR-KHBIB_(
M$Y"G9MM#C!== 8/P;ENCQ2P<RWJ,A:O?[+]NUF_=>\]'_P#%Z<#3WT%TPMY)
MN/SA7WXC7"O6/GUIJ;@"*RV>4,BAKIS]7?15AV<EAMFV1""VI&YT^7-8G3[Z
MI,>UB<A0B;70XE8[%F")$ 08U8=Z]&6AST\P"X.AXYT=5%5^63Q-FTI(G'I2
M@^J;MA2V;3I>X6+";9MKG*#5_6TD;CUS<F=(\84AVL2)%2A&H,&-/H)876+[
M6ZGI=L[PZY:+""32O$GGZL.O>GX+&*UK-L3RWAB5,-20"7JGC46@[?))1-:?
M?9BFD"9X/5#>%!!"@*Y6<246$L*\W+Y"/(K)*RX(E\LO>PZ8J?R:77VST2TR
M)EL[G;E-_JCGB&-\?/XWYPC'1-XUS+:N@A<D@_KF2U0](EK[*-K0H$RD'I&7
M@3C6'1_D9ZPD7ADYQD/>YU8G=54YWJ[WW>G*/X,S95;S!SI*H\95$LB,R<J_
M<HLP3I<SI MSXK:T!*/X@;B,E,'WA.B F:O>Q^YE7:L5\1#O>LS7=!UWY%IC
M:T_NI1$(<8_RCQ-1NL45YP,#ZN*B":*$/L^D,O;:\5N2%&!62K3#T$8#A"&
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MAM@D-Y&Y&LZP:PX/Z4X_A,XKZ>32,MSO8UBO'.'3]=J5?8\(NA>O)7QM'%9
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MT-:HQLIF.WG<$L25O'97&0H@:6-J<D]:T^Z*TH&D'Z!!R=)>+'QZQ]J@4RH
MVXP09@=$DAKTJN.\NPG.HBALS\8X%D,<49>B5=;+XX2]I3 '-P49K:9O1A)I
M(@;&#87=H2MT%6-EI,Z>RWBR%4AO6V;)>3'N0.+X.!KK,DAL[)K= !XD$D7L
M#)$V=]2A2-^SR4Y!!H1I4J-&8G2DAKOJWBWQ/VA<C\92]A1BRED'LS=U2;EF
MMNR)I-^>8;;J>8!E>K%>^0XW;;I4,=?4D^WIS"6?'B4!3U[%04X5>@F:"7[D
M\8G#MSVO-)%.FJ=M3Y?(OM1<]00?HZZ:PJOH_<5;X_&%L@M^AH+8T<@5HA3-
M/T6W.ZE8U'!<$HDZ=R$H+& &PN8PT-4L7MMYO*/0Q"SV<_U7!J2<G] J<DZ4
M575L_2^30B(I(Z6MU&6U#'WF=NII1B9&4H$%5[L9@BRR@ ".EO%_-3C15V<T
MK*U).I3HE^N23W%"OM)+P%S!\O\ DSU,+;7F/9;^"1,PY;(Y"L4[ WJTA:/9
MWI2A( $ 0A'-+>.;F6@+!C]G5P+H;4IC!3D0T%3GLGKZUXF IU:%C&J N@%I
M7E,8([Z WKS-$?%MQ_PQV@'$^@XLL80Y_I/Q_<E=<29FF=\58?)I6S19= 1R
M".6#9U8NLCKIS7#<W"M)ZLJV9PPZQJU6.)IAXX^_;<6CWIYPM)];/.]88Y=/
MC-X:Z#?X=([4H!@=UD(@D;JML;8_))U7\4>JHAKD-YB-43^$5Y*8M#K0JZ,.
MI@SF^.R1 ZLZ01IH2DX0'&A&')6/XY>,;:O1NZ.G])MSY:R)QKYY7+RY9/V>
M(2Y\J0\I553_ &/5K'*VVK;.?ZU/3E;8ETA9G-4U>X)TG,+T03HL+MX# 8#
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MS"J?I02-ZA=2,G*Q$:=(R).<E1%EJ37!,+2HT\[8<9R$R<O7OW\NU,F]/:D
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MWD#L[B7R%O[DW1.KW/4YX1ZPEJX04[:SU5<B;=DT/.)*M'K1*5HKSH:OT[4
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MUE0F)J:RF^K"6(9+'H#"7$(7-A!LMB>VO:C8%B@103CRSY,..I!W3;O45N=
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MF C0PAF=V%U5*II/O-O!N;([**0K7JI-=,"OY'>A)=CJO&/SO%IOS?9T$C=
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MZH_O.O\ KC ?:KLW\KJC^\Z_ZXP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_KC
M?:KLW\KJC^\Z_P"N,!]JNS?RNJ/[SK_KC ?:KLW\KJC^\Z_ZXP'VJ[-_*ZH_
MO.O^N,!]JNS?RNJ/[SK_ *XP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_KC ?:K
MLW\KJC^\Z_ZXP'VJ[-_*ZH_O.O\ KC ?:KLW\KJC^\Z_ZXP'VJ[-_*ZH_O.O
M^N,!]JNS?RNJ/[SK_KC ?:KLW\KJC^\Z_P"N,!]JNS?RNJ/[SK_KC ?:KLW\
MKJC^\Z_ZXP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_ *XP'VJ[-_*ZH_O.O^N,
M!]JNS?RNJ/[SK_KC ?:KLW\KJC^\Z_ZXP'VJ[-_*ZH_O.O\ KC ?:KLW\KJC
M^\Z_ZXP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_KC ?:KLW\KJC^\Z_P"N,!]J
MNS?RNJ/[SK_KC ?:KLW\KJC^\Z_ZXP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_
M *XP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_KC ?:KLW\KJC^\Z_ZXP'VJ[-_*
MZH_O.O\ KC ?:KLW\KJC^\Z_ZXP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_KC
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MZH_O.O\ KC ?:KLW\KJC^\Z_ZXP'VJ[-_*ZH_O.O^N,!]JNS?RNJ/[SK_KC
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M]<M=N*U>VHIM6<N8YI&3W)J/^&=&W3Q'UJ]$!R;3_P"P>G$/1Q(MZT,.O;K
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M P& P& P& P& P& P& P& P& P& P& P& P/$0 #V 0@!$(H6QEB$'6]ECV
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MT':T[ZNKAJ@74"!6[T0^("Y+)3+!8VLLLU_D2-GB[ \OK/&8H$W6GIR<DJ)
MR#T("\U.( M:"U5!="4KU)5K!=O/=C1RV*GE2N0(HY/(DH.5Q]Z4160ND3?P
MMZH\A.)0!ND+*J2B&$/NQC)WL&Q!WH6PU!\>>:G]4WD!FO)+C07X?4O(''II
MAY)Z3'/P/:+IJ0\BSB.0JYD#/$?LVW?0J="%W5.2,X"]9HY"A$+>M;%_9#FN
M_O.YR-Q\.6UO7$W@EZ=/0:X*?J>4484]RJ-E-CA9$\C\6?T.[$20B0PA5.(,
MR/!KHLCI*PQU*)1F^_*("68, >/D9\[W(W$+19\*@DW@EX]55=-JDAKWSX6]
MRN. *761/8M&G1I4V2@@\EA!$WBL6?5+V='PJAN_PK>=LP@H ##"PM[(/*]X
M[(I;5AT7(NKJT:+3J-#9#G:L66;D(/PT;:E9$DAGJ^>O86,4<B*-J;5Q?PYJ
M]8G YJ/4F0[4J2QE!#XX9Y;/'//Z,M/I&,]400VH*2<XXS6J_/+7-(H_0IUF
MAJ<B#-[K7DKB[+8XE4_.5E@CX"6@W;\(7L0?$;UOV!\*'R]^.)PHE]Z13]01
M@%41JRVRF7I:LB5F-LX26T]H-NK+6P*?<82EN!7-GEI"-8D;2&$Q6I2%&'E
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MQH]UC#;D;.@(4IKBP;S0<S0V0;"])S'WH!SD:N)(:A3,:EI)D),[/D" Y/\
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MP26E-]UHO10PL5RMXD[CH6_O$//%4"I:-0KCBKN\3+KC\)LNR[ 9XA;'5BM
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MI"7WY73W]'IC(!,X; 95$8I,FR/RDI>,*^6Q\R>LR\Y"$CV":W M268,(3-
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M]657D>K",&I7(25P(-AJPPX 2E8=B"#_ !F\ED<WM7%K--/$-V5 ;WJ^"5#
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M\QK:G3SV$]?<UU.JJF>NOX?V?-*=:WJH+@;C$2YO<&I4$QF<$2H"EO*(5$F
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MZMQ8SM!,.(3@-WKV&:P+2X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M*TYGY73U?>=ZT98RAZ=G1YFO5UPVNZ4W*JZ.^F[OFI<? 4SIG1Q:R43" P8
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M4'^+7[\!ZP?*#_%K]^ ]8/E!_BU^_ >L'R@_Q:_?@/6#Y0?XM?OP'K!\H/\
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MKICY<X^^+C_+@/T5TQ\N<??%Q_EP'Z*Z8^7./OBX_P N _173'RYQ]\7'^7
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MF1Q=I@EB#JX#<F!(UG,J)I5!+ 23I,6 C07EP& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M3L'1D+O&RNBE76!,CJF06]+;1N2N8Q4=F+G^.36HY1225C>:XA3.TMZ!MBB
MMB3M2;: 1!GOQJ X--X5>> 5O,:S=+@Z.E;=.*M[MJE_D\PF<3D$[<FSR%2^
MKIY>4D=90?!2U+Q,DLJJTE4TKE !Z)VXJ@J *=>X]R'//'A_I^:1"Y(_;/0/
M4EV22V:RA-&-=EVE-H.\S>IZ.@5C,-IM59UT8SUPP1_X5ZE\:0J'UY>4#O(W
MX2-/M:O-$G)$ ,KZ9\5]:])V9=]B_J"Z:I,CI^HH]2?2L-I24URR,=QPB'M<
MJ9(JE<GR7U=-9]"S$+1,W!(K!&GAF3.J4W1:PHWVC$8'$2#Q)4T\M4F"W7#>
MD3F3U(^)YNQV)&G"N 2.#SOA"*(XA4DICC:\UP\Q!2:^-R88GU&Y-J] J&>/
M1!*8&@!"$K)?'+3R6#L<#U+[),;&+O=R\AR=8-QC7T@?<#I>#[?2F+*!@C 4
MVZ[U+) <F"F 4!PT@"$'QGO=;-V%@*GKFT$U.R>!7Q8A]AR>3R6[ ;DZ8IC3
MKVVN9S/YHNK>+^_9HE$6A8YP6LWAL:AJOHLO9QZ+8S1*1[$H."N0O&S3J6G^
M&JSCDUL^)ROQYDUPAYUO!B<XT3:Z)B@\-;:YD\/EJY1%SXW)(/<T ;_HJ7-&
MVXE$XE;+.) G4I49Q <54OC3A=*V3&I!!.D>KFRCX+9,TMRON0TUDQUKY[A\
MWGBN2N;T2G"PP9HMN0U\C>Y<X.#=$7F5.,7;UIP1%(=%D)RB0]#7XN:.::9Y
M3I!/-;3'&.1&J[6BOG(YTBVWQ^3WO3%MT?*3)@>")@0K#FR,7&XJ4&T:=%HM
M<G3B-T:4$PHP/JE_BXYQL.$4;6T^6SZ4P:C.+[%X9:V)4^-K?N55393)2;*Z
MR&1.C.RM[LCL1GW0[,K;')I/;0(EPSCP$^K1'N0QY5XNXW,JGZ!J>]NN>SNC
M$%_4\512A^M:RX02NKB!(U9[FW*H#&Z]K*"5V980'<9*I7*'ME>7UQ$E)*4J
M3$^ADC#G'_QEUG,ZK[&K.>V[<\S6]RQZJ6:\;#<U5>-\Q5.-4T[ J81RB/$1
MZOV>),[W)V:OTS@Y TV#1?22@_:8A.1LL@L-DP=>G6@Z_P"FM:UKV_\ TU[,
M#]P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P-%G_ ",7JQV?QAS-/5%E3FHIK*+ZY8@K?/:YE3Y#)8RIIS?L
M$BSB) _1U<W.B<H]$Z# :6$W0#B][ /6P[WK ZQ4D[NZSZ#N;P_0%/>EOQA7
MP3T#QIQ[W$W1J?31B'9_3%B=D3BBG9@M<AL>$8)RJ<ZRY)&_'E.?Q6CP2<W0
MM>P\_P!8;Z(_YG>D1>0^G:"7L7*5D\SWIUO:/*;$\T6T]-R64U^MA;))'&/2
M"3]*R6(L'+4[F:T^.&A>X?&=K%['Z#"QJC/="-V%%>;^MIW9-\>*-^9%MCP6
M"2EO\^J6;53KH.\IXR39=28RFZ-.4GDT\F;U+'<Q$M2G*6HL]085'!*-A:PI
M0  $(6%Y8\G/9DRJWQN<Z\=T_P _H)9TOP!;G4.Y-U';?1%HMU<J*NLU3'Q-
MKI)U[](+5M!,\)SP)P:7NH%Q2A8 T2OX9'M.<$DT%YH>T>X$/CWK[DJC>:(U
M>W3?)EL]@W<??TELW56QR%T]=#E01\*K'["A,DOVCL"?,IQI"QP&N)86T\LP
MU.X" /6PV?>+WOYZ[;\=<&[DNV,0VG%+R*]%\V9(T\.#M$H@P4Y:5APM2X:>
MG7_Y2PHI@A.E:H_V:*$9LP1>M%^G6@ZM/B\\J">1^3#FV^Y/VL\V6B\I=F=B
MUA9'(+S:#V_L_'H?Q$;%_#"9LKU>H&R1AVF##%-,@S47M$+3R#WGM&:/6@LK
MY%O(OWWTGSMT=9E1-]2TKQ_2GE%K'BQN?HM8EM1/L-<^U-T) (Q+YZM=(^N2
M0,VO[ >5VFL4;]"9Q*;5@SCSS@$[ H#\\IGD6[\OWE[OJ:4F@J:EN1>7/(A7
M_#Y\RC=A6Y$NQUTZJ3H*H66=V"T/$96H(077LM?WTAGTQ#+3.!C0X'*#%(PD
M>Y4A;B]/-GV-3@_)_<_X#\Y.'+'C>NMUYVV4;(;/,O&Y[5G0J^C=*D-:1 0=
M#XE%8Y*I\E6RY<?I4H6MAVDS6E J*$:8'W1#R_>2-1SUV:Z'\0@N"\^?D%&R
M>J)G67-G;U54S9L/M21E,5G'E5)?\!B]]R:2<W$!,7.C<Q&J#I$@$ ])M&6$
MT6@X-M\U78LDXDG5P5+">:>FKOKWJ.OZ<M$ZB*@[1,(YOIJ:QQX>%MU] \=3
M>+Q[IUO6,3FQ#1%M;&Y.:5Q)/^,+7%EICB=AL*XE[?Z;[7Y3@%LTX]<.6]9;
M/U&DJ_H%1"'SHV"P:,4XRN!2B>JT< M2NV>WJ\Z+;XPY(E">(R H]N ,\(QN
M9A1@?2&XS 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# Z_GFW;GJ<7?
MXA*/U8MOP* WMW,XU]::>G+;L*FWZ51 VI)2Y[9ELIK60QN0!2%KT11P=!4:
M](P^T/LW^W U^3KNRS?#)>/E$HZ'RVW>L:7IJG>-[3YPA'0UG3ZWG^I+DZ=L
M8NI%%>.MGN!<LM)TK16J<RY,%J,&N<M)T0DR#V'JAG##@.A_)-VA>E!-\1MF
M&RJE9I3WDV\9\?9>@:<K#KKEBJNCJQNNQ5H93%HQ$.F(Y"+;(50U<QG-4H;E
M9BQO7%*DIP [(-#K86IK7R:S"A)STM,QU<W%4 T>>">\/]+326V]<,_<JYC%
M@Q>NV:N+WCOXA2IYC5809-9+\B;WF.M92..MA"PH:!*4,P\S88)///CTB]LM
M% IFFZF93^R.A>S4?+=ARNN.H+ZCN^0.0W!IB:.VIK4'-4=D-S2F=W5-CENF
MU.Q)RVIF9TX5RPTPDS0\"4VSR[^0VYEGC9J&E^2*?I[I'N&!]6N=A,/6X;RA
M49II]Y6D3$B=)8CC*:/QZRWZ!V)&CCW%C1J4:->9])(0FJ !)4F#"3X9Y>^@
M9!-*_P"57"FZH*[@6>4.8<0V1 $[I+$T-:N>:Y@9][RSJR-MZA>IE)C(Y4(I
M;US0G5'^Y4.:S18QA '8<#(O^0KUPU<^\K4W1V[T4<WOG:W351T0[7<V2M9"
MGRG:222AKF-_6JVR1N,+<6G[/05ITV".(]IH3'LO0?VBUO UL<6>9.2TOXM;
M<C-83AA[6Z%YL[_2\!T595F6 _O$7N"-7W;BO],5X6C.R?B)4KA9T(=E:<TT
M/NEJD4?]QL9(A[. '$K_ "'=Y<5]:^7V97\CJRU[\AT2\65/U!5,#L2UTW)!
M-G='KI/#&:=-L?FRI9):P8%I2PM?(T9>QK%2I#[H*XP!Q2L(?'8WD/\ ('P?
MTEYB[TZ$1U!:UK\V<L^.%;&J=K6P+>)Y>?%5OWBVUJ\2>(Q.:+E4AK:1NS/,
M#-*B]_$#,7MY1IAYZ8T.M!:/J+R_^2+G&UHGR8MI;F!]ZQ9N:)/UY;)%?5/V
M]?M8.<3=[+D</ISGVM$5(PZ26"T6*[ML>$%\G4F2H8:D<3BRRR/9L(1AQW1/
MG([/K*=T\]NG.]7<;<_SRB^=K3'->X:I[ 6L$GFUK(2U=KU,XW+1,%?XSSB_
M4FX[,:CS)C'51BY06!5L@A*<#6@DSKKS)=1<X]PJZJ?8ES10O(:9YH@F 7QT
MM#.K%M?]*16S6=C=)I*Z_P"JJ5B$RHBH_LDO<SFQ"ED[<I"M4D ,//3 4!"
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M<Q^]+3 +T4 O>@^SV8&GCQG=T3CIQ'QM(+!\M-M3&U;>B57S.PN;"?'Y$8E
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MK8+="Y$_+ZAFW"S!SVQJ$:<YK;0R+=A)^?:T5A5LB]U(V6B*<O4I]YO>RA@
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M#K=J=(V!60B\G"45LXU3$IZ]BTZH=1Z>PJ#O:MI-<RTJQ0[,Q:)$:(HM 0+
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M(]N99Z ^/#IT"4"/2,T*D+@(S9I>R=!,#U],<1<K=BFP13TK3<?M176(I**
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M7':?1?%]/F(XU?;E%FEQI2S*O>S%3T&+JXR>HCEFR)/&$BUW6B%\1]+G*QB
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MV3-2:73 "!T<ER)E6R/;*G.6$MY:5(>K]XI$5M0>>:8$LX# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M,".F*WLY^>HZW11X0H@2QNV>)N7J]DZ5@]>@_P!KV!']#^5'A#IV&0NPZ#O
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M7QK<6#,8^[+I:>6F]CBW)2RRS2U!@@IC '""]^ P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M!W9VA_;5C,_-;<]L[@3M.O:G="F<FU<1L6A;)6(5A1R523L0=;](PBU[=?\
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MLL<VQ-')4KB,DDB1$XE(%!QB8\S>A:]@1;T$W=2=64OQO5@KFOE_<X[ @3*
MP,;BT1UZE*P$CLR5MT*B"834P(US@%,X2%U))$?[OW1.A;$/>M:WO _.K.K:
M6XNIA]OV_G]SC=:1Q\A$==W5GCKU*EZ=TL29,L!BI>F6/HU[H:2ND\@2D","
M5L!6A[&+>@AWO L;L0=;T'>]:$+V["'>]>W>@^SV[UK_ *[]GMU[<#\", P^
MH @C#[1:]01:$'VAWL(M>W6]Z]H1:WK?_MO6!^:-+V7[W1@-E>G8_>Z&'9?H
MUKV[%Z_;Z?3K6O\ K[?9@>01:%K0@[T((M:$$0=ZWH6MZ]NMZWK]F];U@?N
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MM\B<[?;3[1:4:D/VA_":*?2/V@TL]BS3][[V_&^^_P"]\3Z_7_:]N!=K 8#
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M4;&:]FU:PR50>.&,2;:-D,8HF^LJ]A:!LZ3?NDNTZ<O:<O\ LE^D/[,#SG]
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MH*T=BSJUM6X)K$9RTT^N@M43,V"1-6- 66XI(\<@+5$'B3:-#)N@K(N>W?\
MCY]CRFUI%*['-^!NV-T[;4NAH(//[TYUC-_FL%#W'+X:WL,8);G^Q*R0H5PS
MB6EL+=4XRW$*0@*O180[+6!UUUG*Y,1Z,\V-$\>0]NK*<6SXR*"%!E3(<I;5
MC[?=J*_(DF(FC],G-2>Z.TR=94X(MJ'=>K/5D@+(]1FBB2@A"MUV>02I&WQY
M4%4?*<VXG63"O*AK:J)7XK>CZ!GEI=,2>YZ_)@*.*40R41$K3KV<0.3P28QX
M\)J]?%WIN^,2IW(E2!,3\0:'GUL@[C2>0OEJ^[=XJ'+' KR.L5:\OS%HZ3J;
M<8C_ #HRT5TB2VPZ/1)6CW((;,;>,^)G4S>'#8?C#FAK8 []#>WB&':VP& P
M& P& P& P& P& P& P& P& P-4?EK:'&!5'2W<<61*U$N\>?0$)Z->OHE&:K
M>73G=T*7U-UM&DP" &'')3^>Y^]O.R0A%[Q:PI=ZUL0 ZP-9%JK;7M/C&PW"
MK&,#AU-Y[^GW&/UHU29U=H *.\0,L06(H\&425LCTG>X)%R.#ZF4KU"PEL5J
M6R56",8$QR@WW8PKU>?XS\^\\^4#A7H.GJLJUMN))3G<W-=9TQ,I+<-/ME?S
M+HVF*OZ<K!AD,HJZIS=%,-LH4<I5,>F(LA.GL >@#-)"+TA8V75S;7,_??C^
MX%1)I&.FFRWNP+7X$M[92IQ9ZZJV4<+=+QIVYEE+J/1ZQ&\<RV3+6_<1-.&,
M*N N;8C (2AG4[&&1<M=O<&TWXJZ XUN:'QNS>D:RKJL^9+0\9HV2,R+I6P>
MH(PY,[)+H\51DH-3+7PF46JC/E(98K*!'S41VGLQP"3O9^@G_FCJ?FS@Z[?)
M' .W+>@'.EN6!V38W3$:DMRO:.&$7MSU.(/7B"G'NJY,_;3)[/!7,<C@H:I8
MV<Y:Y,[BR&$B2 "H($>%%N='EFY4F_C*Z=O="JYGY+E=V>94ZM76V4!U=Q6A
MJU[%N"+V]R5#[+,?BV]NIU%84&A;BL;$CL)$0WG*T[<9[E0(!.!)TMKX7?@?
M-;>?)KVW3],"3\4SWBN[HH8!WA4XZIX1K)+:S;NM)4FV)ME+$ALLIOB[@YMQ
MIZ$T:M>E :/99NM!"'3]CH^Z_'!Y/_**A;GEBA5E\^4OSGR^"0L2Q([Q2HZI
MF,,G5W2C;6M*)-$:]].2Y^;%WK+"%8CK]O'O?NM!]@7)A?5<.LJ!].P??F6H
M?O-U?N2>B@L%$5_5E(P&3F.+=7+L[*98C<ZYD#K(7 ID94"LLU)[KW(@*=FB
MWZB@ZV%,XU6?2E>\T>&^:]E=32*V/&DO:^%I%.87"*-K>K)'SY;K(P5?+N/G
M"W)^A1R.22;FULM5$TLLD7)Q,+JE<]MRA8I,;U"XLD.WO@=$2+7887R&WU0V
M]YPRXI3%>^)O+&WP^L-/Q(VXK4>(EY-)?9,;K =EQ4]?=$<+?WEO1R\#P)"4
MC2)M%EK# M>SA[#=;S%UQR9P>^^22INWK6@-(6\[]P=+]"+F:UU1+=(NB:-N
M98V/M(RVJ&IP)&LNY 15X6^$@:6 #HN0N,=-:QIBQ!* 8&XKDUSCCUS+0[M#
MZ,>N98@XU7"UD3Y]D4?8XF^T]%SV1(9'H"[12-*5;)%ET>:!$D&-I _8@$'W
M @@&6( 0TY^1:R;%X)['57]3# Y.[WY'.8%_'40:&EI4KVXWR"U>^*%7%3]*
M-D$GDID$IBEK2MO<51F@%@01A/H8M:+#[0@SH:F.4.&K!I&#ROO/JSB&54IX
M[8S3=+3&NX7"2X5>3VQ6*^RJ9JV24RFL[3/M:\I183<W.TFK],6D6OI:UO/"
M6L":9[D+-=)2F\9_RYX0IMT1%C(E?TJ[L\?TFNR+)6DYI^SMB.]:3]?-4*MC
M"-0*/"2/J@X)Z(8QZ0&^TC8Q>CV[#>7*HRS36,2.&R-,<MCTM87B,OR-.X.+
M2H5LS\WJ&IT3$.K.K0.S:<>A5&!"H2GDJ21;T,HP ]!%H.K0]<^)V+@CRMU%
M1U+C75-47EW@<PD//-81/7MF?,U,J^#+'NRN89"VQ,'[1C?JNB[SL36G+,.?
MC/>I?8<>JV$866N[R)Q"[>H.*FKD:Z.$.U(5)KWK18S\],-5S"S.HZ7+^@9>
MT6)T$98$>MC;-S\&#15X4(!GR6%MYS>4Y*$QQI@S=D["OG*+3VG$/+=SK.>G
MN-11J^[VYV[3=;SMI'T354S9?L@;9O(88PU0EG92SG1HJ3G9J;&V.,$<$;IT
M=C7Y:]F>M8-W--#M18# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# A
M/HKH6K>5Z=F-Z7*]JV.!PLAL"L$UM#E(Y$^/<A>6Z,1&'Q&,,J98]2F9S65O
M")J:&U&48I7.*PDD&O:/VZ"LU(]\LMF7)&:!M3F/I;DRR+"BLFL"EVOH:+UL
M2SVW&H7MK.EP8K(ZELVU6!EG,41/J58XQQZ4-;V0C/V>60:64H$2&>T9W)0'
M1W0737-%=KG]58_*#Y'F:?C?&(#;&Y$>\?2K>XN5:/ UA^Y@UPB7L3A''X\!
M)/T8_HC4@];WZ!C"&J]\K7)%I<A]'=DPU=-7*M>35]L-5UPL<:;B;3BSG36U
M2MW1EQ$;]MO5?:%E2DNC$<%>%,O0JB1>\*-"<42$E]&]I<Q\_6YR/6]Q)5YT
M\Z@FI\5IUR2Q!%($L+6F'Q=E326;/9IX3J_C3S-IS'8TE< Z,T?('Y E]GL-
M$86$>]#=]06 WG+>5TO(75G54OA=9US;T_34?5]6SR'Q>*V6_3]F@PGK=@6S
M!5:MY<'&KG<9:9(A5C"%-K8=[&+0<#.!^0KF,?$\M[B;G"5.U)PEED9$AB:>
M#N;=;+?-XK)3:Z=Z*653(0,KVV7.791>HL".K IC3'HTHC0O=F@-$%@N=+(J
MBY:/K"XZ/3MZ:K;8AK#8D1*0-")@$!ME;<G= DNK,@UHEKD"(1^T[@F%O9J9
M82849OU@W@31H  ^KV #KUBV(?L#K7K%O6@[$+V:_M"V$.M>W?\ Z:P/G"A1
M $$8$:4 P[T((PIR@B"+6_;H01:!K>MZW_ZX'T!"$&O2 (0Z]N]^P.M!U[1;
MV(6_9KV:]HA;]N__ 'W@   6 )98 EE@#H(  #H  !UKV:"$(=:"$.M?]-:P
M/5M*FV;[_:<C9VMZ%H[91>S=;UK6M;]YZ?7[=:U_[X'PO#$R2))IOD#,U/J#
M1Y2G2)X;TCFDTI(WL1"C29:2>3H\D6][ /T^H.]_LW@<IK6@ZT$.M:UK6M:U
MK7LUK6OV:UK6OV:UK6!^""$8=A&$(P[_ .H1:T(._P#U_;K?MUO]N & !@=@
M, $8!:]@@##H01:_Z^S81:WK>O;@!!",.P#"$81?L$$6M"#O7_MO6_;K>!Y8
M'CH(="V/00Z&+6@B%K6O5O0?;L.MB_Z[T'8M^S_V]N!Q.H\P!>A20+&SZD0T
MND(W_38BT]#0Z]F](Q.FB/CA)=;U^PO9GH_^F!R^PA%Z=B"$6PB]0?;K6_2+
MV;UZ@^W_ *"]F]Z]O_UP/W 8# 8# 8# 8# 8# 8# 8# 8# 8# J_U/UA7'*,
M5A[I,F.=V!,;4FZ&KZ<IBIHV7,;8N&P7%K=7W<7A4>4N#.U: UQIB7NCHY.B
MYM9FAK1'*5JL@L.MB##^:NS8WT!-;$J65TU<W-%]5*P1B7RRF[[98:BD(J\G
M"E[;XM8L,EM;S2QJSG,(=76+." U2U/:@U X(#4ZPE./W7O BZL?*/RM=')?
M2'9\$^W[W4_+(;9.L1M40],BGZ]IJR()[%^GH;&5SP46]QZS:\7-[]$U9BI,
M2\M;DE.]I.QB"6$AM'D#YQE%-<CWY$G60RZN.S[.KVIJ==&-D(-6H)M8K3+%
MZ1!.FU<XH542.BZF&.;8^DBT<M:W1.-*81LP)F@AYO'9',S+WA%.*G!*KUTO
M+*<6V6T24N)(3HV2S$J'PY)6ZZP G[6H;#?8Y%'E_1,8BO:H8F98L]00EAT,
M*XV+Y0JD;YW=\?%QCVA<D3Y+L]T@-JW97-$0&R:Y@4SC,0BL[D:YF2$6@*UW
MG[,Q.9MZQ28SQE4K]V;O1)9H@;UH)LZ=\B'(?/W+5==2V-(3[$Y\O%= &^!.
ML!C8)^3-(]8;&KFI$Q(8SC4OQ,'B];L[C*7U48'VMS U*U(BA")]T(+V-!#2
MF:V\AA);D[*!&G^BB6@M,4U@0"+"-+]'EH]!2!1B)%K9?N]>C8=ZWK]F!]ON
M2ME^Y]T7[K>O9LKT!]WO6]^W>O1[/3[-[_\ I@>H")&6+U%I$Q8O9L/J 04
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MD93[AN0%G:T)3@4CO;ASM;E*+=65NPC3]5UMVIXN+CY>2M?,O+CW4[;4MO\
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M5#)?4[@F,-$:0/>PV.X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# JJ[UGT
MTJ=G14U]!-;<UJ7)<H;6X4#:U D#><J-,1(1*!A]9XDB802]CW^T>P^W?_7
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MC@2(E-L[]@MA>W 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M5--7Y"Q+F.1A2IWUPDAJT]Z0)MG@+3J31!"&U' 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# U0P?R&35V\KMS\ S"OXLRU9'*\C[A4%K(5[N.2RRV2JWK^V)G74
MB;U QLY ]0&;J'1K$GT PQ,R+=C]6P;V$(?Y\\QL9FR[L*377#CHG5U3=%UU
M37+@:IA]DVY:O1C':\>>GJLW%GKN%LLDD3W)K%11X]U;$K8B]R6RF 4'B"6
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M1$(U@;1:2X@M*M;&\8TM>7^"*6GBW@*QN5K*2M2Y\&J>Y]+X]R>TMSQ!B5#
ME3JXD0=1#KLXU8-"KT ])Z4XMB-T4&TW 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MI1&7.2,&HA+8 Z*%?TGI8>%N3$-2L[:OW82!'A+T>\NW+$CKV!3E(S7&G>;
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M>C.6K2Z(YTXJ3];P5YJ^R[K?[Q:8PZ<]IKFB-CPB<M$HD1)[&^_%.3 I5E;
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MOL7D?I)QWS%Q#!N;JQ:H1RK)%,A25JB9X=(UD[ESG,'!Q6+1.<B?'(EK5*S
MHDI)0C-&A,$J\+KG+.>O)%4JB]D#//NQ.^9#W_0-K,<-6IG;FBU4:^M'^KU9
M9!DA,.D+M$WVN_0K6)CD/Q:%><4 LO>][V$46O\ \?B)/G/OCQ@E:SRG7&V>
M!XI93 <KZ<Y[;NBJ$Z$<;[2IG:\Y%9U1.TM8%I+^_6>$V4-"Y.ZC4-JTS90]
MGAV$PL+&T'XC'*C+I\;EK)[:KE>3PW5'5\+FS-!N?(11S':TQZBTS*'*616"
M56:RP&M$+"N;1:&F+1+5*\KTC4*3%(C3S IYRQQW,+>\Y_2O7X:BZ"I[D"G5
MSS/X9$KRK\5:QBR?(',80DYQLV]:=C[B><XRV J*1A8C R'98$R]U=M*4WMT
M+1FPV)=\^+M@\B?1G)<NOB=JU'+O,J6U90Y4/&7&?0656'<<Y9D,>A\V/M6O
MIM$I'&$5;($8CT): 92HQ2H.",[W)HB]A0F1_P#'<C;$'KR&<Z]!.E*U!><[
MY<Z5HJ./K?-;IDO/O8W,3J-P26JLDUG6(].MG16S"CS0/K<YJ=+!;$7[E4$"
M<H&![I9X,.A+V7]TV#TOV[$Y'>?7C?QK)H3/ZJY\W!(W0UN<7R)YD==.;/!'
MVR9B&7PDX:LA,J2+7 M:J 8K-V>6,PG1(<%<?@RZNZ48_(&\]!]N59,+<[MJ
MKCZO%#]$N<GB"P.K=<L7I'K5TD98B*V)(ZO;+(V2/_"Z$H<PJ@N2P]2+?N/=
MI0!8?R/^%LSLWIM@ZSK.=\\QNS#>>3>99HQ=2\G1/K>NP10B4N4NBMJ5Q%95
M)XVEA]S05Q?%I:54?I>VKDIX25*?W83-'! W9/\ Q_Y7TX&NHA'[YYLBU>0N
MFJ=J%@D3QPK7#5?U$FU>$@3S->8K9HR84B=!C9RX>_6AC[NE>(^PJCA:;B"B
M=Z* '/=T^""P.S+O(FAW3-4QN(^YH],R6FY<M,@^\:934Z2R%.)=2==P">5R
M]/:NPALXS%"N:-4D-:AK3@I->[T O0;U*UC%[L=DW8YV79T/FE3O[K"C*"AK
M)!%$=EE:L;9&-(9LAG<Q-?W,NPU\EE&M+4J@"-O^"(]I.PF^W0@A.& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!&]NVK$Z1KB4VE.
M R,V-1)&G4K4D/B,FGLK<U*]P1L[0S1J&0UJ>Y1)7Y[>7%.D2)$24XTT\X.O
M9H/M%H*257Y)81/.$X[W)(Z;N>*(97(+&B;#0<>B+C:-YN,OA-N3ZI&B#$Q>
M%(5)!<SD;G!1&*2S32VIC&<9I8X!3)C5F!F42[YKMQX!JKOJ:1E]B4:M>F*R
MM*/U8T' FL^=I3;K0RJ(#34-);TC;J:V)+)-(4;&V$$$D@6."@'M]V5ZAA"2
M.;.G4_1'&U1]=E0I7#DUJT4P7:&OU+ZG>EL?*?(F"4[C!\B(;4"5P4HM"^'$
MJ E+ ,6O5HOV?LP*C\@]L=U=60CG:Z]\"5+7] = 1*NK+338WN/4HF\7K.Q6
M5LDJ!]/K<CEYE3NT@0L3H688UA>D^A':V5\2'V>K D9V\C$*:/(>R<%G5\_&
M('6*)&]7T !X1A@[-T<]0N0W'%^9%[,8@"KU-Y%S[$'.9%*]*_=!2%$)_<B-
M4@%H(:E7D3Z5D-F]5-/+_'D1ORN>*YZIK>XFA7T67!^GI[)&>"Q2?R0-$T&3
M5,L;'Y,E:)842Q[D4ECFY8M*$6B]!0BE!@?=U!WUV'0MI4I#X=P;!;'@_2UL
MQZFJ+F,H[ %4LL=9@]TW,+E4E6-63AS?+%E<$-+77;VB-#IR=#OBTY&A !M1
ML)0;(8O.7]OJ)'8M]L<3I5Z:8@ME=H,Q5A$3*%UT0SHU3D_FFV4MCT(2NS$R
MMJ4:@YQ-;F\L)01"$  0[W@:_:/\AEO=<T995O\ )?)8)B[0'J"7T2B@=XW2
M=SZND5>QJ*L4I;;G,6G5#8;E&S):BE36<BC2QMTM+0K G*%)1H!)M! M5^6Z
M]97R)$>V[-XDBM:4A94NY\AM;C9^L44_ESNXWKTY N<35$F9!4/$$$310[[8
M*'L8]+EWQH$&DOL($?[\D-B]A=8L,(ZGY9YC0Q\B4JNF8[T+( 3)ME* ">"@
MH2/05^,3+F(I M/>MRS4U]T4,*E+I)M+L6]&^OV!"/?(=W8U\#T]';&#54IO
M:8R^:BC,5J*#.J-KECZR1>'RNV+?ER$U8B<@F(*LI2O)!(E!6B-[6#0%(@C*
M-5E#T&1B[4B6^H.:Z&2,)3G .N.=[!O"AKW;9(G51R:/M<'P1Z=ZV3,&FL)X
M%SM5M@)Y2V+]+1 5H4*X&B [3[,$%5;J\HTQA\QE<)H_F-'=C@C[HKO@"OWA
M]O%'546GUROM 2B^+26C>-UG/3X]':?"QD1Q29I,M&X/HU9(=$? B]\&071W
M?UOS!RW>G2?17"48:5E8KZ:::ZJRF>K"KBDUPO%JVQ&ZK5,J5<NH.N4\5=F5
M7+4)Z$D1+C],'&;3ZVEWK1NPD=T\C]7N!O%[M5C"?9L [2A-[SB(3(A\+CQL
M224=3R^U7!G?XZJ:5Z[4D5K&TYB<$!IB12QN9!Q:@ C"1DZ#CW#R*-Z#QU\^
M^0+=2KS4%],O&KP15>IDE NB^NO;(J&O$B<Z7[CFTSMN F6P!6:(+>G^D0H1
M%ATGV;H981C%>].UKGGO1C)S?P15]B5_SUT99'-JR<S_ +9#5+S*9360&0QZ
M>$T)3<R6!IJ:51;\1LC0W,\S>]"]OL]FM[#;2VG+E#<WGNB(EM<ST24YQ;DZ
MSZ13H%QA!8U:(AP^&1_'$I5 A "=[DKWH0Z%Z ^WTZ#4G-?(9TJ^6UU7$N5^
M0H5?D.XIEB>$7*T//2!5=]&S^2:K:'VDZHJ$HY/5$T1OR8F/31*G9U4D?XVG
MDSH U,B$$L&E0PMM0W7".].@^EJ(3UQ(H6;SM%.:)4<]2A7\(\2$'1\ D,\3
M,[I"SFQ*NA;U""V#:-:G/5*AF*#!:]A6R]A$%5ZY\H+I;2CGA@@G/0U,TZ36
M^1]AA+(]VND9VA!*> ;$<ZV;VQ\D)4#<AIVVZGA"4;I86C,W'"3M[&2X;![!
M!Q5"]^]K6YT=<M!RK@6KZ_2<UR6LF6_9J@[=+FNXTVVE7J*SV1W@\9!S)&CI
MX<EBK@7L],:L:/\ Y7M*";O6O>;#[>/NZNY^NJ_Y^O1I\?\ 5$*Y^OIGA4W2
MS-P[D"]3F,UK,/A58I$HK=-RZ@3.D@;&51M1]$A>R-&FA]S\4#V^\T%B^R^P
MY+S2_4!6E9TR3=MS]*3"91:NHY([.9Z1K= 17<'<; E[I-+8>X]+RF52%D0:
M+:VU(T.+@ZJ!C]V4 A.I/)"L#'Y5);<$(YD#RYR4_P!Q7ST1!;VLIRIR5W-"
M*KCM5PGFFR6ZEK6?'ZX L\[C\H1.=N.Z5HAY[.A4HY2G/TXZ/1H0C."&/:\N
MTEL^,P)WY&XXG70DA4<Q[ZLO&%/UJ0NGGJE(87.)W6(JU)4.;7+F^?WLKL2H
MYBUI60@QN:C!QPXTUV(+/3;-#:Y2]M0V_*?JN\J[5J%\!N.NH7:,*6+"-)5B
MB*SV.-TH83%J31AOPBW;6Z%>^)]0ME&^H&][WK DS 8# 8# 8# 8# 8# 8%4
M>T.MX=Q50LMO"6PZQ+(/96][^RM<57$'R7S&<2)HBLAF&V5,%H;UJ"+M)#%%
MURQP?'<Q(SM*%*:>I/#[  &%:^H_*#!.6^):^Z]?*CLRPGFT*=8;<B=.5NU.
MLC5$-[C$(W,9$JF-BIH^.)0""P1NDQ(G.0NX4A(@^D"5.I5G$HS D_R)=\0/
MQY<Y2&\I1$GVT946E<_P_IF'K"$DML->Q,ZN3RH\A<H2KD\>B$#AK8M>Y ]J
M2!I6ML1C%L)B@U,G/"1.U>H2>.^1;NZK-@Y]BETY7Y\XU TTA)BY\F, H0I2
M6@$D4-+V2T>^-7A]J@2-1H&M;W[O>!B]&6UW7,)\F9;]XQJ&DJ[,;')0JG<-
M[',NI[3.B<D(FMM+@PN<*STI3N)V]@,4_2H/A]:]7NS/;[,".^:_(S"^C^N.
MD^66VO9!$R*:,>1U3:;J[HUL;Z2;JPE^JGZ.<X*W$("#VDB@;Q,*BKGHU0J^
M*4*"E!>RP#]&@@BB_)-TE?Z&(WK7O%[',^.)M=!M/D2>ON@ 3/JF"MH;/6U3
M^+%G<W(ZK31Z/19F?$@5T@9D\S622.,@C5BI((Q*H2@#V3GOKOJ+=4Q_E%I\
M=E//\OG5=6[<=>OJGODMD:'NKJ@G-=P9W=WP@7*+DJCDD<EEJLIQ+6#XX&BQ
MJ=;4[^']I@;+[BNN&T!4$DN6V#SF1@B;0@5NC<S%'2)Z<Y"[JD+,P0>'-R8E
M.MELQETK<TK,R($Y05+JYJTY!0/>&A#@:PI9Y/[]_P#R]X3Y$ZHXHC\WK0=!
MVKT!=,(FO42.L9M5+!5J=T<5L>9 %4C.&VQI"N:X\X[$#1C060J3@(T([1OO
M !*L3[XNUGD'(<;Z2Y9AM++^QK??JY@BB(],)+<:X]&63FNRNA=3:1N"FG*U
M+ M6F5Y]" :2M"]@UH56E8M%^X,"S,6ZG:)9V397(S;&RSS*YYPJ+H0ZQ4<F
M1.#>Z%VO8]PUZ7#M1],@V:WK&$52B6#5B6&:4 <  T27[KUF!"78_D;@O'=V
M<UT](((\S,BZ'LA3:<T:'Q V-'-E4.U@U[2D8N*PDJM&I,6Q:0WE;4=CQ8 &
MI=EEJ%JW9FRF\X @FFONIDTNZ\Z*Y"D,)40R5TO7E+7%"9 J?R'))<E3V\7+
M615+V5K"UH3V$<#LJ!.K Y)AG+/[6DBG1@=*PE%A05N\J]S6M(>?XQS#QLP6
MPX=*MW8UAUBKG_3)%-LKG0G*5PU[4++;GT@"D;%.,U>!EA)7QE; $;VG91$G
M#4F[.])895?7E"G_ !DP<W/?:?+*&JR[SO265O,%54WD*\V"DJHBE>F3=SZ#
ME[OJH:[5.$/C8DRD4B2E(R-L3(D/=!*% "Q)M!G75_DU9^7UO8*;\(EE@I^3
MN3:-ZI$O;IVA9D]BM]V67;%=)(@W"%&W<#$8Q_A=M=MQ$)84K+7A+"27[K8S
M M+?'3":C[;Y JHZ&J9*;UE=LJII*^$OA+45!#HQ0]M7@*0JD!C8N'(25I-5
MB;=)@&I!%C7!/V8+16RC I)R/WIW-UW *5O*)>/RJ(U0-RFM#PCF3SW,%1.&
M*OUK^8U.,F45RFY< F7/;<W)CE0&D+T5I0, 2=JB]BV8$-OV!ILI[R3=)WDG
M07=6?%S)/N/G&]W*CE#] [_^U/6L22--O+:9<[9F_,R2J2V!FBS"_H1N3PQ@
MF9TG:(\$Q<<D$80:CT%I:T[>16-1_9%TEULM:">1+BZTJ17'3)2G6G3XWE=8
M\)%+\D<P,B8N.E3?;3L12<PE6)![SV",/]GMV$,03R*67=BA+$Z&YA:9C:3Q
MPIQ[V]'8G-KX3UW''!KZIE,[9'&NU\T3U7,C&MPK1H@2E=IRTV'EO)AH$X4Z
M/]IV!7N.>6CIO]-76_65D<$PB%U!R.DZI8Y.8P=EI)U*Y/:G*LLD,$DL,:6$
M'.D<2(XU))7%UA21]&M,$6DT6>)"/WGNPA?6BKD[PF\Z96R\^*J@I:M'!N<%
M;C/HEV:*Y7]L5 ;353.C)@>N;JZ+<@.:[19!ING<K28 ]FZ";Z?0((9[7\CL
MEY:M)RJBN^=0W<\P/FJ1==6ZYR*[X51#-'*5CDD=HPH)KY7,&9]#:%FGK8\O
M,$SZ^B&Y"2%*)<Z)-KTFC CVW/+"]L6YI(N?>29WT'65%<R53UKT_*%EBQ:G
MY;557W#%9'8L9C,0KB6M3DY6?<C?6$0<'YRCPE;&0D(TF3:7F+592? 6AY:1
MPZ16E-8%S6_VIQMSK)Z9B/1W5+=:46CQT)<KCBE:6!]+0&GW!E5OEH1*KX#<
M<;=I4MVZ,QR,A8>!$G<#49X-!N,P& P& P& P& P& P& P& P& P& P& P&
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M1)2C4Z1_<X!"66,.;TD3GZT>F1NJ]M,/*+'_ &RRS-!W^W6!8_ 8# 8# 8#
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M1T,S713,*JJ&)^M6;:IZ;;]8)O+V>UX\;4LO>%XA[CC!)-/C641I-[M2,98
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M^D>=Z'OENFE0KFXV7S"4FL5!G.<3^@QJ4*E2^%$+SD($@S#@[).M:UK6M?\
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MZFY."];24UQ2LZ89O9#]+>I8LKC$:3LFDQ!#*6%8<%3H>S AG?3?97;L#\=
M.]^;^E>#+OB\!JA[F,W<DW-UU&12UG\BQ5D?3$0(*;JA(\58".M9Y+8[M;SI
MZ<2'Q KT;M+O>TB<-N_/[-TDQPYQ2=16#3-D3XR0JCVI[HZJYE4443182!M
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MQ<$%<71XMUJEL6ZP96.3P9Q>XXI7L[:0E+,"UKTY0W%0,H2D\-J\066W!Z6
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ML2(UF00L+;3ZXJXZW1,SP[G$G?2$K3K$"4186A2-2&T_ 8# 8# 8# 8# 8#
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M(F./M[BR1QE3,1+>PM[J(*88?<$ZT%G^8N'*[Y#N+I"9T6<QU]2_0YU6R?\
M33"H''X96E9VE!(F? Y98$"31H;>V->K3B39'RW9N*;22M+F/2S1HC51^L"[
MN P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!3/L+DI;TJ3
M3TUKVU7.A.BN<+!5V50UTML6:IXDCCH_19Y@<ZB$U@3RL:T4YK6QX/(%3>[M
M@5S:JV+294E6)E*4HS04VEWBWMGH4N:.O8W8BVX7RT7[GZ/V'"X%48ZNH [F
MVC+5!<KO0$7J1PL^>GHE%YS5*G+F<L=G=[=E[$5]$)RTR'>P;#D.A_#1SE8R
MIS6\W-M;\4&S;FWJ;EBX4=$4/7K"R6[6/3$#;X^1]KV2,_8I&KD%3SF/-<C8
MUAOOS C(4H]^@E:8, 2OT%XS:XO2^^+.DR)P_P "M#D*31!6XK6-N+4M-ZP2
M$(7HZ+P&QVKZ30%&%Q*7O2AV8G#8E)S,-P<R22]A<3AA"$C?"'R4]\FS>D9S
M&8!,NE;!065))%WRLI>ODG3(+\L>;2"T!7JR3 "=1*F5ZB5D/@%S0W$O7N4:
M%"0@";\.' ^AN\</8D1D?19E6>28^JH5U-9ZFW[311;DN ++*;)U(:KK>K)N
M\UI94EL9\:X:>](ZW3K6_P"(CSIIG4J!^[T;L !:#-ZW\._'L2G*5VL&M:XO
M^LZ\YTHKE_F^H+OJJ%V1':$K>GM2QRD+DTK)HED09+85PRV5[<I"_&I4BU1I
M D(WL82A#&%H>,^3&GC&O[ J&%RXUYJ9UO&UK4IZ!ZCB".M=$0FUY$.<+:5B
MNFY:H(<(5%IP[O"IGWLE)M$A<"T(2O=)2QB"W> P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M@_W?0?X6 _3]2/Y5P?[OH/\ "P'Z?J1_*N#_ '?0?X6 _3]2/Y5P?[OH/\+
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M1_*N#_=]!_A8#]/U(_E7!_N^@_PL!^GZD?RK@_W?0?X6 _3]2/Y5P?[OH/\
M"P'Z?J1_*N#_ '?0?X6 _3]2/Y5P?[OH/\+ ?I^I'\JX/]WT'^%@/T_4C^5<
M'^[Z#_"P'Z?J1_*N#_=]!_A8#]/U(_E7!_N^@_PL!^GZD?RK@_W?0?X6 _3]
M2/Y5P?[OH/\ "P'Z?J1_*N#_ '?0?X6 _3]2/Y5P?[OH/\+ ?I^I'\JX/]WT
M'^%@/T_4C^5<'^[Z#_"P'Z?J1_*N#_=]!_A8#]/U(_E7!_N^@_PL!^GZD?RK
M@_W?0?X6 _3]2/Y5P?[OH/\ "P'Z?J1_*N#_ '?0?X6 _3]2/Y5P?[OH/\+
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M1_*N#_=]!_A8#]/U(_E7!_N^@_PL!^GZD?RK@_W?0?X6 _3]2/Y5P?[OH/\
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M.9#$9I3KS%>?)JZG,K4U6;8=HR0+N8M;'(]T=H\9%3E"!1IN7J3%@=CO 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8%>;QY;I[H9?$GJQ$,W1R2#))*UQB75G;=KTM,F]AF@6@$PC!DNI^:0>1.$5
ME&F!")<VJ5)R,XU&0;[O1I18PA*U>U_"JH@L/K*MXRT0N 0"-L\0AD384H$3
M-'8TP(2&QG:&U*#VZ*2H4*<  ^W>Q;]GM%O8M[WL,PP& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
7P& P& P& P& P& P& P& P& P&!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g722206g15a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g15a00.jpg
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M(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X #D%D;V)E &3
M     ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,#_\  $0@#P +2 P$1  (1 0,1 ?_$ (\  0 " @,! 0$            '
M" 8)! 4* P(! 0$                     $   !@,  0 %" 8) P("" <
M P0%!@<! @@)$1(3%%74%947EQA8&M*4U1:6UB%1D2*2TU37"C$C5T$D,AE"
M,S0EM9C869E#<S9V-R81 0                    #_V@ , P$  A$#$0 _
M /?P
M
M
M
M
M
M
M
M
M
M
M
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M [@
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M+4U#[/83=T$::",.IR,Q:6V'%)-D_P#<#T3
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MZF#DS,R*.LZ^3NB1,4M?EC5'VU.A3&*MS=R$A&A6F=2]<:X#)0
M
M                         >?FRN0+GLOLWR$W]4+ OA/1=)V-QS<_&=C2
MEJ<6*#6:]QGFH^(V]2#K*C$I!3Y4ET1HU3#Y3A*>;HT+5"-SQKA>UI/5#40=
M0W1$PICA*P;TH*>0Z@=H[Y&7.3TQ;_CML+R$;4WT#<?=$^L2)9L[E:)RZ"25
MND<CJ1VV;XY.\H'="W>HH++]QT=BE>X78I!GOGC^1<XRVU*=[>N%FG/B>F7,
MT,5HZ$D,ILQLMQ+T+)K"KFH[=A]=S6X6NE'8BII(V-[8XR61[-Z=,U&%.3J2
MJ(/TP&VOQ:3A)$>1.)^3YXWS.*]#UMX^>69U8,'F$/F#.M8VUQB1<"/3N#\]
M-"9G42AKE\.7I7)KPJW=&_;4O=405HH)V,#61T)X_P#HR_\ OCR&] 5H[RYD
ME=&R;@J].3:KL:.HR>4.D;NJ.I5JEU)LL]Z8S,S74AJ(415N7(5Y6L$>735Z
M+QEP3DY+"IG<\?M;L&Z_O)6A0-XLM0W#Q;742H:M)[XO[1[;LND[S:I/;*2_
MZ@96)@M&J%/)W0ITF/8SFR?J4Y+3(T*-&I12%,D;=<'!8Q7S=T['7CIR\=H9
M><ZOGDZN?#[TC7CU)(\<BG71<^YHI2TF#J.O$ID9<Y-&)?9-H57*)3&'1M9G
M9W2E2"0)]=5!WI(,W"*KAYOZ9<*-8[>65/<QUU]7\+^>#HRW8XSQN8NS] ;5
MZIJ&CM^<J+>4;<E4*&2P(A6$>8X6SM&_JK3W&.J2TI>QNIN,!L@X\Y#C?+?D
M'KA32M%N%15=.O%NU$W,]QZ+O3/%IW?T7NNO_F)RM1\V)P@E5[$QI^?-S%[J
M:=(E:0]3L<:87KG.H;S0
M
M            '2DQN/IY X2TAC:292ZM+6P.<C*;DFCXX,;&K=5[,S+'74K"
MY2UM2Y]6G)T^^^2B359V^FN-C=\Y#N@
M
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MKNJ-0M,=B<I;WE0QR)]<UI&Y*=&C/.4'&Z;:::9VQG& EP
M                     &O+OCR#LW"JGG%@S0UO=$3[J2V5=-597U.**]1O
MRZ7)8PX2K&BQ;9,S@\?2I#V]M-QKOLLQZ-\?WO1C^D!QN3/)34G33MT' 9E
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M);FJ5^[)2C-?[AF^,;9P'QJ;RC\IW-T1>M%0J=QAPC5$532]MN_1"6P:V<Z
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M]4*$P[4LIL]N=G5,&7\A^/'M"OYAXU5\OYXF3 WT]_\ /AQ9IBI3%MBX=KU
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M:!N*Y&?$.V>CJTJI^S1L4N"#/A3@L=%,34*WLI,<E]GIN9C?; >D$
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M0DISRO3C1-C<KULX"VX
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M)62_J4C4ZV0JV0UPRS"7MS,LA$"?K$5ZX+8$#XY-RQZWWTPC+.]IIZP7(
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MGFC,-3*]$RF4<;Y1FFD'EIU6-.-(N4?E&;OI@I3@LW7U-\EYV]7?'JY]&?Z
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MA-5*MB--B##0]AV/3C&,9SZ<^C'ISZ/1Z<_^N?1_Z>D!_0
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M.EIG+1X9'!W0.34X)%2 Q60=ZVH9OU=Y$J3X]D,KCEEQBU7U5".9YAUM*54
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MC(U&'Z3N4\E>5JI,5%HDAT9<H25O_<4J7%462F)-QHIW3A;T
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MJUY3RBI#W2^5#,@IC]Z%M77M9<PAC;8SO)&U"A7.;,F1$K7!.2J-3[&8 ;<
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MVFZ58B:22S5&[5KE6I]@2>BV5!;\
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M_,FU>RN6NNNN-%R W7&,>@!/H
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M;GAD>41#DTNK>J+SDM2B<$"DLXHS7.==R]\9Q_1D!W
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M7JFP7*:WH0Y/735>3"-P)CA#8S[M5PMJB4H5**/M[:K*EYI6GK'I3O2&T<
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MRD4??WBUN5HVZ:J>?)9(B6 W&L?E#%7SDFC+DA4)T9GO;!NH+)PG4$[;!L*
M
M
M
M
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MB;O_ (DQ^B ?=:>_Q$W?_$F/T0#[K3W^(F[_ .),?H@'W6GO\1-W_P 28_1
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MR V:@
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MFP6/%'$WWM;OJ3NG,P7_ .W/P7_>"5FGPLQ%HL)MGJ>_)%Z6OR[S/RR)V;6
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ML)
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MS^W^8J%M"<+FQO*:6U9+Y]5D5E4E5-[41MN0VHE#RZG;E)],YT)+SC3&<XP
MM"
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M.ECFR*L&S]UMYL_3\B4?,B]J>X>VMI.&DE@3F)EQ!ZCWTTL_1.2%CP
M
M
M
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MS#(NWX+5[L/NK9+#L&>RRWE[8UVW#9T
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M]8HPPJCI'!B(4^YRU'$/)91RPW'MB,;%9](";
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M33&LWF&QZO&6M8%4TT:6A"C/;8RT-1R8E)KDD[7?<S;8-L0
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MBX9=5:XS"O&/8[%Z>MKD)Q
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MM@*7TYY'^BKN=>386PP^EHY+>H'CRPQ$EW=VV<ND<BDAX;MEVK&DG,QL1RU
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M!?LGL!V929YFVKIHY-SK53K BV12E<'.?<W3+;][G4E2C2-^K<9\U'[J#M2
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M=]#LA)G7GE%G%*H>UI'3;%4UCPOG_@CE_L*G92K5/SHT6*MZ M*Z(?OJYN+
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M<EM=TSD=(US:N)U4-^F4YA@;ZL9]/]./Z<9_IQG'_J
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M#751,KRXE%D.+TWUY$FF*IWEP()VW))7NVC7[P=IIG.FIINV-?Z,8 3:
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MZ+22T+6ZE8B5I$NE7-T$1NDU=DV^BA*YN#:T)S<'$O1!0;FP
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M]')]UC33FRRTG%DAY24W721$HE;WODY"K:-M W,
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MJLKTGL27V;SA/)%*TO0P\QS:2<[:[8,,R VV
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M6\=:;72N&OH]]3757FS',BS,:ZZYP_>KC&/4SC ;/0
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M9RB#@E:717JKV*7(6=NTV*UW38WV"Q
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M9,[=<D\AGK17J-,V-^\=A;Q,/?'K#=ONIP2YNJS<LS4LW4HL+#
M
M
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M /KUK3XTI^B'7Y( ?7K6GQI3]$.OR0 ^O6M/C2GZ(=?D@!]>M:?&E/T0Z_)
M#Z]:T^-*?HAU^2 'UZUI\:4_1#K\D /KUK3XTI^B'7Y( ?7K6GQI3]$.OR0
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MY+__ )"]_P#XFJ =$
M
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M_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\
M^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V
M_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2
M+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML
M3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP
M#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;
M;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB
M_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$
M_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\
M^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V
M_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2
M+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML
M3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP
M#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;
M;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB
M_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$
M_CDB_P ;;^SP#[ML3^.2+_&V_L\ ^[;$_CDB_P ;;^SP#[ML3^.2+_&V_L\
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MCC*[Z)V.,$2>IR]8TD):\[XRN4;Z;>C&A6V0V"5_X_J42^=N?<HZ6#UZ=1,
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M:6)!6+=%9+ CSU[UZFZ=<ED)F2"4^J;'] 7M
M
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MSF"P*BL^ABXE('N(/-;S2BT>6VM'1A?V%:C==-&%MVV3Y),-W)4$[>J;KO\
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MM#2DJHIW_<?=]:3&LA.G>#$6SH6BTPG]O[+^Z LT
M
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M$*-.[Z9AMB-"O"E%LH2Y]Z]G[3VI9NF@=M6EH5_<43+G582IKFD0.?YE%R9
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M[;7?& TAU[R]TO'O$IQ99-M7IU+;7":',5<>V> &*MZOB$M9.?\ %C+51SE
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MK^:8&WR!=*C6!@;CU&[:Q$O<@6Z*G0Q*44<Y[HD6%.YNJ%)J2$D@
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M&'17HN.W6:;:K-LJ,A>P
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MU60P5?*WF)5'<5[1-W:WM_889NZ1XY^0N'M%!>4Y.NX;3@
M
M
M
M
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MW76%M2]*G9_<3]5B;=0&\(
M
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M 9=+F&B6E\1KV;F*OK/76"4Z0*JVEL2;:EEMR$K90[J#G=7HI7&9WP&W\
M
M
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M?]<?ZUT^AUGZ(!]?]<?ZUT^AUGZ(!]?]<?ZUT^AUGZ(!]?\ 7'^M=/H=9^B
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M Z(
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MW"$?$I+^NH/V8 ?=PA'Q*2_KJ#]F 'W<(1\2DOZZ@_9@!]W"$?$I+^NH/V8
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M"GEC;$E%Z\G7:[N"BRRT4N>EF$SWC*_1 H4&%92Y.U*WT2A>['5W:UB=_?\
M'WAUS<S6_P DP1XST(3EX=NG*TM%DZ72I>0D+@2KE$7J:6.:S79A4HDSJ5^\
MQ'M-3W#.2L8.T.] :W8[Y;849Y3V;OG/:CVIB\O\F$AXH6\>9GDKW@#=P<JK
M-OI6#]-9AVQ.L)0;EW(S[R98=H=LKSA25MZ-O7-QJ'*[FMI'%.P?-O8-Q5+Y
M [?BM/6[2<'JBXN?>R+%H^F^39+95%QI#%5]B,,?N>+D,L87V$O1KCG;:-/3
M6AR7MA1C78[4HX)JNJ#]?R;KSQ@\ZW2TWKY$+"QXB-YW:L.YD[R>.866>SEN
MMW5*ANH^Y45EUBPV/JS1UW);C5^5FQ\BW5%KL>UTUQG >J'AJM'*GN.FR-J*
MHL?E&0^K8CVMK^]^CE/6LJKER5.KOHC>WZYWB?6 ED3,H1I$[L6ET=]TR%.=
M[OM@K;0S& \DW))=D\:=2<6./?M8]H51=$_ZA:86E\I_/_6S[TWR/Y!':X'E
MZ*AE=7U"Y,^22#PB#S]&LT3-NC2F1NK=A'JJ*2H\$GG)@OGCQ\T7KYY\<D8G
M'7'U!X\:&.JL0?/<?7N=/KPQU1M!?WI^>LW/F0Y;OW4Q[K\T^]_-7_\ ,]W]
M?^D!IIO&U'Q!GRC3&40WOM1;;QY9.I.7^6>Y8MW58%*<F<QSQSDL?VJ>)6@R
MEW:VLL-C,!>'4YQ4K'"+;LRE N(;R5I1FNONX>E'BU\OID\U=QT]=MLOE@OT
M.\1W&RZ::I9 \;5W(;A*E9S#9-EQ>)'&IF5O.ED@0*#,J2D1!^Q)F--O1C^Z
M TQ\DV5;'2M3^'CBBX+MN8CG[L[L_P K*OHF2MML3J/3>U&;F622A_J.A%=K
MM<@23AJALH=%>Y:IO1N*8Q<E1EDD[Z>SQG ;^:Y\9/'K=IU1R6P]57S.ZK8)
MM5=PI.06;KRTVR8\;R!17K^2W)6.>PZRT/0[/7MPH78QX*8I"[J60PY/J>C)
MSMIOOD/-E'(,Z0S_ (M,^[XCUP]._>HM%&PQ&:6@Z=3="/IA<>8?(W&XHFWC
ML?>+'61B%+M8M$T:!0N:DB-8H2>W*--W+5*-3 WR^0N?6"R>67@"*QZ=3-DB
MKSP1Y))'(HTRRM]:X^\O$=JADWC;X\,J!P(;G-T8EJG)B%2>5N<E-SZY6VNV
M/2 \W7#\PMF4,?A^BE6MG</.O9_1EBQ"QL=G=$]Q3URY3Z2J6N)8Y'7A#(K5
MSS<5@1B9R62QG=,B30T]@9'149[/;T8*.TV/"[=4U7<72G8/E57K^+NV.VV:
MO_)7?5<QR=U;Y4I'R3#*MC*#2,N:2KT%8J[^K;"[1DR[F.&JM(C-3X3KRDI>
MVON_J8#V_L38G961F9TFBHM*TM3>V)BUR]2ZK2TZ!(2E)T6.:T]2L<E6A96,
M&'FF&&G;^G?;;;;.<Y#M0
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M>W;'X5Z(5!N32==#/1O@+X?F*_\ CX_>W^^_^_5[_>(^H'[LO[T_5-;WS/\
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M6M!]>5"-G0D-Z8]V>W8I6Z/+F<0GUV4*U)IJA0;G8PS?;?;.<AW7YMSPO?\
MENY/L!L#Y$ ?FW/"]_Y;N3[ ; ^1 'YMSPO?^6[D^P&P/D0!^;<\+W_ENY/L
M!L#Y$ ?FW/"]_P"6[D^P&P/D0!^;<\+W_ENY/L!L#Y$ ?FW/"]_Y;N3[ ; ^
M1 'YMSPO?^6[D^P&P/D0!^;<\+W_ );N3[ ; ^1 'YMSPO?^6[D^P&P/D0!^
M;<\+W_ENY/L!L#Y$ ?FW/"]_Y;N3[ ; ^1 'YMSPO?\ ENY/L!L#Y$ ?FW/"
M]_Y;N3[ ; ^1 'YMSPO?^6[D^P&P/D0!^;<\+W_ENY/L!L#Y$ ?FW/"]_P"6
M[D^P&P/D0!^;<\+W_ENY/L!L#Y$ ?FW/"]_Y;N3[ ; ^1 'YMSPO?^6[D^P&
MP/D0!^;<\+W_ );N3[ ; ^1 'YMSPO?^6[D^P&P/D0!^;<\+W_ENY/L!L#Y$
M ?FW/"]_Y;N3[ ; ^1 'YMSPO?\ ENY/L!L#Y$ ?FW/"]_Y;N3[ ; ^1 'YM
MSPO?^6[D^P&P/D0!^;<\+W_ENY/L!L#Y$ ?FW/"]_P"6[D^P&P/D0!^;<\+W
M_ENY/L!L#Y$ ?FW/"]_Y;N3[ ; ^1 'YMSPO?^6[D^P&P/D0!^;<\+W_ );N
M3[ ; ^1 'YMSPO?^6[D^P&P/D0!^;<\+W_ENY/L!L#Y$ ?FW/"]_Y;N3[ ;
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MFF?U<0<Y P.,7=U1,:E;[#'796Q.I92]#[-]CBK33U]?^X7KJ9KZ==L9 60
M    :4IU_P =?PT67-YE8\WXGC;[-+ E4AF\O?#;6OQ&8\RB5NZQ^D#J8D;K
M51MZ7=Q=EYQV2R"2B2\[^KIIKKC&N Q7\M!X0/P)1C[7NB/]W@#\M!X0/P)1
MC[7NB/\ =X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_=X _+0>$#\"48^
MU[HC_=X _+0>$#\"48^U[HC_ '> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>
MZ(_W> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_P!W@#\M!X0/P)1C[7NB
M/]W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/\
M=X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_=X
M_+0>$#\"48^U[HC_ '> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W> /R
MT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_P!W@#\M!X0/P)1C[7NB/]W@#\M!
MX0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/\ =X _+0>$
M#\"48^U[HC_=X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_=X _+0>$#\"
M48^U[HC_ '> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W> /RT'A _ E&
M/M>Z(_W> /RT'A _ E&/M>Z(_P!W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[
M7NB/]W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/\ =X _+0>$#\"48^U[
MHC_=X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_
M '> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W>
M /RT'A _ E&/M>Z(_P!W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]W@#
M\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/\ =X _+0>$#\"48^U[HC_=X _+
M0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_ '> /RT'
MA _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W> /RT'A _
M E&/M>Z(_P!W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)
M1C[7NB/]W@#\M!X0/P)1C[7NB/\ =X _+0>$#\"48^U[HC_=X _+0>$#\"48
M^U[HC_=X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_ '> /RT'A _ E&/M
M>Z(_W> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(
M_P!W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]
MW@#\M!X0/P)1C[7NB/\ =X _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_=X
M _+0>$#\"48^U[HC_=X _+0>$#\"48^U[HC_ '> /RT'A _ E&/M>Z(_W> /
MRT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_W> /RT'A _ E&/M>Z(_P!W@#\M
M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]W@#\M!X0/P)1C[7NB/]W@&VCG'G
M"E>2*7A////$'2UO3E=$/":&0M$[2!\3,A+_ "%VE;OH6ZREV?'Y7[[('U6I
MVRH5&YUV.SKKG&F-=<!-X        #5OY<YMTQ67)[O8_/%LLE0)(=*:Z6V.
M]%Q8Z0V+(&%WMNM8NFAU?NBAU2,$)T?R'Y86[NRE&YJRD6N"D1)1YWO:<-I
M  T5]T=0=,\Z^0N!36NGB0S'FRE>+WBZ>IN=VAK->G"852OOEI@LXMVO$*;3
M=69:5#,1Q<D*1%:[FOS$WN361C"I2FSD,8YE[EZ2M^62NF^=7NJKGEUB]!>0
MJX(7;5VS&1*ZHC'+M'7O7]?5M%H9K6[8M=Y7M*%5LM1#2:2I+1M+.E/5G95F
M;)DIX9[U7U+:O3?A\;;YH25RSE>X[QF7-=9MDCBS\D<WZHIS-.RZMY^GZ=FD
M^&\A'(65M>%;HD*782D:N;7M@WV1.3O4T"M,V[VOVZK<\49,%G#W6*!NLVFV
M;NJ'L1J9*FD-O6NONFI%E&R$G.AB@ELA$XYKGZU8GSG3;;!3:;MC&IA><A,-
M1^5GHBVK3TJZ&UMS98TJL^C>B;2I5F@,[MXN#,4YHA;!SFVJ)STJ_P!:IJ4M
M0B>,TVU+/DT%-6M\?<4V?:)UJ$TE;L'XAGE@5=)5YSWU% ZOD<8HBP>E;0KZ
MH2C;8)8IC.,4OQ=TS9=K+KDAD<9)*S:1-NN"K5L:9F79RR<O^;B9)[70C9 F
M4!B1WE+[Q*@KY.3J!Y32)V[QP1KRDZ-F;/M58>AI]2VO;B]\_JU1<+3%N5KK
M4[1G9'*2="&-(9G8HUM48QH=N%V"_(N[*XU8\G0U8W;)(7Y#>5N*&PE1*511
MSI&NDL<H&G6,N]FQFZ('R*D=*&^JU:9.(4[M1>,JB\*-LE!5NN?(_P!V7,\\
M^H812/*L90=;,/7#M4BJ76-:CLHK@CD"?H(D].UFD,D10ZRXFUD;B28@0M&S
M>:P;F>LH/7XTV+ ;9.0[[^]-RUSUTAF-_N<;>-/5_9ZJ)_./SOI&ETQC3>]+
MV(EV]U09=4[4M5&$E*<D$;'EZ:[Y++SMG3 6+      '\SGT8SGT9SZ,9SZ,
M?]<^C_TQ_P!/Z<@//WS(BO\ Z(YEK/R9SGR06-1$WGLA*LI?7$A5UD5P[5]:
M:VNHCJGG.75:[,D><'%<CB:3>-N$F5RA/*2I;OLL*5%ZEZ-V0F!+Y*KQ+1P6
M_':H*L*Y*N7I.W^6:S3HYC+-N@&>45R]7)"8I9<Z;3X_K"#8K85@4HM2J&-
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MQP6$,BAS<WH]JC,<0DMK0@-=GI6O=G$Q,C(UUR<I.-.,SCT[;9S_ $@),
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M
M
M
M
M
M
M
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MJ(4::EYR846%P0
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M$^@
M                                       -!?F,JYSNKI?QDUBVT'47
M4.[[*NMG$RCKXLI_JJK93^[]'MCD6Z/<ICL"LY;HZ1G;7WEO*V9%)9BC^C8P
MC'_<P% ><;NO'EOGV?-%-1-CYXF]^^4B-<QR7C>!2]@F&OCI-;Z/7+7R+PB5
M]1+X54*^:=(.]:H7>.KCR"Z_6_OPB4M"5P4GZIU06"D/;?D&4P!IUS9K(CUK
M-_[*;++645(^#;1ZX5,-).%6?N384\IR7SY'14JC=28E;RS6FS0!W;GW1X):
MMTFS9A:8D*##V?J+I-VZ<M&04GU>HVB?7/5/C*K.*NC]43&9^X51W_PZ[7"X
MS*MX'-%KKO$)&Z%-6FZ)$[D+D:5>9N8N3KC<*-# EBL^B;Y?;NFG+4:Z$KCD
M],MNSR6S*3]%)*FJ\YXLB3<NO_-\39FAP9IUA57&LA?B+7<IA-5)2(I>I:F?
M4I!EN)U4*R0A6'= VF]7+9UK/%T0#IJ.V%UKX4-(LV):_,3U663<%;UQ('&R
M*"9I(]J)7#T;^M<%2B-Y6FFF)SU&BL_*A5C??8,CDODF[ K_ )=J?J!OZ&K.
MVI9U3Q1V;T(91I=:0U(Q<H3FC^?I#=<6-83XZ8DGKY!ZKF[4FKR:IY@M<%BU
M^<$^Y1[6=ZR#<)[MWHWOBJ9K;-"1[HR#V7,U<)X(MZ)2&4,7/5'6&4DZ&M+H
M*#7%2?/JFP-6^C7^P7AOIE(HK])-]%QV#%"Y.L6N!N$QF@7.H;L4UR\>UX]"
M3*V'HV5\Z(>H&BR9W>M*-,.>Z\E]$+9ALY-MJ5O1,LDT1FBBNB&Q.0[*H,Z8
M;Y'[J8:W:HS#_=R TG7;U[V1-H==5!R?H.U8P>U03QH7^AGMC5SRY!+295EI
M]ZPJJ98E:H?SY/I4V1FEIDUFH7-"TS,_$HPF1GI%IZQO6F;9"=*NOSHVL";3
MJY/U=:$PLJV?*7VC$&EH@5-TK++P<H%3$:4/K^TUFZ7;*H_SU6+"U[J6AQ<%
M<KV4I43*5E&TH\&*,*$X?JC_ "*=4=(UBPJWWKZI>3]ZRXENCIM_NF0UK6$N
MC-S2.KNL>@.?]G.;(M7B21$BJ:]B%'-CI."8 O(6*5\Q(V:W9&DPCU4A]:"N
MKHFK)39=Z0B\"'ZJK4\V3A13S0QE?1]3&95$;L8H.WNLG:IH^$?6DP2PE_<D
MS@P)RER5M3(RM4:Q H-.,4%A&D.\K7?;=0J'IU]S"W9!<'(G0%]MM?SE\YCS
M'ZODD'1QMP:GNG833$^=>BI16]!JI 8WV4BG6N79/[OJ:8I9E.IR#(;-N(R)
M>U^1?M9BF74:#JQP0\C\$+R9DF8:_C#FPIWN9=CN6C*_LU6DMT(RH<L&_.C<
MH)0I59C*M1EG[*O9:*SPW(@
M
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M \2R!L#S4< <V6$RB0NQC^_R*)-2V/GH8X]OCZ;LM6*D99)RE7MDXS;8S^\
MSCZH:G]0TOZL:^]F?8A5O'Z?N9'?4.M@@].J(LXW7YN]!E@DJ4I1FCSGTN.N
MY>NV#O3KC. Z*,<\T%"95.9W#:/J&)3>SRUI5DS"-5M#6*46 4Y*,JW$J:O[
M8S)764E."O;)I^JXT_4XW.=]\9VSG(#]U7S[0M%ZNFE)4E4E/:/9*-,\Z5;7
M$/@&KNF;E;HN;D[GK%&=IPN(;UKXM-(T-];4DQ6=MIC7)N_I"7@
M
M
M
M
M              :P[DY4\D$VL^92NI/*VLI&MWMV]\B-4%\/\]V/I"&OW9.5
M\SZSB5.1,ADF,*2S#?>%6N#?^YZO_37 "=Z_I3K..<VS>L)UVRHL?H5^S),P
MWJ#;G.K(B= L.:1"3'L:TPR*S(%)_P!V%2<X['OAF/??>/4-]&--0%1F_C'R
MMIEZ)0N\T:]Q0D*TQRQOSX\>7TGOZ4H[3=0C][(=LG)?>B=<Z>TT_O:>MZ<?
MTX 6]ZPI?J^WRH/IR_VF?Q\:PF2#:9G$<[5=?O[_ !;CJSX8B]B[)5I=8O\
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MB[FM>T8J KBN@K5TAY:1D;4+D5K/9DXD21_^=GA*H7^LIUQDCWKV.G_;+UR
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MR2E@=I; =N".;8IK-HTW.J56^1+:4,KIN\1S61-A)J3*Y+KE0D]M[4O&=]<
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M/Y$ /S$?A9_'_4GT)9G\B 'YB/PL_C_J3Z$LS^1 #\Q'X6?Q_P!2?0EF?R(
M?F(_"S^/^I/H2S/Y$ /S$?A9_'_4GT)9G\B 'YB/PL_C_J3Z$LS^1 #\Q'X6
M?Q_U)]"69_(@!^8C\+/X_P"I/H2S/Y$ /S$?A9_'_4GT)9G\B 'YB/PL_C_J
M3Z$LS^1 #\Q'X6?Q_P!2?0EF?R( ?F(_"S^/^I/H2S/Y$ /S$?A9_'_4GT)9
MG\B 'YB/PL_C_J3Z$LS^1 #\Q'X6?Q_U)]"69_(@!^8C\+/X_P"I/H2S/Y$
M/S$?A9_'_4GT)9G\B 'YB/PL_C_J3Z$LS^1 #\Q'X6?Q_P!2?0EF?R( ?F(_
M"S^/^I/H2S/Y$ /S$?A9_'_4GT)9G\B 'YB/PL_C_J3Z$LS^1 #\Q'X6?Q_U
M)]"69_(@!^8C\+/X_P"I/H2S/Y$ /S$?A9_'_4GT)9G\B 'YB/PL_C_J3Z$L
MS^1 #\Q'X6?Q_P!2?0EF?R( ?F(_"S^/^I/H2S/Y$ /S$?A9_'_4GT)9G\B
M'YB/PL_C_J3Z$LS^1 #\Q'X6?Q_U)]"69_(@!^8C\+/X_P"I/H2S/Y$ /S$?
MA9_'_4GT)9G\B 'YB/PL_C_J3Z$LS^1 #\Q'X6?Q_P!2?0EF?R( ?F(_"S^/
M^I/H2S/Y$ /S$?A9_'_4GT)9G\B 'YB/PL_C_J3Z$LS^1 #\Q'X6?Q_U)]"6
M9_(@!^8C\+/X_P"I/H2S/Y$ /S$?A9_'_4GT)9G\B 'YB/PL_C_J3Z$LS^1
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M]MY/\F 'Y/CP]_#^FOMO)_DP _)\>'OX?TU]MY/\F 'Y/CP]_#^FOMO)_DP
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MN\5H2UYRU2LHYD1[2&0H,K2#T2U8B-+SL Y#/Y7X7=$>IF[JDB]OMW/,UO\
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M@97HQ8ED[-'()*8N]-:MU,0.#+(HZS.:52FVWU+.3&$G[A<T
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MNO@9#X2X6+OB)P6'[YL"R=GDLR1'8VPV'&($WN2)#C4[!P2X @-UYOK=\O\
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MYC+WTTV1LJ=2J.4&G*CE!NV-L!:D
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MH\PQZ.1!K?'Q2<E2EJY-(BGR7+$Z(@DYUW*UWUW"X8
M
M
M
M
M
M
M
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MQ&'!"FR>5ZX0LE\H//!\EPC/C-TMU:NDSMVLX%T,OKS0JB[3M"C6F<.]BU]
M).4^GR%8\HRZQDA#:L7M+>ROZQD5)VM<L-P5J8%F.8^C(YU54[#=4*A%GPV!
MS)&SOT!5VG&$<0=)W")+&F.5Q>P&!D)>G=S2Q:1-#^5E-JY%M[EH84;H>D)S
MKCU@L&
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MZ/6R$O
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MLLL2S2XQ*USC'M$AR].Y;;/#2W-QAVA9A62]0VL
M
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MK^0[29_?Y.RP+>0;0AJ>7N5/;ZZ+4$1)E*Y.VE;FYU1)#L)BL:$%%%Z!9L
M
M
M
M
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M3)YN4NBCE'J0Q1HGR9MDC4\POJHLO<[4KT8VSKKC&=O3G&, +=62P][J^=(
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ME\IZ]L8VT]K8)E2VIMS3MK^^V5&^-*QUMG6R==LUU_[7&<R;.,/'_N?1[O\
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MS;EIGK#]F=);%MBQU+]JI5F-^R7"$U!DDLH_&_M,F%Y+"GW[B>>K\2?BJ_\
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M2RVYQ9=FO!FFA"=,G.P?G7?)N=<9UR%X
M
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M=J& /=BQZ?0:+NM-Q$I[IYT;6](@5;N3@TOR1P6&9U0')DN#E(;F0
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M)W-7+323/2F# %WF2L.5T%/>EZ,Y*;9W7M <BU!U3T7')G>I4"G3.HN"$/\
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MQ*([7O/,WYMJOF&42)5=5TQ"P]8/7;E*]4ZFUH!&(Z_PKI]5&6>5'[QK)SO
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MS:W%&=H:0H(,W*.*WQMIMG7.,@.W
M
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MZ,>CT +W@
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M-<8UUQC777&,8UUQC&,8Q_1C&,8_HQC #^@               _GIQ_7C^T
M]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z
M\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX
M /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C
M^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']
MN #TX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']N #T
MX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ
M_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@ ]./Z\?VX /3C^O']N #TX_KQ_;@
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M_757^: ?.#A\07_KJK_- /G!P^(+_P!=5?YH!\X.'Q!?^NJO\T ^<'#X@O\
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M)M=E3TY+BO9*===-3<93J=,Y_HQZ,^G'_H F$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M%/XGY!^$9Y:.E(POLGF&4W&:_N$4(JUBO*MW*?J)2TJCT3G&DT32R,Q[4R!
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MM(TWT3:F9TW/*UV]&QFF-@FL
M
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ME50YF/?8*:]K#3E;P9$70PUOV5&[[F*,I_:;;9VVSD!+0
M
M                                   Q^616.3N*R6$3!G0R*)3%@>(M
M*(^YE>W;7R.R!N4-+TT.!&<X]LB<FU6:2;KZ<>MIOG ""*+Y$HOG1Z?9/6S%
M+3Y9(8U'(.MF-DVK:ET3%) (<I=5L3KQDEEP3.<2"/P*.K'Q6>E:$*E.AU4*
M-SMB]C<^N LN
M
M
M
5                         __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g722206g28g07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722206g28g07.jpg
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M1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4
M9,     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P  1" "G 1\# 1$  A$! Q$!_\0 FP !  (" P$! 0
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M?LQ&''_[>,K,EQ04&^ $A7Q1$XR5,?EN&FG#W)-S3!@# & , 8 P!@# & ,
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M;4KP153]>=:M7=GLR^2]M4ZRV>C6="!@# & , 8 P!@# & , 8 P!@# & ,
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MTUOU!M^8!@# & , 8 P#0=S[$H--%B)(<.RV*P>CQ:;5*L4E[!;29:OC'5B
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MI=331Y2JVG*F+BJ7QXY')S'0Z+\:Z=3T!RSF, 8 P!@# & , 8 P!@# & ,
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M7LI:R(XDB+]<JR)UWG^*FN6;:SLY9*&"1@# & , 8 P!@# & , 8 P!@# &
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M/2MFM*F'-NM5.YCA%M7**>^T;]:Y.C-H#A-*)*/QS\KCK/4U-I0MC=<&# &
M, 8 P#I6*QQ@2RE_6L48[Q2$>;%UI64!5<1QLA,3;\4^45%Y3,:34/5&J)-8
MW6457H6VR_O%I8FIW;S3Q@B@TZW4R%:)0'P101WCX^$_FB8JE5150D;NY6Y%
M]K([!Z[Z)H6.E>LJ7=-Q@ZM5Q:#37+ZMTW78LQZK1]'IMA*^MIFJCS5X<!D5
M>-#_ &I^JI6AN6SMD;2T;\BM\3TXV;V!AP-@]W=H_P!?_G!7V<GH'5G2J.F-
M>L&5%\8%BY%,=@WM(;[39$DN4D-7@)4:,"SS8L-ZYO\ Z,EF[PTET2?^1G6+
M-\>WQ[4I:EJZ\E.OA^Y=+4>J.M-"_IQ:7U_IFJ.554E%7.Z[K--3O0:7[&W5
MJ8KU?#8=9KE=9 U9$O B%%5%5$7.BQ8E;DJKEW%KV=:XTXQU222T4+HNR)"S
MH0, 8 P!@'!"A"HDB$)(J$)(BB2*G"HJ+RBHJ8:3T>P\MR$M1KJGJC9%T"N;
M>AZOMUA=[%JC9KY0Z^^FRI-OL6K0&T-&8,(0,YL..RTVRVU]HHG(\KC=MDM.
M_P#P:E.O4FSGE.47C^//'_%,W7KN8]&5SZ]9INW]PL^W+:JK+.NU*]MM8ZB=
ML*I3F4\>L)VKV;;J]ZPBM/L2]GGB;+;K:)XPF $2_>YSD)N>J!8[- P#0>T]
MYA]9];;WV#/..$73=2OMD<641C%4JFN?ELMR";5'!9=? 1)45%055<QM)-O8
MU)/1N%W[%.O[8'64?K;TRZMDN4K-)L/:?]?[LW.,#)MOKM/:UW-V^>W*>?-Z
M=+6 S8M163D.NNC&8;#R\1%$RBJJ_CL)_"M6^5E6&^^YZ!Y1@P!@# & , 8
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MOPZ$M45+6ZY35=#416H=735\2LKXS(" ,PH+ 1HS:("(/[6FTY7CY7YRP97
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M H(BB"(BB"(BB<((HG"(B)^B91Z#G &9" XPDEJ!QQ_[JO\ QS0, 8 P!@#
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0 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
